UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Form 8-K

 

 

Current Report

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 9, 2018

 

 

ENDOLOGIX, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   000-28440   68-0328265

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification Number)

2 Musick, Irvine, CA 92618

(Address of principal executive offices, with zip code)

(949) 595-7200

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

 

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 


Item 1.01 Entry into a Material Definitive Agreement.

Credit Agreement

On August 9, 2018 (the “Agreement Date”), Endologix, Inc. (the “Company”) entered into a Credit Agreement (the “Credit Agreement”) with Deerfield ELGX Revolver, LLC and certain of its affiliates (collectively, “Deerfield”), pursuant to which the Company may borrow up to the lesser of $50 million (upon having a $350 million market capitalization, or otherwise $40 million) or its applicable borrowing base from time to time prior to April 2, 2022 (the “ABL Facility”). The borrowing base consists of eligible accounts, eligible inventory and eligible equipment. On the Agreement Date, availability under the ABL Facility was approximately $24.0 million. Any outstanding principal under the ABL Facility will accrue interest at a rate equal to LIBOR (with a 1% floor) plus 5.50% per annum payable in cash. Interest is payable in cash monthly in arrears on the first business day of the immediately succeeding calendar month and on the maturity date. The interest rate will accrue on a minimum amount of $9,750,000, whether or not such amount is drawn (which amount in excess of the revolver usage accruing interest will not be subject to the unused line fee). The Company is subject to other fees in addition to interest on the outstanding principal amount under the ABL Facility, including an unused line fee in the amount of 0.50% (subject to certain amounts that are below $9,750,000 that are not actually drawn but accruing interest as set forth above), a commitment fee of $500,000 (payable $200,000 upon closing, $200,000 on the first anniversary of the closing and $100,000 on the second anniversary of the closing), a $1,000,000 fee upon the expiration of the ABL Facility and an early ABL commitment termination or reduction fee of 2.50% in the first year, 1.50% in the second year, 0.50% in the third year and 0% thereafter. The Credit Agreement has a $22.5 million liquidity requirement, trailing-twelve month and quarterly net revenue tests, fixed charge coverage, capital expenditure limitations and operating expense tests. The Credit Agreement also contains various representations and warranties, events of default (including a cross-default to the Amended Facility Agreement (as defined below) and certain other indebtedness), and affirmative and negative covenants, customary for financings of this type, including reporting requirements, requirements that the Company maintain timely reporting with the U.S. Securities and Exchange Commission (the “Commission”) and restrictions on the ability of the Company and its subsidiaries to incur additional liens on their assets, incur additional indebtedness and acquire and dispose of assets outside the ordinary course of business. The Credit Agreement provides for full cash dominion. The Company’s obligations under the Credit Agreement are secured by a first priority security interest in substantially all of the Company’s assets, including intellectual property, with the priority of such security interest being pari passu with the security interest granted to Deerfield pursuant to the Company’s Amended Facility Agreement, subject to the Exchanged Deerfield Notes (as defined below) being last out in the waterfall in connection with certain application events in a downside scenario.

Amended and Restated Facility Agreement

Also on August 9, 2018, the Company entered into an Amended and Restated Facility Agreement (the “Amended Facility Agreement”) with Deerfield Private Design Fund IV, L.P. and certain of its related funds and affiliates (collectively, “Deerfield”), in order to, among other things, allow for the Company’s entry into the Credit Agreement and the transactions contemplated therein. The Amended Facility Agreement amends and restates in its entirety the Company’s prior Facility Agreement, dated April 3, 2017 with Deerfield (the “Prior Facility Agreement”).

In connection with entering into the Amended Facility Agreement and certain accommodations, concessions and agreements provided by Deerfield (such as extending out the maturity of such Exchanged Deerfield Notes), Deerfield and the Company have exchanged $40.5 million principal amount 3.25% Senior Note held by Deerfield Partner, L.P. for an additional $40.5 million of indebtedness as a last-out waterfall tranche under the Amended Facility Agreement. Such amounts are being amortized $20.25 million (plus 50% of the paid in-kind interest that has accrued as of such date) on April 2, 2022 and $20.25 million (plus the remaining portion of the paid in-kind interest that has accrued as of such date) on April 2, 2023.

Accordingly, the amount outstanding under the Amended Facility Agreement has been increased to a total of $160.5 million.

Any outstanding principal under the Amended Facility Agreement will accrue interest at a rate equal to 5.00% payable in cash and 4.75% payable in kind. The Amended Facility Agreement contains the same operating and financial covenants applicable to the Credit Agreement.

The Company may issue up to a maximum of 2,526,800 shares of the Company’s common stock to Deerfield pursuant to the Amended Facility Agreement in lieu of paying cash to satisfy a portion of its obligation to pay interest owed to Deerfield with respect to the first-out waterfall loans (but not the last-out waterfall loans). Each share of the Company’s common

 

-2-


stock issued to Deerfield in respect of an obligation to pay interest will be valued at 96% of the lesser of the (i) trailing ten (10) day volume weighted average price per share ending on the last trading date prior to issuance and (ii) the last closing bid price of the Company’s common stock on the last trading date prior to issuance.

The Company’s obligations under the Amended Facility Agreement are secured by a first priority security interest in substantially all of the Company’s assets including intellectual property, with the priority of such security interest being pari passu with the security interest granted to Deerfield pursuant to the Credit Agreement subject to the Exchanged Deerfield Notes (as defined below) being last out in the waterfall in connection with certain application events in a downside scenario.

The Amended Facility Agreement contains various representations and warranties, events of default, and affirmative and negative covenants substantially similar to those contained in the Credit Agreement.

Pursuant to the Amended Facility Agreement, Deerfield has the right, but not the obligation, to convert a portion of the outstanding principal amount of the first-out waterfall loan into shares of the Company’s common stock at 96% of the trailing three (3) day volume weighted average price per share on the date of conversion into a maximum of 14,300,000 shares of the Company’s common stock. The first $60 million of the principal amount of the first-out waterfall loan (or exercise price of the Warrants elected to be paid through a reduction in principal, as described below) converted into the Company’s common stock will be credited first against principal and payable in kind interest obligations due in 2021 and then against principal and payable in kind interest obligations due in 2022. Any additional such amounts will be split between principal and payment in kind interest obligations due in 2022 and 2023 and at maturity. The last-out waterfall loans (the “Exchanged Deerfield Notes”) have no equity components.

The Company also agreed to pay Deerfield a $6,113,750 exit fee (with 5,000,000 owed to the first-out waterfall lenders and the other $1,113,750 owed to the last-out waterfall lenders) upon the termination (or a reduction of the outstanding revolver commitments to less than $10,000,000) under the Amended Facility Agreement and to reimburse Deerfield for all expenses incurred by Deerfield in connection with the negotiation and documentation of the Credit Agreement and the Amended Facility Agreement. There are other certain non-callable make whole amounts, yield enhancement payments and change of control fees set forth in the Amended Facility Agreement.

Warrants

In connection with the execution of the Amended Facility Agreement, the Company issued to Deerfield warrants to purchase an aggregate of 8,750,001 shares of common stock of the Company at an exercise price equal to $4.71 per share, which equals the closing bid price of the Company’s common stock on the date of the Amended Facility Agreement (the “Warrants”). The number of shares of common stock of the Company into which the Warrants are exercisable and the exercise price of the Warrants will be adjusted to reflect any stock splits, recapitalizations or similar adjustments in the number of outstanding shares of common stock of the Company.

The Warrants are exercisable commencing on February 9, 2019 and expire on the seventh anniversary of the Agreement Date. The holders of the Warrants may exercise the Warrants for cash, on a cashless basis, or by reduction of the principal owed to Deerfield pursuant to the Amended Facility Agreement.

Registration Rights Agreement

In connection with the Amended Facility Agreement and the issuance of the Warrants, the Company entered into an Amended and Restated Registration Rights Agreement with Deerfield (the “Amended Registration Rights Agreement”). The Amended Registration Rights Agreement amends and restates in its entirety the Company’s prior Registration Rights Agreement, dated April 3, 2017 with Deerfield and pertains to both the Warrants issued pursuant to the Amended Facility Agreement and the warrants issued pursuant to the Prior Facility Agreement (the “Prior Warrants”).

Pursuant to the terms of the Amended Registration Rights Agreement, the Company has agreed to register for resale the shares of common stock of the Company issuable upon the exercise of the Warrants and the Prior Warrants.

 

-3-


The foregoing descriptions of the terms of the Credit Agreement, the Amended Facility Agreement, the Warrants and the Amended Registration Rights Agreement are qualified in their entirety by reference to the text of such documents, copies of which are filed as Exhibits 10.1, 10.2, 4.1, 4.2, 4.3 and 10.3 to this Current Report on Form 8-K.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information included in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03.

Item 3.02 Unregistered Sales of Equity Securities.

The information included in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.02. The securities discussed in Item 1.01 above were issued in a transaction exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”) by virtue of Section 4(a)(2) of the Securities Act and Rule 506 thereunder and exempt from registration or qualification under applicable state securities (or “blue sky”) laws. The securities were issued solely to “accredited investors” (as defined by Rule 501 under the Securities Act).

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits .

 

Exhibit No.    Description

4.1

   Warrant, issued August 9, 2018, issued by Endologix, Inc. to Deerfield Private Design Fund III, L.P.

4.2

   Warrant, issued August 9, 2018, issued by Endologix, Inc. to Deerfield Private Design Fund IV, L.P.

4.3

   Warrant, issued August 9, 2018, issued by Endologix, Inc. to Deerfield Partners, L.P.

4.4

   First Out Waterfall Note ($40,000,000), issued August 9, 2018, issued by Endologix, Inc. to Deerfield Private Design Fund III, L.P.

4.5

   First Out Waterfall Note ($40,000,000), issued August 9, 2018, issued by Endologix, Inc. to Deerfield Private Design Fund IV, L.P.

4.6

   First Out Waterfall Note ($22,320,000), issued August 9, 2018, issued by Endologix, Inc. to Deerfield Partners, L.P.

4.7

   First Out Waterfall Note ($17,680,000), issued August 9, 2018, issued by Endologix, Inc. to Deerfield Partners, L.P.

4.8

   Note, issued August 9, 2018, issued by Endologix, Inc. and certain of its subsidiaries to Deerfield Private Design Fund III, L.P.

4.9

   Note, issued August 9, 2018, issued by Endologix, Inc. and certain of its subsidiaries to Deerfield Private Design Fund IV, L.P.

4.10

   Note, issued August 9, 2018, issued by Endologix, Inc. and certain of its subsidiaries to Deerfield Partners, L.P.

4.11

   Last Out Waterfall Note ($40,500,000), issued August 9, 2018, issued by Endologix, Inc. to Deerfield Partners, L.P.

10.1

   Credit Agreement, dated August 9, 2018, by and among Endologix, Inc. and Deerfield ELGX Revolver, LLC and certain of its affiliates.

10.2

   Amended and Restated Facility Agreement, dated August 9, 2018, by and among Endologix, Inc. and Deerfield Private Design Fund IV, L.P. and certain of its affiliates.

10.3

   Amended and Restated Registration Rights Agreement, dated August 9, 2018, by and between Endologix, Inc. and Deerfield Private Design Fund IV, L.P.

10.4

   Amended and Restated Guaranty and Security Agreement, dated August 9, 2018, by and among Endologix, Inc., its subsidiaries and Deerfield Private Design Fund IV, L.P.

10.5

   Guaranty and Security Agreement, dated August 9, 2018, by and among Endologix, Inc., its subsidiaries and Deerfield ELGX Revolver, LLC.

10.6

   Intercompany Subordination Agreement, dated August 9, 2018, by and among Endologix, Inc., its subsidiaries and Deerfield Private Design Fund IV, L.P.

10.7

   Intercompany Subordination Agreement, dated August 9, 2018, by and among Endologix, Inc., its subsidiaries and Deerfield ELGX Revolver, LLC.

10.8

   Intercreditor Agreement, dated August 9, 2018, by and among Endologix, Inc., its subsidiaries, Deerfield ELGX Revolver, LLC and Deerfield Private Design Fund IV, L.P.

10.9

   Reaffirmation Agreement, dated August 9, 2018, by and among Endologix, Inc., its subsidiaries and Deerfield Private Design Fund IV, L.P.

 

-4-


10.10

   Patent Security Agreement, dated August 9, 2018, by and among Endologix, Inc., certain of its subsidiaries and Deerfield ELGX Revolver, LLC.

10.11

   Trademark Security Agreement, dated August 9, 2018, by and among Endologix, Inc., certain of its subsidiaries and Deerfield ELGX Revolver, LLC.

10.12

   First Supplement to Patent Security Agreement, dated August 9, 2018, by and among Endologix, Inc., certain of its subsidiaries and Deerfield Private Design Fund IV, L.P.

10.13

   First Supplement to Trademark Security Agreement, dated August 9, 2018, by and among Endologix, Inc., certain of its subsidiaries and Deerfield Private Design Fund IV, L.P.

 

-5-


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    ENDOLOGIX, INC.
Date: August 10, 2018     By:   /s/ Vaseem Mahboob
      Vaseem Mahboob
      Chief Financial Officer

 

-6-

Exhibit 4.1

WARRANT

THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAW. THE SECURITIES MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT, EXCEPT PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT, INCLUDING PURSUANT TO SECTION 4(A)(7) OF THE SECURITIES ACT OR RULE 144 UNDER THE SECURITIES ACT OR PURSUANT TO A PRIVATE SALE EFFECTED UNDER APPLICABLE FORMAL OR INFORMAL SEC INTERPRETATION OR GUIDANCE, SUCH AS A SO-CALLED “4[(a)](1) AND A HALF SALE.” NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

AN INVESTMENT IN THESE SECURITIES INVOLVES A HIGH DEGREE OF RISK. HOLDERS MUST RELY ON THEIR OWN ANALYSIS OF THE INVESTMENT AND ASSESSMENT OF THE RISKS INVOLVED.

 

Warrant to Purchase

2,916,667 shares

      Warrant Number:    2018-1

Warrant to Purchase Common Stock

of

Endologix, Inc.

THIS CERTIFIES that Deerfield Private Design Fund III, L.P. or any subsequent holder hereof (“Holder”) has the right to purchase from Endologix, Inc., a Delaware corporation (the “Company”), Two Million Nine Hundred Sixteen Thousand Six Hundred Sixty-Seven (2,916,667) fully paid and nonassessable shares of the Company’s common stock, $0.001 par value per share (“Common Stock”), subject to adjustment as provided herein, at a price equal to the Exercise Price (as defined in Section 3 below), at any time during the Exercise Period (as defined in Section 1 below).

Holder agrees with the Company that this Warrant to Purchase Common Stock of the Company (this “Warrant” or this “Agreement”) is issued and all rights hereunder shall be held subject to all of the conditions, limitations and provisions set forth herein.

1. Date of Issuance and Term .

This Warrant shall be deemed to be issued, and shall be in full force and effect commencing, on August 9, 2018 (“Date of Issuance”). The exercise period of this Warrant begins on (and includes) February 9, 2019, and ends at 5:00 p.m., New York City time, on August 9, 2025 (the “Exercise Period”). This Warrant was issued pursuant to that certain Amended and Restated Facility Agreement (as may be amended, restated, supplemented or otherwise modified from


time to time in accordance with the terms thereof, the “Facility Agreement”) by and among the Company, Deerfield Private Design Fund III, L.P., Deerfield Private Design Fund IV, L.P., and Deerfield Partners, L.P., dated as of August 9, 2018, and in conjunction with that certain Amended and Restated Registration Rights Agreement (as may be amended, restated, supplemented or otherwise modified from time to time in accordance with the terms thereof, the “Registration Rights Agreement”) by and among the Company, Deerfield Private Design Fund III, L.P., Deerfield Private Design Fund IV, L.P., and Deerfield Partners, L.P., dated as of August 9, 2018.

Notwithstanding anything herein to the contrary, the Company shall not issue to Holder, and Holder may not acquire, a number of shares of Common Stock upon exercise of this Warrant to the extent that, upon such exercise, the number of shares of Common Stock then beneficially owned by Holder and its Affiliates and any other persons or entities whose beneficial ownership of Common Stock would be aggregated with Holder’s for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (including shares held by any “group” of which Holder is a member, but excluding shares beneficially owned by virtue of the ownership of securities or rights to acquire securities that have limitations on the right to convert, exercise or purchase similar to the limitation set forth herein), would exceed 4.985% of the total number of shares of Common Stock then issued and outstanding (the “4.985% Cap”); provided, however, that the 4.985% Cap shall only apply to the extent that the Common Stock is deemed to constitute an “equity security” pursuant to Rule 13d-1(i) promulgated under the Exchange Act. For purposes hereof, “group” has the meaning set forth in Section 13(d) of the Exchange Act and applicable regulations of the Securities and Exchange Commission (the “SEC”), and the percentage held by Holder shall be determined in a manner consistent with the provisions of Section 13(d) of the Exchange Act. Upon the written request of Holder, the Company shall, within two (2) Trading Days, confirm orally and in writing to Holder the number of shares of Common Stock then outstanding.

For purposes hereof:

“Affiliate” means any person or entity that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a person or entity, as such terms are used in and construed under Rule 144 (“Rule 144”) under the Securities Act of 1933, as amended (the “Securities Act”). With respect to a Holder, any investment fund or managed account that is managed on a discretionary basis by the same investment manager as such Holder shall, for purposes hereof, be deemed to be an Affiliate of such Holder.

“Asset Sale” means a transaction covered by the provisions of clause (B) of the definition of “Major Transaction” involving the sale or transfer of all or substantially all of the assets of the Company (including, for the avoidance of doubt, all or substantially all of the assets of the Company and its Subsidiaries (as defined in the Facility Agreement), taken as a whole) in connection with which the Company has announced its intention to liquidate and distribute its assets to stockholders.

“Black-Scholes Value” shall mean the Black-Scholes value of this Warrant, or applicable portion thereof, as determined by use of the Black-Scholes Option Pricing Model using the criteria set forth on Schedule 1 hereto.

 

2


“Business Day” means a day other than a Saturday or Sunday or any other day on which commercial banks are authorized or required by law to close in New York City.

“Cashless Default Exercise” shall mean an exercise of this Warrant as a “Cashless Default Exercise” in accordance with Sections 3(c) and 11(b) hereof.

“Cashless Major Exercise” shall mean an exercise of this Warrant or portion thereof as a “Cashless Major Exercise” in accordance with Sections 3(b) and 5(b)(i) hereof.

“Cash Out Major Transaction” means a Major Transaction in which the consideration payable to holders of Common Stock in connection with the Major Transaction consists solely of cash.

“Eligible Market” means the New York Stock Exchange, the NASDAQ Capital Market, the NASDAQ Global Market, the NASDAQ Global Select Market, the NYSE American or, in each case, any successor thereto.

“Parent Entity” of a Person means an entity that, directly or indirectly, controls the applicable Person and whose common stock or equivalent equity security is quoted or listed on an Eligible Market, or, if there is more than one such Person or Parent Entity, the Person or Parent Entity with the largest public market capitalization as of the date of consummation of a Major Transaction.

“Person” means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other entity and a government or any department or agency thereof.

“Standard Settlement Period” means the standard settlement period for equity trades effected on securities exchanges in the United States, expressed in a number of Trading Days, as in effect on the applicable Date of Exercise (as defined in Section 2(b)).

“Stock Event” means a stock split, stock combination, reclassification, payment of stock dividend, recapitalization or other similar transaction of such character that the shares of Common Stock shall be changed into or become exchangeable for a larger or small number of shares.

“Successor Entity” means any Person purchasing the Company’s assets or Common Stock, or any successor entity resulting from such Major Transaction, or if the Warrant is to be exercisable for shares of capital stock of a Parent Entity (as defined above), such Person’s Parent Entity.

“Successor Major Transaction” means either a Takeout Major Transaction or an Asset Sale.

“Successor Major Transaction Consideration” means (i) in the case of a Takeout Major Transaction (other than a Cash Out Major Transaction), the amount of cash and other assets and the number of securities or other property of the Successor Entity or other entity that would be issuable in such Major Transaction, in respect of a number of shares equal to the Successor Major Transaction Conversion Share Amount and (ii) in the case of an Asset Sale or a Cash Out Major Transaction, an amount of cash equal to the Black-Scholes Value of the Warrant.

 

3


“Successor Major Transaction Conversion Share Amount” means an amount equal to the Black-Scholes Value of the Warrant (or such applicable portion subject to a Successor Major Transaction Conversion), divided by the closing price of the Common Stock on the principal securities exchange or other securities market on which the Common Stock is then traded on the Trading Day immediately preceding the date on which the applicable Major Transaction is consummated.

“Takeout Major Transaction” means a transaction covered by the provisions of clause (A) of the definition of “Major Transaction” in which the shares of Common Stock of the Company are converted into the right to receive cash, securities of another entity and/or other assets.

“Trading Day” shall mean any day on which the Common Stock is traded for any period on the NASDAQ Global Select Market (“NasdaqGS”) or, if the NasdaqGS is not the principal trading market for the Common Stock, on the principal securities exchange or other securities market on which the Common Stock is then being traded; provided, however, that during any period in which the Common Stock is not listed or quoted on the NasdaqGS or any other securities exchange or market, the term “Trading Day” shall mean a Business Day.

2. Exercise .

(a) Manner of Exercise . During the Exercise Period (or, in respect of a Cashless Major Exercise, the Cashless Major Exercise Period (as defined below)), this Warrant may be Exercised as to all or any lesser number of whole shares of Common Stock covered hereby (the “Warrant Shares” or the “Shares”) by sending to the Company the Exercise Form attached hereto as Exhibit  A-1 (the “Exercise Form”) duly completed and executed, and, if applicable, the full Exercise Price (as defined below, which may be satisfied by a Cash Exercise, a Cashless Exercise or a Note Exchange Exercise, as each is defined below) for each share of Common Stock as to which this Warrant is Exercised, at the office of the Company, 2 Musick, Irvine, CA 92618, Attention: Chief Financial Officer; Phone: (949) 595-7200, Email: vmahboob@endologix.com, or at such other office or agency as the Company may designate in writing, by overnight mail or electronic mail (any such exercise of the Warrant being hereinafter called an “Exercise” of this Warrant).

(b) Date of Exercise . The “Date of Exercise” of the Warrant shall, in each case, be the date that the Exercise Form attached hereto as Exhibit  A-1 , completed and executed, is sent by electronic mail to the Company, provided that the Exercise Price is satisfied as soon as practicable thereafter but in no event later than two (2) Business Days following the date of such electronic mail. Alternatively, the Date of Exercise shall be defined as the date the original Exercise Form is received by the Company, if Holder has not previously sent the Exercise Form by electronic mail. Upon delivery of the Exercise Form to the Company by electronic mail or otherwise, Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been Exercised, irrespective of the date such Warrant Shares are credited to Holder’s or its designee’s Depository Trust Company (“DTC”) account or the date of delivery of the certificates evidencing such Warrant Shares, as the case may be; provided, however, that in the event an Exercise Form in respect of a Cashless Major Exercise is delivered prior to the occurrence of the applicable Major Transaction, Holder shall be deemed to have become the holder of record of the shares issuable upon such exercise immediately prior to the consummation of such Major Transaction and the Date of Exercise shall

 

4


in such event be deemed to have occurred on the date of the occurrence of the Major Transaction. Holder shall not be required to physically surrender this Warrant to the Company until Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days following the date the final Exercise Form is delivered to the Company. Execution and delivery of an Exercise Form with respect to a partial Exercise shall have the same effect as cancellation of the original Warrant and issuance of a new Warrant evidencing the right to purchase the remaining number of Warrant Shares.

(c) Delivery of Common Stock Upon Exercise . Within the earlier of (x) two (2) Trading Days and (y) the number of Trading Days comprising the Standard Settlement Period after any Date of Exercise (but, in the case of a Cash Exercise, within two (2) Business Days following the Company’s receipt of the full Exercise Price, if later) or in the case of a Cashless Default Exercise (as defined in Section 5(b) below), within the period provided in Section 3(c), as applicable (the “Delivery Period”), the Company shall issue and deliver (or cause its transfer agent (the “Transfer Agent”) to issue and deliver) in accordance with the terms hereof to or upon the order of Holder that number of shares of Common Stock (“Exercise Shares”) for the portion of this Warrant exercised as shall be determined in accordance herewith. Upon the Exercise of this Warrant or any part hereof, the Company shall, at its own cost and expense, take all necessary action, including obtaining and delivering an opinion of counsel, to assure that the Transfer Agent shall issue stock certificates in the name of Holder (or its nominee) or such other persons as designated by Holder and in such denominations as Holder shall specify at Exercise, representing the number of shares of Common Stock issuable upon such Exercise. The Company warrants that no instructions other than these instructions have been or will be given to the Transfer Agent and that, unless waived by Holder, this Warrant and the Exercise Shares will be free-trading, and freely transferable, and will not contain or be subject to a legend (or be subject to any stop transfer instruction) restricting the resale or transferability of the Exercise Shares if the Unrestricted Conditions (as defined below) are met.

The Company shall be responsible for paying all present or future stamp, court or documentary, intangible, recording, filing or similar taxes that arise from any payment or issuance made under, from the execution, delivery, performance or enforcement of, or otherwise with respect to, this Warrant.

(d) Delivery Failure . In addition to any other remedies which may be available to Holder, in the event that the Company fails for any reason to effect delivery of the Exercise Shares by the end of the Delivery Period (a “Delivery Failure”), Holder will be entitled to revoke all or part of the relevant Exercise by delivery of a notice to such effect to the Company whereupon the Company and Holder shall each be restored to their respective positions immediately prior to the delivery of such notice of revocation, except that the Failure Payments under Section 10(b) shall be payable through the date such notice of revocation is given to the Company.

(e) Legends .

(i) Restrictive Legend . Holder understands that until such time as this Warrant, the Exercise Shares and the Failure Payment Shares (as defined below) have been registered under the Securities Act or otherwise may be sold pursuant to Rule 144 or an exemption from registration

 

5


under the Securities Act without any restriction as to the number of securities as of a particular date that can then be immediately sold, this Warrant, the Exercise Shares and the Failure Payment Shares, as applicable, may bear a restrictive legend in substantially the following form (and a stop-transfer order consistent therewith may be placed against transfer of the certificates for such securities):

“THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER SAID ACT, EXCEPT PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER SAID ACT INCLUDING PURSUANT TO SECTION 4(A)(7) OF THE SECURITIES ACT OR RULE 144 UNDER SAID ACT OR PURSUANT TO A PRIVATE SALE EFFECTED UNDER APPLICABLE FORMAL OR INFORMAL SEC INTERPRETATION OR GUIDANCE, SUCH AS A SO-CALLED “4[(a)](1) AND A HALF” SALE.” NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

“THE SALE, TRANSFER OR ASSIGNMENT OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO THE TERMS AND CONDITIONS OF A CERTAIN AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT DATED AS OF AUGUST 9, 2018, AS AMENDED FROM TIME TO TIME, AMONG THE COMPANY AND CERTAIN HOLDERS OF ITS OUTSTANDING SECURITIES. COPIES OF SUCH AGREEMENT MAY BE OBTAINED AT NO COST BY WRITTEN REQUEST MADE BY THE HOLDER OF RECORD OF THIS CERTIFICATE TO THE SECRETARY OF THE COMPANY.”

(ii) Removal of Restrictive Legends . This Warrant and the certificates (or electronic book entries, if applicable) evidencing the Exercise Shares and the Failure Payment Shares, as applicable, shall not contain or be subject to any legend restricting the transfer thereof (including the legend set forth above in subsection 2(e)(i)) or be subject to any stop-transfer instructions: (A) while a registration statement (including a Registration Statement, as defined in the Registration Rights Agreement) covering the sale or resale of such security is effective under the Securities Act, or (B) following any sale of such Warrant, Exercise Shares and/or Failure Payment Shares pursuant to Rule 144, or (C) if such Warrant, Exercise Shares and/or Failure Payment Shares are eligible for sale under Rule 144(b)(1), or (D) at any time on or after the date hereof on which Holder’s holding period for purposes of Rule 144 under the Securities Act and subsection (d)(3)(iii) thereof with respect to such Warrant, Exercise Shares and/or Failure Payment Shares is at least six (6) months and Holder certifies that it is not an “affiliate” (as defined in Rule 144 under the Securities Act), or (E) if such legend is not required under applicable requirements of the

 

6


Securities Act (including judicial interpretations and pronouncements issued by the staff of the SEC) (collectively, the “Unrestricted Conditions”). The Company shall cause its counsel to issue a legal opinion to the Transfer Agent promptly after the Effective Date, or at such other time as any of the Unrestricted Conditions have been met, if required by the Transfer Agent to effect the issuance of this Warrant, the Exercise Shares or the Failure Payment Shares, as applicable, without a restrictive legend or removal of the legend hereunder. If any of the Unrestricted Conditions are met at the time of issuance of this Warrant, the Exercise Shares or the Failure Payment Shares, then such Warrant, Exercise Shares or Failure Payment Shares, as applicable, shall be issued free of all legends and stop-transfer instructions. The Company agrees that following the Effective Date, or at such time as the Unrestricted Conditions are met or such legend is otherwise no longer required under this Section 2(e), it will, no later than the earlier of (x) two (2) Trading Days and (y) the number of Trading Days comprising the Standard Settlement Period following the delivery (the “Unlegended Shares Delivery Deadline”) by Holder to the Company or the Transfer Agent of this Warrant and a certificate representing Exercise Shares and/or Failure Payment Shares, as applicable, issued with a restrictive legend, deliver or cause to be delivered to Holder this Warrant and/or a certificate (or electronic transfer) representing such shares that is free from all restrictive and other legends (and stop transfer instructions). For purposes hereof, “Effective Date” shall mean the date that the first Registration Statement that the Company is required to file pursuant to the Registration Rights Agreement has been declared effective by the SEC.

(iii) Sale of Unlegended Shares . Holder agrees that the removal of the restrictive legend from this Warrant and any certificates representing securities as set forth in Section 2(e) above is predicated upon the Company’s reliance that Holder will sell this Warrant or any Exercise Shares and/or any Failure Payment Shares, as applicable, pursuant to either the registration requirements of the Securities Act, including any applicable prospectus delivery requirements, or an exemption therefrom, and that if such securities are sold pursuant to a Registration Statement, they will be sold in compliance with the plan of distribution set forth therein.

(f) Cancellation of Warrant . This Warrant shall be canceled upon the full Exercise of this Warrant, and, as soon as practical after the Date of Exercise, Holder shall be entitled to receive Common Stock for the number of shares purchased upon such Exercise of this Warrant, and if this Warrant is not Exercised in full, Holder shall be entitled to receive a new Warrant (containing terms identical to this Warrant) representing any unexercised portion of this Warrant in addition to such Common Stock; provided, however, as set forth in Section 2(b), Holder shall not be required to physically surrender this warrant if the Warrant is not Exercised in full.

(g) Holder of Record . Each person in whose name any Warrant for shares of Common Stock is issued shall, for all purposes, be deemed to be Holder of record of such shares on the Date of Exercise, irrespective of the date of delivery of the Common Stock purchased upon the Exercise of this Warrant. Prior to the exercise of this Warrant, nothing in this Warrant shall be construed as conferring upon Holder any rights as a stockholder of the Company.

(h) Delivery of Electronic Shares . In lieu of delivering physical certificates representing the Common Stock issuable upon Exercise or legend removal, or representing Failure Payment Shares, upon written request of Holder, the Company shall use its best efforts to cause the Transfer Agent to electronically transmit the Common Stock issuable upon Exercise to Holder

 

7


by crediting the account of Holder’s prime broker with DTC through its Deposit/Withdrawal at Custodian (DWAC) system. The time periods for delivery and penalties described herein shall apply to the electronic transmittals described herein. Any delivery not effected by electronic transmission shall be effected by delivery of physical certificates.

(i) Buy-In . In addition to any other rights or remedies available to Holder hereunder or otherwise at law or in equity, if the Company fails to cause its Transfer Agent to deliver to Holder a certificate or certificates, or electronic shares through DWAC, representing the Exercise Shares pursuant to an Exercise on or before the last day of the Delivery Period (other than a failure caused by any incorrect or incomplete information provided by Holder to the Company hereunder), and if after such date Holder is required by its broker to purchase (in an open market transaction or otherwise) or Holder or Holder’s brokerage firm otherwise purchases shares of Common Stock to deliver in satisfaction of a sale by Holder of the Exercise Shares which Holder was entitled to receive upon such Exercise (a “Buy-In”), then the Company shall (1) pay in cash to Holder the amount by which (x) Holder’s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (A) the number of Exercise Shares that the Company was required to deliver to Holder in connection with the Exercise at issue by (B) the price at which the sell order giving rise to such purchase obligation was executed, and (2) at the option of Holder, either reinstate the portion of the Warrant and equivalent number of Exercise Shares for which such Exercise was not honored (and refund the Exercise Price therefor, to the extent paid by Holder, and/or reinstate the principal amount of any indebtedness used to satisfy the applicable Exercise Price) or deliver to Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its Exercise and delivery obligations hereunder. For example, if Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted Exercise to cover the sale of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (1) of the immediately preceding sentence the Company shall be required to pay Holder $1,000. Holder shall provide the Company written notice indicating the amounts payable to Holder in respect of the Buy-In, together with applicable confirmations and other evidence reasonably requested by the Company. Nothing herein shall limit Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver certificates representing shares of Common Stock upon Exercise of the Warrant as required pursuant to the terms hereof.

(j) HSR Submissions. If Holder determines that, in connection with the exercise of this Warrant, it and the Company are required to file Premerger Notification Reports with the Federal Trade Commission (the “FTC”) and the United States Department of Justice (“DOJ”) and observe the Waiting Period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended, and the related rules and regulations promulgated thereunder (collectively, the “HSR Act”), the Company agrees to (i) cooperate with Holder in Holder’s preparing and making such submission and any responses to inquiries of the FTC and DOJ; (ii) prepare and make any submission required to be filed by the Company under the HSR Act and respond to inquiries of the FTC and DOJ in connection therewith; and (iii) reimburse Holder for the cost of the required filing fee for Holder’s submission under the HSR Act. For the avoidance of doubt, Holder shall bear all of its other costs and expenses in connection with such submission, including any attorneys’ fees associated therewith.

 

8


3. Payment of Warrant Exercise Price for Cash Exercise or Cashless Exercise; Cashless Major Exercise and Cashless Default Exercise .

(a) Exercise Price . The exercise price shall initially equal $4.71 per share, subject to adjustment pursuant to the terms hereof (as so adjusted, the “Exercise Price”), including but not limited to Section 5 below.

Payment of the Exercise Price may be made by any of the following, or a combination thereof, at the election of Holder:

(i) Cash Exercise : Holder may exercise this Warrant in cash, bank or cashier’s check or wire transfer (a “Cash Exercise”);

(ii) Cashless Exercise : In lieu of paying all or any portion of the Exercise Price in cash, Holder, at its option, may exercise this Warrant (in whole or in part) on a cashless basis by making appropriate notation on the applicable Exercise Form, in which event the Company shall issue Holder a number of shares of Common Stock computed using the following formula (a “Cashless Exercise”):

X = Y (A-B)/A

where:    X = the number of shares of Common Stock to be issued to Holder.

Y = the number of shares of Common Stock for which this Warrant is being Exercised.

A = the Market Price of one (1) share of Common Stock (for purposes of this Section 3(a)(ii), where “Market Price,” as of any date, means the arithmetic average of the Volume Weighted Average Price (as defined below) of the Company’s Common Stock on each of the ten (10) consecutive Trading Days immediately preceding the date in question).

B = the Exercise Price.

As used herein, the “ Volume Weighted Average Price ” for any security as of any date means the volume weighted average sale price on the NasdaqGS as reported by, or based upon data reported by, Bloomberg Financial Markets or an equivalent, reliable reporting service mutually acceptable to and hereafter designated by the Holder and the Company (“ Bloomberg ”), or, if the NasdaqGS is not the principal trading market for such security, the volume weighted average sale price of such security on the principal securities exchange or trading market where such security is listed or traded as reported by Bloomberg, or, if no volume weighted average sale price is reported for such security, then the last closing trade price of such security as reported by Bloomberg, or, if no last closing trade price is reported for such security by Bloomberg, the average of the bid prices of any market makers for such security on the OTC Bulletin Board, the OTCQX Market, the OTCQB Market or the “pink” market of OTC Markets Group. If the Volume Weighted Average Price cannot be calculated for such security on such date in the manner provided above, the Volume Weighted Average Price shall be the fair market value as determined by the Company and the Holder. In the event that a Stock Event is

 

9


consummated during any period for which the arithmetic average of the Volume Weighted Average Prices is to be determined (under this Section or otherwise), the Volume Weighted Average Price for all Trading Days during such period prior to the effectiveness of the Stock Event shall be appropriately adjusted to reflect such Stock Event.

(iii) Note Exchange Exercise: In lieu of paying all or any portion of the Exercise Price in cash, Holder, at its option, may exercise this Warrant (in whole or in part) through a reduction of an amount of principal outstanding under any First Out Waterfall Notes in accordance with Section 2.3(b) of the Facility Agreement, then held by Holder (a “Note Exchange Exercise”)

For purposes of Rule 144 and subsection (d)(3)(ii) thereof, it is intended, understood and acknowledged that (x) this Warrant shall be deemed to have been acquired on April 3, 2017 (the date the First Out Waterfall Notes were originally issued), and (y) the shares of Common Stock issuable upon Exercise of this Warrant in a Cashless Exercise (including a Cashless Major Exercise or Cashless Default Exercise) transaction or a Note Exchange Exercise transaction shall be deemed to have been acquired on April 3, 2017. Accordingly, (A) upon any such Exercise, the Rule 144 holding period for the shares of Common Stock issued thereupon shall be in excess of one (1) year, and (B) provided that Holder is not an “affiliate” (as defined in Rule 144 under the Securities Act) of the Company on the date of such Exercise (which the Company shall assume unless advised otherwise in writing by Holder), an Unrestricted Condition shall be satisfied with respect to the shares of Common Stock issued thereupon and such shares will be freely transferable, without restriction or limitation (including any volume limitation or current public information requirement) under Federal or state securities laws, pursuant to Rule 144 under the Securities Act, and will not contain or be subject to a legend or stop transfer order restricting the resale or transferability of thereof.

As provided in Section 2(b), Holder shall only be required to physically surrender this Warrant in the event that Holder is exercising this Warrant in full.

(b) Cashless Major Exercise. To the extent Holder shall exercise this Warrant as a Cashless Major Exercise pursuant to Section 5(b)(i) and 5(b)(iii) below, Holder shall send to the Company (in any manner permitted under Section 2(a)) the Exercise Form indicating that Holder is exercising this Warrant (or any portion thereof) pursuant to a Cashless Major Exercise, in which event the Company shall issue a number of shares of Common Stock equal to the Black-Scholes Value of the Warrant (or such applicable portion being exercised) divided by the closing price of the Common Stock on the principal securities exchange or other securities market on which the Common Stock is then traded on the Trading Day immediately preceding the date on which the applicable Major Transaction is consummated, or, if in respect of a Cashless Major Exercise made after the date of consummation of the applicable Major Transaction, on the Trading Day immediately preceding the date on which the exercise form in respect of such Cashless Major Exercise is delivered. As provided in Section 2(b), Holder shall only be required to physically surrender this Warrant in the event that Holder is exercising this Warrant in full. Holder shall be permitted to make successive Cashless Major Exercises and send successive Exercise Forms in respect of a Cashless Major Exercise from time to time at any time during the Cashless Major Exercise Period.

 

10


(c) Cashless Default Exercise . To the extent Holder exercises this Warrant as a Cashless Default Exercise pursuant to Section 11(b)(i) below, Holder shall send to the Company (in any manner permitted under Section 2(a)) the Exercise Form indicating that Holder is exercising this Warrant pursuant to a Cashless Default Exercise, in which event the Company shall issue to Holder, within five (5) Trading Days of the applicable Default Notice, a number of shares of Common Stock (which shares shall be valued at the closing price of the Common Stock on the principal securities exchange or other securities market on which the Common Stock is then traded on the Trading Day immediately preceding the date on which the Exercise Form in respect of such Cashless Default Exercise is delivered) equal to the Black-Scholes Value of the remaining unexercised portion of this Warrant (or such portion thereof subject to such exercise) as of the date of such Default Notice (or in the case of an Event of Default referred to in Section 11(a)(vi), on the Trading Day immediately preceding the date the dividend or distribution is declared or, if not first declared, is paid). As provided in Section 2(b), the Holder shall be permitted to make successive Cashless Default Exercises and send successive Exercise Forms in respect of a Cashless Default Exercise, from time to time at any time from and after the date of the applicable Default Notice through the Exercise Period of this Warrant.

(d) Dispute Resolution . In the case of a dispute as to the determination of the closing price or the Volume Weighted Average Price of the Company’s Common Stock or the arithmetic calculation of the Exercise Price, Market Price or the Successor Major Transaction Consideration, or the number of shares issuable upon a Cashless Major Exercise, the Company shall submit the disputed determinations or arithmetic calculations via electronic mail within two (2) Business Days of receipt, or deemed receipt, of the Exercise Form or Major Transaction Early Termination Notice, or other event giving rise to such dispute, as the case may be, to Holder. If Holder and the Company are unable to agree upon such determination or calculation within two (2) Business Days of such disputed determination or arithmetic calculation being submitted to Holder, then the Company shall, within two (2) Business Days submit via electronic mail (i) the disputed determination of the closing price or the Volume Weighted Average Price of the Company’s Common Stock to an independent, reputable investment bank selected by the Company and approved by Holder, which approval shall not be unreasonably withheld, or (ii) the disputed arithmetic calculation of the Exercise Price, Market Price, any Successor Major Transaction Consideration or number of shares issuable upon a Cashless Major Exercise to the Company’s independent, outside registered public accountants. The Company shall use its reasonable best efforts to cause the investment bank or the accountants, as the case may be, to perform the determinations or calculations and notify the Company and Holder of the results no later than five (5) Trading Days from the time it receives the disputed determinations or calculations. Such investment bank’s or accountants’ determination or calculation, as the case may be, shall be binding upon all parties absent demonstrable error, and the Company and Holder shall each pay one half of the fees and costs of such investment banker or accountant. Notwithstanding the existence of a dispute contemplated by this paragraph, if requested by Holder, the Company shall issue to Holder the Exercise Shares not in dispute in accordance with the terms hereof.

4. Transfer and Registration .

(a) Transfer Rights . Subject to the provisions of Section 8 of this Warrant, this Warrant may be transferred on the books of the Company, in whole or in part, in person or by attorney, upon

 

11


surrender of this Warrant properly completed and endorsed. This Warrant shall be canceled upon such surrender and, as soon as practicable thereafter, the person to whom such transfer is made shall be entitled to receive a new Warrant or Warrants as to the portion of this Warrant transferred, and Holder shall be entitled to receive a new Warrant as to the portion hereof retained.

(b) Registrable Securities . The Common Stock issuable upon the Exercise of this Warrant entitles Holder (and applicable assignees or transferees of such Common Stock) to registration and other rights pursuant to the Registration Rights Agreement.

5. Adjustments Upon Certain Events .

(a) Recapitalization or Reclassification . If the Company shall at any time effect a stock split, payment of stock dividend, recapitalization, reclassification or other similar transaction of such character that the shares of Common Stock shall be changed into or become exchangeable for a larger or smaller number of shares, then upon the effective date thereof, the number of shares of Common Stock which Holder shall be entitled to purchase upon Exercise of this Warrant, shall be increased or decreased, as the case may be, in direct proportion to the increase or decrease in the number of shares of Common Stock by reason of such stock split, payment of stock dividend, recapitalization, reclassification or similar transaction, and the Exercise Price shall be, in the case of an increase in the number of shares, proportionally decreased and, in the case of decrease in the number of shares, proportionally increased. The Company shall give Holder the same notice it provides to holders of Common Stock of any transaction described in this Section 5(a).

(b) Rights Upon Major Transaction .

(i) Major Transaction . In the event that a Major Transaction occurs, then (1) in the case of a Successor Major Transaction, Holder, at its option, may elect to cause the conversion of this Warrant (a “Successor Major Transaction Conversion”), in whole or in part, into the right to receive the Successor Major Transaction Consideration, upon consummation of the Major Transaction, and (2) in the case of all other Major Transactions, Holder shall have the right to exercise this Warrant (or any portion thereof), at any time and from time to time following the occurrence of such event, as a Cashless Major Exercise. In the event Holder shall not have exercised any of its rights under clauses (1) or (2) above within the applicable time periods set forth herein, then the Major Transaction shall be treated as an Assumption (as defined below) in accordance with Section 5(b)(ii) below unless Holder waives its rights under this Section 5(b) with respect to such Major Transaction. Each of the following events shall constitute a “Major Transaction”:

(A) a consolidation, merger, exchange of shares, recapitalization, reorganization, business combination or other similar event, (1) following which the holders of Common Stock immediately preceding such consolidation, merger, exchange, recapitalization, reorganization, combination or event either (a) no longer hold a majority of the shares of Common Stock or (b) no longer have the ability to elect a majority of the board of directors of the Company or (2) as a result of which shares of Common Stock shall be changed into (or the shares of Common Stock become entitled to receive) the same or a different

 

12


number of shares of the same or another class or classes of stock or securities of the Company or another entity (collectively, a “Change of Control Transaction”);

(B) the sale or transfer, in one transaction or a series of related transactions, of (I) all or substantially all of the assets of the Company (including, for the avoidance of doubt, all or substantially all of the assets of the Company and its Subsidiaries, taken as a whole) to any Person other than a wholly-owned subsidiary of the Company or (II) assets of the Company (including, for the avoidance of doubt, all or substantially all of the assets of the Company and its Subsidiaries, taken as a whole) for a purchase price equal to more than 50% of the Equity Value (as defined below) of the Company. For purposes of this clause (B), “Equity Value” shall mean (I) the product of (x) the number of issued and outstanding shares of Common Stock on the date the Company delivers the Major Transaction Notice (defined below) multiplied by (y) the per share closing price of the Common Stock on such date on the NasdaqGS as reported by, or based upon data reported by, Bloomberg or, if the NasdaqGS is not the principal trading market for such security, the closing sale price of such security on the principal securities exchange or trading market where such security is listed or traded as reported by Bloomberg;

(C) a purchase, tender or exchange offer made to the holders of outstanding shares of Common Stock, such that following such purchase, tender or exchange offer a Change of Control Transaction shall have occurred;

(D) the liquidation, bankruptcy, insolvency, dissolution or winding-up (or the occurrence of any analogous proceeding) affecting the Company;

(E) the shares of Common Stock cease to be listed, traded or publicly quoted on the NasdaqGS and are not promptly re-listed or requoted on the New York Stock Exchange, the NYSE American, the NASDAQ Global Market or the NASDAQ Capital Market; or

(F) the Common Stock ceases to be registered under Section 12 of the Exchange Act.

(ii) Assumption. Any assumption of Company obligations under this paragraph shall be referred to herein as an “Assumption.” Unless otherwise provided in writing by Holder, the Company shall not consummate a Major Transaction in which the Company is not the surviving entity or as a result of which the Company has a new Parent Entity, unless (A) each Person acquiring the Company’s assets or Common Stock (or Parent Entity thereof, as applicable), or any other successor entity resulting from such Major Transaction (in each case, a “Successor Entity”), assumes in writing all of the obligations of the Company under this Warrant, the Facility Agreement (but, other than with respect to the Company’s obligations pursuant to Section 5.1(e) and 5.1(p) of the Facility Agreement and the other provisions of the Facility Agreement that

 

13


expressly survive the repayment of the Loans (which shall be assumed in any Assumption), only if there are outstanding Loans under the Facility Agreement immediately following the consummation of the Major Transaction) and the Registration Rights Agreement in accordance with the provisions of this Section 5(b)(ii) pursuant to written agreements in form and substance reasonably satisfactory to Holder and approved by Holder prior to the consummation of such Major Transaction (such approval not to be unreasonably withheld or delayed), including agreements to deliver to Holder in exchange for its Warrants a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to the Warrants, that, among other things, (1) is exercisable for the appropriate number of shares of the Successor Entity’s capital stock (without regard to the 4.985% Cap or any other restriction or limitation on exercise, provided that such instrument shall contain a limitation on exercise comparable to that contained in the second paragraph of Section 1 of this Warrant); (2) has an exercise price similar to the then-effective Exercise Price (taking into account any conversion or exchange ratio applicable to the Common Stock in the Major Transaction) and exercise price adjustment provisions similar to those in the Warrants; (3) entitles Holder to such additional securities or other consideration as Holder would be entitled pursuant to Section 5(b)(i) in connection with the Major Transaction; and (4) provides for registration rights similar to those provided by the Registration Rights Agreement, in each case reasonably satisfactory to Holder, and (B) the Successor Entity (including its Parent Entity) is a publicly traded corporation whose common stock is quoted on or listed for trading on an Eligible Market. For the avoidance of doubt, Holder’s reasonable satisfaction referred to in the immediately preceding sentence shall be construed only to apply to confirmation that the warrant or other comparable security and registration rights agreement delivered to Holder upon an assumption hereunder shall conform to the requirements of this Section 5(b)(ii), and this Section 5(b)(ii) shall not be construed as granting consent or approval rights to Holder with respect to the terms of such Major Transaction or to permit Holder to demand any additional consideration in respect of this Warrant other than as provided herein. Upon the occurrence of any Major Transaction, any Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Major Transaction, the provisions of this Warrant and the Registration Rights Agreement referring to the “Company” shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company herein. Upon consummation of the Major Transaction, the Successor Entity shall deliver to Holder confirmation that there shall be issued upon exercise of this Warrant at any time after the consummation of the Major Transaction, in lieu of the shares of Common Stock (or other securities, cash, assets or other property) issuable upon the exercise of the Warrants prior to such Major Transaction, such shares of publicly traded common stock (or their equivalent) of the Successor Entity, as adjusted in accordance with the provisions of this Warrant. The provisions of this Section shall apply similarly and equally to successive Major Transactions and shall be applied without regard to any limitations on the exercise of this Warrant other than any applicable beneficial ownership limitations.

(iii) Major Transaction Notice; Major Transaction Early Termination Right; Notice of Cashless Major Exercise. At least thirty (30) days prior to the consummation of any Major Transaction, but, in any event, within five (5) Trading Days following the first to occur of (x) the date of the public announcement of such Major Transaction if such announcement is made before 4:00 p.m., New York City time, or (y) the day following the public announcement of such Major

 

14


Transaction if such announcement is made on and after 4:00 p.m., New York City time, the Company shall deliver written notice thereof via electronic mail and overnight courier to Holder (a “Major Transaction Notice”). At any time during the period beginning after Holder’s receipt of a Major Transaction Notice in respect of a Successor Major Transaction and ending five (5) Trading Days prior to the consummation of such Major Transaction (the “Early Termination Period”), Holder may elect a Successor Major Transaction Conversion by delivering written notice thereof (“Major Transaction Early Termination Notice”) to the Company, which Major Transaction Early Termination Notice shall indicate the portion of the Warrant (with reference to the number of shares of Common Stock issuable upon a Cash Exercise of such portion, without regard to the 4.985% Cap) that Holder is electing to be treated as a Successor Major Transaction Conversion. The portion of this Warrant subject to early termination pursuant to this Section 5(b)(iii), shall be converted into the right to receive the Successor Major Transaction Consideration

To the extent Holder shall elect to effect a Cashless Major Exercise in respect of a Major Transaction, Holder shall deliver its Exercise Form in accordance with Section 3(b), at any time and from time to time following receipt by Holder of the Major Transaction Notice until the later of (x) the last day of the Exercise Period and (y) the one-year anniversary of the applicable Major Transaction (the “Cashless Major Exercise Period”). For the avoidance of doubt, Holder shall be permitted to make successive Cashless Major Exercises and send successive Exercise Forms in respect of a Cashless Major Exercise from time to time at any time during the Cashless Major Exercise Period.

(iv) Escrow; Payment of Successor Major Transaction Consideration . Following the receipt of a Major Transaction Early Termination Notice in respect of a Successor Major Transaction from Holder, the Company shall not effect a Successor Major Transaction with respect to which Holder has elected a Successor Major Transaction Conversion unless either (A) it obtains, as a condition precedent to such Major Transaction, the written agreement of the Successor Entity that payment of the Successor Major Transaction Consideration shall be made to Holder concurrently with consummation of such Successor Major Transaction, or (B) it shall place the Successor Major Transaction Consideration into an escrow account with an independent escrow agent, and shall instruct the escrow agent to deliver the Successor Major Transaction Consideration to Holder, concurrently with the consummation of the Major Transaction. Notwithstanding clauses (A) and (B) above, Holder shall be treated on a pari passu basis with, and shall not have priority to payments to, the holders of Common Stock in connection with a Major Transaction. For purposes of determining the amount required to be placed in escrow pursuant to the provisions of this subsection (iv) and without affecting the amount of the actual Successor Major Transaction Consideration, the calculation of the price referred to in clause (1) of the first column of Schedule 1 hereto with respect to Stock Price shall be determined based on the Closing Market Price (as defined on Schedule 1) of the Common Stock on the Trading Day immediately preceding the date that the Successor Major Transaction Consideration is deposited with the escrow agent.

(v) Injunction . Following the receipt of a Major Transaction Early Termination Notice from Holder, in the event that the Company attempts to consummate a Successor Major Transaction without either (1) placing the Successor Major Transaction Consideration in escrow in accordance with subsection (iv) above, or (2) obtaining the written agreement of the Successor

 

15


Entity as described in subsection (iv) above, Holder shall have the right to apply for an injunction in any state or federal court sitting in the City of New York, borough of Manhattan to prevent the closing of such Major Transaction until the Successor Major Transaction Consideration is delivered to Holder.

An early termination required by this Section 5(b) shall be made in accordance with the provisions of Section 12. To the extent an early termination required by this Section 5(b) is deemed or determined by a court of competent jurisdiction to be prepayments of the Warrant by the Company, such early termination shall be deemed to be voluntary prepayments. Notwithstanding anything to the contrary in this Section 5, until the Successor Major Transaction Consideration is paid in full, this Warrant may be exercised, in whole or in part, by Holder into shares of Common Stock, or in the event the date of any Exercise is after the consummation of the Major Transaction, shares of publicly traded common stock (or their equivalent) of the Successor Entity pursuant to Section 5(b). The parties hereto agree that in the event of the Company’s early termination of any portion of the Warrant under this Section 5(b), Holder’s damages would be uncertain and difficult to estimate because of the parties’ inability to predict future interest rates and the uncertainty of the availability of a suitable substitute investment opportunity for Holder. Accordingly, any premium due under this Section 5(b) is intended by the parties to be, and shall be deemed, a commercially reasonable estimate of Holder’s actual loss of its investment opportunity and not as a penalty.

(c) Exercise Price Adjusted . As used in this Warrant, the term “Exercise Price” shall mean the purchase price per share specified in Section 3(a) of this Warrant, until the occurrence of an event stated in this Section 5 or otherwise set forth in this Warrant, and thereafter shall mean said price as adjusted from time to time in accordance with the provisions of said subsection. No adjustment made pursuant to any provision of this Section 5 shall have the net effect of increasing the aggregate Exercise Price payable hereunder or, except as expressly provided in Section 5(a), otherwise increasing the Exercise Price.

(d) Adjustments: Additional Shares, Securities or Assets . In the event that at any time, as a result of an adjustment made pursuant to this Section 5 or otherwise, Holder shall, upon Exercise of this Warrant, become entitled to receive shares and/or other securities or assets (other than Common Stock) then, wherever appropriate, all references herein to shares of Common Stock shall be deemed to refer to and include such shares and/or other securities or assets; and thereafter the number of such shares and/or other securities or assets shall be subject to adjustment from time to time in a manner and upon terms as nearly equivalent as practicable to the provisions of this Section 5.

(e) Notice of Adjustments . Whenever the Exercise Price and/or number or type of securities issuable upon Exercise is adjusted pursuant to the terms of this Warrant, the Company shall promptly mail to Holder a notice (an “Exercise Price Adjustment Notice”) setting forth the Exercise Price and/or number or type of securities issuable upon Exercise after such adjustment and setting forth a statement of the facts requiring such adjustment. The Company shall, upon the written request at any time of Holder, furnish to Holder a like Warrant setting forth (i) such adjustment or readjustment, (ii) the Exercise Price at the time in effect and (iii) the number of shares of Common Stock and the amount, if any, of other securities or property which at the time would be received upon Exercise of the Warrant. For purposes of clarification, whether or not

 

16


the Company provides an Exercise Price Adjustment Notice pursuant to this Section 5(e), upon the occurrence of any event that leads to an adjustment of the Exercise Price, Holder would be entitled to receive a number of Exercise Shares based upon the new Exercise Price, as adjusted, for exercises occurring on or after the date of such adjustment, regardless of whether Holder accurately refers to the adjusted Exercise Price in the Exercise Form.

6. Fractional Interests .

No fractional shares or scrip representing fractional shares shall be issuable upon the Exercise of this Warrant, but on Exercise of this Warrant, Holder may purchase only a whole number of shares of Common Stock. If, on Exercise of this Warrant, Holder would be entitled to a fractional share of Common Stock or a right to acquire a fractional share of Common Stock, such fractional share shall be disregarded and the number of shares of Common Stock issuable upon Exercise shall be the next higher whole number of shares.

7. Reservation of Shares .

From and after the date hereof, the Company shall at all times reserve for issuance such number of authorized and unissued shares of Common Stock (or other securities substituted therefor as herein above provided) as shall be sufficient for the Exercise of this Warrant and payment of the Exercise Price. If at any time the number of shares of Common Stock authorized and reserved for issuance is below the number of shares sufficient for the Exercise of this Warrant (a “Share Authorization Failure”) (based on the Exercise Price in effect from time to time), the Company will promptly take all corporate action necessary to authorize and reserve a sufficient number of shares, including calling a special meeting of stockholders to authorize additional shares to meet the Company’s obligations under this Section 7, in the case of an insufficient number of authorized shares, and using its best efforts to obtain stockholder approval of an increase in such authorized number of shares. The Company covenants and agrees that upon the Exercise of this Warrant, all shares of Common Stock issuable upon such Exercise shall be duly and validly issued, fully paid and nonassessable and not subject to preemptive rights, rights of first refusal or similar rights of any Person. The Company covenants and agrees that all shares of Common Stock issuable upon Exercise of this Warrant shall be approved for listing on the NasdaqGS, or, if the NasdaqGS is not the principal trading market for the Common Stock, such principal market on which the Common Stock is traded or listed.

8. Restrictions on Transfer .

(a) Registration or Exemption Required . This Warrant has been issued in a transaction exempt from the registration requirements of the Securities Act by virtue of Section 4(a)(2) of the Securities Act and Rule 506 thereunder and exempt from registration or qualification under applicable state securities (or “blue sky”) laws. None of the Warrant, the Exercise Shares or Failure Payment Shares may be pledged, transferred, sold or assigned except pursuant to an effective registration statement or an exemption to the registration requirements of the Securities Act and applicable state laws, including Rule 144 under the Securities Act, Section 4(a)(7) of the Securities Act or a so-called “4[(a)](1) and a half” transaction.

(b) Assignment . Subject to Section 8(a), Holder may sell, transfer, assign, pledge, or otherwise dispose of this Warrant, in whole or in part. Holder shall deliver a written notice to the

 

17


Company, substantially in the form of the Assignment attached hereto as Exhibit  B , indicating the Person or Persons to whom the Warrant shall be assigned and the respective number of warrants to be assigned to each assignee. The Company shall effect the assignment within three (3) Business Days of its receipt of a completed and executed form of Assignment (the “Transfer Delivery Period”), and shall deliver to the assignee(s) designated by Holder a Warrant or Warrants of like tenor and terms entitling Holder to purchase the appropriate number of shares. This Warrant and the rights evidenced hereby shall inure to the benefit of and be binding upon the successors and assigns of Holder. The provisions of this Warrant are intended to be for the benefit of all Holders from time to time of this Warrant, and shall be enforceable by any such Holder. For avoidance of doubt, in the event Holder notifies the Company that such sale or transfer is a so called “4[(a)](1) and half” transaction, the parties hereto agree that a legal opinion from outside counsel for Holder delivered to counsel for the Company substantially in the form attached hereto as Exhibit  C shall be the only requirement to satisfy an exemption from registration under the Securities Act to effectuate such “4[(a)](1) and half” transaction.

9. Noncircumvention .

The Company hereby covenants and agrees that the Company will not, by amendment of its certificate of incorporation, bylaws or through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issue or sale of securities, or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, and will at all times in good faith carry out all the provisions of this Warrant and take all action as may be required to protect the rights of Holder. Without limiting the generality of the foregoing, the Company (i) shall not increase the par value of any shares of Common Stock receivable upon the exercise of this Warrant above the Exercise Price then in effect, and (ii) shall take all such actions as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable shares of Common Stock upon the exercise of this Warrant.

10. Events of Failure; Definition of Black Scholes Value .

(a) Definition.

The occurrence of each of the following shall be considered to be an “Event of Failure.”

(i) A Delivery Failure occurs, where a “Delivery Failure” shall be deemed to have occurred if the Company fails to use its best efforts to deliver Exercise Shares to Holder within any applicable Delivery Period (other than due to the limitation contained in the second paragraph of Section 1);

(ii) A Legend Removal Failure occurs, where a “Legend Removal Failure” shall be deemed to have occurred if the Company fails to use its best efforts to issue this Warrant and/or Exercise Shares without a restrictive legend, or fails to use it best efforts to remove a restrictive legend, when and as required under Section 2(e) hereof;

(iii) a Transfer Delivery Failure occurs, where a “Transfer Delivery Failure” shall be deemed to have occurred if the Company fails to use its best efforts to deliver a Warrant within any applicable Transfer Delivery Period; and

(iv) a Registration Failure (as defined below).

 

18


For purpose hereof, “Registration Failure” means that (A) the Company fails to file with the SEC on or before the Additional Warrant Filing Deadline (as defined in the Registration Rights Agreement) any Registration Statement required to be filed pursuant to Section 2(a) of the Registration Rights Agreement, (B) the Company fails to use its reasonable best efforts to obtain effectiveness with the SEC, prior to the Additional Warrant Registration Deadline (as defined in the Registration Rights Agreement), and if such Registration Statement does not become effective prior to the Additional Warrant Registration Deadline, as soon as possible thereafter, of any Registration Statement (as defined in the Registration Rights Agreement) that is required to be filed pursuant to Section 2(a) of the Registration Rights Agreement, or fails to use its reasonable best efforts to keep such Registration Statement current and effective as required in Section 3 of the Registration Rights Agreement, (C) the Company fails to file any additional Registration Statement required to be filed pursuant to Section 2(a)(ii) of the Registration Rights Agreement on or before the Additional Filing Deadline (as defined in the Registration Rights Agreement) or fails to use its reasonable best efforts to cause such new Registration Statement to become effective on or before the Additional Registration Deadline (as defined in the Registration Rights Agreement), and if such effectiveness does not occur within such period, as soon as possible thereafter, (D) the Company fails to file any amendment to any Registration Statement, or any additional Registration Statement required to be filed pursuant to Section 3(b) of the Registration Rights Agreement within thirty (30) days of the applicable Registration Trigger Date (as defined in the Registration Rights Agreement), or fails to use its reasonable best efforts to cause such amendment and/or new Registration Statement to become effective within ninety (90) days of the applicable Registration Trigger Date, and, if such effectiveness does not occur within such period, as soon as possible thereafter, (E) any Registration Statement required to be filed under the Registration Rights Agreement, after its initial effectiveness and during the applicable Registration Period (as defined in the Registration Rights Agreement), lapses in effect or, other than on a day during an Allowable Grace Period (as defined in the Registration Rights Agreement), sales of all of the Registrable Securities (as defined in the Registration Rights Agreement) cannot otherwise be made thereunder (whether by reason of the Company’s failure to amend or supplement the prospectus included therein in accordance with the Registration Rights Agreement, the Company’s failure to file and use its reasonable best efforts to obtain effectiveness with the SEC of an additional Registration Statement or amended Registration Statement required pursuant to Section 2(a)(ii) or 3(b) of the Registration Rights Agreement, as applicable, or otherwise), or (F) the Company fails to provide a commercially reasonable written response to any comments to any Registration Statement submitted by the SEC within twenty-five (25) days of the date that such SEC comments are received by the Company.

(b) Failure Payments; Black-Scholes Determination. The Company understands that any Event of Failure (as defined above) could result in economic loss to Holder. In the event that any Event of Failure occurs, as compensation to Holder for such economic loss, the Company agrees to pay to Holder an amount payable, at the Company’s option, either (i) in cash or (ii) in shares of Common Stock that are valued for these purposes at the Volume Weighted Average Price on the date of such calculation (“Failure Payments” and such shares, “Failure Payment Shares”), in each case equal to the total economic loss of Holder determined on a commercially reasonable basis in connection with such Event of Failure for the relevant period (as recalculated on the first Business Day of each month thereafter for as long as Failure Payments shall continue to accrue) from the date of such Event of Failure until the Event of Failure is cured; provided, however, that in the event the Company elects to make Failure Payments in Failure Payment Shares, the

 

19


Company shall issue, and Holder shall only receive, up to such number of shares of Common Stock in respect of Failure Payments such that Holder and any other persons or entities whose beneficial ownership of Common Stock would be aggregated with Holder’s for purposes of Section 13(d) of the Exchange Act (including shares held by any “group” of which Holder is a member, but excluding shares beneficially owned by virtue of the ownership of securities or rights to acquire securities that have limitations on the right to convert, exercise or purchase similar to the limitation set forth herein) shall not collectively beneficially own greater than 4.985% of the total number of shares of Common Stock of the Company then issued and outstanding, and the balance of such Failure Payments shall be paid in cash. For purposes of clarification, it is agreed and understood that Failure Payments shall continue to accrue following any Event of Default until the applicable Default Amount is paid in full. The Company shall satisfy any Failure Payments under this Section pursuant to Section 10(c) below. Failure Payments are in addition to any Shares that Holder is entitled to receive upon Exercise of this Warrant.

(c) Payment of Accrued Failure Payments. The Failure Payments and Failure Payment Shares representing accrued Failure Payments for each Event of Failure shall be paid or issued and delivered, as the case may be, on or before the fifth (5th) Business Day of each month following a month in which Failure Payments accrued. Nothing herein shall limit Holder’s right to pursue actual damages (to the extent in excess of the Failure Payments) for the Company’s Event of Failure, and Holder shall have the right to pursue all remedies available at law or in equity (including a decree of specific performance and/or injunctive relief). Notwithstanding the above, if a particular Event of Failure results in an Event of Default pursuant to Section 11 hereof, then the Failure Payment, for that Event of Failure only, shall be considered to have been satisfied upon payment to Holder of an amount equal to the greater of (i) the Failure Payment, or (ii) the Default Amount, payable in accordance with Section 11.

(d) Maximum Interest Rate. Nothing contained herein or in any document referred to herein or delivered in connection herewith shall be deemed to establish or require the payment of a rate of interest or other charges in excess of the maximum permitted by applicable law. In the event that the rate of interest or dividends required to be paid or other charges hereunder exceed the maximum permitted by such law, any payments in excess of such maximum shall be credited against amounts owed by the Company to Holder and thereby refunded to the Company.

11. Default .

(a) Events Of Default . Each of the following events shall be considered to be an “Event of Default,” unless waived by Holder:

(i) Failure To Effect Registration. With respect to all Registration Failures, a Registration Failure occurs and remains uncured for a period of more than forty-five (45) days (or sixty (60) days in the case where the Company (i) has, by the Filing Deadline (as defined the Registration Rights Agreement) filed a Registration Statement (as defined in the Registration Rights Agreement) covering this Warrant and the number of shares required by the Registration Rights Agreement, and (ii) has responded in writing to any comments to the Registration Statement that the Company has received from the SEC, within ten (10) Business Days of such receipt, and nevertheless the SEC has not declared effective a Registration Statement covering the this

 

20


Warrant and the Shares by the Registration Deadline (as defined in the Registration Rights Agreement)), and such Registration Failure relates solely to the Company’s failure to have the Registration Statement declared effective by the Registration Deadline (as defined in the Registration Rights Agreement) and with respect to a Registration Failure provided in clause (E) of the definition of “Registration Failure,” such Registration Failure occurs and remains uncured for a period of more than forty-five (45) days.

(ii) Failure To Deliver Common Stock . A Delivery Failure (as defined above) occurs and remains uncured for a period of more than twenty (20) days; or at any time, the Company announces or states in writing that it will not honor its obligations to issue shares of Common Stock to Holder upon Exercise by Holder of the Exercise rights of Holder in accordance with the terms of this Warrant.

(iii) Legend Removal Failure . A Legend Removal Failure (as defined above) occurs and remains uncured for a period of twenty (20) days;

(iv) Transfer Delivery Failure . A Transfer Delivery Failure (as defined above) occurs and remains uncured for a period of twenty (20) days;

(v) Corporate Existence; Major Transaction . (A) The Company has failed to (1) place the Successor Major Transaction Consideration into escrow and instruct the escrow agent to release the Successor Major Transaction Consideration to the Holder pursuant to Section 5(b)(iii), or (2) obtain the written agreement of the Successor Entity and cause the Successor Entity to make payment as described in Section 5(b)(iii), (B) the Successor Major Transaction Consideration is not paid contemporaneously with the consummation of the Successor Major Transaction, or (C) with respect to a Major Transaction that is to be treated as an Assumption under the terms hereof, the Company has failed to meet the Assumption requirements of Section 5(b)(i); or

(vi) Section  13 Breach . During the Dividend Restriction Period, the Company declares or pays any dividend or distribution of any kind to the holders of Common Stock of the Company.

(b) Mandatory Early Termination .

(i) Mandatory Early Termination Amount; Cashless Default Exercise . The Company shall notify Holder in writing within two (2) Business Days of the occurrence of an Event of Default. If any Events of Default shall occur then, at the option of Holder, such option exercisable through the delivery of written notice to the Company by such Holder (the “Default Notice”), the Company shall have the right to terminate the outstanding amount of this Warrant and pay to Holder (a “Mandatory Early Termination”), in full satisfaction of its obligations hereunder by delivery of a notice to such effect to Holder within two (2) Business Days following receipt of the Default Notice, an amount payable in cash (the “Mandatory Early Termination Amount” or the “Default Amount”) equal to the Black-Scholes Value of the remaining unexercised portion of this Warrant on the date of such Default Notice (or in the case of an Event of Default referred to in Section 11(a)(vi), on the Trading Day immediately preceding the date the dividend or distribution is declared or, if not first declared, is paid). In the event the Company does not exercise its right to consummate a Mandatory Early Termination, then Holder shall have the right to exercise this Warrant, at any time and from time to time, pursuant to a Cashless Default Exercise in accordance with Section 3(c) above.

 

21


The Mandatory Early Termination Amount shall be payable within five (5) Business Days following the date of the applicable Default Notice.

(ii) Liquidated Damages . The parties hereto acknowledge and agree that the sums payable as Failure Payments or pursuant to a Mandatory Early Termination shall constitute partial liquidated damages and not penalties. The parties further acknowledge that (i) the amount of loss or damages likely to be incurred by Holder is incapable or is difficult to precisely estimate, (ii) the amounts specified bear a reasonable proportion and are not plainly or grossly disproportionate to the probable loss likely to be incurred by Holder, and (iii) the parties are sophisticated business parties and have been represented by sophisticated and able legal and financial counsel and negotiated this agreement at arm’s length.

Upon the occurrence of an Event of Default, the Default Amount, together with all other amounts payable hereunder, shall immediately become due and payable, all without demand, presentment or notice, all of which hereby are expressly waived, together with all costs, including legal fees and expenses, of collection, and Holder shall be entitled to exercise all other rights and remedies available at law or in equity.

(c) Posting Of Bond . In the event that any Event of Default occurs hereunder, the Company may not raise as a legal defense (in any Lawsuit, as defined below, or otherwise) or justification to such Event of Default any claim that such Holder or any one associated or affiliated with such Holder has been engaged in any violation of law, unless the Company has posted a surety bond (a “Surety Bond”) for the benefit of such Holder in the amount of 130% of the aggregate Surety Bond Value (as defined below) of all of Holder’s Warrants (the “Bond Amount”), which Surety Bond shall remain in effect until the completion of litigation of the dispute and the proceeds of which shall be payable to such Holder to the extent Holder obtains judgment.

For purposes hereof, a “Lawsuit” shall mean any lawsuit, arbitration or other dispute resolution filed by either party herein pertaining to any of this Warrant, the Facility Agreement, the Registration Rights Agreement or any other Loan Document (as defined in the Facility Agreement).

“Surety Bond Value,” for the Warrants shall mean 130% of the of the Black-Scholes Value of the remaining unexercised portion of this Warrant on the Trading Day immediately preceding the date that such bond goes into effect.

(d) Injunction And Posting Of Bond . In the event that the Event of Default referred to in subsection (a) of this Section 11 pertains to the Company’s failure to deliver unlegended shares of Common Stock to Holder pursuant to a Warrant Exercise, legend removal request, or otherwise, the Company may not refuse such unlegended share delivery based on any claim that such Holder or any one associated or affiliated with such Holder has been engaged in any violation of law, unless an injunction from a court, on prior notice to Holder, restraining and or enjoining Exercise of all or part of said Warrant shall have been sought and obtained by the Company and the Company has posted a Surety Bond for the benefit of such Holder in the amount of the Bond Amount, which Surety Bond shall remain in effect until the completion of litigation of the dispute and the proceeds of which shall be payable to such Holder to the extent Holder obtains judgment.

 

22


(e) Remedies, Other Obligations, Breaches And Injunctive Relief . The remedies provided in this Warrant shall be cumulative and in addition to all other remedies available under this Warrant, the Facility Agreement, the Registration Rights Agreement and any other Loan Document, at law or in equity (including a decree of specific performance and/or other injunctive relief), and nothing herein shall limit the right of Holder to pursue actual damages for any failure by the Company to comply with the terms of this Warrant. The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to Holder and that the remedy at law for any such breach may be inadequate. The Company therefore agrees that, in the event of any such breach or threatened breach (including a breach or threatened breach of Section 13), the holder of this Warrant shall be entitled, in addition to all other available remedies, to an injunction restraining any breach, without the necessity of showing economic loss and without any bond or other security being required.

12. Holder’s Early Terminations .

(a) Mechanics of Holder s Early Terminations . In the event that the Company does not deliver the applicable Successor Major Transaction Consideration or Default Amount or the Exercise Shares in respect of an election of a Successor Major Transaction Conversion, Cashless Major Exercise, Cashless Default or Exercise, as the case may be, to Holder within the time period or as otherwise required pursuant to the terms hereof, at any time thereafter Holder shall have the option, upon notice to the Company, in lieu of an election of a Successor Major Transaction Conversion, Cashless Major Exercise, Cashless Default Exercise or Exercise, as the case may be, to require the Company to promptly return to Holder all or any portion of this Warrant that was submitted for election of a Successor Major Transaction Conversion, Cashless Major Exercise, Cashless Default Exercise or Exercise, as the case may be. Upon the Company’s receipt of such notice, (x) the applicable election of Successor Major Transaction Conversion, Cashless Major Exercise, Cashless Default Exercise or Exercise, as the case may be, shall be null and void with respect to such applicable portion of this Warrant, (y) the Company shall immediately return this Warrant, or issue a new Warrant to Holder representing the portion of this Warrant that was submitted for election of Successor Major Transaction Conversion, Cashless Major Exercise, Cashless Default Exercise or Exercise, as the case may be, and (z) the Exercise Price of this Warrant or such new Warrant shall be adjusted to the Exercise Price as in effect on the date on which the applicable election of Successor Major Transaction Conversion, Cashless Major Exercise, Cashless Default Exercise or Exercise, as the case may be, is voided. Holder’s delivery of a notice voiding an election of a Successor Major Transaction Conversion, Cashless Major Exercise, Cashless Default Exercise or Exercise, as the case may be, and exercise of its rights following such notice shall not affect the Company’s obligations to make any Failure Payments which have accrued prior to the date of such notice with respect to the Warrant subject to such notice.

13. Dividend Restrictions .

Until the earlier of the expiration of the Exercise Period and the date all of the Warrants are exercised in full (the “Dividend Restriction Period”), the Company shall not declare or pay any dividend or distribution of any kind to the holders of Common Stock of the Company.

14. Benefits of this Warrant .

 

23


Nothing in this Warrant shall be construed to confer upon any person other than the Company and Holder any legal or equitable right, remedy or claim under this Warrant and this Warrant shall be for the sole and exclusive benefit of the Company and Holder.

15. Governing Law .

All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement (whether brought against a party hereto or its respective affiliates, directors, officers, stockholders, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York, borough of Manhattan. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. The parties hereby waive all rights to a trial by jury. If either party shall commence an action or proceeding to enforce any provisions of this Agreement, then the prevailing party in such action or proceeding shall be reimbursed by the other party for its reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.

16. Loss of Warrant .

Upon receipt by the Company of evidence of the loss, theft, destruction or mutilation of this Warrant, and (in the case of loss, theft or destruction) of indemnity or security reasonably satisfactory to the Company, and upon surrender and cancellation of this Warrant, if mutilated, the Company shall execute and deliver a new Warrant of like tenor and date.

17. Notice or Demands .

Except as otherwise provided herein, notices or demands pursuant to this Warrant to be given or made by Holder to or on the Company shall be sufficiently given or made if sent by overnight delivery with a nationally recognized overnight courier service, certified or registered mail, return receipt requested, postage prepaid, and addressed, until another address is designated in writing by the Company, to the address set forth in Section 2(a) above. To the extent any notice or demand pursuant to this Warrant can be made by electronic mail, such notice or demand given or made by Holder to or on the Company shall be sufficiently given or made if it is sent by electronic mail to the addresses that the Company shall designate in writing from time to time. Notices or demands pursuant to this Warrant to be given or made by the Company to or on

 

24


Holder shall be sufficiently given or made if sent by overnight delivery with a nationally recognized overnight courier service or certified or registered mail, return receipt requested, postage prepaid, and addressed, to the address of Holder set forth in the Company’s records, until another address is designated in writing by Holder.

18. Construction .

Unless the context otherwise requires, (a) all references to Articles, Sections, Schedules or Exhibits are to Articles, Sections, Schedules or Exhibits contained in or attached to this Warrant, (b) words in the singular or plural include the singular and plural and pronouns stated in either the masculine, the feminine or neuter gender shall include the masculine, feminine and neuter and (c) the use of the word “including” in this Warrant shall be by way of example rather than limitation.

19. Signatures .

In the event that any signature to this Warrant or any amendment hereto is delivered by electronic mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such “.pdf” signature page were an original thereof. Notwithstanding the foregoing, the Company shall be obligated to deliver to Holder an original signature to this Warrant. At the request of any party, each other party shall promptly re-execute an original form of this Warrant or any amendment hereto and deliver the same to the other party. No party hereto shall raise the use of electronic mail delivery of a “.pdf” format data file to deliver a signature to this Warrant or any amendment hereto or the fact that such signature was transmitted or communicated through the use of electronic mail delivery of a “.pdf” format data file as a defense to the formation or enforceability of a contract, and each party hereto forever waives any such defense.

 

25


IN WITNESS WHEREOF, the undersigned has executed this Warrant as of the 9th day of August, 2018.

 

ENDOLOGIX, INC.
By:  

/s/ Vaseem Mahboob

  Print Name: Vaseem Mahboob
  Title: Chief Financial Officer

 

26


EXHIBIT A-1

EXERCISE FORM FOR WARRANT

TO: [                ]

CHECK THE APPLICABLE BOX:

 

 

Cash Exercise, Cashless Exercise or Note Exchange Exercise

The undersigned hereby irrevocably exercises Warrant Number              (the “Warrant”) with respect to 2,916,667 shares of Common Stock (the “Common Stock”) of Endologix, Inc., a Delaware corporation (the “Company”). [IF APPLICABLE: The undersigned hereby encloses $         as payment of the Exercise Price.]

☐ The undersigned is exercising the Warrant with respect to [            ] shares of Common Stock pursuant to a Cashless Exercise, and hereby makes payment of the Exercise Price with respect to such shares in full, all in accordance with the conditions and provisions of the Warrant applicable to such Cashless Exercise.

☐ The undersigned is exercising the Warrant with respect to [            ] shares of Common Stock pursuant to a Note Exchange Exercise. The undersigned hereby agrees to cancel $         of principal outstanding under Notes of the Company held by Holder in satisfaction of the Exercise Price in accordance with the conditions and provisions of the Warrant applicable to such Note Exchange Exercise.

 

 

Cashless Major Exercise

The undersigned hereby irrevocably exercises the Warrant with respect to ____% of the Warrant currently outstanding pursuant to a Cashless Major Exercise in accordance with the terms of the Warrant.

 

 

Cashless Default Exercise

The undersigned hereby irrevocably exercises the Warrant pursuant to a Cashless Default Exercise, in accordance with the terms of the Warrant.

1. The undersigned requests that any stock certificates for such shares be issued free of any restrictive legend, if appropriate, and, if requested by the undersigned, a warrant representing any unexercised portion hereof be issued, pursuant to the Warrant in the name of the undersigned and delivered to the undersigned at the address set forth below.

2. Capitalized terms used but not otherwise defined in this Exercise Form shall have the meaning ascribed thereto in the Warrant.

Dated:                    

 

 

Signature

 

 

Print Name

 

 

Address

NOTICE

The signature to the foregoing Exercise Form must correspond to the name as written upon the face of the attached Warrant.

 

27


EXHIBIT B

ASSIGNMENT

(To be executed by the registered holder

desiring to transfer the Warrant)

FOR VALUE RECEIVED, the undersigned holder of the attached warrant (the “Warrant”) hereby sells, assigns and transfers unto the person or persons below named the right to purchase                  shares of the Common Stock of Endologix, Inc., a Delaware corporation, evidenced by the attached Warrant and does hereby irrevocably constitute and appoint                  attorney to transfer the said Warrant on the books of the Company, with full power of substitution in the premises.

 

Dated:                         

 

    Signature
Fill in for new registration of Warrant:    

 

Name

   

 

Address

   

 

Please print name and address of assignee

   
(including zip code number)    

NOTICE

The signature to the foregoing Assignment must correspond to the name as written upon the face of the attached Warrant.

 

28


EXHIBIT C

FORM OF OPINION

            , 20    

[                    ]

 

Re:

[                              ] (the “Company”)

Dear Sir:

[                    ] (“[                ]”) intends to transfer          Warrants (the “Warrants”) of the Company to                  (“            ”) without registration under the Securities Act of 1933, as amended (the “Securities Act”). In connection therewith, we have examined and relied upon the truth of representations contained in an Investor Representation Letter attached hereto and have examined such other documents and issues of law as we have deemed relevant.

Based on and subject to the foregoing, we are of the opinion that the transfer of the Warrants by              to              may be effected without registration under the Securities Act [, provided, however, that the Warrants to be transferred to                  contain a legend restricting its transferability pursuant to the Securities Act and that transfer of the Warrants is subject to a stop order] . 1

The foregoing opinion is furnished only to                  and may not be used, circulated, quoted or otherwise referred to or relied upon by you for any purposes other than the purpose for which furnished or by any other person for any purpose, without our prior written consent.

Very truly yours,

 

1  

Only if applicable.

 

29


[FORM OF INVESTOR REPRESENTATION LETTER]

            , 20        

[                                 ]

Gentlemen:

             (“    ”) has agreed to purchase                  Warrants (the “Warrants”) of Endologix, Inc., a Delaware corporation (the “Company”) from [                    ] (“[                    ]”). We understand that the Warrants are “restricted securities.” We represent and warrant that                  is a sophisticated institutional investor that would qualify as an “Accredited Investor” as defined in Rule 501 of Regulation D under the Securities Act of 1933, as amended (the “Securities Act”).

            represents and warrants as of the date hereof as follows:

1. That it is acquiring the Warrants and the shares of common stock, $0.001 par value per share underlying such Warrants (the “Exercise Shares”) solely for its account for investment and not with a view to or for sale or distribution of said Warrants or Exercise Shares or any part thereof in violation of the Securities Act.                  also represents that the entire legal and beneficial interests of the Warrants and Exercise Shares                  is acquiring is being acquired for, and will be held for, its account only;

2. That the Warrants and the Exercise Shares must be held indefinitely unless they are registered under the Securities Act or an exemption from such registration is available.              recognizes that the Company has no obligation to register the Warrants, or to comply with any exemption from such registration;

3. That neither the Warrants nor the Exercise Shares may be sold pursuant to Rule 144 adopted under the Securities Act unless certain conditions are met;

We acknowledge that the Company will place stop orders with respect to the Warrants and the Exercise Shares, and if none of the Unrestricted Conditions (as defined in the Warrants) is satisfied, the Exercise Shares shall bear the following restrictive legend:

“THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER SAID ACT, OR PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER SAID ACT INCLUDING PURSUANT TO SECTION 4(A)(7) OF THE SECURITIES ACT OR RULE 144 UNDER SAID ACT OR PURSUANT TO A PRIVATE SALE EFFECTED UNDER APPLICABLE FORMAL OR INFORMAL SEC INTERPRETATION OR GUIDANCE, SUCH AS A SO-CALLED “4[(a)](1) AND A HALF” SALE.

 

30


NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.”

“THE SALE, TRANSFER OR ASSIGNMENT OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO THE TERMS AND CONDITIONS OF A CERTAIN AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT DATED AS OF AUGUST 9, 2018, AS AMENDED FROM TIME TO TIME, AMONG THE COMPANY AND CERTAIN HOLDERS OF ITS OUTSTANDING SECURITIES. COPIES OF SUCH AGREEMENT MAY BE OBTAINED AT NO COST BY WRITTEN REQUEST MADE BY THE HOLDER OF RECORD OF THIS CERTIFICATE TO THE SECRETARY OF THE COMPANY.”

At any time and from time to time after the date hereof,                  shall, without further consideration, execute and deliver to [                ] or the Company such other instruments or documents and shall take such other actions as they may reasonably request to carry out the transactions contemplated hereby.

Very truly yours,

 

31


Schedule 1

Black-Scholes Value

 

    

Calculation Under Sections 3(b) and 5(b)(iii)

  

Calculation Under Section 10(b) or 11(b)

Remaining Term    Number of calendar days from date of public announcement of the Major Transaction until the last date on which the Warrant may be exercised.    Number of calendar days from the date of the Event of Failure, or in the case of an Event of Default, the date of the Default Notice, until the last date on which the Warrant may be exercised.
Interest Rate    A risk-free interest rate corresponding to the US$ LIBOR/Swap rate for a period equal to the remaining Exercise Period.    A risk-free interest rate corresponding to the US$ LIBOR/Swap rate for a period equal to the remaining Exercise Period.
Cost to Borrow    Zero    Zero
Volatility   

If the first public announcement of the Major Transaction is made at or prior to 4:00 p.m., New York City time, the arithmetic mean of the historical volatility for the 10, 30 and 50 Trading Day periods ending on the date of such first public announcement, obtained from the HVT or similar function on Bloomberg.

 

If the first public announcement of the Major Transaction is made after 4:00 p.m., New York City time, the arithmetic mean of the historical volatility for the 10, 30 and 50 Trading Day periods ending on the next succeeding Trading Day following the date of such first public announcement, obtained from the HVT or similar function on Bloomberg.

   The arithmetic mean of the historical volatility for the 10, 30 and 50 Trading Day periods ending on the date of such determination, obtained from the HVT or similar function on Bloomberg.

 

32


Stock Price    As selected by Holder in its commercially reasonable discretion in order to produce a commercially reasonable result, any of: (1) the closing price of the Common Stock on the NasdaqGS, or, if that is not the principal trading market for the Common Stock, such principal market on which the Common Stock is traded or listed (the “Closing Market Price”) on the Trading Day immediately preceding the date on which a Major Transaction is consummated, (2) the first Closing Market Price following the first public announcement of a Major Transaction, (3) the Closing Market Price as of the date immediately preceding the first public announcement of the Major Transaction or (4) the cash amount payable per share of Common Stock. The Company and Holder acknowledge and agree that any of the above will produce a commercially reasonable result.    The volume Weighted Average Price on the date of such determination.
Dividends    Zero.    Zero.
Strike Price    Exercise Price as defined in section 3(a).    Exercise Price as defined in section 3(a).

 

33

Exhibit 4.2

WARRANT

THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAW. THE SECURITIES MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT, EXCEPT PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT, INCLUDING PURSUANT TO SECTION 4(A)(7) OF THE SECURITIES ACT OR RULE 144 UNDER THE SECURITIES ACT OR PURSUANT TO A PRIVATE SALE EFFECTED UNDER APPLICABLE FORMAL OR INFORMAL SEC INTERPRETATION OR GUIDANCE, SUCH AS A SO-CALLED “4[(a)](1) AND A HALF SALE.” NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

AN INVESTMENT IN THESE SECURITIES INVOLVES A HIGH DEGREE OF RISK. HOLDERS MUST RELY ON THEIR OWN ANALYSIS OF THE INVESTMENT AND ASSESSMENT OF THE RISKS INVOLVED.

 

Warrant to Purchase

2,916,667 shares

   Warrant Number:         2018-2

Warrant to Purchase Common Stock

of

Endologix, Inc.

THIS CERTIFIES that Deerfield Private Design Fund IV, L.P. or any subsequent holder hereof (“Holder”) has the right to purchase from Endologix, Inc., a Delaware corporation (the “Company”), Two Million Nine Hundred Sixteen Thousand Six Hundred Sixty-Seven (2,916,667) fully paid and nonassessable shares of the Company’s common stock, $0.001 par value per share (“Common Stock”), subject to adjustment as provided herein, at a price equal to the Exercise Price (as defined in Section 3 below), at any time during the Exercise Period (as defined in Section 1 below).

Holder agrees with the Company that this Warrant to Purchase Common Stock of the Company (this “Warrant” or this “Agreement”) is issued and all rights hereunder shall be held subject to all of the conditions, limitations and provisions set forth herein.

1. Date of Issuance and Term .

This Warrant shall be deemed to be issued, and shall be in full force and effect commencing, on August 9, 2018 (“Date of Issuance”). The exercise period of this Warrant begins on (and includes) February 9, 2019, and ends at 5:00 p.m., New York City time, on August 9, 2025 (the “Exercise Period”). This Warrant was issued pursuant to that certain Amended and Restated Facility Agreement (as may be amended, restated, supplemented or otherwise modified from


time to time in accordance with the terms thereof, the “Facility Agreement”) by and among the Company, Deerfield Private Design Fund III, L.P., Deerfield Private Design Fund IV, L.P., and Deerfield Partners, L.P., dated as of August 9, 2018, and in conjunction with that certain Amended and Restated Registration Rights Agreement (as may be amended, restated, supplemented or otherwise modified from time to time in accordance with the terms thereof, the “Registration Rights Agreement”) by and among the Company, Deerfield Private Design Fund III, L.P., Deerfield Private Design Fund IV, L.P., and Deerfield Partners, L.P., dated as of August 9, 2018.

Notwithstanding anything herein to the contrary, the Company shall not issue to Holder, and Holder may not acquire, a number of shares of Common Stock upon exercise of this Warrant to the extent that, upon such exercise, the number of shares of Common Stock then beneficially owned by Holder and its Affiliates and any other persons or entities whose beneficial ownership of Common Stock would be aggregated with Holder’s for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (including shares held by any “group” of which Holder is a member, but excluding shares beneficially owned by virtue of the ownership of securities or rights to acquire securities that have limitations on the right to convert, exercise or purchase similar to the limitation set forth herein), would exceed 4.985% of the total number of shares of Common Stock then issued and outstanding (the “4.985% Cap”); provided, however, that the 4.985% Cap shall only apply to the extent that the Common Stock is deemed to constitute an “equity security” pursuant to Rule 13d-1(i) promulgated under the Exchange Act. For purposes hereof, “group” has the meaning set forth in Section 13(d) of the Exchange Act and applicable regulations of the Securities and Exchange Commission (the “SEC”), and the percentage held by Holder shall be determined in a manner consistent with the provisions of Section 13(d) of the Exchange Act. Upon the written request of Holder, the Company shall, within two (2) Trading Days, confirm orally and in writing to Holder the number of shares of Common Stock then outstanding.

For purposes hereof:

“Affiliate” means any person or entity that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a person or entity, as such terms are used in and construed under Rule 144 (“Rule 144”) under the Securities Act of 1933, as amended (the “Securities Act”). With respect to a Holder, any investment fund or managed account that is managed on a discretionary basis by the same investment manager as such Holder shall, for purposes hereof, be deemed to be an Affiliate of such Holder.

“Asset Sale” means a transaction covered by the provisions of clause (B) of the definition of “Major Transaction” involving the sale or transfer of all or substantially all of the assets of the Company (including, for the avoidance of doubt, all or substantially all of the assets of the Company and its Subsidiaries (as defined in the Facility Agreement), taken as a whole) in connection with which the Company has announced its intention to liquidate and distribute its assets to stockholders.

“Black-Scholes Value” shall mean the Black-Scholes value of this Warrant, or applicable portion thereof, as determined by use of the Black-Scholes Option Pricing Model using the criteria set forth on Schedule 1 hereto.

 

2


“Business Day” means a day other than a Saturday or Sunday or any other day on which commercial banks are authorized or required by law to close in New York City.

“Cashless Default Exercise” shall mean an exercise of this Warrant as a “Cashless Default Exercise” in accordance with Sections 3(c) and 11(b) hereof.

“Cashless Major Exercise” shall mean an exercise of this Warrant or portion thereof as a “Cashless Major Exercise” in accordance with Sections 3(b) and 5(b)(i) hereof.

“Cash Out Major Transaction” means a Major Transaction in which the consideration payable to holders of Common Stock in connection with the Major Transaction consists solely of cash.

“Eligible Market” means the New York Stock Exchange, the NASDAQ Capital Market, the NASDAQ Global Market, the NASDAQ Global Select Market, the NYSE American or, in each case, any successor thereto.

“Parent Entity” of a Person means an entity that, directly or indirectly, controls the applicable Person and whose common stock or equivalent equity security is quoted or listed on an Eligible Market, or, if there is more than one such Person or Parent Entity, the Person or Parent Entity with the largest public market capitalization as of the date of consummation of a Major Transaction.

“Person” means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other entity and a government or any department or agency thereof.

“Standard Settlement Period” means the standard settlement period for equity trades effected on securities exchanges in the United States, expressed in a number of Trading Days, as in effect on the applicable Date of Exercise (as defined in Section 2(b)).

“Stock Event” means a stock split, stock combination, reclassification, payment of stock dividend, recapitalization or other similar transaction of such character that the shares of Common Stock shall be changed into or become exchangeable for a larger or small number of shares.

“Successor Entity” means any Person purchasing the Company’s assets or Common Stock, or any successor entity resulting from such Major Transaction, or if the Warrant is to be exercisable for shares of capital stock of a Parent Entity (as defined above), such Person’s Parent Entity.

“Successor Major Transaction” means either a Takeout Major Transaction or an Asset Sale.

“Successor Major Transaction Consideration” means (i) in the case of a Takeout Major Transaction (other than a Cash Out Major Transaction), the amount of cash and other assets and the number of securities or other property of the Successor Entity or other entity that would be issuable in such Major Transaction, in respect of a number of shares equal to the Successor Major Transaction Conversion Share Amount and (ii) in the case of an Asset Sale or a Cash Out Major Transaction, an amount of cash equal to the Black-Scholes Value of the Warrant.

 

3


“Successor Major Transaction Conversion Share Amount” means an amount equal to the Black-Scholes Value of the Warrant (or such applicable portion subject to a Successor Major Transaction Conversion), divided by the closing price of the Common Stock on the principal securities exchange or other securities market on which the Common Stock is then traded on the Trading Day immediately preceding the date on which the applicable Major Transaction is consummated.

“Takeout Major Transaction” means a transaction covered by the provisions of clause (A) of the definition of “Major Transaction” in which the shares of Common Stock of the Company are converted into the right to receive cash, securities of another entity and/or other assets.

“Trading Day” shall mean any day on which the Common Stock is traded for any period on the NASDAQ Global Select Market (“NasdaqGS”) or, if the NasdaqGS is not the principal trading market for the Common Stock, on the principal securities exchange or other securities market on which the Common Stock is then being traded; provided, however, that during any period in which the Common Stock is not listed or quoted on the NasdaqGS or any other securities exchange or market, the term “Trading Day” shall mean a Business Day.

2. Exercise .

(a) Manner of Exercise . During the Exercise Period (or, in respect of a Cashless Major Exercise, the Cashless Major Exercise Period (as defined below)), this Warrant may be Exercised as to all or any lesser number of whole shares of Common Stock covered hereby (the “Warrant Shares” or the “Shares”) by sending to the Company the Exercise Form attached hereto as Exhibit  A-1 (the “Exercise Form”) duly completed and executed, and, if applicable, the full Exercise Price (as defined below, which may be satisfied by a Cash Exercise, a Cashless Exercise or a Note Exchange Exercise, as each is defined below) for each share of Common Stock as to which this Warrant is Exercised, at the office of the Company, 2 Musick, Irvine, CA 92618, Attention: Chief Financial Officer; Phone: (949) 595-7200, Email: vmahboob@endologix.com, or at such other office or agency as the Company may designate in writing, by overnight mail or electronic mail (any such exercise of the Warrant being hereinafter called an “Exercise” of this Warrant).

(b) Date of Exercise . The “Date of Exercise” of the Warrant shall, in each case, be the date that the Exercise Form attached hereto as Exhibit  A-1 , completed and executed, is sent by electronic mail to the Company, provided that the Exercise Price is satisfied as soon as practicable thereafter but in no event later than two (2) Business Days following the date of such electronic mail. Alternatively, the Date of Exercise shall be defined as the date the original Exercise Form is received by the Company, if Holder has not previously sent the Exercise Form by electronic mail. Upon delivery of the Exercise Form to the Company by electronic mail or otherwise, Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been Exercised, irrespective of the date such Warrant Shares are credited to Holder’s or its designee’s Depository Trust Company (“DTC”) account or the date of delivery of the certificates evidencing such Warrant Shares, as the case may be; provided, however, that in the event an Exercise Form in respect of a Cashless Major Exercise is delivered prior to the occurrence of the applicable Major Transaction, Holder shall be deemed to have become the holder of record of the shares issuable upon such exercise immediately prior to the consummation of such Major Transaction and the Date of Exercise shall

 

4


in such event be deemed to have occurred on the date of the occurrence of the Major Transaction. Holder shall not be required to physically surrender this Warrant to the Company until Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days following the date the final Exercise Form is delivered to the Company. Execution and delivery of an Exercise Form with respect to a partial Exercise shall have the same effect as cancellation of the original Warrant and issuance of a new Warrant evidencing the right to purchase the remaining number of Warrant Shares.

(c) Delivery of Common Stock Upon Exercise . Within the earlier of (x) two (2) Trading Days and (y) the number of Trading Days comprising the Standard Settlement Period after any Date of Exercise (but, in the case of a Cash Exercise, within two (2) Business Days following the Company’s receipt of the full Exercise Price, if later) or in the case of a Cashless Default Exercise (as defined in Section 5(b) below), within the period provided in Section 3(c), as applicable (the “Delivery Period”), the Company shall issue and deliver (or cause its transfer agent (the “Transfer Agent”) to issue and deliver) in accordance with the terms hereof to or upon the order of Holder that number of shares of Common Stock (“Exercise Shares”) for the portion of this Warrant exercised as shall be determined in accordance herewith. Upon the Exercise of this Warrant or any part hereof, the Company shall, at its own cost and expense, take all necessary action, including obtaining and delivering an opinion of counsel, to assure that the Transfer Agent shall issue stock certificates in the name of Holder (or its nominee) or such other persons as designated by Holder and in such denominations as Holder shall specify at Exercise, representing the number of shares of Common Stock issuable upon such Exercise. The Company warrants that no instructions other than these instructions have been or will be given to the Transfer Agent and that, unless waived by Holder, this Warrant and the Exercise Shares will be free-trading, and freely transferable, and will not contain or be subject to a legend (or be subject to any stop transfer instruction) restricting the resale or transferability of the Exercise Shares if the Unrestricted Conditions (as defined below) are met.

The Company shall be responsible for paying all present or future stamp, court or documentary, intangible, recording, filing or similar taxes that arise from any payment or issuance made under, from the execution, delivery, performance or enforcement of, or otherwise with respect to, this Warrant.

(d) Delivery Failure . In addition to any other remedies which may be available to Holder, in the event that the Company fails for any reason to effect delivery of the Exercise Shares by the end of the Delivery Period (a “Delivery Failure”), Holder will be entitled to revoke all or part of the relevant Exercise by delivery of a notice to such effect to the Company whereupon the Company and Holder shall each be restored to their respective positions immediately prior to the delivery of such notice of revocation, except that the Failure Payments under Section 10(b) shall be payable through the date such notice of revocation is given to the Company.

(e) Legends .

(i) Restrictive Legend . Holder understands that until such time as this Warrant, the Exercise Shares and the Failure Payment Shares (as defined below) have been registered under the Securities Act or otherwise may be sold pursuant to Rule 144 or an exemption from registration

 

5


under the Securities Act without any restriction as to the number of securities as of a particular date that can then be immediately sold, this Warrant, the Exercise Shares and the Failure Payment Shares, as applicable, may bear a restrictive legend in substantially the following form (and a stop-transfer order consistent therewith may be placed against transfer of the certificates for such securities):

“THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER SAID ACT, EXCEPT PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER SAID ACT INCLUDING PURSUANT TO SECTION 4(A)(7) OF THE SECURITIES ACT OR RULE 144 UNDER SAID ACT OR PURSUANT TO A PRIVATE SALE EFFECTED UNDER APPLICABLE FORMAL OR INFORMAL SEC INTERPRETATION OR GUIDANCE, SUCH AS A SO-CALLED “4[(a)](1) AND A HALF” SALE.” NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

“THE SALE, TRANSFER OR ASSIGNMENT OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO THE TERMS AND CONDITIONS OF A CERTAIN AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT DATED AS OF AUGUST 9, 2018, AS AMENDED FROM TIME TO TIME, AMONG THE COMPANY AND CERTAIN HOLDERS OF ITS OUTSTANDING SECURITIES. COPIES OF SUCH AGREEMENT MAY BE OBTAINED AT NO COST BY WRITTEN REQUEST MADE BY THE HOLDER OF RECORD OF THIS CERTIFICATE TO THE SECRETARY OF THE COMPANY.”

(ii) Removal of Restrictive Legends . This Warrant and the certificates (or electronic book entries, if applicable) evidencing the Exercise Shares and the Failure Payment Shares, as applicable, shall not contain or be subject to any legend restricting the transfer thereof (including the legend set forth above in subsection 2(e)(i)) or be subject to any stop-transfer instructions: (A) while a registration statement (including a Registration Statement, as defined in the Registration Rights Agreement) covering the sale or resale of such security is effective under the Securities Act, or (B) following any sale of such Warrant, Exercise Shares and/or Failure Payment Shares pursuant to Rule 144, or (C) if such Warrant, Exercise Shares and/or Failure Payment Shares are eligible for sale under Rule 144(b)(1), or (D) at any time on or after the date hereof on which Holder’s holding period for purposes of Rule 144 under the Securities Act and subsection (d)(3)(iii) thereof with respect to such Warrant, Exercise Shares and/or Failure Payment Shares is at least six (6) months and Holder certifies that it is not an “affiliate” (as defined in Rule 144 under the Securities Act), or (E) if such legend is not required under applicable requirements of the

 

6


Securities Act (including judicial interpretations and pronouncements issued by the staff of the SEC) (collectively, the “Unrestricted Conditions”). The Company shall cause its counsel to issue a legal opinion to the Transfer Agent promptly after the Effective Date, or at such other time as any of the Unrestricted Conditions have been met, if required by the Transfer Agent to effect the issuance of this Warrant, the Exercise Shares or the Failure Payment Shares, as applicable, without a restrictive legend or removal of the legend hereunder. If any of the Unrestricted Conditions are met at the time of issuance of this Warrant, the Exercise Shares or the Failure Payment Shares, then such Warrant, Exercise Shares or Failure Payment Shares, as applicable, shall be issued free of all legends and stop-transfer instructions. The Company agrees that following the Effective Date, or at such time as the Unrestricted Conditions are met or such legend is otherwise no longer required under this Section 2(e), it will, no later than the earlier of (x) two (2) Trading Days and (y) the number of Trading Days comprising the Standard Settlement Period following the delivery (the “Unlegended Shares Delivery Deadline”) by Holder to the Company or the Transfer Agent of this Warrant and a certificate representing Exercise Shares and/or Failure Payment Shares, as applicable, issued with a restrictive legend, deliver or cause to be delivered to Holder this Warrant and/or a certificate (or electronic transfer) representing such shares that is free from all restrictive and other legends (and stop transfer instructions). For purposes hereof, “Effective Date” shall mean the date that the first Registration Statement that the Company is required to file pursuant to the Registration Rights Agreement has been declared effective by the SEC.

(iii) Sale of Unlegended Shares . Holder agrees that the removal of the restrictive legend from this Warrant and any certificates representing securities as set forth in Section 2(e) above is predicated upon the Company’s reliance that Holder will sell this Warrant or any Exercise Shares and/or any Failure Payment Shares, as applicable, pursuant to either the registration requirements of the Securities Act, including any applicable prospectus delivery requirements, or an exemption therefrom, and that if such securities are sold pursuant to a Registration Statement, they will be sold in compliance with the plan of distribution set forth therein.

(f) Cancellation of Warrant . This Warrant shall be canceled upon the full Exercise of this Warrant, and, as soon as practical after the Date of Exercise, Holder shall be entitled to receive Common Stock for the number of shares purchased upon such Exercise of this Warrant, and if this Warrant is not Exercised in full, Holder shall be entitled to receive a new Warrant (containing terms identical to this Warrant) representing any unexercised portion of this Warrant in addition to such Common Stock; provided, however, as set forth in Section 2(b), Holder shall not be required to physically surrender this warrant if the Warrant is not Exercised in full.

(g) Holder of Record . Each person in whose name any Warrant for shares of Common Stock is issued shall, for all purposes, be deemed to be Holder of record of such shares on the Date of Exercise, irrespective of the date of delivery of the Common Stock purchased upon the Exercise of this Warrant. Prior to the exercise of this Warrant, nothing in this Warrant shall be construed as conferring upon Holder any rights as a stockholder of the Company.

(h) Delivery of Electronic Shares . In lieu of delivering physical certificates representing the Common Stock issuable upon Exercise or legend removal, or representing Failure Payment Shares, upon written request of Holder, the Company shall use its best efforts to cause the Transfer Agent to electronically transmit the Common Stock issuable upon Exercise to Holder

 

7


by crediting the account of Holder’s prime broker with DTC through its Deposit/Withdrawal at Custodian (DWAC) system. The time periods for delivery and penalties described herein shall apply to the electronic transmittals described herein. Any delivery not effected by electronic transmission shall be effected by delivery of physical certificates.

(i) Buy-In . In addition to any other rights or remedies available to Holder hereunder or otherwise at law or in equity, if the Company fails to cause its Transfer Agent to deliver to Holder a certificate or certificates, or electronic shares through DWAC, representing the Exercise Shares pursuant to an Exercise on or before the last day of the Delivery Period (other than a failure caused by any incorrect or incomplete information provided by Holder to the Company hereunder), and if after such date Holder is required by its broker to purchase (in an open market transaction or otherwise) or Holder or Holder’s brokerage firm otherwise purchases shares of Common Stock to deliver in satisfaction of a sale by Holder of the Exercise Shares which Holder was entitled to receive upon such Exercise (a “Buy-In”), then the Company shall (1) pay in cash to Holder the amount by which (x) Holder’s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (A) the number of Exercise Shares that the Company was required to deliver to Holder in connection with the Exercise at issue by (B) the price at which the sell order giving rise to such purchase obligation was executed, and (2) at the option of Holder, either reinstate the portion of the Warrant and equivalent number of Exercise Shares for which such Exercise was not honored (and refund the Exercise Price therefor, to the extent paid by Holder, and/or reinstate the principal amount of any indebtedness used to satisfy the applicable Exercise Price) or deliver to Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its Exercise and delivery obligations hereunder. For example, if Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted Exercise to cover the sale of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (1) of the immediately preceding sentence the Company shall be required to pay Holder $1,000. Holder shall provide the Company written notice indicating the amounts payable to Holder in respect of the Buy-In, together with applicable confirmations and other evidence reasonably requested by the Company. Nothing herein shall limit Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver certificates representing shares of Common Stock upon Exercise of the Warrant as required pursuant to the terms hereof.

(j) HSR Submissions. If Holder determines that, in connection with the exercise of this Warrant, it and the Company are required to file Premerger Notification Reports with the Federal Trade Commission (the “FTC”) and the United States Department of Justice (“DOJ”) and observe the Waiting Period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended, and the related rules and regulations promulgated thereunder (collectively, the “HSR Act”), the Company agrees to (i) cooperate with Holder in Holder’s preparing and making such submission and any responses to inquiries of the FTC and DOJ; (ii) prepare and make any submission required to be filed by the Company under the HSR Act and respond to inquiries of the FTC and DOJ in connection therewith; and (iii) reimburse Holder for the cost of the required filing fee for Holder’s submission under the HSR Act. For the avoidance of doubt, Holder shall bear all of its other costs and expenses in connection with such submission, including any attorneys’ fees associated therewith.

 

8


3. Payment of Warrant Exercise Price for Cash Exercise or Cashless Exercise; Cashless Major Exercise and Cashless Default Exercise .

(a) Exercise Price . The exercise price shall initially equal $4.71 per share, subject to adjustment pursuant to the terms hereof (as so adjusted, the “Exercise Price”), including but not limited to Section 5 below.

Payment of the Exercise Price may be made by any of the following, or a combination thereof, at the election of Holder:

(i) Cash Exercise : Holder may exercise this Warrant in cash, bank or cashier’s check or wire transfer (a “Cash Exercise”);

(ii) Cashless Exercise : In lieu of paying all or any portion of the Exercise Price in cash, Holder, at its option, may exercise this Warrant (in whole or in part) on a cashless basis by making appropriate notation on the applicable Exercise Form, in which event the Company shall issue Holder a number of shares of Common Stock computed using the following formula (a “Cashless Exercise”):

X = Y (A-B)/A

where: X = the number of shares of Common Stock to be issued to Holder.

Y = the number of shares of Common Stock for which this Warrant is being Exercised.

A = the Market Price of one (1) share of Common Stock (for purposes of this Section 3(a)(ii), where “Market Price,” as of any date, means the arithmetic average of the Volume Weighted Average Price (as defined below) of the Company’s Common Stock on each of the ten (10) consecutive Trading Days immediately preceding the date in question).

B = the Exercise Price.

As used herein, the “ Volume Weighted Average Price ” for any security as of any date means the volume weighted average sale price on the NasdaqGS as reported by, or based upon data reported by, Bloomberg Financial Markets or an equivalent, reliable reporting service mutually acceptable to and hereafter designated by the Holder and the Company (“ Bloomberg ”), or, if the NasdaqGS is not the principal trading market for such security, the volume weighted average sale price of such security on the principal securities exchange or trading market where such security is listed or traded as reported by Bloomberg, or, if no volume weighted average sale price is reported for such security, then the last closing trade price of such security as reported by Bloomberg, or, if no last closing trade price is reported for such security by Bloomberg, the average of the bid prices of any market makers for such security on the OTC Bulletin Board, the OTCQX Market, the OTCQB Market or the “pink” market of OTC Markets Group. If the Volume Weighted Average Price cannot be calculated for such security on such date in the manner provided above, the Volume Weighted Average Price shall be the fair market value as determined by the Company and the Holder. In the event that a Stock Event is

 

9


consummated during any period for which the arithmetic average of the Volume Weighted Average Prices is to be determined (under this Section or otherwise), the Volume Weighted Average Price for all Trading Days during such period prior to the effectiveness of the Stock Event shall be appropriately adjusted to reflect such Stock Event.

(iii) Note Exchange Exercise : In lieu of paying all or any portion of the Exercise Price in cash, Holder, at its option, may exercise this Warrant (in whole or in part) through a reduction of an amount of principal outstanding under any First Out Waterfall Notes in accordance with Section 2.3(b) of the Facility Agreement, then held by Holder (a “Note Exchange Exercise”)

For purposes of Rule 144 and subsection (d)(3)(ii) thereof, it is intended, understood and acknowledged that (x) this Warrant shall be deemed to have been acquired on April 3, 2017 (the date the First Out Waterfall Notes were originally issued), and (y) the shares of Common Stock issuable upon Exercise of this Warrant in a Cashless Exercise (including a Cashless Major Exercise or Cashless Default Exercise) transaction or a Note Exchange Exercise transaction shall be deemed to have been acquired on April 3, 2017. Accordingly, (A) upon any such Exercise, the Rule 144 holding period for the shares of Common Stock issued thereupon shall be in excess of one (1) year, and (B) provided that Holder is not an “affiliate” (as defined in Rule 144 under the Securities Act) of the Company on the date of such Exercise (which the Company shall assume unless advised otherwise in writing by Holder), an Unrestricted Condition shall be satisfied with respect to the shares of Common Stock issued thereupon and such shares will be freely transferable, without restriction or limitation (including any volume limitation or current public information requirement) under Federal or state securities laws, pursuant to Rule 144 under the Securities Act, and will not contain or be subject to a legend or stop transfer order restricting the resale or transferability of thereof.

As provided in Section 2(b), Holder shall only be required to physically surrender this Warrant in the event that Holder is exercising this Warrant in full.

(b) Cashless Major Exercise. To the extent Holder shall exercise this Warrant as a Cashless Major Exercise pursuant to Section 5(b)(i) and 5(b)(iii) below, Holder shall send to the Company (in any manner permitted under Section 2(a)) the Exercise Form indicating that Holder is exercising this Warrant (or any portion thereof) pursuant to a Cashless Major Exercise, in which event the Company shall issue a number of shares of Common Stock equal to the Black-Scholes Value of the Warrant (or such applicable portion being exercised) divided by the closing price of the Common Stock on the principal securities exchange or other securities market on which the Common Stock is then traded on the Trading Day immediately preceding the date on which the applicable Major Transaction is consummated, or, if in respect of a Cashless Major Exercise made after the date of consummation of the applicable Major Transaction, on the Trading Day immediately preceding the date on which the exercise form in respect of such Cashless Major Exercise is delivered. As provided in Section 2(b), Holder shall only be required to physically surrender this Warrant in the event that Holder is exercising this Warrant in full. Holder shall be permitted to make successive Cashless Major Exercises and send successive Exercise Forms in respect of a Cashless Major Exercise from time to time at any time during the Cashless Major Exercise Period.

 

10


(c) Cashless Default Exercise . To the extent Holder exercises this Warrant as a Cashless Default Exercise pursuant to Section 11(b)(i) below, Holder shall send to the Company (in any manner permitted under Section 2(a)) the Exercise Form indicating that Holder is exercising this Warrant pursuant to a Cashless Default Exercise, in which event the Company shall issue to Holder, within five (5) Trading Days of the applicable Default Notice, a number of shares of Common Stock (which shares shall be valued at the closing price of the Common Stock on the principal securities exchange or other securities market on which the Common Stock is then traded on the Trading Day immediately preceding the date on which the Exercise Form in respect of such Cashless Default Exercise is delivered) equal to the Black-Scholes Value of the remaining unexercised portion of this Warrant (or such portion thereof subject to such exercise) as of the date of such Default Notice (or in the case of an Event of Default referred to in Section 11(a)(vi), on the Trading Day immediately preceding the date the dividend or distribution is declared or, if not first declared, is paid). As provided in Section 2(b), the Holder shall be permitted to make successive Cashless Default Exercises and send successive Exercise Forms in respect of a Cashless Default Exercise, from time to time at any time from and after the date of the applicable Default Notice through the Exercise Period of this Warrant.

(d) Dispute Resolution . In the case of a dispute as to the determination of the closing price or the Volume Weighted Average Price of the Company’s Common Stock or the arithmetic calculation of the Exercise Price, Market Price or the Successor Major Transaction Consideration, or the number of shares issuable upon a Cashless Major Exercise, the Company shall submit the disputed determinations or arithmetic calculations via electronic mail within two (2) Business Days of receipt, or deemed receipt, of the Exercise Form or Major Transaction Early Termination Notice, or other event giving rise to such dispute, as the case may be, to Holder. If Holder and the Company are unable to agree upon such determination or calculation within two (2) Business Days of such disputed determination or arithmetic calculation being submitted to Holder, then the Company shall, within two (2) Business Days submit via electronic mail (i) the disputed determination of the closing price or the Volume Weighted Average Price of the Company’s Common Stock to an independent, reputable investment bank selected by the Company and approved by Holder, which approval shall not be unreasonably withheld, or (ii) the disputed arithmetic calculation of the Exercise Price, Market Price, any Successor Major Transaction Consideration or number of shares issuable upon a Cashless Major Exercise to the Company’s independent, outside registered public accountants. The Company shall use its reasonable best efforts to cause the investment bank or the accountants, as the case may be, to perform the determinations or calculations and notify the Company and Holder of the results no later than five (5) Trading Days from the time it receives the disputed determinations or calculations. Such investment bank’s or accountants’ determination or calculation, as the case may be, shall be binding upon all parties absent demonstrable error, and the Company and Holder shall each pay one half of the fees and costs of such investment banker or accountant. Notwithstanding the existence of a dispute contemplated by this paragraph, if requested by Holder, the Company shall issue to Holder the Exercise Shares not in dispute in accordance with the terms hereof.

4. Transfer and Registration .

(a) Transfer Rights . Subject to the provisions of Section 8 of this Warrant, this Warrant may be transferred on the books of the Company, in whole or in part, in person or by attorney, upon

 

11


surrender of this Warrant properly completed and endorsed. This Warrant shall be canceled upon such surrender and, as soon as practicable thereafter, the person to whom such transfer is made shall be entitled to receive a new Warrant or Warrants as to the portion of this Warrant transferred, and Holder shall be entitled to receive a new Warrant as to the portion hereof retained.

(b) Registrable Securities . The Common Stock issuable upon the Exercise of this Warrant entitles Holder (and applicable assignees or transferees of such Common Stock) to registration and other rights pursuant to the Registration Rights Agreement.

5. Adjustments Upon Certain Events .

(a) Recapitalization or Reclassification . If the Company shall at any time effect a stock split, payment of stock dividend, recapitalization, reclassification or other similar transaction of such character that the shares of Common Stock shall be changed into or become exchangeable for a larger or smaller number of shares, then upon the effective date thereof, the number of shares of Common Stock which Holder shall be entitled to purchase upon Exercise of this Warrant, shall be increased or decreased, as the case may be, in direct proportion to the increase or decrease in the number of shares of Common Stock by reason of such stock split, payment of stock dividend, recapitalization, reclassification or similar transaction, and the Exercise Price shall be, in the case of an increase in the number of shares, proportionally decreased and, in the case of decrease in the number of shares, proportionally increased. The Company shall give Holder the same notice it provides to holders of Common Stock of any transaction described in this Section 5(a).

(b) Rights Upon Major Transaction .

(i) Major Transaction . In the event that a Major Transaction occurs, then (1) in the case of a Successor Major Transaction, Holder, at its option, may elect to cause the conversion of this Warrant (a “Successor Major Transaction Conversion”), in whole or in part, into the right to receive the Successor Major Transaction Consideration, upon consummation of the Major Transaction, and (2) in the case of all other Major Transactions, Holder shall have the right to exercise this Warrant (or any portion thereof), at any time and from time to time following the occurrence of such event, as a Cashless Major Exercise. In the event Holder shall not have exercised any of its rights under clauses (1) or (2) above within the applicable time periods set forth herein, then the Major Transaction shall be treated as an Assumption (as defined below) in accordance with Section 5(b)(ii) below unless Holder waives its rights under this Section 5(b) with respect to such Major Transaction. Each of the following events shall constitute a “Major Transaction”:

(A) a consolidation, merger, exchange of shares, recapitalization, reorganization, business combination or other similar event, (1) following which the holders of Common Stock immediately preceding such consolidation, merger, exchange, recapitalization, reorganization, combination or event either (a) no longer hold a majority of the shares of Common Stock or (b) no longer have the ability to elect a majority of the board of directors of the Company or (2) as a result of which shares of Common Stock shall be changed into (or the shares of Common Stock become entitled to receive) the same or a different

 

12


number of shares of the same or another class or classes of stock or securities of the Company or another entity (collectively, a “Change of Control Transaction”);

(B) the sale or transfer, in one transaction or a series of related transactions, of (I) all or substantially all of the assets of the Company (including, for the avoidance of doubt, all or substantially all of the assets of the Company and its Subsidiaries, taken as a whole) to any Person other than a wholly-owned subsidiary of the Company or (II) assets of the Company (including, for the avoidance of doubt, all or substantially all of the assets of the Company and its Subsidiaries, taken as a whole) for a purchase price equal to more than 50% of the Equity Value (as defined below) of the Company. For purposes of this clause (B), “Equity Value” shall mean (I) the product of (x) the number of issued and outstanding shares of Common Stock on the date the Company delivers the Major Transaction Notice (defined below) multiplied by (y) the per share closing price of the Common Stock on such date on the NasdaqGS as reported by, or based upon data reported by, Bloomberg or, if the NasdaqGS is not the principal trading market for such security, the closing sale price of such security on the principal securities exchange or trading market where such security is listed or traded as reported by Bloomberg;

(C) a purchase, tender or exchange offer made to the holders of outstanding shares of Common Stock, such that following such purchase, tender or exchange offer a Change of Control Transaction shall have occurred;

(D) the liquidation, bankruptcy, insolvency, dissolution or winding-up (or the occurrence of any analogous proceeding) affecting the Company;

(E) the shares of Common Stock cease to be listed, traded or publicly quoted on the NasdaqGS and are not promptly re-listed or requoted on the New York Stock Exchange, the NYSE American, the NASDAQ Global Market or the NASDAQ Capital Market; or

(F) the Common Stock ceases to be registered under Section 12 of the Exchange Act.

(ii) Assumption. Any assumption of Company obligations under this paragraph shall be referred to herein as an “Assumption.” Unless otherwise provided in writing by Holder, the Company shall not consummate a Major Transaction in which the Company is not the surviving entity or as a result of which the Company has a new Parent Entity, unless (A) each Person acquiring the Company’s assets or Common Stock (or Parent Entity thereof, as applicable), or any other successor entity resulting from such Major Transaction (in each case, a “Successor Entity”), assumes in writing all of the obligations of the Company under this Warrant, the Facility Agreement (but, other than with respect to the Company’s obligations pursuant to Section 5.1(e) and 5.1(p) of the Facility Agreement and the other provisions of the Facility Agreement that

 

13


expressly survive the repayment of the Loans (which shall be assumed in any Assumption), only if there are outstanding Loans under the Facility Agreement immediately following the consummation of the Major Transaction) and the Registration Rights Agreement in accordance with the provisions of this Section 5(b)(ii) pursuant to written agreements in form and substance reasonably satisfactory to Holder and approved by Holder prior to the consummation of such Major Transaction (such approval not to be unreasonably withheld or delayed), including agreements to deliver to Holder in exchange for its Warrants a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to the Warrants, that, among other things, (1) is exercisable for the appropriate number of shares of the Successor Entity’s capital stock (without regard to the 4.985% Cap or any other restriction or limitation on exercise, provided that such instrument shall contain a limitation on exercise comparable to that contained in the second paragraph of Section 1 of this Warrant); (2) has an exercise price similar to the then-effective Exercise Price (taking into account any conversion or exchange ratio applicable to the Common Stock in the Major Transaction) and exercise price adjustment provisions similar to those in the Warrants; (3) entitles Holder to such additional securities or other consideration as Holder would be entitled pursuant to Section 5(b)(i) in connection with the Major Transaction; and (4) provides for registration rights similar to those provided by the Registration Rights Agreement, in each case reasonably satisfactory to Holder, and (B) the Successor Entity (including its Parent Entity) is a publicly traded corporation whose common stock is quoted on or listed for trading on an Eligible Market. For the avoidance of doubt, Holder’s reasonable satisfaction referred to in the immediately preceding sentence shall be construed only to apply to confirmation that the warrant or other comparable security and registration rights agreement delivered to Holder upon an assumption hereunder shall conform to the requirements of this Section 5(b)(ii), and this Section 5(b)(ii) shall not be construed as granting consent or approval rights to Holder with respect to the terms of such Major Transaction or to permit Holder to demand any additional consideration in respect of this Warrant other than as provided herein. Upon the occurrence of any Major Transaction, any Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Major Transaction, the provisions of this Warrant and the Registration Rights Agreement referring to the “Company” shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company herein. Upon consummation of the Major Transaction, the Successor Entity shall deliver to Holder confirmation that there shall be issued upon exercise of this Warrant at any time after the consummation of the Major Transaction, in lieu of the shares of Common Stock (or other securities, cash, assets or other property) issuable upon the exercise of the Warrants prior to such Major Transaction, such shares of publicly traded common stock (or their equivalent) of the Successor Entity, as adjusted in accordance with the provisions of this Warrant. The provisions of this Section shall apply similarly and equally to successive Major Transactions and shall be applied without regard to any limitations on the exercise of this Warrant other than any applicable beneficial ownership limitations.

(iii) Major Transaction Notice; Major Transaction Early Termination Right; Notice of Cashless Major Exercise. At least thirty (30) days prior to the consummation of any Major Transaction, but, in any event, within five (5) Trading Days following the first to occur of (x) the date of the public announcement of such Major Transaction if such announcement is made before 4:00 p.m., New York City time, or (y) the day following the public announcement of such Major

 

14


Transaction if such announcement is made on and after 4:00 p.m., New York City time, the Company shall deliver written notice thereof via electronic mail and overnight courier to Holder (a “Major Transaction Notice”). At any time during the period beginning after Holder’s receipt of a Major Transaction Notice in respect of a Successor Major Transaction and ending five (5) Trading Days prior to the consummation of such Major Transaction (the “Early Termination Period”), Holder may elect a Successor Major Transaction Conversion by delivering written notice thereof (“Major Transaction Early Termination Notice”) to the Company, which Major Transaction Early Termination Notice shall indicate the portion of the Warrant (with reference to the number of shares of Common Stock issuable upon a Cash Exercise of such portion, without regard to the 4.985% Cap) that Holder is electing to be treated as a Successor Major Transaction Conversion. The portion of this Warrant subject to early termination pursuant to this Section 5(b)(iii), shall be converted into the right to receive the Successor Major Transaction Consideration

To the extent Holder shall elect to effect a Cashless Major Exercise in respect of a Major Transaction, Holder shall deliver its Exercise Form in accordance with Section 3(b), at any time and from time to time following receipt by Holder of the Major Transaction Notice until the later of (x) the last day of the Exercise Period and (y) the one-year anniversary of the applicable Major Transaction (the “Cashless Major Exercise Period”). For the avoidance of doubt, Holder shall be permitted to make successive Cashless Major Exercises and send successive Exercise Forms in respect of a Cashless Major Exercise from time to time at any time during the Cashless Major Exercise Period.

(iv) Escrow; Payment of Successor Major Transaction Consideration . Following the receipt of a Major Transaction Early Termination Notice in respect of a Successor Major Transaction from Holder, the Company shall not effect a Successor Major Transaction with respect to which Holder has elected a Successor Major Transaction Conversion unless either (A) it obtains, as a condition precedent to such Major Transaction, the written agreement of the Successor Entity that payment of the Successor Major Transaction Consideration shall be made to Holder concurrently with consummation of such Successor Major Transaction, or (B) it shall place the Successor Major Transaction Consideration into an escrow account with an independent escrow agent, and shall instruct the escrow agent to deliver the Successor Major Transaction Consideration to Holder, concurrently with the consummation of the Major Transaction. Notwithstanding clauses (A) and (B) above, Holder shall be treated on a pari passu basis with, and shall not have priority to payments to, the holders of Common Stock in connection with a Major Transaction. For purposes of determining the amount required to be placed in escrow pursuant to the provisions of this subsection (iv) and without affecting the amount of the actual Successor Major Transaction Consideration, the calculation of the price referred to in clause (1) of the first column of Schedule 1 hereto with respect to Stock Price shall be determined based on the Closing Market Price (as defined on Schedule 1) of the Common Stock on the Trading Day immediately preceding the date that the Successor Major Transaction Consideration is deposited with the escrow agent.

(v) Injunction . Following the receipt of a Major Transaction Early Termination Notice from Holder, in the event that the Company attempts to consummate a Successor Major Transaction without either (1) placing the Successor Major Transaction Consideration in escrow in accordance with subsection (iv) above, or (2) obtaining the written agreement of the Successor

 

15


Entity as described in subsection (iv) above, Holder shall have the right to apply for an injunction in any state or federal court sitting in the City of New York, borough of Manhattan to prevent the closing of such Major Transaction until the Successor Major Transaction Consideration is delivered to Holder.

An early termination required by this Section 5(b) shall be made in accordance with the provisions of Section 12. To the extent an early termination required by this Section 5(b) is deemed or determined by a court of competent jurisdiction to be prepayments of the Warrant by the Company, such early termination shall be deemed to be voluntary prepayments. Notwithstanding anything to the contrary in this Section 5, until the Successor Major Transaction Consideration is paid in full, this Warrant may be exercised, in whole or in part, by Holder into shares of Common Stock, or in the event the date of any Exercise is after the consummation of the Major Transaction, shares of publicly traded common stock (or their equivalent) of the Successor Entity pursuant to Section 5(b). The parties hereto agree that in the event of the Company’s early termination of any portion of the Warrant under this Section 5(b), Holder’s damages would be uncertain and difficult to estimate because of the parties’ inability to predict future interest rates and the uncertainty of the availability of a suitable substitute investment opportunity for Holder. Accordingly, any premium due under this Section 5(b) is intended by the parties to be, and shall be deemed, a commercially reasonable estimate of Holder’s actual loss of its investment opportunity and not as a penalty.

(c) Exercise Price Adjusted . As used in this Warrant, the term “Exercise Price” shall mean the purchase price per share specified in Section 3(a) of this Warrant, until the occurrence of an event stated in this Section 5 or otherwise set forth in this Warrant, and thereafter shall mean said price as adjusted from time to time in accordance with the provisions of said subsection. No adjustment made pursuant to any provision of this Section 5 shall have the net effect of increasing the aggregate Exercise Price payable hereunder or, except as expressly provided in Section 5(a), otherwise increasing the Exercise Price.

(d) Adjustments: Additional Shares, Securities or Assets . In the event that at any time, as a result of an adjustment made pursuant to this Section 5 or otherwise, Holder shall, upon Exercise of this Warrant, become entitled to receive shares and/or other securities or assets (other than Common Stock) then, wherever appropriate, all references herein to shares of Common Stock shall be deemed to refer to and include such shares and/or other securities or assets; and thereafter the number of such shares and/or other securities or assets shall be subject to adjustment from time to time in a manner and upon terms as nearly equivalent as practicable to the provisions of this Section 5.

(e) Notice of Adjustments . Whenever the Exercise Price and/or number or type of securities issuable upon Exercise is adjusted pursuant to the terms of this Warrant, the Company shall promptly mail to Holder a notice (an “Exercise Price Adjustment Notice”) setting forth the Exercise Price and/or number or type of securities issuable upon Exercise after such adjustment and setting forth a statement of the facts requiring such adjustment. The Company shall, upon the written request at any time of Holder, furnish to Holder a like Warrant setting forth (i) such adjustment or readjustment, (ii) the Exercise Price at the time in effect and (iii) the number of shares of Common Stock and the amount, if any, of other securities or property which at the time would be received upon Exercise of the Warrant. For purposes of clarification, whether or not

 

16


the Company provides an Exercise Price Adjustment Notice pursuant to this Section 5(e), upon the occurrence of any event that leads to an adjustment of the Exercise Price, Holder would be entitled to receive a number of Exercise Shares based upon the new Exercise Price, as adjusted, for exercises occurring on or after the date of such adjustment, regardless of whether Holder accurately refers to the adjusted Exercise Price in the Exercise Form.

6. Fractional Interests .

No fractional shares or scrip representing fractional shares shall be issuable upon the Exercise of this Warrant, but on Exercise of this Warrant, Holder may purchase only a whole number of shares of Common Stock. If, on Exercise of this Warrant, Holder would be entitled to a fractional share of Common Stock or a right to acquire a fractional share of Common Stock, such fractional share shall be disregarded and the number of shares of Common Stock issuable upon Exercise shall be the next higher whole number of shares.

7. Reservation of Shares .

From and after the date hereof, the Company shall at all times reserve for issuance such number of authorized and unissued shares of Common Stock (or other securities substituted therefor as herein above provided) as shall be sufficient for the Exercise of this Warrant and payment of the Exercise Price. If at any time the number of shares of Common Stock authorized and reserved for issuance is below the number of shares sufficient for the Exercise of this Warrant (a “Share Authorization Failure”) (based on the Exercise Price in effect from time to time), the Company will promptly take all corporate action necessary to authorize and reserve a sufficient number of shares, including calling a special meeting of stockholders to authorize additional shares to meet the Company’s obligations under this Section 7, in the case of an insufficient number of authorized shares, and using its best efforts to obtain stockholder approval of an increase in such authorized number of shares. The Company covenants and agrees that upon the Exercise of this Warrant, all shares of Common Stock issuable upon such Exercise shall be duly and validly issued, fully paid and nonassessable and not subject to preemptive rights, rights of first refusal or similar rights of any Person. The Company covenants and agrees that all shares of Common Stock issuable upon Exercise of this Warrant shall be approved for listing on the NasdaqGS, or, if the NasdaqGS is not the principal trading market for the Common Stock, such principal market on which the Common Stock is traded or listed.

8. Restrictions on Transfer .

(a) Registration or Exemption Required . This Warrant has been issued in a transaction exempt from the registration requirements of the Securities Act by virtue of Section 4(a)(2) of the Securities Act and Rule 506 thereunder and exempt from registration or qualification under applicable state securities (or “blue sky”) laws. None of the Warrant, the Exercise Shares or Failure Payment Shares may be pledged, transferred, sold or assigned except pursuant to an effective registration statement or an exemption to the registration requirements of the Securities Act and applicable state laws, including Rule 144 under the Securities Act, Section 4(a)(7) of the Securities Act or a so-called “4[(a)](1) and a half” transaction.

(b) Assignment . Subject to Section 8(a), Holder may sell, transfer, assign, pledge, or otherwise dispose of this Warrant, in whole or in part. Holder shall deliver a written notice to the

 

17


Company, substantially in the form of the Assignment attached hereto as Exhibit  B , indicating the Person or Persons to whom the Warrant shall be assigned and the respective number of warrants to be assigned to each assignee. The Company shall effect the assignment within three (3) Business Days of its receipt of a completed and executed form of Assignment (the “Transfer Delivery Period”), and shall deliver to the assignee(s) designated by Holder a Warrant or Warrants of like tenor and terms entitling Holder to purchase the appropriate number of shares. This Warrant and the rights evidenced hereby shall inure to the benefit of and be binding upon the successors and assigns of Holder. The provisions of this Warrant are intended to be for the benefit of all Holders from time to time of this Warrant, and shall be enforceable by any such Holder. For avoidance of doubt, in the event Holder notifies the Company that such sale or transfer is a so called “4[(a)](1) and half” transaction, the parties hereto agree that a legal opinion from outside counsel for Holder delivered to counsel for the Company substantially in the form attached hereto as Exhibit  C shall be the only requirement to satisfy an exemption from registration under the Securities Act to effectuate such “4[(a)](1) and half” transaction.

9. Noncircumvention .

The Company hereby covenants and agrees that the Company will not, by amendment of its certificate of incorporation, bylaws or through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issue or sale of securities, or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, and will at all times in good faith carry out all the provisions of this Warrant and take all action as may be required to protect the rights of Holder. Without limiting the generality of the foregoing, the Company (i) shall not increase the par value of any shares of Common Stock receivable upon the exercise of this Warrant above the Exercise Price then in effect, and (ii) shall take all such actions as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable shares of Common Stock upon the exercise of this Warrant.

10. Events of Failure; Definition of Black Scholes Value .

(a) Definition.

The occurrence of each of the following shall be considered to be an “Event of Failure.”

(i) A Delivery Failure occurs, where a “Delivery Failure” shall be deemed to have occurred if the Company fails to use its best efforts to deliver Exercise Shares to Holder within any applicable Delivery Period (other than due to the limitation contained in the second paragraph of Section 1);

(ii) A Legend Removal Failure occurs, where a “Legend Removal Failure” shall be deemed to have occurred if the Company fails to use its best efforts to issue this Warrant and/or Exercise Shares without a restrictive legend, or fails to use it best efforts to remove a restrictive legend, when and as required under Section 2(e) hereof;

(iii) a Transfer Delivery Failure occurs, where a “Transfer Delivery Failure” shall be deemed to have occurred if the Company fails to use its best efforts to deliver a Warrant within any applicable Transfer Delivery Period; and

(iv) a Registration Failure (as defined below).

 

18


For purpose hereof, “Registration Failure” means that (A) the Company fails to file with the SEC on or before the Additional Warrant Filing Deadline (as defined in the Registration Rights Agreement) any Registration Statement required to be filed pursuant to Section 2(a) of the Registration Rights Agreement, (B) the Company fails to use its reasonable best efforts to obtain effectiveness with the SEC, prior to the Additional Warrant Registration Deadline (as defined in the Registration Rights Agreement), and if such Registration Statement does not become effective prior to the Additional Warrant Registration Deadline, as soon as possible thereafter, of any Registration Statement (as defined in the Registration Rights Agreement) that is required to be filed pursuant to Section 2(a) of the Registration Rights Agreement, or fails to use its reasonable best efforts to keep such Registration Statement current and effective as required in Section 3 of the Registration Rights Agreement, (C) the Company fails to file any additional Registration Statement required to be filed pursuant to Section 2(a)(ii) of the Registration Rights Agreement on or before the Additional Filing Deadline (as defined in the Registration Rights Agreement) or fails to use its reasonable best efforts to cause such new Registration Statement to become effective on or before the Additional Registration Deadline (as defined in the Registration Rights Agreement), and if such effectiveness does not occur within such period, as soon as possible thereafter, (D) the Company fails to file any amendment to any Registration Statement, or any additional Registration Statement required to be filed pursuant to Section 3(b) of the Registration Rights Agreement within thirty (30) days of the applicable Registration Trigger Date (as defined in the Registration Rights Agreement), or fails to use its reasonable best efforts to cause such amendment and/or new Registration Statement to become effective within ninety (90) days of the applicable Registration Trigger Date, and, if such effectiveness does not occur within such period, as soon as possible thereafter, (E) any Registration Statement required to be filed under the Registration Rights Agreement, after its initial effectiveness and during the applicable Registration Period (as defined in the Registration Rights Agreement), lapses in effect or, other than on a day during an Allowable Grace Period (as defined in the Registration Rights Agreement), sales of all of the Registrable Securities (as defined in the Registration Rights Agreement) cannot otherwise be made thereunder (whether by reason of the Company’s failure to amend or supplement the prospectus included therein in accordance with the Registration Rights Agreement, the Company’s failure to file and use its reasonable best efforts to obtain effectiveness with the SEC of an additional Registration Statement or amended Registration Statement required pursuant to Section 2(a)(ii) or 3(b) of the Registration Rights Agreement, as applicable, or otherwise), or (F) the Company fails to provide a commercially reasonable written response to any comments to any Registration Statement submitted by the SEC within twenty-five (25) days of the date that such SEC comments are received by the Company.

(b) Failure Payments; Black-Scholes Determination. The Company understands that any Event of Failure (as defined above) could result in economic loss to Holder. In the event that any Event of Failure occurs, as compensation to Holder for such economic loss, the Company agrees to pay to Holder an amount payable, at the Company’s option, either (i) in cash or (ii) in shares of Common Stock that are valued for these purposes at the Volume Weighted Average Price on the date of such calculation (“Failure Payments” and such shares, “Failure Payment Shares”), in each case equal to the total economic loss of Holder determined on a commercially reasonable basis in connection with such Event of Failure for the relevant period (as recalculated on the first Business Day of each month thereafter for as long as Failure Payments shall continue to accrue) from the date of such Event of Failure until the Event of Failure is cured; provided, however, that in the event the Company elects to make Failure Payments in Failure Payment Shares, the

 

19


Company shall issue, and Holder shall only receive, up to such number of shares of Common Stock in respect of Failure Payments such that Holder and any other persons or entities whose beneficial ownership of Common Stock would be aggregated with Holder’s for purposes of Section 13(d) of the Exchange Act (including shares held by any “group” of which Holder is a member, but excluding shares beneficially owned by virtue of the ownership of securities or rights to acquire securities that have limitations on the right to convert, exercise or purchase similar to the limitation set forth herein) shall not collectively beneficially own greater than 4.985% of the total number of shares of Common Stock of the Company then issued and outstanding, and the balance of such Failure Payments shall be paid in cash. For purposes of clarification, it is agreed and understood that Failure Payments shall continue to accrue following any Event of Default until the applicable Default Amount is paid in full. The Company shall satisfy any Failure Payments under this Section pursuant to Section 10(c) below. Failure Payments are in addition to any Shares that Holder is entitled to receive upon Exercise of this Warrant.

(c) Payment of Accrued Failure Payments. The Failure Payments and Failure Payment Shares representing accrued Failure Payments for each Event of Failure shall be paid or issued and delivered, as the case may be, on or before the fifth (5th) Business Day of each month following a month in which Failure Payments accrued. Nothing herein shall limit Holder’s right to pursue actual damages (to the extent in excess of the Failure Payments) for the Company’s Event of Failure, and Holder shall have the right to pursue all remedies available at law or in equity (including a decree of specific performance and/or injunctive relief). Notwithstanding the above, if a particular Event of Failure results in an Event of Default pursuant to Section 11 hereof, then the Failure Payment, for that Event of Failure only, shall be considered to have been satisfied upon payment to Holder of an amount equal to the greater of (i) the Failure Payment, or (ii) the Default Amount, payable in accordance with Section 11.

(d) Maximum Interest Rate. Nothing contained herein or in any document referred to herein or delivered in connection herewith shall be deemed to establish or require the payment of a rate of interest or other charges in excess of the maximum permitted by applicable law. In the event that the rate of interest or dividends required to be paid or other charges hereunder exceed the maximum permitted by such law, any payments in excess of such maximum shall be credited against amounts owed by the Company to Holder and thereby refunded to the Company.

11. Default .

(a) Events Of Default . Each of the following events shall be considered to be an “Event of Default,” unless waived by Holder:

(i) Failure To Effect Registration. With respect to all Registration Failures, a Registration Failure occurs and remains uncured for a period of more than forty-five (45) days (or sixty (60) days in the case where the Company (i) has, by the Filing Deadline (as defined the Registration Rights Agreement) filed a Registration Statement (as defined in the Registration Rights Agreement) covering this Warrant and the number of shares required by the Registration Rights Agreement, and (ii) has responded in writing to any comments to the Registration Statement that the Company has received from the SEC, within ten (10) Business Days of such receipt, and nevertheless the SEC has not declared effective a Registration Statement covering the this

 

20


Warrant and the Shares by the Registration Deadline (as defined in the Registration Rights Agreement)), and such Registration Failure relates solely to the Company’s failure to have the Registration Statement declared effective by the Registration Deadline (as defined in the Registration Rights Agreement) and with respect to a Registration Failure provided in clause (E) of the definition of “Registration Failure,” such Registration Failure occurs and remains uncured for a period of more than forty-five (45) days.

(ii) Failure To Deliver Common Stock . A Delivery Failure (as defined above) occurs and remains uncured for a period of more than twenty (20) days; or at any time, the Company announces or states in writing that it will not honor its obligations to issue shares of Common Stock to Holder upon Exercise by Holder of the Exercise rights of Holder in accordance with the terms of this Warrant.

(iii) Legend Removal Failure . A Legend Removal Failure (as defined above) occurs and remains uncured for a period of twenty (20) days;

(iv) Transfer Delivery Failure . A Transfer Delivery Failure (as defined above) occurs and remains uncured for a period of twenty (20) days;

(v) Corporate Existence; Major Transaction . (A) The Company has failed to (1) place the Successor Major Transaction Consideration into escrow and instruct the escrow agent to release the Successor Major Transaction Consideration to the Holder pursuant to Section 5(b)(iii), or (2) obtain the written agreement of the Successor Entity and cause the Successor Entity to make payment as described in Section 5(b)(iii), (B) the Successor Major Transaction Consideration is not paid contemporaneously with the consummation of the Successor Major Transaction, or (C) with respect to a Major Transaction that is to be treated as an Assumption under the terms hereof, the Company has failed to meet the Assumption requirements of Section 5(b)(i); or

(vi) Section  13 Breach . During the Dividend Restriction Period, the Company declares or pays any dividend or distribution of any kind to the holders of Common Stock of the Company.

(b) Mandatory Early Termination .

(i) Mandatory Early Termination Amount; Cashless Default Exercise . The Company shall notify Holder in writing within two (2) Business Days of the occurrence of an Event of Default. If any Events of Default shall occur then, at the option of Holder, such option exercisable through the delivery of written notice to the Company by such Holder (the “Default Notice”), the Company shall have the right to terminate the outstanding amount of this Warrant and pay to Holder (a “Mandatory Early Termination”), in full satisfaction of its obligations hereunder by delivery of a notice to such effect to Holder within two (2) Business Days following receipt of the Default Notice, an amount payable in cash (the “Mandatory Early Termination Amount” or the “Default Amount”) equal to the Black-Scholes Value of the remaining unexercised portion of this Warrant on the date of such Default Notice (or in the case of an Event of Default referred to in Section 11(a)(vi), on the Trading Day immediately preceding the date the dividend or distribution is declared or, if not first declared, is paid). In the event the Company does not exercise its right to consummate a Mandatory Early Termination, then Holder shall have the right to exercise this Warrant, at any time and from time to time, pursuant to a Cashless Default Exercise in accordance with Section 3(c) above.

 

21


The Mandatory Early Termination Amount shall be payable within five (5) Business Days following the date of the applicable Default Notice.

(ii) Liquidated Damages . The parties hereto acknowledge and agree that the sums payable as Failure Payments or pursuant to a Mandatory Early Termination shall constitute partial liquidated damages and not penalties. The parties further acknowledge that (i) the amount of loss or damages likely to be incurred by Holder is incapable or is difficult to precisely estimate, (ii) the amounts specified bear a reasonable proportion and are not plainly or grossly disproportionate to the probable loss likely to be incurred by Holder, and (iii) the parties are sophisticated business parties and have been represented by sophisticated and able legal and financial counsel and negotiated this agreement at arm’s length.

Upon the occurrence of an Event of Default, the Default Amount, together with all other amounts payable hereunder, shall immediately become due and payable, all without demand, presentment or notice, all of which hereby are expressly waived, together with all costs, including legal fees and expenses, of collection, and Holder shall be entitled to exercise all other rights and remedies available at law or in equity.

(c) Posting Of Bond . In the event that any Event of Default occurs hereunder, the Company may not raise as a legal defense (in any Lawsuit, as defined below, or otherwise) or justification to such Event of Default any claim that such Holder or any one associated or affiliated with such Holder has been engaged in any violation of law, unless the Company has posted a surety bond (a “Surety Bond”) for the benefit of such Holder in the amount of 130% of the aggregate Surety Bond Value (as defined below) of all of Holder’s Warrants (the “Bond Amount”), which Surety Bond shall remain in effect until the completion of litigation of the dispute and the proceeds of which shall be payable to such Holder to the extent Holder obtains judgment.

For purposes hereof, a “Lawsuit” shall mean any lawsuit, arbitration or other dispute resolution filed by either party herein pertaining to any of this Warrant, the Facility Agreement, the Registration Rights Agreement or any other Loan Document (as defined in the Facility Agreement).

“Surety Bond Value,” for the Warrants shall mean 130% of the of the Black-Scholes Value of the remaining unexercised portion of this Warrant on the Trading Day immediately preceding the date that such bond goes into effect.

(d) Injunction And Posting Of Bond . In the event that the Event of Default referred to in subsection (a) of this Section 11 pertains to the Company’s failure to deliver unlegended shares of Common Stock to Holder pursuant to a Warrant Exercise, legend removal request, or otherwise, the Company may not refuse such unlegended share delivery based on any claim that such Holder or any one associated or affiliated with such Holder has been engaged in any violation of law, unless an injunction from a court, on prior notice to Holder, restraining and or enjoining Exercise of all or part of said Warrant shall have been sought and obtained by the Company and the Company has posted a Surety Bond for the benefit of such Holder in the amount of the Bond Amount, which Surety Bond shall remain in effect until the completion of litigation of the dispute and the proceeds of which shall be payable to such Holder to the extent Holder obtains judgment.

 

22


(e) Remedies, Other Obligations, Breaches And Injunctive Relief . The remedies provided in this Warrant shall be cumulative and in addition to all other remedies available under this Warrant, the Facility Agreement, the Registration Rights Agreement and any other Loan Document, at law or in equity (including a decree of specific performance and/or other injunctive relief), and nothing herein shall limit the right of Holder to pursue actual damages for any failure by the Company to comply with the terms of this Warrant. The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to Holder and that the remedy at law for any such breach may be inadequate. The Company therefore agrees that, in the event of any such breach or threatened breach (including a breach or threatened breach of Section 13), the holder of this Warrant shall be entitled, in addition to all other available remedies, to an injunction restraining any breach, without the necessity of showing economic loss and without any bond or other security being required.

12. Holder’s Early Terminations .

(a) Mechanics of Holder s Early Terminations . In the event that the Company does not deliver the applicable Successor Major Transaction Consideration or Default Amount or the Exercise Shares in respect of an election of a Successor Major Transaction Conversion, Cashless Major Exercise, Cashless Default or Exercise, as the case may be, to Holder within the time period or as otherwise required pursuant to the terms hereof, at any time thereafter Holder shall have the option, upon notice to the Company, in lieu of an election of a Successor Major Transaction Conversion, Cashless Major Exercise, Cashless Default Exercise or Exercise, as the case may be, to require the Company to promptly return to Holder all or any portion of this Warrant that was submitted for election of a Successor Major Transaction Conversion, Cashless Major Exercise, Cashless Default Exercise or Exercise, as the case may be. Upon the Company’s receipt of such notice, (x) the applicable election of Successor Major Transaction Conversion, Cashless Major Exercise, Cashless Default Exercise or Exercise, as the case may be, shall be null and void with respect to such applicable portion of this Warrant, (y) the Company shall immediately return this Warrant, or issue a new Warrant to Holder representing the portion of this Warrant that was submitted for election of Successor Major Transaction Conversion, Cashless Major Exercise, Cashless Default Exercise or Exercise, as the case may be, and (z) the Exercise Price of this Warrant or such new Warrant shall be adjusted to the Exercise Price as in effect on the date on which the applicable election of Successor Major Transaction Conversion, Cashless Major Exercise, Cashless Default Exercise or Exercise, as the case may be, is voided. Holder’s delivery of a notice voiding an election of a Successor Major Transaction Conversion, Cashless Major Exercise, Cashless Default Exercise or Exercise, as the case may be, and exercise of its rights following such notice shall not affect the Company’s obligations to make any Failure Payments which have accrued prior to the date of such notice with respect to the Warrant subject to such notice.

13. Dividend Restrictions .

Until the earlier of the expiration of the Exercise Period and the date all of the Warrants are exercised in full (the “Dividend Restriction Period”), the Company shall not declare or pay any dividend or distribution of any kind to the holders of Common Stock of the Company.

14. Benefits of this Warrant .

 

23


Nothing in this Warrant shall be construed to confer upon any person other than the Company and Holder any legal or equitable right, remedy or claim under this Warrant and this Warrant shall be for the sole and exclusive benefit of the Company and Holder.

15. Governing Law .

All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement (whether brought against a party hereto or its respective affiliates, directors, officers, stockholders, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York, borough of Manhattan. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. The parties hereby waive all rights to a trial by jury. If either party shall commence an action or proceeding to enforce any provisions of this Agreement, then the prevailing party in such action or proceeding shall be reimbursed by the other party for its reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.

16. Loss of Warrant .

Upon receipt by the Company of evidence of the loss, theft, destruction or mutilation of this Warrant, and (in the case of loss, theft or destruction) of indemnity or security reasonably satisfactory to the Company, and upon surrender and cancellation of this Warrant, if mutilated, the Company shall execute and deliver a new Warrant of like tenor and date.

17. Notice or Demands .

Except as otherwise provided herein, notices or demands pursuant to this Warrant to be given or made by Holder to or on the Company shall be sufficiently given or made if sent by overnight delivery with a nationally recognized overnight courier service, certified or registered mail, return receipt requested, postage prepaid, and addressed, until another address is designated in writing by the Company, to the address set forth in Section 2(a) above. To the extent any notice or demand pursuant to this Warrant can be made by electronic mail, such notice or demand given or made by Holder to or on the Company shall be sufficiently given or made if it is sent by electronic mail to the addresses that the Company shall designate in writing from time to time. Notices or demands pursuant to this Warrant to be given or made by the Company to or on

 

24


Holder shall be sufficiently given or made if sent by overnight delivery with a nationally recognized overnight courier service or certified or registered mail, return receipt requested, postage prepaid, and addressed, to the address of Holder set forth in the Company’s records, until another address is designated in writing by Holder.

18. Construction .

Unless the context otherwise requires, (a) all references to Articles, Sections, Schedules or Exhibits are to Articles, Sections, Schedules or Exhibits contained in or attached to this Warrant, (b) words in the singular or plural include the singular and plural and pronouns stated in either the masculine, the feminine or neuter gender shall include the masculine, feminine and neuter and (c) the use of the word “including” in this Warrant shall be by way of example rather than limitation.

19. Signatures .

In the event that any signature to this Warrant or any amendment hereto is delivered by electronic mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such “.pdf” signature page were an original thereof. Notwithstanding the foregoing, the Company shall be obligated to deliver to Holder an original signature to this Warrant. At the request of any party, each other party shall promptly re-execute an original form of this Warrant or any amendment hereto and deliver the same to the other party. No party hereto shall raise the use of electronic mail delivery of a “.pdf” format data file to deliver a signature to this Warrant or any amendment hereto or the fact that such signature was transmitted or communicated through the use of electronic mail delivery of a “.pdf” format data file as a defense to the formation or enforceability of a contract, and each party hereto forever waives any such defense.

 

25


IN WITNESS WHEREOF, the undersigned has executed this Warrant as of the 9th day of August, 2018.

 

ENDOLOGIX, INC.
By:  

/s/ Vaseem Mahboob

  Print Name: Vaseem Mahboob
  Title: Chief Financial Officer

 

26


EXHIBIT A-1

EXERCISE FORM FOR WARRANT

TO: [                    ]

CHECK THE APPLICABLE BOX:

 

Cash Exercise, Cashless Exercise or Note Exchange Exercise

The undersigned hereby irrevocably exercises Warrant Number              (the “Warrant”) with respect to 2,916,667 shares of Common Stock (the “Common Stock”) of Endologix, Inc., a Delaware corporation (the “Company”). [IF APPLICABLE: The undersigned hereby encloses $         as payment of the Exercise Price.]

 

The undersigned is exercising the Warrant with respect to [            ] shares of Common Stock pursuant to a Cashless Exercise, and hereby makes payment of the Exercise Price with respect to such shares in full, all in accordance with the conditions and provisions of the Warrant applicable to such Cashless Exercise.

 

The undersigned is exercising the Warrant with respect to [            ] shares of Common Stock pursuant to a Note Exchange Exercise. The undersigned hereby agrees to cancel $         of principal outstanding under Notes of the Company held by Holder in satisfaction of the Exercise Price in accordance with the conditions and provisions of the Warrant applicable to such Note Exchange Exercise.

 

Cashless Major Exercise

The undersigned hereby irrevocably exercises the Warrant with respect to ____% of the Warrant currently outstanding pursuant to a Cashless Major Exercise in accordance with the terms of the Warrant.

 

Cashless Default Exercise

The undersigned hereby irrevocably exercises the Warrant pursuant to a Cashless Default Exercise, in accordance with the terms of the Warrant.

1. The undersigned requests that any stock certificates for such shares be issued free of any restrictive legend, if appropriate, and, if requested by the undersigned, a warrant representing any unexercised portion hereof be issued, pursuant to the Warrant in the name of the undersigned and delivered to the undersigned at the address set forth below.

2. Capitalized terms used but not otherwise defined in this Exercise Form shall have the meaning ascribed thereto in the Warrant.

Dated:                    

 

 

Signature

 

 

Print Name

 

 

Address

NOTICE

The signature to the foregoing Exercise Form must correspond to the name as written upon the face of the attached Warrant.

 

27


EXHIBIT B

ASSIGNMENT

(To be executed by the registered holder

desiring to transfer the Warrant)

FOR VALUE RECEIVED, the undersigned holder of the attached warrant (the “Warrant”) hereby sells, assigns and transfers unto the person or persons below named the right to purchase                      shares of the Common Stock of Endologix, Inc., a Delaware corporation, evidenced by the attached Warrant and does hereby irrevocably constitute and appoint                      attorney to transfer the said Warrant on the books of the Company, with full power of substitution in the premises.

 

Dated:                         

 

    Signature
Fill in for new registration of Warrant:    

 

Name

   

 

Address

   

 

Please print name and address of assignee

   
(including zip code number)    

NOTICE

The signature to the foregoing Assignment must correspond to the name as written upon the face of the attached Warrant.

 

28


EXHIBIT C

FORM OF OPINION

            , 20        

[                        ]

Re:     [                     ] (the “Company”)

Dear Sir:

[                    ] (“[                    ]”) intends to transfer              Warrants (the “Warrants”) of the Company to                  (“            ”) without registration under the Securities Act of 1933, as amended (the “Securities Act”). In connection therewith, we have examined and relied upon the truth of representations contained in an Investor Representation Letter attached hereto and have examined such other documents and issues of law as we have deemed relevant.

Based on and subject to the foregoing, we are of the opinion that the transfer of the Warrants by              to              may be effected without registration under the Securities Act [, provided, however, that the Warrants to be transferred to              contain a legend restricting its transferability pursuant to the Securities Act and that transfer of the Warrants is subject to a stop order] . 1

The foregoing opinion is furnished only to                          and may not be used, circulated, quoted or otherwise referred to or relied upon by you for any purposes other than the purpose for which furnished or by any other person for any purpose, without our prior written consent.

Very truly yours,

 

1  

Only if applicable.

 

29


[FORM OF INVESTOR REPRESENTATION LETTER]

            , 20        

[                             ]

Gentlemen:

                 (“    ”) has agreed to purchase                  Warrants (the “Warrants”) of Endologix, Inc., a Delaware corporation (the “Company”) from [                    ] (“[                ]”). We understand that the Warrants are “restricted securities.” We represent and warrant that              is a sophisticated institutional investor that would qualify as an “Accredited Investor” as defined in Rule 501 of Regulation D under the Securities Act of 1933, as amended (the “Securities Act”).

            represents and warrants as of the date hereof as follows:

1. That it is acquiring the Warrants and the shares of common stock, $0.001 par value per share underlying such Warrants (the “Exercise Shares”) solely for its account for investment and not with a view to or for sale or distribution of said Warrants or Exercise Shares or any part thereof in violation of the Securities Act.                  also represents that the entire legal and beneficial interests of the Warrants and Exercise Shares                  is acquiring is being acquired for, and will be held for, its account only;

2. That the Warrants and the Exercise Shares must be held indefinitely unless they are registered under the Securities Act or an exemption from such registration is available.                  recognizes that the Company has no obligation to register the Warrants, or to comply with any exemption from such registration;

3. That neither the Warrants nor the Exercise Shares may be sold pursuant to Rule 144 adopted under the Securities Act unless certain conditions are met;

We acknowledge that the Company will place stop orders with respect to the Warrants and the Exercise Shares, and if none of the Unrestricted Conditions (as defined in the Warrants) is satisfied, the Exercise Shares shall bear the following restrictive legend:

“THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER SAID ACT, OR PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER SAID ACT INCLUDING PURSUANT TO SECTION 4(A)(7) OF THE SECURITIES ACT OR RULE 144 UNDER SAID ACT OR PURSUANT TO A PRIVATE SALE EFFECTED UNDER APPLICABLE FORMAL OR INFORMAL SEC INTERPRETATION OR GUIDANCE, SUCH AS A SO-CALLED “4[(a)](1) AND A HALF” SALE.

 

30


NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.”

“THE SALE, TRANSFER OR ASSIGNMENT OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO THE TERMS AND CONDITIONS OF A CERTAIN AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT DATED AS OF AUGUST 9, 2018, AS AMENDED FROM TIME TO TIME, AMONG THE COMPANY AND CERTAIN HOLDERS OF ITS OUTSTANDING SECURITIES. COPIES OF SUCH AGREEMENT MAY BE OBTAINED AT NO COST BY WRITTEN REQUEST MADE BY THE HOLDER OF RECORD OF THIS CERTIFICATE TO THE SECRETARY OF THE COMPANY.”

At any time and from time to time after the date hereof,                  shall, without further consideration, execute and deliver to [                ] or the Company such other instruments or documents and shall take such other actions as they may reasonably request to carry out the transactions contemplated hereby.

Very truly yours,

 

31


Schedule 1

Black-Scholes Value

 

    

Calculation Under Sections 3(b) and 5(b)(iii)

  

Calculation Under Section 10(b) or 11(b)

Remaining Term    Number of calendar days from date of public announcement of the Major Transaction until the last date on which the Warrant may be exercised.    Number of calendar days from the date of the Event of Failure, or in the case of an Event of Default, the date of the Default Notice, until the last date on which the Warrant may be exercised.
Interest Rate    A risk-free interest rate corresponding to the US$ LIBOR/Swap rate for a period equal to the remaining Exercise Period.    A risk-free interest rate corresponding to the US$ LIBOR/Swap rate for a period equal to the remaining Exercise Period.
Cost to Borrow    Zero    Zero
Volatility   

If the first public announcement of the Major Transaction is made at or prior to 4:00 p.m., New York City time, the arithmetic mean of the historical volatility for the 10, 30 and 50 Trading Day periods ending on the date of such first public announcement, obtained from the HVT or similar function on Bloomberg.

If the first public announcement of the Major Transaction is made after 4:00 p.m., New York City time, the arithmetic mean of the historical volatility for the 10, 30 and 50 Trading Day periods ending on the next succeeding Trading Day following the date of such first public announcement, obtained from the HVT or similar function on Bloomberg.

   The arithmetic mean of the historical volatility for the 10, 30 and 50 Trading Day periods ending on the date of such determination, obtained from the HVT or similar function on Bloomberg.

 

32


Stock Price    As selected by Holder in its commercially reasonable discretion in order to produce a commercially reasonable result, any of: (1) the closing price of the Common Stock on the NasdaqGS, or, if that is not the principal trading market for the Common Stock, such principal market on which the Common Stock is traded or listed (the “Closing Market Price”) on the Trading Day immediately preceding the date on which a Major Transaction is consummated, (2) the first Closing Market Price following the first public announcement of a Major Transaction, (3) the Closing Market Price as of the date immediately preceding the first public announcement of the Major Transaction or (4) the cash amount payable per share of Common Stock. The Company and Holder acknowledge and agree that any of the above will produce a commercially reasonable result.    The volume Weighted Average Price on the date of such determination.
Dividends    Zero.    Zero.
Strike Price    Exercise Price as defined in section 3(a).    Exercise Price as defined in section 3(a).

 

33

Exhibit 4.3

WARRANT

THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAW. THE SECURITIES MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT, EXCEPT PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT, INCLUDING PURSUANT TO SECTION 4(A)(7) OF THE SECURITIES ACT OR RULE 144 UNDER THE SECURITIES ACT OR PURSUANT TO A PRIVATE SALE EFFECTED UNDER APPLICABLE FORMAL OR INFORMAL SEC INTERPRETATION OR GUIDANCE, SUCH AS A SO-CALLED “4[(a)](1) AND A HALF SALE.” NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

AN INVESTMENT IN THESE SECURITIES INVOLVES A HIGH DEGREE OF RISK. HOLDERS MUST RELY ON THEIR OWN ANALYSIS OF THE INVESTMENT AND ASSESSMENT OF THE RISKS INVOLVED.

 

Warrant to Purchase

2,916,667 shares

   Warrant Number:     2018-3

Warrant to Purchase Common Stock

of

Endologix, Inc.

THIS CERTIFIES that Deerfield Partners, L.P. or any subsequent holder hereof (“Holder”) has the right to purchase from Endologix, Inc., a Delaware corporation (the “Company”), Two Million Nine Hundred Sixteen Thousand Six Hundred Sixty-Seven (2,916,667) fully paid and nonassessable shares of the Company’s common stock, $0.001 par value per share (“Common Stock”), subject to adjustment as provided herein, at a price equal to the Exercise Price (as defined in Section 3 below), at any time during the Exercise Period (as defined in Section 1 below).

Holder agrees with the Company that this Warrant to Purchase Common Stock of the Company (this “Warrant” or this “Agreement”) is issued and all rights hereunder shall be held subject to all of the conditions, limitations and provisions set forth herein.

1. Date of Issuance and Term .

This Warrant shall be deemed to be issued, and shall be in full force and effect commencing, on August 9, 2018 (“Date of Issuance”). The exercise period of this Warrant begins on (and includes) February 9, 2019, and ends at 5:00 p.m., New York City time, on August 9, 2025 (the “Exercise Period”). This Warrant was issued pursuant to that certain Amended and Restated Facility Agreement (as may be amended, restated, supplemented or otherwise modified from


time to time in accordance with the terms thereof, the “Facility Agreement”) by and among the Company, Deerfield Private Design Fund III, L.P., Deerfield Private Design Fund IV, L.P., and Deerfield Partners, L.P., dated as of August 9, 2018, and in conjunction with that certain Amended and Restated Registration Rights Agreement (as may be amended, restated, supplemented or otherwise modified from time to time in accordance with the terms thereof, the “Registration Rights Agreement”) by and among the Company, Deerfield Private Design Fund III, L.P., Deerfield Private Design Fund IV, L.P., and Deerfield Partners, L.P., dated as of August 9, 2018.

Notwithstanding anything herein to the contrary, the Company shall not issue to Holder, and Holder may not acquire, a number of shares of Common Stock upon exercise of this Warrant to the extent that, upon such exercise, the number of shares of Common Stock then beneficially owned by Holder and its Affiliates and any other persons or entities whose beneficial ownership of Common Stock would be aggregated with Holder’s for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (including shares held by any “group” of which Holder is a member, but excluding shares beneficially owned by virtue of the ownership of securities or rights to acquire securities that have limitations on the right to convert, exercise or purchase similar to the limitation set forth herein), would exceed 4.985% of the total number of shares of Common Stock then issued and outstanding (the “4.985% Cap”); provided, however, that the 4.985% Cap shall only apply to the extent that the Common Stock is deemed to constitute an “equity security” pursuant to Rule 13d-1(i) promulgated under the Exchange Act. For purposes hereof, “group” has the meaning set forth in Section 13(d) of the Exchange Act and applicable regulations of the Securities and Exchange Commission (the “SEC”), and the percentage held by Holder shall be determined in a manner consistent with the provisions of Section 13(d) of the Exchange Act. Upon the written request of Holder, the Company shall, within two (2) Trading Days, confirm orally and in writing to Holder the number of shares of Common Stock then outstanding.

For purposes hereof:

“Affiliate” means any person or entity that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a person or entity, as such terms are used in and construed under Rule 144 (“Rule 144”) under the Securities Act of 1933, as amended (the “Securities Act”). With respect to a Holder, any investment fund or managed account that is managed on a discretionary basis by the same investment manager as such Holder shall, for purposes hereof, be deemed to be an Affiliate of such Holder.

“Asset Sale” means a transaction covered by the provisions of clause (B) of the definition of “Major Transaction” involving the sale or transfer of all or substantially all of the assets of the Company (including, for the avoidance of doubt, all or substantially all of the assets of the Company and its Subsidiaries (as defined in the Facility Agreement), taken as a whole) in connection with which the Company has announced its intention to liquidate and distribute its assets to stockholders.

“Black-Scholes Value” shall mean the Black-Scholes value of this Warrant, or applicable portion thereof, as determined by use of the Black-Scholes Option Pricing Model using the criteria set forth on Schedule 1 hereto.

 

2


“Business Day” means a day other than a Saturday or Sunday or any other day on which commercial banks are authorized or required by law to close in New York City.

“Cashless Default Exercise” shall mean an exercise of this Warrant as a “Cashless Default Exercise” in accordance with Sections 3(c) and 11(b) hereof.

“Cashless Major Exercise” shall mean an exercise of this Warrant or portion thereof as a “Cashless Major Exercise” in accordance with Sections 3(b) and 5(b)(i) hereof.

“Cash Out Major Transaction” means a Major Transaction in which the consideration payable to holders of Common Stock in connection with the Major Transaction consists solely of cash.

“Eligible Market” means the New York Stock Exchange, the NASDAQ Capital Market, the NASDAQ Global Market, the NASDAQ Global Select Market, the NYSE American or, in each case, any successor thereto.

“Parent Entity” of a Person means an entity that, directly or indirectly, controls the applicable Person and whose common stock or equivalent equity security is quoted or listed on an Eligible Market, or, if there is more than one such Person or Parent Entity, the Person or Parent Entity with the largest public market capitalization as of the date of consummation of a Major Transaction.

“Person” means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other entity and a government or any department or agency thereof.

“Standard Settlement Period” means the standard settlement period for equity trades effected on securities exchanges in the United States, expressed in a number of Trading Days, as in effect on the applicable Date of Exercise (as defined in Section 2(b)).

“Stock Event” means a stock split, stock combination, reclassification, payment of stock dividend, recapitalization or other similar transaction of such character that the shares of Common Stock shall be changed into or become exchangeable for a larger or small number of shares.

“Successor Entity” means any Person purchasing the Company’s assets or Common Stock, or any successor entity resulting from such Major Transaction, or if the Warrant is to be exercisable for shares of capital stock of a Parent Entity (as defined above), such Person’s Parent Entity.

“Successor Major Transaction” means either a Takeout Major Transaction or an Asset Sale.

“Successor Major Transaction Consideration” means (i) in the case of a Takeout Major Transaction (other than a Cash Out Major Transaction), the amount of cash and other assets and the number of securities or other property of the Successor Entity or other entity that would be issuable in such Major Transaction, in respect of a number of shares equal to the Successor Major Transaction Conversion Share Amount and (ii) in the case of an Asset Sale or a Cash Out Major Transaction, an amount of cash equal to the Black-Scholes Value of the Warrant.

 

3


“Successor Major Transaction Conversion Share Amount” means an amount equal to the Black-Scholes Value of the Warrant (or such applicable portion subject to a Successor Major Transaction Conversion), divided by the closing price of the Common Stock on the principal securities exchange or other securities market on which the Common Stock is then traded on the Trading Day immediately preceding the date on which the applicable Major Transaction is consummated.

“Takeout Major Transaction” means a transaction covered by the provisions of clause (A) of the definition of “Major Transaction” in which the shares of Common Stock of the Company are converted into the right to receive cash, securities of another entity and/or other assets.

“Trading Day” shall mean any day on which the Common Stock is traded for any period on the NASDAQ Global Select Market (“NasdaqGS”) or, if the NasdaqGS is not the principal trading market for the Common Stock, on the principal securities exchange or other securities market on which the Common Stock is then being traded; provided, however, that during any period in which the Common Stock is not listed or quoted on the NasdaqGS or any other securities exchange or market, the term “Trading Day” shall mean a Business Day.    

2. Exercise .

(a) Manner of Exercise . During the Exercise Period (or, in respect of a Cashless Major Exercise, the Cashless Major Exercise Period (as defined below)), this Warrant may be Exercised as to all or any lesser number of whole shares of Common Stock covered hereby (the “Warrant Shares” or the “Shares”) by sending to the Company the Exercise Form attached hereto as Exhibit  A-1 (the “Exercise Form”) duly completed and executed, and, if applicable, the full Exercise Price (as defined below, which may be satisfied by a Cash Exercise, a Cashless Exercise or a Note Exchange Exercise, as each is defined below) for each share of Common Stock as to which this Warrant is Exercised, at the office of the Company, 2 Musick, Irvine, CA 92618, Attention: Chief Financial Officer; Phone: (949) 595-7200, Email: vmahboob@endologix.com, or at such other office or agency as the Company may designate in writing, by overnight mail or electronic mail (any such exercise of the Warrant being hereinafter called an “Exercise” of this Warrant).

(b) Date of Exercise . The “Date of Exercise” of the Warrant shall, in each case, be the date that the Exercise Form attached hereto as Exhibit  A-1 , completed and executed, is sent by electronic mail to the Company, provided that the Exercise Price is satisfied as soon as practicable thereafter but in no event later than two (2) Business Days following the date of such electronic mail. Alternatively, the Date of Exercise shall be defined as the date the original Exercise Form is received by the Company, if Holder has not previously sent the Exercise Form by electronic mail. Upon delivery of the Exercise Form to the Company by electronic mail or otherwise, Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been Exercised, irrespective of the date such Warrant Shares are credited to Holder’s or its designee’s Depository Trust Company (“DTC”) account or the date of delivery of the certificates evidencing such Warrant Shares, as the case may be; provided, however, that in the event an Exercise Form in respect of a Cashless Major Exercise is delivered prior to the occurrence of the applicable Major Transaction, Holder shall be deemed to have become the holder of record of the shares issuable upon such exercise immediately prior to the consummation of such Major Transaction and the Date of Exercise shall

 

4


in such event be deemed to have occurred on the date of the occurrence of the Major Transaction. Holder shall not be required to physically surrender this Warrant to the Company until Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days following the date the final Exercise Form is delivered to the Company. Execution and delivery of an Exercise Form with respect to a partial Exercise shall have the same effect as cancellation of the original Warrant and issuance of a new Warrant evidencing the right to purchase the remaining number of Warrant Shares.

(c) Delivery of Common Stock Upon Exercise . Within the earlier of (x) two (2) Trading Days and (y) the number of Trading Days comprising the Standard Settlement Period after any Date of Exercise (but, in the case of a Cash Exercise, within two (2) Business Days following the Company’s receipt of the full Exercise Price, if later) or in the case of a Cashless Default Exercise (as defined in Section 5(b) below), within the period provided in Section 3(c), as applicable (the “Delivery Period”), the Company shall issue and deliver (or cause its transfer agent (the “Transfer Agent”) to issue and deliver) in accordance with the terms hereof to or upon the order of Holder that number of shares of Common Stock (“Exercise Shares”) for the portion of this Warrant exercised as shall be determined in accordance herewith. Upon the Exercise of this Warrant or any part hereof, the Company shall, at its own cost and expense, take all necessary action, including obtaining and delivering an opinion of counsel, to assure that the Transfer Agent shall issue stock certificates in the name of Holder (or its nominee) or such other persons as designated by Holder and in such denominations as Holder shall specify at Exercise, representing the number of shares of Common Stock issuable upon such Exercise. The Company warrants that no instructions other than these instructions have been or will be given to the Transfer Agent and that, unless waived by Holder, this Warrant and the Exercise Shares will be free-trading, and freely transferable, and will not contain or be subject to a legend (or be subject to any stop transfer instruction) restricting the resale or transferability of the Exercise Shares if the Unrestricted Conditions (as defined below) are met.

The Company shall be responsible for paying all present or future stamp, court or documentary, intangible, recording, filing or similar taxes that arise from any payment or issuance made under, from the execution, delivery, performance or enforcement of, or otherwise with respect to, this Warrant.

(d) Delivery Failure . In addition to any other remedies which may be available to Holder, in the event that the Company fails for any reason to effect delivery of the Exercise Shares by the end of the Delivery Period (a “Delivery Failure”), Holder will be entitled to revoke all or part of the relevant Exercise by delivery of a notice to such effect to the Company whereupon the Company and Holder shall each be restored to their respective positions immediately prior to the delivery of such notice of revocation, except that the Failure Payments under Section 10(b) shall be payable through the date such notice of revocation is given to the Company.

(e) Legends .

(i) Restrictive Legend . Holder understands that until such time as this Warrant, the Exercise Shares and the Failure Payment Shares (as defined below) have been registered under the Securities Act or otherwise may be sold pursuant to Rule 144 or an exemption from registration

 

5


under the Securities Act without any restriction as to the number of securities as of a particular date that can then be immediately sold, this Warrant, the Exercise Shares and the Failure Payment Shares, as applicable, may bear a restrictive legend in substantially the following form (and a stop-transfer order consistent therewith may be placed against transfer of the certificates for such securities):

“THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER SAID ACT, EXCEPT PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER SAID ACT INCLUDING PURSUANT TO SECTION 4(A)(7) OF THE SECURITIES ACT OR RULE 144 UNDER SAID ACT OR PURSUANT TO A PRIVATE SALE EFFECTED UNDER APPLICABLE FORMAL OR INFORMAL SEC INTERPRETATION OR GUIDANCE, SUCH AS A SO-CALLED “4[(a)](1) AND A HALF” SALE.” NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

“THE SALE, TRANSFER OR ASSIGNMENT OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO THE TERMS AND CONDITIONS OF A CERTAIN AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT DATED AS OF AUGUST 9, 2018, AS AMENDED FROM TIME TO TIME, AMONG THE COMPANY AND CERTAIN HOLDERS OF ITS OUTSTANDING SECURITIES. COPIES OF SUCH AGREEMENT MAY BE OBTAINED AT NO COST BY WRITTEN REQUEST MADE BY THE HOLDER OF RECORD OF THIS CERTIFICATE TO THE SECRETARY OF THE COMPANY.”

(ii) Removal of Restrictive Legends . This Warrant and the certificates (or electronic book entries, if applicable) evidencing the Exercise Shares and the Failure Payment Shares, as applicable, shall not contain or be subject to any legend restricting the transfer thereof (including the legend set forth above in subsection 2(e)(i)) or be subject to any stop-transfer instructions: (A) while a registration statement (including a Registration Statement, as defined in the Registration Rights Agreement) covering the sale or resale of such security is effective under the Securities Act, or (B) following any sale of such Warrant, Exercise Shares and/or Failure Payment Shares pursuant to Rule 144, or (C) if such Warrant, Exercise Shares and/or Failure Payment Shares are eligible for sale under Rule 144(b)(1), or (D) at any time on or after the date hereof on which Holder’s holding period for purposes of Rule 144 under the Securities Act and subsection (d)(3)(iii) thereof with respect to such Warrant, Exercise Shares and/or Failure Payment Shares is at least six (6) months and Holder certifies that it is not an “affiliate” (as defined in Rule 144 under the Securities Act), or (E) if such legend is not required under applicable requirements of the

 

6


Securities Act (including judicial interpretations and pronouncements issued by the staff of the SEC) (collectively, the “Unrestricted Conditions”). The Company shall cause its counsel to issue a legal opinion to the Transfer Agent promptly after the Effective Date, or at such other time as any of the Unrestricted Conditions have been met, if required by the Transfer Agent to effect the issuance of this Warrant, the Exercise Shares or the Failure Payment Shares, as applicable, without a restrictive legend or removal of the legend hereunder. If any of the Unrestricted Conditions are met at the time of issuance of this Warrant, the Exercise Shares or the Failure Payment Shares, then such Warrant, Exercise Shares or Failure Payment Shares, as applicable, shall be issued free of all legends and stop-transfer instructions. The Company agrees that following the Effective Date, or at such time as the Unrestricted Conditions are met or such legend is otherwise no longer required under this Section 2(e), it will, no later than the earlier of (x) two (2) Trading Days and (y) the number of Trading Days comprising the Standard Settlement Period following the delivery (the “Unlegended Shares Delivery Deadline”) by Holder to the Company or the Transfer Agent of this Warrant and a certificate representing Exercise Shares and/or Failure Payment Shares, as applicable, issued with a restrictive legend, deliver or cause to be delivered to Holder this Warrant and/or a certificate (or electronic transfer) representing such shares that is free from all restrictive and other legends (and stop transfer instructions). For purposes hereof, “Effective Date” shall mean the date that the first Registration Statement that the Company is required to file pursuant to the Registration Rights Agreement has been declared effective by the SEC.

(iii) Sale of Unlegended Shares . Holder agrees that the removal of the restrictive legend from this Warrant and any certificates representing securities as set forth in Section 2(e) above is predicated upon the Company’s reliance that Holder will sell this Warrant or any Exercise Shares and/or any Failure Payment Shares, as applicable, pursuant to either the registration requirements of the Securities Act, including any applicable prospectus delivery requirements, or an exemption therefrom, and that if such securities are sold pursuant to a Registration Statement, they will be sold in compliance with the plan of distribution set forth therein.

(f) Cancellation of Warrant . This Warrant shall be canceled upon the full Exercise of this Warrant, and, as soon as practical after the Date of Exercise, Holder shall be entitled to receive Common Stock for the number of shares purchased upon such Exercise of this Warrant, and if this Warrant is not Exercised in full, Holder shall be entitled to receive a new Warrant (containing terms identical to this Warrant) representing any unexercised portion of this Warrant in addition to such Common Stock; provided, however, as set forth in Section 2(b), Holder shall not be required to physically surrender this warrant if the Warrant is not Exercised in full.

(g) Holder of Record . Each person in whose name any Warrant for shares of Common Stock is issued shall, for all purposes, be deemed to be Holder of record of such shares on the Date of Exercise, irrespective of the date of delivery of the Common Stock purchased upon the Exercise of this Warrant. Prior to the exercise of this Warrant, nothing in this Warrant shall be construed as conferring upon Holder any rights as a stockholder of the Company.

(h) Delivery of Electronic Shares . In lieu of delivering physical certificates representing the Common Stock issuable upon Exercise or legend removal, or representing Failure Payment Shares, upon written request of Holder, the Company shall use its best efforts to cause the Transfer Agent to electronically transmit the Common Stock issuable upon Exercise to Holder

 

7


by crediting the account of Holder’s prime broker with DTC through its Deposit/Withdrawal at Custodian (DWAC) system. The time periods for delivery and penalties described herein shall apply to the electronic transmittals described herein. Any delivery not effected by electronic transmission shall be effected by delivery of physical certificates.

(i) Buy-In . In addition to any other rights or remedies available to Holder hereunder or otherwise at law or in equity, if the Company fails to cause its Transfer Agent to deliver to Holder a certificate or certificates, or electronic shares through DWAC, representing the Exercise Shares pursuant to an Exercise on or before the last day of the Delivery Period (other than a failure caused by any incorrect or incomplete information provided by Holder to the Company hereunder), and if after such date Holder is required by its broker to purchase (in an open market transaction or otherwise) or Holder or Holder’s brokerage firm otherwise purchases shares of Common Stock to deliver in satisfaction of a sale by Holder of the Exercise Shares which Holder was entitled to receive upon such Exercise (a “Buy-In”), then the Company shall (1) pay in cash to Holder the amount by which (x) Holder’s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (A) the number of Exercise Shares that the Company was required to deliver to Holder in connection with the Exercise at issue by (B) the price at which the sell order giving rise to such purchase obligation was executed, and (2) at the option of Holder, either reinstate the portion of the Warrant and equivalent number of Exercise Shares for which such Exercise was not honored (and refund the Exercise Price therefor, to the extent paid by Holder, and/or reinstate the principal amount of any indebtedness used to satisfy the applicable Exercise Price) or deliver to Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its Exercise and delivery obligations hereunder. For example, if Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted Exercise to cover the sale of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (1) of the immediately preceding sentence the Company shall be required to pay Holder $1,000. Holder shall provide the Company written notice indicating the amounts payable to Holder in respect of the Buy-In, together with applicable confirmations and other evidence reasonably requested by the Company. Nothing herein shall limit Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver certificates representing shares of Common Stock upon Exercise of the Warrant as required pursuant to the terms hereof.

(j) HSR Submissions. If Holder determines that, in connection with the exercise of this Warrant, it and the Company are required to file Premerger Notification Reports with the Federal Trade Commission (the “FTC”) and the United States Department of Justice (“DOJ”) and observe the Waiting Period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended, and the related rules and regulations promulgated thereunder (collectively, the “HSR Act”), the Company agrees to (i) cooperate with Holder in Holder’s preparing and making such submission and any responses to inquiries of the FTC and DOJ; (ii) prepare and make any submission required to be filed by the Company under the HSR Act and respond to inquiries of the FTC and DOJ in connection therewith; and (iii) reimburse Holder for the cost of the required filing fee for Holder’s submission under the HSR Act. For the avoidance of doubt, Holder shall bear all of its other costs and expenses in connection with such submission, including any attorneys’ fees associated therewith.

 

8


3. Payment of Warrant Exercise Price for Cash Exercise or Cashless Exercise; Cashless Major Exercise and Cashless Default Exercise .

(a) Exercise Price . The exercise price shall initially equal $4.71 per share, subject to adjustment pursuant to the terms hereof (as so adjusted, the “Exercise Price”), including but not limited to Section 5 below.

Payment of the Exercise Price may be made by any of the following, or a combination thereof, at the election of Holder:

(i) Cash Exercise : Holder may exercise this Warrant in cash, bank or cashier’s check or wire transfer (a “Cash Exercise”);

(ii) Cashless Exercise : In lieu of paying all or any portion of the Exercise Price in cash, Holder, at its option, may exercise this Warrant (in whole or in part) on a cashless basis by making appropriate notation on the applicable Exercise Form, in which event the Company shall issue Holder a number of shares of Common Stock computed using the following formula (a “Cashless Exercise”):

X = Y (A-B)/A

 

where:    X = the number of shares of Common Stock to be issued to Holder.
   Y = the number of shares of Common Stock for which this Warrant is being Exercised.
   A = the Market Price of one (1) share of Common Stock (for purposes of this Section 3(a)(ii), where “Market Price,” as of any date, means the arithmetic average of the Volume Weighted Average Price (as defined below) of the Company’s Common Stock on each of the ten (10) consecutive Trading Days immediately preceding the date in question).
   B = the Exercise Price.
   As used herein, the “ Volume Weighted Average Price ” for any security as of any date means the volume weighted average sale price on the NasdaqGS as reported by, or based upon data reported by, Bloomberg Financial Markets or an equivalent, reliable reporting service mutually acceptable to and hereafter designated by the Holder and the Company (“ Bloomberg ”), or, if the NasdaqGS is not the principal trading market for such security, the volume weighted average sale price of such security on the principal securities exchange or trading market where such security is listed or traded as reported by Bloomberg, or, if no volume weighted average sale price is reported for such security, then the last closing trade price of such security as reported by Bloomberg, or, if no last closing trade price is reported for such security by Bloomberg, the average of the bid prices of any market makers for such security on the OTC Bulletin Board, the OTCQX Market, the OTCQB Market or the “pink” market of OTC Markets Group. If the Volume Weighted Average Price cannot be calculated for such security on such date in the manner provided above, the Volume Weighted Average Price shall be the fair market value as determined by the Company and the Holder. In the event that a Stock Event is

 

9


   consummated during any period for which the arithmetic average of the Volume Weighted Average Prices is to be determined (under this Section or otherwise), the Volume Weighted Average Price for all Trading Days during such period prior to the effectiveness of the Stock Event shall be appropriately adjusted to reflect such Stock Event.

(iii) Note Exchange Exercise: In lieu of paying all or any portion of the Exercise Price in cash, Holder, at its option, may exercise this Warrant (in whole or in part) through a reduction of an amount of principal outstanding under any First Out Waterfall Notes in accordance with Section 2.3(b) of the Facility Agreement, then held by Holder (a “Note Exchange Exercise”)

For purposes of Rule 144 and subsection (d)(3)(ii) thereof, it is intended, understood and acknowledged that (x) this Warrant shall be deemed to have been acquired on April 3, 2017 (the date the First Out Waterfall Notes were originally issued), and (y) the shares of Common Stock issuable upon Exercise of this Warrant in a Cashless Exercise (including a Cashless Major Exercise or Cashless Default Exercise) transaction or a Note Exchange Exercise transaction shall be deemed to have been acquired on April 3, 2017. Accordingly, (A) upon any such Exercise, the Rule 144 holding period for the shares of Common Stock issued thereupon shall be in excess of one (1) year, and (B) provided that Holder is not an “affiliate” (as defined in Rule 144 under the Securities Act) of the Company on the date of such Exercise (which the Company shall assume unless advised otherwise in writing by Holder), an Unrestricted Condition shall be satisfied with respect to the shares of Common Stock issued thereupon and such shares will be freely transferable, without restriction or limitation (including any volume limitation or current public information requirement) under Federal or state securities laws, pursuant to Rule 144 under the Securities Act, and will not contain or be subject to a legend or stop transfer order restricting the resale or transferability of thereof.

As provided in Section 2(b), Holder shall only be required to physically surrender this Warrant in the event that Holder is exercising this Warrant in full.

(b) Cashless Major Exercise. To the extent Holder shall exercise this Warrant as a Cashless Major Exercise pursuant to Section 5(b)(i) and 5(b)(iii) below, Holder shall send to the Company (in any manner permitted under Section 2(a)) the Exercise Form indicating that Holder is exercising this Warrant (or any portion thereof) pursuant to a Cashless Major Exercise, in which event the Company shall issue a number of shares of Common Stock equal to the Black-Scholes Value of the Warrant (or such applicable portion being exercised) divided by the closing price of the Common Stock on the principal securities exchange or other securities market on which the Common Stock is then traded on the Trading Day immediately preceding the date on which the applicable Major Transaction is consummated, or, if in respect of a Cashless Major Exercise made after the date of consummation of the applicable Major Transaction, on the Trading Day immediately preceding the date on which the exercise form in respect of such Cashless Major Exercise is delivered. As provided in Section 2(b), Holder shall only be required to physically surrender this Warrant in the event that Holder is exercising this Warrant in full. Holder shall be permitted to make successive Cashless Major Exercises and send successive Exercise Forms in respect of a Cashless Major Exercise from time to time at any time during the Cashless Major Exercise Period.

 

10


(c) Cashless Default Exercise . To the extent Holder exercises this Warrant as a Cashless Default Exercise pursuant to Section 11(b)(i) below, Holder shall send to the Company (in any manner permitted under Section 2(a)) the Exercise Form indicating that Holder is exercising this Warrant pursuant to a Cashless Default Exercise, in which event the Company shall issue to Holder, within five (5) Trading Days of the applicable Default Notice, a number of shares of Common Stock (which shares shall be valued at the closing price of the Common Stock on the principal securities exchange or other securities market on which the Common Stock is then traded on the Trading Day immediately preceding the date on which the Exercise Form in respect of such Cashless Default Exercise is delivered) equal to the Black-Scholes Value of the remaining unexercised portion of this Warrant (or such portion thereof subject to such exercise) as of the date of such Default Notice (or in the case of an Event of Default referred to in Section 11(a)(vi), on the Trading Day immediately preceding the date the dividend or distribution is declared or, if not first declared, is paid). As provided in Section 2(b), the Holder shall be permitted to make successive Cashless Default Exercises and send successive Exercise Forms in respect of a Cashless Default Exercise, from time to time at any time from and after the date of the applicable Default Notice through the Exercise Period of this Warrant.

(d) Dispute Resolution . In the case of a dispute as to the determination of the closing price or the Volume Weighted Average Price of the Company’s Common Stock or the arithmetic calculation of the Exercise Price, Market Price or the Successor Major Transaction Consideration, or the number of shares issuable upon a Cashless Major Exercise, the Company shall submit the disputed determinations or arithmetic calculations via electronic mail within two (2) Business Days of receipt, or deemed receipt, of the Exercise Form or Major Transaction Early Termination Notice, or other event giving rise to such dispute, as the case may be, to Holder. If Holder and the Company are unable to agree upon such determination or calculation within two (2) Business Days of such disputed determination or arithmetic calculation being submitted to Holder, then the Company shall, within two (2) Business Days submit via electronic mail (i) the disputed determination of the closing price or the Volume Weighted Average Price of the Company’s Common Stock to an independent, reputable investment bank selected by the Company and approved by Holder, which approval shall not be unreasonably withheld, or (ii) the disputed arithmetic calculation of the Exercise Price, Market Price, any Successor Major Transaction Consideration or number of shares issuable upon a Cashless Major Exercise to the Company’s independent, outside registered public accountants. The Company shall use its reasonable best efforts to cause the investment bank or the accountants, as the case may be, to perform the determinations or calculations and notify the Company and Holder of the results no later than five (5) Trading Days from the time it receives the disputed determinations or calculations. Such investment bank’s or accountants’ determination or calculation, as the case may be, shall be binding upon all parties absent demonstrable error, and the Company and Holder shall each pay one half of the fees and costs of such investment banker or accountant. Notwithstanding the existence of a dispute contemplated by this paragraph, if requested by Holder, the Company shall issue to Holder the Exercise Shares not in dispute in accordance with the terms hereof.

4. Transfer and Registration .

(a) Transfer Rights . Subject to the provisions of Section 8 of this Warrant, this Warrant may be transferred on the books of the Company, in whole or in part, in person or by attorney, upon

 

11


surrender of this Warrant properly completed and endorsed. This Warrant shall be canceled upon such surrender and, as soon as practicable thereafter, the person to whom such transfer is made shall be entitled to receive a new Warrant or Warrants as to the portion of this Warrant transferred, and Holder shall be entitled to receive a new Warrant as to the portion hereof retained.

(b) Registrable Securities . The Common Stock issuable upon the Exercise of this Warrant entitles Holder (and applicable assignees or transferees of such Common Stock) to registration and other rights pursuant to the Registration Rights Agreement.

5. Adjustments Upon Certain Events .

(a) Recapitalization or Reclassification . If the Company shall at any time effect a stock split, payment of stock dividend, recapitalization, reclassification or other similar transaction of such character that the shares of Common Stock shall be changed into or become exchangeable for a larger or smaller number of shares, then upon the effective date thereof, the number of shares of Common Stock which Holder shall be entitled to purchase upon Exercise of this Warrant, shall be increased or decreased, as the case may be, in direct proportion to the increase or decrease in the number of shares of Common Stock by reason of such stock split, payment of stock dividend, recapitalization, reclassification or similar transaction, and the Exercise Price shall be, in the case of an increase in the number of shares, proportionally decreased and, in the case of decrease in the number of shares, proportionally increased. The Company shall give Holder the same notice it provides to holders of Common Stock of any transaction described in this Section 5(a).

(b) Rights Upon Major Transaction .

(i) Major Transaction . In the event that a Major Transaction occurs, then (1) in the case of a Successor Major Transaction, Holder, at its option, may elect to cause the conversion of this Warrant (a “Successor Major Transaction Conversion”), in whole or in part, into the right to receive the Successor Major Transaction Consideration, upon consummation of the Major Transaction, and (2) in the case of all other Major Transactions, Holder shall have the right to exercise this Warrant (or any portion thereof), at any time and from time to time following the occurrence of such event, as a Cashless Major Exercise. In the event Holder shall not have exercised any of its rights under clauses (1) or (2) above within the applicable time periods set forth herein, then the Major Transaction shall be treated as an Assumption (as defined below) in accordance with Section 5(b)(ii) below unless Holder waives its rights under this Section 5(b) with respect to such Major Transaction. Each of the following events shall constitute a “Major Transaction”:

(A) a consolidation, merger, exchange of shares, recapitalization, reorganization, business combination or other similar event, (1) following which the holders of Common Stock immediately preceding such consolidation, merger, exchange, recapitalization, reorganization, combination or event either (a) no longer hold a majority of the shares of Common Stock or (b) no longer have the ability to elect a majority of the board of directors of the Company or (2) as a result of which shares of Common Stock shall be changed into (or the shares of Common Stock become entitled to receive) the same or a different

 

12


number of shares of the same or another class or classes of stock or securities of the Company or another entity (collectively, a “Change of Control Transaction”);

(B) the sale or transfer, in one transaction or a series of related transactions, of (I) all or substantially all of the assets of the Company (including, for the avoidance of doubt, all or substantially all of the assets of the Company and its Subsidiaries, taken as a whole) to any Person other than a wholly-owned subsidiary of the Company or (II) assets of the Company (including, for the avoidance of doubt, all or substantially all of the assets of the Company and its Subsidiaries, taken as a whole) for a purchase price equal to more than 50% of the Equity Value (as defined below) of the Company. For purposes of this clause (B), “Equity Value” shall mean (I) the product of (x) the number of issued and outstanding shares of Common Stock on the date the Company delivers the Major Transaction Notice (defined below) multiplied by (y) the per share closing price of the Common Stock on such date on the NasdaqGS as reported by, or based upon data reported by, Bloomberg or, if the NasdaqGS is not the principal trading market for such security, the closing sale price of such security on the principal securities exchange or trading market where such security is listed or traded as reported by Bloomberg;

(C) a purchase, tender or exchange offer made to the holders of outstanding shares of Common Stock, such that following such purchase, tender or exchange offer a Change of Control Transaction shall have occurred;

(D) the liquidation, bankruptcy, insolvency, dissolution or winding-up (or the occurrence of any analogous proceeding) affecting the Company;

(E) the shares of Common Stock cease to be listed, traded or publicly quoted on the NasdaqGS and are not promptly re-listed or requoted on the New York Stock Exchange, the NYSE American, the NASDAQ Global Market or the NASDAQ Capital Market; or

(F) the Common Stock ceases to be registered under Section 12 of the Exchange Act.

(ii) Assumption. Any assumption of Company obligations under this paragraph shall be referred to herein as an “Assumption.” Unless otherwise provided in writing by Holder, the Company shall not consummate a Major Transaction in which the Company is not the surviving entity or as a result of which the Company has a new Parent Entity, unless (A) each Person acquiring the Company’s assets or Common Stock (or Parent Entity thereof, as applicable), or any other successor entity resulting from such Major Transaction (in each case, a “Successor Entity”), assumes in writing all of the obligations of the Company under this Warrant, the Facility Agreement (but, other than with respect to the Company’s obligations pursuant to Section 5.1(e) and 5.1(p) of the Facility Agreement and the other provisions of the Facility Agreement that

 

13


expressly survive the repayment of the Loans (which shall be assumed in any Assumption), only if there are outstanding Loans under the Facility Agreement immediately following the consummation of the Major Transaction) and the Registration Rights Agreement in accordance with the provisions of this Section 5(b)(ii) pursuant to written agreements in form and substance reasonably satisfactory to Holder and approved by Holder prior to the consummation of such Major Transaction (such approval not to be unreasonably withheld or delayed), including agreements to deliver to Holder in exchange for its Warrants a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to the Warrants, that, among other things, (1) is exercisable for the appropriate number of shares of the Successor Entity’s capital stock (without regard to the 4.985% Cap or any other restriction or limitation on exercise, provided that such instrument shall contain a limitation on exercise comparable to that contained in the second paragraph of Section 1 of this Warrant); (2) has an exercise price similar to the then-effective Exercise Price (taking into account any conversion or exchange ratio applicable to the Common Stock in the Major Transaction) and exercise price adjustment provisions similar to those in the Warrants; (3) entitles Holder to such additional securities or other consideration as Holder would be entitled pursuant to Section 5(b)(i) in connection with the Major Transaction; and (4) provides for registration rights similar to those provided by the Registration Rights Agreement, in each case reasonably satisfactory to Holder, and (B) the Successor Entity (including its Parent Entity) is a publicly traded corporation whose common stock is quoted on or listed for trading on an Eligible Market. For the avoidance of doubt, Holder’s reasonable satisfaction referred to in the immediately preceding sentence shall be construed only to apply to confirmation that the warrant or other comparable security and registration rights agreement delivered to Holder upon an assumption hereunder shall conform to the requirements of this Section 5(b)(ii), and this Section 5(b)(ii) shall not be construed as granting consent or approval rights to Holder with respect to the terms of such Major Transaction or to permit Holder to demand any additional consideration in respect of this Warrant other than as provided herein. Upon the occurrence of any Major Transaction, any Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Major Transaction, the provisions of this Warrant and the Registration Rights Agreement referring to the “Company” shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company herein. Upon consummation of the Major Transaction, the Successor Entity shall deliver to Holder confirmation that there shall be issued upon exercise of this Warrant at any time after the consummation of the Major Transaction, in lieu of the shares of Common Stock (or other securities, cash, assets or other property) issuable upon the exercise of the Warrants prior to such Major Transaction, such shares of publicly traded common stock (or their equivalent) of the Successor Entity, as adjusted in accordance with the provisions of this Warrant. The provisions of this Section shall apply similarly and equally to successive Major Transactions and shall be applied without regard to any limitations on the exercise of this Warrant other than any applicable beneficial ownership limitations.

(iii) Major Transaction Notice; Major Transaction Early Termination Right; Notice of Cashless Major Exercise. At least thirty (30) days prior to the consummation of any Major Transaction, but, in any event, within five (5) Trading Days following the first to occur of (x) the date of the public announcement of such Major Transaction if such announcement is made before 4:00 p.m., New York City time, or (y) the day following the public announcement of such Major

 

14


Transaction if such announcement is made on and after 4:00 p.m., New York City time, the Company shall deliver written notice thereof via electronic mail and overnight courier to Holder (a “Major Transaction Notice”). At any time during the period beginning after Holder’s receipt of a Major Transaction Notice in respect of a Successor Major Transaction and ending five (5) Trading Days prior to the consummation of such Major Transaction (the “Early Termination Period”), Holder may elect a Successor Major Transaction Conversion by delivering written notice thereof (“Major Transaction Early Termination Notice”) to the Company, which Major Transaction Early Termination Notice shall indicate the portion of the Warrant (with reference to the number of shares of Common Stock issuable upon a Cash Exercise of such portion, without regard to the 4.985% Cap) that Holder is electing to be treated as a Successor Major Transaction Conversion. The portion of this Warrant subject to early termination pursuant to this Section 5(b)(iii), shall be converted into the right to receive the Successor Major Transaction Consideration

To the extent Holder shall elect to effect a Cashless Major Exercise in respect of a Major Transaction, Holder shall deliver its Exercise Form in accordance with Section 3(b), at any time and from time to time following receipt by Holder of the Major Transaction Notice until the later of (x) the last day of the Exercise Period and (y) the one-year anniversary of the applicable Major Transaction (the “Cashless Major Exercise Period”). For the avoidance of doubt, Holder shall be permitted to make successive Cashless Major Exercises and send successive Exercise Forms in respect of a Cashless Major Exercise from time to time at any time during the Cashless Major Exercise Period.

(iv) Escrow; Payment of Successor Major Transaction Consideration . Following the receipt of a Major Transaction Early Termination Notice in respect of a Successor Major Transaction from Holder, the Company shall not effect a Successor Major Transaction with respect to which Holder has elected a Successor Major Transaction Conversion unless either (A) it obtains, as a condition precedent to such Major Transaction, the written agreement of the Successor Entity that payment of the Successor Major Transaction Consideration shall be made to Holder concurrently with consummation of such Successor Major Transaction, or (B) it shall place the Successor Major Transaction Consideration into an escrow account with an independent escrow agent, and shall instruct the escrow agent to deliver the Successor Major Transaction Consideration to Holder, concurrently with the consummation of the Major Transaction. Notwithstanding clauses (A) and (B) above, Holder shall be treated on a pari passu basis with, and shall not have priority to payments to, the holders of Common Stock in connection with a Major Transaction. For purposes of determining the amount required to be placed in escrow pursuant to the provisions of this subsection (iv) and without affecting the amount of the actual Successor Major Transaction Consideration, the calculation of the price referred to in clause (1) of the first column of Schedule 1 hereto with respect to Stock Price shall be determined based on the Closing Market Price (as defined on Schedule 1) of the Common Stock on the Trading Day immediately preceding the date that the Successor Major Transaction Consideration is deposited with the escrow agent.

(v) Injunction . Following the receipt of a Major Transaction Early Termination Notice from Holder, in the event that the Company attempts to consummate a Successor Major Transaction without either (1) placing the Successor Major Transaction Consideration in escrow in accordance with subsection (iv) above, or (2) obtaining the written agreement of the Successor

 

15


Entity as described in subsection (iv) above, Holder shall have the right to apply for an injunction in any state or federal court sitting in the City of New York, borough of Manhattan to prevent the closing of such Major Transaction until the Successor Major Transaction Consideration is delivered to Holder.

An early termination required by this Section 5(b) shall be made in accordance with the provisions of Section 12. To the extent an early termination required by this Section 5(b) is deemed or determined by a court of competent jurisdiction to be prepayments of the Warrant by the Company, such early termination shall be deemed to be voluntary prepayments. Notwithstanding anything to the contrary in this Section 5, until the Successor Major Transaction Consideration is paid in full, this Warrant may be exercised, in whole or in part, by Holder into shares of Common Stock, or in the event the date of any Exercise is after the consummation of the Major Transaction, shares of publicly traded common stock (or their equivalent) of the Successor Entity pursuant to Section 5(b). The parties hereto agree that in the event of the Company’s early termination of any portion of the Warrant under this Section 5(b), Holder’s damages would be uncertain and difficult to estimate because of the parties’ inability to predict future interest rates and the uncertainty of the availability of a suitable substitute investment opportunity for Holder. Accordingly, any premium due under this Section 5(b) is intended by the parties to be, and shall be deemed, a commercially reasonable estimate of Holder’s actual loss of its investment opportunity and not as a penalty.

(c) Exercise Price Adjusted . As used in this Warrant, the term “Exercise Price” shall mean the purchase price per share specified in Section 3(a) of this Warrant, until the occurrence of an event stated in this Section 5 or otherwise set forth in this Warrant, and thereafter shall mean said price as adjusted from time to time in accordance with the provisions of said subsection. No adjustment made pursuant to any provision of this Section 5 shall have the net effect of increasing the aggregate Exercise Price payable hereunder or, except as expressly provided in Section 5(a), otherwise increasing the Exercise Price.

(d) Adjustments: Additional Shares, Securities or Assets . In the event that at any time, as a result of an adjustment made pursuant to this Section 5 or otherwise, Holder shall, upon Exercise of this Warrant, become entitled to receive shares and/or other securities or assets (other than Common Stock) then, wherever appropriate, all references herein to shares of Common Stock shall be deemed to refer to and include such shares and/or other securities or assets; and thereafter the number of such shares and/or other securities or assets shall be subject to adjustment from time to time in a manner and upon terms as nearly equivalent as practicable to the provisions of this Section 5.

(e) Notice of Adjustments . Whenever the Exercise Price and/or number or type of securities issuable upon Exercise is adjusted pursuant to the terms of this Warrant, the Company shall promptly mail to Holder a notice (an “Exercise Price Adjustment Notice”) setting forth the Exercise Price and/or number or type of securities issuable upon Exercise after such adjustment and setting forth a statement of the facts requiring such adjustment. The Company shall, upon the written request at any time of Holder, furnish to Holder a like Warrant setting forth (i) such adjustment or readjustment, (ii) the Exercise Price at the time in effect and (iii) the number of shares of Common Stock and the amount, if any, of other securities or property which at the time would be received upon Exercise of the Warrant. For purposes of clarification, whether or not

 

16


the Company provides an Exercise Price Adjustment Notice pursuant to this Section 5(e), upon the occurrence of any event that leads to an adjustment of the Exercise Price, Holder would be entitled to receive a number of Exercise Shares based upon the new Exercise Price, as adjusted, for exercises occurring on or after the date of such adjustment, regardless of whether Holder accurately refers to the adjusted Exercise Price in the Exercise Form.

6. Fractional Interests .

No fractional shares or scrip representing fractional shares shall be issuable upon the Exercise of this Warrant, but on Exercise of this Warrant, Holder may purchase only a whole number of shares of Common Stock. If, on Exercise of this Warrant, Holder would be entitled to a fractional share of Common Stock or a right to acquire a fractional share of Common Stock, such fractional share shall be disregarded and the number of shares of Common Stock issuable upon Exercise shall be the next higher whole number of shares.

7. Reservation of Shares .

From and after the date hereof, the Company shall at all times reserve for issuance such number of authorized and unissued shares of Common Stock (or other securities substituted therefor as herein above provided) as shall be sufficient for the Exercise of this Warrant and payment of the Exercise Price. If at any time the number of shares of Common Stock authorized and reserved for issuance is below the number of shares sufficient for the Exercise of this Warrant (a “Share Authorization Failure”) (based on the Exercise Price in effect from time to time), the Company will promptly take all corporate action necessary to authorize and reserve a sufficient number of shares, including calling a special meeting of stockholders to authorize additional shares to meet the Company’s obligations under this Section 7, in the case of an insufficient number of authorized shares, and using its best efforts to obtain stockholder approval of an increase in such authorized number of shares. The Company covenants and agrees that upon the Exercise of this Warrant, all shares of Common Stock issuable upon such Exercise shall be duly and validly issued, fully paid and nonassessable and not subject to preemptive rights, rights of first refusal or similar rights of any Person. The Company covenants and agrees that all shares of Common Stock issuable upon Exercise of this Warrant shall be approved for listing on the NasdaqGS, or, if the NasdaqGS is not the principal trading market for the Common Stock, such principal market on which the Common Stock is traded or listed.

8. Restrictions on Transfer .

(a) Registration or Exemption Required . This Warrant has been issued in a transaction exempt from the registration requirements of the Securities Act by virtue of Section 4(a)(2) of the Securities Act and Rule 506 thereunder and exempt from registration or qualification under applicable state securities (or “blue sky”) laws. None of the Warrant, the Exercise Shares or Failure Payment Shares may be pledged, transferred, sold or assigned except pursuant to an effective registration statement or an exemption to the registration requirements of the Securities Act and applicable state laws, including Rule 144 under the Securities Act, Section 4(a)(7) of the Securities Act or a so-called “4[(a)](1) and a half” transaction.

(b) Assignment . Subject to Section 8(a), Holder may sell, transfer, assign, pledge, or otherwise dispose of this Warrant, in whole or in part. Holder shall deliver a written notice to the

 

17


Company, substantially in the form of the Assignment attached hereto as Exhibit  B , indicating the Person or Persons to whom the Warrant shall be assigned and the respective number of warrants to be assigned to each assignee. The Company shall effect the assignment within three (3) Business Days of its receipt of a completed and executed form of Assignment (the “Transfer Delivery Period”), and shall deliver to the assignee(s) designated by Holder a Warrant or Warrants of like tenor and terms entitling Holder to purchase the appropriate number of shares. This Warrant and the rights evidenced hereby shall inure to the benefit of and be binding upon the successors and assigns of Holder. The provisions of this Warrant are intended to be for the benefit of all Holders from time to time of this Warrant, and shall be enforceable by any such Holder. For avoidance of doubt, in the event Holder notifies the Company that such sale or transfer is a so called “4[(a)](1) and half” transaction, the parties hereto agree that a legal opinion from outside counsel for Holder delivered to counsel for the Company substantially in the form attached hereto as Exhibit  C shall be the only requirement to satisfy an exemption from registration under the Securities Act to effectuate such “4[(a)](1) and half” transaction.

9. Noncircumvention .

The Company hereby covenants and agrees that the Company will not, by amendment of its certificate of incorporation, bylaws or through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issue or sale of securities, or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, and will at all times in good faith carry out all the provisions of this Warrant and take all action as may be required to protect the rights of Holder. Without limiting the generality of the foregoing, the Company (i) shall not increase the par value of any shares of Common Stock receivable upon the exercise of this Warrant above the Exercise Price then in effect, and (ii) shall take all such actions as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable shares of Common Stock upon the exercise of this Warrant.

10. Events of Failure; Definition of Black Scholes Value .

(a) Definition.

The occurrence of each of the following shall be considered to be an “Event of Failure.”

(i) A Delivery Failure occurs, where a “Delivery Failure” shall be deemed to have occurred if the Company fails to use its best efforts to deliver Exercise Shares to Holder within any applicable Delivery Period (other than due to the limitation contained in the second paragraph of Section 1);

(ii) A Legend Removal Failure occurs, where a “Legend Removal Failure” shall be deemed to have occurred if the Company fails to use its best efforts to issue this Warrant and/or Exercise Shares without a restrictive legend, or fails to use it best efforts to remove a restrictive legend, when and as required under Section 2(e) hereof;

(iii) a Transfer Delivery Failure occurs, where a “Transfer Delivery Failure” shall be deemed to have occurred if the Company fails to use its best efforts to deliver a Warrant within any applicable Transfer Delivery Period; and

(iv) a Registration Failure (as defined below).

 

18


For purpose hereof, “Registration Failure” means that (A) the Company fails to file with the SEC on or before the Additional Warrant Filing Deadline (as defined in the Registration Rights Agreement) any Registration Statement required to be filed pursuant to Section 2(a) of the Registration Rights Agreement, (B) the Company fails to use its reasonable best efforts to obtain effectiveness with the SEC, prior to the Additional Warrant Registration Deadline (as defined in the Registration Rights Agreement), and if such Registration Statement does not become effective prior to the Additional Warrant Registration Deadline, as soon as possible thereafter, of any Registration Statement (as defined in the Registration Rights Agreement) that is required to be filed pursuant to Section 2(a) of the Registration Rights Agreement, or fails to use its reasonable best efforts to keep such Registration Statement current and effective as required in Section 3 of the Registration Rights Agreement, (C) the Company fails to file any additional Registration Statement required to be filed pursuant to Section 2(a)(ii) of the Registration Rights Agreement on or before the Additional Filing Deadline (as defined in the Registration Rights Agreement) or fails to use its reasonable best efforts to cause such new Registration Statement to become effective on or before the Additional Registration Deadline (as defined in the Registration Rights Agreement), and if such effectiveness does not occur within such period, as soon as possible thereafter, (D) the Company fails to file any amendment to any Registration Statement, or any additional Registration Statement required to be filed pursuant to Section 3(b) of the Registration Rights Agreement within thirty (30) days of the applicable Registration Trigger Date (as defined in the Registration Rights Agreement), or fails to use its reasonable best efforts to cause such amendment and/or new Registration Statement to become effective within ninety (90) days of the applicable Registration Trigger Date, and, if such effectiveness does not occur within such period, as soon as possible thereafter, (E) any Registration Statement required to be filed under the Registration Rights Agreement, after its initial effectiveness and during the applicable Registration Period (as defined in the Registration Rights Agreement), lapses in effect or, other than on a day during an Allowable Grace Period (as defined in the Registration Rights Agreement), sales of all of the Registrable Securities (as defined in the Registration Rights Agreement) cannot otherwise be made thereunder (whether by reason of the Company’s failure to amend or supplement the prospectus included therein in accordance with the Registration Rights Agreement, the Company’s failure to file and use its reasonable best efforts to obtain effectiveness with the SEC of an additional Registration Statement or amended Registration Statement required pursuant to Section 2(a)(ii) or 3(b) of the Registration Rights Agreement, as applicable, or otherwise), or (F) the Company fails to provide a commercially reasonable written response to any comments to any Registration Statement submitted by the SEC within twenty-five (25) days of the date that such SEC comments are received by the Company.

(b) Failure Payments; Black-Scholes Determination. The Company understands that any Event of Failure (as defined above) could result in economic loss to Holder. In the event that any Event of Failure occurs, as compensation to Holder for such economic loss, the Company agrees to pay to Holder an amount payable, at the Company’s option, either (i) in cash or (ii) in shares of Common Stock that are valued for these purposes at the Volume Weighted Average Price on the date of such calculation (“Failure Payments” and such shares, “Failure Payment Shares”), in each case equal to the total economic loss of Holder determined on a commercially reasonable basis in connection with such Event of Failure for the relevant period (as recalculated on the first Business Day of each month thereafter for as long as Failure Payments shall continue to accrue) from the date of such Event of Failure until the Event of Failure is cured; provided, however, that in the event the Company elects to make Failure Payments in Failure Payment Shares, the

 

19


Company shall issue, and Holder shall only receive, up to such number of shares of Common Stock in respect of Failure Payments such that Holder and any other persons or entities whose beneficial ownership of Common Stock would be aggregated with Holder’s for purposes of Section 13(d) of the Exchange Act (including shares held by any “group” of which Holder is a member, but excluding shares beneficially owned by virtue of the ownership of securities or rights to acquire securities that have limitations on the right to convert, exercise or purchase similar to the limitation set forth herein) shall not collectively beneficially own greater than 4.985% of the total number of shares of Common Stock of the Company then issued and outstanding, and the balance of such Failure Payments shall be paid in cash. For purposes of clarification, it is agreed and understood that Failure Payments shall continue to accrue following any Event of Default until the applicable Default Amount is paid in full. The Company shall satisfy any Failure Payments under this Section pursuant to Section 10(c) below. Failure Payments are in addition to any Shares that Holder is entitled to receive upon Exercise of this Warrant.

(c) Payment of Accrued Failure Payments. The Failure Payments and Failure Payment Shares representing accrued Failure Payments for each Event of Failure shall be paid or issued and delivered, as the case may be, on or before the fifth (5th) Business Day of each month following a month in which Failure Payments accrued. Nothing herein shall limit Holder’s right to pursue actual damages (to the extent in excess of the Failure Payments) for the Company’s Event of Failure, and Holder shall have the right to pursue all remedies available at law or in equity (including a decree of specific performance and/or injunctive relief). Notwithstanding the above, if a particular Event of Failure results in an Event of Default pursuant to Section 11 hereof, then the Failure Payment, for that Event of Failure only, shall be considered to have been satisfied upon payment to Holder of an amount equal to the greater of (i) the Failure Payment, or (ii) the Default Amount, payable in accordance with Section 11.

(d) Maximum Interest Rate. Nothing contained herein or in any document referred to herein or delivered in connection herewith shall be deemed to establish or require the payment of a rate of interest or other charges in excess of the maximum permitted by applicable law. In the event that the rate of interest or dividends required to be paid or other charges hereunder exceed the maximum permitted by such law, any payments in excess of such maximum shall be credited against amounts owed by the Company to Holder and thereby refunded to the Company.

11. Default .

(a) Events Of Default . Each of the following events shall be considered to be an “Event of Default,” unless waived by Holder:

(i) Failure To Effect Registration. With respect to all Registration Failures, a Registration Failure occurs and remains uncured for a period of more than forty-five (45) days (or sixty (60) days in the case where the Company (i) has, by the Filing Deadline (as defined the Registration Rights Agreement) filed a Registration Statement (as defined in the Registration Rights Agreement) covering this Warrant and the number of shares required by the Registration Rights Agreement, and (ii) has responded in writing to any comments to the Registration Statement that the Company has received from the SEC, within ten (10) Business Days of such receipt, and nevertheless the SEC has not declared effective a Registration Statement covering the this

 

20


Warrant and the Shares by the Registration Deadline (as defined in the Registration Rights Agreement)), and such Registration Failure relates solely to the Company’s failure to have the Registration Statement declared effective by the Registration Deadline (as defined in the Registration Rights Agreement) and with respect to a Registration Failure provided in clause (E) of the definition of “Registration Failure,” such Registration Failure occurs and remains uncured for a period of more than forty-five (45) days.

(ii) Failure To Deliver Common Stock . A Delivery Failure (as defined above) occurs and remains uncured for a period of more than twenty (20) days; or at any time, the Company announces or states in writing that it will not honor its obligations to issue shares of Common Stock to Holder upon Exercise by Holder of the Exercise rights of Holder in accordance with the terms of this Warrant.

(iii) Legend Removal Failure . A Legend Removal Failure (as defined above) occurs and remains uncured for a period of twenty (20) days;

(iv) Transfer Delivery Failure . A Transfer Delivery Failure (as defined above) occurs and remains uncured for a period of twenty (20) days;

(v) Corporate Existence; Major Transaction . (A) The Company has failed to (1) place the Successor Major Transaction Consideration into escrow and instruct the escrow agent to release the Successor Major Transaction Consideration to the Holder pursuant to Section 5(b)(iii), or (2) obtain the written agreement of the Successor Entity and cause the Successor Entity to make payment as described in Section 5(b)(iii), (B) the Successor Major Transaction Consideration is not paid contemporaneously with the consummation of the Successor Major Transaction, or (C) with respect to a Major Transaction that is to be treated as an Assumption under the terms hereof, the Company has failed to meet the Assumption requirements of Section 5(b)(i); or

(vi) Section  13 Breach . During the Dividend Restriction Period, the Company declares or pays any dividend or distribution of any kind to the holders of Common Stock of the Company.

(b) Mandatory Early Termination .

(i) Mandatory Early Termination Amount; Cashless Default Exercise . The Company shall notify Holder in writing within two (2) Business Days of the occurrence of an Event of Default. If any Events of Default shall occur then, at the option of Holder, such option exercisable through the delivery of written notice to the Company by such Holder (the “Default Notice”), the Company shall have the right to terminate the outstanding amount of this Warrant and pay to Holder (a “Mandatory Early Termination”), in full satisfaction of its obligations hereunder by delivery of a notice to such effect to Holder within two (2) Business Days following receipt of the Default Notice, an amount payable in cash (the “Mandatory Early Termination Amount” or the “Default Amount”) equal to the Black-Scholes Value of the remaining unexercised portion of this Warrant on the date of such Default Notice (or in the case of an Event of Default referred to in Section 11(a)(vi), on the Trading Day immediately preceding the date the dividend or distribution is declared or, if not first declared, is paid). In the event the Company does not exercise its right to consummate a Mandatory Early Termination, then Holder shall have the right to exercise this Warrant, at any time and from time to time, pursuant to a Cashless Default Exercise in accordance with Section 3(c) above.

 

21


The Mandatory Early Termination Amount shall be payable within five (5) Business Days following the date of the applicable Default Notice.

(ii) Liquidated Damages . The parties hereto acknowledge and agree that the sums payable as Failure Payments or pursuant to a Mandatory Early Termination shall constitute partial liquidated damages and not penalties. The parties further acknowledge that (i) the amount of loss or damages likely to be incurred by Holder is incapable or is difficult to precisely estimate, (ii) the amounts specified bear a reasonable proportion and are not plainly or grossly disproportionate to the probable loss likely to be incurred by Holder, and (iii) the parties are sophisticated business parties and have been represented by sophisticated and able legal and financial counsel and negotiated this agreement at arm’s length.

Upon the occurrence of an Event of Default, the Default Amount, together with all other amounts payable hereunder, shall immediately become due and payable, all without demand, presentment or notice, all of which hereby are expressly waived, together with all costs, including legal fees and expenses, of collection, and Holder shall be entitled to exercise all other rights and remedies available at law or in equity.

(c) Posting Of Bond . In the event that any Event of Default occurs hereunder, the Company may not raise as a legal defense (in any Lawsuit, as defined below, or otherwise) or justification to such Event of Default any claim that such Holder or any one associated or affiliated with such Holder has been engaged in any violation of law, unless the Company has posted a surety bond (a “Surety Bond”) for the benefit of such Holder in the amount of 130% of the aggregate Surety Bond Value (as defined below) of all of Holder’s Warrants (the “Bond Amount”), which Surety Bond shall remain in effect until the completion of litigation of the dispute and the proceeds of which shall be payable to such Holder to the extent Holder obtains judgment.

For purposes hereof, a “Lawsuit” shall mean any lawsuit, arbitration or other dispute resolution filed by either party herein pertaining to any of this Warrant, the Facility Agreement, the Registration Rights Agreement or any other Loan Document (as defined in the Facility Agreement).

“Surety Bond Value,” for the Warrants shall mean 130% of the of the Black-Scholes Value of the remaining unexercised portion of this Warrant on the Trading Day immediately preceding the date that such bond goes into effect.

(d) Injunction And Posting Of Bond . In the event that the Event of Default referred to in subsection (a) of this Section 11 pertains to the Company’s failure to deliver unlegended shares of Common Stock to Holder pursuant to a Warrant Exercise, legend removal request, or otherwise, the Company may not refuse such unlegended share delivery based on any claim that such Holder or any one associated or affiliated with such Holder has been engaged in any violation of law, unless an injunction from a court, on prior notice to Holder, restraining and or enjoining Exercise of all or part of said Warrant shall have been sought and obtained by the Company and the Company has posted a Surety Bond for the benefit of such Holder in the amount of the Bond Amount, which Surety Bond shall remain in effect until the completion of litigation of the dispute and the proceeds of which shall be payable to such Holder to the extent Holder obtains judgment.

 

22


(e) Remedies, Other Obligations, Breaches And Injunctive Relief . The remedies provided in this Warrant shall be cumulative and in addition to all other remedies available under this Warrant, the Facility Agreement, the Registration Rights Agreement and any other Loan Document, at law or in equity (including a decree of specific performance and/or other injunctive relief), and nothing herein shall limit the right of Holder to pursue actual damages for any failure by the Company to comply with the terms of this Warrant. The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to Holder and that the remedy at law for any such breach may be inadequate. The Company therefore agrees that, in the event of any such breach or threatened breach (including a breach or threatened breach of Section 13), the holder of this Warrant shall be entitled, in addition to all other available remedies, to an injunction restraining any breach, without the necessity of showing economic loss and without any bond or other security being required.

12. Holder’s Early Terminations .

(a) Mechanics of Holder s Early Terminations . In the event that the Company does not deliver the applicable Successor Major Transaction Consideration or Default Amount or the Exercise Shares in respect of an election of a Successor Major Transaction Conversion, Cashless Major Exercise, Cashless Default or Exercise, as the case may be, to Holder within the time period or as otherwise required pursuant to the terms hereof, at any time thereafter Holder shall have the option, upon notice to the Company, in lieu of an election of a Successor Major Transaction Conversion, Cashless Major Exercise, Cashless Default Exercise or Exercise, as the case may be, to require the Company to promptly return to Holder all or any portion of this Warrant that was submitted for election of a Successor Major Transaction Conversion, Cashless Major Exercise, Cashless Default Exercise or Exercise, as the case may be. Upon the Company’s receipt of such notice, (x) the applicable election of Successor Major Transaction Conversion, Cashless Major Exercise, Cashless Default Exercise or Exercise, as the case may be, shall be null and void with respect to such applicable portion of this Warrant, (y) the Company shall immediately return this Warrant, or issue a new Warrant to Holder representing the portion of this Warrant that was submitted for election of Successor Major Transaction Conversion, Cashless Major Exercise, Cashless Default Exercise or Exercise, as the case may be, and (z) the Exercise Price of this Warrant or such new Warrant shall be adjusted to the Exercise Price as in effect on the date on which the applicable election of Successor Major Transaction Conversion, Cashless Major Exercise, Cashless Default Exercise or Exercise, as the case may be, is voided. Holder’s delivery of a notice voiding an election of a Successor Major Transaction Conversion, Cashless Major Exercise, Cashless Default Exercise or Exercise, as the case may be, and exercise of its rights following such notice shall not affect the Company’s obligations to make any Failure Payments which have accrued prior to the date of such notice with respect to the Warrant subject to such notice.

13. Dividend Restrictions .

Until the earlier of the expiration of the Exercise Period and the date all of the Warrants are exercised in full (the “Dividend Restriction Period”), the Company shall not declare or pay any dividend or distribution of any kind to the holders of Common Stock of the Company.

14. Benefits of this Warrant .

 

23


Nothing in this Warrant shall be construed to confer upon any person other than the Company and Holder any legal or equitable right, remedy or claim under this Warrant and this Warrant shall be for the sole and exclusive benefit of the Company and Holder.

15. Governing Law .

All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement (whether brought against a party hereto or its respective affiliates, directors, officers, stockholders, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York, borough of Manhattan. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. The parties hereby waive all rights to a trial by jury. If either party shall commence an action or proceeding to enforce any provisions of this Agreement, then the prevailing party in such action or proceeding shall be reimbursed by the other party for its reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.

16. Loss of Warrant .

Upon receipt by the Company of evidence of the loss, theft, destruction or mutilation of this Warrant, and (in the case of loss, theft or destruction) of indemnity or security reasonably satisfactory to the Company, and upon surrender and cancellation of this Warrant, if mutilated, the Company shall execute and deliver a new Warrant of like tenor and date.

17. Notice or Demands .

Except as otherwise provided herein, notices or demands pursuant to this Warrant to be given or made by Holder to or on the Company shall be sufficiently given or made if sent by overnight delivery with a nationally recognized overnight courier service, certified or registered mail, return receipt requested, postage prepaid, and addressed, until another address is designated in writing by the Company, to the address set forth in Section 2(a) above. To the extent any notice or demand pursuant to this Warrant can be made by electronic mail, such notice or demand given or made by Holder to or on the Company shall be sufficiently given or made if it is sent by electronic mail to the addresses that the Company shall designate in writing from time to time. Notices or demands pursuant to this Warrant to be given or made by the Company to or on

 

24


Holder shall be sufficiently given or made if sent by overnight delivery with a nationally recognized overnight courier service or certified or registered mail, return receipt requested, postage prepaid, and addressed, to the address of Holder set forth in the Company’s records, until another address is designated in writing by Holder.

18. Construction .

Unless the context otherwise requires, (a) all references to Articles, Sections, Schedules or Exhibits are to Articles, Sections, Schedules or Exhibits contained in or attached to this Warrant, (b) words in the singular or plural include the singular and plural and pronouns stated in either the masculine, the feminine or neuter gender shall include the masculine, feminine and neuter and (c) the use of the word “including” in this Warrant shall be by way of example rather than limitation.

19. Signatures .

In the event that any signature to this Warrant or any amendment hereto is delivered by electronic mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such “.pdf” signature page were an original thereof. Notwithstanding the foregoing, the Company shall be obligated to deliver to Holder an original signature to this Warrant. At the request of any party, each other party shall promptly re-execute an original form of this Warrant or any amendment hereto and deliver the same to the other party. No party hereto shall raise the use of electronic mail delivery of a “.pdf” format data file to deliver a signature to this Warrant or any amendment hereto or the fact that such signature was transmitted or communicated through the use of electronic mail delivery of a “.pdf” format data file as a defense to the formation or enforceability of a contract, and each party hereto forever waives any such defense.

 

25


IN WITNESS WHEREOF, the undersigned has executed this Warrant as of the 9th day of August, 2018.

 

ENDOLOGIX, INC.
By:  

/s/ Vaseem Mahboob

  Print Name: Vaseem Mahboob
  Title: Chief Financial Officer

 

26


EXHIBIT A-1

EXERCISE FORM FOR WARRANT

TO: [                ]

CHECK THE APPLICABLE BOX:

 

Cash Exercise, Cashless Exercise or Note Exchange Exercise

The undersigned hereby irrevocably exercises Warrant Number              (the “Warrant”) with respect to 2,916,667 shares of Common Stock (the “Common Stock”) of Endologix, Inc., a Delaware corporation (the “Company”). [IF APPLICABLE: The undersigned hereby encloses $         as payment of the Exercise Price.]

☐ The undersigned is exercising the Warrant with respect to [            ] shares of Common Stock pursuant to a Cashless Exercise, and hereby makes payment of the Exercise Price with respect to such shares in full, all in accordance with the conditions and provisions of the Warrant applicable to such Cashless Exercise.

☐ The undersigned is exercising the Warrant with respect to [            ] shares of Common Stock pursuant to a Note Exchange Exercise. The undersigned hereby agrees to cancel $         of principal outstanding under Notes of the Company held by Holder in satisfaction of the Exercise Price in accordance with the conditions and provisions of the Warrant applicable to such Note Exchange Exercise.

 

Cashless Major Exercise

The undersigned hereby irrevocably exercises the Warrant with respect to         % of the Warrant currently outstanding pursuant to a Cashless Major Exercise in accordance with the terms of the Warrant.

 

Cashless Default Exercise

The undersigned hereby irrevocably exercises the Warrant pursuant to a Cashless Default Exercise, in accordance with the terms of the Warrant.

1. The undersigned requests that any stock certificates for such shares be issued free of any restrictive legend, if appropriate, and, if requested by the undersigned, a warrant representing any unexercised portion hereof be issued, pursuant to the Warrant in the name of the undersigned and delivered to the undersigned at the address set forth below.

2. Capitalized terms used but not otherwise defined in this Exercise Form shall have the meaning ascribed thereto in the Warrant.

Dated: _______________

 

 

Signature

 

 

Print Name

 

 

Address

NOTICE

The signature to the foregoing Exercise Form must correspond to the name as written upon the face of the attached Warrant.

 

27


EXHIBIT B

ASSIGNMENT

(To be executed by the registered holder

desiring to transfer the Warrant)

FOR VALUE RECEIVED, the undersigned holder of the attached warrant (the “Warrant”) hereby sells, assigns and transfers unto the person or persons below named the right to purchase              shares of the Common Stock of Endologix, Inc., a Delaware corporation, evidenced by the attached Warrant and does hereby irrevocably constitute and appoint              attorney to transfer the said Warrant on the books of the Company, with full power of substitution in the premises.

 

Dated: _______________

 

 

 

Signature

Fill in for new registration of Warrant:

 

 

Name

 

Address

 

Please print name and address of assignee

(including zip code number)

NOTICE

The signature to the foregoing Assignment must correspond to the name as written upon the face of the attached Warrant.

 

28


EXHIBIT C

FORM OF OPINION

            , 20        

[                        ]

Re:     [                     ] (the “Company”)

Dear Sir:

[                ] (“[                ]”) intends to transfer              Warrants (the “Warrants”) of the Company to                  (“                ”) without registration under the Securities Act of 1933, as amended (the “Securities Act”). In connection therewith, we have examined and relied upon the truth of representations contained in an Investor Representation Letter attached hereto and have examined such other documents and issues of law as we have deemed relevant.

Based on and subject to the foregoing, we are of the opinion that the transfer of the Warrants by                  to                  may be effected without registration under the Securities Act [, provided, however, that the Warrants to be transferred to                 contain a legend restricting its transferability pursuant to the Securities Act and that transfer of the Warrants is subject to a stop order] . 1

The foregoing opinion is furnished only to                  and may not be used, circulated, quoted or otherwise referred to or relied upon by you for any purposes other than the purpose for which furnished or by any other person for any purpose, without our prior written consent.

Very truly yours,

 

1  

Only if applicable.

 

29


[FORM OF INVESTOR REPRESENTATION LETTER]

            , 20        

[                ]

Gentlemen:

                 (“        ”) has agreed to purchase                  Warrants (the “Warrants”) of Endologix, Inc., a Delaware corporation (the “Company”) from [                ] (“[                ]”). We understand that the Warrants are “restricted securities.” We represent and warrant that                  is a sophisticated institutional investor that would qualify as an “Accredited Investor” as defined in Rule 501 of Regulation D under the Securities Act of 1933, as amended (the “Securities Act”).

___                 represents and warrants as of the date hereof as follows:

1. That it is acquiring the Warrants and the shares of common stock, $0.001 par value per share underlying such Warrants (the “Exercise Shares”) solely for its account for investment and not with a view to or for sale or distribution of said Warrants or Exercise Shares or any part thereof in violation of the Securities Act.                  also represents that the entire legal and beneficial interests of the Warrants and Exercise Shares                  is acquiring is being acquired for, and will be held for, its account only;

2. That the Warrants and the Exercise Shares must be held indefinitely unless they are registered under the Securities Act or an exemption from such registration is available.                  recognizes that the Company has no obligation to register the Warrants, or to comply with any exemption from such registration;

3. That neither the Warrants nor the Exercise Shares may be sold pursuant to Rule 144 adopted under the Securities Act unless certain conditions are met;

We acknowledge that the Company will place stop orders with respect to the Warrants and the Exercise Shares, and if none of the Unrestricted Conditions (as defined in the Warrants) is satisfied, the Exercise Shares shall bear the following restrictive legend:

“THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER SAID ACT, OR PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER SAID ACT INCLUDING PURSUANT TO SECTION 4(A)(7) OF THE SECURITIES ACT OR RULE 144 UNDER SAID ACT OR PURSUANT TO A PRIVATE SALE EFFECTED UNDER APPLICABLE FORMAL OR INFORMAL SEC INTERPRETATION OR GUIDANCE, SUCH AS A SO-CALLED “4[(a)](1) AND A HALF” SALE.

 

30


NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.”

“THE SALE, TRANSFER OR ASSIGNMENT OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO THE TERMS AND CONDITIONS OF A CERTAIN AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT DATED AS OF AUGUST 9, 2018, AS AMENDED FROM TIME TO TIME, AMONG THE COMPANY AND CERTAIN HOLDERS OF ITS OUTSTANDING SECURITIES. COPIES OF SUCH AGREEMENT MAY BE OBTAINED AT NO COST BY WRITTEN REQUEST MADE BY THE HOLDER OF RECORD OF THIS CERTIFICATE TO THE SECRETARY OF THE COMPANY.”

At any time and from time to time after the date hereof,                  shall, without further consideration, execute and deliver to [                ] or the Company such other instruments or documents and shall take such other actions as they may reasonably request to carry out the transactions contemplated hereby.

Very truly yours,

 

31


Schedule 1

Black-Scholes Value

 

    

Calculation Under Sections 3(b) and 5(b)(iii)

  

Calculation Under Section 10(b) or 11(b)

Remaining Term    Number of calendar days from date of public announcement of the Major Transaction until the last date on which the Warrant may be exercised.    Number of calendar days from the date of the Event of Failure, or in the case of an Event of Default, the date of the Default Notice, until the last date on which the Warrant may be exercised.
Interest Rate    A risk-free interest rate corresponding to the US$ LIBOR/Swap rate for a period equal to the remaining Exercise Period.    A risk-free interest rate corresponding to the US$ LIBOR/Swap rate for a period equal to the remaining Exercise Period.
Cost to Borrow    Zero    Zero
Volatility   

If the first public announcement of the Major Transaction is made at or prior to 4:00 p.m., New York City time, the arithmetic mean of the historical volatility for the 10, 30 and 50 Trading Day periods ending on the date of such first public announcement, obtained from the HVT or similar function on Bloomberg.

 

If the first public announcement of the Major Transaction is made after 4:00 p.m., New York City time, the arithmetic mean of the historical volatility for the 10, 30 and 50 Trading Day periods ending on the next succeeding Trading Day following the date of such first public announcement, obtained from the HVT or similar function on Bloomberg.

   The arithmetic mean of the historical volatility for the 10, 30 and 50 Trading Day periods ending on the date of such determination, obtained from the HVT or similar function on Bloomberg.

 

32


Stock Price    As selected by Holder in its commercially reasonable discretion in order to produce a commercially reasonable result, any of: (1) the closing price of the Common Stock on the NasdaqGS, or, if that is not the principal trading market for the Common Stock, such principal market on which the Common Stock is traded or listed (the “Closing Market Price”) on the Trading Day immediately preceding the date on which a Major Transaction is consummated, (2) the first Closing Market Price following the first public announcement of a Major Transaction, (3) the Closing Market Price as of the date immediately preceding the first public announcement of the Major Transaction or (4) the cash amount payable per share of Common Stock. The Company and Holder acknowledge and agree that any of the above will produce a commercially reasonable result.    The volume Weighted Average Price on the date of such determination.
Dividends    Zero.    Zero.
Strike Price    Exercise Price as defined in section 3(a).    Exercise Price as defined in section 3(a).

 

33

Exhibit 4.4

FIRST OUT WATERFALL NOTE

THE SECURITIES REPRESENTED BY THIS NOTE (AS DEFINED BELOW) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS OR (B) AN OPINION OF COUNSEL, IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR APPLICABLE STATE SECURITIES LAWS OR (II) UNLESS SOLD PURSUANT TO RULE 144 UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN, FINANCING OR INDEBTEDNESS ARRANGEMENT SECURED BY THE SECURITIES.

THE FOLLOWING INFORMATION IS PROVIDED PURSUANT TO TREAS. REG. SECTION 1.1275-3: THE BORROWER (AS DEFINED BELOW) WILL MAKE AVAILABLE ON REQUEST TO HOLDER(S) OF THIS NOTE THE FOLLOWING INFORMATION: ISSUE PRICE, AMOUNT OF ORIGINAL ISSUE DISCOUNT, ISSUE DATE AND YIELD TO MATURITY. THIS NOTE IS BEING AMENDED AND RESTATED AS PART OF AND PURSUANT TO A PLAN OF RECAPITALIZATION AND REORGANIZATION OF THE BORROWER DESCRIBED IN SECTION 368(A)(1)(E) OF THE INTERNAL REVENUE CODE OF 1986, AS AMENDED.

FIRST OUT WATERFALL NOTE

 

First Out Waterfall Lender: Deerfield Private Design Fund III, L.P.
Principal Amount: $40,000,000               Original Issue Date: April 3, 2017
  Amendment and Restatement Date: August 9, 2018

FOR VALUE RECEIVED, the undersigned, Endologix, Inc., a Delaware corporation (the “ Borrower ”), hereby unconditionally promises to pay to the First Out Waterfall Lender set forth above (the “ Lender ”) the “Principal Amount” set forth above, or, if less, the aggregate unpaid Principal (as defined below) amount of the First Out Waterfall Loan (as defined in the Facility Agreement referred to below) of the Lender to the Borrower, payable at such times and in such amounts as are specified in the Facility Agreement.

The Borrower promises to pay interest on the outstanding Principal amount of the First Out Waterfall Loan and any overdue interest from and after the Amendment and Restatement Date (as defined below) until such outstanding Principal amount of the First Out Waterfall Loan and any overdue interest are paid in full, payable at such times and at such interest rates as are specified in the Facility Agreement. The Borrower promises to pay any Non-Callable Make Whole Amount, any CoC Fee and the First Out Waterfall Exit Payment (each, as defined in the Facility Agreement) that is due on the First Out Waterfall Loan in accordance with the Facility Agreement.

 

1


In lieu of making any payment of interest in cash (but not (i) interest payable pursuant to the second sentence of Section 2.6(a) of Facility Agreement, (ii) interest payable-in-kind or (iii) in connection with any Event of Default or late payment hereunder or any other interest payable pursuant to Section 2.7 of the Facility Agreement) and subject to the conditions set forth in Section 2.6 of the Facility Agreement and Exhibit 2.6 to the Facility Agreement, the Borrower may elect to satisfy all or any such payment by the issuance to the Lender of shares of Freely Tradable Common Shares (as defined in Exhibit 2.6) in accordance with the provisions of Exhibit 2.6.

This First Out Waterfall Note (this “ Note ”) was originally issued on April 3, 2017 and amended and restated on August 9, 2018 (the “ Amendment and Restatement Date ”) and is one of the “First Out Waterfall Notes”, “Loan Notes” and “Notes” referred to in, and is entitled to the benefits of, the Amended and Restated Facility Agreement, dated as of August 9, 2018 (as the same may be amended, restated, supplemented or otherwise modified from time to time, the “ Facility Agreement ”), by and among the Borrower, the other Loan Parties party thereto, the Lenders party thereto and Deerfield Private Design Fund IV, L.P., as agent for the Secured Parties, and the other Loan Documents.

The Facility Agreement, among other things, (a) provides for the making of a First Out Waterfall Loan by the Lender to the Borrower in an aggregate amount not to exceed at any time outstanding the “Principal Amount” set forth above, the indebtedness of the Borrower resulting from such First Out Waterfall Loan being evidenced by this Note and (b) contains provisions for acceleration of the maturity of the unpaid Principal amount of this Note upon the happening of certain stated events and also for prepayments pursuant to Section 2.3(c) or Section 5.3 of the Facility Agreement on account of the Principal hereof prior to the maturity hereof upon the terms and conditions specified therein.

1. Definitions .

(a) Certain Defined Terms . Capitalized terms used herein without definition are used as defined in the Facility Agreement. For purposes of this Note, the following terms shall have the following meanings:

(i) “ Affiliate ” means any person or entity that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a person or entity, as such terms are used in and construed under Rule 144 under the Securities Act. With respect to a Lender, any investment fund or managed account that is managed on a discretionary basis by the same investment manager as such Lender will be deemed to be an Affiliate of such Lender. As used in this definition of “Affiliate,” the term “control” means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through ownership of voting securities or partnership or other ownership interest, by contract, or otherwise.

(ii) “ Common Stock ” means the fully paid and nonassessable shares of the Borrower’s common stock, $0.001 par value per share.

 

2


(iii) “ Conversion Amount ” means the Principal amount to be converted.

(iv) “ Conversion Date ” means the date of delivery via facsimile or electronic mail of a Conversion Notice.

(v) “ Conversion Issuance Limit ” means 4,766,667 shares of Common Stock, subject to appropriate adjustment for any Stock Event that occurs after the Amendment and Restatement Date.

(vi) “ Conversion Price ” means, as of any Conversion Date, ninety-six percent (96%) of the arithmetic average of the Volume Weighted Average Prices per share of Common Stock on each of the three (3) Trading Days period preceding the Conversion Date (the “ Measurement Period ”); provided, that in the event that a stock split, stock combination, reclassification, payment of stock dividend, recapitalization or other similar transaction of such character that the shares of Common Stock shall be changed into or become exchangeable for a larger or small number of shares (a “ Stock Event ”) is consummated during the Measurement Period, the Volume Weighted Average Price for all Trading Days during the Measurement Period prior to the effectiveness of such Stock Event shall be appropriately adjusted to reflect such Stock Event, subject to appropriate adjustment for any Stock Event that occurs after the Amendment and Restatement Date.

(vii) “ Conversion Shares ” means fully paid and nonassessable shares of Common Stock issued in connection with the conversion of a Note.

(viii) “ First Amortization Cap ” means 3,166,667 shares of Common Stock, subject to appropriate adjustment for any Stock Event that occurs after the Amendment and Restatement Date.

(ix) “ First Amortization Date ” means April 2, 2021.

(x) “ Market Disruption Event ” means, with respect to any Trading Day and any security of Borrower, (a) a failure by the Principal Market to open for trading during its entire regular trading session, (b) the occurrence or existence prior to 1:00 p.m., New York City time, on such day for such securities of Borrower for more than one half-hour period in the aggregate during regular trading hours of any suspension or limitation imposed on trading (by reason of movements in price exceeding limits permitted by the relevant securities exchange or otherwise) in such securities or in any options, contracts or future contracts relating to such securities, or (c) to the extent “Volume Weighted Average Price” is determined in accordance with clause (b) of the definition thereof, the suspension of trading for the one-half hour period ending on the scheduled close of trading on such day (by reason of movements in price exceeding limits permitted by the stock exchange or otherwise) in such securities of Borrower.

(xi) “ Monthly Conversion Cap ” means 1,733,333 shares of Common Stock, subject to appropriate adjustment for any Stock Event that occurs after the Amendment and Restatement Date.

 

3


(xii) “ Monthly Conversion Cap Period ” means the period commencing on the Amendment and Restatement Date and ending on (and including) August 31, 2018, and each calendar month that begins after the Amendment and Restatement Date and prior to the Maturity Date.

(xiii) “ Principal ” means the outstanding principal amount of this Note as of any date of determination.

(xiv) “ Required Lenders ” means the Required First Out Waterfall Lenders.

(xv) “ Second Amortization Cap ” means 1,600,000 shares of Common Stock, subject to appropriate adjustment for any Stock Event that occurs after the Amendment and Restatement Date.

(xvi) “ Second Amortization Date ” means April 2, 2022.

(xvii) “ Trading Day ” means any day on which the Common Stock is traded for any period on the Principal Market; provided, that for purposes of the definition of “Conversion Shares,” Trading Day shall not include any Trading Day on which there is a Market Disruption Event.

(xviii) “ Volume Weighted Average Pric e ” for any security as of any Trading Day means (a) the volume weighted average sale price of such security on the principal U.S. national or regional securities exchange on which such security is traded as reported by Bloomberg Financial Markets or an equivalent, reliable reporting service mutually acceptable to and hereinafter designated by the Required Lenders and the Borrower (“ Bloomberg ”), or (b) if no volume weighted average sale price is reported for such security, then the closing price per share of such security, or, if no closing price per share is reported for such security by Bloomberg, the average of the last bid and last ask price (or if more than one in either case, the average of the average last bid and average last ask prices) on such Trading Day as reported in the composite transactions for the principal U.S. national or regional securities exchange on which such security is traded. If the security is not listed for trading on a U.S. national or regional securities exchange on the relevant Trading Day, then the Volume Weighted Average Price will be the average of the mid-point of the last bid and last ask prices of the security in the over-the-counter market on the relevant Trading Day as reported by OTC Markets Group or similar organization. If the Volume Weighted Average Price cannot be calculated for such security on such date in the manner provided above, the Volume Weighted Average Price shall be the fair market value as mutually determined by the Borrower and the Lenders holding a majority of the aggregate outstanding Principal amount of the Notes being converted for which the calculation of the Volume Weighted Average Price is required in order to determine the Conversion Price of such Notes. Volume Weighted Average Price will be determine without regard to after-hours trading or any other trading outside of the regular trading hours.

2. Conversion Rights . This Note may be converted into shares of Common Stock on the terms and conditions set forth in this Section  2 (subject to Section 2.3(a) of the Facility Agreement).

 

4


(a) Conversion at Option of the Lender . At any time during the period commencing on (and including) the Amendment and Restatement Date and ending on the close of business on the second business day immediately prior to the Maturity Date, the Lender shall be entitled to convert all or any part of the Principal into Conversion Shares in accordance with this Section  2 at the Conversion Rate (as defined in Section  2(b) ). The Borrower shall not issue any fraction of a share of Common Stock upon any conversion. If the issuance would result in the issuance of a fraction of a share of Common Stock, then the Borrower shall round such fraction of a share of Common Stock up or down to the nearest whole share (with 0.5 rounded up).

(b) Conversion Rate . The number of Conversion Shares issuable upon a conversion of any portion of this Note pursuant to Section  2 shall be determined according to the following formula (the “ Conversion Rate ”):

Conversion Amount

Conversion Price

(c) Mechanics of Conversion . The conversion of this Note shall be conducted in the following manner:

(i) Lender’s Delivery Requirements . To convert a Conversion Amount into Conversion Shares pursuant to Section  2(a) above on any date, Lender shall (A) transmit by facsimile or electronic mail (or otherwise deliver), for receipt on or prior to 5:00 p.m. New York City time on such date, a copy of an executed conversion notice in the form attached hereto as Exhibit A (the “ Conversion Notice ”) to the Borrower (at 2 Musick, Irvine, CA 92618, Attention : Chief Financial Officer; Email : vmahboob@endologix.com, or at such other office or agency as the Borrower may designate in writing), and (B) if required by Section  2(c)(vi) , surrender to a common carrier for delivery to the Borrower, no later than three (3) Business Days after the Conversion Date, of the original Note being converted (or an indemnification undertaking in customary form with respect to this Note in the case of its loss, theft or destruction).

(ii) Borrower’s Response . Upon receipt or deemed receipt by the Borrower of a copy of a Conversion Notice, the Borrower (A) shall immediately send, via facsimile, a confirmation of receipt of such Conversion Notice to the Lender and the Borrower’s designated transfer agent (the “ Transfer Agent ”), which confirmation shall constitute an instruction to the Transfer Agent to process such Conversion Notice in accordance with the terms herein, and (B) on or before the second (2 nd ) Business Day following the date of receipt or deemed receipt by the Borrower of such Conversion Notice (or, if earlier, the end of the standard settlement period for U.S. broker-dealer securities transactions) (the “ Share Delivery Date ”), shall credit such aggregate number of Conversion Shares to which the Lender shall be entitled to the Lender’s or its designee’s balance account with The Depository Trust Company (“ DTC ”) through its Deposit/Withdrawal At Custodian (DWAC) system, for the number of Conversion Shares to which the Lender shall be entitled. If notwithstanding the provisions of Section  2(c)(vi) , the Lender elects to physically surrender this Note for conversion and the Principal represented by this Note is greater than the Principal being converted, then the Borrower shall, as soon as practicable and in no event later than three (3) Business Days after

 

5


receipt of this Note and at its own expense, issue and deliver to the Lender a new Note representing the Principal not converted and cancel this Note. For purposes of Rule 144 under the Securities Act, any Conversion Shares issued to Lender shall be deemed to have been acquired by such Lender on April 3, 2017 (the date this Note was originally issued). Accordingly, (A) upon any conversion of this Note, the Rule 144 holding period for the Conversion Shares acquired thereupon shall be in excess of one (1) year, and (B) provided the Lender is not an Affiliate of the Borrower on the Conversion Date and has not been an Affiliate of the Borrower within the three-month period immediately preceding the Conversion Date (the “ Unrestricted Condition ”), which the Borrower shall assume and Lender hereby represents unless the Lender advises the Borrower otherwise in writing, the Conversion Shares issued to Lender will be freely transferable, without restriction or limitation (including any volume limitation) under Federal or state securities laws, pursuant to Rule 144 under the Securities Act and will not contain or be subject to a legend or stop transfer order restricting the resale or transferability of thereof.

(iii) Dispute Resolution . In the case of a dispute as to the determination of the Conversion Price or the arithmetic calculation of the Conversion Rate, the Borrower shall instruct the Transfer Agent to issue to the Lender the number of Conversion Shares that is not disputed and shall transmit an explanation of the disputed determinations or arithmetic calculations to the Lender via facsimile within two (2) Business Days of receipt or deemed receipt of the Lender’s Conversion Notice or other date of determination. If the Lender and the Borrower are unable to agree upon the determination of the Conversion Price or arithmetic calculation of the Conversion Rate within one (1) Business Day of such disputed determination or arithmetic calculation being transmitted to the Lender, then the Borrower shall promptly (and in any event within two (2) Business Days) submit via facsimile (A) the disputed determination of the Conversion Price to an independent, reputable investment banking firm agreed to by the Borrower and the Required Lenders, or (B) the disputed arithmetic calculation of the Conversion Rate to the Borrower’s independent registered public accounting firm, as the case may be. The Borrower shall direct the investment bank or the accounting firm, as the case may be, to perform the determinations or calculations and notify the Borrower and the Lender of the results no later than two (2) Business Days from the time it receives the disputed determinations or calculations. Such investment bank’s or accounting firm’s determination or calculation, as the case may be, shall be binding upon all parties absent manifest error, and the fees and expenses of such investment bank or accountant shall be paid one-half by the Borrower and one-half by the Lender. Notwithstanding the existence of a dispute contemplated by this paragraph, if requested by the Lender, the Borrower shall issue to the Lender the Conversion Shares not in dispute in accordance with the terms hereof.

(iv) Record Holder . The person or persons entitled to receive the Conversion Shares issuable upon a conversion of this Note shall be treated for all purposes as the legal and record holder or holders of such shares of Common Stock upon delivery by the Lender of the Conversion Notice, or in the case of Conversion Shares the issuance of which is subject to a bona fide dispute that is subject to and being resolved pursuant to, and in compliance with the time periods and other provisions of, the dispute resolution provisions of Section  2(c)(iii) , the first Business Day after the resolution of such bona fide dispute.

(v) Borrower’s Failure to Timely Convert .

 

6


(A) Cash Damages . If by the Share Delivery Date, the Borrower shall fail to credit the Lender’s or its designee’s balance account with DTC with the number of Conversion Shares (free of any restrictive legend, provided the Unrestricted Condition is satisfied), then, in addition to all other available remedies that the Lender may pursue hereunder and under the Facility Agreement, the Borrower shall pay additional damages to the Lender for each day after the Share Delivery Date such conversion is not timely effected in an amount equal to one and one-half percent (1.5%) of the product of (I) the number of Conversion Shares not issued to the Lender or its designee on or prior to the Share Delivery Date and to which the Lender is entitled and (II) the Volume Weighted Average Price of the Common Stock on the Share Delivery Date. Alternatively in lieu of the foregoing damages, subject to Section  2(c)(iii) , at the written election of the Lender made in the Lender’s sole discretion, if, on or after the applicable Conversion Date, the Lender purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by such Lender of Conversion Shares that such Lender anticipated receiving from the Borrower (such purchased shares, “ Buy-In Shares ”), the Borrower shall be obligated to promptly pay to such Lender (in addition to all other available remedies that the Lender may otherwise have), 110% of the amount by which (A) such Lender’s total purchase price (including brokerage commissions, if any) for such Buy-In Shares exceeds (B) the net proceeds received by such Lender from the sale of a number of shares equal to up to the number of Conversion Shares such Lender was entitled to receive but had not received on the Share Delivery Date. If the Borrower fails to pay the additional damages set forth in this Section 2(c)(v)(A) within five (5) Business Days of the date incurred, then the Lender entitled to such payments shall have the right at any time, so long as the Borrower continues to fail to make such payments, to require the Borrower, upon written notice, to immediately issue, in lieu of such cash damages, the number of shares of Common Stock equal to the quotient of (X) the aggregate amount of the damages payments described herein divided by (Y) the Conversion Price specified by the Lender in the Conversion Notice.

(B) Conversion Failure . If for any reason the Lender has not received all of the Conversion Shares it is entitled to prior to the tenth (10th) Business Day after the Share Delivery Date with respect to a conversion of this Note (a “ Conversion Failure ”), then the Lender, upon written notice to the Borrower (a “ Void Conversion Notice ”), may void its conversion with respect to, and retain or have returned, as the case may be, any portion of this Note that has not been converted pursuant to the Lender’s Conversion Notice; provided , that the voiding of the Lender’s Conversion Notice shall not affect the Borrower’s obligations to make any payments that have accrued prior to the date of such notice pursuant to Section  2(c)(v)(A) or otherwise. A Conversion Failure shall constitute an Event of Default under the Facility Agreement and entitle the Lenders to all payments and remedies provided under the Facility Agreement upon the occurrence of an Event of Default.

(vi) Book-Entry . Notwithstanding anything to the contrary set forth herein, upon conversion or repayment of this Note in accordance with the terms hereof, the Lender shall not be required to physically surrender this Note to the Borrower unless all of the Principal is being converted or repaid. The Lender and the Borrower shall maintain records showing the Principal converted or repaid and the dates of such conversions or repayments or shall use such other method, reasonably satisfactory to the Lender and the Borrower, so as not to require physical surrender of this Note upon any such partial conversion or repayment. Notwithstanding the foregoing, if this Note is converted or repaid as aforesaid, the Lender may

 

7


not transfer this Note unless the Lender first physically surrenders this Note to the Borrower, whereupon the Borrower will forthwith issue and deliver upon the order of the Lender a new Note of like tenor, registered as the Lender may request, representing in the aggregate the remaining Principal represented by this Note. The Lender and any assignee, by acceptance of this Note, acknowledge and agree that, by reason of the provisions of this paragraph, following conversion or repayment of any portion of this Note, the Principal of this Note may be less than the “Principal Amount” stated on the face hereof.

(d) Limitations on Conversions .

(i) Beneficial Ownership . Notwithstanding anything herein to the contrary, the Borrower shall not issue to the Lender, and the Lender may not acquire, a number of shares of Common Stock upon conversion of this Note or otherwise issue any shares of Common Stock pursuant hereto or the Facility Agreement to the extent that, upon such conversion, the number of shares of Common Stock then beneficially owned by the Lender and its Affiliates and any other persons or entities whose beneficial ownership of Common Stock would be aggregated with the Lender’s for purposes of Section 13(d) of the Exchange Act (including shares held by any “group” of which the Lender is a member, but excluding shares beneficially owned by virtue of the ownership of the Warrants or other securities or rights to acquire securities that have limitations on the right to convert, exercise or purchase similar to the limitation set forth herein) would exceed 4.985% of the total number of shares of common stock then issued and outstanding (the “ 4.985% Cap ”); provided, however, that the 4.985% Cap shall only apply to the extent that the Common Stock is deemed to constitute an “equity security” pursuant to Rule 13d-1(i) promulgated under the Exchange Act. For purposes hereof, “group” has the meaning set forth in Section 13(d) of the Exchange Act and applicable regulations of the SEC, and the percentage held by the Lender shall be determined in a manner consistent with the provisions of Section 13(d) of the Exchange Act. Upon the written request of the Lender, the Borrower shall, within two (2) Trading Days, confirm orally and in writing to the Lender the number of shares of Common Stock then outstanding.

(ii) Conversion Issuance Limit . Notwithstanding anything to the contrary contained herein, the Borrower shall not issue any shares of Common Stock upon conversion of this Note (including pursuant to Section  2(c)(v)(A) hereof) to the extent that the issuance of such shares of Common Stock together with any previous issuances of shares of Common Stock under this Note would exceed the Conversion Issuance Limit, and Section 2.5(c)(v) shall not apply in respect to any excess amount.

(iii) Other Applicable Limitations on Conversion of the Note . Notwithstanding anything to the contrary herein, this Note shall not be convertible, and the Borrower shall not issue shares of Common Stock upon conversion of this Note (a) at any time after the First Amortization Date, to the extent that the number of shares of Common Stock that would otherwise be issuable to Lender upon such conversion, together with all shares of Common Stock previously issued to Lender upon conversion of this Note after the First Amortization Date, would exceed the First Amortization Cap, or (b)  at any time after the Second Amortization Date, to the extent that the number of shares of Common Stock that would otherwise be issuable to Lender upon such conversion, together with all shares of Common Stock previously issued to Lender upon conversion of this Note after the Second Amortization

 

8


Date, would exceed the Second Amortization Cap, or (c) during any Monthly Conversion Cap Period, to the extent that the number of shares of Common Stock that would otherwise be issuable to Lender upon such conversion, together with all shares previously issued to Lender upon conversion of this Note during the such Monthly Conversion Cap Period, would exceed the Monthly Conversion Cap. For the avoidance of doubt, if the number of shares of Common Stock to be issued as set forth in an Conversion Notice transmitted by the Lender to the Borrower would otherwise require the Borrower to issue a number of shares in excess of the Conversion Issuance Limit, the First Amortization Cap (if after the First Amortization Date), the Second Amortization Cap (if after the Second Amortization Date) or the Monthly Share Cap, the Borrower shall issue to the Lender in accordance herewith the maximum number of shares of Common Stock issuable without exceeding any such applicable limitation, and Section 2.5(c)(v) shall not apply to any excess amount.

3. Voting Rights . Except as required by law, the Lender shall have no voting rights with respect to any of the Conversion Shares until the Conversion Date relating to the conversion of this Note upon which such Conversion Shares are issuable (or in the case of Conversion Shares the issuance of which is subject to a bona fide dispute that is subject to and being resolved pursuant to, and in compliance with the time periods and other provisions of, the dispute resolution provisions of Section  2(c)(iii) , the first Business Day after the resolution of such bona fide dispute).

4. Amendment; Waiver . The provisions of this Note may only be waived or amended, restated, supplemented or otherwise modified in accordance with the Facility Agreement.

5. Specific Shall Not Limit General; Construction . No specific provision contained in this Note shall limit or modify any more general provision contained herein. This Note shall be deemed to be jointly drafted by the Borrower and all Lenders pursuant to the Facility Agreement and shall not be construed against any Person as the drafter hereof.

6. Failure or Indulgence Not Waiver . No delay or omission by the Lender in exercising any power or right hereunder shall impair such right or power or be construed to be a waiver of any default, nor shall any single or partial exercise of any power or right hereunder preclude the full exercise thereof or the exercise of any other power or right. No renewal or extension of this Note or the Facility Agreement, no delay in the enforcement of payment under this Note or the Facility Agreement, and no delay or omission in exercising any right or power under this Note or the Facility Agreement shall affect the liability of the Borrower or any endorser of this Note.

7. Notices . Whenever notice is required to be given under this Note, unless otherwise provided herein, such notice shall be given in accordance with Section 6.1 of the Facility Agreement.

8. Restrictions on Transfer .

(a) Registration or Exemption Required . This Note has been issued in a transaction exempt from the registration requirements of the Securities Act. None of the Note or

 

9


the Conversion Shares issued hereunder may be transferred, sold, assigned, hypothecated or otherwise disposed of except pursuant to an effective registration statement or an exemption to the registration requirements of the Securities Act and applicable state laws, including Rule 144 under the Securities Act, Section 4(a)(7) of the Securities Act or a so-called “4[(a)](1) and a half” transaction.

(b) Assignment . This Note is assignable or transferable, in whole or in part, only to the extent such assignment or transfer is permitted pursuant to the terms of the Facility Agreement; provided that (i) the Lender shall deliver a written notice to the Borrower, substantially in the form of the Assignment attached hereto as Exhibit B , indicating the Person or Persons to whom the Note shall be assigned and the respective Principal amount of the Note to be assigned to each assignee. The Borrower shall effect the assignment within three (3) business days, and shall deliver to the assignee(s) designated by the Lender a Note or Notes of like tenor and terms for the appropriate Principal amount. This Note and the rights evidenced hereby shall inure to the benefit of and be binding upon the successors and assigns of the Lender. The provisions of this Note are intended to be for the benefit of all Lenders from time to time of this Note, and shall be enforceable by any such Lender. This Note is not (and any rights or obligations hereunder are not) not assignable or transferable by the Borrower under any circumstance and any such prohibited assignment or transfer is absolutely void ab initio .

9. Payment of Collection, Enforcement and Other Costs . If (a) this Note is placed in the hands of an attorney for collection or enforcement or is collected or enforced through any legal proceeding; or (b) an attorney is retained to represent the Lender in any bankruptcy, reorganization, receivership of the Borrower or other proceedings affecting Borrower creditors’ rights and involving a claim under this Note, then the Borrower shall pay the costs incurred by the Lender for such collection, enforcement or action, including reasonable attorneys’ fees and disbursements. Subject to the terms of the Facility Agreement, all payments and issuances of shares of Common Stock hereunder will be free and clear of, and without deduction or withholding for, any present or future taxes. The Borrower shall pay all and any costs (administrative or otherwise) imposed by the Borrower’s banks, clearing houses, or any other financial institution, in connection with making any payments and issuing any shares of Common Stock hereunder. The Borrower shall pay all costs and expenses (including attorney’s fees) of the Lender incurred in connection with this Note in accordance with Section 6.3 of the Facility Agreement.

10. Waiver of Notice . Other than those notices required to be provided by the Lender to the Borrower under the terms of the Facility Agreement, the Borrower and every endorser of this Note, or the obligations represented hereby, expressly waives diligence, presentment, protest, demand, notice of dishonor, non-payment or default, and notice of any kind with respect to this Note and the Facility Agreement or the performance of the obligations under this Note and/or the Facility Agreement.

11. Miscellaneous . This Note is a Loan Document, is entitled to the benefits of the Loan Documents and is subject to certain provisions of the Facility Agreement, including Sections 1.2 ( Interpretation ) and 6.4 ( Governing Law; Venue; Jurisdiction; Service of Process; Waiver of Jury Trial ) thereof.

 

10


12. Additional Interpretative Matters . Unless the context otherwise requires, (a) all references to Sections or Exhibits are to Sections or Exhibits contained in or attached to this Note, (b) each accounting term not otherwise defined in this Note has the meaning assigned to it in accordance with GAAP, (c) words in the singular or plural include the singular and plural and pronouns stated in either the masculine, the feminine or neuter gender shall include the masculine, feminine and neuter and (d) the use of the word “including” in this Note shall be by way of example rather than limitation. If a Stock Event occurs during any period over which an average price is being determined, then an appropriate adjustment will be made to such average to reflect such Stock Event.

13. Signatures . In the event that any signature to this Note or any amendment hereto is delivered by electronic mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such “.pdf” signature page were an original thereof. Notwithstanding the foregoing, the Borrower shall be obligated to deliver to the Lender an original signature to this Note. At the request of any party, each other party shall promptly re-execute an original form of this Note or any amendment hereto and deliver the same to the other party. No party hereto shall raise the use of electronic mail delivery of a “.pdf” format data file to deliver a signature to this Note or any amendment hereto or the fact that such signature was transmitted or communicated through the use of electronic mail delivery of a “.pdf” format data file as a defense to the formation or enforceability of a contract, and each party hereto forever waives any such defense.

14. This Note is an amendment and restatement of that certain Loan Note originally issued on April 3, 2017, in the principal amount of $40,000,000.00 (the “ Prior Note ”) and evidences an extension, continuation, and renewal of the indebtedness evidenced by the Prior Note, but this Note replaces the Prior Note with the indebtedness evidenced by the Prior Note now evidenced by this Note. Such Prior Note shall be of no further force and effect upon execution of this Note. The Borrower hereby acknowledges and agrees that the indebtedness under the Prior Note has not been repaid or extinguished and that the execution hereof does not constitute a novation of the Prior Note. Moreover, this Note shall be entitled to all security and collateral to which the Prior Note was entitled, without change or diminution in the priority of any lien or security interest granted to secure the Prior Note.

[Signature Page Follows]

 

11


IN WITNESS WHEREOF, the Borrower has caused this Note to be executed and delivered by its duly authorized officer as of the day and year set forth above.

 

ENDOLOGIX, INC.,

a Delaware corporation

By: /s/ Vaseem Mahboob                                    
Name: Vaseem Mahboob
Title: Chief Financial Officer

 

12


Exhibit A

CONVERSION NOTICE

Reference is made to the First Out Waterfall Note (the “ Note ”) of ENDOLOGIX, INC. , a Delaware corporation (the “ Borrower ”), in the original principal amount of $40,000,000.00. In accordance with and pursuant to the Note, the undersigned hereby elects to convert the Conversion Amount (as defined in the Note) of the Note indicated below into shares of common stock, par value $0.001 per share (the “ Common Stock ”), of the Borrower, as of the date specified below.

Date of Conversion:                                  

Aggregate Conversion Amount to be converted at the Conversion Price (as defined in the Note):

 

                                                                          

Principal, applicable thereto, to be converted:                                                                          

Please confirm the following information:

Conversion Price:                                                                                                                                                        

Number of shares of Common Stock to be issued:                                                                                                   

Please issue the Common Stock into which the Note is being converted in the following name and to the following address:

Issue to:                                                                                                                                                                      

Facsimile Number:                                                                                                                                                    

Authorization:                                                                              

By:                                                                             

Title:                                                                          

Dated:                                                                                       

DTC Participant Number and Name:                                                                                                                                      

Account Number:                                                                                                                                                                    

 

13


Exhibit B

ASSIGNMENT

(To be executed by the registered holder

desiring to transfer the Note)

FOR VALUE RECEIVED, the undersigned holder of the attached First Out Waterfall Note (the “ Note ”) hereby sells, assigns and transfers unto the person or persons below named the right to receive the principal amount of $                     from Endologix, Inc., a Delaware corporation (the “ Borrower ”), evidenced by the attached Note and does hereby irrevocably constitute and appoint                      attorney to transfer the said Note on the books of the Borrower, with full power of substitution in the premises.

 

Dated:                                                  

 

    Signature
Fill in for new registration of Note:    

 

   
Name    

 

   
Address    

 

   
Please print name and address of assignee    
(including zip code number)    

NOTICE

The signature to the foregoing Assignment must correspond to the name as written upon the face of the attached Note.

 

14

Exhibit 4.5

FIRST OUT WATERFALL NOTE

THE SECURITIES REPRESENTED BY THIS NOTE (AS DEFINED BELOW) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS OR (B) AN OPINION OF COUNSEL, IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR APPLICABLE STATE SECURITIES LAWS OR (II) UNLESS SOLD PURSUANT TO RULE 144 UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN, FINANCING OR INDEBTEDNESS ARRANGEMENT SECURED BY THE SECURITIES.

THE FOLLOWING INFORMATION IS PROVIDED PURSUANT TO TREAS. REG. SECTION 1.1275-3: THE BORROWER (AS DEFINED BELOW) WILL MAKE AVAILABLE ON REQUEST TO HOLDER(S) OF THIS NOTE THE FOLLOWING INFORMATION: ISSUE PRICE, AMOUNT OF ORIGINAL ISSUE DISCOUNT, ISSUE DATE AND YIELD TO MATURITY. THIS NOTE IS BEING AMENDED AND RESTATED AS PART OF AND PURSUANT TO A PLAN OF RECAPITALIZATION AND REORGANIZATION OF THE BORROWER DESCRIBED IN SECTION 368(A)(1)(E) OF THE INTERNAL REVENUE CODE OF 1986, AS AMENDED.

FIRST OUT WATERFALL NOTE

 

First Out Waterfall Lender: Deerfield Private Design Fund IV, L.P.
Principal Amount: $40,000,000               Original Issue Date: April 3, 2017
  Amendment and Restatement Date: August 9, 2018

FOR VALUE RECEIVED, the undersigned, Endologix, Inc., a Delaware corporation (the “ Borrower ”), hereby unconditionally promises to pay to the First Out Waterfall Lender set forth above (the “ Lender ”) the “Principal Amount” set forth above, or, if less, the aggregate unpaid Principal (as defined below) amount of the First Out Waterfall Loan (as defined in the Facility Agreement referred to below) of the Lender to the Borrower, payable at such times and in such amounts as are specified in the Facility Agreement.

The Borrower promises to pay interest on the outstanding Principal amount of the First Out Waterfall Loan and any overdue interest from and after the Amendment and Restatement Date (as defined below) until such outstanding Principal amount of the First Out Waterfall Loan and any overdue interest are paid in full, payable at such times and at such interest rates as are specified in the Facility Agreement. The Borrower promises to pay any Non-Callable Make Whole Amount, any CoC Fee and the First Out Waterfall Exit Payment (each, as defined in the Facility Agreement) that is due on the First Out Waterfall Loan in accordance with the Facility Agreement.

 

1


In lieu of making any payment of interest in cash (but not (i) interest payable pursuant to the second sentence of Section 2.6(a) of Facility Agreement, (ii) interest payable-in-kind or (iii) in connection with any Event of Default or late payment hereunder or any other interest payable pursuant to Section 2.7 of the Facility Agreement) and subject to the conditions set forth in Section 2.6 of the Facility Agreement and Exhibit 2.6 to the Facility Agreement, the Borrower may elect to satisfy all or any such payment by the issuance to the Lender of shares of Freely Tradable Common Shares (as defined in Exhibit 2.6) in accordance with the provisions of Exhibit 2.6.

This First Out Waterfall Note (this “ Note ”) was originally issued on April 3, 2017 and amended and restated on August 9, 2018 (the “ Amendment and Restatement Date ”) and is one of the “First Out Waterfall Notes”, “Loan Notes” and “Notes” referred to in, and is entitled to the benefits of, the Amended and Restated Facility Agreement, dated as of August 9, 2018 (as the same may be amended, restated, supplemented or otherwise modified from time to time, the “ Facility Agreement ”), by and among the Borrower, the other Loan Parties party thereto, the Lenders party thereto and Deerfield Private Design Fund IV, L.P., as agent for the Secured Parties, and the other Loan Documents.

The Facility Agreement, among other things, (a) provides for the making of a First Out Waterfall Loan by the Lender to the Borrower in an aggregate amount not to exceed at any time outstanding the “Principal Amount” set forth above, the indebtedness of the Borrower resulting from such First Out Waterfall Loan being evidenced by this Note and (b) contains provisions for acceleration of the maturity of the unpaid Principal amount of this Note upon the happening of certain stated events and also for prepayments pursuant to Section 2.3(c) or Section 5.3 of the Facility Agreement on account of the Principal hereof prior to the maturity hereof upon the terms and conditions specified therein.

1. Definitions .

(a) Certain Defined Terms . Capitalized terms used herein without definition are used as defined in the Facility Agreement. For purposes of this Note, the following terms shall have the following meanings:

(i) “ Affiliate ” means any person or entity that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a person or entity, as such terms are used in and construed under Rule 144 under the Securities Act. With respect to a Lender, any investment fund or managed account that is managed on a discretionary basis by the same investment manager as such Lender will be deemed to be an Affiliate of such Lender. As used in this definition of “Affiliate,” the term “control” means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through ownership of voting securities or partnership or other ownership interest, by contract, or otherwise.

(ii) “ Common Stock ” means the fully paid and nonassessable shares of the Borrower’s common stock, $0.001 par value per share.

 

2


(iii) “ Conversion Amount ” means the Principal amount to be converted.

(iv) “ Conversion Date ” means the date of delivery via facsimile or electronic mail of a Conversion Notice.

(v) “ Conversion Issuance Limit ” means 4,766,667 shares of Common Stock, subject to appropriate adjustment for any Stock Event that occurs after the Amendment and Restatement Date.

(vi) “ Conversion Price ” means, as of any Conversion Date, ninety-six percent (96%) of the arithmetic average of the Volume Weighted Average Prices per share of Common Stock on each of the three (3) Trading Days period preceding the Conversion Date (the “ Measurement Period ”); provided, that in the event that a stock split, stock combination, reclassification, payment of stock dividend, recapitalization or other similar transaction of such character that the shares of Common Stock shall be changed into or become exchangeable for a larger or small number of shares (a “ Stock Event ”) is consummated during the Measurement Period, the Volume Weighted Average Price for all Trading Days during the Measurement Period prior to the effectiveness of such Stock Event shall be appropriately adjusted to reflect such Stock Event, subject to appropriate adjustment for any Stock Event that occurs after the Amendment and Restatement Date.

(vii) “ Conversion Shares ” means fully paid and nonassessable shares of Common Stock issued in connection with the conversion of a Note.

(viii) “ First Amortization Cap ” means 3,166,667 shares of Common Stock, subject to appropriate adjustment for any Stock Event that occurs after the Amendment and Restatement Date.

(ix) “ First Amortization Date ” means April 2, 2021.

(x) “ Market Disruption Event ” means, with respect to any Trading Day and any security of Borrower, (a) a failure by the Principal Market to open for trading during its entire regular trading session, (b) the occurrence or existence prior to 1:00 p.m., New York City time, on such day for such securities of Borrower for more than one half-hour period in the aggregate during regular trading hours of any suspension or limitation imposed on trading (by reason of movements in price exceeding limits permitted by the relevant securities exchange or otherwise) in such securities or in any options, contracts or future contracts relating to such securities, or (c) to the extent “Volume Weighted Average Price” is determined in accordance with clause (b) of the definition thereof, the suspension of trading for the one-half hour period ending on the scheduled close of trading on such day (by reason of movements in price exceeding limits permitted by the stock exchange or otherwise) in such securities of Borrower.

(xi) “ Monthly Conversion Cap ” means 1,733,333 shares of Common Stock, subject to appropriate adjustment for any Stock Event that occurs after the Amendment and Restatement Date.

 

3


(xii) “ Monthly Conversion Cap Period ” means the period commencing on the Amendment and Restatement Date and ending on (and including) August 31, 2018, and each calendar month that begins after the Amendment and Restatement Date and prior to the Maturity Date.

(xiii) “ Principal ” means the outstanding principal amount of this Note as of any date of determination.

(xiv) “ Required Lenders ” means the Required First Out Waterfall Lenders.

(xv) “ Second Amortization Cap ” means 1,600,000 shares of Common Stock, subject to appropriate adjustment for any Stock Event that occurs after the Amendment and Restatement Date.

(xvi) “ Second Amortization Date ” means April 2, 2022.

(xvii) “ Trading Day ” means any day on which the Common Stock is traded for any period on the Principal Market; provided, that for purposes of the definition of “Conversion Shares,” Trading Day shall not include any Trading Day on which there is a Market Disruption Event.

(xviii) “ Volume Weighted Average Pric e ” for any security as of any Trading Day means (a) the volume weighted average sale price of such security on the principal U.S. national or regional securities exchange on which such security is traded as reported by Bloomberg Financial Markets or an equivalent, reliable reporting service mutually acceptable to and hereinafter designated by the Required Lenders and the Borrower (“ Bloomberg ”), or (b) if no volume weighted average sale price is reported for such security, then the closing price per share of such security, or, if no closing price per share is reported for such security by Bloomberg, the average of the last bid and last ask price (or if more than one in either case, the average of the average last bid and average last ask prices) on such Trading Day as reported in the composite transactions for the principal U.S. national or regional securities exchange on which such security is traded. If the security is not listed for trading on a U.S. national or regional securities exchange on the relevant Trading Day, then the Volume Weighted Average Price will be the average of the mid-point of the last bid and last ask prices of the security in the over-the-counter market on the relevant Trading Day as reported by OTC Markets Group or similar organization. If the Volume Weighted Average Price cannot be calculated for such security on such date in the manner provided above, the Volume Weighted Average Price shall be the fair market value as mutually determined by the Borrower and the Lenders holding a majority of the aggregate outstanding Principal amount of the Notes being converted for which the calculation of the Volume Weighted Average Price is required in order to determine the Conversion Price of such Notes. Volume Weighted Average Price will be determine without regard to after-hours trading or any other trading outside of the regular trading hours.

2. Conversion Rights . This Note may be converted into shares of Common Stock on the terms and conditions set forth in this Section  2 (subject to Section 2.3(a) of the Facility Agreement).

 

4


(a) Conversion at Option of the Lender . At any time during the period commencing on (and including) the Amendment and Restatement Date and ending on the close of business on the second business day immediately prior to the Maturity Date, the Lender shall be entitled to convert all or any part of the Principal into Conversion Shares in accordance with this Section  2 at the Conversion Rate (as defined in Section  2(b) ). The Borrower shall not issue any fraction of a share of Common Stock upon any conversion. If the issuance would result in the issuance of a fraction of a share of Common Stock, then the Borrower shall round such fraction of a share of Common Stock up or down to the nearest whole share (with 0.5 rounded up).

(b) Conversion Rate . The number of Conversion Shares issuable upon a conversion of any portion of this Note pursuant to Section  2 shall be determined according to the following formula (the “ Conversion Rate ”):

Conversion Amount

Conversion Price

(c) Mechanics of Conversion . The conversion of this Note shall be conducted in the following manner:

(i) Lender’s Delivery Requirements . To convert a Conversion Amount into Conversion Shares pursuant to Section  2(a) above on any date, Lender shall (A) transmit by facsimile or electronic mail (or otherwise deliver), for receipt on or prior to 5:00 p.m. New York City time on such date, a copy of an executed conversion notice in the form attached hereto as Exhibit A (the “ Conversion Notice ”) to the Borrower (at 2 Musick, Irvine, CA 92618, Attention : Chief Financial Officer; Email : vmahboob@endologix.com, or at such other office or agency as the Borrower may designate in writing), and (B) if required by Section  2(c)(vi) , surrender to a common carrier for delivery to the Borrower, no later than three (3) Business Days after the Conversion Date, of the original Note being converted (or an indemnification undertaking in customary form with respect to this Note in the case of its loss, theft or destruction).

(ii) Borrower’s Response . Upon receipt or deemed receipt by the Borrower of a copy of a Conversion Notice, the Borrower (A) shall immediately send, via facsimile, a confirmation of receipt of such Conversion Notice to the Lender and the Borrower’s designated transfer agent (the “ Transfer Agent ”), which confirmation shall constitute an instruction to the Transfer Agent to process such Conversion Notice in accordance with the terms herein, and (B) on or before the second (2 nd ) Business Day following the date of receipt or deemed receipt by the Borrower of such Conversion Notice (or, if earlier, the end of the standard settlement period for U.S. broker-dealer securities transactions) (the “ Share Delivery Date ”), shall credit such aggregate number of Conversion Shares to which the Lender shall be entitled to the Lender’s or its designee’s balance account with The Depository Trust Company (“ DTC ”) through its Deposit/Withdrawal At Custodian (DWAC) system, for the number of Conversion Shares to which the Lender shall be entitled. If notwithstanding the provisions of Section  2(c)(vi) , the Lender elects to physically surrender this Note for conversion and the Principal represented by this Note is greater than the Principal being converted, then the Borrower shall, as soon as practicable and in no event later than three (3) Business Days after

 

5


receipt of this Note and at its own expense, issue and deliver to the Lender a new Note representing the Principal not converted and cancel this Note. For purposes of Rule 144 under the Securities Act, any Conversion Shares issued to Lender shall be deemed to have been acquired by such Lender on April 3, 2017 (the date this Note was originally issued). Accordingly, (A) upon any conversion of this Note, the Rule 144 holding period for the Conversion Shares acquired thereupon shall be in excess of one (1) year, and (B) provided the Lender is not an Affiliate of the Borrower on the Conversion Date and has not been an Affiliate of the Borrower within the three-month period immediately preceding the Conversion Date (the “ Unrestricted Condition ”), which the Borrower shall assume and Lender hereby represents unless the Lender advises the Borrower otherwise in writing, the Conversion Shares issued to Lender will be freely transferable, without restriction or limitation (including any volume limitation) under Federal or state securities laws, pursuant to Rule 144 under the Securities Act and will not contain or be subject to a legend or stop transfer order restricting the resale or transferability of thereof.

(iii) Dispute Resolution . In the case of a dispute as to the determination of the Conversion Price or the arithmetic calculation of the Conversion Rate, the Borrower shall instruct the Transfer Agent to issue to the Lender the number of Conversion Shares that is not disputed and shall transmit an explanation of the disputed determinations or arithmetic calculations to the Lender via facsimile within two (2) Business Days of receipt or deemed receipt of the Lender’s Conversion Notice or other date of determination. If the Lender and the Borrower are unable to agree upon the determination of the Conversion Price or arithmetic calculation of the Conversion Rate within one (1) Business Day of such disputed determination or arithmetic calculation being transmitted to the Lender, then the Borrower shall promptly (and in any event within two (2) Business Days) submit via facsimile (A) the disputed determination of the Conversion Price to an independent, reputable investment banking firm agreed to by the Borrower and the Required Lenders, or (B) the disputed arithmetic calculation of the Conversion Rate to the Borrower’s independent registered public accounting firm, as the case may be. The Borrower shall direct the investment bank or the accounting firm, as the case may be, to perform the determinations or calculations and notify the Borrower and the Lender of the results no later than two (2) Business Days from the time it receives the disputed determinations or calculations. Such investment bank’s or accounting firm’s determination or calculation, as the case may be, shall be binding upon all parties absent manifest error, and the fees and expenses of such investment bank or accountant shall be paid one-half by the Borrower and one-half by the Lender. Notwithstanding the existence of a dispute contemplated by this paragraph, if requested by the Lender, the Borrower shall issue to the Lender the Conversion Shares not in dispute in accordance with the terms hereof.

(iv) Record Holder . The person or persons entitled to receive the Conversion Shares issuable upon a conversion of this Note shall be treated for all purposes as the legal and record holder or holders of such shares of Common Stock upon delivery by the Lender of the Conversion Notice, or in the case of Conversion Shares the issuance of which is subject to a bona fide dispute that is subject to and being resolved pursuant to, and in compliance with the time periods and other provisions of, the dispute resolution provisions of Section  2(c)(iii) , the first Business Day after the resolution of such bona fide dispute.

(v) Borrower’s Failure to Timely Convert .

 

6


(A) Cash Damages . If by the Share Delivery Date, the Borrower shall fail to credit the Lender’s or its designee’s balance account with DTC with the number of Conversion Shares (free of any restrictive legend, provided the Unrestricted Condition is satisfied), then, in addition to all other available remedies that the Lender may pursue hereunder and under the Facility Agreement, the Borrower shall pay additional damages to the Lender for each day after the Share Delivery Date such conversion is not timely effected in an amount equal to one and one-half percent (1.5%) of the product of (I) the number of Conversion Shares not issued to the Lender or its designee on or prior to the Share Delivery Date and to which the Lender is entitled and (II) the Volume Weighted Average Price of the Common Stock on the Share Delivery Date. Alternatively in lieu of the foregoing damages, subject to Section  2(c)(iii) , at the written election of the Lender made in the Lender’s sole discretion, if, on or after the applicable Conversion Date, the Lender purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by such Lender of Conversion Shares that such Lender anticipated receiving from the Borrower (such purchased shares, “ Buy-In Shares ”), the Borrower shall be obligated to promptly pay to such Lender (in addition to all other available remedies that the Lender may otherwise have), 110% of the amount by which (A) such Lender’s total purchase price (including brokerage commissions, if any) for such Buy-In Shares exceeds (B) the net proceeds received by such Lender from the sale of a number of shares equal to up to the number of Conversion Shares such Lender was entitled to receive but had not received on the Share Delivery Date. If the Borrower fails to pay the additional damages set forth in this Section 2(c)(v)(A) within five (5) Business Days of the date incurred, then the Lender entitled to such payments shall have the right at any time, so long as the Borrower continues to fail to make such payments, to require the Borrower, upon written notice, to immediately issue, in lieu of such cash damages, the number of shares of Common Stock equal to the quotient of (X) the aggregate amount of the damages payments described herein divided by (Y) the Conversion Price specified by the Lender in the Conversion Notice.

(B) Conversion Failure . If for any reason the Lender has not received all of the Conversion Shares it is entitled to prior to the tenth (10th) Business Day after the Share Delivery Date with respect to a conversion of this Note (a “ Conversion Failure ”), then the Lender, upon written notice to the Borrower (a “ Void Conversion Notice ”), may void its conversion with respect to, and retain or have returned, as the case may be, any portion of this Note that has not been converted pursuant to the Lender’s Conversion Notice; provided , that the voiding of the Lender’s Conversion Notice shall not affect the Borrower’s obligations to make any payments that have accrued prior to the date of such notice pursuant to Section  2(c)(v)(A) or otherwise. A Conversion Failure shall constitute an Event of Default under the Facility Agreement and entitle the Lenders to all payments and remedies provided under the Facility Agreement upon the occurrence of an Event of Default.

(vi) Book-Entry . Notwithstanding anything to the contrary set forth herein, upon conversion or repayment of this Note in accordance with the terms hereof, the Lender shall not be required to physically surrender this Note to the Borrower unless all of the Principal is being converted or repaid. The Lender and the Borrower shall maintain records showing the Principal converted or repaid and the dates of such conversions or repayments or shall use such other method, reasonably satisfactory to the Lender and the Borrower, so as not to require physical surrender of this Note upon any such partial conversion or repayment. Notwithstanding the foregoing, if this Note is converted or repaid as aforesaid, the Lender may

 

7


not transfer this Note unless the Lender first physically surrenders this Note to the Borrower, whereupon the Borrower will forthwith issue and deliver upon the order of the Lender a new Note of like tenor, registered as the Lender may request, representing in the aggregate the remaining Principal represented by this Note. The Lender and any assignee, by acceptance of this Note, acknowledge and agree that, by reason of the provisions of this paragraph, following conversion or repayment of any portion of this Note, the Principal of this Note may be less than the “Principal Amount” stated on the face hereof.

(d) Limitations on Conversions .

(i) Beneficial Ownership . Notwithstanding anything herein to the contrary, the Borrower shall not issue to the Lender, and the Lender may not acquire, a number of shares of Common Stock upon conversion of this Note or otherwise issue any shares of Common Stock pursuant hereto or the Facility Agreement to the extent that, upon such conversion, the number of shares of Common Stock then beneficially owned by the Lender and its Affiliates and any other persons or entities whose beneficial ownership of Common Stock would be aggregated with the Lender’s for purposes of Section 13(d) of the Exchange Act (including shares held by any “group” of which the Lender is a member, but excluding shares beneficially owned by virtue of the ownership of the Warrants or other securities or rights to acquire securities that have limitations on the right to convert, exercise or purchase similar to the limitation set forth herein) would exceed 4.985% of the total number of shares of common stock then issued and outstanding (the “ 4.985% Cap ”); provided, however, that the 4.985% Cap shall only apply to the extent that the Common Stock is deemed to constitute an “equity security” pursuant to Rule 13d-1(i) promulgated under the Exchange Act. For purposes hereof, “group” has the meaning set forth in Section 13(d) of the Exchange Act and applicable regulations of the SEC, and the percentage held by the Lender shall be determined in a manner consistent with the provisions of Section 13(d) of the Exchange Act. Upon the written request of the Lender, the Borrower shall, within two (2) Trading Days, confirm orally and in writing to the Lender the number of shares of Common Stock then outstanding.

(ii) Conversion Issuance Limit . Notwithstanding anything to the contrary contained herein, the Borrower shall not issue any shares of Common Stock upon conversion of this Note (including pursuant to Section  2(c)(v)(A) hereof) to the extent that the issuance of such shares of Common Stock together with any previous issuances of shares of Common Stock under this Note would exceed the Conversion Issuance Limit, and Section 2.5(c)(v) shall not apply in respect to any excess amount.

(iii) Other Applicable Limitations on Conversion of the Note . Notwithstanding anything to the contrary herein, this Note shall not be convertible, and the Borrower shall not issue shares of Common Stock upon conversion of this Note (a) at any time after the First Amortization Date, to the extent that the number of shares of Common Stock that would otherwise be issuable to Lender upon such conversion, together with all shares of Common Stock previously issued to Lender upon conversion of this Note after the First Amortization Date, would exceed the First Amortization Cap, or (b)  at any time after the Second Amortization Date, to the extent that the number of shares of Common Stock that would otherwise be issuable to Lender upon such conversion, together with all shares of Common Stock previously issued to Lender upon conversion of this Note after the Second Amortization

 

8


Date, would exceed the Second Amortization Cap, or (c) during any Monthly Conversion Cap Period, to the extent that the number of shares of Common Stock that would otherwise be issuable to Lender upon such conversion, together with all shares previously issued to Lender upon conversion of this Note during the such Monthly Conversion Cap Period, would exceed the Monthly Conversion Cap. For the avoidance of doubt, if the number of shares of Common Stock to be issued as set forth in an Conversion Notice transmitted by the Lender to the Borrower would otherwise require the Borrower to issue a number of shares in excess of the Conversion Issuance Limit, the First Amortization Cap (if after the First Amortization Date), the Second Amortization Cap (if after the Second Amortization Date) or the Monthly Share Cap, the Borrower shall issue to the Lender in accordance herewith the maximum number of shares of Common Stock issuable without exceeding any such applicable limitation, and Section 2.5(c)(v) shall not apply to any excess amount.

3. Voting Rights . Except as required by law, the Lender shall have no voting rights with respect to any of the Conversion Shares until the Conversion Date relating to the conversion of this Note upon which such Conversion Shares are issuable (or in the case of Conversion Shares the issuance of which is subject to a bona fide dispute that is subject to and being resolved pursuant to, and in compliance with the time periods and other provisions of, the dispute resolution provisions of Section  2(c)(iii) , the first Business Day after the resolution of such bona fide dispute).

4. Amendment; Waiver . The provisions of this Note may only be waived or amended, restated, supplemented or otherwise modified in accordance with the Facility Agreement.

5. Specific Shall Not Limit General; Construction . No specific provision contained in this Note shall limit or modify any more general provision contained herein. This Note shall be deemed to be jointly drafted by the Borrower and all Lenders pursuant to the Facility Agreement and shall not be construed against any Person as the drafter hereof.

6. Failure or Indulgence Not Waiver . No delay or omission by the Lender in exercising any power or right hereunder shall impair such right or power or be construed to be a waiver of any default, nor shall any single or partial exercise of any power or right hereunder preclude the full exercise thereof or the exercise of any other power or right. No renewal or extension of this Note or the Facility Agreement, no delay in the enforcement of payment under this Note or the Facility Agreement, and no delay or omission in exercising any right or power under this Note or the Facility Agreement shall affect the liability of the Borrower or any endorser of this Note.

7. Notices . Whenever notice is required to be given under this Note, unless otherwise provided herein, such notice shall be given in accordance with Section 6.1 of the Facility Agreement.

8. Restrictions on Transfer .

(a) Registration or Exemption Required . This Note has been issued in a transaction exempt from the registration requirements of the Securities Act. None of the Note or

 

9


the Conversion Shares issued hereunder may be transferred, sold, assigned, hypothecated or otherwise disposed of except pursuant to an effective registration statement or an exemption to the registration requirements of the Securities Act and applicable state laws, including Rule 144 under the Securities Act, Section 4(a)(7) of the Securities Act or a so-called “4[(a)](1) and a half” transaction.

(b) Assignment . This Note is assignable or transferable, in whole or in part, only to the extent such assignment or transfer is permitted pursuant to the terms of the Facility Agreement; provided that (i) the Lender shall deliver a written notice to the Borrower, substantially in the form of the Assignment attached hereto as Exhibit B , indicating the Person or Persons to whom the Note shall be assigned and the respective Principal amount of the Note to be assigned to each assignee. The Borrower shall effect the assignment within three (3) business days, and shall deliver to the assignee(s) designated by the Lender a Note or Notes of like tenor and terms for the appropriate Principal amount. This Note and the rights evidenced hereby shall inure to the benefit of and be binding upon the successors and assigns of the Lender. The provisions of this Note are intended to be for the benefit of all Lenders from time to time of this Note, and shall be enforceable by any such Lender. This Note is not (and any rights or obligations hereunder are not) not assignable or transferable by the Borrower under any circumstance and any such prohibited assignment or transfer is absolutely void ab initio .

9. Payment of Collection, Enforcement and Other Costs . If (a) this Note is placed in the hands of an attorney for collection or enforcement or is collected or enforced through any legal proceeding; or (b) an attorney is retained to represent the Lender in any bankruptcy, reorganization, receivership of the Borrower or other proceedings affecting Borrower creditors’ rights and involving a claim under this Note, then the Borrower shall pay the costs incurred by the Lender for such collection, enforcement or action, including reasonable attorneys’ fees and disbursements. Subject to the terms of the Facility Agreement, all payments and issuances of shares of Common Stock hereunder will be free and clear of, and without deduction or withholding for, any present or future taxes. The Borrower shall pay all and any costs (administrative or otherwise) imposed by the Borrower’s banks, clearing houses, or any other financial institution, in connection with making any payments and issuing any shares of Common Stock hereunder. The Borrower shall pay all costs and expenses (including attorney’s fees) of the Lender incurred in connection with this Note in accordance with Section 6.3 of the Facility Agreement.

10. Waiver of Notice . Other than those notices required to be provided by the Lender to the Borrower under the terms of the Facility Agreement, the Borrower and every endorser of this Note, or the obligations represented hereby, expressly waives diligence, presentment, protest, demand, notice of dishonor, non-payment or default, and notice of any kind with respect to this Note and the Facility Agreement or the performance of the obligations under this Note and/or the Facility Agreement.

11. Miscellaneous . This Note is a Loan Document, is entitled to the benefits of the Loan Documents and is subject to certain provisions of the Facility Agreement, including Sections 1.2 ( Interpretation ) and 6.4 ( Governing Law; Venue; Jurisdiction; Service of Process; Waiver of Jury Trial ) thereof.

 

10


12. Additional Interpretative Matters . Unless the context otherwise requires, (a) all references to Sections or Exhibits are to Sections or Exhibits contained in or attached to this Note, (b) each accounting term not otherwise defined in this Note has the meaning assigned to it in accordance with GAAP, (c) words in the singular or plural include the singular and plural and pronouns stated in either the masculine, the feminine or neuter gender shall include the masculine, feminine and neuter and (d) the use of the word “including” in this Note shall be by way of example rather than limitation. If a Stock Event occurs during any period over which an average price is being determined, then an appropriate adjustment will be made to such average to reflect such Stock Event.

13. Signatures . In the event that any signature to this Note or any amendment hereto is delivered by electronic mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such “.pdf” signature page were an original thereof. Notwithstanding the foregoing, the Borrower shall be obligated to deliver to the Lender an original signature to this Note. At the request of any party, each other party shall promptly re-execute an original form of this Note or any amendment hereto and deliver the same to the other party. No party hereto shall raise the use of electronic mail delivery of a “.pdf” format data file to deliver a signature to this Note or any amendment hereto or the fact that such signature was transmitted or communicated through the use of electronic mail delivery of a “.pdf” format data file as a defense to the formation or enforceability of a contract, and each party hereto forever waives any such defense.

14. This Note is an amendment and restatement of that certain Loan Note originally issued on April 3, 2017, in the principal amount of $40,000,000.00 (the “ Prior Note ”) and evidences an extension, continuation, and renewal of the indebtedness evidenced by the Prior Note, but this Note replaces the Prior Note with the indebtedness evidenced by the Prior Note now evidenced by this Note. Such Prior Note shall be of no further force and effect upon execution of this Note. The Borrower hereby acknowledges and agrees that the indebtedness under the Prior Note has not been repaid or extinguished and that the execution hereof does not constitute a novation of the Prior Note. Moreover, this Note shall be entitled to all security and collateral to which the Prior Note was entitled, without change or diminution in the priority of any lien or security interest granted to secure the Prior Note.

[Signature Page Follows]

 

11


IN WITNESS WHEREOF, the Borrower has caused this Note to be executed and delivered by its duly authorized officer as of the day and year set forth above.

 

ENDOLOGIX, INC. ,

a Delaware corporation

By: /s/ Vaseem Mahboob                                    
Name: Vaseem Mahboob
Title: Chief Financial Officer

 

12


Exhibit A

CONVERSION NOTICE

Reference is made to the First Out Waterfall Note (the “ Note ”) of ENDOLOGIX, INC. , a Delaware corporation (the “ Borrower ”), in the original principal amount of $40,000,000.00. In accordance with and pursuant to the Note, the undersigned hereby elects to convert the Conversion Amount (as defined in the Note) of the Note indicated below into shares of common stock, par value $0.001 per share (the “ Common Stock ”), of the Borrower, as of the date specified below.

Date of Conversion:                                   

Aggregate Conversion Amount to be converted at the Conversion Price (as defined in the Note):

 

                                                                          

Principal, applicable thereto, to be converted:                                                                          

Please confirm the following information:

Conversion Price:                                                                                                                                                    

Number of shares of Common Stock to be issued:                                                                                                   

Please issue the Common Stock into which the Note is being converted in the following name and to the following address:

Issue to:                                                                                                                                                                      

Facsimile Number:                                                                                                                                                    

Authorization:                                                                              

By:                                                                             

Title:                                                                          

Dated:                                                                                       

DTC Participant Number and Name:                                                                                                                                      

Account Number:                                                                                                                                                                    

 

13


Exhibit B

ASSIGNMENT

(To be executed by the registered holder

desiring to transfer the Note)

FOR VALUE RECEIVED, the undersigned holder of the attached First Out Waterfall Note (the “ Note ”) hereby sells, assigns and transfers unto the person or persons below named the right to receive the principal amount of $                 from Endologix, Inc., a Delaware corporation (the “ Borrower ”), evidenced by the attached Note and does hereby irrevocably constitute and appoint                 attorney to transfer the said Note on the books of the Borrower, with full power of substitution in the premises.

 

Dated:                                                  

 

    Signature
Fill in for new registration of Note:    

 

   
Name    

 

   
Address    

 

   
Please print name and address of assignee    
(including zip code number)    

NOTICE

The signature to the foregoing Assignment must correspond to the name as written upon the face of the attached Note.

 

14

Exhibit 4.6

FIRST OUT WATERFALL NOTE

THE SECURITIES REPRESENTED BY THIS NOTE (AS DEFINED BELOW) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS OR (B) AN OPINION OF COUNSEL, IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR APPLICABLE STATE SECURITIES LAWS OR (II) UNLESS SOLD PURSUANT TO RULE 144 UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN, FINANCING OR INDEBTEDNESS ARRANGEMENT SECURED BY THE SECURITIES.

THE FOLLOWING INFORMATION IS PROVIDED PURSUANT TO TREAS. REG. SECTION 1.1275-3: THE BORROWER (AS DEFINED BELOW) WILL MAKE AVAILABLE ON REQUEST TO HOLDER(S) OF THIS NOTE THE FOLLOWING INFORMATION: ISSUE PRICE, AMOUNT OF ORIGINAL ISSUE DISCOUNT, ISSUE DATE AND YIELD TO MATURITY. THIS NOTE IS BEING AMENDED AND RESTATED AS PART OF AND PURSUANT TO A PLAN OF RECAPITALIZATION AND REORGANIZATION OF THE BORROWER DESCRIBED IN SECTION 368(A)(1)(E) OF THE INTERNAL REVENUE CODE OF 1986, AS AMENDED.

FIRST OUT WATERFALL NOTE

 

First Out Waterfall Lender: Deerfield Partners, L.P.    Original Issue Date: April 3, 2017
Principal Amount: $22,320,000.00    Re-Issuance Date: January 1, 2018
   Amendment and Restatement Date: August 9, 2018

FOR VALUE RECEIVED, the undersigned, Endologix, Inc., a Delaware corporation (the “ Borrower ”), hereby unconditionally promises to pay to the First Out Waterfall Lender set forth above (the “ Lender ”) the “Principal Amount” set forth above, or, if less, the aggregate unpaid Principal (as defined below) amount of the First Out Waterfall Loan (as defined in the Facility Agreement referred to below) of the Lender to the Borrower, payable at such times and in such amounts as are specified in the Facility Agreement.

The Borrower promises to pay interest on the outstanding Principal amount of the First Out Waterfall Loan and any overdue interest from and after the Amendment and Restatement Date (as defined below) until such outstanding Principal amount of the First Out Waterfall Loan and any overdue interest are paid in full, payable at such times and at such interest rates as are specified in the Facility Agreement. The Borrower promises to pay any Non-Callable Make Whole Amount, any CoC Fee and the First Out Waterfall Exit Payment (each, as defined in the Facility Agreement) that is due on the First Out Waterfall Loan in accordance with the Facility Agreement.

 

1


In lieu of making any payment of interest in cash (but not (i) interest payable pursuant to the second sentence of Section 2.6(a) of Facility Agreement, (ii) interest payable-in-kind or (iii) in connection with any Event of Default or late payment hereunder or any other interest payable pursuant to Section 2.7 of the Facility Agreement) and subject to the conditions set forth in Section 2.6 of the Facility Agreement and Exhibit 2.6 to the Facility Agreement, the Borrower may elect to satisfy all or any such payment by the issuance to the Lender of shares of Freely Tradable Common Shares (as defined in Exhibit 2.6) in accordance with the provisions of Exhibit 2.6.

This First Out Waterfall Note (this “ Note ”) was originally issued on April 3, 2017, reissued on January 1, 2018, and amended and restated on August 9, 2018 (the “ Amendment and Restatement Date ”) and is one of the “First Out Waterfall Notes”, “Loan Notes” and “Notes” referred to in, and is entitled to the benefits of, the Amended and Restated Facility Agreement, dated as of August 9, 2018 (as the same may be amended, restated, supplemented or otherwise modified from time to time, the “ Facility Agreement ”), by and among the Borrower, the other Loan Parties party thereto, the Lenders party thereto and Deerfield Private Design Fund IV, L.P., as agent for the Secured Parties, and the other Loan Documents.

The Facility Agreement, among other things, (a) provides for the making of a First Out Waterfall Loan by the Lender to the Borrower in an aggregate amount not to exceed at any time outstanding the “Principal Amount” set forth above, the indebtedness of the Borrower resulting from such First Out Waterfall Loan being evidenced by this Note and (b) contains provisions for acceleration of the maturity of the unpaid Principal amount of this Note upon the happening of certain stated events and also for prepayments pursuant to Section 2.3(c) or Section 5.3 of the Facility Agreement on account of the Principal hereof prior to the maturity hereof upon the terms and conditions specified therein.

1. Definitions .

(a) Certain Defined Terms . Capitalized terms used herein without definition are used as defined in the Facility Agreement. For purposes of this Note, the following terms shall have the following meanings:

(i) “ Affiliate ” means any person or entity that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a person or entity, as such terms are used in and construed under Rule 144 under the Securities Act. With respect to a Lender, any investment fund or managed account that is managed on a discretionary basis by the same investment manager as such Lender will be deemed to be an Affiliate of such Lender. As used in this definition of “Affiliate,” the term “control” means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through ownership of voting securities or partnership or other ownership interest, by contract, or otherwise.

(ii) “ Common Stock ” means the fully paid and nonassessable shares of the Borrower’s common stock, $0.001 par value per share.

 

2


(iii) “ Conversion Amount ” means the Principal amount to be converted.

(iv) “ Conversion Date ” means the date of delivery via facsimile or electronic mail of a Conversion Notice.

(v) “ Conversion Issuance Limit ” means 2,659,800 shares of Common Stock, subject to appropriate adjustment for any Stock Event that occurs after the Amendment and Restatement Date.

(vi) “ Conversion Price ” means, as of any Conversion Date, ninety-six percent (96%) of the arithmetic average of the Volume Weighted Average Prices per share of Common Stock on each of the three (3) Trading Days period preceding the Conversion Date (the “ Measurement Period ”); provided, that in the event that a stock split, stock combination, reclassification, payment of stock dividend, recapitalization or other similar transaction of such character that the shares of Common Stock shall be changed into or become exchangeable for a larger or small number of shares (a “ Stock Event ”) is consummated during the Measurement Period, the Volume Weighted Average Price for all Trading Days during the Measurement Period prior to the effectiveness of such Stock Event shall be appropriately adjusted to reflect such Stock Event, subject to appropriate adjustment for any Stock Event that occurs after the Amendment and Restatement Date.

(vii) “ Conversion Shares ” means fully paid and nonassessable shares of Common Stock issued in connection with the conversion of a Note.

(viii) “ First Amortization Cap ” means 1,767,000 shares of Common Stock, subject to appropriate adjustment for any Stock Event that occurs after the Amendment and Restatement Date.

(ix) “ First Amortization Date ” means April 2, 2021.

(x) “ Market Disruption Event ” means, with respect to any Trading Day and any security of Borrower, (a) a failure by the Principal Market to open for trading during its entire regular trading session, (b) the occurrence or existence prior to 1:00 p.m., New York City time, on such day for such securities of Borrower for more than one half-hour period in the aggregate during regular trading hours of any suspension or limitation imposed on trading (by reason of movements in price exceeding limits permitted by the relevant securities exchange or otherwise) in such securities or in any options, contracts or future contracts relating to such securities, or (c) to the extent “Volume Weighted Average Price” is determined in accordance with clause (b) of the definition thereof, the suspension of trading for the one-half hour period ending on the scheduled close of trading on such day (by reason of movements in price exceeding limits permitted by the stock exchange or otherwise) in such securities of Borrower.

(xi) “ Monthly Conversion Cap ” means 967,200 shares of Common Stock, subject to appropriate adjustment for any Stock Event that occurs after the Amendment and Restatement Date.

 

3


(xii) “ Monthly Conversion Cap Period ” means the period commencing on the Amendment and Restatement Date and ending on (and including) August 31, 2018, and each calendar month that begins after the Amendment and Restatement Date and prior to the Maturity Date.

(xiii) “ Principal ” means the outstanding principal amount of this Note as of any date of determination.

(xiv) “ Required Lenders ” means the Required First Out Waterfall Lenders.

(xv) “ Second Amortization Cap ” means 892,800 shares of Common Stock, subject to appropriate adjustment for any Stock Event that occurs after the Amendment and Restatement Date.

(xvi) “ Second Amortization Date ” means April 2, 2022.

(xvii) “ Trading Day ” means any day on which the Common Stock is traded for any period on the Principal Market; provided, that for purposes of the definition of “Conversion Shares,” Trading Day shall not include any Trading Day on which there is a Market Disruption Event.

(xviii) “ Volume Weighted Average Pric e ” for any security as of any Trading Day means (a) the volume weighted average sale price of such security on the principal U.S. national or regional securities exchange on which such security is traded as reported by Bloomberg Financial Markets or an equivalent, reliable reporting service mutually acceptable to and hereinafter designated by the Required Lenders and the Borrower (“ Bloomberg ”), or (b) if no volume weighted average sale price is reported for such security, then the closing price per share of such security, or, if no closing price per share is reported for such security by Bloomberg, the average of the last bid and last ask price (or if more than one in either case, the average of the average last bid and average last ask prices) on such Trading Day as reported in the composite transactions for the principal U.S. national or regional securities exchange on which such security is traded. If the security is not listed for trading on a U.S. national or regional securities exchange on the relevant Trading Day, then the Volume Weighted Average Price will be the average of the mid-point of the last bid and last ask prices of the security in the over-the-counter market on the relevant Trading Day as reported by OTC Markets Group or similar organization. If the Volume Weighted Average Price cannot be calculated for such security on such date in the manner provided above, the Volume Weighted Average Price shall be the fair market value as mutually determined by the Borrower and the Lenders holding a majority of the aggregate outstanding Principal amount of the Notes being converted for which the calculation of the Volume Weighted Average Price is required in order to determine the Conversion Price of such Notes. Volume Weighted Average Price will be determine without regard to after-hours trading or any other trading outside of the regular trading hours.

2. Conversion Rights . This Note may be converted into shares of Common Stock on the terms and conditions set forth in this Section  2 (subject to Section 2.3(a) of the Facility Agreement).

 

4


(a) Conversion at Option of the Lender . At any time during the period commencing on (and including) the Amendment and Restatement Date and ending on the close of business on the second business day immediately prior to the Maturity Date, the Lender shall be entitled to convert all or any part of the Principal into Conversion Shares in accordance with this Section  2 at the Conversion Rate (as defined in Section  2(b) ). The Borrower shall not issue any fraction of a share of Common Stock upon any conversion. If the issuance would result in the issuance of a fraction of a share of Common Stock, then the Borrower shall round such fraction of a share of Common Stock up or down to the nearest whole share (with 0.5 rounded up).

(b) Conversion Rate . The number of Conversion Shares issuable upon a conversion of any portion of this Note pursuant to Section  2 shall be determined according to the following formula (the “ Conversion Rate ”):

Conversion Amount

Conversion Price

(c) Mechanics of Conversion . The conversion of this Note shall be conducted in the following manner:

(i) Lender’s Delivery Requirements . To convert a Conversion Amount into Conversion Shares pursuant to Section  2(a) above on any date, Lender shall (A) transmit by facsimile or electronic mail (or otherwise deliver), for receipt on or prior to 5:00 p.m. New York City time on such date, a copy of an executed conversion notice in the form attached hereto as Exhibit A (the “ Conversion Notice ”) to the Borrower (at 2 Musick, Irvine, CA 92618, Attention : Chief Financial Officer; Email : vmahboob@endologix.com, or at such other office or agency as the Borrower may designate in writing), and (B) if required by Section  2(c)(vi) , surrender to a common carrier for delivery to the Borrower, no later than three (3) Business Days after the Conversion Date, of the original Note being converted (or an indemnification undertaking in customary form with respect to this Note in the case of its loss, theft or destruction).

(ii) Borrower’s Response . Upon receipt or deemed receipt by the Borrower of a copy of a Conversion Notice, the Borrower (A) shall immediately send, via facsimile, a confirmation of receipt of such Conversion Notice to the Lender and the Borrower’s designated transfer agent (the “ Transfer Agent ”), which confirmation shall constitute an instruction to the Transfer Agent to process such Conversion Notice in accordance with the terms herein, and (B) on or before the second (2 nd ) Business Day following the date of receipt or deemed receipt by the Borrower of such Conversion Notice (or, if earlier, the end of the standard settlement period for U.S. broker-dealer securities transactions) (the “ Share Delivery Date ”), shall credit such aggregate number of Conversion Shares to which the Lender shall be entitled to the Lender’s or its designee’s balance account with The Depository Trust Company (“ DTC ”) through its Deposit/Withdrawal At Custodian (DWAC) system, for the number of Conversion Shares to which the Lender shall be entitled. If notwithstanding the provisions of Section  2(c)(vi) , the Lender elects to physically surrender this Note for conversion and the Principal represented by this Note is greater than the Principal being converted, then the Borrower shall, as soon as practicable and in no event later than three (3) Business Days after

 

5


receipt of this Note and at its own expense, issue and deliver to the Lender a new Note representing the Principal not converted and cancel this Note. For purposes of Rule 144 under the Securities Act, any Conversion Shares issued to Lender shall be deemed to have been acquired by such Lender on April 3, 2017 (the date this Note was originally issued). Accordingly, (A) upon any conversion of this Note, the Rule 144 holding period for the Conversion Shares acquired thereupon shall be in excess of one (1) year, and (B) provided the Lender is not an Affiliate of the Borrower on the Conversion Date and has not been an Affiliate of the Borrower within the three-month period immediately preceding the Conversion Date (the “ Unrestricted Condition ”), which the Borrower shall assume and Lender hereby represents unless the Lender advises the Borrower otherwise in writing, the Conversion Shares issued to Lender will be freely transferable, without restriction or limitation (including any volume limitation) under Federal or state securities laws, pursuant to Rule 144 under the Securities Act and will not contain or be subject to a legend or stop transfer order restricting the resale or transferability of thereof.

(iii) Dispute Resolution . In the case of a dispute as to the determination of the Conversion Price or the arithmetic calculation of the Conversion Rate, the Borrower shall instruct the Transfer Agent to issue to the Lender the number of Conversion Shares that is not disputed and shall transmit an explanation of the disputed determinations or arithmetic calculations to the Lender via facsimile within two (2) Business Days of receipt or deemed receipt of the Lender’s Conversion Notice or other date of determination. If the Lender and the Borrower are unable to agree upon the determination of the Conversion Price or arithmetic calculation of the Conversion Rate within one (1) Business Day of such disputed determination or arithmetic calculation being transmitted to the Lender, then the Borrower shall promptly (and in any event within two (2) Business Days) submit via facsimile (A) the disputed determination of the Conversion Price to an independent, reputable investment banking firm agreed to by the Borrower and the Required Lenders, or (B) the disputed arithmetic calculation of the Conversion Rate to the Borrower’s independent registered public accounting firm, as the case may be. The Borrower shall direct the investment bank or the accounting firm, as the case may be, to perform the determinations or calculations and notify the Borrower and the Lender of the results no later than two (2) Business Days from the time it receives the disputed determinations or calculations. Such investment bank’s or accounting firm’s determination or calculation, as the case may be, shall be binding upon all parties absent manifest error, and the fees and expenses of such investment bank or accountant shall be paid one-half by the Borrower and one-half by the Lender. Notwithstanding the existence of a dispute contemplated by this paragraph, if requested by the Lender, the Borrower shall issue to the Lender the Conversion Shares not in dispute in accordance with the terms hereof.

(iv) Record Holder . The person or persons entitled to receive the Conversion Shares issuable upon a conversion of this Note shall be treated for all purposes as the legal and record holder or holders of such shares of Common Stock upon delivery by the Lender of the Conversion Notice, or in the case of Conversion Shares the issuance of which is subject to a bona fide dispute that is subject to and being resolved pursuant to, and in compliance with the time periods and other provisions of, the dispute resolution provisions of Section  2(c)(iii) , the first Business Day after the resolution of such bona fide dispute.

(v) Borrower’s Failure to Timely Convert .

 

6


(A) Cash Damages . If by the Share Delivery Date, the Borrower shall fail to credit the Lender’s or its designee’s balance account with DTC with the number of Conversion Shares (free of any restrictive legend, provided the Unrestricted Condition is satisfied), then, in addition to all other available remedies that the Lender may pursue hereunder and under the Facility Agreement, the Borrower shall pay additional damages to the Lender for each day after the Share Delivery Date such conversion is not timely effected in an amount equal to one and one-half percent (1.5%) of the product of (I) the number of Conversion Shares not issued to the Lender or its designee on or prior to the Share Delivery Date and to which the Lender is entitled and (II) the Volume Weighted Average Price of the Common Stock on the Share Delivery Date. Alternatively in lieu of the foregoing damages, subject to Section  2(c)(iii) , at the written election of the Lender made in the Lender’s sole discretion, if, on or after the applicable Conversion Date, the Lender purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by such Lender of Conversion Shares that such Lender anticipated receiving from the Borrower (such purchased shares, “ Buy-In Shares ”), the Borrower shall be obligated to promptly pay to such Lender (in addition to all other available remedies that the Lender may otherwise have), 110% of the amount by which (A) such Lender’s total purchase price (including brokerage commissions, if any) for such Buy-In Shares exceeds (B) the net proceeds received by such Lender from the sale of a number of shares equal to up to the number of Conversion Shares such Lender was entitled to receive but had not received on the Share Delivery Date. If the Borrower fails to pay the additional damages set forth in this Section 2(c)(v)(A) within five (5) Business Days of the date incurred, then the Lender entitled to such payments shall have the right at any time, so long as the Borrower continues to fail to make such payments, to require the Borrower, upon written notice, to immediately issue, in lieu of such cash damages, the number of shares of Common Stock equal to the quotient of (X) the aggregate amount of the damages payments described herein divided by (Y) the Conversion Price specified by the Lender in the Conversion Notice.

(B) Conversion Failure . If for any reason the Lender has not received all of the Conversion Shares it is entitled to prior to the tenth (10th) Business Day after the Share Delivery Date with respect to a conversion of this Note (a “ Conversion Failure ”), then the Lender, upon written notice to the Borrower (a “ Void Conversion Notice ”), may void its conversion with respect to, and retain or have returned, as the case may be, any portion of this Note that has not been converted pursuant to the Lender’s Conversion Notice; provided , that the voiding of the Lender’s Conversion Notice shall not affect the Borrower’s obligations to make any payments that have accrued prior to the date of such notice pursuant to Section  2(c)(v)(A) or otherwise. A Conversion Failure shall constitute an Event of Default under the Facility Agreement and entitle the Lenders to all payments and remedies provided under the Facility Agreement upon the occurrence of an Event of Default.

(vi) Book-Entry . Notwithstanding anything to the contrary set forth herein, upon conversion or repayment of this Note in accordance with the terms hereof, the Lender shall not be required to physically surrender this Note to the Borrower unless all of the Principal is being converted or repaid. The Lender and the Borrower shall maintain records showing the Principal converted or repaid and the dates of such conversions or repayments or shall use such other method, reasonably satisfactory to the Lender and the Borrower, so as not to require physical surrender of this Note upon any such partial conversion or repayment. Notwithstanding the foregoing, if this Note is converted or repaid as aforesaid, the Lender may

 

7


not transfer this Note unless the Lender first physically surrenders this Note to the Borrower, whereupon the Borrower will forthwith issue and deliver upon the order of the Lender a new Note of like tenor, registered as the Lender may request, representing in the aggregate the remaining Principal represented by this Note. The Lender and any assignee, by acceptance of this Note, acknowledge and agree that, by reason of the provisions of this paragraph, following conversion or repayment of any portion of this Note, the Principal of this Note may be less than the “Principal Amount” stated on the face hereof.

(d) Limitations on Conversions .

(i) Beneficial Ownership . Notwithstanding anything herein to the contrary, the Borrower shall not issue to the Lender, and the Lender may not acquire, a number of shares of Common Stock upon conversion of this Note or otherwise issue any shares of Common Stock pursuant hereto or the Facility Agreement to the extent that, upon such conversion, the number of shares of Common Stock then beneficially owned by the Lender and its Affiliates and any other persons or entities whose beneficial ownership of Common Stock would be aggregated with the Lender’s for purposes of Section 13(d) of the Exchange Act (including shares held by any “group” of which the Lender is a member, but excluding shares beneficially owned by virtue of the ownership of the Warrants or other securities or rights to acquire securities that have limitations on the right to convert, exercise or purchase similar to the limitation set forth herein) would exceed 4.985% of the total number of shares of common stock then issued and outstanding (the “ 4.985% Cap ”); provided, however, that the 4.985% Cap shall only apply to the extent that the Common Stock is deemed to constitute an “equity security” pursuant to Rule 13d-1(i) promulgated under the Exchange Act. For purposes hereof, “group” has the meaning set forth in Section 13(d) of the Exchange Act and applicable regulations of the SEC, and the percentage held by the Lender shall be determined in a manner consistent with the provisions of Section 13(d) of the Exchange Act. Upon the written request of the Lender, the Borrower shall, within two (2) Trading Days, confirm orally and in writing to the Lender the number of shares of Common Stock then outstanding.

(ii) Conversion Issuance Limit . Notwithstanding anything to the contrary contained herein, the Borrower shall not issue any shares of Common Stock upon conversion of this Note (including pursuant to Section  2(c)(v)(A) hereof) to the extent that the issuance of such shares of Common Stock together with any previous issuances of shares of Common Stock under this Note would exceed the Conversion Issuance Limit, and Section 2.5(c)(v) shall not apply in respect to any excess amount.

(iii) Other Applicable Limitations on Conversion of the Note . Notwithstanding anything to the contrary herein, this Note shall not be convertible, and the Borrower shall not issue shares of Common Stock upon conversion of this Note (a) at any time after the First Amortization Date, to the extent that the number of shares of Common Stock that would otherwise be issuable to Lender upon such conversion, together with all shares of Common Stock previously issued to Lender upon conversion of this Note after the First Amortization Date, would exceed the First Amortization Cap, or (b)  at any time after the Second Amortization Date, to the extent that the number of shares of Common Stock that would otherwise be issuable to Lender upon such conversion, together with all shares of Common Stock previously issued to Lender upon conversion of this Note after the Second Amortization

 

8


Date, would exceed the Second Amortization Cap, or (c) during any Monthly Conversion Cap Period, to the extent that the number of shares of Common Stock that would otherwise be issuable to Lender upon such conversion, together with all shares previously issued to Lender upon conversion of this Note during the such Monthly Conversion Cap Period, would exceed the Monthly Conversion Cap. For the avoidance of doubt, if the number of shares of Common Stock to be issued as set forth in an Conversion Notice transmitted by the Lender to the Borrower would otherwise require the Borrower to issue a number of shares in excess of the Conversion Issuance Limit, the First Amortization Cap (if after the First Amortization Date), the Second Amortization Cap (if after the Second Amortization Date) or the Monthly Share Cap, the Borrower shall issue to the Lender in accordance herewith the maximum number of shares of Common Stock issuable without exceeding any such applicable limitation, and Section 2.5(c)(v) shall not apply to any excess amount.

3. Voting Rights . Except as required by law, the Lender shall have no voting rights with respect to any of the Conversion Shares until the Conversion Date relating to the conversion of this Note upon which such Conversion Shares are issuable (or in the case of Conversion Shares the issuance of which is subject to a bona fide dispute that is subject to and being resolved pursuant to, and in compliance with the time periods and other provisions of, the dispute resolution provisions of Section  2(c)(iii) , the first Business Day after the resolution of such bona fide dispute).

4. Amendment; Waiver . The provisions of this Note may only be waived or amended, restated, supplemented or otherwise modified in accordance with the Facility Agreement.

5. Specific Shall Not Limit General; Construction . No specific provision contained in this Note shall limit or modify any more general provision contained herein. This Note shall be deemed to be jointly drafted by the Borrower and all Lenders pursuant to the Facility Agreement and shall not be construed against any Person as the drafter hereof.

6. Failure or Indulgence Not Waiver . No delay or omission by the Lender in exercising any power or right hereunder shall impair such right or power or be construed to be a waiver of any default, nor shall any single or partial exercise of any power or right hereunder preclude the full exercise thereof or the exercise of any other power or right. No renewal or extension of this Note or the Facility Agreement, no delay in the enforcement of payment under this Note or the Facility Agreement, and no delay or omission in exercising any right or power under this Note or the Facility Agreement shall affect the liability of the Borrower or any endorser of this Note.

7. Notices . Whenever notice is required to be given under this Note, unless otherwise provided herein, such notice shall be given in accordance with Section 6.1 of the Facility Agreement.

8. Restrictions on Transfer .

(a) Registration or Exemption Required . This Note has been issued in a transaction exempt from the registration requirements of the Securities Act. None of the Note or

 

9


the Conversion Shares issued hereunder may be transferred, sold, assigned, hypothecated or otherwise disposed of except pursuant to an effective registration statement or an exemption to the registration requirements of the Securities Act and applicable state laws, including Rule 144 under the Securities Act, Section 4(a)(7) of the Securities Act or a so-called “4[(a)](1) and a half” transaction.

(b) Assignment . This Note is assignable or transferable, in whole or in part, only to the extent such assignment or transfer is permitted pursuant to the terms of the Facility Agreement; provided that (i) the Lender shall deliver a written notice to the Borrower, substantially in the form of the Assignment attached hereto as Exhibit B , indicating the Person or Persons to whom the Note shall be assigned and the respective Principal amount of the Note to be assigned to each assignee. The Borrower shall effect the assignment within three (3) business days, and shall deliver to the assignee(s) designated by the Lender a Note or Notes of like tenor and terms for the appropriate Principal amount. This Note and the rights evidenced hereby shall inure to the benefit of and be binding upon the successors and assigns of the Lender. The provisions of this Note are intended to be for the benefit of all Lenders from time to time of this Note, and shall be enforceable by any such Lender. This Note is not (and any rights or obligations hereunder are not) not assignable or transferable by the Borrower under any circumstance and any such prohibited assignment or transfer is absolutely void ab initio .

9. Payment of Collection, Enforcement and Other Costs . If (a) this Note is placed in the hands of an attorney for collection or enforcement or is collected or enforced through any legal proceeding; or (b) an attorney is retained to represent the Lender in any bankruptcy, reorganization, receivership of the Borrower or other proceedings affecting Borrower creditors’ rights and involving a claim under this Note, then the Borrower shall pay the costs incurred by the Lender for such collection, enforcement or action, including reasonable attorneys’ fees and disbursements. Subject to the terms of the Facility Agreement, all payments and issuances of shares of Common Stock hereunder will be free and clear of, and without deduction or withholding for, any present or future taxes. The Borrower shall pay all and any costs (administrative or otherwise) imposed by the Borrower’s banks, clearing houses, or any other financial institution, in connection with making any payments and issuing any shares of Common Stock hereunder. The Borrower shall pay all costs and expenses (including attorney’s fees) of the Lender incurred in connection with this Note in accordance with Section 6.3 of the Facility Agreement.

10. Waiver of Notice . Other than those notices required to be provided by the Lender to the Borrower under the terms of the Facility Agreement, the Borrower and every endorser of this Note, or the obligations represented hereby, expressly waives diligence, presentment, protest, demand, notice of dishonor, non-payment or default, and notice of any kind with respect to this Note and the Facility Agreement or the performance of the obligations under this Note and/or the Facility Agreement.

11. Miscellaneous . This Note is a Loan Document, is entitled to the benefits of the Loan Documents and is subject to certain provisions of the Facility Agreement, including Sections 1.2 ( Interpretation ) and 6.4 ( Governing Law; Venue; Jurisdiction; Service of Process; Waiver of Jury Trial ) thereof.

 

10


12. Additional Interpretative Matters . Unless the context otherwise requires, (a) all references to Sections or Exhibits are to Sections or Exhibits contained in or attached to this Note, (b) each accounting term not otherwise defined in this Note has the meaning assigned to it in accordance with GAAP, (c) words in the singular or plural include the singular and plural and pronouns stated in either the masculine, the feminine or neuter gender shall include the masculine, feminine and neuter and (d) the use of the word “including” in this Note shall be by way of example rather than limitation. If a Stock Event occurs during any period over which an average price is being determined, then an appropriate adjustment will be made to such average to reflect such Stock Event.

13. Signatures . In the event that any signature to this Note or any amendment hereto is delivered by electronic mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such “.pdf” signature page were an original thereof. Notwithstanding the foregoing, the Borrower shall be obligated to deliver to the Lender an original signature to this Note. At the request of any party, each other party shall promptly re-execute an original form of this Note or any amendment hereto and deliver the same to the other party. No party hereto shall raise the use of electronic mail delivery of a “.pdf” format data file to deliver a signature to this Note or any amendment hereto or the fact that such signature was transmitted or communicated through the use of electronic mail delivery of a “.pdf” format data file as a defense to the formation or enforceability of a contract, and each party hereto forever waives any such defense.

14. This Note is an amendment and restatement of that certain Loan Note originally issued on April 3, 2017 and re-issued on January 1, 2018, in the principal amount of $22,320,000.00 (the “ Prior Note ”) and evidences an extension, continuation, and renewal of the indebtedness evidenced by the Prior Note, but this Note replaces the Prior Note with the indebtedness evidenced by the Prior Note now evidenced by this Note. Such Prior Note shall be of no further force and effect upon execution of this Note. The Borrower hereby acknowledges and agrees that the indebtedness under the Prior Note has not been repaid or extinguished and that the execution hereof does not constitute a novation of the Prior Note. Moreover, this Note shall be entitled to all security and collateral to which the Prior Note was entitled, without change or diminution in the priority of any lien or security interest granted to secure the Prior Note.

[Signature Page Follows]

 

11


IN WITNESS WHEREOF, the Borrower has caused this Note to be executed and delivered by its duly authorized officer as of the day and year set forth above.

 

ENDOLOGIX, INC. ,
a Delaware corporation
By:   /s/ Vaseem Mahboob
Name: Vaseem Mahboob
Title: Chief Financial Officer

 

12


Exhibit A

CONVERSION NOTICE

Reference is made to the First Out Waterfall Note (the “ Note ”) of ENDOLOGIX, INC. , a Delaware corporation (the “ Borrower ”), in the original principal amount of $22,320,000.00. In accordance with and pursuant to the Note, the undersigned hereby elects to convert the Conversion Amount (as defined in the Note) of the Note indicated below into shares of common stock, par value $0.001 per share (the “ Common Stock ”), of the Borrower, as of the date specified below.

Date of Conversion:                     

Aggregate Conversion Amount to be converted at the Conversion Price (as defined in the Note):

 

                                                             

Principal, applicable thereto, to be converted:                                                                  

Please confirm the following information:

Conversion Price:                                                                                                   

Number of shares of Common Stock to be issued:                                              

Please issue the Common Stock into which the Note is being converted in the following name and to the following address:

Issue to:                                                                                                                   

Facsimile Number:                                                                                                   

Authorization:                                                                          

By:                                                                                   

Title:                                                                                

Dated:                                                                                       

DTC Participant Number and Name:                                                                                                               

Account Number:                                                                                                                                              

 

13


Exhibit B

ASSIGNMENT

(To be executed by the registered holder

desiring to transfer the Note)

FOR VALUE RECEIVED, the undersigned holder of the attached First Out Waterfall Note (the “ Note ”) hereby sells, assigns and transfers unto the person or persons below named the right to receive the principal amount of $             from Endologix, Inc., a Delaware corporation (the “ Borrower ”), evidenced by the attached Note and does hereby irrevocably constitute and appoint                  attorney to transfer the said Note on the books of the Borrower, with full power of substitution in the premises.

 

Dated: _______________    

 

    Signature
Fill in for new registration of Note:    

 

   
Name    

 

   
Address    

 

   
Please print name and address of assignee    
(including zip code number)    

NOTICE

The signature to the foregoing Assignment must correspond to the name as written upon the face of the attached Note.

 

14

Exhibit 4.7

FIRST OUT WATERFALL NOTE

THE SECURITIES REPRESENTED BY THIS NOTE (AS DEFINED BELOW) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS OR (B) AN OPINION OF COUNSEL, IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR APPLICABLE STATE SECURITIES LAWS OR (II) UNLESS SOLD PURSUANT TO RULE 144 UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN, FINANCING OR INDEBTEDNESS ARRANGEMENT SECURED BY THE SECURITIES.

THE FOLLOWING INFORMATION IS PROVIDED PURSUANT TO TREAS. REG. SECTION 1.1275-3: THE BORROWER (AS DEFINED BELOW) WILL MAKE AVAILABLE ON REQUEST TO HOLDER(S) OF THIS NOTE THE FOLLOWING INFORMATION: ISSUE PRICE, AMOUNT OF ORIGINAL ISSUE DISCOUNT, ISSUE DATE AND YIELD TO MATURITY. THIS NOTE IS BEING AMENDED AND RESTATED AS PART OF AND PURSUANT TO A PLAN OF RECAPITALIZATION AND REORGANIZATION OF THE BORROWER DESCRIBED IN SECTION 368(A)(1)(E) OF THE INTERNAL REVENUE CODE OF 1986, AS AMENDED.

FIRST OUT WATERFALL NOTE

 

First Out Waterfall Lender: Deerfield Partners, L.P.    Original Issue Date: April 3, 2017
Principal Amount: $17,680,000.00    Amendment and Restatement Date: August 9, 2018

FOR VALUE RECEIVED, the undersigned, Endologix, Inc., a Delaware corporation (the “ Borrower ”), hereby unconditionally promises to pay to the First Out Waterfall Lender set forth above (the “ Lender ”) the “Principal Amount” set forth above, or, if less, the aggregate unpaid Principal (as defined below) amount of the First Out Waterfall Loan (as defined in the Facility Agreement referred to below) of the Lender to the Borrower, payable at such times and in such amounts as are specified in the Facility Agreement.

The Borrower promises to pay interest on the outstanding Principal amount of the First Out Waterfall Loan and any overdue interest from and after the Amendment and Restatement Date (as defined below) until such outstanding Principal amount of the First Out Waterfall Loan and any overdue interest are paid in full, payable at such times and at such interest rates as are specified in the Facility Agreement. The Borrower promises to pay any Non-Callable Make Whole Amount, any CoC Fee and the First Out Waterfall Exit Payment (each, as defined in the Facility Agreement) that is due on the First Out Waterfall Loan in accordance with the Facility Agreement.

 

1


In lieu of making any payment of interest in cash (but not (i) interest payable pursuant to the second sentence of Section 2.6(a) of Facility Agreement, (ii) interest payable-in-kind or (iii) in connection with any Event of Default or late payment hereunder or any other interest payable pursuant to Section 2.7 of the Facility Agreement) and subject to the conditions set forth in Section 2.6 of the Facility Agreement and Exhibit 2.6 to the Facility Agreement, the Borrower may elect to satisfy all or any such payment by the issuance to the Lender of shares of Freely Tradable Common Shares (as defined in Exhibit 2.6) in accordance with the provisions of Exhibit 2.6.

This First Out Waterfall Note (this “ Note ”) was originally issued on April 3, 2017 and amended and restated on August 9, 2018 (the “ Amendment and Restatement Date ”) and is one of the “First Out Waterfall Notes”, “Loan Notes” and “Notes” referred to in, and is entitled to the benefits of, the Amended and Restated Facility Agreement, dated as of August 9, 2018 (as the same may be amended, restated, supplemented or otherwise modified from time to time, the “ Facility Agreement ”), by and among the Borrower, the other Loan Parties party thereto, the Lenders party thereto and Deerfield Private Design Fund IV, L.P., as agent for the Secured Parties, and the other Loan Documents.

The Facility Agreement, among other things, (a) provides for the making of a First Out Waterfall Loan by the Lender to the Borrower in an aggregate amount not to exceed at any time outstanding the “Principal Amount” set forth above, the indebtedness of the Borrower resulting from such First Out Waterfall Loan being evidenced by this Note and (b) contains provisions for acceleration of the maturity of the unpaid Principal amount of this Note upon the happening of certain stated events and also for prepayments pursuant to Section 2.3(c) or Section 5.3 of the Facility Agreement on account of the Principal hereof prior to the maturity hereof upon the terms and conditions specified therein.

1. Definitions .

(a) Certain Defined Terms . Capitalized terms used herein without definition are used as defined in the Facility Agreement. For purposes of this Note, the following terms shall have the following meanings:

(i) “ Affiliate ” means any person or entity that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a person or entity, as such terms are used in and construed under Rule 144 under the Securities Act. With respect to a Lender, any investment fund or managed account that is managed on a discretionary basis by the same investment manager as such Lender will be deemed to be an Affiliate of such Lender. As used in this definition of “Affiliate,” the term “control” means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through ownership of voting securities or partnership or other ownership interest, by contract, or otherwise.

(ii) “ Common Stock ” means the fully paid and nonassessable shares of the Borrower’s common stock, $0.001 par value per share.

 

2


(iii) “ Conversion Amount ” means the Principal amount to be converted.

(iv) “ Conversion Date ” means the date of delivery via facsimile or electronic mail of a Conversion Notice.

(v) “ Conversion Issuance Limit ” means 2,106,867 shares of Common Stock, subject to appropriate adjustment for any Stock Event that occurs after the Amendment and Restatement Date.

(vi) “ Conversion Price ” means, as of any Conversion Date, ninety-six percent (96%) of the arithmetic average of the Volume Weighted Average Prices per share of Common Stock on each of the three (3) Trading Days period preceding the Conversion Date (the “ Measurement Period ”); provided, that in the event that a stock split, stock combination, reclassification, payment of stock dividend, recapitalization or other similar transaction of such character that the shares of Common Stock shall be changed into or become exchangeable for a larger or small number of shares (a “ Stock Event ”) is consummated during the Measurement Period, the Volume Weighted Average Price for all Trading Days during the Measurement Period prior to the effectiveness of such Stock Event shall be appropriately adjusted to reflect such Stock Event, subject to appropriate adjustment for any Stock Event that occurs after the Amendment and Restatement Date.

(vii) “ Conversion Shares ” means fully paid and nonassessable shares of Common Stock issued in connection with the conversion of a Note.

(viii) “ First Amortization Cap ” means 1,399,667 shares of Common Stock, subject to appropriate adjustment for any Stock Event that occurs after the Amendment and Restatement Date.

(ix) “ First Amortization Date ” means April 2, 2021.

(x) “ Market Disruption Event ” means, with respect to any Trading Day and any security of Borrower, (a) a failure by the Principal Market to open for trading during its entire regular trading session, (b) the occurrence or existence prior to 1:00 p.m., New York City time, on such day for such securities of Borrower for more than one half-hour period in the aggregate during regular trading hours of any suspension or limitation imposed on trading (by reason of movements in price exceeding limits permitted by the relevant securities exchange or otherwise) in such securities or in any options, contracts or future contracts relating to such securities, or (c) to the extent “Volume Weighted Average Price” is determined in accordance with clause (b) of the definition thereof, the suspension of trading for the one-half hour period ending on the scheduled close of trading on such day (by reason of movements in price exceeding limits permitted by the stock exchange or otherwise) in such securities of Borrower.

(xi) “ Monthly Conversion Cap ” means 766,133 s hares of Common Stock, subject to appropriate adjustment for any Stock Event that occurs after the Amendment and Restatement Date.

 

3


(xii) “ Monthly Conversion Cap Period ” means the period commencing on the Amendment and Restatement Date and ending on (and including) August 31, 2018, and each calendar month that begins after the Amendment and Restatement Date and prior to the Maturity Date.

(xiii) “ Principal ” means the outstanding principal amount of this Note as of any date of determination.

(xiv) “ Required Lenders ” means the Required First Out Waterfall Lenders.

(xv) “ Second Amortization Cap ” means 707,200 s hares of Common Stock, subject to appropriate adjustment for any Stock Event that occurs after the Amendment and Restatement Date.

(xvi) “ Second Amortization Date ” means April 2, 2022.

(xvii) “ Trading Day ” means any day on which the Common Stock is traded for any period on the Principal Market; provided, that for purposes of the definition of “Conversion Shares,” Trading Day shall not include any Trading Day on which there is a Market Disruption Event.

(xviii) “ Volume Weighted Average Pric e ” for any security as of any Trading Day means (a) the volume weighted average sale price of such security on the principal U.S. national or regional securities exchange on which such security is traded as reported by Bloomberg Financial Markets or an equivalent, reliable reporting service mutually acceptable to and hereinafter designated by the Required Lenders and the Borrower (“ Bloomberg ”), or (b) if no volume weighted average sale price is reported for such security, then the closing price per share of such security, or, if no closing price per share is reported for such security by Bloomberg, the average of the last bid and last ask price (or if more than one in either case, the average of the average last bid and average last ask prices) on such Trading Day as reported in the composite transactions for the principal U.S. national or regional securities exchange on which such security is traded. If the security is not listed for trading on a U.S. national or regional securities exchange on the relevant Trading Day, then the Volume Weighted Average Price will be the average of the mid-point of the last bid and last ask prices of the security in the over-the-counter market on the relevant Trading Day as reported by OTC Markets Group or similar organization. If the Volume Weighted Average Price cannot be calculated for such security on such date in the manner provided above, the Volume Weighted Average Price shall be the fair market value as mutually determined by the Borrower and the Lenders holding a majority of the aggregate outstanding Principal amount of the Notes being converted for which the calculation of the Volume Weighted Average Price is required in order to determine the Conversion Price of such Notes. Volume Weighted Average Price will be determine without regard to after-hours trading or any other trading outside of the regular trading hours.

2. Conversion Rights . This Note may be converted into shares of Common Stock on the terms and conditions set forth in this Section  2 (subject to Section 2.3(a) of the Facility Agreement).

 

4


(a) Conversion at Option of the Lender . At any time during the period commencing on (and including) the Amendment and Restatement Date and ending on the close of business on the second business day immediately prior to the Maturity Date, the Lender shall be entitled to convert all or any part of the Principal into Conversion Shares in accordance with this Section  2 at the Conversion Rate (as defined in Section  2(b) ). The Borrower shall not issue any fraction of a share of Common Stock upon any conversion. If the issuance would result in the issuance of a fraction of a share of Common Stock, then the Borrower shall round such fraction of a share of Common Stock up or down to the nearest whole share (with 0.5 rounded up).

(b) Conversion Rate . The number of Conversion Shares issuable upon a conversion of any portion of this Note pursuant to Section  2 shall be determined according to the following formula (the “ Conversion Rate ”):

Conversion Amount

Conversion Price

(c) Mechanics of Conversion . The conversion of this Note shall be conducted in the following manner:

(i) Lender’s Delivery Requirements . To convert a Conversion Amount into Conversion Shares pursuant to Section  2(a) above on any date, Lender shall (A) transmit by facsimile or electronic mail (or otherwise deliver), for receipt on or prior to 5:00 p.m. New York City time on such date, a copy of an executed conversion notice in the form attached hereto as Exhibit A (the “ Conversion Notice ”) to the Borrower (at 2 Musick, Irvine, CA 92618, Attention : Chief Financial Officer; Email : vmahboob@endologix.com, or at such other office or agency as the Borrower may designate in writing), and (B) if required by Section  2(c)(vi) , surrender to a common carrier for delivery to the Borrower, no later than three (3) Business Days after the Conversion Date, of the original Note being converted (or an indemnification undertaking in customary form with respect to this Note in the case of its loss, theft or destruction).

(ii) Borrower’s Response . Upon receipt or deemed receipt by the Borrower of a copy of a Conversion Notice, the Borrower (A) shall immediately send, via facsimile, a confirmation of receipt of such Conversion Notice to the Lender and the Borrower’s designated transfer agent (the “ Transfer Agent ”), which confirmation shall constitute an instruction to the Transfer Agent to process such Conversion Notice in accordance with the terms herein, and (B) on or before the second (2 nd ) Business Day following the date of receipt or deemed receipt by the Borrower of such Conversion Notice (or, if earlier, the end of the standard settlement period for U.S. broker-dealer securities transactions) (the “ Share Delivery Date ”), shall credit such aggregate number of Conversion Shares to which the Lender shall be entitled to the Lender’s or its designee’s balance account with The Depository Trust Company (“ DTC ”) through its Deposit/Withdrawal At Custodian (DWAC) system, for the number of Conversion Shares to which the Lender shall be entitled. If notwithstanding the provisions of Section  2(c)(vi) , the Lender elects to physically surrender this Note for conversion and the Principal represented by this Note is greater than the Principal being converted, then the Borrower shall, as soon as practicable and in no event later than three (3) Business Days after

 

5


receipt of this Note and at its own expense, issue and deliver to the Lender a new Note representing the Principal not converted and cancel this Note. For purposes of Rule 144 under the Securities Act, any Conversion Shares issued to Lender shall be deemed to have been acquired by such Lender on April 3, 2017 (the date this Note was originally issued). Accordingly, (A) upon any conversion of this Note, the Rule 144 holding period for the Conversion Shares acquired thereupon shall be in excess of one (1) year, and (B) provided the Lender is not an Affiliate of the Borrower on the Conversion Date and has not been an Affiliate of the Borrower within the three-month period immediately preceding the Conversion Date (the “ Unrestricted Condition ”), which the Borrower shall assume and Lender hereby represents unless the Lender advises the Borrower otherwise in writing, the Conversion Shares issued to Lender will be freely transferable, without restriction or limitation (including any volume limitation) under Federal or state securities laws, pursuant to Rule 144 under the Securities Act and will not contain or be subject to a legend or stop transfer order restricting the resale or transferability of thereof.

(iii) Dispute Resolution . In the case of a dispute as to the determination of the Conversion Price or the arithmetic calculation of the Conversion Rate, the Borrower shall instruct the Transfer Agent to issue to the Lender the number of Conversion Shares that is not disputed and shall transmit an explanation of the disputed determinations or arithmetic calculations to the Lender via facsimile within two (2) Business Days of receipt or deemed receipt of the Lender’s Conversion Notice or other date of determination. If the Lender and the Borrower are unable to agree upon the determination of the Conversion Price or arithmetic calculation of the Conversion Rate within one (1) Business Day of such disputed determination or arithmetic calculation being transmitted to the Lender, then the Borrower shall promptly (and in any event within two (2) Business Days) submit via facsimile (A) the disputed determination of the Conversion Price to an independent, reputable investment banking firm agreed to by the Borrower and the Required Lenders, or (B) the disputed arithmetic calculation of the Conversion Rate to the Borrower’s independent registered public accounting firm, as the case may be. The Borrower shall direct the investment bank or the accounting firm, as the case may be, to perform the determinations or calculations and notify the Borrower and the Lender of the results no later than two (2) Business Days from the time it receives the disputed determinations or calculations. Such investment bank’s or accounting firm’s determination or calculation, as the case may be, shall be binding upon all parties absent manifest error, and the fees and expenses of such investment bank or accountant shall be paid one-half by the Borrower and one-half by the Lender. Notwithstanding the existence of a dispute contemplated by this paragraph, if requested by the Lender, the Borrower shall issue to the Lender the Conversion Shares not in dispute in accordance with the terms hereof.

(iv) Record Holder . The person or persons entitled to receive the Conversion Shares issuable upon a conversion of this Note shall be treated for all purposes as the legal and record holder or holders of such shares of Common Stock upon delivery by the Lender of the Conversion Notice, or in the case of Conversion Shares the issuance of which is subject to a bona fide dispute that is subject to and being resolved pursuant to, and in compliance with the time periods and other provisions of, the dispute resolution provisions of Section  2(c)(iii) , the first Business Day after the resolution of such bona fide dispute.

(v) Borrower’s Failure to Timely Convert .

 

6


(A) Cash Damages . If by the Share Delivery Date, the Borrower shall fail to credit the Lender’s or its designee’s balance account with DTC with the number of Conversion Shares (free of any restrictive legend, provided the Unrestricted Condition is satisfied), then, in addition to all other available remedies that the Lender may pursue hereunder and under the Facility Agreement, the Borrower shall pay additional damages to the Lender for each day after the Share Delivery Date such conversion is not timely effected in an amount equal to one and one-half percent (1.5%) of the product of (I) the number of Conversion Shares not issued to the Lender or its designee on or prior to the Share Delivery Date and to which the Lender is entitled and (II) the Volume Weighted Average Price of the Common Stock on the Share Delivery Date. Alternatively in lieu of the foregoing damages, subject to Section  2(c)(iii) , at the written election of the Lender made in the Lender’s sole discretion, if, on or after the applicable Conversion Date, the Lender purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by such Lender of Conversion Shares that such Lender anticipated receiving from the Borrower (such purchased shares, “ Buy-In Shares ”), the Borrower shall be obligated to promptly pay to such Lender (in addition to all other available remedies that the Lender may otherwise have), 110% of the amount by which (A) such Lender’s total purchase price (including brokerage commissions, if any) for such Buy-In Shares exceeds (B) the net proceeds received by such Lender from the sale of a number of shares equal to up to the number of Conversion Shares such Lender was entitled to receive but had not received on the Share Delivery Date. If the Borrower fails to pay the additional damages set forth in this Section 2(c)(v)(A) within five (5) Business Days of the date incurred, then the Lender entitled to such payments shall have the right at any time, so long as the Borrower continues to fail to make such payments, to require the Borrower, upon written notice, to immediately issue, in lieu of such cash damages, the number of shares of Common Stock equal to the quotient of (X) the aggregate amount of the damages payments described herein divided by (Y) the Conversion Price specified by the Lender in the Conversion Notice.

(B) Conversion Failure . If for any reason the Lender has not received all of the Conversion Shares it is entitled to prior to the tenth (10th) Business Day after the Share Delivery Date with respect to a conversion of this Note (a “ Conversion Failure ”), then the Lender, upon written notice to the Borrower (a “ Void Conversion Notice ”), may void its conversion with respect to, and retain or have returned, as the case may be, any portion of this Note that has not been converted pursuant to the Lender’s Conversion Notice; provided , that the voiding of the Lender’s Conversion Notice shall not affect the Borrower’s obligations to make any payments that have accrued prior to the date of such notice pursuant to Section  2(c)(v)(A) or otherwise. A Conversion Failure shall constitute an Event of Default under the Facility Agreement and entitle the Lenders to all payments and remedies provided under the Facility Agreement upon the occurrence of an Event of Default.

(vi) Book-Entry . Notwithstanding anything to the contrary set forth herein, upon conversion or repayment of this Note in accordance with the terms hereof, the Lender shall not be required to physically surrender this Note to the Borrower unless all of the Principal is being converted or repaid. The Lender and the Borrower shall maintain records showing the Principal converted or repaid and the dates of such conversions or repayments or shall use such other method, reasonably satisfactory to the Lender and the Borrower, so as not to require physical surrender of this Note upon any such partial conversion or repayment. Notwithstanding the foregoing, if this Note is converted or repaid as aforesaid, the Lender may

 

7


not transfer this Note unless the Lender first physically surrenders this Note to the Borrower, whereupon the Borrower will forthwith issue and deliver upon the order of the Lender a new Note of like tenor, registered as the Lender may request, representing in the aggregate the remaining Principal represented by this Note. The Lender and any assignee, by acceptance of this Note, acknowledge and agree that, by reason of the provisions of this paragraph, following conversion or repayment of any portion of this Note, the Principal of this Note may be less than the “Principal Amount” stated on the face hereof.

(d) Limitations on Conversions .

(i) Beneficial Ownership . Notwithstanding anything herein to the contrary, the Borrower shall not issue to the Lender, and the Lender may not acquire, a number of shares of Common Stock upon conversion of this Note or otherwise issue any shares of Common Stock pursuant hereto or the Facility Agreement to the extent that, upon such conversion, the number of shares of Common Stock then beneficially owned by the Lender and its Affiliates and any other persons or entities whose beneficial ownership of Common Stock would be aggregated with the Lender’s for purposes of Section 13(d) of the Exchange Act (including shares held by any “group” of which the Lender is a member, but excluding shares beneficially owned by virtue of the ownership of the Warrants or other securities or rights to acquire securities that have limitations on the right to convert, exercise or purchase similar to the limitation set forth herein) would exceed 4.985% of the total number of shares of common stock then issued and outstanding (the “ 4.985% Cap ”); provided, however, that the 4.985% Cap shall only apply to the extent that the Common Stock is deemed to constitute an “equity security” pursuant to Rule 13d-1(i) promulgated under the Exchange Act. For purposes hereof, “group” has the meaning set forth in Section 13(d) of the Exchange Act and applicable regulations of the SEC, and the percentage held by the Lender shall be determined in a manner consistent with the provisions of Section 13(d) of the Exchange Act. Upon the written request of the Lender, the Borrower shall, within two (2) Trading Days, confirm orally and in writing to the Lender the number of shares of Common Stock then outstanding.

(ii) Conversion Issuance Limit . Notwithstanding anything to the contrary contained herein, the Borrower shall not issue any shares of Common Stock upon conversion of this Note (including pursuant to Section  2(c)(v)(A) hereof) to the extent that the issuance of such shares of Common Stock together with any previous issuances of shares of Common Stock under this Note would exceed the Conversion Issuance Limit, and Section 2.5(c)(v) shall not apply in respect to any excess amount.

(iii) Other Applicable Limitations on Conversion of the Note . Notwithstanding anything to the contrary herein, this Note shall not be convertible, and the Borrower shall not issue shares of Common Stock upon conversion of this Note (a) at any time after the First Amortization Date, to the extent that the number of shares of Common Stock that would otherwise be issuable to Lender upon such conversion, together with all shares of Common Stock previously issued to Lender upon conversion of this Note after the First Amortization Date, would exceed the First Amortization Cap, or (b)  at any time after the Second Amortization Date, to the extent that the number of shares of Common Stock that would otherwise be issuable to Lender upon such conversion, together with all shares of Common Stock previously issued to Lender upon conversion of this Note after the Second Amortization

 

8


Date, would exceed the Second Amortization Cap, or (c) during any Monthly Conversion Cap Period, to the extent that the number of shares of Common Stock that would otherwise be issuable to Lender upon such conversion, together with all shares previously issued to Lender upon conversion of this Note during the such Monthly Conversion Cap Period, would exceed the Monthly Conversion Cap. For the avoidance of doubt, if the number of shares of Common Stock to be issued as set forth in an Conversion Notice transmitted by the Lender to the Borrower would otherwise require the Borrower to issue a number of shares in excess of the Conversion Issuance Limit, the First Amortization Cap (if after the First Amortization Date), the Second Amortization Cap (if after the Second Amortization Date) or the Monthly Share Cap, the Borrower shall issue to the Lender in accordance herewith the maximum number of shares of Common Stock issuable without exceeding any such applicable limitation, and Section 2.5(c)(v) shall not apply to any excess amount.

3. Voting Rights . Except as required by law, the Lender shall have no voting rights with respect to any of the Conversion Shares until the Conversion Date relating to the conversion of this Note upon which such Conversion Shares are issuable (or in the case of Conversion Shares the issuance of which is subject to a bona fide dispute that is subject to and being resolved pursuant to, and in compliance with the time periods and other provisions of, the dispute resolution provisions of Section  2(c)(iii) , the first Business Day after the resolution of such bona fide dispute).

4. Amendment; Waiver . The provisions of this Note may only be waived or amended, restated, supplemented or otherwise modified in accordance with the Facility Agreement.

5. Specific Shall Not Limit General; Construction . No specific provision contained in this Note shall limit or modify any more general provision contained herein. This Note shall be deemed to be jointly drafted by the Borrower and all Lenders pursuant to the Facility Agreement and shall not be construed against any Person as the drafter hereof.

6. Failure or Indulgence Not Waiver . No delay or omission by the Lender in exercising any power or right hereunder shall impair such right or power or be construed to be a waiver of any default, nor shall any single or partial exercise of any power or right hereunder preclude the full exercise thereof or the exercise of any other power or right. No renewal or extension of this Note or the Facility Agreement, no delay in the enforcement of payment under this Note or the Facility Agreement, and no delay or omission in exercising any right or power under this Note or the Facility Agreement shall affect the liability of the Borrower or any endorser of this Note.

7. Notices . Whenever notice is required to be given under this Note, unless otherwise provided herein, such notice shall be given in accordance with Section 6.1 of the Facility Agreement.

8. Restrictions on Transfer .

(a) Registration or Exemption Required . This Note has been issued in a transaction exempt from the registration requirements of the Securities Act. None of the Note or

 

9


the Conversion Shares issued hereunder may be transferred, sold, assigned, hypothecated or otherwise disposed of except pursuant to an effective registration statement or an exemption to the registration requirements of the Securities Act and applicable state laws, including Rule 144 under the Securities Act, Section 4(a)(7) of the Securities Act or a so-called “4[(a)](1) and a half” transaction.

(b) Assignment . This Note is assignable or transferable, in whole or in part, only to the extent such assignment or transfer is permitted pursuant to the terms of the Facility Agreement; provided that (i) the Lender shall deliver a written notice to the Borrower, substantially in the form of the Assignment attached hereto as Exhibit B , indicating the Person or Persons to whom the Note shall be assigned and the respective Principal amount of the Note to be assigned to each assignee. The Borrower shall effect the assignment within three (3) business days, and shall deliver to the assignee(s) designated by the Lender a Note or Notes of like tenor and terms for the appropriate Principal amount. This Note and the rights evidenced hereby shall inure to the benefit of and be binding upon the successors and assigns of the Lender. The provisions of this Note are intended to be for the benefit of all Lenders from time to time of this Note, and shall be enforceable by any such Lender. This Note is not (and any rights or obligations hereunder are not) not assignable or transferable by the Borrower under any circumstance and any such prohibited assignment or transfer is absolutely void ab initio .

9. Payment of Collection, Enforcement and Other Costs . If (a) this Note is placed in the hands of an attorney for collection or enforcement or is collected or enforced through any legal proceeding; or (b) an attorney is retained to represent the Lender in any bankruptcy, reorganization, receivership of the Borrower or other proceedings affecting Borrower creditors’ rights and involving a claim under this Note, then the Borrower shall pay the costs incurred by the Lender for such collection, enforcement or action, including reasonable attorneys’ fees and disbursements. Subject to the terms of the Facility Agreement, all payments and issuances of shares of Common Stock hereunder will be free and clear of, and without deduction or withholding for, any present or future taxes. The Borrower shall pay all and any costs (administrative or otherwise) imposed by the Borrower’s banks, clearing houses, or any other financial institution, in connection with making any payments and issuing any shares of Common Stock hereunder. The Borrower shall pay all costs and expenses (including attorney’s fees) of the Lender incurred in connection with this Note in accordance with Section 6.3 of the Facility Agreement.

10. Waiver of Notice . Other than those notices required to be provided by the Lender to the Borrower under the terms of the Facility Agreement, the Borrower and every endorser of this Note, or the obligations represented hereby, expressly waives diligence, presentment, protest, demand, notice of dishonor, non-payment or default, and notice of any kind with respect to this Note and the Facility Agreement or the performance of the obligations under this Note and/or the Facility Agreement.

11. Miscellaneous . This Note is a Loan Document, is entitled to the benefits of the Loan Documents and is subject to certain provisions of the Facility Agreement, including Sections 1.2 ( Interpretation ) and 6.4 ( Governing Law; Venue; Jurisdiction; Service of Process; Waiver of Jury Trial ) thereof.

 

10


12. Additional Interpretative Matters . Unless the context otherwise requires, (a) all references to Sections or Exhibits are to Sections or Exhibits contained in or attached to this Note, (b) each accounting term not otherwise defined in this Note has the meaning assigned to it in accordance with GAAP, (c) words in the singular or plural include the singular and plural and pronouns stated in either the masculine, the feminine or neuter gender shall include the masculine, feminine and neuter and (d) the use of the word “including” in this Note shall be by way of example rather than limitation. If a Stock Event occurs during any period over which an average price is being determined, then an appropriate adjustment will be made to such average to reflect such Stock Event.

13. Signatures . In the event that any signature to this Note or any amendment hereto is delivered by electronic mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such “.pdf” signature page were an original thereof. Notwithstanding the foregoing, the Borrower shall be obligated to deliver to the Lender an original signature to this Note. At the request of any party, each other party shall promptly re-execute an original form of this Note or any amendment hereto and deliver the same to the other party. No party hereto shall raise the use of electronic mail delivery of a “.pdf” format data file to deliver a signature to this Note or any amendment hereto or the fact that such signature was transmitted or communicated through the use of electronic mail delivery of a “.pdf” format data file as a defense to the formation or enforceability of a contract, and each party hereto forever waives any such defense.

14. This Note is an amendment and restatement of that certain Loan Note originally issued on April 3, 2017, in the principal amount of $17,680,000.00 (the “ Prior Note ”) and evidences an extension, continuation, and renewal of the indebtedness evidenced by the Prior Note, but this Note replaces the Prior Note with the indebtedness evidenced by the Prior Note now evidenced by this Note. Such Prior Note shall be of no further force and effect upon execution of this Note. The Borrower hereby acknowledges and agrees that the indebtedness under the Prior Note has not been repaid or extinguished and that the execution hereof does not constitute a novation of the Prior Note. Moreover, this Note shall be entitled to all security and collateral to which the Prior Note was entitled, without change or diminution in the priority of any lien or security interest granted to secure the Prior Note.

[Signature Page Follows]

 

11


IN WITNESS WHEREOF, the Borrower has caused this Note to be executed and delivered by its duly authorized officer as of the day and year set forth above.

 

ENDOLOGIX, INC. ,
a Delaware corporation
By:   /s/ Vaseem Mahboob
Name: Vaseem Mahboob
Title: Chief Financial Officer

 

12


Exhibit A

CONVERSION NOTICE

Reference is made to the First Out Waterfall Note (the “ Note ”) of ENDOLOGIX, INC. , a Delaware corporation (the “ Borrower ”), in the original principal amount of $17,680,000.00. In accordance with and pursuant to the Note, the undersigned hereby elects to convert the Conversion Amount (as defined in the Note) of the Note indicated below into shares of common stock, par value $0.001 per share (the “ Common Stock ”), of the Borrower, as of the date specified below.

Date of Conversion:                     

Aggregate Conversion Amount to be converted at the Conversion Price (as defined in the Note):

 

                                                             

Principal, applicable thereto, to be converted:                                                                  

Please confirm the following information:

Conversion Price:                                                                                                   

Number of shares of Common Stock to be issued:                                              

Please issue the Common Stock into which the Note is being converted in the following name and to the following address:

Issue to:                                                                                                                   

Facsimile Number:                                                                                                   

Authorization:                                                                          

By:                                                                                   

Title:                                                                                

Dated:                                                                                       

DTC Participant Number and Name:                                                                                                               

Account Number:                                                                                                                                              

 

13


Exhibit B

ASSIGNMENT

(To be executed by the registered holder

desiring to transfer the Note)

FOR VALUE RECEIVED, the undersigned holder of the attached First Out Waterfall Note (the “ Note ”) hereby sells, assigns and transfers unto the person or persons below named the right to receive the principal amount of $             from Endologix, Inc., a Delaware corporation (the “ Borrower ”), evidenced by the attached Note and does hereby irrevocably constitute and appoint                  attorney to transfer the said Note on the books of the Borrower, with full power of substitution in the premises.

 

Dated: _______________    

 

    Signature
Fill in for new registration of Note:    

 

   
Name    

 

   
Address    

 

   
Please print name and address of assignee    
(including zip code number)    

NOTICE

The signature to the foregoing Assignment must correspond to the name as written upon the face of the attached Note.

 

14

Exhibit 4.8

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS OR (B) AN OPINION OF COUNSEL, IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR APPLICABLE STATE SECURITIES LAWS OR (II) UNLESS SOLD PURSUANT TO RULE 144 UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN, FINANCING OR INDEBTEDNESS ARRANGEMENT SECURED BY THE SECURITIES.

NOTE

 

Lender: Deerfield Private Design Fund III, L.P.

Principal Amount: $16,666,666.66

   August 9, 2018

FOR VALUE RECEIVED, each of the undersigned, Endologix, Inc., a Delaware corporation, CVD/RMS Acquisition Corp., a Delaware corporation, Nellix, Inc., a Delaware corporation, TriVascular Technologies, Inc., a Delaware corporation, TriVascular, Inc., a California corporation, TriVascular Canada, LLC, a Delaware limited liability company, TriVascular Sales LLC, a Texas limited liability company, and RMS/Endologix Sideways Merger Corp., a Delaware corporation (collectively, the “ Borrowers ”), hereby unconditionally promises to pay to the Lender set forth above (the “ Lender ”) the principal amount set forth above, or, if less, the aggregate unpaid principal amount of the Loan (as defined in the Credit Agreement referred to below) of the Lender to the Borrowers, payable at such times and in such amounts as are specified in the Credit Agreement.

The Borrowers promise to pay interest on the outstanding principal amount of the Loan and any overdue interest from and after the Closing Date until such outstanding principal amount of the Loan and any overdue interest are paid in full, payable at such times and at such interest rates as are specified in the Credit Agreement. Demand, diligence, presentment, protest and notice of non-payment and protest are hereby waived by each Borrower.

Principal and interest are payable in Dollars to the Lender in the manner set forth in the Credit Agreement.

This Note (this “ Note ”) is one of the “Notes” referred to in, and is entitled to the benefits of, the Credit Agreement, dated as of August 9, 2018 (as the same may be amended, restated, supplemented or otherwise modified from time to time, the “ Credit Agreement ”), by and among the Borrowers, the other Credit Parties party thereto, the Lenders party thereto and Deerfield ELGX Revolver, LLC, as agent for the Secured Parties, and the other Security Documents. Capitalized terms used herein without definition are used as defined in the Credit Agreement.

The Credit Agreement, among other things, (a) provides for the making of Loans by the Lender to the Borrowers in an aggregate amount not to exceed at any time outstanding the principal amount set forth above, the indebtedness of the Borrowers resulting from such Loan being evidenced by this Note and (b) contains provisions for acceleration of the maturity of the unpaid principal amount of this Note and the termination of the Revolver Commitments upon the happening of certain stated events and also for prepayments pursuant to Section 2.03 and the other provisions of the Credit Agreement on account of the principal hereof prior to the maturity hereof upon the terms and conditions specified therein.

 

1


This Note is a Loan Document, is entitled to the benefits of the Loan Documents and is subject to certain provisions of the Credit Agreement, including Section 1.04 ( Construction ) and Article XII ( CHOICE OF LAW AND VENUE; JURY TRIAL WAIVER; JUDICIAL REFERENCE PROVISION ) thereof.

This Note is assignable or transferable only to the extent such assignment or transfer is permitted pursuant to the terms of the Credit Agreement.

Subject to the terms of the Credit Agreement, all payments will be free and clear of, and without deduction or withholding for, any present or future taxes. The Borrowers shall pay all and any costs (administrative or otherwise) imposed by the Borrowers’ banks, clearing houses, or any other financial institution, in connection with making any payments hereunder.

The Borrowers shall pay all costs and expenses (including attorney’s fees) of the Lender incurred in connection with this Note in accordance with Section 15.07 of the Credit Agreement.

Other than those notices expressly required to be provided by the Lender to the Borrower Representative under the terms of the Credit Agreement, the Borrowers and every endorser of this Note, or the obligations represented hereby, expressly waives presentment, protest, demand, notice of dishonor or default, and notice of any kind with respect to this Note and the Credit Agreement or the performance of the obligations under this Note and/or the Credit Agreement. No renewal or extension of this Note or the Credit Agreement, no delay in the enforcement of payment of this Note or the Credit Agreement, and no delay or omission in exercising any right or power under this Note or the Credit Agreement shall affect the liability of any Borrower or any endorser of this Note.

No delay or omission by the Lender in exercising any power or right hereunder shall impair such right or power or be construed to be a waiver of any default, nor shall any single or partial exercise of any power or right hereunder preclude the full exercise thereof or the exercise of any other power or right. The provisions of this Note may be waived or amended, restated, supplemented or otherwise modified only in a writing signed by the Borrower Representative and the Lender.

This Note shall be governed by, and be construed and enforced in accordance with, the laws of the State of New York applicable to contracts made and to be performed in such State.

[Signature Page Follows]

 

2


IN WITNESS WHEREOF, the Borrowers have caused this Note to be executed and delivered by their duly authorized officers as of the day and year set forth above.

 

ENDOLOGIX, INC.,
a Delaware corporation
By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer
CVD/RMS ACQUISITION CORP.,
a Delaware corporation
By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer
NELLIX, INC.,
a Delaware corporation
By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer

TRIVASCULAR TECHNOLOGIES, INC.,

a Delaware corporation

By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer
TRIVASCULAR, INC.,
a California corporation
By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer
TRIVASCULAR CANADA, LLC,
a Delaware limited liability company
By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer

[Signature Page to Note]


TRIVASCULAR SALES LLC,

a Texas limited liability company

By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer and Secretary

RMS/ENDOLOGIX SIDEWAYS

MERGER CORP.,

a Delaware corporation

By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer and Secretary

[Signature Page to Note]

Exhibit 4.9

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS OR (B) AN OPINION OF COUNSEL, IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR APPLICABLE STATE SECURITIES LAWS OR (II) UNLESS SOLD PURSUANT TO RULE 144 UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN, FINANCING OR INDEBTEDNESS ARRANGEMENT SECURED BY THE SECURITIES.

NOTE

 

Lender: Deerfield Private Design Fund IV, L.P.

  

Principal Amount: $16,666,666.67

   August 9, 2018

FOR VALUE RECEIVED, each of the undersigned, Endologix, Inc., a Delaware corporation, CVD/RMS Acquisition Corp., a Delaware corporation, Nellix, Inc., a Delaware corporation, TriVascular Technologies, Inc., a Delaware corporation, TriVascular, Inc., a California corporation, TriVascular Canada, LLC, a Delaware limited liability company, TriVascular Sales LLC, a Texas limited liability company, and RMS/Endologix Sideways Merger Corp., a Delaware corporation (collectively, the “ Borrowers ”), hereby unconditionally promises to pay to the Lender set forth above (the “ Lender ”) the principal amount set forth above, or, if less, the aggregate unpaid principal amount of the Loan (as defined in the Credit Agreement referred to below) of the Lender to the Borrowers, payable at such times and in such amounts as are specified in the Credit Agreement.

The Borrowers promise to pay interest on the outstanding principal amount of the Loan and any overdue interest from and after the Closing Date until such outstanding principal amount of the Loan and any overdue interest are paid in full, payable at such times and at such interest rates as are specified in the Credit Agreement. Demand, diligence, presentment, protest and notice of non-payment and protest are hereby waived by each Borrower.

Principal and interest are payable in Dollars to the Lender in the manner set forth in the Credit Agreement.

This Note (this “ Note ”) is one of the “Notes” referred to in, and is entitled to the benefits of, the Credit Agreement, dated as of August 9, 2018 (as the same may be amended, restated, supplemented or otherwise modified from time to time, the “ Credit Agreement ”), by and among the Borrowers, the other Credit Parties party thereto, the Lenders party thereto and Deerfield ELGX Revolver, LLC, as agent for the Secured Parties, and the other Security Documents. Capitalized terms used herein without definition are used as defined in the Credit Agreement.

The Credit Agreement, among other things, (a) provides for the making of Loans by the Lender to the Borrowers in an aggregate amount not to exceed at any time outstanding the principal amount set forth above, the indebtedness of the Borrowers resulting from such Loan being evidenced by this Note and (b) contains provisions for acceleration of the maturity of the unpaid principal amount of this Note and the termination of the Revolver Commitments upon the happening of certain stated events and also for prepayments pursuant to Section 2.03 and the other provisions of the Credit Agreement on account of the principal hereof prior to the maturity hereof upon the terms and conditions specified therein.

 

1


This Note is a Loan Document, is entitled to the benefits of the Loan Documents and is subject to certain provisions of the Credit Agreement, including Section 1.04 ( Construction ) and Article XII ( CHOICE OF LAW AND VENUE; JURY TRIAL WAIVER; JUDICIAL REFERENCE PROVISION ) thereof.

This Note is assignable or transferable only to the extent such assignment or transfer is permitted pursuant to the terms of the Credit Agreement.

Subject to the terms of the Credit Agreement, all payments will be free and clear of, and without deduction or withholding for, any present or future taxes. The Borrowers shall pay all and any costs (administrative or otherwise) imposed by the Borrowers’ banks, clearing houses, or any other financial institution, in connection with making any payments hereunder.

The Borrowers shall pay all costs and expenses (including attorney’s fees) of the Lender incurred in connection with this Note in accordance with Section 15.07 of the Credit Agreement.

Other than those notices expressly required to be provided by the Lender to the Borrower Representative under the terms of the Credit Agreement, the Borrowers and every endorser of this Note, or the obligations represented hereby, expressly waives presentment, protest, demand, notice of dishonor or default, and notice of any kind with respect to this Note and the Credit Agreement or the performance of the obligations under this Note and/or the Credit Agreement. No renewal or extension of this Note or the Credit Agreement, no delay in the enforcement of payment of this Note or the Credit Agreement, and no delay or omission in exercising any right or power under this Note or the Credit Agreement shall affect the liability of any Borrower or any endorser of this Note.

No delay or omission by the Lender in exercising any power or right hereunder shall impair such right or power or be construed to be a waiver of any default, nor shall any single or partial exercise of any power or right hereunder preclude the full exercise thereof or the exercise of any other power or right. The provisions of this Note may be waived or amended, restated, supplemented or otherwise modified only in a writing signed by the Borrower Representative and the Lender.

This Note shall be governed by, and be construed and enforced in accordance with, the laws of the State of New York applicable to contracts made and to be performed in such State.

[Signature Page Follows]

 

2


IN WITNESS WHEREOF, the Borrowers have caused this Note to be executed and delivered by their duly authorized officers as of the day and year set forth above.

 

ENDOLOGIX, INC. ,
a Delaware corporation
By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer
CVD/RMS ACQUISITION CORP. ,
a Delaware corporation
By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer
NELLIX, INC. ,
a Delaware corporation
By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer

TRIVASCULAR TECHNOLOGIES, INC. ,

a Delaware corporation

By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer
TRIVASCULAR, INC. ,
a California corporation
By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer
TRIVASCULAR CANADA, LLC ,
a Delaware limited liability company
By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer

[Signature Page to Note]


TRIVASCULAR SALES LLC ,

a Texas limited liability company

By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer and Secretary
RMS/ENDOLOGIX SIDEWAYS

MERGER CORP. ,

a Delaware corporation

By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer and Secretary

[Signature Page to Note]

Exhibit 4.10

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS OR (B) AN OPINION OF COUNSEL, IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR APPLICABLE STATE SECURITIES LAWS OR (II) UNLESS SOLD PURSUANT TO RULE 144 UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN, FINANCING OR INDEBTEDNESS ARRANGEMENT SECURED BY THE SECURITIES.

NOTE

 

Lender: Deerfield Partners, L.P.

  

Principal Amount: $16,666,666.67

   August 9, 2018

FOR VALUE RECEIVED, each of the undersigned, Endologix, Inc., a Delaware corporation, CVD/RMS Acquisition Corp., a Delaware corporation, Nellix, Inc., a Delaware corporation, TriVascular Technologies, Inc., a Delaware corporation, TriVascular, Inc., a California corporation, TriVascular Canada, LLC, a Delaware limited liability company, TriVascular Sales LLC, a Texas limited liability company, and RMS/Endologix Sideways Merger Corp., a Delaware corporation (collectively, the “ Borrowers ”), hereby unconditionally promises to pay to the Lender set forth above (the “ Lender ”) the principal amount set forth above, or, if less, the aggregate unpaid principal amount of the Loan (as defined in the Credit Agreement referred to below) of the Lender to the Borrowers, payable at such times and in such amounts as are specified in the Credit Agreement.

The Borrowers promise to pay interest on the outstanding principal amount of the Loan and any overdue interest from and after the Closing Date until such outstanding principal amount of the Loan and any overdue interest are paid in full, payable at such times and at such interest rates as are specified in the Credit Agreement. Demand, diligence, presentment, protest and notice of non-payment and protest are hereby waived by each Borrower.

Principal and interest are payable in Dollars to the Lender in the manner set forth in the Credit Agreement.

This Note (this “ Note ”) is one of the “Notes” referred to in, and is entitled to the benefits of, the Credit Agreement, dated as of August 9, 2018 (as the same may be amended, restated, supplemented or otherwise modified from time to time, the “ Credit Agreement ”), by and among the Borrowers, the other Credit Parties party thereto, the Lenders party thereto and Deerfield ELGX Revolver, LLC, as agent for the Secured Parties, and the other Security Documents. Capitalized terms used herein without definition are used as defined in the Credit Agreement.

The Credit Agreement, among other things, (a) provides for the making of Loans by the Lender to the Borrowers in an aggregate amount not to exceed at any time outstanding the principal amount set forth above, the indebtedness of the Borrowers resulting from such Loan being evidenced by this Note and (b) contains provisions for acceleration of the maturity of the unpaid principal amount of this Note and the termination of the Revolver Commitments upon the happening of certain stated events and also for prepayments pursuant to Section 2.03 and the other provisions of the Credit Agreement on account of the principal hereof prior to the maturity hereof upon the terms and conditions specified therein.

 

1


This Note is a Loan Document, is entitled to the benefits of the Loan Documents and is subject to certain provisions of the Credit Agreement, including Section 1.04 ( Construction ) and Article XII ( CHOICE OF LAW AND VENUE; JURY TRIAL WAIVER; JUDICIAL REFERENCE PROVISION ) thereof.

This Note is assignable or transferable only to the extent such assignment or transfer is permitted pursuant to the terms of the Credit Agreement.

Subject to the terms of the Credit Agreement, all payments will be free and clear of, and without deduction or withholding for, any present or future taxes. The Borrowers shall pay all and any costs (administrative or otherwise) imposed by the Borrowers’ banks, clearing houses, or any other financial institution, in connection with making any payments hereunder.

The Borrowers shall pay all costs and expenses (including attorney’s fees) of the Lender incurred in connection with this Note in accordance with Section 15.07 of the Credit Agreement.

Other than those notices expressly required to be provided by the Lender to the Borrower Representative under the terms of the Credit Agreement, the Borrowers and every endorser of this Note, or the obligations represented hereby, expressly waives presentment, protest, demand, notice of dishonor or default, and notice of any kind with respect to this Note and the Credit Agreement or the performance of the obligations under this Note and/or the Credit Agreement. No renewal or extension of this Note or the Credit Agreement, no delay in the enforcement of payment of this Note or the Credit Agreement, and no delay or omission in exercising any right or power under this Note or the Credit Agreement shall affect the liability of any Borrower or any endorser of this Note.

No delay or omission by the Lender in exercising any power or right hereunder shall impair such right or power or be construed to be a waiver of any default, nor shall any single or partial exercise of any power or right hereunder preclude the full exercise thereof or the exercise of any other power or right. The provisions of this Note may be waived or amended, restated, supplemented or otherwise modified only in a writing signed by the Borrower Representative and the Lender.

This Note shall be governed by, and be construed and enforced in accordance with, the laws of the State of New York applicable to contracts made and to be performed in such State.

[Signature Page Follows]

 

2


IN WITNESS WHEREOF, the Borrowers have caused this Note to be executed and delivered by their duly authorized officers as of the day and year set forth above.

 

ENDOLOGIX, INC. ,
a Delaware corporation
By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer
CVD/RMS ACQUISITION CORP. ,
a Delaware corporation
By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer
NELLIX, INC. ,
a Delaware corporation
By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer

TRIVASCULAR TECHNOLOGIES, INC. ,

a Delaware corporation

By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer
TRIVASCULAR, INC. ,
a California corporation
By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer
TRIVASCULAR CANADA, LLC ,
a Delaware limited liability company
By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer

[Signature Page to Note]


TRIVASCULAR SALES LLC,

a Texas limited liability company

By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer and Secretary
RMS/ENDOLOGIX SIDEWAYS

MERGER CORP.,

a Delaware corporation

By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer and Secretary

[Signature Page to Note]

Exhibit 4.11

LAST OUT WATERFALL NOTE

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS OR (B) AN OPINION OF COUNSEL, IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR APPLICABLE STATE SECURITIES LAWS OR (II) UNLESS SOLD PURSUANT TO RULE 144 UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN, FINANCING OR INDEBTEDNESS ARRANGEMENT SECURED BY THE SECURITIES.

LAST OUT WATERFALL NOTE

 

Last Out Waterfall Lender: DEERFIELD PARTNERS, L.P.   
Principal Amount: $40,500,000    August 9, 2018

FOR VALUE RECEIVED, the undersigned, Endologix, Inc., a Delaware corporation (the “ Borrower ”), hereby unconditionally promises to pay to the Last Out Waterfall Lender set forth above (the “ Last Out Waterfall Lender ”) the Principal Amount set forth above (the “ Principal Amount ”), or, if less, the aggregate unpaid principal amount of the Last Out Waterfall Loan (as defined in the Facility Agreement referred to below) of the Last Out Waterfall Lender to the Borrower, payable at such times and in such amounts as are specified in the Facility Agreement.

The Borrower promises to pay interest on the outstanding principal amount of the Last Out Waterfall Loan and any overdue interest from and after the Agreement Date until such outstanding principal amount of the Last Out Waterfall Loan and any overdue interest are paid in full, payable at such times, in such type (such as cash or paid in-kind) and at such interest rates as are specified in the Facility Agreement. The Borrower promises to pay any Non-Callable Make Whole Amount, any CoC Fee and the Exit Payment that is due on the Last Out Waterfall Loan in accordance with the Facility Agreement. Demand, diligence, presentment, protest and notice of non-payment and protest are hereby waived by the Borrower.

Principal and interest (and any Non-Callable Make Whole Amount, any CoC Fee and the Exit Payment) are payable in Dollars ( provided that the PIK Interest Payment is paid in-kind pursuant to Section 2.6(a) of the Facility Agreement) to the Last Out Waterfall Lender in the manner set forth in the Facility Agreement.

This Last Out Waterfall Note (this “ Last Out Waterfall Note ”) is one of the “Last Out Waterfall Notes”, “Loan Notes” and “Notes” referred to in, and is entitled to the benefits of, the Amended and Restated Facility Agreement, dated as of August 9, 2018 (as the same may be amended, restated, supplemented or otherwise modified from time to time, the “ Facility Agreement ”), by and among the Borrower, the other Loan Parties party thereto, the Lenders (including the Last Out Waterfall Lender) party thereto and Deerfield Private Design Fund IV, L.P., as agent for the Secured Parties, and the other Loan Documents. Capitalized terms used herein without definition are used as defined in the Facility Agreement.

 

1


The Facility Agreement, among other things, (a) provides for the making of a Last Out Waterfall Loan by the Last Out Waterfall Lender to the Borrower in an aggregate amount not to exceed at any time outstanding the Principal Amount, the indebtedness of the Borrower resulting from such Last Out Waterfall Loan being evidenced by this Last Out Waterfall Note and (b) contains provisions for acceleration of the maturity of the unpaid principal amount of this Last Out Waterfall Note upon the happening of certain stated events and also for prepayments pursuant to Section 2.3(c) or Section 5.3 of the Facility Agreement on account of the principal hereof prior to the maturity hereof upon the terms and conditions specified therein.

This Last Out Waterfall Note is a Loan Document, is entitled to the benefits of the Loan Documents and is subject to certain provisions of the Facility Agreement, including Sections 1.2 ( Interpretation ) and 6.4 ( Governing Law; Venue; Jurisdiction; Service of Process; Waiver of Jury Trial ) thereof.

This Last Out Waterfall Note is assignable or transferable to the extent such assignment or transfer is permitted pursuant to the terms of the Facility Agreement.

Subject to the terms of the Facility Agreement, all payments will be free and clear of, and without deduction or withholding for, any present or future taxes. The Borrower shall pay all and any costs (administrative or otherwise) imposed by the Borrower’s banks, clearing houses, or any other financial institution, in connection with making any payments hereunder.

The Borrower shall pay all costs and expenses (including attorney’s fees) of the Last Out Waterfall Lender incurred in connection with this Last Out Waterfall Note in accordance with Section 6.3 of the Facility Agreement.

Other than those notices required to be provided by the Last Out Waterfall Lender to the Borrower under the terms of the Facility Agreement, the Borrower and every endorser of this Last Out Waterfall Note, or the obligations represented hereby, expressly waives presentment, protest, demand, notice of dishonor or default, and notice of any kind with respect to this Last Out Waterfall Note and the Facility Agreement or the performance of the obligations under this Last Out Waterfall Note and/or the Facility Agreement. No renewal or extension of this Last Out Waterfall Note or the Facility Agreement, no delay in the enforcement of payment of this Last Out Waterfall Note or the Facility Agreement, and no delay or omission in exercising any right or power under this Last Out Waterfall Note or the Facility Agreement shall affect the liability of the Borrower or any endorser of this Last Out Waterfall Note.

No delay or omission by the Last Out Waterfall Lender in exercising any power or right hereunder shall impair such right or power or be construed to be a waiver of any default, nor shall any single or partial exercise of any power or right hereunder preclude the full exercise thereof or the exercise of any other power or right. The provisions of this Last Out Waterfall Note may be waived or amended, restated, supplemented or otherwise modified only in a writing signed by the Borrower and the Last Out Waterfall Lender.

This Last Out Waterfall Note shall be governed by, and be construed and enforced in accordance with, the laws of the State of New York applicable to contracts made and to be performed in such State.

[Signature Page Follows]

 

2


IN WITNESS WHEREOF, the Borrower has caused this Last Out Waterfall Note to be executed and delivered by its duly authorized officer as of the day and year set forth above.

 

ENDOLOGIX, INC.,

a Delaware corporation

By:   /s/ Vaseem Mahboob
Name:   Vaseem Mahboob
Title:   Chief Executive Officer

 

3

Exhibit 10.1

Execution Version

 

 

 

CREDIT AGREEMENT

by and among

DEERFIELD ELGX REVOLVER, LLC,

as Agent,

THE LENDERS THAT ARE PARTIES HERETO,

as the Lenders,

ENDOLOGIX, INC.,

each of its direct and indirect subsidiaries listed on the signature pages hereto and any additional borrower that hereafter becomes party hereto, each as Borrower, and collectively as Borrowers

Closing Date: August 9, 2018

 

 

 


TABLE OF CONTENTS

 

         Page  

ARTICLE I. DEFINITIONS AND CONSTRUCTION

     1  

1.01

  Definitions      1  

1.02

  Accounting Terms      48  

1.03

  Code      48  

1.04

  Construction      48  

1.05

  Time References      49  

1.06

  Schedules and Exhibits      49  

ARTICLE II. LOANS AND TERMS OF PAYMENT

     49  

2.01

  Revolving Loans      49  

2.02

  Borrowing Procedures and Settlements      50  

2.03

  Payments; Reductions of Commitments; Prepayments      53  

2.04

  Promise to Pay; Promissory Notes      56  

2.05

  Interest Rates: Rates, Payments, and Calculations      56  

2.06

  [Reserved]      58  

2.07

  Designated Account      58  

2.08

  Maintenance of Loan Account; Statements of Obligations      59  

2.09

  Fees, Changes, Damages and Revolver Exit Payment      59  

2.10

  [Reserved]      62  

2.11

  Capital Requirements      62  

2.12

  Collections; Crediting Payments      63  

2.13

  Appointment of Borrower Representative      64  

2.14

  Joint and Several Liability of Borrowers      65  

ARTICLE III. CONDITIONS; TERM OF AGREEMENT

     68  

3.01

  Conditions Precedent to the Initial Extension of Credit      68  

3.02

  Conditions Precedent to all Extensions of Credit      70  

3.03

  Effect of Maturity      71  

3.04

  Conditions Subsequent      71  

ARTICLE IV. REPRESENTATIONS AND WARRANTIES

     71  

4.01

  Due Organization and Qualification; No Event of Default; Solvency      72  

4.02

  Existence; Power and Authority      72  

4.03

  Litigation      72  

4.04

  Due Authorization; No Conflict      73  

4.05

  Permits and Authorizations      74  

4.06

  Title to Assets; No Encumbrances      74  

4.07

  Intellectual Property      74  

4.08

  No Default      75  

4.09

  Taxes      75  

4.10

  Compliance with Laws      75  

4.11

  SEC Filings      76  

4.12

  Financial Statements      76  

 

-i-


TABLE OF CONTENTS

(continued)

 

         Page  

4.13

  Internal Controls      77  

4.14

  ERISA      77  

4.15

  Subsidiaries      78  

4.16

  No Dividends      78  

4.17

  Stock      78  

4.18

  Material Contracts      79  

4.19

  Use of Proceeds      79  

4.20

  Environmental Condition      79  

4.21

  Governmental Regulation      80  

4.22

  Employee and Labor Matters      80  

4.23

  Name and Address; Properties      81  

4.24

  Sanctions      81  

4.25

  Anti-Money Laundering      81  

4.26

  Anti-Corruption      81  

4.27

  Anti-Terrorism      81  

4.28

  Sarbanes-Oxley      82  

4.29

  Accounting Practices      82  

4.30

  Common Stock      82  

4.31

  DTC      82  

4.32

  Fees      82  

4.33

  Products; Regulatory Required Permits      83  

4.34

  No Violation of Healthcare Laws      83  

4.35

  No Third Party Payor Program      84  

4.36

  Conduct of Business at Facilities      84  

4.37

  No Adulteration; Product Manufacturing      84  

4.38

  FDA      84  

4.39

  Margin Stock      85  

4.40

  Complete Disclosure      85  

4.41

  Investments      85  

4.42

  Schedules      85  

4.43

  Eligible Accounts      86  

4.44

  Eligible Inventory      86  

4.45

  Location of Inventory      86  

4.46

  Inventory and Equipment Records      86  

4.47

  No Violation of Usury Laws      86  

4.48

  Eligible Equipment      86  

ARTICLE V. AFFIRMATIVE COVENANTS

     87  

5.01

  Existence; Permits      87  

5.02

  Compliance with Laws      87  

5.03

  Insurance      87  

5.04

  Taxes      88  

5.05

  Reports, Notices      88  

5.06

  Inspection      90  

5.07

  Disclosure Updates      90  

 

-ii-


TABLE OF CONTENTS

(continued)

 

         Page  

5.08

  Cash Management      91  

5.09

  Further Assurances      91  

5.10

  Environmental      92  

5.11

  ERISA      92  

5.12

  FDA; Healthcare Laws      93  

5.13

  Regulatory Required Permits      93  

5.14

  Material Contracts      93  

5.15

  Notices Regarding Indebtedness      93  

5.16

  Reporting      93  

5.17

  Lender Meetings      95  

5.18

  Location of Collateral      95  

5.19

  Updated Borrowing Base Certificate      95  

5.20

  Announcing Form 8-K      95  

5.21

  Eligible Equipment      97  

5.22

  Maximum Revolver Related Notices      97  

ARTICLE VI. NEGATIVE COVENANTS

     98  

6.01

  Restrictions on Fundamental Changes      98  

6.02

  Joint Ventures; Restricted Payments      98  

6.03

  Liens      99  

6.04

  Disposal of Assets      99  

6.05

  Indebtedness      99  

6.06

  Investments      99  

6.07

  Transactions with Affiliates      99  

6.08

  ERISA      100  

6.09

  Nature of Business      100  

6.10

  Amendments to Organizational Documents and Material Contracts      100  

6.11

  Changes to Fiscal Year; GAAP      101  

6.12

  Prepayments and Amendments      101  

6.13

  Restrictions on Distributions      101  

6.14

  Sanctions; Anti-Corruption      101  

6.15

  Sale Leaseback Transactions      102  

6.16

  Environmental      102  

6.17

  Investment Company      102  

6.18

  Intercreditor Agreement; Term Debt      102  

6.19

  Payment of Convertible Notes      102  

6.20

  Commingling of Assets      103  

6.21

  Limitation on Issuance of Stock      103  

6.22

  Use of Proceeds      103  

6.23

  Anti-Layering      103  

6.24

  Convertible Notes Restrictions      103  

ARTICLE VII. FINANCIAL COVENANTS

     104  

7.01

  Financial Covenants      104  

 

-iii-


TABLE OF CONTENTS

(continued)

 

         Page  

ARTICLE VIII. EVENTS OF DEFAULT

     105  

8.01

  Payments      105  

8.02

  Covenants      106  

8.03

  Representations, etc.      106  

8.04

  Insolvency; Bankruptcy      106  

8.05

  Judgments      107  

8.06

  No Governmental Authorization      107  

8.07

  Agreement Invalid Under Applicable Law      107  

8.08

  Cross-Default      107  

8.09

  Loan Documents; Security Interests      107  

8.10

  ERISA      108  

8.11

  Product Withdrawal      108  

8.12

  Change in Law      108  

8.13

  Material Contract Default      108  

8.14

  Other Default or Breach      108  

8.15

  Criminal Proceedings      109  

8.16

  Payment of Subordinated Debt      109  

8.17

  Any Intercreditor Agreement Provisions Invalid      109  

8.18

  Guaranty      109  

8.19

  Subordination Provisions      109  

8.20

  Change in Control      109  

8.21

  Not Publicly Traded      109  

8.22

  Term Debt Defaults      109  

ARTICLE IX. RIGHTS AND REMEDIES

     110  

9.01

  Rights and Remedies      110  

9.02

  Remedies Cumulative      110  

ARTICLE X. WAIVERS; INDEMNIFICATION

     111  

10.01

  Demand; Protest; etc.      111  

10.02

  The Lender Group’s Liability for Collateral      111  

10.03

  Indemnification      111  

ARTICLE XI. NOTICES

     112  

ARTICLE XII. CHOICE OF LAW AND VENUE; JURY TRIAL WAIVER; JUDICIAL REFERENCE PROVISION

     113  

ARTICLE XIII. ASSIGNMENTS AND PARTICIPATIONS; SUCCESSORS

     115  

13.01

  Assignments and Participations      115  

13.02

  Successors      118  

 

-iv-


TABLE OF CONTENTS

(continued)

 

         Page  

ARTICLE XIV. AMENDMENTS; WAIVERS

     119  

14.01

  Amendments and Waivers      119  

14.02

  [Reserved]      120  

14.03

  No Waivers; Cumulative Remedies      120  

ARTICLE XV. AGENT; THE LENDER GROUP

     120  

15.01

  Appointment and Authorization of Agent      120  

15.02

  Delegation of Duties      121  

15.03

  Liability of Agent      121  

15.04

  Reliance by Agent      122  

15.05

  Notice of Default or Event of Default      122  

15.06

  Credit Decision      122  

15.07

  Costs and Expenses; Indemnification      123  

15.08

  Agent in Individual Capacity      123  

15.09

  Assignment by Agent; Resignation of Agent; Successor Agent      123  

15.10

  Lender in Individual Capacity      124  

15.11

  Collateral Matters      124  

15.12

  Restrictions on Actions by Lenders; Sharing of Payments      126  

15.13

  Agency for Perfection      126  

15.14

  Payments by Agent to the Lenders      127  

15.15

  Concerning the Collateral and Related Loan Documents      127  

15.16

  Several Obligations; No Liability      127  

15.17

  Right to Request and Act on Instructions      127  

ARTICLE XVI. WITHHOLDING TAXES

     128  

16.01

  Payments      128  

16.02

  Exemptions      128  

16.03

  Refunds      130  

ARTICLE XVII. GENERAL PROVISIONS

     130  

17.01

  Effectiveness      130  

17.02

  Article and Section Headings      130  

17.03

  Interpretation      130  

17.04

  Severability of Provisions      131  

17.05

  Debtor-Creditor Relationship      131  

17.06

  Counterparts; Electronic Execution      131  

17.07

  Revival and Reinstatement of Obligations; Certain Waivers      131  

17.08

  Confidentiality      131  

17.09

  Survival      132  

17.10

  Patriot Act      133  

17.11

  Integration      133  

17.12

  No Setoff      133  

 

-v-


TABLE OF CONTENTS

(continued)

 

         Page  

17.13

 

Intercreditor Agreement

     133  

 

-vi-


EXHIBITS AND SCHEDULES

 

Exhibit A-1

   Form of Assignment and Acceptance

Exhibit B-1

   Form of Borrowing Base Certificate (Agent)

Exhibit B-2

   Form of Borrowing Base Certificate (Third Party Agent)

Exhibit C-1

   Form of Compliance Certificate

Exhibit P-1

   Form of Perfection Certificate

Schedule A-1

   Agent’s Account

Schedule A-2

   Authorized Person

Schedule C-1

   Commitments

Schedule D-1

   Designated Account

Schedule E-1

   Approved Account Debtor

Schedule P-1

   Existing Investments

Schedule 4.01(d)

   Existing Liens

Schedule 4.01(f)

   Existing Indebtedness

Schedule 4.03

   Litigation

Schedule 4.06

   Real Estate

Schedule 4.07

   Intellectual Property

Schedule 4.15

   Borrower’s Subsidiaries

Schedule 4.17

   Borrower’s Outstanding Shares of Stock, Options and Warrants

Schedule 4.18

   Material Contracts

Schedule 4.20

   Environmental

Schedule 4.22

   Labor Relations

Schedule 4.23

   Jurisdiction of Organization, Legal Name, Organizational Identification Number and Chief Executive Office

Schedule 4.33(a)

   FDA/Governmental Notices

Schedule 4.41

   Stock of the Subsidiaries of the Loan Parties

Schedule 4.45

   Inventory Location

Schedule 5.20

   Other Loan Documents to be Form 8-K Exhibits

Schedule 6.05

   Contingent Obligations

Schedule 6.07

   Transactions with Affiliates

 

-vii-


CREDIT AGREEMENT

THIS CREDIT AGREEMENT (this “ Agreement ”), is entered into as of August 9, 2018, by and among the lenders identified on the signature pages hereof (each of such lenders, together with its successors and permitted assigns, is referred to hereinafter as a “Lender”, as that term is hereinafter further defined), DEERFIELD ELGX REVOLVER, LLC , a Delaware limited liability company, as Agent for each member of the Lender Group, Endologix, Inc. , a Delaware corporation (“ Endologix ”), each of its direct and indirect Subsidiaries set forth on the signature pages hereto and any additional borrower that may hereafter be added to this Agreement (individually as a “ Borrower ”, and collectively with any entities that become party hereto as Borrower and each of their successors and permitted assigns, the “ Borrowers ”).

RECITALS

Borrowers have requested that Lenders make available to Borrowers the financing facility described herein. Lenders are willing to extend such credit to Borrowers under the terms and conditions set forth.

AGREEMENT

NOW, THEREFORE , in consideration of the mutual covenants and agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:

ARTICLE I.

DEFINITIONS AND CONSTRUCTION.

1.01 Definitions . As used in this Agreement, the following terms shall have the meanings set forth below:

2.25% Convertible Note Documents ” means the 2.25% Convertible Notes, the 2.25% Senior Note Indenture and each other document or agreement from time to time entered into in connection with the foregoing.

2.25% Convertible Notes ” means those certain 2.25% senior unsecured notes, governed by the terms of a base indenture, as supplemented by the first supplemental indenture relating to the 2.25% senior notes (together, the “ 2.25% Senior Notes Indenture ”), between Endologix and Wells Fargo Bank, National Association, as trustee, each of which were entered into on December 10, 2013.

2.25% Senior Notes Indenture ” has the meaning provided therefor in the definition of “2.25% Convertible Notes.”

3.25% Convertible Notes ” means those certain 3.25% senior unsecured notes, governed by the terms of a base indenture, as supplemented by the second supplemental indenture relating to the 3.25% senior notes (together, the “ 3.25% Senior Notes Indenture ”), between Endologix and Wells Fargo Bank, National Association, as trustee, each of which were entered into on November 2, 2015, as the same may be amended, restated, refinanced, supplemented or otherwise modified in connection with a Permitted 3.25% Convertible Note Refinancing.

3.25% Convertible Note Documents ” means the 3.25% Convertible Notes, the 3.25% Senior Note Indenture and each other document or agreement from time to entered into in connection with the


foregoing, as the same may be amended, restated, refinanced, supplemented or otherwise modified in on with a Permitted 3.25% Convertible Note Refinancing.

3.25% Senior Notes Indenture ” has the meaning provided therefor in the definition of “3.25% Convertible Notes.”

10-K ” means an annual report on Form 10-K (or successor form thereto), as required to be filed pursuant to the Exchange Act.

10-Q ” means a quarterly report on Form 10-Q (or successor form thereto), as required to be filed pursuant to the Exchange Act.

Account ” means an account (as that term is defined in the Code).

Account Debtor ” means any Person who is obligated on an Account, chattel paper, or a general intangible.

Acquisition ” means any transaction or series of related transactions for the purpose of or resulting, directly or indirectly, in (a) the acquisition of all or substantially all of the assets of a Person, or of any business or division of a Person, (b) the acquisition of in excess of fifty percent (50%) of the Stock of any Person or otherwise causing any Person to become a Subsidiary of the Borrower, (c) a merger or consolidation or any other combination with another Person or (d) the acquisition (including through licensing) of any Product or Intellectual Property of or from another Person if the Acquisition Consideration paid in connection with such acquisition is in excess of $5,000,000 individually or in the aggregate with respect to all such acquisitions in any twelve (12) month period.

Acquisition Consideration ” has the meaning specified therefor in the definition of “Permitted Acquisitions.”

Administrative Questionnaire ” has the meaning specified therefor in Section  13.01(a) .

Affected Lender ” has the meaning specified therefor in Section  2.11(b) .

Affiliate ” means, with respect to any Person, (a) any Person that directly or indirectly controls such Person, (b) any Person which is controlled by or is under common control with such controlling Person, and (c) each of such Person’s (other than, with respect to any Lender, any Lender’s) officers or directors (or Persons functioning in substantially similar roles) and the spouses, parents, descendants and siblings of such officers, directors or other Persons. As used in this definition, the term “control” of a Person means the possession, directly or indirectly, of the power to vote five percent (5%) or more of any class of voting securities of such Person or to direct or cause the direction of the management or policies of a Person, whether through the ownership of voting securities, by contract or otherwise.

Agent ” means Deerfield Revolver, in its capacity as administrative agent for itself and for the other members of the Lender Group hereunder, as such capacity is established in, and subject to the provisions of, Article XV , and the successors and assigns of Deerfield Revolver in such capacity, and including, when the context may require, during any Third Party Agent Retention Period, any Third Party Agent.

Agent-Related Persons ” means Agent (including, for the avoidance of doubt, any Third Party Agent), together with its Affiliates, controlling persons and their respective directors, officers, employees,

 

2


partners, advisors, agents and other representatives of each of the foregoing and their respective successors.

Agent’s Account ” means the Deposit Account of Agent (or, during a Third Party Agent Retention Period, any Third Party Agent) identified on Schedule A-1 (or such other Deposit Account of Agent (or, during a Third Party Agent Retention Period, such Third Party Agent) that has been designated as such, in writing, by Agent (or, during a Third Party Agent Retention Period, such Third Party Agent) to Borrowers and the Lenders).

Agent’s Liens ” means the Liens granted by Borrowers or their Subsidiaries to Agent (or any Third Party Agent) under the Loan Documents and securing the Obligations.

Agreement ” means this Credit Agreement.

All-in Yield ” means the interest rate (including margins and floors), original issue discount and fees paid to all lenders (or consenting lenders) of such debt or their Affiliates (based on the remaining life to maturity), but not including any fees not paid to all lenders (such as fees to initial purchasers (i.e., investment banks in Rule 144A offerings), underwriters or lead agents).

Announcing Form 8-K ” has the meaning specified therefor in Section  5.20 .

Anti-Corruption Laws ” means any and all laws, rules, and regulations of any jurisdiction applicable to any Loan Party or any Subsidiary of any Loan Party from time to time concerning or relating to bribery or corruption, including, without limitation, the FCPA, as amended, the UK Bribery Act 2010 and other similar legislation in any other jurisdictions.

Anti-Money Laundering Laws ” means any and all laws, rules, and regulations in effect from time to time related to terrorism or money laundering, including, without limitation, (i) all applicable requirements of the Currency and Foreign Transactions Reporting Act of 1970 (31 U.S.C. 5311 et. seq., (the Bank Secrecy Act)), as amended by Title III of the USA Patriot Act, (ii) the Trading with the Enemy Act, (iii) Executive Order No. 13224 on Terrorist Financing, effective September 24, 2001 (66 Fed. Reg. 49079), and any other enabling legislation, executive order or regulations issued pursuant or relating thereto and (iv) other applicable federal or state laws relating to “know your customer” or anti-money laundering rules and regulations.

Anti-Terrorism Laws ” means any and all laws, regulations, rules, orders, etc. in effect from time to time relating to anti-money laundering and terrorism, including, without limitation, Executive Order No. 13224 (effective September 24, 2001), Trading with the Enemy Act, as amended, and each of the foreign assets control regulations of the United States Treasury Department (31 CFR, Subtitle B, Chapter V, as amended), and the USA Patriot Act (Pub. L. No. 107-56 (Oct. 12, 2001)).

Applicable Laws ” means, with respect to any Person, the common law and any federal, state, local, foreign, multinational or international laws, statutes, codes, treaties, standards, rules and regulations, guidelines, ordinances, orders, judgments, writs, injunctions, decrees (including administrative or judicial precedents or authorities) and the interpretation or administration thereof by, and other determinations, directives, requirements or requests of, any Governmental Authority, in each case whether or not having the force of law and that are applicable to or binding upon such Person or any of its property or to which such Person or any of its property is subject. “Applicable Laws” includes Healthcare Laws and Environmental Laws.

Applicable Revolver Reduction Premium ” has the meaning specified in Section  2.09(d)(iii) .

 

3


Application Event ” means the occurrence of (a) a failure by Borrowers to repay all of the Obligations in full in cash on the Maturity Date, or (b) an Event of Default and the election by Agent or the Required Lenders to require that payments and proceeds of Collateral be applied pursuant to Section  2.03(b)(ii) .

Approved Fund ” means any (a) investment company, fund, trust, securitization vehicle or conduit that is (or will be) engaged in making, purchasing, holding or otherwise investing in commercial loans and similar extensions of credit, or (b) any Person (other than a natural person) which temporarily warehouses loans for any Lender or any entity described in the preceding clause (a) and that, with respect to each of the preceding clauses (a) and (b), is administered or managed by (i) a Lender, (ii) an Affiliate of a Lender, or (iii) a Person (other than a natural person) or an Affiliate of a Person (other than a natural person) that administers or manages a Lender.

Assignee ” has the meaning specified therefor in Section  13.01(a) .

Assignment and Acceptance ” means an Assignment and Acceptance Agreement substantially in the form of Exhibit A-1 or any other form agreed by the Agent.

Authorizations ” means, with respect to any Person, any permits (including Regulatory Required Permits), approvals, authorizations, licenses, registrations, certificates, clearances, concessions, grants, franchises, variances or permissions from, and any other contractual obligations with, any Governmental Authority, in each case whether or not having the force of law and applicable to or binding upon such Person or any of its property or to which such Person or any of its property is subject, and any supplements or amendments with respect to the foregoing.

Authorized Person ” means any one of the individuals identified on Schedule A-2 , as such schedule is updated from time to time by written notice from Borrowers to Agent (and, during any Third Party Agent Retention Period, also to the Third Party Agent).

Authorized Officer ” means the chief executive officer, the president or the chief financial officer of the Borrower Representative or any other officer of the Borrower Representative having substantially the same authority and responsibility.

Availability ” means, as of any date of determination, the amount that Borrowers are entitled to borrow as Revolving Loans under Section  2.01 (after giving effect to the then outstanding Revolver Usage).

Average Availability ” means, with respect to any period, the sum of the aggregate amount of Availability for each Business Day in such period (calculated as of the end of each respective Business Day) divided by the number of Business Days in such period.

Average Revolver Usage ” means, with respect to any period, the sum of the aggregate amount of Revolver Usage for each Business Day in such period (calculated as of the end of each respective Business Day) divided by the number of Business Days in such period.

Bank of America Cash Collateral Account ” means that certain deposit account #1453234066 of Borrower at Bank of America, N.A. (or such replacement deposit account provided by Bank of America, N.A. or by another commercial bank) established and maintained for the sole purpose of providing cash collateral in favor of Bank of America, N.A. (or such replacement commercial bank) for obligations of the Borrower in respect of certain commercial credit cards (or with respect to a replacement commercial bank, similar commercial credit cards to those provided by Bank of America, N.A. as of the Closing

 

4


Date) provided to the Borrower by Bank of America, N.A. (or such replacement commercial bank); provided that the aggregate amount on deposit in such deposit account (or such replacement deposit account) shall not at any time exceed $2,500,000.

Bankruptcy Code ” means title 11 of the United States Code, as in effect from time to time.

Blocked Account ” has the meaning specified therefor in Section  2.12(a) .

Board of Governors ” means the Board of Governors of the Federal Reserve System of the United States (or any successor).

Borrowers ” has the meaning specified therefor in the preamble.

Borrower Representative ” means Endologix, in its capacity as Borrower Representative pursuant to the provisions of Section  2.13 , or any successor Borrower Representative selected by Borrowers and approved by Agent.

Borrowing ” means a borrowing consisting of Loans made on the same day by the Lenders (or Agent on behalf thereof), or by Agent in the case of an Extraordinary Advance.

Borrowing Base means, as of any date of determination, an amount equal to:

(a) the lesser of:

(i) the Maximum Revolver Amount, and

(ii) an amount equal to:

(A) an amount not to exceed 85% of the aggregate amount of Eligible Accounts; less

(B) the amount, if any, of the Dilution Reserve; plus

(C) the least of (1) the product of 50% multiplied by the value (calculated at the lower of cost or market based on the Borrowers’ historical accounting practices) of Eligible Inventory at such time, (2) the product of 85% multiplied by the Net Orderly Liquidation Value of Eligible Inventory (such determination may be made as to different categories of Eligible Inventory based upon the Net Orderly Liquidation Value applicable to such categories) at such time, (3) the Inventory Cap and (4) an amount equal to 40% of the Borrowing Base; plus

(D) an amount not to exceed 50% of the Net Book Value of Eligible Equipment;

less

(b) the aggregate amount of all Reserves in effect at such time;

provided , that, the Borrowing Base will be automatically adjusted down, if necessary, such that (1) availability from Eligible Foreign Accounts shall never exceed the lesser of (x) $5,000,000 and (y) 20% of the Borrowing Base and (2) availability from Eligible Equipment shall never exceed $2,000,000; and

 

5


provided , further , that, as of any date of determination prior to the Trigger Date, the Borrowing Base shall never exceed an amount equal to (i) 75% of the Borrowing Base plus (ii) Qualified Cash as of such date.

Borrowing Base Certificate ” means each of the Borrowing Base Certificate (Agent) and Borrowing Base Certificate (Third Party Agent), as the context may require.

Borrowing Base Certificate (Agent) ” means a certificate in the form of Exhibit B-1 , which Borrowing Base Certificate (Agent) shall be delivered to Agent in accordance with the terms of this Agreement.

Borrowing Base Certificate (Third Party Agent) ” means a certificate in the form of Exhibit B-2 , which Borrowing Base Certificate (Third Party Agent) shall be delivered to a Third Party Agent during a Third Party Agent Retention Period in accordance with the terms of this Agreement.

Business Day ” means any day excluding Saturday, Sunday, and any day which is a legal holiday under the laws of the State of New York or which is a day on which Agent (or, during any Third Party Agent Retention Period, the Third Party Agent) is otherwise closed for transacting business with the public, except that, if a determination of a Business Day shall relate to amounts accruing interest at the LIBOR Rate, the term “Business Day” also shall exclude any day on which banks are closed for dealings in Dollar deposits in the London interbank market.

Capital Expenditures ” means, with respect to any Person for any period, the amount of all expenditures by such Person and its Subsidiaries during such period that are capital expenditures as determined in accordance with GAAP, whether such expenditures are paid in cash or financed, but excluding, without duplication (a) expenditures made during such period in connection with the replacement, substitution, or restoration of assets or properties, (b) with respect to the purchase price of assets that are purchased substantially contemporaneously with the trade-in of existing assets during such period, the amount that the gross amount of such purchase price is reduced by the credit granted by the seller of such assets for the assets being traded in at such time, (c) expenditures made during such period to consummate one or more Permitted Acquisitions, (d) expenditures made during such period to the extent made with the identifiable proceeds of an equity investment in Borrowers which equity investment is made substantially contemporaneously with the making of the expenditure, and (e) expenditures during such period that, pursuant to a written agreement, are reimbursed by a third Person (excluding the Loan Parties and their Affiliates).

Capital Lease ” means, with respect to any Person, any lease of or other arrangement conveying the right to use, any property by such Person as lessee that has been or should be accounted for as a capital lease on a balance sheet of such Person prepared in accordance with GAAP.

Capital Lease Obligations ” means, at any time, with respect to any Capital Lease, any lease entered into as part of any sale leaseback transaction of any Person or any synthetic lease, the amount of all obligations of such Person that is (or that would be, if such synthetic lease or other lease were accounted for as a Capital Lease) capitalized on a balance sheet of such Person prepared in accordance with GAAP.

Capped Call ” means the capped call transactions referenced in Schedule 6.05 in respect of the 2.25% Convertible Notes and any like transactions that are economically similar to such transactions entered into in connection with any Indebtedness contemplated under clause (j) of the definition of Permitted Indebtedness.

 

6


Cash Equivalents ” means (a) any readily-marketable securities (i) issued by, or directly, unconditionally and fully guaranteed or insured by the United States federal government or (ii) issued by any agency of the United States federal government the obligations of which are fully backed by the full faith and credit of the United States federal government, (b) any readily-marketable direct obligations issued by any other agency of the United States federal government, any state of the United States or any political subdivision of any such state or any public instrumentality thereof, in each case having a rating of at least “A-1” from S&P or at least “P-1” from Moody’s, (c) any commercial paper rated at least “A-1” by S&P or “P-1” by Moody’s and issued by any Person organized under the laws of any state of the United States, (d) any United States dollar-denominated time deposit, insured certificate of deposit, overnight bank deposit or bankers’ acceptance issued or accepted by any commercial bank that is (A) organized under the laws of the United States, any state thereof or the District of Columbia, (B) “adequately capitalized” (as defined in the regulations of its primary federal banking regulators) and (C) has Tier 1 capital (as defined in such regulations) in excess of $250,000,000, (e) shares of any United States money market fund that (i) has substantially all of its assets invested continuously in the types of investments referred to in clause (a), (b), (c) or (d) above with maturities as set forth in the proviso below, (ii) has net assets in excess of $500,000,000 and (iii) has obtained from either S&P or Moody’s the highest rating obtainable for money market funds in the United States; provided , however , that the maturities of all obligations specified in any of clauses (a), (b), (c) or (d) above shall not exceed one year and (f) investments made in accordance with Endologix’ investment policy in effect as of the Closing Date that was provided to the Agent’s counsel on March 14, 2017 at 12:15 p.m. New York time, and any amendments thereto that do not, when taken as a whole, materially increase the risk of the investments made by Endologix from time to time from Endologix’ investment policy in effect as of the Closing Date.

Cash Management Services ” means any cash management or related services including treasury, depository, return items, overdraft, controlled disbursement, merchant store value cards, e-payables services, electronic funds transfer, interstate depository network, automatic clearing house transfer (including the Automated Clearing House processing of electronic funds transfers through the direct Federal Reserve Fedline system) and other customary cash management arrangements.

Change in Law ” means the occurrence after the Closing Date of: (a) the adoption or effectiveness of any law, rule, regulation, judicial ruling, judgment or treaty, (b) any change in any law, rule, regulation, judicial ruling, judgment or treaty or in the administration, interpretation, implementation or application by any Governmental Authority of any law, rule, regulation, guideline or treaty, or (c) the making or issuance by any Governmental Authority of any request, rule, guideline or directive, whether or not having the force of law; provided that notwithstanding anything in the Agreement to the contrary, (i) the Dodd-Frank Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines or directives thereunder or issued in connection therewith and (ii) all requests, rules, guidelines or directives concerning capital adequacy promulgated by the Bank for International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or the United States or foreign regulatory authorities shall, in each case, be deemed to be a “Change in Law,” regardless of the date enacted, adopted or issued.

Change in Control ” or “ Change of Control ” means any of the following events: (a) any Person or two or more Persons acting in concert shall have acquired beneficial ownership, directly or indirectly, of, or shall have acquired by contract or otherwise, or shall have entered into a contract or arrangement that, upon consummation, will result in its or their acquisition of or control over, voting Stock of Endologix (or other securities convertible into such voting Stock) representing more than 50% of the combined voting power of all voting Stock of Endologix; (b) Endologix shall have ceased to own, directly or indirectly, 100% of the Stock of any of its Subsidiaries (with the exception of any Subsidiaries permitted to be dissolved or merged to the extent otherwise permitted by this Agreement and other than,

 

7


solely with respect to Foreign Subsidiaries, directors qualifying shares as necessary to comply with foreign law); (c) the occurrence of a “Change of Control”, “Change in Control”, “Fundamental Change” or terms of similar import under the 2.25% Convertible Note Documents, the 3.25% Convertible Note Documents, the Term Debt Documents or any Permitted Japan Lifeline Unsecured Debt Documents; or (d) the occurrence of any “Major Transaction” (as defined in any Warrant). As used herein, “beneficial ownership” shall have the meaning provided in Rule 13d-3 of the SEC under the Exchange Act; provided that no Change in Control shall be deemed to have occurred with respect to a “Permitted Successor Transaction” (as defined in the Term Loan Credit Agreement as in effect on the Closing Date) which prohibits the Term Lenders from delivering a “Put Notice” (as defined in the Term Loan Credit Agreement as in effect on the Closing Date) under the Term Loan Credit Agreement as in effect on the Closing Date.

Closing Date ” means the date of this Agreement.

CMS ” means the federal Centers for Medicare and Medicaid Services (formerly the federal Health Care Financing Administration), and any successor Governmental Authority.

Code ” means the New York Uniform Commercial Code, as in effect from time to time.

Collateral ” means all assets and interests in assets and proceeds thereof now owned or hereafter acquired by Borrowers or any of their Subsidiaries in or upon which a Lien is granted by such Person in favor of Agent (or, during any Third Party Agent Retention Period, the Third Party Agent) or the Lenders under any of the Loan Documents, including the “Collateral” (as defined in the Guaranty and Security Agreement).

Collateral Access Agreement ” means a landlord waiver, bailee letter, or acknowledgement agreement of any lessor, warehouseman, processor, consignee, or other Person in possession of, having a Lien upon, or having rights or interests in the Loan Parties’ or their Subsidiaries’ Collateral or books and records, in each case, in form and substance reasonably satisfactory to Agent and the Lenders.

Commitment ” means, with respect to each Lender, its Revolver Commitment and, with respect to all Lenders, their Revolver Commitments, in each case as such Dollar amounts are set forth beside such Lender’s name under the applicable heading on Schedule C-1 or in the Assignment and Acceptance pursuant to which such Lender became a Lender hereunder, as such amounts may be reduced or increased from time to time pursuant to assignments made in accordance with the provisions of Section  13.01 .

Commitment Fee ” has the meaning specified therefor in Section  2.09(e) .

Common Stock ” means the “Common Stock” of Endologix, with a $0.001 par value per share.

Compliance Certificate ” means a certificate, duly executed by an Authorized Officer of the Borrower Representative, appropriately completed and substantially in the form of Exhibit C-1 hereto.

Contingent Obligation ” means, with respect to any Person, any direct or indirect liability of such Person: (a) with respect to any Indebtedness of another Person (a “ Third Party Obligation ”) if the purpose or intent of such Person incurring such liability, or the effect thereof, is to provide assurance to the obligee of such Third Party Obligation that such Third Party Obligation will be paid or discharged, or that any agreement relating thereto will be complied with, or that any holder of such Third Party Obligation will be protected, in whole or in part, against loss with respect thereto; (b) with respect to any undrawn portion of any letter of credit issued for the account of such Person or as to which such Person is otherwise liable for the reimbursement of any drawing; (c) under any Swap Contract, to the extent not yet

 

8


due and payable; (d) to make take-or-pay or similar payments if required regardless of nonperformance by any other party or parties to an agreement; or (e) for any obligations of another Person pursuant to any Guarantee or pursuant to any agreement to purchase, repurchase or otherwise acquire any obligation or any property constituting security therefor, to provide funds for the payment or discharge of such obligation or to preserve the solvency, financial condition or level of income of another Person. The amount of any Contingent Obligation shall be equal to the amount of the obligation so Guaranteed or otherwise supported or, if not a fixed and determinable amount, the maximum amount so Guaranteed or otherwise supported.

Control Agreement ” means a control agreement, in form and substance reasonably satisfactory to Agent and the Lenders, executed and delivered by Borrowers or one of their Subsidiaries, Agent, Term Agent and the applicable securities intermediary (with respect to a Securities Account) or bank (with respect to a Deposit Account).

Convertible Note Documents ” means, collectively the 2.25% Convertible Note Documents and the 3.25% Convertible Note Documents (which, for the avoidance of doubt, shall include the indenture and each other document or agreement from time to time entered into in connection with any Permitted 3.25% Convertible Note Refinancing, in each case, to the extent such indenture, documents or agreements are permitted pursuant to the terms of the definition of “Permitted 3.25% Convertible Note Refinancing”).

Copyrights ” has the meaning specified therefor in the Guaranty and Secured Agreement.

Copyright Security Agreement ” has the meaning specified therefor in the Guaranty and Security Agreement.

Correction ” means the repair, modification, adjustment, relabeling, destruction, or inspection (including patient monitoring) of a product or device without its physical removal from its point of use to some other location.

Cortland ” means Cortland Capital Market Services LLC, a Delaware limited liability company, and its Affiliates and its and their successors and assigns.

DEA ” means the Drug Enforcement Administration of the United States of America, any comparable state or local Governmental Authority, any comparable Governmental Authority in any non-United States jurisdiction, and any successor agency of any of the foregoing.

Deerfield Revolver ” means Deerfield ELGX Revolver, LLC and its successors and assigns.

Default ” means an event, condition, or default that, with the giving of notice, the passage of time, or both, would be an Event of Default.

Deposit Account ” means any deposit account (as that term is defined in the Code).

Depositary Bank ” has the meaning specified therefor in Section  2.12(a) .

Designated Account ” means the Deposit Account of Borrower Representative identified on Schedule D-1 (or such other Deposit Account of Borrower Representative located at Designated Account Bank that has been designated as such, in writing, by Borrowers to Agent (and, during any Third Party Agent Retention Period, also to the Third Party Agent)).

 

9


Designated Account Bank ” has the meaning specified therefor in Schedule D-1 (or such other bank that is located within the United States that has been designated as such, in writing, by Borrowers to Agent (and, during any Third Party Agent Retention Period, also to the Third Party Agent)).

Dilution ” means, as of any date of determination, a percentage, based upon the experience of the immediately prior three (3) months, that is the result of dividing the Dollar amount of (a) bad debt write-downs, discounts, advertising allowances, credits, or other dilutive items with respect to Borrowers’ Accounts during such period, by (b) Borrowers’ billings with respect to Accounts during such period.

Dilution Reserve ” means, as of any date of determination, an amount sufficient to reduce the advance rate against Eligible Accounts by one (1) percentage point for each percentage point by which Dilution is in excess of 5%.

Dispose ” and “ Disposition ” mean (a) the sale, lease, license, transfer, assignment, conveyance or other disposition of any assets or property (including any transfer or conveyance of any assets or property pursuant to a division or split of a limited liability company or other entity or Person into two or more limited liability companies or other entities or Persons), and (b) the sale or transfer by the Borrower or any Subsidiary of the Borrower of any Stock issued by any Subsidiary of the Borrower.

Disqualified Stock ” means any Stock which, by its terms (or by the terms of any security or other Stock into which it is convertible or for which it is exchangeable), or upon the happening of any event or condition, (a) matures or is mandatorily redeemable (other than solely for Stock that does not constitute Disqualified Stock), pursuant to a sinking fund obligation or otherwise, or is redeemable (in each case, other than solely for Stock that does not constitute Disqualified Stock) at the option of the holder thereof, in whole or in part, on or prior to the date that is one year and one day following the Maturity Date (excluding any provisions requiring redemption upon a “change in control” or similar event, provided that such “change in control” or similar event results in the occurrence of the payment in full in cash of all of the Obligations (other than unasserted contingent indemnification obligations) and the termination of all of the Commitments, (b) is convertible into or exchangeable for (i) debt securities or (ii) any Stock referred to in (a) above, in each case, at any time on or prior to the date that is one year and one day following the Maturity Date at the time such Stock was issued, or (c) is entitled to receive scheduled dividends or distributions in cash prior to the date that is one year and one day following the Maturity Date.

Dollars ” or “ $ ” means United States dollars.

Domestic Subsidiary ” means, with respect to any Person, a Subsidiary of such Person, which is organized, incorporated or otherwise formed under the laws of the United States or any state thereof or the District of Columbia.

 

10


Drug Application ” means a new drug application, an abbreviated drug application, or a product license application for any Product, as appropriate, as those terms are defined in the FDCA.

DTC ” has the meaning specified therefor in Section  4.31 .

EBITDA ” means, for any period, Borrowers and their Subsidiaries’ net income, plus (to the extent deducted from net income in the determination thereof) interest expense, taxes, depreciation and amortization for such period, all calculated on a consolidated basis in accordance with GAAP, consistently applied and determined as of and at the end of such period. For purposes of this Agreement, EBITDA for any period shall be determined by disregarding any extraordinary, unusual or non-recurring items of income during such period.

Eligible Accounts ” means Eligible Domestic Accounts and Eligible Foreign Accounts.

Eligible Domestic Accounts ” means those Accounts created by a Borrower in the ordinary course of its business, that arise out of its sale of goods or rendition of services in the United States that have been acknowledged as accepted by the applicable Account Debtor, that comply with each of the representations and warranties respecting Eligible Domestic Accounts made in the Loan Documents, and that are not excluded as ineligible by virtue of one or more of the excluding criteria set forth below; provided , that such criteria may be revised from time to time by Agent in Agent’s (including, during any Third Party Agent Retention Period, the Third Party Agent’s) Permitted Discretion to address the results of any field examination performed by (or on behalf of) Agent (or, during any Third Party Agent Retention Period, the Third Party Agent) from time to time after the Closing Date. In determining the amount to be included, Eligible Domestic Accounts shall be calculated net of customer deposits, unapplied cash, taxes, discounts, credits, allowances, and rebates. Subject to the proviso to the first sentence of this definition, Eligible Domestic Accounts shall not include the following:

(a) Accounts that the Account Debtor has failed to pay within 90 days of original invoice date, Accounts that are more than 60 days past due or have a credit balance that is more than 60 days past due, or Accounts with selling terms of more than 60 days (or, with respect to Twins & Martin, 120 days),

(b) Accounts owed by an Account Debtor (or its Affiliates) where 50% or more of all Accounts owed by that Account Debtor (or its Affiliates) are deemed ineligible under clause (a) above,

(c) Accounts with respect to which the Account Debtor is an Affiliate of a Loan Party or an employee or agent of a Loan Party or any Affiliate of a Loan Party,

(d) Accounts arising in a transaction wherein goods are placed on consignment or are sold pursuant to a guaranteed sale, a sale or return, a sale on approval, a bill and hold, or any other terms by reason of which the payment by the Account Debtor may be conditional,

(e) Accounts that are not payable in Dollars,

(f) Accounts with respect to which the Account Debtor either (i) does not maintain its chief executive office in the United States or (ii) is not organized under the laws of the United States or any state thereof,

(g) Accounts of a Loan Party with respect to which the Account Debtor is either (i) the United States or any department, agency, or instrumentality of the United States (exclusive, however, of (x) Accounts with respect to which such Loan Party has complied, to the reasonable satisfaction of Agent

 

11


(or, at the sole option of Agent during any Third Party Agent Retention Period, the Third Party Agent), with the Assignment of Claims Act, 31 USC §3727 and (y) up to $1,000,000, in the aggregate, of Accounts where the Account Debtor is satisfactory to Agent (including, during any Third Party Agent Retention Period, the Third Party Agent) in its Permitted Discretion), or (ii) any state of the United States,

(h) Accounts with respect to which the Account Debtor is a creditor of a Loan Party, has or has asserted a right of recoupment or setoff, or has disputed its obligation to pay all or any portion of the Account, but only to the extent of such claim, right of recoupment or setoff, or dispute,

(i) Accounts with respect to an Account Debtor whose total obligations owing to the Loan Parties exceed 20% of all Eligible Accounts, to the extent of the obligations owing by such Account Debtor in excess of such percentage; provided , that, in each case, the amount of Eligible Accounts that are excluded because they exceed the foregoing percentage shall be determined by Agent (or, at the sole option of Agent during any Third Party Agent Retention Period, the Third Party Agent) based on all of the otherwise Eligible Accounts prior to giving effect to any eliminations based upon the foregoing concentration limit,

(j) Accounts with respect to which the Account Debtor is subject to an Insolvency Proceeding, is not Solvent, has gone out of business, or as to which a Loan Party has received notice of an imminent Insolvency Proceeding or a material impairment of the financial condition of such Account Debtor,

(k) Accounts, the collection of which, Agent (including, during any Third Party Agent Retention Period, the Third Party Agent), in its Permitted Discretion, believes to be doubtful, including by reason of the Account Debtor’s financial condition,

(l) Accounts that are not subject to a valid and perfected first priority Agent’s Lien,

(m) Accounts with respect to which (i) the goods giving rise to such Account have not been shipped and billed to the Account Debtor, or (ii) the services giving rise to such Account have not been performed and billed to the Account Debtor,

(n) Accounts with respect to which the Account Debtor is a Sanctioned Person or Sanctioned Entity,

(o) Accounts with respect to which the Account Debtor is an individual,

(p) Accounts that represent the right to receive progress payments or other advance billings that are due prior to the completion of performance by a Loan Party of the subject contract for goods or services, or

(q) Accounts where the Account or the applicable Account Debtor fails to meet such other specifications and requirements which may be from time to time established by Agent (including, during any Third Party Agent Retention Period, the Third Party Agent) in its Permitted Discretion.

Eligible Assignee ” means (a) a Lender, (b) an Affiliate of a Lender, (c) a Related Fund, and (d) any other Person (other than a natural person) approved by Agent; provided , however , that solely with respect to clause (d) above, no such Person shall include (i) Borrowers or any of Borrowers’ Affiliates or (ii) unless an Event of Default has occurred and is continuing, (A) any direct competitor of the Loan Parties, in each case, as determined by Agent in its reasonable discretion, (B) any investor or fund that has

 

12


publicly announced in writing its intention to obtain control of Endologix publicly or otherwise to the knowledge of the assigning Lender, or (D) any Person listed in the email delivered by prior counsel to Endologix to counsel to the Agent on March 16, 2017 at 5:00 p.m. (Pacific time) and any Affiliates or Approved Funds of any such Person actually known to the assigning Lender and to the Agent to be Affiliates or Approved Funds of any such Person.

Eligible Foreign Accounts ” means those Accounts created by a Borrower in the Ordinary Course of Business, have been acknowledged as accepted by the applicable Account Debtor, that comply with each of the representations and warranties respecting Eligible Foreign Accounts made in the Loan Documents, and with respect to which the applicable Account Debtor does not have its principal place of business in the United States (but is not located in an OFAC sanctioned country), and in each case that are: (i) supported by an irrevocable letter of credit reasonably satisfactory to Agent and the Lenders (as to form, substance, and issuer or domestic confirming bank) that has been delivered to Agent and is directly drawable by Agent, (ii) covered by credit insurance in form, substance, and amount, and by an insurer, reasonably satisfactory to Agent and the Lenders or (iii) generated by an Account Debtor with its principal place of business in a jurisdiction approved by Agent (including, during any Third Party Agent Retention Period, the Third Party Agent) on a case-by-case basis in its Permitted Discretion; provided , that it is understood that the Account Debtors set forth on Schedule E-1 are in approved jurisdictions as of the date hereof. In addition, Eligible Foreign Accounts shall only include Accounts that are not excluded as ineligible by virtue of one or more of the excluding criteria set forth below; provided , that such criteria may be revised from time to time by Agent in Agent’s (including, during any Third Party Agent Retention Period, the Third Party Agent’s) Permitted Discretion to address the results of any field examination performed by (or on behalf of) Agent (or, during any Third Party Agent Retention Period, the Third Party Agent) from time to time after the Closing Date. In determining the amount to be included, Eligible Foreign Accounts shall be calculated net of customer deposits, unapplied cash, taxes, discounts, credits, allowances, and rebates. Subject to the proviso to the second sentence of this definition, Eligible Foreign Accounts shall not include the following:

(a) Accounts that the Account Debtor has failed to pay within 90 days of original invoice date, Accounts that are more than 60 days past due or have a credit balance that is more than 60 days past due, or Accounts with selling terms of more than 60 days,

(b) Accounts owed by an Account Debtor (or its Affiliates) where 50% or more of all Accounts owed by that Account Debtor (or its Affiliates) are deemed ineligible under clause (a) above,

(c) Accounts with respect to which the Account Debtor is an Affiliate of a Loan Party or an employee or agent of a Loan Party or any Affiliate of a Loan Party,

(d) Accounts arising in a transaction wherein goods are placed on consignment or are sold pursuant to a guaranteed sale, a sale or return, a sale on approval, a bill and hold, or any other terms by reason of which the payment by the Account Debtor may be conditional,

(e) Accounts that are not payable in US Dollars,

(f) Accounts with respect to which the Account Debtor is the government of any foreign country or sovereign state, or of any state, province, municipality, or other political subdivision thereof, or of any department, agency, public corporation, or other instrumentality thereof,

(g) Accounts of a Loan Party with respect to which the Account Debtor is either (i) the United States or any department, agency, or instrumentality of the United States (exclusive, however, of

 

13


Accounts with respect to which such Loan Party has complied, to the reasonable satisfaction of Agent (or, at the sole option of Agent during any Third Party Agent Retention Period, the Third Party Agent), with the Assignment of Claims Act, 31 USC §3727), or (ii) any state of the United States,

(h) Accounts with respect to which the Account Debtor is a creditor of a Loan Party, has or has asserted a right of recoupment or setoff, or has disputed its obligation to pay all or any portion of the Account, but only to the extent of such claim, right of recoupment or setoff, or dispute,

(i) Accounts with respect to an Account Debtor whose total obligations owing to the Loan Parties exceed 20% of all Eligible Accounts, to the extent of the obligations owing by such Account Debtor in excess of such percentage; provided , that, in each case, the amount of Eligible Accounts that are excluded because they exceed the foregoing percentage shall be determined by Agent (or, at the sole option of Agent during any Third Party Agent Retention Period, the Third Party Agent) based on all of the otherwise Eligible Accounts prior to giving effect to any eliminations based upon the foregoing concentration limit,

(j) Accounts with respect to which the Account Debtor is subject to an Insolvency Proceeding, is not Solvent, has gone out of business, or as to which a Loan Party has received notice of an imminent Insolvency Proceeding or a material impairment of the financial condition of such Account Debtor,

(k) Accounts, the collection of which, Agent (including, during any Third Party Agent Retention Period, the Third Party Agent), in its Permitted Discretion, believes to be doubtful, including by reason of the Account Debtor’s financial condition,

(l) Accounts that are not subject to a valid and perfected first priority Agent’s Lien,

(m) Accounts with respect to which (i) the goods giving rise to such Account have not been shipped and billed to the Account Debtor, or (ii) the services giving rise to such Account have not been performed and billed to the Account Debtor,

(n) Accounts with respect to which the Account Debtor is a Sanctioned Person or Sanctioned Entity,

(o) Accounts with respect to which the Account Debtor is an individual,

(p) Accounts that represent the right to receive progress payments or other advance billings that are due prior to the completion of performance by a Loan Party of the subject contract for goods or services, or

(q) Accounts where the Account or the applicable Account Debtor fails to meet such other specifications and requirements which may be from time to time established by Agent (including, during any Third Party Agent Retention Period, the Third Party Agent) in its Permitted Discretion.

Eligible Equipment ” means, subject to the criteria below, all Equipment that is: (a) owned by a Borrower (and for which a Borrower has good and lawful title thereto) free and clear of all Liens other than Liens in favor of Agent securing the Obligations, (b) installed in a facility in the United States (i) owned by a Borrower or (ii) leased by a Loan Party and subject to a landlord’s agreement in favor of Agent that is in form and substance reasonably satisfactory to Agent and the Lenders, (c) in good working order and operating condition (ordinary wear and tear excepted), (d) not obsolete, outdated or surplus

 

14


Equipment, (e) subject to a first priority Lien in favor of Agent (for the benefit of itself and the Lenders), (f) not “fixtures” under the Applicable Laws of the jurisdiction in which such Equipment is located, (g) subject to liability and property and casualty insurance with insurers reasonable acceptable to Agent and the Lenders and in an amount reasonably acceptable to Agent and the Lenders naming Agent as an additional insured and lender’s loss payee on such insurance policies with evidence reflecting such that is reasonably satisfactory to Agent and the Lenders, and (h) not determined by Agent (or, during any Third Party Agent Retention Period, the Third Party Agent) in its Permitted Discretion to be unacceptable due to age, type, category, quality or quantity and/or for any other reason whatsoever. In addition, Agent (and, during any Third Party Agent Retention Period, the Third Party Agent) reserves the right, at any time and from time to time after the Closing Date (including on the basis of any appraisal conducted after the Closing Date), to adjust any of the applicable criteria, to establish new criteria and to adjust advance rates with respect to Eligible Equipment in its reasonable and good faith credit judgment and discretion, subject to the approval of Required Lenders in the case of adjustments or new criteria or changes in advance rates which have the effect of making more credit available.

Eligible Inventory ” means Inventory of a Loan Party, that complies with each of the representations and warranties respecting Eligible Inventory made in the Loan Documents, and that is not excluded as ineligible by virtue of one or more of the excluding criteria set forth below; provided , that such criteria may be revised from time to time by Agent in Agent’s (including, during any Third Party Agent Retention Period, the Third Party Agent’s) Permitted Discretion to address the results of any field examination or appraisal performed by (or on behalf of) Agent (or, during any Third Party Agent Retention Period, the Third Party Agent) from time to time after the Closing Date. In determining the amount to be so included, Inventory shall be valued at the lower of cost or market on a basis consistent with Borrowers’ historical accounting practices. Subject to the proviso to the first sentence of this definition, an item of Inventory shall not be included in Eligible Inventory if:

(a) such Loan Party does not have good, valid, and marketable title thereto,

(b) such Loan Party does not have actual and exclusive possession thereof (either directly or through a bailee or agent of such Loan Party),

(c) it is not located at one of the locations in the continental United States set forth on Schedule 4.45 or is Trunk Inventory,

(d) it is in-transit,

(e) it is located on Real Property leased by such Loan Party or in a contract warehouse, in each case, unless it is subject to a Collateral Access Agreement executed by the lessor or warehouseman, as the case may be, and unless it is segregated or otherwise separately identifiable from goods of others, if any, stored on the premises, or Agent (or, during any Third Party Agent Retention Period, the Third Party Agent) has established a Landlord Reserve with respect to such location,

(f) it is not held for sale in the Borrowers’ Ordinary Course of Business (unless it consists of first quality raw materials) or is not of good and merchantable quality, or it has not been approved for sale by the Borrowers, or it is quarantined from Borrowers’ general Inventory population or is rejected by Borrowers’ Material Review Board,

(g) it is not subject to a valid and perfected first priority Agent’s Lien,

 

15


(h) it consists of goods returned or rejected by such Loan Party’s customers or is subject to a Recall,

(i) it consists of goods that are obsolete or slow moving, restrictive or custom items, display or demo items, discontinued items, work-in-process, items used in research and development, or goods that constitute spare parts, packaging and shipping materials, supplies used or consumed in such Loan Party’s business, bill and hold goods, defective goods, “seconds,” or Inventory acquired on consignment, or Inventory on consignment with third parties,

(j) such Inventory is not covered by casualty insurance reasonably acceptable to Agent and the Lenders,

(k) it consists of goods that can be transported or sold only with licenses that are not readily available or of any substances defined or designated as hazardous or toxic waste, hazardous or toxic material, hazardous or toxic substance, or similar term, by any environmental law or any Governmental Authority applicable to Borrowers or their business, operations or assets,

(l) it does not meet all standards imposed by any Governmental Authority in all material respects, including with respect to its production, acquisition, sale or importation (as the case may be,

(m) it has expired or is obsolete,

(n) such Inventory is located at the Santa Rosa location and a reserve has been established on the books of the Borrowers against such Inventory in accordance with Endologix’s standards in place regarding aged Inventory,

(o) it is held for rental or lease by or on behalf of Borrowers,

(p) it is subject to third party trademark, licensing or other proprietary rights, unless Agent is satisfied that such Inventory can be freely sold by Agent on and after the occurrence of an Event of a Default despite such third party rights, or

(q) it fails to meet such other specifications and requirements which may from time to time be established by Agent (including, during any Third Party Agent Retention Period, the Third Party Agent) in its Permitted Discretion. Notwithstanding the foregoing, the valuation of Inventory shall be subject to any legal limitations on sale and transfer of such Inventory.

Employee ” means any employee of any Loan Party or any Subsidiary of any Loan Party.

Employee Benefit Plan ” means any “employee benefit plan” within the meaning of Section 3(3) of ERISA, under which (A) any current or former employee, director or independent contractor of the Borrower or any of its Subsidiaries has any present or future right to benefits or compensation and which is contributed to, sponsored by or maintained by the Borrower or any of its Subsidiaries or (B) the Borrower or any of its Subsidiaries has had or has or could reasonably be expected, individually or in the aggregate, to have any present or future obligation or liability.

Environmental Action ” means any written complaint, summons, citation, notice, directive, order, claim, litigation, investigation, judicial or administrative proceeding, judgment, letter, or other written communication from any Governmental Authority, or any third party involving violations of or liability under Environmental Laws or releases of Hazardous Materials, including, without limitation, (a) from any

 

16


assets, properties, or businesses of any Borrower, any Subsidiary of a Borrower, or any of their predecessors in interest, (b) from adjoining properties or businesses, or (c) from or onto any facilities which received Hazardous Materials generated by any Borrower, any Subsidiary of any Borrower, or any of their predecessors in interest.

Environmental Laws ” means all Applicable Laws, Authorizations and permits imposing liability or standards of conduct for or relating to the regulation and protection of human health, safety, the workplace, the environment and natural resources, and including public notification requirements and environmental transfer of ownership, notification or approval statutes.

Environmental Liabilities ” means all Liabilities (including costs of removal and remedial actions, natural resource damages and costs and expenses of investigation and feasibility studies, including the cost of environmental consultants and attorneys’ costs) that may be imposed on, incurred by or asserted against any Loan Party or any Subsidiary of any Loan Party as a result of, or related to, any claim, suit, action, investigation, proceeding or demand by any Person, whether based in contract, tort, implied or express warranty, strict liability, criminal or civil statute or common law or otherwise, arising under any Environmental Law resulting from the ownership, lease, sublease or other operation or occupation of property by any Loan Party or any Subsidiary of any Loan Party, whether on, prior or after the date hereof.

Environmental Permits ” has the meaning specified therefor in Section  4.20(a) .

Equipment ” means all “equipment,” as such term is defined in the UCC, now owned or hereafter acquired by any Loan Party, wherever located.

ERISA ” means the Employee Retirement Income Security Act of 1974, as amended and applicable published guidance thereunder.

ERISA Affiliate ” means collectively the Borrower, any Subsidiary of Borrower and any Person under common control or treated as a single employer with, Borrower or any Subsidiary of Borrower within the meaning of IRC Section 414 (b), (c), (m) or (o) or under ERISA.

ERISA Event ” means any of the following: (a) a reportable event described in Section 4043(b) or (c) of ERISA (other than an event for which the 30-day notice period is waived) with respect to a Title IV Plan; (b) the withdrawal of any ERISA Affiliate from a Title IV Plan subject to Section 4063 of ERISA during a plan year in which it was a substantial employer, as defined in Section 4001(a)(2) of ERISA; (c) the complete or partial withdrawal of any ERISA Affiliate from any Multiemployer Plan; (d) with respect to any Multiemployer Plan, the filing of a notice of insolvency or termination, or treatment of a plan amendment as termination, under Section 4041A of ERISA; (e) the filing of a notice of intent to terminate a Title IV Plan, or treatment of a plan amendment as termination, under Section 4041 of ERISA; (f) the institution of proceedings to terminate a Title IV Plan or Multiemployer Plan by the PBGC; (g) the failure to make any required contribution to any Title IV Plan or Multiemployer Plan when due; (h) the imposition of a Lien under Section 412 or 430(k) of the IRC or Section 303 or 4068 of ERISA on any property (or rights to property, whether real or personal) of any ERISA Affiliate; (i) the failure of an Employee Benefit Plan or any trust thereunder intended to qualify for tax exempt status under Section 401 or 501 of the IRC or other Applicable Law to qualify thereunder; (j) a Title IV plan is in “at risk” status within the meaning of IRC Section 430(i); (k) a Multiemployer Plan is in “endangered status” or “critical status” within the meaning of Section 432(b) of the IRC; and (l) any other event or condition that constitutes grounds under Section 4042 of ERISA for the termination of, or the appointment of a trustee to administer, any Title IV Plan or Multiemployer Plan or for the imposition of

 

17


any Liability upon any ERISA Affiliate under Title IV of ERISA other than for contributions to Title IV Plans and Multiemployer Plans in the ordinary course and PBGC premiums due but not delinquent

Event of Default ” has the meaning specified therefor in Article VIII .

Excess Availability ” means, as of any date of determination, the amount equal to Availability minus the aggregate amount, if any, of all trade payables of Borrowers and their Subsidiaries aged in excess of thirty (30) days with respect thereto and all book overdrafts of Borrowers and their Subsidiaries in excess of historical practices with respect thereto, in each case as determined by Agent (including, during any Third Party Agent Retention Period, the Third Party Agent) in its Permitted Discretion.

Exchange Act ” means the Securities Exchange Act of 1934, as amended, including the rules and regulations promulgated thereunder.

Excluded Accounts ” has the meaning specified therefor in Section  5.08 .

Excluded Domestic Holdco ” means a wholly-owned Domestic Subsidiary of a Borrower substantially all of the assets of which consist of Stock of Excluded Foreign Subsidiaries held directly or indirectly by such Subsidiary and which does not engage in any business, operations or activity other than that of a holding company, excluding for purposes of such determination, Indebtedness of such Excluded Foreign Subsidiaries.

Excluded Foreign Subsidiary ” means any Foreign Subsidiary which is a controlled foreign corporation (as defined in the IRC) that has not guaranteed or pledged any of its assets to secure, or with respect to which there shall not have been pledged two-thirds or more of the voting Stock to secure, any Indebtedness (other than the Obligations) of a Loan Party.

Excluded Property ” means, collectively:

(a) voting shares of any (A) Excluded Foreign Subsidiary of Borrower or (B) Excluded Domestic Holdco, in each case, in excess of 65% of all of the issued and outstanding voting shares of capital stock of such subsidiary;

(b) any lease, license, contract, property right or agreement as to which, if and to the extent that, and only for so long as, the grant of a security interest therein shall (1) constitute or result in a breach, termination or default under any such lease, license, contract, property right or agreement or render it unenforceable, (2) be prohibited by any applicable law or (3) require the consent of any third party (in each case of clauses (1), (2) and (3), other than to the extent that any such breach, termination, default, prohibition or requirement for consent would be rendered ineffective pursuant to Sections 9-406, 9-407, 9-408 or 9-409 of the UCC of any relevant jurisdiction or any other applicable Law), provided that such security interest shall attach immediately to each portion of such lease, license, contract, property rights or agreement that does not result in any of the consequences specified above;

(c) any “intent to use” trademark applications for which a statement of use has not been filed (but only until such statement is filed);

(d) motor vehicles and other assets, in each instance, in which perfection of a security requires notation on certificates of title with a value, individually, of less than $250,000;

(e) without in any way limiting clause (a) above, equity interests in any Person (other than wholly owned Subsidiaries) to the extent not permitted by the terms of such Person’s organizational or

 

18


joint venture documents (so long as such joint venture was not entered into (or such Subsidiary was not formed) in contravention of the terms of the Loan Documents and such prohibition did not arise in anticipation of the restrictions under the Loan Documents);

(f) any assets financed by purchase money Indebtedness or Capital Leases, to the extent such purchase money Indebtedness or Capital Lease is permitted hereunder, if the documentation governing such purchase money Indebtedness or Capital Leases securing such purchase money Indebtedness or Capital Leases prohibits the creation of a security interest or lien thereon or requires the consent of any Person as a condition to the creation of any other security interest or lien on such property or if such contract or other agreement would be breached or give any party the right to terminate it as a result of creation of such security interest or lien;

(g) those assets as to which Agent determines (in its sole discretion) that the cost of obtaining such a security interest or perfection thereof are excessive in relation to the benefit to the Lender Group of the security to be afforded thereby; and

(h) the Bank of America Cash Collateral Account;

provided , however , notwithstanding anything to the contrary herein or under the other Loan Documents, “Excluded Property” shall not include (i) any proceeds, products, substitutions, receivables or replacements of Excluded Property (unless such proceeds, products, substitutions, receivables or replacements would otherwise constitute Excluded Property), or (ii) any assets or property provided as security or collateral for the Term Debt or for which a Lien has been granted in favor of Term Agent, any Term Lender or any other Person party to the Term Debt Documents.

Excluded Subsidiary ” means (a) any Excluded Domestic Holdco and (b) any Excluded Foreign Subsidiary.

Excluded Taxes ” means (i) any Tax imposed on or measured by the net income (however denominated) of any Recipient (including any branch profits Taxes and franchise Taxes), in each case (A) imposed by the jurisdiction (or by any political subdivision or taxing authority thereof) in which such Recipient is organized or the jurisdiction (or by any political subdivision or taxing authority thereof) in which such Recipient’s principal office is located or, in the case of any Lender or Participant, the jurisdiction (or by any political subdivision or taxing authority thereof) in which such Lender’s or such Participant’s applicable lending office is located, or (B) imposed as a result of a present or former connection between such Recipient and the jurisdiction (or any political subdivision or taxing authority thereof) imposing such Tax (other than any such connection arising from such Recipient having executed, delivered, become a party to, performed its obligations under, received payment under, received or perfected a security interest under, engaged in any other transaction pursuant to, or enforced its rights or remedies hereunder or any other Loan Document, or sold or assigned an interest in any Loan or Loan Document); (ii) Taxes resulting from a Recipient’s failure to comply with the requirements of Section  16.02 , (iii) any United States federal withholding Taxes imposed on amounts payable to or for the account of a Foreign Lender based upon the applicable withholding rate pursuant to the law in effect at the time such Foreign Lender acquires its interest in the Loan or Commitment (or designates a new lending office), except to the extent such Foreign Lender (or its assignor, if any) was previously entitled to receive amounts pursuant to Section  16.01 , if any, with respect to such withholding Tax at the time such Foreign Lender changed its lending office (or became a party hereto), and (iv) any withholding Taxes imposed under FATCA on amounts payable to or for the account of such Recipient.

Extraordinary Advances ” has the meaning specified therefor in Section  2.02(c)(iii) .

 

19


FATCA ” means Sections 1471 through 1474 of the IRC, as of the Closing Date (or any amended or successor version that is substantively comparable and not materially more onerous to comply with) and (a) any current or future regulations or official interpretations thereof (b) any agreements entered into pursuant to Section 1471(b)(1) of the IRC, and (c) any intergovernmental agreement entered into by the United States (or any fiscal or regulatory legislation, rules, or practices adopted pursuant to any such intergovernmental agreement entered into in connection therewith).

FCPA ” means the U.S. Foreign Corrupt Practices Act of 1977.

FDA ” means the Food and Drug Administration of the United States of America, any comparable state or local Governmental Authority, any comparable Governmental Authority in any non- United States jurisdiction, and any successor agency of any of the foregoing.

FDCA ” means the Federal Food, Drug and Cosmetic Act, as amended, 21 U.S.C. Section 301 et seq., and all regulations promulgated thereunder.

Federal Reserve Board ” means the Board of Governors of the Federal Reserve System or any entity succeeding to any of its principal functions.

First Period ” has the meaning specified in Section  2.09(d)(ii) .

Fixed Charge Coverage Ratio ” means, as of any date of determination and with respect to Borrowers determined on a consolidated basis in accordance with GAAP, the ratio of (a) for the applicable Measurement Period ending on such date, EBITDA minus Capital Expenditures (other than Capital Expenditures financed with Indebtedness (other than Revolving Loans)) made or incurred during such Measurement Period or the proceeds of Stock, to (b) Fixed Charges for such Measurement Period.

Fixed Charges ” means, with respect to any fiscal period and with respect to Borrowers determined on a consolidated basis in accordance with GAAP, the sum, without duplication, of (a) Interest Expense accrued (other than interest paid-in-kind, amortization of financing fees, and other non-cash Interest Expense) during such period, (b) principal payments in respect of Indebtedness that are required to be paid during such period, (c) all federal, state, and local income taxes accrued during such period, and (d) all Restricted Payments paid (whether in cash or other property, other than common Stock) during such period.

Foreign Benefit Plan ” means any employee benefit plan that is subject to the laws of a jurisdiction outside the United States, including those mandated by a government other than that of the United States of America.

Foreign Lender ” means any Lender or Participant that is not a United States person within the meaning of IRC section 7701(a)(30).

Foreign Subsidiary ” means, with respect to any Person, a Subsidiary of such Person, which Subsidiary is not a Domestic Subsidiary.

Funding Date ” means the date on which a Borrowing occurs.

GAAP ” means generally accepted accounting principles as in effect from time to time in the United States, consistently applied, subject to the provisions of Section  1.02 .

 

20


Global Excess Liquidity ” means, as of any date of determination by Agent (or, during any Third Party Agent Retention Period, the Third Party Agent), the sum of (a) without duplication of clause (b) of this definition, Qualified Cash plus (b) without duplication of clause (a) of this definition, unrestricted cash and Cash Equivalents of Loan Parties that is in Excluded Accounts maintained by a branch office of the bank or securities intermediary located outside the United States in an aggregate amount not to exceed the lesser of (i) $10,000,000 and (ii) 20% of clause (a) of this definition, plus (c)(i) without duplication of any cash or Cash Equivalents from any Borrowing or Loan made hereunder or under the other Loan Documents that would count towards either of clause (a) or clause (b) of this definition and (ii) solely to the extent the applicable conditions in Article  III (and any additional conditions to Borrowing or the making of Loans hereunder or under the Loan Documents that may be added or included from time to time after the Closing Date) have been satisfied (or would be satisfied if a Borrowing or a Loan would have been made hereunder or under the other Loan Documents) as of such date of determination (after giving effect to any such Borrowing or Loan hereunder or thereunder and any Revolver Usage as of such date), the amount of Availability. 1

Good Manufacturing Practices ” means current good manufacturing practices, as set forth in 21 C.F.R. Parts 210, 211, 820 and any comparable foreign requirements.

Governmental Authority ” means any nation, sovereign, government, quasi-governmental agency, governmental department, ministry, cabinet, commission, board, bureau, agency, court, tribunal, regulatory authority, instrumentality, judicial, legislative, fiscal or administrative or public body or entity, whether domestic or foreign, federal, state, local or other political subdivision thereof, having jurisdiction over the matter or matters and Person or Persons in question or having the authority to exercise executive, legislative, taxing, judicial, regulatory or administrative functions of or pertaining to government, including any central bank, securities exchange, regulatory body, arbitrator, public sector entity, supra-national entity and any self-regulatory organization.

Guarantee ” by any Person means any obligation, contingent or otherwise, of such Person directly or indirectly guaranteeing any Indebtedness or other obligation of any other Person and, without limiting the generality of the foregoing, any obligation, direct or indirect, contingent or otherwise, of such Person (a) to purchase or pay (or advance or supply funds for the purchase or payment of) such Indebtedness or other obligation (whether arising by virtue of partnership arrangements, by agreement to keep-well, to purchase assets, goods, securities or services, to take-or-pay, or to maintain financial statement conditions or otherwise), or (b) entered into for the purpose of assuring in any other manner the obligee of such Indebtedness or other obligation of the payment thereof or to protect such obligee against loss in respect thereof (in whole or in part), provided, however, that the term Guarantee shall not include endorsements for collection or deposit in the Ordinary Course of Business. The term “Guarantee” used as a verb has a corresponding meaning.

Guarantor ” means (a) each Subsidiary of Borrowers (other than any Excluded Subsidiary), and (b) each other Person that becomes a guarantor after the Closing Date pursuant to Section  5.09 .

 

1  

DLA: as mentioned by email yesterday, if we cannot get the control agreements and landlord waivers done by this morning, then we will provide up to a 20 day post-closing period to allow the company to get them in place where availability with still count for the global liquidity test (but not under any circumstance for any borrowing purposes).

 

21


Guaranty and Security Agreement ” means the Guaranty and Security Agreement, dated as of the Closing Date, in form and substance reasonably satisfactory to Agent and the Lenders, executed and delivered by Borrowers and each of the Guarantors to Agent.

Hazardous Materials ” means any substance, material or waste that is classified, regulated or otherwise characterized under any Environmental Law as hazardous, toxic, a contaminant or a pollutant or by other words of similar meaning or regulatory effect, including petroleum or any fraction thereof, asbestos, polychlorinated biphenyls and radioactive substances.

Healthcare Laws ” means all Applicable Laws relating to the procurement, development, provision, clinical and non-clinical evaluation or investigation, product approval or clearance, manufacture, production, analysis, distribution, dispensing, importation, exportation, use, handling, quality, reimbursement, sale, labeling, advertising, promotion, or post-market requirements of any drug, medical device, clinical laboratory service, food, dietary supplement or other product (including, without limitation, any ingredient or component of, or accessory to, the foregoing products) subject to regulation under the FDCA or otherwise regulated by the FDA, or subject to regulation under the Clinical Laboratory Improvement Amendments of 1988 (42 U.S.C. §263a et seq) and its implementing regulations (42 C.F.R. Part 493) and similar state or foreign laws, controlled substances laws, pharmacy laws, consumer product safety laws, Medicare, Medicaid, and all laws, policies, procedures, requirements and regulations pursuant to which Regulatory Required Permits are issued, in each case, as the same may be amended from time to time.

Immaterial Subsidiaries ” shall mean, as of any date of determination, any Subsidiary of the Borrower that is not a Loan Party that, when measured as of the most recent fiscal quarter end or fiscal year end for which Endologix has filed its 10-K or 10-Q, when taken together with all other Immaterial Subsidiaries as of such date, (i) did not have assets with a value in excess of 5.0% of the total property and assets of the Loan Parties and their Subsidiaries on a consolidated basis set forth in the balance sheet included in such 10-K or 10-Q in accordance with GAAP and on a pro forma basis and (ii) did not have revenues representing in excess of 5.0% of total revenues of the Loan Parties and their Subsidiaries on a consolidated basis.

Indebtedness ” means the following with respect to any Person:

(a) all indebtedness for borrowed money of such Person;

(b) the deferred purchase price of assets or services (other than trade payables entered into in the Ordinary Course of Business and which are not more than 120 days past due and other than items covered by clause (xiv) of this definition) of such Person, which in accordance with GAAP should be shown to be a liability on the balance sheet;

(c) all guarantees of Indebtedness by such Person;

(d) the face amount of all letters of credit issued or acceptance facilities established for the account of such Person (or for which such Person is liable), including without duplication, all drafts drawn thereunder;

(e) all Capital Lease Obligations of such Person;

(f) all indebtedness (including indebtedness of other types covered by the other clauses of this definition) of such Person or another Person secured by any Lien on any assets or property of such Person, whether or not such indebtedness has been assumed or is recourse (with the amount thereof, in the

 

22


case of any such indebtedness that has not been assumed by such Person, being measured as the lower of (y) fair market value of such property and (z) the amount of the indebtedness secured);

(g) all indebtedness created or arising under any conditional sale or title retention agreement, or incurred as financing, in either case with respect to assets or property acquired by such Person (even if the rights and remedies of the seller or lender under such agreement in the event of default are limited to repossession or sale of such assets or property);

(h) all obligations of such Persons evidenced by notes, bonds, debentures or similar instruments, including obligations so evidenced incurred in connection with the acquisition of property, assets or businesses;

(i) all obligations of such Person, whether or not contingent, in respect of Disqualified Stock, valued at, in the case of redeemable preferred Stock, the greater of the voluntary liquidation preference and the involuntary liquidation preference of such Stock plus accrued and unpaid dividends;

(j) all direct or indirect liability, contingent or otherwise, of such Person with respect to any other Indebtedness, lease, dividend or other obligation of another Person if the primary purpose or intent of the Person incurring such liability, or the primary effect thereof, is to provide assurance to the obligee of such liability that such liability will be paid or discharged, or that any agreements relating thereto will be complied with, or that the holders of such liability will be protected (in whole or in part) against loss with respect thereto;

(k) all direct or indirect liability, contingent or otherwise, of such Person under Swap Contracts;

(l) all direct or indirect liability, contingent or otherwise, of such Person to make take-or-pay or similar payments if required regardless of nonperformance by any other party or parties to an agreement;

(m) all direct or indirect liability, contingent or otherwise, of such Person for the obligations of another Person through any agreement to purchase, repurchase or otherwise acquire such obligation or any assets or property constituting security therefor, to provide funds for the payment or discharge of such obligation or to maintain the solvency, financial condition or any balance sheet item or level of income of another Person;

(n) earn-outs, all purchase price adjustments, profit sharing arrangements, deferred purchase money amounts and similar payment obligations (or continuing obligations of any nature of such Person arising out of purchase and sale contracts) (including in connection with Permitted Acquisitions), but only to the extent the same (x) have become due and payable and are recorded as a liability on the balance sheet of such Person and (y) are payable in cash;

(o) all off-balance sheet liabilities of such Person; or

(p) all obligations arising under non-compete agreements, bonus, deferred compensation, incentive compensation or similar arrangements, other than those arising in the Ordinary Course of Business.

Indemnified Liabilities ” has the meaning specified therefor in Section  10.03 .

Indemnified Person ” has the meaning specified therefor in Section  10.03 .

 

23


Indemnified Taxes ” means, any Taxes other than Excluded Taxes, imposed on or with respect to any payment made by or on account of any obligation of Borrowers under any Loan Document.

Insolvency Proceeding ” means any proceeding commenced by or against any Person under any provision of the Bankruptcy Code or under any other state or federal bankruptcy or insolvency law, assignments for the benefit of creditors, formal or informal moratoria, compositions, extensions generally with creditors, or proceedings seeking reorganization, arrangement, or other similar relief.

Intellectual Property ” means all Intellectual Property Licenses and all Copyrights, copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work, whether published or unpublished, any Patents, patents, patent applications and like protections, including improvements, divisions, continuations, renewals, reissues, extensions, and continuations-in-part of the same, Trademarks, trademarks, trade names, service marks, mask works, rights of use of any name, domain names, or any other similar rights, any applications therefor, whether registered or not, know-how, operating manuals, trade secret rights, clinical and non-clinical data, rights to unpatented inventions, and any claims for damage by way of any past, present, or future infringement of any of the foregoing.

Intellectual Property Licenses ” has the meaning specified therefor in the Guaranty and Security Agreement.

Intercompany Subordination Agreement ” means an intercompany subordination agreement, dated as of the Closing Date, executed and delivered by Borrowers, each of their Subsidiaries, and Agent, the form and substance of which is reasonably satisfactory to Agent and the Lenders.

Intercreditor Agreement ” means that certain Intercreditor Agreement, dated as of the Closing Date, by and between Agent and the Term Agent and acknowledged and agreed by the Loan Parties, as amended, restated, supplemented or otherwise modified from time to time in accordance with the terms thereof.

Interest Expense ” means, for any period, the aggregate of the interest expense of Borrowers for such period, determined on a consolidated basis in accordance with GAAP.

Internal Controls ” has the meaning ascribed to it in Section  4.13(a) .

Inventory ” means inventory (as that term is defined in the Code).

Inventory Cap ” means, initially, $10,000,000; provided , that, (x) after the first anniversary of the Closing Date, such cap may be increased to $15,000,000 to the extent the following conditions have been met: (i) Agent (or, during any Third Party Agent Retention Period, the Third Party Agent) shall have received an appraisal detailing the value of Borrowers’ Intellectual Property, in scope and with results acceptable to Agent (and, during any Third Party Agent Retention Period, also the Third Party Agent) and (ii) Borrowers’ shall have achieved TTM EBITDA of greater than $0 for two consecutive fiscal quarters and (y) the Inventory Cap shall be reduced to $0 in the event that Market Capitalization of Endologix is less than $200,000,000.

Investment ” has the meaning specified therefor in Section  6.06 .

Investment Company Act ” means the Investment Company Act of 1940, as amended, including the rules and regulations promulgated thereunder.

 

24


IP ” means all Intellectual Property that is necessary for the conduct of the Loan Parties’ business as currently conducted.

IRC ” means the Internal Revenue Code of 1986, as in effect from time to time.

Landlord Reserve ” means, as to each location at which Borrowers have Collateral or books and records located and as to which a Collateral Access Agreement has not been received by Agent, a reserve in an amount equal to the greater of (a) the number of months’ rent for which the landlord will have, under applicable law, a Lien in the Collateral of Borrowers to secure the payment of rent or other amounts under the lease relative to such location, or (b) three (3) months’ rent under the lease relative to such location.

Latest Balance Sheet Date ” has the meaning specified therefor in Section  4.12 .

Lender ” has the meaning specified therefor in the preamble, shall include any other Person made a party hereto pursuant to the provisions of Section  13.01 and “ Lenders ” means each of the Lenders or any one or more of them.

Lender Group ” means each of the Lenders and Agent (including, during any Third Party Agent Retention Period, the Third Party Agent), any other Secured Party or any one or more of them.

Lender Group Expenses ” means all (a) costs or expenses (including taxes and insurance premiums) required to be paid by Borrowers or their Subsidiaries under any of the Loan Documents that are paid, advanced, or incurred by the Lender Group, (b) documented out-of-pocket fees or charges paid or incurred by Agent or any Third Party Agent in connection with the Lender Group’s transactions with Borrowers or their Subsidiaries under any of the Loan Documents, including, without limitation, the fees and out-of-pocket expenses of Agent’s and any Third Party Agent’s outside counsel and reasonable out-of-pocket costs incurred in connection with travel and due diligence, photocopying, notarization, couriers and messengers, telecommunication, public record searches, filing fees, recording fees, publication, real estate surveys, real estate title policies and endorsements, and environmental audits, (c) Agent’s or any Third Party Agent’s customary fees and charges imposed or incurred in connection with any background checks or OFAC/PEP searches related to Borrowers or their Subsidiaries, (d) Agent’s and any Third Party Agent’s fees and charges (as adjusted from time to time) with respect to the disbursement of funds (or the receipt of funds) to or for the account of Borrowers (whether by wire transfer or otherwise), together with any out-of-pocket costs and expenses incurred in connection therewith, (e) customary charges imposed or incurred by Agent or any Third Party Agent resulting from the dishonor of checks payable by or to any Loan Party, (f) costs and expenses paid or incurred by the Lender Group to correct any default or enforce any provision of the Loan Documents, or during the continuance of an Event of Default, in gaining possession of, maintaining, handling, preserving, storing, shipping, selling, preparing for sale, or advertising to sell the Collateral, or any portion thereof, irrespective of whether a sale is consummated, (g) reasonable consulting or advisory fees and expenses of Agent and any Third Party Agent and fees and expenses related to any field examination, appraisal, or valuation to the extent of the fees and charges, and due diligence expenses, including in connection with periodic reviews of insurance and Collateral, (h) Agent’s, any Third Party Agent’s and Lenders’ reasonable costs and expenses (including reasonable documented attorneys’ fees and expenses) relative to third party subpoenas, claims or any other lawsuit or adverse proceeding paid or incurred, whether in enforcing or defending the Loan Documents or otherwise in connection with the transactions contemplated by the Loan Documents, Agent’s Liens in and to the Collateral, or the Lender Group’s relationship with Borrowers or any of their Subsidiaries, (i) Agent’s and any Third Party Agent’s reasonable documented costs and expenses (including reasonable documented attorneys’ fees and due diligence expenses) incurred in advising, structuring, drafting, reviewing, administering (including travel, meals, and lodging), syndicating (including reasonable costs and

 

25


expenses relative to the rating of any Loan, CUSIP, DXSyndicate™, SyndTrak or other communication costs incurred in connection with a syndication of the loan facilities), or amending, restating, supplementing, waiving, or modifying the Loan Documents and (j) Agent’s, any Third Party Agent’s and each Lender’s costs and expenses (including reasonable documented attorneys, accountants, consultants, and other advisors fees and expenses) incurred in terminating, enforcing (including attorneys, accountants, consultants, and other advisors fees and expenses incurred in connection with a “workout,” a “restructuring,” or an Insolvency Proceeding concerning Borrowers or any of their Subsidiaries or in exercising rights or remedies under the Loan Documents), or defending the Loan Documents, irrespective of whether a lawsuit or other adverse proceeding is brought, or in taking any enforcement action or any Remedial Action with respect to the Collateral.

Lender-Related Person ” means, with respect to any Lender, such Lender, together with such Lender’s Affiliates, officers, directors, employees, attorneys, and agents.

Liabilities ” means all claims, actions, suits, judgments, damages, losses, liabilities, obligations, responsibilities, fines, penalties, sanctions, costs, fees, Taxes, commissions, charges, disbursements and expenses (including those incurred upon any appeal or in connection with the preparation for and/or response to any subpoena or request for document production relating thereto), in each case of any kind or nature (including interest accrued thereon or as a result thereto and fees, charges and disbursements of financial, legal and other advisors and consultants), whether joint or several, and whether or not indirect, contingent, consequential, actual, punitive, treble or otherwise.

LIBOR Adjustment Date ” means the first calendar day of such calendar month.

LIBOR Rate ” means the greater of (a) 1.00% and (b) the rate per annum equal to the London interbank offered rate administered by ICE Benchmark Administration Limited or a comparable, replacement or successor rate, which rate is approved by Agent, as published on the applicable Bloomberg screen (or such other commercially available source providing such quotations as may be designated by Agent from time to time), for deposits in Dollars for a term of thirty (30) days on or about 11:00 a.m. (London time) two (2) Business Days prior to the LIBOR Adjustment Date. The LIBOR Rate may not be the lowest or best rate at which Agent calculates interest or extends credit. The LIBOR Rate for each calendar month shall be adjusted (if necessary) on each LIBOR Adjustment Datewhich determination shall be conclusive in the absence of manifest error; provided that to the extent a comparable, replacement or successor rate is approved by Agent in connection herewith, the approved rate shall be applied in a manner consistent with market practice.

Lien ” means any lien, pledge, preferential arrangement, mortgage, security interest, deed of trust, charge, assignment, hypothecation, title retention or other encumbrance on or with respect to property or interest in property having the practical effect of constituting a security interest, in each case with respect to the payment of any obligation with, or from the proceeds of, any asset or revenue of any kind. For purposes of this Agreement and the other Loan Documents, any Loan Party or any Subsidiary shall be deemed to own subject to a Lien any asset which it has acquired or holds subject to the interest of a vendor or lessor under any conditional sale agreement, capital lease or other title retention agreement relating to such asset.

Liquidated Damages ” has the meaning specified in Section  2.09(d)(i) .

Loan ” means any Revolving Loan or Extraordinary Advance made (or to be made) hereunder.

Loan Account ” has the meaning specified therefor in Section  2.08 .

 

26


Loan Documents ” means the Agreement, any Notes, the Control Agreements, any Borrowing Base Certificate, each Compliance Certificate, the Intercreditor Agreement, the Guaranty and Security Agreement, the Intercompany Subordination Agreement, the Patent Security Agreement, the Trademark Security Agreement, the Copyright Security Agreement, any note or notes executed by Borrowers in connection with the Agreement and payable to any member of the Lender Group, and any other instrument or agreement entered into, now or in the future, by Borrowers or any of their Subsidiaries and any member of the Lender Group in connection with the Agreement.

Loan Party ” means any Borrower or any Guarantor.

Lockbox ” has the meaning specified therefor in Section  2.12(a) .

Margin Stock ” means “margin stock” as such term is defined in Regulation T, U or X of the Federal Reserve Board.

Market Capitalization ” shall mean, on any date of determination, an amount equal to (i) the total number of issued and outstanding shares of common Stock of Endologix on the date of measurement multiplied by (ii) the arithmetic mean of the closing prices per share of such Stock on the Nasdaq Stock Market for the 30 consecutive trading days immediately preceding such date of determination.

Market Withdrawal ” means a Person’s Removal or Correction of a distributed product which involves a minor violation that would not be subject to legal action by the FDA or which involves no violation (e.g., normal stock rotation practices and routine equipment adjustments and repairs, etc.).

Material Adverse Effect ” means a material adverse effect on (a) the business, operations, results of operations, financial condition or properties of the Loan Parties and their Subsidiaries, taken as a whole, (b) the legality, validity or enforceability of any provision of any Loan Document, (c) the ability of any Loan Party to timely perform the Obligations, (d) the creation, perfection or priority of the Liens, taken as a whole for the Collateral, granted under the Loan Documents, or (e) the rights and remedies of the Secured Parties under any Loan Document.

Material Contracts ” means (a) the Operative Documents, (b) the Term Debt Documents, (c) the Convertible Note Documents, (d) the agreements listed on Schedule 4.18 , (e) the Permitted Japan Lifeline Unsecured Debt Documents and (f) each other agreement or contract to which such Loan Party or its Subsidiaries is a party the termination of which could reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect; provided that Capped Calls shall not be considered Material Contracts.

Material Intangible Assets ” means all of (i) each Loan Party’s Intellectual Property and (ii) license or sublicense agreements or other agreements with respect to rights in Intellectual Property (including each Intellectual Property License), in each case that are material to the financial condition, business or operations of the applicable Loan Party.

Maturity Date ” means April 2, 2022.

Maximum Revolver Amount ” means $40,000,000 ( provided that such amount shall be increased to $50,000,000 during any Maximum Revolver Increased Amount Period), decreased by the amount of reductions in the Revolver Commitments made in accordance with Section  2.03(c) .

 

27


Maximum Revolver Decreased Market Capitalization Event ” means any time, after a Maximum Revolver Increased Amount Trigger Event occurs, the Market Capitalization of Endologix decreases to an amount less than or equal to $350,000,000.

Maximum Revolver Decreased Market Capitalization Notice Trigger Event ” means the first occurrence of a Maximum Revolver Decreased Market Capitalization Event after a Maximum Revolver Increased Amount Trigger Event has occurred and was continuing immediately before such Maximum Revolver Decreased Market Capitalization Event occurred.

Maximum Revolver Decreased Market Capitalization Overadvance Amount ” means, at any time a Maximum Revolver Decreased Market Capitalization Overadvance Event occurs, if Revolver Usage at such time is in excess of $40,000,000, the result of (a) the amount of the Revolver Usage, minus (b) $40,000,000.

Maximum Revolver Decreased Market Capitalization Overadvance Event ” means any time that the Market Capitalization of Endologix is less than or equal to $350,000,000 and the Revolver Usage is more than $40,000,000.

Maximum Revolver Increased Amount Period ” means from the time a Maximum Revolver Increased Amount Trigger Event occurs until the time that the Market Capitalization of Endologix is less than or equal to $350,000,000.

Maximum Revolver Increased Amount Trigger Event ” means, at any time that the Market Capitalization of Endologix is in excess of $350,000,000 for at least ten (10) consecutive Business Days, the Borrower Representative delivers an officer’s certificate executed by an Authorized Officer of the Borrower Representative to the Agent (and, during a Third Party Agent Retention Period, also the Third Party Agent) certifying as such and providing reasonable detail thereof, all in form and substance reasonably satisfactory to the Agent (and, during a Third Party Agent Retention Period, also the Third Party Agent).

Measurement Period ” means, at any date of determination, the most recently completed twelve (12) fiscal months of Borrowers for which financial statements have been delivered pursuant to Section  5.05(a) .

Medicaid ” means the medical assistance programs administered by state agencies and approved by CMS pursuant to the terms of Title XIX of the Social Security Act, codified at 42 U.S.C. 1396 et seq.

Medicare ” means the program of health benefits for the aged and disabled administered by CMS pursuant to the terms of Title XVIII of the Social Security Act, codified at 42 U.S.C. 1395 et seq.

Monthly Cash Burn Amount ” means, with respect to Borrowers, an amount equal to Borrower’s change in cash and Cash Equivalents, without giving effect to any increase resulting from contributions or proceeds of financings, for either (a) the immediately preceding eighteen (18) month period as determined as of the last day of the month immediately preceding the proposed consummation of the Permitted Acquisition or voluntary prepayment, as applicable, and based upon the financial statements delivered to Agent (and, during any Third Party Agent Retention Period, also the Third Party Agent) in accordance with this Agreement for such period, not including unusual or non-recurring expenses or (b) the immediately succeeding eighteen (18) month period based upon the projections delivered to Agent (or any Third Party Agent, as applicable) prior to the Closing Date, not including unusual or non-recurring expenses, using whichever calculation as between clause (a) and clause (b) demonstrates a higher burn rate (or, in other words, more cash used), in either case, divided by eighteen (18).

 

28


Monthly Collateral Monitoring Fee ” has the meaning specified therefor in Section  2.09(f) .

Moody’s ” has the meaning specified therefor in the definition of Cash Equivalents.

Multiemployer Plan ” means any multiemployer plan, as defined in Section 3(37) or 4001(a)(3) of ERISA, as to which any ERISA Affiliate incurs or otherwise has, or could reasonably be expected to have, any obligation or Liabilities (including under Section 4212 of ERISA).

Necessary Documents ” has the meaning specified therefor in Section  4.05 .

Net Book Value of Eligible Equipment ” means, at any time, the then-current book value of all Eligible Equipment (giving effect to any adjustments to such book value on or prior to the date of measurement thereof) less all accumulated depreciation and amortization of such Equipment through the date of measurement, all as determined in accordance with GAAP.

Net Orderly Liquidation Value ” means, at any time, the orderly liquidation value with respect to the applicable asset as set forth in the most recent appraisal acceptable to Agent (and, during any Third Party Agent Retention Period, also the Third Party Agent), upon which Agent (and any Third Party Agent) is expressly entitled to rely, prepared by an appraiser acceptable to Agent (and, during any Third Party Agent Retention Period, also the Third Party Agent), net of operating expenses, liquidation expenses and commissions set forth in such appraisal; provided , that to the extent operating expenses, liquidation expenses and commissions set forth in such appraisal are not allocated to specific categories of Inventory, such operating expenses, liquidation expenses and commissions may be allocated by Agent (or, during any Third Party Agent Retention Period at the sole option of Agent, the Third Party Agent) to specific assets as determined in Agent’s (including, during any Third Party Agent Retention Period, the Third Party Agent’s) Permitted Discretion; and provided further , that the liquidation timeframe is acceptable to Agent (and, during any Third Party Agent Retention Period, also the Third Party Agent).

Net Revenue ” means, for any period, (a) the Loan Parties’ gross revenues during such period, less (b)(i) trade, quantity and cash discounts allowed by the Loan Parties, (ii) discounts, refunds, rebates, charge backs, retroactive price adjustments and any other allowances which effectively reduce net selling price, (iii) product returns and allowances, (iv) allowances for shipping or other distribution expenses, (v) set-offs and counterclaims, and (vi) any other similar and customary deductions used by the Loan Parties in determining net revenues, all, in respect of (a) and (b), as determined in accordance with GAAP and in the Ordinary Course of Business.

Non-Third Party Agent Retention Period ” means any period of time that is not during a Third Party Agent Retention Period.

Note ” means any promissory note evidencing any of the Obligations and/or the Commitments issued by the Borrowers in favor of the Agent or any Lender.

Obligations ” means all loans (including the Revolving Loans (inclusive of Extraordinary Advances)), debts, principal, interest (including any interest that accrues after the commencement of an Insolvency Proceeding, regardless of whether allowed or allowable in whole or in part as a claim in any such Insolvency Proceeding), premiums, liabilities (including all amounts charged to the Loan Account pursuant to this Agreement), obligations (including indemnification obligations), fees (including the fees and other amounts set forth in Section  2.09 ), Lender Group Expenses (including any fees or expenses that accrue after the commencement of an Insolvency Proceeding, regardless of whether allowed or allowable in whole or in part as a claim in any such Insolvency Proceeding), guaranties, and all covenants and duties of any other kind and description owing by any Loan Party arising out of, under, pursuant to, in

 

29


connection with, or evidenced by the Agreement or any of the other Loan Documents and irrespective of whether for the payment of money, whether direct or indirect, absolute or contingent, due or to become due, now existing or hereafter arising, and including all interest not paid when due and all other expenses or other amounts that Borrowers are required to pay or reimburse by the Loan Documents or by law or otherwise in connection with the Loan Documents. Without limiting the generality of the foregoing, the Obligations of Borrowers under the Loan Documents include the obligation to pay (i) the principal of the Loans, (ii) interest accrued on the Loans, (iii) [reserved], (iv) Third Party Agent commissions, fees and charges, (v) Lender Group Expenses, (vi) fees payable hereunder or any of the other Loan Documents, and (vii) indemnities and other amounts payable by any Loan Party under any Loan Document. Any reference in the Agreement or in the Loan Documents to the Obligations shall include all or any portion thereof and any extensions, modifications, renewals, or alterations thereof, both prior and subsequent to any Insolvency Proceeding.

OFAC ” means The Office of Foreign Assets Control of the U.S. Department of the Treasury.

Operating Expenditures ” means, with respect to any Person for any period, the amount of all expenditures (whether such expenditures are paid in cash, financed or otherwise) by such Person and its Subsidiaries during such period that are reported as operating expenses (including expenditures related to research and development, clinical and regulatory affairs, marketing and sales, and general and administrative) on the income statements of such Person and its Subsidiaries that are included in such Person’s financial statements (including those financial statements required by Section  5.05(a) ), which amount shall (i) be in compliance and accordance with GAAP and any SEC requirements and regulations, but (ii) exclude one-time non-recurring expenditures that are not regularly incurred in the Ordinary Course of Business of such Person and its Subsidiaries.

Operative Documents ” means the Loan Documents and the Term Debt Documents.

Ordinary Course of Business ” means, in respect of any transaction involving any Loan Party, the ordinary course of business of such Loan Party, as conducted by such Loan Party in accordance with past practices, as applicable.

Organizational Documents ” means, with respect to any Loan Party, the documents by which such Person was organized (such as a certificate of incorporation, certificate of limited partnership or articles of organization, and including, without limitation, any certificates of designation for preferred stock or other forms of preferred equity) and which relate to the internal governance of such Person (such as by-laws, a partnership agreement or an operating, limited liability company or members agreement), including any and all shareholder agreements or voting agreements relating to the capital stock or other equity interests of such Person.

Originating Lender ” has the meaning specified therefor in Section  13.01(e) .

Overadvance ” means, as of any date of determination, that the Revolver Usage is greater than any of the limitations set forth in Section  2.01 .

Participant ” has the meaning specified therefor in Section  13.01(e) .

Participant Register ” has the meaning specified therefor in Section  13.01(i) .

Patents ” has the meaning specified therefor in the Guaranty and Security Agreement.

 

30


Patent Security Agreement ” has the meaning specified therefor in the Guaranty and Security Agreement.

Patriot Act ” means Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism (USA Patriot Act of 2001).

Perfection Certificate ” means a certificate in the form of Exhibit P-1 .

Permitted 3.25% Convertible Note Refinancing ” has the meaning provided therefor in the definition of “Permitted Indebtedness.”

Permitted Acquisition ” means any Acquisition by a Loan Party, in each case, to the extent that each of the following conditions shall have been satisfied:

(a) the Borrower Representative shall have delivered to (x) during any Non-Third Party Agent Retention Period, subject to Section  5.20 , Agent, or (y) during any Third Party Agent Retention Period, the Third Party Agent, in each case, (i) at least ten (10) Business Days prior to the closing of the proposed Acquisition: (A) a description of the proposed Acquisition; (B) to the extent available, a due diligence package (including, to the extent available, a quality of earnings report); and (C) the most recent drafts (or, if available, executed counterparts) of the respective agreements, documents or instruments pursuant to which such Acquisition is to be consummated, any available schedules and exhibits to such agreements, documents or instruments and all other material ancillary agreements, instruments and documents to be executed or delivered in connection therewith, and to the extent required under the related acquisition agreement, all required regulatory and third party approvals and copies of any environmental assessments and (ii) at the earlier of (A) the time of closing of the proposed Acquisition or (B) as early before the closing of the proposed Acquisition as available, in each case, final, fully executed copies of the respective agreements, documents or instruments pursuant to which such Acquisition is to be consummated and all schedules and exhibits to such agreements, documents or instruments and all other material ancillary agreements, instruments and documents executed or delivered in connection therewith;

(b) the Loan Parties (including any new Subsidiary to the extent required by Section  5.09 shall execute and deliver the agreements, instruments and other documents to the extent required by Section  5.09 ;

(c) no Event of Default or Default has occurred and is continuing, or would exist after giving pro forma effect to, the proposed Acquisition;

(d) all transactions in connection with such Acquisition shall be consummated, in all material respects, in accordance with applicable laws;

(e) the assets acquired in such Acquisition are for use in the same line of business as the Loan Parties are currently engaged or a line of business reasonably related thereto;

(f) such Acquisition shall not be hostile and, if applicable, shall have been approved by the board of directors (or other similar body) and/or the stockholders or other equity holders of any Person being acquired in such Acquisition;

(g) no Indebtedness or Liens are assumed or created (other than Permitted Liens and Permitted Indebtedness) in connection with such Acquisition;

 

31


(h) all conditions to “Permitted Acquisition” (as defined in the Term Credit Agreement as of the Closing Date) have been satisfied and (i) during any Non-Third Party Agent Retention Period, Agent shall have received, subject to Section  5.20 , any requested evidence showing satisfaction thereof and (ii) during any Third Party Agent Retention Period, the Third Party Agent shall have received any requested evidence showing satisfaction thereof; and

(i) the total consideration paid or payable (including without limitation, costs and expenses, deferred purchase price, seller notes and other liabilities incurred, assumed or to be reflected on a consolidated balance sheet of the Loan Parties and their Subsidiaries after giving effect to such Acquisition but excluding (A) any equity interests issued as consideration for such Acquisition and (B) the net proceeds of any issuance of equity interests made after the Closing Date that are used for purposes of such Acquisition) (such amounts, collectively, the “ Acquisition Consideration ”) shall be in an amount not to exceed $15,000,000 in the aggregate for all such Acquisitions during the term of this Agreement; provided, however, that, in the case of each Acquisition, (1) during any Non-Third Party Agent Retention Period, subject to Section  5.20 , to the extent requested by Agent, Agent, and (2) during any Non-Third Party Agent Retention Period, the Third Party Agent, in each case, has received prior to the consummation of such Acquisition evidence satisfactory to Agent (or such Third Party Agent) that Borrowers have, immediately before and immediately after giving effect to the consummation of such Acquisition, unrestricted cash (it being understood and agreed that cash and Cash Equivalents shall not be considered “restricted” cash for purposes of this proviso solely due to compliance by the Loan Parties with the requirements set forth in Section  5.08 ) in one or more deposit accounts subject to a Control Agreement in an aggregate amount equal to or greater than the positive value of the product of (x) eighteen (18) multiplied by (y) the Monthly Cash Burn Amount, as determined as of the last day of the month immediately preceding such Acquisition.

Notwithstanding the foregoing, no Accounts, Inventory or Equipment acquired by a Loan Party in a Permitted Acquisition shall be included as Eligible Accounts, Eligible Equipment or Eligible Inventory until a field examination (and, if required by Agent (or, during any Third Party Agent Retention Period, the Third Party Agent), an Inventory appraisal or an Equipment appraisal, as applicable) with respect thereto has been completed to the reasonable satisfaction of Agent (and, during any Third Party Agent Retention Period, the Third Party Agent), including the establishment of reserves required in Agent’s (or, during any Third Party Agent Retention Period, the Third Party Agent’s) reasonable discretion; provided that field examinations and appraisals in connection with Permitted Acquisitions shall not count against the limited number of field examinations or appraisals for which expense reimbursement may be sought.

Permitted Contingent Obligations ” means:

(a) Contingent Obligations arising in respect of the Indebtedness under the Loan Documents;

(b) Contingent Obligations resulting from endorsements for collection or deposit in the Ordinary Course of Business;

(c) Contingent Obligations outstanding on the date of this Agreement and set forth on Schedule 6.05 (but not including any refinancings, extensions, increases or amendments to the indebtedness underlying such Contingent Obligations other than extensions of the maturity thereof without any other material change in terms adverse to the Lenders);

(d) Contingent Obligations incurred in the Ordinary Course of Business with respect to surety and appeal bonds, performance bonds and other similar obligations not to exceed $2,000,000 in the aggregate at any time outstanding;

 

32


(e) Contingent Obligations arising under indemnity agreements with title insurers to cause such title insurers to issue to Agent mortgagee title insurance policies;

(f) Contingent Obligations arising with respect to customary indemnification obligations in favor of purchasers in connection with dispositions of personal property assets permitted under Section  6.04 ;

(g) so long as there exists no Event of Default both immediately before and immediately after giving effect to any such transaction, Contingent Obligations existing or arising under any Swap Contract or Capped Call; provided, however, that such obligations are (or were) entered into by Borrower or an Affiliate of Borrower for the purpose of directly mitigating risks associated with liabilities, commitments, investments, assets, or property held or reasonably anticipated by such Person and not for purposes of speculation and either (i) with respect to a Swap Contract or a Capped Call, are (or were) entered into in the Ordinary Course of Business or (ii) with respect to a Capped Call, are (or were) entered into in connection with the 2.25% Convertible Notes, the 3.25% Convertible Notes, any refinancings thereof permitted hereunder or in connection with this Agreement or any of the other Loan Documents;

(h) guarantees by (i) one or more Loan Parties of the obligations of Foreign Subsidiaries up to $1,000,000 in the aggregate at any time outstanding, (ii) any Loan Party of the obligations of any other Loan Party (but, for the avoidance of doubt, excluding any Immaterial Subsidiary that may be a Loan Party where, before and immediately after giving effect to such guarantee (including any rights of contribution set forth in the Loan Documents or otherwise), the Loan Parties cannot represent and warrant that such Immaterial Subsidiary is Solvent on an individual basis) and (iii) any Foreign Subsidiary of the obligations of any other Foreign Subsidiary;

(i) Contingent Obligations arising in respect of the Indebtedness under, subject to the terms of the Intercreditor Agreement and this Agreement, the Term Debt Documents; and

(j) other Contingent Obligations not permitted by clauses (a) through (i) above, not to exceed $2,500,000 in the aggregate at any time outstanding.

Permitted Discretion ” means a determination made in the exercise of reasonable (from the perspective of a secured asset-based lender) business judgment.

Permitted Dispositions ” means:

(a) dispositions of inventory in the Ordinary Course of Business;

(b) dispositions of furniture, fixtures and equipment (excluding any Collateral included in the Borrowing Base) in the Ordinary Course of Business that the applicable Loan Party or Subsidiary determines in good faith is no longer used or useful in the business of such Loan Party and its Subsidiaries (or such Subsidiary and its subsidiaries);

(c) to the extent constituting a Disposition, Permitted Investments and Permitted Licenses;

(d) disposals of obsolete, worn out or surplus tangible personal property;

(e) without limiting transactions permitted under Article VI hereof, dispositions by any Loan Party to any other Loan Party so long as each Loan Party (other than, with respect to any transferring Person, an Immaterial Subsidiary) will remain Solvent after giving effect to the transfer;

 

33


(f) abandonment of Intellectual Property that does not constitute a Material Intangible Asset;

(g) the unwinding or terminating of Swap Contracts or any Capped Call permitted by clause (g) of the definition of “Permitted Contingent Obligations” either (i) with respect to a Swap Contract or a Capped Call, in the Ordinary Course of Business or (ii) with respect to a Capped Call, that were entered into in connection with the 2.25% Convertible Notes, the 3.25% Convertible Notes, any Permitted 3.25% Convertible Note Refinancing permitted hereunder or in connection with this Agreement or any of the other Loan Documents;

(h) dispositions of equipment (excluding any Collateral included in the Borrowing Base) or real property to the extent that (i) such property is exchanged for credit against the purchase price of replacement property or (ii) the proceeds of such disposition are promptly applied to the purchase price of such replacement property;

(i) the entering into of any Permitted License;

(j) Dispositions by any Foreign Subsidiary to any other Foreign Subsidiary or to any Loan Party;

(k) Dispositions approved by the Required Lenders in writing;

(l) to the extent constituting a Disposition, the payment of cash and Cash Equivalents in the Ordinary Course of Business; and

(m) other Dispositions (excluding dispositions of Intellectual Property) the proceeds of which, when aggregated with the proceeds of all other Dispositions made pursuant to this clause (m) are less than $2,500,000 during the term of this Agreement; provided that (i) the consideration received for such assets shall be in an amount at least equal to the fair market value thereof (determined in good faith by the board of directors (or similar governing body) of the applicable Loan Party that owned such assets), (ii) no less than 75% thereof shall be paid in cash, and (iii) no Default or Event of Default then exists or would arise therefrom; provided , that , with respect to any such Disposition not in the Ordinary Course of Business under this clause (m) involving Collateral that is included in the Borrowing Base, Borrower Representative shall have provided (x) during a Non-Third Party Agent Retention Period, Agent with a certificate from an Authorized Officer of the Borrower Representative at least five (5) Business Days prior to such Disposition certifying that such Disposition shall not result in an Overadvance, together with, subject to Section  5.20 , such evidence thereof that is reasonably requested by Agent, and (y) during a Third Party Agent Retention Period, the Third Party Agent with a Borrowing Base Certificate (Third Party Agent) at least five (5) Business Days prior to such Disposition evidencing to Agent’s (and, during any Third Party Agent Retention Period, also the Third Party Agent’s) reasonable satisfaction that such Disposition shall not result in an Overadvance; and

(n) to the extent constituting Dispositions, Recalls of Products (or components of Products) returned to suppliers in the Ordinary Course of Business as required by Applicable Law or the FDA with the consideration paid for such Products (or such components of Products) returned to the Loan Party or Subsidiary that purchased and returned such Product (or such components of Products); and

(o) (i) Recalls of Products (or components of Products) that are not included as Eligible Inventory and are not included in the Borrowing Base from customers to the extent required by Applicable Law or the FDA and (ii) the Dispositions of such Products that were Recalled in the Ordinary Course of Business and for fair market value and on fair market terms.

 

34


Permitted Indebtedness ” means each of the following:

(a) Indebtedness evidenced by this Agreement and the other Loan Documents;

(b) Indebtedness incurred as a result of endorsing negotiable instruments received in the Ordinary Course of Business;

(c) Capital Leases and purchase money Indebtedness not to exceed $5,000,000 at any time (whether in the form of a loan or a lease) used solely to acquire equipment used in the Ordinary Course of Business and secured only by such equipment; provided that no such equipment shall be included as “Eligible Equipment” or in the Borrowing Base.

(d) Indebtedness existing on the Closing Date and described on Schedule 4.01(f) (but not including any refinancings, extensions, increases or amendments to such Indebtedness other than Permitted Refinancings);

(e) so long as there exists no Event of Default both immediately before and immediately after giving effect to any such transaction, Indebtedness existing or arising under any Swap Contract or Capped Call; provided, however, that such obligations are (or were) entered into by a Borrower or an Affiliate of a Borrower for the purpose of directly mitigating risks associated with liabilities, commitments, investments, assets, or property held or reasonably anticipated by such Person and not for purposes of speculation and either (i) with respect to a Swap Contract or a Capped Call, are (or were) entered into in the Ordinary Course of Business or (ii) with respect to a Capped Call, are (or were) entered into in connection with the 2.25% Convertible Notes, the 3.25% Convertible Notes, any Permitted 3.25% Convertible Note Refinancing permitted hereunder or in connection with this Agreement or any of the other Loan Documents;

(f) Indebtedness in the form of insurance premiums financed through the applicable insurance company;

(g) trade accounts payable arising and paid within 120 days of the date when due and in the Ordinary Course of Business;

(h) Subordinated Debt;

(i) the Term Debt under the Term Credit Facility, in accordance with the terms of the Intercreditor Agreement and this Agreement;

(j) Indebtedness of the Loan Parties incurred under the 3.25% Convertible Notes in an aggregate principal amount not to exceed the aggregate principal amount outstanding on the Closing Date after giving effect to any repayments or prepayments thereon on the Closing Date, and, so long as no Event of Default has occurred and is continuing, any refinancing or extension thereof or new issuance in connection with the exchange thereof and/or a new issuance all or any portion of the proceeds of which will be used in connection with the repurchase or other refinancing of all or any portion thereof therewith that (i) has an aggregate outstanding principal amount not greater than $200,000,000 (when taking into account all such existing, refinanced, extended and newly issued Indebtedness), and does not provide for any amortization payments or other principal payments of any kind in advance of the date that is one year and one day after the Maturity Date, (ii) has a maturity no shorter than the date that is one year and one day after the Maturity Date (in the case of clause (i) and clause (ii), it being understood that, in each case, any provision requiring an offer to purchase such Indebtedness as a result of a change in control,

 

35


fundamental change, delisting, asset sale or similar provision or any exercise or conversion of Stock (other than Disqualified Stock) shall not violate the foregoing restrictions in clause (i) or clause (ii)), (iii) is unsecured, (iv) does not have one or more obligors that are not Loan Parties, (v) contains terms that are prevailing market terms at the time of issuing or initial borrowing for the type of financing and for the quality of issuer or borrower, as determined by Endologix and its advisors in their reasonable business judgment, (vi) does not have an All-in Yield greater than the lesser of (A) 6% per annum and (B) an All-in Yield that would result in more than $10,000,000 per annum being paid in interest thereunder, (vii) does not cause Endologix either on an individual basis or together with its Subsidiaries (on a consolidated basis), immediately before, at the time of and immediately after giving effect to such Indebtedness (and after giving effect to the use of the proceeds thereof), to be no longer be Solvent (or such Persons are not Solvent immediately prior to giving effect thereto), and (vii) if in existence at such time or on the same date, is permitted under the Term Debt Documents (collectively, a “ Permitted 3.25% Convertible Note Refinancing ”);

(k) Indebtedness of the Borrowers incurred under the 2.25% Convertible Notes in an aggregate principal amount not to exceed the aggregate principal amount outstanding on the Closing Date minus any prepayments, repayments, redemptions or payments thereon made on the Closing Date or from time to time thereafter;

(l) without limiting the provisions of Article VI with respect to any Investment by a Loan Party, Indebtedness consisting of unsecured intercompany loans and advances (i) incurred by any Loan Party owing to one or more other Loan Parties, (ii) incurred by any Foreign Subsidiaries owing to any Loan Party solely to the extent constituting a Permitted Investment made by such Loan Party, or (iii) incurred by any Foreign Subsidiaries owing to any other Foreign Subsidiary;

(m) Indebtedness related to commercial credit cards provided by Bank of America, N.A. (or such other commercial bank permitted under the definition of “Bank of America Cash Collateral Account) that, in the aggregate outstanding at any one time, does not exceed $2,500,000, which Indebtedness may be secured by Liens permitted pursuant to clause (r) of the definition of Permitted Liens;

(n) to the extent constituting Indebtedness, any Permitted Contingent Obligations;

(o) unsecured Indebtedness incurred in respect of netting services, overdraft protection and other like services, in each case, incurred in the Ordinary Course of Business;

(p) unsecured earn-out obligations and other similar contingent purchase price obligations incurred in connection with a Permitted Acquisition to the extent earned and payable and permitted pursuant to the definition of Permitted Acquisition and the other terms of this Agreement;

(q) any other unsecured Indebtedness incurred by the Loan Parties or any of their Subsidiaries in an aggregate outstanding amount not to exceed $2,500,000 at any one time; and

(r) unsecured Indebtedness in an amount not to exceed $4,280,500 pursuant to a promissory note dated on or around the Agreement Date, by the Borrower in favor of Japan Lifeline Co., Ltd. (the “ Permitted Japan Lifeline Unsecured Debt ”), so long as (i) no prepayments, repayment, redemptions or payments shall be made with respect to the Permitted Japan Lifeline Unsecured Debt at any time until ninety-one (91) days after all of the Obligations have been paid in full, (ii) the all-in interest rate and pricing charged thereon shall not exceed 2.5% per annum and such interest shall not be paid more frequently than annually in arrears, (iii) no fees shall be paid thereon, (iv) such unsecured Indebtedness

 

36


shall not be assigned or otherwise transferred by Japan Lifeline Co., Ltd. without the consent of the Agent, (v) Japan Lifeline Co., Ltd. (and any successor or assign thereof) shall enter into a subordination agreement with the Agent, in form and substance reasonably satisfactory to the Agent and the Lenders, and (vi) subordination provisions are included in such promissory note and any related documents (collectively, the “Permitted Japan Lifeline Unsecured Debt Documents”) in a manner, and in form and substance, reasonably satisfactory to the Agent and the Lenders and such Permitted Japan Lifeline Unsecured Debt Documents shall be in form and substance reasonably satisfactory to the Agent and the Lenders.

Permitted Investments ” means:

(a) Investments (i) shown on Schedule P-1 and existing on the Closing Date and (ii) Subsidiaries made prior to the Closing Date;

(b) Investments in cash and Cash Equivalents;

(c) Investments consisting of the endorsement of negotiable instruments for deposit or collection or similar transactions in the Ordinary Course of Business;

(d) Investments consisting of (i) travel advances and employee relocation loans and other employee loans and advances in the Ordinary Course of Business, and (ii) loans to employees, officers or directors relating to the purchase of equity securities of a Loan Party or its Subsidiaries pursuant to employee stock purchase plans or agreements approved by such Borrower’s board of directors (or other governing body), but the aggregate of all such loans outstanding may not exceed $500,000 at any time;

(e) Investments (including debt obligations) received in connection with the bankruptcy or reorganization of customers or suppliers and in settlement of delinquent obligations of, and other disputes with, customers or suppliers arising in the Ordinary Course of Business;

(f) Investments consisting of notes receivable of, or prepaid royalties and other credit extensions, to customers and suppliers who are not Affiliates, in the Ordinary Course of Business, provided, however, that this subpart (f) shall not apply to Investments of Loan Parties in any Subsidiary;

(g) Investments consisting of (i) deposit accounts in which Agent has received a Control Agreement, and (ii) deposit accounts that are Excluded Accounts (subject to any caps and applicable restrictions set forth in such definition);

(h) Investments by any Loan Party in any Subsidiary now owned or hereafter created by such Loan Party, which Subsidiary is a Loan Party or has otherwise provided a Guarantee of the Obligations of the Loan Party which Guarantee is secured by a Lien granted by such Subsidiary to Agent in all or substantially all of its property of the type described in the Guaranty and Security Agreement and otherwise made in compliance with Section  5.09 ;

(i) Investments by (A) any Loan Party consisting solely of cash and Cash Equivalents in a Foreign Subsidiary; provided that at the time of the making of such Investment and immediately after giving effect thereto (i) no Event of Default has occurred and is continuing and (ii) Loan Parties have unrestricted (it being understood and agreed that cash and Cash Equivalents shall not be considered “restricted” cash for purposes of this proviso solely due to compliance by the Loan Parties with the requirements set forth in Section  7.01(b) ) cash and Cash Equivalents in an aggregate amount of not less than $10,000,000, which cash and Cash Equivalents (x) are subject to a first priority perfected lien in

 

37


favor of Agent for the benefit of Lender Group (subject to Permitted Liens), (y) are held in a deposit account that is subject to a Control Agreement or a securities account subject to a Control Agreement and (z) unless the same could not be reasonably expected to reduce the amounts in such accounts below $10,000,000 at the time of such Investment and immediately after giving effect thereto, do not include any drawn or committed but unpaid drafts, ACH or EFT transactions and (B) a non-Loan Party Foreign Subsidiary in another non-Loan Party Foreign Subsidiary; provided , that , Investments pursuant to clause (i)(A) above shall be subject to the proviso at the end of this definition;

(j) Investments by any Loan Party consisting solely of inventory in any wholly-owned Foreign Subsidiaries, to the extent (i) such Investments are made in the Ordinary Course of Business consistent with its customary practices as in effect on and immediately prior to the Closing Date and (ii) no Event of Default exists or would arise therefrom and (iii) no “Event of Default” (as defined in the Term Credit Agreement as in effect as of the Closing Date) then exists or would arise therefrom; provided , that (x) no such Investment shall result in an Overadvance and (y) such Investments shall be subject to the proviso at the end of this definition;

(k) so long as no Default or Event of Default shall have occurred and be continuing at the time thereof or would result therefrom, Investments consisting solely of cash and Cash Equivalents in joint ventures or similar arrangements in an amount not to exceed $5,000,000 in the aggregate during the term of this Agreement; provided , that , such Investments shall be subject to the proviso at the end of this definition;

(l) Permitted Acquisitions;

(m) Investments deemed to exist under any Swap Contracts or Capped Calls; provided, however, that such obligations are (or were) entered into by a Borrower or an Affiliate of a Borrower for the purpose of directly mitigating risks associated with liabilities, commitments, investments, assets, or property held or reasonably anticipated by such Person and not for purposes of speculation and are (or were) entered into either (i) with respect to a Swap Contract or a Capped Call, in the Ordinary Course of Business or (ii) with respect to a Capped Call, in connection with the 2.25% Convertible Notes, the 3.25% Convertible Notes, any Permitted 3.25% Convertible Note Refinancing permitted hereunder or in connection with this Agreement or any of the other Loan Documents; and

(n) other Investments in an amount not exceeding $5,000,000 in the aggregate; provided , that , such Investments shall be subject to the proviso at the end of this definition;

provided , that , that Investments pursuant to clauses (i), (j), (k), and (n) of this definition of “Permitted Investments” shall not exceed $12,000,000 in the aggregate in any calendar year and, provided , further , that with respect to clause (j) above, such Investments consisting solely of Inventory in Foreign Subsidiaries shall be valued at the lesser of cost and book value.

Permitted Japan Lifeline Unsecured Debt ” has the meaning specified therefor in clause (r) of the definition of “Permitted Indebtedness”.

Permitted Japan Lifeline Unsecured Debt Documents ” has the meaning specified therefor in clause (r) of the definition of “Permitted Indebtedness”.

Permitted License ” means (a) any non-exclusive license of patent rights of a Loan Party or its Subsidiaries so long as all such Permitted Licenses are granted to third parties in the Ordinary Course of Business, do not result in a legal transfer of title to the licensed property, and have been granted in exchange for fair consideration, and (b) any exclusive license of patent rights of Borrower or its Subsidiaries so long as such Permitted Licenses do not result in a legal transfer of title to the licensed

 

38


property, are exclusive solely as to discrete geographical areas outside of the United States, and have been granted in exchange for fair consideration.

Permitted Liens ” means:

(a) Liens set forth on Schedule 4.01(d) ; provided , that to qualify as a Permitted Lien, any such Lien described on Schedule 4.01(d) shall only secure the Indebtedness that it secures on the Closing Date;

(b) Liens in favor of the Secured Parties under the Loan Documents;

(c) carriers’, warehousemen’s, mechanics’, landlords’, materialmen’s, repairmen’s or other similar Liens arising in the Ordinary Course of Business which are not delinquent or remain payable without penalty or which are being contested in good faith and by appropriate proceedings, which proceedings have the effect of preventing the forfeiture or sale of the assets or property subject thereto and for which adequate reserves in accordance with GAAP are being maintained;

(d) Liens for Taxes, assessments or governmental charges or levies not past due or payable or that are being contested in good faith by appropriate proceedings and for which adequate reserves in accordance with GAAP are being maintained;

(e) (i) Liens arising from judgments, decrees or attachments in circumstances not constituting an Event of Default or Default and (ii) pledges or cash deposits made in lieu of, or to secure the performance of, judgment or appeal bonds in respect to such judgments and proceedings;

(f) Liens in favor of financial institutions arising in connection with the Borrower’s or its Subsidiaries’ deposit accounts maintained in the Ordinary Course of Business held at such institutions to secure standard fees for services charged by, but not financing made available by, such institutions;

(g) Liens (other than any Lien imposed by ERISA) consisting of pledges or deposits required in the Ordinary Course of Business in connection with workers’ compensation, unemployment insurance and other social security legislation or to secure the performance of tenders, statutory obligations, surety, stay, customs and appeals bonds, bids, leases, governmental contract, trade contracts, performance and return of money bonds and other similar obligations (exclusive of obligations for the payment of borrowed money or other funded Indebtedness) or to secure liability to insurance carriers;

(h) easements, rights of way, restrictions and other similar encumbrances affecting real property which, in the aggregate, are not substantial in amount, do not materially affect the value or marketability of such real property and which do not in any case materially interfere with the conduct of the business of any Loan Party or its Subsidiaries;

(i) (i) any interest or title of a lessor, sublessor, licensor or sublicensor under any lease or license not prohibited by this Agreement or (ii) non-exclusive licenses and sublicenses granted by a Loan Party or any Subsidiary of a Loan Party and leases and subleases (by a Loan Party or any Subsidiary of a Loan Party as lessor or sublessor) to third parties in the Ordinary Course of Business not materially interfering with the business of the Loan Parties or any of their Subsidiaries;

(j) Liens of a collection bank arising under Section 4-210 of the UCC (or equivalent in foreign jurisdictions) on items in the course of collection;

 

39


(k) Liens on any assets or property acquired or held by any Loan Party or any Subsidiary of any Loan Party securing Indebtedness incurred or assumed for the purpose of financing (or refinancing) all or any part of the cost of acquiring such assets or property and permitted under clause (c) of the definition of “Permitted Indebtedness”; provided that (i) such Lien attaches solely to the assets or property so acquired in such transaction and the proceeds thereof and (ii) the principal amount of the Indebtedness secured thereby does not exceed 100% of the cost of such assets or property;

(l) Liens securing Capital Leases permitted under clause (d) of the definition of “Permitted Indebtedness”;

(m) Liens arising from the filing of precautionary uniform commercial code financing statements with respect to any lease not prohibited by this Agreement;

(n) Liens arising out of consignment or similar arrangements for the sale of goods entered into by a Borrower or any Subsidiary of a Borrower in the Ordinary Course of Business;

(o) Liens in favor of customs and revenue authorities arising as a matter of law which secure payment of customs duties in connection with the importation of goods in the Ordinary Course of Business;

(p) Liens on unearned insurance premiums securing the financing thereof to the extent permitted under clause (f) of the definition of “Permitted Indebtedness”;

(q) [reserved];

(r) Liens on assets of the Loan Parties and their Subsidiaries arising in connection with seller notes, earn-outs and other similar payment obligations constituting Acquisition Consideration in connection with Permitted Acquisitions so long as such Liens are subject at all times to a Subordination Agreement;

(s) Liens granted under the Term Credit Facility, to the extent subject to the terms of the Intercreditor Agreement and this Agreement (“ Permitted Term Facility Liens ”); and

(t) Liens in favor of Bank of America, N.A. (or such other commercial bank permitted under the definition of “Bank of America Cash Collateral Account”) on the Bank of America Cash Collateral Account; provided that if Endologix is using credit card services from the Agent or a Lender that are required to be secured, Endologix shall promptly use commercially reasonable efforts to terminate the Liens in respect of the Bank of America Cash Collateral Account.

Permitted Priority Liens ” means (a) solely with respect to the specific assets or property covered thereby, the Liens granted pursuant to, and in accordance with, clause (u) of the definition of “Permitted Liens ,” (b) Permitted Liens granted over specific property pursuant to clauses (f) (solely with respect to such applicable deposit accounts), (i) (solely with respect to the interest in such applicable lease, sublease, license or sublicense or the assets owned by such lessor, sublessor, licensor or sublicensor underlying same), (k) (solely with respect to the property permitted to be secured by such Indebtedness permitted pursuant to clause (c) of the definition of “Permitted Indebtedness”), (l) (solely with respect to the property that is part of the Capital Lease), (m) (solely with respect to the specific assets covered by such lease that are owned by such lessor), (n) (with respect to the goods permitted to be consigned thereby), (p) (solely with respect to such cash held by such insurance agency for such insurance premiums), and (t) (solely with respect to the Bank of America Cash Collateral Account) of the definition of “Permitted

 

40


Liens”, but, in each case, only to the extent only such Lien (i) attaches solely to the assets or property so acquired in such transaction and the proceeds thereof and (ii) has prior priority to the Permitted Term Facility Liens, and (c) to the extent not otherwise covered by clause (b) above, non-consensual Permitted Liens that are solely provided by operation of (and in compliance with) Applicable Law.

Permitted Refinancing ” means Indebtedness constituting a refinancing or extension of Indebtedness evidenced by the permitted under clause (d) of the definition of “Permitted Indebtedness” and that (a) has an aggregate outstanding principal amount not greater than the aggregate principal amount of the Indebtedness being refinanced or extended, (b) has a weighted average maturity (measured as of the date of such refinancing or extension) and maturity no shorter than that of the Indebtedness being refinanced or extended, (c) is not entered into as part of a sale leaseback transaction, (d) is not secured by a Lien on any assets other than the collateral securing the Indebtedness being refinanced or extended, (e) the obligors of which are the same as the obligors of the Indebtedness being refinanced or extended and (f) is otherwise on terms no less favorable to Loan Parties and their Subsidiaries, taken as a whole, than those of the Indebtedness being refinanced or extended.

Permitted Term Facility Liens ” has the meaning provided therefor in clause (s) of the definition of “Permitted Liens”.

Person ” means and includes any natural person, individual, partnership, joint venture, corporation, trust, limited liability company, limited liability partnership, joint stock company, unincorporated organization, government entity or any political subdivision or agency thereof, or any other entity.

Prime Rate ” means, at any time, the prime rate published in the “Money Rates” column of The Wall Street Journal at such time, and in the event that The Wall Street Journal is not available at such time, the prime rate published in another publication as determined by Agent in its discretion.

Principal Market ” means the NASDAQ Global Select Market (or any successor to the foregoing).

Pro Rata Share ” means, as of any date of determination:

(a) with respect to a Lender’s obligation to make all or a portion of the Revolving Loans, with respect to such Lender’s right to receive payments of interest, fees, and principal with respect to the Revolving Loans, and with respect to all other computations and other matters related to the Revolver Commitments or the Revolving Loans, the percentage obtained by dividing (i) the Revolving Loan Exposure of such Lender by (ii) the aggregate Revolving Loan Exposure of all Lenders,

(b) [reserved], or

(c) with respect to all other matters and for all other matters as to a particular Lender (including the indemnification obligations arising under Section  15.07 ), the percentage obtained by dividing (i) the Revolving Loan Exposure of such Lender by (ii) the aggregate Revolving Loan Exposure of all Lenders, in any such case as the applicable percentage may be adjusted by assignments permitted pursuant to Section  13.01 ; provided , that if all of the Loans and other Obligations have been repaid in full in cash and all Commitments have been terminated, Pro Rata Share under this clause shall be determined as if the Revolving Loan Exposures had not been repaid, collateralized, or terminated and shall be based upon the Revolving Loan Exposures as they existed immediately prior to their repayment, collateralization, or termination.

 

41


Products ” means, from time to time, any products currently manufactured, sold, developed, tested or marketed by any Loan Party or any of a Loan Party’s Subsidiaries.

Protective Advances ” has the meaning specified therefor in Section  2.02(c)(i) .

Qualified Cash ” means, as of any date of determination, the amount of unrestricted cash and Cash Equivalents of Loan Parties that is in Deposit Accounts or in Securities Accounts, or any combination thereof, and which such Deposit Account or Securities Account is the subject of a Control Agreement and is maintained by a branch office of the bank or securities intermediary located within the United States.

Real Property ” means any real property owned, leased, subleased or otherwise operated or occupied by any Loan Party or any Subsidiary of any Loan Party.

Recall ” means a Person’s Removal or Correction of a marketed product that the FDA considers to be in violation of the laws it administers and against which the FDA would initiate legal action (e.g., seizure).

Recipient ” means (a) Agent, (b) any Lender, or (c) during any Third Party Agent Retention Period, the Third Party Agent, as applicable.

Record ” means information that is inscribed on a tangible medium or that is stored in an electronic or other medium and is retrievable in perceivable form.

Register ” has the meaning specified therefor in Section  13.01(i) .

Registered Loan ” has the meaning specified therefor in Section  13.01(i) .

Regulation D ” means Regulation D of the Board of Governors of the Federal Reserve System as in effect from time to time and any successor to all or a portion thereof establishing reserve requirements.

Regulatory Required Permit ” means any and all licenses, clearances, exemptions, approvals, registrations, and permits issued by the FDA, DEA or any other applicable Governmental Authority, including, without limitation, Drug Applications, any 510(k) premarket clearance, grant of a de novo request, premarket approval application (“PMA”), or investigational device exemption (“IDE”), or the foreign equivalent to any of the foregoing necessary for the design, testing, manufacture, processing, assembly, packaging, labeling, marketing, distribution, commercialization, import, export, or sale of any Product by any applicable Loan Party (or Loan Parties) and its (or their) Subsidiaries as such activities are being conducted by such Loan Party (or Loan Parties) and its (or their) Subsidiaries with respect to such Product at such time; and any device listings and device establishment registrations under 21 C.F.R. Part 807, and any drug listings and drug establishment registrations under 21 U.S.C. Section 510, registrations issued by DEA under 21 U.S.C. Section 823 (if applicable to any Product) and those issued by State governments for the conduct of the Loan Parties’ or any of their Subsidiaries’ business.

Related Fund ” means (a) any Person (other than a natural person) that is engaged in making, purchasing, holding or investing in bank loans and similar extensions of credit in the ordinary course and that is administered, advised or managed by (i) a Lender, (ii) an Affiliate of a Lender or (iii) an entity or an Affiliate of an entity that administers, advises or manages a Lender, or (b) any Approved Fund.

 

42


Related Parties ” means, with respect to any Person, such Person’s Affiliates and the partners, directors, officers, employees, agents, trustees, administrators, managers, attorneys, advisors and representatives of such Person and of such Person’s Affiliates.

Releases ” means any release, threatened release, spill, emission, leaking, pumping, pouring, emitting, emptying, escape, injection, deposit, disposal, discharge, dispersal, dumping, leaching or migration of Hazardous Material into or through the environment.

Removal ” means the physical removal of a product from its point of use to some other location for repair, modification, adjustment, relabeling, destruction or inspection.

Required Lenders ” means, at any time, Lenders the aggregate Pro Rata Shares of which (calculated under clause (d) of the definition of Pro Rata Shares) exceed 50%.

Reserves ” means, as of any date of determination, those reserves that Agent (including, during any Third Party Agent Retention Period, the Third Party Agent) deems necessary or appropriate, in its Permitted Discretion and subject to Section  2.01(c) , to establish and maintain (including reserves with respect to (a) sums that Borrowers or their Subsidiaries are required to pay under any Section hereof or any other Loan Document (such as taxes, assessments, insurance premiums, or, in the case of leased assets, rents or other amounts payable under such leases) and has failed to pay, and (b) amounts owing by Borrowers or their Subsidiaries to any Person to the extent secured by a Lien on, or trust over, any of the Collateral (other than a Permitted Lien), which Lien or trust, in the Permitted Discretion of Agent (including, during any Third Party Agent Retention Period, the Third Party Agent) likely would have a priority superior to Agent’s Liens (such as Liens or trusts in favor of landlords, warehousemen, carriers, mechanics, materialmen, laborers, or suppliers, or Liens or trusts for ad valorem, excise, sales, or other taxes where given priority under applicable law) in and to such item of the Collateral) with respect to the Borrowing Base or the Maximum Revolver Amount. Without limiting the foregoing, to the extent that any Accounts, Inventory or Equipment are included in the most recently delivered Borrowing Base Certificate and such Accounts, Inventory or Equipment are no longer eligible in accordance with the definitions of “Eligible Domestic Accounts”, “Eligible Foreign Accounts”, “Eligible Inventory” and “Eligible Equipment”, as applicable, Agent (and, during any Third Party Agent Retention Period, the Third Party Agent) may establish Reserves against the Borrowing Base in the amount of any such Accounts, Inventory or Equipment prior to delivery of an updated Borrowing Base Certificate that removes such items.

Restricted Payment ” means, with respect to any Person, (i) the declaration or making of any dividend payment or other distribution of assets, properties, cash, rights, obligations or securities on account of any of its Stock, (ii) the purchasing, redemption or other acquisition for value of any of its Stock (other than, when no Default or Event of Default has occurred or is continuing (or would occur after giving effect to any such purchase, redemption or other acquisition) and to the extent there would be pro forma compliance with the financial covenants in Article  VII (after giving effect to any such purchase, redemption or other acquisition), solely pursuant to Endologix’ stock option exchange program on the terms set forth, and specifically described (and without giving effect to any changes thereto that would be adverse to the Lender Group), in that certain proxy statement of Endologix filed with the SEC on April 20, 2018, Endologix shall have the ability to provide certain qualified employees of Endologix (which shall not include name executive officers or board of directors of Endologix and only with respect to “Eligible Participants” (as described therein)) the option to surrender certain “out-of-the-money” or “underwater” options with an exercise price of $6.50 or greater that are “Eligible Options” (as described therein) for cancellation in exchange for a grant of a lesser number of new restricted stock units of Endolgoix that may be settled for shares of Endologix’ common stock under Endologix’ amended and restated 2015 stock incentive plan of Endologix that is attached to such aforementioned proxy statement

 

43


(and without giving effect to any material changes thereto), all as further specifically described (and without giving effect to any material changes thereto) in such proxy statement) now or hereafter outstanding or (iii) the making of any payment or prepayment of principal of, premium, if any, interest, fees, redemption, exchange, purchase, retirement, defeasance, sinking fund or similar payment with respect to, any Indebtedness subordinated to the Obligations as to right and time of payment or as to other rights and remedies thereunder. For the avoidance of doubt, the entry into, any payments or deliveries in respect of, and the performance, exercise and/or settlement of the Borrower’s 2.25% Convertible Notes, 3.25% Convertible Notes (including, for the avoidance of doubt, any Permitted 3.25% Convertible Note Refinancing), Capped Calls, or under the Term Debt Facility are not Restricted Payments.

Revolver Commitment ” means, with respect to each Revolving Lender, its Revolver Commitment, and, with respect to all Revolving Lenders, their Revolver Commitments, in each case as such Dollar amounts are set forth beside such Revolving Lender’s name under the applicable heading on Schedule C-1 or in the Assignment and Acceptance pursuant to which such Revolving Lender became a Revolving Lender hereunder, as such amounts may be reduced or increased from time to time pursuant to assignments made in accordance with the provisions of Section  13.01 . Notwithstanding anything to the contrary in this Agreement, the Revolver Commitment shall never be more than the Maximum Revolver Amount.

Revolver Exit Payment ” has the meaning specified thereof in Section  2.09(g) .

Revolver Usage ” means, as of any date of determination, the amount of outstanding Revolving Loans (inclusive of Protective Advances).

Revolving Facility ” means, at any time, the aggregate amount of the Revolving Lenders’ Revolver Commitments at such time.

Revolving Lender ” means a Lender that has a Revolver Commitment or that has an outstanding Revolving Loan.

Revolving Loan Exposure ” means, with respect to any Revolving Lender, as of any date of determination (a) prior to the termination of the Revolver Commitments, the amount of such Lender’s Revolver Commitment, and (b) after the termination of the Revolver Commitments, the aggregate outstanding principal amount of the Revolving Loans of such Lender.

Revolving Loans ” has the meaning specified therefor in Section  2.01(a) .

Sanctioned Entity ” means (a) a country or a government of a country, (b) an agency of the government of a country, (c) an organization directly or indirectly controlled by a country or its government, (d) a Person resident in or determined to be resident in a country, in each case, that is subject to a country sanctions program administered and enforced by OFAC.

Sanctioned Person ” means a Person named on the list of Specially Designated Nationals maintained by OFAC.

Sanctions ” means all economic or financial sanctions or trade embargoes imposed, administered or enforced from time to time by (a) the U.S. government, including those administered by OFAC or the U.S. Department of State, or (b) the United Nations Security Council, the European Union or Her Majesty’s Treasury of the United Kingdom.

S&P ” has the meaning specified therefor in the definition of Cash Equivalents.

 

44


SEC ” means the United States Securities and Exchange Commission and any successor thereto.

Second Period ” has the meaning specified in Section  2.09(d)(ii) .

Secured Parties ” means Agent (including any Third Party Agent), the Lenders and all Indemnified Persons.

Securities Account ” means a securities account (as that term is defined in the Code).

Securities Act ” means the Securities Act of 1933, as amended, including the rules and regulations promulgated thereunder.

Securitization ” has the meaning specified therefor in Section  13.01(h) .

Settlement ” has the meaning specified therefor in Section  2.02(d)(i) .

Settlement Date ” has the meaning specified therefor in Section  2.02(d)(i) .

Solvent ” means, with respect to any Person as of any date of determination, that, as of such date, (a) the value of the assets of such Person at a “fair valuation”’ (as referenced in the Bankruptcy Code) is greater than the total amount of liabilities (including contingent and unliquidated liabilities) of such Person, (b) such Person is able to pay all liabilities of such Person as such liabilities mature, and (c) such Person does not have unreasonably small capital in relation to such Person’s business as contemplated as of the Closing Date. In computing the amount of contingent or unliquidated liabilities at any time, such liabilities shall be computed at the amount that, in light of all the facts and circumstances existing at such time, represents the amount that can reasonably be expected to become an actual or matured liability.

Stock ” means (a) all shares of capital stock (whether denominated as common stock or preferred stock), equity interests, beneficial, partnership or membership interests, joint venture interests, participations or other ownership or profit interests in or equivalents (regardless of how designated) of or in a Person (other than an individual), whether voting or non-voting; and (b) all securities convertible into or exchangeable for any other Stock and all warrants, options or other rights (other than the 2.25% Convertible Notes, the 3.25% Convertible Notes, any Permitted 3.25% Convertible Note Refinancing permitted hereunder, any Capped Call transactions, and the Warrants) to purchase, subscribe for or otherwise acquire any other Stock, whether or not presently convertible, exchangeable or exercisable.

Subordinated Debt ” means any Indebtedness of the Loan Parties incurred pursuant to the terms of the Subordinated Debt Documents and with the prior written consent of Agent and the Lenders, all of which documents must be in form and substance acceptable to Agent and the Lenders in their sole discretion. As of the Closing Date, there is no Subordinated Debt.

Subordinated Debt Documents ” means any documents evidencing and/or securing Indebtedness governed by a Subordination Agreement, all of which documents must be in form and substance acceptable to Agent and the Lenders in their sole discretion. As of the Closing Date, there are no Subordinated Debt Documents.

Subordination Agreement ” means any agreement between Agent and another creditor of one or more Loan Parties, as the same may be amended, supplemented, restated or otherwise modified from time to time in accordance with the terms thereof, pursuant to which the Indebtedness owing from any Loan Party or Loan Parties and/or the Liens securing such Indebtedness granted by any Loan Party or Loan Parties to such creditor are subordinated in any way to the Obligations and the Liens created under the

 

45


Guaranty and Security Agreement, the terms and provisions of such Subordination Agreements to have been agreed to by, and be acceptable to, Agent in the exercise of its sole discretion.

Subordination Provisions ” has the meaning specified therefor in Section  8.19 .

Subsidiary ” or “ Subsidiaries ” means, with respect to any Person, (a) any corporation of which an aggregate of more than fifty percent (50%) of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, capital stock of any other class or classes of such corporation shall have or might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, owned legally or beneficially by such Person or one or more Subsidiaries of such Person, or with respect to which any such Person has the right to vote or designate the vote of more than fifty percent (50%) of such capital stock whether by proxy, agreement, operation of law or otherwise, and (b) any partnership or limited liability company in which such Person and/or one or more Subsidiaries of such Person shall have an interest (whether in the form of voting or participation in profits or capital contribution) of more than fifty percent (50%) or of which any such Person is a general partner or may exercise the powers of a general partner. Unless the context otherwise requires, each reference to a Subsidiary shall be a reference to a Subsidiary of a Loan Party.

Swap Contract ” means any agreement, contract or transaction that constitutes a “swap” within the meaning of Section 1a(47) of the Commodity Exchange Act, not including Capped Calls.

Taxes ” means any taxes, levies, imposts, duties, fees, assessments or other charges of whatever nature now or hereafter imposed by any jurisdiction or by any political subdivision or taxing authority thereof or therein, and all interest, penalties or similar liabilities with respect thereto.

Tax Affiliate ” means (a) the Borrower and its Subsidiaries and (b) any Affiliate of the Borrower with which the Borrower files or is required to file consolidated, combined or unitary tax returns.

Term Agent ” has the meaning ascribed to such term in the definition of “Term Credit Agreement” herein.

Term Credit Agreement ” means that certain Amended and Restated Facility Agreement, dated as of August 9, 2018, by and among Endologix, the other Persons party thereto from time to time as “Loan Parties” (as defined therein), Deerfield Private Design Fund IV, L.P., in its capacity as “Agent” (as defined therein, in such capacity, the “ Term Agent ”) and the financial institutions or other entities from time to time party thereto, each as a “Lender (as defined therein, the “ Term Lenders ”), as amended, restated, supplemented or otherwise modified in accordance and in compliance with the Intercreditor Agreement and this Agreement.

Term Debt ” means the “Facility Obligations” as defined in the Intercreditor Agreement.

Term Debt Documents ” means the “Facility Documents” as defined in the Intercreditor Agreement.

Term Lenders ” has the meaning ascribed to such term in the definition of “Term Credit Agreement” herein.

Third Period ” has the meaning specified in Section  2.09(d)(ii) .

 

46


Third Party Agent ” means any Person other than Deerfield Revolver and its Affiliates that (a) (i) becomes the Agent under the Loan Documents or (ii) is retained or hired as an agent or a subagent of the Agent to perform certain duties and responsibilities of (or receive certain rights and benefits provided to) the Agent under the Loan Documents, (b) Borrower Representative has been informed of as being a Third Party Agent, and (c) has not (i) been removed from such role or position of the type set forth in clause (a)(i) or clause (a)(ii) by Deerfield Revolver (or any such succeeding Agent to Deerfield Revolver”) or (ii) had such role or position be terminated pursuant to the terms of any agreement between the Third Party Agent and Agent (each of the events in clause (c)(i) and clause (c)(ii) above, a “ Third Party Agent Termination Event ”). It being understood and agreed that as of the Closing Date, Cortland shall be deemed to be a Third Party Agent so long as a Third Party Agent Termination Event has not occurred.

Third Party Agent Retention Period ” means any period of time when any Person is acting or performing as a Third Party Agent pursuant to the definition of “Third Party Agent.”

Third Party Agent Termination Event ” has the meaning specified therefor in the definition of “Third Party Agent”.

Third Party Obligation ” has the meaning provided therefor in the definition of “Contingent Obligation.”

Third Party Payor ” means Medicare, Medicaid, TRICARE, and other state or federal health care program, Blue Cross and/or Blue Shield, private health care insurers and managed care organizations.

Third Party Payor Programs ” means all private or governmental programs providing health care benefits, whether directly through insurance or otherwise, that are sponsored by a Third Party Payor.

Title IV Plan ” means an Employee Benefit Plan subject to Title IV of ERISA, other than a Multiemployer Plan, to which any ERISA Affiliate incurs or otherwise has or could reasonably be expected to have any obligation or Liabilities (including under Section 4069 of ERISA).

Trademarks ” has the meaning specified therefor in the Guaranty and Security Agreement.

Trademark Security Agreement ” has the meaning specified therefor in the Guaranty and Security Agreement.

Trigger Date ” means the date that Borrowers shall have delivered quarterly financial statements to Agent (and, during any Third Party Agent Retention Period, also to the Third Party Agent) in accordance with Section  5.05(a) that demonstrate that Endologix and its Subsidiaries shall have achieved TTM EBITDA of $20,000,000 or greater.

TRICARE ” means the program administered pursuant to 10 U.S.C. Section 1071 et. seq), Sections 1320a-7 and 1320a-7a of Title 42 of the United States Code and the regulations promulgated pursuant to such statutes.

Trunk Inventory ” means “trunk stock inventory” that is in the possession of sales personnel of the Borrowers.

TTM EBITDA ” means, as of any date of determination, EBITDA for the 12-month period most recently ended.

 

47


UCC ” means the Uniform Commercial Code of any applicable jurisdiction and, if the applicable jurisdiction shall not have any Uniform Commercial Code, the Uniform Commercial Code as in effect from time to time in the State of New York.

United States ” and “ U.S. ” means the United States of America.

Unused Line Fee ” has the meaning specified therefor in Section  2.09(b) .

Voidable Transfer ” has the meaning specified therefor in Section  17.07 .

Withholding Agent ” means any Borrower and Agent.

1.02 Accounting Terms . All accounting terms not specifically defined herein shall be construed in accordance with GAAP; provided , that if Borrowers notifies Agent that Borrowers request an amendment to any provision hereof to eliminate the effect of any Accounting Change occurring after the Closing Date or in the application thereof on the operation of such provision (or if Agent notifies Borrowers that the Required Lenders request an amendment to any provision hereof for such purpose), regardless of whether any such notice is given before or after such Accounting Change or in the application thereof, then Agent and Borrowers agree that they will negotiate in good faith amendments to the provisions of this Agreement that are directly affected by such Accounting Change with the intent of having the respective positions of the Lenders and Borrowers after such Accounting Change conform as nearly as possible to their respective positions prior to giving effect to such Accounting Change and, until any such amendments have been agreed upon and agreed to by the Required Lenders, the provisions in this Agreement shall be calculated as if no such Accounting Change had occurred; provided, further , that all obligations of any Person that are or would be characterized as an operating lease as determined in accordance with GAAP as in effect on the Closing Date (whether or not such operating lease was in effect on such date) shall continue to be accounted for as an operating lease (and not as a capital lease obligation) for purposes of this Agreement regardless of any change in GAAP following the Effective Date that would otherwise require such obligation to be recharacterized as a capital lease obligation, to the extent that financial reporting shall not be affected hereby. When used herein, the term “financial statements” shall include the notes and schedules thereto. Whenever the term “Borrowers” is used in respect of a financial covenant or a related definition, it shall be understood to mean Borrowers and their Subsidiaries on a consolidated basis, unless the context clearly requires otherwise. Notwithstanding anything to the contrary contained herein, all financial statements delivered hereunder shall be prepared, and all financial covenants contained herein shall be calculated, without giving effect to any election under the Statement of Financial Accounting Standards No. 159 (or any similar accounting principle) permitting a Person to value its financial liabilities or Indebtedness at the fair value thereof.

1.03 Code . Any terms used in this Agreement that are defined in the Code shall be construed and defined as set forth in the Code unless otherwise defined herein; provided , that to the extent that the Code is used to define any term herein and such term is defined differently in different Articles of the Code, the definition of such term contained in Article 9 of the Code shall govern.

1.04 Construction . Unless the context of this Agreement or any other Loan Document clearly requires otherwise, references to the plural include the singular, references to the singular include the plural, the terms “includes” and “including” are not limiting, and the term “or” has, except where otherwise indicated, the inclusive meaning represented by the phrase “and/or.” The words “hereof,” “herein,” “hereby,” “hereunder,” and similar terms in this Agreement or any other Loan Document refer to this Agreement or such other Loan Document, as the case may be, as a whole and not to any particular provision of this Agreement or such other Loan Document, as the case may be. Section, subsection,

 

48


clause, schedule, and exhibit references herein are to this Agreement unless otherwise specified. Any reference in this Agreement or in any other Loan Document to any agreement, instrument, or document shall include all alterations, amendments, changes, extensions, modifications, renewals, replacements, substitutions, joinders, and supplements, thereto and thereof, as applicable (subject to any restrictions on such alterations, amendments, changes, extensions, modifications, renewals, replacements, substitutions, joinders, and supplements set forth herein). The words “asset” and “property” shall be construed to have the same meaning and effect and to refer to any and all tangible and intangible assets and properties. Unless expressly stated otherwise herein or in any other Loan Document, any reference herein or in any other Loan Document to the satisfaction, repayment, or payment in full of the Obligations shall mean (a) the payment or repayment in full in cash of (i) the principal amount of, and interest accrued and unpaid with respect to, all outstanding Loans, together with the payment of any premium applicable to the repayment of the Loans, (ii) all Lender Group Expenses that have accrued and are unpaid regardless of whether demand has been made therefor, (iii) all fees or charges that have accrued (or are owed) hereunder or under any other Loan Document and are unpaid, (b) [reserved], (c) the receipt by Agent of cash collateral in order to secure any other contingent Obligations for which a claim or demand for payment has been made on or prior to such time or in respect of matters or circumstances known to Agent or a Lender at such time that are reasonably expected to result in any loss, cost, damage, or expense (including attorneys’ fees and legal expenses), such cash collateral to be in such amount as Agent reasonably determines is appropriate to secure such contingent Obligations, (d) the payment or repayment in full in cash of all other outstanding Obligations (other than unasserted contingent indemnification Obligations), and (e) the termination of all of the Commitments. Any reference herein to any Person shall be construed to include such Person’s successors and assigns; provided that no assign of any Loan Party of any of its rights or obligations under this Agreement or the other Loan Documents is permitted and any such assignment shall be absolutely void ab initio . Any requirement of a writing contained herein or in any other Loan Document shall be satisfied by the transmission of a Record. The terms “shall” and “will” are used interchangeably in this Agreement and the other Loan Documents and mean for the Loan Parties and their Subsidiaries to have an absolute obligation to perform or do (or not perform or do) a certain action or event, as the context may require.

1.05 Time References . Unless the context of this Agreement or any other Loan Document clearly requires otherwise, all references to time of day refer to Eastern standard time or Eastern daylight saving time, as in effect in New York, New York on such day. For purposes of the computation of a period of time from a specified date to a later specified date, the word “from” means “from and including” and the words “to” and “until” each means “to and including”; provided that, with respect to a computation of fees or interest payable to Agent (including any Third Party Agent), any Lender or any other member of the Lender Group, such period shall in any event consist of at least one full day.

1.06 Schedules and Exhibits . All of the schedules and exhibits attached to this Agreement shall be deemed incorporated herein by reference.

ARTICLE II.

LOANS AND TERMS OF PAYMENT.

2.01 Revolving Loans .

(a) Subject to the terms and conditions of this Agreement, and during the term of this Agreement, each Revolving Lender agrees (severally, not jointly or jointly and severally) to make revolving loans (all such loans, collectively, the “ Revolving Loans ”) to Borrowers under a revolving credit facility in an amount at any one time outstanding not to exceed the lesser of:

 

49


(i) such Lender’s Revolver Commitment, or

(ii) such Lender’s Pro Rata Share of an amount equal to the lesser of:

(A) the amount equal to (1) the Maximum Revolver Amount less (2) the Revolver Usage at such time, and

(B) the amount equal to (1) the Borrowing Base as of such date (based upon (x) during a Non-Third Party Agent Retention Period, the most recent Borrowing Base Certificate (Agent) delivered by Borrowers to Agent or (y) during a Third Party Agent Retention Period, the most recent Borrowing Base Certificate (Third Party Agent) delivered by Borrowers to Third Party Agent, less (2) the Revolver Usage at such time.

(b) Amounts borrowed pursuant to this Section  2.01 may be repaid and, subject to the terms and conditions of this Agreement, reborrowed at any time during the term of this Agreement. The outstanding principal amount of the Revolving Loans, together with interest accrued and unpaid thereon, shall constitute Obligations and shall be due and payable on the Maturity Date or, if earlier, on the date on which they are declared due and payable pursuant to the terms of this Agreement.

(c) Notwithstanding anything to the contrary in this Section  2.01 , Agent may at any time establish one or more Reserves against the Borrowing Base or the Maximum Revolver Amount as Agent (or, during any Third Party Agent Retention Period, a Third Party Agent) may deem proper and appropriate in Agent’s (including, during any Third Party Agent Retention Period, a Third Party Agent’s) Permitted Discretion in its capacity as an asset based lender. A Reserve may limit the Availability, reduce the Borrowing Base (by reduction of an advance rate set forth in the Borrowing Base or otherwise), or otherwise restrict a Borrower’s ability to borrow hereunder. Agent (or, during any Third Party Agent Retention Period, a Third Party Agent) shall endeavor to notify Borrower Representative promptly after the establishment of any Reserve; provided, however, under no circumstance shall the delivery or receipt of any such notice constitute a condition to Agent’s (or, during any Third Party Agent Retention Period, a Third Party Agent’s) establishment of any Reserve. For the avoidance of doubt, Agent (or, during any Third Party Agent Retention Period, a Third Party Agent) may in Agent’s (including, during any Third Party Agent Retention Period, such Third Party Agent’s) Permitted Discretion (but Agent (or such Third Party Agent, as applicable) shall have no obligation in any circumstance to) increase, reduce or release any Reserve that was previously established under this Section  2.01(c) .

2.02 Borrowing Procedures and Settlements .

(a) Procedure for Borrowing Loans . Each Borrowing shall be made by a written request by an Authorized Person delivered to Agent (and, during any Third Party Agent Retention Period, also to the Third Party Agent) and received by Agent (and, during any Third Party Agent Retention Period, also to the Third Party Agent) no later than 1:00 p.m. on the Business Day that is three (3) Business Days prior to the requested Funding Date, specifying (i) the amount of such Borrowing, and (ii) the requested Funding Date (which shall be a Business Day); provided , that Agent may, in its sole discretion, elect to accept as timely requests that are received later than 1:00 p.m. on the applicable Business Day.

(b) Making of Loans .

(i) After receipt of a request for a Borrowing pursuant to Section  2.02(a) , Agent (or, during any Third Party Agent Retention Period, the Third Party Agent) shall promptly notify the Lenders

 

50


by telecopy, telephone, email, or other electronic form of transmission, of the requested Borrowing. If Agent has notified the Lenders of a requested Borrowing on the Business Day that is one (1) Business Day prior to the Funding Date, then each Lender shall make the amount of such Lender’s Pro Rata Share of the requested Borrowing (or such lesser Availability amount) available to the Borrowers on the applicable Funding Date by transferring immediately available funds equal to such amount to the Borrowers; provided , that, subject to the provisions of Section  2.02(c)(ii) , no Lender shall have an obligation to make any Revolving Loan, if (1) one or more of the applicable conditions precedent set forth in Article III will not be satisfied on the requested Funding Date for the applicable Borrowing unless such condition has been waived, or (2) the requested Borrowing would exceed the Availability on such Funding Date. Agent shall charge to the Loan Account usual and customary fees for the wire transfer of each Borrowing.

(ii) Each Borrower and each Lender hereby authorizes Agent to make Revolving Loans on behalf of the Lenders, at any time in its sole discretion, to pay principal owing in respect of the Loans and interest, fees, expenses and other charges payable by any Loan Party from time to time arising under this Agreement or any other Loan Document.

(c) Protective Advances and Optional Overadvances .

(i) Any contrary provision of this Agreement or any other Loan Document notwithstanding, but subject to Section  2.02(c)(iv) , at any time (A) after the occurrence and during the continuance of a Default or an Event of Default, or (B) that any of the other applicable conditions precedent set forth in Article III are not satisfied, Agent hereby is authorized by Borrowers and the Lenders, from time to time, in Agent’s sole discretion, to make Revolving Loans to, or for the benefit of, Borrowers, on behalf of the Revolving Lenders, that Agent, in its Permitted Discretion, deems necessary or desirable (1) to preserve or protect the Collateral, or any portion thereof, or (2) to enhance the likelihood of repayment of the Obligations (the Revolving Loans described in this Section  2.02(c)(i) shall be referred to as “ Protective Advances ”). Notwithstanding the foregoing, no Protective Advance shall be made which would cause (A) the aggregate amount of all Protective Advances outstanding at any one time to exceed 10% of the Maximum Revolver Amount unless the Required Lenders otherwise agree or (B) the aggregate amount of Revolver Usage outstanding at any one time to exceed the Maximum Revolver Amount.

(ii) Any contrary provision of this Agreement or any other Loan Document notwithstanding, but subject to Section  2.02(c)(iv) , the Lenders hereby authorize Agent, and Agent may, but is not obligated to, knowingly and intentionally, continue to make Revolving Loans to Borrowers notwithstanding that an Overadvance exists or would be created thereby, so long as (A) after giving effect to such Revolving Loans, the outstanding Revolver Usage does not exceed the Borrowing Base by more than 10% of the Maximum Revolver Amount (unless Required Lenders agree to a higher amount), and (B) after giving effect to such Revolving Loans, the outstanding Revolver Usage (except for and excluding amounts charged to the Loan Account for interest, fees, or Lender Group Expenses) does not exceed the Maximum Revolver Amount. In the event Agent obtains actual knowledge that an Overadvance exists, regardless of the amount of, or reason for, such excess, Agent shall notify the Lenders as soon as practicable and the Lenders with Revolver Commitments thereupon shall, together with Agent, jointly determine the terms of arrangements that shall be implemented with Borrowers intended to eliminate the Overadvance within thirty (30) days. In such circumstances, if any Lender with a Revolver Commitment objects to the proposed terms of reduction or repayment of any Overadvance, the terms of reduction or repayment thereof shall be implemented according to the determination of the Required Lenders. The foregoing provisions are meant for the benefit of the Lenders and Agent and are not meant for the benefit of Borrowers, which shall continue to be bound by the provisions of Section

 

51


2.03(e) . Each Lender with a Revolver Commitment shall be obligated to make Revolving Loans in accordance with Section  2.02(b) in, or settle Overadvances made by Agent with Agent as provided in Section  2.02(d) , as applicable) for, the amount of such Lender’s Pro Rata Share of any unintentional Overadvances by Agent reported to such Lender, any intentional Overadvances made as permitted under this Section  2.02(c)(ii) , and any Overadvances resulting from the charging to the Loan Account of interest, fees, or Lender Group Expenses.

(iii) Each Protective Advance and each Overadvance (each, an “ Extraordinary Advance ”) shall be deemed to be a Revolving Loan hereunder. Prior to Settlement with respect to Extraordinary Advances, all payments on the Extraordinary Advances made by Agent, including interest thereon, shall be payable to Agent solely for its own account. The Extraordinary Advances shall be repayable on demand, secured by Agent’s Liens, constitute Obligations hereunder, and bear interest at the rate applicable from time to time to Revolving Loans. The provisions of this Section  2.02(c) are for the exclusive benefit of Agent and the Lenders and are not intended to benefit Borrowers (or any other Loan Party) in any way.

(iv) Notwithstanding anything contained in this Agreement or any other Loan Document to the contrary: (A) no Extraordinary Advance may be made by Agent if such Extraordinary Advance would cause the aggregate principal amount of Extraordinary Advances outstanding to exceed an amount equal to 10% of the Maximum Revolver Amount; and (B) to the extent that the making of any Extraordinary Advance causes the aggregate Revolver Usage to exceed the Maximum Revolver Amount, such portion of such Extraordinary Advance shall be for Agent’s sole and separate account and not for the account of any Lender and shall be entitled to priority in repayment in accordance with Section  2.03(b) .

(d) Settlement . It is agreed that each Lender’s funded portion of the Revolving Loans is intended by the Lenders to equal, at all times, such Lender’s Pro Rata Share of the outstanding Revolving Loans. Such agreement notwithstanding, Agent and the Lenders agree (which agreement shall not be for the benefit of Borrowers) that in order to facilitate the administration of this Agreement and the other Loan Documents, settlement among the Lenders as to any Extraordinary Advances shall take place on a periodic basis in accordance with the following provisions:

(i) Solely when any Extraordinary Advances are outstanding, Agent shall request settlement (“ Settlement ”) with the Lenders on a weekly basis, or on a more frequent basis if so determined by Agent in its sole discretion (A) for itself, with respect to the outstanding Extraordinary Advances, and (B) with respect to Borrowers’ or their Subsidiaries’ payments or other amounts received, as to each by notifying the Lenders by telecopy, telephone, or other similar form of transmission, of such requested Settlement, no later than 2:00 p.m. on the Business Day immediately prior to the date of such requested Settlement (the date of such requested Settlement being the “ Settlement Date ”). Such notice of a Settlement Date shall include a summary statement of the amount of outstanding Extraordinary Advances for the period since the prior Settlement Date. Subject to the terms and conditions contained herein (including Section  2.02(g) ): (1) if the amount of the Revolving Loans (including Extraordinary Advances) made by a Lender that is not a Defaulting Lender exceeds such Lender’s Pro Rata Share of the Revolving Loans (including Extraordinary Advances) as of a Settlement Date, then Agent shall, by no later than 12:00 p.m. on the Settlement Date, transfer in immediately available funds to a Deposit Account of such Lender (as such Lender may designate), an amount such that each such Lender shall, upon receipt of such amount, have as of the Settlement Date, its Pro Rata Share of the Revolving Loans (including Extraordinary Advances), and (2) if the amount of the Revolving Loans (including Extraordinary Advances) made by a Lender is less than such Lender’s Pro Rata Share of the Revolving Loans (including Extraordinary Advances) as of a Settlement Date, such Lender shall no later than 12:00 p.m. on the Settlement Date transfer in immediately available funds to Agent’s Account, an amount such

 

52


that each such Lender shall, upon transfer of such amount, have as of the Settlement Date, its Pro Rata Share of the Revolving Loans (including Extraordinary Advances). Such amounts made available to Agent under clause (2) of the immediately preceding sentence shall be applied against the amounts of the applicable Extraordinary Advances and shall constitute Revolving Loans of such Lenders.

(ii) In determining whether a Lender’s balance of the Revolving Loans (including Extraordinary Advances) is less than, equal to, or greater than such Lender’s Pro Rata Share of the Revolving Loans (including Extraordinary Advances) as of a Settlement Date, Agent shall, as part of the relevant Settlement, apply to such balance the portion of payments actually received in good funds by Agent with respect to principal, interest, fees payable by Borrowers and allocable to the Lenders hereunder, and proceeds of Collateral.

(iii) Between Settlement Dates, Agent, solely to the extent Extraordinary Advances for the account of Agent are outstanding, may apply any payments or other amounts received by Agent, that in accordance with the terms of this Agreement would be applied to the reduction of the Revolving Loans, to the Extraordinary Advances. During the period between Settlement Dates, Agent with respect to Extraordinary Advances, and each Lender with respect to the Revolving Loans other than Extraordinary Advances, shall be entitled to interest at the applicable rate or rates payable under this Agreement on the daily amount of funds employed by Agent, or the Lenders, as applicable.

(e) Notation . During any Third Party Agent Retention Period, Agent, as a non-fiduciary agent for Borrowers, shall maintain a register showing the principal amount of the Loans owing to each Lender and/or Extraordinary Advances owing to Agent, and the interests therein of each Lender, from time to time and such register shall, absent manifest error, conclusively be presumed to be correct and accurate. During any Non-Third Party Agent Retention Period, the Borrower Representative shall maintain such Loan Account and shall make such Loan Account available to Agent and the Lenders upon request therefrom. Upon the request of any Third Party Agent upon the commencement of any Third Party Agent Retention Period, the Borrower Representative shall share such Loan Account and any of its applicable books and records with the Third Party Agent, and with respect to any discrepancies between the books, records or Loan Account of the Borrower Representative, on the one hand, and the books, records or Loan Account of any Lender, the Agent or the Third Party Agent, on the other hand, the books, records and Loan Account of such Lender, Agent or Third Party Agent shall govern and control in the absence of demonstrable error.

(f) [ Reserved ].

(g) Independent Obligations . All Loans (other than Extraordinary Advances) shall be made by the Lenders contemporaneously and in accordance with their Pro Rata Shares. It is understood that (i) no Lender shall be responsible for any failure by any other Lender to perform its obligation to make any Loan (or other extension of credit) hereunder, nor shall any Commitment of any Lender be increased or decreased as a result of any failure by any other Lender to perform its obligations hereunder, and (ii) no failure by any Lender to perform its obligations hereunder shall excuse any other Lender from its obligations hereunder.

2.03 Payments; Reductions of Commitments; Prepayments .

(a) Payments by Borrowers . Except as otherwise expressly provided herein, all payments by Borrowers shall be made to each Lender based on such Lender’s Pro Rata Share and shall be made in immediately available funds, no later than 1:30 p.m. on the date specified herein. Any payment received by Agent (or, during any Third Party Agent Retention Period, any Third Party Agent) or any Lender later

 

53


than 1:30 p.m. may be deemed to have been received on the following Business Day and any applicable interest or fee shall continue to accrue until such following Business Day.

(b) Apportionment and Application .

(i) So long as no Application Event has occurred and is continuing, all principal and interest payments shall be paid by the Borrowers (and any such amounts received by Agent (or, during any Third Party Agent Retention Period, the Third Party Agent) shall be apportioned) ratably among the Lenders (according to the unpaid principal balance of the Obligations to which such payments relate held by each Lender) and all payments of fees and expenses shall be paid by the Borrowers (and any such amounts received by Agent (or, during any Third Party Agent Retention Period, the Third Party Agent) (other than fees or expenses that are for Agent’s or such Third Party Agent’s (as applicable) separate account) shall be apportioned) ratably among the Lenders having a Pro Rata Share of the type of Commitment or Obligation to which a particular fee or expense relates. Subject to Section  2.03(b)(iv) , all payments to be made hereunder by Borrowers shall be remitted to the Lenders (other than amounts owed specifically to Agent or any Third Party Agent (as applicable)) and all such payments, and all proceeds of Collateral paid by the Borrowers to the Lenders or received by Agent (or any Third Party Agent (as applicable)), shall be applied, so long as no Application Event has occurred and is continuing, to reduce the balance of the Loans and other Obligations outstanding and, thereafter, to Borrowers (to be wired to the Designated Account) or such other Person entitled thereto under Applicable Law.

(ii) At any time that an Application Event has occurred and is continuing, all payments remitted to Agent (or any Third Party Agent (as applicable)) or the Lenders and all proceeds of Collateral received by Agent (or any Third Party Agent (as applicable)) or the Lenders shall be applied as follows:

(A) first , to pay any Lender Group Expenses (including cost or expense reimbursements) or indemnities then due to Agent under the Loan Documents, until paid in full in cash,

(B) second , to pay any fees or premiums then due to Agent under the Loan Documents until paid in full in cash,

(C) third , to pay interest due in respect of all Protective Advances until paid in full in cash,

(D) fourth , to pay the principal of all Protective Advances until paid in full in cash,

(E) fifth , ratably, to pay any Lender Group Expenses (including cost or expense reimbursements) or indemnities then due to any of the Lenders under the Loan Documents, until paid in full in cash,

(F) sixth , ratably, to pay any fees or premiums then due to any of the Lenders under the Loan Documents until paid in full in cash,

(G) seventh , ratably, to pay interest accrued in respect of the Loans (other than Protective Advances) until paid in full in cash,

(H) eighth , ratably, to pay the principal of all Loans until paid in full in cash,

 

54


(I) ninth , to pay any other Obligations until paid in full in cash, and

(J) tenth , to Borrowers (to be wired to the Designated Account) or such other Person entitled thereto under Applicable Law.

(iii) Agent (or the Third Party Agent, as applicable) promptly shall distribute to each Lender, pursuant to the applicable wire instructions received from each Lender in writing, such funds as it may be entitled to receive that have been delivered to Agent (or the Third Party Agent, as applicable) instead of such Lender, subject to a Settlement delay as provided in Section  2.02(d) .

(iv) In each instance, so long as no Application Event has occurred and is continuing, Section  2.03(b)(i) shall not apply to any payment made by Borrowers to Agent and specified by Borrowers to be for the payment of specific Obligations then due and payable (or prepayable) under any provision of this Agreement or any other Loan Document.

(v) For purposes of Section  2.03(b)(ii) , “paid in full” of a type of Obligation means payment in cash or immediately available funds of all amounts owing on account of such type of Obligation, including interest accrued after the commencement of any Insolvency Proceeding, default interest, interest on interest, any premium or prepayment penalty, Commitment Fee, Liquidated Damages and expense reimbursements, irrespective of whether any of the foregoing would be or is allowed or disallowed in whole or in part in any Insolvency Proceeding.

(vi) In the event of a direct conflict between the priority provisions of this Section  2.03 and any other provision contained in this Agreement or any other Loan Document, it is the intention of the parties hereto that such provisions be read together and construed, to the fullest extent possible, to be in concert with each other. In the event of any actual, irreconcilable conflict that cannot be resolved as aforesaid then the terms and provisions of this Section  2.03 shall control and govern.

(c) Reduction of Revolver Commitments . The Revolver Commitments shall terminate on the Maturity Date. The Revolver Commitments may be reduced by the Borrower subject to payment of Liquidated Damages in accordance with Section  2.09(d) , to an amount (which may be zero) not less than the sum of (i) the Revolver Usage as of such date, plus (ii) the principal amount of all Revolving Loans not yet made as to which a request has been given by Borrowers under Section  2.02(a) . Each such reduction pursuant to clause (i)  shall be in an aggregate amount of $5,000,000 or any whole multiple of $1,000,000 in excess thereof (unless the Revolver Commitments are being reduced to zero and the amount of the Revolver Commitments in effect immediately prior to such reduction are less than $5,000,000), shall be made by providing not less than 10 Business Days prior written notice to Agent (and, during any Third Party Agent Retention Period, the Third Party Agent) and the Lenders, and shall be irrevocable. Each such reduction of the Revolver Commitments shall be permanent, shall be accompanied by any payment of Liquidated Damages required pursuant to Section  2.09(d) and shall reduce the Revolver Commitments of each Lender proportionately in accordance with its ratable share thereof.

(d) Optional Prepayments . Upon at least one (1) Business Day prior written notice the Borrowers may prepay the Loans at any time, in whole or in part, plus accrued and unpaid interest on the principal amount being prepaid to the prepayment date and all fees, costs, expenses and other amounts related thereto. No prepayment of Revolving Loans under this Section  2.03(d) shall result in a permanent reduction of the Revolver Commitments.

(e) Mandatory Prepayments .

 

55


(i) If, at any time, (i) the Revolver Usage on such date exceeds (ii) either (A) the Borrowing Base reflected in the Borrowing Base Certificate most recently delivered by Borrower to Agent (or, during the Third Party Agent Retention Period, the Third Party Agent) (as adjusted by Agent (or the Third Party Agent, as applicable) for Reserves established by Agent (or the Third Party Agent, as applicable) from time to time) or (B) the Maximum Revolver Amount, then Borrower shall immediately prepay the Obligations in accordance with Section  2.03(f) in an aggregate amount equal to the amount of such excess. No prepayment pursuant to this Section  2.03(e) shall result in a reduction in the Maximum Revolver Amount.

(ii) If, at any time, a Maximum Decreased Market Capitalization Overadvance Event occurs, then Borrower shall immediately prepay the Obligations in accordance with Section  2.03(f) in an aggregate amount equal to the Maximum Decreased Market Capitalization Overadvance Amount.

(f) Application of Payments . Each prepayment pursuant to Section  2.03(e)  shall, (i) so long as no Application Event shall have occurred and be continuing, be applied to the outstanding principal amount of the Revolving Loans until paid in full in cash, and (ii) if an Application Event shall have occurred and be continuing, be applied in the manner set forth in Section  2.03(b)(ii) .

2.04 Promise to Pay; Promissory Notes .

(a) Borrowers promise to pay all of the Obligations (including principal, interest, premiums, if any, fees, costs, and expenses (including Lender Group Expenses)) in cash to Agent and the Lenders in full on the Maturity Date or, if earlier, on the date on which the Obligations become due and payable pursuant to the terms of this Agreement.

(b) Any Lender may request that any portion of its Commitments or the Loans made by it be evidenced by one or more Notes. In such event, Borrowers (on a joint and several basis) shall execute and deliver to such Lender the requested Notes payable to the order of such Lender in a form furnished by Agent. Thereafter, the portion of the Commitments and Loans evidenced by such Notes and interest thereon shall at all times be represented by one or more Notes in such form payable to the order of the payee named therein.

2.05 Interest Rates: Rates, Payments, and Calculations .

(a) Interest Rates . Except as provided in Section  2.05(c) , all Revolving Loans and other Obligations shall bear interest at a per annum rate equal to the LIBOR Rate plus 5.50%; provided , that, notwithstanding anything to the contrary in this Agreement, to the extent that the aggregate Revolver Usage was less than $9,750,000 for any month, then, on the interest payment date in respect of such month, additional Revolving Loans shall be deemed outstanding in order to increase Aggregate Revolving Usage for such month to $9,750,000 for purposes of this Section  2.05(a) .

(b) [ Reserved ].

(c) Default Rate . Upon the occurrence and during the continuation of (i) an Event of Default described in Section  8.04 , automatically, and (ii) any other Event of Default, at the election of Agent or the Required Lenders in its (or their) sole discretion, all Obligations that have been charged to the Loan Account pursuant to the terms hereof shall bear interest at a per annum rate equal to two (2) percentage points above the per annum rate otherwise applicable hereunder or thereunder.

 

56


(d) Payment . Except to the extent provided to the contrary in Section  2.09 , (i) all interest and all other fees payable hereunder or under any of the other Loan Documents shall be due and payable in cash, in arrears for the preceding calendar month, on the first Business Day of each month and (ii) all costs and expenses payable hereunder or under any of the other Loan Documents, and all Lender Group Expenses shall be due and payable on the earlier of (A) the first day of the month following the date on which the applicable costs, expenses, or Lender Group Expenses were first incurred or (B) the date on which demand therefor is made by Agent (including, during any Third Party Agent Retention Period, the Third Party Agent) or any Lender (it being acknowledged and agreed that (1) any charging of such costs, expenses or Lender Group Expenses to the Loan Account pursuant to the provisions of the following sentence shall be deemed to constitute a demand for payment thereof for the purposes of this subclause  (B) and (2) Agent (and, during any Third Party Agent Retention Period, the Third Party Agent) and each Lender is authorized and directed to deduct and retain sufficient amounts from any deposits paid by Borrowers to Agent (including, during any Third Party Agent Retention Period, the Third Party Agent) or any Lender on or prior to the Closing Date or pursuant to the terms hereof or of any other Loan Document, as applicable). Borrowers agree that (x) its obligations contained in the first sentence of this Section  2.05(d) shall survive payment or satisfaction in full of all other Obligations and a termination of all of the Commitments and (y) all payments of the Lender Group Expenses shall be non-refundable under all circumstances. Borrowers hereby authorize Agent (including, during any Third Party Agent Retention Period, the Third Party Agent), from time to time without prior notice to Borrowers, to charge to the Loan Account (I) on the first day of each month, all interest accrued during the prior month on the Loans hereunder, (II) [reserved], (III) as and when incurred or accrued, all fees and costs provided for in Section  2.09(a) , (IV) on the first day of each month, the Unused Line Fee accrued during the prior month pursuant to Section  2.05(b) , (V) as and when due and payable, all other fees payable hereunder or under any of the other Loan Documents, (VI) [reserved], (VII) as and when incurred or accrued, all other Lender Group Expenses, and (VIII) as and when due and payable, all other payment obligations payable under any Loan Document. All amounts (including interest, fees, costs, expenses, Lender Group Expenses, or other amounts payable hereunder or under any other Loan Document) charged to the Loan Account shall thereupon constitute Revolving Loans hereunder, shall constitute Obligations hereunder, and shall initially accrue interest at the rate then applicable to Revolving Loans.

(e) Computation . All interest and fees chargeable under the Loan Documents shall be computed on the basis of a 360 day year, in each case, for the actual number of days elapsed in the period during which the interest or fees accrue.

(f) Intent to Limit Charges to Maximum Lawful Rate . In no event shall the interest rate or rates payable under this Agreement, plus any other amounts paid in connection herewith, exceed the highest rate permissible under any law that a court of competent jurisdiction shall, in a final determination, deem applicable. Borrowers and the Lender Group, in executing and delivering this Agreement, intend legally to agree upon the rate or rates of interest and manner of payment stated within it; provided , that, anything contained herein to the contrary notwithstanding, if such rate or rates of interest or manner of payment exceeds the maximum allowable under applicable law, then, ipso facto, as of the date of this Agreement, Borrowers are and shall be liable only for the payment of such maximum amount as is allowed by law, and payment received from Borrowers in excess of such legal maximum, whenever received, shall be applied to reduce the principal balance of the Obligations to the extent of such excess.

(g) Inability to Determine Interest Rate . If, at any applicable time, the basis for determining the LIBOR Rate ceases to be reported on the applicable page of the Bloomberg screen and if Agent shall have reasonably determined (which determination shall be conclusive and binding upon the Lenders) that, by reason of circumstances affecting the relevant market, other adequate and reasonable means do not

 

57


exist for ascertaining the interest rate applicable to the offering of Dollar deposits to major banks in the London interbank eurodollar market for the applicable period, then Agent shall forthwith give notice thereof to the Borrower Representative. If such notice is given, (i) the interest rate applicable to the Revolving Loans and other Obligations shall be the Prime Rate plus 4.50% determined and effective immediately, (ii) each reference herein to the “LIBOR Rate” shall be deemed thereafter to be a reference to the Prime Rate, and (iii) subject to Section  2.05(i) , such substituted rate shall thereafter be determined by Agent in accordance with the terms hereof. Until notice contemplated by Section  2.05(i) is furnished by Agent, the LIBOR Rate shall not apply to any Loan or any other Obligations.

(h) LIBOR Rate Unlawful or Impractical . In the event that any change in market conditions or any Change in Law shall at any time after the date hereof, in the reasonable opinion of any Lender, make it unlawful or impractical for such Lender to fund or maintain Loans bearing interest at the LIBOR Rate or to continue such funding or maintaining, or to determine or charge interest rates at the LIBOR Rate, such Lender shall give notice of such changed circumstances to Agent, the other Lenders and the Borrower Representative and (i) in the case of any outstanding Loans of such Lender bearing interest at the LIBOR Rate, the date specified in such Lender’s notice shall be deemed to be the last day such Loans shall bear interest at the LIBOR Rate, and interest upon the Loans of such Lender thereafter shall accrue interest at the Prime Rate, and (y) such Prime Rate shall continue to be applicable to the Obligations until such Lender determines that it would no longer be unlawful or impractical to fund or maintain Loans bearing interest at the LIBOR Rate.

(i) Reinstatement of LIBOR Rate . If there has been at any time an interest rate substituted for the LIBOR Rate in accordance with this Section  2.05 and if in the reasonable opinion of Agent, the circumstances causing such substitution have ceased, then Agent shall promptly notify Borrower Representative in writing of such cessation, and thereafter the LIBOR Rate shall be determined as originally defined hereby. Nevertheless, thereafter the provisions of Sections 2.05(a) , (g) and (h)  shall continue to be effective.

(j) Special Provisions Applicable to LIBOR Rate . The LIBOR Rate may be adjusted by Agent with respect to any Lender on a prospective basis to take into account any additional or increased costs to such Lender of maintaining or obtaining any eurodollar deposits or increased costs (other than Taxes which shall be governed by Article XVI ), in each case, due to changes in applicable law, including any Changes in Law and changes in the reserve requirements imposed by the Board of Governors, which additional or increased costs would increase the cost of funding or maintaining loans bearing interest at the LIBOR Rate. In any such event, the affected Lender shall give the Borrower Representative, Agent and the other Lenders notice of such a determination and adjustment and, upon its receipt of the notice from the affected Lender, Borrowers may, by notice to such affected Lender (i) require such Lender to furnish to the Borrower Representative a statement setting forth in reasonable detail the basis for adjusting such LIBOR Rate and the method for determining the amount of such adjustment, or (ii) repay the Loans of such Lender with respect to which such adjustment is made.

2.06 [Reserved].

2.07 Designated Account . Agent (including, during any Third Party Agent Retention Period, the Third Party Agent) and the Lenders are authorized to make the Loans under this Agreement based upon written or other instructions received from anyone purporting to be an Authorized Person or, without instructions, if pursuant to Section  2.05(d) . Borrower Representative agrees to establish and maintain the Designated Account with the Designated Account Bank for the purpose of receiving the proceeds of the Loans requested by Borrowers and made by Agent (including, during any Third Party Agent Retention Period, the Third Party Agent) or the Lenders hereunder. Unless otherwise agreed by

 

58


Agent and Borrowers, any Loan requested by Borrowers and made by Agent (including, during any Third Party Agent Retention Period, the Third Party Agent) or the Lenders hereunder shall be made to the Designated Account.

2.08 Maintenance of Loan Account; Statements of Obligations . During any Third Party Agent Retention Period, the Third Party Agent, as a non-fiduciary agent for Borrowers, shall maintain an account on its books in the name of Borrower Representative (the “ Loan Account ”) on which Borrowers will be charged with the Loans (including Extraordinary Advances) made by Agent (including by such Third Party Agent, as applicable) or the Lenders to Borrowers or for Borrowers’ account, and with all other payment Obligations hereunder or under the other Loan Documents, including, accrued interest, fees and expenses, and Lender Group Expenses. During any Non-Third Party Agent Retention Period, the Borrower Representative shall maintain such Loan Account and shall make such Loan Account available to Agent and the Lenders upon request therefrom. Upon the request of any Third Party Agent upon the commencement of any Third Party Agent Retention Period, the Borrower Representative shall share such Loan Account and any of its applicable books and records with the Third Party Agent, and with respect to any discrepancies between the books, records or Loan Account of the Borrower Representative, on the one hand, and the books, records or Loan Account of any Lender, the Agent or the Third Party Agent, on the other hand, the books, records and Loan Account of such Lender, Agent or Third Party Agent shall govern and control in the absence of manifest error. In accordance with Section  2.12 , the Loan Account will be credited with all payments received by Agent or any Lender from Borrowers or for Borrowers’ account (and, during any Third Party Agent Retention Period, that the Third Party Agent is aware of or has been notified of). During any Third Party Agent Retention Period, the Third Party Agent shall make available to Borrower Representative monthly statements regarding the Loan Account, including the principal amount of the Loans, interest accrued hereunder, fees accrued or charged hereunder or under the other Loan Documents, and a summary itemization of all charges and expenses constituting Lender Group Expenses accrued hereunder or under the other Loan Documents, and each such statement, absent manifest error, shall be conclusively presumed to be correct and accurate and constitute an account stated between Borrowers and the Lender Group unless, within 30 days after Agent first makes such a statement available to Borrower Representative, Borrower Representative shall deliver to Agent written objection thereto describing the error or errors contained in such statement.

2.09 Fees, Changes, Damages and Revolver Exit Payment.

(a) Agent and Third Party Agent Fees . Borrowers shall pay in cash to Agent, for the account of Agent (or the Lenders set forth in such agreement), as and when due and payable under the terms of any agreement between the Borrowers and Agent (or such Lenders), the fees set forth in such agreement. At any time there is a Third Party Agent, Borrowers shall timely pay in cash (or timely reimburse in cash the paying Person for) such fees, costs and expenses of the Third Party Agent that are charged to (or incurred on behalf of) the Agent, any Lender, any other member of the Lender Group or any Loan Party (or any Agent-Related Persons or Lender-Related Persons).

(b) Unused Line Fee . Borrowers shall pay in cash to the Lenders, based on their Pro Rata Share of the Revolver Commitments, an unused line fee (the “ Unused Line Fee ”) in an amount equal to 0.50% times the result of (i) the aggregate amount of the Revolver Commitments, less (ii) the greater of (A) $9,750,000 and (B) the Average Revolver Usage during the immediately preceding month (or portion thereof), which Unused Line Fee shall be due and payable on the first Business Day of each month from and after the Closing Date up to the first day of the month prior to the date on which all of the Obligations are paid in full in cash and all of the Revolver Commitments are terminated and on the date on which all of the Obligations are paid in full in cash and all of the Revolver Commitments are terminated.

 

59


(c) Field Examination and Other Fees . Borrowers shall pay in cash to Agent (including, during any Third Party Agent Retention Period, the Third Party Agent) and the Lenders, field examination, appraisal, and valuation fees and charges as and when incurred or chargeable; provided , that for so long as no Default or Event of Default shall have occurred and be continuing, Borrowers shall not be obligated to reimburse Agent for more than (A) two field examinations in any twelve month period, (B) two Inventory appraisals, and (C) two Equipment appraisals; provided that any additional field examinations or appraisals required by Agent in any given twelve month period shall be performed at the expense of Agent; and, provided , further , that if a Default or Event of Default shall have occurred and be continuing, Agent may conduct additional field examinations and appraisals at Borrowers’ sole expense. For the avoidance of doubt, the reimbursement limitations set forth in this Section  2.09(c) shall not apply to field examinations and appraisals conducted in connection with a Permitted Acquisition.

(d) Liquidated Damages .

(i) Borrowers shall pay in cash liquidated damages in connection with any termination or reduction of the Revolver Commitments prior to the third anniversary of the Closing Date or any acceleration (including in connection with an Insolvency Proceeding) of the Obligations, in each case in accordance with this Section  2.09(d) (“ Liquidated Damages ”).

(ii) If, prior to the third anniversary of the Closing Date, (A) the Commitments are terminated and the Obligations prepaid in full or (B) pursuant to the terms of this Agreement or any other Loan Document, either (1) Agent or the Required Lenders demand prepayment of the outstanding Obligations in whole or in part during the continuation of an Event of Default, or (2) repayment of the outstanding Obligations is otherwise accelerated in whole or in part (including in connection with an Insolvency Proceeding) under Section  9.01 , then , at the time of such termination (in accordance with clause (A)) or the time of such demand or acceleration (in accordance with clause (B)), and in addition to the principal balance of the Loans, all accrued and unpaid interest thereon, all fees, costs, expenses, and other amounts payable to Agent and Lenders in connection with the Revolving Facility and all other Obligations paid to Agent and Lenders under this Agreement and the other Loan Documents, Borrowers shall pay in cash Liquidated Damages to the Lenders (or, during any Third Party Agent Retention Period, the Third Party Agent for the benefit of the Lenders), based on their Pro Rata Share, in an amount equal to the (y) Maximum Revolver Amount multiplied by (z)(I) 2.50% if such prepayment, demand or acceleration occurs prior to August 9, 2019 (the “ First Period ”), (II) 1.50% if such prepayment, demand or acceleration occurs on or after the First Period but prior to the August 9, 2020 (the “ Second Period ”), (III) 0.50% if such prepayment, demand or acceleration occurs at Second Period but prior to August 9, 2021 (the “ Third Period ”), and (IV) 0% if such prepayment, demand or acceleration occurs on or after August 9, 2021.

(iii) If, prior to the third anniversary of the Closing Date, Borrower Representative has sent a notice of partial reduction of the Revolving Facility pursuant to the provisions of Section  2.03(c) , then on the date set forth as the date of reduction in such notice, Borrower shall pay to the Lenders (or, during any Third Party Agent Retention Period, the Third Party Agent for the benefit of the Lenders), in cash, the applicable Revolver Reduction Premium determined as of such date. For purposes of this Section, “ Applicable Revolver Reduction Premium ” means, as of any date of determination, an amount equal to (A) during the First Period, 2.50% times the amount of the reduction of the Revolving Commitments on such date, (B) during the Second Period, 1.50% times the amount of the reduction of the Revolving Commitments on such date, (C) during the Third Period, 0.50% times the amount of the reduction of the Revolving Commitments on such date and (D) 0% times the amount of the reduction of the Revolving Commitment on or after August 9, 2021.

 

60


(iv) Borrower acknowledges and agrees that it would be difficult or impractical to calculate Lenders’ actual damages from early termination of the Revolving Facility and Lenders’ compensation from Loans hereunder following such early termination or reduction, the Liquidated Damages provided in this Section  2.09(d) are intended to be fair and reasonable approximations of such damages, and that the Liquidated Damages are not intended to be penalties.

(e) Commitment Fee . On the Closing Date, Borrowers shall pay in cash to the Lenders (or, during any Third Party Agent Retention Period, the Third Party Agent for the benefit of the Lenders), based on their Pro Rata Share, an amount equal to $500,000 (the “ Commitment Fee ”), which shall be fully-earned on the Closing Date and payable on the following schedule: (i) $200,000 shall be payable in cash on the Closing Date, (ii) $200,000 shall be payable on the one-year anniversary of the Closing Date, and (iii) $100,000 shall be payable on the two-year anniversary of the Closing Date. Notwithstanding the foregoing, if (A) the Revolver Commitments are terminated and the Loans repaid or (B) the Revolver Commitments are terminated or the Obligations become due and payable, in each case of clause (A) and clause (B), on any date prior to the two-year anniversary of the Closing Date for any reason (such as an acceleration of the Loans following the occurrence of an Event of Default, an exercise of Agent’s (including, any Third Party Agent’s) or any Lender’s rights or remedies available under the Loan Documents or an exercise of any rights or remedies by the Term Agent, a Term Lender or any other party to the Term Debt Documents, upon the consummation of a Change in Control, by any optional prepayment or otherwise), then, on such date, any portion of the Commitment Fee that has not previously been paid shall be automatically, due and payable. The Commitment Fee shall be non-refundable upon any payment thereof. The parties hereto acknowledge and agree that Agent and the Lenders would not have entered into this Agreement and the Lenders would not provide the Revolver Commitments, the financial accommodations and other accommodations under this Agreement and the other Loan Documents without the Loan Parties agreeing to pay the Commitment Fee in the aforementioned instances. The parties hereto also acknowledge and agree that the Commitment Fee set forth in this Section  2.09(e) is not intended to act as a penalty or to punish any Borrower or any other Loan Party for any such payment, repayment, redemption or prepayment.

(f) Collateral Monitoring Fee . Borrowers shall pay in cash to the Lenders (or, during any Third Party Agent Retention Period, the Third Party Agent for the benefit of the Lenders), based on their Pro Rata Share, an amount equal to $5,000 (the “ Monthly Collateral Monitoring Fee ”) monthly in advance on the first Business Day of each month from and after the Closing Date, commencing with the first such date after the Closing Date, until all of the Revolver Commitments have been terminated, all of the Obligations have been repaid and this Agreement has terminated. The Monthly Collateral Monitoring Fee shall be fully-earned on each such date such amount is due or payable under this Agreement and is non-refundable upon being paid.

(g) Exit Payment . Notwithstanding anything to the contrary in the Loan Documents, on the date when the Revolver Commitments (in each case, whether before, at the time of or after the Maturity Date or any acceleration, bankruptcy, insolvency or otherwise) are reduced or terminated in an amount that causes (or such lesser amount of Revolver Commitments that are so reduced or terminated that the Lenders have agreed to cause) the remaining amount of outstanding Revolver Commitments to be less than $10,000,000, the Borrowers shall pay in cash at such time to the Lenders (based on their Pro Rata Share of such Revolver Commitments) a non-refundable exit payment (the “ Revolver Exit Payment ”) in a total amount equal to $1,000,000. The parties to this Agreement acknowledge and agree that the Agent and the Lenders would not have entered into this Agreement and the other Loan Documents without the Borrowers agreeing to pay the Revolver Exit Payment in the aforementioned instances. The parties to this Agreement further acknowledge and agree that the Revolver Exit Payment set forth in this

 

61


Section  2.09(g) is not intended to act as a penalty or to punish the Borrowers or any other Loan Parties for any such Revolver Commitment reduction or termination.

2.10 [Reserved] .

2.11 Capital Requirements .

(a) If, after the date hereof, any Lender determines that (i) any Change in Law regarding capital or reserve requirements for banks or bank holding companies, or (ii) compliance by such Lender, or their respective parent bank holding companies, with any guideline, request or directive of any Governmental Authority regarding capital adequacy (whether or not having the force of law), has the effect of reducing the return on such Lender’s or such holding companies’ capital as a consequence of such Lender’s commitments, Loans, participations or other obligations hereunder to a level below that which such Lender or such holding companies could have achieved but for such Change in Law or compliance (taking into consideration such Lender’s or such holding companies’ then existing policies with respect to capital adequacy and assuming the full utilization of such entity’s capital) by any amount deemed by such Lender to be material, then such Lender may notify Borrower Representative and Agent thereof. Following receipt of such notice, Borrowers agree to pay such Lender on demand the amount of such reduction of return of capital as and when such reduction is determined, payable within 30 days after presentation by such Lender of a statement in the amount and setting forth in reasonable detail such Lender’s calculation thereof and the assumptions upon which such calculation was based (which statement shall be deemed true and correct absent manifest error). In determining such amount, such Lender may use any reasonable averaging and attribution methods. Failure or delay on the part of any Lender to demand compensation pursuant to this Section shall not constitute a waiver of such Lender’s right to demand such compensation; provided that Borrowers shall not be required to compensate a Lender pursuant to this Section for any reductions in return incurred more than 180 days prior to the date that such Lender notifies Borrower Representative or any other Borrower of such Change in Law giving rise to such reductions and of such Lender’s intention to claim compensation therefor; provided further that if such claim arises by reason of the Change in Law that is retroactive, then the 180-day period referred to above shall be extended to include the period of retroactive effect thereof.

(b) If any Lender requests additional or increased costs referred to in Section  2.05(j) or amounts under Section  2.11(a) or sends a notice under Section  2.05(h) relative to changed circumstances (such Lender, an “ Affected Lender ”), then such Affected Lender shall use reasonable efforts to promptly designate a different one of its lending offices or to assign its rights and obligations hereunder to another of its offices or branches, if (i) in the reasonable judgment of such Affected Lender, such designation or assignment would eliminate or reduce amounts payable pursuant to Section  2.05(j) or Section  2.11(a) , as applicable, or would eliminate the illegality or impracticality of funding or maintaining Loans bearing interest at the LIBOR Rate and (ii) in the reasonable judgment of such Affected Lender, such designation or assignment would not subject it to any material unreimbursed cost or expense and would not otherwise be materially disadvantageous to it. Borrowers agree to pay all reasonable out-of-pocket costs and expenses incurred by such Affected Lender in connection with any such designation or assignment.

(c) Notwithstanding anything herein to the contrary, the protection of Sections 2.05(h) and 2.05(j) and this Section  2.11 shall be available to each Lender (as applicable) regardless of any possible contention of the invalidity or inapplicability of the law, rule, regulation, judicial ruling, judgment, guideline, treaty or other change or condition which shall have occurred or been imposed, so long as it shall be customary for lenders affected thereby to comply therewith. Notwithstanding any other provision herein, no Lender shall demand compensation pursuant to this Section  2.11 if it shall not at the time be

 

62


the general policy or practice of such Lender (as the case may be) to demand such compensation in similar circumstances under comparable provisions of other credit agreements, if any.

2.12 Collections; Crediting Payments .

(a) The Loan Parties shall establish and maintain cash management services of a type, number, with a financial institution (the “ Depositary Bank ”) and on terms, in each case, reasonably satisfactory to Agent (including, during any Third Party Agent Retention Period, the Third Party Agent), and shall open a lockbox (the “ Lockbox ”) with the Depositary Bank. Collected funds in the Lockbox shall be deposited into an account with the Depository Bank established by Agent (or, during any Third Party Agent Retention Period, the Third Party Agent) and subject to Agent’s (or, during any Third Party Agent Retention Period, the Third Party Agent’s) sole dominion and control (including, but not limited to the sole power of withdrawal) (the “ Blocked Account ”). Each Loan Party shall take reasonable steps to (i) ensure that all of its Account Debtors forward payment of the amounts owed by such Account Debtors directly to the Lockbox or to the Blocked Account, and (ii) deposit or cause to be deposited promptly, and in any event no later than the first Business Day after the date of receipt thereof, all of the Loan Parties’ collections and proceeds of Collateral (including those sent directly by Account Debtors to any Loan Party) into the Blocked Account. Each Deposit Account (excluding any Excluded Account) of a Loan Party and each Securities Account (excluding any Excluded Account) of a Loan Party shall be subject to a Control Agreement among such Loan Party, the applicable bank or securities intermediary, Agent and Term Agent, and no Loan Party will permit any Investment consisting of cash, Cash Equivalents or amounts credited to a Deposit Account (excluding any Excluded Account) or a Securities Account (excluding any Excluded Account) to be maintained in a Deposit Account or Securities Account unless such Deposit Account or Securities Account, as applicable, is subject to a Control Agreement among such Loan Party, the applicable bank or securities intermediary, and Agent. The agreement(s) relating to the Blocked Account between Agent, such financial institution and Borrowers shall be in form and content satisfactory to Agent.

(b) The Loan Parties shall cause Persons processing or collecting any credit card payments or proceeds of receivables on behalf of the Loan Parties to deliver such payments or proceeds to the Blocked Account promptly, but not less frequently than once every week.

(c) On each Business Day, Agent (or, during any Third Party Agent Retention Period, the Third Party Agent) shall withdraw available funds from the Blocked Account, deposit such funds in the Agent’s Account, and credit available funds received in the Agent’s Account to the payment of the Obligations. Agent shall credit to the payment of the Obligations any other form of funds received by Agent (or Third Party Agent, as applicable) in the Agent’s Account for which Agent (or Third Party Agent, as applicable) has received notice that such funds are collected and available to Agent (or Third Party Agent, as applicable) (i) on the same day of Agent’s (or Third Party Agent, as applicable) receipt of such notice if such notice is received by Agent (or Third Party Agent, as applicable) on or before 2 p.m. Eastern Time on a Business Day, and (ii) on the Business Day immediately following Agent’s (or Third Party Agent’s, as applicable) receipt of such notice if such notice is received by Agent (or Third Party Agent, as applicable) after 2 p.m. Eastern Time on a Business Day, or if such notice is received by Agent (or the Third Party Agent, as applicable) on a day that is not a Business Day. It is understood and agreed that transfer of funds from the Blocked Account to the Agent’s Account may take up to two (2) Business Days. Aggregate principal and interest payments shall be apportioned ratably among the Lenders (according to the unpaid principal balance of the Obligations to which such payments relate held by each Lender) and payments of fees and expenses (other than fees or expenses that are for Agent’s (or Third Party Agent’s, as applicable) separate account) shall be apportioned ratably among the Lenders having a Pro Rata Share of the type of Obligation or Commitment to which a particular fee relates. All payments

 

63


and proceeds of Collateral received by Agent (or the Third Party Agent, as applicable) shall be applied in accordance with Section  2.03(b) .

(d) All funds credited to the payment of the Obligations in accordance with Section  2.12(a) above are conditional upon final payment to Agent (or the Third Party Agent, as applicable) in cash or solvent credits of the items giving rise to such funds. If any item credited to the payment of the Obligations is not paid to Agent (or the Third Party Agent, as applicable) (or payment thereof is rescinded or required to be returned by the Agent (or the Third Party Agent, as applicable)), the amount of any credit given for such item shall be charged to the balance of the Obligations whether or not the item is returned.

(e) For purposes of computing interest on the Obligations, Borrowers acknowledge that interest shall continue to accrue on the amount of any funds credited to the payment of the Obligations in accordance with this Section  2.12 for three Business Days after the date so credited. The parties acknowledge and agree that the economic benefit of the foregoing provisions of this Section  2.12(e) shall be for the exclusive benefit of Agent (and the Third Party Agent, as applicable) and the Lenders.

2.13 Appointment of Borrower Representative .

(a) Each Borrower hereby irrevocably appoints and constitutes Borrower Representative as its agent and attorney-in-fact to request and receive Loans and other Obligations in the name or on behalf of such Borrower and any other Borrowers, deliver requests for Borrowings Notices of Borrowing, and Borrowing Base Certificates, give instructions with respect to the disbursement of the proceeds of the Loans, giving and receiving all other notices and consents hereunder or under any of the other Loan Documents and taking all other actions (including in respect of compliance with covenants) in the name or on behalf of any Borrower or Borrowers pursuant to this Agreement and the other Loan Documents. Agent (including any Third Party Agent, as applicable) and Lenders may disburse the Loans to such bank account or Deposit Account of Borrower Representative or a Borrower or otherwise make such Loans to a Borrower, in each case as Borrower Representative may designate or direct, without notice to any other Borrower. Notwithstanding anything to the contrary contained herein, Agent (or, during any Third Party Agent Retention Period, the Third Party Agent) may at any time and from time to time require that Loans to or for the account of any Borrower be disbursed directly to an operating account of such Borrower.

(b) Borrower Representative hereby accepts the appointment by Borrowers to act as the agent and attorney-in-fact of Borrowers pursuant to this Section  2.13 . Borrower Representative shall ensure that the disbursement of any Loans that are at any time requested by or to be remitted to or for the account of a Borrower, shall be remitted or issued to or for the account of such Borrower.

(c) Each Borrower hereby irrevocably appoints and constitutes Borrower Representative as its agent to receive statements on account and all other notices from Agent and/or Lenders with respect to the Obligations or otherwise under or in connection with this Agreement and the other Loan Documents.

(d) Any notice, election, representation, warranty, agreement or undertaking made or delivered by or on behalf of any Borrower by Borrower Representative shall be deemed for all purposes to have been made or delivered by such Borrower, as the case may be, and shall be binding upon and enforceable against such Borrower to the same extent as if made or delivered directly by such Borrower.

(e) No resignation by or termination of the appointment of Borrower Representative as agent and attorney-in-fact as aforesaid shall be effective, except after ten (10) Business Days’ prior written notice to Agent (and, during any Third Party Agent Retention Period, also to the Third Party Agent) and

 

64


the Lenders. If the Borrower Representative resigns under this Agreement, Borrowers shall be entitled to appoint a successor Borrower Representative (which shall be a Borrower and shall be reasonably acceptable to Agent as such successor). Upon the acceptance of its appointment as successor Borrower Representative hereunder, such successor Borrower Representative shall succeed to all the rights, powers and duties of the retiring Borrower Representative and the term “Borrower Representative” shall mean such successor Borrower Representative for all purposes of this Agreement and the other Loan Documents, and the retiring or terminated Borrower Representative’s appointment, powers and duties as Borrower Representative shall be thereupon terminated.

2.14 Joint and Several Liability of Borrowers .

(a) Each Borrower is accepting joint and several liability hereunder and under the other Loan Documents in consideration of the financial accommodations to be provided by the Lender Group under this Agreement, for the mutual benefit, directly and indirectly, of each Borrower and in consideration of the undertakings of the other Borrowers to accept joint and several liability for the Obligations.

(b) Each Borrower, jointly and severally, hereby irrevocably and unconditionally accepts, not merely as a surety but also as a co-debtor, joint and several liability with the other Borrowers, with respect to the payment and performance of all of the Obligations (including any Obligations arising under this Section  2.14 ), it being the intention of the parties hereto that all the Obligations shall be the joint and several obligations of each Borrower without preferences or distinction among them.

(c) If and to the extent that any Borrower shall fail to make any payment with respect to any of the Obligations as and when due or to perform any of the Obligations in accordance with the terms thereof, then in each such event the other Borrowers will make such payment with respect to, or perform, such Obligation.

(d) The Obligations of each Borrower under the provisions of this Section  2.14 constitute the absolute and unconditional, full recourse Obligations of each Borrower enforceable against each Borrower to the full extent of its properties and assets, irrespective of the validity, regularity or enforceability of this Agreement or any other circumstances whatsoever.

(e) Except as otherwise expressly provided in this Agreement, each Borrower hereby waives notice of acceptance of its joint and several liability, notice of any Advances issued under or pursuant to this Agreement, notice of the occurrence of any Default, Event of Default, or of any demand for any payment under this Agreement or any other Loan Document, notice of any action at any time taken or omitted by Agent (including any Third Party Agent), the Lenders or any other member of the Lender Group under or in respect of any of the Obligations, any requirement of diligence or to mitigate damages and, generally, to the extent permitted by applicable law, all demands, notices and other formalities of every kind in connection with this Agreement (except as otherwise provided in this Agreement) and the other Loan Documents. Each Borrower hereby assents to, and waives notice of, any extension or postponement of the time for the payment of any of the Obligations, the acceptance of any payment of any of the Obligations, the acceptance of any partial payment thereon, any waiver, consent or other action or acquiescence by Agent (including any Third Party Agent), the Lenders or any other member of the Lender Group at any time or times in respect of any default by any Borrower in the performance or satisfaction of any term, covenant, condition or provision of this Agreement, any and all other indulgences whatsoever by Agent (including any Third Party Agent), the Lenders or any other member of the Lender Group in respect of any of the Obligations, and the taking, addition, substitution or release, in whole or in part, at any time or times, of any security for any of the Obligations or the addition, substitution or release, in whole or in part, of any Borrower. Without limiting the generality of the

 

65


foregoing, each Borrower assents to any other action or delay in acting or failure to act on the part of Agent (including any Third Party Agent), any Lender or any other member of the Lender Group with respect to the failure by any Borrower to comply with any of its respective Obligations, including, without limitation, any failure strictly or diligently to assert any right or to pursue any remedy or to comply fully with applicable laws or regulations thereunder, which might, but for the provisions of this Section  2.14 afford grounds for terminating, discharging or relieving any Borrower, in whole or in part, from any of its Obligations under this Section  2.14 , it being the intention of each Borrower that, so long as any of the Obligations hereunder and under the other Loan Documents remain unsatisfied and unpaid in full in cash and the Revolver Commitments have not been terminated, the Obligations of each Borrower under this Section  2.14 shall not be discharged except by performance and then only to the extent of such performance. The Obligations of each Borrower under this Section  2.14 shall not be diminished or rendered unenforceable by any winding up, reorganization, arrangement, liquidation, reconstruction, division, split, merger, consolidation or similar proceeding with respect to any Borrower or any other Loan Party or Agent (including any Third Party Agent), any Lender or any other member of the Lender Group.

(f) Each Borrower represents and warrants to Agent (including any Third Party Agent), the Lenders and the other members of the Lender Group that such Borrower is currently informed of the financial condition of the other Borrowers and of all other circumstances which a diligent inquiry would reveal and which bear upon the risk of nonpayment of the Obligations. Each Borrower further represents and warrants to Agent (including any Third Party Agent), the Lenders and the other members of the Lender Group that such Borrower has read and understands the terms and conditions of the Loan Documents. Each Borrower hereby covenants that such Borrower will continue to keep informed of the other Borrowers’ financial condition, the financial condition of other Guarantors and Loan Parties, if any, and of all other circumstances which bear upon the risk of nonpayment or nonperformance of the Obligations.

(g) Each Borrower waives all rights and defenses arising out of an election of remedies by Agent (including any Third Party Agent), any Lender or any other member of the Lender Group, even though that election of remedies, such as a nonjudicial foreclosure with respect to security for a guaranteed obligation, has destroyed Agent’s (including any Third Party Agent’s), such Lender’s or such other member of the Lender Group’s rights of subrogation and reimbursement against any Borrower by the operation of Section 580(d) of the California Code of Civil Procedure, any comparable statute, or otherwise.

(h) Each Borrower waives all rights and defenses that such Borrower may have because the Obligations are or become secured by Real Property. This means, among other things:

(i) Agent (including any Third Party Agent), the Lenders and the other members of the Lender Group may collect from such Borrower without first foreclosing on any Real Property Collateral or personal property Collateral pledged by Borrowers.

(ii) If Agent (including any Third Party Agent), any Lender or any other member of the Lender Group forecloses on any Real Property Collateral pledged by any Borrower or any Guarantor:

(A) the amount of the Obligations may be reduced only by the price for which such Collateral is sold at the foreclosure sale, even if such Collateral is worth more than the sale price; and

 

66


(B) Agent (including any Third Party Agent), the Lenders and the other members of the Lender Group may collect from such Borrower even if Agent or Lenders, by foreclosing on the Real Property Collateral, has destroyed any right such Borrower may have to collect from the other Borrowers.

This is an unconditional and irrevocable waiver of any rights and defenses such Borrower may have because the Obligations are secured by Real Property. These rights and defenses include, but are not limited to, any rights or defenses based upon Section 580a, 580b, 580d or 726 of the California Code of Civil Procedure or any comparable statutes or Applicable Laws.

(i) The provisions of this Section  2.14 are made for the benefit of Agent (including any Third Party Agent), Lenders, the other members of the Lender Group and their respective successors and assigns, and may be enforced by it or them from time to time against any or all Borrowers as often as occasion therefor may arise and without requirement on the part of Agent (including any Third Party Agent), any Lender, any other member of the Lender Group, any of their respective successors or assigns first to marshal any of its or their claims or to exercise any of its or their rights against any Borrower or to exhaust any remedies available to it or them against any Borrower or to resort to any other source or means of obtaining payment of any of the Obligations hereunder or to elect any other remedy. The provisions of this Section  2.14 shall remain in effect until all of the Obligations shall have been paid in full in cash, and all of the Commitments have been terminated, in accordance with the terms of this Agreement. If at any time, any payment, or any part thereof, made in respect of any of the Obligations, is rescinded or must otherwise be restored or returned by Agent (including any Third Party Agent), any Lender or any other member of the Lender Group upon the insolvency, bankruptcy or reorganization of any Borrower, or otherwise, the provisions of this Section  2.14 will forthwith be reinstated in effect, as though such payment had not been made.

(j) Until the Obligations have been paid in full in cash and all of the Commitments have been terminated, each Borrower hereby agrees that it will not enforce any of its rights of contribution or subrogation against any other Borrower with respect to any liability incurred by it hereunder or under any of the other Loan Documents, any payments made by it to Agent (including any Third Party Agent), any Lender or any other member of the Lender Group with respect to any of the Obligations or any collateral security therefor. Any claim which any Borrower may have against any other Borrower with respect to any payments to Agent (including any Third Party Agent), any Lender or any other member of the Lender Group hereunder or under any other Loan Documents are hereby expressly made subordinate and junior in right of payment, without limitation as to any increases in the Obligations arising hereunder or thereunder, to the prior payment in full in cash of the Obligations and a termination of all of the Commitments, and, in the event of any Insolvency Proceeding or any insolvency, bankruptcy, receivership, liquidation, reorganization or other similar proceeding under the laws of any jurisdiction relating to any Borrower, its debts or its assets, whether voluntary or involuntary, all such Obligations shall be paid in full in cash and all Commitments shall be terminated before any payment or distribution of any character, whether in cash, securities or other property, shall be made to any other Borrower therefor.

(k) Each Borrower hereby agrees that, after the occurrence and during the continuance of any Default or Event of Default, the payment of any amounts due with respect to the indebtedness owing by any Borrower to any other Borrower is hereby subordinated to the prior payment in full in cash of the Obligations and a termination of all of the Commitments. Each Borrower hereby agrees that after the occurrence and during the continuance of any Event of Default and direction from Agent or the Required Lenders, such Borrower will not demand, sue for or otherwise attempt to collect any indebtedness of any other Borrower owing to such Borrower until all of the Obligations shall have been paid in full in cash

 

67


and all of the Commitments have been terminated. If, notwithstanding the foregoing sentence, such Borrower shall collect, enforce or receive any amounts in respect of such indebtedness, such amounts shall be collected, enforced and received by such Borrower as trustee for Agent (or, during any Third Party Agent Retention Period, the Third Party Agent), and such Borrower shall deliver any such amounts to Agent (or, during any Third Party Agent Retention Period, the Third Party Agent) for application to the Obligations in accordance with Section  2.03(b) .

ARTICLE III.

CONDITIONS; TERM OF AGREEMENT.

3.01 Conditions Precedent to the Initial Extension of Credit . The effectiveness of this Agreement is subject to the fulfillment, to the satisfaction of Agent (including any Third Party Agent) and each Lender, of each of the following conditions precedent:

(a) a Third Party Agent Retention Period shall exist with Cortland as the Third Party Agent;

(b) Agent shall have received appropriate financing statements on Form UCC-1 duly filed (or to be filed) in such office or offices as may be necessary or, in the opinion of Agent, desirable to perfect Agent’s Liens in and to the Collateral;

(c) Agent (including any Third Party Agent) and the Lenders shall have received each of the following documents, in form and substance satisfactory to Agent (including any Third Party Agent) and the Lenders, duly executed and delivered, and each such document shall be in full force and effect:

(i) this Agreement;

(ii) a completed Borrowing Base Certificate (Third Party Agent) dated as of July 31, 2018;

(iii) the Control Agreements required by Agent or the Lenders to be delivered on the Closing Date;

(iv) the Notes;

(v) the Guaranty and Security Agreement;

(vi) the Intercompany Subordination Agreement;

(vii) a Perfection Certificate;

(viii) the Copyright Security Agreement;

(ix) the Patent Security Agreement;

(x) the Intercreditor Agreement; and

(xi) the Trademark Security Agreement;

(d) Agent shall have received a certificate from an Authorized Officer of each Loan Party:

 

68


(i) attesting to the resolutions of such Loan Party’s board of directors authorizing its execution, delivery, and performance of the Loan Documents to which it is a party,

(ii) authorizing specific officers of such Loan Party to execute the same, attesting to the incumbency and signatures of such specific officers of such Loan Party,

(iii) attesting to copies of each Loan Party’s Organizational Documents, as amended, modified, or supplemented to the Closing Date, which Organizational Documents shall be (A) certified by an Authorized Officer of such Loan Party, and (B) with respect to Organizational Documents that are charter documents, certified as of a recent date (not more than thirty (30) days prior to the Closing Date) by the appropriate governmental official,

(iv) attesting to certificates of status with respect to each Loan Party, dated within ten (10) days of the Closing Date, such certificates to be issued by the appropriate officer of the jurisdiction of organization of such Loan Party, which certificates shall indicate that such Loan Party is in good standing in such jurisdiction, and

(v) attesting to certificates of status with respect to each Loan Party, each dated within thirty (30) days of the Closing Date, such certificates to be issued by the appropriate officer of the jurisdictions (other than the jurisdiction of organization of such Loan Party) in which such Loan Party’s failure to be duly qualified or licensed would constitute a Material Adverse Effect, which certificates shall indicate that such Loan Party is in good standing in such jurisdictions;

(e) after giving effect to any Loans funded on the Closing Date, the payment of all fees, costs and expenses required to be paid by Borrowers, Excess Availability plus Qualified Cash shall be greater than or equal to $22,500,000;

(f) since December 31, 2017, there shall not have occurred a Material Adverse Effect;

(g) [reserved];

(h) Agent and the Lenders shall have received all requested Collateral Access Agreements in favor of Agent, from all mortgagees, landlords and operators of warehouses in which a Loan Party operates or maintains any Collateral; provided that any locations not subject to such Collateral Access Agreements shall be subject to a Landlord Reserve at Agent’s (including, during any Third Party Agent Retention Period, the Third Party Agent’s) Permitted Discretion;

(i) Agent and the Lenders shall have received a certificate of insurance, together with the endorsements thereto, as are required by Section  5.03 , the form and substance of which shall be satisfactory to Agent and the Lenders;

(j) Agent and the Lenders shall have received an opinion of the Loan Parties’ counsel in form and substance reasonably satisfactory to Agent and the Lenders;

(k) Agent (including any Third Party Agent) and the Lenders shall have completed its business, legal, and collateral due diligence, including (i) a collateral audit and review of Borrowers’ and their Subsidiaries books and records and verification of Borrowers’ representations and warranties to Agent (including any Third Party Agent) and the Lenders, the results of which shall be satisfactory to Agent (including any Third Party Agent) and the Lenders, (ii) an inspection of each of the locations where the Loan Parties’ and their Subsidiaries’ Inventory and Equipment is located, the results of which shall be

 

69


satisfactory to Agent (including any Third Party Agent) and the Lenders, (iii) satisfactory review by Agent (including any Third Party Agent) and the Lenders of all contracts with Federal, state, municipal and governmental agencies, and (iv) a review of the Loan Parties’ and their Subsidiaries’ insurance, which shall in each case be satisfactory to Agent and the Lenders;

(l) Agent (including any Third Party Agent) and the Lenders shall have received completed reference and background checks with respect to Borrowers’ senior management, the results of which are satisfactory to Agent (including any Third Party Agent) and the Lenders in Agent’s (including any Third Party Agent’s) and each Lender’s sole discretion;

(m) Agent (including any Third Party Agent) and the Lenders shall have received an audit of Eligible Accounts, and an appraisal of the Eligible Inventory (and, if requested by Agent (or any Third Party Agent), Eligible Equipment), in each case the results of which shall be satisfactory to Agent (including any Third Party Agent) and the Lenders;

(n) Borrowers shall have paid in cash all Lender Group Expenses incurred in connection with the transactions evidenced by this Agreement or any other Loan Documents and paid all fees in cash required to be paid in accordance with the terms of this Agreement and the other Loan Documents;

(o) Borrowers and each of their Subsidiaries shall have received all licenses, approvals or evidence of other actions required by any Governmental Authority in connection with the execution and delivery by Borrowers or their Subsidiaries of the Loan Documents or with the consummation of the transactions contemplated thereby;

(p) Agent and the Lenders shall have received the Term Debt Documents, in form and substance reasonably satisfactory to Agent and the Lenders;

(q) the final corporate and capital structure of Borrowers and their Subsidiaries shall be reasonably satisfactory to Agent (including any Third Party Agent) and the Lenders;

(r) all other documents and legal matters in connection with the transactions contemplated by this Agreement or any other Loan Document shall have been delivered, executed, or recorded and shall be in form and substance satisfactory to Agent and the Lenders.

3.02 Conditions Precedent to all Extensions of Credit . The obligation of the Lender Group (or any member thereof) to make any Loans hereunder (or to extend any other credit hereunder) at any time shall be subject to the following conditions precedent:

(a) the representations and warranties of Borrowers or their Subsidiaries contained in this Agreement or in the other Loan Documents shall be true and correct in all material respects (except that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof) on and as of the date of such extension of credit, as though made on and as of such date (except to the extent that such representations and warranties relate solely to an earlier date, in which case such representations and warranties shall be true and correct in all material respects (except that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof) as of such earlier date);

(b) no Default or Event of Default shall have occurred and be continuing on the date of such extension of credit, nor shall either result from the making thereof;

 

70


(c) the receipt by Agent (and/or the Third Party Agent, as applicable) from Borrower Representative of (A) a request for Borrowing pursuant to the requirements of Section  2.02(a) , and (B) in the case of clause (i) (solely with respect to Revolving Loans or Revolver Commitments), (x) during a Non-Third Party Agent Retention Period, if requested by Agent within one Business Day of receipt of such request for Borrowing, an updated Borrowing Base Certificate (Agent), and (y) during a Third Party Agent Retention Period, an updated Borrowing Base Certificate (Third Party Agent) no later than 12:00 p.m. on the date of such request;

(d) after giving effect to the making of any such Loan, (i) the Revolver Usage on such date (after giving effect to any such proposed Loan or credit extension) does not exceed (ii) either (A) the Borrowing Base reflected in the Borrowing Base Certificate referred to in Section  3.02(c) above (as adjusted by Agent (or the Third Party Agent, as applicable) for Reserves established by Agent (or the Third Party Agent, as applicable) from time to time) or (B) the Maximum Revolver Amount; and

(e) after giving effect to the making of any such Loan, a Maximum Decreased Market Capitalization Overadvance Event shall not have occurred.

3.03 Effect of Maturity . On the Maturity Date, all commitments (including the Commitments) of the Lender Group to provide additional credit hereunder shall automatically be terminated and all of the Obligations immediately shall become due and payable without notice or demand and Borrowers shall be required to repay all of the Obligations in full in cash. No termination of the obligations of the Lender Group in accordance with this Agreement (other than payment in full in cash of all of the Obligations and termination of all of the Commitments) shall relieve or discharge any Loan Party of its duties, obligations, or covenants hereunder or under any other Loan Document and Agent’s Liens in the Collateral shall continue to secure the Obligations and shall remain in effect until all Obligations have been paid in full in cash and the Commitments have been terminated. When all of the Obligations have been paid in full in cash and the Lender Group’s obligations to provide additional credit under the Loan Documents (and all of the Commitments) have been terminated irrevocably, Agent will, at Borrowers’ sole expense, execute and deliver any termination statements, lien releases, discharges of security interests, and other similar discharge or release documents (and, if applicable, in recordable form) as are reasonably necessary to release, as of record, Agent’s Liens and all notices of security interests and liens previously filed by Agent.

3.04 Conditions Subsequent . The obligation of the Lender Group (or any member thereof) to continue to make Revolving Loans (or otherwise extend credit hereunder) is subject to the fulfillment, on or before the date applicable thereto, of the conditions subsequent set forth on Schedule 3.04 (the failure by Borrowers to so perform or cause to be performed such conditions subsequent as and when required by the terms thereof (unless such date is extended, in writing, by Agent in its sole discretion, which Agent may do without obtaining the consent of the other members of the Lender Group), shall constitute an immediate Event of Default).

ARTICLE IV.

REPRESENTATIONS AND WARRANTIES.

In order to induce the Agent and the Lenders to enter into this Agreement, each of the Borrowers make the following representations and warranties to the Lender Group which shall be true, correct, and complete, in all material respects (except that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof), as of the Closing Date, and shall be true, correct, and complete, in all material respects (except that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified

 

71


or modified by materiality in the text thereof), as of the date of the making of each Loan (or other extension of credit) made thereafter, as though made on and as of the date of such Loan (or other extension of credit) (except to the extent that such representations and warranties relate solely to an earlier date, in which case such representations and warranties shall be true and correct in all material respects (except that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof) as of such earlier date) and such representations and warranties shall survive the execution and delivery of this Agreement:

4.01 Due Organization and Qualification; No Event of Default; Solvency .

(a) Each Loan Party is (i) conducting its business in compliance with its Organizational Documents and (ii) not in violation of its Organizational Documents. Each Loan Party’s Organizational Documents are in full force and effect.

(b) No Default or Event of Default has occurred or will result from the transactions contemplated by the Loan Documents.

(c) Each Loan Party (i) is Solvent and (ii) has not taken action, and no such action has been taken by a third party, for its winding up, dissolution or liquidation or similar executory or judicial proceeding or for the appointment of a liquidator, custodian, receiver, trustee, administrator or other similar officer for any Loan Party or any or all of its assets or revenues; provided, however, that, for the avoidance of doubt, no such representation in this Section  4.01(c) is made in respect of any Immaterial Subsidiary.

(d) No Lien exists on any Loan Party’s assets, except for Permitted Liens.

(e) The obligation of the Loan Parties to make any payment under this Agreement or the other Loan Documents (together with all charges in connection therewith) is absolute and unconditional.

(f) No Indebtedness of any Loan Party exists other than Permitted Indebtedness.

4.02 Existence; Power and Authority . Each Loan Party is validly existing as a corporation, limited liability company or limited partnership, as applicable, and is in good standing under the laws of the jurisdiction of its incorporation, organization or formation, as applicable. Each Loan Party (i) has full power and authority (and all governmental licenses, authorizations, Permits, consents and approvals) to (A) own its properties and conduct its business (solely with respect to governmental licenses, authorizations, Permits, consents and approvals, except where the failure to have such governmental licenses, authorizations, Permits, consents and approvals could not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect) and (B) to enter into, and perform its obligations under, the Loan Documents and consummate the transactions contemplated under the Loan Documents, and (ii) is duly qualified as a foreign corporation, limited liability company or limited partnership, as applicable, and licensed and in good standing, under the laws of each jurisdiction where its ownership, lease or operation of property or the conduct of its business requires such qualification or license, in each case of this clause (ii), where the failure to be so qualified, licensed or in good standing could reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect.

4.03 Litigation .

(a) Other than as set forth on Schedule 4.03 , there is no pending or, to the knowledge of the Loan Parrties, threatened, any action, suit or other proceeding before any Governmental Authority (i) to

 

72


which any Loan Party is a party, (ii) which purports to affect or pertain to the Loan Documents, the Transactions or any other transaction contemplated hereby or thereby or (iii) which has as the subject thereof any assets owned by any Loan Party or any of its Subsidiaries, in each case which could reasonably be expected to result in monetary judgments or relief, individually or in the aggregate, in excess of $2,000,000.

(b) Other than as set forth on Schedule 4.03 , there are no current or, to the knowledge of any of the Loan Parties, pending, legal actions, suits or other proceedings, in each case which could reasonably be expected to result in monetary judgments or relief, individually or in the aggregate, in excess of $2,000,000, to which any Loan Party or any of its Subsidiaries or any of their respective assets is subject. With respect to each action suit, proceeding, claim, event or disclosure listed on Schedule 4.03 , none of them could reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect.

(c) No injunction, writ, temporary restraining order or any order of any nature has been issued by any court or other Governmental Authority purporting to enjoin or restrain the execution, delivery or performance of this Agreement or any other Loan Document or directing that the transactions provided for herein or therein not be consummated as herein or therein provided.

(d) Other than as set forth on Schedule 4.03 , none of the current directors (or equivalent persons) or current officers of any of the Borrowers and their respective Subsidiaries have been involved as a defendant in securities-related litigation or other securities-related legal proceedings during the past five years.

(e) No Loan Party is subject to any proceeding, suit or, to any Loan Party’s knowledge, investigation by any federal, state or local government or quasi-governmental body, agency, board or authority or any other administrative or investigative body (including the Office of the Inspector General of the United States Department of Health and Human Services) which would reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect on any Loan Party.

4.04 Due Authorization; No Conflict .

(a) As to each Loan Party, the execution, delivery, and performance by such Loan Party of the Loan Documents to which it is a party have been duly authorized by all necessary action on the part of such Loan Party and no further consent or authorization is required by the Loan Party, the Loan Party’s board of directors (or other equivalent governing body) or the holders of the Loan Party’s Stock. Each of this Agreement and the other Loan Documents has been duly executed and delivered by each of the Loan Parties and constitutes a valid, legal and binding obligation of each Loan Party, enforceable in accordance with its respective terms, except as such enforceability may be limited by applicable insolvency, bankruptcy, reorganization, moratorium or other similar laws affecting creditors’ rights generally.

(b) The execution, delivery and performance of this Agreement and the other Loan Documents by each Loan Party party thereto and the consummation of the transactions contemplated herein and therein will not (i) conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, or result in the creation or imposition of any Lien (other than pursuant to the Loan Documents) upon any assets of any such Loan Party pursuant to, any agreement, document or instrument to which such Loan Party is a party or by which any Loan Party is bound or to which any of the assets or property of any Loan Party is subject, except, with respect to this clause (i), as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, (ii) result in any violation of or conflict with the provisions of the Organizational Documents, (iii) result in

 

73


the violation of any Applicable Law, (iv) result in the violation of any judgment, order, rule, regulation or decree of any Governmental Authority, or (v) violate, conflict with or cause a breach or a default under any agreement or instrument binding upon it, except, with respect to clauses (iii) and (v) only, as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. No consent, approval, Authorization or order of, or registration or filing with any Governmental Authority is required for (x) the execution, delivery and performance of this Agreement or any of the other Loan Documents, and the issuance of the Securities hereunder and thereunder, and (y) the consummation by any Loan Party of the Transactions or the other transactions contemplated hereby or thereby, except for (A) the filings necessary to perfect the Liens created by the applicable Loan Documents and (B) any necessary filings with the SEC.

(c) Other than has been obtained, no Authorization is required for (i) the execution and delivery of this Agreement or the other Loan Documents, or (ii) the consummation of the Transactions and the other transactions contemplated hereby and thereby.

(d) Each Loan Party and its Subsidiaries are in compliance with Applicable Law except as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.

4.05 Permits and Authorizations . Except as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, (a) (i) each Loan Party holds, and is operating in compliance in all material respects with, all franchises, grants, Authorizations, licenses, permits, easements, consents, certificates and orders of any Governmental Authority (collectively, “ Necessary Documents ”) required for the conduct of its business and (ii) all Necessary Documents are valid and in full force and effect and (b) no Loan Party has (i) received written notice of any revocation, non-renewal, amendment, expiration, suspension, limitation, withdrawal, cancellation or other modification of any of the Necessary Documents and (ii) reason to believe that any of the Necessary Documents will not be renewed in the ordinary course of business.

4.06 Title to Assets; No Encumbrances . As of the Closing Date, the Real Property listed in Schedule 4.06 constitutes all of the Real Property of each Loan Party and each of its Subsidiaries. Each Loan Party has good and marketable title to all of its assets and property free and clear of all Liens, except Permitted Liens. Except as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, the property held under lease by each Loan Party is held under valid, subsisting and enforceable leases with only such exceptions with respect to any particular lease as do not interfere in any material respect with the conduct of the business of such Loan Party.

4.07 Intellectual Property . Each Loan Party owns, or, to the knowledge of the Loan Parties and their Subsidiaries, has the right to use pursuant to a valid and enforceable written license, all IP, in each case (and without any knowledge qualifier applicable thereto) free and clear of any Liens other than Permitted Licenses and Permitted Liens. All IP that is registered with or issued by a Governmental Authority that is currently in the name of a Loan Party is, to the knowledge of the Loan Parties and their Subsidiaries, valid and enforceable. Each patent constituting a Material Intangible Asset is, to the knowledge of the Loan Parties and their Subsidiaries, valid and enforceable and no part of the Material Intangible Assets has been judged invalid or unenforceable, in whole or in part. Except as set forth on Schedule 4.07 , as of the Closing Date, there is no pending or, to the knowledge of the Loan Parties, threatened action, suit, other proceeding or claim by any Person challenging or contesting the validity, ownership, or enforceability of any Material Intangible Asset, the use thereof by any Loan Party, or other rights of any Loan Party in or to any Material Intangible Asset, and no Loan Party has received any written notice regarding any such action, suit, other proceeding or claim. At all times after the Closing Date when this representation is made or deemed made, there is no pending or, to the knowledge of the

 

74


Borrowers, threatened action, suit, other proceeding or claim by any Person challenging or contesting the validity, ownership, or enforceability of any Material Intangible Asset, the use thereof by any Loan Party, or other rights of any Loan Party in or to any Material Intangible Asset, and no Borrower has received any written notice regarding any such action, suit, other proceeding or claim, except that could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. With respect to each action, suit, proceeding, claim, challenge, contest, event and disclosure listed on Schedule 4.07 , none of them could reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect. Neither the conduct of the business of any Loan Party, nor any Loan Party, has infringed, misappropriated or otherwise violated, or is infringing, misappropriating or otherwise violating, any Intellectual Property of any Person, except as could not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect. Other than as set forth on Schedule 4.03 , on the Agreement Date, there is no pending or, to the knowledge of the Loan Parties, threatened action, suit, other proceeding or claim by any Person alleging that any Loan Party is infringing, misappropriating or violating, or otherwise using without authorization, any Intellectual Property of any Person, and no Loan Party has received any written notice regarding, any such action, suit, other proceeding or claim. With respect to each action, suit, proceeding, claim, event or disclosure listed on Schedule  4.03 , none of them could reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect. Other than as set forth in Section 3.b. of the Perfection Certificate dated as of (and delivered by the Loan Parties on) the Closing Date, no Loan Party is a party to, or bound by, any options, licenses, franchise or other agreements, written or oral, relating to trademarks, patents, copyrights, other know-how or IP (or granting any right, title or interest in or to any IP) that require annual payments in excess of $25,000 individually.

4.08 No Default . No Loan Party is, except as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, in breach of or otherwise in default under, and no event has occurred which, with notice or lapse of time or both, would constitute such breach or other default in the performance of any agreement or condition contained in any agreement under which it may be bound, or to which any of its assets is subject

4.09 Taxes . All U.S. federal, state and local income and franchise and other material Tax returns, reports and statements (collectively, the “ Tax Returns ”) required to be filed by any Tax Affiliates have been filed with the appropriate Governmental Authorities, all such Tax Returns are true and correct in all material respects, and all Taxes, assessments and other governmental charges and impositions reflected therein or otherwise due and payable have been paid prior to the date on which any material Liability may be added thereto for non-payment thereof except for those contested in good faith by appropriate proceedings diligently conducted and for which adequate reserves are maintained on the books of the appropriate Tax Affiliate in accordance with GAAP. As of the Closing Date, no material Tax Return is under audit or examination by any Governmental Authority, and no Tax Affiliate has received written notice from any Governmental Authority of any audit or examination or any assertion of any claim for material Taxes. To the extent material, proper and accurate amounts have been withheld by each Tax Affiliate from their respective employees for all periods in full and complete compliance with the Tax, social security and unemployment withholding provisions of Applicable Law and such withholdings have been timely paid to the respective Governmental Authorities. No Tax Affiliate has participated in a “listed transaction” within the meaning of Treasury Regulation Section 1.6011-4(b)(2) or has been a member of an affiliated, combined or unitary group other than the group of which a Tax Affiliate is the common parent.

4.10 Compliance with Laws . Except as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect after the Closing Date, each Loan Party: (a) at all times has complied with all Applicable Laws; (b) has not received any warning letter or other correspondence

 

75


or notice from the any Governmental Authority alleging or asserting noncompliance with any Applicable Laws or any Authorizations; (c) possesses and complies with the Authorizations, which are valid and in full force and effect; (d) has not received written notice that any Governmental Authority has taken, is taking or intends to take action to limit, suspend, cancel, withdraw, modify or revoke any Authorization and has no knowledge that any Governmental Authority is considering such action; (e) has filed, obtained, maintained or submitted all reports, documents, forms, notices, applications, records, claims, submissions, renewals and supplements or amendments as required by any Applicable Laws or Authorizations and (f) has not received any notice, and are not aware, of any violation of applicable antitrust laws, employment or landlord-tenant laws of any federal, state or local government or quasi-governmental body, agency, board or other authority with respect to the Loan Parties.

4.11 SEC Filings . Endologix has filed all of the SEC Documents, within the time frames prescribed by the SEC for the filing of such SEC Documents such that each filing was timely filed with the SEC. Endologix has filed and made publicly available on the SEC’s Electronic Data Gathering, Analysis, and Retrieval system (including any successor thereto, “ EDGAR ”) on or prior to the date this representation is made, true, correct and complete copies of the SEC Documents. As of their respective dates, each of the SEC Documents complied in all material respects with the requirements of the Securities Act and/or the Exchange Act (as applicable) applicable to the SEC Documents. None of the SEC Documents, at the time they were filed with the SEC, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. Since the filing of the SEC Documents, no event has occurred that would require an amendment or supplement to any of the SEC Documents and as to which such an amendment or a supplement has not been filed and made publicly available on EDGAR (and true, correct and complete copies of such amendment or supplement, if any, have been delivered to the Secured Parties or their respective representatives) on or prior to the date this representation is made. Endologix has not received any written comments from the SEC staff that have not been resolved, to the knowledge of Endologix, to the satisfaction of the SEC staff.

4.12 Financial Statements . As of their respective dates, the consolidated financial statements of Endologix and its Subsidiaries included in the SEC Documents complied as to form in all material respects with applicable accounting requirements and the published rules and regulations of the SEC with respect thereto. Such financial statements have been prepared in accordance with GAAP, consistently applied (subject, in the case of unaudited quarterly financial statements, to normal year-end adjustments and lack of footnote disclosures), and fairly present in all material respects the consolidated financial position of Endologix and its Subsidiaries as of the dates thereof and the consolidated results of their operations, cash flows and changes in stockholders equity for the periods then ended (subject, in the case of unaudited quarterly financial statements, to normal year-end audit adjustments and lack of footnote disclosures). The accounting firm that expressed its opinion with respect to the consolidated financial statements included in Endologix’s most recently filed annual report on 10-K, and reviewed the consolidated financial statements included in the Endologix’s most recently filed quarterly report on 10-Q, was independent of Endologix pursuant to the standards set forth in Rule 2-01 of Regulation S-X promulgated by the SEC and as required by the applicable rules and guidance from the Public Company Accounting Oversight Board (United States), and such firm was otherwise qualified to render such opinion under Applicable Law and the rules and regulations of the SEC. There is no transaction, arrangement or other relationship between Endologix (or any of its Subsidiaries) and an unconsolidated or other off-balance-sheet Person that is required to be disclosed by Endologix in the SEC Documents that has not been so disclosed in the SEC Documents. Neither Endologix nor any of its Subsidiaries is required to file or will be required to file any agreement, note, lease, mortgage, deed or other instrument entered into prior to the date this representation is made and to which the Borrower or any of its Subsidiaries is a party or by which Endologix or any of its Subsidiaries is bound that has not been

 

76


previously filed as an exhibit (including by way of incorporation by reference) to the Borrower’s reports filed or made with the SEC under the Exchange Act. Other than (i) the liabilities assumed or created pursuant to this Agreement and the other Loan Documents and any fees and expenses in connection therewith, (ii) liabilities accrued for in the latest balance sheet included in Endologix’s most recent periodic report (on 10-Q or 10-K) filed prior to the date this representation is made (the date of such balance sheet, the “ Latest Balance Sheet Date ”), (iii) liabilities incurred in the ordinary course of business consistent with past practice since the later of the (A) Closing Date and (B) the Latest Balance Sheet Date and (iv) liabilities set forth on the Schedules to this Agreement, Endologix and its Subsidiaries do not have any other material liabilities (whether fixed or unfixed, known or unknown, absolute or contingent, asserted or unasserted, choate or inchoate, liquidated or unliquidated, or secured or unsecured, and regardless of when any action, claim, suit or proceeding with respect thereto is instituted). Since December 31, 2016, there has been no Material Adverse Effect or any event or circumstance which could reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect. All financial performance projections delivered to any Secured Party, including the financial performance projections delivered on or prior to the Closing Date, if any, represent Endologix’s and its Subsidiaries’ good faith estimate of future financial performance and are based on assumptions believed by Endologix and its Subsidiaries to be fair and reasonable in light of current market conditions, it being acknowledged and agreed by Agent and the Lenders that projections as to future events are not to be viewed as facts and that the actual results during the period or periods covered by such projections may differ from the projected results and such differences may be material.

4.13 Internal Controls .

(a) Each Borrower and its respective Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset and liability accountability, (iii) access to assets or incurrence of liability is permitted only in accordance with management’s general or specific authorization and (iv) the recorded accountability for assets and liabilities is compared with the existing assets and liabilities at reasonable intervals and appropriate action is taken with respect to any differences (such internal accounting controls (including clauses (i) – (iv) above), collectively, “ Internal Controls ”).

(b) Endologix and its Subsidiaries has timely filed and made publicly available on EDGAR all certifications, statements and documents required by Rule 13a-14 or Rule 15d-14 under the Exchange Act. Endologix and its Subsidiaries maintain disclosure controls and procedures required by Rule 13a-15 or Rule 15d-15 under the Exchange Act; such controls and procedures are effective to ensure that the information required to be disclosed by Endologix and its Subsidiaries in the reports that they file with or submit to the SEC (i) is recorded, processed, summarized and reported accurately within the time periods specified in the SEC’s rules and forms and (ii) is accumulated and communicated to Endologix’s (and, to the extent applicable, its Subsidiaries’) management, including its or their principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. Endologix and its Subsidiaries maintain internal control (including Internal Controls) over financial reporting required by Rule 13a-15 or Rule 15d-15 under the Exchange Act; such internal control (including Internal Controls) over financial reporting is effective and does not contain any material weaknesses.

4.14 ERISA . (i) No Loan Party has engaged, and to the knowledge of the Loan Parties, no other Person has engaged in any “prohibited transaction” as defined under Section 406 of ERISA or Section 4975 of the IRC that is not exempt under ERISA Section 408 or Section 4975 of the IRC, under

 

77


any applicable regulations and published interpretations thereunder or under any applicable prohibited transaction, individual or class exemption issued by the Department of Labor, with respect to any Employee Benefit Plan, except as for such transaction that could not be expected, individually or in the aggregate, to have a Material Adverse Effect, (ii) (A) at no time within the last seven years has the Borrower or any ERISA Affiliate maintained, sponsored, participated in, contributed to or had any Liability with respect to, and (B) no Loan Party or any ERISA Affiliate has any Liability or obligation in respect of, any Title IV Plan, Multiemployer Plan or any multiple employer plan for which the Borrower or any ERISA Affiliate has incurred or could incur Liability under Section 4063 or 4064 of ERISA, (iii) each Employee Benefit Plan is and has been operated in compliance with its terms and all Applicable Laws, including ERISA and the IRC, except for such failures to comply that could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, (iv) (A) no ERISA Event has occurred and (B) no event or condition exists or existed that could reasonably be expected to subject the Borrower or any ERISA Affiliate to any tax, fine, lien, penalty or Liability imposed by ERISA, the IRC or other Applicable Law, except for any such ERISA Event or tax, fine, lien, penalty or liability that could not be expected, individually or in the aggregate, to have a Material Adverse Effect, and (v) no Loan Party maintains or has any obligation or Liability with respect to any Foreign Benefit Plan that, individually or in the aggregate, could be expected to have a Material Adverse Effect.

4.15 Subsidiaries . As of the Closing Date, the Borrower’s Subsidiaries are set forth in Schedule 4.15 and the information set forth in Schedule 4.15 is true, correct and complete.

4.16 No Dividends . Subsequent to December 31, 2015, the Borrower has not declared or paid any dividends or made any distribution of any kind with respect to its Stock, except as permitted hereunder.

4.17 Stock .

(a) All of the issued and outstanding shares of Stock of Endologix are duly authorized and validly issued, fully paid and nonassessable, have been issued in compliance with all applicable federal and state and foreign securities laws, were not issued in violation of or subject to any preemptive rights or other rights to subscribe for or purchase securities that have not been waived in writing.

(b) As of the Closing Date, all of Endologix’s authorized, issued and outstanding shares of Stock of Endologix and each of its Subsidiaries are set forth in Schedule 4.17 , and, except as set forth in Schedule 4.17 , there are no (i) Stock options or other Stock incentive plans, employee Stock purchase plans or other plans, programs or arrangements of Endologix or any of its Subsidiaries under which Stock options, Stock or other Stock-based or Stock-linked awards are issued or issuable to officers, directors, employees, consultants or other Persons, (ii) outstanding options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible into or exchangeable or exercisable for, any Stock of Endologix or any of its Subsidiaries, or contracts, commitments, understandings or arrangements by which Endologix or any of its Subsidiaries is or may become bound to issue additional Stock of Endologix or any of its Subsidiaries, or options, warrants or scrip for rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible into or exercisable or exchangeable for, any shares of Stock of Endologix or any of its Subsidiaries, (iii) agreements or arrangements under which Endologix or any of its Subsidiaries is obligated to register the sale of any of their securities or Stock under the Securities Act (except the Registration Rights Agreement), (iv) outstanding Stock, securities or instruments of Endologix or any of its Subsidiaries that contain any redemption or similar provisions, or contracts, commitments, understandings or arrangements by which Endologix or any of its Subsidiaries is or may become bound to redeem a security of Endologix other than under the Convertible Note Documents, (v) Stock or other

 

78


securities or instruments containing anti-dilution or similar provisions that may be triggered by the issuance of securities of Endologix or any of its Subsidiaries other than under the Convertible Note Documents or (vii) stock appreciation rights or “phantom stock” plans or agreements or any similar plans or agreements to which Endologix or any of its Subsidiaries is a party or by which Endologix or any of its Subsidiaries is otherwise subject or bound. There are no (X) stockholders’ agreements, voting agreements or similar agreements to which Endologix or any of its Subsidiaries is a party or by which Endologix or any of its Subsidiaries is otherwise subject or bound, other than in connection with clauses (i), (k) and (n) of the definition of “Permitted Investments”, (Y) preemptive rights or any other similar rights to which any Stock of the Endologix or any of its Subsidiaries is subject or (Z) any restrictions upon the voting or transfer of any Stock of Endologix or any of its Subsidiaries (other than restrictions on transfer imposed by U.S. federal and state securities laws and other than as set forth in the Loan Documents, the Term Debt Documents and, if such instrument is permitted hereunder to be secured, the documents governing the Permitted 3.25% Convertible Note Refinancing).

(c) Endologix has furnished to Agent and each Lender true, correct and complete copies of each Loan Party’s Organizational Documents and any amendments, restatements, supplements or modifications thereto, and all documents, agreements and instruments containing the terms of all securities and Stock convertible into, or exercisable or exchangeable for, Common Stock or other Stock of any Loan Party or its Subsidiaries, and the material rights of the holders thereof in respect thereto.

4.18 Material Contracts .

(a) Except for the Operative Documents, the Convertible Note Documents and the agreements set forth on Schedule 4.18 , as of the Closing Date there are no Material Contracts. The consummation of the transactions contemplated by the Loan Documents will not give rise to a right to termination in favor of any party to any Material Contract (other than any Loan Party), except for such Material Contracts the noncompliance with which would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.

(b) None of the Borrowers nor any of their respective Subsidiaries are in breach or default under any Material Contract, and, to the knowledge of the Borrowers, no other party to a Material Contract is in default or breach thereunder, except where any breach or default would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.

4.19 Use of Proceeds . The proceeds of the Loans are intended to be and shall be used (a) on the Closing Date, to pay the fees, costs, and expenses incurred in connection with this Agreement, the other Loan Documents, and the transactions contemplated hereby and thereby, and (b) thereafter, consistent with the terms and conditions hereof, for general working capital and other corporate purposes (including that no part of the proceeds of the loans made to Borrowers will be used to purchase or carry any such Margin Stock or to extend credit to others for the purpose of purchasing or carrying any such Margin Stock or for any purpose that violates the provisions of Regulation T, U or X of the Board of Governors).

4.20 Environmental Condition . Except as set forth in Schedule 4.20 and except where any failures to comply could not reasonably be expected, either individually or in the aggregate, to result in a Material Adverse Effect, each Loan Party and each Subsidiary of each Loan Party:

(a) is and has been in compliance with all applicable Environmental Laws, including obtaining and maintaining all permits, licenses, consents, Authorizations and registrations required by any applicable Environmental Law (“ Environmental Permits ”),

 

79


(b) is not party to, and no Real Property currently (or to the knowledge of any Loan Party previously) owned, leased, subleased, operated or otherwise occupied by or for any such Person is subject to or the subject of, any contractual obligation or any pending or, to the knowledge of any Loan Party, threatened, order, action, investigation, suit, proceeding, audit, Lien, claim, demand, dispute or notice of violation or of potential liability or similar notice relating in any manner to any Environmental Law,

(c) has not caused or suffered to occur a Release of Hazardous Materials at, to or from any Real Property,

(d) does not currently (or to the knowledge of any Loan Party, did not previously) own, lease, sublease operate or otherwise occupy any Real Property that is contaminated by any Hazardous Materials and

(e) is not, and has not been, engaged in, and has not permitted any current or former tenant to engage in, operations in violation of any Environmental Law and knows of no facts, circumstances or conditions reasonably constituting notice of a violation of any Environmental Law, including receipt of any information request or notice of potential responsibility under the Comprehensive Environmental Response, Compensation and Liability Act or similar Environmental Laws.

4.21 Governmental Regulation . None of any Loan Party, any Person controlling any Loan Party or any Subsidiary of any Loan Party is (a) a company registered or required to be registered as an “investment company,” or a company “controlled” by a “registered investment company” or a “principal underwriter” of an “investment company” within the meaning of the Investment Company Act, or otherwise registered or required to be registered, or subject to the restrictions imposed, by the Investment Company Act, or (b) subject to regulation under the Federal Power Act, the Interstate Commerce Act, any state public utilities code, or any other federal or state statute, rule or regulation limiting its ability to incur Indebtedness, pledge its assets, perform its obligations under the Loan Documents or which may otherwise render all or any portion of the Obligations unenforceable.

4.22 Employee and Labor Matters . There are no strikes, boycotts, grievances, work stoppages, slowdowns, lockouts or other job actions existing, pending (or, to the knowledge of any Loan Party, threatened) against or involving any Loan Party or any Subsidiary of any Loan Party, except for those that could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. Except as set forth on Schedule 4.22 , or except as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, as of the Closing Date, (a) there is no memorandum of understanding, collective bargaining or similar agreement, and there is no ongoing negotiation or duty to negotiate, with any union, labor organization, works council or similar representative covering any Employee or otherwise binding any Loan Party or any Subsidiary of any Loan Party, (b) to the Loan Parties’ knowledge, no petition for certification or election of any such representative is existing or pending with respect to any Employee, (c) to the Loan Parties’ knowledge, no such representative has sought certification or recognition with respect to any Employee, and (d) to the Loan Parties’ knowledge, no Employee or his or her representative is engaged in any organizing efforts. Except as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, all current and former Employees are and have been correctly classified as exempt or non-exempt under, and are and have been paid in accordance with, all applicable federal, state, and local wage and hour laws. Further, all individuals who perform or have performed services for any Loan Party or any Subsidiary of any Loan Party are or were correctly classified under each Employee Benefit Plan, ERISA, the Internal Revenue Code and other Applicable Law as common law employees, independent contractors or other non-employee basis, or leased employees, except as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. Each Loan Party and Subsidiary of

 

80


any Loan Party are in material compliance with all Applicable Laws concerning employment, including without limitation hiring, background checks, compensation, benefits, wages (including payment of overtime), wage deductions and withholdings, classification, immigration, work authorization, employment eligibility verification, reporting, taxation, occupational health and safety, equal rights, labor relations, accommodations, breaks, notices, employment policies, paid or unpaid time off work, accessibility, privacy, and workers’ compensation, except for such noncompliance that could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.

4.23 Name and Address; Properties . During five (5) years preceding the Closing Date, no Loan Party has been known by and has used any other name, whether corporate, fictitious or otherwise, except as set forth on Schedule 4.23 . Schedule 4.23 also lists (a) each Loan Party’s jurisdiction of organization and legal name and (b) each Loan Party’s organizational identification number. Each Loan Party’s chief executive office or sole place of business, in each case as of the Closing Date, is at the chief executive office or sole place of business address identified as such in Schedule 4.23 and no Loan Party maintains any other offices or facilities except as described therein.

4.24 Sanctions . Each Loan Party and each Subsidiary of each Loan Party is in compliance in all material respects with all Sanctions laws as administered by OFAC and the U.S. State Department. No Loan Party and no Subsidiary of a Loan Party (i) is a Person on the list of the Specially Designated Nationals and Blocked Persons (the “ SDN List ”), (ii) is a Person who is otherwise the target of Sanctions laws such that a U.S. Person cannot deal or otherwise engage in business transactions with such Person, (iii) is a Sanctioned Entity, (iv) is owned or controlled by (including by virtue of such Person being a director or owning voting shares or interests), or acts, directly or indirectly, for or on behalf of, any Person on the SDN List or a Sanctioned Entity such that the entry into, or performance under, this Agreement or any other Loan Document would be prohibited by U.S. law, (v) has its assets located in Sanctioned Entities., (vi) derives revenues from investments in, or transactions with Sanctioned Persons or Sanctioned Entities. No proceeds of any Loan will be used to fund any operations in, finance any investments or activities in, or make any payments to, a Sanctioned Person or a Sanctioned Entity.

4.25 Anti-Money Laundering . Each Loan Party and each Subsidiary of each Loan Party is in compliance with all Anti-Money Laundering Laws. No action, suit or proceeding by or before any court or Governmental Authority with respect to compliance with such Anti-Money Laundering Laws is pending or threatened to the knowledge of each Loan Party and each Subsidiary of each Loan Party.

4.26 Anti-Corruption . Each Loan Party and each Subsidiary of each Loan Party is in compliance in all material respects with all applicable Anti-Corruption Laws, including the FCPA. None of any Loan Party or any Subsidiary of a Loan Party, nor to the knowledge of any Loan Party or any Subsidiary thereof, any director, officer, agent, employee or other Person acting on behalf of the Loan Party or any Subsidiary of a Loan Party, has taken any action, directly or indirectly, that would result in a violation of applicable Anti-Corruption Laws. No part of the proceeds of the Loans will be used by any Loan Party or any of their Affiliates, directly or indirectly, for any payments to any governmental official or employee, political party, official of a political party, candidate for political office, or anyone else acting in an official capacity, in order to obtain, retain or direct business or obtain any improper advantage, in violation of the FCPA. The Loan Partiesand each Subsidiary of a Loan Party maintains and implements policies and procedures designed to ensure compliance by the Loan Parties, their Subsidiaries and their respective directors, officers, employees and agents with Sanctions, Anti-Money Laundering Laws and Anti-Corruption Laws.

4.27 Anti-Terrorism . To the extent applicable, each Loan Party and each of its Affiliates is in compliance, in all material respects, with all Anti-Terrorism Laws.

 

81


4.28 Sarbanes-Oxley . Each Borrower and its Subsidiaries are in all material respects in compliance with applicable provisions of the Sarbanes-Oxley Act of 2002, as amended, and the rules and regulations thereunder (collectively, “ Sarbanes-Oxley ”).

4.29 Accounting Practices . No Borrower, any their respective Subsidiaries nor, to the Borrowers’ or such Subsidiaries’ knowledge, any director, officer or employee, of any of the Borrowers or any of their respective Subsidiaries, has received or otherwise obtained any material complaint, allegation, assertion or claim, whether written or oral, regarding the accounting or auditing practices, procedures, methodologies or methods of such Borrower or any of its Subsidiaries or its internal accounting controls, including any complaint, allegation, assertion or claim that such Borrower or any of its Subsidiaries has engaged in questionable accounting or auditing practices. No attorney representing any Borrower or any of its Subsidiaries, whether or not employed by such Borrower or any of its Subsidiaries, has reported evidence of a material violation of securities laws or breach of fiduciary duty or similar violation by such Borrower or any of its Subsidiaries or any of their respective officers, directors, employees or agents to the Borrower’s or any of its Subsidiaries’ board of directors (or equivalent governing body) or any committee thereof or to any director (or equivalent person) or officer of such Borrower or any of its Subsidiaries pursuant to Section 307 of Sarbanes-Oxley, and the SEC’s rules and regulations promulgated thereunder. There have been no internal or SEC investigations regarding accounting or revenue recognition discussed with, reviewed by or initiated at the direction of the chief executive officer, the principal financial officer or the principal accounting officer (in each case, or officer holding such equivalent position) of any Borrower or any of their respective Subsidiaries, any Borrower’s or any of their respective Subsidiaries’ board of directors (or equivalent governing body) or any committee thereof.

4.30 Common Stock . The Common Stock is registered pursuant to Section 12(b) of the Exchange Act, and neither Endologix nor any of its Subsidiaries has taken, or will take, any action designed to terminate, or which to the knowledge of Endologix and its Subsidiaries is likely to have the effect of terminating, the registration of the Common Stock under the Exchange Act, nor has Endologix or any of its Subsidiaries received any notification that the SEC is contemplating terminating such registration. Neither Endologix nor any of its Subsidiaries is in violation of any of the rules, regulations or requirements of the Principal Market, and, to the knowledge of Endologix and its Subsidiaries, there are no facts or circumstances that could reasonably lead to suspension or termination of trading of the Common Stock on the Principal Market. For not less than the five (5) years preceding the Closing Date, (i) the Common Stock has been listed or designated for quotation, as applicable, on the Principal Market, (ii) trading in the Common Stock has not been suspended or deregistered by the SEC or the Principal Market, and (iii) neither Endologix nor any of its Subsidiaries has received any communication, written or oral, from the SEC or the Principal Market regarding the suspension or termination of trading of the Common Stock on the Principal Market.

4.31 DTC . The Common Stock is eligible for clearing through The Depository Trust Company (“ DTC ”), through its Deposit/Withdrawal At Custodian (DWAC) system, and Endologix is eligible for and participating in the Direct Registration System (DRS) of DTC with respect to the Common Stock. The transfer agent for the Common Stock is a participant in, and the Common Stock is eligible for transfer pursuant to, DTC’s Fast Automated Securities Transfer Program. The Common Stock is not, and has not at any time been, subject to any DTC “chill,” “freeze” or similar restriction with respect to any DTC services, including the clearing of transactions in shares of Common Stock through DTC.

4.32 Fees . The Borrowers and the other Loan Parties are solely and jointly and severally responsible for the payment of any fees, costs, expenses and commissions of any placement agent, broker

 

82


or financial adviser relating to or arising out of the transactions contemplated by the Loan Documents. The Borrowers and the other Loan Parties will pay, and hold each of the Secured Parties harmless against, any liability, loss or expense (including attorneys’ fees, costs and expenses) arising in connection with any claim for any such payment, other than those arising from the gross negligence or willful misconduct of Agent or any Lender as determined by a final, non-appealable judgment of a court of competent jurisdiction.

4.33 Products; Regulatory Required Permits .

(a) Except as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, each Loan Party and its Subsidiaries has made all notifications, submissions, and reports required by the FDA, any other Governmental Authority or any Healthcare Law, and all such notifications, submissions and reports were true, complete, and correct in all respects as of the date of submission to FDA, any other Governmental Authority or to such other Person required by any Healthcare Law. There has not been any violation of any Healthcare Laws by any Loan Party or its Subsidiaries in its product development efforts, submissions, record keeping and reports to the FDA or any other Governmental Authority that could reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. To the knowledge of each Loan Party and each of its Subsidiaries, there are no civil or criminal proceedings relating to any Loan Party or any of its Subsidiaries or any officer, director or employee of any Loan Party or Subsidiary of any Loan Party that involve a matter within or related to the FDA’s or any other Governmental Authority’s jurisdiction or any off-label promotion or allegations of non-compliance with Healthcare Laws. Other than as expressly set forth on Section  4.33(a) , as of the Agreement Date, no Loan Party nor any Affiliate thereof has received any material adverse notice (written or oral) from the FDA or any other Governmental Authority that has not been finally and fully resolved in accordance and compliance with Applicable Law and all FDA and other Governmental Authority standards, regulations and requirements regarding any Product or regarding (i) any actions or inactions of any Loan Party or any of its Subsidiaries or any officer, director or employee of any Loan Party or Subsidiaries of any Loan Party, including with respect to any off-label promotion or (ii) alleging non-compliance with Healthcare Laws. At all times after the Closing Date when this representation is made or deemed made, except as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, no Loan Party nor any Affiliate thereof has received (A) any notice (written or oral) from the FDA or any other Governmental Authority regarding (y) any Product or (z) any actions or inactions of any Loan Party or any of its Subsidiaries or any officer, director or employee of any Loan Party or Subsidiaries of any Loan Party, and (B) any material adverse notice (written or oral) from the FDA or any Governmental Authority (i) any actions or inactions of any Loan Party or any of its Subsidiaries or any officer, director or employee of any Loan Party or Subsidiaries of any Loan Party, including with respect to any off-label promotion or (ii) alleging non-compliance with Healthcare Laws.

(b) With respect to any Product, (i) the Loan Parties and their respective Subsidiaries have received, and such Product is the subject of, all Regulatory Required Permits needed in connection with the design, testing, manufacture, processing, assembly, packaging, labeling, marketing, distribution, commercialization, import, export or sale of such Product as currently being conducted by or on behalf of such Loan Parties or Subsidiaries, except where the failure to have such Regulatory Required Permits would not have a Material Adverse Effect, and (ii) such Product is being designed, tested, manufactured, processed, assembled, packaged, labeled, marketed, distributed, commercialized, imported, exported or sold, as the case may be, except as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, in compliance with all Applicable Laws and Authorizations.

4.34 No Violation of Healthcare Laws .

 

83


(a) No Loan Party is in violation of any Healthcare Laws, except where any such violation would not have a Material Adverse Effect.

(b) Except as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, each Loan Party and its Subsidiaries is in compliance with the written procedures, record-keeping and reporting requirements required by (or of) (i) the FDA or any comparable Governmental Authority pertaining to the reporting of adverse events involving the Products or concerning the actions or inactions of the Loan Parties and their Subsidiaries and the directors, officers and employees of the Loan Parties and their Subsidiaries, including with respect to off-label promotion, as applicable, and (ii) Healthcare Laws.

4.35 No Third Party Payor Program . No Loan Party is a participating provider under contract to provide health care services and receive payment or reimbursement for such services under any Third Party Payor Program.

4.36 Conduct of Business at Facilities . No Loan Party has received any written notice that any Governmental Authority, including, without limitation, the FDA, the Office of the Inspector General of the United States Department of Health and Human Services or the United States Department of Justice has commenced or threatened to initiate any investigation or action against a Loan Party; or any action to enjoin a Loan Party, or any of its officers, directors, employees, equityholders, agents or Affiliates, from conducting their businesses at any facility owned or used by them or for any civil penalty, injunction, seizure or criminal action, in each case, which could reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect.

4.37 No Adulteration; Product Manufacturing . Each Product, except as would not be reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, (a) is not adulterated or misbranded within the meaning of the FDCA; (b) is not an article prohibited from introduction into interstate commerce under the provisions of Sections 404, 505 or 512 of the FDCA; (c) has been and/or shall be manufactured, imported, possessed, owned, warehoused, marketed, promoted, sold, labeled, furnished, distributed and marketed, and each service has been conducted, in accordance with all applicable Authorizations and Applicable Laws; and (d) has been and/or shall be manufactured in accordance with Good Manufacturing Practices.

4.38 FDA .

(a) To the knowledge of the Loan Parties’ Authorized Officers, neither any of the Loan Parties nor any of the Loan Parties’ officers, directors, employees, equityholders, agents or Affiliates has ever (i) made an untrue statement of material fact, fraudulent statement to the FDA or any other Governmental Authority or in any documents or records prepared or maintained to comply with the FDCA; (ii) failed to disclose a material fact required to be disclosed to the FDA or any other Governmental Authority; (iii) been investigated by the FDA, National Institutes of Health, Office of the Inspector General for the Department of Health and Human Services, Department of Justice, or other comparable Governmental Authority for data or healthcare program fraud; or (iv) committed an act, made a statement, or failed to make a statement that could reasonably be expected to provide a basis for the FDA to invoke its policy respecting “Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities,” set forth in 56 Fed. Regulation 46191 (September 10, 1991).

(b) No Loan Party has received from the FDA a Warning Letter, Form FDA-483, “Untitled Letter,” other correspondence or notice setting forth allegedly objectionable observations or alleged violations of laws or regulations enforced by the FDA, or any comparable correspondence from any state

 

84


or local authority responsible for regulating drug or device products and establishments, or any comparable correspondence from any foreign counterpart of the FDA, or any comparable correspondence from any foreign counterpart of any state or local authority with regard to any Product or the manufacture, processing, packing, or holding thereof, in each case, which could reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect.

(c) As of the Closing Date, none of the Loan Parties has engaged in any material Recalls, Market Withdrawals or other forms of product retrieval from the marketplace of any Products that has not been finally and fully completed prior to the Closing Date in accordance and compliance with Applicable Law and all FDA and other Governmental Authority standards, regulations and requirements. After the Closing Date on each date that this representation and warranty is made or deemed made, none of the Loan Parties has engaged in any Recalls, Market Withdrawals or other forms of product retrieval from the marketplace of any Products that has not been finally and fully completed prior to the date such representation and warranty is made of deemed made in accordance and compliance with Applicable Law and all FDA and other Governmental Authority standards, regulations and requirements, except to the extent any such engagement or action could not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect. None of the Products (for the avoidance of doubt, including those in the immediately preceding two sentences that have been so finally and fully completed) have been subject to a Recall, Market Withdrawal, or other Correction or Removal, nor is any such action currently under consideration by Endologix or, to the knowledge of Endologix, any manufacturer or supplier of a Product, that could reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect. Endologix has not been restrained in its ability to manufacture, process, distribute, supply, import, export, market, or sell any of the Products, except to the extent that would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.

4.39 Margin Stock . None of the proceeds from the Loans have been or will be used, directly or indirectly, for the purpose of purchasing or carrying any Margin Stock, for the purpose of reducing or retiring any Indebtedness which was originally incurred to purchase or carry any Margin Stock or for any other purpose which might cause any of the Loans to be considered a “purpose credit” within the meaning of Regulation T, U or X of the Federal Reserve Board. No Loan Party nor any of their Subsidiaries is engaged principally, or as one of its important activities, in the business of extending credit for the purpose of purchasing or carrying any Margin Stock.

4.40 Complete Disclosure . None of the written information (financial or otherwise) (other than projections, other forward-looking information and industry information) furnished by or on behalf of any Borrower to Agent (including any Third Party Agent), any Lender or any other member of the Lender Group in connection with the consummation of the transactions contemplated by the Loan Documents contains any untrue statement of a material fact or omits to state a material fact necessary to make the statements contained herein or therein not materially misleading in light of the circumstances under which such statements were made.

4.41 Investments . The Loan Parties do not own any stock, partnership interests, limited liability company interest or other equity securities or Subsidiaries except for Permitted Investments. As of the Closing Date, set forth on Schedule P-1 (as such Schedule may be updated from time to time to reflect changes resulting from transactions permitted under this Agreement) is a complete and accurate description of the authorized Stock of the Subsidiaries of the Loan Parties, by class, and, as of the Closing Date, a description of the number of shares of each such class that are issued and outstanding.

4.42 Schedules . All information set forth in the Schedules to this Agreement is true, accurate and complete in all material respects as of the Closing Date and any other subsequent date in which the

 

85


Loan Parties are requested to update such Schedules. All information set forth in the Perfection Certificate is true, accurate and complete in all material respects as of the Closing Date and any other subsequent date in which the Loan Parties are requested to update such certificate.

4.43 Eligible Accounts . As to each Account that is identified by the Borrowers as Eligible Account in a Borrowing Base Certificate submitted to Agent (or to any Third Party Agent, as applicable), such Account is (a) a bona fide existing payment obligation of the applicable Account Debtor created by the sale and delivery of Inventory or the rendition of services to such Account Debtor in the ordinary course of a Loan Party’s business, (b) owed to a Loan Party without any known defenses, disputes, offsets, counterclaims, or rights of return or cancellation, and (c) not excluded as ineligible by virtue of one or more of the excluding criteria (other than any Agent-discretionary criteria) set forth in the definition of Eligible Accounts.

4.44 Eligible Inventory . As to each item of Inventory that is identified by the Borrowers as Eligible Inventory in a Borrowing Base Certificate submitted to Agent (or any Third Party Agent), such Inventory is (a) of good and merchantable quality, free from known defects, and (b) not excluded as ineligible by virtue of one or more of the excluding criteria (other than any Agent-discretionary criteria) set forth in the definition of Eligible Inventory.

4.45 Location of Inventory and Equipment . The Inventory and Equipment of the Borrowers is located only at, or in-transit between, the locations identified on Schedule 4.45 (as such Schedule may be updated pursuant to Section  5.18 ). With respect to any Inventory and Equipment listed at locations that are outside the United States (and with respect to any Inventory and Equipment on consignment at any location (other than, with respect to clause (ii), in which case such clause shall not apply to all consignment locations but only those outside the United States)), (i) any failure of the Agent and the other Secured Parties to (A) be fully protected on the Inventory or be fully protected or perfected with respect to any Liens granted to the Agent (for the benefit of the Secured Parties) on any such Inventory, or (B) have absolute or full access to such locations when exercising rights and remedies after the occurrence and during the continuance of an Event of Default, in each case of clause (i)(A) and clause (i)(B), does not, individually or in the aggregate, cause a Material Adverse Effect to occur, and (ii) as of the Agreement Date, the cost paid by the Borrowers and its Subsidiaries for such Inventory and Equipment listed at such locations outside the United States, or on consignment at any location outside the United States, does not exceed $10,000,000.

4.46 Inventory and Equipment Records . Each Loan Party keeps correct and accurate records itemizing and describing the type, quality, and quantity of its and their Subsidiaries’ Inventory and Equipment and the book value thereof.

4.47 No Violation of Usury Laws . The rate of interest paid on any of the Obligations, and the method and manner of the calculation thereof, do not violate any usury laws or other Applicable Laws, any of the Organizational Documents, or any of the Loan Documents.

4.48 Eligible Equipment . As to each item of Equipment that is identified by the Borrowers as Eligible Equipment in a Borrowing Base Certificate submitted to Agent (or any Third Party Agent), such Equipment is (a) of good and merchantable quality, free from known defects, and (b) not excluded as ineligible by virtue of one or more of the excluding criteria (other than any Agent-discretionary criteria) set forth in the definition of Eligible Equipment.

 

86


ARTICLE V.

AFFIRMATIVE COVENANTS.

Borrowers covenant and agree that, until termination of all of the Commitments and payment in full in cash of the Obligations:

5.01 Existence; Permits .

(a) The Loan Parties shall and shall cause their Subsidiaries to (i) preserve and maintain in full force and effect its organizational existence and good standing under the Applicable Laws of its jurisdiction of incorporation, organization or formation, as applicable, other than as permitted under Section  6.01 , and (ii) preserve and maintain all qualifications to do business in each other jurisdiction not covered by clause (i) above that the failure to be so qualified could reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.

(b) The Loan Parties shall, and shall cause their Subsidiaries to, obtain, make and keep in full force and effect all licenses, certificates, approvals, registrations, clearances, Authorizations and permits required to conduct their businesses, except where the failure to make and keep such licenses, certificates, approvals, registrations, clearances, authorizations and permits in full force and effect could not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect.

(c) Each Loan Party shall, except as otherwise permitted by this Agreement, maintain, and shall cause each of its Subsidiaries to maintain, and preserve all its assets and property which is used or useful in its business in good working order and condition, ordinary wear and tear excepted and shall make all necessary repairs thereto and renewals and replacements thereof, except, in each case, where the failure to do so could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.

5.02 Compliance with Laws . The Loan Parties will, and will cause each of their Subsidiaries to, (a) comply in all material respects with all Applicable Laws, except where the necessity of compliance therewith is contested in good faith by appropriate proceedings or where failure to do so could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, and (b) maintain in effect and enforce policies and procedures designed to ensure compliance by the Borrowers, their Subsidiaries and their respective directors, officers and employees with Anti-Corruption Laws, Anti-Money Laundering Laws, Anti-Terrorism Laws and applicable Sanctions.

5.03 Insurance . The Loan Parties shall, and shall cause each of their Subsidiaries to, maintain with financially sound and reputable insurance companies with respect to their assets, properties and business, against such hazards and liabilities, of such types and in such amounts, as is customarily maintained by companies in the same or similar businesses similarly situated. All property insurance policies covering the Collateral are to be made payable to Agent for the benefit of Agent, the Lenders and the other members of the Lender Group, as their interests may appear, in case of loss, pursuant to a standard lender’s loss payable endorsement with a standard noncontributory “lender” or “secured party” clause and are to contain such other provisions as Agent may reasonably require to fully protect the Lenders’ interest in the Collateral and to any payments to be made under such policies. All certificates and endorsements of property and general liability insurance are to be delivered to Agent by the Loan Parties, with the lender’s loss payable (but only in respect of Collateral) and additional insured endorsements in favor of Agent and shall provide for not less than 30 days (10 days in the case of non-payment) prior written notice to Agent of the exercise of any right of cancellation or any modification thereof; provided, however, that, for the avoidance of doubt, Agent need not be named on any workers

 

87


compensation or D&O policies. If Loan Parties or their Subsidiaries fail to maintain such insurance, Agent may arrange for such insurance, but at Borrowers’ expense and without any responsibility on Agent’s part for obtaining the insurance, the solvency of the insurance companies, the adequacy of the coverage, or the collection of claims. The Loan Parties shall give Agent prompt written notice of any loss exceeding $500,000 covered by any of the Loan Parties’ or any of their Subsidiaries’ casualty or business interruption insurance. Upon the occurrence and during the continuance of an Event of Default, Agent shall have the sole right to file claims under any property and general liability insurance policies in respect of the Collateral, to receive, receipt and give acquittance for any payments that may be payable thereunder, and to execute any and all endorsements, receipts, releases, assignments, reassignments or other documents that may be necessary to effect the collection, compromise or settlement of any claims under any such insurance policies. A true and complete listing of such insurance, including issuers, coverages and deductibles, shall be provided by the Loan Parties to Agent promptly following Agent’s request (or to the Third Party Agent promptly following the Third Party Agent’s request during any Third Party Agent Retention Period).

5.04 Taxes . Each Loan Party shall, and shall cause each of its Subsidiaries to, pay, discharge and perform as the same shall become due and payable or required to be performed all Tax liabilities, assessments and governmental charges or levies upon it or its property, unless the same are being contested in good faith by appropriate proceedings diligently prosecuted which stay the enforcement of any Lien and for which adequate reserves in accordance with GAAP are being maintained by such Person.

5.05 Reports, Notices .

(a) Endologix and its Subsidiaries shall (i) timely (without giving effect to any extensions pursuant to Rule 12b-25 of the Exchange Act) file all reports required to be filed with the SEC pursuant to the Exchange Act, and Endologix and its Subsidiaries shall not terminate the registration of the Common Stock under the Exchange Act or otherwise terminate its status as an issuer required to file reports under the Exchange Act, even if the securities laws would otherwise permit any such termination, and (ii) deliver to Agent (and, during any Third Party Agent Retention Period, also the Third Party Agent) a Compliance Certificate with each of its 10-Q and 10-K filings on the date such filings are made (or, if earlier, are required by the SEC to be made) with the SEC; provided that, with respect to clause  (ii) only, solely to the extent any earnings or revenue report for the same period is publicly reported or is filed with the SEC prior to the time when any 10-Q or 10-K containing the applicable quarterly or annual financial statements is filed with the SEC and to the extent the earnings or revenue set forth in any such earnings or revenue report would result in a financial covenant default under Article  VII , the Compliance Certificate shall instead be delivered by the Loan Parties to the Agent (and, during any Third Party Agent Retention Period, also the Third Party Agent) and the Lenders on the same day as such earnings or revenue report is publicly reported or is filed with the SEC. Each of such reports in clause (i)  of the immediately preceding sentence will comply in all material respects with the applicable requirements of the Exchange Act and each of such reports and such Compliance Certificate will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The consolidated financial statements included in such reports will comply as to form in all material respects with applicable accounting requirements and the published rules and regulations of the SEC with respect thereto, will be prepared in accordance with GAAP, consistently applied (subject, in the case of unaudited quarterly financial statements, to normal year-end adjustments and lack of footnote disclosures), and will fairly present in all material respects the consolidated financial position of Endologix and its Subsidiaries as of the dates thereof and the consolidated results of their operations, cash flows and changes in stockholders equity for the periods presented (subject, in the case of unaudited quarterly financial

 

88


statements, to normal year-end audit adjustments and lack of footnote disclosures). Each Borrower hereby agrees that the Borrower Representative shall send to each Secured Party copies of (A) any notices and other information made available or given to the holders of the Stock of Endologix generally, contemporaneously with Endologix making available or giving such notices and other information to such holders of Stock (it being understood and agreed that delivery shall be deemed to have occurred if such notices or other information is posted to EDGAR) and (B) all other documents, reports, financial data and other information not available on EDGAR that does not contain any material nonpublic information of the Borrower, that any Secured Party may reasonably request.

(b) Each of the Borrowers and their Subsidiaries will deliver to (x) during any Non-Third Party Agent Retention Period, subject to Section  5.20 , Agent, and (y) during any Third Party Agent Retention Period, the Third Party Agent, each of the reports, certificates or other items set forth below at the following times in form satisfactory to Agent (or such Third Party Agent):

(i) (A) within five (5) Business Days after the filing of its 10-K or 10-Q, as the case may be, an updated Perfection Certificate (provided that Endologix shall include in the 10-K or 10-Q, as the case may be, any material nonpublic information included in the Perfection Certificate delivered during any Non-Third Party Agent Retention Period (or delivered to Agent (other than the Third Party Agent) or any Lender at any time) that would not otherwise be included in such 10-Q or 10-K); and (B) upon the reasonable request of any Secured Party, the such additional business, financial, corporate affairs, perfection certificates, items or documents related to creation, perfection or priority of Agent’s Liens in the Collateral and other information as any Secured Party may from time to time reasonably request;

(ii) promptly, but in any event within two (2) Business Days after the knowledge of the occurrence of (A) written notice of any Default or Event of Default and (B) so long as such type of notification would not be material nonpublic information of the Borrower (except during a Third Party Agent Retention Period, in which case, such material nonpublic information shall be provided but only to the Third Party Agent), written notice of any claims (other than in connection with the denial of plan claims in the ordinary course of business), litigation, arbitration, mediation or administrative or regulatory proceedings that are instituted or threatened against any Loan Party, or claims of infringement by any Person with respect to any Intellectual Property rights of a Loan Party, in each case of this clause (B), to the extent such claim, litigation, arbitration, mediation or administrative or regulatory proceeding could reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect; and

(iii) during any Third Party Agent Retention Period, as soon as available, but in any event within thirty (30) days after the end of each fiscal month during each fiscal year, an unaudited consolidated and consolidating balance sheet and income statement of Endologix and its Subsidiaries’ operations during such month and for the portion of the fiscal year then ended, including comparisons to the figures in the corresponding month and year-to-date portion of the immediately preceding fiscal year of Endologix and its Subsidiaries.

(c) Further, if Endologix is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act, the Loan Parties will provide to Agent (and, during any Third Party Agent Retention Period, also the Third Party Agent) and each Lender (A) quarterly financial statements for Endologix and its Subsidiaries within 45 days after the end of each fiscal quarter of Endologix, and an audited annual financial statements within 120 days after the end of each fiscal year of Endologix prepared in accordance with GAAP with a report thereon by Endologix’s independent certified public accountants, which accountants shall be reasonably acceptable to Agent, and (B) on the same day as delivery to Term Agent, any Term Lender or any other secured party under the Term Debt Documents, any additional financial

 

89


statements, certificates, reports, notices, agreements, instruments and documents provided under (or in connection with) the Term Debt Documents. Any such annual audited financial statements, audit or report of Endologix’s independent certified public accountants (and any annual audited financial statements, audit or report of Endologix’s independent certified public accountants on any consolidated financial statements included in any SEC Document) shall (i) contain an unqualified opinion (subject to the exception set forth below in clause (ii) of this sentence), stating that such consolidated financial statements present fairly in all material respects the financial position and condition and results of operations of the Borrower and its Subsidiaries as of the dates and for the periods and have been prepared in conformity with GAAP applied on a basis consistent with prior years, and (ii) not include any explanatory paragraph expressing substantial doubt as to going concern status (other than any such paragraph arising from the impending maturity of the Loans solely in the case of the audit delivered with respect to the fiscal year immediately prior to the fiscal year during which the applicable maturity is scheduled).

(d) Endologix and its Subsidiaries shall, prior to making any prepayment pursuant to Section  6.18(a) , deliver to Agent, subject to Section  5.20 (or, during any Third Party Agent Retention Period, the Third Party Agent), a budget and projections of cash flows for the one-year period following such prepayment reflecting such prepayment and showing sources and uses for all required repayments of Indebtedness coming due during such one-year period.

5.06 Inspection . The Loan Parties will, and will cause each of their Subsidiaries to, permit Agent (including any Third Party Agent), any Lender, and each of their respective duly authorized representatives or agents to, with respect to each owned, leased or controlled property, at all times and without notice, at the sole option of Agent or any Lender: (i) provide access to such property to Agent (including any Third Party Agent), the Lenders and their respective representatives and agents, as frequently as Agent or any Lender determines to be appropriate; and (ii) permit Agent (including any Third Party Agent) or any Lender to conduct field examinations, appraise, inspect, and make extracts and copies (or take originals if reasonably necessary) from all of such Loan Party’s and its Subsidiaries’ books and records, and evaluate and conduct appraisals and evaluations in any manner and through any medium that Agent or any Lender considers advisable, in each instance, subject to Section  2.09(c) , at the Loan Parties’ sole expense. Any Lender may accompany Agent (including any Third Party Agent) or its representatives in connection with such inspection. Notwithstanding the foregoing, the Loan Parties shall (and shall cause each of their respective Subsidiaries to) comply with (and coordinate with Agent and the Lenders and their representatives and agents to make sure of compliance with) Section  5.20 in connection with any such inspection, examination, audit or analysis.

5.07 Disclosure Updates . Each Loan Party shall ensure that all written information, exhibits and reports furnished to any Agent (including any Third Party Agent), any Lender or any other member of the Lender Group, when taken as a whole, do not and will not contain any untrue statement of a material fact and do not and will not omit to state any material fact or any fact necessary to make the statements contained therein not materially misleading in light of the circumstances in which made, and will promptly disclose, after knowledge of any defect of a material fact, untrue statement of material fact, material misstatement or error of a material fact, to Agent (including, during any Third Party Agent Retention Period, the Third Party Agent) and the Lenders and correct any such defect, untrue statement of material fact, material misstatement or error of a material fact that has been discovered therein or in any Loan Document or in the execution, acknowledgement or recordation thereof; it being acknowledged and agreed that any projections provided to the Lender Group are not to be viewed as facts, are not a guarantee of financial performance, and are subject to uncertainties and contingencies.

 

90


5.08 Cash Management . Each Loan Party shall enter into, and cause each depository, securities intermediary or commodities intermediary to enter into, Control Agreements with respect to each deposit, securities, commodity or similar account maintained by such Person (other than (i) deposit accounts exclusively used for payroll, payroll taxes and other employee wage and benefit payments to or for the benefit of the Borrowers’ employees and identified to Agent by the Borrower Representative as such, (ii) zero balance accounts; provided that such accounts have been identified to Agent by the Borrower Representative as such, (iii) such other petty cash deposit accounts, amounts on deposit in which do not exceed $100,000 in the aggregate at any one time, (iv) escrow, trust and fiduciary accounts, (v) each account of Excluded Foreign Subsidiaries, (vi) deposit account #XXXXX7912 of TriVascular Canada LLC at Bank of Montreal; provided the aggregate amount on deposit in such deposit account(s) does not exceed 1,000,000 Canadian dollars at any time, (vii) the Bank of America Cash Collateral Account (such accounts in clauses (i) through (vii), the “ Excluded Accounts ”)) as of and after the Closing Date; provided that (x) the Loan Parties shall have until the date that is forty-five (45) days following the closing date of any Permitted Acquisition (or such later date as may be agreed to by Agent in its sole reasonable discretion) to comply with the provisions of this Section  5.08 ) with regard to such accounts (other than Excluded Accounts) of the Borrowers acquired in connection with such Permitted Acquisition, and (y) for deposit accounts, securities accounts and commodities accounts opened after the Closing Date, the Loan Parties shall have until the date that is thirty (30) days following the opening of any such new account (or such later date as may be agreed to by Agent in its sole reasonable discretion) to comply with this Section  5.08 .

5.09 Further Assurances . Promptly upon request by Agent (or, during any Third Party Agent Retention Period, the Third Party Agent), the Borrowers shall (and, subject to the limitations set forth herein and in the other Loan Documents, shall cause each of their Subsidiaries to) take such additional actions and execute such documents as Agent (or, during any Third Party Agent Retention Period, the Third Party Agent) may reasonably require from time to time in order (i) to carry out more effectively the purposes of this Agreement or any other Loan Document, (ii) to subject to the Liens created by any of the Loan Documents on any of the assets or properties, rights or interests covered by any of the Loan Documents, (iii) to perfect and maintain the validity, effectiveness and priority of any of the Loan Documents and the Liens intended to be created thereby, and (iv) to better assure, grant, preserve, protect and confirm to the Secured Parties the rights granted or now or hereafter intended to be granted to the Secured Parties under any Loan Document. The Loan Parties will notify Agent in writing prior to (and on) (x) the date of formation or acquisition of any Subsidiary and (y) any division or split of any Loan Party into two or more Subsidiaries, limited liability companies, other entities or other Persons. Without limiting the generality of the foregoing, the Loan Parties shall cause (y) each of their Subsidiaries (other than Excluded Subsidiaries) promptly after (but, in any event, (A) within fifteen (15) days thereof for any Subsidiary that is not an Immaterial Subsidiary and (B) within thirty (30) days thereof for any Immaterial Subsidiary) after the date of the formation or acquisition thereof (and any Subsidiaries, limited liability companies, other entities or other Persons for which any Loan Party divides or splits itself into), to guaranty the Obligations and to cause each such Subsidiary to grant to Agent, for the benefit of the Secured Parties, a security interest in, subject to the limitations set forth herein and in the Loan Documents, all of such Subsidiary’s (and, with respect to any such division or split of a Loan Party, all such Subsidiary’s limited liability company’s, other entity’s or other Person’s) assets and property (including any assets or property allocated, distributed, conveyed or otherwise transferred pursuant to any division or split of any Loan Party into any Subsidiaries, limited liability companies, other entities or other Persons for which any Loan Party divides or splits itself into) assets and property to secure such guaranty and (z) any holder (that is a Loan Party) of the Stock of such Subsidiary to provide, promptly after (but, in any event, (A) within fifteen (15) days thereof for any Loan Party or any Subsidiary that is not an Immaterial Subsidiary and (B) within thirty (30) days thereof for any Immaterial Subsidiary) the date (x) of the formation or acquisition of such Subsidiary or (y) any division or split of any Loan Party

 

91


into two or more Subsidiaries, limited liability companies, other entities or other Persons, in each case, supplements and further pledges to the Loan Documents as are necessary (or requested by Agent) to evidence Agent’s Lien in such Stock of such Subsidiary. Furthermore, the Borrower shall notify Agent and the Lenders in writing promptly after (but, in any event, (A) within fifteen (15) days thereof for any Loan Party or any Subsidiary that is not an Immaterial Subsidiary and (B) within thirty (30) days thereof for any Immaterial Subsidiary) the date of the issuance by or to any Loan Party (other than by Endologix) of any Stock of any corporation or any other Person that has “opted into” Article 8 of the UCC (in each case, other than Excluded Property) to have its Stock constitute “securities” under Article 8 of the UCC and each Loan Party shall pledge, and shall cause each of its Subsidiaries (other than Excluded Subsidiaries but including any Subsidiaries, limited liability companies, other entities or other Persons for which any such Loan Party divides or splits itself into) to pledge, all of the Stock of each of its Subsidiaries (other than Excluded Subsidiaries), and sixty-five percent (65%) of the outstanding voting Stock and one hundred percent (100%) of the outstanding non-voting Stock of each Excluded Foreign Subsidiary and each Excluded Domestic Holdco, directly owned by a Loan Party, in each instance, to Agent, for the benefit of the Secured Parties, to secure the Obligations, promptly after formation or acquisition (or division or split) of such Subsidiary. The Loan Parties shall deliver, or cause to be delivered, to Agent, appropriate resolutions, secretary certificates, certified Organizational Documents and, if reasonably requested by Agent, legal opinions relating to the matters described in this Section  5.09 (which opinions shall be in form and substance reasonably acceptable to Agent and, to the extent applicable, substantially similar to the opinions delivered on the Closing Date), in each instance with respect to (1) each Loan Party or Subsidiary formed or acquired (and each Subsidiary, limited liability company, other entity or other Person for which a Loan Party divides or splits itself into), (2) and each Loan Party or Person (other than a Loan Party) whose Stock is being pledged, and (3) the assets and property that are allocated distributed, conveyed or otherwise transferred pursuant to any division or split of any Loan Party into any Subsidiaries, limited liability companies, other entities or other Persons for which any Loan Party divides or splits itself into, in each case of clauses (1) through (3), after the Closing Date. In connection with each pledge of Stock, the Loan Parties shall deliver, or cause to be delivered, to Agent, irrevocable proxies and Stock powers and/or assignments, as applicable, duly executed in blank.

5.10 Environmental . The Loan Parties will, and will cause each of their Subsidiaries to, comply with, and maintain its Real Property, whether owned, leased, subleased or otherwise operated or occupied, in compliance with all applicable Environmental Laws and Healthcare Laws or that is required by orders and directives of any Governmental Authority, except where the failure to comply could not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect.

5.11 ERISA . Promptly upon becoming aware that any of the following events has occurred, the Borrowers will provide written notice to the Agent (and, during any Third Party Agent Retention Period, also the Third Party Agent) specifying the nature of such event, what action the Loan Party or any ERISA Affiliates has taken, is taking or proposes to take with respect thereto and, when known, if applicable, any action taken or threatened by the Internal Revenue Service, the Department of Labor or the PBGC with respect thereto: (i) any ERISA Event which could reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, (ii) a “prohibited transaction” as defined under Section 406 of ERISA or Section 4975 of the IRC that is not exempt under ERISA Section 408 or Section 4975 of the IRC, under any applicable regulations and published interpretations thereunder or under any applicable prohibited transaction, individual or class exemption issued by the Department of Labor, with respect to any Employee Benefit Plan, which could reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, or (iii) the imposition of any Lien on any asset of a Loan Party or a Subsidiary of a Loan Party with respect to any Title IV Plan or Multiemployer Plan.

 

92


5.12 FDA; Healthcare Laws . Each Loan Party and its Subsidiaries will comply with (a) in all respects with all Healthcare Laws and their implementation by any applicable Governmental Authority, except as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, and (b) (i) in all respects with all lawful requests of any Governmental Authority applicable to its Products, except as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, and (ii) in all material respect with requests of any Governmental Authority applicable to its Products that is required by Applicable Law (or court order or proceeding) to be complied with. Except as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, all Products developed, manufactured, tested, distributed, promoted or marketed by or on behalf of any Loan Party or any of its Subsidiaries that are subject to the jurisdiction of the FDA or comparable Governmental Authority shall be (A) developed, tested, manufactured, distributed, promoted and marketed in compliance with the Healthcare Laws and each other Applicable Law, including Healthcare Laws and other Applicable Laws governing or relating to product approval or premarket notification, good manufacturing practices, promoting, labeling, advertising, record-keeping, and adverse event reporting, and (B) tested, investigated, distributed, labeled, promoted, marketed, and sold in compliance with Healthcare Laws and all other Applicable Laws.

5.13 Regulatory Required Permits . Except as could not reasonably be expected, individually or in the aggregate to have a Material Adverse Effect, Endologix shall, and shall cause each Loan Party to, (a) obtain all Regulatory Required Permits necessary for compliance in all respects with Applicable Laws with respect to the design, testing, manufacturing, developing, processing, assembly, packaging, labeling, distribution, commercialization, import, export, selling or marketing of Products, and (ii) maintain and comply fully and completely in all respects with all such Regulatory Required Permits.

5.14 Material Contracts . Each Loan Party will comply, and cause each Subsidiary to comply, with the requirements of all Applicable Laws and Material Contracts, except to the extent that failure to so comply could not reasonably be expected to (a) individually or in the aggregate, have a Material Adverse Effect, or (b) result in any Lien upon either (i) a material portion of the assets of any such Person in favor of any Governmental Authority, or (ii) any Collateral (other than Permitted Liens).

5.15 Notices Regarding Indebtedness . Borrowers shall within two (2) Business Days after delivery by a Loan Party or receipt or knowledge thereof, provide written notice to Agent (and, during any Third Party Agent Retention Period, also the Third Party Agent) of (a) any default or event of default under any of the Convertible Note Documents or any Term Debt Documents, and of any amendments, restatements, supplements, waivers or other modifications to (or any consents to any events or actions under) any of the Convertible Note Documents or any Term Debt Documents, and (b) any prepayment of any Indebtedness.

5.16 Reporting .

(a) Borrower Representative will deliver, on behalf of each of the Borrowers, each of the documents set forth below at the following times in form satisfactory to Agent (and, during any Third Party Agent Retention Period, also the Third Party Agent):

(i) (A) subject to Section  5.20 , during any Non-Third Party Agent Retention Period, upon the request of Agent, to Agent, monthly (no later than the fifteenth (15th) Business Day of each month), and with each request for a Borrowing, an executed Borrowing Base Certificate (Agent), together with all supporting documentation that is not material nonpublic information unless expressly requested in writing by Agent; and (B) during any Third Party Agent Retention Period, to the Third Party Agent, monthly (no later than the fifteenth (15th) Business Day of each month), and with each request for a

 

93


Borrowing, an executed Borrowing Base Certificate (Third Party Agent), together with all supporting documentation;

(ii) during any Third Party Agent Retention Period, to the Third Party Agent, monthly (no later than the fifteenth (15th) Business Day of each month), and with each request for a Borrowing, (A) a detailed aging, by total, of each Borrower’s Accounts, together with a reconciliation and supporting documentation for any reconciling items noted (delivered electronically in an acceptable format, if such Borrower has implemented electronic reporting), (B) a general ledger trial balance and a detailed calculation of those Accounts that are not eligible for the Borrowing Base, if such Borrower has not implemented electronic reporting, and (C) a summary aging, by vendor, of such Borrower’s accounts payable and any book overdraft (delivered electronically in an acceptable format, if each Loan Party has implemented electronic reporting) and an aging, by vendor, of any held checks;

(iii) during any Third Party Agent Retention Period, to the Third Party Agent, monthly (no later than the fifteenth (15th) Business Day of each month), and with each request for a Borrowing, an Account roll-forward from the previous Borrowing Base Certificate delivered or most recent request for a Borrowing, in a format acceptable to Agent and such Third Party Agent in their discretion, with supporting details supplied from sales journals, collection journals, credit registers and any other records, tied to the beginning and ending account receivable balances of each Loan Party’s general ledger;

(iv) during any Third Party Agent Retention Period, to the Third Party Agent, monthly (no later than the fifteenth (15th) Business Day of each month), (A) a detailed report regarding each Borrower’s and its Subsidiaries’ cash and Cash Equivalents, (B) a perpetual Inventory report and Equipment report, and a calculation of the net book value (calculated in accordance with GAAP on a basis consistent with such Borrower’s historical accounting practices) of Eligible Inventory and Eligible Equipment at the end of such period and (C) a determination of the Market Capitalization of Endologix as of the last day of the previous month;

(v) during any Third Party Agent Retention Period, to the Third Party Agent, monthly (no later than the thirtieth (30th) day of each month), a reconciliation of Accounts and trade accounts payable of each Loan Party’s general ledger accounts to its monthly financial statements including any book reserves related to each category;

(vi) during any Third Party Agent Retention Period, to the Third Party Agent, (A) on the last day of each fiscal quarter, (I) a report regarding each Borrower’s and its Subsidiaries’ accrued but unpaid, ad valorem taxes and (II) unless required to be provided under Section  5.05(b)(i) for the same fiscal quarter, a Perfection Certificate or a supplement to the Perfection Certificate, and (B) no later than the fifteenth (15th) Business Day after the end of each fiscal quarter, an updated report of the reserves established on the Borrowers’ books regarding excess and obsolete Inventory and excess and obsolete Equipment;

(vii) during any Third Party Agent Retention Period, to the Third Party Agent, on the last day of each fiscal year, a detailed list of each Borrower’s customers, with address and contact information;

(viii) during any Third Party Agent Retention Period, to the extent a Borrower conducts any physical inventory audits or physical equipment audits during the course of any fiscal year, it shall provide the Third Party Agent with a certified report of such audit within ten (10) Business Days after the completion thereof;

 

94


(ix) (A) promptly, and in any event within two (2) Business Days after the knowledge that Borrowers do not maintain Global Excess Liquidity in an amount of at least $22,500,000, notice thereof and (B) promptly within one (1) Business Day after written request by the Agent (or, during any Third Party Agent Retention Period, the Third Party Agent), to Agent (or such Third Party Agent, as applicable) written evidence reasonably satisfactory to the Agent (or such Third Party Agent, as applicable) demonstrating compliance with Section  7.01(b) ; and

(x) promptly, upon request by Agent, subject to (other than with respect to the Third Party Agent during any Third Party Agent Retention Period) Section  5.20 , (A) an insurance claim report, (B) a detailed report describing accrued expenses or (C) such other reports as to the Collateral or the financial condition of each Borrower and its Subsidiaries, as Agent may reasonably request.

(b) Notwithstanding clause (a) above, to the extent (i) Borrowers do not have at least $22,500,000 of Global Excess Liquidity, or (ii) any Event of Default then exists, the items, certificates and information set forth in clause (a)(i), (a)(ii), (a)(iii) and (a)(iv) shall be delivered to the Agent (or Third Party Agent, as applicable) on a weekly basis (on the second (2nd) Business Day of such week).

5.17 Lender Meetings . Borrowers will, within ninety (90) days after the close of each fiscal year of Borrowers, at the request of Agent (or, during any Third Party Agent Retention Period, the Third Party Agent) or of the Required Lenders and upon reasonable prior notice, hold a meeting (at a mutually agreeable location and time or, at the option of Agent, by conference call) with Agent (or, during any Third Party Agent Retention Period, the Third Party Agent) and any Lenders who choose to attend such meeting at which meeting shall be reviewed the financial results of the previous fiscal year and the financial condition of Borrowers and their Subsidiaries and the projections presented for the current fiscal year of Borrowers.

5.18 Location of Collateral . The Loan Parties will keep its Inventory and Equipment (other than Inventory or Equipment that is in-transit, Trunk Inventory or subject to consignment) only at the locations identified on Schedule  4.45 and their chief executive offices only at the locations identified on Schedule 4.23 ; provided , that Borrowers may amend Schedule 4.45 or Schedule 4.23 so long as such amendment occurs by written notice to Agent not less than ten (10) days prior to the date on which such Inventory and Equipment is moved to such new location or such chief executive office is relocated and so long as such new location is within the continental United States.

5.19 Updated Borrowing Base Certificate . Within three (3) Business Days of the written request of Required Lenders, Borrower Representative shall deliver an updated executed Borrowing Base Certificate reflecting changes in the Eligible Accounts availability since the last Borrowing Base Certificate.

5.20 Announcing Form 8-K . At or prior to 7:30 a.m. (New York City time) on the first (1st) Business Day following the Closing Date, Endologix shall file a Form 8-K with the SEC describing the terms of the transactions contemplated by the Loan Documents and the Term Debt Documents and including as exhibits to such Form 8-K this Agreement (including the schedules, annexes and exhibits hereto), the other Loan Documents listed on Schedule  5.20 (other than the Perfection Certificated executed and delivered on the Closing Date to the Agent), the Term Credit Agreement and the other agreements and instruments required to be filed pursuant to Section 5.1(q) of the Term Credit Agreement (such Form 8-K, the “ Announcing Form 8-K ”). Subject to the foregoing, no Borrower or its Subsidiaries shall issue any press releases or any other public statements with respect to the transactions contemplated by any Loan Document or disclosing the name of Agent, any Lender or any other member of the Lender Group; provided , however , that Endologix shall be entitled, without the prior approval of Agent or any

 

95


Lender, to make any press release or other public disclosure with respect to such transactions (i) in substantial conformity with the Announcing Form 8-K and contemporaneously therewith and (ii) as is required by Applicable Laws ( provided that each of the Agent and Lenders shall be consulted by Endologix in connection with any such press release or other public disclosure prior to its release and shall be provided with a copy thereof other than filings required by the Exchange Act to be made with the SEC, which Endologix may make without such consultation or notice). From and after Endologix’s filing of the Announcing Form 8-K, no member of the Lender Group shall be (or shall be deemed to be) in possession of any material nonpublic information received from the Borrowers or any of their respective Subsidiaries or Affiliates or any of its or their respective officers, directors, employees, attorneys, representatives or agents, except, during any Third Party Agent Retention Period, information provided solely to the Third Party Agent as and to the extent required hereby that is marked as material nonpublic information by the Borrower Representative in good faith at the time such information is provided to the Third Party Agent. Without limiting the foregoing, the Loan Parties represent and warrant that no Loan Document or other agreement, instrument, certificate, information or other document provided by any Loan Party or any of its Related Parties to any member of the Lender Group on or about the Closing Date that is not filed as an exhibit to the Announcing Form 8-K constitutes, or contains, reflects or references any information that constitutes material nonpublic information with respect to the Loan Parties or any of their Subsidiaries or Affiliates (except to the extent the same information is expressly set forth in the Announcing Form 8-K or an exhibit thereto). Notwithstanding any other requirement of this Agreement or other Loan Document, each Borrower shall not, and shall cause each of its Subsidiaries and Affiliates and its and each of their respective officers, directors, employees, attorneys, representatives and agents (it being understood and agreed that the Third Party Agent is not an agent, employee, attorney or representative of any Borrower, its Subsidiaries or its Affiliates) to not, provide any member of the Lender Group with any material nonpublic information regarding the Borrowers or any of their Subsidiaries or Affiliates from and after the filing of the Announcing Form 8-K with the SEC without the express prior written consent of such member of the Lender Group; provided , however , that a Borrower may provide material nonpublic information to the Third Party Agent during any Third Party Agent Retention Period as and to the extent required hereby and to the extent such information is marked as material nonpublic information by the Borrower Representative in good faith at the time such information is provided to the Third Party Agent. Each of the parties hereto acknowledges and agrees that no member of the Lender Group nor any Affiliate of any member of the Lender Group (other than the Third Party Agent) shall be deemed to be in possession of any material nonpublic information provided to any Third Party Agent unless and until such Third Party Agent actually provides such information to such member of the Lender Group or Affiliate thereof (as applicable); and the Borrowers agree not to (and the Borrowers agree to not have their Subsidiaries or Affiliates) assert any contrary position. Each Borrower hereby acknowledges and agrees that no member of the Lender Group (nor any Affiliate thereof) shall have any duty of trust or confidence with respect to, or obligation not to trade in any securities on the basis of, any material nonpublic information regarding the Borrowers or any of their respective Subsidiaries or Affiliates (A) provided by, or on behalf of, the Borrowers or any of their respective Subsidiaries or Affiliates, or any of its or their respective officers, directors, employees, attorneys, representatives or agents, in breach or violation of any of the representations, covenants, provisions or agreements set forth in this Section  5.20 or otherwise or (B) otherwise possessed (or continued to be possessed) by any member of the Lender Group (or any Affiliate thereof) as a result of a breach or violation of any representation, covenant, provision or agreement set forth in this Section  5.20 . Notwithstanding anything to the contrary herein or in any other Loan Document, in the event that a Borrower believes in good faith that a notice or communication to any member of the Lender Group contains material nonpublic information relating to the Borrowers or any other Loan Party or any of their Affiliates or Subsidiaries (other than material nonpublic information being contemporaneously publicly disclosed through the filing with the SEC of a Form 8-K, 10-K or 10-Q or issuance of a broadly disseminated press release, in any such case as identified to any member of the Lender Group, as

 

96


applicable), such Borrower shall so indicate to such member of the Lender Group contemporaneously with delivery of such notice or communication, and such indication shall provide such member of the Lender Group (other than the Third Party Agent during any Third Party Agent Retention Period) the means to refuse to receive such notice or communication; and in the absence of any such indication, such member of the Lender Group shall be allowed to presume that all matters relating to such notice or communication do not constitute material nonpublic information relating to the Borrowers, any other Loan Party or any of their Affiliates or Subsidiaries, or any of their respective property or Stock. Upon receipt or delivery by any Loan Party or any of its Subsidiaries of any notice or other communication in accordance with the terms of the Loan Documents, unless the Borrower Representative has in good faith determined that the matters relating to such notice do not constitute material, nonpublic information relating to the Borrowers or any other Loan Party or any of their Affiliates or Subsidiaries or their respective property or Stock (and other than a notice or communication delivered to the Third Party Agent during any Third Party Agent Retention Period), Endologix shall, within one Business Day after any such receipt or delivery publicly disclose the material, nonpublic information contained in the notice or communication; provided , however , that Endologix shall in no event be obligated to make public disclosure of any material nonpublic information contained in any Borrowing Base Certificate (Agent) delivered solely at the written request of Agent or any Lender in accordance herewith at a time when the Borrower Representative notifies Agent or such Lender in writing in good faith that such Borrowing Base Certificate (Agent) would contain material nonpublic information and Agent or such Lender agrees in writing to accept such Borrowing Base Certificate (Agent) notwithstanding such material nonpublic information included therein (in each case, other than, for the avoidance of doubt, a Borrowing Base Certificate (Agent) delivered in connection with the filing of a 10-Q or 10-K or with respect to any other filing with the SEC)). In the event of a breach of any of the foregoing covenants by any Borrower or any of its Subsidiaries or Affiliates, or any of its or their respective officers, directors (or equivalent persons), employees, attorneys, representatives or agents (it being understood and agreed that the Third Party Agent is not an agent, employee, attorney or representative of any Borrower, its Subsidiaries or its Affiliates), in addition to any other remedies provided in the Loan Documents or otherwise available at law or in equity, the members of the Lender Group shall have the right to make a public disclosure in the form of a press release, public advertisement or otherwise, of the applicable material nonpublic information regarding the Borrowers or its Subsidiaries or Affiliates without the prior approval by any Borrower or its Subsidiaries or Affiliates, or any of its or their respective officers, directors (or equivalent persons), employees, attorneys, representatives or agents, and no member of the Lender Group shall have any liability to any Borrower, any of its Subsidiaries or Affiliates or any of its or their respective officers, directors (or equivalent persons), employees, equityholders, attorneys, representatives or agents for any such disclosure.

5.21 Eligible Equipment . Each Borrower will use commercially reasonable efforts to at all times keep its furniture, fixtures and Equipment in good repair and physical condition. In addition to the foregoing, from time to time, Agent (including, during any Third Party Agent Retention Period, the Third Party Agent) may require Borrowers to obtain and (a) subject to Section  5.20 , deliver to Agent, or (b) during any Third Party Agent Retention Period, deliver to the Third Party Agent, in each case of clause (a) and clause (b), appraisal reports in form and substance and from appraisers reasonably satisfactory to Agent (or, as applicable, the Third Party Agent) stating the then current fair market values of all or any portion of furniture, fixtures and equipment owned by each Borrower or any of its Subsidiaries.

5.22 Maximum Revolver Related Notices . Each Borrower will provide written notice to Agent (and, during any Third Party Agent Retention Period, also the Third Party Agent) immediately upon the occurrence of: (a) any Maximum Revolver Decreased Market Capitalization Notice Trigger Event (including reasonable details related thereto) and (b) any Maximum Revolver Decreased Market

 

97


Capitalization Overadvance Event (including reasonable details related thereto and reasonable details and calculations of the Maximum Revolver Decreased Market Capitalization Overadvance Amount).

ARTICLE VI.

NEGATIVE COVENANTS.

Borrowers covenant and agree that, until termination of all of the Commitments and payment in full in cash of the Obligations:

6.01 Restrictions on Fundamental Changes . The Loan Parties will not, and will not permit any of their Subsidiaries to, directly or indirectly, (I) merge with, consolidate with or into, dissolve or liquidate into or convey, transfer, lease or otherwise dispose of (whether in one transaction or in a series of transactions) all or substantially all of its assets (whether now owned or hereafter acquired) to or in favor of any Person, except (a) a Subsidiary that is not a Loan Party may merge into any Loan Party or any Subsidiary of a Loan Party (provided that, (w) to the extent such Subsidiary that is not a Loan Party has its equity pledged to Agent, then any Person it merges with must also have its equity pledged to Agent by at least the same percentage and (x) if such merger is with a Loan Party, such Loan Party must be the surviving entity of any such merger), (b) a Loan Party may merge into any other Loan Party (provided that, (y) to the extent such Loan Party being merged has its equity pledged to Agent, then any Person it merges with must also have its equity pledged to Agent by at least the same percentage and (z) to the extent the Borrower is part of such transaction, the Borrower must be the surviving Person), (c) any Subsidiary of Endologix may liquidate or dissolve if (i) the Borrowers determine in good faith that such liquidation or dissolution is in the best interests of the Borrowers and it is not materially disadvantageous to the Secured Parties and (ii) to the extent such Subsidiary is a Loan Party, any such assets or business held by such subject Subsidiary shall be transferred to, or otherwise owned or conducted by, a Loan Party after giving effect to such liquidation or dissolution, and (d) in connection with Permitted Acquisitions, or (II) divide (or otherwise split) itself or themselves into two or more limited liability companies or other entities or Persons. None of the Loan Parties shall establish or form any Subsidiary, unless such Subsidiary complies with Section  5.09 , if applicable, and such Subsidiary (if not an Excluded Subsidiary) executes and/or delivers all other documents, agreements and instruments reasonably requested by Agent or the Required Lenders to perfect a Lien in favor of Agent (for the benefit of the Secured Parties and Lender Group) on such Subsidiary’s (if not an Excluded Subsidiary) assets and to make such Subsidiary (if not an Excluded Subsidiary) a Loan Party under the Loan Documents.

6.02 Joint Ventures; Restricted Payments . The Loan Parties will not, and will not permit any of its Subsidiaries to, (a) enter into any joint venture or any similar arrangement, other than as may be permitted under Permitted Investments, or (b) make any Restricted Payments, other than (i) dividends by any direct or indirect Subsidiary of any Loan Party (A) that are not Loan Parties to such Loan Party’s parent or parent entities or (B) that are Loan Parties, to such Loan Party’s parent or parent entities that are Loan Parties; (ii) dividends payable solely in common Stock; (iii) repurchases of Stock of former employees, directors or consultants so long as an Event of Default does not exist at the time of such repurchase and would not exist after giving effect to such repurchase, provided, however, that such repurchase does not exceed $2,500,000 in the aggregate per fiscal year; (iv) any Restricted Payments made under Subordinated Debt Documents to the extent permitted under the terms of the applicable Subordination Agreement; and (v) any Restricted Payments made to the “Secured Parties” (as defined in the Term Credit Agreement) pursuant to the terms of the Term Debt Documents, the “Warrants” (as defined in the Term Credit Agreement) and the “Registration Rights Agreement” (as defined in the Term Credit Agreement).

 

98


6.03 Liens . The Loan Parties will not, and will not permit any of their Subsidiaries to directly or indirectly make, create, incur, assume or suffer to exist any Lien upon or with respect to any of its assets or property, of any kind, whether now owned or hereafter acquired, or any income or profits therefrom, except Permitted Liens.

6.04 Disposal of Assets . Other than Permitted Dispositions or transactions expressly permitted by Section  6.01 , Borrowers will not, and will not permit any of their Subsidiaries to directly or indirectly Dispose of (whether in one or a series of transactions) any assets or property (including the Stock of any Subsidiary of any Loan Party, whether in a public or private offering or otherwise, and accounts and notes receivable, with or without recourse).

6.05 Indebtedness ; Contingent Obligations . The Loan Parties will not, and will not permit any of its Subsidiaries to, directly or indirectly, create, incur, assume, guarantee, permit to exist or be liable with respect to any Indebtedness, other than Permitted Indebtedness. The Loan Parties will not, and will not permit any of their Subsidiaries to, directly or indirectly, create, assume, incur or suffer to exist any Contingent Obligations, except for Permitted Contingent Obligations.

6.06 Investments . The Loan Parties will not, and will not permit any of its Subsidiaries to, directly or indirectly, (a) purchase or acquire any Stock, or any obligations or other securities of, or any interest in, any Person, including the establishment or creation of a Subsidiary, (b) make or commit to make any Acquisitions, or any other acquisition of any of the assets of another Person other than (i) Permitted Investments or (ii) in the Ordinary Course of Business, or of any business or division of any Person, including by way of merger, consolidation, other combination or otherwise other than Permitted Investments, (c) make, purchase or acquire any advance, loan, extension of credit (other than trade payables in the ordinary course of business) or capital contribution to or any other investment in, any Person including the Borrower, any Affiliate of the Borrower or any Subsidiary of the Borrower or (d) enter into any joint venture or any similar arrangement (the items described in clauses (a), (b), (c) and (d) are referred to as “Investments”), except for Permitted Investments.

6.07 Transactions with Affiliates . Except as otherwise disclosed on Schedule 6.07 , and except for transactions that contain terms that are no less favorable to the applicable Loan Party or any Subsidiary of a Loan Party, as the case may be, than those which might be obtained from a third party not an Affiliate of any Loan Party, no Loan Party will, or permit any Subsidiary to, directly or indirectly, enter into or permit to exist any transaction (including the purchase, sale, lease or exchange of any property or the rendering of any service) with any Affiliate of any Loan Party that is not itself a Loan Party; provided that, Loan Parties may enter into and maintain written agreements between any Loan Party and any Foreign Subsidiary of a Loan Party for management services for compensation in the Ordinary Course of Business consistent with past practices that are customary and reasonably appropriate to do for companies in the same industry as the Loan Parties provided by management and officers of the Loan Parties to such Foreign Subsidiaries that do not have certain management or officers, and such transactions may result in non-interest bearing accounts payables for the unpaid compensation owed by such Foreign Subsidiaries to the Loan Parties for such management services in an amount not to exceed $40,000,000 (which payables may be equitized by the Loan Parties, provided that (y) equitization of such payables shall not reduce the outstanding amount of payables that count towards the $40,000,000 cap above for purposes of determining whether the Loan Parties have complied with this provisions (with such equitized amounts deemed to be outstanding at all times thereafter for purposes of the $40,000,000 capped amount) and (z) at the time of any such equitization, any such Stock received by any Loan Party in connection with such equitization shall be pledged, and a first priority security interest and Lien thereon shall be granted, to the Agent (for the benefit of the Lender Group) and such Loan Party shall take such perfection and priority actions reasonably requested by the Agent in accordance with the Loan

 

99


Documents), in each case of the foregoing in this proviso, so long as (a) any such management or officers of the Loan Parties involved in such transactions, agreements and arrangements will have sufficient and reasonable time, energy and resources to still represent and service such Loan Parties themselves after taking into such transactions, agreements and arrangements, (a) any such agreement, instrument, arrangement or document evidencing any of the foregoing transactions, equitization or actions shall be entered into (i) in good faith by such Loan Party, (A) in a manner to not contravene or impair the Collateral and benefits that are intended to be provided and afforded to the Lender Group under the Loan Documents, and (B) without (I) the intention of such Loan Party of causing (or resulting in) the Collateral to be taken from the Secured Parties and provided to Foreign Subsidiaries that are not Loan Parties at the detriment of the Secured Parties and for the benefit of such Foreign Subsidiaries, and (II) the effect of defrauding the Secured Parties, (C) the upstream economics received (or potentially to be received) by any applicable Loan Party in connection with any such transaction, agreement or arrangement described above in this proviso, when combined with the potential downstream economics, time, energy and recourses exhausted or disposed of in connection therewith shall be reasonably adequate and sufficient to enable the Loan Parties to timely satisfy all of the Obligations and all of their other obligations and agreements under the Loan Documents, (D) all cash, Cash Equivalents, other assets and proceeds received or provided to the Loan Parties in connection with the foregoing shall all be part of the (and constitute) Collateral and the Agent (for the benefit of the Lender Group) shall have a first priority security interest and Lien thereon, (E) at the reasonable request of the Agent, all such account payables will be evidenced by a promissory note issued to the applicable Loan Party by the applicable Foreign Subsidiary and pledged to the Agent and the original thereof delivered, along with an executed allonge to the Agent in form and substance satisfactory to the Agent, (F) no Default or Event of Default has occurred and is continuing or would result therefrom, and (G) no such agreement, arrangement, transaction or action could reasonable be expected, individually or in the aggregate, to result in a Material Adverse Effect.

6.08 ERISA . No ERISA Affiliate shall cause or suffer to exist (a) any event that could result in the imposition of a Lien on any asset of a Loan Party or a Subsidiary of a Borrower with respect to any Title IV Plan or Multiemployer Plan, or (b) any other ERISA Event, which other ERISA Event could reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.

6.09 Nature of Business . The Loan Parties will not, and will not permit any of their Subsidiaries to engage in any line of business different from those lines of business carried on by it on the Closing Date and businesses reasonably related thereto.

6.10 Amendments to Organizational Documents and Material Contracts . Except as permitted under Section  6.01 , no Loan Party shall, and no Loan Party shall permit any of its Subsidiaries to, directly or indirectly amend or otherwise modify any of its Organizational Documents or, after the execution thereof, any agreements or documents evidencing or contemplating any Permitted Acquisition in any respect materially adverse to any Secured Party. No Loan Party will, or will permit any Subsidiary to, directly or indirectly, amend, restate, supplement, change, waive or otherwise modify any Material Contract, which amendment, restatement, supplement, change, waiver or modification in any case: (a) is contrary to (or is in violation or breach of) the terms and provisions of this Agreement or any other Loan Document (including the Intercreditor Agreement); or (b) could reasonably be expected to be materially adverse to the rights, interests or privileges of Agent or the Lenders or their ability to enforce the same (it being understood that any modification that changes the stated maturity date of the 3.25% Convertible Notes to an earlier date shall be materially adverse to the Agent and the Lenders); provided, however, that the foregoing shall not restrict (x) any changes expressly required under the terms of the 2.25% Convertible Notes as of the Closing Date, the 3.25% Convertible Notes as of the Closing Date or any indenture governing any Permitted 3.25% Convertible Note Refinancing meeting the requirements set

 

100


forth in the definition of “Permitted 3.25% Convertible Note Refinancing”, or (y) any modifications of the Term Credit Agreement expressly permitted by the Intercreditor Agreement and not otherwise materially adverse to Agent or the Lenders.

6.11 Changes to Fiscal Year; GAAP . No Loan Party shall, and no Loan Party shall suffer or permit any of its Subsidiaries to, (a) make any significant change in accounting treatment or reporting practices, except as required by GAAP, (b) change the fiscal year or method for determining the fiscal quarters of any Loan Party or of any Subsidiary of any Loan Party, (c) change its name as it appears in official filings in its jurisdiction of organization or formation, or (d) change its jurisdiction of organization or formation, in the case of clauses (c) and (d), without, subject to Section  5.20 , at least ten (10) days’ prior written notice to Agent (or such shorter period as may be agreed by Agent in its sole reasonable discretion).

6.12 Prepayments and Amendments . The Loan Parties will not, and will not permit any of their Affiliates to (A) declare, pay, make or set aside any amount for payment in respect of Subordinated Debt, except for payments made in full compliance with and permitted under the Subordination Agreement, (B) amend or otherwise modify the terms of any Subordinated Debt, except for amendments and modifications made in full compliance with the Subordination Agreement; or (C) declare, pay, make or set aside any amount for payment in respect of any Indebtedness hereinafter incurred that, by its terms, or by separate agreement, is subordinated to the Obligations, except for payments made in full compliance with and permitted under the subordination provisions applicable thereto.

6.13 Restrictions on Distributions . No Loan Party shall, and no Loan Party shall permit any of its Subsidiaries to, directly or indirectly, create or otherwise cause or suffer to exist or become effective any consensual restriction or encumbrance of any kind on the ability of any Loan Party or Subsidiary to pay dividends or make any other distribution on any of such Loan Party’s or Subsidiary’s Stock or to pay fees, including management fees, or make other payments and distributions to any Loan Party or any other Loan Party, except for those in the Loan Documents and the Term Debt Documents. No Loan Party shall, and no Loan Party shall permit any of its Subsidiaries to, directly or indirectly (a) enter into, assume or become subject to any contractual obligation prohibiting or otherwise restricting the existence of any Lien upon any of its assets in favor of Agent, whether now owned or hereafter acquired or (b) create or otherwise suffer to exist or become effective any consensual encumbrance or restriction of any kind on the ability of any Subsidiary to (i) pay any Indebtedness owed to any Borrower or any of its Subsidiaries, (ii) make loans or advances to any Borrower or any of their Subsidiaries or (iii) transfer any of its property or assets to any Borrower or any of their Subsidiaries, except (A) those in the Loan Documents and the Term Debt Documents, (B) an encumbrance or restriction consisting of customary non-assignment provisions in leases or licenses entered into in the Ordinary Course of Business, (C) customary provisions in joint venture agreement and other similar agreements that restrict the transfer of ownership interests in such joint ventures or provisions limiting the disposition or distribution of assets or property (other than dividends on a pro rata basis based on ownership percentage) of the applicable joint venture, which limitation is applicable only to the assets that are the subject of such agreements; provided that such agreement was not entered into in contravention of the terms of this Agreement, and (D) limitations set forth in Subordinated Debt (if acceptable to the Agent in its sole discretion).

6.14 Sanctions; Anti-Corruption . No Loan Party shall, and no Loan Party shall permit any of its Subsidiaries to fail to comply with the Anti-Money Laundering Laws and Anti-Terrorism Laws. No Loan Party or Subsidiary of a Loan Party, nor to the knowledge of any Loan Party or any of its Subsidiaries, any director, officer, agent, employee or other Person acting on behalf of any Loan Party or any such Subsidiary, will request or use the proceeds of any Loan, directly or indirectly, (a) for any payments to any Person, including any government official or employee, political party, official of a

 

101


political party, candidate for political office or anyone else acting in an official capacity, in order to obtain, retain or direct business or obtain any improper advantage, or otherwise take any action, directly or indirectly, that would result in a violation of any Anti-Corruption Laws, (b) for the purpose of funding, financing or facilitating any activities, business or transaction of or with any Person on the SDN List or a government of a country or territory subject to comprehensive Sanctions, to the extent such activities, business or transaction would be prohibited by Sanctions if conducted by a corporation incorporated in the United States or in a European Union member state, (c) in any manner that would result in the violation of any Sanctions applicable to any party hereto, or (d) to fund any activities or business of or with any Person, or in any country or territory, that, at the time of such funding, is, or whose government is, the subject of sanctions pursuant to any Anti-Terrorism Laws. Furthermore, the Loan Parties will not, directly or indirectly, use the proceeds of the Transaction, or lend, contribute or otherwise make available such proceeds to any Subsidiary, Affiliate, joint venture partner or other Person, to fund any activities of or business with any Person, or in any country or territory, that, at the time of such funding, is the subject of Sanctions, or in any other manner that will result in a violation by any Person participating in the Transaction of any Sanctions. No Loan Party shall, and no Loan Party shall permit any of its Subsidiaries to directly or indirectly, knowingly enter into any Material Contracts with any Person on the SDN List.

6.15 Sale Leaseback Transactions . No Loan Party shall, and no Loan Party shall permit any of its Subsidiaries to, engage in a sale leaseback, synthetic lease or similar transaction involving any of its assets, including pursuant to a substantially contemporaneous transaction, whereby a Loan Party or one of its Subsidiaries sells or transfers all or substantially all of its right, title and interest in an asset and, in connection therewith, acquires or leases back the right to use such asset.

6.16 Environmental . No Loan Party shall, and no Loan Party shall permit any of its Subsidiaries to, cause or suffer to exist any Release of any Hazardous Material at, to or from any Real Property that would violate or form the basis of Liability under any Environmental Law or Healthcare Law, other than such violations or liabilities that could not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect.

6.17 Investment Company . No Loan Party shall, and no Loan Party shall permit any of its Subsidiaries to, be an “investment company” or a company “controlled” by an “investment company,” as such terms are defined in the Investment Company Act, or to otherwise be registered or required to be registered, or be subject to the restrictions imposed by, the Investment Company Act.

6.18 Intercreditor Agreement; Term Debt . No Loan Party shall, and no Loan Party shall permit any of its Subsidiaries to, (a) make any prepayment, payment, redemption or repayment or take any action, with respect to the Term Debt that is in violation or breach of the Intercreditor Agreement, (b) make any amendment, restatement, supplement or modification of any Term Debt Document in violation or breach of the Intercreditor Agreement or that is materially adverse to Agent or the Lenders; or (c) join any Subsidiary or any Affiliate of any Loan Party as a borrower, guarantor or obligor, or have such Person pledge or grant a Lien on any of its property or assets, under the Term Debt Documents, unless, in each case, the same Person becomes a Loan Party in the same capacity (and/or pledges and grants Liens on the same property or assets (and with the same Lien priority and which such Liens shall be subject to the terms of the Intercreditor Agreement) under the Loan Documents and such Person executes and delivers such agreements, instruments and documents reasonably requested by Agent to effectuate any of the foregoing in this clause  (c) and such Subsidiary or Affiliate shall be subject to the terms of the Intercreditor Agreement.

6.19 Payment of Convertible Notes and Permitted Japan Lifeline Unsecured Debt . No Loan Party will, or will permit any Subsidiary to, declare, pay, make any payment in respect of (I) the

 

102


3.25% Convertible Notes or the 2.25% Convertible Notes, except for: (a) regularly scheduled payments of interest and principal as set forth in the applicable Convertible Note Documents (in addition to allowing any cash principal payments at maturity of the applicable 3.25% Convertible Notes and the 2.25% Convertible Notes, such amounts may also be paid in the applicable Stock of the Borrower or through any other conversion feature that does not effectively cause more payments to be made at maturity thereof than the cash principal payments currently provided for in the applicable Convertible Note Documents as of the Closing Date), (b) in connection with any Permitted 3.25% Convertible Note Refinancing, (c) the issuance of shares of common stock of the Borrower in connection with any conversion of the 3.25% Convertible Notes, the 2.25% Convertible Notes or any convertible notes that are not Disqualified Stock issued in a Permitted 3.25% Convertible Note Refinancing, and any cash solely in lieu of fractional shares (but no other cash settlement other than as otherwise permitted by this Section  6.19 ), (d) payments and conversions (other than for any Disqualified Stock) made in connection with the repurchase (whether for cash, upon exchange and/or for other consideration), redemption and retirement in respect of the 2.25% Convertible Notes or 3.25% Convertible Notes in a single or series of related transactions; provided that (i) no Event of Default exists at the time such payments are made or would exist immediately after giving effect thereto and (ii) such cash payments are made solely (A) with proceeds received by Endologix from the issuance of its common Stock after the Closing Date for the purpose of making such payment, and (B) regarding the 3.25% Convertible Notes, with the proceeds of Indebtedness raised in a Permitted 3.25% Convertible Note Refinancing, and (e) if the foregoing conditions do not otherwise permit such payment, then, with the express prior written consent of the Agent (which may be withheld in its sole discretion), payments in connection with the retirement, redemption and repurchase of the 2.25% Convertible Notes or the 3.25% Convertible Notes or (II) the Permitted Japan Lifeline Unsecured Debt, except with respect to any interest payments expressly permitted under the definition of “Permitted Japan Lifeline Unsecured Debt”.

6.20 Commingling of Assets . (a) No Loan Party will, or permit any Subsidiary to commingle any of its assets (including any bank accounts, cash or Cash Equivalents) with the assets of any Person; and (b) no Loan Party will, or permit any Subsidiary to enter into or own any interest in a joint venture that is not itself a corporation or limited liability company or other legal entity in respect of which the equity holders are not liable for the obligations of such entity as a matter of law.

6.21 Limitation on Issuance of Stock . Endologix shall not issue any Stock (a) senior to its shares of Common Stock or (b) convertible into or exercisable or exchangeable for Stock senior to its Common Stock.

6.22 Use of Proceeds . The Loan Parties will not, and will not permit any of their Subsidiaries to use the proceeds of any Loan or other extension of credit made hereunder for any purpose other than as described in Section  4.19 .

6.23 Anti-Layering . No Loan Party shall, or permit any Subsidiary to, create, incur or suffer to exist any Indebtedness which is subordinated or junior (either in respect of Lien priority or in right of payment or any combination thereof) to any of the Term Debt unless such Indebtedness is expressly subordinated or junior to the Obligations (both in terms of Lien Priority and in right of payment) on terms and conditions acceptable to Agent and the Lenders (it being understood and agreed that this Section  6.23 shall in no way limit the incurrence of unsecured Indebtedness otherwise permitted under this Agreement that is not payment subordinated to the Term Debt when not also payment subordinated to the same extent to the Obligations).

6.24 Convertible Notes Restrictions . No Loan Party shall, or shall permit any Subsidiary to, amend, restate, supplement, change, waive or otherwise modify the terms of any Indebtedness referred to

 

103


in Section  6.19 above (other than with respect to 3.25% Convertible Notes, in connection with a Permitted 3.25% Convertible Note Refinancing) if the effect of such amendment, restatement, supplement, change, waiver or modification is to (a) increase the interest rate or fees on, or change the manner or timing of payment of, such Indebtedness if in any way adverse to the Agent or the Lenders, (b) accelerate or shorten the dates upon which payments of principal or interest are due on, or the principal amount of, such Indebtedness, (c) change in a manner adverse to any Loan Party, any of its Subsidiaries, Agent or any Lender any event of default or add or make more restrictive any covenant with respect to such Indebtedness, (d) change the prepayment provisions of such Indebtedness or any of the defined terms related thereto in a manner adverse to Agent or the Lenders, or (e) change or amend any other term if such change or amendment would materially increase the obligations of the obligor or confer additional material rights on the holder of such Indebtedness in a manner adverse to any Loan Party, any of its Subsidiaries, Agent or the Lenders; provided , however , that (y) the foregoing shall not restrict any changes expressly required under the terms of the 3.25% Convertible Notes as in effect as of the Prior Agreement Date, the 2.25% Convertible Notes as in effect as of the Closing Date or any changes that are permitted to be made hereunder in connection with a Permitted 3.25% Convertible Note Refinancing or any changes expressly required under any indenture governing any Permitted 3.25% Convertible Note Refinancing that satisfies the conditions and requirements set forth in the definition of “Permitted 3.25% Convertible Note Refinancing” and (z) the exchange of the “Exchanged Deerfield Convertible Notes” (as defined in the Term Credit Agreement) for the “Last Out Waterfall Loans” (as defined in the Term Credit Agreement) under the Term Credit Agreement on the Closing Date shall not be restricted by this Section  6.24 . The Loan Parties will, prior to entering into any such amendment, restatement, supplement, change, waiver or modification, deliver to Agent (and, during any Third Party Agent Retention Period, also the Third Party Agent) reasonably in advance of the execution thereof, any final or execution form copy thereof.

ARTICLE VII.

FINANCIAL COVENANTS.

7.01 Financial Covenants . Each of the Borrowers covenant and agree that, until termination of all of the Commitments and payment in full in cash of the Obligations, the Loan Parties will not permit:

(a) Fixed Charge Coverage Ratio . Commencing as of the Trigger Date, the Fixed Charge Coverage Ratio for any Measurement Period, tested quarterly beginning with the fiscal quarter ending September 30, 2018, to be less than 1.00:1.00.

(b) Minimum Global Excess Liquidity . On the (i) the last Business Day of each month and (ii) each date that a Borrowing Base Certificate is required to be delivered in accordance with Section  5.16 , Global Excess Liquidity to be less than $22,500,000.

(c) TTM Minimum Net Revenue . Their consolidated Net Revenue for any Measurement Period, tested quarterly beginning with the fiscal quarter ending September 30, 2018, to be less than the amounts set forth below:

 

Measurement Period Ending

   Minimum Net
Revenue for
Measurement Period
 

September 30, 2018

   $ 155,000,000  

December 31, 2018

   $ 145,000,000  

 

104


March 31, 2019 and the last day of each fiscal quarter ending thereafter through (and including) December 31, 2019

   $ 130,000,000  

March 31, 2020 and the last day of each fiscal quarter ending thereafter

   $ 140,000,000  

(d) Quarterly Minimum Net Revenue . Their consolidated Net Revenue for any fiscal quarter of Endologix, tested quarterly beginning with the fiscal quarter ending March 31, 2019 and on the last day of each fiscal quarter ending thereafter, to be less than $30,000,000.

(e) Maximum Consolidated Capital Expenditures . The aggregate amount of consolidated Capital Expenditures made by the Loan Parties and their Subsidiaries to exceed the amounts set forth below:

 

Fiscal Year

   Amount  

2018

   $ 2,500,000  

2019

   $ 3,000,000  

2020

   $ 5,000,000  

2021

   $ 2,000,000  

(f) Maximum Consolidated Operating Expenditures . The aggregate amount of Operating Expenditures made by the Loan Parties and their Subsidiaries for any Measurement Period, tested for the fiscal quarters of Endologix ending December 31 2018 and December 31, 2019, to exceed the amounts set forth below:

 

Fiscal Year

   Amount  

December 31, 2018

   $ 160,000,000  

December 31, 2019

   $ 140,000,000  

ARTICLE VIII.

EVENTS OF DEFAULT.

Any one or more of the following events shall constitute an event of default (each, an “ Event of Default ”) under this Agreement:

8.01 Payments . Any Borrower or any other Loan Party shall have failed (i) to pay when and as required to be paid herein or in any other Loan Document, any amount of principal of any Loan, including after maturity of the Loans, or (ii) to pay within three (3) Business Days after the same shall become due, all or any portion of the Obligations consisting of interest, fees, or charges due the Lender Group, reimbursement of Lender Group Expenses, or other amounts (other than any portion thereof constituting principal) constituting Obligations (including Liquidated Damages or any remaining Commitment Fee, as applicable, and any portion of the Obligations that accrues after the commencement

 

105


of an Insolvency Proceeding, regardless of whether allowed or allowable in whole or in part as a claim in any such Insolvency Proceeding).

8.02 Covenants . If any Loan Party or any of their Subsidiaries shall have failed to comply with or observe (a)(i)  Section 3.04 , 5.01(a)(i) , 5.01(b) , 5.02 , 5.03 , 5.04 , 5.05 , 5.06 , 5.08 , 5.09 , 5.10 , 5.13 , 5.14 , 5.15 , 5.16 , 5.17 , 5.19 , 5.20 , 5.21 or 5.22 of this Agreement, Article VI of this Agreement, Article VII of this Agreement, (ii) Sections 5.2(a), 5.2(c), 5.2(d), 5.3, 5.4, 5.5, 5.7, 5.9 and 5.10 of the Guaranty and Security Agreement or (iii) any provision of any Note, (b) Section 5.1 of the Guaranty and Security Agreement and such failure, with respect to this Section  8.02(b) only, shall not have been cured within ten (10) days after the earlier to occur of (y) the date upon which any officer of any Loan Party or any of its Subsidiaries becomes aware of such failure and (z) the date upon which written notice thereof is given to any Loan Party or any of its Subsidiaries by any Secured Party or (c) any covenant contained in any Loan Document (other than the covenants described in Section  8.01 , Section  8.02(a) or Section  8.02(b) above), and such failure, with respect to this Section  8.02(c) only, shall not have been cured within thirty (30) days after the earlier to occur of (y) the date upon which any officer of any Loan Party or any of its Subsidiaries becomes aware of such failure and (z) the date upon which written notice thereof is given to any Loan Party or any of its Subsidiaries by any Secured Party.

8.03 Representations, etc . Any representation, warranty, or certification, made by any Loan Party in any Loan Document or delivered in writing to Agent (including any Third Party Agent), any Lender or any other member of the Lender Group in connection with this Agreement or any other Loan Document shall have been incorrect, false or misleading in any material respect (except to the extent that such representation or warranty is qualified by reference to materiality or Material Adverse Effect, to which extent it shall have been incorrect, false or misleading in any respect) as of the date it was made; it being acknowledged and agreed that any projections provided to the Secured Parties are not to be viewed as facts, are not a guarantee of financial performance, and are subject to uncertainties and contingencies.

8.04 Insolvency; Bankruptcy . (a) Any Loan Party or any of its Subsidiaries (other than Immaterial Subsidiaries) shall generally be unable to pay its debts as such debts become due, or shall admit in writing its inability to pay its debts as they come due or shall make a general assignment for the benefit of creditors; (b) any Loan Party or any of its Subsidiaries (other than Immaterial Subsidiaries) shall declare a moratorium on the payment of its debts; (c) the commencement by any Loan Party or any of its Subsidiaries (other than Immaterial Subsidiaries) of proceedings to be adjudicated bankrupt or insolvent, or the consent by it to the commencement of bankruptcy or insolvency proceedings against it, or the filing by it of a petition or answer or consent seeking reorganization, intervention or other similar relief under any Applicable Law, or the consent by it to the filing of any such petition or to the appointment of an intervenor, receiver, liquidator, assignee, trustee, sequestrator or other similar official of all or substantially all of its assets; (d) the commencement against any Loan Party or any of its Subsidiaries (other than Immaterial Subsidiaries) of a proceeding in any court of competent jurisdiction under any bankruptcy or other Applicable Law (as now or hereafter in effect) seeking its liquidation, winding up, dissolution, reorganization, arrangement or adjustment, or the appointment of an intervenor, receiver, liquidator, assignee, trustee, sequestrator or other similar official, and any of the following events occur: (i) such Loan Party or such Subsidiary consents to the institution of such Insolvency Proceeding against it, (ii) the petition commencing the Insolvency Proceeding is not timely controverted, (iii) the petition commencing any such proceeding shall continue undismissed, or any order, judgment or decree approving or ordering any of the foregoing shall continue unstayed or otherwise in effect, for a period of sixty (60) calendar days of the date of filing thereof, or (iv) an interim trustee is appointed to take possession of all or any substantial portion of the properties or assets of, or to operate all or any substantial portion of the business of, such Loan Party or its Subsidiary; (e) the making by any Loan Party or any of its Subsidiaries (other than Immaterial Subsidiaries) of an assignment for the benefit of

 

106


creditors, or the admission by it in writing of its inability to pay its debt generally as they become due; or (f) any other event shall have occurred which under any Applicable Law would have an effect analogous to any of those events listed above in this Section  8.04 .

8.05 Judgments . One or more judgments, orders or decrees or settlements shall be rendered against any Loan Party or any Subsidiary of a Loan Party that exceeds by more than $1,000,000 any insurance coverage applicable thereto (to the extent the relevant insurer has been notified of such claim and has not denied coverage therefor) or one or more non-monetary judgments, orders or decrees or settlements shall be rendered against any Loan Party or any Subsidiary of a Loan Party that could reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect, and in either case (i) enforcement proceedings shall have been commenced by any creditor upon any such judgment, order or decree or (ii) there shall be any period of twenty (20) consecutive days during which such judgment, order or decree shall not have been vacated or discharged or there shall not be in effect (by reason of a pending appeal or otherwise) any stay of enforcement thereof.

8.06 No Governmental Authorization . Any authorization of a Governmental Authority necessary for the execution, delivery or performance of any Loan Document or for the validity or enforceability of any of the Obligations under any Loan Document is not given or is withdrawn or ceases to remain in full force or effect.

8.07 Agreement Invalid Under Applicable Law . Any Applicable Law shall purport to render any material provision of any Loan Document invalid or unenforceable or shall purport to prevent or materially delay the performance or observance by any Loan Party or any of its Subsidiaries of the Obligations (which, for the avoidance of doubt, shall not apply to the process of SEC comments in respect of share registration).

8.08 Cross-Default . Any Loan Party or any Subsidiary of any Loan Party (a) shall fail to make any payment in respect of any Indebtedness having an individual principal amount (including undrawn committed or available amounts and including amounts owing to all creditors under any combined or syndicated credit arrangement) in excess of $3,000,000 or having an aggregate principal amount (including undrawn committed or available amounts and including amounts owing to all creditors under any combined or syndicated credit arrangement) of more than $8,000,000 when due (whether by scheduled maturity, required prepayment, acceleration, demand or otherwise) and such failure continues after the applicable grace or notice period, if any, specified in the documents relating thereto on the date of such failure; or (b) shall fail to perform or observe any other condition or covenant, or any other event shall occur or condition exist, under any agreement or instrument relating to any such Indebtedness of the type covered in Section  8.08(a) above, if the effect of such failure, event or condition is to cause, or to permit the holder or holders of such Indebtedness or beneficiary or beneficiaries of such Indebtedness (or a trustee or agent on behalf of such holder or holders or beneficiary or beneficiaries) to cause, such Indebtedness to be declared to be due and payable (or otherwise required immediately to be prepaid, redeemed, purchased or defeased) prior to its stated maturity (without regard to any subordination terms with respect thereto) or cash collateral in respect thereof to be demanded; provided however that, notwithstanding the foregoing, any event or condition that occurs that permits holders of convertible Indebtedness permitted hereunder to convert such Indebtedness into Stock (other than Disqualified Stock) or such other consideration permitted pursuant to Section  6.19 pursuant to the terms of the applicable indenture shall not constitute a Default or Event of Default hereunder on such basis alone.

8.09 Loan Documents; Security Interests . Any material provision of any Loan Document shall for any reason cease to be valid and binding on or enforceable against any Loan Party or any Subsidiary of any Loan Party party thereto or any Loan Party or any Subsidiary of any Loan Party shall so

 

107


state in writing or bring an action to limit its obligations or liabilities thereunder or otherwise contest the validity, binding effect or enforceability of the Loan Documents; or any Loan Document shall for any reason (other than pursuant to the terms thereof) cease to create a valid security interest in any of the Collateral in excess of such Collateral that has a fair market value of $50,000 as determined by the Agent in its sole reasonable discretion (to the extent that such perfection or priority is required hereby) purported to be covered thereby or such security interest shall for any reason cease to be a perfected and first priority security interest (subject only to the prior priority of the Permitted Priority Liens).

8.10 ERISA . (a) The occurrence of any ERISA Event that could reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect or (b) the imposition of a Lien on any asset of a Loan Party or a Subsidiary of a Loan Party with respect to any Title IV Plan or Multiemployer Plan.

8.11 Product Withdrawal . The voluntary withdrawal or institution of any action or proceeding by the FDA or similar Governmental Authority to order the withdrawal of any Product or Product category from the market or to enjoin a Loan Party, such Loan Party’s Subsidiaries or any representative of a Loan Party or its Subsidiaries from testing, manufacturing, processing, assembly, packaging, labeling, marketing, importing, exporting, selling or distributing any Product or Product category that has, individually or in the aggregate, resulted (or could reasonably be expected, individually or in the aggregate, to result) in a Material Adverse Effect, (ii) the institution of any action or proceeding by the DEA, the FDA, or any other Governmental Authority to revoke, suspend, reject, withdraw, limit, or restrict any Regulatory Required Permit held by a Loan Party, its Subsidiaries or any representative of a Loan Party or its Subsidiaries, which, in each case of this clause (ii), has, individually or in the aggregate resulted (or could reasonably be expected, individually or in the aggregate, to result) in a Material Adverse Effect, (iii) the commencement of any enforcement action against a Loan Party, a Loan Party’s Subsidiaries or any representative of a Loan Party or its Subsidiaries (with respect to the business of a Loan Party or its Subsidiaries) by the DEA, the FDA, or any other Governmental Authority which has, individually or in the aggregate, resulted (or could reasonably be expected, individually or in the aggregate, to result) in a Material Adverse Effect, or (iv) the occurrence of adverse test results in connection with a Product which has, individually or in the aggregate, resulted (or could reasonably be expected, individually or in the aggregate, to result) in a Material Adverse Effect.

8.12 Change in Law . The introduction of, or any change in, any law or regulation governing or affecting the healthcare industry, including any Healthcare Laws, that has or could reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.

8.13 Material Contract Default . Any Loan Party defaults under or breaches any Material Contract (after any applicable grace period contained therein), or a Material Contract shall be terminated by a third party or parties party thereto prior to the expiration thereof (other than in accordance with its terms), the 3.25% Convertible Notes, any Permitted 3.25% Convertible Note Refinancing, the 2.25% Convertible Notes, any Term Debt Document or any Permitted Japan Lifeline Unsecured Debt Documents or there is a loss of a material right of a Loan Party under any Material Contract to which it is a party, in each case which could reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect.

8.14 Other Default or Breach . The occurrence of any breach or default under any terms or provisions of any Convertible Note Document, any Term Debt Document, any Permitted Japan Lifeline Unsecured Debt Documents or any Subordinated Debt Document or the occurrence of any event requiring the prepayment or mandatory redemption of any 3.25% Convertible Note (or any Permitted 3.25% Convertible Note Refinancing thereof or any indenture or related document governing any Permitted

 

108


3.25% Convertible Note Refinancing), any 2.25% Convertible Note, any Term Debt Document, any Permitted Japan Lifeline Unsecured Debt Documents or of any Subordinated Debt; provided , however , that, notwithstanding the foregoing, any event or condition that occurs that permits holders of convertible Indebtedness permitted hereunder to convert such Indebtedness into Stock (other than Disqualified Stock) or such other consideration permitted pursuant to Section  6.19 pursuant to the terms of the applicable agreement shall not constitute a Default or Event of Default hereunder on such basis alone.

8.15 Criminal Proceedings . The institution by any Governmental Authority of criminal proceedings against any Loan Party.

8.16 Payment of Subordinated Debt . Any Loan Party makes any payment on account of any Indebtedness that has been subordinated to any of the Obligations, other than payments specifically permitted by the terms of such subordination.

8.17 Any Intercreditor Agreement Provisions Invalid . Any provisions of the Intercreditor Agreement shall for any reason be revoked or invalidated, or otherwise cease to be in full force and effect, other than in accordance with the terms thereof, or any Person shall contest in any manner the validity or enforceability thereof or deny that it has any further liability or obligation thereunder.

8.18 Guaranty . If the obligation of any Guarantor under the guaranty contained in the Guaranty and Security Agreement is limited or terminated by operation of law or by such Guarantor (other than in accordance with the terms of this Agreement).

8.19 Subordination Provisions . (a) Any subordination provisions in respect of the documents evidencing or governing any Subordinated Debt (the “Subordination Provisions”) shall, in whole or in part, terminate, cease to be effective or cease to be legally valid, binding and enforceable against any holder of the applicable Subordinated Debt; or (b) any Borrower or any other Loan Party shall, directly or indirectly, disavow or contest in any manner (i) the effectiveness, validity or enforceability of any of the Subordination Provisions, (ii) that the Subordination Provisions exist for the benefit of the Lender Group or (iii) that all payments of principal of or premium and interest on the applicable Subordinated Indebtedness, or realized from the liquidation of any property of any Loan Party, shall be subject to any of the Subordination Provisions.

8.20 Change in Control . A Change in Control shall occur.

8.21 Not Publicly Traded . The Common Stock shall cease to be registered under the Exchange Act or to be listed on the Principal Market.

8.22 Term Debt Defaults . Any Loan Party or any Subsidiary (a) fails to make any payment when due (whether by scheduled maturity, required prepayment, acceleration, demand, or otherwise) in respect of the Term Debt, or (b) fails to observe or perform any other agreement or condition relating to the Term Debt or contained in any instrument or agreement evidencing, securing or relating thereto, or any other event occurs, the effect of which default or other event is to cause, or to permit the holder or holders of such Term Debt or the beneficiary or beneficiaries of any Guarantee related thereto (or a trustee or agent on behalf of such holder or holders or beneficiary or beneficiaries) to cause, such Term Debt to be demanded or to become due or to be repurchased, prepaid, defeased or redeemed (automatically or otherwise), or an offer to repurchase, prepay, defease or redeem such Term Debt to be made, prior to its stated maturity, or such Guarantee to become payable or cash collateral in respect thereof to be demanded.

 

109


ARTICLE IX.

RIGHTS AND REMEDIES.

9.01 Rights and Remedies . Upon the occurrence and during the continuation of an Event of Default, Agent may, and, at the instruction of the Required Lenders, shall (in each case under clauses (a) or (b) by written notice to Borrower Representative), in addition to any other rights or remedies provided for hereunder or under any other Loan Document or by applicable law, do any one or more of the following:

(a) declare the principal of, and any and all accrued and unpaid interest and fees (including Liquidated Damages, as applicable) in respect of, the Loans and all other Obligations, whether evidenced by this Agreement or by any of the other Loan Documents to be immediately due and payable, whereupon the same shall become and be immediately due and payable and Borrowers shall be obligated to repay all of such Obligations in full in cash, without presentment, demand, protest, or further notice or other requirements of any kind, all of which are hereby expressly waived by Borrowers;

(b) declare the Commitments terminated, whereupon the Commitments shall immediately be terminated together with any obligation of any Revolving Lender to make Revolving Loans; and

(c) exercise all other rights and remedies available to Agent or the Lenders under the Loan Documents, under applicable law, or in equity.

Notwithstanding anything to the contrary in this Agreement, and the other Loan Documents, each Borrower hereby irrevocably and unconditionally constitutes and appoints Agent and any of Agent’s Affiliates, attorneys, representatives or agents, with full power of substitution, as such Borrower’s true and lawful attorney-in-fact with full irrevocable and unconditional power and authority in the place and stead of such Borrower and in the name of such Borrower or in its own name, for the purpose of carrying out the terms of this Agreement, and the other Loan Documents, to take any appropriate steps or actions and to execute and deliver (and perform under on such Borrower’s behalf) any agreement, document or instrument that may be necessary or desirable to accomplish the purposes and/or effectuate the items and actions set forth in this Agreement, and the other Loan Documents, in each case, (i) that any such Loan Party fails to take that are required under such documents, agreements or instruments or (ii) during the existence of any Event of Default.

The foregoing to the contrary notwithstanding, upon the occurrence of any Event of Default described in Section  8.04 , in addition to the remedies set forth above, without any notice to Borrower Representative or any other Person or any act by the Lender Group, the Commitments shall automatically terminate and the Obligations, inclusive of the principal of, and any and all accrued and unpaid interest and fees (including Liquidated Damages, as applicable) in respect of, the Loans and all other Obligations, whether evidenced by this Agreement or by any of the other Loan Documents, shall automatically become and be immediately due and payable and Borrowers shall automatically be obligated to repay all of such Obligations in full in cash, without presentment, demand, protest, or notice or other requirements of any kind, all of which are expressly waived by Borrowers.

9.02 Remedies Cumulative . The rights and remedies of the Lender Group under this Agreement, the other Loan Documents, and all other agreements shall be cumulative. The Lender Group shall have all other rights and remedies not inconsistent herewith as provided under the Code, by law, or in equity. No exercise by the Lender Group of one right or remedy shall be deemed an election, and no waiver by the Lender Group of any Event of Default shall be deemed a continuing waiver. No delay by the Lender Group shall constitute a waiver, election, or acquiescence by it.

 

110


ARTICLE X.

WAIVERS; INDEMNIFICATION.

10.01 Demand; Protest; etc . Borrowers waive demand, protest, notice of protest, notice of default or dishonor, notice of payment and nonpayment, nonpayment at maturity, release, compromise, settlement, extension, or renewal of documents, instruments, chattel paper, and guarantees at any time held by the Lender Group on which Borrowers may in any way be liable.

10.02 The Lender Group s Liability for Collateral . Borrowers hereby agree that: (a) so long as Agent complies with its obligations, if any, under the Code, the Lender Group shall not in any way or manner be liable or responsible for: (i) the safekeeping of the Collateral, (ii) any loss or damage thereto occurring or arising in any manner or fashion from any cause, (iii) any diminution in the value thereof, or (iv) any act or default of any carrier, warehouseman, bailee, forwarding agency, or other Person, and (b) all risk of loss, damage, or destruction of the Collateral shall be borne by Borrowers.

10.03 Indemnification . Borrowers shall pay, indemnify, defend, and hold the Agent-Related Persons, the Lender-Related Persons, and each Participant (each, an “ Indemnified Person ”) harmless (to the fullest extent permitted by law) from and against any and all losses, claims, demands, suits, actions, investigations, proceedings, liabilities, fines, costs, penalties, and damages, and all reasonable fees and disbursements of attorneys, experts, or consultants and all other costs and expenses, joint and several, actually incurred in connection therewith or in connection with the enforcement of this indemnification (as and when they are incurred and irrespective of whether suit is brought), at any time asserted against, imposed upon, or incurred by any of them (a) in connection with or as a result of or related to the execution and delivery, enforcement, performance, or administration (including any restructuring or workout with respect hereto) of this Agreement, any of the other Loan Documents, or any claim, litigation, investigation or proceeding relating to any of the foregoing, regardless of whether any Indemnified Person is a party thereto, whether or not such claim, litigation, investigation or proceeding are brought by Borrowers or their equity holders, affiliates, creditors or any other person, or the transactions contemplated hereby or thereby or the monitoring of Borrowers’ and their Subsidiaries’ compliance with the terms of the Loan Documents, and to reimburse each Indemnified Person within thirty (30) days after written demand for any reasonable, actual documented out-of-pocket expenses incurred in connection with investigating or defending any of the foregoing ( provided , that the indemnification in this clause (a) shall not extend to any Taxes other than any Taxes that represent losses, claims, damages, etc. arising from any non-Tax claim), (b) with respect to any actual or prospective investigation, litigation, or proceeding related to this Agreement, any other Loan Document, the making of any Loans hereunder, or the use of the proceeds of the Loans provided hereunder (irrespective of whether any Loan Party or Indemnified Person is a party thereto), or any act, omission, event, or circumstance in any manner related thereto, and (c) in connection with or arising out of any presence or release of Hazardous Materials at, on, under, to or from any assets or properties owned, leased or operated by Borrowers or any of their Subsidiaries or any Environmental Actions, Environmental Liabilities or Remedial Actions related in any way to Borrowers, any of their Subsidiaries or any assets, properties, operations or actions of Borrowers or any of their Subsidiaries or any other violations of or liabilities arising under Environmental Law or Environmental Permits by or relating to Borrowers or any of their Subsidiaries or any assets or properties owned, leased or operated by Borrowers or any of their Subsidiaries (each and all of the foregoing, the “ Indemnified Liabilities ”). The foregoing to the contrary notwithstanding, Borrowers shall have no obligation to any Indemnified Person under this Section  10.03 with respect to any Indemnified Liability (A) that a court of competent jurisdiction finally determines to have resulted from the gross negligence, bad faith or willful misconduct of such Indemnified Person or its Affiliates or any officers, directors, employees, controlling persons or members of the foregoing or (B) arising out of a material breach by such Indemnified Person of its obligations hereunder. This provision

 

111


shall survive the termination of this Agreement, the termination of the Commitments and the repayment in full in cash of the Obligations. If any Indemnified Person makes any payment to any other Indemnified Person with respect to an Indemnified Liability as to which Borrowers were required to indemnify the Indemnified Person receiving such payment, the Indemnified Person making such payment is entitled to be indemnified and reimbursed by Borrowers with respect thereto. WITHOUT LIMITATION, THE FOREGOING INDEMNITY SHALL APPLY TO EACH INDEMNIFIED PERSON WITH RESPECT TO INDEMNIFIED LIABILITIES WHICH IN WHOLE OR IN PART ARE CAUSED BY OR ARISE OUT OF ANY NEGLIGENT ACT OR OMISSION OF SUCH INDEMNIFIED PERSON OR OF ANY OTHER PERSON. THE PROVISIONS OF THIS SECTION 10.03 SHALL SURVIVE THE RESIGNATION OR TERMINATION OF AGENT AND TERMINATION OF THIS AGREEMENT.

ARTICLE XI.

NOTICES.

Unless otherwise provided in this Agreement, all notices or demands relating to this Agreement or any other Loan Document shall be in writing and (except for financial statements and other informational documents which may be sent by first-class mail, postage prepaid) shall be personally delivered or sent by registered or certified mail (postage prepaid, return receipt requested), overnight courier, electronic mail (at such email addresses as a party may designate in accordance herewith), or telefacsimile. In the case of notices or demands to Borrower Representative or Agent, as the case may be, they shall be sent to the respective address set forth below:

If to Borrower

Representative:                           Endologix, Inc.

2 Musick

Irvine, CA 92618

E-mail: vmahboob@endologix.com

E-mail: jtejedor@endologix.com

Attn: Vaseem Mahboob, CFO

Attn: James Tejedor, Treasury Manager

with copies to:                            DLA Piper LLP

1251 Avenue of the Americas

New York, New York 10020-1104

Email: gregory.ruback@dlapiper.com

Attn: Greg Ruback, Esq.

Fax No.: (212) 884-8682

If to Agent:                                 Deerfield ELGX Revolver, LLC

c/o Deerfield Management Company, L.P.

780 Third Avenue, 37 th Floor

New York, NY 10017

Facsimile: 212-599-3075

E-mail: dclark@deerfield.com

Attn: David J. Clark, Esq

with copies to:                            Katten Muchin Rosenman LLP

2029 Century Park East, Suite 2600

Los Angeles, CA 90067-3012

 

112


Facsimile: (310) 788-4471

E-mail: kristopher.ring@kattenlaw.com and

mark.wood@kattenlaw.com

Attn: Kristopher J. Ring, Esq.

Attn: Mark D. Wood, Esq.

and, solely to the extent that Cortland Capital Market Services

LLC is the Third Party Agent during any Third Party Agent

Retention Period:

Cortland Capital Market Services LLC

225 W. Washington Street, 9th Floor

Chicago, IL 60606

E-mail: CortlandABLServices@cortlandglobal.com and

legal@cortlandglobal.com

Attn: ABL Services

Any party hereto may change the address at which they are to receive notices hereunder, by notice in writing in the foregoing manner given to the other party (or, in the case of any Third Party Agent, in the notice delivered to Borrower Representative pursuant to clause (b) of the definition of “Third Party Agent” herein). All notices or demands sent in accordance with this Article XI , shall be deemed received on the earlier of the date of actual receipt or three (3) Business Days after the deposit thereof in the mail; provided , that (a) notices sent by overnight courier service shall be deemed to have been given when received, (b) notices by facsimile shall be deemed to have been given when sent (except that, if not given during normal business hours for the recipient, shall be deemed to have been given at the opening of business on the next Business Day for the recipient) and (c) notices by electronic mail shall be deemed received upon the sender’s receipt of an acknowledgment from the intended recipient (such as by the “return receipt requested” function, as available, return email or other written acknowledgment).

ARTICLE XII.

CHOICE OF LAW AND VENUE; JURY TRIAL WAIVER;

JUDICIAL REFERENCE PROVISION.

(a) THE VALIDITY OF THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS (UNLESS EXPRESSLY PROVIDED TO THE CONTRARY IN ANOTHER LOAN DOCUMENT IN RESPECT OF SUCH OTHER LOAN DOCUMENT), THE CONSTRUCTION, INTERPRETATION, AND ENFORCEMENT HEREOF AND THEREOF, THE RIGHTS OF THE PARTIES HERETO AND THERETO WITH RESPECT TO ALL MATTERS ARISING HEREUNDER OR THEREUNDER OR RELATED HERETO OR THERETO, AND ANY CLAIMS, CONTROVERSIES OR DISPUTES ARISING HEREUNDER OR THEREUNDER OR RELATED HERETO OR THERETO SHALL BE DETERMINED UNDER, GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK.

(b) THE PARTIES AGREE THAT ALL ACTIONS OR PROCEEDINGS ARISING IN CONNECTION WITH THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS SHALL BE TRIED AND LITIGATED ONLY IN THE STATE AND, TO THE EXTENT PERMITTED BY APPLICABLE LAW, FEDERAL COURTS LOCATED IN THE COUNTY OF NEW YORK, STATE OF NEW YORK; PROVIDED , THAT ANY SUIT SEEKING ENFORCEMENT AGAINST ANY COLLATERAL OR OTHER PROPERTY MAY BE BROUGHT, AT AGENT’S OPTION, IN THE COURTS OF ANY JURISDICTION WHERE AGENT ELECTS TO BRING SUCH ACTION OR

 

113


WHERE SUCH COLLATERAL OR OTHER PROPERTY MAY BE FOUND. BORROWERS AND EACH MEMBER OF THE LENDER GROUP WAIVE, TO THE EXTENT PERMITTED UNDER APPLICABLE LAW, ANY RIGHT EACH MAY HAVE TO ASSERT THE DOCTRINE OF FORUM NON CONVENIENS OR TO OBJECT TO VENUE TO THE EXTENT ANY PROCEEDING IS BROUGHT IN ACCORDANCE WITH THIS SECTION 12(b) .

(c) TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, BORROWERS AND EACH MEMBER OF THE LENDER GROUP HEREBY WAIVE THEIR RESPECTIVE RIGHTS, IF ANY, TO A JURY TRIAL OF ANY CLAIM, CONTROVERSY, DISPUTE OR CAUSE OF ACTION DIRECTLY OR INDIRECTLY BASED UPON OR ARISING OUT OF ANY OF THE LOAN DOCUMENTS OR ANY OF THE TRANSACTIONS CONTEMPLATED THEREIN, INCLUDING CONTRACT CLAIMS, TORT CLAIMS, BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW OR STATUTORY CLAIMS (EACH A “ CLAIM ”). BORROWERS AND EACH MEMBER OF THE LENDER GROUP REPRESENT THAT EACH HAS REVIEWED THIS WAIVER AND EACH KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. IN THE EVENT OF LITIGATION, A COPY OF THIS AGREEMENT MAY BE FILED AS A WRITTEN CONSENT TO A TRIAL BY THE COURT.

(d) BORROWERS HEREBY IRREVOCABLY AND UNCONDITIONALLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE COMMERCIAL DIVISION, NEW YORK STATE SUPREME COURT AND THE FEDERAL COURTS, IN EACH CASE, SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN (AND, IN EACH CASE, THE APPLICABLE STATE AND FEDERAL APPEALS COURTS SITTING IN THE CITY OF NEW YORK OR, IF NOT AVAILABLE OR APPLICABLE, THE STATE OF NEW YORK), IN ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO ANY LOAN DOCUMENTS, OR FOR RECOGNITION OR ENFORCEMENT OF ANY JUDGMENT. EACH OF THE PARTIES HERETO AGREES THAT A FINAL JUDGMENT IN ANY SUCH ACTION OR PROCEEDING SHALL BE CONCLUSIVE AND MAY BE ENFORCED IN OTHER JURISDICTIONS BY SUIT ON THE JUDGMENT OR IN ANY OTHER MANNER PROVIDED BY LAW. NOTHING IN THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT SHALL AFFECT ANY RIGHT THAT AGENT MAY OTHERWISE HAVE TO BRING ANY ACTION OR PROCEEDING RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT AGAINST ANY LOAN PARTY OR ITS PROPERTIES IN THE COURTS OF ANY JURISDICTION.

(e) NO CLAIM MAY BE MADE BY ANY LOAN PARTY AGAINST AGENT (INCLUDING ANY THIRD PARTY AGENT), ANY LENDER OR ANY AFFILIATE, DIRECTOR, OFFICER, EMPLOYEE, COUNSEL, REPRESENTATIVE, AGENT, OR ATTORNEY-IN-FACT OF ANY OF THEM FOR ANY SPECIAL, INDIRECT, CONSEQUENTIAL, PUNITIVE OR EXEMPLARY DAMAGES OR LOSSES IN RESPECT OF ANY CLAIM FOR BREACH OF CONTRACT OR ANY OTHER THEORY OF LIABILITY ARISING OUT OF OR RELATED TO THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT, OR ANY ACT, OMISSION, OR EVENT OCCURRING IN CONNECTION THEREWITH, AND EACH LOAN PARTY HEREBY WAIVES, RELEASES, AND AGREES NOT TO SUE UPON ANY CLAIM FOR SUCH DAMAGES, WHETHER OR NOT ACCRUED AND WHETHER OR NOT KNOWN OR SUSPECTED TO EXIST IN ITS FAVOR.

 

114


ARTICLE XIII.

ASSIGNMENTS AND PARTICIPATIONS; SUCCESSORS.

13.01 Assignments and Participations .

(a) Subject to the conditions set forth in clause (a)(ii) below, any Lender may assign and delegate all or any portion of its rights and duties under the Loan Documents (including the Obligations owed to it and its Commitments) to one or more Eligible Assignee (each, an “ Assignee ”), without the prior written consent of any other Person (other than as expressly required in the definition of “Eligible Assignee”).

 

  (i)

Assignments shall be subject to the following additional conditions:

(A) [reserved];

(B) the amount of the Commitments and the other rights and obligations of the assigning Lender hereunder and under the other Loan Documents subject to each such assignment (determined as of the date the Assignment and Acceptance with respect to such assignment is delivered to Agent) shall be in a minimum amount (unless waived by Agent) of $1,000,000 (except such minimum amount shall not apply to (I) an assignment or delegation by any Lender to any other Lender, an Affiliate of any Lender, or a Related Fund of such Lender, (II) an assignment or delegation of all remaining Commitments held by such assigning Lender or (III) a group of new Lenders, each of which is an Affiliate of each other or a Related Fund of such new Lender to the extent that the aggregate amount to be assigned to all such new Lenders is at least $1,000,000);

(C) each partial assignment shall be made as an assignment of a proportionate part of all the assigning Lender’s rights and obligations under this Agreement;

(D) the parties to each assignment shall execute and deliver to Agent an Assignment and Acceptance; provided , that Borrowers and Agent may continue to deal solely and directly with the assigning Lender in connection with the interest so assigned to an Assignee until (1) such Lender and the Assignee have delivered Agent an Assignment and Acceptance, and (2) unless waived by Agent, the assigning Lender or Assignee has paid to Agent, for Agent’s separate account, a processing fee in the amount of $3,500; and

(E) the assignee, if it is not a Lender, unless waived by Agent, shall deliver to Agent an Administrative Questionnaire in a form approved by Agent (the “ Administrative Questionnaire ”) and all documentation and other information required by regulatory authorities under applicable “know your customer” and anti-money laundering rules and regulations, including, without limitation, the USA PATRIOT Act.

(b) From and after the date that Agent receives the executed Assignment and Acceptance and, if applicable, payment of the required processing fee, (i) the Assignee thereunder shall be a party hereto and, to the extent that rights and obligations hereunder have been assigned to it pursuant to such Assignment and Acceptance, shall be a “Lender” and shall have the rights and obligations of a Lender under the Loan Documents, and (ii) the assigning Lender shall, to the extent that rights and obligations hereunder and under the other Loan Documents have been assigned by it pursuant to such Assignment

 

115


and Acceptance, relinquish its rights (except with respect to Section  10.03 ) and be released from any future obligations under this Agreement (and in the case of an Assignment and Acceptance covering all or the remaining portion of an assigning Lender’s rights and obligations under this Agreement and the other Loan Documents, such Lender shall cease to be a party hereto and thereto); provided , that nothing contained herein shall release any assigning Lender from obligations that survive the termination of this Agreement, including such assigning Lender’s obligations under Article XV and Section  17.08(a) .

(c) By executing and delivering an Assignment and Acceptance, the assigning Lender thereunder and the Assignee thereunder confirm to and agree with each other and the other parties hereto as follows: (i) other than as provided in such Assignment and Acceptance, such assigning Lender makes no representation or warranty and assumes no responsibility with respect to any statements, warranties or representations made in or in connection with this Agreement or the execution, legality, validity, enforceability, genuineness, sufficiency or value of this Agreement or any other Loan Document furnished pursuant hereto, (ii) such assigning Lender makes no representation or warranty and assumes no responsibility with respect to the financial condition of any Loan Party or the performance or observance by any Loan Party of any of its obligations under this Agreement or any other Loan Document furnished pursuant hereto, (iii) such Assignee confirms that it has received a copy of this Agreement, together with such other documents and information as it has deemed appropriate to make its own credit analysis and decision to enter into such Assignment and Acceptance, (iv) such Assignee will, independently and without reliance upon Agent, such assigning Lender or any other Lender, and based on such documents and information as it shall deem appropriate at the time, continue to make its own credit decisions in taking or not taking action under this Agreement, (v) such Assignee appoints and authorizes Agent (and, during any Third Party Agent Retention Period, the Third Party Agent) to take such actions and to exercise such powers under this Agreement and the other Loan Documents as are delegated to Agent (or the Third Party Agent, as applicable), by the terms hereof and thereof, together with such powers as are reasonably incidental thereto, and (vi) such Assignee agrees that it will perform all of the obligations which by the terms of this Agreement are required to be performed by it as a Lender.

(d) Immediately upon Agent’s receipt of the required processing fee, if applicable, and delivery of notice to the assigning Lender pursuant to Section  13.01(b) , this Agreement shall be deemed to be amended to the extent, but only to the extent, necessary to reflect the addition of the Assignee and the resulting adjustment of the Commitments arising therefrom. The Commitment allocated to each Assignee shall reduce such Commitments of the assigning Lender pro tanto .

(e) Any Lender may at any time sell to one or more commercial banks, financial institutions, or other Persons (a “ Participant ”) participating interests in all or any portion of its Obligations, its Commitment, and the other rights and interests of that Lender (the “ Originating Lender ”) hereunder and under the other Loan Documents; provided , that (i) the Originating Lender shall remain a “Lender” for all purposes of this Agreement and the other Loan Documents and the Participant receiving the participating interest in the Obligations, the Commitments, and the other rights and interests of the Originating Lender hereunder shall not constitute a “Lender” hereunder or under the other Loan Documents and the Originating Lender’s obligations under this Agreement shall remain unchanged, (ii) the Originating Lender shall remain solely responsible for the performance of such obligations, (iii) Borrowers, Agent (any Third Party Agent), and the Lenders shall continue to deal solely and directly with the Originating Lender in connection with the Originating Lender’s rights and obligations under this Agreement and the other Loan Documents, (iv) no Lender shall transfer or grant any participating interest under which the Participant has the right to approve any amendment to, or any consent or waiver with respect to, this Agreement or any other Loan Document, except to the extent such amendment to, or consent or waiver with respect to this Agreement or of any other Loan Document would (A) extend the final maturity date of the Obligations hereunder in which such Participant is participating, (B) reduce the interest rate

 

116


applicable to the Obligations hereunder in which such Participant is participating, (C) release all or substantially all of the Collateral or guaranties (except to the extent expressly provided herein or in any of the Loan Documents) supporting the Obligations hereunder in which such Participant is participating, (D) postpone the payment of, or reduce the amount of, the interest or fees payable to such Participant through such Lender (other than a waiver of default interest), or (E) decreases the amount or postpones the due dates of scheduled principal repayments or prepayments or premiums payable to such Participant through such Lender, (v) no participation shall be sold to a natural person, (vi) no participation shall be sold to a Loan Party or an Affiliate of a Loan Party, and (vii) all amounts payable by Borrowers hereunder shall be determined as if such Lender had not sold such participation, except that, if amounts outstanding under this Agreement are due and unpaid, or shall have been declared or shall have become due and payable upon the occurrence of an Event of Default, each Participant shall be deemed to have the right of set off in respect of its participating interest in amounts owing under this Agreement to the same extent as if the amount of its participating interest were owing directly to it as a Lender under this Agreement. The rights of any Participant only shall be derivative through the Originating Lender with whom such Participant participates and no Participant shall have any rights under this Agreement or the other Loan Documents or any direct rights as to the other Lenders, Agent (or any Third Party Agent), Borrowers, the Collateral, or otherwise in respect of the Obligations. No Participant shall have the right to participate directly in the making of decisions by the Lenders among themselves.

(f) In connection with any such assignment or participation or proposed assignment or participation or any grant of a security interest in, or pledge of, its rights under and interest in this Agreement, a Lender may, subject to the provisions of Section  17.08 , disclose all documents and information which it now or hereafter may have relating to Borrowers and their Subsidiaries and their Affiliates and their respective businesses and Stock and properties.

(g) Any other provision in this Agreement notwithstanding, any Lender may at any time create a security interest in, or pledge, all or any portion of its rights under and interest in this Agreement in favor of any Federal Reserve Bank in accordance with Regulation A of the Federal Reserve Bank or U.S. Treasury Regulation 31 CFR §203.24, and such Federal Reserve Bank may enforce such pledge or security interest in any manner permitted under applicable law. Notwithstanding anything to the contrary herein, (i) any Lender shall be permitted to pledge or grant a security interest in all or a portion of such Lender’s rights hereunder including, but not limited to, any Loans (without the consent of, or notice to or any other action by, any other party hereto) to secure the obligations of such Lender or any of its Affiliates to any Person providing any loan, letter of credit or other extension of credit to or for the account of such Lender or any of its Affiliates and any agent, trustee or representative of such Person and (ii) Agent shall be permitted to pledge or grant a security interest in all or any portion of its rights hereunder or under the other Loan Documents, including, but not limited to, rights to payment (without the consent of, or notice to or any other action by, any other party hereto), to secure the obligations of Agent or any of its Affiliates to any Person providing any loan, letter of credit to or for the account of Agent or any of its Affiliates and any agent, trustee or representative of such Person; provided in each case, that no such pledge or assignment of a security interest shall release such Lender or Agent from its obligations hereunder or substitute any such pledgee or assignee for such Lender or Agent as a party hereto.

(h) The Loan Parties hereby acknowledge that the Lenders and their Affiliates may securitize the Loans (a “Securitization”) through the pledge of the Loans as collateral security for loans to the Lenders or their Affiliates or through the sale of the Loans or the issuance of direct or indirect interests in the Loans to their controlled Affiliates, which loans to the Lenders or their Affiliates or direct or indirect interests may be rated by Moody’s, S&P or one or more other rating agencies. The Loan Parties shall, to the extent commercially reasonable, cooperate with the Lenders and their Affiliates to effect any and all

 

117


Securitizations. Notwithstanding the foregoing, no such Securitization shall release the Lender party thereto from any of its obligations hereunder except in accordance with Section  13.01(a) .

(i) During any Third Party Agent Retention Period, the Third Party Agent (as a non-fiduciary agent on behalf of Borrowers) shall maintain, or cause to be maintained, a register (the “ Register ”) on which it enters the name and address of each Lender as the registered owner of the Loans and/or Revolver Commitments (and the principal amount thereof and stated interest thereon) held by such Lender (each, a “ Registered Loan ”). During any Non-Third Party Agent Retention Period, the Borrower Representative shall maintain such Register and shall make such Register available to any member of the Lender Group at any reasonable time upon reasonable prior notice to the Borrower Representative. Upon the request of any Third Party Agent upon the commencement of any Third Party Agent Retention Period, the Borrower Representative shall share such Register with the Third Party Agent, and with respect to any discrepancies between the records or Register of the Borrower Representative, on the one hand, and the records or Register of any Lender, the Agent or the Third Party Agent, on the other hand, the records and Register of such Lender, Agent or Third Party Agent shall govern and control absent manifest error. Other than in connection with an assignment by a Lender of all or any portion of its portion of the Loans and/or Revolver Commitments to an Affiliate of such Lender or a Related Fund of such Lender (i) a Registered Loan (and the registered note, if any, evidencing the same) may be assigned or sold in whole or in part only by registration of such assignment or sale on the Register (and each registered note shall expressly so provide) and (ii) any assignment or sale of all or part of such Registered Loan (and the registered note, if any, evidencing the same) may be effected only by registration of such assignment or sale on the Register, together with the surrender of the registered note, if any, evidencing the same duly endorsed by (or accompanied by a written instrument of assignment or sale duly executed by) the holder of such registered note, whereupon, at the request of the designated assignee(s) or transferee(s), one or more new registered notes in the same aggregate principal amount shall be issued to the designated assignee(s) or transferee(s). Prior to the registration of assignment or sale of any Registered Loan (and the registered note, if any evidencing the same), Borrowers shall treat the Person in whose name such Registered Loan (and the registered note, if any, evidencing the same) is registered as the owner thereof for the purpose of receiving all payments thereon and for all other purposes, notwithstanding notice to the contrary. In the case of any assignment by a Lender of all or any portion of its Loans and/or Revolver Commitments to an Affiliate of such Lender or a Related Fund of such Lender, and which assignment is not recorded in the Register, the assigning Lender, on behalf of Borrowers, shall maintain a register comparable to the Register.

(j) In the event that a Lender sells participations in the Registered Loan, such Lender, as a non-fiduciary agent on behalf of Borrowers, shall maintain (or cause to be maintained) a register on which it enters the name of all participants in the Registered Loans held by it (and the principal amount (and stated interest thereon) of the portion of such Registered Loans that is subject to such participations) (the “ Participant Register ”). A Registered Loan (and the Registered Note, if any, evidencing the same) may be participated in whole or in part only by registration of such participation on the Participant Register (and each registered note shall expressly so provide). Any participation of such Registered Loan (and the registered note, if any, evidencing the same) may be effected only by the registration of such participation on the Participant Register.

(k) Agent shall make a copy of the Register (and each Lender shall make a copy of its Participant Register to the extent it has one) available for review by Borrowers from time to time as Borrowers may reasonably request.

13.02 Successors . This Agreement shall bind and inure to the benefit of the respective successors and assigns of each of the parties; provided , that Borrowers and other Loan Parties may not

 

118


assign this Agreement or any of the other Loan Documents or any rights, obligations or duties hereunder or thereunder without Agent’s and all the Lenders’ prior written consent and any prohibited assignment shall be absolutely void ab initio . No consent to assignment by Agent and/or the Lenders shall release Borrowers from their Obligations. A Lender may assign this Agreement and the other Loan Documents and its rights and duties hereunder and thereunder pursuant to Section  13.01 and, except as expressly required pursuant to Section  13.01 , no consent or approval by Borrowers is required in connection with any such assignment. For the avoidance of doubt, Agent may delegate any of its rights, duties and obligations to any Third Party Agent during any Third Party Agent Retention Period.

ARTICLE XIV.

AMENDMENTS; WAIVERS.

14.01 Amendments and Waivers .

(a) No amendment, waiver or other modification of any provision of this Agreement or any other Loan Document, and no consent with respect to any departure by Borrowers therefrom, shall be effective unless the same shall be in writing and signed by the Agent, the Required Lenders (or by Agent at the written request of the Required Lenders) and the Loan Parties that are party thereto and then any such waiver or consent shall be effective, but only in the specific instance and for the specific purpose for which given; provided , that no such waiver, amendment, or consent shall, unless in writing and signed by all of the Lenders directly affected thereby and all of the Loan Parties that are party thereto, do any of the following:

(i) increase the amount of or extend the expiration date of any Commitment of any Lender or amend, modify, or eliminate the last sentence of Section  2.03(c)(i) ,

(ii) postpone or delay any date fixed by this Agreement or any other Loan Document for any payment of principal, interest, fees (including Liquidated Damages), or other amounts due hereunder or under any other Loan Document,

(iii) reduce the principal of, or the rate of interest on, any loan or other extension of credit hereunder, or reduce any fees or other amounts payable hereunder or under any other Loan Document (except (A) in connection with the waiver of applicability of Section  2.05(c) (which waiver shall be effective with the written consent of the Required Lenders) and (B) that any amendment or modification of defined terms used in the financial covenants in this Agreement shall not constitute a reduction in the rate of interest or a reduction of fees for purposes of this clause (iii)),

(iv) amend, modify, or eliminate this Section or any provision of this Agreement providing for consent or other action by all Lenders,

(v) amend, modify, or eliminate 3.02 ,

(vi) amend, modify, or eliminate Section  15.11 ,

(vii) other than as permitted by Section  15.11 , release Agent’s Lien in and to all or substantially all of the Collateral,

(viii) amend, modify, or eliminate the definitions of “Required Lenders” or “Pro Rata Share”,

 

119


(ix) contractually subordinate any of Agent’s Liens,

(x) other than in connection with a merger, liquidation, dissolution or sale of such Person expressly permitted by the terms hereof or the other Loan Documents, release Borrowers or any Guarantor from any obligation for the payment of money or consent to the assignment or transfer by Borrowers or any Guarantor of any of its rights or duties under this Agreement or the other Loan Documents,

(xi) amend, modify, or eliminate any of the provisions of Section  2.03(b)(i) or (ii)  Section  2.03(e) , or

(xii) amend, modify, or eliminate any of the provisions of Section  13.01 with respect to assignments to, or participations with, Persons who are Loan Parties or Affiliates of Loan Parties;

(b) No amendment, waiver, modification, or consent shall amend, modify, waive, or eliminate,

(i) [reserved], and

(ii) any provision of Article XV pertaining to Agent, or any other rights or duties of Agent under this Agreement or the other Loan Documents, without the written consent of Agent, Borrowers, and the Required Lenders.

14.02 [Reserved] .

14.03 No Waivers; Cumulative Remedies . No failure by Agent (including any Third Party Agent), any Lender or any other member of the Lender Group to exercise any right, remedy, or option under this Agreement or any other Loan Document, or delay by Agent (including any Third Party Agent), any Lender or any other member of the Lender Group in exercising the same, will operate as a waiver thereof. No waiver by Agent (including any Third Party Agent), any Lender or any other member of the Lender Group will be effective unless it is in writing, and then only to the extent specifically stated. No waiver by Agent (including any Third Party Agent), any Lender or any other member of the Lender Group on any occasion shall affect or diminish Agent’s (including any Third Party Agent’s), each Lender’s and each other member of the Lender Group’s rights thereafter to require strict performance by Borrowers and the other Loan Parties of any provision of this Agreement or any other Loan Document. Agent’s (including any Third Party Agent’s), each Lender’s and each other member of the Lender Group’s rights under this Agreement and the other Loan Documents will be cumulative and not exclusive of any other right or remedy that Agent (including any Third Party Agent), any Lender or any other member of the Lender Group may have.

ARTICLE XV.

AGENT; THE LENDER GROUP.

15.01 Appointment and Authorization of Agent (and any Third Party Agent) . Each Lender hereby irrevocably appoints and authorizes Agent (including any Third Party Agent) to enter into each of the Loan Documents to which it is a party (other than this Agreement) on its behalf and to take such actions as Agent (or such Third Party Agent) on its behalf and to exercise such powers under the Loan Documents as are delegated to Agent (or such Third Party Agent) by the terms thereof, together with all such powers as are reasonably incidental thereto. Subject to the terms of Section  14.01 and to the terms of the other Loan Documents, Agent is authorized and empowered to amend, modify, or waive any

 

120


provisions of this Agreement or the other Loan Documents on behalf of Lenders. The provisions of this Article  XV are solely for the benefit of Agent (including any Third Party Agent) and Lenders and neither any Borrower nor any other Loan Party shall have any rights as a third party beneficiary of any of the provisions hereof. In performing its functions and duties under this Agreement, Agent (and any Third Party Agent) shall act solely as agent of Lenders and does not assume and shall not be deemed to have assumed any obligation toward or relationship of agency or trust with or for any Borrower or any other Loan Party. Agent may perform any of its duties hereunder, or under the Loan Documents, by or through its agents, subagents, servicers, trustees, investment managers or employees or any Third Party Agent. Agent shall have the same rights and powers under the Loan Documents as any other Lender and may exercise or refrain from exercising the same as though it were not Agent, and Agent and its Affiliates may lend money to, invest in and generally engage in any kind of business with each Loan Party or Affiliate of any Loan Party as if it were not Agent hereunder. The duties of Agent shall be mechanical and administrative in nature. Agent shall not have by reason of this Agreement or the other Loan Documents a fiduciary relationship in respect of any Lender. Nothing in this Agreement or any of the other Loan Documents is intended to or shall be construed to impose upon Agent any obligations in respect of this Agreement or any of the other Loan Documents except as expressly set forth herein or therein.

15.02 Delegation of Duties . Agent may execute any of its duties under this Agreement or any other Loan Document by or through agents, employees, attorneys in fact or any Third Party Agent and shall be entitled to advice of counsel concerning all matters pertaining to such duties. Agent shall not be responsible for the negligence or misconduct of any agent, attorney in fact or Third Party Agent that it selects as long as such selection was made without a final, non-appealable binding decision of a court of competent jurisdiction to be from the gross negligence or willful misconduct of Agent.

15.03 Liability of Agent . Neither Agent nor any of its directors, officers, agents, subagents, trustees, investment managers, servicers or employees shall be liable to any Lender for any action taken or not taken by it in connection with the Loan Documents, except that Agent shall be liable with respect to its specific duties set forth hereunder but only to the extent of its own gross negligence or willful misconduct in the discharge thereof as determined by a final non-appealable judgment of a court of competent jurisdiction. Neither Agent nor any of its directors, officers, agents, subagents, trustees, investment managers, servicers or employees shall be responsible for or have any duty to ascertain, inquire into or verify (a) any statement, warranty or representation made in connection with any Loan Document or any borrowing hereunder; (b) the performance or observance of any of the covenants or agreements specified in any Loan Document; (c) the satisfaction of any condition specified in any Loan Document; (d) the validity, effectiveness, sufficiency or genuineness of any Loan Document, any Lien purported to be created or perfected thereby or any other instrument or writing furnished in connection therewith; (e) the existence or non-existence of any Default or Event of Default; or (f) the financial condition of any Loan Party. Agent shall not incur any liability by acting in reliance upon any notice, consent, certificate, statement, or other writing (which may be a bank wire, facsimile or electronic transmission or similar writing) believed by it to be genuine or to be signed by the proper party or parties. Agent shall not be liable for any apportionment or distribution of payments made by it in good faith and if any such apportionment or distribution is subsequently determined to have been made in error the sole recourse of any Lender to whom payment was due but not made, shall be to recover from other Lenders any payment in excess of the amount to which they are determined to be entitled (and such other Lenders hereby agree to return to such Lender any such erroneous payments received by them). Agent may consult with legal counsel, independent public accountants and other experts selected by it and shall not be liable for any action taken or omitted to be taken by it in good faith in accordance with the advice of such counsel, accountants or experts.

 

121


15.04 Reliance by Agent . Agent shall be entitled to rely, and shall be fully protected in relying, upon any writing, resolution, notice, consent, certificate, affidavit, letter, telegram, telefacsimile or other electronic method of transmission, telex or telephone message, statement or other document or conversation believed by it to be genuine and correct and to have been signed, sent, or made by the proper Person or Persons, and upon advice and statements of legal counsel (including counsel to Borrowers or any other Loan Party or counsel to any Lender), independent accountants and other experts selected by Agent. Agent shall be fully justified in failing or refusing to take any action under this Agreement or any other Loan Document unless Agent shall first receive such advice or concurrence of the Lenders as it deems appropriate and until such instructions are received, Agent shall act, or refrain from acting, as it deems advisable. If Agent so requests, it shall first be indemnified to its reasonable satisfaction by the Lenders against any and all liability and expense that may be incurred by it by reason of taking or continuing to take any such action. Agent shall in all cases be fully protected in acting, or in refraining from acting, under this Agreement or any other Loan Document in accordance with a request or consent of the Required Lenders and such request and any action taken or failure to act pursuant thereto shall be binding upon all of the Lenders.

15.05 Notice of Default or Event of Default . Agent shall not be deemed to have knowledge or notice of the occurrence of any Default or Event of Default, except with respect to defaults in the payment of principal, interest, fees, and expenses required to be paid to Agent for the account of the Lenders and, except with respect to Events of Default of which Agent has actual knowledge, unless Agent shall have received written notice from a Lender or Borrowers referring to this Agreement, describing such Default or Event of Default, and stating that such notice is a “notice of default.” Agent promptly will notify the Lenders of its receipt of any such notice or of any Event of Default of which Agent has actual knowledge. If any Lender obtains actual knowledge of any Event of Default, such Lender promptly shall notify the other Lenders and Agent of such Event of Default. Each Lender shall be solely responsible for giving any notices to its Participants, if any. Subject to Section  15.04 , Agent shall take such action with respect to such Default or Event of Default as may be requested by the Required Lenders in accordance with Article IX ; provided , that unless and until Agent has received any such request, Agent may (but shall not be obligated to) take such action, or refrain from taking such action, with respect to such Default or Event of Default as it shall deem advisable.

15.06 Credit Decision . Each Lender acknowledges that none of the Agent-Related Persons has made any representation or warranty to it, and that no act by Agent hereinafter taken, including any review of the affairs of Borrowers and their Subsidiaries or Affiliates, shall be deemed to constitute any representation or warranty by any Agent-Related Person to any Lender. Each Lender represents to Agent that it has, independently and without reliance upon any Agent-Related Person and based on such due diligence, documents and information as it has deemed appropriate, made its own appraisal of an investigation into the business, prospects, operations, property, financial and other condition and creditworthiness of Borrowers or any other Person party to a Loan Document, and all applicable bank regulatory laws relating to the transactions contemplated hereby, and made its own decision to enter into this Agreement and to extend credit to Borrowers. Each Lender also represents that it will, independently and without reliance upon any Agent-Related Person and based on such documents and information as it shall deem appropriate at the time, continue to make its own credit analysis, appraisals and decisions in taking or not taking action under this Agreement and the other Loan Documents, and to make such investigations as it deems necessary to inform itself as to the business, prospects, operations, property, financial and other condition and creditworthiness of Borrowers or any other Person party to a Loan Document. Except for notices, reports, and other documents expressly herein required to be furnished to the Lenders by Agent, Agent shall not have any duty or responsibility to provide any Lender with any credit or other information concerning the business, prospects, operations, property, financial and other condition or creditworthiness of Borrowers or any other Person party to a Loan Document that may come

 

122


into the possession of any of the Agent-Related Persons. Each Lender acknowledges that Agent does not have any duty or responsibility, either initially or on a continuing basis (except to the extent, if any, that is expressly specified herein) to provide such Lender with any credit or other information with respect to Borrowers, their Affiliates or any of their respective business, legal, financial or other affairs, and irrespective of whether such information came into Agent’s or its Affiliates’ or representatives’ possession before or after the date on which such Lender became a party to this Agreement.

15.07 Costs and Expenses; Indemnification . Agent may incur and pay Lender Group Expenses to the extent Agent reasonably deems necessary or appropriate for the performance and fulfillment of its functions, powers, and obligations pursuant to the Loan Documents, including with respect to due diligence expenses and periodic reviews of insurance and Collateral, court costs, attorneys’ fees and expenses, fees and expenses of financial accountants, advisors, consultants, and appraisers, costs of collection by outside collection agencies, auctioneer fees and expenses, and costs of security guards or insurance premiums paid to maintain the Collateral, whether or not Borrowers or the other Loan Parties are obligated to reimburse Agent or Lenders for such expenses pursuant to this Agreement or otherwise. Agent is authorized and directed to deduct and retain sufficient amounts from (a) any deposits paid on or prior to the Closing Date and any subsequent deposits paid by Borrowers or any other Loan Party to Agent hereunder or under any other Loan Document, or (b) payments or proceeds of the Collateral received by Agent to reimburse Agent for such out-of-pocket costs and expenses prior to the distribution of any amounts to Lenders. In the event Agent is not reimbursed for such costs and expenses by Borrowers, any other Loan Party or their Subsidiaries, each Lender hereby agrees that it is and shall be obligated to pay to Agent such Lender’s ratable thereof. Whether or not the transactions contemplated hereby are consummated, (i) Agent is authorized and directed to deduct and retain sufficient amounts from any deposits paid on or prior to the Closing Date and any subsequent deposits paid by Borrowers or any other Loan Party to Agent hereunder or under any other Loan Document for the payment of the Indemnified Liabilities and (ii) each of the Lenders, on a ratable basis, shall indemnify and defend the Agent-Related Persons (to the extent not reimbursed by or on behalf of Borrowers and without limiting the obligation of Borrowers to do so) from and against any and all Indemnified Liabilities; provided , that no Lender shall be liable for the payment to any Agent-Related Person of any portion of such Indemnified Liabilities resulting solely from such Person’s gross negligence or willful misconduct as determined by a final, non-appealable and binding decision of a court of competent jurisdiction. Without limitation of the foregoing, each Lender shall reimburse Agent upon demand for such Lender’s ratable share of any costs or out of pocket expenses (including attorneys, accountants, advisors, and consultants fees and expenses) incurred by Agent in connection with the preparation, execution, delivery, administration, modification, amendment, or enforcement (whether through negotiations, legal proceedings or otherwise) of, or legal advice in respect of rights or responsibilities under, this Agreement or any other Loan Document to the extent that Agent is not reimbursed for such expenses by or on behalf of Borrowers and the other Loan Parties. The undertaking in this Section shall survive the payment of all Obligations hereunder and the resignation or replacement of Agent (and any resignation, replacement or termination of any Third Party Agent).

15.08 Agent in Individual Capacity . Agent and its Affiliates may make loans to, issue letters of credit for the account of, accept deposits from, acquire Stock in, and generally engage in any kind of banking, trust, financial advisory, underwriting, or other business with Borrowers and their Subsidiaries and Affiliates and any other Person party to any Loan Document as though Agent were not Agent hereunder, and, in each case, without notice to or consent of the other members of the Lender Group. The terms “Lender” and “Lenders” include Agent in its individual capacity.

15.09 Assignment by Agent; Resignation of Agent; Successor Agent .

 

123


(a) Agent may resign as Agent upon thirty (30) days’ notice to the Lenders (or such lesser period agreed to by the Required Lenders). If Agent resigns under this Agreement, Agent may appoint, with the consent of the Required Lenders, a successor Agent. If no successor Agent is appointed prior to the effective date of the resignation of Agent, the Required Lenders may appoint a successor Agent from among the Lenders or may appoint another Person as a successor Agent. Upon the acceptance of its appointment as successor Agent hereunder, such successor Agent shall succeed to all the rights, powers and duties of the retiring Agent and the term “Agent” shall mean such successor Agent, and the retiring Agent’s appointment, powers and duties as Agent shall be terminated. If no successor Agent has accepted appointment as Agent by the date which is 30 days (or such lesser period agreed to by the Required Lenders) following a retiring Agent’s notice of resignation, the retiring Agent’s resignation shall nevertheless thereupon become effective and the Required Lenders shall perform all of the duties of Agent hereunder (and all payments, communications and determinations provided to be made by, to or through Agent shall instead be made by or to each Lender directly) until such time, if any, as the Required Lenders appoint a successor Agent as provided for above.

(b) Upon (i) an assignment permitted by Section  15.09(a) above, or (ii) the acceptance of a successor’s appointment as Agent pursuant to Section  15.09(a) above, such successor shall succeed to and become vested with all of the rights, powers, privileges and duties of the retiring (or retired) Agent, and the retiring Agent shall be discharged from all of its duties and obligations hereunder and under the other Loan Documents (if not already discharged therefrom as provided above in this Section  15.09 ). The fees payable by Borrowers to a successor Agent shall be the same as those payable to its predecessor unless otherwise agreed between Borrowers and such successor. After the retiring Agent’s resignation hereunder and under the other Loan Documents, the provisions of this Article  XV and Section  15.09 shall continue in effect for the benefit of such retiring Agent and its agents and subagents and its Third Party Agents in respect of any actions taken or omitted to be taken by any of them while the retiring Agent was acting or was continuing to act as Agent.

(c) Notwithstanding anything to the contrary in any of the Loan Documents, any Third Party Agent that becomes the Agent or a subagent of Agent and any delegation, assignment or other transfer of duties, responsibilities or rights of Agent to any Third Party Agent, in each case, does not require the consent of any Person (other than Agent) and shall be permitted at all times under the Loan Documents.

15.10 Lender in Individual Capacity . Any Lender and its respective Affiliates may make loans to, issue letters of credit for the account of, accept deposits from, acquire Stock in and generally engage in any kind of banking, trust, financial advisory, underwriting, or other business with Borrowers and their Subsidiaries and Affiliates and any other Person party to any Loan Documents as though such Lender were not a Lender hereunder without notice to or consent of the other members of the Lender Group.

15.11 Collateral Matters .

(a) Lenders irrevocably authorize Agent, at its sole option and in its sole discretion, to release any Lien granted to or held by Agent under any Loan Document (a) upon termination of all of the Commitments and payment in full in cash of all Obligations; (b) constituting property sold or disposed of as part of or in connection with any disposition permitted by Section  6.04 that is not to another Loan Party (it being understood and agreed that Agent may (but is not required to) conclusively rely without further inquiry on a certificate of an Authorized Officer as to the sale or other disposition of property being made in full compliance with Section  6.04 and the other provisions of the Loan Documents); or (c) in connection with a credit bid or purchase authorized under this Section  15.11 . Upon request by

 

124


Agent at any time, Lenders will confirm Agent’s authority to release particular types or items of Collateral pursuant to this Section  15.11 .

(b) The Loan Parties and the members of the Lender Group hereby irrevocably authorize Agent, based upon the instruction of the Required Lenders, to (A) consent to, credit bid or purchase (either directly or indirectly through one or more entities) all or any portion of the Collateral at any sale thereof conducted under the provisions of the Bankruptcy Code, including Section 363 of the Bankruptcy Code, (B) credit bid or purchase (either directly or indirectly through one or more entities) all or any portion of the Collateral at any sale or other disposition thereof conducted under the provisions of the Code, including pursuant to Sections 9-610 or 9-620 of the Code, or (C) credit bid or purchase (either directly or indirectly through one or more entities) all or any portion of the Collateral at any other sale or foreclosure conducted or consented to by Agent in accordance with applicable law in any judicial action or proceeding or by the exercise of any legal or equitable remedy. In connection with any such credit bid or purchase, (1) the Obligations owed to the Lenders shall be entitled to be, and shall be, credit bid on a ratable basis (with Obligations with respect to contingent or unliquidated claims being estimated for such purpose if the fixing or liquidation thereof would not impair or unduly delay the ability of Agent to credit bid or purchase at such sale or other disposition of the Collateral and, if such contingent or unliquidated claims cannot be estimated without impairing or unduly delaying the ability of Agent to credit bid at such sale or other disposition, then such claims shall be disregarded, not credit bid, and not entitled to any interest in the Collateral that is the subject of such credit bid or purchase) and the Lenders whose Obligations are credit bid shall be entitled to receive interests (ratably based upon the proportion of their Obligations credit bid in relation to the aggregate amount of Obligations so credit bid) in the Collateral that is the subject of such credit bid or purchase (or in the Stock of the any entities that are used to consummate such credit bid or purchase), and (2) Agent, based upon the instruction of the Required Lenders, may accept non-cash consideration, including debt and equity securities issued by any entities used to consummate such credit bid or purchase and in connection therewith Agent may reduce the Obligations owed to the Lenders (ratably based upon the proportion of their Obligations credit bid in relation to the aggregate amount of Obligations so credit bid) based upon the value of such non-cash consideration. Except as provided above, Agent will not execute and deliver a release of any Lien on any Collateral without the prior written authorization of (y) if the release is of all or substantially all of the Collateral, all of the Lenders, or (z) otherwise, the Required Lenders. Upon request by Agent at any time, the Lenders will confirm in writing Agent’s authority to release any such Liens on particular types or items of Collateral pursuant to this Section  15.11 ; provided , that (x) anything to the contrary contained in any of the Loan Documents notwithstanding, Agent shall not be required to execute any document or take any action necessary to evidence such release on terms that, in Agent’s opinion, could expose Agent to liability or create any obligation or entail any consequence other than the release of such Lien without recourse, representation, or warranty, and (y) such release shall not in any manner discharge, affect, or impair the Obligations or any Liens (other than those expressly released) upon (or obligations of Borrowers and the other Loan Parties in respect of) any and all interests retained by Borrowers and the other Loan Parties, including, the proceeds of any sale, all of which shall continue to constitute part of the Collateral. Each Lender further hereby irrevocably authorizes Agent, at its option and in its sole discretion, to subordinate any Lien granted to or held by Agent under any Loan Document to the holder of any Permitted Lien on such property if such Permitted Lien secures Permitted Purchase Money Indebtedness.

(c) Agent shall have no obligation whatsoever to any of the Lenders (i) to verify or assure that the Collateral exists or is owned by Borrowers, the other Loan Parties or their Subsidiaries or is cared for, protected, or insured or has been encumbered, (ii) to verify or assure that Agent’s Liens have been properly or sufficiently or lawfully created, perfected, protected, or enforced or are entitled to any particular priority, (iii) to verify or assure that any particular items of Collateral meet the eligibility

 

125


criteria applicable in respect thereof, (iv) to impose, maintain, increase, reduce, implement, or eliminate any particular reserve hereunder or to determine whether the amount of any reserve is appropriate or not, or (v) to exercise at all or in any particular manner or under any duty of care, disclosure or fidelity, or to continue exercising, any of the rights, authorities and powers granted or available to Agent pursuant to any of the Loan Documents, it being understood and agreed that in respect of the Collateral, or any act, omission, or event related thereto, subject to the terms and conditions contained herein, Agent may act in any manner it may deem appropriate, in its sole discretion given Agent’s own interest in the Collateral in its capacity as one of the Lenders and that Agent shall have no other duty or liability whatsoever to any Lender as to any of the foregoing, except as otherwise expressly provided herein.

15.12 Restrictions on Actions by Lenders; Sharing of Payments .

(a) Each of the Lenders agrees that it shall not, without the express written consent of Agent, and that it shall, to the extent it is lawfully entitled to do so, upon the written request of Agent, set off against the Obligations, any amounts owing by such Lender to Borrowers, the other Loan Parties or their Subsidiaries or any deposit accounts of Borrowers, the other Loan Parties or their Subsidiaries now or hereafter maintained with such Lender. Each of the Lenders further agrees that it shall not, unless specifically requested to do so in writing by Agent, take or cause to be taken any action, including, the commencement of any legal or equitable proceedings to enforce any Loan Document against Borrowers or any Guarantor or to foreclose any Lien on, or otherwise enforce any security interest in, any of the Collateral.

(b) If, at any time or times any Lender shall receive (i) by payment, foreclosure, setoff, or otherwise, any proceeds of Collateral or any payments with respect to the Obligations, except for any such proceeds or payments received by such Lender from Agent pursuant to the terms of this Agreement, or (ii) payments from Agent in excess of such Lender’s Pro Rata Share of all such distributions by Agent, such Lender promptly shall (A) turn the same over to Agent, in kind, and with such endorsements as may be required to negotiate the same to Agent, or in immediately available funds, as applicable, for the account of all of the Lenders and for application to the Obligations in accordance with the applicable provisions of this Agreement, or (B) purchase, without recourse or warranty, an undivided interest and participation in the Obligations owed to the other Lenders so that such excess payment received shall be applied ratably as among the Lenders in accordance with their Pro Rata Shares; provided , that to the extent that such excess payment received by the purchasing party is thereafter recovered from it, those purchases of participations shall be rescinded in whole or in part, as applicable, and the applicable portion of the purchase price paid therefor shall be returned to such purchasing party, but without interest except to the extent that such purchasing party is required to pay interest in connection with the recovery of the excess payment.

15.13 Agency for Perfection . Agent and each other member of the Lender Group hereby appoint each other member of the Lender Group and any Third Party Agent as agent for the purpose of perfecting Agent’s security interest and Liens in the Collateral and assets which, in accordance with the Uniform Commercial Code in any applicable jurisdiction, can be perfected by possession or control. Should any member of the Lender Group (other than Agent) obtain possession or control of any such assets, such member of the Lender Group shall notify Agent thereof, and, promptly upon Agent’s request therefor, shall deliver such assets to Agent or in accordance with Agent’s instructions or transfer control to Agent in accordance with Agent’s instructions. Each member of the Lender Group (other than Agent) agrees that it will not have any right individually to enforce or seek to enforce any Loan Document or to realize upon any Collateral unless instructed to do so by Agent (or consented to by Agent), it being understood and agreed by the members of the Lender Group that such rights and remedies may be exercised only by Agent.

 

126


15.14 Payments by Agent to the Lenders . All payments to be made by Agent (or any Third Party Agent) to the Lenders shall be made by bank wire transfer of immediately available funds pursuant to such wire transfer instructions as each party may designate for itself by written notice to Agent (or such Third Party Agent). Concurrently with each such payment, Agent (or, during any Third Party Agent Retention Period, the Third Party Agent with the approval of Agent) shall identify whether such payment (or any portion thereof) represents principal, premium, fees, interest or other amounts of the Obligations.

15.15 Concerning the Collateral and Related Loan Documents . Each member of the Lender Group authorizes and directs Agent to enter into this Agreement and the other Loan Documents. Each member of the Lender Group agrees that any action taken by Agent in accordance with the terms of this Agreement or the other Loan Documents relating to the Collateral and the exercise by Agent of its powers set forth therein or herein, together with such other powers that are reasonably incidental thereto, shall be binding upon all of the members of the Lender Group.

15.16 Several Obligations; No Liability . Notwithstanding that certain of the Loan Documents now or hereafter may have been or will be executed only by or in favor of Agent in its capacity as such, and not by or in favor of the Lenders, any and all obligations on the part of Agent (if any) to make any credit available hereunder shall constitute the several (and not joint) obligations of the respective Lenders on a ratable basis, according to their respective Commitments, to make an amount of such credit not to exceed, in principal amount, at any one time outstanding, the amount of their respective Commitments. Nothing contained herein shall confer upon any Lender any interest in, or subject any Lender to any liability for, or in respect of, the business, assets, profits, losses, or liabilities of any other Lender. Each Lender shall be solely responsible for notifying its Participants of any matters relating to the Loan Documents to the extent any such notice may be required, and no Lender shall have any obligation, duty, or liability to any Participant of any other Lender. Except as provided in Section  15.07 , no member of the Lender Group shall have any liability for the acts of any other member of the Lender Group. No Lender shall be responsible to Borrowers, any other Loan Party, any of their Subsidiaries or Affiliates or any other Person for any failure by any other Lender to fulfill its obligations to make credit available hereunder, nor to advance for such Lender or on its behalf, nor to take any other action on behalf of such Lender hereunder or in connection with the financing contemplated herein.

15.17 Right to Request and Act on Instructions . Agent may at any time request instructions from Lenders with respect to any actions or approvals which by the terms of this Agreement or of any of the other Loan Documents Agent is permitted or desires to take or to grant, and if such instructions are promptly requested, Agent shall be absolutely entitled to refrain from taking any action or to withhold any approval and shall not be under any liability whatsoever to any Person for refraining from any action or withholding any approval under any of the Loan Documents until it shall have received such instructions from Required Lenders or all or such other portion of the Lenders as shall be prescribed by this Agreement. Without limiting the foregoing, no Lender shall have any right of action whatsoever against Agent as a result of Agent acting or refraining from acting under this Agreement or any of the other Loan Documents in accordance with the instructions of Required Lenders (or all or such other portion of the Lenders as shall be prescribed by this Agreement) and, notwithstanding the instructions of Required Lenders (or such other applicable portion of the Lenders), Agent shall have no obligation to take any action if it believes, in good faith, that such action would violate Applicable Law or exposes Agent to any liability for which it has not received satisfactory indemnification in accordance with the provisions of Section  15.07 .

 

127


ARTICLE XVI.

WITHHOLDING TAXES.

16.01 Payments .

(a) All payments by or on account of any obligation of any Loan Party under any Loan Document will be made free and clear of, and without deduction or withholding for, any present or future Taxes except as otherwise required by applicable law, and in the event any deduction or withholding of Indemnified Taxes is required, Borrowers shall comply with the next sentence of this Section  16.01 . If any Applicable Law requires the deduction or withholding of any Tax from any such payment by a Withholding Agent, then (a) the applicable Withholding Agent shall be entitled to make such deduction or withholding and shall timely pay the full amount deducted or withheld to the relevant Governmental Authority in accordance with Applicable Law, and (b) if such Taxes are Indemnified Taxes, then the sum payable by the applicable Loan Party shall be increased as necessary so that after such deduction or withholding has been made (including such deductions and withholdings applicable to additional sums payable under this Section  16.01 ) the applicable Recipient receives an amount equal to the sum it would have received had no such deduction or withholding been made. Borrowers will furnish to Agent (including any Third Party Agent) and the Lenders as promptly as possible after the date the payment of any Indemnified Tax is due pursuant to Applicable Law, the original or certified copy of tax receipts issued by such Governmental Authority evidencing such payment by Borrowers, a copy of the return reporting such payment or other evidence of such payment reasonably satisfactory to Agent and the Lenders. Borrowers agree to pay any present or future stamp, value added or documentary Taxes or any other excise or property Taxes, charges, or similar levies that arise from any payment made hereunder or from the execution, delivery, performance, recordation, or filing of, or otherwise with respect to this Agreement or any other Loan Document.

(b) Borrowers shall reimburse and indemnify, within ten days after receipt of demand therefor, each Recipient for all Indemnified Taxes (including all Indemnified Taxes imposed on amounts payable under this Section  16.01(b) ) paid or payable by such Recipient, whether or not such Indemnified Taxes were correctly or legally asserted. A certificate of the applicable Recipient(s) setting forth the amounts to be paid thereunder and delivered to the Borrowers shall be conclusive, absent manifest error.

16.02 Exemptions .

(a) If a Lender or Participant is entitled to claim an exemption or reduction from United States withholding tax, such Lender or Participant agrees with and in favor of Agent, to deliver to Agent (or, in the case of a Participant, to the Lender granting the participation only) one of the following before receiving its first payment under this Agreement:

(i) if such Lender or Participant is entitled to claim an exemption from United States withholding tax pursuant to the portfolio interest exception, (A) a statement (a “ Portfolio Interest Certificate ”) of the Lender or Participant, signed under penalty of perjury, that it is not a (I) a “bank” as described in Section 881(c)(3)(A) of the IRC, (II) a 10% shareholder of Borrowers (within the meaning of Section 871(h)(3)(B) of the IRC), or (III) a controlled foreign corporation related to Borrowers within the meaning of Section 864(d)(4) of the IRC, and (B) a properly completed and executed IRS Form W-8BEN, Form W-8BEN-E or Form W-8IMY (with proper attachments). If such Lender or Participant is a partnership and one or more direct or indirect partners of such Lender or Participant are claiming the portfolio interest exemption, such Lender or Participant may provide a Portfolio Interest Certificate on behalf of such partners.

 

128


(ii) if such Lender or Participant is entitled to claim an exemption from, or a reduction of, withholding tax under a United States tax treaty, a properly completed and executed copy of IRS Form W-8BEN or Form W-8BEN-E;

(iii) if such Lender or Participant is entitled to claim that interest paid under this Agreement is exempt from United States withholding tax because it is effectively connected with a United States trade or business of such Lender, a properly completed and executed copy of IRS Form W-8ECI;

(iv) if such Lender or Participant is entitled to claim that interest paid under this Agreement is exempt from United States withholding tax because such Lender or Participant serves as an intermediary, a properly completed and executed copy of IRS Form W-8IMY (with proper attachments);

(v) a properly completed and executed copy of any other form or forms, including IRS Form W-9, as may be required under the IRC or other laws of the United States as a condition to exemption from, or reduction of, United States withholding or backup withholding tax; or

(vi) a properly completed form or forms, and other required documentation (to be designated under Sections 1471 and 1472 of the IRC) to claim an exemption from any withholding tax imposed under FATCA.

(b) Each Lender or Participant shall provide new forms (or successor forms) to Agent (or, in the case of a Participant, to the Lender granting the participation only) at the time or times reasonably requested by Agent (or, in the case of a Participant, the Lender granting the participation only), but only if such Lender or such Participant is legally able to deliver such forms, and shall promptly notify of any change in circumstances which would modify or render invalid any claimed exemption or reduction.

(c) If a Lender or Participant claims an exemption from withholding tax in a jurisdiction other than the United States, such Lender or such Participant agrees with and in favor of Agent, to deliver to Agent (or, in the case of a Participant, to the Lender granting the participation only) any such form or forms, as may be required under the laws of such jurisdiction as a condition to exemption from, or reduction of, foreign withholding or backup withholding tax before receiving its first payment under this Agreement, and at the time or times reasonably requested by Agent, but only if such Lender or such Participant is legally able to deliver such forms, provided , that nothing in this Section  16.02(c) shall require a Lender or Participant to disclose any information that it deems to be confidential (including without limitation, its tax returns). Each Lender and each Participant shall provide new forms (or successor forms) and shall promptly notify Agent (or, in the case of a Participant, to the Lender granting the participation only) of any change in circumstances which would modify or render invalid any claimed exemption or reduction.

(d) If a Lender or Participant claims exemption from, or reduction of, withholding tax and such Lender or Participant sells, assigns, grants a participation in, or otherwise transfers all or part of the Obligations of Borrowers and the other Loan Parties to such Lender or Participant, such Lender or Participant agrees to notify Agent (or, in the case of a sale of a participation interest, to the Lender granting the participation only) of the percentage amount in which it is no longer the beneficial owner of Obligations of Borrowers and the other Loan Parties to such Lender or Participant. To the extent of such percentage amount, Agent will treat such Lender’s or such Participant’s documentation provided pursuant to Section  16.02(a) or 16.02(c) as no longer valid. With respect to such percentage amount, such Participant or Assignee may provide new documentation, pursuant to Section  16.02(a) or 16.02(c) , if applicable. Borrowers and the other Loan Parties agree that each Participant shall be entitled to the

 

129


benefits of this Article XVI with respect to its participation in any portion of the Commitments and the Obligations so long as such Participant complies with the obligations set forth in this Article XVI with respect thereto.

(e) If a payment made to a Lender under any Loan Document would be subject to U.S. federal withholding Tax imposed by FATCA if such Lender were to fail to comply with the applicable reporting requirements of FATCA (including those contained in Section 1471(b) or 1472(b) of the IRC, as applicable), such Lender shall deliver to Agent (or, in the case of a Participant, to the Lender granting the participation only) at the time or times prescribed by law and at such time or times reasonably requested by Agent (or, in the case of a Participant, the Lender granting the participation) such documentation prescribed by applicable law (including as prescribed by Section 1471(b)(3)(C)(i) of the IRC) and such additional documentation reasonably requested by Agent (or, in the case of a Participant, the Lender granting the participation) as may be necessary for Agent or Borrowers to comply with their obligations under FATCA and to determine that such Lender has complied with such Lender’s obligations under FATCA or to determine the amount to deduct and withhold from such payment. Solely for purposes of this clause (e), “FATCA” shall include any amendments made to FATCA after the date of this Agreement.

16.03 Refunds . If Agent or a Lender determines, in its sole discretion, that it has received a refund of any Indemnified Taxes to which Borrowers have paid additional amounts pursuant to this Article XVI , so long as no Default or Event of Default has occurred and is continuing, it shall pay over such refund to Borrowers (but only to the extent of payments made, or additional amounts paid, by Borrowers under this Article XVI with respect to Indemnified Taxes giving rise to such a refund), net of all out-of-pocket expenses of Agent or such Lender and without interest (other than any interest paid by the applicable Governmental Authority with respect to such a refund); provided , that Borrowers, upon the request of Agent or such Lender, agree to repay the amount paid over to Borrowers (plus any penalties, interest or other charges, imposed by the applicable Governmental Authority, other than such penalties, interest or other charges imposed as a result of the willful misconduct or gross negligence of Agent hereunder) to Agent or such Lender in the event Agent or such Lender is required to repay such refund to such Governmental Authority. Notwithstanding anything in this Agreement to the contrary, this Article XVI shall not be construed to require Agent or any Lender to make available its tax returns (or any other information which it deems confidential) to Borrowers, the other Loan Parties, their Subsidiaries, their Affiliates or any other Person.

ARTICLE XVII.

GENERAL PROVISIONS.

17.01 Effectiveness . This Agreement shall be binding and deemed effective when executed by Borrowers, Agent, and each Lender whose signature is provided for on the signature pages hereof.

17.02 Article and Section Headings . Headings and numbers have been set forth herein for convenience only. Unless the contrary is compelled by the context, everything contained in each Article and Section applies equally to this entire Agreement.

17.03 Interpretation . Neither this Agreement nor any uncertainty or ambiguity herein shall be construed against the Lender Group or Borrowers, whether under any rule of construction or otherwise. On the contrary, this Agreement has been reviewed by all parties and shall be construed and interpreted according to the ordinary meaning of the words used so as to accomplish fairly the purposes and intentions of all parties hereto.

 

130


17.04 Severability of Provisions . Each provision of this Agreement shall be severable from every other provision of this Agreement for the purpose of determining the legal enforceability of any specific provision.

17.05 Debtor-Creditor Relationship . The relationship between the members of the Lender Group, on the one hand, and the Loan Parties, on the other hand, is solely that of creditor and debtor. No member of the Lender Group has (or shall be deemed to have) any fiduciary relationship or duty to any Loan Party arising out of or in connection with the Loan Documents or the transactions contemplated thereby, and there is no agency or joint venture relationship between the members of the Lender Group, on the one hand, and the Loan Parties, on the other hand, by virtue of any Loan Document or any transaction contemplated therein.

17.06 Counterparts; Electronic Execution . This Agreement may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, shall be deemed to be an original, and all of which, when taken together, shall constitute but one and the same Agreement. Delivery of an executed counterpart of this Agreement by telefacsimile or other electronic method of transmission shall be equally as effective as delivery of an original executed counterpart of this Agreement. Any party delivering an executed counterpart of this Agreement by telefacsimile or other electronic method of transmission also shall deliver an original executed counterpart of this Agreement but the failure to deliver an original executed counterpart shall not affect the validity, enforceability, and binding effect of this Agreement. The foregoing shall apply to each other Loan Document mutatis mutandis .

17.07 Revival and Reinstatement of Obligations; Certain Waivers . If any member of the Lender Group repays, refunds, restores, or returns in whole or in part, any payment or property (including any proceeds of Collateral) previously paid or transferred to such member of the Lender Group in full or partial satisfaction of any Obligation or on account of any other obligation of any Loan Party under any Loan Document, because the payment, transfer, or the incurrence of the obligation so satisfied is asserted or declared to be void, voidable, or otherwise recoverable under any law relating to creditors’ rights, including provisions of the Bankruptcy Code relating to fraudulent transfers, preferences, or other voidable or recoverable obligations or transfers (each, a “ Voidable Transfer ”), or because such member of the Lender Group elects to do so on the reasonable advice of its counsel in connection with a claim that the payment, transfer, or incurrence is or may be a Voidable Transfer, then, as to any such Voidable Transfer, or the amount thereof that such member of the Lender Group elects to repay, restore, or return (including pursuant to a settlement of any claim in respect thereof), and as to all reasonable costs, expenses, and attorneys’ fees of such member of the Lender Group related thereto, the liability of the Loan Parties with respect to the amount or property paid, refunded, restored, or returned will automatically and immediately be revived, reinstated, and restored and will exist. If, prior to any of the foregoing, any provision of this Agreement or any other Loan Document shall have been terminated or cancelled, such provision of this Agreement or such other Loan Document, shall be reinstated in full force and effect and such prior release, termination, cancellation or surrender shall not diminish, release, discharge, impair or otherwise affect the obligation of any Loan Party in respect of such liability or any Collateral securing such liability.

17.08 Confidentiality .

(a) Each of the Agent and the Lenders agrees to maintain the confidentiality of the Information (as defined below), except that Information may be disclosed (a) to its Affiliates and to the Agent-Related Persons and Lender-Related Persons (it being understood that the Persons to whom such disclosure is made will be informed of the confidential nature of such Information and instructed to keep

 

131


such Information confidential), (b) to the extent required or requested by any regulatory authority purporting to have jurisdiction over such Person, the Agent-Related Persons or Lender-Related Persons (including any self-regulatory authority), (c) to the extent required by Applicable Laws or regulations or by any subpoena or similar legal process, (d) to any member of the Lender Group or any other party hereto, (e) in connection with the exercise of any remedies hereunder or under any other Loan Document or any action or proceeding relating to this Agreement or any other Loan Document or the enforcement of rights hereunder or thereunder, (f) subject to an agreement containing provisions substantially the same as those of this Section  17.08 , to (i) any Assignee of or Participant in, or any prospective assignee of or Participant in, any of its rights and obligations under this Agreement or the other Loan Documents or (ii) any actual or prospective party (or the Agent-Related Persons or the Lender-Related Persons or any Related Party) to any transaction under which payments are to be made by reference to the Loan Parties and their obligations, this Agreement, the other Loan Documents or payments hereunder or thereunder, (g) on a confidential basis to (i) any rating agency in connection with rating any Loan Party or its Subsidiaries or the credit facilities provided hereunder or (ii) the CUSIP Service Bureau or any similar agency in connection with the issuance and monitoring of CUSIP numbers or other market identifiers with respect to the credit facilities provided hereunder, (h) with the consent of any Loan Party or any of its Affiliates, (i) to the extent such Information (x) becomes publicly available other than as a result of a breach of this Section  17.08(a) or (y) becomes available to any member of the Lender Group or any of its Affiliates on a nonconfidential basis from a source other than Endologix, or (j) as provided in Section  5.20 . In addition, Agent (including any Third Party Agent) and the Lenders may disclose the existence of this Agreement and the other Loan Documents and information about this Agreement and the other Loan Documents to market data collectors, similar service providers to the lending industry and service providers to Agent (including any Third Party Agent) and the Lenders in connection with the administration of the Loans and other Obligations and this Agreement and the other Loan Documents

(b) For purposes of this Section, “ Information ” means all information received from a Loan Party relating to the Loan Parties or any Subsidiary thereof or any of their respective businesses, other than any such information that is available to the Agent, any Lender or any other member of the Lender Group on a nonconfidential basis prior to disclosure by such Loan Party or any Subsidiary of such Loan Party; provided that, notwithstanding anything to the contrary in the Loan Documents, in the case of information received from the Borrowers, the Loan Parties or any of their Subsidiaries after the Closing Date, such Information is both (y) clearly identified at the time of delivery as confidential and (z) provided to Agent and the Lenders at a time when Agent and such Lenders have requested in writing to receive material nonpublic information. Any Person required to maintain the confidentiality of Information as provided in this Section  17.08 shall be considered to have complied with its obligation to do so if such Person has exercised the same degree of care to maintain the confidentiality of such Information as such Person would accord to its own confidential information.

17.09 Survival . All representations and warranties made by the Loan Parties in the Loan Documents and in the certificates or other instruments delivered in connection with or pursuant to this Agreement or any other Loan Document shall be considered to have been relied upon by the other parties hereto and shall survive the execution and delivery of the Loan Documents and the making of any Loans and the providing of the Commitments, regardless of any investigation made by any such other party or on its behalf and notwithstanding that Agent, any Third Party Agent, any Lender or any other member of the Lender Group may have had notice or knowledge of any Default or Event of Default or incorrect representation or warranty at the time any credit is extended hereunder, and shall continue in full force and effect as long as the principal of, or any accrued interest on, any Loan or any fee or any other amount payable under this Agreement or any of the other Loan Documents or any other Obligations are outstanding or unpaid and so long as all of the Commitments have not expired or been terminated.

 

132


17.10 Patriot Act . Agent (including any Third Party Agent) and each Lender that is subject to the requirements of the Patriot Act hereby notifies Borrowers that pursuant to the requirements of the Act, they are required to obtain, verify and record information that identifies the Loan Parties, which information includes the names, address and tax identification numbers of the Loan Parties and other information that will allow Agent (or such Third Party Agent) or such Lender to identify the Loan Parties in accordance with the Patriot Act. In addition, if Agent (including any Third Party Agent) or any Lender is required by law or regulation or internal policies to do so, it shall have the right to periodically conduct (a) Patriot Act searches, OFAC/PEP searches, and customary individual background checks for the Loan Parties and (b) OFAC/PEP searches and customary individual background checks for the Loan Parties’ senior management and key principals, and Borrowers and the other Loan Parties agree to cooperate in respect of the conduct of such searches and further agree that the reasonable costs and charges for such searches shall constitute Lender Group Expenses hereunder and be for the account of Borrowers and the other Loan Parties. This notice is given in accordance with the requirements of the Patriot Act and is effective for Agent.

17.11 Integration . This Agreement, together with the other Loan Documents, reflects the entire understanding of the parties with respect to the transactions contemplated hereby and shall not be contradicted or qualified by any other agreement, oral or written, before the date hereof.

17.12 No Setoff . All payments made by each Loan Party hereunder or under any note or other Loan Document will be made in immediately available funds and without setoff, counterclaim, or other defense.

17.13 Intercreditor Agreement . Notwithstanding anything to the contrary in this Agreement or in any other Loan Document: (i) the Liens granted to the Agent pursuant to the Loan Documents and the exercise of any right related to any Collateral shall be subject, in each case, to the terms of the Intercreditor Agreement, (ii) in the event of any conflict between the express terms and provisions of this Agreement or any other Loan Document, on the one hand, and of the Intercreditor Agreement, on the other hand, the terms and provisions of the Intercreditor Agreement, shall control, and (iii) each Lender hereunder authorizes and instructs Agent to execute the Intercreditor Agreement on behalf of such Lender, and such Lender agrees to be bound by the terms thereof.

[Signature pages to follow.]

 

133


IN WITNESS WHEREOF , the parties hereto have caused this Agreement to be executed and delivered as of the date first above written.

 

BORROWERS:      ENDOLOGIX, INC., a Delaware corporation
     By:  

/s/ Vaseem Mahboob

       Name: Vaseem Mahboob
       Title: Chief Financial Officer
     CVD/RMS ACQUISITION CORP., a Delaware corporation
     By:  

/s/ Vaseem Mahboob

       Name: Vaseem Mahboob
       Title: Chief Financial Officer and Secretary
     NELLIX, INC., a Delaware corporation
     By:  

/s/ Vaseem Mahboob

       Name: Vaseem Mahboob
       Title: Chief Financial Officer and Secretary
     TRIVASCULAR TECHNOLOGIES, INC., a Delaware corporation
     By:  

/s/ Vaseem Mahboob

       Name: Vaseem Mahboob
       Title: Chief Financial Officer and Secretary
     TRIVASCULAR, INC., a California corporation
     By:  

/s/ Vaseem Mahboob

       Name: Vaseem Mahboob
       Title: Chief Financial Officer and Secretary

ABL Credit Agreement


TRIVASCULAR SALES LLC, a Texas limited liability company
By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer and Secretary
ENDOLOGIX CANADA, LLC, a Delaware limited liability company
By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer and Secretary
RMS/ENDOLOGIX SIDEWAYS MERGER CORP., a Delaware corporation
By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer and Secretary

ABL Credit Agreement


 

DEERFIELD ELGX REVOLVER, LLC, a Delaware limited liability company, as Agent
By: Deerfield Management Company, L.P. (Series C), Manager
By: Flynn Management LLC, General Partner
By:  

/s/ David J. Clark

Name:   David J. Clark
Title:   Authorized Signatory

ABL Credit Agreement


DEERFIELD PRIVATE DESIGN FUND IV, L.P., as a Lender
By: Deerfield Mgmt IV, L.P., General Partner
By: J.E. Flynn Capital IV, LLC, General Partner
By:  

/s/ David J. Clark

Name:   David J. Clark
Title:   Authorized Signatory
DEERFIELD PRIVATE DESIGN FUND III, L.P., as a Lender
By: Deerfield Mgmt III, L.P., General Partner
By: J.E. Flynn Capital III, LLC, General Partner
By:  

/s/ David J. Clark

Name:   David J. Clark
Title:   Authorized Signatory
DEERFIELD PARTNERS, L.P., as a Lender
By: Deerfield Mgmt, L.P., General Partner
By: J.E. Flynn Capital, LLC, General Partner
By:  

/s/ David J. Clark

Name:   David J. Clark
Title:   Authorized Signatory

ABL Credit Agreement


EXHIBIT A-1

FORM OF ASSIGNMENT AND ACCEPTANCE AGREEMENT

This ASSIGNMENT AND ACCEPTANCE AGREEMENT (“ Assignment Agreement ”) is entered into as of                                                                           between                                                                               (“ Assignor ”) and                                                                       (“ Assignee ”). Reference is made to the Credit Agreement described in Annex I hereto (the “ Credit Agreement ”). Capitalized terms used herein and not otherwise defined shall have the meanings ascribed to them in the Credit Agreement.

1. In accordance with the terms and conditions of Article XIII of the Credit Agreement, the Assignor hereby sells and assigns to the Assignee, and the Assignee hereby purchases and assumes from the Assignor, that interest in and to the Assignor’s rights and obligations under the Loan Documents as of the date hereof with respect to the Obligations owing to the Assignor, and Assignor’s portion of the Commitments, all to the extent specified on Annex I (the “ Assigned Interest ”).

2. The Assignor (a) represents and warrants that (i) it is the legal and beneficial owner of the interest being assigned by it hereunder and that such interest is free and clear of any lien, encumbrance or other adverse claim and (ii) it has full power and authority, and has taken all action necessary, to execute and deliver this Assignment Agreement and to consummate the transactions contemplated hereby; (b) makes no representation or warranty and assumes no responsibility with respect to (i) any statements, representations or warranties made in or in connection with the Loan Documents, or (ii) the execution, legality, validity, enforceability, genuineness, sufficiency or value of the Loan Documents or any other instrument or document furnished pursuant thereto; (c) makes no representation or warranty and assumes no responsibility with respect to the financial condition of any Borrower, its Subsidiaries or any Guarantor or the performance or observance by any Borrower, its Subsidiaries or any Guarantor of any of their respective obligations under the Loan Documents or any other instrument or document furnished pursuant thereto, and (d) represents and warrants that the amount set forth as the Purchase Price on Annex I represents the amount owed by the Borrowers to Assignor with respect to Assignor’s share of the Revolving Loans assigned hereunder, as reflected on Assignor’s books and records.

3. The Assignee (a) represents and warrants that (i) it has full power and authority, and has taken all action necessary, to execute and deliver this Assignment Agreement and to consummate the transactions contemplated hereby; (ii) it satisfies the requirements, if any, specified in the Credit Agreement that are required to be satisfied by it in order to acquire the Assigned Interest and become a Lender (including, without limitation, the requirements set forth in Section  13.01 of the Credit Agreement); (iii) from and after the Effective Date, it shall be bound by the provisions of the Credit Agreement as a Lender thereunder and, to the extent of the Assigned Interest, shall have the obligations of a Lender thereunder; (iv) it is sophisticated with respect to decisions to acquire assets of the type represented by the assigned interest and either it, or the person exercising discretion in making its decision to acquire such assigned interest, is experienced in acquiring assets of such type; (b) confirms that it has received copies of the Credit Agreement and the other Loan Documents, together with copies of the financial statements referred to therein and such other documents and information as it has deemed appropriate to make its own credit analysis and decision to enter into this Assignment Agreement; (c) agrees that it will, independently and without reliance upon Agent, Assignor, or any other Lender, based upon such documents and information as it shall deem appropriate at the time, continue to make its own credit decisions in taking or not taking any action under the Loan Documents; (d) appoints and authorizes the Agent to take such action as agent on its behalf and to exercise such powers under the Loan Documents as are delegated to Agent by the terms thereof, together with such powers as are reasonably


incidental thereto; (e) agrees that it will perform in accordance with their terms all of the obligations which by the terms of the Loan Documents are required to be performed by it as a Lender; [ and (f)  attaches the forms prescribed by the Internal Revenue Service of the United States certifying as to the Assignee’s status for purposes of determining exemption from United States withholding taxes with respect to all payments to be made to the Assignee under the Credit Agreement or such other documents as are necessary to indicate that all such payments are subject to such rates at a rate reduced by an applicable tax treaty. ]

4. Following the execution of this Assignment Agreement by the Assignor and Assignee, the Assignor will deliver this Assignment Agreement to the Agent for recording by the Agent. The effective date of this Assignment (the “ Settlement Date ”) shall be the latest to occur of (a) the date of the execution and delivery hereof by the Assignor and the Assignee, (b) the receipt by Agent for its sole and separate account a processing fee in the amount of $3,500 (if required by the Credit Agreement), (c) the receipt of any required consent of the Agent, and (d) the date specified in Annex I .

5. As of the Settlement Date (a) the Assignee shall be a party to the Credit Agreement and, to the extent of the interest assigned pursuant to this Assignment Agreement, have the rights and obligations of a Lender thereunder and under the other Loan Documents, and (b) the Assignor shall, to the extent of the interest assigned pursuant to this Assignment Agreement, relinquish its rights and be released from its obligations under the Credit Agreement and the other Loan Documents, provided , however , that nothing contained herein shall release any assigning Lender from obligations that survive the termination of this Agreement, including such assigning Lender’s obligations under Article XV of the Credit Agreement.

6. Upon the Settlement Date, Assignee shall pay to Assignor the Purchase Price (as set forth in Annex I ). From and after the Settlement Date, Agent shall make all payments that are due and payable to the holder of the interest assigned hereunder (including payments of principal, interest, fees and other amounts) to Assignor for amounts which have accrued up to but excluding the Settlement Date and to Assignee for amounts which have accrued from and after the Settlement Date. On the Settlement Date, Assignor shall pay to Assignee an amount equal to the portion of any interest, fee, or any other charge that was paid to Assignor prior to the Settlement Date on account of the interest assigned hereunder and that are due and payable to Assignee with respect thereto, to the extent that such interest, fee or other charge relates to the period of time from and after the Settlement Date.

7. This Assignment Agreement may be executed in counterparts and by the parties hereto in separate counterparts, each of which when so executed and delivered shall be an original, but all of which shall together constitute one and the same instrument. This Assignment Agreement may be executed and delivered by telecopier or other electronic transmission all with the same force and effect as if the same were a fully executed and delivered original manual counterpart.

8. THIS ASSIGNMENT AGREEMENT SHALL BE SUBJECT TO THE PROVISIONS REGARDING CHOICE OF LAW AND VENUE, JURY TRIAL WAIVER, AND JUDICIAL REFERENCE SET FORTH IN ARTICLE XII OF THE CREDIT AGREEMENT, AND SUCH PROVISIONS ARE INCORPORATED HEREIN BY THIS REFERENCE, MUTATIS MUTANDIS .

[Remainder of page intentionally left blank. Signature page to follow.]


IN WITNESS WHEREOF , the parties hereto have caused this Assignment Agreement and Annex I hereto to be executed by their respective officers, as of the first date written above.

 

 

 

[NAME OF ASSIGNOR]
as Assignor
 

 

 

 

By    
Name:  
Title  

 

 

 

 

[NAME OF ASSIGNOR]

as Assignor
 

 

 

 

By    
Name:  
Title  

[Signature Page to Assignment and Acceptance Agreement]


[ACCEPTED THIS          DAY OF                             

 

DEERFIELD ELGX REVOLVER, LLC ,
as Agent
By:  

 

Name:
Title:] 2

 

 

2

NTD: Agent’s consent to be provided solely to the extent required by Section  13.01 of the Credit Agreement

 

[Signature Page to Assignment and Acceptance Agreement]


ANNEX FOR ASSIGNMENT AND ACCEPTANCE

ANNEX I

Borrowers:

Endologix, Inc., a Delaware corporation

CVD/RMS Acquisition Corp., a Delaware corporation

Nellix, Inc., a Delaware corporation

TriVascular Technologies, Inc., a Delaware corporation,

TriVascular, Inc., a California corporation

TriVascular Canada, LLC, a Delaware limited liability company

TriVascular Sales, LLC, a Texas limited liability company

RMS/Endologix Sideways Merger Corp., a Delaware corporation

Name and Date of Credit Agreement:

Credit Agreement dated as of August 9, 2018 (as amended, restated, supplemented, or otherwise modified from time to time, the “ Credit Agreement ”) by and among Borrowers, the lenders party thereto as “ Lenders ”, and Deerfield ELGX Revolver, LLC, as administrative agent for each member of the Lender Group (in such capacity, together with its successors and assigns in such capacity, “ Agent ”).

 

Date of Assignment Agreement:    __________   
Amounts:      
  (a)   Assigned Amount of Revolver Commitment    $__________   
  (b)   Assigned Amount of Revolving Loans    $__________   
Settlement Date:    __________   
Purchase Price    $__________   
Notice and Payment Instructions, etc.      

 

  Assignee:    Assignor:
 

 

     

 

  
 

 

     

 

  
 

 

     

 

  


LOGO


LOGO


EXHIBIT C-1

FORM OF COMPLIANCE CERTIFICATE

This Compliance Certificate (this “ Compliance Certificate ”) is given by                                     , an Authorized Officer of Endologix, Inc., a Delaware corporation (the “ Borrower Representative ”), pursuant to that certain Credit Agreement dated as of August 9, 2018, by and among the Borrower Representative, the other Borrowers signatory thereto and any additional Borrower that may hereafter be added thereto, collectively, “ Borrowers ”), Deerfield ELGX Revolver, LLC, as Agent, and the financial institutions or other entities from time to time parties hereto, each as a Lender (as such agreement may have been amended, restated, supplemented or otherwise modified from time to time, the “ Credit Agreement ”). Capitalized terms used herein without definition shall have the meanings set forth in the Credit Agreement.

The undersigned Authorized Officer hereby certifies to Agent and Lenders that:

(a) the financial statements delivered with this Compliance Certificate in accordance with Section  5.05 of the Credit Agreement fairly present in all material respects the results of operations and financial condition of Borrowers and their Consolidated Subsidiaries as of the dates and the accounting period covered by such financial statements;

(b) I have reviewed the terms of the Credit Agreement and have made, or caused to be made under my supervision, a review in reasonable detail of the transactions and conditions of Borrowers and their Subsidiaries during the accounting period covered by such financial statements, and such review has not disclosed the existence during or at the end of such accounting period, and I have no knowledge of the existence as of the date hereof (or at any time during the term of the period covered by this Compliance Certificate), of any condition or event that constitutes a Default or an Event of Default, except as set forth in Schedule 1 hereto, which includes a description of the nature and period of existence of such Default or an Event of Default and what action Borrowers have taken, are undertaking and propose to take with respect thereto;

(c) except as noted on Schedule 2 attached hereto, (i) Schedule 4 to the Guaranty and Security Agreement contains a complete and accurate list of all business locations of Borrowers and Guarantors and all other information that is required to be included thereon in Section 4.4 of the Guaranty and Security Agreement (and without giving effect to any “Closing Date” qualifier therein) and (ii) Schedule 3 to the Guaranty and Security Agreement contains all legal names under of the Borrowers and Guarantors as they appear on their organizational documents and such other information that is required to be included thereon in Section 4.3 of the Guaranty and Security Agreement (and without giving effect to any “Closing Date” qualifier therein); and in each case of clause (i) and clause (ii) above, Schedule 2 specifically notes any changes in such locations, legal names and other information;

(d) except as noted on Schedule 3 attached hereto, the undersigned has no knowledge of (i) any federal or state Tax Liens having been filed against any Borrower, any Guarantor or any Collateral, or (ii) any failure of any Borrower or any Guarantor to make required payments of withholding or other Tax obligations of any Borrower or any Guarantor during the accounting period to which the attached statements pertain or any subsequent period;

(e) [reserved];

(f) except as noted on Schedule 4 attached hereto, Schedule 4.03 to the Credit Agreement is true, correct and complete in all material respects as it relates to the representations and warranties set


forth in Section 4.03 of the Credit Agreement (except that such materiality qualifier shall not be applicable to any such representation and warranty in Section 4.03 of the Credit Agreement that already is qualified or modified by materiality in the text thereof);

(g) [reserved];

(h) except as noted on Schedule 6 attached hereto, no Borrower or Guarantor has acquired, by purchase or otherwise, any Chattel Paper, Letter of Credit Rights, Instruments in excess of $250,000 in the aggregate, Documents or Investment Property (other than in the equity interests of Subsidiaries of the Borrowers) that has not previously been reported to Agent on any Schedule 6 to any previous Compliance Certificate delivered by Borrower Representative to Agent;

(i) except as noted on Schedule 7 attached hereto, no Borrower or Guarantor is aware of any commercial tort claim that has not previously been reported to Agent on any Schedule 7 to any previous Compliance Certificate delivered by Borrower Representative to Agent; and

(j) Borrowers and any Guarantors are in compliance with the covenants contained in Article VII of the Credit Agreement, and in any Guarantee constituting a part of the Loan Documents, as demonstrated by the calculation of such covenants set forth in Schedule  8 hereto, except as expressly set forth in Schedule  8 ; in determining such compliance, the calculations set forth therein have been made: and such calculations and the certifications contained therein are true, correct and complete.

To the extent any schedule attached hereto contains updated information, such schedule shall be amended with respect to the Credit Agreement, Guaranty and Security Agreement or the Term Credit Agreement, as applicable.

The foregoing certifications are made as of the date hereof, and the foregoing computations are made and calculated as of                                 , 20     (end of the applicable period).

 

Sincerely,
ENDOLOGIX, INC.
By: ________________________________
Name: ______________________________
Title: ______________________________


SCHEDULE 2

BUSINESS LOCATIONS; LEGAL NAMES


SCHEDULE 3

TAX


SCHEDULE 4

LITIGATION


SCHEDULE 6

CHATTEL PAPER, LETTER OF CREDIT RIGHTS, INSTRUMENTS, DOCUMENTS AND

INVESTMENT PROPERTY


SCHEDULE 7

FINANCIAL COVENANTS


1. EXHIBIT P-1

2. FORM OF PERFECTION CERTIFICATE

August 9, 2018

Each of the parties signatory hereto hereby represents and warrants to (i) the Agent (as defined in the Facility Agreement defined below) and the Lenders (as defined in the Facility Agreement defined below) with reference to that certain Amended and Restated Facility Agreement dated as of the date hereof, by and among the Loan Parties (as defined in the Facility Agreement defined below), the Lenders (as defined in the Facility Agreement defined below) party thereto, and Deerfield Private Design Fund IV, L.P., as the Agent (as amended, restated, supplemented or otherwise modified, the “ Facility Agreement ”), and (ii) the Agent (as defined in the Credit Agreement defined below) and the Lenders (as defined in the Credit Agreement defined below) with reference to that certain Credit Agreement dated as of the date hereof, by and among the Borrowers (as defined in the Credit Agreement defined below; such Borrowers, collectively with the “Loan Parties” under the Facility Agreement, are referred to as the “ Loan Parties ” herein except in clause (i) above), the Lenders (as defined in the Credit Agreement defined below) party thereto, and Deerfield ELGX Revolver, LLC, as the Agent (as amended, restated, supplemented or otherwise modified, the “ Credit Agreement ”) (terms that are not defined herein but are defined in such Facility Agreement and/or such Credit Agreement have the same meanings herein as specified therein, as applicable), as follows:

3. 1. NAMES AND OTHER ORGANIZATIONAL RELATED INFORMATION OF LOAN PARTIES AND THEIR SUBSIDIARIES

a. The name of each Loan Party and each of its Subsidiaries, as it appears in such Loan Party’s or Subsidiary’s current Certificate of Incorporation, Certificate of Formation or similar organizational document as in effect on this date, is:

 

Entity Name

  

Parent/Subsidiary

  

Sub Parent of ________________

  

Sub Parent of ________________

  

Sub Parent of ________________

b. The federal employer identification number of each Loan Party and each of its Subsidiaries is:

 

Loan Party/Subsidiary

  

Federal Employer Identification Number

  
  
  

 

6


c. The Loan Parties and their Subsidiaries, respectively, are formed under the laws of the following jurisdictions:

 

Loan Party/Subsidiary

  

State/Country

  
  
  

d. The organizational identification number of each Loan Party issued by its respective jurisdiction of formation is:

 

Loan Party

  

Organizational Identification Number

  
  
  

e. Each Loan Party, respectively, transacts business in the following jurisdictions (list jurisdictions other than jurisdictions of formation):

 

Loan Party

  

Jurisdiction(s)

  
  
  

f. Each Loan Party, respectively, is duly qualified to transact business as a foreign entity in the following jurisdictions (list jurisdictions other than jurisdictions of formation):

 

Loan Party

  

Jurisdiction(s)

  
  
  

g. The following is a list of all other names (including fictitious names, d/b/a’s, trade names or similar names and including former legal names (as defined in Section 9-503(a) of the UCC)) currently used by a Loan Party or any of its Subsidiaries or used by a Loan Party or any of its Subsidiaries within the past five years:

 

Loan Party/Subsidiary

  

Name

  

Period of Use

 

7


h. The following are the names of all entities which have been merged into any Loan Party or any of its Subsidiaries during the past five years:

 

Loan Party/Subsidiary

  

Name of Merged Entity

  

Year of Merger

     

i. The following are the names and addresses of all entities from whom any Loan Party or any of its Subsidiaries has acquired any personal property in a transaction not in the ordinary course of business during the past five years, together with the date of such acquisition and the type of personal property acquired (e.g., equipment, inventory, etc.):

 

Name

  

Address

  

Date of Acquisition

  

Type of Property

        

4. 2. LOCATIONS OF LOAN PARTIES AND THEIR SUBSIDIARIES

a. The chief executive offices of each Loan Party and each of the Loan Parties’ Subsidiaries, respectively, are presently located at the following addresses:

 

Complete Street and Mailing Address, including County and Zip Code

  

Loan Party/Subsidiary

  

b. The books and records of each Loan Party and those of their Subsidiaries, respectively, are located at the following additional addresses (complete this clause b only if different from clause a above):

 

Complete Street and Mailing Address, including Zip Code

  

Loan Party/Subsidiary

  

c. The following are all the locations where a Loan Party or any of the Loan Parties’ Subsidiaries, respectively, owns or leases, or occupies any real property:

 

Complete Mailing Address, including Zip Code

  

Leased/
Owned/
Occupied

  

Loan Party/Subsidiary

 

8


           
           

d. The following are all of the locations where a Loan Party or any of the Loan Parties’ Subsidiaries, respectively, maintains any inventory, equipment or other property:

 

Complete Address

  

Loan

Party/Subsidiary

  
  

e. The following are the names and addresses of all warehousemen, bailees, or other third-parties who have possession of any of the Loan Parties’ inventory or equipment or the inventory or equipment of any of the Loan Parties’ Subsidiaries:

 

Name

  

Complete Street and Mailing Address, including Zip Code

  

Loan Party/Subsidiary

     

5. f.The following is a complete list of all other offices or other facilities (other than those described above) where a Loan Party or any of the Loan Parties’ Subsidiaries has done business in the past 5 years.

6.

 

Complete Address

   Loan
Party/Subsidiary
7.    8.
9.    10.

11. 3. INTELLECTUAL PROPERTY

a. Set forth below is a list of all patents, copyrights, trademarks, trade names and service marks registered or for which applications are pending in the name of a Loan Party or any of the Loan Parties’ Subsidiaries, excluding those that are expired or abandoned to the extent permitted pursuant to clause (f) of the definition of “Permitted Dispositions” in each of the Facility Agreement and the Credit Agreement. Please include the name of such intellectual property, the grant date or application date, as applicable, the registration or application number, as applicable, and the country of such registration or application.

 

Loan

Party/

Subsidiary

  

Name of

Intellectual

Property

  

Registered/

Application

Pending

  

Grant/
Application

Date

  

Registration/
Application

Number

  

Country of
Registration/
Application

 

9


                          
                          

b. Set forth below is a list of all licenses, franchise or other agreements relating to trademarks, patents, copyrights and other know-how to which a Loan Party or any of the Loan Parties’ Subsidiaries is a party and that require annual payments in excess of $25,000 individually.

12. 4. INVESTMENT PROPERTY; INSTRUMENTS; ACCOUNTS

a. The following is a complete list of all stocks, bonds, debentures, notes, commodity contracts and other securities (as defined in Article 8 of the Uniform Commercial Code), owned by a Loan Party or any of the Loan Parties’ Subsidiaries:

 

Name of Issuer

  

Description and Value of Security

  

Loan Party/Subsidiary

     
     
     

b. The following are all banks and other financial institutions, securities intermediary or commodity intermediary at which any Loan Party or any of the Loan Parties’ Subsidiaries maintains deposit, securities, commodities or similar accounts, which correctly identifies the name, address and any other relevant contact information with respect to each depository or intermediary, the name in which the account is held, a description of the purpose of the account, and the complete account number therefor:

 

Bank Name

  

Address and

Other Contact

Information

  

Name in Which

Account is Held

  

Purpose of
Account

  

Complete Account
Number

           
           

c. The following are all securities or commodity intermediaries at which a Loan Party or any of the Loan Parties’ Subsidiaries maintains securities accounts or commodities accounts:

 

10


Securities or

Commodities

Intermediary

Name

  

Address and

Other Contact

Information

  

Name in Which

Account is Held

  

Purpose of
Account

  

Complete Account
Number

           

d. Does any Loan Party or any of the Loan Parties’ Subsidiaries or is it contemplated that any Loan Party or any of the Loan Parties’ Subsidiaries will regularly receive letters of credit from customers or other third parties to secure payments of sums owed to such company?

e. The following is a list of letters of credit naming a Loan Party or any of the Loan Parties’ Subsidiaries as “beneficiary” thereunder:

 

LC Number

  

Name of LC Issuer

  

LC Applicant

  

Loan
Party/
Subsidiary

        

f. The approximate aggregate total amount of funds, amounts, and other assets of any kind in the             Account is $                     .

13. 5. INDEBTEDNESS

Set forth below is a list and attached hereto are copies of, all agreements, promissory notes, indentures and other documents relating to any indebtedness for borrowed money of a Loan Party or any of the Loan Parties’ Subsidiaries, including without limitation loan agreements, note indentures, letters of credit, reimbursement agreements, mortgages and guaranties of the indebtedness for borrowed money of others.

 

Debtor

  

14. Creditor

  

15. Amount of Indebtedness
Outstanding

  

16. Maturity Date

   17.    18.    19.
   20.    21.    22.

23. 6. ENCUMBRANCES

Other than the Liens already described in Section 1.j. above, the property of the Loan Parties and/or any of the Loan Parties’ Subsidiaries is subject to the following Liens or encumbrances:

 

Loan Party/Subsidiary

  

Name of Holder of Lien

  

Description of Property Encumbered

     

 

11


     
     
     

 

7.

LITIGATION; COMMERCIAL TORT CLAIMS

a. The following is a complete list of pending and threatened litigation or claims involving amounts claimed against a Loan Party or any of the Loan Parties’ Subsidiaries in an indefinite amount or in excess of $25,000 in each case:

b. The following are the only claims (including, without limitation, commercial tort claims) which a Loan Party or any of the Loan Parties’ Subsidiaries has against others (other than claims on accounts receivable), which such Loan Party or Subsidiary is asserting or intends to assert, and in which the potential recovery exceeds $25,000:

8. TAXES

The following tax assessments against any of the Loan Parties or any of the Loan Parties’ Subsidiaries are currently outstanding and unpaid:

 

Assessing Authority

  

Amount and Description

  

24. 9. INSURANCE BROKER

The following brokers handle the Loan Parties’ and the Loan Parties’ Subsidiaries’ property and liability insurance:

 

25. Broker

  

Contact

  

26. Telephone

  

27. Fax

  

28. Email

   29.    30.    31.    32.

[remainder of page intentionally left blank]

 

12


The Loan Parties agree to advise you of any change or modification to any of the foregoing information or any supplemental information provided on any continuation pages attached hereto, and, until such notice is received by you, you shall be entitled to rely upon such information and presume it is correct. The Loan Parties acknowledge that your acceptance of this Perfection Certificate and any continuation pages does not imply any commitment on your part to enter into a loan transaction with the Loan Parties, and that any such commitment may only be made by an express written loan commitment, signed by one of your authorized officers. The Loan Parties agree that this Perfection Certificate shall constitute a “Loan Document” under the Facility Agreement and a “Loan Document” under the Credit Agreement.

Dated as of the date first written above

 

LOAN PARTIES:     ENDOLOGIX, INC., a Delaware corporation
    By:  

 

    Name:  
    Title:  
   

CVD/RMS ACQUISITION CORP.,

a Delaware corporation

    By:  

 

    Name:  
    Title:  
    NELLIX, INC., a Delaware corporation
    By:  

 

    Name:  
    Title:  
   

TRIVASCULAR TECHNOLOGIES, INC.,

a Delaware corporation

    By:  

 

    Name:  
    Title:  

[Signature Page to Perfection Certificate]


LOAN PARTIES CONTINUED:     TRIVASCULAR, INC., a California corporation
    By:   

 

    Name:   
    Title:   
   

ENDOLOGIX CANADA, LLC,

a Delaware limited liability company

    By:   

 

    Name:   
    Title:   
   

TRIVASCULAR SALES LLC,

a Texas limited liability company

    By:   

 

    Name:   
    Title:   
   

RMS/ENDOLOGIX SIDEWAYS MERGER CORP.,

a Delaware corporation

    By:   

 

    Name:   
    Title:   

[Signature Page to Perfection Certificate]


Schedule A-1

Agent’s Account

Beneficiary Bank: The Northern Trust International Banking Corporation, New Jersey

SWIFT: CNORUS33

Fedwire ABA: 026001122

CHIPS ABA: 0112

Beneficiary Name: Deerfield ELGX Revolver

LLC Beneficiary account:143057-20010


Schedule A-2

Authorized Person

Vaseem Mahboob

Cindy Pinto

Tim Brady

James Tejedor


Schedule C-1

Commitments

 

Lender

   Revolver Commitment  

Deerfield Private Design Fund III, L.P.

   $ 16,666,666.66  

Deerfield Private Design Fund IV, L.P.

   $ 16,666,666.67  

Deerfield Partners, L.P.

   $ 16,666,666.67  
  

 

 

 

Total

   $ 50,000,000  
  

 

 

 


Schedule D-1

Designated Account

 

Wire Payment Instruction:   
Beneficiary: Endologix, Inc.   
Beneficiary Address: 2 Musick, lrvine, CA 92618, USA   
Account Number: 1453531702   
  
Bank Name: Bank of America   
Bank Address: 333 South Hope Street, Los Angeles, CA 90071, USA   
Domestic ABA/Routing Account Number: 026009593   
International Swift Code: BOFAUS3N   


Schedule E-1

Approved Account Debtors

 

Angiocor S.A.
Endo T&D Limited LTD
Japan Lifeline Co., Ltd


Schedule P-1

Existing Investments

 

Name of Issuer    Description and Value of Security    Loan Party/Subsidiary

Cianna Medical, Inc.

   8,677 Shares of Series A Preferred Stock    Endologix, Inc.


Schedule 4.01(d)

Existing Liens

None.


Schedule 4.01(f)

Existing Indebtedness

None.


Schedule 4.03

Litigation

Vicky Nguyen v. Endologix, Inc., et al.: (Filed January 3, 2017 in the United States District Court, Central District of California; Case No. 2:17-cv-00017). A putative shareholder class action pending in the U.S. District Court for the Central District of California. Lead plaintiff in Nguyen asserts multiple causes of action for securities fraud based on allegations that Borrower and two of its executives misled investors by opining optimistically about Borrower’s prospects for FDA pre-market approval of the Nellix EVAS System. On December 5, 2017, the District Court granted Borrower’s motion to dismiss lead plaintiff’s First Amended Complaint, with leave to amend. On January 9, 2018, lead plaintiff filed a Second Amended Complaint. Borrower intends to move for dismissal of the Second Amended Complaint with prejudice. The hearing on Borrower’s Motion to Dismiss lead plaintiff’s Second Amended Complaint has been set for August 10, 2018.

Derivative Lawsuits: As of June 11, 2017, Four shareholders have filed derivative lawsuits on behalf of Borrower, the nominal plaintiff, based on allegations substantially similar to those alleged by lead plaintiff in Nguyen. Those actions consist of: Sindlinger v. McDermott et al., Case No. BC662280 (Los Angeles Superior Court); Abraham v. McDermott et al., Case No. 30-2018-00968971-CU-BT-CSC (Orange County Superior Court); and Green v. McDermott et al., Case No. 8:17-cv-01155-AB (PLAx), consolidated with Cocco v. McDermott et al., Case No. 8:17-cv-01183-AB (PLAx) (U.S. District Court for the Central District of California). Plaintiffs in the Sindlinger and Green derivative actions have agreed to stay litigation pending resolution of the Nguyen action. Endologix is currently negotiating a similar agreement with the Abraham plaintiff. A related case, Ahmed v. Endologix, Inc., et al. (Filed January 11, 2017 in the United States District Court, Central District of California; Case No. 8:17-cv-00061) was consolidated into Nguyen v. Endologix, Inc.

SEC Investigation: In July 2017, Borrower learned that the United States Securities and Exchange Commission (“SEC”) issued a Formal Order of Investigation to investigate, among other things, events surrounding the Nellix EVAS System and the prospect of its FDA pre-market approval. Borrower is fully cooperating with the investigation. Borrower continues to produce materials responsive to the SEC’s subpoenas.

Certain Notices: The Loan Parties have received three unrelated notices from individuals claiming that certain of our products read on certain issued patents held by such individuals. The Loan Parties, after consultation with independent patent counsel, strongly disagree with these claims; however, it is possible that should these claims proceed to litigation, that Borrower’s aggregate liability arising for monetary judgements or other reliefs arising out of these matters could exceed $2,000,000. Since it is presently not possible to determine the outcome of any future discussions with these individuals in regard to their patents, and whether or not litigation will ensue, or the outcomes associated with potential litigation, no provision has been made in Borrower’s financial statements for the ultimate resolution.


Schedule 4.06

Real Estate

Owned Real Property :

 

Loan Party or Subsidiary

  

Complete street and mailing address, including zip code

N.A.   

Leased Real Property :

 

Loan Party or Subsidiary

  

Complete street and mailing address,

including zip code

  

Landlord name and contact information

Endologix, Inc.    2 Musick, Irvine, County of Orange, California 92618 U.S.A.; 33 and 35 Hammond, Irvine, County of Orange, California 92618 U.S.A.    The Northwestern Mutual Life Insurance Company
Endologix International Holdings B.V.    Burgemeester Burgerslaan 40, 5245 NH Rosmalen, The Netherlands    N.A.
TriVascular Technologies, Inc.    3910 Brickway Blvd., Santa Rosa, County of Sonoma, CA 95403 U.S.A.    Sonoma Airport Properties LLC
Endologix Singapore Private Limited   

10 Anson Road #21-04 & #21-04A

International Plaza Singapore 079903

   Stamcorp International Pte Ltd.
Endologix International B.V.   

Rahmannstraße 11, 65760

Eschborn, Germany

   N.A.

Subleased Real Property :

 

Loan Party or Subsidiary

  

Complete street and mailing address,

including zip code

  

Landlord and sublandlord name and

contact information

Other Real Property Operated or Occupied:

 

Loan Party or Subsidiary

  

Complete street and mailing address,

including zip code

  

Nature of use

ELGX South Korea Ltd.    A-311, M-Sate, 114 Beopwon-ro, Songpa-gu, Seoul, South Korea    Office


Schedule 4.07

Intellectual Property

The items disclosed in Schedule 4.03 with the lead-in “Certain Notices”.

On May 7, 2018, Borrower received notice from Medtronic, Inc. (“Medtronic”) that Medtronic believes Borrower’s Ovation product appears to use one or more claims of certain Medtronic patents. Borrower is assessing this claim. Medtronic has invited Borrower to engage in discussions to obtain a non-exclusive license to these patents. Borrower has a robust patent portfolio at its disposal, and after conducting analysis believes that one or more of Medtronic’s products appears to use one or more claims of Borrower’s patents. Since it is presently not possible to determine the outcome of any future discussions with Medtronic in regard to the respective parties’ patents, and whether or not litigation will ensue, or the outcomes associated with potential litigation, no provision has been made in Borrower’s financial statements for the ultimate resolution.


Schedule 4.15

Borrower’s Subsidiaries

 

Parent

  

Percentage
ownership

  

Name of
Subsidiary

  

Jurisdiction of
Subsidiary

  

Date of formation
of Subsidiary

  

Federal employer
ID no. of
Subsidiary

  

Organizational
identification no.
of Subsidiary

Endologix, Inc.    100%    Nellix, Inc.    Delaware    03/20/2001    94-3398416    3359980
Endologix, Inc.    100%    CVD/RMS Acquisition Corp.    Delaware    12/13/1998    33-0928438    2955166
Endologix, Inc.    100%    RMS/Endologix Sideways Merger Corp.    Delaware    05/30/2002    03-0512974    3530477
Endologix, Inc.    100%    Endologix Singapore Private Limited    Singapore    01/13/2015    N.A.    N.A.
Endologix, Inc.    100%    ELGX International Holdings GP    Cayman Islands    07/05/2011    N.A.    N.A.
Endologix, Inc.    100%    Endologix New Zealand Co.    New Zealand    05/31/2012    N.A.    N.A.
Endologix, Inc.    100%    ELGX South Korea Ltd.    South Korea    12/07/2017    N.A.    N.A.

Endologix, Inc.

ELGX International Holdings GP

  

99%

 

1%

   Endologix Bermuda L.P.    Bermuda    07/24/2012    N.A.    N.A.
Endologix International Holdings B.V.    100%    Endologix Poland spolkda z ograniczona odpowiedzialnoscia    Poland    03/26/2015    N.A.    N.A.
Endologix Bermuda L.P.    100%    Endologix International Holdings B.V.    The Netherlands    08/22/2011    N.A.    N.A.
Endologix International Holdings B.V.    100%    Endologix Italia S.r.l.    Italy    06/04/2012    N.A.    N.A.
Endologix International holdings B.V.    100%    Endologix International B.V.    The Netherlands    08/22/2011    N.A.    N.A.
Endologix, Inc.    100%    TriVascular Technologies, Inc.    Delaware    07/11/2007    87-0807313    4387054
TriVascular Technologies, Inc.    100%    TriVascular, Inc.    California    01/05/1998    68-0402620    C2065374
TriVascular, Inc.    100%    TriVascular Sales, LLC    Texas    08/23/2012    46-0859179    0801644988


Parent

  

Percentage
ownership

  

Name of
Subsidiary

  

Jurisdiction of
Subsidiary

  

Date of formation
of Subsidiary

  

Federal employer
ID no. of
Subsidiary

  

Organizational
identification no.
of Subsidiary

TriVascular, Inc.    100%    Endologix Canada, LLC    Delaware    11/25/2014    N.A.    5647226
TriVascular, Inc.    100%    TriVascular Germany GmbH    Germany    05/14/2012    N.A.    N.A.
TriVascular, Inc.    100%    TriVascular Switzerland Sarl    Switzerland    04/30/2010    N.A.    N.A.
TriVascular, Inc.    100%    TriVascular Italia S.R.L.    Italy    04/08/2010    N.A.    N.A.


Schedule 4.17

Borrower’s Outstanding Shares of Stock, Options and Warrants

 

Name of Issuer

  

Authorized Securities

  

Issued and Outstanding Securities

  

Certificated
(Yes or No)

  

Loan Party/
Subsidiary Owner

Endologix, Inc.   

170,000,000 Shares of Common Stock, $0.001 par value

 

  

84,946,471 Shares of Common Stock Issued and 84,557,225 Outstanding 3

 

   Yes    N.A.
   5,000,000 Shares of Preferred Stock, $0.001 par value, undesignated    Zero Shares of Preferred Stock    Yes, when issued    N.A.
Nellix, Inc.    1,000 Shares of Common Stock, $0.001 par value    100 Shares of Common Stock    Yes    Endologix, Inc.
CVD/RMS Acquisition Corp.    100 Shares of Common Stock, $0.001 par value    100 Shares of Common Stock    Yes    Endologix, Inc.
ELGX South Korea, Ltd.    20,000 Contribution Units, KRW 5,000 par value    20,000 Contribution Units    No    Endologix, Inc.
RMS/Endologix Sideways Merger Corp.    100 Shares of Common Stock, $0.001 par value    100 Shares of Common Stock    Yes    Endologix, Inc.
TriVascular Technologies, Inc.    1,000 Shares of Common Stock, $0.001 par value    100 Shares of Common Stock    Yes    Endologix, Inc.
ELGX International Holdings GP    Unspecified Number of Partnership Interests    Unspecified Number of Partnership Interests    No    Endologix, Inc.
Endologix Bermuda, L.P.    Unspecified Number of Partnership Interests    Unspecified Number of Partnership Interests    No    Endologix, Inc.
Endologix Singapore Private Limited    Unspecified Number of Company Interests    Unspecified Number of Company Interests    No    Endologix, Inc.
Endologix New Zealand Co.    Unspecified Number of Company Interests    Unspecified Number of Company Interests    No    Endologix, Inc.

 

3  

As of August 7, 2018. There have been no material changes to such amount as of the Agreement Date.


Name of Issuer

  

Authorized Securities

  

Issued and Outstanding Securities

  

Certificated
(Yes or No)

  

Loan Party/
Subsidiary Owner

TriVascular, Inc.    100 Shares of Common stock, $0.01 par value    100 Shares of Common Stock    No    TriVascular Technologies, Inc.
Endologix International Holdings B.V.    Unspecified Number of Company Interests    Unspecified Number of Company Interests    No    Endologix Bermuda, L.P.
Endologix Poland spolkda z ograniczona odpowiedzialnoscia    Unspecified Number of Company Interests    Unspecified Number of Company Interests    No    Endologix International Holdings B.V.
Endologix International B.V.    Unspecified Number of Company Interests    Unspecified Number of Company Interests    No    Endologix International Holdings B.V.
Endologix Italia S.r.l    Unspecified Number of Company Interests    Unspecified Number of Company Interests    No    Endologix International Holdings B.V.
TriVascular Sales LLC    1,000 Units of Membership Interests    1,000 Units of Membership Interests    No    TriVascular, Inc.
Endologix Canada, LLC    1,000 Units of Membership Interests    1,000 Units of Membership Interests    No    TriVascular, Inc.
TriVascular Italia Sarl    Unspecified Number of Company Interests    Unspecified Number of Company Interests    No    TriVascular, Inc.
TriVascular Germany GmbH    Unspecified number of Company Interests    Unspecified number of Company Interests    No    TriVascular, Inc.
TriVascular Switzerland Sárl    Unspecified number of Company Interests    Unspecified number of Company Interests    No    TriVascular, Inc.

Options and Equity Incentive/Compensation Plans:

Equity Awards : Borrower’s 2015 Stock Incentive Plan as amended (the “2015 Plan”) authorizes the grant of equity awards to purchase up to 10.3 million shares of Common Stock. As of July 31, 2018, approximately 9.6 million shares were reserved for issuance under outstanding stock options, including stock options granted under equity compensation plans preceding the 2015 Plan, and 1.6 million shares were subject to unvested restricted stock awards. The outstanding stock options have exercise prices ranging from $1.64 to $17.58 and a weighted average exercise price of $7.28. There have been no material changes to the items discussed in this paragraph as of the Agreement Date.

Amended and Restated 2006 Employee Stock Purchase Plan (the “ESPP”) : As of July 31, 2018, approximately 0.7 million shares of Common Stock were available for issuance under the ESPP. There have been no material changes to such amount as of the Agreement Date.


2017 Inducement Stock Incentive Plan : The Board has reserved 2,000,000 shares of Borrower’s Common Stock for issuance pursuant to awards granted under the 2017 Inducement Stock Incentive Plan. As of July 31, 2018, approximately 1.5 million shares of Common Stock were available for issuance under this plan. There have been no material changes to such amount as of the Agreement Date.

Non-Plan Inducement Grants : In connection with its merger with TriVascular Technologies, Inc., on February 4, 2016 Borrower issued non-plan inducement stock options to purchase 1.4 million shares of Common Stock at an exercise price of $7.53 per share, and non-plan inducement restricted stock units for 0.3 million shares of Common Stock.

Warrants:

In connection with its merger with TriVascular Technologies, Inc. on February 3, 2016, Borrower assumed unexercised out-of-the-money warrants of TriVascular Technologies, Inc., which converted into warrants to purchase 35,094 shares of Common Stock, 24,272 at an exercise price of $12.58 per share and 10,822 at an exercise price of $28.21 per share.

Pursuant to the terms of the Prior Facility Agreement, Borrower issued warrants to Lenders to purchase an aggregate of 6,470,000 shares of Common Stock of Borrower at an exercise price of $9.23 per share. The number of shares of Common Stock of Borrower into which the warrants are exercisable and the exercise price of the warrants will be adjusted to reflect any stock splits, recapitalizations or similar adjustments in the number of outstanding shares of Common Stock of Borrower.

Pursuant to the Agreement, Borrower is issuing warrants to Lenders to purchase an aggregate of 8,750,000 shares of Common Stock of Borrower at an exercise price equal to the closing bid price on the date of grant. The number of shares of Common Stock of Borrower into which the warrants are exercisable and the exercise price of the warrants will be adjusted to reflect any stock splits, recapitalizations or similar adjustments in the number of outstanding shares of Common Stock of Borrower.

Convertible Notes:

2.25% Convertible Notes : On December 10, 2013, Borrower issued $86.3 million aggregate principal amount of 2.25% Convertible Notes. The initial conversion rate of the 2.25% Convertible Notes is 41.6051 shares of Common Stock per $1,000 principal amount of 2.25% Convertible Notes, which represents an initial conversion price of approximately $24.04 per share. On April 3, 2017, Borrower entered into the Prior Facility Agreement with Deerfield and used proceeds from the Deerfield loan to repurchase $68 million aggregate principal amount of outstanding 2.25% Senior Notes, plus the accrued but unpaid interest thereon, from the holders thereof in privately negotiated transactions. As of the Agreement Date, there is currently $18.278 million aggregate principal amount of 2.25% Convertible Notes outstanding.

3.25% Convertible Notes : On November 2, 2015, Borrower issued $125.0 million aggregate principal amount of 3.25% Convertible Notes. The initial conversion rate of the 3.25% Convertible Notes is 89.4314 shares of Common Stock per $1,000 principal amount of 3.25% Convertible Notes, which represents an initial conversion price of approximately $11.18 per share. Pursuant to the terms of the Facility Agreement with Deerfield, $40.5 million of the aggregate principal amount of the 3.25% Convertible Notes will be cancelled on the Agreement


Date, and $84.5 million aggregate principal amount of 3.25% Convertible Notes will remain outstanding thereafter.

Pursuant to this Agreement the Borrower may issue, upon exercise under the Notes by Lenders, Conversion Shares in accordance with the terms of the Notes and Interest Payment Shares in accordance with this Agreement.

Other Rights to Securities of Borrower:

In connection with its merger with Nellix, Inc. (“Nellix”), Borrower agreed to issue shares of Common Stock to the former stockholders of Nellix upon Borrower’s receipt of FDA approval to sell its Nellix EVAS System in the United States (the “PMA Milestone”). The number of shares of Common Stock issuable to the former stockholders of Nellix upon achievement of the PMA Milestone shall equal the quotient obtained by dividing $15.0 million by the average per share closing price of Common Stock on The Nasdaq Global Select Market for each of the 30 consecutive trading days ending with the fifth trading day immediately preceding the date of Borrower’s receipt of FDA approval to sell its Nellix EVAS System in the United States, subject to a stock price floor of $4.50 per share, but not subject to a stock price ceiling.

In June 2018, Borrower received the approval of its stockholders to conduct an exchange program (“Exchange Program”) in which eligible employee stock option holders would have the ability to exchange certain “out-of-the-money” stock options for restricted stock units (“RSUs”) of Borrower pursuant to fixed exchange ratios. Borrower intends to consummate this Exchange Program. The material terms of the Exchange Program are as set forth in proposal 6 of the Company’s definitive proxy statement in respect of its annual meeting of stockholders held on June 14, 2018.

Registration Rights

Registration Rights Agreements dated as of April 3, 2017 and the Agreement Date, respectively, by and among the Borrower the Lenders and Agent. .

Agreement and Plan of Merger and Reorganization, dated October 27, 2010, by and among Borrowerthe, Nepal Acquisition Corporation, Nellix, Inc., certain of Nellix, Inc.’s stockholders listed therein and Essex Woodlands Health Ventures, Inc., as representative of Nellix, Inc.’s stockholders (Section 6.12 contains registration obligation)

At-the-Market Equity Offering Sales Agreement, dated May 31, 2018, by and between Borrower and Stifel, Nicolaus & Company, Incorporated pursuant to which Stifel has agreed to use commercially reasonable efforts to sell on the Company’s behalf up to $50,000,000 in aggregate gross process of the Company’s common stock pursuant to the terms instructed by the Company. The Company is obligated to pay Stifel at a fixed commission rate of up to 3.0% of the gross sales price of its common stock sold pursuant to the agreement.


Schedule 4.18

Material Contracts

 

 

Cross License Agreement dated as of October 26, 2011, by and between Borrower and Bard Peripheral Vascular, Inc.

 

 

Settlement Agreement, dated October 16, 2012 by and among Borrower, Cook Incorporated, Cook Group and Cook Medical, Inc.

 

 

Standard Industrial/Commercial Multi-Tenant Lease—Net, for 2 Musick, Irvine, California and 33 & 35 Hammond, Irvine, dated June 12, 2013, by and between Borrower and The Northwestern Mutual Life Insurance Company.

 

 

Lease for Santa Rosa facility for the building located at 3910 Brickway Boulevard, Santa Rosa, California as set forth in the Third Amendment to Lease, by and between Trivascular, Inc. and Sonoma Airport Properties LLC and the earlier agreements described herein.


Schedule 4.20

Environmental

None.


Schedule 4.22

Labor Relations

None.


Schedule 4.23

Jurisdiction of Organization, Legal Name, Organizational Identification Number and Chief Executive Office

 

Loan Party

  

Jurisdiction of
organization

  

All other
jurisdictions of
organization
of Loan Party
for 5 years
preceding the
Agreement
Date

  

Legal name

  

All other legal
names of Loan
Party for 5 years
preceding the
Agreement Date

  

Organizational
identification
no.

  

Location of chief
executive office or sole
place of business: other
offices or facilities

Endologix, Inc.    Delaware    N.A.    Same as loan party name at left    N.A.    2338745    2 Musick, Irvine, County of Orange, California 92618 U.S.A.
Endologix, Inc.    Delaware    N.A.    Same as loan party name at left    N.A.    2338745    33 and 35 Hammond, Irvine, County of Orange, California 92618 U.S.A.
Nellix, Inc.    Delaware    N.A.    Same as loan party name at left    N.A.    3359980    2 Musick, Irvine, County of Orange, California 92618 U.S.A.
CVD/RMS Acquisition Corp.    Delaware    N.A.    Same as loan party name at left    N.A.    2955166    2 Musick, Irvine, County of Orange, California 92618 U.S.A.
TriVascular Technologies, Inc.    Delaware    N.A.    Same as loan party name at left    N.A.    4387054    3910 Brickway Blvd., Santa Rosa, County of Sonoma, CA 95403 U.S.A
TriVascular, Inc.    California    N.A.    Same as loan party name at left    N.A.    C2065374    3910 Brickway Blvd., Santa Rosa, County of Sonoma, CA 95403 U.S.A
Endologix Canada, LLC    Delaware    N.A.    Same as loan party name at left    Trivascular Canada LLC    5647226    3910 Brickway Blvd., Santa Rosa, County of Sonoma, CA 95403 U.S.A


RMS/Endologix Sideways Merger Corp.    Delaware    N.A.    Same as loan party name at left    N.A.    3530477    2 Musick, Irvine, County of Orange, California 92618 U.S.A.
Trivascular Sales LLC    Texas    N.A.    Same as loan party name at left    N.A.    801644988    3910 Brickway Blvd., Santa Rosa, County of Sonoma, CA 95403 U.S.A


Schedule 4.33(a)

Governmental Notices Regarding Products

Ovation ® System

On August 2018, Borrower intends to issue a global field safety notice related to reinforce information contained within the IFU in order to reduce the occurrence of polymer leaks.


Schedule 4.41

See above Schedule 4.17.


Schedule 4.45

Inventory Location

The following are all of the locations where a Loan Party or any of the Loan Parties’ Subsidiaries, respectively, maintains Inventory:

 

Complete Address

  

Loan Party/Subsidiary

2 Musick, Irvine, County of Orange, CA 92618 U.S.A.    Endologix, Inc.
33 & 35 Hammond, Irvine, County of Orange, CA 92618 U.S.A    Endologix, Inc.
3910 Brickway Blvd., Santa Rosa, County of Sonoma, CA 95403 U.S.A.   

TriVascular Technologies, Inc.

TriVascular, Inc.

10 Anson Road #21-04 & #21-04A

International Plaza Singapore 079903

   Endologix, Inc.
A-311, M-Sate, 114 Beopwon-ro, Songpa-gu, Seoul, South Korea    Endologix, Inc.
Burgemeester Burgerslaan 40, 5245 NH Rosmalen, The Netherlands    Endologix International Holdings B.V.
Rahmannstraße 11, 65760 Eschborn, Germany    Endologix International B.V.

The following are the names and addresses of all warehousemen, bailees, or other third parties who have possession of any of the Loan Parties’ Inventory or the Inventory of any of the Loan Parties’ Subsidiaries:

 

Name

  

Complete Street and Mailing Address, including Zip Code

  

Loan Party/Subsidiary

UPS   

378 Commercial Street, Malden, MA 02148

165 Chubb Avenue, Lyndhurst, NJ 07071

1130 Commerce Blvd, Swedesboro, NJ 08085

2250 Outerloop Drive, Louisville, KY 40219

   Endologix, Inc.
Rhenus    Centaurusweg 123, 5015 TC Tilburg, The Netherlands    Endologix International Holdings B.V.


Name

  

Complete Street and Mailing Address, including Zip Code

  

Loan Party/Subsidiary

STOK UK Limited    One Fleet Place, London EC4M 7Ws    Endologix International B.V.
TNT Express Korea    54 Yangcheon-ro, Gangseo-gu, Seoul 07522    Endologix, Inc.

In addition to the foregoing:

 

   

In the Ordinary Course of Business, the Loan Party or any of the Loan Parties Subsidiaries’ sales representatives hold Trunk Inventory in their possession for sales calls and procedures, which Trunk Inventory is not held at a specific location or locations.

 

   

Certain Inventory of the Loan Party or any of the Loan Parties’ Subsidiaries is held by numerous third parties on a consignment basis at various locations.


Schedule 6.05

Contingent Obligations

 

 

Base Capped Call Confirmation, dated December 4, 2013, between the Borrower and Bank of America, N.A.

 

 

Additional Capped Call Confirmation, dated December 5, 2013, between the Borrower and Bank of America, N.A.

The capped call transactions contemplated by the documents listed above relate to the 2.25% Convertible Notes. The capped call transactions are expected to reduce the potential dilution and/or offset the potential cash payments that the Borrower may be required to make in excess of the principal amount upon conversion of the 2.25% Convertible Notes in the event that the market price per share of the Borrower’s common stock, as measured under the terms of the capped call transactions, is greater than the strike price of the capped call transactions, which initially corresponds to the $24.04 conversion price of the 2.25% Convertible Notes. The Borrower will not be required to make any cash payments to Bank of America, N.A. upon the exercise of the options that are a part of the capped call transactions, but rather will be entitled to receive from Bank of America, N.A. a number of shares of the Borrower’s common stock and/or an amount of cash based on the amount by which the market price per share of Common Stock of the Borrower, as measured under the terms of the capped call transactions, is greater than the strike price of the capped call transactions during the relevant valuation period.


Schedule 5.20

Other Loan Documents to Be Form 8-K Exhibits

Each of the following agreements, instruments and documents, including the schedules, exhibits and annexes thereto:

 

   

the Agreement

 

   

the Notes;

 

   

the Guaranty and Security Agreement;

 

   

the Intercompany Subordination Agreement;

 

   

the Intercreditor Agreement;

 

   

the Patent Security Agreement; and

 

   

the Trademark Security Agreement.


Schedule 6.07

Transactions with Affiliates

Investments of Inventory pursuant to clause (j) of the definition of Permitted Investments

Exhibit 10.2

Execution Version

AMENDED AND RESTATED

FACILITY AGREEMENT

dated as of August 9, 2018

by and among

Endologix, Inc.,

as the Borrower,

the other Loan Parties party hereto from time to time,

the Lenders

and

Deerfield Private Design Fund IV, L.P.,

as agent for itself and the Lenders


Table of Contents

 

ARTICLE 1 DEFINITIONS

     2  

Section 1.1

   General Definitions      2  

Section 1.2

   Interpretation      41  

Section 1.3

   Business Day Adjustment      42  

Section 1.4

   Loan Records      42  

Section 1.5

   Accounting Terms and Principles      43  

Section 1.6

   Tax Treatment      43  

Section 1.7

   Officers      44  

Section 1.8

   Joint Drafting and Negotiation      44  

ARTICLE 2 AGREEMENT FOR THE LOANS

     44  

Section 2.1

   Use of Proceeds      44  

Section 2.2

   Disbursements      44  

Section 2.3

   Payments; Prepayments; No Call; Non-Callable Make Whole Amount      45  

Section 2.4

   Payment Details      49  

Section 2.5

   Taxes      49  

Section 2.6

   Interest      51  

Section 2.7

   Yield Enhancement Payment; Default Interest      52  

Section 2.8

   Delivery of Warrants      53  

ARTICLE 3 REPRESENTATIONS AND WARRANTIES

     54  

Section 3.1

   Representations and Warranties of the Loan Parties      54  

Section 3.2

   Borrower Acknowledgment      69  

Section 3.3

   Representations and Warranties of the Lenders      69  

ARTICLE 4 CLOSING CONDITIONS

     70  

Section 4.1

   Conditions to the Disbursement      70  

ARTICLE 5 PARTICULAR COVENANTS AND EVENTS OF DEFAULT

     73  

Section 5.1

   Affirmative Covenants      73  

Section 5.2

   Negative Covenants      81  

Section 5.3

   Change of Control      89  

Section 5.4

   General Acceleration Provision upon Events of Default      90  

Section 5.5

   Additional Remedies      95  

Section 5.6

   Recovery of Amounts Due      95  

Section 5.7

   Credit Bidding      95  

ARTICLE 6 MISCELLANEOUS

     96  

Section 6.1

   Notices      96  

Section 6.2

   Waiver of Notice      97  

Section 6.3

   Fees, Charges, Costs and Expenses Reimbursement      97  

Section 6.4

   Governing Law      98  

Section 6.5

   Successors and Assigns          98  

 

i


Section 6.6

   Entire Agreement; Amendments      99  

Section 6.7

   Severability      100  

Section 6.8

   Counterparts      100  

Section 6.9

   Survival      100  

Section 6.10

   No Waiver      102  

Section 6.11

   Indemnity      102  

Section 6.12

   No Usury      103  

Section 6.13

   Specific Performance      103  

Section 6.14

   Further Assurances      104  

Section 6.15

   Agent      104  

Section 6.16

   USA Patriot Act      106  

Section 6.17

   Placement Agent      107  

Section 6.18

   No Fiduciary Relationship      107  

Section 6.19

   Joint and Several      107  

Section 6.20

   No Third Parties Benefited      107  

Section 6.21

   Binding Effect      107  

Section 6.22

   Marshaling; Payments Set Aside      107  

Section 6.23

   No Waiver; Cumulative Remedies      107  

Section 6.24

   Right of Setoff      107  

Section 6.25

   Independent Nature of Secured Parties      108  

Section 6.26

   Sharing of Payments, Etc.      108  

Section 6.27

   Confidentiality      108  

Section 6.28

   Intercreditor Agreement      109  

Section 6.29

   Acknowledgment of Prior Obligations and Continuation Thereof      110  

Section 6.30

   No Novation      110  

Section 6.31

   Survival of Any Existing Unmatured Events of Default and Events of Default      111  
Annex

 

Annex A    Disbursement Amount and Warrants

 

Exhibits

 

Exhibit 2.6    Share Payment Provisions

 

Exhibit A-1    Form of First Out Waterfall Note

 

Exhibit A-2    Form of Last Out Waterfall Note

 

Exhibit B    Form of Perfection Certificate

 

Exhibit C-1    Form of Initial Warrant

 

Exhibit C-1    Form of Additional Warrant

 

Exhibit D    Closing Checklist

 

Exhibit E    Form of Amended and Restated Registration Rights Agreement

 

Exhibit F    Form of Compliance Certificate

 

Schedules

 

Schedule P-1    Existing Investments

 

Schedule 2.4    List of Agreement Date Lenders and Such Lenders’ Wire Instructions and Information for Notices

 

 

ii


Schedule 3.1(d)    Existing Liens
Schedule 3.1(f)    Existing Indebtedness
Schedule 3.1(h)    Litigation
Schedule 3.1(m)    Real Estate
Schedule 3.1(x)    Borrower’s Subsidiaries
Schedule 3.1(z)    Borrower’s Outstanding Shares of Stock, Options and Warrants
Schedule 3.1(aa)    Material Contracts
Schedule 3.1(dd)    Environmental
Schedule 3.1(ff)    Labor Relations
Schedule 3.1(gg)    Jurisdiction of Organization, Legal Name, Organizational Identification Number and Chief Executive Office
Schedule 3.1(hh)    Inventory Locations
Schedule 3.1(jjj)    Stock of the Subsidiaries of the Loan Parties
Schedule 5.1(q)    Other Loan Documents to Be Form 8-K Exhibits
Schedule 5.2(iv)    Contingent Obligations
Schedule 5.2(vii)    Transactions with Affiliates

 

 

iii


AMENDED AND RESTATED

FACILITY AGREEMENT

This AMENDED AND RESTATED FACILITY AGREEMENT (this “ Agreement ”), dated as of August 9, 2018, by and among Endologix, Inc., a Delaware corporation (the “ Borrower ”), the other Loan Parties (as defined below) party hereto from time to time, the lenders party hereto from time to time (including the First Out Waterfall Lenders (as defined below) and the Last Out Waterfall Lenders (as defined below)), Deerfield Private Design Fund IV, L.P. (“ Deerfield Facility Entity ”), as agent for itself and the Lenders (in such capacity, together with its successors and assigns in such capacity, “ Agent ,” and, together with the Lenders, the Borrower and the other Loan Parties party hereto, the “ Parties ”).

W I T N E S S E T H:

WHEREAS, the Loan Parties party thereto, Agent and the lenders party thereto are parties to that certain Facility Agreement dated as of the Prior Agreement Date (as amended, restated, supplemented or otherwise modified from time to time prior to the effectiveness hereof, the “ Prior Facility Agreement ”);

WHEREAS, Agent, the Lenders party hereto and the Loan Parties party hereto have agreed to amend and restate the Prior Facility Agreement in its entirety to read as set forth in this Agreement, and it has been agreed by such parties that the “Loans”, “Disbursements” and other “Obligations” outstanding under the Prior Facility Agreement or any Prior Loan Document shall continue under and be governed by and deemed to be outstanding under this Agreement, it being agreed and understood that this Agreement does not constitute a novation, satisfaction, payment or re-borrowing of any obligation or “Obligation” under the Prior Facility Agreement or any other Prior Loan Document, nor does this Agreement operate as a waiver of any right, power or remedy of Agent, any Lender or any other Secured Party under any Loan Document;

WHEREAS, pursuant to a recapitalization of the Borrower involving and in consideration of, among other things, (a) the amendment and restatement of the Prior Facility Agreement and the entry into this Agreement, (b) certain accommodations under the Prior Facility Agreement and this Agreement made in favor of the Loan Parties with respect to certain actions previously taken by the Loan Parties and their Subsidiaries, and (c) Deerfield Partners, L.P. (as the sole Last Out Waterfall Lender as of the Agreement Date) agreeing to extend the date of payment of the principal that would have otherwise been due until the Maturity Date with respect to such 3.25% Convertible Notes that it held and to forgo certain other benefits it had under such 3.25% Convertible Notes, it and the Loan Parties have agreed to exchange $40,500,000 of the 3.25% Convertible Notes held by Deerfield Partners, L.P. (but, for the avoidance of doubt, not any other 3.25% Convertible Notes) (the “ Exchanged Deerfield Convertible Notes ”) for a new tranche of loans in the principal amount of $40,500,000 under this Agreement, which shall constitute the Last Out Waterfall Loans and part of the Last Out Waterfall Obligations, Loans and Obligations hereunder and which such new tranche of loans shall receive the interest and other amounts and payments applicable to such loans under this Agreement and the other Loan Documents and shall be afforded the security, the Liens (including the priority thereof), the Guarantees and the other benefits applicable to such loans hereunder and under the other Loan Documents;

WHEREAS, Borrower desires to continue to secure all of the Obligations (including the Last Out Waterfall Loans) by continuing to grant to Agent, for the benefit of the Secured Parties, a first priority (subject only to the prior priority of the Permitted Priority Liens) perfected Lien upon substantially all of its personal and real property including all of the issued and outstanding Stock of its direct Subsidiaries (in each case, other than Excluded Property); and


WHEREAS, each of the Loan Parties is willing to continue to guaranty all of the Obligations (including the Last Out Waterfall Loans), and to continue to grant to Agent, for the benefit of the Secured Parties, a first priority (subject only to the prior priority of the Permitted Priority Liens) perfected Lien upon all of its respective personal and real property, including all of the issued and outstanding Stock of its direct Subsidiaries (in each case, other than Excluded Property) which are issued to a Loan Party.

NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree to amend and restate the Prior Facility Agreement and to provide for the Last Out Waterfall Loans hereunder, and the Prior Facility Agreement is hereby amended and restated in its entirety (and the Last Out Waterfall Loans are provided for hereunder) pursuant to the terms hereof, as follows:

ARTICLE 1

DEFINITIONS

Section  1.1 General Definitions . Wherever used in this Agreement, the Exhibits or the Schedules attached hereto, unless the context otherwise requires, the following terms have the following meanings:

2.25% Convertible Note Documents ” means the 2.25% Convertible Notes, the 2.25% Senior Note Indenture and each other document or agreement from time to time entered into in connection with the foregoing.

2.25% Convertible Notes ” means those certain 2.25% senior unsecured notes, governed by the terms of a base indenture, as supplemented by the first supplemental indenture relating to the 2.25% senior notes (together, the “ 2.25% Senior Notes Indenture ”), between the Borrower and Wells Fargo Bank, National Association, as trustee, each of which were entered into on December 10, 2013.

2.25% Senior Notes Indenture ” has the meaning provided therefor in the definition of “2.25% Convertible Notes.”

3.25% Convertible Notes ” means those certain 3.25% senior unsecured notes, governed by the terms of a base indenture, as supplemented by the second supplemental indenture relating to the 3.25% senior notes (together, the “ 3.25% Senior Notes Indenture ”), between the Borrower and Wells Fargo Bank, National Association, as trustee, each of which were entered into on November 2, 2015, as the same may be amended, restated, refinanced, supplemented or otherwise modified in connection with a Permitted 3.25% Convertible Note Refinancing.

3.25% Convertible Note Documents ” means the 3.25% Convertible Notes, the 3.25% Senior Note Indenture and each other document or agreement from time to entered into in connection with the foregoing, as the same may be amended, restated, refinanced, supplemented or otherwise modified in on with a Permitted 3.25% Convertible Note Refinancing.

3.25% Senior Notes Indenture ” has the meaning provided therefor in the definition of “3.25% Convertible Notes.”

10-K ” means an annual report on Form 10-K (or successor form thereto), as required to be filed pursuant to the Exchange Act.

 

2


10-Q ” means a quarterly report on Form 10-Q (or successor form thereto), as required to be filed pursuant to the Exchange Act.

ABL Agent ” has the meaning assigned to such term in the definition of “ABL Credit Facility” herein.

ABL Credit Agreement ” and “ ABL Credit Facility ” mean that certain Credit Agreement, dated as of the Agreement Date, by and among the Borrower, the other Persons party thereto from time to time as “Borrowers” (as defined therein) or guarantors therein, Deerfield ELGX Revolver, LLC, in its capacity as Agent (as defined therein (including any Third Party Agent (as defined therein)), in such capacity, together with its successors and assigns in such capacity, the “ ABL Agent ”) and the financial institutions or other entities from time to time parties thereto, each as a Lender (as defined therein), as amended, restated, supplemented or otherwise modified in accordance and in compliance with the Intercreditor Agreement.

ABL Debt ” means “ABL Obligations” as defined in the Intercreditor Agreement.

ABL Debt Documents ” means “ABL Documents” as defined in the Intercreditor Agreement.

ABL Lenders ” means the lenders under the ABL Debt Documents.

Accounts ” means, collectively, (a) any right to payment of a monetary obligation, whether or not earned by performance, (b) without duplication, any “account” (as defined in the UCC), any accounts receivable (whether in the form of payments for services rendered or goods sold, rents, license fees or otherwise), any “health-care-insurance receivables” (as defined in the UCC), any “payment intangibles” (as defined in the UCC) and all other rights to payment and/or reimbursement of every kind and description, whether or not earned by performance, (c) all accounts, “general intangibles” (as defined in the UCC), Intellectual Property, rights, remedies, Guarantees, “supporting obligations” (as defined in the UCC), “letter-of-credit rights” (as defined in the UCC) and security interests in respect of the foregoing, all rights of enforcement and collection, all books and records evidencing or related to the foregoing, and all rights under the Loan Documents in respect of the foregoing, (d) all information and data compiled or derived by any Loan Party or to which any Loan Party is entitled in respect of or related to the foregoing, and (e) all proceeds of any of the foregoing.

Acquisition ” means any transaction or series of related transactions for the purpose of or resulting, directly or indirectly, in (a) the acquisition of all or substantially all of the assets of a Person, or of any business or division of a Person, (b) the acquisition of in excess of fifty percent (50%) of the Stock of any Person or otherwise causing any Person to become a Subsidiary of the Borrower, (c) a merger or consolidation or any other combination with another Person or (d) the acquisition (including through licensing) of any Product or Intellectual Property of or from another Person if the Acquisition Consideration paid in connection with such acquisition is in excess of $5,000,000 individually or in the aggregate with respect to all such acquisitions in any twelve (12) month period.

Acquisition Consideration ” has the meaning set forth in the definition of “Permitted Acquisitions.”

Additional Amounts ” has the meaning set forth in Section 2.5(a).

Additional Warrants” has the meaning set forth in Section  2.8(d).

Affiliate ” means, with respect to any Person, (a) any Person that directly or indirectly controls such Person, (b) any Person which is controlled by or is under common control with such controlling

 

3


Person, and (c) each of such Person’s (other than, with respect to any Lender, any Lender’s) officers or directors (or Persons functioning in substantially similar roles) and the spouses, parents, descendants and siblings of such officers, directors or other Persons. As used in this definition, the term “control” of a Person means the possession, directly or indirectly, of the power to vote five percent (5%) or more of any class of voting securities of such Person or to direct or cause the direction of the management or policies of a Person, whether through the ownership of voting securities, by contract or otherwise.

Agent ” has the meaning set forth in the preamble to this Agreement.

Agreement ” has the meaning set forth in the preamble to this Agreement.

Agreement Date ” means the date of this Agreement.

All-in Yield ” means the interest rate (including margins and floors), original issue discount and fees paid to all lenders (or consenting lenders) of such debt or their Affiliates (based on the remaining life to maturity), but not including any fees not paid to all lenders (such as fees to initial purchasers (i.e., investment banks in Rule 144A offerings), underwriters or lead agents).

Amortization Payments ” means (i) with respect to the First Out Waterfall Loans, the three principal payments due on April 2, 2021, April 2, 2022 and on the Maturity Date that are set forth in the second column of the table in Section 2.3(a) and (ii) with respect to the Last Out Waterfall Loans, the two principal payments due on April 2, 2022 and on the Maturity Date that are set forth in the third column of the table in Section 2.3(a).

Announcing Form 8-K ” has the meaning set forth in Section 5.1(q).

Anti-Corruption Laws ” means any and all laws, rules, and regulations of any jurisdiction applicable to any Loan Party or any Subsidiary of any Loan Party from time to time concerning or relating to bribery or corruption, including, without limitation, the FCPA, as amended, the UK Bribery Act 2010 and other similar legislation in any other jurisdictions.

Anti-Money Laundering Laws ” means any and all laws, rules, and regulations in effect from time to time related to terrorism or money laundering, including, without limitation, (i) all applicable requirements of the Currency and Foreign Transactions Reporting Act of 1970 (31 U.S.C. 5311 et. seq., (the Bank Secrecy Act)), as amended by Title III of the USA Patriot Act, (ii) the Trading with the Enemy Act, (iii) Executive Order No. 13224 on Terrorist Financing, effective September 24, 2001 (66 Fed. Reg. 49079), and any other enabling legislation, executive order or regulations issued pursuant or relating thereto and (iv) other applicable federal or state laws relating to “know your customer” or anti-money laundering rules and regulations.

Anti-Terrorism Laws ” means any and all laws, regulations, rules, orders, etc. in effect from time to time relating to anti-money laundering and terrorism, including, without limitation, Executive Order No. 13224 (effective September 24, 2001), Trading with the Enemy Act, as amended, and each of the foreign assets control regulations of the United States Treasury Department (31 CFR, Subtitle B, Chapter V, as amended), and the USA Patriot Act (Pub. L. No. 107-56 (Oct. 12, 2001)).

Applicable Laws ” means, with respect to any Person, the common law and any federal, state, local, foreign, multinational or international laws, statutes, codes, treaties, standards, rules and regulations, guidelines, ordinances, orders, judgments, writs, injunctions, decrees (including administrative or judicial precedents or authorities) and the interpretation or administration thereof by, and other determinations, directives, requirements or requests of, any Governmental Authority, in each case whether or not having

 

4


the force of law and that are applicable to or binding upon such Person or any of its property or to which such Person or any of its property is subject. “Applicable Laws” includes Healthcare Laws and Environmental Laws.

Application Event ” means the occurrence of (a) a failure by the Loan Parties to repay all of the Obligations (other than (y) unasserted contingent indemnification obligations and (z) those Obligations under any Warrant or the Registration Rights Agreement that are not (or do not become) due or payable on the Maturity Date) in full in cash on the Maturity Date, (b) any Insolvency Proceeding or any event of the type set forth in Section 5.4(d), (c) any acceleration of the Obligations, (d) a foreclosure or an exercise of rights or remedies on any of the Collateral at the time of, or after, an Event of Default has occurred and is continuing, (e) any exercise of remedies by the Agent or the Required Lenders at the time of, or after, an Event of Default has occurred and is continuing or (f) any “Application Event” (as defined in the Intercreditor Agreement).

Approved Fund ” means any (a) investment company, fund, trust, securitization vehicle or conduit that is (or will be) engaged in making, purchasing, holding or otherwise investing in commercial loans and similar extensions of credit, or (b) any Person (other than a natural person) which temporarily warehouses loans for any Lender or any entity described in the preceding clause (a) and that, with respect to each of the preceding clauses (a) and (b), is administered or managed by (i) a Lender, (ii) an Affiliate of a Lender, or (iii) a Person (other than a natural person) or an Affiliate of a Person (other than a natural person) that administers or manages a Lender.

Authorizations ” means, with respect to any Person, any permits (including Regulatory Required Permits), approvals, authorizations, licenses, registrations, certificates, clearances, concessions, grants, franchises, variances or permissions from, and any other contractual obligations with, any Governmental Authority, in each case whether or not having the force of law and applicable to or binding upon such Person or any of its property or to which such Person or any of its property is subject, and any supplements or amendments with respect to the foregoing.

Authorized Officer ” means the chief executive officer, the president or the chief financial officer of the Borrower or any other officer of the Borrower having substantially the same authority and responsibility.

Bank of America Cash Collateral Account ” means that certain deposit account #1453234066 of Borrower at Bank of America, N.A. (or such replacement deposit account provided by Bank of America, N.A. or by another commercial bank) established and maintained for the sole purpose of providing cash collateral in favor of Bank of America, N.A. (or such replacement commercial bank) for obligations of the Borrower in respect of certain commercial credit cards (or with respect to a replacement commercial bank, similar commercial credit cards to those provided by Bank of America, N.A. as of the Prior Agreement Date) provided to the Borrower by Bank of America, N.A. (or such replacement commercial bank); provided that the aggregate amount on deposit in such deposit account (or such replacement deposit account) shall not at any time exceed $2,500,000.

Bankruptcy Code ” means title 11 of the United States Code, as in effect from time to time.

Bloomberg ” has the meaning set forth in the definition of “Volume Weighted Average Price.”

Borrower ” has the meaning set forth in the preamble to this Agreement.

Business Day ” means a day other than Saturday or Sunday on which banks are open for business in New York, New York.

 

5


Capital Expenditures ” means, with respect to any Person for any period, the amount of all expenditures by such Person and its Subsidiaries during such period that are capital expenditures as determined in accordance with GAAP, whether such expenditures are paid in cash or financed, but excluding, without duplication (a) expenditures made during such period in connection with the replacement, substitution, or restoration of assets or properties, (b) with respect to the purchase price of assets that are purchased substantially contemporaneously with the trade-in of existing assets during such period, the amount that the gross amount of such purchase price is reduced by the credit granted by the seller of such assets for the assets being traded in at such time, (c) expenditures made during such period to consummate one or more Permitted Acquisitions, (d) expenditures made during such period to the extent made with the identifiable proceeds of an equity investment in the Borrower which equity investment is made substantially contemporaneously with the making of the expenditure, and (e) expenditures during such period that, pursuant to a written agreement, are reimbursed by a third Person (excluding the Loan Parties and their Affiliates).

Capital Lease ” means, with respect to any Person, any lease of or other arrangement conveying the right to use, any property by such Person as lessee that has been or should be accounted for as a capital lease on a balance sheet of such Person prepared in accordance with GAAP.

Capital Lease Obligations ” means, at any time, with respect to any Capital Lease, any lease entered into as part of any sale leaseback transaction of any Person or any synthetic lease, the amount of all obligations of such Person that is (or that would be, if such synthetic lease or other lease were accounted for as a Capital Lease) capitalized on a balance sheet of such Person prepared in accordance with GAAP.

Capped Call ” means the capped call transactions referenced in Schedule 5.2(iv) in respect of the 2.25% Convertible Notes and any like transactions that are economically similar to such transactions entered into in connection with any Indebtedness contemplated under clause (k) of the definition of Permitted Indebtedness.

Cash Equivalents ” means (a) any readily-marketable securities (i) issued by, or directly, unconditionally and fully guaranteed or insured by the United States federal government or (ii) issued by any agency of the United States federal government the obligations of which are fully backed by the full faith and credit of the United States federal government, (b) any readily-marketable direct obligations issued by any other agency of the United States federal government, any state of the United States or any political subdivision of any such state or any public instrumentality thereof, in each case having a rating of at least “A-1” from S&P or at least “P-1” from Moody’s, (c) any commercial paper rated at least “A-1” by S&P or “P-1” by Moody’s and issued by any Person organized under the laws of any state of the United States, (d) any United States dollar-denominated time deposit, insured certificate of deposit, overnight bank deposit or bankers’ acceptance issued or accepted by any commercial bank that is (A) organized under the laws of the United States, any state thereof or the District of Columbia, (B) “adequately capitalized” (as defined in the regulations of its primary federal banking regulators) and (C) has Tier 1 capital (as defined in such regulations) in excess of $250,000,000, (e) shares of any United States money market fund that (i) has substantially all of its assets invested continuously in the types of investments referred to in clause (a), (b), (c) or (d) above with maturities as set forth in the proviso below, (ii) has net assets in excess of $500,000,000 and (iii) has obtained from either S&P or Moody’s the highest rating obtainable for money market funds in the United States; provided , however , that the maturities of all obligations specified in any of clauses (a), (b), (c) or (d) above shall not exceed one year and (f) investments made in accordance with the Borrower’s investment policy in effect as of the Prior Agreement Date that was provided to the Agent’s counsel on March 14, 2017 at 12:15 p.m. New York time, and any amendments thereto that do not, when taken as a whole, materially increase the risk of the investments made by the Borrower from time to time from Borrower’s investment policy in effect as of the Prior Agreement Date.

 

6


Cash Interest Rate ” means 5.00% per annum for the principal amount of the Loans and any overdue interest thereon, plus any additional amounts set forth in Section 2.7(b).

Change of Control ” or “ Change in Control ” means any of the following events: (a) any Person or two or more Persons acting in concert shall have acquired beneficial ownership, directly or indirectly, of, or shall have acquired by contract or otherwise, or shall have entered into a contract or arrangement that, upon consummation, will result in its or their acquisition of or control over, voting Stock of the Borrower (or other securities convertible into such voting Stock) representing more than 50% of the combined voting power of all voting Stock of the Borrower; (b) the Borrower shall have ceased to own, directly or indirectly, 100% of the Stock of any of its Subsidiaries (with the exception of any Subsidiaries permitted to be dissolved or merged to the extent otherwise permitted by this Agreement and other than, solely with respect to Foreign Subsidiaries, directors qualifying shares as necessary to comply with foreign law); (c) the occurrence of a “Change of Control”, “Change in Control”, “Fundamental Change” or terms of similar import under the 2.25% Convertible Note Documents, the 3.25% Convertible Note Documents, the ABL Debt Documents or any Permitted Japan Lifeline Unsecured Debt Documents; or (d) the occurrence of any “Major Transaction” (as defined in any Warrant). As used herein, “beneficial ownership” shall have the meaning provided in Rule 13d-3 of the SEC under the Exchange Act.

CMS ” means the federal Centers for Medicare and Medicaid Services (formerly the federal Health Care Financing Administration), and any successor Governmental Authority.

CoC Fee” means:

(a) if both (1) principal on the Loans are (or are obligated or required to be) prepaid, repaid, redeemed or paid (in each case, for the avoidance of doubt, other than any Amortization Payments) in full (or in part) prior to the Maturity Date and (2) a Change of Control is consummated (or a first public announcement of a potential Change of Control is made) prior to the Maturity Date (and, for the avoidance of doubt, with respect to any such public announcement, where a Change of Control is ultimately consummated (whether before, on the date of or after the Maturity Date)), $4,200,000 (or, if such amount is prepaid, repaid, redeemed or paid in connection with a partial (as opposed to full) prepayment, repayment, redemption or payment of the Loans (in each case, for the avoidance of doubt, other than any Amortization Payments), then such ratable portion of such amount based on the principal amount of such Loans prepaid, repaid, redeemed or repaid (in each case, for the avoidance of doubt, other than any Amortization Payments));

(b) if both (1) principal on the Loans are (or are obligated or required to be) prepaid, repaid, redeemed or paid (in each case, for the avoidance of doubt, other than any Amortization Payments) in full (or in part) prior to the Maturity Date and (2) a potential Change of Control is first publicly announced (or a Change of Control is consummated) both (A) on or after the Maturity Date and (B) within 150 days after such prepayment, repayment, redemption or payment in full (or in part) of principal on the Loans (in each case, for the avoidance of doubt, other than any Amortization Payments) prior to the Maturity Date, an amount in cash equal to all interest payments that would have been required on the prepaid, repaid, redeemed or paid Loans (or the Loans obligated or required to be prepaid, repaid, redeemed or paid) from the date of such prepayment, repayment, redemption or payment (or the date such prepayment, repayment, redemption or payment was obligated or required to be made) through and including the Maturity Date (in each case, for the avoidance of doubt, other than any Amortization Payments); or

(c) if both (1) principal on the Loans are (or are obligated or required to be) prepaid, repaid, redeemed or paid (in each case, for the avoidance of doubt, other than any Amortization Payments) in full prior to the Maturity Date and (2) a potential Change of Control is first publicly announced (or a

 

7


Change of Control is consummated) both (A) on or after the Maturity Date and (B) more than 150 days after such prepayment, repayment, redemption or payment (in each case, for the avoidance of doubt, other than any Amortization Payments) in full of the Loans prior to the Maturity Date, $0.

Code ” means the Internal Revenue Code of 1986, as amended, and any Treasury Regulations promulgated thereunder.

Collateral ” has the meaning given to it in the Security Agreement.

Collateral Access Agreement ” means a landlord waiver, bailee letter, or acknowledgement agreement of any lessor, warehouseman, processor, consignee, or other Person in possession of, having a Lien upon, or having rights or interests in the Loan Parties’ or their Subsidiaries’ Collateral or books and records, in each case, in form and substance reasonably satisfactory to Agent.

Common Stock ” means the “Common Stock” of the Borrower, with a $0.001 par value per share.

Compliance Certificate ” means a certificate, duly executed by an Authorized Officer of the Borrower, appropriately completed and substantially in the form of Exhibit F hereto.

Contingent Obligation ” means, with respect to any Person, any direct or indirect liability of such Person: (a) with respect to any Indebtedness of another Person (a “ Third Party Obligation ”) if the purpose or intent of such Person incurring such liability, or the effect thereof, is to provide assurance to the obligee of such Third Party Obligation that such Third Party Obligation will be paid or discharged, or that any agreement relating thereto will be complied with, or that any holder of such Third Party Obligation will be protected, in whole or in part, against loss with respect thereto; (b) with respect to any undrawn portion of any letter of credit issued for the account of such Person or as to which such Person is otherwise liable for the reimbursement of any drawing; (c) under any Swap Contract, to the extent not yet due and payable; (d) to make take-or-pay or similar payments if required regardless of nonperformance by any other party or parties to an agreement; or (e) for any obligations of another Person pursuant to any Guarantee or pursuant to any agreement to purchase, repurchase or otherwise acquire any obligation or any property constituting security therefor, to provide funds for the payment or discharge of such obligation or to preserve the solvency, financial condition or level of income of another Person. The amount of any Contingent Obligation shall be equal to the amount of the obligation so Guaranteed or otherwise supported or, if not a fixed and determinable amount, the maximum amount so Guaranteed or otherwise supported.

Control Agreement ” means, with respect to any deposit account, securities account, commodity account, securities entitlement or commodity contract, an agreement, in form and substance reasonably satisfactory to Agent, among Agent, the financial institution or other Person at which such account is maintained or with which such entitlement or contract is carried and the Loan Party maintaining such account or owning such entitlement or contract, effective to grant “control” (within the meaning of Articles 8 and 9 under the applicable UCC) over such account to Agent.

Conversion Shares ” has the meaning set forth in Section 3.1(z).

Convertible Note Documents ” means, collectively, the 2.25% Convertible Note Documents and the 3.25% Convertible Note Documents (which, for the avoidance of doubt, shall include the indenture and each other document or agreement from time to time entered into in connection with any Permitted 3.25% Convertible Note Refinancing, in each case, to the extent such indenture, documents or agreements are permitted pursuant to the terms of the definition of “Permitted 3.25% Convertible Note Refinancing).

 

8


Convertible Securities ” means any Stock or securities (other than Options) directly or indirectly convertible into or exchangeable or exercisable for shares of Common Stock.

Copyrights ” has the meaning set forth in the Security Agreement.

Copyright Security Agreement ” means any copyright security agreement executed and delivered by a Loan Party to Agent, on behalf of the Secured Parties, as the same may be amended, restated, supplemented or otherwise modified and in effect from time to time.

Correction ” means the repair, modification, adjustment, relabeling, destruction, or inspection (including patient monitoring) of a product or device without its physical removal from its point of use to some other location.

Current Balance Sheet ” has the meaning set forth in the definition of “Enterprise Value.”

DEA ” means the Drug Enforcement Administration of the United States of America, any comparable state or local Governmental Authority, any comparable Governmental Authority in any non-United States jurisdiction, and any successor agency of any of the foregoing.

Deerfield Facility Entity ” has the meaning set forth in the preamble to this Agreement.

Default ” means any event which, with the giving of notice, lapse of time or fulfillment of any other applicable condition (or any combination of the foregoing), would constitute an Event of Default.

Disbursements ” has the meaning set forth in Section 2.2(a)(ii).

Dispose ” and “ Disposition ” mean (a) the sale, lease, license, transfer, assignment, conveyance or other disposition of any assets or property (including any transfer or conveyance of any assets or property pursuant to a division or split of a limited liability company or other entity or Person into two or more limited liability companies or other entities or Persons) and (b) the sale or transfer by the Borrower or any Subsidiary of the Borrower of any Stock issued by any Subsidiary of the Borrower.

Disqualified Stock ” means any Stock which, by its terms (or by the terms of any security or other Stock into which it is convertible or for which it is exchangeable), or upon the happening of any event or condition, (a) matures or is mandatorily redeemable (other than solely for Stock that does not constitute Disqualified Stock), pursuant to a sinking fund obligation or otherwise, or is redeemable (in each case, other than solely for Stock that does not constitute Disqualified Stock) at the option of the holder thereof, in whole or in part, on or prior to the date that is one year and one day following the Maturity Date (excluding any provisions requiring redemption upon a “change in control” or similar event, provided that such “change in control” or similar event results in the occurrence of the payment in full in cash of all of the Obligations (other than (i) unasserted contingent indemnification obligations and (ii) Obligations under the Warrants and the Registration Rights Agreement that are not due and payable at the time such other Obligations are paid in full in cash)), (b) is convertible into or exchangeable for (i) debt securities or (ii) any Stock referred to in (a) above, in each case, at any time on or prior to the date that is one year and one day following the Maturity Date at the time such Stock was issued, or (c) is entitled to receive scheduled dividends or distributions in cash prior to the date that is one year and one day following the Maturity Date.

Dollars ” and the “ $ ” sign mean the lawful currency of the United States of America.

Domestic Subsidiary means any Subsidiary incorporated, organized or otherwise formed under the laws of the United States, any state thereof or the District of Columbia.

 

9


Drug Application ” means a new drug application, an abbreviated drug application, or a product license application for any Product, as appropriate, as those terms are defined in the FDCA.

DTC ” has the meaning set forth in Section 3.1(qq).

EBITDA ” means, at any date of determination, an amount equal to (a) Net Income of the Successor Entity for the most recently completed trailing four quarter measurement period, plus (b) in each case, to the extent deducted in determining Net Income (whether in cash, paid in-kind or otherwise) for such period, without duplication, (i) Interest Expense of the Successor Entity for such trailing four quarter period, (ii) income taxes of the Successor Entity for such trailing four quarter period, (iii) depreciation and amortization of the Successor Entity for such trailing four quarter period; provided that, with respect of all components of the foregoing clause (a) and clause (b) of this definition, such amounts shall be limited to those of Successor Entity only (and not any of its Subsidiaries) unless such Subsidiaries (other than any Excluded Subsidiaries) become Guarantors under the Loan Documents and provide a Lien on all of their assets and property that would constitute Collateral under the Loan Documents and take such other actions that would be required by Section 5.1(l) (such actions of such Subsidiaries in such instance, the “ Successor Entity Subsidiary Joinder Actions ”).

Eligible Assignee ” means (a) a Lender, (b) an Affiliate of a Lender, (c) an Approved Fund, and (d) any other Person (other than a natural person) approved by Agent; provided, however , that with respect to clause (d) above, no such Person shall include (i) Borrower or any of Borrower’s Affiliates or (ii) unless an Event of Default has occurred and is continuing, (A) any direct competitor of Loan Parties, in each case, as determined by Agent in its reasonable discretion, (B) any investor or fund that has publicly announced in writing its intention to obtain control of the Borrower publicly or otherwise to the knowledge of the assigning Lender, or (D) any Person listed in the email delivered by counsel to the Borrower to counsel to the Agent on March 16, 2017 at 5:00 p.m. (Pacific time) and any Affiliates or Approved Funds of any such Person actually known to the assigning Lender and to the Agent to be Affiliates or Approved Funds of any such Person.

Employee ” means any employee of any Loan Party or any Subsidiary of any Loan Party.

Employee Benefit Plan ” means any “employee benefit plan” within the meaning of Section 3(3) of ERISA, under which (A) any current or former employee, director or independent contractor of the Borrower or any of its Subsidiaries has any present or future right to benefits or compensation and which is contributed to, sponsored by or maintained by the Borrower or any of its Subsidiaries or (B) the Borrower or any of its Subsidiaries has had or has or could reasonably be expected, individually or in the aggregate, to have any present or future obligation or liability.

Enterprise Value ” means (a) the Market Cap, minus (b) the amount of the Indebtedness of the Successor Entity and its Subsidiaries as shown on a consolidated basis on the latest balance sheet publicly filed under the Exchange Act prior to the announcement date of the Successor Entity Transaction (the “ Current Balance Sheet ”), plus (c) the amount of cash and Cash Equivalents (without giving effect to clause (f) of the definition of “Cash Equivalents) of the Successor Entity and its Subsidiaries as shown on a consolidated basis on the Current Balance Sheet.

Environmental Laws ” means all Applicable Laws, Authorizations and permits imposing liability or standards of conduct for or relating to the regulation and protection of human health, safety, the workplace, the environment and natural resources, and including public notification requirements and environmental transfer of ownership, notification or approval statutes.

 

10


Environmental Liabilities ” means all Liabilities (including costs of removal and remedial actions, natural resource damages and costs and expenses of investigation and feasibility studies, including the cost of environmental consultants and attorneys’ costs) that may be imposed on, incurred by or asserted against any Loan Party or any Subsidiary of any Loan Party as a result of, or related to, any claim, suit, action, investigation, proceeding or demand by any Person, whether based in contract, tort, implied or express warranty, strict liability, criminal or civil statute or common law or otherwise, arising under any Environmental Law resulting from the ownership, lease, sublease or other operation or occupation of property by any Loan Party or any Subsidiary of any Loan Party, whether on, prior or after the Agreement Date.

Equipment ” means equipment (as that term is defined in the UCC).

ERISA ” means the Employee Retirement Income Security Act of 1974, as amended and applicable published guidance thereunder.

ERISA Affiliate ” means collectively the Borrower, any Subsidiary of Borrower and any Person under common control or treated as a single employer with, Borrower or any Subsidiary of Borrower within the meaning of Code Section 414 (b), (c), (m) or (o) or under ERISA.

ERISA Event ” means any of the following: (a) a reportable event described in Section 4043(b) or (c) of ERISA (other than an event for which the 30-day notice period is waived) with respect to a Title IV Plan; (b) the withdrawal of any ERISA Affiliate from a Title IV Plan subject to Section 4063 of ERISA during a plan year in which it was a substantial employer, as defined in Section 4001(a)(2) of ERISA; (c) the complete or partial withdrawal of any ERISA Affiliate from any Multiemployer Plan; (d) with respect to any Multiemployer Plan, the filing of a notice of insolvency or termination, or treatment of a plan amendment as termination, under Section 4041A of ERISA; (e) the filing of a notice of intent to terminate a Title IV Plan, or treatment of a plan amendment as termination, under Section 4041 of ERISA; (f) the institution of proceedings to terminate a Title IV Plan or Multiemployer Plan by the PBGC; (g) the failure to make any required contribution to any Title IV Plan or Multiemployer Plan when due; (h) the imposition of a Lien under Section 412 or 430(k) of the Code or Section 303 or 4068 of ERISA on any property (or rights to property, whether real or personal) of any ERISA Affiliate; (i) the failure of an Employee Benefit Plan or any trust thereunder intended to qualify for tax exempt status under Section 401 or 501 of the Code or other Applicable Law to qualify thereunder; (j) a Title IV plan is in “at risk” status within the meaning of Code Section 430(i); (k) a Multiemployer Plan is in “endangered status” or “critical status” within the meaning of Section 432(b) of the Code; and (l) any other event or condition that constitutes grounds under Section 4042 of ERISA for the termination of, or the appointment of a trustee to administer, any Title IV Plan or Multiemployer Plan or for the imposition of any Liability upon any ERISA Affiliate under Title IV of ERISA other than for contributions to Title IV Plans and Multiemployer Plans in the ordinary course and PBGC premiums due but not delinquent.

Exercise Price ” has the meaning provided therefor in the Warrants.

Event of Default ” has the meaning set forth in Section 5.4.

Exchange Act ” means the Securities Exchange Act of 1934, as amended, including the rules and regulations promulgated thereunder.

Exchanged Deerfield Convertible Notes ” has the meaning specified therefor in the recitals hereto.

Excluded Accounts ” has the meaning set forth in Section 5.1(k).

 

11


Excluded Domestic Holdco means a wholly-owned Domestic Subsidiary of the Borrower substantially all of the assets of which consist of Stock of Excluded Foreign Subsidiaries held directly or indirectly by such Subsidiary and which does not engage in any business, operations or activity other than that of a holding company, excluding for purposes of such determination, Indebtedness of such Excluded Foreign Subsidiaries.

Excluded Foreign Subsidiary ” means any Foreign Subsidiary which is a controlled foreign corporation (as defined in the Code) that has not guaranteed or pledged any of its assets to secure, or with respect to which there shall not have been pledged two-thirds or more of the voting Stock to secure, any Indebtedness (other than the Obligations) of a Loan Party.

Excluded Property ” means, collectively:

(a) voting shares of any (A) Excluded Foreign Subsidiary of Borrower or (B) Excluded Domestic Holdco, in each case, in excess of 65% of all of the issued and outstanding voting shares of capital stock of such subsidiary;

(b) any lease, license, contract, property right or agreement as to which, if and to the extent that, and only for so long as, the grant of a security interest therein shall (1) constitute or result in a breach, termination or default under any such lease, license, contract, property right or agreement or render it unenforceable, (2) be prohibited by any applicable law or (3) require the consent of any third party (in each case of clauses (1), (2) and (3), other than to the extent that any such breach, termination, default, prohibition or requirement for consent would be rendered ineffective pursuant to Sections 9-406, 9-407, 9-408 or 9-409 of the UCC of any relevant jurisdiction or any other applicable Law), provided that such security interest shall attach immediately to each portion of such lease, license, contract, property rights or agreement that does not result in any of the consequences specified above;

(c) any “intent to use” trademark applications for which a statement of use has not been filed (but only until such statement is filed);

(d) motor vehicles and other assets, in each instance, in which perfection of a security requires notation on certificates of title with a value, individually, of less than $250,000;

(e) without in any way limiting clause (a) above, equity interests in any Person (other than wholly owned Subsidiaries) to the extent not permitted by the terms of such Person’s organizational or joint venture documents (so long as such joint venture was not entered into (or such Subsidiary was not formed) in contravention of the terms of the Loan Documents and such prohibition did not arise in anticipation of the restrictions under the Loan Documents);

(f) any assets financed by purchase money Indebtedness or Capital Leases, to the extent such purchase money Indebtedness or Capital Lease is permitted hereunder, if the documentation governing such purchase money Indebtedness or Capital Leases securing such purchase money Indebtedness or Capital Leases prohibits the creation of a security interest or lien thereon or requires the consent of any Person as a condition to the creation of any other security interest or lien on such property or if such contract or other agreement would be breached or give any party the right to terminate it as a result of creation of such security interest or lien;

(g) those assets as to which Agent determines (in its sole discretion) that the cost of obtaining such a security interest or perfection thereof are excessive in relation to the benefit to Agent and the Lenders of the security to be afforded thereby; and

 

12


(h) the Bank of America Cash Collateral Account;

provided , however , notwithstanding anything to the contrary herein or under the other Loan Documents, “Excluded Property” shall not include (a) any proceeds, products, substitutions, receivables or replacements of Excluded Property (unless such proceeds, products, substitutions, receivables or replacements would otherwise constitute Excluded Property) or (b) any assets or property provided as security or collateral for the ABL Debt or for which a Lien has been granted in favor of ABL Agent, any ABL Lender or any other Person party to the ABL Debt Documents.

Excluded Subsidiary ” means (a) any Excluded Domestic Holdco and (b) any Excluded Foreign Subsidiary.

Excluded Taxes ” means with respect to any Lender, (a) Taxes imposed on (or measured by) such Lender’s net income or franchise Taxes and branch profits Taxes in each case (i) imposed as a result of such Lender being organized under the laws of, or having its principal office, or applicable lending office located in the jurisdiction imposing such Tax (or any political subdivision thereof), or (ii) that are Other Connection Taxes, (b) any United States federal withholding Tax imposed on amounts payable to such Lender under the laws in effect at the time such Lender becomes a party to this Agreement or such Lender changes its lending office, except to the extent such Lender acquired its interest in the Loan from a transferor that was entitled, immediately before such transfer, to receive Additional Amounts with respect to such withholding Tax pursuant to Section 2.5(a) or was itself so entitled immediately before changing its lending office, (c) any Tax imposed on amounts payable to such Lender directly as a result of such Lender’s failure to comply with Section 2.5(d) other than as a result of a change in Applicable Law occurring subsequent to the date such Lender became a party to this Agreement, or (d) any United States federal withholding Tax imposed on amounts payable to such Lender under FATCA.

Existing ABL Agent ” has the meaning assigned to such term in the definition of “Existing ABL Credit Facility” herein.

Existing ABL Credit Facility ” means that certain Credit and Security Agreement, dated as of July 29, 2016, by and among the Borrower, the other Persons party thereto from time to time as “Borrowers” (as defined therein), Midcap Financial Trust, a Delaware statutory trust, as Agent (as defined therein, in such capacity, the “ Existing ABL Agent ”) and the financial institutions or other entities from time to time parties thereto, each as a Lender (as defined therein) (in such capacity, the “ Existing ABL Lenders ”), as amended, restated, supplemented or otherwise modified prior to the Prior Agreement Date.

Existing ABL Debt Documents ” shall have the meaning of “Loan Documents” (as defined in the Existing ABL Credit Facility).

Existing ABL Lenders ” has the meaning assigned to such term in the definition of “Existing ABL Credit Facility” herein.

Exit Payment ” means the First Out Waterfall Loan Exit Payment and/or the Last Out Waterfall Loan Exit Payment, as the context may require.

FATCA ” means Sections 1471 through 1474 of the Code as of the Agreement Date (or any amended or successor version that is substantively comparable and not materially more onerous to comply with), any regulations or official interpretations thereof and any agreements entered into pursuant to Section 1471(b)(1) of the Code and any applicable intergovernmental agreements entered into with respect to the foregoing.

 

13


FCPA ” has the meaning set forth in Section 3.1(jj).

FDA ” means the Food and Drug Administration of the United States of America, any comparable state or local Governmental Authority, any comparable Governmental Authority in any non- United States jurisdiction, and any successor agency of any of the foregoing.

FDCA ” means the Federal Food, Drug and Cosmetic Act, as amended, 21 U.S.C. Section 301 et seq., and all regulations promulgated thereunder.

Federal Reserve Board ” means the Board of Governors of the Federal Reserve System or any entity succeeding to any of its principal functions.

Final Payment ” means such cash amount as may be necessary to repay the outstanding principal amount of the Loans and any other Obligations (including, for the avoidance of doubt, for any applicable Non-Callable Make Whole Amount payable hereunder and the CoC Fee payable hereunder, but excluding (A) unasserted contingent indemnification obligations and (B) those Obligations under the Warrants and the Registration Rights Agreement or in respect of any Stock), owing by the Borrower and the other Loan Parties to the Secured Parties pursuant to the Loan Documents; provided that the foregoing shall be subject to the second sentence of Section 6.22.

First Amortization Date ” has the meaning set forth in Section 2.3(a).

First Out Waterfall Disbursement ” has the meaning set forth in Section 2.2(a)(i).

First Out Waterfall Lender ” means any Lender to which any First Out Waterfall Obligations are owing and its successors and assigns (in each case, in its capacity as such).

First Out Waterfall Loan ” is defined in Section 2.2(a)(i) hereof.

First Out Waterfall Loan Exit Payment ” has the meaning set forth in Section 2.7(d).

First Out Waterfall Notes ” has the meaning set forth in the definition of “Loan Notes”.

First Out Waterfall Obligations ” means the Obligations in respect of First Out Waterfall Loans, including any Non-Callable Make Whole Amount, any CoC Fee, the First Out Waterfall Loan Exit Payment, all interest, fees, expenses, costs, liabilities, indebtedness and other obligations (monetary (including post-petition interest, costs, fees, expense and other amounts, whether allowed or not) or otherwise) of (or owed by) the Borrower and the other Loan Parties under or in connection with the Loan Documents, in each case, howsoever created, arising or evidenced, whether direct or indirect (including those acquired by assignment), absolute or contingent, now or hereafter existing, or due or to become due, and irrespective of whether the same are added to the principal amount of the First Out Waterfall Obligations.

First Out Waterfall Pro Rata Share ” means, with respect to any First Out Waterfall Lender, the percentage obtained by dividing (a) the unpaid principal amount of such First Out Waterfall Lender’s portion of the First Out Waterfall Loans, by (b) the unpaid principal amount of all First Out Waterfall Loans.

First Out Waterfall Secured Parties ” means the Secured Parties (other than the Last Out Secured Parties).

 

14


First Out Waterfall Securities ” has the meaning set forth in Section 3.1(z).

Foreign Benefit Plan ” means any employee benefit plan that is subject to the laws of a jurisdiction outside the United States, including those mandated by a government other than that of the United States of America.

Foreign Lender ” has the meaning set forth in Section 2.5(d).

Foreign Subsidiary ” means, with respect to any Person, a Subsidiary of such Person, which Subsidiary is not a Domestic Subsidiary.

GAAP ” means generally accepted accounting principles as in effect from time to time in the United States applied on a consistent basis, subject to the provisions of Section 1.5.

General Intangible ” means any “general intangible” as defined in Article 9 of the UCC, and any personal property, including things in action, other than accounts, chattel paper, commercial tort claims, deposit accounts, documents, goods, instruments, investment property, letter-of-credit rights, letters of credit, money, and oil, gas or other minerals before extraction, but including payment intangibles and software.

Global Excess Liquidity ” means, as of any date of determination by Agent, the sum of (a) without duplication of clause (b) of this definition, unrestricted cash and Cash Equivalents maintained in the deposit accounts or securities accounts of the Loan Parties, in each case, subject to Control Agreements in compliance with the provisions of Section 5.1(k), plus (b) without duplication of clause (a) of this definition, unrestricted cash and Cash Equivalents of Loan Parties that is in Excluded Accounts maintained by a branch office of the bank or securities intermediary located outside the United States in an aggregate amount not to exceed the lesser of (i) $10,000,000 and (ii) 20% of clause (a) of this definition, plus (c) without duplication of any cash or Cash Equivalents from any borrowing under the ABL Debt Documents that would count towards either of clause (a) or clause (b) of this definition and solely to the extent the applicable conditions in Article III of the ABL Credit Agreement (and any additional conditions to borrowing under the ABL Credit Agreement that may be added or included in the ABL Debt Documents from time to time after the Agreement Date) have been satisfied (or would be satisfied if a borrowing would have been made thereunder) as of such date of determination after giving effect to any borrowing thereunder and any “Revolver Usage” (as defined in the ABL Credit Agreement as of the Agreement Date) as of such date, the amount of “Availability” (as defined in the ABL Credit Agreement as of the Agreement Date).

Good Manufacturing Practices ” means current good manufacturing practices, as set forth in 21 C.F.R. Parts 210, 211, 820 and any comparable foreign requirements.

Governmental Authority ” means any nation, sovereign, government, quasi-governmental agency, governmental department, ministry, cabinet, commission, board, bureau, agency, court, tribunal, regulatory authority, instrumentality, judicial, legislative, fiscal or administrative or public body or entity, whether domestic or foreign, federal, state, local or other political subdivision thereof, having jurisdiction over the matter or matters and Person or Persons in question or having the authority to exercise executive, legislative, taxing, judicial, regulatory or administrative functions of or pertaining to government, including any central bank, securities exchange, regulatory body, arbitrator, public sector entity, supra-national entity and any self-regulatory organization.

Guarantee ” by any Person means any obligation, contingent or otherwise, of such Person directly or indirectly guaranteeing any Indebtedness or other obligation of any other Person and, without limiting

 

15


the generality of the foregoing, any obligation, direct or indirect, contingent or otherwise, of such Person (a) to purchase or pay (or advance or supply funds for the purchase or payment of) such Indebtedness or other obligation (whether arising by virtue of partnership arrangements, by agreement to keep-well, to purchase assets, goods, securities or services, to take-or-pay, or to maintain financial statement conditions or otherwise), or (b) entered into for the purpose of assuring in any other manner the obligee of such Indebtedness or other obligation of the payment thereof or to protect such obligee against loss in respect thereof (in whole or in part), provided , however , that the term Guarantee shall not include endorsements for collection or deposit in the Ordinary Course of Business. The term “ Guarantee ” used as a verb has a corresponding meaning.

Guarantor ” means each Subsidiary of the Borrower (other than any Excluded Subsidiary) or other Person who provides a guaranty of the Obligations under the Security Agreement or other Loan Document.

Hazardous Material ” means any substance, material or waste that is classified, regulated or otherwise characterized under any Environmental Law as hazardous, toxic, a contaminant or a pollutant or by other words of similar meaning or regulatory effect, including petroleum or any fraction thereof, asbestos, polychlorinated biphenyls and radioactive substances.

Healthcare Laws ” means all Applicable Laws relating to the procurement, development, provision, clinical and non-clinical evaluation or investigation, product approval or clearance, manufacture, production, analysis, distribution, dispensing, importation, exportation, use, handling, quality, reimbursement, sale, labeling, advertising, promotion, or post-market requirements of any drug, medical device, clinical laboratory service, food, dietary supplement or other product (including, without limitation, any ingredient or component of, or accessory to, the foregoing products) subject to regulation under the FDCA or otherwise regulated by the FDA, or subject to regulation under the Clinical Laboratory Improvement Amendments of 1988 (42 U.S.C. §263a et seq.) and its implementing regulations (42 C.F.R. Part 493) and similar state or foreign laws, controlled substances laws, pharmacy laws, consumer product safety laws, Medicare, Medicaid, and all laws, policies, procedures, requirements and regulations pursuant to which Regulatory Required Permits are issued, in each case, as the same may be amended from time to time.

Immaterial Subsidiaries ” shall mean, as of any date of determination, any Subsidiary of the Borrower that is not a Loan Party that, when measured as of the most recent fiscal quarter end or fiscal year end for which the Borrower has filed its 10-K or 10-Q, when taken together with all other Immaterial Subsidiaries as of such date, (i) did not have assets with a value in excess of 5.0% of the total property and assets of the Loan Parties and their Subsidiaries on a consolidated basis set forth in the balance sheet included in such 10-K or 10-Q in accordance with GAAP and on a pro forma basis and (ii) did not have revenues representing in excess of 5.0% of total revenues of the Loan Parties and their Subsidiaries on a consolidated basis.

In Connection with a Change of Control ” means any prepayment, repayment, redemption or other payment (in each case, whether in full or in part) of the Obligations (other than unasserted contingent indemnification obligations and any Obligations under the Warrants or the Registration Rights Agreement or in respect of any Stock) that is both (1) made, or that is obligated or required to be made (including as a result of the Lenders’ exercise of the Put Right), hereunder prior to (but not including) the Maturity Date and (2) either: (a) such prepayment, repayment, redemption or other payment is made (or is obligated or required to be made) at any time during the period that commences 150 days prior to the earlier to occur of (i) the first public announcement of a potential Change of Control (and, for the avoidance of doubt, where a Change of Control is ultimately consummated before, on the date of or after the Maturity Date) or (ii) the consummation of a Change of Control, and ends on the consummation of a Change of Control, (b) such prepayment, repayment, redemption or other payment is otherwise made (or is obligated or required to be made) as a result of a Change of Control, or (c) such prepayment, repayment, redemption or other payment is made (or is obligated or required to be

 

16


made, whether through acceleration or otherwise) at any time on or after a Successor Entity Transaction.

Indebtedness ” means the following with respect to any Person:

(i) all indebtedness for borrowed money of such Person;

(ii) the deferred purchase price of assets or services (other than trade payables entered into in the Ordinary Course of Business and which are not more than 120 days past due and other than items covered by clause (xiv) of this definition) of such Person, which in accordance with GAAP should be shown to be a liability on the balance sheet;

(iii) all guarantees of Indebtedness by such Person;

(iv) the face amount of all letters of credit issued or acceptance facilities established for the account of such Person (or for which such Person is liable), including without duplication, all drafts drawn thereunder;

(v) all Capital Lease Obligations of such Person;

(vi) all indebtedness (including indebtedness of other types covered by the other clauses of this definition) of such Person or another Person secured by any Lien on any assets or property of such Person, whether or not such indebtedness has been assumed or is recourse (with the amount thereof, in the case of any such indebtedness that has not been assumed by such Person, being measured as the lower of (y) fair market value of such property and (z) the amount of the indebtedness secured);

(vii) all indebtedness created or arising under any conditional sale or title retention agreement, or incurred as financing, in either case with respect to assets or property acquired by such Person (even if the rights and remedies of the seller or lender under such agreement in the event of default are limited to repossession or sale of such assets or property);

(viii) all obligations of such Persons evidenced by notes, bonds, debentures or similar instruments, including obligations so evidenced incurred in connection with the acquisition of property, assets or businesses;

(ix) all obligations of such Person, whether or not contingent, in respect of Disqualified Stock, valued at, in the case of redeemable preferred Stock, the greater of the voluntary liquidation preference and the involuntary liquidation preference of such Stock plus accrued and unpaid dividends;

(x) all direct or indirect liability, contingent or otherwise, of such Person with respect to any other Indebtedness, lease, dividend or other obligation of another Person if the primary purpose or intent of the Person incurring such liability, or the primary effect thereof, is to provide assurance to the obligee of such liability that such liability will be paid or discharged, or that any agreements relating thereto will be complied with, or that the holders of such liability will be protected (in whole or in part) against loss with respect thereto;

 

17


(xi) all direct or indirect liability, contingent or otherwise, of such Person under Swap Contracts;

(xii) all direct or indirect liability, contingent or otherwise, of such Person to make take-or-pay or similar payments if required regardless of nonperformance by any other party or parties to an agreement;

(xiii) all direct or indirect liability, contingent or otherwise, of such Person for the obligations of another Person through any agreement to purchase, repurchase or otherwise acquire such obligation or any assets or property constituting security therefor, to provide funds for the payment or discharge of such obligation or to maintain the solvency, financial condition or any balance sheet item or level of income of another Person;

(xiv) earn-outs, all purchase price adjustments, profit sharing arrangements, deferred purchase money amounts and similar payment obligations (or continuing obligations of any nature of such Person arising out of purchase and sale contracts) (including in connection with Permitted Acquisitions), but only to the extent the same (x) have become due and payable and are recorded as a liability on the balance sheet of such Person and (y) are payable in cash;

(xv) all off-balance sheet liabilities of such Person; or

(xvi) all obligations arising under non-compete agreements, bonus, deferred compensation, incentive compensation or similar arrangements, other than those arising in the Ordinary Course of Business.

Indemnified Person ” has the meaning set forth in Section 6.11(a).

Indemnified Taxes ” means (a) any Tax imposed on or with respect to any payments made by or on account of any Obligation of any Loan Party under any Loan Document, other than an Excluded Tax, and (b) to the extent not otherwise described in clause (a) above in this definition, Other Taxes.

Indemnity ” has the meaning set forth in Section 6.11(a).

Initial Warrants ” has the meaning set forth in Section 2.8(a).

Insolvency Proceeding ” means any proceeding commenced by or against any Person under any provision of the Bankruptcy Code or under any other state or federal bankruptcy or insolvency law, assignments for the benefit of creditors, formal or informal moratoria, compositions, extensions generally with creditors, or proceedings seeking reorganization, arrangement, or other similar relief.

Intellectual Property ” means all Intellectual Property Licenses and all Copyrights, copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work, whether published or unpublished, any Patents, patents, patent applications and like protections, including improvements, divisions, continuations, renewals, reissues, extensions, and continuations-in-part of the same, Trademarks, trademarks, trade names, service marks, mask works, rights of use of any name, domain names, or any other similar rights, any applications therefor, whether registered or not, know-how, operating manuals, trade secret rights, clinical and non-clinical data, rights to unpatented inventions, and any claims for damage by way of any past, present, or future infringement of any of the foregoing.

 

18


Intellectual Property Licenses ” has the meaning set forth in the Security Agreement.

Intercompany Subordination Agreement ” means an intercompany subordination agreement, dated as of the Agreement Date, executed and delivered by the Loan Parties, each of their Subsidiaries, and Agent, the form and substance of which is reasonably satisfactory to Agent.

Intercreditor Agreement ” means the Intercreditor Agreement dated as of the Agreement Date by and among Agent and ABL Agent and acknowledged and agreed by the Loan Parties, as amended, restated, supplemented or otherwise modified from time to time in accordance with the terms thereof.

Interest Expense ” means, for any period, interest expense for the Successor Entity set forth in the Successor Entity’s most recent publicly reported income statement; provided that such amounts shall be limited to those incurred by the Successor Entity only (and not any of its Subsidiaries) unless such Subsidiaries (other than any Excluded Subsidiaries) have completed and consummated the Successor Entity Subsidiary Joinder Actions.

Interest Payment Date ” has the meaning set forth in Section 2.6(a).

Interest Payment Shares ” means any shares of Common Stock issued or issuable pursuant to Section 2.6 and Exhibit 2.6.

Interest Rate ” means (a) solely with respect to any period that occurs prior to (but not including) the Agreement Date, 6.87% per annum for the principal amount of the “Loans” (as defined in the Prior Facility Agreement) and any overdue interest thereon, plus any additional amounts set forth in Section 2.7(b) of the Prior Facility Agreement, and (b) at all times on or after the Agreement Date, 9.75% per annum for the principal amount of the Loans and any overdue interest thereon, plus any additional amounts set forth in Section 2.7(b).

Internal Controls ” has the meaning set forth in Section 3.1(u).

Inventory ” means inventory (as that term is defined in the UCC).

Investment ” has the meaning set forth in Section 5.2(v).

Investment Company Act ” means the Investment Company Act of 1940, as amended, including the rules and regulations promulgated thereunder.

IP ” means all Intellectual Property that is necessary for the conduct of the Loan Parties’ business as currently conducted.

IRS ” means the United States Internal Revenue Service.

Last Out Waterfall Disbursement ” has the meaning set forth in Section 2.2(a)(ii).

Last Out Waterfall Lender ” means any Lender to which any Last Out Waterfall Obligations are owing and its successors and assigns (in each case, in its capacity as such). For the avoidance of doubt, a Lender may be both a First Out Waterfall Lender and a Last Out Waterfall Lender.

Last Out Waterfall Loan ” is defined in Section 2.2(a) hereof.

Last Out Waterfall Loan Exit Payment ” has the meaning set forth in Section 2.7(e).

 

19


Last Out Waterfall Notes ” has the meaning set forth in the definition of “Loan Notes”.

Last Out Waterfall Obligations ” means the Obligations in respect of Last Out Waterfall Loans, including, without limitation, any Non-Callable Make Whole Amount, any CoC Fee, the Last Out Waterfall Loan Exit Payment all interest, fees, expenses, costs, liabilities, indebtedness and other obligations (monetary (including post-petition interest, costs, fees, expense and other amounts, whether allowed or not) or otherwise) of (or owed by) the Borrower and the other Loan Parties under or in connection with the Loan Documents, in each case, howsoever created, arising or evidenced, whether direct or indirect (including those acquired by assignment), absolute or contingent, now or hereafter existing, or due or to become due, and irrespective of whether the same are added to the principal amount of the Last Out Waterfall Obligations.

Last Out Waterfall Pro Rata Share ” means, with respect to any Last Out Waterfall Lender, the percentage obtained by dividing (a) the unpaid principal amount of such Last Out Waterfall Lender’s portion of the Last Out Waterfall Loans, by (b) the unpaid principal amount of all Last Out Waterfall Loans.

Last Out Waterfall Secured Parties ” means the Last Out Waterfall Lenders and each of their respective directors, partners, officers, employees, agents, counsel and advisors that are Indemnified Persons.

Latest Balance Sheet ” has the meaning set forth in Section 3.1(t).

Lenders ” means the lenders party to this Agreement from time to time, including the First Out Waterfall Lenders and the Last Out Waterfall Lenders, and their successors and assigns.

Liabilities ” means all claims, actions, suits, judgments, damages, losses, liabilities, obligations, responsibilities, fines, penalties, sanctions, costs, fees, Taxes, commissions, charges, disbursements and expenses (including those incurred upon any appeal or in connection with the preparation for and/or response to any subpoena or request for document production relating thereto), in each case of any kind or nature (including interest accrued thereon or as a result thereto and fees, charges and disbursements of financial, legal and other advisors and consultants), whether joint or several, and whether or not indirect, contingent, consequential, actual, punitive, treble or otherwise.

Lien ” means any lien, pledge, preferential arrangement, mortgage, security interest, deed of trust, charge, assignment, hypothecation, title retention or other encumbrance on or with respect to property or interest in property having the practical effect of constituting a security interest, in each case with respect to the payment of any obligation with, or from the proceeds of, any asset or revenue of any kind. For purposes of this Agreement and the other Loan Documents, any Loan Party or any Subsidiary shall be deemed to own subject to a Lien any asset which it has acquired or holds subject to the interest of a vendor or lessor under any conditional sale agreement, capital lease or other title retention agreement relating to such asset.

Loan ” means any loan made available from time to time by the Lenders to the Borrower pursuant to this Agreement, including any First Out Waterfall Loans and any Last Out Waterfall Loans, or, as the context may require, the principal amount thereof from time to time outstanding. “Loan” shall include any Disbursement.

Loan Disbursement Request ” means that certain Loan Disbursement Request, dated as of the Prior Agreement Date, executed and delivered by the Borrower in favor of the Secured Parties.

Loan Documents ” means this Agreement, the Notes, the Security Agreement, the Control Agreements, the Intercompany Subordination Agreement, the Intercreditor Agreement, the Reaffirmation

 

20


Agreement, the Collateral Access Agreements, the Warrants, the Registration Rights Agreement, each Perfection Certificate, each Compliance Certificate, the Loan Disbursement Request, the Patent Security Agreements, the Trademark Security Agreements, the Copyright Security Agreements, and other documents, agreements and instruments delivered in connection with any of the foregoing (in each case, including all schedules, exhibits, annexes and other attachments thereto) and dated the Prior Agreement Date, the Agreement Date or subsequent thereto, whether or not specifically mentioned herein or therein, in each case, as amended, restated, supplemented or otherwise modified from time to time.

Loan Notes ” means (x) any note issued to any of the First Out Waterfall Lenders evidencing any First Out Waterfall Loan or First Out Waterfall Disbursement funded by such First Out Waterfall Lender (or its predecessor) pursuant to the Prior Facility Agreement, as such Loan Note is amended and restated pursuant to this Agreement to be in the form of convertible loan note attached hereto as Exhibit A-1, and any convertible loan note in substantially such form issued after the Agreement Date to any First Out Waterfall Lender that holds any First Out Waterfall Loan or First Out Waterfall Disbursement (collectively, the “ First Out Waterfall Notes ”), and (y) any note issued to any of the Last Out Waterfall Lenders evidencing any Last Out Waterfall Loan or Last Out Waterfall Disbursement held by such Last Out Waterfall Lender pursuant to this Agreement in the form of loan note attached hereto as Exhibit A-2 (collectively, the “ Last Out Waterfall Notes ”); in each case of clause (x) and clause (y), as may be further amended, restated, supplemented or otherwise modified from time to time.

Loan Parties ” means the collective reference to the Borrower and all of the Guarantors.

Loss ” has the meaning set forth in Section 6.11(a).

Margin Stock ” means “margin stock” as such term is defined in Regulation T, U or X of the Federal Reserve Board.

Market Cap ” means the number of outstanding shares of common stock of the Successor Entity listed on a National Securities Exchange, multiplied by the per share Volume Weighted Average Price for such common stock as of the Trading Day immediately preceding the announcement of the Successor Entity Transaction.

Market Withdrawal ” means a Person’s Removal or Correction of a distributed product which involves a minor violation that would not be subject to legal action by the FDA or which involves no violation (e.g., normal stock rotation practices and routine equipment adjustments and repairs, etc.).

Material Adverse Effect ” means a material adverse effect on (a) the business, operations, results of operations, financial condition or properties of the Loan Parties and their Subsidiaries, taken as a whole, (b) the legality, validity or enforceability of any provision of any Loan Document, (c) the ability of any Loan Party to timely perform the Obligations, (d) the creation, perfection or priority of the Liens, taken as a whole for the Collateral, granted under the Loan Documents, or (e) the rights and remedies of the Secured Parties under any Loan Document.

Material Contracts ” means (a) the Operative Documents, (b) the Convertible Note Documents, (c) the agreements listed on Schedule 3.1(aa), (d) the ABL Debt Documents, (e) the Permitted Japan Lifeline Unsecured Debt Documents and (f) each other agreement or contract to which such Loan Party or its Subsidiaries is a party the termination of which could reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect; provided that Capped Calls shall not be considered Material Contracts.

 

21


Material Intangible Assets ” means all of (i) each Loan Party’s Intellectual Property and (ii) license or sublicense agreements or other agreements with respect to rights in Intellectual Property (including each Intellectual Property License), in each case that are material to the financial condition, business or operations of the applicable Loan Party.

Maturity Date ” means April 2, 2023.

Maturity Date Payment of First Out Waterfall Loans ” has the meaning set forth in Section 2.3(a).

Measurement Period ” means, at any date of determination, the most recently completed twelve (12) fiscal months of the Loan Parties for which (a) the 10-K or 10-Q for such period was filed (or, to the extent earlier, was required by the SEC to be filed) with the SEC or (b) financial statements are required to be delivered in Section 5.1(aa).

Medicaid ” means the medical assistance programs administered by state agencies and approved by CMS pursuant to the terms of Title XIX of the Social Security Act, codified at 42 U.S.C. 1396 et seq.

Medicare ” means the program of health benefits for the aged and disabled administered by CMS pursuant to the terms of Title XVIII of the Social Security Act, codified at 42 U.S.C. 1395 et seq.

Multiemployer Plan ” means any multiemployer plan, as defined in Section 3(37) or 4001(a)(3) of ERISA, as to which any ERISA Affiliate incurs or otherwise has, or could reasonably be expected, individually or in the aggregate, to have, any obligation or Liabilities (including under Section 4212 of ERISA).

National Securities Exchange ” means the New York Stock Exchange, the Nasdaq Global Select Market or the Nasdaq Global Market (or, in each case, a successor thereto).

Necessary Documents ” has the meaning set forth in Section 3.1(l).

Net Income ” means, for any period, the net income (or loss) of the Successor Entity set forth in the Successor Entity’s most recent publicly reported income statement; provided that such amounts shall be limited to those of the Successor Entity only (and not any of its Subsidiaries) unless such Subsidiaries (other than any Excluded Subsidiaries) have completed and consummated the Successor Entity Subsidiary Joinder Actions.

Net Revenue ” means, for any period, (a) the Loan Parties’ gross revenues during such period, less (b)(i) trade, quantity and cash discounts allowed by the Loan Parties, (ii) discounts, refunds, rebates, charge backs, retroactive price adjustments and any other allowances which effectively reduce net selling price, (iii) product returns and allowances, (iv) allowances for shipping or other distribution expenses, (v) set-offs and counterclaims, and (vi) any other similar and customary deductions used by the Loan Parties in determining net revenues, all, in respect of (a) and (b), as determined in accordance with GAAP and in the Ordinary Course of Business.

Non-Callable Make Whole Amount ” means, on any date of prepayment or early redemption of all or any portion of the Loans, an amount in cash equal to all required interest payments due on the Loans that are prepaid from the date of repayment or early redemption through and including the date that is the First Amortization Date, plus any accrued and unpaid interest and fees and unpaid costs and expenses incurred pursuant to the terms of the Loan Documents.

Notes ” means the Loan Notes.

 

22


Obligations ” means all Loans and Disbursements, any Non-Callable Make Whole Amount, any CoC Fee, the Exit Payment, interest, fees, expenses, costs, liabilities, indebtedness and other obligations (monetary (including post-petition interest, costs, fees, expenses and other amounts, whether allowed or not) or otherwise) of (or owed by) the Borrower and the other Loan Parties under or in connection with the Loan Documents, in each case howsoever created, arising or evidenced, whether direct or indirect (including those acquired by assignment), absolute or contingent, now or hereafter existing, or due or to become due, and irrespective of whether the same are added to the principal amount of the Obligations. For the avoidance of doubt, “Obligations” shall include the First Out Waterfall Obligations and the Last Out Waterfall Obligations.

OFAC ” has the meaning set forth in Section 3.1(jj).

OID ” means original issue discount.

Operating Expenditures ” means, with respect to any Person for any period, the amount of all expenditures (whether such expenditures are paid in cash, financed or otherwise) by such Person and its Subsidiaries during such period that are reported as operating expenses (including expenditures related to research and development, clinical and regulatory affairs, marketing and sales, and general and administrative) on the income statements of such Person and its Subsidiaries that are included in such Person’s financial statements (including those financial statements required by Section 5.1(h) and Section 5.1(aa), as applicable), which amount shall (i) be in compliance and accordance with GAAP and any SEC requirements and regulations, but (ii) exclude one-time, non-recurring expenditures that are not regularly incurred in the Ordinary Course of Business of such Person and its Subsidiaries.

Operative Documents ” means the Loan Documents, the “Loan Documents” (as defined in the ABL Credit Facility as of the Agreement Date) and the “Subordinated Debt Documents” (as defined in the ABL Credit Facility as of the Agreement Date).

Options ” means any rights, warrants or options to subscribe for or purchase shares of Common Stock or Convertible Securities.

Ordinary Course of Business ” means, in respect of any transaction involving any Loan Party, the ordinary course of business of such Loan Party, as conducted by such Loan Party in accordance with past practices, as applicable.

Organizational Documents ” means, with respect to any Loan Party, the documents by which such Person was organized (such as a certificate of incorporation, certificate of limited partnership or articles of organization, and including, without limitation, any certificates of designation for preferred stock or other forms of preferred equity) and which relate to the internal governance of such Person (such as by-laws, a partnership agreement or an operating, limited liability company or members agreement), including any and all shareholder agreements or voting agreements relating to the capital stock or other equity interests of such Person.

Other Connection Taxes ” means with respect to any Lender, Taxes imposed as a result of a present or former connection between such Lender and the jurisdiction imposing such Tax (except a connection arising solely from such Lender having executed, delivered, become a party to, performed its obligations or received a payment under, received or perfected a security interest under, engaged in any transaction pursuant to or enforced any Loan Document, or sold or assigned an interest in any Loan Document).

 

23


Other Taxes ” means any and all present or future stamp, value added or documentary or any other excise or property Taxes arising from any payment made hereunder or from the execution, delivery, performance, recordation or filing of, or otherwise with respect to, any Loan Document.

Outstanding Items ” has the meaning set forth in Section 5.1(z).

Participant ” has the meaning set forth in Section 6.5.

Parties ” has the meaning set forth in the preamble to this Agreement.

Patents ” has the meaning set forth in the Security Agreement.

Patent Security Agreement ” means any patent security agreement executed and delivered by any Loan Party to Agent, on behalf of the Secured Parties, as the same may be amended, restated, supplemented or otherwise modified and in effect from time to time.

PBGC ” means the United States Pension Benefit Guaranty Corporation or any successor thereto.

Perfection Certificate ” means each perfection certificate executed or delivered from time to time by any Loan Party or any of its Subsidiaries to any Secured Party, in substantially the form of Exhibit B.

Permitted 3.25% Convertible Note Refinancing ” has the meaning provided therefor in the definition of “Permitted Indebtedness.”

Permitted ABL Credit Facility Liens ” has the meaning provided therefor in clause (u) of the definition of “Permitted Liens”.

Permitted Acquisition ” means any Acquisition by a Loan Party, in each case, to the extent that each of the following conditions shall have been satisfied:

(a) the Borrower shall have delivered to Agent (i) at least ten (10) Business Days prior to the closing of the proposed Acquisition: (A) a description of the proposed Acquisition; (B) to the extent available, a due diligence package (including, to the extent available, a quality of earnings report); and (C) the most recent drafts (or, if available, executed counterparts) of the respective agreements, documents or instruments pursuant to which such Acquisition is to be consummated, any available schedules and exhibits to such agreements, documents or instruments and all other material ancillary agreements, instruments and documents to be executed or delivered in connection therewith, and to the extent required under the related acquisition agreement, all required regulatory and third party approvals and copies of any environmental assessments and (ii) at the earlier of (A) the time of closing of the proposed Acquisition or (B) as early before the closing of the proposed Acquisition as available, in each case, final, fully executed copies of the respective agreements, documents or instruments pursuant to which such Acquisition is to be consummated and all schedules and exhibits to such agreements, documents or instruments and all other material ancillary agreements, instruments and documents executed or delivered in connection therewith;

(b) the Loan Parties (including any new Subsidiary to the extent required by Section 5.1(l)) shall execute and deliver the agreements, instruments and other documents to the extent required by Section 5.1(l);

(c) no Event of Default or Default has occurred and is continuing, or would exist after giving pro forma effect to, the proposed Acquisition;

 

24


(d) all transactions in connection with such Acquisition shall be consummated, in all material respects, in accordance with applicable laws;

(e) the assets acquired in such Acquisition are for use in the same line of business as the Loan Parties are currently engaged or a line of business reasonably related thereto;

(f) such Acquisition shall not be hostile and, if applicable, shall have been approved by the board of directors (or other similar body) and/or the stockholders or other equity holders of any Person being acquired in such Acquisition;

(g) no Indebtedness or Liens are assumed or created (other than Permitted Liens and Permitted Indebtedness) in connection with such Acquisition;

(h) all conditions to “Permitted Acquisitions” (as defined in the ABL Credit Facility as of the Agreement Date) have been satisfied and Agent shall have received any requested evidence showing satisfaction thereof; and

(i) the total consideration paid or payable (including without limitation, costs and expenses, deferred purchase price, seller notes and other liabilities incurred, assumed or to be reflected on a consolidated balance sheet of the Loan Parties and their Subsidiaries after giving effect to such Acquisition but excluding (A) any equity interests issued as consideration for such Acquisition and (B) the net proceeds of any issuance of equity interests made after the Agreement Date that are used for purposes of such Acquisition) (such amounts, collectively, the “ Acquisition Consideration ”) shall be in an amount not to exceed $15,000,000 in the aggregate for all such Acquisitions during the term of this Agreement; provided , however , that, in the case of each Acquisition, Agent has received prior to the consummation of such Acquisition evidence satisfactory to Agent that Borrower has, immediately before and immediately after giving effect to the consummation of such Acquisition, unrestricted cash (it being understood and agreed that cash and Cash Equivalents shall not be considered “restricted” cash for purposes of this proviso solely due to compliance by the Loan Parties with the requirements set forth in Section 5.1(k)) in one or more deposit accounts subject to a Control Agreement in an aggregate amount equal to or greater than the positive value of the product of (x) eighteen (18) multiplied by (y) the “Monthly Cash Burn Amount” (as defined in the ABL Credit Facility as of the Agreement Date), as determined as of the last day of the month immediately preceding such Acquisition.

Permitted Contingent Obligations ” means

(a) Contingent Obligations arising in respect of the Indebtedness under the Loan Documents;

(b) Contingent Obligations resulting from endorsements for collection or deposit in the Ordinary Course of Business;

(c) Contingent Obligations outstanding on the Prior Agreement Date and set forth on Schedule 5.2(iv) (but not including any refinancings, extensions, increases or amendments to the indebtedness underlying such Contingent Obligations other than extensions of the maturity thereof without any other material change in terms adverse to the Lenders);

(d) Contingent Obligations incurred in the Ordinary Course of Business with respect to surety and appeal bonds, performance bonds and other similar obligations not to exceed $2,000,000 in the aggregate at any time outstanding;

 

25


(e) Contingent Obligations arising under indemnity agreements with title insurers to cause such title insurers to issue to Agent mortgagee title insurance policies;

(f) Contingent Obligations arising with respect to customary indemnification obligations in favor of purchasers in connection with dispositions of personal property assets permitted under Section 5.2;

(g) so long as there exists no Event of Default both immediately before and immediately after giving effect to any such transaction, Contingent Obligations existing or arising under any Swap Contract or Capped Call; provided , however , that such obligations are (or were) entered into by Borrower or an Affiliate of Borrower for the purpose of directly mitigating risks associated with liabilities, commitments, investments, assets, or property held or reasonably anticipated by such Person and not for purposes of speculation and either (i) with respect to a Swap Contract or a Capped Call, are (or were) entered into in the Ordinary Course of Business or (ii) with respect to a Capped Call, are (or were) entered into in connection with the 2.25% Convertible Notes, the 3.25% Convertible Notes, any refinancings thereof permitted hereunder or in connection with this Agreement or any of the other Loan Documents;

(h) guarantees by (A) one or more Loan Parties of the obligations of Foreign Subsidiaries up to $1,000,000 in the aggregate at any time outstanding, (B) any Loan Party of the obligations of any other Loan Party (but, for the avoidance of doubt, excluding any Immaterial Subsidiary that may be a Loan Party where, before and immediately after giving effect to such guarantee (including any rights of contribution set forth in the Loan Documents or otherwise), the Loan Parties cannot represent and warrant that such Immaterial Subsidiary is Solvent on an individual basis) and (C) any Foreign Subsidiary of the obligations of any other Foreign Subsidiary;

(i) [reserved];

(j) Contingent Obligations arising in respect of the Indebtedness under the ABL Debt Documents; and

(k) other Contingent Obligations not permitted by clauses (a) through (j) above, not to exceed $2,500,000 in the aggregate at any time outstanding.

Permitted Dispositions ” means each of the following:

(a) dispositions of inventory in the Ordinary Course of Business;

(b) dispositions of furniture, fixtures and equipment in the Ordinary Course of Business that the applicable Loan Party or Subsidiary determines in good faith is no longer used or useful in the business of such Loan Party and its Subsidiaries (or such Subsidiary and its subsidiaries);

(c) to the extent constituting a Disposition, Permitted Investments and Permitted Licenses;

(d) disposals of obsolete, worn out or surplus tangible personal property;

(e) without limiting transactions permitted under Section 5.2 hereof, dispositions by any Loan Party to any other Loan Party so long as each Loan Party (other than, with respect to any transferring Person, an Immaterial Subsidiary) will remain Solvent after giving effect to the transfer;

 

26


(f) abandonment of Intellectual Property that does not constitute a Material Intangible Asset;

(g) the unwinding or terminating of Swap Contracts or any Capped Call permitted by clause (g) of the definition of “Permitted Contingent Obligations” either (i) with respect to a Swap Contract or a Capped Call, in the Ordinary Course of Business or (ii) with respect to a Capped Call, that were entered into in connection with the 2.25% Convertible Notes, the 3.25% Convertible Notes, any Permitted 3.25% Convertible Note Refinancing permitted hereunder or in connection with this Agreement or any of the other Loan Documents;

(h) dispositions of equipment or real property to the extent that (i) such property is exchanged for credit against the purchase price of replacement property or (ii) the proceeds of such disposition are promptly applied to the purchase price of such replacement property;

(i) the entering into of any Permitted License;

(j) Dispositions by any Foreign Subsidiary to any other Foreign Subsidiary or to any Loan Party;

(k) Dispositions approved by Agent in writing;

(l) to the extent constituting a Disposition, the payment of cash and Cash Equivalents in the Ordinary Course of Business;

(m) other Dispositions (excluding dispositions of Intellectual Property) the proceeds of which, when aggregated with the proceeds of all other Dispositions made pursuant to this clause (m) are less than $2,500,000 during the term of this Agreement; provided that (i) the consideration received for such assets shall be in an amount at least equal to the fair market value thereof (determined in good faith by the board of directors (or similar governing body) of the applicable Loan Party that owned such assets), (ii) no less than 75% thereof shall be paid in cash and (iii) no Default or Event of Default then exists or would arise therefrom; provided that the requirements and conditions set forth in the proviso in clause (m) of the definition of “Permitted Dispositions” in the ABL Credit Facility as in effect as of the Agreement Date have been completely satisfied;

(n) to the extent constituting Dispositions, Recalls of Products (or components of Products) returned to suppliers in the Ordinary Course of Business as required by Applicable Law or the FDA with the consideration paid for such Products (or such components of Products) returned to the Loan Party or Subsidiary that purchased and returned such Product (or such components of Products); and

(o) (i) Recalls of Products (or components of Products) from customers to the extent required by Applicable Law or the FDA and (ii) the Dispositions of such Products that were Recalled in the Ordinary Course of Business and for fair market value and on fair market terms.

Permitted Indebtedness ” means each of the following:

(a) the Loan Parties’ and their Subsidiaries’ Indebtedness to Agent and each Lender under this Agreement and the other Loan Documents;

(b) Indebtedness incurred as a result of endorsing negotiable instruments received in the Ordinary Course of Business;

 

27


(c) Capital Leases and purchase money Indebtedness not to exceed $5,000,000 at any time (whether in the form of a loan or a lease) used solely to acquire equipment used in the Ordinary Course of Business and secured only by such equipment;

(d) Indebtedness existing on the Agreement Date and described on Schedule 3.1(f) (but not including any refinancings, extensions, increases or amendments to such Indebtedness other than Permitted Refinancings);

(e) so long as there exists no Event of Default both immediately before and immediately after giving effect to any such transaction, Indebtedness existing or arising under any Swap Contract or Capped Call; provided , however , that such obligations are (or were) entered into by Borrower or an Affiliate of Borrower for the purpose of directly mitigating risks associated with liabilities, commitments, investments, assets, or property held or reasonably anticipated by such Person and not for purposes of speculation and either (i) with respect to a Swap Contract or a Capped Call, are (or were) entered into in the Ordinary Course of Business or (ii) with respect to a Capped Call, are (or were) entered into in connection with the 2.25% Convertible Notes, the 3.25% Convertible Notes, any Permitted 3.25% Convertible Note Refinancing permitted hereunder or in connection with this Agreement or any of the other Loan Documents;

(f) Indebtedness in the form of insurance premiums financed through the applicable insurance company;

(g) trade accounts payable arising and paid within 120 days of the date when due and in the Ordinary Course of Business;

(h) unsecured Indebtedness in an amount not to exceed $4,280,500 pursuant to a promissory note dated on or around the Agreement Date, by the Borrower in favor of Japan Lifeline Co., Ltd. (the “ Permitted Japan Lifeline Unsecured Debt ”), so long as (i) no prepayments, repayment, redemptions or payments shall be made with respect to the Permitted Japan Lifeline Unsecured Debt at any time until ninety-one (91) days after all of the Obligations have been paid in full, (ii) the all-in interest rate and pricing charged thereon shall not exceed 2.5% per annum and such interest shall not be paid more frequently than annually in arrears, (iii) no fees shall be paid thereon, (iv) such unsecured Indebtedness shall not be assigned or otherwise transferred by Japan Lifeline Co., Ltd. without the consent of the Agent, (v) Japan Lifeline Co., Ltd. (and any successor or assign thereof) shall enter into a subordination agreement with the Agent, in form and substance reasonably satisfactory to the Agent and the Lenders, and (vi) subordination provisions are included in such promissory note and any related documents (collectively, the “ Permitted Japan Lifeline Unsecured Debt Documents ”) in a manner, and in form and substance, reasonably satisfactory to the Agent and the Lenders and such Permitted Japan Lifeline Unsecured Debt Documents shall be in form and substance reasonably satisfactory to the Agent and the Lenders;

(i) Subordinated Debt;

(j) the ABL Debt under the ABL Credit Facility, in accordance with the terms of the Intercreditor Agreement and this Agreement;

(k) Indebtedness of the Loan Parties incurred under the 3.25% Convertible Notes in an aggregate principal amount not to exceed the aggregate principal amount outstanding on the Agreement Date after giving effect to any repayments or prepayments thereon on or prior to the Agreement Date (which, for the avoidance of doubt, shall not be greater than the aggregate principal amount outstanding on the Prior Agreement Date), and, so long as no Event of Default has occurred and is continuing, any refinancing or extension thereof or new issuance in connection with the exchange thereof and/or a new

 

28


issuance all or any portion of the proceeds of which will be used in connection with the repurchase or other refinancing of all or any portion thereof therewith that (i) has an aggregate outstanding principal amount not greater than $200,000,000 (when taking into account all such existing, refinanced, extended and newly issued Indebtedness), and does not provide for any amortization payments or other principal payments of any kind in advance of the date that is one year and one day after the Maturity Date, (ii) has a maturity no shorter than the date that is one year and one day after the Maturity Date (in the case of clause (i) and clause (ii), it being understood that, in each case, any provision requiring an offer to purchase such Indebtedness as a result of a change in control, fundamental change, delisting, asset sale or similar provision or any exercise or conversion of Stock (other than Disqualified Stock) shall not violate the foregoing restrictions in clause (i) or clause (ii)), (iii) is unsecured, (iv) does not have one or more obligors that are not Loan Parties, (v) contains terms that are prevailing market terms at the time of issuing or initial borrowing for the type of financing and for the quality of issuer or borrower, as determined by Borrower and its advisors in their reasonable business judgment, (vi) does not have an All-in Yield greater than the lesser of (A) 6% per annum and (B) an All-in Yield that would result in more than $10,000,000 per annum being paid in interest thereunder, (vii) does not cause Borrower either on an individual basis or together with its Subsidiaries (on a consolidated basis), immediately before, at the time of and immediately after giving effect to such Indebtedness (and after giving effect to the use of the proceeds thereof), to be no longer be Solvent (or such Persons are not Solvent immediately prior to giving effect thereto), and (vii) if in existence at such time or on the same date, is permitted under the ABL Debt Documents (collectively, a “ Permitted 3.25% Convertible Note Refinancing ”);

(l) Indebtedness of the Loan Parties incurred under the 2.25% Convertible Notes in an aggregate principal amount not to exceed the aggregate principal amount outstanding on the Agreement Date minus any prepayments, repayments, redemptions or payments thereon made on the Agreement Date or from time to time thereafter (which, for the avoidance of doubt, such aggregate principal amount shall not be greater than the amount outstanding as of the Prior Agreement Date);

(m) without limiting the provisions of Section 5.2 with respect to any Investment by a Loan Party, Indebtedness consisting of unsecured intercompany loans and advances (i) incurred by any Loan Party owing to one or more other Loan Parties, (ii) incurred by any Foreign Subsidiaries owing to any Loan Party solely to the extent constituting a Permitted Investment made by such Loan Party, or (iii) incurred by any Foreign Subsidiaries owing to any other Foreign Subsidiary;

(n) Indebtedness related to commercial credit cards provided by Bank of America, N.A. (or such other commercial bank permitted under the definition of “Bank of America Cash Collateral Account) that, in the aggregate outstanding at any one time, does not exceed $2,500,000, which Indebtedness may be secured by Liens permitted pursuant to clause (t) of the definition of Permitted Liens;

(o) to the extent constituting Indebtedness, any Permitted Contingent Obligations; and

(p) unsecured Indebtedness incurred in respect of netting services, overdraft protection and other like services, in each case, incurred in the Ordinary Course of Business;

(q) unsecured earn-out obligations and other similar contingent purchase price obligations incurred in connection with a Permitted Acquisition to the extent earned and payable and permitted pursuant to the definition of Permitted Acquisition and the other terms of this Agreement; and

(r) any other unsecured Indebtedness incurred by the Loan Parties or any of their Subsidiaries in an aggregate outstanding amount not to exceed $2,500,000 at any one time.

Permitted Investments ” means each of the following:

 

29


(a) Investments (i) shown on Schedule P-1 and existing on the Agreement Date and (ii) in Subsidiaries made prior to the Agreement Date;

(b) Investments in cash and Cash Equivalents;

(c) Investments consisting of the endorsement of negotiable instruments for deposit or collection or similar transactions in the Ordinary Course of Business;

(d) Investments consisting of (i) travel advances and employee relocation loans and other employee loans and advances in the Ordinary Course of Business, and (ii) loans to employees, officers or directors relating to the purchase of equity securities of Loan Parties or their Subsidiaries pursuant to employee stock purchase plans or agreements approved by Loan Parties’ board of directors (or other governing body), but the aggregate of all such loans outstanding may not exceed $500,000 at any time;

(e) Investments (including debt obligations) received in connection with the bankruptcy or reorganization of customers or suppliers and in settlement of delinquent obligations of, and other disputes with, customers or suppliers arising in the Ordinary Course of Business;

(f) Investments consisting of notes receivable of, or prepaid royalties and other credit extensions, to customers and suppliers who are not Affiliates, in the Ordinary Course of Business, provided, however, that this subpart (f) shall not apply to Investments of Loan Parties in any Subsidiary;

(g) Investments consisting of (i) deposit accounts in which Agent has received a Control Agreement, and (ii) deposit accounts that are Excluded Accounts (subject to any caps and applicable restrictions set forth in such definition);

(h) Investments by any Loan Party in any Subsidiary now owned or hereafter created by such Loan Party, which Subsidiary is a Loan Party or has otherwise provided a Guarantee of the Obligations of the Loan Parties which Guarantee is secured by a Lien granted by such Subsidiary to Agent in all or substantially all of its property of the type described in the Security Agreement and otherwise made in compliance with Section 5.1(l);

(i) Investments by (A) any Loan Party consisting solely of cash and Cash Equivalents in a Foreign Subsidiary; provided that at the time of the making of such Investment and immediately after giving effect thereto (i) no Event of Default has occurred and is continuing and (ii) Loan Parties have unrestricted (it being understood and agreed that cash and Cash Equivalents shall not be considered “restricted” cash for purposes of this proviso solely due to compliance by the Loan Parties with the requirements set forth in Section 5.1(k)) cash and Cash Equivalents in an aggregate amount of not less than $10,000,000, which cash and Cash Equivalents (x) are subject to a first priority perfected lien in favor of Agent for the benefit of Lenders (subject to Permitted Liens), (y) are held in a deposit account that is subject to a Control Agreement or a securities account subject to a Control Agreement and (z) unless the same could not be reasonably expected to reduce the amounts in such accounts below $10,000,000 at the time of such Investment and immediately after giving effect thereto, do not include any drawn or committed but unpaid drafts, ACH or EFT transactions and (B) a non-Loan Party Foreign Subsidiary in another non-Loan Party Foreign Subsidiary; provided , that , Investments pursuant to clause (i)(A) above shall be subject to the proviso at the end of this definition;

(j) Investments by any Loan Party consisting solely of inventory in any wholly-owned Foreign Subsidiaries, to the extent (i) such Investments are made in the Ordinary Course of Business consistent with its customary practices as in effect on and immediately prior to the Prior

 

30


Agreement Date, (ii) no Event of Default then exists or would arise therefrom and (iii) no “Event of Default” (as defined in the ABL Credit Facility as in effect as of the Agreement Date) then exists or would arise therefrom; provided that (y) no such Investment shall result in an “Overadvance” (as defined in the ABL Credit Facility as in effect as of the Agreement Date) and (z) such Investments shall be subject to the proviso at the end of this definition;

(k) so long as no Default or Event of Default shall have occurred and be continuing at the time thereof or would result therefrom, Investments consisting solely of cash and Cash Equivalents in joint ventures or similar arrangements in an amount not to exceed $5,000,000 in the aggregate during the term of this Agreement; provided , that , such Investments shall be subject to the proviso at the end of this definition;

(l) Permitted Acquisitions;

(m) Investments deemed to exist under any Swap Contracts or Capped Calls; provided , however , that such obligations are (or were) entered into by Borrower or an Affiliate of Borrower for the purpose of directly mitigating risks associated with liabilities, commitments, investments, assets, or property held or reasonably anticipated by such Person and not for purposes of speculation and are (or were) entered into either (i) with respect to a Swap Contract or a Capped Call, in the Ordinary Course of Business or (ii) with respect to a Capped Call, in connection with the 2.25% Convertible Notes, the 3.25% Convertible Notes, any Permitted 3.25% Convertible Note Refinancing permitted hereunder or in connection with this Agreement or any of the other Loan Documents; and

(n) other Investments in an amount not exceeding $5,000,000 in the aggregate; provided , that , such Investments shall be subject to the proviso at the end of this definition;

provided , that , Investments pursuant to clauses (i), (j), (k), and (n) of this definition of “Permitted Investments” shall not exceed $12,000,000 in the aggregate in any calendar year (or such lesser amount provided in the ABL Credit Facility from time to time) and, provided , further , that with respect to clause (j) above, such Investments consisting solely of Inventory in Foreign Subsidiaries shall be valued at the lesser of cost and book value.

Permitted Japan Lifeline Unsecured Debt ” has the meaning specified therefor in clause (h) of the definition of “Permitted Indebtedness”.

Permitted Japan Lifeline Unsecured Debt Documents ” has the meaning specified therefor in clause (h) of the definition of “Permitted Indebtedness”.

Permitted License ” means (a) any non-exclusive license of patent rights of a Loan Party or its Subsidiaries so long as all such Permitted Licenses are granted to third parties in the Ordinary Course of Business, do not result in a legal transfer of title to the licensed property, and have been granted in exchange for fair consideration, and (b) any exclusive license of patent rights of a Loan Party or its Subsidiaries so long as such Permitted Licenses do not result in a legal transfer of title to the licensed property, are exclusive solely as to discrete geographical areas outside of the United States, and have been granted in exchange for fair consideration.

Permitted Liens ” means each of the following:

(a) Liens existing on the Prior Agreement Date and set forth on Schedule 3.1(d); provided , that to qualify as a Permitted Lien, any such Lien described on Schedule 3.1(d) shall only secure the Indebtedness that it secures on the Prior Agreement Date;

 

31


(b) Liens in favor of the Secured Parties under the Loan Documents;

(c) carriers’, warehousemen’s, mechanics’, landlords’, materialmen’s, repairmen’s or other similar Liens arising in the Ordinary Course of Business which are not delinquent or remain payable without penalty or which are being contested in good faith and by appropriate proceedings, which proceedings have the effect of preventing the forfeiture or sale of the assets or property subject thereto and for which adequate reserves in accordance with GAAP are being maintained;

(d) Liens for Taxes, assessments or governmental charges or levies not past due or payable or that are being contested in good faith by appropriate proceedings and for which adequate reserves in accordance with GAAP are being maintained;

(e) (A) Liens arising from judgments, decrees or attachments in circumstances not constituting an Event of Default or Default and (B) pledges or cash deposits made in lieu of, or to secure the performance of, judgment or appeal bonds in respect to such judgments and proceedings;

(f) Liens in favor of financial institutions arising in connection with the Borrower’s or its Subsidiaries’ deposit accounts maintained in the Ordinary Course of Business held at such institutions to secure standard fees for services charged by, but not financing made available by, such institutions;

(g) Liens (other than any Lien imposed by ERISA) consisting of pledges or deposits required in the Ordinary Course of Business in connection with workers’ compensation, unemployment insurance and other social security legislation or to secure the performance of tenders, statutory obligations, surety, stay, customs and appeals bonds, bids, leases, governmental contract, trade contracts, performance and return of money bonds and other similar obligations (exclusive of obligations for the payment of borrowed money or other funded Indebtedness) or to secure liability to insurance carriers;

(h) easements, rights of way, restrictions and other similar encumbrances affecting real property which, in the aggregate, are not substantial in amount, do not materially affect the value or marketability of such real property and which do not in any case materially interfere with the conduct of the business of any Loan Party or its Subsidiaries;

(i) (i) any interest or title of a lessor, sublessor, licensor or sublicensor under any lease or license not prohibited by this Agreement or (ii) non-exclusive licenses and sublicenses granted by a Loan Party or any Subsidiary of a Loan Party and leases and subleases (by a Loan Party or any Subsidiary of a Loan Party as lessor or sublessor) to third parties in the Ordinary Course of Business not materially interfering with the business of the Loan Parties or any of their Subsidiaries;

(j) Liens of a collection bank arising under Section 4-210 of the UCC (or equivalent in foreign jurisdictions) on items in the course of collection;

(k) Liens on any assets or property acquired or held by any Loan Party or any Subsidiary of any Loan Party securing Indebtedness incurred or assumed for the purpose of financing (or refinancing) all or any part of the cost of acquiring such assets or property and permitted under clause (c) of the definition of “Permitted Indebtedness”; provided that (i) such Lien attaches solely to the assets or property so acquired in such transaction and the proceeds thereof and (ii) the principal amount of the Indebtedness secured thereby does not exceed 100% of the cost of such assets or property;

(l) Liens securing Capital Leases permitted under clause (c) of the definition of “Permitted Indebtedness”;

 

32


(m) Liens arising from the filing of precautionary uniform commercial code financing statements with respect to any lease not prohibited by this Agreement;

(n) Liens arising out of consignment or similar arrangements for the sale of goods entered into by the Borrower or any Subsidiary of the Borrower in the Ordinary Course of Business;

(o) Liens in favor of customs and revenue authorities arising as a matter of law which secure payment of customs duties in connection with the importation of goods in the Ordinary Course of Business;

(p) Liens on unearned insurance premiums securing the financing thereof to the extent permitted under clause (f) of the definition of “Permitted Indebtedness”;

(q) [reserved];

(r) Liens on assets of the Loan Parties and their Subsidiaries arising in connection with seller notes, earn-outs and other similar payment obligations constituting Acquisition Consideration in connection with Permitted Acquisitions so long as such Liens are subject at all times to a Subordination Agreement;

(s) [reserved];

(t) Liens in favor of Bank of America, N.A. (or such other commercial bank permitted under the definition of “Bank of America Cash Collateral Account”) on the Bank of America Cash Collateral Account; provided that if Borrower is using credit card services from the agent or a lender under ABL Debt Documents that are required to be secured, Borrower shall promptly use commercially reasonable efforts to terminate the Liens in respect of the Bank of America Cash Collateral Account; and

(u) Liens granted under the ABL Credit Facility, in accordance with, and to the extent subject to, the terms of the Intercreditor Agreement (“ Permitted ABL Credit Facility Liens ”).

Permitted Priority Liens ” means (a) solely with respect to the specific assets or property covered thereby, the Liens granted pursuant to, and in accordance with, clause (u) of the definition of “Permitted Liens ,” (b) Permitted Liens granted over specific property pursuant to clauses (f) (solely with respect to such applicable deposit accounts), (i) (solely with respect to the interest in such applicable lease, sublease, license or sublicense or the assets owned by such lessor, sublessor, licensor or sublicensor underlying same), (k) (solely with respect to the property permitted to be secured by such Indebtedness permitted pursuant to clause (c) of the definition of “Permitted Indebtedness”), (l) (solely with respect to the property that is part of the Capital Lease), (m) (solely with respect to the specific assets covered by such lease that are owned by such lessor), (n) (with respect to the goods permitted to be consigned thereby), (p) (solely with respect to such cash held by such insurance agency for such insurance premiums), and (t) (solely with respect to the Bank of America Cash Collateral Account) of the definition of “Permitted Liens”, but, in each case, only to the extent only such Lien (i) attaches solely to the assets or property so acquired in such transaction and the proceeds thereof and (ii) has prior priority to the Permitted ABL Credit Facility Liens, and (c) to the extent not otherwise covered by clause (b) above, non-consensual Permitted Liens that are solely provided by operation of (and in compliance with) Applicable Law.

Permitted Refinancing ” means Indebtedness constituting a refinancing or extension of Indebtedness evidenced by the permitted under clause (d) of the definition of “Permitted Indebtedness” and that (a) has an aggregate outstanding principal amount not greater than the aggregate principal amount of the Indebtedness being refinanced or extended, (b) has a weighted average maturity (measured as of the

 

33


date of such refinancing or extension) and maturity no shorter than that of the Indebtedness being refinanced or extended, (c) is not entered into as part of a sale leaseback transaction, (d) is not secured by a Lien on any assets other than the collateral securing the Indebtedness being refinanced or extended, (e) the obligors of which are the same as the obligors of the Indebtedness being refinanced or extended and (f) is otherwise on terms no less favorable to Loan Parties and their Subsidiaries, taken as a whole, than those of the Indebtedness being refinanced or extended.

Permitted Successor Transaction ” means a transaction that satisfies all of the following conditions: (A) the Stock of the Borrower is acquired by, or the Borrower is merged with, a corporation (each such transaction, a “ Successor Entity Transaction ”) that (i) is organized in a state of the United States that has both a Market Cap and an Enterprise Value of at least $2,000,000,000 (as reasonably determined by the Agent), (ii) has common Stock registered under Section 12 of the Exchange Act and listed on a National Securities Exchange, (iii) is current in its reporting requirements under the Exchange Act and (iv) is in compliance with all applicable listing standards of the National Securities Exchange on which its common stock is listed (such successor corporation, a “ Successor Entity ”), (B) before, at the time of and after giving effect to such Successor Entity Transaction, no Event of Default has occurred and is continuing, (C) Agent (for the benefit of the Secured Parties) maintains a first priority security interest (subject only to the Permitted Priority Liens) in all of the Collateral of the Loan Parties, and the Successor Entity and the Loan Parties shall take such actions and execute and deliver such documents, instruments and agreements required by Agent to effectuate the foregoing in this clause (i)(C), (D) in connection with any such Successor Entity Transaction, the Successor Entity shall take such actions and execute such documents, instruments and agreements as may be reasonably required by Agent to assume all of the Obligations on behalf of the Borrower and all Guarantors shall reaffirm and ratify its Guarantee of the Obligations and the Liens securing the Obligations the Borrower and such Guarantors granted under the Loan Documents to secure such Guarantees and Obligations, in each case, in a manner reasonably satisfactory to the Agent, (E) the Successor Entity and/or the Borrower shall take such actions requested by the Agent or any holder of the Warrants to effectuate the bargain, intention and agreements previously set forth in the Warrants, the Registration Rights Agreement and the other Loan Documents, (F) before, at the time of and after giving effect to such Successor Entity Transaction, the Successor Entity ( provided that the amounts related to the Successor Entity shall be limited to those incurred by the Successor Entity only (and not any of its Subsidiaries) unless such Subsidiaries (other than any Excluded Subsidiaries) have completed and consummated the Successor Entity Subsidiary Joinder Actions), the Loan Parties and their Subsidiaries shall have a Total Leverage Ratio on a pro forma basis (after giving effect to the Successor Entity Transaction and any Indebtedness that will remain or be assumed after such consummation thereof) of no greater than 2:1 and the Successor Entity and the Loan Parties shall deliver a certificate certifying to the same and providing such evidence and calculations thereof that may be reasonably requested by Agent, (H) the Successor Entity both on an individual basis and together with the Loan Parties and their Subsidiaries (on a consolidated basis), immediately before, at the time of and immediately after giving effect to such Successor Entity Transaction, is/are Solvent, (I) before, at the time of and after giving effect to such Successor Entity Transaction, the representations and warranties set forth in the Loan Documents (and the Prior Loan Documents) are true, correct and complete in all material respects (without giving effect to any double materiality) as of the Prior Agreement Date, the Agreement Date and the date thereof (or, if such representation or warranty is made as of such earlier specified date, as of such earlier specified date), (J) (1) each Subsidiary of the Successor Entity that was a Subsidiary of the Borrower immediately prior to the consummation of the Successor Entity Transaction shall comply with Section 5.1(l) and shall take such actions and execute and deliver such agreements, instruments and other documents in connection therewith as reasonably requested by Agent and (2) if the Subsidiaries of the Successor Entity immediately prior to giving effect to the Successor Entity Transaction and that will remain Subsidiaries of the Successor Entity after giving effect to the Successor Entity Transaction are to be included in the components of the definition of “Total Leverage Ratio” (and all components of the various definitions of the capitalized financial terms used in such definitions and the definitions of each such other capitalized financial term

 

34


related thereto) to determine whether clause (F) above is satisfied, such Subsidiaries of the Successor Entity (other than any Excluded Subsidiaries) have completed and consummated the Successor Entity Subsidiary Joinder Actions in a manner reasonably satisfactory to Agent, and (K) the Successor Entity and the Loan Parties shall deliver a certificate certifying that each of the foregoing conditions in this definition have been satisfied.

Person ” means and includes any natural person, individual, partnership, joint venture, corporation, trust, limited liability company, limited liability partnership, joint stock company, unincorporated organization, government entity or any political subdivision or agency thereof, or any other entity.

PIK Interest Payment ” has the meaning set forth in Section 2.6(a).

PIK Interest Rate ” means 4.75% per annum for the principal amount of the Loans and any overdue interest thereon.

Portfolio Interest Certificate ” has the meaning set forth in Section 2.5(d).

Principal Market ” means the NASDAQ Global Select Market (or any successor to the foregoing).

Prior Agreement Date ” means April 3, 2017.

Prior Facility Agreement ” has the meaning specified therefor in the recitals hereto.

Prior Loan Documents ” has the meaning specified therefor in Section 6.29.

Pro Rata Loan Share ” means, with respect to any Lender, the applicable amount specified opposite such Lender’s name on Annex A under the column “Total Disbursement Amount” (as such amount may be increased, decreased or otherwise adjusted from time to time in accordance with the terms hereof (including pursuant to any PIK Interest Payment or pursuant to any assignment and transfers by the Lenders hereunder) and the actual principal amount outstanding related thereto).

Pro Rata Share ” means, with respect to any Lender, the applicable percentage (as adjusted from time to time in accordance with the terms hereof) obtained by dividing (a) such Lender’s Pro Rata Loan Share of the outstanding Loans, by (b) the total outstanding amount of Loans held by all Lenders.

Products ” means, from time to time, any products currently manufactured, sold, developed, tested or marketed by any Loan Party or any of a Loan Party’s Subsidiaries.

Put Notice ” has the meaning set forth in Section 5.3.

Reaffirmation Agreement ” means that certain Reaffirmation Agreement, dated as of the Agreement Date, by the Loan Parties party thereto in favor of Agent.

Real Estate ” means any real property owned, leased, subleased or otherwise operated or occupied by any Loan Party or any Subsidiary of any Loan Party.

Recall ” means a Person’s Removal or Correction of a marketed product that the FDA considers to be in violation of the laws it administers and against which the FDA would initiate legal action (e.g., seizure).

Register ” has the meaning set forth in Section 1.4(b).

 

35


Registration Rights Agreement ” means that certain Amended and Restated Registration Rights Agreement dated as of the Agreement Date entered into by the Borrower and the Lenders and substantially in the form of Exhibit E (as may be amended, restated, supplemented or otherwise modified from time to time).

Regulation D ” means Regulation D of the Board of Governors of the Federal Reserve System as in effect from time to time and any successor to all or a portion thereof establishing reserve requirements.

Regulatory Required Permit ” means any and all licenses, clearances, exemptions, approvals, registrations, and permits issued by the FDA, DEA or any other applicable Governmental Authority, including, without limitation, Drug Applications, any 510(k) premarket clearance, grant of a de novo request, premarket approval application (“PMA”), or investigational device exemption (“IDE”), or the foreign equivalent to any of the foregoing necessary for the design, testing, manufacture, processing, assembly, packaging, labeling, marketing, distribution, commercialization, import, export, or sale of any Product by any applicable Loan Party (or Loan Parties) and its (or their) Subsidiaries as such activities are being conducted by such Loan Party (or Loan Parties) and its (or their) Subsidiaries with respect to such Product at such time; and any device listings and device establishment registrations under 21 C.F.R. Part 807, and any drug listings and drug establishment registrations under 21 U.S.C. Section 510, registrations issued by DEA under 21 U.S.C. Section 823 (if applicable to any Product) and those issued by State governments for the conduct of the Loan Parties’ or any of their Subsidiaries’ business.

Related Parties ” means, with respect to any Person, such Person’s Affiliates and the partners, directors, officers, employees, agents, trustees, administrators, managers, attorneys, advisors and representatives of such Person and of such Person’s Affiliates.

Releases ” means any release, threatened release, spill, emission, leaking, pumping, pouring, emitting, emptying, escape, injection, deposit, disposal, discharge, dispersal, dumping, leaching or migration of Hazardous Material into or through the environment.

Removal ” means the physical removal of a product from its point of use to some other location for repair, modification, adjustment, relabeling, destruction or inspection.

Reporting Period ” has the meaning set forth in Section 5.1(h).

Required First Out Waterfall Lenders ” means, at any time, the First Out Waterfall Lenders whose First Out Waterfall Pro Rata Share aggregate more than fifty percent (50%).

Required Last Out Waterfall Lenders ” means, at any time, Last Out Waterfall Lenders whose Last Out Waterfall Pro Rata Share aggregate more than fifty percent (50%).

Required Lenders ” means, at any time, both the Required First Out Waterfall Lenders and the Required Last Out Waterfall Lenders, unless all of the First Out Waterfall Obligations (other than (y) unasserted contingent indemnification First Out Waterfall Obligations and (z) those First Out Waterfall Obligations under any Warrant or the Registration Rights Agreement that are not due or payable at the time when all other First Out Waterfall Obligations are paid in full in cash) have been paid in full in cash and any Last Out Waterfall Obligations remain outstanding, in which case, the term “Required Lenders” shall mean only the Required Last Out Waterfall Lenders.

Restricted Payment ” means, with respect to any Person, (i) the declaration or making of any dividend payment or other distribution of assets, properties, cash, rights, obligations or securities on account of any of its Stock, (ii) the purchasing, redemption or other acquisition for value of any of its Stock

 

36


(other than, when no Default or Event of Default has occurred or is continuing (or would occur after giving effect to any such purchase, redemption or other acquisition) and to the extent there would be pro forma compliance with the financial covenants in Sections 5.2(xxiv) through (xxix) (after giving effect to any such purchase, redemption or other acquisition), solely pursuant to the Borrower’s stock option exchange program on the terms set forth, and specifically described (and without giving effect to any changes thereto that would be adverse to the Secured Parties), in that certain proxy statement of the Borrower filed with the SEC on April 20, 2018, the Borrower shall have the ability to provide certain qualified employees of the Borrower (which shall not include name executive officers or board of directors of the Borrower and only with respect to “Eligible Participants” (as described therein)) the option to surrender certain “out-of-the-money” or “underwater” options with an exercise price of $6.50 or greater that are “Eligible Options” (as described therein) for cancellation in exchange for a grant of a lesser number of new restricted stock units of the Borrower that may be settled for shares of the Borrower’s common stock under the Borrower’s amended and restated 2015 stock incentive plan of the Borrower that is attached to such aforementioned proxy statement (and without giving effect to any material changes thereto), all as further specifically described (and without giving effect to any material changes thereto) in such proxy statement) now or hereafter outstanding or (iii) the making of any payment or prepayment of principal of, premium, if any, interest, fees, redemption, exchange, purchase, retirement, defeasance, sinking fund or similar payment with respect to, any Indebtedness subordinated to the Obligations as to right and time of payment or as to other rights and remedies thereunder. For the avoidance of doubt, the entry into, any payments or deliveries in respect of, and the performance, exercise and/or settlement of the Borrower’s 2.25% Convertible Notes, 3.25% Convertible Notes (including, for the avoidance of doubt, any Permitted 3.25% Convertible Note Refinancing), Capped Calls, Warrants or under the ABL Credit Facility are not Restricted Payments.

Rights Plan ” has the meaning set forth in Section 3.1(rr).

Sanctioned Entity ” means (a) a country or a government of a country, (b) an agency of the government of a country, (c) an organization directly or indirectly controlled by a country or its government, (d) a Person resident in or determined to be resident in a country, in each case, that is subject to a country sanctions program administered and enforced by OFAC.

Sanctioned Person ” means a Person named on the list of specially designated nationals maintained by OFAC.

Sanctions ” means all economic or financial sanctions or trade embargoes imposed, administered or enforced from time to time by (a) the U.S. government, including those administered by OFAC or the U.S. Department of State, or (b) the United Nations Security Council, the European Union or Her Majesty’s Treasury of the United Kingdom.

Sarbanes-Oxley ” has the meaning set forth in Section 3.1(kk).

Scheduled First Amortization Payment of First Out Waterfall Loans ” has the meaning set forth in Section 2.3(a).

Scheduled Second Amortization Payment of First Out Waterfall Loans ” has the meaning set forth in Section 2.3(a).

SDN List ” has the meaning set forth in Section 3.1(jj).

SEC ” means the United States Securities and Exchange Commission.

 

37


SEC Documents ” means all reports, schedules, forms, statements and other documents filed by the Borrower with the SEC pursuant to the Securities Act or the Exchange Act since January 1, 2016 (including all financial statements and schedules included therein, all exhibits thereto and all documents incorporated by reference therein).

Second Amortization Date ” has the meaning set forth in Section 2.3(a).

Secured Parties ” means Agent, the Lenders and all Indemnified Persons.

Securities ” means the Loans, the Notes, and the related guaranties set forth in the Security Agreement of the Guarantors, the Interest Payment Shares, the Conversion Shares, the Warrants and the Warrant Shares.

Securities Act ” means the Securities Act of 1933, as amended, including the rules and regulations promulgated thereunder.

Security Agreement ” means the Amended and Restated Guaranty and Security Agreement executed and delivered on the Agreement Date pursuant to which the Loan Parties party thereto continue to grant to Agent for the benefit of the Secured Parties a security interest in all of their Collateral to secure the Obligations, as amended, restated, supplemented or otherwise modified from time to time.

Solvent ” means, with respect to any Person as of any date of determination, that, as of such date, (a) the value of the assets of such Person at a “fair valuation” (as referenced in the Bankruptcy Code) is greater than the total amount of liabilities (including contingent and unliquidated liabilities) of such Person, (b) such Person is able to pay all liabilities of such Person as such liabilities mature and (c) such Person does not have unreasonably small capital in relation to such Person’s business as contemplated as of the Agreement Date. In computing the amount of contingent or unliquidated liabilities at any time, such liabilities shall be computed at the amount that, in light of all the facts and circumstances existing at such time, represents the amount that can reasonably be expected to become an actual or matured liability.

Stock ” means (a) all shares of capital stock (whether denominated as common stock or preferred stock), equity interests, beneficial, partnership or membership interests, joint venture interests, participations or other ownership or profit interests in or equivalents (regardless of how designated) of or in a Person (other than an individual), whether voting or non-voting; and (b) all securities convertible into or exchangeable for any other Stock and all warrants, options or other rights (other than the 2.25% Convertible Notes, the 3.25% Convertible Notes, any Permitted 3.25% Convertible Note Refinancing permitted hereunder, any Capped Call transactions, and the Warrants) to purchase, subscribe for or otherwise acquire any other Stock, whether or not presently convertible, exchangeable or exercisable.

Subordinated Debt ” means any Indebtedness of the Loan Parties incurred pursuant to the terms of the Subordinated Debt Documents and with the prior written consent of Agent, all of which documents must be in form and substance acceptable to Agent in its sole discretion. As of the Agreement Date, there is no Subordinated Debt.

Subordinated Debt Documents ” means any documents evidencing and/or securing Indebtedness governed by a Subordination Agreement, all of which documents must be in form and substance acceptable to Agent in its sole discretion. As of the Agreement Date, there are no Subordinated Debt Documents.

Subordination Agreement ” means any agreement between Agent and another creditor of one or more Loan Parties, as the same may be amended, supplemented, restated or otherwise modified from time to time in accordance with the terms thereof, pursuant to which the Indebtedness owing from any Loan

 

38


Party or Loan Parties and/or the Liens securing such Indebtedness granted by any Loan Party or Loan Parties to such creditor are subordinated in any way to the Obligations and the Liens created under the Security Agreement, the terms and provisions of such Subordination Agreements to have been agreed to by, and be acceptable to, Agent in the exercise of its sole discretion.

Subordination Provisions ” has the meaning set forth in Section 5.4(v)(i).

Subsidiary ” or “ Subsidiaries ” means, with respect to any Person, (a) any corporation of which an aggregate of more than fifty percent (50%) of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, capital stock of any other class or classes of such corporation shall have or might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, owned legally or beneficially by such Person or one or more Subsidiaries of such Person, or with respect to which any such Person has the right to vote or designate the vote of more than fifty percent (50%) of such capital stock whether by proxy, agreement, operation of law or otherwise, and (b) any partnership or limited liability company in which such Person and/or one or more Subsidiaries of such Person shall have an interest (whether in the form of voting or participation in profits or capital contribution) of more than fifty percent (50%) or of which any such Person is a general partner or may exercise the powers of a general partner. Unless the context otherwise requires, each reference to a Subsidiary shall be a reference to a Subsidiary of a Loan Party.

Successor Entity ” has the meaning set forth in the definition of “Permitted Successor Transaction.”

Successor Entity Subsidiary Joinder Actions ” has the meaning set forth in the definition of “EBITDA”.

Successor Entity Transaction ” has the meaning set forth in the definition of “Permitted Successor Transaction.”

Swap Contract ” means any agreement, contract or transaction that constitutes a “swap” within the meaning of Section 1a(47) of the Commodity Exchange Act, not including Capped Calls.

Tax Affiliate ” means (a) the Borrower and its Subsidiaries and (b) any Affiliate of the Borrower with which the Borrower files or is required to file consolidated, combined or unitary tax returns.

Taxes ” means all present or future taxes, levies, imposts, stamp or other duties, deductions, charges or withholdings imposed by an Governmental Authority, together with any interest, additions to tax, penalties or other Liabilities with respect thereto.

Tax Returns ” has the meaning set forth in Section 3.1(p).

Third Party Obligation ” has the meaning provided therefor in the definition of “Contingent Obligation.”

Third Party Payor ” means Medicare, Medicaid, TRICARE, and other state or federal health care program, Blue Cross and/or Blue Shield, private health care insurers and managed care organizations.

Third Party Payor Programs ” means all private or governmental programs providing health care benefits, whether through insurance or otherwise, that are sponsored by a Third Party Payor.

 

39


Title IV Plan ” means an Employee Benefit Plan subject to Title IV of ERISA, other than a Multiemployer Plan, to which any ERISA Affiliate incurs or otherwise has or could reasonably be expected to have any obligation or Liabilities (including under Section 4069 of ERISA).

Total Leverage Ratio ” means, with respect to any measurement period, the ratio of (a) Indebtedness reflected as liabilities on the Successor Entity’s most recent publicly reported balance sheet as of the last day of such measurement period to (b) EBITDA as of the last day for such measurement period; provided that, in each case of clause (a) and clause (b), such amounts shall be limited to those incurred by the Successor Entity only (and not any of its Subsidiaries) unless such Subsidiaries (other than any Excluded Subsidiaries) have completed and consummated the Successor Entity Subsidiary Joinder Actions.

Trademarks ” has the meaning set forth in the Security Agreement.

Trademark Security Agreement ” means any trademark security agreement executed and delivered by any Loan Party to Agent, on behalf of the Secured Parties, as the same may be amended, restated, supplemented or otherwise modified and in effect from time to time.

Trading Day ” means any day on which the common Stock of the applicable Person is traded for at least six hours on a National Securities Exchange.

Transactions ” means (a) the repayment of certain existing Indebtedness (including certain of the 2.25% Convertible Notes and, in connection with any loans funded on the Prior Agreement Date under the Existing ABL Credit Facility or any other obligations outstanding on the Prior Agreement Date under the Existing ABL Credit Facility, all of the Indebtedness and other obligations evidenced by the Existing ABL Credit Facility and the Existing ABL Debt Documents), (b) the funding of the Disbursements, and (c) the payment of fees, commissions, costs and expenses in connection with each of the foregoing.

TRICARE ” means the program administered pursuant to 10 U.S.C. Section 1071 et seq., Sections 1320a-7 and 1320a-7a of Title 42 of the United States Code and the regulations promulgated pursuant to such statutes.

Trunk Inventory ” means “trunk stock inventory” that is in the possession of sales personnel of the Loan Parties.

UCC ” means the Uniform Commercial Code of any applicable jurisdiction and, if the applicable jurisdiction shall not have any Uniform Commercial Code, the Uniform Commercial Code as in effect from time to time in the State of New York.

United States ” and “ U.S. ” each means the United States of America.

USA Patriot Act ” means the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001, P.L. 107-56, as amended from time to time.

Volume Weighted Average Price ” for any security as of any Trading Day means the volume weighted average sale price of such security on the National Securities Exchange on which such security is listed as reported by Bloomberg Financial Markets or an equivalent, reliable reporting service reasonably selected by the Agent (“ Bloomberg ”). Volume Weighted Average Price will be determined without regard to after-hours trading or any other trading outside of the regular trading hours.

Warrant Distributions ” has the meaning set forth in Section 3.1(z).

 

40


Warrants ” means the Initial Warrants and the Additional Warrants.

Warrant Shares ” has the meaning set forth in Section 3.1(z).

Section  1.2 Interpretation . In this Agreement and the other Loan Documents, unless the context otherwise requires, all words and personal pronouns relating thereto shall be read and construed as the number and gender of the party or parties requires and the verb shall be read and construed as agreeing with the required word and pronoun. The division of this Agreement and the other Loan Documents into Articles and Sections and the use of headings and captions is for convenience of reference only and shall not modify or affect the interpretation or construction of this Agreement or any of its provisions. The words “herein,” “hereof,” “hereunder,” “hereinafter” and “hereto” and words of similar import refer to this Agreement (or other applicable Loan Document) as a whole and not to any particular Article or Section hereof (or thereof). The term “or” has, except where otherwise indicated, the inclusive meaning represented by the phrase “and/or.” The term “documents” and “agreements” include any and all instruments, documents, agreements, certificates, indentures, notices and other writings, however evidenced. The use in any of the Loan Documents of the word “include” or “including,” when following any general statement, term or matter, shall not be construed to limit such statement, term or matter to the specific items or matters set forth immediately following such word or to similar items or matters, whether or not non-limiting language (such as “without limitation” or “but not limited to” or words of similar import) is used with reference thereto, but rather shall be deemed to refer to all other items or matters that fall within the broadest possible scope of such general statement, term or matter. References to a specified Article, Exhibit, Section or Schedule shall be construed as a reference to that specified Article, Exhibit, Section or Schedule of this Agreement (or other applicable Loan Document). Unless specifically stated otherwise, any reference to any of the Loan Documents means such document as the same shall be amended, restated, supplemented or otherwise modified and from time to time in effect. The references to “asset” (or “assets”) and “property” (or “properties”) in the Loan Documents are meant to be mean the same and are used throughout the Loan Documents interchangeably, and such words shall be deemed to refer to any and all tangible and intangible assets and properties, including cash, securities, Stock, accounts and contract rights. Unless otherwise specified herein or therein, all terms defined in any Loan Document shall have the defined meanings when used in any certificate or other document made or delivered pursuant hereto or thereto. The meanings of defined terms shall be equally applicable to the singular and plural forms of the defined terms. Terms (including uncapitalized terms) not otherwise defined herein and that are defined in the UCC shall have the meanings therein described. In the computation of periods of time from a specified date to a later specified date, the word “from” means “from and including”; the word “since” means “since and including”; the words “to” and “until” each mean “to but excluding,” and the word “through” means “to and including.” If any provision of this Agreement or any other Loan Document refers to any action taken or to be taken by any Person, or which such Person is prohibited from taking, unless otherwise expressly stated, such provision shall be interpreted to encompass any and all means, direct or indirect, of taking, or not taking, such action. References to any statute or regulation may be made by using either the common or public name thereof or a specific cite reference and, except as otherwise provided with respect to FATCA, are to be construed as including all statutory and regulatory provisions related thereto or consolidating, amending, replacing, supplementing or interpreting the statute or regulation, and any reference to any law or regulation, shall, unless otherwise specified, refer to such law or regulation as amended, modified or supplemented from time to time. Whenever any reference is made in any Loan Document to any Person such reference shall be construed to include such Person’s permitted successors and permitted assigns. Any financial ratios required to be satisfied in order for a specific action to be permitted under any Loan Document shall be calculated by dividing the appropriate component by the other component, carrying the result to one place more than the number of places by which such ratio is expressed herein or therein and rounding the result up or down to the nearest number (with a rounding-up if there is no nearest number). Unless otherwise specified, all references in any Loan Document to times of day shall be references to New York City time. Notwithstanding anything to the contrary in any Loan Document, any

 

41


reference to “Organizational Document” or “Organizational Documents” of any Loan Party or any of its Subsidiaries in any Loan Document shall mean such written documents, agreements and arrangements that are in effect on the Prior Agreement Date after giving effect to the Transactions occurring on the Prior Agreement Date that have been approved by Agent, without giving effect to any amendment, restatement, change, supplement, waiver or other modification thereto or thereof that is not permitted by Section 5.2(x). The terms “shall” and “will” are used interchangeably in this Agreement and the other Loan Documents and mean for the Loan Parties and their Subsidiaries to have an absolute obligation to perform or do (or not perform or do) a certain action or event, as the context may require. Any reference to “payment in full”, “paid in full”, “repaid in full”, “prepaid in full”, “redeemed in full”, “no Obligations remain outstanding” or any other term or word of similar effect used in this Agreement or any other Loan Document with respect to the Loans or the Obligations shall mean all Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and the Exit Payment) (other than (y) unasserted contingent indemnification obligations and (z) those Obligations under any Warrant or the Registration Rights Agreement that are not due or payable at the time when all other Obligations are paid in full in cash) have been repaid in full in cash, have been fully performed and no longer remain outstanding.

Section  1.3 Business Day Adjustment . Except as otherwise expressly stated herein or in any other Loan Document, if the day by which any payment or other performance is due to be made is not a Business Day, that payment or performance shall be made by the next succeeding Business Day unless that next succeeding Business Day falls in a different calendar month, in which case that payment or other performance shall be made by the Business Day immediately preceding the day by which such payment or other performance is due to be made; provided that interest will continue to accrue each additional day in connection therewith.

Section  1.4 Loan Records .

(a) The Borrower shall record on its books and records the amount of the Loan, the type and tranche of the Loans (whether the Loan is a First Out Waterfall Loan or a Last Out Waterfall Loan), the interest rate applicable thereto, all payments of principal and interest thereon and the principal balance thereof from time to time outstanding.

(b) The Borrower shall establish and maintain at its address referred to in Section 6.1, a record of ownership (the “ Register ”) in which the Borrower agrees to register by book entry the interests (including any rights to receive payment hereunder) of each Lender in the Loan (including whether the Lender is a First Out Waterfall Lender or a Last Out Waterfall Lender and whether the Loan is a First Out Waterfall Loan or a Last Out Waterfall Lender), and any assignment of any such interest or interests. The Borrower shall maintain such Register in accordance with usual and customary business practices and the Borrower shall record (1) the names and addresses of the Lenders (and any change thereto pursuant to this Agreement), (2) the amount of the Loan (and whether the amount of such Loan is related to a First Out Waterfall Loan or a Last Out Waterfall Loan) and each funding of any participation therein, (3) the amount of any principal, interest, fee or other amount due and payable or paid, and (4) any other payment received by the Lenders from the Borrower and its application to the Loan.

(c) The Loans made by each Lender are evidenced by this Agreement and the Loan Notes issued pursuant to the Prior Facility Agreement. On the Agreement Date, the Borrower shall execute and deliver to (x) each First Out Waterfall Lender, a new First Out Waterfall Note and (y) each Last Out Waterfall Lender, a new Last Out Waterfall Note, and after the Agreement Date the Borrower shall execute and deliver to each Lender (and/or, if applicable and if so requested by any assignee Lender pursuant to the assignment provisions of Section 6.5) on the date of request by such Lender an amended and restated Loan Note or new Loan Note (which (i) if to a First Out Waterfall Lender, shall be substantially in the form of a First Out Waterfall Note attached hereto as Exhibit A-1, and (ii) if to a Last Out Waterfall Lender, shall be

 

42


substantially in the form of a Last Out Waterfall Note attached hereto as Exhibit A-2 (in each case, with any amendment and restatement mechanics built in as necessary that are in form and substance reasonably satisfactory to such applicable Lender and the Agent)), in each case, payable to such Lender in an amount equal to the unpaid principal amount of the Loans held by such Lender (which, at the request of such Lender shall be in the form of separate Loan Notes (taking into account the type and tranche of Loan) for separate or different parts of the Loans (taking into account the type and tranche of Loan) held by such Lender). For the avoidance of doubt, each “Loan Note” (as defined in the Prior Facility Agreement) issued, executed and/or delivered by the Borrower prior to the Agreement Date remains valid, binding and enforceable against the Borrower and continues to evidence and cover the Loans and other Obligations owed to such Lender that is the holder or beneficiary of such Loan Note and, effective on the Agreement Date, shall be deemed amended and restated to be in the form of the First Out Waterfall Loan Note attached hereto as Exhibit A-1 (whether or not the new First Out Waterfall Loan Notes have then been delivered to the First Out Waterfall Lenders as required hereby). On and after the Agreement Date, the principal of, and accrued and unpaid interest on, the First Out Waterfall Notes (and the First Out Waterfall Loans evidenced thereby) shall be convertible into shares of Common Stock as provided in the First Out Waterfall Notes. Notwithstanding anything to the contrary contained in this Agreement, the Loans (including any Note(s) evidencing the Loans) are registered obligations, the right, title and interest of the Lenders and their successors and assignees in and to the Loan shall be transferable only upon notation of such transfer in the Register and no assignment thereof shall be effective until recorded therein. This Section 1.4 shall be construed so that the Loan is at all times maintained in “registered form” within the meaning of Sections 163(f), 871(h)(2) and 881(c)(2) of the Code.

(d) The Borrower, Agent and the Lenders shall treat each Person whose name is recorded in the Register as a Lender for all purposes of this Agreement. Information contained in the Register with respect to any Lender shall be available for access by the Borrower, Agent or such Lender at any reasonable time and from time to time upon reasonable prior notice, or when an Event of Default or Default exists, with just notice (whether reasonable or not) by Agent or any such Lender.

Section  1.5 Accounting Terms and Principles . All accounting determinations required to be made pursuant hereto shall, unless expressly otherwise provided herein, be made in accordance with GAAP. No change in the accounting principles used in the preparation of any financial statement hereafter adopted by the Borrower or its Subsidiaries (including, with respect to GAAP, any change in GAAP that would require leases that would be classified as operating leases under GAAP on the Agreement Date to be reclassified as Capital Leases) shall be given effect for purposes of measuring compliance with any provision of this Agreement or otherwise determining any relevant ratios and baskets which govern whether any action is permitted hereunder unless the Borrower and the Agent agree to modify such provisions to reflect such changes in GAAP, and unless such provisions are modified, all financial statements and similar documents provided hereunder shall be provided together with a reconciliation between the calculations and amounts set forth therein before and after giving effect to such changes in GAAP. Notwithstanding any other provision contained herein or in any other Loan Document, all terms of an accounting or financial nature used herein and in the other Loan Documents shall be construed, and all computations of amounts and ratios referred to herein and in the other Loan Documents shall be made, without giving effect to any election under Statement of Financial Accounting Standards No. 159 (Codification of Accounting Standards 825-10) to value any Indebtedness or other liabilities of any Loan Party or any Subsidiary at “fair value,” as defined therein.

Section  1.6 Tax Treatment . It is the intention and agreement of the Parties that the changes to the Borrower’s existing indebtedness owed to the Lenders that are being effectuated pursuant to this Agreement shall be treated for federal income tax purposes as made pursuant to and as part of a plan of recapitalization and reorganization of the Borrower described in Section 368(a)(1)(E) of the Code. The

 

43


Parties shall prepare their income Tax Returns consistent with this treatment unless otherwise required by applicable federal income Tax law.

Section  1.7 Officers . Any document, agreement or instrument delivered under the Loan Documents that is signed by an Authorized Officer or another officer of a Loan Party shall be conclusively presumed to have been authorized by all necessary corporate, partnership and/or other action on the part of such Loan Party and such Authorized Officer or other officer shall be conclusively presumed to have acted on behalf of such Loan Party in such person’s capacity as an officer of such Loan Party and not in any individual capacity.

Section  1.8 Joint Drafting and Negotiation . The parties hereto have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question or intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provisions of this Agreement.

ARTICLE 2

AGREEMENT FOR THE LOANS

Section  2.1 Use of Proceeds . The proceeds of the Disbursements were or will be used solely (i) to refinance certain of the existing Indebtedness (including a certain amount of the existing 2.25% Convertible Notes), (ii) to provide funds for the Borrower’s working capital and general corporate purposes, and (iii) to pay a portion of the fees, costs and expenses related to the Prior Facility Agreement and this Agreement.

Section 2.2 Disbursements.

(a) The Disbursements .

(i) Subject to the terms and conditions of the Prior Facility Agreement and this Agreement and in reliance on the representations and warranties in the Prior Loan Documents and the Loan Documents, the First Out Waterfall Lenders (or its predecessors) on the Prior Agreement Date severally and not jointly advanced to the Borrower on such date, the principal amount set forth opposite such First Out Waterfall Lender’s (or its predecessors) name in Annex A of the Prior Facility Agreement under the heading “Disbursement Amount” appearing therein (such advances and loans, the “ First Out Waterfall Loan ”). Amounts borrowed under Section 2.2(a) of the Prior Facility Agreement (and/or mentioned in this Section 2.2(a)(i)) are referred to as the “ First Out Waterfall Disbursement .”

(ii) In reliance on the representations and warranties, conditions and terms in this Agreement and the other Loan Documents, the Last Out Waterfall Lender on the Agreement Date hereby exchanges its Exchanged Deerfield Convertible Notes for a loan under this Agreement in the principal amount set forth opposite the Last Out Waterfall Lender’s name in Annex A of this Agreement under the heading “Last Out Waterfall Loan Commitment” appearing therein (such loan, the “ Last Out Waterfall Loan ”). The amount of the Last Out Waterfall Loan is also referred to as the “ Last Out Waterfall Disbursement ” (together with the First Out Waterfall Disbursement, the “ Disbursements ”).

 

44


(b) No Re-Borrowing of Disbursements or Loans. Any Loans or Disbursements which are paid, repaid, prepaid or redeemed may not be re-borrowed under any circumstance.

Section 2.3 Payments; Prepayments; No Call; Non-Callable Make Whole Amount; First Out Waterfall Note Conversions.

(a) The Borrower shall pay in cash on the earliest of (i)(A) the dates set forth in the second column of the table below, to each of the First Out Waterfall Lenders, based on their First Out Waterfall Pro Rata Share of the outstanding principal amount of the First Out Waterfall Loans and their pro rata share of all other First Out Waterfall Obligations, in the amounts set forth in the second column of the table below and (B) the dates set forth in the third column of the table below, to each of the Last Out Waterfall Lenders, based on their Last Out Waterfall Pro Rata Share of the outstanding principal amount of the Last Out Waterfall Loans and their pro rata share of all other Last Out Waterfall Obligations, in the amounts set forth in the third column of the table below (in each case of clause (A)(i) and clause (A)(ii) above, as such installments may hereafter be adjusted as a result of prepayments made pursuant to this Section 2.3 with the application of any such prepayment being applied and adjusted as set forth in Section 2.3(e)), (ii) the date the principal amount of the Obligations are declared to be or automatically becomes due and payable following an Event of Default, to each of the Lenders, based on the application set forth in Section 2.3(d), all of the outstanding Obligations (other than (y) unasserted contingent indemnification obligations and (z) those Obligations under any Warrant or the Registration Rights Agreement that are not due or payable at the time when all other Obligations are paid in full in cash) , and (iii) on the date provided for in Section 5.3, to each of the Lenders, based on the application set forth in Section 2.3(d), all of the outstanding Obligations (other than (y) unasserted contingent indemnification obligations and (z) those Obligations under any Warrant or the Registration Rights Agreement that are not due or payable at the time when all other Obligations are paid in full in cash):

 

Payment Dates

  

Principal Amortization

Payment of First Out Waterfall Loan

  

Principal Amortization Payment

of Last Out Waterfall Loan

April 2, 2021 (the “ First Amortization Date ”)    One-third (1/3rd) of the principal amount of all the First Out Waterfall Loans as of the First Amortization Date after taking into account the PIK Interest Payments added to the principal of the First Out Waterfall Loans on or before the First Amortization Date (such payment of First Out Waterfall Loans, the “ Scheduled First Amortization Payment of First Out Waterfall Loans ”)    $0
April 2, 2022 (the “ Second Amortization Date ”)    One-half (1/2) of the principal amount of all the First Out Waterfall Loans as of the Second Amortization Date after taking into account the PIK Interest Payments added to the principal of the First Out Waterfall Loans (including any prior cash payment of the PIK Interest Payments on the First Out Waterfall Loans made as part of the Scheduled First Amortization Payment of First Out Waterfall Loans) on or before the    One-half (1/2) of the principal amount of all the Last Out Waterfall Loans as of the Second Amortization Date after taking into account the PIK Interest Payments added to the principal of the Last Out Waterfall Loans on or before the Second Amortization Date

 

45


  

Second Amortization Date (such payment of First Out Waterfall Loans, the “ Scheduled Second Amortization Payment of First Out Waterfall Loans ”)

 

  
Maturity Date    All remaining outstanding principal amounts of the First Out Waterfall Loans as of the Maturity Date after taking into account the PIK Interest Payments added to the principal of the First Out Waterfall Loans on or before the Maturity Date (such payment of First Out Waterfall Loans, the “ Maturity Date Payment of First Out Waterfall Loans ”), or such lesser outstanding amount of the First Out Waterfall Loans, plus all other First Out Waterfall Obligations outstanding as of the Maturity Date (other than (y) unasserted contingent indemnification obligations and (z) those First Out Waterfall Obligations under any Warrant or the Registration Rights Agreement that are not due or payable at the time when all other First Lien Waterfall Obligations are paid in full in cash)    All remaining outstanding principal amounts of the Last Out Waterfall Loans as of the Maturity Date after taking into account the PIK Interest Payments added to the principal of the Last Out Waterfall Loans on or before the Maturity Date, plus all other Last Out Waterfall Obligations outstanding as of the Maturity Date (other than unasserted contingent indemnification obligations)

(b) Any First Out Waterfall Lender which is also a holder of Warrants may, at such First Out Waterfall Lender’s sole option, in accordance with Section 3(a)(iii) of the applicable Warrant, pay the Exercise Price (as defined in the applicable Warrant) by reducing the principal amount of such First Out Waterfall Lender’s First Out Waterfall Loans in an amount equal to such Exercise Price, which reduction shall be applied as set forth in Section 2.3(f). For the avoidance of doubt, this Section 2.3(b) is not applicable (and not available) to any Last Out Waterfall Notes or Last Out Waterfall Loans.

(c) Notwithstanding anything to the contrary in any of the Loan Documents, outstanding principal amounts on the Loans shall not be permitted to be prepaid, repaid, redeemed or paid prior to the First Amortization Date except solely as required or permitted by Section 5.3 or otherwise as set forth in this Section 2.3(c). If any principal on Loans are prepaid, repaid, redeemed or paid (A) prior to the First Amortization Date for any reason (such as an acceleration of the Loans following the occurrence of an Event of Default, an exercise of any Secured Party’s rights or remedies available under the Loan Documents, an exercise of any rights or remedies by ABL Agent, an ABL Lender or any other party to the ABL Debt Documents, upon the consummation of a Change of Control, pursuant to Section 5.3, by any optional prepayment or otherwise), then the amount (in addition to the principal amount of the Loans and any accrued and unpaid interest owed thereon) required to be prepaid, repaid, redeemed or paid shall be the Non-Callable Make Whole Amount applicable to the principal amount of Loans so prepaid, repaid, redeemed or paid ( plus , if In Connection with a Change of Control, the CoC Fee) or (B) on or after the First Amortization Date but prior to the Maturity Date, In Connection with a Change of Control, then the amount (in addition to the principal amount of the Loans and any accrued and unpaid interest owed thereon) required to be prepaid, repaid, redeemed or paid shall be the CoC Fee. The Non-Callable Make Whole Amount (together with any applicable CoC Fee) shall be paid by the Borrower to the Lenders based on their Pro Rata Share of the principal amount of the Loans on the date of such prepayment, repayment, redemption or payment. The Parties acknowledge and agree that, in light of the impracticality and extreme

 

46


difficulty of ascertaining actual damages, the Non-Callable Make Whole Amount and any CoC Fee are intended to be a reasonable calculation of the actual damages that would be suffered by the Secured Parties as a result of any such prepayment, repayment, redemption or payment. The parties hereto further acknowledge and agree that the Non-Callable Make Whole Amount and the CoC Fee are not intended to act as a penalty or to punish the Borrower for any such prepayment, repayment, redemption or payment. For the avoidance of doubt, other than as set forth above in clause (B) in the second sentence of this Section 2.3(c), prepayments of the Loans made on or after the First Amortization Date, in whole or in part, are permitted and may be made without premium or penalty.

(d) Each prepayment, repayment, redemption and payment by the Borrower or any Loan Party (and all proceeds of Collateral) shall be applied as follows:

(i) So long as no Application Event has occurred and in continuing, to (A)(1) all principal amortization payments of the Loans shall be paid as set forth in Section 2.3(a) and (2) all other principal prepayments, repayments, redemptions and payments and all interest payments shall be paid by the Borrower and the other Loan Parties (and any such amounts received by Agent shall be apportioned) ratably among the Secured Parties (according to the unpaid principal balance of the principal and interest to which such payments relate held by each Secured Party) and (B) all payments of fees, expenses and other Obligations (that, for the avoidance of doubt, are not covered in clause (A) above) shall be paid by the Borrower and the other Loan Parties (and any such amounts received by Agent shall be apportioned), other than such fees, expenses or other Obligations that are, based on the express terms of the Loan Documents, for a Secured Party’s separate account, ratably among the Secured Parties having a Pro Rata Share of the type of Obligation to which such a particular fee, expense or other Obligation relates. All payments to be made hereunder by the Borrower or the other Loan Parties shall be remitted to the Lenders (other than amounts owed specifically to Agent or such other Secured Party) and all such payments, and all proceeds of Collateral paid by the Borrower or any other Loan Party to the Lenders or received by Agent (or any other Secured Party), shall be applied, so long as no Application Event has occurred and is continuing, to reduce the balance of the Loans and other Obligations outstanding.

(ii) At any time that an Application Event has occurred and is continuing, as follows: (i) first, to all fees, costs and expenses (including any attorneys’ fees) owed to Agent under the Loan Documents, (ii) second, ratably to all fees, costs and expenses (including any attorneys’ fees) owed to any First Out Waterfall Lender under the Loan Documents, (iii) third, ratably to accrued and unpaid interest owed to the First Out Waterfall Lenders under the Loan Documents, (iv) fourth, ratably to the principal amount of the Loans (including any Non-Callable Make Whole Amount, any CoC Fee and the First Out Waterfall Loan Exit Payment, if applicable) owed to the First Out Waterfall Lenders, (v) fifth, ratably to all other First Out Obligations (other than any First Out Obligations in respect of any Warrant or the Registration Rights Agreement that are not at such time owing, due or unpaid) owing to Agent or the other First Out Waterfall Secured Parties, and with respect to any such First Out Waterfall Obligations owed to Agent and the other First Out Waterfall Secured Parties, shall be allocated ratably among Agent and the other First Out Waterfall Secured Parties based on their pro rata share of such other First Out Waterfall Secured Parties, (vi) sixth, ratably to all fees, costs and expenses (including any attorneys’ fees) owed to any Last Out Waterfall Lender under the Loan Documents, (vii) seventh, ratably to accrued and unpaid interest owed to the Last Out Waterfall Lenders under the Loan Documents, (viii) eighth, ratably to the principal amount of the Loans (including any Non-Callable Make Whole Amount and any CoC Fee, if applicable) owed

 

47


to the Last Out Waterfall Lenders, and (ix) ninth, ratably, to all other Last Out Waterfall Obligations owing to any Last Out Waterfall Secured Party, and, with respect to any such Last Out Waterfall Obligations owed to the Last Out Waterfall Secured Parties, shall be allocated ratably among the Last Out Waterfall Secured Parties based on their pro rata share of such other Last Out Waterfall Obligations. With respect to any prepayments, repayments, redemptions, payments or distributions in cash, property or other assets that any Last Out Waterfall Lender pays over to Agent or any First Out Waterfall Lender under the terms of this Agreement, such Last Out Waterfall Lender will be subrogated to the rights of First Out Waterfall Lenders; provided , that no Last Out Waterfall Lender may assert or enforce any such rights of subrogation it may acquire as a result of any prepayment, repayment, redemption, payment or distribution hereunder until all First Out Waterfall Obligations (other than (y) unasserted contingent indemnification obligations and (z) those First Out Waterfall Obligations under any Warrant or the Registration Rights Agreement) have been paid in full in cash. Each Last Out Waterfall Lender agrees that any prepayments, repayments, redemptions, payments or distributions in respect of the Last Out Waterfall Obligations received by such Last Out Waterfall Lender in violation of this Agreement shall be as promptly as practicable paid over to Agent, for the benefit of the First Out Waterfall First Out Waterfall Lenders, in respect of the First Out Waterfall Obligations, in the same form as received, with any necessary endorsements, to be applied in accordance with this Agreement, and each Last Out Waterfall Lender hereby authorizes Agent to make any such endorsements as agent for the Last Out Waterfall Lenders (which authorization, being coupled with an interest, is irrevocable).

(e) Any principal of any Loan that is prepaid, repaid, redeemed or paid pursuant to Section 2.3(c) or Section 5.3 shall be applied to the scheduled principal payments of the Loans in the inverse order of maturity.

(f) (i) From and after the Agreement Date, any conversion of principal under a First Out Waterfall Note by any First Out Waterfall Lender or payment by any First Out Waterfall Lender of the Exercise Price of any Warrant by reducing the principal amount of such First Out Waterfall Lender’s First Out Waterfall Loan in an amount equal to such Exercise Price, shall be applied against, and reduce, the Scheduled First Amortization Payment of First Out Waterfall Loans that is owed to such First Out Waterfall Lender until the earlier of (A) the time the Scheduled First Amortization Payment of First Out Waterfall Loans that is owed to such converting or exercising First Out Waterfall Lender(s) has been satisfied in full through conversions thereof and/or payments of the Exercise Price of Warrants, and (B) 5:00 p.m. (New York City time) on the Trading Day immediately preceding the First Amortization Date; (ii) from and after the earlier of the time set forth in clauses (i)(A) and (i)(B) above, any conversions of principal under a First Out Waterfall Note issued to any such converting First Out Waterfall Lender or payment by any First Out Waterfall Lender of the Exercise Price of any Warrant by reducing the principal amount of such First Out Waterfall Lender’s First Out Waterfall Loan in an amount equal to such Exercise Price shall be applied against, and reduce, the Scheduled Second Amortization Payment of First Out Waterfall Loans owed to such First Out Waterfall Lender until the earliest of (A) the time that an aggregate of $60,000,000 has been applied against, and reduced, the Scheduled Amortization Payments pursuant to this clause (ii) and clause (i) above, (B) the time the Scheduled Second Amortization Payment of First Out Waterfall Loans that is owed to such converting or exercising First Out Waterfall Lender(s) has been satisfied in full through conversions thereof and/or payments of the Exercise Price of Warrants, and (C) 5:00 p.m. (New York City time) on the Trading Day immediately preceding the Second Amortization Date; and (iii) from and after the earliest of the times set forth in clauses (ii)(A) and (ii)(B) above, one-half (50%) of any conversion of principal under a First Out Waterfall Note issued to any such converting First Out Waterfall Lender or payment by any First Out Waterfall Lender of the Exercise Price of any Warrant by reducing the principal amount of such First Out Waterfall Lender’s First Out Waterfall Loan in an amount equal to such Exercise

 

48


Price shall be applied against, and reduce, the Scheduled Second Amortization Payment owed to such converting or exercising First Out Waterfall Lender and the other half (50%) shall be applied against, and reduce, the principal amount payable on the Maturity Date to such converting or exercising First Out Waterfall Lender, until the earlier of (X) the time the Scheduled Second Amortization Payment owed to such converting or exercising First Out Waterfall Lenders has been satisfied in full through conversions thereof and/or payments of the Exercise Price of Warrants, and (Y) 5:00 p.m. (New York City time) on the Trading Day immediately preceding the Second Amortization Date; and (iii) thereafter, any conversion of principal under the First Out Waterfall Notes issued to such converting First Out Waterfall Lender(s) or payment by any First Out Waterfall Lender of the Exercise Price of any Warrant by reducing the principal amount of such First Out Waterfall Lender’s First Out Waterfall Loan in an amount equal to such Exercise Price shall be applied against, and reduce, the principal amount due and payable on the Maturity Date to such converting or exercising First Out Waterfall Lender . Each Lender and the Borrower acknowledges and agrees that, following the date hereof, to the extent any conversion of any First Out Waterfall Note issued to a converting First Out Waterfall Lender or payment by any First Out Waterfall Lender of the Exercise Price of any Warrant by reducing the principal amount of such First Out Waterfall Lender’s First Out Waterfall Loan in an amount equal to such Exercise Price reduces the principal payment due and payable on any date to such converting or exercising First Out Waterfall Lender, such reduction shall be applied to the portion of such payment due under the applicable First Out Waterfall Notes held by each of the converting First Out Waterfall Lender on a pro rata basis in accordance with each such converting First Out Waterfall Lender’s First Out Waterfall Lender Percentage with respect to the First Out Waterfall Notes. For the avoidance of doubt, this Section 2.3(f) is not applicable (and not available) to any Last Out Waterfall Notes or Last Out Waterfall Loans.

Section  2.4 Payment Details . All payments of the Obligations by the Borrower hereunder and under any of the other Loan Documents shall be made without setoff or counterclaim and shall be paid in cash in Dollars. Payments of any amounts and other Obligations due to Agent or the Lenders under this Agreement or the other Loan Documents shall be made in Dollars in immediately available funds prior to 2:00 p.m. (New York City time) on such date that any such payment is due, using such wire information or address for Agent or such applicable Lender that is set forth on Schedule 2.4 or at such other bank or place as Agent or such applicable Lenders shall from time to time designate in a writing delivered to the Borrower at least five (5) Business Days prior to the date such payment is due. The Borrower shall pay all and any fees, costs and expenses (administrative or otherwise) imposed by banks, clearing houses or any other financial institutions in connection with making any payments under any of the Loan Documents.

Section  2.5 Taxes .

(a) Any and all payments on account of any Obligation of a Loan Party hereunder or under any other Loan Document (in each case in this Section 2.5, for the avoidance of doubt, not including Obligations in respect of any Warrant or the Registration Rights Agreement) shall be made, in accordance with this Section 2.5, free and clear of and without deduction or withholding for any and all present or future Taxes except as required by Applicable Law. If any Loan Party shall be required by Applicable Law to deduct or withhold any Taxes from or in respect of any sum payable hereunder or under any other Loan Document, (i) such Loan Party shall make such deduction or withholding, (ii) such Loan Party shall pay the full amount deducted or withheld to the relevant Governmental Authority in accordance with Applicable Law, and (iii) to the extent that the deduction or withholding is made on account of Indemnified Taxes, the sum payable by the applicable Loan Party shall be increased by as much as shall be necessary so that after making the required deduction or withholding (including deductions or withholdings applicable to additional sums payable under this Section 2.5), each Lender shall receive an amount equal to the sum it would have received had no such deduction or withholding been made (any and all such additional amounts payable shall hereafter be referred to as the “ Additional Amounts ”). Within thirty (30) days after the date of any payment of such Taxes, the Borrower shall furnish to the applicable Lender the original or a certified

 

49


copy of a receipt evidencing payment thereof or other evidence of such payment reasonably satisfactory to such Lender.

(b) In addition, the Loan Parties agree to pay and authorize each Lender to pay in their name, all Other Taxes. Within 30 days after the date of any payment of Other Taxes by any Loan Party, the Borrower shall furnish to the applicable Lender the original or a certified copy of a receipt evidencing payment thereof or other evidence of such payment reasonably satisfactory to such Lender.

(c) The Borrower shall reimburse and indemnify, within ten (10) days after receipt of demand therefor, each Lender for all Indemnified Taxes (including all Indemnified Taxes imposed on amounts payable under this Section 2.5(c)) paid or payable by such Lender, whether or not such Indemnified Taxes were correctly or legally asserted. A certificate of the applicable Lender(s) setting forth the amounts to be paid thereunder and delivered to the Borrower shall be conclusive, absent manifest error.

(d) Any Lender that is entitled to an exemption from or reduction of withholding Tax with respect to payments made under any Loan Document shall deliver to the Borrower and the Agent, at the time or times reasonably requested by the Borrower or the Agent, such properly completed and executed documentation reasonably requested by the Borrower or the Agent as will permit such payments to be made without withholding or at a reduced rate of withholding. In addition, any Lender, if reasonably requested by the Borrower or the Agent, shall deliver such other documentation prescribed by Applicable Law. Notwithstanding anything to the contrary in the preceding sentence, the completion, execution and submission of such documentation (other than such documentation set forth below in this Section 2.5(d)) shall not be required if in the Lender’s good faith judgment such completion, execution or submission would subject such Lender to any material unreimbursed cost or expense or would materially prejudice the legal or commercial position of such Lender. Without limiting the generality of the foregoing each Lender that is a United States person (as such term is defined in Section 7701(a)(30) of the Code) shall, on or before the date on which the Lender becomes a party to this Agreement, provide to Borrower and the Agent a properly completed and executed IRS Form W-9 certifying that such Lender is not subject to backup withholding tax. Each Lender that is not a United States person (as such term is defined in Section 7701(a)(30) of the Code) (a “ Foreign Lender ”) and is entitled to an exemption from or reduction of U.S. federal withholding tax with respect to payments under this Agreement shall, on or before the date on which such Lender becomes a party to this Agreement, provide Borrower and the Agent with a properly completed and executed IRS Form W-8ECI, W-8BEN-E, W-8IMY (with proper attachments) or other applicable forms or any other applicable certificate or document reasonably requested by the Borrower or the Agent and prescribed by Applicable Law as a basis for claiming exemption from or a reduction in U.S. federal withholding Tax, duly completed, together with such supplementary documentation as may be prescribed by Applicable Law to permit the Borrower to determine the withholding or deduction required to be made and, if such Foreign Lender is relying on the portfolio interest exception of Section 871(h) or Section 881(c) of the Code (or any successor provision thereto), shall also provide the Borrower with a certificate (the “ Portfolio Interest Certificate ”) representing that such Foreign Lender is not a “bank” for purposes of Section 881(c) of the Code (or any successor provision thereto), is not a 10% holder of the Borrower described in Section 871(h)(3)(B) of the Code (or any successor provision thereto), and is not a controlled foreign corporation receiving interest from a related person (within the meaning of Sections 881(c)(3)(C) and 864(d)(4) of the Code or any successor provisions thereto). If the Foreign Lender is a partnership and one or more direct or indirect partners of such Foreign Lender are claiming the portfolio interest exemption, such Foreign Lender may provide a Portfolio Interest Certificate on behalf of such partners. Each Lender shall provide new forms (or successor forms) as reasonably requested by the Borrower or the Agent from time to time and shall notify the Borrower and the Agent in writing within a reasonable time after becoming aware of any event requiring a change in the most recent forms previously delivered by such Lender to the Borrower or the Agent.

 

50


(e) If a payment to a Lender under this Agreement would be subject to U.S. federal withholding tax imposed by FATCA if such Lender were to fail to comply with the applicable reporting requirements of FATCA, such Lender shall deliver to the Borrower, at the times prescribed by law or as reasonably requested by Borrower or the Agent, such documentation as is required in order for the Borrower or the Agent to comply with its obligations under FATCA, to determine that such Lender has or has not complied with its obligations under FATCA or to determine the amount to deduct and withhold from such payment. Solely for purposes of this Section 2.5(e), “FATCA” shall include any amendments made to FATCA after the Agreement Date.

(f) If a Lender determines, in its sole discretion exercised in good faith, that it has received a refund of any Indemnified Taxes as to which it has been indemnified pursuant to this Section 2.5 (including all Indemnified Taxes imposed on amounts payable under Section 2.5(c)), such Lender shall promptly pay such refund (but only to the extent of indemnity payments made under this Section 2.5 with respect to the Taxes refunded) to the Borrower, net of all out-of-pocket expense (including any Taxes imposed thereon) of such Lender incurred in obtaining such refund or making such payment, provided that the Borrower, upon the request of such Lender, agrees to repay the amount paid over to the Borrower (plus any penalties, interest or other charges imposed by the relevant Governmental Authority) to such Lender if such Lender is required to repay such refund to such Governmental Authority. Notwithstanding anything to the contrary in this Section 2.5(f), in no event shall a Lender be required to pay any amount to the Borrower pursuant to this Section 2.5(f), the payment of which would place such Lender in a less favorable net after-Tax position than such Lender would have been in if the Tax subject to indemnification and giving rise to such refund had not been deducted or otherwise imposed and the indemnification payments with respect to such Tax had never been paid. Nothing in this Section 2.5(f) shall require any Lender to disclose any information it deems confidential (including its tax returns) to any Person, including the Borrower.

Section 2.6 Interest.

(a) From (and including) and after the Prior Agreement Date, the outstanding principal amount of the Loans and any overdue interest shall bear interest at the Interest Rate (calculated on the basis of a 360-day year for the actual number of days elapsed in each month). From (and including) the Prior Agreement Date until (but not including) the Agreement Date, interest with respect to the Interest Rate shall be paid in cash to the Lenders quarterly in arrears for the preceding calendar quarter on the on the first Business Day of each calendar quarter, whether by acceleration or otherwise, commencing on July 1, 2017 and on the first Business Day of each October, January, April and July thereafter through and including the calendar quarter commencing October 1, 2018. From (and including) and after the Agreement Date, interest with respect to the Cash Interest Rate (which, for the avoidance of doubt, does not include any interest mentioned in the immediately preceding sentence) shall be paid in cash to the Lenders quarterly in arrears for the preceding calendar quarter on the first Business Day of each calendar quarter, whether by acceleration or otherwise, commencing on July 1, 2017 and on the first Business Day of each October, January, April and July thereafter, and on the maturity (and on any date of prepayment, repayment, redemption or payment of the principal) of the Loans (each, an “ Interest Payment Date ”); provided, however, from and after the Agreement Date, that in lieu of making any payment of interest with respect to the Cash Interest Rate in cash on an Interest Payment Date pursuant to this Section 2.6 (but not interest payable (x) pursuant to the immediately preceding sentence, (y) pursuant to Section 2.7 and (z) with respect to the PIK Interest Rate) and subject to the conditions set forth in Exhibit 2.6, the Borrower may elect to satisfy all or any part of such payment with respect to First Out Waterfall Loans only (and, for the avoidance of doubt, not any Last Out Waterfall Loans) by the issuance to the First Out Waterfall Lenders of shares of Freely Tradable Common Shares (as defined in Exhibit 2.6) in accordance with the provisions of Exhibit 2.6; provided that, not later than the first Business Day prior to the applicable Interest Payment Date, the Borrower shall provide written notice to the Agent of the amount of such payment satisfied pursuant to Exhibit 2.6. From (and including) and after the Agreement Date, interest with respect

 

51


to the PIK Interest Rate shall be paid in-kind on each Interest Payment Date (which, for the avoidance of doubt, does not include any interest mentioned in the second sentence of this Section 2.6(a)) by increasing the principal amount of the Loans by an amount equal to the interest that has accrued at the PIK Interest Rate during such period (such payment, a “ PIK Interest Payment ”). Following an increase in the principal amount of the Loans as a result of a PIK Interest Payment, the Loans will bear interest at the Interest Rate on such increased principal amount from and after the date of such PIK Interest Payment and such increased principal amount shall constitute “Obligations”.

(b) [Reserved].

(c) All interest, fees and other amounts under each Loan Document shall be calculated on the basis of a 360-day year for the actual number of days elapsed.

Section  2.7 Yield Enhancement Payment; Default Interest ; CoC Fee; Exit Payment .

(a) On the Prior Agreement Date, the Borrower paid in cash in Dollars to such First Out Waterfall Lender (as such First Out Waterfall Lender funding such First Out Waterfall Disbursement directed) a yield enhancement payment in the amount of two and twenty-fifths of one hundred percent (2.25%) of the principal amount of such First Out Waterfall Disbursement funded by such First Out Waterfall Lender on the Prior Agreement Date as consideration for providing such First Out Waterfall Disbursement, and such payment, at the sole option of the applicable Lender, was able to be deducted from such First Out Waterfall Disbursement. Such payment was fully earned when it was paid (or when it was deducted from such First Out Waterfall Disbursement) and is not and shall not be refundable for any reason whatsoever.

(b) At the election (which upon such election, to the extent permitted by Applicable Law, such additional interest rate shall retroactively apply to the first day of existence of such Event of Default) of Agent or the Required Lenders while any Event of Default exists (or automatically while any Event of Default under Section 5.4(a) or 5.4(d) exists), the Borrower shall pay interest (after as well as before entry of judgment thereon to the extent permitted by Applicable Law) on the Obligations (other than Obligations under any Warrant or the Registration Rights Agreement) and past due interest thereon, if any, from and after the date of occurrence of such Event of Default, at a rate per annum which is determined by adding (i) with respect to any Event of Default under Section 5.4(a), ten percent (10.0%) per annum to the Interest Rate then in effect for the Loans and (ii) with respect to any other Event of Default, two percent (2%) per annum to the Interest Rate then in effect for the Loans. Such additional interest shall be payable in cash on demand.

(c) Upon prepayment, repayment, redemption or payment of any principal of the Loans at any time (including, for the avoidance of doubt, before, after and on the date of the First Amortization Date but excluding, for the avoidance of doubt, Loans paid in full on the Maturity Date) In Connection with a Change of Control, Borrower shall pay to the Secured Parties the CoC Fee (in addition to any principal Obligations required to be paid pursuant to Section 5.3 and any applicable Non-Callable Make Whole Amount due pursuant to Section 2.3(c)) based on their Pro Rata Share of the principal of the Loans on the date of such prepayment, repayment, redemption or payment of such Loans; provided, however that if such prepayment, repayment, redemption or payment is In Connection with a Change of Control but prior to the consummation of the Change of Control, the CoC Fee shall be due and payable contemporaneously with the consummation of a Change of Control. The CoC Fee shall be non-refundable upon receiving payment thereof. The Parties acknowledge and agree that, in light of the impracticality and extreme difficulty of ascertaining actual damages occurring In Connection with a Change of Control, the CoC Fee is intended to be a reasonable calculation of the actual damages that would be suffered by the Secured Parties as a result of any such prepayment, repayment, redemption or payment. The parties hereto

 

52


further acknowledge and agree that the CoC Fee is not intended to act as a penalty or to punish the Borrower for any such prepayment, repayment, redemption or payment.

(d) Notwithstanding anything to the contrary in the Loan Documents, on the date when the remaining First Out Waterfall Loans outstanding are paid, repaid, redeemed or prepaid (in each case, whether before, at the time of or after the Maturity Date or any acceleration, bankruptcy, insolvency or otherwise), in an amount that causes (or such lesser amount of outstanding First Out Waterfall Loans that are so paid, repaid, redeemed or prepaid that the First Out Waterfall Lenders have agreed to cause) the principal amount of remaining First Out Waterfall Loans outstanding to be less than $10,000,000, the Borrower shall pay in cash at such time to the First Out Waterfall Lenders (based on their First Out Waterfall Pro Rata Share of such First Out Waterfall Loans) a non-refundable exit payment (the “ First Out Waterfall Loan Exit Payment ”) in a total amount equal to $5,000,000. The Parties acknowledge and agree that the Agent and the First Out Waterfall Lenders would not have entered into this Agreement and the other Loan Documents without the Borrower agreeing to pay the First Out Waterfall Loan Exit Payment in the aforementioned instances. The Parties further acknowledge and agree that the First Out Waterfall Loan Exit Payment set forth in this Section 2.7(d) is not intended to act as a penalty or to punish the Borrower or any other Loan Party for any such payment, repayment, redemption or prepayment.

(e) Notwithstanding anything to the contrary in the Loan Documents, on the date when the remaining Last Out Waterfall Loans outstanding are paid, repaid, redeemed or prepaid (in each case, whether before, at the time of or after the Maturity Date or any acceleration, bankruptcy, insolvency or otherwise), in an amount that causes (or such lesser amount of outstanding Last Out Waterfall Loans that are so paid, repaid, redeemed or prepaid that the Last Out Waterfall Lenders have agreed to cause) the principal amount of remaining Last Out Waterfall Loans outstanding to be less than $10,000,000, the Borrower shall pay in cash at such time to the Last Out Waterfall Lenders (based on their Last Out Waterfall Pro Rata Share of such Last Out Waterfall Loans) a non-refundable exit payment (the “ Last Out Waterfall Loan Exit Payment ”) in a total amount equal to $1,113,750. The Parties acknowledge and agree that the Agent and the Last Out Waterfall Lenders would not have entered into this Agreement and the other Loan Documents without the Borrower agreeing to pay the Last Out Waterfall Loan Exit Payment in the aforementioned instances. The Parties further acknowledge and agree that the Last Out Waterfall Loan Exit Payment set forth in this Section 2.7(d) is not intended to act as a penalty or to punish the Borrower or any other Loan Party for any such payment, repayment, redemption or prepayment.

Section  2.8 Delivery of Warrants .

(a) On the Prior Agreement Date under the Prior Facility Agreement, the Borrower issued to the First Out Waterfall Lenders (or their predecessors) warrants to purchase 6,470,000 shares of Common Stock at an Exercise Price of $9.23 per share (each as subject to any adjustments provided for therein), each in substantially in the form of Exhibit C-1 attached hereto (as may be amended, restated, supplemented or otherwise modified from time to time, the “ Initial Warrants ”), with an expiration date of April 3, 2024.

(b) [Reserved].

(c) As of the Agreement Date, the Initial Warrants are allocated among the First Out Waterfall Lenders as set forth on Annex A.

(d) On the Agreement Date, the Borrower shall issue to the First Out Waterfall Lenders, based on such First Out Waterfall Lenders’ First Out Waterfall Pro Rata Share, warrants to purchase 8,750,000 shares of Common Stock at an Exercise Price of $4.71 per share (each as subject to any adjustments provided for therein), each in substantially in the form of Exhibit C-2 attached hereto (as may

 

53


be amended, restated, supplemented or otherwise modified from time to time, the “ Additional Warrants ”), with an expiration date of August 9, 2025

(e) The Additional Warrants issued pursuant to Section 2.8(d) shall be allocated on the Agreement Date to the First Waterfall Lenders as set forth on Annex A.

ARTICLE 3

REPRESENTATIONS AND WARRANTIES

Section  3.1 Representations and Warranties of the Loan Parties . The Loan Parties, jointly and severally, represent and warrant (A) with respect to Section 3.1(g)(i)(B), the first two sentences of Section 3.1(i), Section 3.1(y), Section 3.1(z)(A) and (C), Section 3.1(ee), the first sentence of Section 3.1(mm), Section 3.1(nn), Section 3.1(oo), Section 3.1(rr), Section 3.1(ss) and Section 3.1(tt), at all times, and (B) with respect to all other provisions of Section 3.1, (I) as of the Prior Agreement Date (in the form and substance thereof in the Prior Facility Agreement) and the Agreement Date (if the form and substance of this Agreement) and (II) as of each date that this Agreement is amended or modified (or any date any consent or waiver related to this Agreement is entered into or otherwise executed and delivered) in accordance with Section 6.6(b) (but with respect to any representation or warranty that speaks as of an earlier date, such representation and warranty shall continue to speak only as of such earlier date):

(a) Each Loan Party is (i) conducting its business in compliance with its Organizational Documents and (ii) not in violation of its Organizational Documents. Each Loan Party’s Organizational Documents are in full force and effect.

(b) No Default or Event of Default has occurred or will result from the transactions contemplated by the Loan Documents.

(c) Each Loan Party (i) is Solvent and (ii) has not taken action, and no such action has been taken by a third party, for its winding up, dissolution or liquidation or similar executory or judicial proceeding or for the appointment of a liquidator, custodian, receiver, trustee, administrator or other similar officer for any Loan Party or any or all of its assets or revenues; provided , however , that, for the avoidance of doubt, no such representation in this Section 3.1(c) is made in respect of any Immaterial Subsidiary.

(d) No Lien exists on any Loan Party’s assets, except for Permitted Liens.

(e) The obligation of the Loan Parties to make any payment under this Agreement or the other Loan Documents (together with all charges in connection therewith) is absolute and unconditional.

(f) No Indebtedness of any Loan Party exists other than Permitted Indebtedness.

(g) Each Loan Party is validly existing as a corporation, limited liability company or limited partnership, as applicable, and is in good standing under the laws of the jurisdiction of its incorporation, organization or formation, as applicable. Each Loan Party (i) has full power and authority (and all governmental licenses, authorizations, Permits, consents and approvals) to (A) own its properties and conduct its business (solely with respect to governmental licenses, authorizations, Permits, consents and approvals, except where the failure to have such governmental licenses, authorizations, Permits, consents and approvals could not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect) and (B) to (x) issue the Securities in accordance with the Loan Documents, (y) enter into, and perform its obligations under, the Loan Documents, including the issuance of the Securities

 

54


and the reservation for issuance of the Interest Payment Shares, the Conversion Shares and the Warrant Shares, and (z) consummate the transactions contemplated under the Loan Documents, and (ii) is duly qualified as a foreign corporation, limited liability company or limited partnership, as applicable, and licensed and in good standing, under the laws of each jurisdiction where its ownership, lease or operation of property or the conduct of its business requires such qualification or license, in each case of this clause (ii), where the failure to be so qualified, licensed or in good standing could reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect.

(h) Other than as set forth on Schedule 3.1(h), there is no pending or, to the knowledge of the Loan Parties, threatened, any action, suit or other proceeding before any Governmental Authority (i) to which any Loan Party is a party, (ii) which purports to affect or pertain to the Loan Documents, the Transactions or any other transaction contemplated hereby or thereby or (iii) which has as the subject thereof any assets owned by any Loan Party or any of its Subsidiaries, in each case which could reasonably be expected to result in monetary judgments or relief, individually or in the aggregate, in excess of $2,000,000. Other than as set forth on Schedule 3.1(h), there are no current or, to the knowledge of the Loan Parties, pending, legal actions, suits or other proceedings, in each case which could reasonably be expected to result in monetary judgments or relief, individually or in the aggregate, in excess of $ 2,000,000, to which any Loan Party or any of its Subsidiaries or any of their respective assets is subject. With respect to each action, suit, proceeding, claim, event or disclosure listed on Schedule 3.1(h), none of them could reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect. No injunction, writ, temporary restraining order or any order of any nature has been issued by any court or other Governmental Authority purporting to enjoin or restrain the execution, delivery or performance of this Agreement or any other Loan Document or directing that the transactions provided for herein or therein not be consummated as herein or therein provided. Other than as set forth on Schedule 3.1(h), none of the current directors (or equivalent persons) or current officers of the Borrower and its Subsidiaries has been involved as a defendant in securities-related litigation or other securities-related legal proceedings during the past five years.

(i) The execution, delivery and performance of each of this Agreement and the other Loan Documents, including the issuance of the Securities hereunder, has been, duly authorized by each Loan Party and no further consent or authorization is required by any Loan Party, any Loan Party’s board of directors (or other equivalent governing body) or the holders of any Loan Party’s Stock. Each of this Agreement and the other Loan Documents has been duly executed and delivered by each of the Loan Parties and constitutes a valid, legal and binding obligation of each Loan Party, enforceable in accordance with its respective terms, except as such enforceability may be limited by applicable insolvency, bankruptcy, reorganization, moratorium or other similar laws affecting creditors’ rights generally. The execution, delivery and performance of this Agreement and the other Loan Documents by each Loan Party thereto and the consummation of the transactions (including the issuance of the Securities hereunder and thereunder) contemplated herein and therein will not (A) conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, or result in the creation or imposition of any Lien (other than pursuant to the Loan Documents) upon any assets of any such Loan Party pursuant to, any agreement, document or instrument to which such Loan Party is a party or by which any Loan Party is bound or to which any of the assets or property of any Loan Party is subject, except, with respect to this clause (A), as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, (B) result in any violation of or conflict with the provisions of the Organizational Documents, (C) result in the violation of any Applicable Law, (D) result in the violation of any judgment, order, rule, regulation or decree of any Governmental Authority, or (E) violate, conflict with or cause a breach or a default under any agreement or instrument binding upon it, except, with respect to clauses (C) and (E) only, as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. No consent, approval, Authorization or order of, or registration or filing with any Governmental Authority is required for (i) the execution, delivery and performance of this Agreement or

 

55


any of the other Loan Documents, and the issuance of the Securities hereunder and thereunder, and (ii) the consummation by any Loan Party of the Transactions or the other transactions contemplated hereby or thereby, except for (A) the filings necessary to perfect the Liens created by the applicable Loan Documents and (B) any necessary filings with the SEC.

(j) Other than has been obtained, no Authorization is required for (i) the execution and delivery of this Agreement or the other Loan Documents, or (ii) the consummation of the Transactions and the other transactions contemplated hereby and thereby, including (other than the Authorization set forth on Schedule 3.1(j)) the issuance and exercise of the Warrants.

(k) Each Loan Party and its Subsidiaries are in compliance with Applicable Law except as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.

(l) Except as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, (i) (A) each Loan Party holds, and is operating in compliance in all material respects with, all franchises, grants, Authorizations, licenses, permits, easements, consents, certificates and orders of any Governmental Authority (collectively, “ Necessary Documents ”) required for the conduct of its business and (B) all Necessary Documents are valid and in full force and effect and (ii) no Loan Party has (A) received written notice of any revocation, non-renewal, amendment, expiration, suspension, limitation, withdrawal, cancellation or other modification of any of the Necessary Documents and (B) reason to believe that any of the Necessary Documents will not be renewed in the ordinary course of business.

(m) As of the Agreement Date, the Real Estate listed in Schedule 3.1(m) constitutes all of the Real Estate of each Loan Party and each of its Subsidiaries. Each Loan Party has good and marketable title to all of its assets and property free and clear of all Liens, except Permitted Liens. Except as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, the property held under lease by each Loan Party is held under valid, subsisting and enforceable leases with only such exceptions with respect to any particular lease as do not interfere in any material respect with the conduct of the business of such Loan Party.

(n) Each Loan Party (i) owns, or, to the knowledge of the Loan Parties and their Subsidiaries, has the right to use pursuant to a valid and enforceable written license, all IP, in each case (and without any knowledge qualifier applicable thereto) free and clear of any Liens other than Permitted Licenses and Permitted Liens. All IP that is registered with or issued by a Governmental Authority that is currently in the name of a Loan Party is, to the knowledge of the Loan Parties and their Subsidiaries, valid and enforceable. Each patent constituting a Material Intangible Asset is, to the knowledge of the Loan Parties and their Subsidiaries, valid and enforceable and no part of the Material Intangible Assets has been judged invalid or unenforceable, in whole or in part; and, except as set forth on Schedule 3.1(n), there is no pending or, to the knowledge of the Loan Parties, threatened action, suit, other proceeding or claim by any Person challenging or contesting the validity, ownership, or enforceability of any Material Intangible Asset, the use thereof by any Loan Party, or other rights of any Loan Party in or to any Material Intangible Asset, and no Loan Party has received any written notice regarding any such action, suit, other proceeding or claim. With respect to each action, suit, proceeding, claim, challenge, contest, event and disclosure listed on Schedule 3.1(n), none of them could reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect. Neither the conduct of the business of any Loan Party, nor any Loan Party, has infringed, misappropriated or otherwise violated, or is infringing, misappropriating or otherwise violating, any Intellectual Property of any Person, except as could not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect. Other than as set forth on Schedule 3.1(h), there is no pending or, to the knowledge of the Loan Parties, threatened action, suit, other proceeding or claim by any

 

56


Person alleging that any Loan Party is infringing, misappropriating or violating, or otherwise using without authorization, any Intellectual Property of any Person, and no Loan Party has received any written notice regarding, any such action, suit, other proceeding or claim. With respect to each action, suit, proceeding, claim, event or disclosure listed on Schedule 3.1(h), none of them could reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect. Other than as set forth in Section 3.b. of the Perfection Certificate dated as of (and delivered by the Loan Parties on) the Agreement Date, no Loan Party is a party to, or bound by, any options, licenses, franchise or other agreements, written or oral, relating to trademarks, patents, copyrights, other know-how or IP (or granting any right, title or interest in or to any IP) that require annual payments in excess of $25,000 individually.

(o) No Loan Party is, except as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, in breach of or otherwise in default under, and no event has occurred which, with notice or lapse of time or both, would constitute such breach or other default in the performance of any agreement or condition contained in any agreement under which it may be bound, or to which any of its assets is subject.

(p) All U.S. federal, state and local income and franchise and other material Tax returns, reports and statements (collectively, the “ Tax Returns ”) required to be filed by any Tax Affiliates have been filed with the appropriate Governmental Authorities, all such Tax Returns are true and correct in all material respects, and all Taxes, assessments and other governmental charges and impositions reflected therein or otherwise due and payable have been paid prior to the date on which any material Liability may be added thereto for non-payment thereof except for those contested in good faith by appropriate proceedings diligently conducted and for which adequate reserves are maintained on the books of the appropriate Tax Affiliate in accordance with GAAP. As of the Agreement Date, no material Tax Return is under audit or examination by any Governmental Authority, and no Tax Affiliate has received written notice from any Governmental Authority of any audit or examination or any assertion of any claim for material Taxes. To the extent material, proper and accurate amounts have been withheld by each Tax Affiliate from their respective employees for all periods in full and complete compliance with the Tax, social security and unemployment withholding provisions of Applicable Law and such withholdings have been timely paid to the respective Governmental Authorities. No Tax Affiliate has participated in a “listed transaction” within the meaning of Treasury Regulation Section 1.6011-4(b)(2) or has been a member of an affiliated, combined or unitary group other than the group of which a Tax Affiliate is the common parent.

(q) The exchange of the Exchanged Deerfield Convertible Notes for the Last Out Waterfall Loans under this Agreement and the other Loan Documents does not violate or otherwise breach any provision of any of the 3.25% Convertible Note Documents or any other agreements, instruments or documents evidencing any Indebtedness or cause any other holder of any 3.25% Convertible Notes to become due prior to their stated maturity therein.

(r) Except as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect after the Prior Agreement Date or the Agreement Date, each Loan Party: (i) at all times has complied with all Applicable Laws; (ii) has not received any warning letter or other correspondence or notice from the any Governmental Authority alleging or asserting noncompliance with any Applicable Laws or any Authorizations; (iii) possesses and complies with the Authorizations, which are valid and in full force and effect; (iv) has not received written notice that any Governmental Authority has taken, is taking or intends to take action to limit, suspend, cancel, withdraw, modify or revoke any Authorization and has no knowledge that any Governmental Authority is considering such action; and (v) has filed, obtained, maintained or submitted all reports, documents, forms, notices, applications, records, claims, submissions, renewals and supplements or amendments as required by any Applicable Laws or Authorizations.

 

57


(s) The Borrower has filed all of the SEC Documents, within the time frames prescribed by the SEC for the filing of such SEC Documents such that each filing was timely filed with the SEC. The Borrower filed and made publicly available on the SEC’s Electronic Data Gathering, Analysis, and Retrieval system (including any successor thereto, “ EDGAR ”) on or prior to the date this representation is made, true, correct and complete copies of the SEC Documents. As of their respective dates, each of the SEC Documents complied in all material respects with the requirements of the Securities Act and/or the Exchange Act (as applicable) applicable to the SEC Documents. None of the SEC Documents, at the time they were filed with the SEC, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. Since the filing of the SEC Documents, no event has occurred that would require an amendment or supplement to any of the SEC Documents and as to which such an amendment or a supplement has not been filed and made publicly available on EDGAR (and true, correct and complete copies of such amendment or supplement, if any, have been delivered to the Secured Parties or their respective representatives) on or prior to the date this representation is made. The Borrower has not received any written comments from the SEC staff that have not been resolved, to the knowledge of the Borrower, to the satisfaction of the SEC staff.

(t) As of their respective dates, the consolidated financial statements of the Borrower and its Subsidiaries included in the SEC Documents complied as to form in all material respects with applicable accounting requirements and the published rules and regulations of the SEC with respect thereto. Such financial statements have been prepared in accordance with GAAP, consistently applied (subject, in the case of unaudited quarterly financial statements, to normal year-end adjustments and lack of footnote disclosures), and fairly present in all material respects the consolidated financial position of the Borrower and its Subsidiaries as of the dates thereof and the consolidated results of their operations, cash flows and changes in stockholders equity for the periods then ended (subject, in the case of unaudited quarterly financial statements, to normal year-end audit adjustments and lack of footnote disclosures). The accounting firm that expressed its opinion with respect to the consolidated financial statements included in the Borrower’s most recently filed annual report on 10-K, and reviewed the consolidated financial statements included in the Borrower’s most recently filed quarterly report on 10-Q, was independent of the Borrower pursuant to the standards set forth in Rule 2-01 of Regulation S-X promulgated by the SEC and as required by the applicable rules and guidance from the Public Company Accounting Oversight Board (United States), and such firm was otherwise qualified to render such opinion under Applicable Law and the rules and regulations of the SEC. There is no transaction, arrangement or other relationship between the Borrower (or any of its Subsidiaries) and an unconsolidated or other off-balance-sheet Person that is required to be disclosed by the Borrower in the SEC Documents that has not been so disclosed in the SEC Documents. Neither the Borrower nor any of its Subsidiaries is required to file or will be required to file any agreement, note, lease, mortgage, deed or other instrument entered into prior to the date this representation is made and to which the Borrower or any of its Subsidiaries is a party or by which the Borrower or any of its Subsidiaries is bound that has not been previously filed as an exhibit (including by way of incorporation by reference) to the Borrower’s reports filed or made with the SEC under the Exchange Act. Other than (i) the liabilities assumed or created pursuant to this Agreement and the other Loan Documents and any fees and expenses in connection therewith, (ii) liabilities accrued for in the latest balance sheet included in the Borrower’s most recent periodic report (on 10-Q or 10-K) filed prior to the Prior Agreement Date (the date of such balance sheet, the “ Latest Balance Sheet Date ”), (iii) liabilities incurred in the ordinary course of business consistent with past practice since the later of the (A) Prior Agreement Date and (B) the Latest Balance Sheet Date and (iv) liabilities set forth on the Schedules to this Agreement, the Borrower and its Subsidiaries do not have any other material liabilities (whether fixed or unfixed, known or unknown, absolute or contingent, asserted or unasserted, choate or inchoate, liquidated or unliquidated, or secured or unsecured, and regardless of when any action, claim, suit or proceeding with respect thereto is instituted). Since December 31, 2016, there has been no Material Adverse Effect or any event or circumstance which could reasonably be expected, individually or in the aggregate, to result in a

 

58


Material Adverse Effect. All financial performance projections delivered to any Secured Party, including the financial performance projections delivered on or prior to the Agreement Date, if any, represent the Borrower’s and its Subsidiaries’ good faith estimate of future financial performance and are based on assumptions believed by the Borrower and its Subsidiaries to be fair and reasonable in light of current market conditions, it being acknowledged and agreed by Agent and the Lenders that projections as to future events are not to be viewed as facts and that the actual results during the period or periods covered by such projections may differ from the projected results and such differences may be material.

(u) The Borrower and its Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset and liability accountability, (iii) access to assets or incurrence of liability is permitted only in accordance with management’s general or specific authorization and (iv) the recorded accountability for assets and liabilities is compared with the existing assets and liabilities at reasonable intervals and appropriate action is taken with respect to any differences (such internal accounting controls (including clauses (i) – (iv) above), collectively, “ Internal Controls ”). The Borrower and its Subsidiaries have timely filed and made publicly available on EDGAR all certifications, statements and documents required by Rule 13a-14 or Rule 15d-14 under the Exchange Act. The Borrower and its Subsidiaries maintain disclosure controls and procedures required by Rule 13a-15 or Rule 15d-15 under the Exchange Act; such controls and procedures are effective to ensure that the information required to be disclosed by the Borrower and its Subsidiaries in the reports that they file with or submit to the SEC (A) is recorded, processed, summarized and reported accurately within the time periods specified in the SEC’s rules and forms and (B) is accumulated and communicated to the Borrower’s (and, to the extent applicable, its Subsidiaries’) management, including its or their principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. The Borrower and its Subsidiaries maintain internal control (including Internal Controls) over financial reporting required by Rule 13a-15 or Rule 15d-15 under the Exchange Act; such internal control (including Internal Controls) over financial reporting is effective and does not contain any material weaknesses.

(v) [Reserved].

(w) (i) No Loan Party has engaged, and to the knowledge of the Loan Parties, no other Person has engaged in any “prohibited transaction” as defined under Section 406 of ERISA or Section 4975 of the Code that is not exempt under ERISA Section 408 or Section 4975 of the Code, under any applicable regulations and published interpretations thereunder or under any applicable prohibited transaction, individual or class exemption issued by the Department of Labor, with respect to any Employee Benefit Plan, except as for such transaction that could not be expected, individually or in the aggregate, to have a Material Adverse Effect, (ii) (A) at no time within the last seven years has the Borrower or any ERISA Affiliate maintained, sponsored, participated in, contributed to or had any Liability with respect to, and (B) no Loan Party or any ERISA Affiliate has any Liability or obligation in respect of, any Title IV Plan, Multiemployer Plan or any multiple employer plan for which the Borrower or any ERISA Affiliate has incurred or could incur Liability under Section 4063 or 4064 of ERISA, (iii) each Employee Benefit Plan is and has been operated in compliance with its terms and all Applicable Laws, including ERISA and the Code, except for such failures to comply that could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, (iv) (A) no ERISA Event has occurred and (B) no event or condition exists or existed that could reasonably be expected to subject the Borrower or any ERISA Affiliate to any tax, fine, lien, penalty or Liability imposed by ERISA, the Code or other Applicable Law, except for any such ERISA Event or tax, fine, lien, penalty or liability that could not be expected, individually or in the aggregate, to have a Material Adverse Effect, and (v) no Loan Party maintains or has

 

59


any obligation or Liability with respect to any Foreign Benefit Plan that, individually or in the aggregate, could be expected to have a Material Adverse Effect.

(x) As of the Agreement Date, the Borrower’s Subsidiaries are set forth in Schedule 3.1(x) and the information set forth in Schedule 3.1(x) is true, correct and complete.

(y) Subsequent to December 31, 2015, the Borrower has not declared or paid any dividends or made any distribution of any kind with respect to its Stock, except as permitted hereunder.

(z) (A) All of the issued and outstanding shares of Stock of the Borrower are duly authorized and validly issued, fully paid and nonassessable, have been issued in compliance with all applicable federal and state and foreign securities laws, were not issued in violation of or subject to any preemptive rights or other rights to subscribe for or purchase securities that have not been waived in writing. The Borrower has reserved for issuance the maximum of 14,300,000 shares of Common Stock initially issuable upon conversion of the First Out Waterfall Notes (the “ Conversion Shares ”) (computed without regard to any limitations on the number of shares that may be issued on conversion thereof) and 2,526,800 shares for issuance as Interest Payment Shares pursuant to Section 2.6 and Exhibit 2.6. The Borrower has reserved for issuance an aggregate number of shares of Common Stock (6,470,000 shares for the Initial Warrants and 8,750,000 shares for the Additional Warrants) sufficient to cover all shares initially issuable upon exercise of the Warrants (the “Warrant Shares”) (computed without regard to any limitations on the number of shares that may be issued on exercise thereof). The Conversion Shares, the Interest Payment Shares, the Warrants, the Warrant Shares and any other distributions required to be made now or in the future pursuant to the Warrants (the “ Warrant Distributions ”) have been duly authorized. The holders of the Initial Warrants are entitled to the rights set forth in the Initial Warrants. Upon issuance of the Additional Warrants in accordance with the terms of this Agreement, the holders of the Additional Warrants will be entitled to the rights set forth in the Additional Warrants. Upon exercise of the Warrants in accordance with terms thereof, the Warrant Shares will be validly issued, fully paid and non-assessable and free from all taxes and Liens with respect to the issue thereof, with the holders thereof being entitled to all rights accorded to a holder of Common Stock. Upon conversion of the First Out Waterfall Notes in accordance with the terms thereof, the Conversion Shares will be validly issued, fully paid and non-assessable and free from all taxes and Liens with respect to the issue thereof, with the holders thereof being entitled to all rights accorded to a holder of Common Stock. Upon issuance in accordance with the terms of this Agreement (including Exhibit 2.6), the Interest Payment Shares will be validly issued, fully paid and non-assessable and free from all taxes and Liens with respect to the issue thereof, with the holders thereof being entitled to all rights accorded to a holder of Common Stock. (B) The issuance by the Borrower of the Securities is exempt from registration under the Securities Act and applicable state securities laws. For purposes of Rule 144 under the Securities Act, (I) the amendments set forth in, and other provisions of, this Agreement and other Loan Documents effect an exchange of securities issued pursuant to the Prior Loan Documents for the First Out Waterfall Loans, First Out Waterfall Notes (together with the related guaranties set forth in the Security Agreement of the Guarantors) and the Additional Warrants (collectively, the “ First Out Waterfall Securities ”) under this Agreement, (II) the holding period for each of the Initial Warrants, the First Out Waterfall Securities and any shares of Common Stock issued as Interest Payment Shares pursuant to this Agreement (including Exhibit 2.6), upon conversion of any of the First Out Waterfall Notes or upon exercise of any of the Warrants pursuant to a Cashless Exercise, Cashless Major Exercise, Cashless Default Exercise or Note Exchange Exercise (each as defined in the Warrants) shall be deemed to have commenced on the Prior Agreement Date, and (III) the holding period for each of the Last Out Waterfall Loans and the Last Out Waterfall Notes (together with the related guaranties set forth in the Security Agreement of the Guarantors) shall be deemed to have commenced on November 2, 2015 (the date the Exchanged Deerfield Convertible Notes were original issued). Provided that a First Out Waterfall Lender is not an Affiliate of the Borrower on the date of issuance of any Interest Payment Shares to such First Out Waterfall Lender pursuant to this Agreement (including Exhibit 2.6), conversion of any of the

 

60


First Out Waterfall Notes by such First Out Waterfall Lender or exercise of any of the Warrants by such First Out Waterfall Lender pursuant to a Cashless Exercise, Cashless Major Exercise, Cashless Default Exercise or Note Exchange Exercise and has not been an Affiliate of the Borrower within the three-month period immediately preceding such date (which the Borrower shall assume unless advised otherwise in writing by such First Out Waterfall Lender), the Interest Payment Shares, Conversion Shares or Warrant Shares (as applicable) issued to such First Out Waterfall Lender will be freely transferable, without restriction or limitation (including any volume limitation or current public information requirement) under Federal or state securities laws, pursuant to Rule 144 under the Securities Act, and will not contain or be subject to a legend or stop transfer order restricting the resale or transferability of thereof. (C) As of the Agreement Date, all of the Borrower’s authorized, issued and outstanding shares of Stock of the Borrower and each of its Subsidiaries are set forth in Schedule 3.1(z), and, except as set forth in Schedule 3.1(z), there are no (i) Stock options or other Stock incentive plans, employee Stock purchase plans or other plans, programs or arrangements of the Borrower or any of its Subsidiaries under which Stock options, Stock or other Stock-based or Stock-linked awards are issued or issuable to officers, directors, employees, consultants or other Persons, (ii) outstanding options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible into or exchangeable or exercisable for, any Stock of the Borrower or any of its Subsidiaries, or contracts, commitments, understandings or arrangements by which the Borrower or any of its Subsidiaries is or may become bound to issue additional Stock of the Borrower or any of its Subsidiaries, or options, warrants or scrip for rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible into or exercisable or exchangeable for, any shares of Stock of the Borrower or any of its Subsidiaries, (iii) agreements or arrangements under which the Borrower or any of its Subsidiaries is obligated to register the sale of any of their securities or Stock under the Securities Act (except the Registration Rights Agreement), (iv) outstanding Stock, securities or instruments of the Borrower or any of its Subsidiaries that contain any redemption or similar provisions, or contracts, commitments, understandings or arrangements by which the Borrower or any of its Subsidiaries is or may become bound to redeem a security of the Borrower other than under the Convertible Note Documents, (v) Stock or other securities or instruments containing anti-dilution or similar provisions that may be triggered by the issuance of securities of the Borrower or any of its Subsidiaries other than under the Convertible Note Documents or (vi) stock appreciation rights or “phantom stock” plans or agreements or any similar plans or agreements to which Borrower or any of its Subsidiaries is a party or by which the Borrower or any of its Subsidiaries is otherwise subject or bound. There are no (X) stockholders’ agreements, voting agreements or similar agreements to which Borrower or any of its Subsidiaries is a party or by which the Borrower or any of its Subsidiaries is otherwise subject or bound, other than in connection with clauses (i), (k) and (n) of the definition of “Permitted Investments”, (Y) preemptive rights or any other similar rights to which any Stock of the Borrower or any of its Subsidiaries is subject or (Z) any restrictions upon the voting or transfer of any Stock of the Borrower or any of its Subsidiaries (other than restrictions on transfer imposed by U.S. federal and state securities laws and other than as set forth in the Loan Documents, the ABL Debt Documents and, if such instrument is permitted hereunder to be secured, the documents governing the Permitted 3.25% Convertible Note Refinancing). (C) The issuance and delivery of the First Out Waterfall Notes and the Warrants does not and, assuming full exercise of the Warrants, full conversion of the First Out Waterfall Notes and issuance of the maximum number of Interest Payment Shares, the exercise of the Warrants, the conversion of the First Out Waterfall Notes and the issuance of the Warrant Shares, the Conversion Shares and the Interest Payment Shares, will not: (i) require approval from any Governmental Authority; (ii) obligate the Borrower to issue shares of Common Stock or other securities to any Person (other than the Secured Parties); and (iii) will not result in a right of any holder of the Borrower’s securities to adjust the exercise, conversion, exchange or reset price under and will not result in any other adjustments (automatic or otherwise) under, any securities of the Borrower. (D) The Borrower has furnished to Agent and each Lender true, correct and complete copies of each Loan Party’s Organizational Documents and any amendments, restatements, supplements or modifications thereto, and all documents, agreements and instruments containing the terms of all securities and Stock convertible into, or exercisable or exchangeable

 

61


for, Common Stock or other Stock of any Loan Party or its Subsidiaries, and the material rights of the holders thereof in respect thereto.

(aa) Except for the Operative Documents, the Convertible Note Documents and the agreements set forth on Schedule 3.1(aa), as of the Agreement Date there are no Material Contracts. The consummation of the transactions contemplated by the Loan Documents will not give rise to a right to termination in favor of any party to any Material Contract (other than any Loan Party), except for such Material Contracts the noncompliance with which would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.

(bb) Neither the Borrower nor its Subsidiaries are in breach or default under any Material Contract, and, to the knowledge of the Loan Parties, no other party to a Material Contract is in default or breach thereunder, except where any breach or default would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.

(cc) The proceeds of the Loans are intended to be and shall be used solely for the purposes set forth in and permitted by Section 2.1.

(dd) Except as set forth in Schedule 3.1(dd) and except where any failures to comply could not reasonably be expected, either individually or in the aggregate, to result in a Material Adverse Effect, each Loan Party and each Subsidiary of each Loan Party (a) is and has been in compliance with all applicable Environmental Laws, including obtaining and maintaining all permits, licenses, consents, Authorizations and registrations required by any applicable Environmental Law, (b) is not party to, and no Real Estate currently (or to the knowledge of any Loan Party, previously) owned, leased, subleased, operated or otherwise occupied by or for any such Person is subject to or the subject of, any contractual obligation or any pending or, to the knowledge of any Loan Party, threatened, order, action, investigation, suit, proceeding, audit, Lien, claim, demand, dispute or notice of violation or of potential liability or similar notice relating in any manner to any Environmental Law, (c) has not caused or suffered to occur a Release of Hazardous Materials at, to or from any Real Estate, (d) does not currently (or to the knowledge of any Loan Party, did not previously) own, lease, sublease, operate or otherwise occupy any Real Estate that is contaminated by any Hazardous Materials and (e) is not, and has not been, engaged in, and has not permitted any current or former tenant to engage in, operations in violation of any Environmental Law and knows of no facts, circumstances or conditions reasonably constituting notice of a violation of any Environmental Law, including receipt of any information request or notice of potential responsibility under the Comprehensive Environmental Response, Compensation and Liability Act or similar Environmental Laws.

(ee) None of any Loan Party, any Person controlling any Loan Party or any Subsidiary of any Loan Party is (a) a company registered or required to be registered as an “investment company,” or a company “controlled” by an “investment company” or a “principal underwriter” of a “registered investment company” within the meaning of the Investment Company Act, or otherwise registered or required to be registered, or subject to the restrictions imposed, by the Investment Company Act, or (b) subject to regulation under the Federal Power Act, the Interstate Commerce Act, any state public utilities code, or any other federal or state statute, rule or regulation limiting its ability to incur Indebtedness, pledge its assets, perform its obligations under the Loan Documents or which may otherwise render all or any portion of the Obligations unenforceable.

(ff) There are no strikes, boycotts, grievances, work stoppages, slowdowns, lockouts or other job actions existing, pending (or, to the knowledge of any Loan Party, threatened) against or involving any Loan Party or any Subsidiary of any Loan Party, except for those that could not reasonably be

 

62


expected, individually or in the aggregate, to have a Material Adverse Effect. Except as set forth on Schedule 3.1(ff), or except as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, as of the Agreement Date, (a) there is no memorandum of understanding, collective bargaining or similar agreement, and there is no ongoing negotiation or duty to negotiate, with any union, labor organization, works council or similar representative covering any Employee or otherwise binding any Loan Party or any Subsidiary of any Loan Party, (b) to the Loan Parties’ knowledge, no petition for certification or election of any such representative is existing or pending with respect to any Employee, (c) to the Loan Parties’ knowledge, no such representative has sought certification or recognition with respect to any Employee, and (d) to the Loan Parties’ knowledge, no Employee or his or her representative is engaged in any organizing efforts. Except as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, all current and former Employees are and have been correctly classified as exempt or non-exempt under, and are and have been paid in accordance with, all applicable federal, state, and local wage and hour laws. Further, all individuals who perform or have performed services for any Loan Party or any Subsidiary of any Loan Party are or were correctly classified under each Employee Benefit Plan, ERISA, the Internal Revenue Code and other Applicable Law as common law employees, independent contractors or other non-employee basis, or leased employees, except as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. Each Loan Party and Subsidiary of any Loan Party are in material compliance with all Applicable Laws concerning employment, including without limitation hiring, background checks, compensation, benefits, wages (including payment of overtime), wage deductions and withholdings, classification, immigration, work authorization, employment eligibility verification, reporting, taxation, occupational health and safety, equal rights, labor relations, accommodations, breaks, notices, employment policies, paid or unpaid time off work, accessibility, privacy, and workers’ compensation, except for such noncompliance that could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.

(gg) During five (5) years preceding the Agreement Date, no Loan Party has been known by and has used any other name, whether corporate, fictitious or otherwise, except as set forth on Schedule 3.1(gg). Schedule 3.1(gg) also lists (a) each Loan Party’s jurisdiction of organization and legal name and (b) each Loan Party’s organizational identification number. Each Loan Party’s chief executive office or sole place of business, in each case as of the Agreement Date, is at the chief executive office or sole place of business address identified as such in Schedule 3.1(gg) and no Loan Party maintains any other offices or facilities except as described therein.

(hh) The Inventory and Equipment of the Loan Parties is located only at, or in-transit between, the locations identified on Schedule 3.1(hh). With respect to any Inventory and Equipment listed at locations that are outside the United States (and with respect to any Inventory and Equipment on consignment at any location), (i) any failure of the Agent and the other Secured Parties to (A) be fully protected on the Inventory and Equipment or be fully protected or perfected with respect to any Liens granted to the Agent (for the benefit of the Secured Parties) on any such Inventory or Equipment, or (B) have absolute or full access to such locations when exercising rights and remedies after the occurrence and during the continuance of an Event of Default, in each case of clause (i)(A) and clause (i)(B), does not, individually or in the aggregate, cause a Material Adverse Effect to occur, and (ii) as of the Agreement Date, the cost paid by the Loan Parties and their Subsidiaries for such Inventory and Equipment listed at such locations outside the United States, or on consignment at any location outside the United States, does not exceed $10,000,000.

(ii) Each Loan Party keeps correct and accurate records itemizing and describing the type, quality and quantity of its and their Subsidiaries’ Inventory and the book value thereof.

(jj) Each Loan Party and each Subsidiary of each Loan Party is in compliance in all material respects with all Sanctions laws as administered by the U.S. Treasury Department’s Office of

 

63


Foreign Assets Control (“ OFAC ”) and the U.S. State Department. No Loan Party and no Subsidiary of a Loan Party (i) is a Person on the list of the Specially Designated Nationals and Blocked Persons (the “ SDN List ”), (ii) is a Person who is otherwise the target of Sanctions laws such that a U.S. Person cannot deal or otherwise engage in business transactions with such Person, (iii) is a Sanctioned Entity, (iv) is owned or controlled by (including by virtue of such Person being a director or owning voting shares or interests), or acts, directly or indirectly, for or on behalf of, any Person on the SDN List or a Sanctioned Entity such that the entry into, or performance under, this Agreement or any other Loan Document would be prohibited by U.S. law, (v) has its assets located in Sanctioned Entities, (vi) derives revenues from investments in, or transactions with Sanctioned Persons or Sanctioned Entities. No proceeds of any Loan will be used to fund any operations in, finance any investments or activities in, or make any payments to, a Sanctioned Person or a Sanctioned Entity. Each Loan Party and each Subsidiary of each Loan Party is in compliance with all Anti-Money Laundering Laws. No action, suit or proceeding by or before any court or Governmental Authority with respect to compliance with such Anti-Money Laundering Laws is pending or threatened to the knowledge of each Loan Party and each Subsidiary of each Loan Party. Each Loan Party and each Subsidiary of each Loan Party is in compliance in all material respects with all applicable Anti-Corruption Laws, including the U.S. Foreign Corrupt Practices Act of 1977 (“ FCPA ”). None of any Loan Party or any Subsidiary of a Loan Party, nor to the knowledge of any Loan Party or any Subsidiary thereof, any director, officer, agent, employee or other Person acting on behalf of the Loan Party or any Subsidiary of a Loan Party, has taken any action, directly or indirectly, that would result in a violation of applicable Anti-Corruption Laws. No part of the proceeds of the Loans will be used by any Loan Party or any of their Affiliates, directly or indirectly, for any payments to any governmental official or employee, political party, official of a political party, candidate for political office or anyone else acting in an official capacity, in order to obtain, retain or direct business or obtain any improper advantage, in violation of the FCPA. The Loan Party and each Subsidiary of a Loan Party maintains and implements policies and procedures designed to ensure compliance by the Loan Parties, their Subsidiaries and their respective directors, officers, employees and agents with Sanctions, Anti-Money Laundering Laws and Anti-Corruption Laws. To the extent applicable, each Loan Party and each of its Affiliates is in compliance, in all material respects, with all Anti-Terrorism Laws.

(kk) The Borrower and its Subsidiaries are in all material respects in compliance with applicable provisions of the Sarbanes-Oxley Act of 2002, as amended, and the rules and regulations thereunder (collectively, “ Sarbanes-Oxley ”).

(ll) Neither the Borrower nor any of its Subsidiaries nor, to the Borrower’s or any of its Subsidiaries’ knowledge, any director, officer or employee, of the Borrower or any of its Subsidiaries, has received or otherwise obtained any material complaint, allegation, assertion or claim, whether written or oral, regarding the accounting or auditing practices, procedures, methodologies or methods of the Borrower or any of its Subsidiaries or its internal accounting controls, including any complaint, allegation, assertion or claim that the Borrower or any of its Subsidiaries has engaged in questionable accounting or auditing practices. No attorney representing the Borrower or any of its Subsidiaries, whether or not employed by the Borrower or any of its Subsidiaries, has reported evidence of a material violation of securities laws or breach of fiduciary duty or similar violation by the Borrower or any of its Subsidiaries or any of their respective officers, directors, employees or agents to the Borrower’s or any of its Subsidiaries’ board of directors (or equivalent governing body) or any committee thereof or to any director (or equivalent person) or officer of the Borrower or any of its Subsidiaries pursuant to Section 307 of Sarbanes-Oxley, and the SEC’s rules and regulations promulgated thereunder. There have been no internal or SEC investigations regarding accounting or revenue recognition discussed with, reviewed by or initiated at the direction of the chief executive officer, the principal financial officer or the principal accounting officer (in each case, or officer holding such equivalent position) of the Borrower or any of its Subsidiaries, the Borrower’s or any of its Subsidiaries’ board of directors (or equivalent governing body) or any committee thereof.

 

64


(mm) The Borrower is not, and never has been, a “shell company” (as defined in Rule 12b-2 under the Exchange Act). The Borrower is eligible to register the Warrant Shares for resale by the holders thereof on a registration statement on Form S-3 under the Securities Act.

(nn) Neither the Borrower, nor any of its Affiliates, nor any Person acting on its or their behalf, has engaged or will engage in any form of general solicitation or general advertising (within the meaning of Regulation D under the Securities Act) in connection with the offer, sale or issuance of the Securities.

(oo) Neither the Borrower, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made, or will make, any offers or sales of any security or Stock or solicited any offers to buy any security or Stock, under circumstances that would require registration of any of the Securities under the Securities Act or cause this offering of the Securities to be integrated with prior offerings by the Borrower for purposes of the Securities Act or any applicable holder of Stock approval provisions of the Principal Market or any other authority.

(pp) The Common Stock is registered pursuant to Section 12(b) of the Exchange Act, and neither the Borrower nor any of its Subsidiaries has taken, or will take, any action designed to terminate, or which to the knowledge of the Borrower and its Subsidiaries is likely to have the effect of terminating, the registration of the Common Stock under the Exchange Act, nor has the Borrower or any of its Subsidiaries received any notification that the SEC is contemplating terminating such registration. Neither the Borrower nor any of its Subsidiaries is in violation of any of the rules, regulations or requirements of the Principal Market, and, to the knowledge of the Borrower and its Subsidiaries, there are no facts or circumstances that could reasonably lead to suspension or termination of trading of the Common Stock on the Principal Market. For not less than the five years preceding the Agreement Date, (i) the Common Stock has been listed or designated for quotation, as applicable, on the Principal Market, (ii) trading in the Common Stock has not been suspended or deregistered by the SEC or the Principal Market, and (iii) neither the Borrower nor any of its Subsidiaries has received any communication, written or oral, from the SEC or the Principal Market regarding the suspension or termination of trading of the Common Stock on the Principal Market.

(qq) The Common Stock is eligible for clearing through The Depository Trust Company (“ DTC ”), through its Deposit/Withdrawal At Custodian (DWAC) system, and the Borrower is eligible for and participating in the Direct Registration System (DRS) of DTC with respect to the Common Stock. The transfer agent for the Common Stock is a participant in, and the Common Stock is eligible for transfer pursuant to, DTC’s Fast Automated Securities Transfer Program. The Common Stock is not, and has not at any time been, subject to any DTC “chill,” “freeze” or similar restriction with respect to any DTC services, including the clearing of transactions in shares of Common Stock through DTC.

(rr) The Borrower and the Borrower’s board of directors (or equivalent governing body) have taken all necessary action, if any, in order to render inapplicable any control share acquisition, business combination or other similar anti-takeover provision under the Borrower’s Organizational Documents or the laws of the State of Delaware that is or could become applicable to any of the Secured Parties as a result of the transactions contemplated by the Loan Documents and the Borrower’s fulfilling its obligations with respect thereto, including the Borrower’s issuance of the Securities and any Secured Party’s ownership of the Securities. As of the Agreement Date, the Borrower has not adopted a stockholders rights plan (or “poison pill”) or similar arrangement relating to accumulations of beneficial ownership of Common Stock or a change in control of the Borrower (any such plan or arrangement, a “ Rights Plan ”), and after the Prior Agreement Date, the Borrower will not have adopted any Rights Plan that in any way interferes with, or otherwise adversely affects, any First Out Waterfall Lender’s (or other holder’s) exercise in full of its rights under the Warrants and the First Out Waterfall Notes or ownership of

 

65


all of the Warrant Shares, the Conversion Shares and the Interest Payment Shares or that otherwise affects or applies to any First Out Waterfall Lender (or such other holder of Warrants or Warrant Shares) in any respect that is less favorable than its effect on the most favorably treated holder of Stock of the Borrower under such Rights Plan.

(ss) It is understood and acknowledged by the Borrower that none of the Secured Parties nor holders of the Securities has been asked to agree, nor has any Secured Party agreed, to desist from purchasing or selling, long and/or short, Stock or other securities of the Borrower, or “derivative” securities or Stock based on Stock or other securities issued by the Borrower or to hold the Securities for any specified term; and no Secured Party nor holder of Securities shall be deemed to have any affiliation with or control over any arm’s length counterparty in any “derivative” transaction. The Borrower further understands and acknowledges that (i) one or more Secured Parties or holders of Securities may engage in hedging and/or trading activities at various times during the period that the Securities are outstanding, and (ii) such hedging and/or trading activities, if any, can reduce the value of the Stock held by the existing holders of Stock of the Borrower, both at and after the time the hedging and/or trading activities are being conducted. The Borrower acknowledges that any such hedging and/or trading activities do not constitute a breach of any Loan Document or affect the rights of any Secured Party or holder of Securities under any Loan Document. The Borrower further acknowledges that its obligations under the Loan Documents, including its obligation to issue the Warrant Shares upon exercise of the Warrants and the Conversion Shares upon conversion of the First Out Waterfall Notes, are unconditional and absolute and not subject to any right of set off, counterclaim, delay or reduction, regardless of any claim any Loan Party may have against any of the Secured Parties and regardless of the dilutive effect that such issuance may have on the ownership of the other stockholders of the Borrower.

(tt) The Borrower and the other Loan Parties are solely and jointly and severally responsible for the payment of any fees, costs, expenses and commissions of any placement agent, broker or financial adviser relating to or arising out of the transactions contemplated by the Loan Documents. The Borrower and the other Loan Parties will pay, and hold each of the Secured Parties harmless against, any liability, loss or expense (including attorneys’ fees, costs and expenses) arising in connection with any claim for any such payment, other than those arising from the gross negligence or willful misconduct of Agent or any Lender as determined by a final, non-appealable judgment of a court of competent jurisdiction.

(uu) Except as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, each Loan Party and its Subsidiaries has made all notifications, submissions, and reports required by the FDA, any other Governmental Authority or any Healthcare Law, and all such notifications, submissions and reports were true, complete, and correct in all respects as of the date of submission to FDA, any other Governmental Authority or to such other Person required by any Healthcare Law. There has not been any violation of any Healthcare Laws by any Loan Party or its Subsidiaries in its product development efforts, submissions, record keeping and reports to the FDA or any other Governmental Authority that could reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. To the knowledge of each Loan Party and each of its Subsidiaries, there are no civil or criminal proceedings relating to any Loan Party or any of its Subsidiaries or any officer, director or employee of any Loan Party or Subsidiary of any Loan Party that involve a matter within or related to the FDA’s or any other Governmental Authority’s jurisdiction or any off-label promotion or allegations of non-compliance with Healthcare Laws. Other than as expressly set forth on Schedule 3.1(uu), no Loan Party nor any Affiliate thereof has received any material adverse notice (written or oral) from the FDA or any other Governmental Authority that has not been finally and fully resolved in accordance and compliance with Applicable Law and all FDA and other Governmental Authority standards, regulations and requirements regarding any Product or regarding (i) any actions or inactions of any Loan Party or any

 

66


of its Subsidiaries or any officer, director or employee of any Loan Party or Subsidiaries of any Loan Party, including with respect to any off-label promotion or (ii) alleging non-compliance with Healthcare Laws.

(vv) With respect to any Product, (i) the Loan Parties and their Subsidiaries have received, and such Product is the subject of, all Regulatory Required Permits needed in connection with the design, testing, manufacture, processing, assembly, packaging, labeling, marketing, distribution, commercialization, import, export or sale of such Product as currently being conducted by or on behalf of such Loan Parties or Subsidiaries, except where the failure to have such Regulatory Required Permits would not have a Material Adverse Effect, and (ii) such Product is being designed, tested, manufactured, processed, assembled, packaged, labeled, marketed, distributed, commercialized, imported, exported or sold, as the case may be, except as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, in compliance with all Applicable Laws and Authorizations.

(ww) None of the Loan Parties are in violation of any Healthcare Laws, except where any such violation would not have a Material Adverse Effect.

(xx) Except as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, each Loan Party and its Subsidiaries is in compliance with the written procedures, record-keeping and reporting requirements required by (or of) (i) the FDA or any comparable Governmental Authority pertaining to the reporting of adverse events involving the Products or concerning the actions or inactions of the Loan Parties and their Subsidiaries and the directors, officers and employees of the Loan Parties and their Subsidiaries, including with respect to off-label promotion, as applicable, and (ii) Healthcare Laws.

(yy) No Loan Party is a participating provider under contract to provide health care services and receive payment or reimbursement for such services under any Third Party Payor Program.

(zz) To the knowledge of the Loan Parties’ Authorized Officers, neither any of the Loan Parties nor any of the Loan Parties’ officers, directors, employees, equityholders, agents or Affiliates has ever (i) made an untrue statement of material fact, fraudulent statement to the FDA or any other Governmental Authority or in any documents or records prepared or maintained to comply with the FDCA; (ii) failed to disclose a material fact required to be disclosed to the FDA or any other Governmental Authority; (iii) been investigated by the FDA, National Institutes of Health, Office of the Inspector General for the Department of Health and Human Services, Department of Justice, or other comparable Governmental Authority for data or healthcare program fraud; or (iv) committed an act, made a statement, or failed to make a statement that could reasonably be expected to provide a basis for the FDA to invoke its policy respecting “Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities,” set forth in 56 Fed. Regulation 46191 (September 10, 1991).

(aaa) No Loan Party has received any written notice that any Governmental Authority, including the FDA, the Office of the Inspector General of the United States Department of Health and Human Services or the United States Department of Justice has commenced or threatened to initiate any investigation or action against a Loan Party, any action to enjoin a Loan Party, or any of its officers, directors, employees, equityholders, agents or Affiliates, from conducting their businesses at any facility owned or used by them or for any civil penalty, injunction, seizure or criminal action, in each case, which could reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect.

(bbb) No Loan Party has received from the FDA a Warning Letter, Form FDA-483, “Untitled Letter,” other correspondence or notice setting forth allegedly objectionable observations or alleged violations of laws or regulations enforced by the FDA, or any comparable correspondence from any state or local authority responsible for regulating drug or device products and establishments, or any

 

67


comparable correspondence from any foreign counterpart of the FDA, or any comparable correspondence from any foreign counterpart of any state or local authority with regard to any Product or the manufacture, processing, packing, or holding thereof, in each case, which could reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect.

(ccc) None of the Loan Parties has engaged in any material Recalls, Market Withdrawals or other forms of product retrieval from the marketplace of any Products that has been not been finally and fully completed prior to the Agreement Date in accordance and compliance with Applicable Law and all FDA and other Governmental Authority standards, regulations and requirements. None of the Products (for the avoidance of doubt, including those in the immediately preceding sentence that have been so finally and fully completed) have been subject to a Recall, Market Withdrawal, or other Correction or Removal, nor is any such action currently under consideration by Borrower or, to the knowledge of Borrower, any manufacturer or supplier of a Product, that could reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect. Borrower has not been restrained in its ability to manufacture, process, distribute, supply, import, export, market, or sell any of the Products, except to the extent that would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.

(ddd) Each Product, except as would not be reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, (a) is not adulterated or misbranded within the meaning of the FDCA; (b) is not an article prohibited from introduction into interstate commerce under the provisions of Sections 404, 505 or 512 of the FDCA; (c) has been and/or shall be manufactured, imported, possessed, owned, warehoused, marketed, promoted, sold, labeled, furnished, distributed and marketed, and each service has been conducted, in accordance with all applicable Authorizations and Applicable Laws; and (d) has been and/or shall be manufactured in accordance with Good Manufacturing Practices.

(eee) No Loan Party is subject to any proceeding, suit or, to any Loan Party’s knowledge, investigation by any federal, state or local government or quasi-governmental body, agency, board or authority or any other administrative or investigative body (including the Office of the Inspector General of the United States Department of Health and Human Services) which would reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect on any Loan Party;

(fff) The Loan Parties have not received any notice, and are not aware, of any violation of applicable antitrust laws, employment or landlord-tenant laws of any federal, state or local government or quasi-governmental body, agency, board or other authority with respect to the Loan Parties that could reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect.

(ggg) None of the proceeds from the Loans have been or will be used, directly or indirectly, for the purpose of purchasing or carrying any Margin Stock, for the purpose of reducing or retiring any Indebtedness which was originally incurred to purchase or carry any Margin Stock or for any other purpose which might cause any of the Loans to be considered a “purpose credit” within the meaning of Regulation T, U or X of the Federal Reserve Board. No Loan Party nor any of their Subsidiaries is engaged principally, or as one of its important activities, in the business of extending credit for the purpose of purchasing or carrying any Margin Stock.

(hhh) None of the written information (financial or otherwise) (other than projections, other forward-looking information and industry information) furnished by or on behalf of any Loan Party to Agent or any Lender in connection with the consummation of the transactions contemplated by the Loan Documents contains any untrue statement of a material fact or omits to state a material fact necessary to make the statements contained herein or therein not materially misleading in light of the circumstances under which such statements were made.

 

68


(iii) The rate of interest paid under the Notes and other Loan Documents or on any other Obligations, and the method and manner of the calculation thereof, do not violate any usury law or other Applicable Laws, any of the Organizational Documents, or any of the Loan Documents.

(jjj) The Loan Parties do not own any stock, partnership interests, limited liability company interest or other equity securities or Subsidiaries except for Permitted Investments. As of the Agreement Date, set forth on Schedule 3.1(jjj) (as such Schedule may be updated from time to time to reflect changes resulting from transactions permitted under this Agreement) is a complete and accurate description of the authorized Stock of the Subsidiaries of the Loan Parties, by class, and a description of the number of shares of each such class that are issued and outstanding.

(kkk) All information set forth in the Schedules is true, accurate and complete in all material respects as of the Agreement Date and any other subsequent date in which the Loan Parties are requested to update such Schedules. All information set forth in the Perfection Certificate is true, accurate and complete in all material respects as of the Agreement Date and any other subsequent date in which the Loan Parties are requested to update such certificate.

Section  3.2 Borrower Acknowledgment . The Loan Parties (on their behalf and on their Subsidiaries’ behalf) acknowledge that they have made the representations and warranties referred to in Section 3.1 with the intention of persuading Agent and the Lenders to enter into the Loan Documents and that Agent and the Lenders have entered into the Loan Documents on the basis of, and in full reliance on, each of such representations and warranties, each of which shall survive the execution and delivery of this Agreement, the other Loan Documents, the making of any Disbursement and the issuance of the Securities until the later of (a)(i) all of the Obligations are repaid in full and (ii) all of the Warrants have expired or been terminated and (b) the end of the Reporting Period.

Section  3.3 Representations and Warranties of the Lenders . Each Lender, severally and not jointly, represents and warrants to the Borrower as of the Agreement Date that:

(a) Such Lender (i) acquired the Loans and the Notes (together with the related guaranties set forth in the Security Agreement of the Guarantors) provided by such Lender, the Warrants related to the First Out Waterfall Loans made by such Lender hereunder, and in the case of the Last Out Waterfall Lender, the Exchanged Deerfield Convertible Notes, and (ii) upon any cash exercise of such Lender’s Warrants, will acquire the Warrant Shares then-issuable upon exercise thereof for its own account and not with a view towards, or for resale in connection with, the public sale or distribution thereof, except pursuant to sales registered under, or exempted from, the registration requirements of the Securities Act; provided , however , that by making the representations herein, such Lender does not agree to hold any of the Securities for any minimum or other specific term and reserves the right to assign, transfer or otherwise dispose of any of the Securities at any time in accordance with or pursuant to a registration statement or an exemption under the Securities Act.

(b) Such Lender is an “accredited investor” as that term is defined in Rule 501(a) of Regulation D.

(c) Such Lender understands that the Securities are being offered and sold to it in reliance on specific exemptions from the registration requirements of the United States federal and state securities laws and that the Borrower is relying in part upon the truth and accuracy of, and such Lender’s compliance with, the representations, warranties, agreements, acknowledgments and understandings of such Lender set forth herein in order to determine the availability of such exemptions.

 

69


(d) Such Lender and its advisors, if any, have been furnished with all materials relating to the business, finances and operations of the Loan Parties and their Subsidiaries and materials relating to the offer and sale of the Securities that have been requested by such Lender. Such Lender and its advisors, if any, have been afforded the opportunity to ask questions of the Loan Parties. Neither such inquiries nor any other due diligence investigations conducted by such Lender or its advisors, if any, or its representatives shall modify, amend or otherwise affect such Lender’s right to rely on the representations and warranties of the Loan Parties and their Subsidiaries contained in Article 3 and elsewhere in the Loan Documents. Such Lender can bear the economic risk of a total loss of its investment in the Securities being offered and has such knowledge and experience in business and financial matters so as to enable it to understand the risks of and investment decision with respect to its investment in the Securities.

(e) Such Lender understands that no United States federal or state agency or any other government or Governmental Authority has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of the investment in the Securities nor have such authorities passed upon or endorsed the merits of the offering of the Securities.

(f) Such Lender is duly organized and validly existing under the laws of the jurisdiction of its formation.

(g) Each Loan Document to which such Lender is a party has been duly authorized, executed and delivered by such Lender and constitutes the valid and legally binding obligation of such Lender, enforceable against such Lender in accordance with its terms, except as such enforceability may be limited by (i) applicable insolvency, bankruptcy, reorganization, moratorium or other similar laws affecting creditors’ rights generally, and (ii) applicable equitable principles (whether considered in a proceeding at law or in equity).

(h) Such Lender has the requisite power and authority to enter into and perform its obligations under each of the Loan Documents to which such Lender is a party.

(i) Such Lender understands that the Securities are characterized as “restricted securities” under the U.S. federal securities laws inasmuch as they were, or are being, acquired from the Borrower (or the Guarantors, as applicable) in a transaction not involving a public offering and that none of the Securities may be resold and/or hedged except pursuant to an effective registration statement under the Securities Act or an exemption from the registration requirements of the Securities Act, including Rule 144 under the Securities Act, Section 4(a)(7) of the Securities Act or a so-called “4[(a)] and a half” transaction (without limiting the representations and warranties of the Borrower set forth in Section 3.1(z)).

ARTICLE 4

CLOSING CONDITIONS

Section  4.1 Conditions to the Disbursement s. The effectiveness of this Agreement and the other Loan Documents being executed and delivered on the Agreement Date, in each case, shall be subject to the fulfillment and satisfaction of all of the following conditions:

(a) Agent and the Lenders shall have received executed counterparts of each of the following documents and the Loan Documents and other agreements, instruments and documents set forth on the closing checklist attached hereto as Exhibit D, each in form and substance satisfactory to Agent:

(i) this Agreement

 

70


(ii) the Control Agreements required to be delivered on the Agreement Date pursuant to this Agreement and the other Loan Documents;

(iii) the Security Agreement;

(iv) the Intercompany Subordination Agreement;

(v) the Copyright Security Agreement;

(vi) the Patent Security Agreement;

(vii) the Intercreditor Agreement; and

(viii) the Trademark Security Agreement;

(b) the Additional Warrants shall have been duly executed, issued and delivered to the Lenders in accordance with Section 2.8;

(c) each representation and warranty by any Loan Party or any of its Subsidiaries contained herein or in any other Loan Document is true, correct and complete in all material respects (without duplication of any materiality qualified contained therein) as of such date, except to the extent that such representation or warranty expressly relates to an earlier date (in which event such representations and warranties were true, correct and complete in all material respects (without duplication of any materiality qualifier contained therein) as of such earlier date);

(d) neither the Borrower nor any of its Subsidiaries shall have any Indebtedness, other than Permitted Indebtedness and all other Indebtedness shall be paid off pursuant to payoff letters reasonably satisfactory to Agent and any Liens relating thereto shall be terminated in a manner reasonably satisfactory to Agent;

(e) all actions necessary to establish that Agent (for the benefit of itself and the Lenders) will have perfected first priority security interests (subject only to the prior priority of the Permitted Priority Liens and Liens in the Collateral under the Loan Documents shall have been taken;

(f) all fees required to be paid on the Agreement Date pursuant to this Agreement and the other Loan Documents and all costs and expenses required to be paid on the Agreement Date (including pursuant to Section 6.3) pursuant to this Agreement and the other Loan Documents shall have been paid in cash to the applicable Secured Parties;

(g) subject to Section 5.1(q), Agent shall have received all documents required to be received pursuant to Section 3.01 and Section 3.02 of the ABL Credit Facility;

(h) all accrued interest on the Exchanged Deerfield Convertible Notes under the 3.25% Convertible Note Documents through and including the Agreement Date (plus an additional day of interest to the extent all such accrued interest thereon is not paid by the payment deadline time set forth in the 3.25% Convertible Note Documents) shall have been paid in cash to Deerfield Partners, L.P., as the holder of the Exchanged Deerfield Convertible Notes;

(i) no Default or Event of Default (both under the Prior Loan Documents and the Loan Documents) shall have occurred or would result from the transactions being consummated on the

 

71


Agreement Date (including the funding of any loans or disbursements to the Loan Parties or their Subsidiaries by any Person on the Agreement Date and any use of the proceeds thereof);

(j) [reserved];

(k) the Borrower shall have delivered to the Secured Parties a letter from the transfer agent for the Common Stock certifying the number of shares of Common Stock outstanding as of a date within two (2) Business Days prior to the Agreement Date;

(l) [reserved];

(m) Agent shall have received a certificate from a responsible officer of each Loan Party:

(i) attesting to the resolutions of such Loan Party’s board of directors authorizing its execution, delivery, and performance of the Loan Documents to which it is a party,

(ii) authorizing specific officers of such Loan Party to execute the same, attesting to the incumbency and signatures of such specific officers of such Loan Party,

(iii) attesting to copies of each Loan Party’s Organizational Documents, as amended, modified, or supplemented to the Agreement Date, which Organizational Documents shall be (A) certified by an Authorized Person of such Loan Party, and (B) with respect to Organizational Documents that are charter documents, certified as of a recent date (not more than thirty (30) days prior to the Agreement Date) by the appropriate governmental official,

(iv) attesting to certificates of status with respect to each Loan Party, dated within ten (10) days of the Agreement Date, such certificates to be issued by the appropriate officer of the jurisdiction of organization of such Loan Party, which certificates shall indicate that such Loan Party is in good standing in such jurisdiction,

(v) attesting to certificates of status with respect to each Loan Party, each dated within thirty (30) days of the Agreement Date, such certificates to be issued by the appropriate officer of the jurisdictions (other than the jurisdiction of organization of such Loan Party) in which such Loan Party’s failure to be duly qualified or licensed would constitute a Material Adverse Effect, which certificates shall indicate that such Loan Party is in good standing in such jurisdictions, and

(vi) Agent shall have received all requested collateral access agreements in favor of Agent, from all mortgagees, landlords and operators of warehouses in which a Loan Party operates or maintains any Collateral;

(n) Agent shall have received an opinion of the Loan Parties’ counsel in form and substance reasonably satisfactory to Agent; and

(o) Agent shall have received the ABL Debt Documents, which shall be in form and substance reasonably satisfactory to the Agent and the Lenders and the Agent and the Lenders shall have received evidence reasonably satisfactory to them that all conditions set forth in the ABL Debt Documents to make such documents effective and closed and to fund loans thereunder have been satisfied in all

 

72


respects.

ARTICLE 5

PARTICULAR COVENANTS AND EVENTS OF DEFAULT

Section 5.1 Affirmative Covenants.

For so long as the Obligations (other than unasserted contingent indemnification obligations and other than those Obligations under any Warrant or the Registration Rights Agreement; provided that Sections 5.1(h), (p), (s) and (aa) shall survive until the end of the Reporting Period) remain outstanding:

(a) The Loan Parties will and will cause their Subsidiaries to (i) preserve and maintain in full force and effect its organizational existence and good standing under the Applicable Laws of its jurisdiction of incorporation, organization or formation, as applicable, other than as permitted under Section 5.2(i), and (ii) preserve and maintain all qualifications to do business in each other jurisdiction not covered by clause (i) above that the failure to be so qualified could reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.

(b) The Loan Parties will, and will cause their Subsidiaries to, (i) comply in all material respects with all Applicable Laws, except where the necessity of compliance therewith is contested in good faith by appropriate proceedings or where failure to do so could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, and (ii) maintain in effect and enforce policies and procedures designed to ensure compliance by the Loan Parties, their Subsidiaries and their respective directors, officers and employees with Anti-Corruption Laws, Anti-Money Laundering Laws and applicable Sanctions.

(c) The Loan Parties will, and will cause their Subsidiaries to, obtain, make and keep in full force and effect all licenses, certificates, approvals, registrations, clearances, Authorizations and permits required to conduct their businesses, except where the failure to make and keep such licenses, certificates, approvals, registrations, clearances, authorizations and permits in full force and effect could not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect.

(d) Each Loan Party will, except as otherwise permitted by this Agreement, maintain, and will cause each of its Subsidiaries to maintain, and preserve all its assets and property which is used or useful in its business in good working order and condition, ordinary wear and tear excepted and will make all necessary repairs thereto and renewals and replacements thereof, except, in each case, where the failure to do so could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.

(e) The Loan Parties will, and will cause each of their Subsidiaries to, maintain with financially sound and reputable insurance companies with respect to their assets, properties and business, against such hazards and liabilities, of such types and in such amounts, as is customarily maintained by companies in the same or similar businesses similarly situated. All property insurance policies covering the Collateral are to be made payable to Agent for the benefit of Agent and the Lenders, as their interests may appear, in case of loss, pursuant to a standard lender’s loss payable endorsement with a standard noncontributory “lender” or “secured party” clause and are to contain such other provisions as Agent may reasonably require to fully protect the Lenders’ interest in the Collateral and to any payments to be made under such policies. All certificates and endorsements of property and general liability insurance are to be delivered to Agent by the Loan Parties, with the lender’s loss payable (but only in respect of Collateral) and additional insured endorsements in favor of Agent and will provide for not less than 30 days (10 days in the case of non-payment) prior written notice to Agent of the exercise of any right of cancellation or any

 

73


modification thereof; provided , however , that, for the avoidance of doubt, Agent need not be named on any workers compensation or D&O policies. If Loan Parties or their Subsidiaries fail to maintain such insurance, Agent may arrange for such insurance, but at Loan Parties’ expense and without any responsibility on Agent’s part for obtaining the insurance, the solvency of the insurance companies, the adequacy of the coverage, or the collection of claims. The Loan Parties shall give Agent prompt written notice of any loss exceeding $500,000 covered by any Loan Party’s or any Loan Party’s Subsidiary’s casualty or business interruption insurance. Upon the occurrence and during the continuance of an Event of Default, Agent shall have the sole right to file claims under any property and general liability insurance policies in respect of the Collateral, to receive, receipt and give acquittance for any payments that may be payable thereunder, and to execute any and all endorsements, receipts, releases, assignments, reassignments or other documents that may be necessary to effect the collection, compromise or settlement of any claims under any such insurance policies. A true and complete listing of such insurance, including issuers, coverages and deductibles, will be provided by the Loan Parties to Agent promptly following Agent’s request.

(f) Each Loan Party will, and will cause each of its Subsidiaries to, pay, discharge and perform as the same shall become due and payable or required to be performed all Tax liabilities, assessments and governmental charges or levies upon it or its property, unless the same are being contested in good faith by appropriate proceedings diligently prosecuted which stay the enforcement of any Lien and for which adequate reserves in accordance with GAAP are being maintained by such Person.

(g) The Loan Parties will promptly after knowledge (and, in any event, within two (2) Business Days after knowledge) notify the Agent of the occurrence of (A) any Default or Event of Default and (B) so long as such type of notification would not be material nonpublic information of the Borrower, any claims (other than in connection with the denial of plan claims in the ordinary course of business), litigation, arbitration, mediation or administrative or regulatory proceedings that are instituted or threatened against any Loan Party, or claims of infringement by any Person with respect to any Intellectual Property rights of a Loan Party, in each case of this clause (B), to the extent such claim, litigation, arbitration, mediation or administrative or regulatory proceeding could reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.

(h) From the Prior Agreement Date until the later of (y) the first date on which no Warrants remain outstanding, and (z) the first date on which the Secured Parties no longer own any Securities (the period ending on such latest date, the “ Reporting Period ”), the Borrower and its Subsidiaries will (i) timely (without giving effect to any extensions pursuant to Rule 12b-25 of the Exchange Act) file all reports required to be filed with the SEC pursuant to the Exchange Act, and the Borrower and its Subsidiaries will not terminate the registration of the Common Stock under the Exchange Act or otherwise terminate its status as an issuer required to file reports under the Exchange Act, even if the securities laws would otherwise permit any such termination and (ii) deliver to Agent a Compliance Certificate with each of its 10-Q and 10-K filings on the date such filings are made (or, if earlier, are required by the SEC to be made) with the SEC; provided that, with respect to clause (ii) only, solely to the extent any earnings or revenue report for the same period is publicly reported or is filed with the SEC prior to the time when any 10-Q or 10-K containing the applicable quarterly or annual financial statements is filed with the SEC and to the extent the earnings or revenue set forth in any such earnings or revenue report would result in a financial covenant default under Section 5.2(xxv), the Compliance Certificate shall instead be delivered by the Loan Parties to the Agent and the Lenders on the same day as such earnings or revenue report is publicly reported or is filed with the SEC. Each of such reports in Section 5.1(h)(i) above will comply in all material respects with the applicable requirements of the Exchange Act and each of such reports in Section 5.1(h)(i) above and such Compliance Certificate will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The consolidated financial statements

 

74


included in such reports will comply as to form in all material respects with applicable accounting requirements and the published rules and regulations of the SEC with respect thereto, will be prepared in accordance with GAAP, consistently applied (subject, in the case of unaudited quarterly financial statements, to normal year-end adjustments and lack of footnote disclosures), and will fairly present in all material respects the consolidated financial position of the Borrower and its Subsidiaries as of the dates thereof and the consolidated results of their operations, cash flows and changes in stockholders equity for the periods presented (subject, in the case of unaudited quarterly financial statements, to normal year-end audit adjustments and lack of footnote disclosures). The Borrower hereby agrees that, during the Reporting Period, the Borrower will send to each Secured Party copies of (A) any notices and other information made available or given to the holders of the Stock of the Borrower generally, contemporaneously with the Borrower’s making available or giving such notices and other information to such holders of Stock (it being understood and agreed that delivery will be deemed to have occurred if such notices or other information is posted to EDGAR) and (B) all other documents, reports, financial data and other information not available on EDGAR that does not contain any material nonpublic information of the Borrower, that any Secured Party may reasonably request.

(i) Each Loan Party will, and will cause each of its Subsidiaries to, with respect to each owned, leased or controlled property, at all times and without notice, at the sole option of Agent or any Lender: (a) provide access to such property to Agent, the Lenders and their respective representatives and agents, as frequently as Agent or any Lender determines to be appropriate; and (b) permit Agent or any Lender to conduct field examinations, appraise, inspect, and make extracts and copies (or take originals if reasonably necessary) from all of such Loan Party’s and its Subsidiaries’ books and records, and evaluate and conduct appraisals and evaluations in any manner and through any medium that Agent or any Lender considers advisable, in each instance, at the Loan Parties’ sole expense. Any Lender may accompany Agent or its representatives in connection with such inspection. Notwithstanding the foregoing, the Loan Parties will (and will cause each of their respective Subsidiaries to) comply with (and coordinate with Agent and the Lenders and their representatives and agents to make sure of compliance with) Section 5.1(q) in connection with any such inspection, examination, audit or analysis.

(j) Each Loan Party will ensure that all written information, exhibits and reports furnished to any Secured Party, when taken as a whole, do not and will not contain any untrue statement of a material fact and do not and will not omit to state any material fact or any fact necessary to make the statements contained therein not materially misleading in light of the circumstances in which made, and will promptly disclose, after knowledge of any defect of a material fact, untrue statement of material fact, material misstatement or error of a material fact, to Agent and the Lenders and correct any such defect, untrue statement of material fact, material misstatement or error of a material fact that has been discovered therein or in any Loan Document or in the execution, acknowledgement or recordation thereof; it being acknowledged and agreed that any projections provided to the Secured Parties are not to be viewed as facts, are not a guarantee of financial performance, and are subject to uncertainties and contingencies.

(k) Each Loan Party will enter into, and cause each depository, securities intermediary or commodities intermediary to enter into, Control Agreements with respect to each deposit, securities, commodity or similar account maintained by such Person (other than (i) deposit accounts exclusively used for payroll, payroll taxes and other employee wage and benefit payments to or for the benefit of the Borrower’s employees and identified to Agent by the Borrower as such, (ii) zero balance accounts; provided that such accounts have been identified to Agent by the Borrower as such, (iii) such other petty cash deposit accounts, amounts on deposit in which do not exceed $100,000 in the aggregate at any one time, (iv) escrow, trust and fiduciary accounts, (v) each account of Excluded Foreign Subsidiaries, (vi) deposit account #XXXXX7912 of TriVascular Canada LLC at Bank of Montreal; provided the aggregate amount on deposit in such deposit account(s) does not exceed 1,000,000 Canadian dollars at any time, and (vii) the Bank of America Cash Collateral Account (such accounts in clauses (i) through (vii), the

 

75


Excluded Accounts ”)) as of and after the Prior Agreement Date; provided that (x) the Loan Parties will have until the date that is forty-five (45) days following the closing date of any Permitted Acquisition (or such later date as may be agreed to by Agent in its sole reasonable discretion) to comply with the provisions of this Section 5.1(k) with regard to such accounts (other than Excluded Accounts) of the Loan Parties acquired in connection with such Permitted Acquisition, and (y) for deposit accounts, securities accounts and commodities accounts opened after the Agreement Date, the Loan Parties will have until the date that is thirty (30) days following the opening of any such new account (or such later date as may be agreed to by Agent in its sole reasonable discretion) to comply with this clause (k). Upon written request by the Agent, the Loan Parties will provide Agent with written evidence reasonably satisfactory to the Agent as of such Business Day or the next Business Day showing compliance with Section 5.2(xxiv).

(l) Promptly upon request by Agent, the Loan Parties will (and, subject to the limitations set forth herein and in the other Loan Documents, will cause each of their Subsidiaries to) take such additional actions and execute such documents as Agent may reasonably require from time to time in order (i) to carry out more effectively the purposes of this Agreement or any other Loan Document, (ii) to subject to the Liens created by any of the Loan Documents any of the assets or properties, rights or interests covered by any of the Loan Documents, (iii) to perfect and maintain the validity, effectiveness and priority of any of the Loan Documents and the Liens intended to be created thereby, and (iv) to better assure, grant, preserve, protect and confirm to the Secured Parties the rights granted or now or hereafter intended to be granted to the Secured Parties under any Loan Document. The Loan Parties will notify Agent in writing prior to (and on) (x) the date of formation or acquisition of any Subsidiary and (y) any division or split of any Loan Party into two or more Subsidiaries, limited liability companies, other entities or other Persons. Without limiting the generality of the foregoing, the Loan Parties will cause (y) each of their Subsidiaries (other than Excluded Subsidiaries) promptly after (but, in any event, (A) within fifteen (15) days thereof for any Subsidiary that is not an Immaterial Subsidiary and (B) within thirty (30) days thereof for any Immaterial Subsidiary) the date of the formation or acquisition thereof (and any Subsidiaries, limited liability companies, other entities or other Persons for which any Loan Party divides or splits itself into), to guaranty the Obligations and to cause each such Subsidiary (and any such Subsidiary, limited liability company, other entity or other Person for which any Loan Party divides or splits itself into) to grant to Agent, for the benefit of the Secured Parties, a security interest in, subject to the limitations set forth herein and in the Loan Documents, all of such Subsidiary’s (and, with respect to any such division or split of a Loan Party, all such Subsidiary’s limited liability company’s, other entity’s or other Person’s) assets and property (including any assets or property allocated, distributed, conveyed or otherwise transferred pursuant to any division or split of any Loan Party into any Subsidiaries, limited liability companies, other entities or other Persons for which any Loan Party divides or splits itself into) to secure such guaranty and (z) any holder (that is a Loan Party) of the Stock of such Subsidiary to provide, promptly after (but, in any event, (A) within fifteen (15) days thereof for any Subsidiary that is not an Immaterial Subsidiary and (B) within thirty (30) days thereof for any Immaterial Subsidiary) the date of (x) the formation or acquisition of such Subsidiary or (y) any division or split of any Loan Party into two or more Subsidiaries, limited liability companies, other entities or other Persons, in each case, supplements and further pledges to the Loan Documents as are necessary (or requested by Agent) to evidence Agent’s Lien in the Stock of such Subsidiary. Furthermore, the Borrower will notify Agent and the Lenders in writing promptly after (but, in any event, (A) within fifteen (15) days thereof for any Loan Party or any Subsidiary that is not an Immaterial Subsidiary and (B) within thirty (30) days thereof for any Immaterial Subsidiary) the date of the issuance by or to any Loan Party (other than by the Borrower) of any Stock of any corporation or any other Person that has “opted into” Article 8 of the UCC (in each case, other than Excluded Property) to have its Stock constitute “securities” under Article 8 of the UCC and each Loan Party will pledge, and will cause each of its Subsidiaries (other than Excluded Subsidiaries) to pledge, all of the Stock of each of its Subsidiaries (other than Excluded Subsidiaries but including any Subsidiaries, limited liability companies, other entities or other Persons for which any such Loan Party divides or splits itself into), and sixty-five percent (65%) of the outstanding voting Stock and one hundred percent (100%) of the outstanding

 

76


non-voting Stock of each Excluded Foreign Subsidiary and each Excluded Domestic Holdco, directly owned by a Loan Party, in each instance, to Agent, for the benefit of the Secured Parties, to secure the Obligations, promptly after formation or acquisition (or division or split) of such Subsidiary. The Loan Parties will deliver, or cause to be delivered, to Agent, appropriate resolutions, secretary certificates, certified Organizational Documents and, if reasonably requested by Agent, legal opinions relating to the matters described in this Section 5.1(l) (which opinions will be in form and substance reasonably acceptable to Agent and, to the extent applicable, substantially similar to the opinions delivered on the Prior Agreement Date and the Agreement Date), in each instance with respect to (1) each Loan Party or Subsidiary formed or acquired (and each Subsidiary, limited liability company, other entity or other Person for which a Loan Party divides or splits itself into), (2) each Loan Party or Person (other than a Loan Party) whose Stock is being pledged, and (3) the assets and property that are allocated, distributed, conveyed or otherwise transferred pursuant to any division or split of any Loan Party into any Subsidiaries, limited liability companies, other entities or other Persons for which any Loan Party divides or splits itself into, in each case of clauses (1) through (3), after the Prior Agreement Date. In connection with each pledge of Stock, the Loan Parties will deliver, or cause to be delivered, to Agent, irrevocable proxies and Stock powers and/or assignments, as applicable, duly executed in blank.

(m) Each Loan Party will, and will cause each of its Subsidiaries to, comply with, and maintain its Real Estate, whether owned, leased, subleased or otherwise operated or occupied, in compliance with all applicable Environmental Laws and Healthcare Laws or that is required by orders and directives of any Governmental Authority, except where the failure to comply could not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect.

(n) Promptly upon becoming aware that any of the following events has occurred, the Borrower will provide written notice to the Agent specifying the nature of such event, what action the Loan Party or any ERISA Affiliates has taken, is taking or proposes to take with respect thereto and, when known, if applicable, any action taken or threatened by the Internal Revenue Service, the Department of Labor or the PBGC with respect thereto: (i) any ERISA Event which could reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, (ii) a “prohibited transaction” as defined under Section 406 of ERISA or Section 4975 of the Code that is not exempt under ERISA Section 408 or Section 4975 of the Code, under any applicable regulations and published interpretations thereunder or under any applicable prohibited transaction, individual or class exemption issued by the Department of Labor, with respect to any Employee Benefit Plan, which could reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, or (iii) the imposition of any Lien on any asset of a Loan Party or a Subsidiary of a Loan Party with respect to any Title IV Plan or Multiemployer Plan.

(o) The Borrower agrees to timely file a Form D with respect to the Securities as required under Regulation D and to provide a copy thereof to each Secured Party promptly after such filing. The Borrower will make all filings and reports relating to the offer and sale of the Securities required under applicable securities or “Blue Sky” laws of the states of the United States following the Prior Agreement Date.

(p) The Borrower will take all actions necessary to cause the Common Stock to remain listed on the Principal Market during the Reporting Period. The Borrower will not, and will cause each of the Subsidiaries not to, take any action that would be reasonably expected to result in the delisting or suspension or termination of trading of the Common Stock on the Principal Market. The Loan Parties will pay all fees, costs and expenses in connection with satisfying its obligations under this Section 5.1(p). The Borrower shall take all action necessary to at all times have authorized, and reserved for the purpose of issuance, a sufficient number of Common Shares to enable the Borrower to satisfy its obligations under the Warrants and the First Out Waterfall Notes (computed without regard to any limitations on the number of shares that may be issued on exercise or conversion thereof).

 

77


(q) At or prior to 7:30 a.m. (New York City time) on the first (1st) Business Day following the Agreement Date, the Borrower will file a Form 8-K with the SEC describing the terms of the transactions contemplated by the Loan Documents and the ABL Credit Facility and the ABL Debt Documents and including as exhibits to such Form 8-K this Agreement (including the schedules, annexes and exhibit forms hereto), the forms of Notes, the form of Additional Warrant, the Registration Rights Agreement, the other Loan Documents listed on Schedule 5.1(q) and the ABL Credit Facility and the ABL Debt Documents (such Form 8-K, the “ Announcing Form 8-K ”). Subject to the foregoing, no Loan Party will issue any press releases or any other public statements with respect to the transactions contemplated by any Loan Document or disclosing the name of any Secured Party; provided , however , that the Borrower will be entitled, without the prior approval of any Secured Party, to make any press release or other public disclosure with respect to such transactions (i) in substantial conformity with the Announcing Form 8-K and contemporaneously therewith and (ii) as is required by Applicable Law and regulations ( provided that each Secured Party will be consulted by the Borrower in connection with any such press release or other public disclosure prior to its release and will be provided with a copy thereof by the borrower other than filings required by the Exchange Act to be made with the SEC, which Borrower may make without such consultation or notice). From and after the Borrower’s filing of the Announcing Form 8-K, no Secured Party shall be in possession of any material nonpublic information received from the Borrower or any of its Subsidiaries or Affiliates or any of its or their respective officers, directors, employees, attorneys, representatives or agents. Without limiting the foregoing, the Loan Parties represent and warrant that no Loan Document or other agreement, instrument, certificate, information or other document provided by any Loan Party or any of its Related Parties to any Secured Party on or about the Agreement Date that is not filed as an exhibit to the Announcing Form 8-K constitutes, or contains, reflects or references any information that constitutes, material nonpublic information with respect to the Borrower or any of its Subidiaries or Affiliates (except to the extent the same information is expressly set forth in the Announcing Form 8-K or an exhibit thereto). Notwithstanding any other requirement of this Agreement or any other Loan Document, each Loan Party will not, and will cause each of its Subsidiaries and Affiliates and its and each of their respective officers, directors, employees. Attorneys, representatives and agents to not, provide any Secured Party with any material nonpublic information regarding the Borrower or any of its Subsidiaries or Affiliates from and after the filing of the Announcing Form 8-K with the SEC without the express prior written consent of such Secured Party. Each Loan Party hereby acknowledges and agrees that no Secured Party (nor any of such Secured Party’s Affiliates) shall have any duty of trust or confidence with respect to, or any obligation not to trade in any securities on the basis of, any material nonpublic information regarding the Borrower or any of its Subsidiaries or Affiliates (A) provided by, or on behalf of, the Borrower or any of its Subsidiaries or Affiliates, or any of its or their respective officers, directors, employees, attorneys, representatives or agents, in breach or violation of any of the representations, covenants, provisions or agreements set forth in this Section 5.1(q) or (B) otherwise possessed (or continued to be possessed) by any Secured Party (or any Affiliate thereof) as a result of any breach or violation of any representation, covenant, provision or agreement set forth in this Section 5.1(q). Notwithstanding anything to the contrary herein, in the event that any Loan Party believes that a notice or communication to any Secured Party contains material, nonpublic information relating to any Loan Party, any of its Subsidiaries or Affiliates or any of their respective property or Stock, the Borrower will so indicate to the Secured Parties contemporaneously with delivery of such notice or communication, and such indication shall provide the Secured Parties the means to refuse to receive such notice or communication; and in the absence of any such indication, the holders of the Securities shall be allowed to presume that all matters relating to such notice or communication do not constitute material, nonpublic information relating to any Loan Party, any of its Subsidiaries or Affiliates or any of their respective property or Stock. Upon receipt or delivery by any Loan Party or any of its Subsidiaries of any notice in accordance with the terms of the Loan Documents, unless the Borrower has in good faith determined that the matters relating to such notice do not constitute material, nonpublic information relating to any Loan Party or any of its Subsidiaries or Affiliates or their respective property or Stock, the Loan Parties will, within one Business Day after any such receipt or delivery publicly disclose such material, nonpublic information. In the event of a breach of

 

78


any of the foregoing covenants by any Loan Party or any of its Subsidiaries or Affiliates, or any of its or their respective officers, directors (or equivalent persons), employees, attorneys, representatives or agents, in addition to any other remedies provided in the Loan Documents or otherwise available at law or in equity, the Secured Parties shall have the right to make a public disclosure in the form of a press release, public advertisement or otherwise, of the applicable material nonpublic information regarding the Borrower or its Subsidiaries or Affiliates without the prior approval by any Loan Party or its Subsidiaries or Affiliates, or any of its or their respective officers, directors (or equivalent persons), employees, attorneys, representatives or agents, and no Secured Party shall have any liability to any Loan Party, any of its Subsidiaries or Affiliates or any of its or their respective officers, directors (or equivalent persons), employees, equityholders, attorneys, representatives or agents for any such disclosure.

(r) The Borrower acknowledges and agrees that the Securities may be pledged by a holder thereof in connection with a bona fide margin agreement or other loan, financing or Indebtedness secured by the Securities. The pledge of Securities shall not be deemed to be a transfer, sale or assignment of the Securities under the Loan Documents, and no such holder effecting any such pledge of Securities shall be required to provide any Loan Party or any of its Subsidiaries with any notice thereof or otherwise make any delivery to any Loan Party pursuant to any Loan Document. The Borrower hereby agrees to execute and deliver such documentation as a pledgee of the Securities may reasonably request in connection with a pledge of the Securities to such pledgee by a holder of Securities.

(s) During the Reporting Period, except as otherwise provided in the Loan Documents, the Borrower will not in any manner issue or sell any Options or Convertible Securities that are convertible into or exchangeable or exercisable for shares of Common Stock at a price that varies or may vary with the market price of the Common Stock, including by way of one or more resets to a fixed price or increases in the number of shares of Common Stock issued or issuable, or at a price that upon the passage of time or the occurrence of certain events automatically is reduced or is adjusted or at the option of any Person may be reduced or adjusted, whether or not based on a formulation of the then current market price of the Common Stock (other than proportional adjustments as a result of subdivisions or combinations of the Common Stock in the form of stock splits, stock dividends, reverse stock splits, combinations or recapitalizations). For the avoidance of doubt, this clause (s) does not prohibit any convertible notes contemplated under clause (k) of the definition of “Permitted Indebtedness” with a fixed conversion rate subject to anti-dilution adjustments or other provisions related to the conversion price and/or conversion rate that are broadly similar to the analogous provisions in the 2.25% Convertible Note Documents or the 3.25% Convertible Note Documents or any Permitted 3.25% Convertible Note Refinancing permitted hereunder.

(t) Within five Business Days after the filing (or, to the extent earlier, the date filing is required by the SEC) of its 10-K or 10-Q with the SEC (and by each date that the financial statements are required to be delivered in Section 5.1(aa)), as the case may be, the Loan Parties and their Subsidiaries will deliver to Agent an updated Perfection Certificate. Upon the reasonable request of any Secured Party, the Loan Parties and their Subsidiaries will promptly deliver to such Secured Party such additional business, financial, corporate affairs, perfection certificates, items or documents related to creation, perfection or priority of Agent’s Liens in the Collateral and other information as any Secured Party may from time to time reasonably request.

(u) Except as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, the Borrower will, and will cause each Loan Party to, (i) obtain all Regulatory Required Permits necessary for compliance in all respects with Applicable Laws with respect to the design, testing, manufacturing, developing, processing, assembly, packaging, labeling, distribution, commercialization, import, export, selling or marketing of Products, and (ii) maintain and comply fully and completely in all respects with all such Regulatory Required Permits.

 

79


(v) Each Loan Party will comply, and cause each Subsidiary to comply, with the requirements of all Applicable Laws and Material Contracts, except to the extent that failure to so comply could not reasonably be expected to (a) individually or in the aggregate, have a Material Adverse Effect, or (b) result in any Lien upon either (i) a material portion of the assets of any such Person in favor of any Governmental Authority, or (ii) any Collateral (other than Permitted Liens).

(w) The Borrower will, within two Business Days after delivery by a Loan Party or receipt or knowledge thereof, provide written notice to Agent of any default or event of default under any of the ABL Debt Documents, any of the Convertible Note Documents or any of the Permitted Japan Lifeline Unsecured Debt Documents, and of any amendments, restatements, supplements, waivers or other modifications to (or any consents to any events or actions under) any of the ABL Debt Documents, any of the Convertible Note Documents or any of the Permitted Japan Lifeline Unsecured Debt Documents or any prepayment of any of the Indebtedness thereunder.

(x) The Loan Parties will keep its Inventory and Equipment (other than Inventory or Equipment that is in-transit, Trunk Inventory or subject to consignment) only at the locations identified on Schedule 3.1(hh) and their chief executive offices only at the locations identified on Schedule 3.1(gg).

(y) Each Loan Party and its Subsidiaries will comply with (A) in all respects with all Healthcare Laws and their implementation by any applicable Governmental Authority, except as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, and (B) (1) in all respects with all lawful requests of any Governmental Authority applicable to its Products, except as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, and (2) in all material respect with requests of any Governmental Authority applicable to its Products that is required by Applicable Law (or court order or proceeding) to be complied with. Except as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, all Products developed, manufactured, tested, distributed, promoted or marketed by or on behalf of any Loan Party or any of its Subsidiaries that are subject to the jurisdiction of the FDA or comparable Governmental Authority shall be (i) developed, tested, manufactured, distributed, promoted and marketed in compliance with the Healthcare Laws and each other Applicable Law, including Healthcare Laws and other Applicable Laws governing or relating to product approval or premarket notification, good manufacturing practices, promoting, labeling, advertising, record-keeping, and adverse event reporting, and (ii) tested, investigated, distributed, labeled, promoted, marketed, and sold in compliance with Healthcare Laws and all other Applicable Laws.

(z) Notwithstanding the conditions precedent set forth in Article 4 or any other provision set forth herein to the contrary above, the Loan Parties have informed the Agent that certain of such items required to be delivered to the Agent and/or the Lenders or otherwise satisfied as conditions precedent to the effectiveness of this Agreement will not be delivered to Agent and the Lenders as of the Agreement Date. Therefore, with respect to the items set forth in this Section 5.1(z) below (collectively, the “ Outstanding Items ”), the Loan Parties will, and the Loan Parties will cause their Subsidiaries to, deliver (or otherwise satisfy) each Outstanding Item to the satisfaction of the Agent in the form and manner set forth below for such Outstanding Item within twenty (20) days after the Agreement Date (or within such longer time or different form or manner as the Agent may agree in its sole discretion):

(i) Collateral Access Agreements with respect to the leases of real property located at: (1) 2 Musick and 33 and 35 Hammond, Irvine, County of Orange, CA 92618 U.S.A., and (2) 3910 Brickway Blvd., Santa Rosa, County of Sonoma, CA 95403 U.S.A.;

(ii) Collateral Access Agreement with respect to Collateral held by UPS at the following locations: (1) 378 Commercial Street, Malden, MA 02148, (2) 165 Chubb

 

80


Avenue, Lyndhurst, NJ 07071, (3) 1130 Commerce Blvd, Swedesboro, NJ 08085, and (4) 2250 Outerloop Drive, Louisville, KY 40219; and

(iii) Control Agreements with respect to the accounts of the Loan Parties located at (1) Wells Fargo (with respect to the account ending in 5279), (2) Bank of America (with respect to each of the accounts ending in 1702 and 3910), and (3) Silicon Valley Bank (with respect to the account ending in 5539).

(aa) If the Borrower is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act, the Loan Parties will deliver to Agent and each Lender, as soon as available, but in any event within thirty (30) days after the end of each fiscal month during each fiscal year, an unaudited consolidated and consolidating balance sheet and income statement of Borrower and its Subsidiaries’ operations during such month and for the portion of the fiscal year then ended, including comparisons to the figures in the corresponding month and year-to-date portion of the immediately preceding fiscal year of Borrower and its Subsidiaries. Further, if the Borrower is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act, the Loan Parties will provide to Agent and each Lender (A) quarterly financial statements for the Borrower and its Subsidiaries and a Compliance Certificate for such period within 45 days after the end of each fiscal quarter of the Borrower, and an audited annual financial statements and a Compliance Certificate for such period within 120 days after the end of each fiscal year of the Borrower prepared in accordance with GAAP with a report thereon by the Borrower’s independent certified public accountants, which accountants shall be reasonably acceptable to Agent and (B) on the same day as delivery to ABL Agent, any ABL Lender or any other secured party under the ABL Debt Documents, any additional financial statements, certificates, reports, notices, agreements, instruments and documents provided under (or in connection with) the ABL Debt Documents. Any such annual audited financial statements, audit or report of the Borrower’s independent certified public accountants (and any annual audited financial statements, audit or report of the Borrower’s independent certified public accountants on any consolidated financial statements included in any SEC Document filed during the Reporting Period, and including those required by Section 5.1(h)) shall (i) contain an unqualified opinion (subject to the exception set forth below in clause (ii) of this sentence), stating that such consolidated financial statements present fairly in all material respects the financial position and condition and results of operations of the Borrower and its Subsidiaries as of the dates and for the periods and have been prepared in conformity with GAAP applied on a basis consistent with prior years, and (ii) not include any explanatory paragraph expressing substantial doubt as to going concern status (other than any such paragraph arising from the impending maturity of the Loans solely in the case of the audit delivered with respect to the fiscal year immediately prior to the fiscal year during which the applicable maturity is scheduled).

Section 5.2 Negative Covenants.

For so long as the Obligations (other than unasserted contingent indemnification obligations and other than those Obligations under any Warrant or the Registration Rights Agreement; provided that Section 5.2(xvii) shall survive until the end of the Reporting Period) remain outstanding:

(i) No Loan Party will, nor will it permit any of its Subsidiaries to, directly or indirectly, (A) merge with, consolidate with or into, dissolve or liquidate into or convey, transfer, lease or otherwise dispose of (whether in one transaction or in a series of transactions) all or substantially all of its assets (whether now owned or hereafter acquired) to or in favor of any Person, except (1) a Subsidiary that is not a Loan Party may merge into any Loan Party or any Subsidiary of a Loan Party ( provided that, (w) to the extent such Subsidiary that is not a Loan Party has its equity pledged to Agent, then any Person it merges with must also have its equity pledged to Agent by at least the same percentage and (x) if such merger is with a Loan Party, such Loan Party must be the surviving entity of any

 

81


such merger), (2) a Loan Party may merge into any other Loan Party ( provided that, (y) to the extent such Loan Party being merged has its equity pledged to Agent, then any Person it merges with must also have its equity pledged to Agent by at least the same percentage and (z) to the extent the Borrower is part of such transaction, the Borrower must be the surviving Person), (3) any Subsidiary of the Borrower (other than, for the avoidance of doubt, the Borrower) may liquidate or dissolve if (i) the Borrower determines in good faith that such liquidation or dissolution is in the best interests of the Borrower and it is not materially disadvantageous to the Secured Parties and (ii) to the extent such Subsidiary is a Loan Party, any such assets or business held by such subject Subsidiary shall be transferred to, or otherwise owned or conducted by, a Loan Party after giving effect to such liquidation or dissolution, and (4) in connection with Permitted Acquisitions, or (B) divide (or otherwise split) itself or themselves into two or more limited liability companies or other entities or Persons. None of the Loan Parties will establish or form any Subsidiary, unless such Subsidiary complies with Section 5.1(l), if applicable, and such Subsidiary (if not an Excluded Subsidiary) executes and/or delivers all other documents, agreements and instruments reasonably requested by Agent or the Required Lenders to perfect a Lien in favor of Agent (for the benefit of the Secured Parties) on such Subsidiary’s (if not an Excluded Subsidiary) assets and to make such Subsidiary (if not an Excluded Subsidiary) a Guarantor under the Loan Documents.

(ii) No Loan Party will, nor will it permit any of its Subsidiaries to, (a) enter into any joint venture or any similar arrangement, other than as may be permitted under Permitted Investments or (b) make any Restricted Payments, other than (1) dividends by any direct or indirect Subsidiary of any Loan Party (A) that are not Loan Parties to its parent or parent entities or (B) that are Loan Parties to its parent or parent entities that are Loan Parties; (2) dividends payable solely in common Stock; (3) repurchases of Stock of former employees, directors or consultants so long as an Event of Default does not exist at the time of such repurchase and would not exist after giving effect to such repurchase, provided , however , that such repurchase does not exceed $2,500,000 in the aggregate per fiscal year; (4) any Restricted Payments made under Subordinated Debt Documents to the extent permitted under the terms of the applicable Subordination Agreement; and (5) any Restricted Payments made to the Secured Parties pursuant to the Loan Documents.

(iii) No Loan Party will, nor will it permit any of its Subsidiaries to, (a) directly or indirectly make, create, incur, assume or suffer to exist any Lien upon or with respect to any of its assets or property, of any kind, whether now owned or hereafter acquired, or any income or profits therefrom, except Permitted Liens, or (b) directly or indirectly Dispose of (whether in one or a series of transactions) any assets or property (including the Stock of any Subsidiary of any Loan Party, whether in a public or private offering or otherwise, and accounts and notes receivable, with or without recourse), except Permitted Dispositions or as otherwise expressly permitted by Section 5.2(i).

(iv) No Loan Party will, nor will it permit any of its Subsidiaries to, directly or indirectly, create, incur, assume, guarantee, permit to exist or be liable with respect to any Indebtedness, other than Permitted Indebtedness. No Loan Party will, or will permit any Subsidiary to, directly or indirectly, create, assume, incur or suffer to exist any Contingent Obligations, except for Permitted Contingent Obligations.

(v) No Loan Party will, nor will it permit any of its Subsidiaries to, directly or indirectly, (i) purchase or acquire any Stock, or any obligations or other securities of, or any interest in, any Person, including the establishment or creation of a Subsidiary, or (ii)

 

82


make or commit to make any Acquisitions, or any other acquisition of any of the assets of another Person other than (A) Permitted Investments or (B) in the Ordinary Course of Business, or of any business or division of any Person, including by way of merger, consolidation, other combination or otherwise other than Permitted Investments, (iii) make, purchase or acquire any advance, loan, extension of credit (other than trade payables in the ordinary course of business) or capital contribution to or any other investment in, any Person including the Borrower, any Affiliate of the Borrower or any Subsidiary of the Borrower or (iv) enter into any joint venture or any similar arrangement (the items described in clauses (i), (ii), (iii) and (iv) are referred to as “ Investments ”), except for Permitted Investments.

(vi) No Loan Party will, or will permit any of its Subsidiaries to, use the proceeds of the Loans for any purpose other than as expressly permitted by Section 2.1.

(vii) Except as otherwise disclosed on Schedule 5.2(vii), and except for transactions that contain terms that are no less favorable to the applicable Loan Party or any Subsidiary, as the case may be, than those which might be obtained from a third party not an Affiliate of any Loan Party, no Loan Party will, or will permit any Subsidiary to, directly or indirectly, enter into or permit to exist any transaction (including the purchase, sale, lease or exchange of any property or the rendering of any service) with any Affiliate of any Loan Party that is not itself a Loan Party; provided that, Loan Parties may enter into and maintain written agreements between any Loan Party and any Foreign Subsidiary of a Loan Party for management services for compensation in the Ordinary Course of Business consistent with past practices that are customary and reasonably appropriate to do for companies in the same industry as the Loan Parties provided by management and officers of the Loan Parties to such Foreign Subsidiaries that do not have certain management or officers, and such transactions may result in non-interest bearing accounts payables for the unpaid compensation owed by such Foreign Subsidiaries to the Loan Parties for such management services in an amount not to exceed $40,000,000 (which payables may be equitized by the Loan Parties, provided that (y) equitization of such payables shall not reduce the outstanding amount of payables that count towards the $40,000,000 cap above for purposes of determining whether the Loan Parties have complied with this provisions (with such equitized amounts deemed to be outstanding at all times thereafter for purposes of the $40,000,000 capped amount) and (z) at the time of any such equitization, any such Stock received by any Loan Party in connection with such equitization shall be pledged, and a first priority security interest and Lien thereon shall be granted, to the Agent (for the benefit of the Secured Parties) and such Loan Party shall take such perfection and priority actions reasonably requested by the Agent in accordance with the Loan Documents), in each case of the foregoing in this proviso, so long as (a) any such management or officers of the Loan Parties involved in such transactions, agreements and arrangements will have sufficient and reasonable time, energy and resources to still represent and service such Loan Parties themselves after taking into such transactions, agreements and arrangements, (b) any such agreement, instrument, arrangement or document evidencing any of the foregoing transactions, equitization or actions shall be entered into in good faith by such Loan Party, (i) in a manner to not contravene or impair the Collateral and benefits that are intended to be provided and afforded to the Secured Parties under the Loan Documents, and (ii) without (A) the intention of such Loan Party of causing (or resulting in) the Collateral to be taken from the Secured Parties and provided to Foreign Subsidiaries that are not Loan Parties at the detriment of the Secured Parties and for the benefit of such Foreign Subsidiaries, and (B) the effect of defrauding the Secured Parties, (c) the upstream economics received (or potentially to be received) by any applicable Loan Party in

 

83


connection with any such transaction, agreement or arrangement described above in this proviso, when combined with the potential downstream economics, time, energy and recourses exhausted or disposed of in connection therewith shall be reasonably adequate and sufficient to enable the Loan Parties to timely satisfy all of the Obligations and all of their other obligations and agreements under the Loan Documents, (d) all cash, Cash Equivalents, other assets and proceeds received or provided to the Loan Parties in connection with the foregoing shall all be part of the (and constitute) Collateral and the Agent (for the benefit of the Secured Parties) shall have a first priority security interest and Lien thereon, (e) at the reasonable request of the Agent, all such account payables will be evidenced by a promissory note issued to the applicable Loan Party by the applicable Foreign Subsidiary and pledged to the Agent and the original thereof delivered, along with an executed allonge to the Agent in form and substance satisfactory to the Agent, (f) no Default or Event of Default has occurred and is continuing or would result therefrom, and (g) no such agreement, arrangement, transaction or action could reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect.

(viii) No ERISA Affiliate will cause or suffer to exist (a) any event that could result in the imposition of a Lien on any asset of a Loan Party or a Subsidiary of a Loan Party with respect to any Title IV Plan or Multiemployer Plan, or (b) any other ERISA Event, which other ERISA Event could reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.

(ix) No Loan Party will, and no Loan Party will permit any of its Subsidiaries to, engage in any line of business different from those lines of business carried on by it on the Prior Agreement Date and businesses reasonably related thereto.

(x) Except as permitted under Section 5.2(i), no Loan Party will, and no Loan Party will permit any of its Subsidiaries to, directly or indirectly amend or otherwise modify any of its Organizational Documents or, after the execution thereof, any agreements or documents evidencing or contemplating any Permitted Acquisition in any respect materially adverse to any Secured Party. No Loan Party will, or will permit any Subsidiary to, directly or indirectly, amend, restate, supplement, change, waive or otherwise modify any Material Contract, which amendment, restatement, supplement, change, waiver or modification in any case: (a) is contrary to (or is in violation or breach of) the terms and provisions of this Agreement or any other Loan Document (including the Intercreditor Agreement); or (b) could reasonably be expected to be materially adverse to the rights, interests or privileges of Agent or the Lenders or their ability to enforce the same (it being understood that any modification that changes the stated maturity date of the 3.25% Convertible Notes to an earlier date shall be materially adverse to Agent and the Lenders); provided , however , that the foregoing shall not restrict (x) any changes expressly required under the terms of the 2.25% Convertible Notes as of the Prior Agreement Date, the 3.25% Convertible Notes as of the Prior Agreement Date or any indenture governing any Permitted 3.25% Convertible Note Refinancing meeting the requirements set forth in the definition of “Permitted 3.25% Convertible Note Refinancing” or (y) any modifications of the ABL Credit Facility expressly permitted by the Intercreditor Agreement and not otherwise materially adverse to Agent or the Lenders.

(xi) No Loan Party will, and no Loan Party will suffer or permit any of its Subsidiaries to, (a) make any significant change in accounting treatment or reporting practices, except as required by GAAP, (b) change the fiscal year or method for determining the fiscal quarters of any Loan Party or of any Subsidiary of any Loan Party,

 

84


(c) change its name as it appears in official filings in its jurisdiction of organization or formation, or (d) change its jurisdiction of organization or formation, in the case of clauses (c) and (d), without at least ten (10) days’ prior written notice to Agent (or such shorter period as may be agreed by Agent in its sole reasonable discretion).

(xii) No Loan Party will, nor will it permit any of its Affiliates to, (A) declare, pay, make or set aside any amount for payment in respect of Subordinated Debt, except for payments made in full compliance with and permitted under the Subordination Agreement, (B) amend or otherwise modify the terms of any Subordinated Debt, except for amendments and modifications made in full compliance with the Subordination Agreement; or (C) declare, pay, make or set aside any amount for payment in respect of any Indebtedness hereinafter incurred that, by its terms, or by separate agreement, is subordinated to the Obligations, except for payments made in full compliance with and permitted under the subordination provisions applicable thereto.

(xiii) No Loan Party will, and no Loan Party will permit any of its Subsidiaries to, directly or indirectly, create or otherwise cause or suffer to exist or become effective any consensual restriction or encumbrance of any kind on the ability of any Loan Party or Subsidiary to pay dividends or make any other distribution on any of such Loan Party’s or Subsidiary’s Stock or to pay fees, including management fees, or make other payments and distributions to the Borrower or any other Loan Party, except for those in the Loan Documents and the ABL Debt Documents. No Loan Party will, and no Loan Party will permit any of its Subsidiaries to, directly or indirectly (y) enter into, assume or become subject to any contractual obligation prohibiting or otherwise restricting the existence of any Lien upon any of its assets in favor of Agent, whether now owned or hereafter acquired or (z) create or otherwise suffer to exist or become effective any consensual encumbrance or restriction of any kind on the ability of any Subsidiary to (1) pay any Indebtedness owed to Borrower or any of its Subsidiaries, (2) make loans or advances to Borrower or any of its Subsidiaries or (3) transfer any of its property or assets to Borrower or any of its Subsidiaries, except (A) those in the Loan Documents and the ABL Debt Documents, (B) an encumbrance or restriction consisting of customary non-assignment provisions in leases or licenses entered into in the Ordinary Course of Business, (C) customary provisions in joint venture agreement and other similar agreements that restrict the transfer of ownership interests in such joint ventures or provisions limiting the disposition or distribution of assets or property (other than dividends on a pro rata basis based on ownership percentage) of the applicable joint venture, which limitation is applicable only to the assets that are the subject of such agreements; provided that such agreement was not entered into in contravention of the terms of this Agreement, and (D) limitations set forth in Subordinated Debt (if acceptable to the Agent in its sole discretion).

(xiv) No Loan Party will, and no Loan Party will permit any of its Subsidiaries to fail to comply with the Anti-Money Laundering Laws and Anti-Terrorism Laws. No Loan Party or Subsidiary of a Loan Party, nor to the knowledge of any Loan Party or any of its Subsidiaries, any director, officer, agent, employee or other Person acting on behalf of any Loan Party or any such Subsidiary, will request or use the proceeds of any Loan, directly or indirectly, (A) for any payments to any Person, including any government official or employee, political party, official of a political party, candidate for political office or anyone else acting in an official capacity, in order to obtain, retain or direct business or obtain any improper advantage, or otherwise take any action, directly or indirectly, that would result in a violation of any Anti-Corruption Laws, (B) for the purpose of funding, financing or facilitating any activities, business or transaction of or with any

 

85


Person on the SDN List or a government of a country or territory subject to comprehensive Sanctions, to the extent such activities, business or transaction would be prohibited by Sanctions if conducted by a corporation incorporated in the United States or in a European Union member state, (C) in any manner that would result in the violation of any Sanctions applicable to any party hereto, or (D) to fund any activities or business of or with any Person, or in any country or territory, that, at the time of such funding, is, or whose government is, the subject of sanctions pursuant to any Anti-Terrorism Laws. Furthermore, the Loan Parties will not, directly or indirectly, use the proceeds of the Transaction, or lend, contribute or otherwise make available such proceeds to any Subsidiary, Affiliate, joint venture partner or other Person, to fund any activities of or business with any Person, or in any country or territory, that, at the time of such funding, is the subject of Sanctions, or in any other manner that will result in a violation by any Person participating in the Transaction of any Sanctions. No Loan Party will, or will permit any Subsidiary to, directly or indirectly, knowingly enter into any Material Contracts with any Person on the SDN List.

(xv) No Loan Party will, and no Loan Party will permit any of its Subsidiaries to, engage in a sale leaseback, synthetic lease or similar transaction involving any of its assets, including pursuant to a substantially contemporaneous transaction, whereby a Loan Party or one of its Subsidiaries sells or transfers all or substantially all of its right, title and interest in an asset and, in connection therewith, acquires or leases back the right to use such asset.

(xvi) No Loan Party will, and no Loan Party will permit any of its Subsidiaries to, cause or suffer to exist any Release of any Hazardous Material at, to or from any Real Estate that would violate or form the basis of Liability under any Environmental Law or Healthcare Law, other than such violations or liabilities that could not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect.

(xvii) No Loan Party will, and no Loan Party will permit any of its Subsidiaries to, be an “investment company” or a company “controlled” by an “investment company,” as such terms are defined in the Investment Company Act, or to otherwise be registered or required to be registered, or be subject to the restrictions imposed by, the Investment Company Act.

(xviii) No Loan Party will, and no Loan Party will permit any of its Subsidiaries to, (A) make any prepayment, payment, redemption or repayment or take any action, with respect to the ABL Debt that is in violation or breach of the Intercreditor Agreement; (B) make any amendment, restatement, supplement or modification of any ABL Debt Document in violation or breach of the Intercreditor Agreement or that is materially adverse to Agent or the Lenders; or (C) join any Subsidiary or any Affiliate of any Loan Party as a borrower, guarantor or obligor, or have such Person pledge or grant a Lien on any of its property or assets, under the ABL Debt Documents, unless, in each case, the same Person becomes a Loan Party in the same capacity (and/or pledges and grants Liens on the same property or assets (and with the same Lien priority and which such Liens shall be subject to the terms of the Intercreditor Agreement)) under the Loan Documents and such Person executes and delivers such agreements, instruments and documents reasonably requested by Agent to effectuate any of the foregoing in this clause (C) and such Subsidiary or Affiliate shall be subject to the terms of the Intercreditor Agreement.

 

86


(xix) Notwithstanding anything to the contrary in this Agreement or in any other Loan Documents, no Loan Party will, and no Loan Party will permit any of its Subsidiaries to, create, incur or suffer to exist any Indebtedness which is subordinated or junior (either in respect of Lien priority or in right of payment or any combination thereof) to any of the ABL Debt unless such Indebtedness is expressly subordinated or junior to the Obligations (both in terms of Lien priority and in right of payment) on terms and conditions acceptable to Agent and the Lenders; it being understood and agreed that the foregoing shall in no way limit the incurrence of unsecured Indebtedness otherwise permitted hereunder that is not payment subordinated to the ABL Debt when not also payment subordinated to the same extent to the Obligations.

(xx) No Loan Party will, or will permit any Subsidiary to, declare, pay, make any payment in respect of (I) the 3.25% Convertible Notes or the 2.25% Convertible Notes, except for: (a) regularly scheduled payments of interest and principal as set forth in the applicable Convertible Note Documents (in addition to allowing any cash principal payments at maturity of the applicable 3.25% Convertible Notes and the 2.25% Convertible Notes, such amounts may also be paid in the applicable Stock of the Borrower or through any other conversion feature that does not effectively cause more payments to be made at maturity thereof than the cash principal payments currently provided for in the applicable Convertible Note Documents as of the Prior Agreement Date), (b) in connection with any Permitted 3.25% Convertible Note Refinancing, (c) the issuance of shares of common stock of the Borrower in connection with any conversion of the 3.25% Convertible Notes, the 2.25% Convertible Notes or any convertible notes that are not Disqualified Stock issued in a Permitted 3.25% Convertible Note Refinancing, and any cash solely in lieu of fractional shares (but no other cash settlement other than as otherwise permitted by this clause (xx)), (d) payments and conversions (other than for any Disqualified Stock) made in connection with the repurchase (whether for cash, upon exchange and/or for other consideration), redemption and retirement in respect of the 2.25% Convertible Notes or 3.25% Convertible Notes in a single or series of related transactions; provided that (1) no Event of Default exists at the time such payments are made or would exist immediately after giving effect thereto and (2) such cash payments are made solely (A) with proceeds received by the Borrower from the issuance of its common Stock after the Agreement Date for the purpose of making such payment, (B) [reserved] and (C) regarding the 3.25% Convertible Notes, with the proceeds of Indebtedness raised in a Permitted 3.25% Convertible Note Refinancing, and (e) if the foregoing conditions do not otherwise permit such payment, then, with the express prior written consent of the Agent (which may be withheld in its sole discretion), payments in connection with the retirement, redemption and repurchase of the 2.25% Convertible Notes or the 3.25% Convertible Notes, or (II) the Permitted Japan Lifeline Unsecured Debt, except with respect to any interest payments expressly permitted under the definition of “Permitted Japan Lifeline Unsecured Debt.

(xxi) (a) No Loan Party will, or permit any Subsidiary to, commingle any of its assets (including any bank accounts, cash or Cash Equivalents) with the assets of any Person; and (b) no Loan Party will, or permit any Subsidiary to enter into or own any interest in a joint venture that is not itself a corporation or limited liability company or other legal entity in respect of which the equity holders are not liable for the obligations of such entity as a matter of law.

(xxii) No Loan Party will, or will permit any Subsidiary to, amend, restate, supplement, change, waive or otherwise modify the terms of any Indebtedness referred to

 

87


in Section 5.2(xx) above (other than with respect to 3.25% Convertible Notes, in connection with a Permitted 3.25% Convertible Note Refinancing) if the effect of such amendment, restatement, supplement, change, waiver or modification is to (a) increase the interest rate or fees on, or change the manner or timing of payment of, such Indebtedness if in any way adverse to the Agent or the Lenders, (b) accelerate or shorten the dates upon which payments of principal or interest are due on, or the principal amount of, such Indebtedness, (c) change in a manner adverse to any Loan Party, any of its Subsidiaries, Agent or any Lender any event of default or add or make more restrictive any covenant with respect to such Indebtedness, (d) change the prepayment provisions of such Indebtedness or any of the defined terms related thereto in a manner adverse to Agent or the Lenders, or (e) change or amend any other term if such change or amendment would materially increase the obligations of the obligor or confer additional material rights on the holder of such Indebtedness in a manner adverse to any Loan Party, any of its Subsidiaries, Agent or Lenders; provided , however , that (y) the foregoing shall not restrict any changes expressly required under the terms of the 3.25% Convertible Notes as in effect as of the Prior Agreement Date, the 2.25% Convertible Notes as in effect as of the Prior Agreement Date or any changes that are permitted to be made hereunder in connection with a Permitted 3.25% Convertible Note Refinancing or any changes expressly required under any indenture governing any Permitted 3.25% Convertible Note Refinancing that satisfies the conditions and requirements set forth in the definition of “Permitted 3.25% Convertible Note Refinancing” and (z) for the avoidance of doubt, the exchange of the Exchanged Deerfield Convertible Notes for the Last Out Waterfall Loans under this Agreement shall not be restricted by this Section 5.2(xxiii). The Loan Parties will, prior to entering into any such amendment, restatement, supplement, change, waiver or modification, deliver to Agent reasonably in advance of the execution thereof, any final or execution form copy thereof.

(xxiii) Borrower will not issue any Stock (a) senior to its shares of Common Stock or (b) convertible into or exercisable or exchangeable for Stock senior to its Common Stock.

(xxiv) As of (A) the end of the last Business Day of each calendar month and (B) each date that a Borrowing Base Certificate (as defined in the ABL Credit Facility) is required to be delivered under the ABL Credit Facility or any other ABL Debt Document, the Loan Parties will not permit Global Excess Liquidity to be less than $22,500,000.

(xxv) No Loan Party will permit the consolidated Net Revenue of the Loan Parties for any Measurement Period, tested quarterly beginning with the fiscal quarter ending September 30, 2018, to be less than the amounts set forth below:

 

Measurement Period Ending

   Minimum Net Revenue for Measurement
Period
 

September 30, 2018

   $ 155,000,000  

December 31, 2018

   $ 145,000,000  

March 31, 2019 and the last day of each fiscal quarter ending thereafter through (and including) December 31, 2019

   $ 130,000,000  

 

88


March 31, 2020 and the last day of each fiscal quarter ending thereafter

   $ 140,000,000  

(xxvi) No Loan Party will permit the consolidated Net Revenue of the Loan Parties for any fiscal quarter of the Borrower, tested quarterly beginning with the fiscal quarter ending March 31, 2019 and on the last day of each fiscal quarter ending thereafter, to be less than $30,000,000.

(xxvii) No Loan Party will, or will permit any Subsidiary to, have the aggregate amount of Operating Expenditures made by the Loan Parties and their Subsidiaries for any Measurement Period, tested for the fiscal quarters of the Borrower ending December 31, 2018 and December 31, 2019, to exceed the amounts set forth below:

 

Measurement Period Ending

   Amount  

December 31, 2018

   $ 160,000,000  

December 31, 2019

   $ 140,000,000  

(xxviii) Commencing as of the “Trigger Date” (as defined in the ABL Credit Agreement as of the Agreement Date), no Loan Party, will, or will permit any Subsidiary, to have a “Fixed Charge Coverage Ratio” (such term, and all components and subcomponents thereof, as defined in the ABL Credit Agreement as of the Agreement Date) for any Measurement Period, tested quarterly beginning with the fiscal quarter ending September 30, 2018, to be less than 1.00:1.00.

(xxix) No Loan Party will, or will permit any Subsidiary to, have the aggregate amount of consolidated Capital Expenditures made by the Loan Parties and their Subsidiaries to exceed the amounts set forth below:

 

Fiscal Year

   Amount  

2018

   $ 2,500,000  

2019

   $ 3,000,000  

2020

   $ 5,000,000  

2021

   $ 2,000,000  

Section 5.3 Change of Control.

(a) Lender’s Put Option . The Borrower, on behalf of the Loan Parties and their Subsidiaries, will give Agent written notice of a Change of Control at least fifteen (15) days prior to the consummation thereof but in any event not later than two (2) Business Days following the first public announcement thereof. Other than with respect to a Permitted Successor Transaction (in, which case, no such Put Notice may be delivered by the Lenders), the Lenders, within five (5) days after the receipt of such notice, in the exercise of their sole discretion, may deliver a notice to the Borrower (the “ Put Notice ”) that

 

89


the Final Payment (including, for the avoidance of doubt, any applicable Non-Callable Make Whole Amount and the CoC Fee) shall be due and payable upon the consummation of such Change of Control, with no further action taken by any Person as of or after the date of such Put Notice. If the Lenders deliver a Put Notice, then simultaneously with consummation of such Change of Control (other than a Permitted Successor Transaction), the Borrower will make (or cause to be made) the Final Payment (including, for the avoidance of doubt, any applicable Non-Callable Make Whole Amount and the CoC Fee) to the Lenders as of the date of such Put Notice. In such case of a Put Notice delivered with respect to any Change of Control (other than a Permitted Successor Transaction), the Loan Parties will make arrangements satisfactory to the Agent, as determined by the Agent in its sole discretion, that the Final Payment will be paid in full to the Lenders, in each case, concurrently with the consummation of such Change of Control (other than a Permitted Successor Transaction) (which arrangements may include obtaining a written agreement from the acquiring Person, as applicable, that payment of the Final Payment will be made to the Lenders upon the consummation of such Change of Control (other than a Permitted Successor Transaction)). The Loan Parties hereby acknowledge and agree that, if the Loan Parties or any of their Subsidiaries of Affiliates violate or breach any portion of this Section 5.3(a), the Secured Parties shall have the right to apply for an injunction in any state or federal courts sitting in the City of New York to prevent the consummation of such Change of Control, unless, if the Lenders have exercised their Put Right, arrangements reasonably satisfactory to the Agent for the Final Payment (including, for the avoidance of doubt, any applicable Non-Callable Make Whole Amount and the CoC Fee) have been made (or, as applicable, paid) and, if the Lenders have not exercised their Put Right, arrangements reasonably satisfactory to the Agent in respect of the Loans have been made. The Loan Parties will not, and will not permit any of their Subsidiaries to consummate any Change of Control (other than a Permitted Successor Transaction) without complying in all respects with the applicable provisions of this Section 5.3(a). Notwithstanding anything to the contrary in this Agreement, for the avoidance of doubt, the Black-Scholes payments or exercises related to a “Major Transaction” (as defined in any Warrant) that are set forth in the Warrants are in addition to any Final Payment.

(b) Borrower’s Prepayment Right . Notwithstanding anything to the contrary in this Agreement and for the avoidance of doubt, Borrower shall be permitted to prepay the Loans and other Obligations (other than Obligations under the Warrant and the Registration Rights Agreement, the treatment of which are addressed separately in such agreements) so long as (i) to the extent any such prepayment is made prior to the First Amortization Date, the applicable Non-Callable Make Whole Amount on the Loans so prepaid is paid at the same time in accordance with Section 2.3(c) and (ii) if In Connection with a Change of Control, the CoC Fee is paid at the time set forth in Section 2.7(c).

Section  5.4 General Acceleration Provision upon Events of Default . For so long as the Obligations (other than unasserted contingent indemnification obligations and other than those Obligations under any Warrant or the Registration Rights Agreement) remain outstanding, if one or more of the events specified in this Section 5.4 shall have happened or occurred and have continued beyond any applicable cure period expressly provided in this Section 5.4 (each, an “ Event of Default ”), the Required Lenders or Agent may, or Agent (upon written election by the Required Lenders but subject to the protections for Agent set forth in Section 6.15) shall, by (subject to Section 5.5(a), which, for the avoidance of doubt, shall not require any such notice and shall occur automatically) written notice to the Borrower, declare the principal of, and accrued and unpaid interest on, all of the Loans and other Obligations or any part of any of them (together with any other amounts accrued or payable under the Loan Documents) to be, and the same shall thereupon become, immediately due and payable, without any further notice and without any presentment, demand or protest of any kind, all of which are hereby expressly waived by the Borrower and the other Loan Parties, appoint a receiver for the Loan Parties and their Subsidiaries, and take any further action available at law or in equity or that are provided in the Loan Documents, including the sale or transfer of the Loan and other Obligations and all other rights acquired in connection with the Loan or the other Obligations or under the Loan Documents:

 

90


(a) The Borrower or any other Loan Party shall have failed (i) to pay when and as required to be paid herein or in any other Loan Document, any amount of principal of any Loan, including after maturity of the Loans, or (ii) to pay within three (3) Business Days after the same shall become due, interest on any Loan, any fee or any other amount or Obligation payable hereunder or pursuant to any other Loan Document.

(b) Any Loan Party shall have failed to comply with or observe (i)(A) Section 1.4, Section 2.1, Section 5.1(a), 5.1(b), 5.1(c), 5.1(e), 5.1(f), 5.1(g), 5.1(h), 5.1(i), 5.1(k), 5.1(l), 5.1(m), 5.1(o), 5.1(p), 5.1(q), 5.1(r), 5.1(s), 5.1(t), 5.1(u), 5.1(v), 5.1(w), 5.1(x), 5.1(y), 5.1(z) or 5.1(aa), Section 5.2 or Section 5.3 of this Agreement, (B) Sections 5.2(a), 5.2(c), 5.2(d), 5.3, 5.4, 5.5, 5.7, 5.9(a), 5.9(c) and 5.10 of the Security Agreement or (C) any provision of any Note, (ii) Section 5.1 of the Security Agreement and such failure, with respect to this Section 5.2(b)(ii) only, shall not have been cured within ten (10) days after the earlier to occur of (y) the date upon which any officer of any Loan Party or any of its Subsidiaries becomes aware of such failure and (z) the date upon which written notice thereof is given to any Loan Party or any of its Subsidiaries by any Secured Party or (iii) any covenant contained in any Loan Document (other than the covenants described in Section 5.4(a), Section 5.4(b)(i) or Section 5.4(b)(ii) above and other than in respect of the Warrants or the Registration Rights Agreement), and such failure, with respect to this Section 5.2(b)(iii) only, shall not have been cured within thirty (30) days after the earlier to occur of (y) the date upon which any officer of any Loan Party or any of its Subsidiaries becomes aware of such failure and (z) the date upon which written notice thereof is given to any Loan Party or any of its Subsidiaries by any Secured Party.

(c) Any representation, warranty, or certification, made by any Loan Party in any Loan Document or delivered in writing to Agent or any Lender in connection with this Agreement or any other Loan Document shall have been incorrect, false or misleading in any material respect (except to the extent that such representation or warranty is qualified by reference to materiality or Material Adverse Effect, to which extent it shall have been incorrect, false or misleading in any respect) as of the date it was made; it being acknowledged and agreed that any projections provided to the Secured Parties are not to be viewed as facts, are not a guarantee of financial performance, and are subject to uncertainties and contingencies.

(d) (i) Any Loan Party or any of its Subsidiaries (other than Immaterial Subsidiaries) shall generally be unable to pay its debts as such debts become due, or shall admit in writing its inability to pay its debts as they come due or shall make a general assignment for the benefit of creditors; (ii) any Loan Party or any of its Subsidiaries (other than Immaterial Subsidiaries) shall declare a moratorium on the payment of its debts; (iii) the commencement by any Loan Party or any of its Subsidiaries (other than Immaterial Subsidiaries) of proceedings to be adjudicated bankrupt or insolvent, or the consent by it to the commencement of bankruptcy or insolvency proceedings against it, or the filing by it of a petition or answer or consent seeking reorganization, intervention or other similar relief under any Applicable Law, or the consent by it to the filing of any such petition or to the appointment of an intervenor, receiver, liquidator, assignee, trustee, sequestrator or other similar official of all or substantially all of its assets; (iv) the commencement against any Loan Party or any of its Subsidiaries (other than Immaterial Subsidiaries) of a proceeding in any court of competent jurisdiction under any bankruptcy or other Applicable Law (as now or hereafter in effect) seeking its liquidation, winding up, dissolution, reorganization, arrangement or adjustment, or the appointment of an intervenor, receiver, liquidator, assignee, trustee, sequestrator or other similar official, and any of the following events occur: (A) such Loan Party or such Subsidiary consents to the institution of such Insolvency Proceeding against it, (B) the petition commencing the Insolvency Proceeding is not timely controverted, (C) the petition commencing any such proceeding shall continue undismissed, or any order, judgment or decree approving or ordering any of the foregoing shall continue unstayed or otherwise in effect, for a period of sixty (60) calendar days of the date of filing thereof, or (D) an interim trustee is appointed to take possession of all or any substantial portion of the properties or assets

 

91


of, or to operate all or any substantial portion of the business of, such Loan Party or its Subsidiary; (v) the making by any Loan Party or any of its Subsidiaries (other than Immaterial Subsidiaries) of an assignment for the benefit of creditors, or the admission by it in writing of its inability to pay its debt generally as they become due; or (vi) any other event shall have occurred which under any Applicable Law would have an effect analogous to any of those events listed above in this Section 5.4(d).

(e) One or more judgments, orders or decrees or settlements shall be rendered against any Loan Party or any Subsidiary of a Loan Party that exceeds by more than $1,000,000 any insurance coverage applicable thereto (to the extent the relevant insurer has been notified of such claim and has not denied coverage therefor) or one or more non-monetary judgments, orders or decrees or settlements shall be rendered against any Loan Party or any Subsidiary of a Loan Party that could reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect, and in either case (i) enforcement proceedings shall have been commenced by any creditor upon any such judgment, order or decree or (ii) there shall be any period of twenty (20) consecutive days during which such judgment, order or decree shall not have been vacated or discharged or there shall not be in effect (by reason of a pending appeal or otherwise) any stay of enforcement thereof.

(f) Any authorization of a Governmental Authority necessary for the execution, delivery or performance of any Loan Document or for the validity or enforceability of any of the Obligations under any Loan Document is not given or is withdrawn or ceases to remain in full force or effect.

(g) Any Applicable Law shall purport to render any material provision of any Loan Document invalid or unenforceable or shall purport to prevent or materially delay the performance or observance by any Loan Party or any of its Subsidiaries of the Obligations (which, for the avoidance of doubt, shall not apply to the process of SEC comments in respect of share registration).

(h) Any Loan Party or any Subsidiary of any Loan Party (i) shall fail to make any payment in respect of any Indebtedness having an individual principal amount (including undrawn committed or available amounts and including amounts owing to all creditors under any combined or syndicated credit arrangement) in excess of $3,000,000 or having an aggregate principal amount (including undrawn committed or available amounts and including amounts owing to all creditors under any combined or syndicated credit arrangement) of more than $8,000,000 when due (whether by scheduled maturity, required prepayment, acceleration, demand or otherwise) and such failure continues after the applicable grace or notice period, if any, specified in the documents relating thereto on the date of such failure; or (ii) shall fail to perform or observe any other condition or covenant, or any other event shall occur or condition exist, under any agreement or instrument relating to any such Indebtedness of the type covered in Section 5.4(h)(i) above, if the effect of such failure, event or condition is to cause, or to permit the holder or holders of such Indebtedness or beneficiary or beneficiaries of such Indebtedness (or a trustee or agent on behalf of such holder or holders or beneficiary or beneficiaries) to cause, such Indebtedness to be declared to be due and payable (or otherwise required immediately to be prepaid, redeemed, purchased or defeased) prior to its stated maturity (without regard to any subordination terms with respect thereto) or cash collateral in respect thereof to be demanded; provided however that, notwithstanding the foregoing, any event or condition that occurs that permits holders of convertible Indebtedness permitted hereunder to convert such Indebtedness into Stock (other than Disqualified Stock) or such other consideration permitted pursuant to Section 5.2(xx) pursuant to the terms of the applicable indenture shall not constitute a Default or Event of Default hereunder on such basis alone.

(i) Any material provision of any Loan Document shall for any reason cease to be valid and binding on or enforceable against any Loan Party or any Subsidiary of any Loan Party thereto or any Loan Party or any Subsidiary of any Loan Party shall so state in writing or bring an action to limit its

 

92


obligations or liabilities thereunder or otherwise contest the validity, binding effect or enforceability of the Loan Documents; or any Loan Document shall for any reason (other than pursuant to the terms thereof) cease to create a valid security interest in any of the Collateral in excess of such Collateral that has a fair market value of $50,000 as determined by the Agent in its sole reasonable discretion (to the extent that such perfection or priority is required hereby) purported to be covered thereby or such security interest shall for any reason cease to be a perfected and first priority security interest (subject only to the prior priority of the Permitted Priority Liens).

(j) (i) The occurrence of any ERISA Event that could reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect or (ii) the imposition of a Lien on any asset of a Loan Party or a Subsidiary of a Loan Party with respect to any Title IV Plan or Multiemployer Plan.

(k) The occurrence of any Event of Default (as such term is defined in the Warrants).

(l) The Common Stock shall cease to be registered under the Exchange Act or to be listed on the Principal Market.

(m) The voluntary withdrawal or institution of any action or proceeding by the FDA or similar Governmental Authority to order the withdrawal of any Product or Product category from the market or to enjoin a Loan Party, such Loan Party’s Subsidiaries or any representative of a Loan Party or its Subsidiaries from testing, manufacturing, processing, assembly, packaging, labeling, marketing, importing, exporting, selling or distributing any Product or Product category that has, individually or in the aggregate, resulted (or could reasonably be expected, individually or in the aggregate, to result) in a Material Adverse Effect, (ii) the institution of any action or proceeding by the DEA, the FDA, or any other Governmental Authority to revoke, suspend, reject, withdraw, limit, or restrict any Regulatory Required Permit held by a Loan Party, its Subsidiaries or any representative of a Loan Party or its Subsidiaries, which, in each case of this clause (ii), has, individually or in the aggregate, resulted (or could reasonably be expected, individually or in the aggregate, to result) in a Material Adverse Effect, (iii) the commencement of any enforcement action against a Loan Party, a Loan Party’s Subsidiaries or any representative of a Loan Party or its Subsidiaries (with respect to the business of a Loan Party or its Subsidiaries) by the DEA, the FDA, or any other Governmental Authority which has, individually or in the aggregate, resulted (or could reasonably be expected, individually or in the aggregate, to result) in a Material Adverse Effect, or (iv) the occurrence of adverse test results in connection with a Product which has, individually or in the aggregate, resulted (or could reasonably be expected, individually or in the aggregate, to result) in a Material Adverse Effect.

(n) The introduction of, or any change in, any law or regulation governing or affecting the healthcare industry, including any Healthcare Laws, that has or could reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.

(o) Any Loan Party defaults under or breaches any Material Contract (after any applicable grace period contained therein), or a Material Contract shall be terminated by a third party or parties party thereto prior to the expiration thereof (other than in accordance with its terms) (other than the Warrant), the 3.25% Convertible Notes, any Permitted 3.25% Convertible Note Refinancing, the 2.25% Convertible Notes, any ABL Debt or any ABL Debt Documents or any Permitted Japan Lifeline Unsecured Debt Documents, or there is a loss of a material right of a Loan Party under any Material Contract to which it is a party, in each case which could reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect.

(p) The occurrence of any breach or default under any terms or provisions of any Convertible Note Document, any ABL Debt Document, any Permitted Japan Lifeline Unsecured Debt

 

93


Documents or any Subordinated Debt Document or the occurrence of any event requiring the prepayment or mandatory redemption of any 3.25% Convertible Note (or any Permitted 3.25% Convertible Note Refinancing thereof or any indenture or related document governing any Permitted 3.25% Convertible Note Refinancing), any 2.25% Convertible Note, any ABL Debt Document, any Permitted Japan Lifeline Unsecured Debt Documents or of any Subordinated Debt; provided , however , that, notwithstanding the foregoing, any event or condition that occurs that permits holders of convertible Indebtedness permitted hereunder to convert such Indebtedness into Stock (other than Disqualified Stock) or such other consideration permitted pursuant to Section 5.2(xx) pursuant to the terms of the applicable agreement shall not constitute a Default or Event of Default hereunder on such basis alone.

(q) The institution by any Governmental Authority of criminal proceedings against any Loan Party.

(r) Any Loan Party makes any payment on account of any Indebtedness that has been subordinated to any of the Obligations, other than payments specifically permitted by the terms of such subordination.

(s) Any Loan Party or any Subsidiary (A) fails to make any payment when due (whether by scheduled maturity, required prepayment, acceleration, demand, or otherwise) in respect of the ABL Debt, or (B) fails to observe or perform any other agreement or condition relating to the ABL Debt or contained in any instrument or agreement evidencing, securing or relating thereto, or any other event occurs, the effect of which default or other event is to cause, or to permit the holder or holders of such ABL Debt or the beneficiary or beneficiaries of any Guarantee related thereto (or a trustee or agent on behalf of such holder or holders or beneficiary or beneficiaries) to cause, such ABL Debt to be demanded or to become due or to be repurchased, prepaid, defeased or redeemed (automatically or otherwise), or an offer to repurchase, prepay, defease or redeem such ABL Debt to be made, prior to its stated maturity, or such Guarantee to become payable or cash collateral in respect thereof to be demanded.

(t) Any provisions of the Intercreditor Agreement shall for any reason be revoked or invalidated, or otherwise cease to be in full force and effect, other than in accordance with the terms thereof, or any Person shall contest in any manner the validity or enforceability thereof or deny that it has any further liability or obligation thereunder.

(u) If the obligation of any Guarantor under the guaranty contained in the Security Agreement is limited or terminated by operation of law or by such Guarantor (other than in accordance with the terms of this Agreement).

(v) (i) Any subordination provisions in respect of the documents evidencing or governing any Subordinated Debt (the “ Subordination Provisions ”) shall, in whole or in part, terminate, cease to be effective or cease to be legally valid, binding and enforceable against any holder of the applicable Subordinated Debt; or (ii) any Borrower or any other Loan Party shall, directly or indirectly, disavow or contest in any manner (A) the effectiveness, validity or enforceability of any of the Subordination Provisions, (B) that the Subordination Provisions exist for the benefit of the Secured Parties or (C) that all payments of principal of or premium and interest on the applicable Subordinated Indebtedness, or realized from the liquidation of any property of any Loan Party, shall be subject to any of the Subordination Provisions.

(w) A Change of Control shall occur.

(x) The Borrower at any time announces or states in writing that it will not honor its obligations to issue shares of Common Stock to a First Out Waterfall Lender upon conversion of any of the

 

94


First Out Waterfall Notes in accordance with the terms thereof.

Section 5.5 Additional Remedies.

(a) Automatic Acceleration on Dissolution or Bankruptcy . Notwithstanding any other provisions of this Agreement, if an Event of Default under Section 5.4(d) shall occur, the principal of the Loans (together with any interest, other amounts and Obligations accrued or payable under this Agreement or the other Loan Documents (including the Exit Payment, any Non-Callable Make Whole Amount and any CoC Fee, if applicable)) shall thereupon become immediately and automatically due and payable, in each case, without any presentment, demand, protest or notice of any kind, all of which are hereby expressly waived by the Borrower and the other Loan Parties.

(b) Power of Attorney . Notwithstanding anything to the contrary in this Agreement, the Warrants, and the other Loan Documents, each Loan Party hereby irrevocably and unconditionally constitutes and appoints Agent and any of Agent’s Affiliates, attorneys, representatives or agents, with full power of substitution, as such Loan Party’s true and lawful attorney-in-fact with full irrevocable and unconditional power and authority in the place and stead of such Loan Party and in the name of such Loan Party or in its own name, for the purpose of carrying out the terms of this Agreement, the Warrants, and the other Loan Documents, to take any appropriate steps or actions and to execute and deliver (and perform under on such Loan Party’s behalf) any agreement, document or instrument that may be necessary or desirable to accomplish the purposes and/or effectuate the items and actions set forth in this Agreement, the Warrants, and the other Loan Documents, in each case, (i) that any such Loan Party fails to take that are required under such documents, agreements or instruments, (ii) during the existence of any Event of Default, or (iii) in delivering the original shares of Common Stock to be issued under any Warrants to the applicable holder thereof upon such holder exercising its rights pursuant to the terms of such Warrants.

Section  5.6 Recovery of Amounts Due . If any Obligation or other amount payable hereunder or under any of the other Loan Documents is not paid as and when due, the Borrower and the other Loan Parties hereby authorize Agent and the Lenders to proceed, to the fullest extent permitted by Applicable Law, without prior notice, by right of set-off, banker’s lien or counterclaim, against any moneys or other assets of the Borrower or any other Loan Party to the full extent of all Obligations or other amounts payable to Agent and/or the Secured Parties.

Section  5.7 Credit Bidding . The Loan Parties and the Lenders hereby irrevocably authorize Agent based upon the written instruction of the Lenders, to (a) credit bid and in such manner purchase (either directly or through one or more acquisition vehicles) all or any portion of the Collateral at any sale thereof conducted under the provisions of the Bankruptcy Code, including under Section 363 of the Bankruptcy Code or any similar laws in any other jurisdictions to which a Loan Party is subject, or (b) credit bid and in such manner purchase (either directly or through one or more acquisition vehicles) all or any portion of the Collateral at any other sale or foreclosure conducted by (or with the consent or at the direction of) Agent (whether by judicial action or otherwise) in accordance with Applicable Law. In connection with any such credit bid and purchase, the Obligations owed to any Lender shall be entitled to be, and shall be, credit bid on a ratable basis (with Obligations with respect to contingent or unliquidated claims being estimated for such purpose if the fixing or liquidation thereof would not unduly delay the ability of Agent to credit bid and purchase at such sale or other disposition of the Collateral and, if such claims cannot be estimated without unduly delaying the ability of Agent to credit bid, then such claims shall be disregarded, not credit bid, and not entitled to any interest in the asset or assets purchased by means of such credit bid) and the Lenders whose Obligations are credit bid shall be entitled to receive interests (ratably based upon the proportion of their Obligations credit bid in relation to the aggregate amount of Obligations so credit bid) in the asset or assets so purchased (or in the Stock of the acquisition vehicle or

 

95


vehicles that are used to consummate such purchase). Except as provided above and otherwise expressly provided for herein or in the other Loan Documents, Agent will not execute nor deliver a release of any Lien on any Collateral. Upon request by Agent or the Borrower at any time, the Lenders will confirm in writing Agent’s authority to release any such Liens on particular types or items of Collateral pursuant to this Section 5.7.

ARTICLE 6

MISCELLANEOUS

Section  6.1 Notices . Any notices or other information (including an financial information) required or permitted to be given under the terms hereof shall be sent by certified or registered mail (return receipt requested) or delivered personally or by courier (including a recognized overnight delivery service) or by facsimile or by electronic mail and shall be effective five (5) days after being placed in the mail, if mailed by regular United States mail, or upon receipt, if delivered personally or by courier (including a recognized overnight delivery service) or by facsimile, or when received by electronic mail in each case addressed to a party as follows (or such other address, facsimile or electronic mail address provided by such party to such other parties pursuant to the below (or such later address, facsimile or electronic mail address provided in accordance herewith):

If to the Borrower or any other Loan Party:

Endologix, Inc.

2 Musick

Irvine, CA 92618

E-mail: vmahboob@endologix.com

E-mail: jtejedor@endologix.com

Attn: Vaseem Mahboob, CFO

Attn: James Tejedor, Treasury Manager

With a copy to (which shall not be deemed to constitute notice):

DLA Piper LLP (US)

444 West Lake Street, Suite 900

Chicago, IL 60606

E-mail: gregory.ruback@dlapiper.com

Attn: Gregory Ruback

If to Agent:

c/o Deerfield Management Company, L.P.

780 Third Avenue, 37 th Floor

New York, NY 10017

Facsimile: 212-599-3075

E-mail: dclark@deerfield.com

Attn: David J. Clark, Esq.

With a copy to (which shall not be deemed to constitute notice):

Katten Muchin Rosenman LLP

2029 Century Park, East, Suite 2600

 

96


Los Angeles, CA 90067-3012

Facsimile: (310) 788-4471

E-mail: Kristopher.ring@kattenlaw.com and mark.wood@kattenlaw.com

Attn: Kristopher J. Ring, Esq.

Attn: Mark D. Wood, Esq.

If to any Lender, the information for notices included on Schedule 2.4 or pursuant to any assignment agreement assigning any Obligations to any new Lender.

Section  6.2 Waiver of Notice . Whenever any notice is required to be given to the Lenders or the Borrower under the any of the Loan Documents, a waiver thereof in writing signed by the Person or Persons entitled to such notice, whether before or after the time stated therein, shall be deemed equivalent to the giving of such notice.

Section  6.3 Fees, Charges, Costs and Expenses Reimbursement . The Loan Parties agree to pay on or prior to the Agreement Date and, within ten (10) Business Days (or such later date as the Agent may agree in its sole discretion) after delivery of an invoice therefor after the Agreement Date, (a) all reasonable fees, reasonable costs and reasonable, out-of-pocket expenses of Agent and the Lenders and of legal counsel to Agent and the Lenders of negotiation, documentation, preparation, execution, delivery and closing, of the Loan Documents (and the Prior Loan Documents) and in connection with the consummation of the Transactions and the other transactions contemplated hereby and thereby, (b) any consents, amendments, waivers or other modifications to the Loan Documents (and the Prior Loan Documents) or otherwise in connection with the consummation of the Transactions and the other transactions contemplated hereby and thereby, (c) all fees, costs and expenses of creating and perfecting Liens in favor of Agent on behalf of the Secured Parties pursuant to any Loan Document (or any Prior Loan Documents), including filing and recording fees, expenses and Taxes, search fees, title insurance premiums, and fees, costs, expenses and disbursements of counsel to Agent and the Lenders and of counsel providing any opinions that Agent or the Lenders may request in respect of any Loan Documents (or any Prior Loan Documents) or the Liens created pursuant to the Loan Documents (or any Prior Loan Documents), (d) all costs and expenses incurred by Agent or any Lender in connection with the custody or preservation of any of the Collateral, (e) all costs and expenses, including the reasonable out-of-pocket documented fees, costs and expenses of legal counsel to Agent and the Lenders and reasonable out-of-pocket documented fees, costs and expenses of accountants, advisors and consultants, incurred by Agent, any Lender and its counsel relating to efforts to protect, evaluate, assess or dispose of any of the Collateral, (f) all costs and expenses, including fees, costs and expenses of legal counsel to Agent and the Lenders and all fees, costs and expenses of accountants, advisors and consultants and costs of settlement, incurred by the Agent and the Lenders in enforcing any of the Loan Documents (or the Prior Loan Documents) or any Obligations of, or in collecting any payments due from, any Loan Party hereunder or under the other Loan Documents or the Prior Loan Documents (including in connection with the sale of, collection from, or other realization upon any of the Collateral or the enforcement of the Loan Documents or the Prior Loan Documents) or in connection with any refinancing or restructuring of the credit arrangements provided under this Agreement in the nature of a “work-out” or pursuant to any proceeding or event of the type set forth in Section 5.4(d), (g) the cost of purchasing insurance that the Loan Parties fail to obtain as required by the Loan Documents, (h) providing any notices under the Loan Documents or the Prior Loan Documents that are required or recommended by Applicable Law (i) providing any new Notes or amended and restated Notes and (j) any other actions taken after the Prior Agreement Date related to the Obligations or the Loan Documents or the Prior Loan Document. Without limiting any of the foregoing provisions of this Section 6.3, any action taken by any Loan Party under or with respect to any Loan Document or any Prior Loan Document, even if required under any Loan Document or any Prior Loan Document or at the request of the Agent or any other Secured Party, shall be at the sole expense of such Loan Party, and neither Agent nor any other Secured

 

97


Party shall be required under any Loan Document or any Prior Loan Document to reimburse any Loan Party or any Subsidiary of any Loan Party therefor.

Section  6.4 Governing Law ; Venue; Jurisdiction; Service of Process; Waiver of Jury Trial. All questions concerning the construction, validity, enforcement and interpretation of this Agreement and, unless otherwise expressly stated therein, the other Loan Documents shall be governed by and construed and enforced in accordance with the laws of the State of New York applicable to contracts made and to be performed in such State. Each Party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement and, unless otherwise expressly stated therein, the other Loan Documents (whether brought against a party hereto or its respective Affiliates, directors, officers, shareholders, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York, Borough of Manhattan. Each Party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, borough of Manhattan for the adjudication of any dispute hereunder or under the other Loan Documents or in connection herewith or with the other Loan Documents or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, or that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each Party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such Party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. THE PARTIES HERETO, TO THE EXTENT PERMITTED BY LAW, WAIVE ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, SUIT, OR PROCEEDING ARISING OUT OF, IN CONNECTION WITH OR RELATING TO, THIS AGREEMENT, THE OTHER LOAN DOCUMENTS AND ANY TRANSACTION CONTEMPLATED HEREBY AND THEREBY. THIS WAIVER APPLIES TO ANY ACTION, SUIT OR PROCEEDING WHETHER SOUNDING IN TORT, CONTRACT OR OTHERWISE. EACH PARTY HERETO (A) CERTIFIES THAT NO OTHER PARTY AND NO AGENT, REPRESENTATIVE OR OTHER PERSON AFFILIATED WITH OR RELATED TO ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THE LOAN DOCUMENTS, AS APPLICABLE, BY THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 6.4.

Section  6.5 Successors and Assigns . This Agreement shall bind and inure to the respective successors and assigns of the Parties, except that no Loan Party may assign or otherwise transfer all or any part of their rights or obligations (including the Obligations) under the Loan Documents without the prior written consent of all of the Lenders (other than in any Permitted Successor Transaction), and any prohibited assignment by the Loan Parties shall be absolutely void ab initio . Any Lender may assign or transfer its rights or Obligations under the Loan Documents to an Eligible Assignee, so long as (a) with respect to any assignment to a Person mentioned in clause (d) of the definition of “Eligible Assignee”, the amount of such assignment is for Loans in an aggregate principal amount not less than $5,000,000 (or, if less, the entire remaining principal amount of Loans held by such Lender); provided that such threshold amount shall be aggregated between such Persons that are assignees mentioned in such clause (d) of the definition of “Eligible Assignee” that are Affiliates of each other. Upon a Lender’s assignment of any of the Loans held by it in accordance with this Section 6.5, such Lender shall provide notice of the transfer to Borrower (with a copy to Agent) for recordation in the Register pursuant to Section 1.4. Upon receipt of a notice of a permitted transfer of an interest in a Loan, the Borrower shall record the identity of the transferee and other relevant information in the Register and the transferee shall (to the extent of the interests

 

98


transferred to such transferee) have all the rights and obligations of, and shall be deemed, a Lender with respect to such Loan hereunder or under the other Loan Documents. Notwithstanding anything to the contrary in any Loan Document, no Lender shall assign or transfer, or provide any participation in, any of the Loans or other Obligations to any Loan Party or any of their Affiliates without the written consent of Agent. If a Lender sells participating interests in its Loans or other interests hereunder (any such Person, a “ Participant ”), (i) such Lender’s obligations hereunder with respect to those sold to the Participant shall remain unchanged for all purposes, (ii) the Borrower and Agent shall continue to deal solely and directly with such Lender in connection with such Lender’s rights and obligations hereunder with respect to those sold to the Participant, and (iii) all amounts payable by the Borrower shall be determined as if such Lender had not sold such participation and shall be paid directly to such Lender.

In addition to the other rights provided in this Section 6.5, each Secured Party may grant a security interest in, or otherwise assign as collateral, any of its rights under the Loan Documents, whether now owned or hereafter acquired (including rights to payments of principal or interest on the Loans), to any holder of, or trustee for the benefit of the holders of, such Secured Party’s Indebtedness or equity securities; provided however that no such security interest or assignment shall release such Secured Party from any of its obligations hereunder or substitute any such holder of a security interest or assignee for such Secured Party as a party hereto.

Section  6.6 Entire Agreement; Amendments .

(a) The Loan Documents contain the entire understanding of the Parties with respect to the matters covered thereby and supersede any and all other written and oral communications, negotiations, commitments and writings with respect thereto.

(b) No amendment, restatement, modification, supplement, change, termination or waiver of any provision of this Agreement or the other Loan Documents (other than the Warrants, the Registration Rights Agreement, any Control Agreement or any similar agreement or any landlord agreement or bailee or mortgagee waiver, each of which may be amended, restated, modified, supplemented, changed, terminated, waived or consented to in accordance with the terms thereof), and no consent to any departure by any Loan Party therefrom, shall in any event be effective without the written concurrence of the Borrower, the Agent and the Required Lenders; provided that (1) no such amendment, restatement, modification, supplement, change, termination, waiver or consent to this Agreement shall, without the consent of each Lender with Obligations directly and adversely affected thereby, do any of the following: (i) reduce any Loan of such Lender; (ii) postpone the Maturity Date or other scheduled final maturity date of any Loan of such Lender, or postpone the date or reduce the amount of any scheduled payment (but not mandatory prepayment) of principal of any Loan of such Lender; (iii) decrease the interest rate borne by any Loan of such Lender (other than any waiver of any increase in the interest rate applicable to any of the Loans pursuant to Section 2.7(b)) or the amount of any premium or fees payable hereunder; (iv) amend this proviso of this Section 6.6(b) to the extent providing for consent by all directly and adversely affected Lenders in a manner to remove such consent; or (v) amend the definitions of “Required Lenders”, “Required First Out Waterfall Lenders” and “Required Last Out Waterfall Lenders”, (2) any amendment, restatement, supplement, change or other modification (or any waiver or agreement with respect) to the definitions of “Required Lenders”, “Required First Out Waterfall Lenders” or “Required Last Out Waterfall Lenders” or the proviso in this Section 6.6(b) may be conducted or agreed to with just the consent of each Lender and without the consent of any Loan Party or any of its Subsidiaries, and (3) any amendment, restatement, modification, change, supplement, change, termination, waiver or consent to this Agreement that (x) affects only the First Out Waterfall Lenders requires only the consent of the Required First Out Waterfall Lenders and (y) affects only the Last Out Waterfall Lenders requires only the consent of the Required Lenders.

 

99


(c) No consideration shall be offered or paid (in any form, whether cash, Stock, other property or otherwise) to any Secured Party to amend, restate, supplement, modify or change or consent to a waiver of (or a diversion from) any provision of any of the Loan Documents unless the same consideration also is offered to all of the Lenders under the Loan Documents. For clarification purposes, this provision constitutes a separate right granted to each Lender and is not intended for the Borrower or any other Loan Party to treat the Lenders as a class and shall not be construed in any way as the Lenders acting in concert or otherwise as a group with respect to the purchase, disposition or voting of securities or Stock or otherwise.

Section  6.7 Severability . If any provision of this Agreement or any of the other Loan Documents shall be invalid, illegal or unenforceable in any respect under any law, the validity, legality and enforceability of the remaining provisions hereof or thereof shall not in any way be affected or impaired thereby. The Parties shall endeavor in good faith negotiations to replace the invalid, illegal or unenforceable provisions with valid provisions the economic effect of which comes as close as possible to that of the invalid, illegal or unenforceable provision.

Section  6.8 Counterparts . This Agreement may be executed in several counterparts, and by each Party on separate counterparts, each of which and any photocopies, facsimile copies and other electronic methods of transmission thereof shall be deemed an original, but all of which together shall constitute one and the same agreement.

Section 6.9 Survival; Releases of Guarantees and Liens.

(a) In addition to Section 3.2, this Agreement and all agreements, representations and warranties and covenants made in the Loan Documents, and in any document, certificate or statement delivered pursuant thereto or in connection therewith shall be considered to have been relied upon by the other Parties and shall survive the execution and delivery of this Agreement and the other Loan Documents and the making of the Loan hereunder or thereunder, in each case until termination of such provision in accordance with this Section 6.9, regardless of any investigation made by any such other Party or on its behalf. Agent and the Lenders shall not be deemed to have waived, by reason of making the Loan, any Event of Default that may arise by reason of such representation or warranty proving to have been false or misleading, notwithstanding that the Lenders may have had notice or knowledge of any such Event of Default or may have had notice or knowledge that such representation or warranty was false or misleading at the time the applicable Disbursement was made.

(b) All representations and warranties made hereunder and in any other Loan Document or other document delivered pursuant hereto or thereto or in connection herewith or therewith shall survive the execution and delivery hereof and thereof (and, with respect to Section 3.1(g)(i)(B), the first two sentences of Section 3.1(i), Section 3.1 (y), Section 3.1 (z)(A) and (C), Section 3.1(ee), the first sentence of Section 3.1(mm), Section 3.1(nn), Section 3.1(oo), Section 3.1(rr), Section 3.1(ss) and Section 3.1 (tt), shall continue to be made in accordance with the terms hereof and thereof, including at all times after the execution and delivery hereof and thereof). Such representations and warranties have been or will be relied upon by the Secured Parties, regardless of any investigation made by the Secured Parties or on their behalf and notwithstanding that any Secured Party may have had notice or knowledge of any Default at the time of any Loan, and shall continue in full force and effect as long as either (i) any Loan or any other Obligation hereunder shall remain outstanding, unpaid or unsatisfied or (ii) the Maturity Date has not occurred. Notwithstanding anything to the contrary in the Loan Documents, the obligations of the Loan Parties under Section 2.5 and the obligations of the Loan Parties and the Lenders under this Article 6 shall survive and remain in full force and effect regardless of the consummation of the transactions contemplated hereby, the repayment of the Loans and the other Obligations, the expiration or termination of the Warrants or the termination of this Agreement or any of the other Loan Documents or any provision hereof or thereof. For the avoidance of doubt and notwithstanding anything to the contrary in any Loan Documents, (a) the

 

100


making of the representations and warranties herein or in any other Loan Document that relate to the Warrants or any securities laws shall survive the payment in full of the Loans and any other Obligations until such time that Warrants are fully and completely paid, performed, extinguished and terminated in accordance with their terms, (b) all rights set forth in the Warrants and the Registration Rights Agreement and all transactions contemplated thereby (other than this Agreement and the other Loan Documents with respect to provisions that are not mentioned herein or therein to survive the payment in full of the Loans) shall continue to, and at all times, exist until (i) with respect to the Warrants, such Warrants are fully and completely paid, performed, extinguished and terminated in accordance with their terms and (ii) with respect to the Registration Rights Agreement, such Registration Rights Agreement is fully and completely terminated in accordance with its terms, (c) Sections 5.1(h), (p), (s) and (aa) and Section 5.2(xvii) will survive until the end of the Reporting Period, but all other affirmative and negative covenants, events of default, fees, penalties and other provisions not expressly surviving pursuant to this Section 6.9 shall terminate upon the payment in full of the Obligations (not including unasserted contingent indemnification obligations or any Obligations in respect of the Warrants, the Registration Rights Agreement or any Stock) and (d) all Liens granted on the Collateral under any Loan Document shall remain in effect and shall continue to secure the Obligations under the Loan Documents (x) until all of the Obligations (other than unasserted contingent indemnification obligations and other than any Obligations under any Warrant or the Registration Rights Agreement) have been paid in full in cash in accordance with such Loan Documents and (y) other than Liens on any Collateral disposed of in a Permitted Disposition or as otherwise agreed in writing by the Required Lenders (or such greater percentage of Lenders required pursuant to Section 6.6) (but such release shall only be for the Liens on such Collateral so disposed in a Permitted Disposition or as may be agreed in writing by the Required Lenders (or such greater percentage of Lenders required pursuant to Section 6.6)).

(c) Upon payment in full of all Obligations (other than unasserted contingent indemnification obligations and other than any Obligations in connection with any Warrant or the Registration Rights Agreement) in cash in accordance with the Loan Documents, subject to the second sentence of Section 6.22, all Collateral shall be automatically released from the Liens created by the Security Agreement, any other Loan Document or otherwise and all rights of the Secured Parties in the Collateral shall automatically terminate, all without delivery of any instrument or any additional performance by any Person.

(d) Notwithstanding anything to the contrary contained herein or in any other Loan Document, the Agent is hereby unconditionally authorized and instructed by each Secured Party (without requirement of notice to or consent of any Secured Party) to take any action to release or terminate any Lien granted under the Loan Documents to secure the Obligations in the Collateral upon (i) payment in full of all Obligations (other than unasserted contingent indemnification obligations and other than the Obligations under any Warrant or the Registration Rights Agreement) in cash in accordance with the Loan Documents, (ii) a written agreement by the requisite number of Lenders required by Section 6.6 and (iii) a Permitted Disposition (but solely in the Collateral so disposed of in a Permitted Disposition and not in any other property or assets).

(e) In each case in accordance with this Section 6.9 whereby a Lien on all or a portion of the Collateral is released, the Agent will (and each Lender irrevocably authorizes and instructs the Agent to), at the Borrower’s expense, execute and deliver to the applicable Loan Party such documents as such Loan Party may reasonably request to evidence the release of (i) all Collateral from the Liens granted under the Loan Documents upon payment in full of all Obligations (other than unasserted contingent indemnification obligations and other than the Obligations under any Warrant or the Registration Rights Agreement) in cash in accordance with the Loan Documents, in each case, in accordance with the terms of the Loan Documents and this Section 6.9, (ii) Collateral permitted to be sold pursuant to clause (d)(ii) of

 

101


this Section 6.9 (but solely in such Collateral) and (iii) the Liens on that Collateral sold pursuant to a Permitted Disposition (but solely in such Collateral sold pursuant to such Permitted Disposition).

(f) Notwithstanding anything to the contrary in the Loan Documents and for the avoidance of doubt, the holders of the Warrants and parties to the Registration Rights Agreement shall be entitled to exercise all rights and remedies available to them under law and at equity and under the Warrants and the Registration Rights Agreement for any breaches of provisions that survive the payment in full of the Obligations (other than the payment in full of unasserted contingent indemnification obligations and other than Obligations under any Warrant or the Registration Rights Agreement).

Section  6.10 No Waiver . Neither the failure of, nor any delay on the part of, any Party in exercising any right, power or privilege hereunder, or under any agreement, document or instrument mentioned herein or under any other Loan Document, shall operate as a waiver thereof, nor shall any single or partial exercise of any right, power or privilege hereunder, under any other Loan Document or under any other agreement, document or instrument mentioned herein, preclude other or further exercise thereof or the exercise of any other right, power or privilege; nor shall any waiver of any right, power, privilege or default hereunder, under any other Loan Document or under any agreement, document or instrument mentioned herein, constitute a waiver of any other right, power, privilege or default or constitute a waiver of any default of the same or of any other term or provision. No course of dealing and no delay in exercising, or omission to exercise, any right, power or remedy accruing to Agent or the Lenders upon any breach, Default or Event of Default under this Agreement, any other Loan Document or any other agreement shall impair any such right, power or remedy or be construed to be a waiver thereof or an acquiescence therein; nor shall the action of Agent or the Lenders in respect of any such breach, Default or Event of Default or any acquiescence by it therein, affect or impair any right, power or remedy of Agent or the Lenders in respect of any other breach, Default or any Event of Default. All rights and remedies herein or in the other Loan Documents provided are cumulative and not exclusive of any rights or remedies otherwise provided by (or available at) law or in equity.

Section 6.11 Indemnity.

(a) The Loan Parties shall, at all times, indemnify and hold harmless (the “ Indemnity ”) the Secured Parties and each of their respective directors, partners, officers, employees, agents, counsel and advisors (each, an “ Indemnified Person ”) in connection with any losses, claims (including the reasonable attorneys’ fees incurred in defending against such claims), damages, liabilities, penalties or other expenses arising out of, or relating to, the Loan Documents or the Prior Loan Documents, the extension of credit hereunder or the Loan or the other Obligations or the use or intended use of the Loan or the other Obligations, which an Indemnified Person may incur or to which an Indemnified Person may become subject (each, a “ Loss ”). The Indemnity shall not apply to the extent that a court or arbitral tribunal of competent jurisdiction issues a final non-appealable judgment that such Loss of an Indemnified Person resulted from the gross negligence, bad faith or willful misconduct of such Indemnified Person. The Indemnity is independent of and in addition to any other agreement of any Party under any Loan Document to pay any amount to the Secured Parties, and any exclusion of any obligation to pay any amount under this Section 6.11(a) shall not affect the requirement to pay such amount under any other section hereof or under any other agreement. For the avoidance of doubt, this Section 6.11 shall not apply to Taxes other than Taxes that represent losses, claims, damages, etc. arising from any non-Tax claim.

(b) An Indemnified Person shall have the right to retain its own legal counsel with the fees, costs and expenses of such legal counsel and of such Indemnified Person to be paid by the indemnifying Person. The indemnification required by this Section 6.11 shall be made and paid by such indemnifying Person within ten (10) Business Days of written demand by such Indemnified Person.

 

102


(c) No settlement of any Loss shall be entered into by such indemnifying Person without the written consent of the applicable Indemnified Person.

(d) No Loan Party shall, nor shall it permit any of its Subsidiaries, assert, and each Loan Party on behalf of itself and its Subsidiaries, hereby waives, any claim, loss or amount against any Indemnified Person with respect to any special, indirect, consequential or punitive damages (as opposed to direct or actual damages) arising out of, in connection with, or as a result of, this Agreement or the other Loan Documents or any undertaking or transaction contemplated hereby or thereby. No Indemnified Person shall be liable for any damages arising from the use by unintended recipients of any information or other materials distributed by it through telecommunications, electronic or other information transmission systems in connection with the Loan Documents or the transactions contemplated hereby or thereby.

Section  6.12 No Usury . The Loan Documents are hereby expressly limited so that in no contingency or event whatsoever, whether by reason of acceleration or otherwise, shall the amount paid or agreed to be paid to Agent or the Lenders for the Loan or the other Obligations exceed the maximum amount permissible under Applicable Law. If from any circumstance whatsoever fulfillment of any provision hereof or any other Loan Document, at the time performance of such provision shall be due, shall involve transcending the limit of validity prescribed by law, then, ipso facto , the obligation to be fulfilled shall be reduced to the limit of such validity, and if from any such circumstance Agent or the Lenders shall ever receive anything which might be deemed interest under Applicable Law, that would exceed the highest lawful rate, such amount that would be deemed excessive interest shall be applied to the reduction of the principal amount owing on account of the Loan or the other Obligations, or if such deemed excessive interest exceeds the unpaid balance of principal of the Loan or the other Obligations, such deemed excess shall be refunded to the Borrower. All sums paid or agreed to be paid to the Lenders for the Loan or the other Obligations shall, to the extent permitted by Applicable Law, be deemed to be amortized, prorated, allocated and spread throughout the full term of the Loan and the other Obligations until payment in full so that the deemed rate of interest on account of the Loan and the other Obligations is uniform throughout the term thereof. The terms and provisions of this Section shall control and supersede every other provision of this Agreement, the Notes and the other Loan Documents.

Section  6.13 Specific Performance . The Loan Parties agree that irreparable damage, for which monetary relief, even if available, would not be an adequate remedy, would occur in the event that any provision of the Loan Documents is not performed in accordance with its specific terms or is otherwise breached, including if the Loan Parties hereto fail to take any action required of them hereunder or thereunder to consummate the transactions contemplated by the Loan Documents. In light of the foregoing, the Loan Parties hereby agree that, until all Obligations have been paid in full in accordance with the Loan Documents, (a) the Secured Parties shall be entitled to an injunction or injunctions, specific performance or other equitable relief to prevent breaches of the Loan Documents and to enforce specifically the terms and provisions hereof and thereof in the courts described in Section 6.4 without proof of damages or otherwise and (b) the right of specific performance and other equitable relief is an integral part of the transactions contemplated by the Loan Documents and without that right, the Secured Parties would not have entered into the Loan Documents or have provided Loans or Disbursements hereunder or under the other Loan Documents. The Loan Parties hereby agree not to assert (or have any of their Subsidiaries or their attorneys, agents or representatives assert or any other Person on their behalf to assert) that a remedy of specific performance or other equitable relief is unenforceable, invalid, contrary to Applicable Law or inequitable for any reason, and not to assert that a remedy of monetary damages would provide an adequate remedy or that the parties otherwise have an adequate remedy at law. The Loan Parties hereby acknowledge and agree that any Secured Party seeking an injunction or injunctions to prevent breaches of, or defaults under, the Loan Documents, to prevent any Default or Event of Default and to enforce specifically the terms and provisions of the Loan Documents in accordance with this Section 6.13 shall not be required to provide any bond or other security in connection with any such injunction or other order or proceeding. The remedies

 

103


available to the Secured Parties pursuant to this Section 6.13 shall be in addition to any other remedy which may be available under the Loan Documents, at law, in equity or otherwise.

Section  6.14 Further Assurances . From time to time, the Loan Parties shall perform any and all acts and execute and deliver to Agent and the Lenders such additional documents, agreements and instruments as may be reasonably requested by Agent or any of the Lenders to carry out the purposes of any Loan Document or to preserve and protect Agent’s or the Lenders’ rights as contemplated therein.

Section  6.15 Agent .

(a) Each Lender hereby irrevocably appoints Deerfield Private Design Fund IV, L.P. (together with any successor Agent appointed by Deerfield Private Design Fund IV, L.P. or any successor Agent that was appointed by the Lenders or any prior Agent) as Agent hereunder and under the other Loan Documents and authorizes Agent to (i) execute and deliver the Loan Documents and accept delivery thereof on its behalf from any Loan Party, (ii) take such other actions on its behalf and to exercise all rights, powers and remedies and perform the duties as are expressly delegated to Agent under the Loan Documents and (iii) exercise such powers as are reasonably incidental thereto. Notwithstanding any provision to the contrary contained elsewhere in this Agreement or in any other Loan Document, Agent shall not have any duty or responsibility except those expressly set forth herein, nor shall Agent have or be deemed to have any fiduciary relationship with any Lender or participant, and no implied covenants, functions, responsibilities, duties, obligations or liabilities shall be read into this Agreement or any other Loan Document or otherwise exist against Agent. Without limiting the generality of the foregoing sentence, the use of the term “agent” herein and in other Loan Documents with reference to Agent is not intended to connote any fiduciary or other implied (or express) obligations arising under agency doctrine of any Applicable Law. Instead, such term is used merely as a matter of market custom, and is intended to create or reflect only an administrative relationship between independent contracting parties.

(b) Agent may execute any of its duties under this Agreement or any other Loan Document by or through agents, employees or attorneys in fact and shall be entitled to advice of counsel and other consultants or experts concerning all matters pertaining to such duties. Agent shall not be responsible for the negligence or misconduct of any agent or attorney in fact that it selects in the absence of gross negligence or willful misconduct as determined by a final, non-appealable judgment of a court of competent jurisdiction.

(c) None of Agent nor any of its directors, officers, employees, attorneys, advisors, representatives or agents shall (i) be liable for any action taken or omitted to be taken by any of them under or in connection with this Agreement or any other Loan Document or the Transactions or the transactions contemplated hereby or thereby (except to the extent resulting from its own gross negligence or willful misconduct in connection with its duties expressly set forth herein as determined by a final, non-appealable judgment of a court of competent jurisdiction), or (ii) be responsible in any manner to any Lender or participant for any recital, statement, representation or warranty made by any Loan Party or Affiliate of any Loan Party, or any officer thereof, contained in this Agreement or in any other Loan Document, or in any certificate, report, statement or other document referred to or provided for in, or received by the Agent under or in connection with, this Agreement or any other Loan Document, or the validity, effectiveness, genuineness, enforceability or sufficiency of this Agreement or any other Loan Document (or the creation, perfection or priority of any Lien or security interest therein), or for any failure of any Loan Party or any other party to any Loan Document to perform its obligations (including the Obligations) hereunder or thereunder. Agent shall not be under any obligation to any Lender to ascertain or to inquire as to the observance or performance of any of the agreements contained in, or conditions of, this Agreement or any other Loan Document, or to inspect the properties, books or records of any Loan Party or any Loan Party’s Subsidiaries or Affiliates.

 

104


(d) Agent shall be entitled to rely, and shall be fully protected in relying, upon any writing, communication, signature, resolution, representation, notice, consent, certificate, electronic mail message, affidavit, letter, telegram, facsimile, telex or telephone message, statement or other document or conversation believed by it to be genuine and correct and to have been signed, sent or made by the proper Person or Persons, and upon advice and statements of legal counsel (including counsel to any Loan Party), independent accountants and other experts selected by Agent. Agent shall be fully justified in failing or refusing to take any action under this Agreement or any other Loan Document unless it shall first receive such advice or concurrence of the Lenders as it deems appropriate and, if it so requests, shall receive confirmation from the Lenders of their obligation to indemnify Agent against any and all liabilities and expenses (including any fees and expenses of counsel to Agent) which may be incurred by it by reason of taking or continuing to take any such action. Agent shall in all cases be fully protected in acting, or in refraining from acting, under this Agreement or any other Loan Document in accordance with a request or consent of the Lenders and such request and any action taken or failure to act pursuant thereto shall be binding upon each Lender.

(e) Agent shall not be deemed to have knowledge or notice of the occurrence of any Event of Default or Default, unless Agent shall have received written notice from a Lender or any Loan Party referring to this Agreement and the other Loan Documents, describing such Event of Default or Default and stating that such notice is a “notice of default.” Agent shall take such action with respect to such Event of Default or Default as may be requested by the Lenders; provided that unless and until the Agent has received any such request, the Agent may (but shall not be obligated to) take such action, or refrain from taking such action, with respect to such Event of Default or Default as it shall deem advisable or in the best interest of itself and the Lenders.

(f) Each Lender acknowledges that Agent has not made any representation or warranty to it, and that no act by Agent hereafter taken, including any consent and acceptance of any assignment or review of the affairs of the Loan Parties or any of their Subsidiaries, shall be deemed to constitute any representation or warranty by Agent to any Lender as to any matter, including whether Agent has disclosed material information in its possession. Each Lender represents to Agent that it has, independently and without reliance upon Agent and based on such documents and information as it has deemed appropriate, made its own appraisal of and investigation into the business, prospects, operations, property, financial and other condition and creditworthiness of Borrower and the other Loan Parties, and made its own decision to enter into this Agreement and the other Loan Documents and to extend credit to Borrower hereunder and under the other Loan Documents. Each Lender also represents that it will, independently and without reliance upon Agent and based on such documents and information as it shall deem appropriate at the time, continue to make its own credit analysis, appraisals and decisions in taking or not taking action under this Agreement and the other Loan Documents, and to make such investigations as it deems necessary or appropriate to inform itself as to the business, prospects, operations, property, financial and other condition and creditworthiness of Borrower and the other Loan Parties. Except for notices, reports and other documents expressly herein required to be furnished to the Lenders by Agent, Agent shall not have any duty or responsibility to provide any Lender with any credit or other information concerning the business, prospects, operations, property, financial or other condition or creditworthiness of Borrower or any other Loan Party which may come into the possession of Agent.

(g) Whether or not the transactions contemplated hereby are consummated, each Lender shall indemnify upon demand Agent and its directors, officers, partners, employees, attorneys, advisors, representatives and agents (to the extent not reimbursed by or on behalf of any Loan Party and without limiting the obligation of Borrower to do so), according to its applicable Pro Rata Share, from and against any and all losses, claims (including the reasonable attorneys’ fees incurred in defending against such claims), damages, liabilities, penalties or other expenses arising out of, or relating to, any of Agent’s duties, responsibilities or actions set forth in or that taken pursuant to the Loan Documents; provided that no

 

105


Lender shall be liable for any payment to any such Person of any portion of the foregoing to the extent determined by a final, non-appealable judgment by a court of competent jurisdiction to have resulted from the applicable Person’s own gross negligence or willful misconduct. No action taken in accordance with the directions of the Lenders shall be deemed to constitute gross negligence or willful misconduct for purposes of this Section 6.15(g). Without limitation of the foregoing, each Lender shall reimburse Agent upon demand for its ratable share of any costs or out of pocket expenses incurred by Agent in connection with the preparation, execution, delivery, administration, modification, amendment or enforcement (whether through negotiations, legal proceedings or otherwise) of, or legal advice in respect of rights or responsibilities under, this Agreement, any other Loan Document or any document contemplated by or referred to herein or therein, to the extent that Agent is not reimbursed for such fees, costs and expenses by or on behalf of the Loan Parties. The undertaking in this Section 6.15(g) shall survive repayment of the Loans and the other Obligations, any foreclosure under, or modification, release or discharge of, any or all of the Loan Documents, termination of this Agreement or the other Loan Documents and the resignation or replacement of Agent.

(h) Agent may resign as Agent upon thirty (30) days’ notice to the Lenders. If Agent resigns under this Agreement, the Lenders shall appoint from among the Lenders a successor Agent for such successor Agent and the Lenders. If no successor Agent is appointed prior to the effective date of the resignation of Agent, Agent may appoint, after consulting with the Lenders, a successor Agent from among the Lenders. Upon the acceptance of its appointment as successor Agent hereunder, such successor Agent shall succeed to all the rights, powers and duties of the retiring Agent and the term “Agent” shall mean such successor Agent, and the retiring Agent’s appointment, powers and duties as Agent shall be terminated. After any retiring Agent’s resignation hereunder as Agent, the provisions of this Section 6.15 shall inure to its benefit as to any actions taken or omitted to be taken by it while it was Agent under this Agreement and the other Loan Documents. If no successor Agent has accepted appointment as Agent by the date which is 30 days following a retiring Agent’s notice of resignation, the retiring Agent’s resignation shall nevertheless thereupon become effective and the Lenders shall perform all of the duties of Agent hereunder until such time, if any, as the Lenders appoint a successor Agent as provided for above.

(i) Agent hereby appoints each other Lender and other Secured Party as its agent (and each Lender and other Secured Party hereby accepts such appointment) for the purpose of perfecting Agent’s Liens in assets which, in accordance with Article 8 or Article 9, as applicable, of the UCC can be perfected by possession or control. Should any Lender or other Secured Party obtain possession or control of any such Collateral, such Lender or other Secured Party shall notify Agent thereof, and, promptly upon Agent’s request therefor shall deliver possession or control of such Collateral to Agent or in accordance with Agent’s instructions.

Section  6.16 USA Patriot Act . Each Lender that is subject to the USA Patriot Act (and Agent (for itself and not on behalf of any Lender)) hereby notifies the Loan Parties that, pursuant to the requirements of the USA Patriot Act, it is required to obtain, verify and record information that identifies each Loan Party, which information includes the name, address and tax identification numbers of each Loan Party and other information that will allow such Lender or Agent to identify each Loan Party in accordance with the USA Patriot Act. In addition, if Agent or any other Secured Party is required by law or regulation or internal policies to do so, it shall have the right to periodically conduct (a) USA Patriot Act searches, OFAC/PEP searches, and customary individual background checks for the Loan Parties and (b) OFAC/PEP searches and customary individual background checks for the Loan Parties’ senior management and key principals, and the Loan Parties agree to cooperate in respect of the conduct of such searches and further agree that the reasonable costs and charges for such searches shall paid for, and reimbursed by, the Loan Parties and be for the account of the Loan Parties. This notice is given in accordance with the requirements of the USA Patriot Act and is effective for Agent and the Lenders.

 

106


Section  6.17 Placement Agent . The Borrower and the other Loan Parties shall be solely responsible for the payment of any fees, costs, expenses and commissions of any placement agent, broker or financial adviser relating to or arising out of the transactions contemplated by the Loan Documents. The Borrower and the other Loan Parties shall pay, and hold each of the Secured Parties harmless against, any liability, loss or expense (including attorneys’ fees, costs and expenses) arising in connection with any claim for any such payment.

Section  6.18 No Fiduciary Relationship . No Secured Party has any fiduciary relationship or duty to any Loan Party arising out of or in connection with, and there is no agency, tenancy or joint venture relationship between the Secured Parties and the Loan Parties by virtue of, any Loan Document or any transaction contemplated therein.

Section  6.19 Joint and Several . The obligations of the Loan Parties hereunder and under the other Loan Documents are joint and several. Without limiting the generality of the foregoing, reference is hereby made to Sections 2, 4 and 8.3 of the Security Agreement, to which the obligations of the Loan Parties are subject.

Section  6.20 No Third Parties Benefited . This Agreement is made and entered into for the sole protection and legal benefit of the Loan Parties and the Secured Parties party hereto (and the indemnitees mentioned herein), and their successors and permitted assigns, and no other Person shall be a direct or indirect legal beneficiary of, or have any direct or indirect cause of action or claim in connection with, this Agreement or any of the other Loan Documents. No Secured Party shall have any obligation to any Person not a party to this Agreement or the other Loan Documents.

Section  6.21 Binding Effect . This Agreement shall become effective when it shall have been executed by each of the Loan Parties party hereto, each Lender party hereto and Agent and such executed counterparts have been delivered to Agent pursuant to the terms of this Agreement. Thereafter, it shall be binding upon and inure to the benefit of, each Loan Party hereto and each Secured Party thereto and the indemnitees mentioned herein and, in each case, their respective successors and permitted assigns.

Section  6.22 Marshaling; Payments Set Aside . No Secured Party shall be under any obligation to marshal any property in favor of any Loan Party or any other Person or against or in payment of any Obligation. To the extent that any Secured Party receives a payment from the Borrower, from any other Loan Party, from the proceeds of the Collateral, from the exercise of its rights of setoff, any enforcement action or otherwise, and such payment is subsequently, in whole or in part, invalidated, declared to be fraudulent or preferential, set aside or required to be repaid to a trustee, receiver or any other party, then to the extent of such recovery, the Obligation or part thereof originally intended to be satisfied, and all Liens, rights and remedies therefor, shall be revived and continued in full force and effect as if such payment had not occurred.

Section  6.23 No Waiver; Cumulative Remedies . No failure to exercise and no delay in exercising, on the part of any Secured Party, any right, remedy, power or privilege under any Loan Document, shall operate as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege. No course of dealing between any Loan Party, any Affiliate of any Loan Party or any Secured Party shall be effective to amend, modify or discharge any provision of any of the Loan Documents.

Section  6.24 Right of Setoff . Each Secured Party and each of its Affiliates is hereby authorized, without notice or demand (each of which is hereby waived by each Loan Party), at any time and from time to time during the continuance of any Event of Default and to the fullest extent permitted by

 

107


Applicable Law, to set off and apply any and all deposits (whether general or special, time or demand, provisional or final) at any time held and other Indebtedness, claims or other obligations at any time owing by any Secured Party or any of its Affiliates to or for the credit or the account of the Borrower or any other Loan Party against any Obligation of any Loan Party now or hereafter existing, whether or not any demand was made under any Loan Document with respect to such Obligation and even though such Obligation may be unmatured. No Lender shall exercise any such right of setoff without the prior consent of Agent. Each Secured Party agrees promptly to notify Agent after any such setoff and application made by such Secured Party or its Affiliates. The rights under this Section 6.24 are in addition to any other rights and remedies (including other rights of setoff) that any Secured Party or any of its Affiliates may have.

Section  6.25 Independent Nature of Secured Parties . The obligations of each Secured Party under the Loan Documents are several and not joint with the obligations of any other Secured Party, and no Secured Party shall be responsible in any way for the performance of the obligations of any other Secured Party under the Loan Documents. Each Secured Party shall be responsible only for its own representations, warranties, agreements and covenants under the Loan Documents. The decision of each Lender to acquire the Securities pursuant to the Loan Documents has been made by such Lender independently of any other Lender and independently of any information, materials, statements or opinions as to the business, affairs, operations, assets, properties, liabilities, results of operations, condition (financial or otherwise) or prospects of the Borrower or any of its Subsidiaries which may have been made or given by any other Secured Party or by any agent, attorney, advisor, representative or employee of any other Secured Party, and no Secured Party or any of its agents, attorneys, advisors, representatives or employees shall have any liability to any other Secured Party (or any other Person) relating to or arising from any such information, materials, statements or opinions. Nothing contained in the Loan Documents, and no action taken by any Secured Party pursuant hereto or thereto (including a Lender’s acquisition of Obligations, Notes or Warrants at the same time as any other Secured Party), shall be deemed to constitute the Secured Parties as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Secured Parties are in any way acting in concert or as a group with respect to such Obligations or the transactions contemplated by any of the Loan Documents. Each Secured Party shall be entitled to independently protect and enforce its rights, including the rights arising out of the Loan Documents, and it shall not be necessary for any other Secured Party to be joined as an additional party in any proceeding for such purpose.

Section  6.26 Sharing of Payments, Etc. If any Lender, directly or through any of its Affiliates, obtains any payment of any Obligation of any Loan Party (whether voluntary, involuntary or through the exercise of any right of setoff or the receipt of any Collateral or “proceeds” (as defined under the applicable UCC) of Collateral) (and other than pursuant to Section 6.5) and such payment exceeds the amount such Lender would have been entitled to receive if all payments had gone to, and been distributed in accordance with the provisions of the Loan Documents, such Lender shall purchase for cash from other Lenders such participations in their Obligations as necessary for such Lender to share such excess payment with such Lenders to ensure such payment is applied as though it had been applied in accordance with this Agreement; provided , however , that (i) if such payment is rescinded or otherwise recovered from such Lender in whole or in part, such purchase shall be rescinded and the purchase price therefor shall be returned to such Lender without interest and (ii) such Lender shall, to the fullest extent permitted by Applicable Law, be able to exercise all its rights of payment (including the right of setoff) with respect to such participation as fully as if such Lender were the direct creditor of the applicable Loan Party in the amount of such participation.

Section  6.27 Confidentiality .

(a) Each of the Agent and the Lenders agrees to maintain the confidentiality of the Information (as defined below), except that Information may be disclosed (i) to its Affiliates and to its

 

108


Related Parties (it being understood that the Persons to whom such disclosure is made will be informed of the confidential nature of such Information and instructed to keep such Information confidential), (ii) to the extent required or requested by any regulatory authority purporting to have jurisdiction over such Person or its Related Parties (including any self-regulatory authority), (iii) to the extent required by Applicable Laws or regulations or by any subpoena or similar legal process, (iv) to any Secured Party or any other party hereto, (v) in connection with the exercise of any remedies hereunder or under any other Loan Document or any action or proceeding relating to this Agreement or any other Loan Document or the enforcement of rights hereunder or thereunder, (vi) subject to an agreement containing provisions substantially the same as those of this Section, to (A) any assignee of or Participant in, or any prospective assignee of or Participant in, any of its rights and obligations under this Agreement or the other Loan Documents or (B) any actual or prospective party (or its Related Parties) to any transaction under which payments are to be made by reference to the Loan Parties and their obligations, this Agreement, the other Loan Documents or payments hereunder or thereunder, (vii) on a confidential basis to (A) any rating agency in connection with rating any Loan Party or its Subsidiaries or the credit facilities provided hereunder or (B) the CUSIP Service Bureau or any similar agency in connection with the issuance and monitoring of CUSIP numbers or other market identifiers with respect to the credit facilities provided hereunder, (viii) with the consent of any Loan Party or any of its Affiliates, (ix) to the extent such Information (A) becomes publicly available other than as a result of a breach of this Section 6.27(a) or (B) becomes available to any Secured Party or any of its Affiliates on a nonconfidential basis from a source other than the Borrower, or (x) as provided in Section 5.1(q). In addition, the Secured Parties may disclose the existence of this Agreement and information about this Agreement to market data collectors, similar service providers to the lending industry and service providers to the Secured Parties in connection with the administration of the Loans and this Agreement and the other Loan Documents.

(b) For purposes of this Section, “Information” means all information received from a Loan Party relating to the Loan Parties or any Subsidiary or any of their respective businesses, other than any such information that is available to Agent or any Lender on a nonconfidential basis prior to disclosure by such Loan Party or any Subsidiary; provided that, notwithstanding anything to the contrary in the Loan Documents, in the case of information received from the Borrower or any of its Subsidiaries after the Prior Agreement Date, such Information is both (y) clearly identified at the time of delivery as confidential and (z) provided to the Secured Parties at a time when the Secured Parties have requested in writing to receive material nonpublic information. Any Person required to maintain the confidentiality of Information as provided in this Section 6.27 shall be considered to have complied with its obligation to do so if such Person has exercised the same degree of care to maintain the confidentiality of such Information as such Person would accord to its own confidential information.

(c) The Loan Parties and their Affiliates agree that they will not issue any press release announcing the transactions contemplated hereby without the prior written consent of the Agent, unless (and only to the extent that) the Loan Parties or such Affiliate is required to do so under Applicable Law and, in any event the Loan Parties and their Affiliates will provide the Agent with a copy of, and consult with the Agent before issuing, any such press release or other public disclosure with respect to this Agreement or the other Loan Documents or the transactions contemplated hereby or thereby and will consider in good faith any comments of the Agent.

Section  6.28 Intercreditor Agreement .

(a) Notwithstanding anything to the contrary in this Agreement or in any other Loan Document: (i) the Liens granted to the Agent in favor of the Secured Parties pursuant to the Loan Documents and the exercise of any right related to any Collateral shall be subject, in each case, to the terms of the Intercreditor Agreement, (ii) in the event of any conflict between the express terms and provisions of this Agreement or any other Loan Document, on the one hand, and of the Intercreditor Agreement, on the

 

109


other hand, the terms and provisions of the Intercreditor Agreement, shall control, (iii) any Collateral held by (or in the possession or control of) the ABL Agent (or its agents or bailees) shall be held as agent and bailee for security, Lien perfection and control purposes in favor of Agent (for the benefit of the Secured Parties) in accordance with the terms of the Intercreditor Agreement and the Loan Documents, and (iv) each Lender (and, by its acceptance of the benefits of any Loan Document, each other Secured Party) hereunder authorizes and instructs Agent to execute the Intercreditor Agreement on behalf of such Lender, and such Lender agrees to be bound by the terms thereof.

(b) Each Lender (and, by its acceptance of the benefits of any Loan Document, each other Secured Party) hereunder authorizes and instructs the Agent, as Agent and on behalf of such Lender or other Secured Party, to enter into one or more intercreditor agreements (including any Intercreditor Agreement) from time to time pursuant to, or as contemplated by, the terms of this Agreement and agrees that it will be bound by the terms and provisions thereof and will take no actions contrary to the terms and provisions thereof.

Section  6.29 Acknowledgment of Prior Obligations and Continuation Thereof. Each of the Loan Parties (a) consent to the amendment and restatement of the Prior Facility Agreement by this Agreement (and any other “Loan Documents” (as defined in the Prior Facility Agreement, the “ Prior Loan Documents ”) that are being amended and restated); (b) acknowledges and agrees that (i) there are “Obligations” (as defined in the Prior Facility Agreement) owing to the Secured Parties that will continue to be owed and owing to the Secured Parties as Obligations under this Agreement and the other Loan Documents, including the obligations under the Initial Warrants and the Registration Rights Agreement that existed immediately prior to the effectiveness of this Agreement, and (ii) the prior grant or grants of Liens or security interests in favor of any of the Agent or the other Secured Parties in such Loan Parties’ properties and assets, under each Prior Loan Document continue to exist and will continue to exist under the Loan Documents, and each Loan Document to which it is a party shall be in respect of the Obligations of each of the Loan Parties under this Agreement and the other Loan Documents; provided , however , that such security interests or Liens shall be as modified (if applicable) pursuant to the terms of the Loan Documents applicable thereto which are entered into on the Agreement Date, if any; (c) reaffirms (i) all of the Obligations (as defined in the Prior Facility Agreement) owing to the Secured Parties, and (ii) all prior or concurrent grants of Liens or security interests in favor of any of the Agent or the Secured Parties under each Prior Loan Document and each Loan Document; provided , however , that such Liens or security interests shall be as modified (if applicable) pursuant to the terms of the Loan Documents applicable thereto which are entered into on the Agreement Date, if any; and (d) agrees that, except as expressly amended hereby or unless being amended and restated concurrently herewith, each of the Prior Loan Documents to which it is a party is and shall remain in full force and effect. Each of the Loan Parties hereby confirms and agrees that all outstanding principal, interest and fees (including such accrued and unpaid principal, interest, and fees set forth in the immediately preceding sentence) and other “Obligations” (as defined in the Priority Facility Agreement) under the Prior Facility Agreement and the other Prior Loan Documents immediately prior to the Agreement Date shall, from and after the Agreement Date, be, without duplication, Obligations owing and payable pursuant to this Agreement and the other Loan Documents as in effect from time to time, shall accrue interest thereon as specified in this Agreement, and shall be secured by the Loan Documents. Although each of the Loan Parties has been informed of the matters set forth herein and has acknowledged and agreed to the same, it understands that no Secured Party shall have any obligation to inform it of such matters in the future or to seek its acknowledgement or agreement to future amendments, restatements, supplements or other modifications, and nothing herein shall create such a duty.

Section  6.30 No Novation . This Agreement does not extinguish the obligations for the payment of money outstanding under the Prior Facility Agreement or the other Prior Loan Documents or discharge or release the obligations or the Liens or priority of any pledge, security agreement or any other security therefor or any of the obligations under the Prior Loan Documents (including the Initial Warrants

 

110


and the Registration Rights Agreement). Nothing herein contained shall be construed as a substitution or novation of the obligations outstanding under the Prior Facility Agreement, the other Prior Loan Documents or agreements, instruments or documents securing the same, which shall remain in full force and effect, except as modified hereby or by agreements, instruments or documents executed concurrently herewith. Nothing expressed or implied in this Agreement shall be construed as a release or other discharge of any Loan Party from any of its obligations or liabilities under the Prior Facility Agreement and the other Prior Loan Documents or any of the security agreements, pledge agreements, guaranties or other loan documents executed in connection therewith. Each of Loan Parties hereby (a) confirms and agrees that each Prior Loan Document and each Initial Warrant to which it is a party that is not being amended and restated concurrently herewith is, and shall continue to be, in full force and effect and is hereby ratified and confirmed in all respects except that on and after the Agreement Date, all references in any such Prior Loan Document to (i) “the Facility Agreement,” “thereto,” “thereof,” “thereunder” or words of like import referring to the Prior Facility Agreement shall mean the Prior Facility Agreement as amended and restated by this Agreement or (ii) any other Prior Loan Document being amended and restated, “thereto,”, thereof,” thereunder,” or words of like import referring to such Prior Loan Document shall mean such Prior Loan Document as amended and restated by the corresponding Loan Document; and (b) confirms and agrees that to the extent that any such Prior Loan Document purports to assign or pledge to any of the Agent or the other Secured Parties or to grant to any of the Agent or the other Secured Parties a security interest in or Lien on, any collateral as security for the obligations of any Loan Party, as the case may be, from time to time existing in respect of the Prior Facility Agreement or the other Prior Loan Documents, such pledge or assignment or grant of the security interest or Lien is hereby ratified and confirmed in all respects with respect to this Agreement and the other Loan Documents.

Section  6.31 Survival of Any Existing Unmatured Events of Default and Events of Default . Notwithstanding anything to the contrary in this Agreement, the other Loan Documents (including the Warrants and the Registration Rights Agreement) or otherwise, except as expressly set forth otherwise in any Loan Document, (a) any “Default” and any “Event of Default” under the Prior Loan Documents, the Warrants or the Registration Rights Agreement (including any incorrect or inaccurate (or breach of a) representation, warranty or certification made under the Prior Facility Agreement, any other Prior Loan Document, any Warrant or the Registration Rights Agreement) arising on or prior to the Agreement Date shall continue to exist under this Agreement and the other Loan Documents and (b) such amendments, amendments and restatements, supplements and modifications made to the Prior Facility Agreement and the other Prior Loan Documents, any Warrant or the Registration Rights Agreement shall not be deemed to be a waiver, forbearance or other modification thereof. Any representation, warranty or certification made under the Prior Loan Documents, the Warrants and the Registration Rights Agreement that continued to be made after initially being made shall continue to be made under this Agreement, the Loan Documents, the Warrants and the Registration Rights Agreement, as amended (but, for the avoidance of doubt, without giving effect to any such amendment with respect to the making of such representation, warranty or certification prior to the date of such amendment), and any incorrectness, inaccurateness or breach of any such representation, warranty or certification shall be a breach or violation under this Agreement, the Loan Documents, the Warrants and the Registration Rights Agreement and subject to the rights and remedies provided hereunder and thereunder for any such breach or violation of a representation, warranty or certification.

[SIGNATURE PAGE FOLLOWS]

 

111


IN WITNESS WHEREOF, the Parties have caused this Agreement to be duly executed as of the first day written above.

 

BORROWER:

ENDOLOGIX, INC.,

a Delaware corporation

By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer
OTHER LOAN PARTIES:

CVD/RMS ACQUISITION CORP.,

a Delaware corporation

By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer and Secretary

NELLIX, INC.,

a Delaware corporation

By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer and Secretary

TRIVASCULAR TECHNOLOGIES, INC.,

a Delaware corporation

By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer and Secretary

TRIVASCULAR, INC.,

a California corporation

By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer and Secretary

[Signature Page to Amended and Restated Facility Agreement]


ENDOLOGIX CANADA, LLC ,

a Delaware limited liability company

By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer and Secretary

TRIVASCULAR SALES LLC ,

a Texas limited liability company

By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer and Secretary

RMS/ENDOLOGIX SIDEWAYS MERGER CORP. ,

a Delaware corporation

By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer and Secretary

[Signature Page to Amended and Restated Facility Agreement]


LENDERS:
DEERFIELD PRIVATE DESIGN FUND III, L.P.
By: Deerfield Mgmt III, L.P., General Partner
By: J.E. Flynn Capital III, LLC, General Partner
By:  

/s/ David J. Clark

Name:   David J. Clark
Title:   Authorized Signatory
DEERFIELD PARTNERS, L.P.
By: Deerfield Mgmt, L.P., General Partner
By: J.E. Flynn Capital, LLC, General Partner
By:  

/s/ David J. Clark

Name:   David J. Clark
Title:   Authorized Signatory
DEERFIELD PRIVATE DESIGN FUND IV, L.P.
By: Deerfield Mgmt IV, L.P., General Partner
By: J.E. Flynn Capital IV, LLC, General Partner
By:  

/s/ David J. Clark

Name:   David J. Clark
Title:   Authorized Signatory

[Signature Page to Amended and Restated Facility Agreement]


AGENT:
DEERFIELD PRIVATE DESIGN FUND IV, L.P.
By: Deerfield Mgmt IV, L.P., General Partner
By: J.E. Flynn Capital IV, LLC, General Partner
By:  

/s/ David J. Clark

Name:   David J. Clark
Title:   Authorized Signatory

[Signature Page to Amended and Restated Facility Agreement]


ANNEX A

DISBURSEMENT AMOUNTS AND WARRANTS

 

Lender

   First Out
Waterfall Loan
     Last Out
Waterfall Loan
     Total
Disbursement
Amount
     Fraction
of Total
Initial
Warrants
    Fraction of Total
Additional
Warrants
 

Deerfield Private Design Fund III, L.P.

   $ 40,000,000      $ 0      $ 40,000,000        1/3       1/3  

Deerfield Private Design Fund IV, L.P.

   $ 40,000,000      $ 0      $ 40,000,000        1/3       1/3  

Deerfield Partners, L.P.

   $ 40,000,000      $ 40,500,000      $ 80,500,000        1/3       1/3  
  

 

 

    

 

 

    

 

 

    

 

 

   

 

 

 

Total

   $ 120,000,000      $ 40,500,000      $ 160,500,000        100     100
  

 

 

    

 

 

    

 

 

    

 

 

   

 

 

 


Exhibit 2.6

Share Payment Provisions

If the Borrower elects, in lieu of paying in cash any interest due and payable under Section 2.6 of the Amended and Restated Facility Agreement to which this Exhibit is attached (the “ Agreement ”), to satisfy any such amounts due through the issuance of Freely Tradeable Shares (as defined below), pursuant to Section 2.6 of the Agreement, the following terms shall apply:

1. Defined Terms . Capitalized terms used in this Exhibit 2.6 and not otherwise defined herein shall have the meanings set forth in the Agreement. For purposes of this Exhibit, the following terms shall have the following meanings:

Bloomberg ” means Bloomberg Financial Markets or an equivalent, reliable reporting service mutually acceptable to and designated by the Borrower and the Required Lenders.

Credit Amount ” has the meaning set forth in Section  4 of this Exhibit.

Delisting Event ” means any of the following: (i) the Common Stock is not listed on a Principal Market, (ii) trading in the Common Stock on the Principal Market is suspended, or (iii) the Borrower is not in compliance with any material rule or regulation applicable to the trading or listing of the Common Stock on the Principal Market.

Failure Amount ” has the meaning set forth in Section  8 of this Exhibit.

Freely Tradeable Shares ” means any shares of Common Stock which, at the time of issuance thereof, (i) are duly authorized, validly issued, fully paid and non-assessable; (ii) are eligible for resale by the Lenders, without limitation or restriction (including any volume limitation or current public information requirement) under state or Federal securities laws, pursuant to Rule 144 under the Securities Act; and (iii) do not bear, and are not subject to, any restrictive legend, stop transfer or similar restriction.

Interest Payment Shares ” means a number of shares of Common Stock equal to the applicable Share Issuance Amount divided by the Interest Payment Share Price.

Interest Payment Share Price ” means, as of any Interest Payment Date, ninety-six percent (96%) of the lesser of: (i) the Last Bid Price prior to such Interest Payment Date and (ii) the arithmetic average of the Volume Weighted Average Price per share of Common Stock on each of the ten (10) consecutive Trading Days immediately preceding the Interest Payment Date (the “ Measurement Period ”); provided, that in the event that a Stock Event is consummated during the Measurement Period, the Volume Weighted Average Price for all Trading Days during the Measurement Period prior to the effectiveness of such Stock Event shall be appropriately adjusted to reflect such Stock Event.

Last Bid Price ” means, with respect to any security as of any time of determination, the last bid price on the Principal Market as reported by, or based upon data reported by, Bloomberg Financial Markets or an equivalent, reliable reporting service mutually acceptable to and designated by the Borrower and the Lenders (“Bloomberg”).

Major Transaction ” shall have the meaning given to such term in the Warrants.

Major Transaction Notice ” shall have the meaning given to such term in the Warrants.

Market Capitalization ” means, as of any date of determination, the product of (i) the number of


issued and outstanding shares of Common Stock as of such date (exclusive of any shares of Common Stock issuable directly or indirectly upon exercise of the Warrants or any other Options or conversion of the Notes or any other Convertible Securities), multiplied by (ii) the closing price per share of Common Stock as of the preceding Trading Day on the Principal Market, as reported by, or based upon data reported by, Bloomberg.

Share Delivery Failure ” has the meaning set forth in Section  8 of this Exhibit.

Share Issuance Amount ” has the meaning set forth in Section  3 of this Exhibit.

Share Issuance Limit ” means 2,526,800 shares of Common Stock, subject to appropriate adjustment for any Stock Events occurring after August 9, 2018, and a “ Lender’s Share Issuance Limit ” means such Lender’s First Out Waterfall Pro Rata Share of the Share Issuance Limit.

Share Issuance Notice ” has the meaning set forth in Section  3 of this Exhibit.

Stock Event ” shall have the meaning given to such term in the Notes.

Trading Day ” means any day on which the Common Stock is traded for at least six hours on the Principal Market.

Volume Weighted Average Price ” means, for the Common Stock as of any Trading Day, the volume weighted average sale price of the Common Stock on the Principal Market as reported by Bloomberg. Volume Weighted Average Price will be determine without regard to after-hours trading or any other trading outside of the regular trading hours.

Withholding Date ” means the first date on which the Borrower withholds or determines that it is required to withhold any Taxes as a result of the provisions of this Exhibit or the issuance of any shares of Common Stock, or consummation of any transactions, as contemplated hereby.

2. General . Subject to the terms and conditions of this Exhibit, the Borrower’s valid exercise of its share issuance rights under this Exhibit and subsequent fulfillment of its obligations hereunder (including delivery of all of the requisite Daily Issuance Shares and payment of the Share Issuance Amount, if any) shall be deemed to satisfy its obligation to pay interest on the applicable Interest Payment Date for which such share issuance right is being exercised.

3. Exercise of Share Issuance Rights . On any date that is not more than fifteen (15) and not less than ten (10) Trading Days prior to any Interest Payment Date, the Borrower may deliver to each of the Lenders notice by electronic mail or facsimile (a “ Share Issuance Notice ”) of its intention to issue Freely Tradeable Shares pursuant to the provisions of this Exhibit in order to satisfy interest due on such Interest Payment Date under Section 2.6 of the Agreement by delivering such Freely Tradeable Shares to the Lenders; provided , however , that the Borrower may not deliver a Share Issuance Notice (a) during the occurrence of a Delisting Event, (b) at any time following such time as the Borrower has delivered (or is obligated to deliver) a Major Transaction Notice in respect of a Major Transaction, (c) at any time following the occurrence, and during the continuance, of an Event of Default or a Default, (d) from and after a Withholding Date, (e) if, as of the close of trading on the immediately preceding Trading Day, the Market Capitalization is less than $200,000,000, (f) if the aggregate number of shares of Common Stock issued pursuant to prior Share Issuance Notices has equaled the Share Issuance Limit, (g) unless all material information regarding the Borrower (including any material information that


may be included in, or reflected by, the Share Issuance Notice, but excluding any material information relating to the Borrower’s operating results for the fiscal quarter in which the Share Issuance Notice is delivered other than operating results that would trigger non-compliance with a covenant hereunder or in the ABL Credit Facility) has been publicly disclosed in a report filed pursuant to the Exchange Act or has been otherwise publicly disclosed in a manner calculated to reach the securities marketplace through one of the Borrower’s recognized channels of distribution, (h) unless all shares of Common Stock issuable pursuant to such Share Issuance Notice are eligible for resale by the Lenders without limitation or restriction, including any volume limitations, under state or Federal securities laws pursuant to Rule 144 under the Securities Act, (i) unless the Borrower is in compliance with the “current public information” requirement of Rule 144(c) under the Securities Act, (j) if the transfer agent for the Common Stock is not participating in DTC’s Fast Automated Securities Transfer Program, (k) if any Lender, after consultation with counsel of its choosing, advises the Borrower that the receipt or resale of Common Stock issued or issuable hereunder would result in such Lender being deemed an “underwriter” within the meaning of Section 2(11) under the Securities Act or (1) if the arithmetic average of the Volume Weighted Average Prices on each of the ten (10) consecutive Trading Days immediately preceding such date is less than $2.00 (collectively, the “ Share Issuance Conditions ”). Subject to such provisions, a Share Issuance Notice shall be irrevocable, shall specify the aggregate amount of interest subject to such Share Issuance Notice, in each case, broken out by the amount due each Lender (such amount, a “ Share Issuance Amount ”). If the Lenders do not confirm receipt of the Share Issuance Notice within three (3) Trading Days of the delivery thereof, the Borrower shall thereafter use its reasonable best efforts to confirm (by email, telephonically or otherwise) such receipt, and in no event shall the Issuance Period commence unless and until the Lenders have confirmed such receipt. For the avoidance of doubt, the Borrower may exercise its right under this Exhibit 2.6, and may deliver a Share Issuance Notice, only one time with respect to the interest due and payable on any Interest Payment Date.

4. Share Issuance . On the applicable Interest Payment Date, by no later than 9:00 a.m., New York City time, the Borrower shall deliver to each Lender its First Out Waterfall Pro Rata Share of the applicable Interest Payment Shares by causing the transfer agent for the Common Stock to electronically transmit such Interest Payment Shares to such Lender by crediting to the account of such Lender’s prime broker (as specified by such Lender no later than one Trading Day prior to the Interest Payment Date) with DTC through its Deposit/Withdrawal at Custodian (DWAC) system its First Out Waterfall Pro Rata Share of such Interest Payment Shares determined pursuant to Section  6 of this Exhibit. Concurrently with the valid delivery of the related Interest Payment Shares on the Interest Payment Date, an amount (the “ Credit Amount ”) of interest payable on such Interest Payment Date equal to the product of (x) the number of Interest Payment Shares issued and delivered to a Lender on such date multiplied by (y) the applicable Interest Payment Share Price, shall be deemed to have been satisfied.

All shares of Common Stock issued and delivered pursuant to this Section  4 shall be Freely Tradeable Shares (and for the avoidance of doubt, only Freely Tradeable Shares shall be deemed to constitute Interest Payment Shares and be applied to any Credit Amount). In connection with the issuance and delivery of any shares of Common Stock to the Lenders pursuant to this Section  4 , the Borrower shall deliver to the Lenders, by no later than the last Business Day prior to the Interest Payment Date for which a Share Issuance Notice has been delivered, an opinion of counsel reasonably satisfactory to the Lenders, substantially in the form attached as Annex 1 to this Exhibit, relating to all shares of Common Stock to be issued and delivered to the Lenders (as Freely Tradeable Shares) on the Interest Payment Date. For purposes of determining whether any shares of Common Stock are Freely Tradeable Shares, each Lender represents (and counsel is entitled to rely on the representation for purposes of issuing the opinion contemplated above), unless it


notifies Borrower otherwise at least five (5) days prior to the applicable Interest Payment Date, that it will not be an Affiliate of the Borrower on the Interest Payment Date and will not have been an Affiliate of the Borrower within the three-month period immediately preceding the Interest Payment Date.

5. Limitations on Share Issuances . Notwithstanding anything herein to the contrary, the Borrower shall not issue to any Lender, and no Lender may acquire, a number of shares of Common Stock hereunder to the extent that, upon such issuance, the number of shares of Common Stock then beneficially owned by such Lender and its Affiliates and any other persons or entities whose beneficial ownership of Common Stock would be aggregated with such Lender’s for purposes of Section 13(d) of the Exchange Act (including shares held by any “group” of which the Lender is a member, but excluding shares beneficially owned by virtue of the ownership of securities or rights to acquire securities (including the Warrants) that have limitations on the right to convert, exercise or acquire similar to the limitation set forth herein), would exceed 4.985% of the total number of shares of Common Stock then issued and outstanding (the “ 4.985% Cap ”). For purposes hereof, “group” has the meaning set forth in Section 13(d) of the Exchange Act and applicable regulations of the SEC, and the percentage held by each Lender shall be determined in a manner consistent with the provisions of Section 13(d) of the Exchange Act. All Share Issuance Notices shall set forth the number of shares of Common Stock then outstanding. Upon written request of any Lender at any time, the Borrower shall, within one (1) Business Day, confirm orally and in writing to such Lender the number of shares of Common Stock then outstanding. At any time following delivery of a Share Issuance Notice and ending on the last Trading Day prior to the applicable Interest Payment Date, each Lender shall have the right to deliver notice to the Borrower (a “ Cap Notice ”) stating the maximum number of shares of Common Stock that may be issued to such Lender without exceeding the maximum number of shares that such Lender may receive under the 4.985% Cap (the “ Maximum Share Amount ”), which shall be conclusive and binding upon the Borrower and such Lender. In no event shall (a) the number of shares issued to a Lender pursuant to any Share Issuance Notice exceed the Maximum Share Amount specified in such Lender’s Cap Notice; or (b) the aggregate number of shares issued to a Lender pursuant to any Share Issuance Notice, together with the shares previously issued to such Lender pursuant to Share Issuance Notices, exceed such Lender’s Share Issuance Limit. For the avoidance of doubt, the Borrower shall not be entitled, or permitted, to issue an aggregate number of shares of Common Stock pursuant to this Exhibit 2.6 in excess of the Share Issuance Limit.

6. Allocation Among Lenders . Subject to Section  5 of this Exhibit, all shares of Common Stock issuable to the Lenders pursuant to this Exhibit, all Credit Amounts and all Failure Amounts shall be allocated pro rata among the Lenders based on each Lender’s First Out Waterfall Pro Rata Share, in each case unless the Lenders notify the Borrower in writing of any different allocation ratio.

7. Termination of Right to Issue Shares . If any of the Share Issuance Conditions is not satisfied at any time following the delivery of a Share Issuance Notice and prior to the Interest Payment Date to which the Share Issuance Notice relates, the Borrower shall immediately notify each of the Lenders of such failure and the Borrower shall not be permitted to issue shares of common Stock in lieu of the cash interest owed on the such Interest Payment Date.

8. Failure to Deliver Share Issuance Shares . If the Borrower fails on any Interest Payment Date to cause the delivery of the Interest Payment Shares required to be delivered on that date, and such failure is not cured within one (1) Trading Day following such Interest Payment Date (a “ Share Delivery Failure ”), the Share Issuance Amount in respect to such Interest Payment Date shall not be reduced in respect of such Interest Payment Shares until such shares are


actually issued and delivered, and in addition to all other rights and remedies of the Lenders and the Lenders under this Exhibit, the Agreement and the other Loan Documents, (a) the Borrower shall promptly pay to each of the Lenders, for each day that such Share Delivery Failure occurs or continues, an amount equal to five percent (5%) of the amount that would have constituted such Lender’s Credit Amount on such day had such failure not occurred (the “ Failure Amount ”); and (b) if any Lender is required by its broker to purchase (in an open market transaction or otherwise) or any Lender or such Lender’s brokerage firm otherwise purchases shares of Common Stock to deliver in satisfaction of a sale by such Lender of the Interest Payment Shares which such Lender was entitled to receive on such Interest Payment Date, then the Borrower shall (1) pay in cash to such Lender the amount by which (X) such Lender’s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (Y) the amount obtained by multiplying (I) the number of Interest Payment Shares that the Borrower was required to deliver to such Lender on such Interest Payment Date, times (II) the price at which the sell order giving rise to such purchase obligation was executed.

9. Borrower Reporting . The Borrower shall file with the SEC a Current Report on Form 8-K disclosing its delivery of a Share Issuance Notice, no later than 8:35 a.m., New York City time, on the Trading Day immediately following the date of the Share Issuance Notice.


Annex 1 to Exhibit 2.6—Payment Share Provisions

[Date]

[Transfer Agent Name and Address]

Attention: [                ]

Re:    Endologix, Inc. (the “ Borrower ”)

Ladies and Gentlemen:

Pursuant to Section 3 of Exhibit 2.6 (the “ Exhibit ”) of that certain Amended and Restated Facility Agreement (the “ Facility Agreement ”), dated as of August 9, 2018, between the Borrower and the Lenders party thereto from time to time (each an “ Lender ” and collectively, the “ Lenders ”), the Borrower has delivered to the Lenders a Share Issuance Notice (as defined in the Exhibit), dated as of [                ,             ], pursuant to which the Borrower has elected to satisfy certain payment obligations under the Facility Agreement by issuing shares of Common Stock to the Lenders. Capitalized terms used but not defined herein shall have the meanings set forth in the Facility Agreement or the Exhibit, as applicable.

We are counsel for the Borrower and have been requested to furnish to you an opinion with respect to all of the shares of Common Stock of the Borrower that will be issued to the Lenders in connection the abovementioned Share Issuance Notice (the “ Shares ”).

As a basis for this opinion, we have received and reviewed (1) the Facility Agreement, including the Exhibit, (2) the Share Issuance Notice, (3) an officer’s certificate from the Borrower and (4) such other documents as we have deemed relevant or necessary.    

On the basis of the foregoing and assuming the accuracy of the aforementioned representations of each Lender, it is our opinion that the Shares may be resold by each Lender without restriction under the Securities Act of 1933, as amended, and, accordingly, the Shares may be issued without any restrictive legend to each Lender or its designee in accordance with each such Lender’s instructions with respect to Shares delivered to such Lender.

Any questions concerning the foregoing opinion should be communicated to [                                ] of this firm.

Very truly yours,

[_____________________________]

_____________________________

[__________________],[_______________]

cc:     [Lenders]


EXHIBIT A-1

FORM OF FIRST OUT WATERFALL NOTE

THE SECURITIES REPRESENTED BY THIS NOTE (AS DEFINED BELOW) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS OR (B) AN OPINION OF COUNSEL, IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR APPLICABLE STATE SECURITIES LAWS OR (II) UNLESS SOLD PURSUANT TO RULE 144 UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN, FINANCING OR INDEBTEDNESS ARRANGEMENT SECURED BY THE SECURITIES.

THE FOLLOWING INFORMATION IS PROVIDED PURSUANT TO TREAS. REG. SECTION 1.1275-3: THE BORROWER (AS DEFINED BELOW) WILL MAKE AVAILABLE ON REQUEST TO HOLDER(S) OF THIS NOTE THE FOLLOWING INFORMATION: ISSUE PRICE, AMOUNT OF ORIGINAL ISSUE DISCOUNT, ISSUE DATE AND YIELD TO MATURITY. THIS NOTE IS BEING AMENDED AND RESTATED AS PART OF AND PURSUANT TO A PLAN OF RECAPITALIZATION AND REORGANIZATION OF THE BORROWER DESCRIBED IN SECTION 368(A)(1)(E) OF THE INTERNAL REVENUE CODE OF 1986, AS AMENDED.

FIRST OUT WATERFALL NOTE

 

First Out Waterfall Lender: _____________________    Original Issue Date: April 3, 2017
Principal Amount: $[__________]    [Re-Issuance Date: January 1, 2018] 1
   Amendment and Restatement Date: August 9, 2018

FOR VALUE RECEIVED, the undersigned, Endologix, Inc., a Delaware corporation (the “ Borrower ”), hereby unconditionally promises to pay to the First Out Waterfall Lender set forth above (the “ Lender ”) the “Principal Amount” set forth above, or, if less, the aggregate unpaid Principal (as defined below) amount of the First Out Waterfall Loan (as defined in the Facility Agreement referred to below) of the Lender to the Borrower, payable at such times and in such amounts as are specified in the Facility Agreement.

The Borrower promises to pay interest on the outstanding Principal amount of the First Out Waterfall Loan and any overdue interest from and after the Amendment and Restatement Date (as defined below) until such outstanding Principal amount of the First Out Waterfall Loan and any overdue interest are paid in full, payable at such times and at such interest rates as are specified in the Facility Agreement. The Borrower promises to pay any Non-Callable Make Whole Amount, any CoC Fee and the First Out Waterfall Exit Payment (each, as defined in the Facility Agreement) that is due on the First Out Waterfall Loan in accordance with the Facility Agreement.

 

1  

NTD: Only to be included for the note that was re-issued on January 1, 2018 in connection with its transfer to Deerfield Partners.

 

EX. A - 1


In lieu of making any payment of interest in cash (but not (i) interest payable pursuant to the second sentence of Section 2.6(a) of Facility Agreement, (ii) interest payable-in-kind or (iii) in connection with any Event of Default or late payment hereunder or any other interest payable pursuant to Section 2.7 of the Facility Agreement) and subject to the conditions set forth in Section 2.6 of the Facility Agreement and Exhibit 2.6 to the Facility Agreement, the Borrower may elect to satisfy all or any such payment by the issuance to the Lender of shares of Freely Tradable Common Shares (as defined in Exhibit 2.6) in accordance with the provisions of Exhibit 2.6.

This First Out Waterfall Note (this “ Note ”) was originally issued on April 3, 2017 [, reissued on January  1, 2018] , 2 and amended and restated on August 9, 2018 (the “ Amendment and Restatement Date ”) and is one of the “First Out Waterfall Notes”, “Loan Notes” and “Notes” referred to in, and is entitled to the benefits of, the Amended and Restated Facility Agreement, dated as of August 9, 2018 (as the same may be amended, restated, supplemented or otherwise modified from time to time, the “ Facility Agreement ”), by and among the Borrower, the other Loan Parties party thereto, the Lenders party thereto and Deerfield Private Design Fund IV, L.P., as agent for the Secured Parties, and the other Loan Documents.

The Facility Agreement, among other things, (a) provides for the making of a First Out Waterfall Loan by the Lender to the Borrower in an aggregate amount not to exceed at any time outstanding the “Principal Amount” set forth above, the indebtedness of the Borrower resulting from such First Out Waterfall Loan being evidenced by this Note and (b) contains provisions for acceleration of the maturity of the unpaid Principal amount of this Note upon the happening of certain stated events and also for prepayments pursuant to Section 2.3(c) or Section 5.3 of the Facility Agreement on account of the Principal hereof prior to the maturity hereof upon the terms and conditions specified therein.

1. Definitions .

(a) Certain Defined Terms . Capitalized terms used herein without definition are used as defined in the Facility Agreement. For purposes of this Note, the following terms shall have the following meanings:

(i) “ Affiliate ” means any person or entity that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a person or entity, as such terms are used in and construed under Rule 144 under the Securities Act. With respect to a Lender, any investment fund or managed account that is managed on a discretionary basis by the same investment manager as such Lender will be deemed to be an Affiliate of such Lender. As used in this definition of “Affiliate,” the term “control” means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through ownership of voting securities or partnership or other ownership interest, by contract, or otherwise.

(ii) “ Common Stock ” means the fully paid and nonassessable shares of the Borrower’s common stock, $0.001 par value per share.

(iii) “ Conversion Amount ” means the Principal amount to be converted.

(iv) “ Conversion Date ” means the date of delivery via facsimile or electronic mail of a Conversion Notice.

 

 

2  

NTD: Only to be included for the note that was re-issued on January 1, 2018 in connection with its transfer to Deerfield Partners.

 

EX. A - 2


(v) “ Conversion Issuance Limit ” means [            ] 3 shares of Common Stock, subject to appropriate adjustment for any Stock Event that occurs after the Amendment and Restatement Date.

(vi) “ Conversion Price ” means, as of any Conversion Date, ninety-six percent (96%) of the arithmetic average of the Volume Weighted Average Prices per share of Common Stock on each of the three (3) Trading Days period preceding the Conversion Date (the “ Measurement Period ”); provided, that in the event that a stock split, stock combination, reclassification, payment of stock dividend, recapitalization or other similar transaction of such character that the shares of Common Stock shall be changed into or become exchangeable for a larger or small number of shares (a “ Stock Event ”) is consummated during the Measurement Period, the Volume Weighted Average Price for all Trading Days during the Measurement Period prior to the effectiveness of such Stock Event shall be appropriately adjusted to reflect such Stock Event, subject to appropriate adjustment for any Stock Event that occurs after the Amendment and Restatement Date.

(vii) “ Conversion Shares ” means fully paid and nonassessable shares of Common Stock issued in connection with the conversion of a Note.

(viii) “ First Amortization Cap ” means [            ] 4 shares of Common Stock, subject to appropriate adjustment for any Stock Event that occurs after the Amendment and Restatement Date.

(ix) “ First Amortization Date ” means April 2, 2021.

(x) “ Market Disruption Event ” means, with respect to any Trading Day and any security of Borrower, (a) a failure by the Principal Market to open for trading during its entire regular trading session, (b) the occurrence or existence prior to 1:00 p.m., New York City time, on such day for such securities of Borrower for more than one half-hour period in the aggregate during regular trading hours of any suspension or limitation imposed on trading (by reason of movements in price exceeding limits permitted by the relevant securities exchange or otherwise) in such securities or in any options, contracts or future contracts relating to such securities, or (c) to the extent “Volume Weighted Average Price” is determined in accordance with clause (b) of the definition thereof, the suspension of trading for the one-half hour period ending on the scheduled close of trading on such day (by reason of movements in price exceeding limits permitted by the stock exchange or otherwise) in such securities of Borrower.

(xi) “ Monthly Conversion Cap ” means [            ] 5 shares of Common Stock, subject to appropriate adjustment for any Stock Event that occurs after the Amendment and Restatement Date.

(xii) “ Monthly Conversion Cap Period ” means the period commencing on the Amendment and Restatement Date and ending on (and including) August 31, 2018, and each calendar month that begins after the Amendment and Restatement Date and prior to the Maturity Date.

(xiii) “ Principal ” means the outstanding principal amount of this Note as of any date of determination.

 

 

3  

To be equal to Lender’s First Out Waterfall Pro Rata Share of 14,300,000 shares.

4  

To be equal to Lender’s First Out Waterfall Pro Rata Share of 9,500,000 shares.

5  

To be equal to Lender’s First Out Waterfall Pro Rata Share of 5,200,000 shares.

 

EX. A - 3


(xiv) “ Required Lenders ” means the Required First Out Waterfall Lenders.

(xv) “ Second Amortization Cap ” means [            ] 6 shares of Common Stock, subject to appropriate adjustment for any Stock Event that occurs after the Amendment and Restatement Date.

(xvi) “ Second Amortization Date ” means April 2, 2022.

(xvii) “ Trading Day ” means any day on which the Common Stock is traded for any period on the Principal Market; provided, that for purposes of the definition of “Conversion Shares,” Trading Day shall not include any Trading Day on which there is a Market Disruption Event.

(xviii) “ Volume Weighted Average Pric e ” for any security as of any Trading Day means (a) the volume weighted average sale price of such security on the principal U.S. national or regional securities exchange on which such security is traded as reported by Bloomberg Financial Markets or an equivalent, reliable reporting service mutually acceptable to and hereinafter designated by the Required Lenders and the Borrower (“ Bloomberg ”), or (b) if no volume weighted average sale price is reported for such security, then the closing price per share of such security, or, if no closing price per share is reported for such security by Bloomberg, the average of the last bid and last ask price (or if more than one in either case, the average of the average last bid and average last ask prices) on such Trading Day as reported in the composite transactions for the principal U.S. national or regional securities exchange on which such security is traded. If the security is not listed for trading on a U.S. national or regional securities exchange on the relevant Trading Day, then the Volume Weighted Average Price will be the average of the mid-point of the last bid and last ask prices of the security in the over-the-counter market on the relevant Trading Day as reported by OTC Markets Group or similar organization. If the Volume Weighted Average Price cannot be calculated for such security on such date in the manner provided above, the Volume Weighted Average Price shall be the fair market value as mutually determined by the Borrower and the Lenders holding a majority of the aggregate outstanding Principal amount of the Notes being converted for which the calculation of the Volume Weighted Average Price is required in order to determine the Conversion Price of such Notes. Volume Weighted Average Price will be determine without regard to after-hours trading or any other trading outside of the regular trading hours.

2. Conversion Rights . This Note may be converted into shares of Common Stock on the terms and conditions set forth in this Section  2 (subject to Section 2.3(a) of the Facility Agreement).

(a) Conversion at Option of the Lender . At any time during the period commencing on (and including) the Amendment and Restatement Date and ending on the close of business on the second business day immediately prior to the Maturity Date, the Lender shall be entitled to convert all or any part of the Principal into Conversion Shares in accordance with this Section  2 at the Conversion Rate (as defined in Section  2(b) ). The Borrower shall not issue any fraction of a share of Common Stock upon any conversion. If the issuance would result in the issuance of a fraction of a share of Common Stock, then the Borrower shall round such fraction of a share of Common Stock up or down to the nearest whole share (with 0.5 rounded up).

(b) Conversion Rate . The number of Conversion Shares issuable upon a conversion of any portion of this Note pursuant to Section  2 shall be determined according to the following formula (the “ Conversion Rate ”):

 

 

6  

To be equal to Lender’s First Out Waterfall Pro Rata Share of 4,800,000 shares.

 

EX. A - 4


Conversion Amount

Conversion Price

(c) Mechanics of Conversion . The conversion of this Note shall be conducted in the following manner:

(i) Lender’s Delivery Requirements . To convert a Conversion Amount into Conversion Shares pursuant to Section  2(a) above on any date, Lender shall (A) transmit by facsimile or electronic mail (or otherwise deliver), for receipt on or prior to 5:00 p.m. New York City time on such date, a copy of an executed conversion notice in the form attached hereto as Exhibit A (the “ Conversion Notice ”) to the Borrower (at 2 Musick, Irvine, CA 92618, Attention : Chief Financial Officer; Email : vmahboob@endologix.com, or at such other office or agency as the Borrower may designate in writing), and (B) if required by Section  2(c)(vi) , surrender to a common carrier for delivery to the Borrower, no later than three (3) Business Days after the Conversion Date, of the original Note being converted (or an indemnification undertaking in customary form with respect to this Note in the case of its loss, theft or destruction).

(ii) Borrower’s Response . Upon receipt or deemed receipt by the Borrower of a copy of a Conversion Notice, the Borrower (A) shall immediately send, via facsimile, a confirmation of receipt of such Conversion Notice to the Lender and the Borrower’s designated transfer agent (the “ Transfer Agent ”), which confirmation shall constitute an instruction to the Transfer Agent to process such Conversion Notice in accordance with the terms herein, and (B) on or before the second (2 nd ) Business Day following the date of receipt or deemed receipt by the Borrower of such Conversion Notice (or, if earlier, the end of the standard settlement period for U.S. broker-dealer securities transactions) (the “ Share Delivery Date ”), shall credit such aggregate number of Conversion Shares to which the Lender shall be entitled to the Lender’s or its designee’s balance account with The Depository Trust Company (“ DTC ”) through its Deposit/Withdrawal At Custodian (DWAC) system, for the number of Conversion Shares to which the Lender shall be entitled. If notwithstanding the provisions of Section  2(c)(vi) , the Lender elects to physically surrender this Note for conversion and the Principal represented by this Note is greater than the Principal being converted, then the Borrower shall, as soon as practicable and in no event later than three (3) Business Days after receipt of this Note and at its own expense, issue and deliver to the Lender a new Note representing the Principal not converted and cancel this Note. For purposes of Rule 144 under the Securities Act, any Conversion Shares issued to Lender shall be deemed to have been acquired by such Lender on April 3, 2017 (the date this Note was originally issued). Accordingly, (A) upon any conversion of this Note, the Rule 144 holding period for the Conversion Shares acquired thereupon shall be in excess of one (1) year, and (B) provided the Lender is not an Affiliate of the Borrower on the Conversion Date and has not been an Affiliate of the Borrower within the three-month period immediately preceding the Conversion Date (the “ Unrestricted Condition ”), which the Borrower shall assume and Lender hereby represents unless the Lender advises the Borrower otherwise in writing, the Conversion Shares issued to Lender will be freely transferable, without restriction or limitation (including any volume limitation) under Federal or state securities laws, pursuant to Rule 144 under the Securities Act and will not contain or be subject to a legend or stop transfer order restricting the resale or transferability of thereof.

(iii) Dispute Resolution . In the case of a dispute as to the determination of the Conversion Price or the arithmetic calculation of the Conversion Rate, the Borrower shall instruct the Transfer Agent to issue to the Lender the number of Conversion Shares that is not disputed and shall transmit an explanation of the disputed determinations or arithmetic calculations to the Lender via facsimile within two (2) Business Days of receipt or deemed receipt of the Lender’s Conversion Notice or other date of determination. If the Lender and the Borrower are unable to agree upon the determination of the Conversion Price or arithmetic calculation of the Conversion Rate within one (1) Business Day of such disputed determination or arithmetic calculation being transmitted to the Lender, then the Borrower shall

 

EX. A - 5


promptly (and in any event within two (2) Business Days) submit via facsimile (A) the disputed determination of the Conversion Price to an independent, reputable investment banking firm agreed to by the Borrower and the Required Lenders, or (B) the disputed arithmetic calculation of the Conversion Rate to the Borrower’s independent registered public accounting firm, as the case may be. The Borrower shall direct the investment bank or the accounting firm, as the case may be, to perform the determinations or calculations and notify the Borrower and the Lender of the results no later than two (2) Business Days from the time it receives the disputed determinations or calculations. Such investment bank’s or accounting firm’s determination or calculation, as the case may be, shall be binding upon all parties absent manifest error, and the fees and expenses of such investment bank or accountant shall be paid one-half by the Borrower and one-half by the Lender. Notwithstanding the existence of a dispute contemplated by this paragraph, if requested by the Lender, the Borrower shall issue to the Lender the Conversion Shares not in dispute in accordance with the terms hereof.

(iv) Record Holder . The person or persons entitled to receive the Conversion Shares issuable upon a conversion of this Note shall be treated for all purposes as the legal and record holder or holders of such shares of Common Stock upon delivery by the Lender of the Conversion Notice, or in the case of Conversion Shares the issuance of which is subject to a bona fide dispute that is subject to and being resolved pursuant to, and in compliance with the time periods and other provisions of, the dispute resolution provisions of Section  2(c)(iii) , the first Business Day after the resolution of such bona fide dispute.

(v) Borrower’s Failure to Timely Convert .

(A) Cash Damages . If by the Share Delivery Date, the Borrower shall fail to credit the Lender’s or its designee’s balance account with DTC with the number of Conversion Shares (free of any restrictive legend, provided the Unrestricted Condition is satisfied), then, in addition to all other available remedies that the Lender may pursue hereunder and under the Facility Agreement, the Borrower shall pay additional damages to the Lender for each day after the Share Delivery Date such conversion is not timely effected in an amount equal to one and one-half percent (1.5%) of the product of (I) the number of Conversion Shares not issued to the Lender or its designee on or prior to the Share Delivery Date and to which the Lender is entitled and (II) the Volume Weighted Average Price of the Common Stock on the Share Delivery Date. Alternatively in lieu of the foregoing damages, subject to Section  2(c)(iii) , at the written election of the Lender made in the Lender’s sole discretion, if, on or after the applicable Conversion Date, the Lender purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by such Lender of Conversion Shares that such Lender anticipated receiving from the Borrower (such purchased shares, “ Buy-In Shares ”), the Borrower shall be obligated to promptly pay to such Lender (in addition to all other available remedies that the Lender may otherwise have), 110% of the amount by which (A) such Lender’s total purchase price (including brokerage commissions, if any) for such Buy-In Shares exceeds (B) the net proceeds received by such Lender from the sale of a number of shares equal to up to the number of Conversion Shares such Lender was entitled to receive but had not received on the Share Delivery Date. If the Borrower fails to pay the additional damages set forth in this Section 2(c)(v)(A) within five (5) Business Days of the date incurred, then the Lender entitled to such payments shall have the right at any time, so long as the Borrower continues to fail to make such payments, to require the Borrower, upon written notice, to immediately issue, in lieu of such cash damages, the number of shares of Common Stock equal to the quotient of (X) the aggregate amount of the damages payments described herein divided by (Y) the Conversion Price specified by the Lender in the Conversion Notice.

(B) Conversion Failure . If for any reason the Lender has not received all of the Conversion Shares it is entitled to prior to the tenth (10th) Business Day after the Share Delivery Date with respect to a conversion of this Note (a “ Conversion Failure ”), then the Lender, upon written

 

EX. A - 6


notice to the Borrower (a “ Void Conversion Notice ”), may void its conversion with respect to, and retain or have returned, as the case may be, any portion of this Note that has not been converted pursuant to the Lender’s Conversion Notice; provided , that the voiding of the Lender’s Conversion Notice shall not affect the Borrower’s obligations to make any payments that have accrued prior to the date of such notice pursuant to Section  2(c)(v)(A) or otherwise. A Conversion Failure shall constitute an Event of Default under the Facility Agreement and entitle the Lenders to all payments and remedies provided under the Facility Agreement upon the occurrence of an Event of Default.

(vi) Book-Entry . Notwithstanding anything to the contrary set forth herein, upon conversion or repayment of this Note in accordance with the terms hereof, the Lender shall not be required to physically surrender this Note to the Borrower unless all of the Principal is being converted or repaid. The Lender and the Borrower shall maintain records showing the Principal converted or repaid and the dates of such conversions or repayments or shall use such other method, reasonably satisfactory to the Lender and the Borrower, so as not to require physical surrender of this Note upon any such partial conversion or repayment. Notwithstanding the foregoing, if this Note is converted or repaid as aforesaid, the Lender may not transfer this Note unless the Lender first physically surrenders this Note to the Borrower, whereupon the Borrower will forthwith issue and deliver upon the order of the Lender a new Note of like tenor, registered as the Lender may request, representing in the aggregate the remaining Principal represented by this Note. The Lender and any assignee, by acceptance of this Note, acknowledge and agree that, by reason of the provisions of this paragraph, following conversion or repayment of any portion of this Note, the Principal of this Note may be less than the “Principal Amount” stated on the face hereof.

(d) Limitations on Conversions .

(i) Beneficial Ownership . Notwithstanding anything herein to the contrary, the Borrower shall not issue to the Lender, and the Lender may not acquire, a number of shares of Common Stock upon conversion of this Note or otherwise issue any shares of Common Stock pursuant hereto or the Facility Agreement to the extent that, upon such conversion, the number of shares of Common Stock then beneficially owned by the Lender and its Affiliates and any other persons or entities whose beneficial ownership of Common Stock would be aggregated with the Lender’s for purposes of Section 13(d) of the Exchange Act (including shares held by any “group” of which the Lender is a member, but excluding shares beneficially owned by virtue of the ownership of the Warrants or other securities or rights to acquire securities that have limitations on the right to convert, exercise or purchase similar to the limitation set forth herein) would exceed 4.985% of the total number of shares of common stock then issued and outstanding (the “ 4.985% Cap ”); provided, however, that the 4.985% Cap shall only apply to the extent that the Common Stock is deemed to constitute an “equity security” pursuant to Rule 13d-1(i) promulgated under the Exchange Act. For purposes hereof, “group” has the meaning set forth in Section 13(d) of the Exchange Act and applicable regulations of the SEC, and the percentage held by the Lender shall be determined in a manner consistent with the provisions of Section 13(d) of the Exchange Act. Upon the written request of the Lender, the Borrower shall, within two (2) Trading Days, confirm orally and in writing to the Lender the number of shares of Common Stock then outstanding.

(ii) Conversion Issuance Limit . Notwithstanding anything to the contrary contained herein, the Borrower shall not issue any shares of Common Stock upon conversion of this Note (including pursuant to Section  2(c)(v)(A) hereof) to the extent that the issuance of such shares of Common Stock together with any previous issuances of shares of Common Stock under this Note would exceed the Conversion Issuance Limit, and Section 2.5(c)(v) shall not apply in respect to any excess amount.

(iii) Other Applicable Limitations on Conversion of the Note . Notwithstanding anything to the contrary herein, this Note shall not be convertible, and the Borrower shall not issue shares of

 

EX. A - 7


Common Stock upon conversion of this Note (a) at any time after the First Amortization Date, to the extent that the number of shares of Common Stock that would otherwise be issuable to Lender upon such conversion, together with all shares of Common Stock previously issued to Lender upon conversion of this Note after the First Amortization Date, would exceed the First Amortization Cap, or (b)  at any time after the Second Amortization Date, to the extent that the number of shares of Common Stock that would otherwise be issuable to Lender upon such conversion, together with all shares of Common Stock previously issued to Lender upon conversion of this Note after the Second Amortization Date, would exceed the Second Amortization Cap, or (c) during any Monthly Conversion Cap Period, to the extent that the number of shares of Common Stock that would otherwise be issuable to Lender upon such conversion, together with all shares previously issued to Lender upon conversion of this Note during the such Monthly Conversion Cap Period, would exceed the Monthly Conversion Cap. For the avoidance of doubt, if the number of shares of Common Stock to be issued as set forth in an Conversion Notice transmitted by the Lender to the Borrower would otherwise require the Borrower to issue a number of shares in excess of the Conversion Issuance Limit, the First Amortization Cap (if after the First Amortization Date), the Second Amortization Cap (if after the Second Amortization Date) or the Monthly Share Cap, the Borrower shall issue to the Lender in accordance herewith the maximum number of shares of Common Stock issuable without exceeding any such applicable limitation, and Section 2.5(c)(v) shall not apply to any excess amount.

3. Voting Rights . Except as required by law, the Lender shall have no voting rights with respect to any of the Conversion Shares until the Conversion Date relating to the conversion of this Note upon which such Conversion Shares are issuable (or in the case of Conversion Shares the issuance of which is subject to a bona fide dispute that is subject to and being resolved pursuant to, and in compliance with the time periods and other provisions of, the dispute resolution provisions of Section  2(c)(iii) , the first Business Day after the resolution of such bona fide dispute).

4. Amendment; Waiver . The provisions of this Note may only be waived or amended, restated, supplemented or otherwise modified in accordance with the Facility Agreement.

5. Specific Shall Not Limit General; Construction . No specific provision contained in this Note shall limit or modify any more general provision contained herein. This Note shall be deemed to be jointly drafted by the Borrower and all Lenders pursuant to the Facility Agreement and shall not be construed against any Person as the drafter hereof.

6. Failure or Indulgence Not Waiver . No delay or omission by the Lender in exercising any power or right hereunder shall impair such right or power or be construed to be a waiver of any default, nor shall any single or partial exercise of any power or right hereunder preclude the full exercise thereof or the exercise of any other power or right. No renewal or extension of this Note or the Facility Agreement, no delay in the enforcement of payment under this Note or the Facility Agreement, and no delay or omission in exercising any right or power under this Note or the Facility Agreement shall affect the liability of the Borrower or any endorser of this Note.

7. Notices . Whenever notice is required to be given under this Note, unless otherwise provided herein, such notice shall be given in accordance with Section 6.1 of the Facility Agreement.

8. Restrictions on Transfer .

(a) Registration or Exemption Required . This Note has been issued in a transaction exempt from the registration requirements of the Securities Act. None of the Note or the Conversion Shares issued hereunder may be transferred, sold, assigned, hypothecated or otherwise disposed of except pursuant to an effective registration statement or an exemption to the registration requirements of the Securities Act and applicable state laws, including Rule 144 under the Securities Act, Section 4(a)(7) of the Securities Act

 

EX. A - 8


or a so-called “4[(a)](1) and a half” transaction.

(b) Assignment . This Note is assignable or transferable, in whole or in part, only to the extent such assignment or transfer is permitted pursuant to the terms of the Facility Agreement; provided that (i) the Lender shall deliver a written notice to the Borrower, substantially in the form of the Assignment attached hereto as Exhibit B , indicating the Person or Persons to whom the Note shall be assigned and the respective Principal amount of the Note to be assigned to each assignee. The Borrower shall effect the assignment within three (3) business days, and shall deliver to the assignee(s) designated by the Lender a Note or Notes of like tenor and terms for the appropriate Principal amount. This Note and the rights evidenced hereby shall inure to the benefit of and be binding upon the successors and assigns of the Lender. The provisions of this Note are intended to be for the benefit of all Lenders from time to time of this Note, and shall be enforceable by any such Lender. This Note is not (and any rights or obligations hereunder are not) not assignable or transferable by the Borrower under any circumstance and any such prohibited assignment or transfer is absolutely void ab initio .

9. Payment of Collection, Enforcement and Other Costs . If (a) this Note is placed in the hands of an attorney for collection or enforcement or is collected or enforced through any legal proceeding; or (b) an attorney is retained to represent the Lender in any bankruptcy, reorganization, receivership of the Borrower or other proceedings affecting Borrower creditors’ rights and involving a claim under this Note, then the Borrower shall pay the costs incurred by the Lender for such collection, enforcement or action, including reasonable attorneys’ fees and disbursements. Subject to the terms of the Facility Agreement, all payments and issuances of shares of Common Stock hereunder will be free and clear of, and without deduction or withholding for, any present or future taxes. The Borrower shall pay all and any costs (administrative or otherwise) imposed by the Borrower’s banks, clearing houses, or any other financial institution, in connection with making any payments and issuing any shares of Common Stock hereunder. The Borrower shall pay all costs and expenses (including attorney’s fees) of the Lender incurred in connection with this Note in accordance with Section 6.3 of the Facility Agreement.

10. Waiver of Notice . Other than those notices required to be provided by the Lender to the Borrower under the terms of the Facility Agreement, the Borrower and every endorser of this Note, or the obligations represented hereby, expressly waives diligence, presentment, protest, demand, notice of dishonor, non-payment or default, and notice of any kind with respect to this Note and the Facility Agreement or the performance of the obligations under this Note and/or the Facility Agreement.

11. Miscellaneous . This Note is a Loan Document, is entitled to the benefits of the Loan Documents and is subject to certain provisions of the Facility Agreement, including Sections 1.2 ( Interpretation ) and 6.4 ( Governing Law; Venue; Jurisdiction; Service of Process; Waiver of Jury Trial ) thereof.

12. Additional Interpretative Matters . Unless the context otherwise requires, (a) all references to Sections or Exhibits are to Sections or Exhibits contained in or attached to this Note, (b) each accounting term not otherwise defined in this Note has the meaning assigned to it in accordance with GAAP, (c) words in the singular or plural include the singular and plural and pronouns stated in either the masculine, the feminine or neuter gender shall include the masculine, feminine and neuter and (d) the use of the word “including” in this Note shall be by way of example rather than limitation. If a Stock Event occurs during any period over which an average price is being determined, then an appropriate adjustment will be made to such average to reflect such Stock Event.

13. Signatures . In the event that any signature to this Note or any amendment hereto is delivered by electronic mail delivery of a “.pdf” format data file, such signature shall create a valid and

 

EX. A - 9


binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such “.pdf” signature page were an original thereof. Notwithstanding the foregoing, the Borrower shall be obligated to deliver to the Lender an original signature to this Note. At the request of any party, each other party shall promptly re-execute an original form of this Note or any amendment hereto and deliver the same to the other party. No party hereto shall raise the use of electronic mail delivery of a “.pdf” format data file to deliver a signature to this Note or any amendment hereto or the fact that such signature was transmitted or communicated through the use of electronic mail delivery of a “.pdf” format data file as a defense to the formation or enforceability of a contract, and each party hereto forever waives any such defense.

14. This Note is an amendment and restatement of that certain Loan Note originally issued on April 3, 2017 [and re-issued on January  1, 2018] , 7 in the principal amount of $[        ] (the “ Prior Note ”) and evidences an extension, continuation, and renewal of the indebtedness evidenced by the Prior Note, but this Note replaces the Prior Note with the indebtedness evidenced by the Prior Note now evidenced by this Note. Such Prior Note shall be of no further force and effect upon execution of this Note. The Borrower hereby acknowledges and agrees that the indebtedness under the Prior Note has not been repaid or extinguished and that the execution hereof does not constitute a novation of the Prior Note. Moreover, this Note shall be entitled to all security and collateral to which the Prior Note was entitled, without change or diminution in the priority of any lien or security interest granted to secure the Prior Note.

[Signature Page Follows]

 

 

7  

NTD: Only to be included for the note that was re-issued on January 1, 2018 in connection with its transfer to Deerfield Partners.

 

EX. A - 10


IN WITNESS WHEREOF, the Borrower has caused this Note to be executed and delivered by its duly authorized officer as of the day and year set forth above.

 

ENDOLOGIX, INC. ,

a Delaware corporation

By: ________________________________
Name: ______________________________
Title: ______________________________

 

EX. A - 11


Exhibit A

CONVERSION NOTICE

Reference is made to the First Out Waterfall Note (the “ Note ”) of ENDOLOGIX, INC. , a Delaware corporation (the “ Borrower ”), in the original principal amount of $[                ]. In accordance with and pursuant to the Note, the undersigned hereby elects to convert the Conversion Amount (as defined in the Note) of the Note indicated below into shares of common stock, par value $0.001 per share (the “ Common Stock ”), of the Borrower, as of the date specified below.

Date of Conversion:                         

Aggregate Conversion Amount to be converted at the Conversion Price (as defined in the Note):

____________________

Principal, applicable thereto, to be converted:                                                          

Please confirm the following information:

Conversion Price:                                                                                                                                                                                     

Number of shares of Common Stock to be issued:                                 Please issue the Common Stock into which the Note is being converted in the following name and to the following address:

Issue to:                                                                                                                                                                                                     

Facsimile Number:                                                                  

Authorization:                                                                         

By:                                                                             

Title:                                                                           

Dated:                                                                                     

DTC Participant Number and Name:                                                                                                                                                        

Account Number:                                                                                                                                                                                         


Exhibit B

ASSIGNMENT

(To be executed by the registered holder

desiring to transfer the Note)

FOR VALUE RECEIVED, the undersigned holder of the attached First Out Waterfall Note (the “ Note ”) hereby sells, assigns and transfers unto the person or persons below named the right to receive the principal amount of $                 from Endologix, Inc., a Delaware corporation (the “ Borrower ”), evidenced by the attached Note and does hereby irrevocably constitute and appoint                  attorney to transfer the said Note on the books of the Borrower, with full power of substitution in the premises.

 

Dated: _______________   

 

Signature

Fill in for new registration of Note:

 

 

Name

 
 

 

Address

 
 

 

Please print name and address of assignee

 
(including zip code number)  

NOTICE

The signature to the foregoing Assignment must correspond to the name as written upon the face of the attached Note.


EXHIBIT A-2

FORM OF LAST OUT WATERFALL NOTE

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS OR (B) AN OPINION OF COUNSEL, IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR APPLICABLE STATE SECURITIES LAWS OR (II) UNLESS SOLD PURSUANT TO RULE 144 UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN, FINANCING OR INDEBTEDNESS ARRANGEMENT SECURED BY THE SECURITIES.

LAST OUT WATERFALL NOTE

 

Last Out Waterfall Lender: _____________________   
Principal Amount: $_______    ___________, 20__

FOR VALUE RECEIVED, the undersigned, Endologix, Inc., a Delaware corporation (the “ Borrower ”), hereby unconditionally promises to pay to the Last Out Waterfall Lender set forth above (the “ Last Out Waterfall Lender ”) the Principal Amount set forth above (the “ Principal Amount ”), or, if less, the aggregate unpaid principal amount of the Last Out Waterfall Loan (as defined in the Facility Agreement referred to below) of the Last Out Waterfall Lender to the Borrower, payable at such times and in such amounts as are specified in the Facility Agreement.

The Borrower promises to pay interest on the outstanding principal amount of the Last Out Waterfall Loan and any overdue interest from and after the Agreement Date until such outstanding principal amount of the Last Out Waterfall Loan and any overdue interest are paid in full, payable at such times, in such type (such as cash or paid in-kind) and at such interest rates as are specified in the Facility Agreement. The Borrower promises to pay any Non-Callable Make Whole Amount, any CoC Fee and the Exit Payment that is due on the Last Out Waterfall Loan in accordance with the Facility Agreement. Demand, diligence, presentment, protest and notice of non-payment and protest are hereby waived by the Borrower.

Principal and interest (and any Non-Callable Make Whole Amount, any CoC Fee and the Exit Payment) are payable in Dollars ( provided that the PIK Interest Payment is paid in-kind pursuant to Section 2.6(a) of the Facility Agreement) to the Last Out Waterfall Lender in the manner set forth in the Facility Agreement.

This Last Out Waterfall Note (this “ Last Out Waterfall Note ”) is one of the “Last Out Waterfall Notes”, “Loan Notes” and “Notes” referred to in, and is entitled to the benefits of, the Amended and Restated Facility Agreement, dated as of August 9, 2018 (as the same may be amended, restated,

 

EX. A-2 - 1


supplemented or otherwise modified from time to time, the “ Facility Agreement ”), by and among the Borrower, the other Loan Parties party thereto, the Lenders (including the Last Out Waterfall Lender) party thereto and Deerfield Private Design Fund IV, L.P., as agent for the Secured Parties, and the other Loan Documents. Capitalized terms used herein without definition are used as defined in the Facility Agreement.

The Facility Agreement, among other things, (a) provides for the making of a Last Out Waterfall Loan by the Last Out Waterfall Lender to the Borrower in an aggregate amount not to exceed at any time outstanding the Principal Amount, the indebtedness of the Borrower resulting from such Last Out Waterfall Loan being evidenced by this Last Out Waterfall Note and (b) contains provisions for acceleration of the maturity of the unpaid principal amount of this Last Out Waterfall Note upon the happening of certain stated events and also for prepayments pursuant to Section 2.3(c) or Section 5.3 of the Facility Agreement on account of the principal hereof prior to the maturity hereof upon the terms and conditions specified therein.

This Last Out Waterfall Note is a Loan Document, is entitled to the benefits of the Loan Documents and is subject to certain provisions of the Facility Agreement, including Sections 1.2 ( Interpretation ) and 6.4 ( Governing Law; Venue; Jurisdiction; Service of Process; Waiver of Jury Trial ) thereof.

This Last Out Waterfall Note is assignable or transferable to the extent such assignment or transfer is permitted pursuant to the terms of the Facility Agreement.

Subject to the terms of the Facility Agreement, all payments will be free and clear of, and without deduction or withholding for, any present or future taxes. The Borrower shall pay all and any costs (administrative or otherwise) imposed by the Borrower’s banks, clearing houses, or any other financial institution, in connection with making any payments hereunder.

The Borrower shall pay all costs and expenses (including attorney’s fees) of the Last Out Waterfall Lender incurred in connection with this Last Out Waterfall Note in accordance with Section 6.3 of the Facility Agreement.

Other than those notices required to be provided by the Last Out Waterfall Lender to the Borrower under the terms of the Facility Agreement, the Borrower and every endorser of this Last Out Waterfall Note, or the obligations represented hereby, expressly waives presentment, protest, demand, notice of dishonor or default, and notice of any kind with respect to this Last Out Waterfall Note and the Facility Agreement or the performance of the obligations under this Last Out Waterfall Note and/or the Facility Agreement. No renewal or extension of this Last Out Waterfall Note or the Facility Agreement, no delay in the enforcement of payment of this Last Out Waterfall Note or the Facility Agreement, and no delay or omission in exercising any right or power under this Last Out Waterfall Note or the Facility Agreement shall affect the liability of the Borrower or any endorser of this Last Out Waterfall Note.

No delay or omission by the Last Out Waterfall Lender in exercising any power or right hereunder shall impair such right or power or be construed to be a waiver of any default, nor shall any single or partial exercise of any power or right hereunder preclude the full exercise thereof or the exercise of any other power or right. The provisions of this Last Out Waterfall Note may be waived or amended, restated, supplemented or otherwise modified only in a writing signed by the Borrower and the Last Out Waterfall Lender.

This Last Out Waterfall Note shall be governed by, and be construed and enforced in accordance with, the laws of the State of New York applicable to contracts made and to be performed in such State.

[Signature Page Follows]

 

EX. A-2 - 2


IN WITNESS WHEREOF, the Borrower has caused this Last Out Waterfall Note to be executed and delivered by its duly authorized officer as of the day and year set forth above.

 

ENDOLOGIX, INC. ,

a Delaware corporation

By:  

 

Name:  

 

Title:  

 

 

EX. A-2 - 1


EXHIBIT B

FORM OF PERFECTION CERTIFICATE

 

 

EX. A-2 - 2


EXHIBIT C-1

FORM OF INITIAL WARRANT

THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAW. THE SECURITIES MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT, OR PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT, INCLUDING PURSUANT TO SECTION 4(A)(7) OF THE SECURITIES ACT OR RULE 144 UNDER THE SECURITIES ACT OR PURSUANT TO A PRIVATE SALE EFFECTED UNDER APPLICABLE FORMAL OR INFORMAL SEC INTERPRETATION OR GUIDANCE, SUCH AS A SO-CALLED “4[(a)](1) AND A HALF SALE.” NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

AN INVESTMENT IN THESE SECURITIES INVOLVES A HIGH DEGREE OF RISK. HOLDERS MUST RELY ON THEIR OWN ANALYSIS OF THE INVESTMENT AND ASSESSMENT OF THE RISKS INVOLVED.

 

Warrant to Purchase shares

   Warrant Number:

Warrant to Purchase Common Stock

of

Endologix, Inc.

THIS CERTIFIES that                      or any subsequent holder hereof (“Holder”) has the right to purchase from Endologix, Inc., a Delaware corporation (the “Company”),                  (            ) fully paid and nonassessable shares of the Company’s common stock, $0.001 par value per share (“Common Stock”), subject to adjustment as provided herein, at a price equal to the Exercise Price (as defined in Section 3 below), at any time during the Term (as defined in Section 1 below).

Holder agrees with the Company that this Warrant to Purchase Common Stock of the Company (this “Warrant” or this “Agreement”) is issued and all rights hereunder shall be held subject to all of the conditions, limitations and provisions set forth herein.

1. Date of Issuance and Term .

This Warrant shall be deemed to be issued on                      (“Date of Issuance”). The term of this Warrant begins on the Date of Issuance and ends at 5:00 p.m., New York City time, on the date that is seven (7) years after the Date of Issuance (the “Term”). This Warrant was issued pursuant to that certain Facility Agreement (as may be amended, restated, supplemented or otherwise modified from time to time in accordance with the terms thereof, the “Facility Agreement”) by and among the Company and Deerfield Private Design Fund III, L.P., Deerfield Private Design Fund IV, L.P., Deerfield Partners, L.P. and Deerfield International Master Fund, L.P., dated as of April 3, 2017, and in conjunction with that certain Registration Rights Agreement (as may be amended, restated, supplemented or otherwise modified from


time to time in accordance with the terms thereof, the “Registration Rights Agreement”) by and among the Company and Deerfield Private Design Fund III, L.P., Deerfield Private Design Fund IV, L.P., Deerfield Partners, L.P. and Deerfield International Master Fund, L.P., dated as of April 3, 2017.

Notwithstanding anything herein to the contrary, the Company shall not issue to Holder, and Holder may not acquire, a number of shares of Common Stock upon exercise of this Warrant to the extent that, upon such exercise, the number of shares of Common Stock then beneficially owned by Holder and its Affiliates and any other persons or entities whose beneficial ownership of Common Stock would be aggregated with Holder’s for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (including shares held by any “group” of which Holder is a member, but excluding shares beneficially owned by virtue of the ownership of securities or rights to acquire securities that have limitations on the right to convert, exercise or purchase similar to the limitation set forth herein), would exceed 4.985% of the total number of shares of Common Stock then issued and outstanding (the “4.985% Cap”); provided, however, that the 4.985% Cap shall only apply to the extent that the Common Stock is deemed to constitute an “equity security” pursuant to Rule 13d-1(i) promulgated under the Exchange Act. For purposes hereof, “group” has the meaning set forth in Section 13(d) of the Exchange Act and applicable regulations of the Securities and Exchange Commission (the “SEC”), and the percentage held by Holder shall be determined in a manner consistent with the provisions of Section 13(d) of the Exchange Act. Upon the written request of Holder, the Company shall, within two (2) Trading Days, confirm orally and in writing to Holder the number of shares of Common Stock then outstanding.

For purposes hereof:

“Affiliate” means any person or entity that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a person or entity, as such terms are used in and construed under Rule 144 (“Rule 144”) under the Securities Act of 1933, as amended (the “Securities Act”). With respect to a Holder, any investment fund or managed account that is managed on a discretionary basis by the same investment manager as such Holder shall, for purposes hereof, be deemed to be an Affiliate of such Holder.

“Asset Sale” means a transaction covered by the provisions of clause (B) of the definition of “Major Transaction” involving the sale or transfer of all or substantially all of the assets of the Company (including, for the avoidance of doubt, all or substantially all of the assets of the Company and its Subsidiaries (as defined in the Facility Agreement), taken as a whole) in connection with which the Company has announced its intention to liquidate and distribute its assets to stockholders.

“Black-Scholes Value” shall mean the Black-Scholes value of this Warrant, or applicable portion thereof, as determined by use of the Black-Scholes Option Pricing Model using the criteria set forth on Schedule 1 hereto.

“Business Day” means a day other than a Saturday or Sunday or any other day on which commercial banks are authorized or required by law to close in New York City.

“Cashless Default Exercise” shall mean an exercise of this Warrant as a “Cashless Default Exercise” in accordance with Sections 3(c) and 11(b) hereof.

“Cashless Major Exercise” shall mean an exercise of this Warrant or portion thereof as a “Cashless Major Exercise” in accordance with Sections 3(b) and 5(b)(i) hereof.

“Cash Out Major Transaction” means a Major Transaction in which the consideration payable to holders of Common Stock in connection with the Major Transaction consists solely of cash.

 

4


“Eligible Market” means the New York Stock Exchange, the NASDAQ Capital Market, the NASDAQ Global Market, the NASDAQ Global Select Market, the NYSE MKT or, in each case, any successor thereto.

“Parent Entity” of a Person means an entity that, directly or indirectly, controls the applicable Person and whose common stock or equivalent equity security is quoted or listed on an Eligible Market, or, if there is more than one such Person or Parent Entity, the Person or Parent Entity with the largest public market capitalization as of the date of consummation of a Major Transaction.

“Person” means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other entity and a government or any department or agency thereof.

“Standard Settlement Period” means the standard settlement period for equity trades effected on securities exchanges in the United States, expressed in a number of Trading Days, as in effect on the applicable Date of Exercise (as defined in Section 2(b)).

“Successor Entity” means any Person purchasing the Company’s assets or Common Stock, or any successor entity resulting from such Major Transaction, or if the Warrant is to be exercisable for shares of capital stock of a Parent Entity (as defined above), such Person’s Parent Entity.

“Successor Major Transaction” means either a Takeout Major Transaction or an Asset Sale.

“Successor Major Transaction Consideration” means (i) in the case of a Takeout Major Transaction (other than a Cash Out Major Transaction), the amount of cash and other assets and the number of securities or other property of the Successor Entity or other entity that would be issuable in such Major Transaction, in respect of a number of shares equal to the Successor Major Transaction Conversion Share Amount and (ii) in the case of an Asset Sale or a Cash Out Major Transaction, an amount of cash equal to the Black-Scholes Value of the Warrant.

“Successor Major Transaction Conversion Share Amount” means an amount equal to the Black-Scholes Value of the Warrant (or such applicable portion subject to a Successor Major Transaction Conversion), divided by the closing price of the Common Stock on the principal securities exchange or other securities market on which the Common Stock is then traded on the Trading Day immediately preceding the date on which the applicable Major Transaction is consummated.

“Takeout Major Transaction” means a transaction covered by the provisions of clause (A) of the definition of “Major Transaction” in which the shares of Common Stock of the Company are converted into the right to receive cash, securities of another entity and/or other assets.

“Trading Day” shall mean any day on which the Common Stock is traded for any period on the NASDAQ Global Select Market (“NasdaqGS”) or, if the NasdaqGS is not the principal trading market for the Common Stock, on the principal securities exchange or other securities market on which the Common Stock is then being traded; provided, however, that during any period in which the Common Stock is not listed or quoted on the NasdaqGS or any other securities exchange or market, the term “Trading Day” shall mean a Business Day.

2. Exercise .

(a) Manner of Exercise . During the Term (or, in respect of a Cashless Major Exercise, the Cashless Major Exercise Period (as defined below)), this Warrant may be Exercised as to all or any lesser number of whole

 

5


shares of Common Stock covered hereby (the “Warrant Shares” or the “Shares”) by sending to the Company the Exercise Form attached hereto as Exhibit  A-1 (the “Exercise Form”) duly completed and executed, and, if applicable, the full Exercise Price (as defined below, which may be satisfied by a Cash Exercise, a Cashless Exercise or a Note Exchange Exercise, as each is defined below) for each share of Common Stock as to which this Warrant is Exercised, at the office of the Company, 2 Musick, Irvine, CA 92618, Attention: Chief Financial Officer; Phone: (949) 595-7200, Email: vmahboob@endologix.com, or at such other office or agency as the Company may designate in writing, by overnight mail or electronic mail (any such exercise of the Warrant being hereinafter called an “Exercise” of this Warrant).

(b) Date of Exercise . The “Date of Exercise” of the Warrant shall, in each case, be the date that the Exercise Form attached hereto as Exhibit  A-1 , completed and executed, is sent by electronic mail to the Company, provided that the Exercise Price is satisfied as soon as practicable thereafter but in no event later than two (2) Business Days following the date of such electronic mail. Alternatively, the Date of Exercise shall be defined as the date the original Exercise Form is received by the Company, if Holder has not previously sent the Exercise Form by electronic mail. Upon delivery of the Exercise Form to the Company by electronic mail or otherwise, Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been Exercised, irrespective of the date such Warrant Shares are credited to Holder’s or its designee’s Depository Trust Company (“DTC”) account or the date of delivery of the certificates evidencing such Warrant Shares, as the case may be; provided, however, that in the event an Exercise Form in respect of a Cashless Major Exercise is delivered prior to the occurrence of the applicable Major Transaction, Holder shall be deemed to have become the holder of record of the shares issuable upon such exercise immediately prior to the consummation of such Major Transaction and the Date of Exercise shall in such event be deemed to have occurred on the date of the occurrence of the Major Transaction. Holder shall not be required to physically surrender this Warrant to the Company until Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days following the date the final Exercise Form is delivered to the Company. Execution and delivery of an Exercise Form with respect to a partial Exercise shall have the same effect as cancellation of the original Warrant and issuance of a New Warrant evidencing the right to purchase the remaining number of Warrant Shares.

(c) Delivery of Common Stock Upon Exercise . Within the earlier of (x) three (3) Trading Days and (y) the number of Trading Days comprising the Standard Settlement Period after any Date of Exercise (but, in the case of a Cash Exercise, within two (2) Business Days following the Company’s receipt of the full Exercise Price, if later) or in the case of a Cashless Default Exercise (as defined in Section 5(b) below), within the period provided in Section 3(c), as applicable (the “Delivery Period”), the Company shall issue and deliver (or cause its transfer agent (the “Transfer Agent”) to issue and deliver) in accordance with the terms hereof to or upon the order of Holder that number of shares of Common Stock (“Exercise Shares”) for the portion of this Warrant exercised as shall be determined in accordance herewith. Upon the Exercise of this Warrant or any part hereof, the Company shall, at its own cost and expense, take all necessary action, including obtaining and delivering an opinion of counsel, to assure that the Transfer Agent shall issue stock certificates in the name of Holder (or its nominee) or such other persons as designated by Holder and in such denominations as Holder shall specify at Exercise, representing the number of shares of Common Stock issuable upon such Exercise. The Company warrants that no instructions other than these instructions have been or will be given to the Transfer Agent and that, unless waived by Holder, this Warrant and the Exercise Shares will be free-trading, and freely transferable, and will not contain or be subject to a legend (or be subject to any stop transfer instruction) restricting the resale or transferability of the Exercise Shares if the Unrestricted Conditions (as defined below) are met.

 

6


The Company shall be responsible for paying all present or future stamp, court or documentary, intangible, recording, filing or similar taxes that arise from any payment or issuance made under, from the execution, delivery, performance or enforcement of, or otherwise with respect to, this Warrant.

(d) Delivery Failure . In addition to any other remedies which may be available to Holder, in the event that the Company fails for any reason to effect delivery of the Exercise Shares by the end of the Delivery Period (a “Delivery Failure”), Holder will be entitled to revoke all or part of the relevant Exercise by delivery of a notice to such effect to the Company whereupon the Company and Holder shall each be restored to their respective positions immediately prior to the delivery of such notice of revocation, except that the Failure Payments under Section 10(b) shall be payable through the date such notice of revocation is given to the Company.

(e) Legends .

(i) Restrictive Legend . Holder understands that until such time as this Warrant, the Exercise Shares and the Failure Payment Shares (as defined below) have been registered under the Securities Act or otherwise may be sold pursuant to Rule 144 or an exemption from registration under the Securities Act without any restriction as to the number of securities as of a particular date that can then be immediately sold, this Warrant, the Exercise Shares and the Failure Payment Shares, as applicable, may bear a restrictive legend in substantially the following form (and a stop-transfer order consistent therewith may be placed against transfer of the certificates for such securities):

“THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER SAID ACT, OR PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER SAID ACT INCLUDING PURSUANT TO SECTION 4(A)(7) OF THE SECURITIES ACT OR RULE 144 UNDER SAID ACT OR PURSUANT TO A PRIVATE SALE EFFECTED UNDER APPLICABLE FORMAL OR INFORMAL SEC INTERPRETATION OR GUIDANCE, SUCH AS A SO-CALLED “4[(a)](1) AND A HALF” SALE.” NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

“THE SALE, TRANSFER OR ASSIGNMENT OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO THE TERMS AND CONDITIONS OF A CERTAIN REGISTRATION RIGHTS AGREEMENT DATED AS OF APRIL 3, 2017, AS AMENDED FROM TIME TO TIME, AMONG THE COMPANY AND CERTAIN HOLDERS OF ITS OUTSTANDING SECURITIES. COPIES OF SUCH AGREEMENT MAY BE OBTAINED AT NO COST BY WRITTEN REQUEST MADE BY THE HOLDER OF RECORD OF THIS CERTIFICATE TO THE SECRETARY OF THE COMPANY.”

(ii) Removal of Restrictive Legends . This Warrant and the certificates (or electronic book entries, if applicable) evidencing the Exercise Shares and the Failure Payment Shares, as applicable, shall not contain or be subject to any legend restricting the transfer thereof (including the legend set forth above in subsection

 

7


2(e)(i)) or be subject to any stop-transfer instructions: (A) while a registration statement (including a Registration Statement, as defined in the Registration Rights Agreement) covering the sale or resale of such security is effective under the Securities Act, or (B) following any sale of such Warrant, Exercise Shares and/or Failure Payment Shares pursuant to Rule 144, or (C) if such Warrant, Exercise Shares and/or Failure Payment Shares are eligible for sale under Rule 144(b)(1), or (D) if such legend is not required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the SEC) (collectively, the “Unrestricted Conditions”). The Company shall cause its counsel to issue a legal opinion to the Transfer Agent promptly after the Effective Date, or at such other time as any of the Unrestricted Conditions have been met, if required by the Transfer Agent to effect the issuance of this Warrant, the Exercise Shares or the Failure Payment Shares, as applicable, without a restrictive legend or removal of the legend hereunder. If any of the Unrestricted Conditions are met at the time of issuance of this Warrant, the Exercise Shares or the Failure Payment Shares, then such Warrant, Exercise Shares or Failure Payment Shares, as applicable, shall be issued free of all legends and stop-transfer instructions. The Company agrees that following the Effective Date, or at such time as the Unrestricted Conditions are met or such legend is otherwise no longer required under this Section 2(e), it will, no later than the earlier of (x) three (3) Trading Days and (y) the number of Trading Days comprising the Standard Settlement Period following the delivery (the “Unlegended Shares Delivery Deadline”) by Holder to the Company or the Transfer Agent of this Warrant and a certificate representing Exercise Shares and/or Failure Payment Shares, as applicable, issued with a restrictive legend (such third Trading Day, the “Legend Removal Date”), deliver or cause to be delivered to Holder this Warrant and/or a certificate (or electronic transfer) representing such shares that is free from all restrictive and other legends (and stop transfer instructions). For purposes hereof, “Effective Date” shall mean the date that the first Registration Statement that the Company is required to file pursuant to the Registration Rights Agreement has been declared effective by the SEC.

(iii) Sale of Unlegended Shares . Holder agrees that the removal of the restrictive legend from this Warrant and any certificates representing securities as set forth in Section 2(e) above is predicated upon the Company’s reliance that Holder will sell this Warrant or any Exercise Shares and/or any Failure Payment Shares, as applicable, pursuant to either the registration requirements of the Securities Act, including any applicable prospectus delivery requirements, or an exemption therefrom, and that if such securities are sold pursuant to a Registration Statement, they will be sold in compliance with the plan of distribution set forth therein.

(f) Cancellation of Warrant . This Warrant shall be canceled upon the full Exercise of this Warrant, and, as soon as practical after the Date of Exercise, Holder shall be entitled to receive Common Stock for the number of shares purchased upon such Exercise of this Warrant, and if this Warrant is not Exercised in full, Holder shall be entitled to receive a new Warrant (containing terms identical to this Warrant) representing any unexercised portion of this Warrant in addition to such Common Stock; provided, however, as set forth in Section 2(b), Holder shall not be required to physically surrender this warrant if the Warrant is not Exercised in full.

(g) Holder of Record . Each person in whose name any Warrant for shares of Common Stock is issued shall, for all purposes, be deemed to be Holder of record of such shares on the Date of Exercise, irrespective of the date of delivery of the Common Stock purchased upon the Exercise of this Warrant. Prior to the exercise of this Warrant, nothing in this Warrant shall be construed as conferring upon Holder any rights as a stockholder of the Company.

(h) Delivery of Electronic Shares . In lieu of delivering physical certificates representing the Common Stock issuable upon Exercise or legend removal, or representing Failure Payment Shares, upon written request of Holder, the Company shall use its best efforts to cause the Transfer Agent to electronically transmit the Common Stock issuable upon Exercise to Holder by crediting the account of Holder’s prime

 

8


broker with DTC through its Deposit/Withdrawal at Custodian (DWAC) system. The time periods for delivery and penalties described herein shall apply to the electronic transmittals described herein. Any delivery not effected by electronic transmission shall be effected by delivery of physical certificates.

(i) Buy-In . In addition to any other rights or remedies available to Holder hereunder or otherwise at law or in equity, if the Company fails to cause its Transfer Agent to deliver to Holder a certificate or certificates, or electronic shares through DWAC, representing the Exercise Shares pursuant to an Exercise on or before the last day of the Delivery Period (other than a failure caused by any incorrect or incomplete information provided by Holder to the Company hereunder), and if after such date Holder is required by its broker to purchase (in an open market transaction or otherwise) or Holder or Holder’s brokerage firm otherwise purchases shares of Common Stock to deliver in satisfaction of a sale by Holder of the Exercise Shares which Holder was entitled to receive upon such Exercise (a “Buy-In”), then the Company shall (1) pay in cash to Holder the amount by which (x) Holder’s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (A) the number of Exercise Shares that the Company was required to deliver to Holder in connection with the Exercise at issue by (B) the price at which the sell order giving rise to such purchase obligation was executed, and (2) at the option of Holder, either reinstate the portion of the Warrant and equivalent number of Exercise Shares for which such Exercise was not honored (and refund the Exercise Price therefor, to the extent paid by Holder, and/or reinstate the principal amount of any indebtedness used to satisfy the applicable Exercise Price) or deliver to Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its Exercise and delivery obligations hereunder. For example, if Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted Exercise to cover the sale of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (1) of the immediately preceding sentence the Company shall be required to pay Holder $1,000. Holder shall provide the Company written notice indicating the amounts payable to Holder in respect of the Buy-In, together with applicable confirmations and other evidence reasonably requested by the Company. Nothing herein shall limit Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver certificates representing shares of Common Stock upon Exercise of the Warrant as required pursuant to the terms hereof.

(j) HSR Submissions. If Holder determines that, in connection with the exercise of this Warrant, it and the Company are required to file Premerger Notification Reports with the Federal Trade Commission (the “FTC”) and the United States Department of Justice (“DOJ”) and observe the Waiting Period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended, and the related rules and regulations promulgated thereunder (collectively, the “HSR Act”), the Company agrees to (i) cooperate with Holder in Holder’s preparing and making such submission and any responses to inquiries of the FTC and DOJ; (ii) prepare and make any submission required to be filed by the Company under the HSR Act and respond to inquiries of the FTC and DOJ in connection therewith; and (iii) reimburse Holder for the cost of the required filing fee for Holder’s submission under the HSR Act. For the avoidance of doubt, Holder shall bear all of its other costs and expenses in connection with such submission, including any attorneys’ fees associated therewith.

3. Payment of Warrant Exercise Price for Cash Exercise or Cashless Exercise; Cashless Major Exercise and Cashless Default Exercise .

(a) Exercise Price . The exercise price shall initially equal $________ per share, subject to adjustment pursuant to the terms hereof (as so adjusted, the “Exercise Price”), including but not limited to Section 5 below.

 

9


Payment of the Exercise Price may be made by either of the following, or a combination thereof, at the election of Holder:

(i) Cash Exercise : Holder may exercise this Warrant in cash, bank or cashier’s check or wire transfer (a “Cash Exercise”);

(ii) Cashless Exercise : In lieu of paying all or any portion of the Exercise Price in cash, Holder, at its option, may exercise this Warrant (in whole or in part) on a cashless basis by making appropriate notation on the applicable Exercise Form, in which event the Company shall issue Holder a number of shares of Common Stock computed using the following formula (a “Cashless Exercise”):

X = Y (A-B)/A

where: X = the number of shares of Common Stock to be issued to Holder.

Y = the number of shares of Common Stock for which this Warrant is being Exercised.

A = the Market Price of one (1) share of Common Stock (for purposes of this Section 3(a)(ii), where “Market Price,” as of any date, means the Volume Weighted Average Price (as defined herein) of the Company’s Common Stock over the ten (10) consecutive Trading Day period immediately preceding the Date of Exercise or other date in question, as applicable.

B = the Exercise Price.

As used herein, the “Volume Weighted Average Price” for any security as of any date means the volume weighted average sale price on the NasdaqGS as reported by, or based upon data reported by, Bloomberg Financial Markets or an equivalent, reliable reporting service mutually acceptable to and hereafter designated by holders of a majority in interest of the Warrants and the Company (“Bloomberg”) or, if the NasdaqGS is not the principal trading market for such security, the volume weighted average sale price of such security on the principal securities exchange or trading market where such security is listed or traded as reported by Bloomberg, or, if no volume weighted average sale price is reported for such security, then the last closing trade price of such security as reported by Bloomberg, or, if no last closing trade price is reported for such security by Bloomberg, the average of the bid prices of any market makers for such security that are listed or quoted on the OTC Bulletin Board, the OTCQX Market, the OTCQB Market or on the “pink” market of OTC Markets Group Inc. If the Volume Weighted Average Price cannot be calculated for such security on such date in the manner provided above, the volume weighted average price shall be the fair market value as mutually determined by the Company and Holders of a majority in interest of the Warrants being Exercised for which the calculation of the volume weighted average price is required in order to determine the Exercise Price of such Warrants.

(iii) Note Exchange Exercise : In lieu of paying all or any portion of the Exercise Price in cash, Holder, at its option, may exercise this Warrant (in whole or in part) through a reduction of an amount of principal outstanding under any Notes in accordance with Section 2.3(b) of the Facility Agreement, then held by Holder (a “Note Exchange Exercise”)

For purposes of Rule 144 and subsection (d)(3)(ii) thereof, it is intended, understood and acknowledged that the Common Stock issuable upon Exercise of this Warrant in a Cashless Exercise transaction or a Note Exchange Exercise transaction shall be deemed to have been acquired at the time this Warrant was issued (in the case of a Cashless Exercise) or at the time the applicable Note was issued (in the case of a Note Exchange Exercise). Moreover, it is intended, understood and acknowledged that the holding period for the

 

10


Common Stock issuable upon Exercise of this Warrant in a Cashless Exercise transaction or a Note Exchange Exercise transaction shall be deemed to have commenced on the date this Warrant was issued (in the case of a Cashless Exercise) or on the date the applicable Note was issued (in the case of a Note Exchange Exercise). As provided in Section 2(b), Holder shall only be required to physically surrender this Warrant in the event that Holder is exercising this Warrant in full.

(b) Cashless Major Exercise. To the extent Holder shall exercise this Warrant as a Cashless Major Exercise pursuant to Section 5(b)(i) and 5(b)(iii) below, Holder shall send to the Company (in any manner permitted under Section 2(a)) the Exercise Form indicating that Holder is exercising this Warrant (or any portion thereof) pursuant to a Cashless Major Exercise, in which event the Company shall issue a number of shares of Common Stock equal to the Black-Scholes Value of the Warrant (or such applicable portion being exercised) divided by the closing price of the Common Stock on the principal securities exchange or other securities market on which the Common Stock is then traded on the Trading Day immediately preceding the date on which the applicable Major Transaction is consummated, or, if in respect of a Cashless Major Exercise made after the date of consummation of the applicable Major Transaction, on the Trading Day immediately preceding the date on which the exercise form in respect of such Cashless Major Exercise is delivered. As provided in Section 2(b), Holder shall only be required to physically surrender this Warrant in the event that Holder is exercising this Warrant in full. Holder shall be permitted to make successive Cashless Major Exercises and send successive Exercise Forms in respect of a Cashless Major Exercise from time to time at any time during the Cashless Major Exercise Period.

(c) Cashless Default Exercise . To the extent Holder exercises this Warrant as a Cashless Default Exercise pursuant to Section 11(b)(i) below, Holder shall send to the Company (in any manner permitted under Section 2(a)) the Exercise Form indicating that Holder is exercising this Warrant pursuant to a Cashless Default Exercise, in which event the Company shall issue to Holder, within five (5) Trading Days of the applicable Default Notice, a number of shares of Common Stock (which shares shall be valued at the closing price of the Common Stock on the principal securities exchange or other securities market on which the Common Stock is then traded on the Trading Day immediately preceding the date on which the Exercise Form in respect of such Cashless Default Exercise is delivered) equal to the Black-Scholes Value of the remaining unexercised portion of this Warrant (or such portion thereof subject to such exercise) as of the date of such Default Notice (or in the case of an Event of Default referred to in Section 11(a)(vi), on the Trading Day immediately preceding the date the dividend or distribution is declared or, if not first declared, is paid). As provided in Section 2(b), the Holder shall be permitted to make successive Cashless Default Exercises and send successive Exercise Forms in respect of a Cashless Default Exercise, from time to time at any time from and after the date of the applicable Default Notice through the Term of this Warrant.

(d) Dispute Resolution . In the case of a dispute as to the determination of the closing price or the Volume Weighted Average Price of the Company’s Common Stock or the arithmetic calculation of the Exercise Price, Market Price or the Successor Major Transaction Consideration, or the number of shares issuable upon a Cashless Major Exercise, the Company shall submit the disputed determinations or arithmetic calculations via electronic mail within two (2) Business Days of receipt, or deemed receipt, of the Exercise Form or Major Transaction Early Termination Notice, or other event giving rise to such dispute, as the case may be, to Holder. If Holder and the Company are unable to agree upon such determination or calculation within two (2) Business Days of such disputed determination or arithmetic calculation being submitted to Holder, then the Company shall, within two (2) Business Days submit via electronic mail (i) the disputed determination of the closing price or the Volume Weighted Average Price of the Company’s Common Stock to an independent, reputable investment bank selected by the Company and approved by Holder, which approval shall not be unreasonably withheld, or (ii) the disputed arithmetic calculation of the Exercise Price, Market Price, any Successor Major Transaction Consideration or number of shares issuable upon a Cashless Major Exercise to the Company’s independent, outside registered public accountants. The Company shall use its reasonable best efforts to cause the investment bank or the accountants, as the case

 

11


may be, to perform the determinations or calculations and notify the Company and Holder of the results no later than five (5) Trading Days from the time it receives the disputed determinations or calculations. Such investment bank’s or accountants’ determination or calculation, as the case may be, shall be binding upon all parties absent demonstrable error, and the Company and Holder shall each pay one half of the fees and costs of such investment banker or accountant. Notwithstanding the existence of a dispute contemplated by this paragraph, if requested by Holder, the Company shall issue to Holder the Exercise Shares not in dispute in accordance with the terms hereof.

4. Transfer and Registration .

(a) Transfer Rights . Subject to the provisions of Section 8 of this Warrant, this Warrant may be transferred on the books of the Company, in whole or in part, in person or by attorney, upon surrender of this Warrant properly completed and endorsed. This Warrant shall be canceled upon such surrender and, as soon as practicable thereafter, the person to whom such transfer is made shall be entitled to receive a new Warrant or Warrants as to the portion of this Warrant transferred, and Holder shall be entitled to receive a new Warrant as to the portion hereof retained.

(b) Registrable Securities . The Common Stock issuable upon the Exercise of this Warrant entitles Holder (and applicable assignees or transferees of such Common Stock) to registration and other rights pursuant to the Registration Rights Agreement.

5. Adjustments Upon Certain Events .

(a) Recapitalization or Reclassification . If the Company shall at any time effect a stock split, payment of stock dividend, recapitalization, reclassification or other similar transaction of such character that the shares of Common Stock shall be changed into or become exchangeable for a larger or smaller number of shares, then upon the effective date thereof, the number of shares of Common Stock which Holder shall be entitled to purchase upon Exercise of this Warrant, shall be increased or decreased, as the case may be, in direct proportion to the increase or decrease in the number of shares of Common Stock by reason of such stock split, payment of stock dividend, recapitalization, reclassification or similar transaction, and the Exercise Price shall be, in the case of an increase in the number of shares, proportionally decreased and, in the case of decrease in the number of shares, proportionally increased. The Company shall give Holder the same notice it provides to holders of Common Stock of any transaction described in this Section 5(a).

(b) Rights Upon Major Transaction .

(i) Major Transaction . In the event that a Major Transaction occurs, then (1) in the case of a Successor Major Transaction, Holder, at its option, may elect to cause the conversion of this Warrant (a “Successor Major Transaction Conversion”), in whole or in part, into the right to receive the Successor Major Transaction Consideration, upon consummation of the Major Transaction, and (2) in the case of all other Major Transactions, Holder shall have the right to exercise this Warrant (or any portion thereof), at any time and from time to time following the occurrence of such event, as a Cashless Major Exercise. In the event Holder shall not have exercised any of its rights under clauses (1) or (2) above within the applicable time periods set forth herein, then the Major Transaction shall be treated as an Assumption (as defined below) in accordance with Section 5(b)(ii) below unless Holder waives its rights under this Section 5(b) with respect to such Major Transaction. Each of the following events shall constitute a “Major Transaction”:

(A) a consolidation, merger, exchange of shares, recapitalization, reorganization, business combination or other similar event, (1) following which the holders of Common Stock immediately preceding such consolidation, merger, exchange, recapitalization, reorganization, combination or event either

 

12


(a) no longer hold a majority of the shares of Common Stock or (b) no longer have the ability to elect a majority of the board of directors of the Company or (2) as a result of which shares of Common Stock shall be changed into (or the shares of Common Stock become entitled to receive) the same or a different number of shares of the same or another class or classes of stock or securities of the Company or another entity (collectively, a “Change of Control Transaction”);

(B) the sale or transfer, in one transaction or a series of related transactions, of (I) all or substantially all of the assets of the Company (including, for the avoidance of doubt, all or substantially all of the assets of the Company and its Subsidiaries, taken as a whole) to any Person other than a wholly-owned subsidiary of the Company or (II) assets of the Company (including, for the avoidance of doubt, all or substantially all of the assets of the Company and its Subsidiaries, taken as a whole) for a purchase price equal to more than 50% of the Equity Value (as defined below) of the Company. For purposes of this clause (B), “Equity Value” shall mean (I) the product of (x) the number of issued and outstanding shares of Common Stock on the date the Company delivers the Major Transaction Notice (defined below) multiplied by (y) the per share closing price of the Common Stock on such date on the NasdaqGS as reported by, or based upon data reported by, Bloomberg or, if the NasdaqGS is not the principal trading market for such security, the closing sale price of such security on the principal securities exchange or trading market where such security is listed or traded as reported by Bloomberg;

(C) a purchase, tender or exchange offer made to the holders of outstanding shares of Common Stock, such that following such purchase, tender or exchange offer a Change of Control Transaction shall have occurred;

(D) the liquidation, bankruptcy, insolvency, dissolution or winding-up (or the occurrence of any analogous proceeding) affecting the Company;

(E) the shares of Common Stock cease to be listed, traded or publicly quoted on the NasdaqGS and are not promptly re-listed or requoted on the New York Stock Exchange, the NYSE MKT, the NASDAQ Global Market or the NASDAQ Capital Market; or

(F) the Common Stock ceases to be registered under Section 12 of the Exchange Act.

(ii) Assumption. Any assumption of Company obligations under this paragraph shall be referred to herein as an “Assumption.” Unless otherwise provided in writing by Holder, the Company shall not consummate a Major Transaction in which the Company is not the surviving entity or as a result of which the Company has a new Parent Entity, unless (A) each Person acquiring the Company’s assets or Common Stock (or Parent Entity thereof, as applicable), or any other successor entity resulting from such Major Transaction (in each case, a “Successor Entity”), assumes in writing all of the obligations of the Company under this Warrant, the Facility Agreement (but, other than with respect to the Company’s obligations pursuant to Section 5.1(e) and 5.1(p) of the Facility Agreement and the other provisions of the Facility Agreement that expressly survive the repayment of the Loans (which shall be assumed in any Assumption), only if there are outstanding Loans under the Facility Agreement immediately following the consummation of the Major Transaction) and the Registration Rights Agreement in accordance with the provisions of this Section

 

13


5(b)(ii) pursuant to written agreements in form and substance reasonably satisfactory to Holder and approved by Holder prior to the consummation of such Major Transaction (such approval not to be unreasonably withheld or delayed), including agreements to deliver to Holder in exchange for its Warrants a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to the Warrants, that, among other things, (1) is exercisable for the appropriate number of shares of the Successor Entity’s capital stock (without regard to the 4.985% Cap or any other restriction or limitation on exercise, provided that such instrument shall contain a limitation on exercise comparable to that contained in the second paragraph of Section 1 of this Warrant), (2) has an exercise price similar to the then-effective Exercise Price (taking into account any conversion or exchange ratio applicable to the Common Stock in the Major Transaction) and exercise price adjustment provisions similar to those in the Warrants; or (3) entitles Holder to such additional securities or other consideration as Holder would be entitled pursuant to Section 5(b)(i) in connection with the Major Transaction; and (4) provides for registration rights similar to those provided by the Registration Rights Agreement, in each case reasonably satisfactory to Holder, and (B) the Successor Entity (including its Parent Entity) is a publicly traded corporation whose common stock is quoted on or listed for trading on an Eligible Market. For the avoidance of doubt, Holders’ reasonable satisfaction referred to in the immediately preceding sentence shall be construed only to apply to confirmation that the warrant or other comparable security and registration rights agreement delivered to Holder upon an assumption hereunder shall conform to the requirements of this Section 5(b)(ii), and this Section 5(b)(ii) shall not be construed as granting consent or approval rights to Holder with respect to the terms of such Major Transaction or to permit Holder to demand any additional consideration in respect of this Warrant other than as provided herein. Upon the occurrence of any Major Transaction, any Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Major Transaction, the provisions of this Warrant and the Registration Rights Agreement referring to the “Company” shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company herein. Upon consummation of the Major Transaction, the Successor Entity shall deliver to Holder confirmation that there shall be issued upon exercise of this Warrant at any time after the consummation of the Major Transaction, in lieu of the shares of Common Stock (or other securities, cash, assets or other property) issuable upon the exercise of the Warrants prior to such Major Transaction, such shares of publicly traded common stock (or their equivalent) of the Successor Entity, as adjusted in accordance with the provisions of this Warrant. The provisions of this Section shall apply similarly and equally to successive Major Transactions and shall be applied without regard to any limitations on the exercise of this Warrant other than any applicable beneficial ownership limitations.

(iii) Major Transaction Notice; Major Transaction Early Termination Right; Notice of Cashless Major Exercise. At least thirty (30) days prior to the consummation of any Major Transaction, but, in any event, within five (5) Trading Days following the first to occur of (x) the date of the public announcement of such Major Transaction if such announcement is made before 4:00 p.m., New York City time, or (y) the day following the public announcement of such Major Transaction if such announcement is made on and after 4:00 p.m., New York City time, the Company shall deliver written notice thereof via electronic mail and overnight courier to Holder (a “Major Transaction Notice”). At any time during the period beginning after Holder’s receipt of a Major Transaction Notice in respect of a Successor Major Transaction and ending five (5) Trading Days prior to the consummation of such Major Transaction (the “Early Termination Period”), Holder may elect a Successor Major Transaction Conversion by delivering written notice thereof (“Major Transaction Early Termination Notice”) to the Company, which Major Transaction Early Termination Notice shall indicate the portion of the Warrant (with reference to the number of shares of Common Stock issuable upon a Cash Exercise of such portion, without regard to the 4.985% Cap) that Holder is electing to be treated as a Successor Major Transaction Conversion. The portion of this Warrant subject to early termination pursuant to this Section 5(b)(iii), shall be converted into the right to receive the Successor Major Transaction Consideration

 

14


To the extent Holder shall elect to effect a Cashless Major Exercise in respect of a Major Transaction, Holder shall deliver its Exercise Form in accordance with Section 3(b), at any time and from time to time following receipt by Holder of the Major Transaction Notice until the later of (x) the Term of this Warrant and (y) the one-year anniversary of the applicable Major Transaction (the “Cashless Major Exercise Period”). For the avoidance of doubt, Holder shall be permitted to make successive Cashless Major Exercises and send successive Exercise Forms in respect of a Cashless Major Exercise from time to time at any time during the Cashless Major Exercise Period.

(iv) Escrow; Payment of Successor Major Transaction Consideration . Following the receipt of a Major Transaction Early Termination Notice in respect of a Successor Major Transaction from Holder, the Company shall not effect a Successor Major Transaction with respect to which Holder has elected a Successor Major Transaction Conversion unless either (A) it obtains, as a condition precedent to such Major Transaction, the written agreement of the Successor Entity that payment of the Successor Major Transaction Consideration shall be made to Holder concurrently with consummation of such Successor Major Transaction, or (B) it shall place the Successor Major Transaction Consideration into an escrow account with an independent escrow agent, and shall instruct the escrow agent to deliver the Successor Major Transaction Consideration to Holder, concurrently with the consummation of the Major Transaction. Notwithstanding clauses (A) and (B) above, Holder shall be treated on a pari passu basis with, and shall not have priority to payments to, the holders of Common Stock in connection with a Major Transaction. For purposes of determining the amount required to be placed in escrow pursuant to the provisions of this subsection (iv) and without affecting the amount of the actual Successor Major Transaction Consideration, the calculation of the price referred to in clause (1) of the first column of Schedule 1 hereto with respect to Stock Price shall be determined based on the Closing Market Price (as defined on Schedule I) of the Common Stock on the Trading Day immediately preceding the date that the Successor Major Transaction Consideration is deposited with the escrow agent.

(v) Injunction . Following the receipt of a Major Transaction Early Termination Notice from Holder, in the event that the Company attempts to consummate a Successor Major Transaction without either (1) placing the Successor Major Transaction Consideration in escrow in accordance with subsection (iv) above, or (2) obtaining the written agreement of the Successor Entity as described in subsection (iv) above, Holder shall have the right to apply for an injunction in any state or federal court sitting in the City of New York, Borough of Manhattan to prevent the closing of such Major Transaction until the Successor Major Transaction Consideration is delivered to Holder.

An early termination required by this Section 5(b) shall be made in accordance with the provisions of Section 12. To the extent an early termination required by this Section 5(b) is deemed or determined by a court of competent jurisdiction to be prepayments of the Warrant by the Company, such early termination shall be deemed to be voluntary prepayments. Notwithstanding anything to the contrary in this Section 5, until the Successor Major Transaction Consideration is paid in full, this Warrant may be exercised, in whole or in part, by Holder into shares of Common Stock, or in the event the Exercise Date is after the consummation of the Major Transaction, shares of publicly traded common stock (or their equivalent) of the Successor Entity pursuant to Section 5(b). The parties hereto agree that in the event of the Company’s early termination of any portion of the Warrant under this Section 5(b), Holder’s damages would be uncertain and difficult to estimate because of the parties’ inability to predict future interest rates and the uncertainty of the availability of a suitable substitute investment opportunity for Holder. Accordingly, any premium due under this Section 5(b) is intended by the parties to be, and shall be deemed, a commercially reasonable estimate of Holder’s actual loss of its investment opportunity and not as a penalty.

(c) Exercise Price Adjusted . As used in this Warrant, the term “Exercise Price” shall mean the purchase price per share specified in Section 3(a) of this Warrant, until the occurrence of an event stated in this Section 5 or otherwise set forth in this Warrant, and thereafter shall mean said price as adjusted from time to

 

15


time in accordance with the provisions of said subsection. No adjustment made pursuant to any provision of this Section 5 shall have the net effect of increasing the aggregate Exercise Price payable hereunder or, except as expressly provided in Section 5(a), otherwise increasing the Exercise Price.

(d) Adjustments: Additional Shares, Securities or Assets . In the event that at any time, as a result of an adjustment made pursuant to this Section 5 or otherwise, Holder shall, upon Exercise of this Warrant, become entitled to receive shares and/or other securities or assets (other than Common Stock) then, wherever appropriate, all references herein to shares of Common Stock shall be deemed to refer to and include such shares and/or other securities or assets; and thereafter the number of such shares and/or other securities or assets shall be subject to adjustment from time to time in a manner and upon terms as nearly equivalent as practicable to the provisions of this Section 5.

(e) Notice of Adjustments . Whenever the Exercise Price and/or number or type of securities issuable upon Exercise is adjusted pursuant to the terms of this Warrant, the Company shall promptly mail to Holder a notice (an “Exercise Price Adjustment Notice”) setting forth the Exercise Price and/or number or type of securities issuable upon Exercise after such adjustment and setting forth a statement of the facts requiring such adjustment. The Company shall, upon the written request at any time of Holder, furnish to Holder a like Warrant setting forth (i) such adjustment or readjustment, (ii) the Exercise Price at the time in effect and (iii) the number of shares of Common Stock and the amount, if any, of other securities or property which at the time would be received upon Exercise of the Warrant. For purposes of clarification, whether or not the Company provides an Exercise Price Adjustment Notice pursuant to this Section 5(e), upon the occurrence of any event that leads to an adjustment of the Exercise Price, Holder would be entitled to receive a number of Exercise Shares based upon the new Exercise Price, as adjusted, for exercises occurring on or after the date of such adjustment, regardless of whether Holder accurately refers to the adjusted Exercise Price in the Exercise Form.

6. Fractional Interests .

No fractional shares or scrip representing fractional shares shall be issuable upon the Exercise of this Warrant, but on Exercise of this Warrant, Holder may purchase only a whole number of shares of Common Stock. If, on Exercise of this Warrant, Holder would be entitled to a fractional share of Common Stock or a right to acquire a fractional share of Common Stock, such fractional share shall be disregarded and the number of shares of Common Stock issuable upon Exercise shall be the next higher whole number of shares.

7. Reservation of Shares .

From and after the date hereof, the Company shall at all times reserve for issuance such number of authorized and unissued shares of Common Stock (or other securities substituted therefor as herein above provided) as shall be sufficient for the Exercise of this Warrant and payment of the Exercise Price. If at any time the number of shares of Common Stock authorized and reserved for issuance is below the number of shares sufficient for the Exercise of this Warrant (a “Share Authorization Failure”) (based on the Exercise Price in effect from time to time), the Company will promptly take all corporate action necessary to authorize and reserve a sufficient number of shares, including calling a special meeting of stockholders to authorize additional shares to meet the Company’s obligations under this Section 7, in the case of an insufficient number of authorized shares, and using its best efforts to obtain stockholder approval of an increase in such authorized number of shares. The Company covenants and agrees that upon the Exercise of this Warrant, all shares of Common Stock issuable upon such Exercise shall be duly and validly issued, fully paid and nonassessable and not subject to preemptive rights, rights of first refusal or similar rights of any Person. The Company covenants and agrees that all shares of Common Stock issuable upon Exercise of this Warrant shall be approved for listing on the NasdaqGS, or, if the NasdaqGS is not the principal

 

16


trading market for the Common Stock, such principal market on which the Common Stock is traded or listed.

8. Restrictions on Transfer .

(a) Registration or Exemption Required . This Warrant has been issued in a transaction exempt from the registration requirements of the Securities Act by virtue of Section 4(a)(2) of the Securities Act and Rule 506 thereunder and exempt from registration or qualification under applicable state securities (or “blue sky”) laws. None of the Warrant, the Exercise Shares or Failure Payment Shares may be pledged, transferred, sold or assigned except pursuant to an effective registration statement or an exemption to the registration requirements of the Securities Act and applicable state laws, including Section 4(a)(7) of the Securities Act or a so-called “4[(a)](1) and a half” transaction.

(b) Assignment . Subject to Section 8(a), Holder may sell, transfer, assign, pledge, or otherwise dispose of this Warrant, in whole or in part. Holder shall deliver a written notice to the Company, substantially in the form of the Assignment attached hereto as Exhibit  B , indicating the Person or Persons to whom the Warrant shall be assigned and the respective number of warrants to be assigned to each assignee. The Company shall effect the assignment within three (3) Business Days of its receipt of a completed and executed form of Assignment (the “Transfer Delivery Period”), and shall deliver to the assignee(s) designated by Holder a Warrant or Warrants of like tenor and terms entitling Holder to purchase the appropriate number of shares. This Warrant and the rights evidenced hereby shall inure to the benefit of and be binding upon the successors and assigns of Holder. The provisions of this Warrant are intended to be for the benefit of all Holders from time to time of this Warrant, and shall be enforceable by any such Holder. For avoidance of doubt, in the event Holder notifies the Company that such sale or transfer is a so called “4[(a)](1) and half” transaction, the parties hereto agree that a legal opinion from outside counsel for Holder delivered to counsel for the Company substantially in the form attached hereto as Exhibit  C shall be the only requirement to satisfy an exemption from registration under the Securities Act to effectuate such “4[(a)](1) and half” transaction.

9. Noncircumvention .

The Company hereby covenants and agrees that the Company will not, by amendment of its certificate of incorporation, bylaws or through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issue or sale of securities, or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, and will at all times in good faith carry out all the provisions of this Warrant and take all action as may be required to protect the rights of Holder. Without limiting the generality of the foregoing, the Company (i) shall not increase the par value of any shares of Common Stock receivable upon the exercise of this Warrant above the Exercise Price then in effect, and (ii) shall take all such actions as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable shares of Common Stock upon the exercise of this Warrant.

10. Events of Failure; Definition of Black Scholes Value .

(a) Definition.

The occurrence of each of the following shall be considered to be an “Event of Failure.”

(i) A Delivery Failure occurs, where a “Delivery Failure” shall be deemed to have occurred if the Company fails to use its best efforts to deliver Exercise Shares to Holder within any applicable Delivery Period (other than due to the limitation contained in the second paragraph of Section 1);

 

17


(ii) A Legend Removal Failure occurs, where a “Legend Removal Failure” shall be deemed to have occurred if the Company fails to use its best efforts to issue this Warrant and/or Exercise Shares without a restrictive legend, or fails to use it best efforts to remove a restrictive legend, when and as required under Section 2(e) hereof;

(iii) a Transfer Delivery Failure occurs, where a “Transfer Delivery Failure” shall be deemed to have occurred if the Company fails to use its best efforts to deliver a Warrant within any applicable Transfer Delivery Period; and

(iv) a Registration Failure (as defined below).

For purpose hereof, “Registration Failure” means that (A) the Company fails to file with the SEC on or before the Filing Deadline (as defined in the Registration Rights Agreement) any Registration Statement required to be filed pursuant to Section 2(a) of the Registration Rights Agreement, (B) the Company fails to use its reasonable best efforts to obtain effectiveness with the SEC, prior to the Registration Deadline (as defined in the Registration Rights Agreement), and if such Registration Statement does not become effective prior to the Registration Deadline, as soon as possible thereafter, of any Registration Statement (as defined in the Registration Rights Agreement) that is required to be filed pursuant to Section 2(a) of the Registration Rights Agreement, or fails to use its reasonable best efforts to keep such Registration Statement current and effective as required in Section 3 of the Registration Rights Agreement, (C) the Company fails to file any additional Registration Statement required to be filed pursuant to Section 2(a)(ii) of the Registration Rights Agreement on or before the Additional Filing Deadline or fails to use its reasonable best efforts to cause such new Registration Statement to become effective on or before the Additional Registration Deadline, and if such effectiveness does not occur within such period, as soon as possible thereafter, (D) the Company fails to file any amendment to any Registration Statement, or any additional Registration Statement required to be filed pursuant to Section 3(b) of the Registration Rights Agreement within thirty (30) days of the applicable Registration Trigger Date (as defined in the Registration Rights Agreement), or fails to use its reasonable best efforts to cause such amendment and/or new Registration Statement to become effective within ninety (90) days of the applicable Registration Trigger Date, and, if such effectiveness does not occur within such period, as soon as possible thereafter, (E) any Registration Statement required to be filed under the Registration Rights Agreement, after its initial effectiveness and during the Registration Period (as defined in the Registration Rights Agreement), lapses in effect or, other than on a day during an Allowable Grace Period (as defined in the Registration Rights Agreement), sales of all of the Registrable Securities (as defined in the Registration Rights Agreement) cannot otherwise be made thereunder (whether by reason of the Company’s failure to amend or supplement the prospectus included therein in accordance with the Registration Rights Agreement, the Company’s failure to file and use its reasonable best efforts to obtain effectiveness with the SEC of an additional Registration Statement or amended Registration Statement required pursuant to Sections 2(a)(ii) or 3(b) of the Registration Rights Agreement, as applicable, or otherwise), or (F) the Company fails to provide a commercially reasonable written response to any comments to any Registration Statement submitted by the SEC within twenty-five (25) days of the date that such SEC comments are received by the Company.

(b) Failure Payments; Black-Scholes Determination. The Company understands that any Event of Failure (as defined above) could result in economic loss to Holder. In the event that any Event of Failure occurs, as compensation to Holder for such economic loss, the Company agrees to pay to Holder an amount payable, at the Company’s option, either (i) in cash or (ii) in shares of Common Stock that are valued for these purposes at the Volume Weighted Average Price on the date of such calculation (“Failure Payments” and such shares, “Failure Payment Shares”), in each case equal to the total economic loss of Holder determined on a commercially reasonable basis in connection with such Event of Failure for the relevant period (as recalculated on the first Business Day of each month thereafter for as long as Failure Payments shall continue to accrue) from the date of such Event of Failure until the Event of Failure is cured; provided, however, that in the event the Company elects to make Failure Payments in Failure Payment Shares, the Company shall issue, and Holder shall only receive, up to such number of shares of Common Stock in

 

18


respect of Failure Payments such that Holder and any other persons or entities whose beneficial ownership of Common Stock would be aggregated with Holder’s for purposes of Section 13(d) of the Exchange Act (including shares held by any “group” of which Holder is a member, but excluding shares beneficially owned by virtue of the ownership of securities or rights to acquire securities that have limitations on the right to convert, exercise or purchase similar to the limitation set forth herein) shall not collectively beneficially own greater than 4.985% of the total number of shares of Common Stock of the Company then issued and outstanding, and the balance of such Failure Payments shall be paid in cash. For purposes of clarification, it is agreed and understood that Failure Payments shall continue to accrue following any Event of Default until the applicable Default Amount is paid in full. The Company shall satisfy any Failure Payments under this Section pursuant to Section 10(c) below. Failure Payments are in addition to any Shares that Holder is entitled to receive upon Exercise of this Warrant.

(c) Payment of Accrued Failure Payments. The Failure Payments and Failure Payment Shares representing accrued Failure Payments for each Event of Failure shall be paid or issued and delivered, as the case may be, on or before the fifth (5th) Business Day of each month following a month in which Failure Payments accrued. Nothing herein shall limit Holder’s right to pursue actual damages (to the extent in excess of the Failure Payments) for the Company’s Event of Failure, and Holder shall have the right to pursue all remedies available at law or in equity (including a decree of specific performance and/or injunctive relief). Notwithstanding the above, if a particular Event of Failure results in an Event of Default pursuant to Section 11 hereof, then the Failure Payment, for that Event of Failure only, shall be considered to have been satisfied upon payment to Holder of an amount equal to the greater of (i) the Failure Payment, or (ii) the Default Amount, payable in accordance with Section 11.

(d) Maximum Interest Rate. Nothing contained herein or in any document referred to herein or delivered in connection herewith shall be deemed to establish or require the payment of a rate of interest or other charges in excess of the maximum permitted by applicable law. In the event that the rate of interest or dividends required to be paid or other charges hereunder exceed the maximum permitted by such law, any payments in excess of such maximum shall be credited against amounts owed by the Company to Holder and thereby refunded to the Company.

11. Default .

(a) Events Of Default . Each of the following events shall be considered to be an “Event of Default,” unless waived by Holder:

(i) Failure To Effect Registration. With respect to all Registration Failures, a Registration Failure occurs and remains uncured for a period of more than forty-five (45) days (or sixty (60) days in the case where the Company (i) has, by the Filing Deadline (as defined the Registration Rights Agreement) filed a Registration Statement (as defined in the Registration Rights Agreement) covering this Warrant and the number of shares required by the Registration Rights Agreement, and (ii) has responded in writing to any comments to the Registration Statement that the Company has received from the SEC, within ten (10) Business Days of such receipt, and nevertheless the SEC has not declared effective a Registration Statement covering the this Warrant and the Shares by the Registration Deadline (as defined in the Registration Rights Agreement)), and such Registration Failure relates solely to the Company’s failure to have the Registration Statement declared effective by the Registration Deadline (as defined in the Registration Rights Agreement) and with respect to a Registration Failure provided in clause (E) of the definition of “Registration Failure,” such Registration Failure occurs and remains uncured for a period of more than forty-five (45) days.

(ii) Failure To Deliver Common Stock . A Delivery Failure (as defined above) occurs and remains uncured for a period of more than twenty (20) days; or at any time, the Company announces or states in writing that

 

19


it will not honor its obligations to issue shares of Common Stock to Holder upon Exercise by Holder of the Exercise rights of Holder in accordance with the terms of this Warrant.

(iii) Legend Removal Failure . A Legend Removal Failure (as defined above) occurs and remains uncured for a period of twenty (20) days;

(iv) Transfer Delivery Failure . A Transfer Delivery Failure (as defined above) occurs and remains uncured for a period of twenty (20) days;

(v) Corporate Existence; Major Transaction . (A) The Company has failed to (1) place the Successor Major Transaction Consideration into escrow and instruct the escrow agent to release the Successor Major Transaction Consideration to the Holder pursuant to Section 5(b)(iii), or (2) obtain the written agreement of the Successor Entity and cause the Successor Entity to make payment as described in Section 5(b)(iii), (B) the Successor Major Transaction Consideration is not paid contemporaneously with the consummation of the Successor Major Transaction, or (C) with respect to a Major Transaction that is to be treated as an Assumption under the terms hereof, the Company has failed to meet the Assumption requirements of Section 5(b)(i); or

(vi) Section  13 Breach . During the Dividend Restriction Period, the Company declares or pays any dividend or distribution of any kind to the holders of Common Stock of the Company.

(b) Mandatory Early Termination .

(i) Mandatory Early Termination Amount; Cashless Default Exercise . The Company shall notify Holder in writing within two (2) Business Days of the occurrence of an Event of Default. If any Events of Default shall occur then, at the option of Holder, such option exercisable through the delivery of written notice to the Company by such Holder (the “Default Notice”), the Company shall have the right to terminate the outstanding amount of this Warrant and pay to Holder (a “Mandatory Early Termination”), in full satisfaction of its obligations hereunder by delivery of a notice to such effect to Holder within two (2) Business Days following receipt of the Default Notice, an amount payable in cash (the “Mandatory Early Termination Amount” or the “Default Amount”) equal to the Black-Scholes Value of the remaining unexercised portion of this Warrant on the date of such Default Notice (or in the case of an Event of Default referred to in Section 11(a)(vi), on the Trading Day immediately preceding the date the dividend or distribution is declared or, if not first declared, is paid). In the event the Company does not exercise its right to consummate a Mandatory Early Termination, then Holder shall have the right to exercise this Warrant, at any time and from time to time, pursuant to a Cashless Default Exercise in accordance with Section 3(c) above.

The Mandatory Early Termination Amount shall be payable within five (5) Business Days following the date of the applicable Default Notice.

(ii) Liquidated Damages . The parties hereto acknowledge and agree that the sums payable as Failure Payments or pursuant to a Mandatory Early Termination shall constitute partial liquidated damages and not penalties. The parties further acknowledge that (i) the amount of loss or damages likely to be incurred by Holder is incapable or is difficult to precisely estimate, (ii) the amounts specified bear a reasonable proportion and are not plainly or grossly disproportionate to the probable loss likely to be incurred by Holder, and (iii) the parties are sophisticated business parties and have been represented by sophisticated and able legal and financial counsel and negotiated this Agreement at arm’s length.

Upon the occurrence of an Event of Default, the Default Amount, together with all other amounts payable hereunder, shall immediately become due and payable, all without demand, presentment or notice, all of

 

20


which hereby are expressly waived, together with all costs, including legal fees and expenses, of collection, and Holder shall be entitled to exercise all other rights and remedies available at law or in equity.

(c) Posting Of Bond . In the event that any Event of Default occurs hereunder, the Company may not raise as a legal defense (in any Lawsuit, as defined below, or otherwise) or justification to such Event of Default any claim that such Holder or any one associated or affiliated with such Holder has been engaged in any violation of law, unless the Company has posted a surety bond (a “Surety Bond”) for the benefit of such Holder in the amount of 130% of the aggregate Surety Bond Value (as defined below) of all of Holder’s Warrants (the “Bond Amount”), which Surety Bond shall remain in effect until the completion of litigation of the dispute and the proceeds of which shall be payable to such Holder to the extent Holder obtains judgment.

For purposes hereof, a “Lawsuit” shall mean any lawsuit, arbitration or other dispute resolution filed by either party herein pertaining to any of this Warrant, the Facility Agreement, the Registration Rights Agreement or any other Loan Document (as defined in the Facility Agreement).

“Surety Bond Value,” for the Warrants shall mean 130% of the of the Black-Scholes Value of the remaining unexercised portion of this Warrant on the Trading Day immediately preceding the date that such bond goes into effect.

(d) Injunction And Posting Of Bond . In the event that the Event of Default referred to in subsection (a) of this Section 11 pertains to the Company’s failure to deliver unlegended shares of Common Stock to Holder pursuant to a Warrant Exercise, legend removal request, or otherwise, the Company may not refuse such unlegended share delivery based on any claim that such Holder or any one associated or affiliated with such Holder has been engaged in any violation of law, unless an injunction from a court, on prior notice to Holder, restraining and or enjoining Exercise of all or part of said Warrant shall have been sought and obtained by the Company and the Company has posted a Surety Bond for the benefit of such Holder in the amount of the Bond Amount, which Surety Bond shall remain in effect until the completion of litigation of the dispute and the proceeds of which shall be payable to such Holder to the extent Holder obtains judgment.

(e) Remedies, Other Obligations, Breaches And Injunctive Relief . The remedies provided in this Warrant shall be cumulative and in addition to all other remedies available under this Warrant, the Facility Agreement, the Registration Rights Agreement and any other Loan Document, at law or in equity (including a decree of specific performance and/or other injunctive relief), and nothing herein shall limit the right of Holder to pursue actual damages for any failure by the Company to comply with the terms of this Warrant. The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to Holder and that the remedy at law for any such breach may be inadequate. The Company therefore agrees that, in the event of any such breach or threatened breach (including a breach or threatened breach of Section 13), the holder of this Warrant shall be entitled, in addition to all other available remedies, to an injunction restraining any breach, without the necessity of showing economic loss and without any bond or other security being required.

12. Holder’s Early Terminations .

(a) Mechanics of Holder’s Early Terminations . In the event that the Company does not deliver the applicable Successor Major Transaction Consideration or Default Amount or the Exercise Shares in respect of an election of a Successor Major Transaction Conversion, Cashless Major Exercise, Cashless Default or Exercise, as the case may be, to Holder within the time period or as otherwise required pursuant to the terms hereof, at any time thereafter Holder shall have the option, upon notice to the Company, in lieu of an election of a Successor Major Transaction Conversion, Cashless Major Exercise, Cashless Default Exercise

 

21


or Exercise, as the case may be, to require the Company to promptly return to Holder all or any portion of this Warrant that was submitted for election of a Successor Major Transaction Conversion, Cashless Major Exercise, Cashless Default Exercise or Exercise, as the case may be. Upon the Company’s receipt of such notice, (x) the applicable election of Successor Major Transaction Conversion, Cashless Major Exercise, Cashless Default Exercise or Exercise, as the case may be, shall be null and void with respect to such applicable portion of this Warrant, (y) the Company shall immediately return this Warrant, or issue a new Warrant to Holder representing the portion of this Warrant that was submitted for election of Successor Major Transaction Conversion, Cashless Major Exercise, Cashless Default Exercise or Exercise, as the case may be, and (z) the Exercise Price of this Warrant or such new Warrant shall be adjusted to the Exercise Price as in effect on the date on which the applicable election of Successor Major Transaction Conversion, Cashless Major Exercise, Cashless Default Exercise or Exercise, as the case may be, is voided. Holder’s delivery of a notice voiding an election of a Successor Major Transaction Conversion, Cashless Major Exercise, Cashless Default Exercise or Exercise, as the case may be, and exercise of its rights following such notice shall not affect the Company’s obligations to make any Failure Payments which have accrued prior to the date of such notice with respect to the Warrant subject to such notice.

13. Dividend Restrictions .

Until the earlier of the expiration of the Term and the date Holder Exercises this Warrant in full (the “Dividend Restriction Period”), the Company shall not declare or pay any dividend or distribution of any kind to the holders of Common Stock of the Company.

14. Benefits of this Warrant .

Nothing in this Warrant shall be construed to confer upon any person other than the Company and Holder any legal or equitable right, remedy or claim under this Warrant and this Warrant shall be for the sole and exclusive benefit of the Company and Holder.

15. Governing Law .

All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement (whether brought against a party hereto or its respective affiliates, directors, officers, stockholders, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York, Borough of Manhattan. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. The parties hereby waive all rights to a trial by jury. If either party shall commence an action or proceeding to enforce any provisions of this Agreement, then the prevailing party in such action or proceeding shall be reimbursed by the other party for its reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.

 

22


16. Loss of Warrant .

Upon receipt by the Company of evidence of the loss, theft, destruction or mutilation of this Warrant, and (in the case of loss, theft or destruction) of indemnity or security reasonably satisfactory to the Company, and upon surrender and cancellation of this Warrant, if mutilated, the Company shall execute and deliver a new Warrant of like tenor and date.

17. Notice or Demands .

Except as otherwise provided herein, notices or demands pursuant to this Warrant to be given or made by Holder to or on the Company shall be sufficiently given or made if sent by overnight delivery with a nationally recognized overnight courier service, certified or registered mail, return receipt requested, postage prepaid, and addressed, until another address is designated in writing by the Company, to the address set forth in Section 2(a) above. To the extent any notice or demand pursuant to this Warrant can be made by electronic mail, such notice or demand given or made by Holder to or on the Company shall be sufficiently given or made if it is sent by electronic mail to the addresses that the Company shall designate in writing from time to time. Notices or demands pursuant to this Warrant to be given or made by the Company to or on Holder shall be sufficiently given or made if sent by overnight delivery with a nationally recognized overnight courier service or certified or registered mail, return receipt requested, postage prepaid, and addressed, to the address of Holder set forth in the Company’s records, until another address is designated in writing by Holder.

17. Construction .

Unless the context otherwise requires, (a) all references to Articles, Sections, Schedules or Exhibits are to Articles, Sections, Schedules or Exhibits contained in or attached to this Warrant, (b) words in the singular or plural include the singular and plural and pronouns stated in either the masculine, the feminine or neuter gender shall include the masculine, feminine and neuter and (c) the use of the word “including” in this Warrant shall be by way of example rather than limitation.

18. Signatures .

In the event that any signature to this Warrant or any amendment hereto is delivered by electronic mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such “.pdf” signature page were an original thereof. Notwithstanding the foregoing, the Company shall be obligated to deliver to Holder an original signature to this Warrant. At the request of any party, each other party shall promptly re-execute an original form of this Warrant or any amendment hereto and deliver the same to the other party. No party hereto shall raise the use of electronic mail delivery of a “.pdf” format data file to deliver a signature to this Warrant or any amendment hereto or the fact that such signature was transmitted or communicated through the use of electronic mail delivery of a “.pdf” format data file as a defense to the formation or enforceability of a contract, and each party hereto forever waives any such defense.

 

23


IN WITNESS WHEREOF, the undersigned has executed this Warrant as of the              day of             , 20    .

 

ENDOLOGIX, INC.
By:    
 

Print Name:

Title:

 

24


EXHIBIT A-1

EXERCISE FORM FOR WARRANT

TO: [                     ]

CHECK THE APPLICABLE BOX:

 

  

Cash Exercise, Cashless Exercise or Note Exchange Exercise

 

The undersigned hereby irrevocably exercises Warrant Number          (the “Warrant”) with respect to [            ] shares of Common Stock (the “Common Stock”) of Endologix, Inc., a Delaware corporation (the “Company”). [IF APPLICABLE: The undersigned hereby encloses $         as payment of the Exercise Price.]

 

☐ The undersigned is exercising the Warrant with respect to [            ] shares of Common Stock pursuant to a Cashless Exercise, and hereby makes payment of the Exercise Price with respect to such shares in full, all in accordance with the conditions and provisions of the Warrant applicable to such Cashless Exercise.

 

☐ The undersigned is exercising the Warrant with respect to [            ] shares of Common Stock pursuant to a Note Exchange Exercise. The undersigned hereby agrees to cancel $         of principal outstanding under Notes of the Company held by Holder in satisfaction of the Exercise Price in accordance with the conditions and provisions of the Warrant applicable to such Note Exchange Exercise.

  

Cashless Major Exercise

 

The undersigned hereby irrevocably exercises the Warrant with respect to         % of the Warrant currently outstanding pursuant to a Cashless Major Exercise in accordance with the terms of the Warrant.

☐       

Cashless Default Exercise

 

The undersigned hereby irrevocably exercises the Warrant pursuant to a Cashless Default Exercise, in accordance with the terms of the Warrant.

1. The undersigned requests that any stock certificates for such shares be issued free of any restrictive legend, if appropriate, and, if requested by the undersigned, a warrant representing any unexercised portion hereof be issued, pursuant to the Warrant in the name of the undersigned and delivered to the undersigned at the address set forth below.

2. Capitalized terms used but not otherwise defined in this Exercise Form shall have the meaning ascribed thereto in the Warrant.

Dated: _______________

 

 

Signature

 

 

Print Name

 

 

Address

 

25


NOTICE

The signature to the foregoing Exercise Form must correspond to the name as written upon the face of the attached Warrant in every particular, without alteration or enlargement or any change whatsoever.

 

26


EXHIBIT B

ASSIGNMENT

(To be executed by the registered holder

desiring to transfer the Warrant)

FOR VALUE RECEIVED, the undersigned holder of the attached warrant (the “Warrant”) hereby sells, assigns and transfers unto the person or persons below named the right to purchase                  shares of the Common Stock of [ ], a Delaware corporation, evidenced by the attached Warrant and does hereby irrevocably constitute and appoint                  attorney to transfer the said Warrant on the books of the Company, with full power of substitution in the premises.

 

Dated: _______________    
       
      Signature
     

Fill in for new registration of Warrant:

 

 

Name

 
 

 

Address

 
 

 

Please print name and address of assignee

 
(including zip code number)  

NOTICE

The signature to the foregoing Assignment must correspond to the name as written upon the face of the attached Warrant in every particular, without alteration or enlargement or any change whatsoever.

 

27


EXHIBIT C

FORM OF OPINION

______, 20__

[                    ]

Re: [ ] (the “Company”)

Dear Sir:

[                    ] (“[                    ]”) intends to transfer             Warrants (the “Warrants”) of the Company to                      (“                    ”) without registration under the Securities Act of 1933, as amended (the “Securities Act”). In connection therewith, we have examined and relied upon the truth of representations contained in an Investor Representation Letter attached hereto and have examined such other documents and issues of law as we have deemed relevant.

Based on and subject to the foregoing, we are of the opinion that the transfer of the Warrants by              to              may be effected without registration under the Securities Act, provided, however, that the Warrants to be transferred to              contain a legend restricting its transferability pursuant to the Securities Act and that transfer of the Warrants is subject to a stop order.

The foregoing opinion is furnished only to                      and may not be used, circulated, quoted or otherwise referred to or relied upon by you for any purposes other than the purpose for which furnished or by any other person for any purpose, without our prior written consent.

Very truly yours,

 

28


[FORM OF INVESTOR REPRESENTATION LETTER]

_____, 20__

[_________________]

Gentlemen:

                     (“        ”) has agreed to purchase                  Warrants (the “Warrants”) of [ ] (the “Company”) from [                    ] (“[                    ]”). We understand that the Warrants are “restricted securities.” We represent and warrant that ______ is a sophisticated institutional investor that would qualify as an “Accredited Investor” as defined in Rule 501 of Regulation D under the Securities Act of 1933, as amended (the “Securities Act”).

________ represents and warrants as of the date hereof as follows:

1. That it is acquiring the Warrants and the shares of common stock, $0.001 par value per share underlying such Warrants (the “Exercise Shares”) solely for its account for investment and not with a view to or for sale or distribution of said Warrants or Exercise Shares or any part thereof in violation of the Securities Act.                  also represents that the entire legal and beneficial interests of the Warrants and Exercise Shares                      is acquiring is being acquired for, and will be held for, its account only;

2. That the Warrants and the Exercise Shares must be held indefinitely unless they are registered under the Securities Act or an exemption from such registration is available.                      recognizes that the Company has no obligation to register the Warrants, or to comply with any exemption from such registration;

3. That neither the Warrants nor the Exercise Shares may be sold pursuant to Rule 144 adopted under the Securities Act unless certain conditions are met;

We acknowledge that the Company will place stop orders with respect to the Warrants and the Exercise Shares, and if a registration statement is not effective, the Exercise Shares shall bear the following restrictive legend:

“THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER SAID ACT, OR PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER SAID ACT INCLUDING PURSUANT TO SECTION 4(A)(7) OF THE SECURITIES ACT OR RULE 144 UNDER SAID ACT OR PURSUANT TO A PRIVATE SALE EFFECTED UNDER APPLICABLE FORMAL OR INFORMAL SEC INTERPRETATION OR GUIDANCE, SUCH AS A SO-CALLED “4[(a)](1) AND A HALF” SALE. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.”

 

29


“THE SALE, TRANSFER OR ASSIGNMENT OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO THE TERMS AND CONDITIONS OF A CERTAIN REGISTRATION RIGHTS AGREEMENT DATED AS OF APRIL 3, 2017, AS AMENDED FROM TIME TO TIME, AMONG THE COMPANY AND CERTAIN HOLDERS OF ITS OUTSTANDING SECURITIES. COPIES OF SUCH AGREEMENT MAY BE OBTAINED AT NO COST BY WRITTEN REQUEST MADE BY THE HOLDER OF RECORD OF THIS CERTIFICATE TO THE SECRETARY OF THE COMPANY.”

At any time and from time to time after the date hereof,                      shall, without further consideration, execute and deliver to [                    ] or the Company such other instruments or documents and shall take such other actions as they may reasonably request to carry out the transactions contemplated hereby.

Very truly yours,

 

30


Schedule 1

Black-Scholes Value

 

    

Calculation Under Sections 3(b) and 5(b)(iii)

  

Calculation Under Section 10(b) or 11(b)

Remaining Term    Number of calendar days from date of public announcement of the Major Transaction until the last date on which the Warrant may be exercised.    Number of calendar days from the date of the Event of Failure, or in the case of an Event of Default, the date of the Default Notice, until the last date on which the Warrant may be exercised.
Interest Rate    A risk-free interest rate corresponding to the US$ LIBOR/Swap rate for a period equal to the Remaining Term.    A risk-free interest rate corresponding to the US$ LIBOR/Swap rate for a period equal to the Remaining Term.
Cost to Borrow    Zero    Zero
Volatility   

If the first public announcement of the Major Transaction is made at or prior to 4:00 p.m., New York City time, the arithmetic mean of the historical volatility for the 10, 30 and 50 Trading Day periods ending on the date of such first public announcement, obtained from the HVT or similar function on Bloomberg.

 

If the first public announcement of the Major Transaction is made after 4:00 p.m., New York City time, the arithmetic mean of the historical volatility for the 10, 30 and 50 Trading Day periods ending on the next succeeding Trading Day following the date of such first public announcement, obtained from the HVT or similar function on Bloomberg.

   The arithmetic mean of the historical volatility for the 10, 30 and 50 Trading Day periods ending on the date of such determination, obtained from the HVT or similar function on Bloomberg.
Stock Price    As selected by Holder in its commercially reasonable discretion in order to produce a commercially reasonable result, any of: (1) the closing price of the Common Stock on NYSE, or, if that is not the principal trading market for the Common Stock, such principal market on which the Common Stock is traded or listed (the “Closing Market Price”) on the Trading Day immediately preceding the date on which a Major Transaction is consummated, (2) the first Closing Market    The volume Weighted Average Price on the date of such determination.


   Price following the first public announcement of a Major Transaction, (3) the Closing Market Price as of the date immediately preceding the first public announcement of the Major Transaction or (4) the cash amount payable per share of Common Stock. The Company and Holder acknowledge and agree that any of the above will produce a commercially reasonable result.   
Dividends    Zero.    Zero.
Strike Price    Exercise Price as defined in section 3(a).    Exercise Price as defined in section 3(a).


EXHIBIT C-2

FORM OF ADDITIOANL WARRANT

THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAW. THE SECURITIES MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT, EXCEPT PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT, INCLUDING PURSUANT TO SECTION 4(A)(7) OF THE SECURITIES ACT OR RULE 144 UNDER THE SECURITIES ACT OR PURSUANT TO A PRIVATE SALE EFFECTED UNDER APPLICABLE FORMAL OR INFORMAL SEC INTERPRETATION OR GUIDANCE, SUCH AS A SO-CALLED “4[(a)](1) AND A HALF SALE.” NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

AN INVESTMENT IN THESE SECURITIES INVOLVES A HIGH DEGREE OF RISK. HOLDERS MUST RELY ON THEIR OWN ANALYSIS OF THE INVESTMENT AND ASSESSMENT OF THE RISKS INVOLVED.

Warrant to Purchase

[                    ] 8 shares

Warrant Number: 2018-[    ]

Warrant to Purchase Common Stock

of

Endologix, Inc.

THIS CERTIFIES that [                            ] or any subsequent holder hereof (“Holder”) has the right to purchase from Endologix, Inc., a Delaware corporation (the “Company”), [                            ] ([                    ]) fully paid and nonassessable shares of the Company’s common stock, $0.001 par value per share (“Common Stock”), subject to adjustment as provided herein, at a price equal to the Exercise Price (as defined in Section 3 below), at any time during the Exercise Period (as defined in Section 1 below).

Holder agrees with the Company that this Warrant to Purchase Common Stock of the Company (this “Warrant” or this “Agreement”) is issued and all rights hereunder shall be held subject to all of the conditions, limitations and provisions set forth herein.

18. Date of Issuance and Term .

This Warrant shall be deemed to be issued, and shall be in full force and effect commencing, on August 9, 2018 (“Date of Issuance”). The exercise period of this Warrant begins on (and includes) February 9, 2019, and ends at 5:00 p.m., New York City time, on August 9, 2025 (the “Exercise Period”). This Warrant was issued pursuant to that certain Amended and Restated Facility Agreement (as may be amended, restated, supplemented or otherwise modified from time to time in accordance with the terms thereof, the “Facility Agreement”) by and among the Company and Deerfield Private Design Fund III, L.P., Deerfield Private

 

 

8  

Total number of shares to equal 8,750,000, divided among the funds (1/3 each).


Design Fund IV, L.P., and Deerfield Partners, L.P., dated as of August 9, 2018, and in conjunction with that certain Amended and Restated Registration Rights Agreement (as may be amended, restated, supplemented or otherwise modified from time to time in accordance with the terms thereof, the “Registration Rights Agreement”) by and among the Company and Deerfield Private Design Fund III, L.P., Deerfield Private Design Fund IV, L.P., and Deerfield Partners, L.P., dated as of August 9, 2018.

Notwithstanding anything herein to the contrary, the Company shall not issue to Holder, and Holder may not acquire, a number of shares of Common Stock upon exercise of this Warrant to the extent that, upon such exercise, the number of shares of Common Stock then beneficially owned by Holder and its Affiliates and any other persons or entities whose beneficial ownership of Common Stock would be aggregated with Holder’s for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (including shares held by any “group” of which Holder is a member, but excluding shares beneficially owned by virtue of the ownership of securities or rights to acquire securities that have limitations on the right to convert, exercise or purchase similar to the limitation set forth herein), would exceed 4.985% of the total number of shares of Common Stock then issued and outstanding (the “4.985% Cap”); provided, however, that the 4.985% Cap shall only apply to the extent that the Common Stock is deemed to constitute an “equity security” pursuant to Rule 13d-1(i) promulgated under the Exchange Act. For purposes hereof, “group” has the meaning set forth in Section 13(d) of the Exchange Act and applicable regulations of the Securities and Exchange Commission (the “SEC”), and the percentage held by Holder shall be determined in a manner consistent with the provisions of Section 13(d) of the Exchange Act. Upon the written request of Holder, the Company shall, within two (2) Trading Days, confirm orally and in writing to Holder the number of shares of Common Stock then outstanding.

For purposes hereof:

“Affiliate” means any person or entity that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a person or entity, as such terms are used in and construed under Rule 144 (“Rule 144”) under the Securities Act of 1933, as amended (the “Securities Act”). With respect to a Holder, any investment fund or managed account that is managed on a discretionary basis by the same investment manager as such Holder shall, for purposes hereof, be deemed to be an Affiliate of such Holder.

“Asset Sale” means a transaction covered by the provisions of clause (B) of the definition of “Major Transaction” involving the sale or transfer of all or substantially all of the assets of the Company (including, for the avoidance of doubt, all or substantially all of the assets of the Company and its Subsidiaries (as defined in the Facility Agreement), taken as a whole) in connection with which the Company has announced its intention to liquidate and distribute its assets to stockholders.

“Black-Scholes Value” shall mean the Black-Scholes value of this Warrant, or applicable portion thereof, as determined by use of the Black-Scholes Option Pricing Model using the criteria set forth on Schedule 1 hereto.

“Business Day” means a day other than a Saturday or Sunday or any other day on which commercial banks are authorized or required by law to close in New York City.

“Cashless Default Exercise” shall mean an exercise of this Warrant as a “Cashless Default Exercise” in accordance with Sections 3(c) and 11(b) hereof.

“Cashless Major Exercise” shall mean an exercise of this Warrant or portion thereof as a “Cashless Major Exercise” in accordance with Sections 3(b) and 5(b)(i) hereof.

 

4


“Cash Out Major Transaction” means a Major Transaction in which the consideration payable to holders of Common Stock in connection with the Major Transaction consists solely of cash.

“Eligible Market” means the New York Stock Exchange, the NASDAQ Capital Market, the NASDAQ Global Market, the NASDAQ Global Select Market, the NYSE American or, in each case, any successor thereto.

“Parent Entity” of a Person means an entity that, directly or indirectly, controls the applicable Person and whose common stock or equivalent equity security is quoted or listed on an Eligible Market, or, if there is more than one such Person or Parent Entity, the Person or Parent Entity with the largest public market capitalization as of the date of consummation of a Major Transaction.

“Person” means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other entity and a government or any department or agency thereof.

“Standard Settlement Period” means the standard settlement period for equity trades effected on securities exchanges in the United States, expressed in a number of Trading Days, as in effect on the applicable Date of Exercise (as defined in Section 2(b)).

“Stock Event” means a stock split, stock combination, reclassification, payment of stock dividend, recapitalization or other similar transaction of such character that the shares of Common Stock shall be changed into or become exchangeable for a larger or small number of shares.

“Successor Entity” means any Person purchasing the Company’s assets or Common Stock, or any successor entity resulting from such Major Transaction, or if the Warrant is to be exercisable for shares of capital stock of a Parent Entity (as defined above), such Person’s Parent Entity.

“Successor Major Transaction” means either a Takeout Major Transaction or an Asset Sale.

“Successor Major Transaction Consideration” means (i) in the case of a Takeout Major Transaction (other than a Cash Out Major Transaction), the amount of cash and other assets and the number of securities or other property of the Successor Entity or other entity that would be issuable in such Major Transaction, in respect of a number of shares equal to the Successor Major Transaction Conversion Share Amount and (ii) in the case of an Asset Sale or a Cash Out Major Transaction, an amount of cash equal to the Black-Scholes Value of the Warrant.

“Successor Major Transaction Conversion Share Amount” means an amount equal to the Black-Scholes Value of the Warrant (or such applicable portion subject to a Successor Major Transaction Conversion), divided by the closing price of the Common Stock on the principal securities exchange or other securities market on which the Common Stock is then traded on the Trading Day immediately preceding the date on which the applicable Major Transaction is consummated.

“Takeout Major Transaction” means a transaction covered by the provisions of clause (A) of the definition of “Major Transaction” in which the shares of Common Stock of the Company are converted into the right to receive cash, securities of another entity and/or other assets.

“Trading Day” shall mean any day on which the Common Stock is traded for any period on the NASDAQ Global Select Market (“NasdaqGS”) or, if the NasdaqGS is not the principal trading market for the Common Stock, on the principal securities exchange or other securities market on which the Common Stock is then being traded; provided, however, that during any period in which the Common Stock is not

 

5


listed or quoted on the NasdaqGS or any other securities exchange or market, the term “Trading Day” shall mean a Business Day.

19. Exercise .

(a) Manner of Exercise . During the Exercise Period (or, in respect of a Cashless Major Exercise, the Cashless Major Exercise Period (as defined below)), this Warrant may be Exercised as to all or any lesser number of whole shares of Common Stock covered hereby (the “Warrant Shares” or the “Shares”) by sending to the Company the Exercise Form attached hereto as Exhibit  A-1 (the “Exercise Form”) duly completed and executed, and, if applicable, the full Exercise Price (as defined below, which may be satisfied by a Cash Exercise, a Cashless Exercise or a Note Exchange Exercise, as each is defined below) for each share of Common Stock as to which this Warrant is Exercised, at the office of the Company, 2 Musick, Irvine, CA 92618, Attention: Chief Financial Officer; Phone: (949) 595-7200, Email: vmahboob@endologix.com, or at such other office or agency as the Company may designate in writing, by overnight mail or electronic mail (any such exercise of the Warrant being hereinafter called an “Exercise” of this Warrant).

(b) Date of Exercise . The “Date of Exercise” of the Warrant shall, in each case, be the date that the Exercise Form attached hereto as Exhibit  A-1 , completed and executed, is sent by electronic mail to the Company, provided that the Exercise Price is satisfied as soon as practicable thereafter but in no event later than two (2) Business Days following the date of such electronic mail. Alternatively, the Date of Exercise shall be defined as the date the original Exercise Form is received by the Company, if Holder has not previously sent the Exercise Form by electronic mail. Upon delivery of the Exercise Form to the Company by electronic mail or otherwise, Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been Exercised, irrespective of the date such Warrant Shares are credited to Holder’s or its designee’s Depository Trust Company (“DTC”) account or the date of delivery of the certificates evidencing such Warrant Shares, as the case may be; provided, however, that in the event an Exercise Form in respect of a Cashless Major Exercise is delivered prior to the occurrence of the applicable Major Transaction, Holder shall be deemed to have become the holder of record of the shares issuable upon such exercise immediately prior to the consummation of such Major Transaction and the Date of Exercise shall in such event be deemed to have occurred on the date of the occurrence of the Major Transaction. Holder shall not be required to physically surrender this Warrant to the Company until Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days following the date the final Exercise Form is delivered to the Company. Execution and delivery of an Exercise Form with respect to a partial Exercise shall have the same effect as cancellation of the original Warrant and issuance of a new Warrant evidencing the right to purchase the remaining number of Warrant Shares.

(c) Delivery of Common Stock Upon Exercise . Within the earlier of (x) two (2) Trading Days and (y) the number of Trading Days comprising the Standard Settlement Period after any Date of Exercise (but, in the case of a Cash Exercise, within two (2) Business Days following the Company’s receipt of the full Exercise Price, if later) or in the case of a Cashless Default Exercise (as defined in Section 5(b) below), within the period provided in Section 3(c), as applicable (the “Delivery Period”), the Company shall issue and deliver (or cause its transfer agent (the “Transfer Agent”) to issue and deliver) in accordance with the terms hereof to or upon the order of Holder that number of shares of Common Stock (“Exercise Shares”) for the portion of this Warrant exercised as shall be determined in accordance herewith. Upon the Exercise of this Warrant or any part hereof, the Company shall, at its own cost and expense, take all necessary action, including obtaining and delivering an opinion of counsel, to assure that the Transfer Agent shall issue stock certificates in the name of Holder (or its nominee) or such other persons as designated by Holder and in such denominations as Holder shall specify at Exercise, representing the number of shares of Common

 

6


Stock issuable upon such Exercise. The Company warrants that no instructions other than these instructions have been or will be given to the Transfer Agent and that, unless waived by Holder, this Warrant and the Exercise Shares will be free-trading, and freely transferable, and will not contain or be subject to a legend (or be subject to any stop transfer instruction) restricting the resale or transferability of the Exercise Shares if the Unrestricted Conditions (as defined below) are met.

The Company shall be responsible for paying all present or future stamp, court or documentary, intangible, recording, filing or similar taxes that arise from any payment or issuance made under, from the execution, delivery, performance or enforcement of, or otherwise with respect to, this Warrant.

(d) Delivery Failure . In addition to any other remedies which may be available to Holder, in the event that the Company fails for any reason to effect delivery of the Exercise Shares by the end of the Delivery Period (a “Delivery Failure”), Holder will be entitled to revoke all or part of the relevant Exercise by delivery of a notice to such effect to the Company whereupon the Company and Holder shall each be restored to their respective positions immediately prior to the delivery of such notice of revocation, except that the Failure Payments under Section 10(b) shall be payable through the date such notice of revocation is given to the Company.

(e) Legends .

(i) Restrictive Legend . Holder understands that until such time as this Warrant, the Exercise Shares and the Failure Payment Shares (as defined below) have been registered under the Securities Act or otherwise may be sold pursuant to Rule 144 or an exemption from registration under the Securities Act without any restriction as to the number of securities as of a particular date that can then be immediately sold, this Warrant, the Exercise Shares and the Failure Payment Shares, as applicable, may bear a restrictive legend in substantially the following form (and a stop-transfer order consistent therewith may be placed against transfer of the certificates for such securities):

“THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER SAID ACT, EXCEPT PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER SAID ACT INCLUDING PURSUANT TO SECTION 4(A)(7) OF THE SECURITIES ACT OR RULE 144 UNDER SAID ACT OR PURSUANT TO A PRIVATE SALE EFFECTED UNDER APPLICABLE FORMAL OR INFORMAL SEC INTERPRETATION OR GUIDANCE, SUCH AS A SO-CALLED “4[(a)](1) AND A HALF” SALE.” NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

“THE SALE, TRANSFER OR ASSIGNMENT OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO THE TERMS AND CONDITIONS OF A CERTAIN AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT DATED AS OF AUGUST 9, 2018, AS AMENDED FROM TIME TO TIME, AMONG THE COMPANY AND CERTAIN HOLDERS OF ITS OUTSTANDING SECURITIES. COPIES OF SUCH AGREEMENT MAY BE OBTAINED AT NO COST BY WRITTEN

 

7


REQUEST MADE BY THE HOLDER OF RECORD OF THIS CERTIFICATE TO THE SECRETARY OF THE COMPANY.”

(ii) Removal of Restrictive Legends . This Warrant and the certificates (or electronic book entries, if applicable) evidencing the Exercise Shares and the Failure Payment Shares, as applicable, shall not contain or be subject to any legend restricting the transfer thereof (including the legend set forth above in subsection 2(e)(i)) or be subject to any stop-transfer instructions: (A) while a registration statement (including a Registration Statement, as defined in the Registration Rights Agreement) covering the sale or resale of such security is effective under the Securities Act, or (B) following any sale of such Warrant, Exercise Shares and/or Failure Payment Shares pursuant to Rule 144, or (C) if such Warrant, Exercise Shares and/or Failure Payment Shares are eligible for sale under Rule 144(b)(1), or (D) at any time on or after the date hereof on which Holder’s holding period for purposes of Rule 144 under the Securities Act and subsection (d)(3)(iii) thereof with respect to such Warrant, Exercise Shares and/or Failure Payment Shares is at least six (6) months and Holder certifies that it is not an “affiliate” (as defined in Rule 144 under the Securities Act), or (E) if such legend is not required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the SEC) (collectively, the “Unrestricted Conditions”). The Company shall cause its counsel to issue a legal opinion to the Transfer Agent promptly after the Effective Date, or at such other time as any of the Unrestricted Conditions have been met, if required by the Transfer Agent to effect the issuance of this Warrant, the Exercise Shares or the Failure Payment Shares, as applicable, without a restrictive legend or removal of the legend hereunder. If any of the Unrestricted Conditions are met at the time of issuance of this Warrant, the Exercise Shares or the Failure Payment Shares, then such Warrant, Exercise Shares or Failure Payment Shares, as applicable, shall be issued free of all legends and stop-transfer instructions. The Company agrees that following the Effective Date, or at such time as the Unrestricted Conditions are met or such legend is otherwise no longer required under this Section 2(e), it will, no later than the earlier of (x) two (2) Trading Days and (y) the number of Trading Days comprising the Standard Settlement Period following the delivery (the “Unlegended Shares Delivery Deadline”) by Holder to the Company or the Transfer Agent of this Warrant and a certificate representing Exercise Shares and/or Failure Payment Shares, as applicable, issued with a restrictive legend, deliver or cause to be delivered to Holder this Warrant and/or a certificate (or electronic transfer) representing such shares that is free from all restrictive and other legends (and stop transfer instructions). For purposes hereof, “Effective Date” shall mean the date that the first Registration Statement that the Company is required to file pursuant to the Registration Rights Agreement has been declared effective by the SEC.

(iii) Sale of Unlegended Shares . Holder agrees that the removal of the restrictive legend from this Warrant and any certificates representing securities as set forth in Section 2(e) above is predicated upon the Company’s reliance that Holder will sell this Warrant or any Exercise Shares and/or any Failure Payment Shares, as applicable, pursuant to either the registration requirements of the Securities Act, including any applicable prospectus delivery requirements, or an exemption therefrom, and that if such securities are sold pursuant to a Registration Statement, they will be sold in compliance with the plan of distribution set forth therein.

(f) Cancellation of Warrant . This Warrant shall be canceled upon the full Exercise of this Warrant, and, as soon as practical after the Date of Exercise, Holder shall be entitled to receive Common Stock for the number of shares purchased upon such Exercise of this Warrant, and if this Warrant is not Exercised in full, Holder shall be entitled to receive a new Warrant (containing terms identical to this Warrant) representing any unexercised portion of this Warrant in addition to such Common Stock; provided, however, as set forth in Section 2(b), Holder shall not be required to physically surrender this warrant if the Warrant is not Exercised in full.

 

8


(g) Holder of Record . Each person in whose name any Warrant for shares of Common Stock is issued shall, for all purposes, be deemed to be Holder of record of such shares on the Date of Exercise, irrespective of the date of delivery of the Common Stock purchased upon the Exercise of this Warrant. Prior to the exercise of this Warrant, nothing in this Warrant shall be construed as conferring upon Holder any rights as a stockholder of the Company.

(h) Delivery of Electronic Shares . In lieu of delivering physical certificates representing the Common Stock issuable upon Exercise or legend removal, or representing Failure Payment Shares, upon written request of Holder, the Company shall use its best efforts to cause the Transfer Agent to electronically transmit the Common Stock issuable upon Exercise to Holder by crediting the account of Holder’s prime broker with DTC through its Deposit/Withdrawal at Custodian (DWAC) system. The time periods for delivery and penalties described herein shall apply to the electronic transmittals described herein. Any delivery not effected by electronic transmission shall be effected by delivery of physical certificates.

(i) Buy-In . In addition to any other rights or remedies available to Holder hereunder or otherwise at law or in equity, if the Company fails to cause its Transfer Agent to deliver to Holder a certificate or certificates, or electronic shares through DWAC, representing the Exercise Shares pursuant to an Exercise on or before the last day of the Delivery Period (other than a failure caused by any incorrect or incomplete information provided by Holder to the Company hereunder), and if after such date Holder is required by its broker to purchase (in an open market transaction or otherwise) or Holder or Holder’s brokerage firm otherwise purchases shares of Common Stock to deliver in satisfaction of a sale by Holder of the Exercise Shares which Holder was entitled to receive upon such Exercise (a “Buy-In”), then the Company shall (1) pay in cash to Holder the amount by which (x) Holder’s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (A) the number of Exercise Shares that the Company was required to deliver to Holder in connection with the Exercise at issue by (B) the price at which the sell order giving rise to such purchase obligation was executed, and (2) at the option of Holder, either reinstate the portion of the Warrant and equivalent number of Exercise Shares for which such Exercise was not honored (and refund the Exercise Price therefor, to the extent paid by Holder, and/or reinstate the principal amount of any indebtedness used to satisfy the applicable Exercise Price) or deliver to Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its Exercise and delivery obligations hereunder. For example, if Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted Exercise to cover the sale of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (1) of the immediately preceding sentence the Company shall be required to pay Holder $1,000. Holder shall provide the Company written notice indicating the amounts payable to Holder in respect of the Buy-In, together with applicable confirmations and other evidence reasonably requested by the Company. Nothing herein shall limit Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver certificates representing shares of Common Stock upon Exercise of the Warrant as required pursuant to the terms hereof.

(j) HSR Submissions. If Holder determines that, in connection with the exercise of this Warrant, it and the Company are required to file Premerger Notification Reports with the Federal Trade Commission (the “FTC”) and the United States Department of Justice (“DOJ”) and observe the Waiting Period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended, and the related rules and regulations promulgated thereunder (collectively, the “HSR Act”), the Company agrees to (i) cooperate with Holder in Holder’s preparing and making such submission and any responses to inquiries of the FTC and DOJ; (ii) prepare and make any submission required to be filed by the Company under the HSR Act and respond to inquiries of the FTC and DOJ in connection therewith; and (iii) reimburse Holder for the cost of the required filing fee for Holder’s submission under the HSR Act. For the avoidance of doubt, Holder shall

 

9


bear all of its other costs and expenses in connection with such submission, including any attorneys’ fees associated therewith.

20. Payment of Warrant Exercise Price for Cash Exercise or Cashless Exercise; Cashless Major Exercise and Cashless Default Exercise .

(a) Exercise Price . The exercise price shall initially equal $ [        ] 9 per share, subject to adjustment pursuant to the terms hereof (as so adjusted, the “Exercise Price”), including but not limited to Section 5 below.

Payment of the Exercise Price may be made by any of the following, or a combination thereof, at the election of Holder:

(i) Cash Exercise : Holder may exercise this Warrant in cash, bank or cashier’s check or wire transfer (a “Cash Exercise”);

(ii) Cashless Exercise : In lieu of paying all or any portion of the Exercise Price in cash, Holder, at its option, may exercise this Warrant (in whole or in part) on a cashless basis by making appropriate notation on the applicable Exercise Form, in which event the Company shall issue Holder a number of shares of Common Stock computed using the following formula (a “Cashless Exercise”):

X = Y (A-B)/A

where: X = the number of shares of Common Stock to be issued to Holder.

Y = the number of shares of Common Stock for which this Warrant is being Exercised.

A = the Market Price of one (1) share of Common Stock (for purposes of this Section 3(a)(ii), where “Market Price,” as of any date, means the arithmetic average of the Volume Weighted Average Price (as defined below) of the Company’s Common Stock on each of the ten (10) consecutive Trading Days immediately preceding the date in question).

B = the Exercise Price.

As used herein, the “ Volume Weighted Average Price ” for any security as of any date means the volume weighted average sale price on the NasdaqGS as reported by, or based upon data reported by, Bloomberg Financial Markets or an equivalent, reliable reporting service mutually acceptable to and hereafter designated by the Holder and the Company (“ Bloomberg ”), or, if the NasdaqGS is not the principal trading market for such security, the volume weighted average sale price of such security on the principal securities exchange or trading market where such security is listed or traded as reported by Bloomberg, or, if no volume weighted average sale price is reported for such security, then the last closing trade price of such security as reported by Bloomberg, or, if no last closing trade price is reported for such security by Bloomberg, the average of the bid prices of any market makers for such security on the OTC Bulletin Board, the OTCQX Market, the OTCQB Market or the “pink” market of OTC Markets Group. If the Volume Weighted Average Price cannot be calculated for such security on such date in the manner provided above, the Volume Weighted Average Price shall be the fair market value as determined by the Company and the Holder. In the event that a Stock Event [Term is not defined. Do you want to reference the term as used in the Note?] is consummated during any period for which the arithmetic average of the Volume Weighted Average Prices is to be determined (under this Section or otherwise), the

 

9  

To be equal to the closing bid price on the trading day prior to signing.

 

10


Volume Weighted Average Price for all Trading Days during such period prior to the effectiveness of the Stock Event shall be appropriately adjusted to reflect such Stock Event.

(iii) Note Exchange Exercise : In lieu of paying all or any portion of the Exercise Price in cash, Holder, at its option, may exercise this Warrant (in whole or in part) through a reduction of an amount of principal outstanding under any First Out Waterfall Notes in accordance with Section 2.3(b) of the Facility Agreement, then held by Holder (a “Note Exchange Exercise”)

For purposes of Rule 144 and subsection (d)(3)(ii) thereof, it is intended, understood and acknowledged that (x) this Warrant shall be deemed to have been acquired on April 3, 2017 (the date the First Out Waterfall Notes were originally issued), and (y) the shares of Common Stock issuable upon Exercise of this Warrant in a Cashless Exercise (including a Cashless Major Exercise or Cashless Default Exercise) transaction or a Note Exchange Exercise transaction shall be deemed to have been acquired on April 3, 2017. Accordingly, (A) upon any such Exercise, the Rule 144 holding period for the shares of Common Stock issued thereupon shall be in excess of one (1) year, and (B) provided that Holder is not an “affiliate” (as defined in Rule 144 under the Securities Act) of the Company on the date of such Exercise (which the Company shall assume unless advised otherwise in writing by Holder), an Unrestricted Condition shall be satisfied with respect to the shares of Common Stock issued thereupon and such shares will be freely transferable, without restriction or limitation (including any volume limitation or current public information requirement) under Federal or state securities laws, pursuant to Rule 144 under the Securities Act, and will not contain or be subject to a legend or stop transfer order restricting the resale or transferability of thereof.

As provided in Section 2(b), Holder shall only be required to physically surrender this Warrant in the event that Holder is exercising this Warrant in full.

(b) Cashless Major Exercise. To the extent Holder shall exercise this Warrant as a Cashless Major Exercise pursuant to Section 5(b)(i) and 5(b)(iii) below, Holder shall send to the Company (in any manner permitted under Section 2(a)) the Exercise Form indicating that Holder is exercising this Warrant (or any portion thereof) pursuant to a Cashless Major Exercise, in which event the Company shall issue a number of shares of Common Stock equal to the Black-Scholes Value of the Warrant (or such applicable portion being exercised) divided by the closing price of the Common Stock on the principal securities exchange or other securities market on which the Common Stock is then traded on the Trading Day immediately preceding the date on which the applicable Major Transaction is consummated, or, if in respect of a Cashless Major Exercise made after the date of consummation of the applicable Major Transaction, on the Trading Day immediately preceding the date on which the exercise form in respect of such Cashless Major Exercise is delivered. As provided in Section 2(b), Holder shall only be required to physically surrender this Warrant in the event that Holder is exercising this Warrant in full. Holder shall be permitted to make successive Cashless Major Exercises and send successive Exercise Forms in respect of a Cashless Major Exercise from time to time at any time during the Cashless Major Exercise Period.

(c) Cashless Default Exercise . To the extent Holder exercises this Warrant as a Cashless Default Exercise pursuant to Section 11(b)(i) below, Holder shall send to the Company (in any manner permitted under Section 2(a)) the Exercise Form indicating that Holder is exercising this Warrant pursuant to a Cashless Default Exercise, in which event the Company shall issue to Holder, within five (5) Trading Days of the applicable Default Notice, a number of shares of Common Stock (which shares shall be valued at the closing price of the Common Stock on the principal securities exchange or other securities market on which the Common Stock is then traded on the Trading Day immediately preceding the date on which the Exercise Form in respect of such Cashless Default Exercise is delivered) equal to the Black-Scholes Value of the remaining unexercised portion of this Warrant (or such portion thereof subject to such exercise) as of the date of such Default Notice (or in the case of an Event of Default referred to in Section 11(a)(vi), on the Trading Day immediately preceding the date the dividend or distribution is declared or, if not first declared,

 

11


is paid). As provided in Section 2(b), the Holder shall be permitted to make successive Cashless Default Exercises and send successive Exercise Forms in respect of a Cashless Default Exercise, from time to time at any time from and after the date of the applicable Default Notice through the Exercise Period of this Warrant.

(b) Dispute Resolution . In the case of a dispute as to the determination of the closing price or the Volume Weighted Average Price of the Company’s Common Stock or the arithmetic calculation of the Exercise Price, Market Price or the Successor Major Transaction Consideration, or the number of shares issuable upon a Cashless Major Exercise, the Company shall submit the disputed determinations or arithmetic calculations via electronic mail within two (2) Business Days of receipt, or deemed receipt, of the Exercise Form or Major Transaction Early Termination Notice, or other event giving rise to such dispute, as the case may be, to Holder. If Holder and the Company are unable to agree upon such determination or calculation within two (2) Business Days of such disputed determination or arithmetic calculation being submitted to Holder, then the Company shall, within two (2) Business Days submit via electronic mail (i) the disputed determination of the closing price or the Volume Weighted Average Price of the Company’s Common Stock to an independent, reputable investment bank selected by the Company and approved by Holder, which approval shall not be unreasonably withheld, or (ii) the disputed arithmetic calculation of the Exercise Price, Market Price, any Successor Major Transaction Consideration or number of shares issuable upon a Cashless Major Exercise to the Company’s independent, outside registered public accountants. The Company shall use its reasonable best efforts to cause the investment bank or the accountants, as the case may be, to perform the determinations or calculations and notify the Company and Holder of the results no later than five (5) Trading Days from the time it receives the disputed determinations or calculations. Such investment bank’s or accountants’ determination or calculation, as the case may be, shall be binding upon all parties absent demonstrable error, and the Company and Holder shall each pay one half of the fees and costs of such investment banker or accountant. Notwithstanding the existence of a dispute contemplated by this paragraph, if requested by Holder, the Company shall issue to Holder the Exercise Shares not in dispute in accordance with the terms hereof.

21. Transfer and Registration .

(a) Transfer Rights . Subject to the provisions of Section 8 of this Warrant, this Warrant may be transferred on the books of the Company, in whole or in part, in person or by attorney, upon surrender of this Warrant properly completed and endorsed. This Warrant shall be canceled upon such surrender and, as soon as practicable thereafter, the person to whom such transfer is made shall be entitled to receive a new Warrant or Warrants as to the portion of this Warrant transferred, and Holder shall be entitled to receive a new Warrant as to the portion hereof retained.

(b) Registrable Securities . The Common Stock issuable upon the Exercise of this Warrant entitles Holder (and applicable assignees or transferees of such Common Stock) to registration and other rights pursuant to the Registration Rights Agreement.

22. Adjustments Upon Certain Events .

(a) Recapitalization or Reclassification . If the Company shall at any time effect a stock split, payment of stock dividend, recapitalization, reclassification or other similar transaction of such character that the shares of Common Stock shall be changed into or become exchangeable for a larger or smaller number of shares, then upon the effective date thereof, the number of shares of Common Stock which Holder shall be entitled to purchase upon Exercise of this Warrant, shall be increased or decreased, as the case may be, in direct proportion to the increase or decrease in the number of shares of Common Stock by reason of such stock split, payment of stock dividend, recapitalization, reclassification or similar transaction, and the Exercise Price shall be, in the case of an increase in the number of shares, proportionally decreased and, in the case of

 

12


decrease in the number of shares, proportionally increased. The Company shall give Holder the same notice it provides to holders of Common Stock of any transaction described in this Section 5(a).

(b) Rights Upon Major Transaction .

(i) Major Transaction . In the event that a Major Transaction occurs, then (1) in the case of a Successor Major Transaction, Holder, at its option, may elect to cause the conversion of this Warrant (a “Successor Major Transaction Conversion”), in whole or in part, into the right to receive the Successor Major Transaction Consideration, upon consummation of the Major Transaction, and (2) in the case of all other Major Transactions, Holder shall have the right to exercise this Warrant (or any portion thereof), at any time and from time to time following the occurrence of such event, as a Cashless Major Exercise. In the event Holder shall not have exercised any of its rights under clauses (1) or (2) above within the applicable time periods set forth herein, then the Major Transaction shall be treated as an Assumption (as defined below) in accordance with Section 5(b)(ii) below unless Holder waives its rights under this Section 5(b) with respect to such Major Transaction. Each of the following events shall constitute a “Major Transaction”:

(A) a consolidation, merger, exchange of shares, recapitalization, reorganization, business combination or other similar event, (1) following which the holders of Common Stock immediately preceding such consolidation, merger, exchange, recapitalization, reorganization, combination or event either (a) no longer hold a majority of the shares of Common Stock or (b) no longer have the ability to elect a majority of the board of directors of the Company or (2) as a result of which shares of Common Stock shall be changed into (or the shares of Common Stock become entitled to receive) the same or a different number of shares of the same or another class or classes of stock or securities of the Company or another entity (collectively, a “Change of Control Transaction”);

(B) the sale or transfer, in one transaction or a series of related transactions, of (I) all or substantially all of the assets of the Company (including, for the avoidance of doubt, all or substantially all of the assets of the Company and its Subsidiaries, taken as a whole) to any Person other than a wholly-owned subsidiary of the Company or (II) assets of the Company (including, for the avoidance of doubt, all or substantially all of the assets of the Company and its Subsidiaries, taken as a whole) for a purchase price equal to more than 50% of the Equity Value (as defined below) of the Company. For purposes of this clause (B), “Equity Value” shall mean (I) the product of (x) the number of issued and outstanding shares of Common Stock on the date the Company delivers the Major Transaction Notice (defined below) multiplied by (y) the per share closing price of the Common Stock on such date on the NasdaqGS as reported by, or based upon data reported by, Bloomberg or, if the NasdaqGS is not the principal trading market for such security, the closing sale price of such security on the principal securities exchange or trading market where such security is listed or traded as reported by Bloomberg;

(C) a purchase, tender or exchange offer made to the holders of outstanding shares of Common Stock, such that following such purchase, tender or exchange offer a Change of Control Transaction shall have occurred;

(D) the liquidation, bankruptcy, insolvency, dissolution or winding-up (or the occurrence of any analogous proceeding) affecting the Company;

 

13


(E) the shares of Common Stock cease to be listed, traded or publicly quoted on the NasdaqGS and are not promptly re-listed or requoted on the New York Stock Exchange, the NYSE American, the NASDAQ Global Market or the NASDAQ Capital Market; or

(F) the Common Stock ceases to be registered under Section 12 of the Exchange Act.

(ii) Assumption. Any assumption of Company obligations under this paragraph shall be referred to herein as an “Assumption.” Unless otherwise provided in writing by Holder, the Company shall not consummate a Major Transaction in which the Company is not the surviving entity or as a result of which the Company has a new Parent Entity, unless (A) each Person acquiring the Company’s assets or Common Stock (or Parent Entity thereof, as applicable), or any other successor entity resulting from such Major Transaction (in each case, a “Successor Entity”), assumes in writing all of the obligations of the Company under this Warrant, the Facility Agreement (but, other than with respect to the Company’s obligations pursuant to Section 5.1(e) and 5.1(p) of the Facility Agreement and the other provisions of the Facility Agreement that expressly survive the repayment of the Loans (which shall be assumed in any Assumption), only if there are outstanding Loans under the Facility Agreement immediately following the consummation of the Major Transaction) and the Registration Rights Agreement in accordance with the provisions of this Section 5(b)(ii) pursuant to written agreements in form and substance reasonably satisfactory to Holder and approved by Holder prior to the consummation of such Major Transaction (such approval not to be unreasonably withheld or delayed), including agreements to deliver to Holder in exchange for its Warrants a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to the Warrants, that, among other things, (1) is exercisable for the appropriate number of shares of the Successor Entity’s capital stock (without regard to the 4.985% Cap or any other restriction or limitation on exercise, provided that such instrument shall contain a limitation on exercise comparable to that contained in the second paragraph of Section 1 of this Warrant); (2) has an exercise price similar to the then-effective Exercise Price (taking into account any conversion or exchange ratio applicable to the Common Stock in the Major Transaction) and exercise price adjustment provisions similar to those in the Warrants; (3) entitles Holder to such additional securities or other consideration as Holder would be entitled pursuant to Section 5(b)(i) in connection with the Major Transaction; and (4) provides for registration rights similar to those provided by the Registration Rights Agreement, in each case reasonably satisfactory to Holder, and (B) the Successor Entity (including its Parent Entity) is a publicly traded corporation whose common stock is quoted on or listed for trading on an Eligible Market. For the avoidance of doubt, Holder’s reasonable satisfaction referred to in the immediately preceding sentence shall be construed only to apply to confirmation that the warrant or other comparable security and registration rights agreement delivered to Holder upon an assumption hereunder shall conform to the requirements of this Section 5(b)(ii), and this Section 5(b)(ii) shall not be construed as granting consent or approval rights to Holder with respect to the terms of such Major Transaction or to permit Holder to demand any additional consideration in respect of this Warrant other than as provided herein. Upon the occurrence of any Major Transaction, any Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Major Transaction, the provisions of this Warrant and the Registration Rights Agreement referring to the “Company” shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company herein. Upon consummation of the Major Transaction, the Successor Entity shall deliver to Holder confirmation that there shall be issued upon exercise of this Warrant at any time after the consummation of the Major Transaction, in lieu of the shares of Common Stock (or other securities, cash, assets or other property) issuable upon the exercise of the Warrants prior to such Major Transaction, such shares of publicly traded common stock (or their equivalent) of the Successor Entity, as adjusted in accordance with the provisions of this Warrant. The provisions of this Section shall apply

 

14


similarly and equally to successive Major Transactions and shall be applied without regard to any limitations on the exercise of this Warrant other than any applicable beneficial ownership limitations.

(iii) Major Transaction Notice; Major Transaction Early Termination Right; Notice of Cashless Major Exercise. At least thirty (30) days prior to the consummation of any Major Transaction, but, in any event, within five (5) Trading Days following the first to occur of (x) the date of the public announcement of such Major Transaction if such announcement is made before 4:00 p.m., New York City time, or (y) the day following the public announcement of such Major Transaction if such announcement is made on and after 4:00 p.m., New York City time, the Company shall deliver written notice thereof via electronic mail and overnight courier to Holder (a “Major Transaction Notice”). At any time during the period beginning after Holder’s receipt of a Major Transaction Notice in respect of a Successor Major Transaction and ending five (5) Trading Days prior to the consummation of such Major Transaction (the “Early Termination Period”), Holder may elect a Successor Major Transaction Conversion by delivering written notice thereof (“Major Transaction Early Termination Notice”) to the Company, which Major Transaction Early Termination Notice shall indicate the portion of the Warrant (with reference to the number of shares of Common Stock issuable upon a Cash Exercise of such portion, without regard to the 4.985% Cap) that Holder is electing to be treated as a Successor Major Transaction Conversion. The portion of this Warrant subject to early termination pursuant to this Section 5(b)(iii), shall be converted into the right to receive the Successor Major Transaction Consideration

To the extent Holder shall elect to effect a Cashless Major Exercise in respect of a Major Transaction, Holder shall deliver its Exercise Form in accordance with Section 3(b), at any time and from time to time following receipt by Holder of the Major Transaction Notice until the later of (x) the last day of the Exercise Period and (y) the one-year anniversary of the applicable Major Transaction (the “Cashless Major Exercise Period”). For the avoidance of doubt, Holder shall be permitted to make successive Cashless Major Exercises and send successive Exercise Forms in respect of a Cashless Major Exercise from time to time at any time during the Cashless Major Exercise Period.

(iv) Escrow; Payment of Successor Major Transaction Consideration . Following the receipt of a Major Transaction Early Termination Notice in respect of a Successor Major Transaction from Holder, the Company shall not effect a Successor Major Transaction with respect to which Holder has elected a Successor Major Transaction Conversion unless either (A) it obtains, as a condition precedent to such Major Transaction, the written agreement of the Successor Entity that payment of the Successor Major Transaction Consideration shall be made to Holder concurrently with consummation of such Successor Major Transaction, or (B) it shall place the Successor Major Transaction Consideration into an escrow account with an independent escrow agent, and shall instruct the escrow agent to deliver the Successor Major Transaction Consideration to Holder, concurrently with the consummation of the Major Transaction. Notwithstanding clauses (A) and (B) above, Holder shall be treated on a pari passu basis with, and shall not have priority to payments to, the holders of Common Stock in connection with a Major Transaction. For purposes of determining the amount required to be placed in escrow pursuant to the provisions of this subsection (iv) and without affecting the amount of the actual Successor Major Transaction Consideration, the calculation of the price referred to in clause (1) of the first column of Schedule 1 hereto with respect to Stock Price shall be determined based on the Closing Market Price (as defined on Schedule 1) of the Common Stock on the Trading Day immediately preceding the date that the Successor Major Transaction Consideration is deposited with the escrow agent.

(v) Injunction . Following the receipt of a Major Transaction Early Termination Notice from Holder, in the event that the Company attempts to consummate a Successor Major Transaction without either (1) placing the Successor Major Transaction Consideration in escrow in accordance with subsection (iv) above, or (2) obtaining the written agreement of the Successor Entity as described in subsection (iv) above, Holder shall have the right to apply for an injunction in any state or federal court sitting in the City of New York,

 

15


borough of Manhattan to prevent the closing of such Major Transaction until the Successor Major Transaction Consideration is delivered to Holder.

An early termination required by this Section 5(b) shall be made in accordance with the provisions of Section 12. To the extent an early termination required by this Section 5(b) is deemed or determined by a court of competent jurisdiction to be prepayments of the Warrant by the Company, such early termination shall be deemed to be voluntary prepayments. Notwithstanding anything to the contrary in this Section 5, until the Successor Major Transaction Consideration is paid in full, this Warrant may be exercised, in whole or in part, by Holder into shares of Common Stock, or in the event the date of any Exercise is after the consummation of the Major Transaction, shares of publicly traded common stock (or their equivalent) of the Successor Entity pursuant to Section 5(b). The parties hereto agree that in the event of the Company’s early termination of any portion of the Warrant under this Section 5(b), Holder’s damages would be uncertain and difficult to estimate because of the parties’ inability to predict future interest rates and the uncertainty of the availability of a suitable substitute investment opportunity for Holder. Accordingly, any premium due under this Section 5(b) is intended by the parties to be, and shall be deemed, a commercially reasonable estimate of Holder’s actual loss of its investment opportunity and not as a penalty.

(c) Exercise Price Adjusted . As used in this Warrant, the term “Exercise Price” shall mean the purchase price per share specified in Section 3(a) of this Warrant, until the occurrence of an event stated in this Section 5 or otherwise set forth in this Warrant, and thereafter shall mean said price as adjusted from time to time in accordance with the provisions of said subsection. No adjustment made pursuant to any provision of this Section 5 shall have the net effect of increasing the aggregate Exercise Price payable hereunder or, except as expressly provided in Section 5(a), otherwise increasing the Exercise Price.

(d) Adjustments: Additional Shares, Securities or Assets . In the event that at any time, as a result of an adjustment made pursuant to this Section 5 or otherwise, Holder shall, upon Exercise of this Warrant, become entitled to receive shares and/or other securities or assets (other than Common Stock) then, wherever appropriate, all references herein to shares of Common Stock shall be deemed to refer to and include such shares and/or other securities or assets; and thereafter the number of such shares and/or other securities or assets shall be subject to adjustment from time to time in a manner and upon terms as nearly equivalent as practicable to the provisions of this Section 5.

(e) Notice of Adjustments . Whenever the Exercise Price and/or number or type of securities issuable upon Exercise is adjusted pursuant to the terms of this Warrant, the Company shall promptly mail to Holder a notice (an “Exercise Price Adjustment Notice”) setting forth the Exercise Price and/or number or type of securities issuable upon Exercise after such adjustment and setting forth a statement of the facts requiring such adjustment. The Company shall, upon the written request at any time of Holder, furnish to Holder a like Warrant setting forth (i) such adjustment or readjustment, (ii) the Exercise Price at the time in effect and (iii) the number of shares of Common Stock and the amount, if any, of other securities or property which at the time would be received upon Exercise of the Warrant. For purposes of clarification, whether or not the Company provides an Exercise Price Adjustment Notice pursuant to this Section 5(e), upon the occurrence of any event that leads to an adjustment of the Exercise Price, Holder would be entitled to receive a number of Exercise Shares based upon the new Exercise Price, as adjusted, for exercises occurring on or after the date of such adjustment, regardless of whether Holder accurately refers to the adjusted Exercise Price in the Exercise Form.

23. Fractional Interests .

No fractional shares or scrip representing fractional shares shall be issuable upon the Exercise of this Warrant, but on Exercise of this Warrant, Holder may purchase only a whole number of shares of Common Stock. If, on Exercise of this Warrant, Holder would be entitled to a fractional share of Common Stock or a

 

16


right to acquire a fractional share of Common Stock, such fractional share shall be disregarded and the number of shares of Common Stock issuable upon Exercise shall be the next higher whole number of shares.

24. Reservation of Shares .

From and after the date hereof, the Company shall at all times reserve for issuance such number of authorized and unissued shares of Common Stock (or other securities substituted therefor as herein above provided) as shall be sufficient for the Exercise of this Warrant and payment of the Exercise Price. If at any time the number of shares of Common Stock authorized and reserved for issuance is below the number of shares sufficient for the Exercise of this Warrant (a “Share Authorization Failure”) (based on the Exercise Price in effect from time to time), the Company will promptly take all corporate action necessary to authorize and reserve a sufficient number of shares, including calling a special meeting of stockholders to authorize additional shares to meet the Company’s obligations under this Section 7, in the case of an insufficient number of authorized shares, and using its best efforts to obtain stockholder approval of an increase in such authorized number of shares. The Company covenants and agrees that upon the Exercise of this Warrant, all shares of Common Stock issuable upon such Exercise shall be duly and validly issued, fully paid and nonassessable and not subject to preemptive rights, rights of first refusal or similar rights of any Person. The Company covenants and agrees that all shares of Common Stock issuable upon Exercise of this Warrant shall be approved for listing on the NasdaqGS, or, if the NasdaqGS is not the principal trading market for the Common Stock, such principal market on which the Common Stock is traded or listed.

25. Restrictions on Transfer .

(a) Registration or Exemption Required . This Warrant has been issued in a transaction exempt from the registration requirements of the Securities Act by virtue of Section 4(a)(2) of the Securities Act and Rule 506 thereunder and exempt from registration or qualification under applicable state securities (or “blue sky”) laws. None of the Warrant, the Exercise Shares or Failure Payment Shares may be pledged, transferred, sold or assigned except pursuant to an effective registration statement or an exemption to the registration requirements of the Securities Act and applicable state laws, including Rule 144 under the Securities Act, Section 4(a)(7) of the Securities Act or a so-called “4[(a)](1) and a half” transaction.

(b) Assignment . Subject to Section 8(a), Holder may sell, transfer, assign, pledge, or otherwise dispose of this Warrant, in whole or in part. Holder shall deliver a written notice to the Company, substantially in the form of the Assignment attached hereto as Exhibit  B , indicating the Person or Persons to whom the Warrant shall be assigned and the respective number of warrants to be assigned to each assignee. The Company shall effect the assignment within three (3) Business Days of its receipt of a completed and executed form of Assignment (the “Transfer Delivery Period”), and shall deliver to the assignee(s) designated by Holder a Warrant or Warrants of like tenor and terms entitling Holder to purchase the appropriate number of shares. This Warrant and the rights evidenced hereby shall inure to the benefit of and be binding upon the successors and assigns of Holder. The provisions of this Warrant are intended to be for the benefit of all Holders from time to time of this Warrant, and shall be enforceable by any such Holder. For avoidance of doubt, in the event Holder notifies the Company that such sale or transfer is a so called “4[(a)](1) and half” transaction, the parties hereto agree that a legal opinion from outside counsel for Holder delivered to counsel for the Company substantially in the form attached hereto as Exhibit  C shall be the only requirement to satisfy an exemption from registration under the Securities Act to effectuate such “4[(a)](1) and half” transaction.

 

17


26. Noncircumvention .

The Company hereby covenants and agrees that the Company will not, by amendment of its certificate of incorporation, bylaws or through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issue or sale of securities, or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, and will at all times in good faith carry out all the provisions of this Warrant and take all action as may be required to protect the rights of Holder. Without limiting the generality of the foregoing, the Company (i) shall not increase the par value of any shares of Common Stock receivable upon the exercise of this Warrant above the Exercise Price then in effect, and (ii) shall take all such actions as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable shares of Common Stock upon the exercise of this Warrant.

27. Events of Failure; Definition of Black Scholes Value .

(a) Definition.

The occurrence of each of the following shall be considered to be an “Event of Failure.”

(i) A Delivery Failure occurs, where a “Delivery Failure” shall be deemed to have occurred if the Company fails to use its best efforts to deliver Exercise Shares to Holder within any applicable Delivery Period (other than due to the limitation contained in the second paragraph of Section 1);

(ii) A Legend Removal Failure occurs, where a “Legend Removal Failure” shall be deemed to have occurred if the Company fails to use its best efforts to issue this Warrant and/or Exercise Shares without a restrictive legend, or fails to use it best efforts to remove a restrictive legend, when and as required under Section 2(e) hereof;

(iii) a Transfer Delivery Failure occurs, where a “Transfer Delivery Failure” shall be deemed to have occurred if the Company fails to use its best efforts to deliver a Warrant within any applicable Transfer Delivery Period; and

(iv) a Registration Failure (as defined below).

For purpose hereof, “Registration Failure” means that (A) the Company fails to file with the SEC on or before the Additional Warrant Filing Deadline (as defined in the Registration Rights Agreement) any Registration Statement required to be filed pursuant to Section 2(a) of the Registration Rights Agreement, (B) the Company fails to use its reasonable best efforts to obtain effectiveness with the SEC, prior to the Additional Warrant Registration Deadline (as defined in the Registration Rights Agreement), and if such Registration Statement does not become effective prior to the Additional Warrant Registration Deadline, as soon as possible thereafter, of any Registration Statement (as defined in the Registration Rights Agreement) that is required to be filed pursuant to Section 2(a) of the Registration Rights Agreement, or fails to use its reasonable best efforts to keep such Registration Statement current and effective as required in Section 3 of the Registration Rights Agreement, (C) the Company fails to file any additional Registration Statement required to be filed pursuant to Section 2(a)(ii) of the Registration Rights Agreement on or before the Additional Filing Deadline (as defined in the Registration Rights Agreement) or fails to use its reasonable best efforts to cause such new Registration Statement to become effective on or before the Additional Registration Deadline (as defined in the Registration Rights Agreement), and if such effectiveness does not occur within such period, as soon as possible thereafter, (D) the Company fails to file any amendment to any Registration Statement, or any additional Registration Statement required to be filed pursuant to Section 3(b) of the Registration Rights Agreement within thirty (30) days of the applicable Registration Trigger Date (as defined in the Registration Rights Agreement), or fails to use its reasonable best efforts to cause such amendment and/or new Registration Statement to become effective within ninety (90) days of the applicable Registration Trigger Date, and, if such effectiveness does not occur within such period, as

 

18


soon as possible thereafter, (E) any Registration Statement required to be filed under the Registration Rights Agreement, after its initial effectiveness and during the applicable Registration Period (as defined in the Registration Rights Agreement), lapses in effect or, other than on a day during an Allowable Grace Period (as defined in the Registration Rights Agreement), sales of all of the Registrable Securities (as defined in the Registration Rights Agreement) cannot otherwise be made thereunder (whether by reason of the Company’s failure to amend or supplement the prospectus included therein in accordance with the Registration Rights Agreement, the Company’s failure to file and use its reasonable best efforts to obtain effectiveness with the SEC of an additional Registration Statement or amended Registration Statement required pursuant to Section 2(a)(ii) or 3(b) of the Registration Rights Agreement, as applicable, or otherwise), or (F) the Company fails to provide a commercially reasonable written response to any comments to any Registration Statement submitted by the SEC within twenty-five (25) days of the date that such SEC comments are received by the Company.

(b) Failure Payments; Black-Scholes Determination. The Company understands that any Event of Failure (as defined above) could result in economic loss to Holder. In the event that any Event of Failure occurs, as compensation to Holder for such economic loss, the Company agrees to pay to Holder an amount payable, at the Company’s option, either (i) in cash or (ii) in shares of Common Stock that are valued for these purposes at the Volume Weighted Average Price on the date of such calculation (“Failure Payments” and such shares, “Failure Payment Shares”), in each case equal to the total economic loss of Holder determined on a commercially reasonable basis in connection with such Event of Failure for the relevant period (as recalculated on the first Business Day of each month thereafter for as long as Failure Payments shall continue to accrue) from the date of such Event of Failure until the Event of Failure is cured; provided, however, that in the event the Company elects to make Failure Payments in Failure Payment Shares, the Company shall issue, and Holder shall only receive, up to such number of shares of Common Stock in respect of Failure Payments such that Holder and any other persons or entities whose beneficial ownership of Common Stock would be aggregated with Holder’s for purposes of Section 13(d) of the Exchange Act (including shares held by any “group” of which Holder is a member, but excluding shares beneficially owned by virtue of the ownership of securities or rights to acquire securities that have limitations on the right to convert, exercise or purchase similar to the limitation set forth herein) shall not collectively beneficially own greater than 4.985% of the total number of shares of Common Stock of the Company then issued and outstanding, and the balance of such Failure Payments shall be paid in cash. For purposes of clarification, it is agreed and understood that Failure Payments shall continue to accrue following any Event of Default until the applicable Default Amount is paid in full. The Company shall satisfy any Failure Payments under this Section pursuant to Section 10(c) below. Failure Payments are in addition to any Shares that Holder is entitled to receive upon Exercise of this Warrant.

(c) Payment of Accrued Failure Payments. The Failure Payments and Failure Payment Shares representing accrued Failure Payments for each Event of Failure shall be paid or issued and delivered, as the case may be, on or before the fifth (5th) Business Day of each month following a month in which Failure Payments accrued. Nothing herein shall limit Holder’s right to pursue actual damages (to the extent in excess of the Failure Payments) for the Company’s Event of Failure, and Holder shall have the right to pursue all remedies available at law or in equity (including a decree of specific performance and/or injunctive relief). Notwithstanding the above, if a particular Event of Failure results in an Event of Default pursuant to Section 11 hereof, then the Failure Payment, for that Event of Failure only, shall be considered to have been satisfied upon payment to Holder of an amount equal to the greater of (i) the Failure Payment, or (ii) the Default Amount, payable in accordance with Section 11.

(d) Maximum Interest Rate. Nothing contained herein or in any document referred to herein or delivered in connection herewith shall be deemed to establish or require the payment of a rate of interest or other charges in excess of the maximum permitted by applicable law. In the event that the rate of interest or dividends required to be paid or other charges hereunder exceed the maximum permitted by such law, any payments

 

19


in excess of such maximum shall be credited against amounts owed by the Company to Holder and thereby refunded to the Company.

28. Default .

(a) Events Of Default . Each of the following events shall be considered to be an “Event of Default,” unless waived by Holder:

(i) Failure To Effect Registration. With respect to all Registration Failures, a Registration Failure occurs and remains uncured for a period of more than forty-five (45) days (or sixty (60) days in the case where the Company (i) has, by the Filing Deadline (as defined the Registration Rights Agreement) filed a Registration Statement (as defined in the Registration Rights Agreement) covering this Warrant and the number of shares required by the Registration Rights Agreement, and (ii) has responded in writing to any comments to the Registration Statement that the Company has received from the SEC, within ten (10) Business Days of such receipt, and nevertheless the SEC has not declared effective a Registration Statement covering the this Warrant and the Shares by the Registration Deadline (as defined in the Registration Rights Agreement)), and such Registration Failure relates solely to the Company’s failure to have the Registration Statement declared effective by the Registration Deadline (as defined in the Registration Rights Agreement) and with respect to a Registration Failure provided in clause (E) of the definition of “Registration Failure,” such Registration Failure occurs and remains uncured for a period of more than forty-five (45) days.

(ii) Failure To Deliver Common Stock . A Delivery Failure (as defined above) occurs and remains uncured for a period of more than twenty (20) days; or at any time, the Company announces or states in writing that it will not honor its obligations to issue shares of Common Stock to Holder upon Exercise by Holder of the Exercise rights of Holder in accordance with the terms of this Warrant.

(iii) Legend Removal Failure . A Legend Removal Failure (as defined above) occurs and remains uncured for a period of twenty (20) days;

(iv) Transfer Delivery Failure . A Transfer Delivery Failure (as defined above) occurs and remains uncured for a period of twenty (20) days;

(v) Corporate Existence; Major Transaction . (A) The Company has failed to (1) place the Successor Major Transaction Consideration into escrow and instruct the escrow agent to release the Successor Major Transaction Consideration to the Holder pursuant to Section 5(b)(iii), or (2) obtain the written agreement of the Successor Entity and cause the Successor Entity to make payment as described in Section 5(b)(iii), (B) the Successor Major Transaction Consideration is not paid contemporaneously with the consummation of the Successor Major Transaction, or (C) with respect to a Major Transaction that is to be treated as an Assumption under the terms hereof, the Company has failed to meet the Assumption requirements of Section 5(b)(i); or

(vi) Section  13 Breach . During the Dividend Restriction Period, the Company declares or pays any dividend or distribution of any kind to the holders of Common Stock of the Company.

(b) Mandatory Early Termination .

(i) Mandatory Early Termination Amount; Cashless Default Exercise . The Company shall notify Holder in writing within two (2) Business Days of the occurrence of an Event of Default. If any Events of Default shall occur then, at the option of Holder, such option exercisable through the delivery of written notice to the Company by such Holder (the “Default Notice”), the Company shall have the right to terminate the outstanding amount of this Warrant and pay to Holder (a “Mandatory Early Termination”), in full

 

20


satisfaction of its obligations hereunder by delivery of a notice to such effect to Holder within two (2) Business Days following receipt of the Default Notice, an amount payable in cash (the “Mandatory Early Termination Amount” or the “Default Amount”) equal to the Black-Scholes Value of the remaining unexercised portion of this Warrant on the date of such Default Notice (or in the case of an Event of Default referred to in Section 11(a)(vi), on the Trading Day immediately preceding the date the dividend or distribution is declared or, if not first declared, is paid). In the event the Company does not exercise its right to consummate a Mandatory Early Termination, then Holder shall have the right to exercise this Warrant, at any time and from time to time, pursuant to a Cashless Default Exercise in accordance with Section 3(c) above.

The Mandatory Early Termination Amount shall be payable within five (5) Business Days following the date of the applicable Default Notice.

(ii) Liquidated Damages . The parties hereto acknowledge and agree that the sums payable as Failure Payments or pursuant to a Mandatory Early Termination shall constitute partial liquidated damages and not penalties. The parties further acknowledge that (i) the amount of loss or damages likely to be incurred by Holder is incapable or is difficult to precisely estimate, (ii) the amounts specified bear a reasonable proportion and are not plainly or grossly disproportionate to the probable loss likely to be incurred by Holder, and (iii) the parties are sophisticated business parties and have been represented by sophisticated and able legal and financial counsel and negotiated this agreement at arm’s length.

Upon the occurrence of an Event of Default, the Default Amount, together with all other amounts payable hereunder, shall immediately become due and payable, all without demand, presentment or notice, all of which hereby are expressly waived, together with all costs, including legal fees and expenses, of collection, and Holder shall be entitled to exercise all other rights and remedies available at law or in equity.

(c) Posting Of Bond . In the event that any Event of Default occurs hereunder, the Company may not raise as a legal defense (in any Lawsuit, as defined below, or otherwise) or justification to such Event of Default any claim that such Holder or any one associated or affiliated with such Holder has been engaged in any violation of law, unless the Company has posted a surety bond (a “Surety Bond”) for the benefit of such Holder in the amount of 130% of the aggregate Surety Bond Value (as defined below) of all of Holder’s Warrants (the “Bond Amount”), which Surety Bond shall remain in effect until the completion of litigation of the dispute and the proceeds of which shall be payable to such Holder to the extent Holder obtains judgment.

For purposes hereof, a “Lawsuit” shall mean any lawsuit, arbitration or other dispute resolution filed by either party herein pertaining to any of this Warrant, the Facility Agreement, the Registration Rights Agreement or any other Loan Document (as defined in the Facility Agreement).

“Surety Bond Value,” for the Warrants shall mean 130% of the of the Black-Scholes Value of the remaining unexercised portion of this Warrant on the Trading Day immediately preceding the date that such bond goes into effect.

(d) Injunction And Posting Of Bond . In the event that the Event of Default referred to in subsection (a) of this Section 11 pertains to the Company’s failure to deliver unlegended shares of Common Stock to Holder pursuant to a Warrant Exercise, legend removal request, or otherwise, the Company may not refuse such unlegended share delivery based on any claim that such Holder or any one associated or affiliated with such Holder has been engaged in any violation of law, unless an injunction from a court, on prior notice to Holder, restraining and or enjoining Exercise of all or part of said Warrant shall have been sought and obtained by the Company and the Company has posted a Surety Bond for the benefit of such Holder in the amount of the Bond Amount, which Surety Bond shall remain in effect until the completion of litigation of

 

21


the dispute and the proceeds of which shall be payable to such Holder to the extent Holder obtains judgment.

(e) Remedies, Other Obligations, Breaches And Injunctive Relief . The remedies provided in this Warrant shall be cumulative and in addition to all other remedies available under this Warrant, the Facility Agreement, the Registration Rights Agreement and any other Loan Document, at law or in equity (including a decree of specific performance and/or other injunctive relief), and nothing herein shall limit the right of Holder to pursue actual damages for any failure by the Company to comply with the terms of this Warrant. The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to Holder and that the remedy at law for any such breach may be inadequate. The Company therefore agrees that, in the event of any such breach or threatened breach (including a breach or threatened breach of Section 13), the holder of this Warrant shall be entitled, in addition to all other available remedies, to an injunction restraining any breach, without the necessity of showing economic loss and without any bond or other security being required.

29. Holder’s Early Terminations .

(a) Mechanics of Holder’s Early Terminations . In the event that the Company does not deliver the applicable Successor Major Transaction Consideration or Default Amount or the Exercise Shares in respect of an election of a Successor Major Transaction Conversion, Cashless Major Exercise, Cashless Default or Exercise, as the case may be, to Holder within the time period or as otherwise required pursuant to the terms hereof, at any time thereafter Holder shall have the option, upon notice to the Company, in lieu of an election of a Successor Major Transaction Conversion, Cashless Major Exercise, Cashless Default Exercise or Exercise, as the case may be, to require the Company to promptly return to Holder all or any portion of this Warrant that was submitted for election of a Successor Major Transaction Conversion, Cashless Major Exercise, Cashless Default Exercise or Exercise, as the case may be. Upon the Company’s receipt of such notice, (x) the applicable election of Successor Major Transaction Conversion, Cashless Major Exercise, Cashless Default Exercise or Exercise, as the case may be, shall be null and void with respect to such applicable portion of this Warrant, (y) the Company shall immediately return this Warrant, or issue a new Warrant to Holder representing the portion of this Warrant that was submitted for election of Successor Major Transaction Conversion, Cashless Major Exercise, Cashless Default Exercise or Exercise, as the case may be, and (z) the Exercise Price of this Warrant or such new Warrant shall be adjusted to the Exercise Price as in effect on the date on which the applicable election of Successor Major Transaction Conversion, Cashless Major Exercise, Cashless Default Exercise or Exercise, as the case may be, is voided. Holder’s delivery of a notice voiding an election of a Successor Major Transaction Conversion, Cashless Major Exercise, Cashless Default Exercise or Exercise, as the case may be, and exercise of its rights following such notice shall not affect the Company’s obligations to make any Failure Payments which have accrued prior to the date of such notice with respect to the Warrant subject to such notice.

30. Dividend Restrictions .

Until the earlier of the expiration of the Exercise Period and the date all of the Warrants are exercised in full (the “Dividend Restriction Period”), the Company shall not declare or pay any dividend or distribution of any kind to the holders of Common Stock of the Company.

31. Benefits of this Warrant .

Nothing in this Warrant shall be construed to confer upon any person other than the Company and Holder any legal or equitable right, remedy or claim under this Warrant and this Warrant shall be for the sole and exclusive benefit of the Company and Holder.

 

22


32. Governing Law .

All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement (whether brought against a party hereto or its respective affiliates, directors, officers, stockholders, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York, borough of Manhattan. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. The parties hereby waive all rights to a trial by jury. If either party shall commence an action or proceeding to enforce any provisions of this Agreement, then the prevailing party in such action or proceeding shall be reimbursed by the other party for its reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.

33. Loss of Warrant .

Upon receipt by the Company of evidence of the loss, theft, destruction or mutilation of this Warrant, and (in the case of loss, theft or destruction) of indemnity or security reasonably satisfactory to the Company, and upon surrender and cancellation of this Warrant, if mutilated, the Company shall execute and deliver a new Warrant of like tenor and date.

34. Notice or Demands .

Except as otherwise provided herein, notices or demands pursuant to this Warrant to be given or made by Holder to or on the Company shall be sufficiently given or made if sent by overnight delivery with a nationally recognized overnight courier service, certified or registered mail, return receipt requested, postage prepaid, and addressed, until another address is designated in writing by the Company, to the address set forth in Section 2(a) above. To the extent any notice or demand pursuant to this Warrant can be made by electronic mail, such notice or demand given or made by Holder to or on the Company shall be sufficiently given or made if it is sent by electronic mail to the addresses that the Company shall designate in writing from time to time. Notices or demands pursuant to this Warrant to be given or made by the Company to or on Holder shall be sufficiently given or made if sent by overnight delivery with a nationally recognized overnight courier service or certified or registered mail, return receipt requested, postage prepaid, and addressed, to the address of Holder set forth in the Company’s records, until another address is designated in writing by Holder.

18. Construction .

Unless the context otherwise requires, (a) all references to Articles, Sections, Schedules or Exhibits are to Articles, Sections, Schedules or Exhibits contained in or attached to this Warrant, (b) words in the singular or plural include the singular and plural and pronouns stated in either the masculine, the feminine or neuter

 

23


gender shall include the masculine, feminine and neuter and (c) the use of the word “including” in this Warrant shall be by way of example rather than limitation.

19. Signatures .

In the event that any signature to this Warrant or any amendment hereto is delivered by electronic mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such “.pdf” signature page were an original thereof. Notwithstanding the foregoing, the Company shall be obligated to deliver to Holder an original signature to this Warrant. At the request of any party, each other party shall promptly re-execute an original form of this Warrant or any amendment hereto and deliver the same to the other party. No party hereto shall raise the use of electronic mail delivery of a “.pdf” format data file to deliver a signature to this Warrant or any amendment hereto or the fact that such signature was transmitted or communicated through the use of electronic mail delivery of a “.pdf” format data file as a defense to the formation or enforceability of a contract, and each party hereto forever waives any such defense.

 

24


IN WITNESS WHEREOF, the undersigned has executed this Warrant as of the          day of             , 20    .

 

ENDOLOGIX, INC.
By:    
 

Print Name:

Title:

 

25


EXHIBIT A-1

EXERCISE FORM FOR WARRANT

TO: [                     ]

CHECK THE APPLICABLE BOX:

 

☐       

Cash Exercise, Cashless Exercise or Note Exchange Exercise

 

The undersigned hereby irrevocably exercises Warrant Number          (the “Warrant”) with respect to [            ] shares of Common Stock (the “Common Stock”) of Endologix, Inc., a Delaware corporation (the “Company”). [IF APPLICABLE: The undersigned hereby encloses $         as payment of the Exercise Price.]

 

☐ The undersigned is exercising the Warrant with respect to [            ] shares of Common Stock pursuant to a Cashless Exercise, and hereby makes payment of the Exercise Price with respect to such shares in full, all in accordance with the conditions and provisions of the Warrant applicable to such Cashless Exercise.

 

☐ The undersigned is exercising the Warrant with respect to [            ] shares of Common Stock pursuant to a Note Exchange Exercise. The undersigned hereby agrees to cancel $         of principal outstanding under Notes of the Company held by Holder in satisfaction of the Exercise Price in accordance with the conditions and provisions of the Warrant applicable to such Note Exchange Exercise.

☐       

Cashless Major Exercise

 

The undersigned hereby irrevocably exercises the Warrant with respect to         % of the Warrant currently outstanding pursuant to a Cashless Major Exercise in accordance with the terms of the Warrant.

☐       

Cashless Default Exercise

 

The undersigned hereby irrevocably exercises the Warrant pursuant to a Cashless Default Exercise, in accordance with the terms of the Warrant.

1. The undersigned requests that any stock certificates for such shares be issued free of any restrictive legend, if appropriate, and, if requested by the undersigned, a warrant representing any unexercised portion hereof be issued, pursuant to the Warrant in the name of the undersigned and delivered to the undersigned at the address set forth below.

2. Capitalized terms used but not otherwise defined in this Exercise Form shall have the meaning ascribed thereto in the Warrant.

Dated: _______________

 

 

Signature

 

 

Print Name

 

 

Address

NOTICE

 

26


The signature to the foregoing Exercise Form must correspond to the name as written upon the face of the attached Warrant.

 

27


EXHIBIT B

ASSIGNMENT

(To be executed by the registered holder

desiring to transfer the Warrant)

FOR VALUE RECEIVED, the undersigned holder of the attached warrant (the “Warrant”) hereby sells, assigns and transfers unto the person or persons below named the right to purchase                      shares of the Common Stock of [ ], a Delaware corporation, evidenced by the attached Warrant and does hereby irrevocably constitute and appoint                      attorney to transfer the said Warrant on the books of the Company, with full power of substitution in the premises.

 

Dated: _______________   

 

Signature

Fill in for new registration of Warrant:

 

 

Name

 
 

 

Address

 
 

 

Please print name and address of assignee

 
(including zip code number)  

NOTICE

The signature to the foregoing Assignment must correspond to the name as written upon the face of the attached Warrant.

 

28


EXHIBIT C

FORM OF OPINION

______, 20__

[                    ]

Re: [ ] (the “Company”)

Dear Sir:

[                    ] (“[                    ]”) intends to transfer              Warrants (the “Warrants”) of the Company to                  (“                ”) without registration under the Securities Act of 1933, as amended (the “Securities Act”). In connection therewith, we have examined and relied upon the truth of representations contained in an Investor Representation Letter attached hereto and have examined such other documents and issues of law as we have deemed relevant.

Based on and subject to the foregoing, we are of the opinion that the transfer of the Warrants by              to              may be effected without registration under the Securities Act [, provided, however, that the Warrants to be transferred to              contain a legend restricting its transferability pursuant to the Securities Act and that transfer of the Warrants is subject to a stop order] . 10

The foregoing opinion is furnished only to                      and may not be used, circulated, quoted or otherwise referred to or relied upon by you for any purposes other than the purpose for which furnished or by any other person for any purpose, without our prior written consent.

Very truly yours,

 

10  

Only if applicable.

 

29


[FORM OF INVESTOR REPRESENTATION LETTER]

_____, 20__

[                                 ]

Gentlemen:

                 (“    ”) has agreed to purchase              Warrants (the “Warrants”) of [ ] (the “Company”) from [                    ] (“[                ]”). We understand that the Warrants are “restricted securities.” We represent and warrant that              is a sophisticated institutional investor that would qualify as an “Accredited Investor” as defined in Rule 501 of Regulation D under the Securities Act of 1933, as amended (the “Securities Act”).

________ represents and warrants as of the date hereof as follows:

1. That it is acquiring the Warrants and the shares of common stock, $0.001 par value per share underlying such Warrants (the “Exercise Shares”) solely for its account for investment and not with a view to or for sale or distribution of said Warrants or Exercise Shares or any part thereof in violation of the Securities Act.              also represents that the entire legal and beneficial interests of the Warrants and Exercise Shares                  is acquiring is being acquired for, and will be held for, its account only;

2. That the Warrants and the Exercise Shares must be held indefinitely unless they are registered under the Securities Act or an exemption from such registration is available.                  recognizes that the Company has no obligation to register the Warrants, or to comply with any exemption from such registration;

3. That neither the Warrants nor the Exercise Shares may be sold pursuant to Rule 144 adopted under the Securities Act unless certain conditions are met;

We acknowledge that the Company will place stop orders with respect to the Warrants and the Exercise Shares, and if none of the Unrestricted Conditions (as defined in the Warrants) is satisfied, the Exercise Shares shall bear the following restrictive legend:

“THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER SAID ACT, OR PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER SAID ACT INCLUDING PURSUANT TO SECTION 4(A)(7) OF THE SECURITIES ACT OR RULE 144 UNDER SAID ACT OR PURSUANT TO A PRIVATE SALE EFFECTED UNDER APPLICABLE FORMAL OR INFORMAL SEC INTERPRETATION OR GUIDANCE, SUCH AS A SO-CALLED “4[(a)](1) AND A HALF” SALE. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.”

 

30


“THE SALE, TRANSFER OR ASSIGNMENT OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO THE TERMS AND CONDITIONS OF A CERTAIN AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT DATED AS OF AUGUST 9, 2018, AS AMENDED FROM TIME TO TIME, AMONG THE COMPANY AND CERTAIN HOLDERS OF ITS OUTSTANDING SECURITIES. COPIES OF SUCH AGREEMENT MAY BE OBTAINED AT NO COST BY WRITTEN REQUEST MADE BY THE HOLDER OF RECORD OF THIS CERTIFICATE TO THE SECRETARY OF THE COMPANY.”

At any time and from time to time after the date hereof,                  shall, without further consideration, execute and deliver to [                ] or the Company such other instruments or documents and shall take such other actions as they may reasonably request to carry out the transactions contemplated hereby.

Very truly yours,

 

31


Schedule 1

Black-Scholes Value

 

    

Calculation Under Sections 3(b) and 5(b)(iii)

  

Calculation Under Section 10(b) or 11(b)

Remaining Term    Number of calendar days from date of public announcement of the Major Transaction until the last date on which the Warrant may be exercised.    Number of calendar days from the date of the Event of Failure, or in the case of an Event of Default, the date of the Default Notice, until the last date on which the Warrant may be exercised.
Interest Rate    A risk-free interest rate corresponding to the US$ LIBOR/Swap rate for a period equal to the remaining Exercise Period.    A risk-free interest rate corresponding to the US$ LIBOR/Swap rate for a period equal to the remaining Exercise Period.
Cost to Borrow    Zero    Zero
Volatility   

If the first public announcement of the Major Transaction is made at or prior to 4:00 p.m., New York City time, the arithmetic mean of the historical volatility for the 10, 30 and 50 Trading Day periods ending on the date of such first public announcement, obtained from the HVT or similar function on Bloomberg.

 

If the first public announcement of the Major Transaction is made after 4:00 p.m., New York City time, the arithmetic mean of the historical volatility for the 10, 30 and 50 Trading Day periods ending on the next succeeding Trading Day following the date of such first public announcement, obtained from the HVT or similar function on Bloomberg.

   The arithmetic mean of the historical volatility for the 10, 30 and 50 Trading Day periods ending on the date of such determination, obtained from the HVT or similar function on Bloomberg.
Stock Price    As selected by Holder in its commercially reasonable discretion in order to produce a commercially reasonable result, any of: (1) the closing price of the Common Stock on the NasdaqGS, or, if that is not the principal trading market for the Common Stock, such principal market on which the Common Stock is traded or listed (the “Closing Market Price”) on the Trading Day immediately preceding the date on which a Major Transaction is consummated, (2) the first Closing Market    The volume Weighted Average Price on the date of such determination.


   Price following the first public announcement of a Major Transaction, (3) the Closing Market Price as of the date immediately preceding the first public announcement of the Major Transaction or (4) the cash amount payable per share of Common Stock. The Company and Holder acknowledge and agree that any of the above will produce a commercially reasonable result.   
Dividends    Zero.    Zero.
Strike Price    Exercise Price as defined in section 3(a).    Exercise Price as defined in section 3(a).


EXHIBIT D

DEERFIELD / ENDOLOGIX

CLOSING CHECKLIST

Facility Agreement Parties:

 

Term Borrower    Endologix, Inc., a Delaware corporation
Term Guarantors (collectively with the Term Borrower, the “Loan Parties”)    See attached Schedule A
Term Lenders    Deerfield Private Design Fund IV, L.P.; Deerfield Partners, L.P.; and Deerfield Private Design Fund III, L.P.
Term Agent    Deerfield Private Design Fund IV, L.P.
Katten    Katten Muchin Rosenman LLP, Counsel to Term Agent
DLA    DLA Piper LLP (US), Counsel to the Loan Parties

ABL Agreement Parties:

 

ABL Borrowers (also referred to as the “Credit Parties”)    Endologix, Inc., a Delaware corporation, and as listed on attached Schedule A
ABL Lenders    Deerfield Private Design Fund IV, L.P.; Deerfield Partners, L.P.; and Deerfield Private Design Fund III, L.P.
ABL Agent    Deerfield ELGX Revolver, LLC
Katten    Katten Muchin Rosenman LLP, Counsel to ABL Agent
DLA    DLA Piper LLP (US), Counsel to the Credit Parties

FACILITY AGREEMENT DOCUMENTS AND DELIVERABLES:

 

    

Document

  

Responsible

Party

  

Signatures

  

Status

A.    DEBT DOCUMENTS – AGREEMENTS
1.    Amended and Restated Facility Agreement    Katten   

Term Borrower

Term Guarantors

Term Agent

Term Lenders

   Katten revised draft 8/8
   Annexes to Amended and Restated Facility Agreement         
   Disbursement Amount and Warrants    Katten    N/A   


    

Document

  

Responsible

Party

  

Signatures

  

Status

   Schedules to Amended and Restated Facility Agreement          Final
       

Schedule P-1—Existing Investments

   Loan Parties/DLA    N/A   
  

Schedule 2.4—List of Agreement Date Lenders and Such Lenders’ Wire Instructions and Information for Notices

   Katten/Agent    N/A   
  

Schedule 3.1(d)—Existing Liens

   Loan Parties/DLA    N/A   
  

Schedule 3.1(f)—Existing Indebtedness

   Loan Parties/DLA    N/A   
  

Schedule 3.1(h)—Litigation

   Loan Parties/DLA    N/A   
  

Schedule 3.1(j)—Authorizations

   Loan Parties/DLA    N/A   
  

Schedule 3.1(m)—Real Estate

   Loan Parties/DLA    N/A   
  

Schedule 3.1(n)—Intellectual Property

   Loan Parties/DLA    N/A   
  

Schedule 3.1(x)—Borrower’s Subsidiaries

   Loan Parties/DLA    N/A   
  

Schedule 3.1(z)—Borrower’s Outstanding Shares of Stock, Options and Warrants

   Loan Parties/DLA    N/A   
  

Schedule 3.1(aa)—Material Contracts

   Loan Parties/DLA    N/A   
  

Schedule 3.1(dd)—Environmental

   Loan Parties/DLA    N/A   
  

Schedule 3.1(ff)—Labor Relations

   Loan Parties/DLA    N/A   
  

Schedule 3.1(gg)—Jurisdiction of Organization, Legal Name, Organizational Identification Number and Chief Executive Office

   Loan Parties/DLA    N/A   
  

Schedule 3.1(jjj)—Stock of the Subsidiaries of the Loan Parties

   Loan Parties/DLA    N/A   
  

Schedule 3.1(hh)—Inventory Locations

   Loan Parties/DLA    N/A   
  

Schedule 3.1(uu)—FDA/Governmental Notices

   Loan Parties/DLA    N/A   
  

Schedule 5.1(q)—Other Loan Documents to Be Form 8-K Exhibits

   Katten    N/A   

 

4


    

Document

  

Responsible

Party

  

Signatures

  

Status

  

Schedule 5.2(iv)—Contingent Obligations

   Loan Parties/DLA    N/A   
  

Schedule 5.2(vii)—Transactions with Affiliates

   Loan Parties/DLA    N/A   
   Exhibits to Amended and Restated Facility Agreement         
  

Exhibit A-1—Form of First Out Waterfall Note

   Katten    N/A    Final
  

Exhibit A-2—Form of Last Out Waterfall Note

   Katten    N/A    Final
  

Exhibit B—Form of Perfection Certificate

   Katten    N/A    Final
  

Exhibit C-1—Form of Initial Warrant

   Katten    N/A    Final
  

Exhibit C-2—Form of Additional Warrant

   Katten    N/A    Final
  

Exhibit D—Closing Checklist

   Katten    N/A    Final
  

Exhibit E—Form of Amended and Restated Registration Rights Agreement

   Katten    N/A    Final
  

Exhibit F—Form of Compliance Certificate

   Katten    N/A    Final
  

Exhibit 2.6—Share Payment Provisions

   Katten    N/A    Final
2.    First Out Waterfall Notes in favor of each Term Lender    Katten    Term Borrower    Executed
3.    Last Out Waterfall Note for Deerfield Partners, L.P.    Katten    Term Borrower    Executed
4.    Amended and Restated Guaranty and Security Agreement    Katten   

Term Borrower

Term Guarantors

Term Agent

   Executed
   Schedules to Amended and Restated Guaranty and Security Agreement    DLA       Final
  

Schedule 1–Pledged Equity and Pledged Debt Instruments

   Loan Parties/DLA    N/A   
  

Schedule 1A—Pledged Investment Property

   Loan Parties/DLA    N/A   
  

Schedule 2—Filings and Perfection

   Loan Parties/DLA    N/A   
  

Schedule 3—Grantor Information    

   Loan Parties/DLA    N/A   

 

5


    

Document

  

Responsible

Party

  

Signatures

  

Status

  

Schedule 4—Places of Business/Location of Collateral

   Loan Parties/DLA    N/A   
  

Schedule 5—Commercial Tort Claims

   Loan Parties/DLA    N/A   
  

Schedule 6—Accounts

   Loan Parties/DLA    N/A   
  

Schedule 7—Real Property

   Loan Parties/DLA    N/A   
  

Schedule 8—Copyrights

   Loan Parties/DLA    N/A   
  

Schedule 9—Intellectual Property Licenses

   Loan Parties/DLA    N/A   
  

Schedule 10—Patents

   Loan Parties/DLA    N/A   
  

Schedule 11—Trademarks

   Loan Parties/DLA    N/A   
5.   

Perfection Certificate

   Katten (form)/Loan Parties/DLA (substance)   

Term Borrower

Term Guarantors

   Executed
6.    UCC-1 Financing Statements for Endologix Canada, LLC    Katten    N/A    Recorded
7.    UCC-3 Financing Statement for Endologix Canada, LLC    Katten    N/A    Recorded
8.    Original Warrants in favor of each Term Lender    Katten    Term Borrower    Executed
9.    Amended and Restated Registration Rights Agreement    Katten   

Term Borrower

Term Lenders

   Executed
10.    Reaffirmation Agreement    Katten   

Term Borrower

Term Guarantors

Term Agent

   Executed
11.    First Supplement to Patent Security Agreement(s)    Katten   

Applicable Term Borrower/Guarantor(s)

Term Agent

   Executed
   Schedule to First Supplement to Patent Security Agreement(s)    DLA       Final
12.    First Supplement to Trademark Security Agreement(s)    Katten   

Applicable Term Borrower/Guarantor(s)

Term Agent

   Executed
   Schedule to First Supplement to Trademark Security Agreement(s)    DLA       Final

 

6


    

Document

  

Responsible

Party

  

Signatures

  

Status

13.    Executed Insurance Certificates of the Loan Parties and their Subsidiaries evidencing liability and casualty insurance, naming Term Agent on behalf of the Secured Parties as additional insured (liability insurance) or lender’s loss payee (casualty insurance) and providing for 30 days’ prior written notice before any such policy may be modified or cancelled (or 10 days’ prior written notice in the case of failure to pay any premiums thereunder)    DLA    Insurance Broker (for insurance certificates)    Final (revised versions to come post-closing removing Trivascular Canada)
14.    Intercreditor Agreement    Katten   

Term Borrower

ABL Borrowers

Term Agent

ABL Agent

   Executed
15.    Irrevocable Proxies    Katten    Applicable Term Guarantors    Executed
16.    8,677 Shares of Series A Preferred Stock in Cianna Medical, Inc. (with corresponding Stock Power)    DLA    Term Borrower    Executed
17.    Intercompany Subordination Agreement    Katten   

Term Borrower

Term Guarantors

Term Agent

   Executed
B.    CERTIFICATES AND MISCELLANEOUS
18.    Lien Searches and IP Searches for Loan Parties    Katten    N/A    Final
19.    Secretary’s Certificate of each Loan Party, attaching Organization Documents, resolutions, incumbency and good standings    DLA    Term Guarantors    Executed
  

A. Certificate of Incorporation or Formation

   DLA    See attached Schedule A    See attached Schedule A
  

B. Bylaws or Operating Agreement

   DLA    See attached Schedule A    See attached Schedule A
  

C. Resolutions

   DLA    See attached Schedule A    See attached Schedule A
  

D. Incumbency

   DLA    See attached Schedule A    See attached Schedule A
  

E.  Good Standings  

   DLA    See attached Schedule A    See attached Schedule A

 

7


    

Document

  

Responsible

Party

  

Signatures

  

Status

20.   

Agreement Date Officer’s Certificate from an Authorized Officer of Endologix, Inc. certifying to each of the following:

 

a)  The conditions set forth in Section 2.2(a) have been satisfied and the terms set forth in Section 2.2(a) have been completely complied with

 

b)  No Default or Event of Default shall have occurred or would result from the Disbursement or the use of the proceeds therefrom

 

c)  All of the representations and warranties in the Loan Documents are true and correct

 

d)  All conditions set forth in Section 4.1 of the Facility Agreement have been satisfied

   DLA   

Term Borrower

Term Guarantors

   Executed
21.    Solvency Certificate    DLA   

Term Borrower

Term Guarantors

   Executed
22.    Legal Opinion of the Loan Parties    DLA    DLA    Executed
23.    Transfer Agent Letter as to shares outstanding        Loan Parties    Transfer Agent    Executed

 

8


    

Document

  

Responsible

Party

  

Signatures

  

Status

24.   

Landlord/Bailee Waivers

 

A. 2 Musick and 35 Hammond, Irvine, County of Orange, CA 92618 U.S.A.

 

B. 3910 Brickway Blvd., Santa Rosa, County of Sonoma, CA 95403 U.S.A.

 

C. UPS Warehouse Lien Agreement

 

•  378 Commercial Street, Malden, MA 02148

 

•  165 Chubb Avenue, Lyndhurst, NJ 07071

 

•  1130 Commerce Blvd, Swedesboro, NJ 08085

 

•  2250 Outerloop Drive, Louisville, KY 40219

   Loan Parties/DLA   

Applicable Loan Parties

Applicable Landlord

Term Agent

ABL Agent

  

A. Executed

B. Executed

C. Katten comments 8/6 (to be finalized post-closing)

25.   

Account Control Agreements

 

A.Wells Fargo

 

B.Bank of America (with Activation)

 

C.Bank of America (without Activation)

 

D.Silicon Valley Bank (amendment)

   Loan Parties/DLA   

Applicable Loan Parties

Applicable Bank

Term Agent

ABL Agent

  

A. Executed

B. Executed

C. Executed

D. Executed

26.    Executed Insurance Endorsements of the Loan Parties and their Subsidiaries evidencing liability and casualty insurance, naming Term Agent on behalf of the Secured Parties as additional insured (liability insurance) or lender’s loss payee (casualty insurance) and providing for 30 days’ prior written notice before any such policy may be modified or cancelled (or 10 days’ prior written notice in the case of failure to pay any premiums thereunder)    DLA    Insurance Carriers (for insurance endorsements)    To come post-closing, adding Endologix Canada, LLC and removing ACF Finco

 

9


ABL AGREEMENT DOCUMENTS AND DELIVERABLES

 

    

Document

  

Responsible

Party

  

Signatures

  

Status

A.    DEBT DOCUMENTS – AGREEMENTS
1.    Credit Agreement    Katten   

ABL Borrowers

ABL Agent

ABL Lender

   Executed
   Schedules to Credit Agreement          Final
   Schedule A-1 – Agent’s Account    Credit Parties/DLA    N/A   
   Schedule A-2 – Authorized Person    Credit Parties/DLA    N/A   
   Schedule C-1 – Commitments    Credit Parties/DLA    N/A   
   Schedule D-1 – Designated Account    Credit Parties/DLA    N/A   
   Schedule E-1 – Approved Account Debtor    Credit Parties/DLA    N/A   
   Schedule P-1 – Existing Investments    Credit Parties/DLA    N/A   
   Schedule 4.01(d) – Existing Liens    Credit Parties/DLA    N/A   
   Schedule 4.01(f) – Existing Indebtedness    Credit Parties/DLA    N/A   
   Schedule 4.03 – Litigation    Credit Parties/DLA    N/A   
   Schedule 4.06 – Real Estate    Credit Parties/DLA    N/A   
   Schedule 4.07 – Intellectual Property    Credit Parties/DLA    N/A   
   Schedule 4.15 – Borrower’s Subsidiaries    Credit Parties/DLA    N/A   
   Schedule 4.17 – Borrower’s Outstanding Shares of Stock, Options and Warrants    Credit Parties/DLA    N/A   
   Schedule 4.18 – Material Contracts    Credit Parties/DLA    N/A   
   Schedule 4.20 – Environmental    Credit Parties/DLA    N/A   
   Schedule 4.22 – Labor Relations    Credit Parties/DLA    N/A   
   Schedule 4.23 – Jurisdiction of Organization, Legal Name, Organizational Identification Number and Chief Executive Office    Credit Parties/DLA    N/A   
   Schedule 4.33(a) – FDA/ Governmental Notices    Credit Parties/DLA    N/A   
   Schedule 4.41 – Stock of the Subsidiaries of the Loan Parties    Credit Parties/DLA    N/A   

 

10


    

Document

  

Responsible

Party

  

Signatures

  

Status

   Schedule 4.45 – Inventory Location    Credit Parties/DLA    N/A   
   Schedule 6.05 – Contingent Obligations    Credit Parties/DLA    N/A   
   Schedule 6.07 – Transactions with Affiliates    Credit Parties/DLA    N/A   
   Exhibits to Credit Agreement         
  

Exhibit A -1 — Form of Assignment and Acceptance

   Katten    N/A    Final
  

Exhibit B-1 – Form of Borrowing Base Certificate (Agent)

   Katten    N/A    Final
  

Exhibit B-2 – Form of Borrowing Base Certificate (Third Party Agent)

   Katten    N/A    Final
  

Exhibit C-1 – Form of Compliance Certificate

   Katten    N/A    Final
  

Exhibit P-1 – Form of Perfection Certificate

   Katten    N/A    Final
2.    Original Notes in favor of each ABL Lender    Katten    ABL Borrower    Executed
3.    Guaranty and Security Agreement    Katten   

ABL Borrowers

ABL Agent

   Executed
   Schedules to Guaranty and Security Agreement    DLA      
   Schedule 1 – Pledged Equity and Pledged Debt Instruments         
  

Schedule 1A – Pledged Investment Property

        
  

Schedule 2 – Filings and Perfection

        
  

Schedule 3 – Grantor Information

        
  

Schedule 4 – Places of Business / Location of Collateral

        
  

Schedule 5 – Commercial Tort Claims

        
  

Schedule 6—Accounts

        
  

Schedule 7 – Real Property

        
  

Schedule 8—Copyrights

        

 

11


    

Document

  

Responsible

Party

  

Signatures

  

Status

  

Schedule 9 – Intellectual Property Licenses

        
  

Schedule 10—Patents

        
  

Schedule 11—Trademarks

        
   Annexes to Guaranty and Security Agreement         
  

Annex I – Form of Joinder and Security Agreement

        
4.    Perfection Certificate    Katten (form)/Credit Parties/DLA (substance)    See above    See above
5.    UCC-1 Financing Statements for each Credit Party    Katten    N/A    Agreed
6.    Executed Insurance Certificates of the Credit Parties and their Subsidiaries evidencing liability and casualty insurance, naming the ABL Agent on behalf of the Secured Parties as additional insured (liability insurance) or lender’s loss payee (casualty insurance) and providing for 30 days’ prior written notice before any such policy may be modified or cancelled (or 10 days’ prior written notice in the case of failure to pay any premiums thereunder)    DLA    Insurance Broker    Final (revised versions to come post-closing removing Trivascular Canada)
7.    Intercreditor Agreement    Katten    See above    See above
8.    Intercompany Subordination Agreement    DLA/Katten   

ABL Borrowers

ABL Agent

   Executed
9.    Patent Security Agreement(s)    Katten   

Applicable ABL Borrower(s)

ABL Agent

   Executed
   Schedule to Patent Security Agreement(s)    DLA       Final
10.    Trademark Security Agreement(s)    Katten   

Applicable ABL Borrower(s)

ABL Agent

   Executed
   Schedule to Trademark Security Agreement(s)    DLA       Final
B.    CERTIFICATES AND MISCELLANEOUS
11.    Lien Searches and IP Searches for Credit Parties    DLA    N/A    See above

 

12


    

Document

  

Responsible

Party

  

Signatures

  

Status

12.    Secretary’s Certificate of each Credit Party, attaching Organization Documents, resolutions, incumbency and good standings    DLA    ABL Borrowers   
  

A. Certificate of Incorporation or Formation

   DLA    See attached Schedule A    See attached Schedule A
  

B. Bylaws or Operating Agreement

   DLA    See attached Schedule A    See attached Schedule A
  

C. Resolutions

   DLA    See attached Schedule A    See attached Schedule A
  

D. Incumbency

   DLA    See attached Schedule A    See attached Schedule A
  

E.  Good Standings

   DLA    See attached Schedule A    See attached Schedule A
13.   

Agreement Date Officer’s Certificate from an Authorized Officer of Endologix, Inc. certifying to each of the following:

 

a)  Since December 31, 2017, the absence of any MAE

 

b)  The representations and warranties of each Credit Party contained in the Financing Documents are true, correct and complete on and as of the Closing Date, except to the extent that any such representation or warranty relates to a specific date in which case such representation or warranty is true and correct as of such earlier date

 

c)  All conditions set forth in Section 7.1 of the Facility Agreement have been satisfied

 

d)  Immediately after such borrowing and after application of the proceeds thereof or after

   DLA    ABL Borrowers    Executed

 

13


    

Document

  

Responsible

Party

  

Signatures

  

Status

  

such issuance, the Revolving Loan Outstandings will not exceed the Revolving Loan Limit

 

e)  Immediately before and after such advance or issuance, no Default or Event of Default shall have occurred and be continuing

        
14.    Solvency Certificate    DLA    ABL Borrower    Executed
15.    Borrowing Base Certificate    DLA    ABL Borrower    Final
16.    Legal Opinion of the Credit Parties    DLA    DLA    Executed
17.    Receipt by the ABL Agent and the ABL Lender of any fees, costs and expenses required to be paid on or before the Closing Date    Credit Parties    N/A    Final
18.    Receipt by ABL Agent and ABL Lender at least 3 Business Days prior to the Agreement Date all KYC and anti-money laundering rules and regulations    Credit Parties    Credit Parties    Final
19.    Cortland Administrative Services Agreement    ABL Agent   

Deerfield ELGX Revolver, LLC (Customer)

Cortland Capital Market Services LLC (Administrator)

   Executed
20.    Cortland Fee Proposal    ABL Agent       Agreed
21.    Landlord/Bailee Waivers    Credit Parties/DLA    See above    See above
22.    Account Control Agreements    Credit Parties/DLA    See above    See above

 

14


    

Document

  

Responsible

Party

  

Signatures

  

Status

23.    Executed Insurance Endorsements of the Credit Parties and their Subsidiaries evidencing liability and casualty insurance, naming the ABL Agent on behalf of the Secured Parties as additional insured (liability insurance) or lender’s loss payee (casualty insurance) and providing for 30 days’ prior written notice before any such policy may be modified or cancelled (or 10 days’ prior written notice in the case of failure to pay any premiums thereunder)    DLA    Insurance Carriers    To come post-closing, adding Endologix Canada, LLC and removing ACF Finco

Schedule A

Secretary’s Certificates

 

Borrower/Guarantor

  

Loan Party/
Credit Party

  

Certificate of
Formation /
Articles of
Organization

  

Operating
Agreement /
Bylaws

  

Resolutions

  

Incumbency

  

Good
Standings

Facility Agreement

  

ABL
Agreement

Borrower    Borrower    Endologix, Inc., a Delaware corporation    Rec’d    Rec’d    Executed    Executed    Rec’d CA, DE
Guarantor    Borrower    CVD/RMS Acquisition Corp., a Delaware corporation    Rec’d    Rec’d    Executed    Executed    Rec’d DE
Guarantor    Borrower    Nellix, Inc., a Delaware corporation    Rec’d    Rec’d    Executed    Executed    Rec’d DE
Guarantor    Borrower    TriVascular Technologies, Inc., a Delaware corporation    Rec’d    Rec’d    Executed    Executed    Rec’d CA, DE

 

15


Guarantor    Borrower    TriVascular, Inc., a California corporation    Rec’d    Rec’d    Executed    Executed    Rec’d CA
Guarantor    Borrower    Endologix Canada, LLC, a Delaware limited liability company (f/k/a Trivascular Canada, LLC)    Rec’d    Rec’d    Executed    Executed    Rec’d CA, DE
Guarantor    Borrower    TriVascular Sales LLC, a Texas limited liability company    Rec’d    Rec’d    Executed    Executed    Rec’d TX
Guarantor    Borrower    RMS/Endologix Sideways Merger Corp., a Delaware corporation    Rec’d    Rec’d    Executed    Executed    Rec’d DE

 

16


EXHIBIT E

FORM OF

AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT

AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of August 9, 2018, by and among Endologix, Inc., a Delaware corporation (the “Company”), and Deerfield Private Design Fund IV, L.P., Deerfield Partners, L.P. and Deerfield Private Design Fund III, L.P. (each individually, a “Lender” and together, the “Lenders”).

WHEREAS:

A. In connection with the Facility Agreement, dated as of April 3, 2017, by and among the Company, the Lenders, Deerfield International Master Fund, L.P. (the “Prior Lender”), the other Loan Parties (as defined therein) and Deerfield Private Design Fund IV, L.P., as agent for itself and the other Lenders (as the same has heretofore been amended, modified, restated or otherwise supplemented, the “Existing Facility Agreement”), (i) the Company issued the Initial Warrants (as defined in the Amended Facility Agreement (as defined below)) to the Lenders in the amounts described in the Existing Facility Agreement, each of which Initial Warrants is exercisable into shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”); and

B. In connection with the Facility Agreement, the Company, the Lenders and the Prior Lender executed and delivered that certain Registration Rights Agreement, dated as of April 3, 2017 (the “Existing Registration Rights Agreement”).

C. Pursuant to the Existing Registration Rights Agreement, the Company filed with the United States Securities and Exchange Commission (“SEC”) a Registration Statement (File No. 333-217602) on Form S-3, which registered the resale of an aggregate of 6,470,000 Common Shares issuable upon exercise of the Initial Warrants and was declared effective by the SEC as of May 22, 2017 (the “Existing Registration Statement”). On May 22, 2017, pursuant to Rule 424(b)(3) under the Securities Act (as defined below), the Company filed a final prospectus as part of the Existing Registration Statement (the “Initial Prospectus”). For the avoidance of doubt, the Existing Registration Statements and the Initial Prospectus constitute a Registration Statement and Prospectus (each as defined in this Agreement), respectively, under this Agreement.

D. Effective as of January 1, 2018, the Prior Lender transferred and assigned its Initial Warrants and its rights under the Existing Registration Rights Agreement to Deerfield Partners, L.P. (the “Warrant Transfer”).

F. Contemporaneously with the execution of this Agreement, the Company, the Lenders, the other Loan Parties (as defined therein) and Deerfield Private Design Fund IV, L.P., as agent for itself and the other Lenders, are entering into an Amended and Restated Facility Agreement, dated as of the date hereof (as the same may hereafter be amended, modified, restated or otherwise supplemented from time to time, the “Amended Facility Agreement”), which amends and restates the Existing Facility Agreement in its entirety. All capitalized terms used and not otherwise defined herein shall have the respective meanings set forth in the Amended Facility Agreement.

G. The Amended Facility Agreement, among other things, provides for the issuance of the Additional Warrants (as defined in the Amended Facility Agreement).

H. The parties hereto desire to amend and restate the Existing Registration Rights Agreement to provide for

 

17


certain changes relating to the issuance of the Additional Warrants.

I. To induce the Lenders to execute and deliver the Amended Facility Agreement, the Company has agreed to provide certain registration rights under the Securities Act of 1933, as amended, and the rules and regulations thereunder, or any similar successor statute (collectively, the “Securities Act”), and applicable state securities laws.

NOW, THEREFORE , in consideration of the premises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and each of the Lenders hereby agree as follows:

1. DEFINITIONS.

a. As used in this Agreement, the following terms shall have the following meanings:

(i) “Additional Filing Deadline” means, with respect to any Registration Statements that may be required pursuant to Section 2(a)(ii), (A) the first date or time that such Registrable Securities may then be included in a Registration Statement if such Registration Statement is required because the SEC shall have notified the Company in writing that certain Registrable Securities were not eligible for inclusion on a previously filed Registration Statement, or (B) if such additional Registration Statement is required for a reason other than as described in (A) above, the twentieth (20 th ) day following the date on which the Company first knows, or reasonably should have known, that such additional Registration Statement is required.

(ii) “Additional Registration Deadline” means, with respect to any additional Registration Statement(s) required pursuant to Section 2(a)(ii), the thirtieth (30 th ) day following (A) the first date or time that such Registrable Securities may then be included in a Registration Statement if such Registration Statement is required because the SEC shall have notified the Company in writing that certain Registrable Securities were not eligible for inclusion on a previously filed Registration Statement, or (B) if such additional Registration Statement is required for a reason other than as described in (A) above, the fortieth (40 th ) day following the date on which the Company first knows, or reasonably should have known, that such additional Registration Statement(s) is required.

(iii) “Investor” means any Lender and any transferee or assignee who agrees to become bound by the provisions of this Agreement in accordance with Section 10 hereof.

(iv) “Exchange Act” means the Securities Exchange Act of 1934, as amended, together with the rules and regulations promulgated thereunder, and any successor statute.

(v) “FINRA” means the Financial Industry Regulatory Authority (or successor thereto).

(vi) “Filing Deadline,” for the Registration Statement required pursuant to Section 2(a)(i), shall mean September 6, 2018, and for each Registration Statement required pursuant to Section 2(a)(ii) shall mean the Additional Filing Deadline.

(vii) “Person” means and includes any natural person, partnership, joint venture, corporation, trust, limited liability company, limited company, joint stock company, unincorporated organization, government entity or any political subdivision or agency thereof, or any other entity.

(viii) “Prospectus” means (i) any prospectus (preliminary or final) included in any Registration Statement (including the Initial Prospectus), as may be amended or supplemented by any prospectus supplement with respect to the terms of the offering of any portion of the Registrable Securities covered by such Registration

 

18


Statement and by all other amendments and supplements to such prospectus, including post-effective amendments, and all material incorporated by reference in such prospectus, and (ii) any “free writing prospectus” as defined in Rule 405 under the Securities Act relating to any offering of Registrable Securities pursuant to a Registration Statement.

(ix) “Register,” “Registered,” and “Registration” refer to a registration effected by preparing and filing a Registration Statement or Statements in compliance with the Securities Act and pursuant to Rule 415, and the declaration or ordering of effectiveness of such Registration Statement by the United States Securities and Exchange Commission (the “SEC”).

(x) “Registrable Securities,” for a given Registration, means (a) any shares of Common Stock (the “Warrant Shares”) issued or issuable upon exercise of, or otherwise pursuant to, the Warrants (without giving effect to any limitations on exercise set forth in the Warrants), (b) any shares of capital stock issued or issuable as a dividend on or in exchange for or otherwise with respect to any of the foregoing, (c) any additional shares of Common Stock issuable in connection with any anti-dilution provisions in the Warrants, (d) any other shares of Common Stock issuable pursuant to the terms of the Warrants or this Agreement, and (e) any securities issued or issuable upon any stock split, dividend or other distribution, recapitalization or similar event with respect to any of the foregoing.

(xi) “Registration Deadline” shall mean, for purposes of the Registration Statement required pursuant to Section 2(a)(i), the earlier of (i) the date that is seventy-five (75) days after the date that the applicable Registration Statement is actually filed or (ii) the date that is seventy-five (75) days after the applicable Filing Deadline and, with respect to any Registration Statement required pursuant to Section 2(a)(ii), the Additional Registration Deadline.

(xii) “Registration Statement(s)” means any registration statement(s) of the Company filed under the Securities Act that covers the resale of any of the Registrable Securities pursuant to the provisions of this Agreement (including the Existing Registration Statement), all amendments and supplements to such Registration Statement, including post-effective amendments, and all exhibits to, and all material incorporated by reference in, such Registration Statement.

(xiii) “Rule 415” means Rule 415 under the Securities Act or any successor rule providing for the offering of securities on a continuous basis

(xiv) “Warrants” means the Warrants (including, for the avoidance of doubt, both the Initial Warrants and the Additional Warrants) issued by the Company pursuant to the Existing Facility Agreement and the Amended Facility Agreement.

2. REGISTRATION.

a. MANDATORY REGISTRATION. (i) Following the Agreement Date, the Company shall prepare, and, on or prior to the applicable Filing Deadline, file with the SEC a Registration Statement (the “Mandatory Registration Statement”) on Form S-3 (or, if Form S-3 is not then available, on such form of Registration Statement as is then available to effect a registration of the Registrable Securities, subject to the consent of the Investors, which consent shall not be unreasonably withheld), covering the resale of all of the Registrable Securities that are not at that time covered by the Existing Registration Statement (as then in effect and available for resale of the Registrable Securities covered thereby), which Registration Statement, to the extent allowable under the Securities Act and the rules and regulations promulgated thereunder (including Rule 416), shall state that such Registration Statement also covers such indeterminate number of additional shares of Common Stock as may become issuable upon exercise of or otherwise pursuant to the Warrants or the Warrant Shares to prevent dilution resulting from stock splits, stock dividends, stock

 

19


issuances or similar transactions. The number of shares of Common Stock initially included in such Registration Statement shall be no less than the aggregate number of Warrant Shares that are then issuable upon exercise of or otherwise pursuant to the Warrants, without regard to any limitations on the Investors’ ability to exercise the Warrants. Each Registration Statement (and each amendment or supplement thereto, and each request for acceleration of effectiveness thereof) shall be provided to (and shall be subject to the approval, which shall not be unreasonably withheld or delayed, of) the Investors and their counsel prior to its filing or other submission.

(ii) If for any reason, despite the Company’s use of its best efforts to include all of the Registrable Securities in the Registration Statement filed pursuant to Section 2 (a)(i) above (and subject to Section 3(q) below), the SEC does not permit all such Registrable Securities to be included in such Registration Statement, or for any other reason any Registrable Securities are not then included in a Registration Statement (including the Existing Registration Statement), then the Company shall prepare, and, as soon as practicable but in no event later than the Additional Filing Deadline, file with the SEC an additional Registration Statement covering the resale of all Registrable Securities not already covered by an existing and effective Registration Statement for an offering to be made on a continuous basis pursuant to Rule 415.

(iii) Unless the SEC does not so permit or otherwise directed by the Buyers, each Registration Statement filed pursuant to this Section 2(a) or Section 3(b) shall include a combined prospectus for the resale of the Registrable Securities registered by such Registration Statement, the Existing Registration Statement and any other Registration Statement previously filed hereunder, and shall be deemed a post-effective amendment to the Existing Registration Statement or, other previously filed Registration Statement in accordance with Rule 429 under the Securities Act.

b. PIGGY-BACK REGISTRATIONS. If at any time prior to the expiration of the Registration Period (as hereinafter defined) the Company shall determine (i) to file with the SEC a registration statement under the Securities Act relating to an offering for its own account or for the account of any other holder of its equity securities (other than securities being registered on Form S-4 or Form S-8 or their then equivalents relating to equity securities to be issued solely in connection with any acquisition of any entity or business or equity securities issuable in connection with stock option or other employee benefit plans), and/or (ii) otherwise to effect an underwritten offering of any securities of the Company of a type included in a then effective Registration Statement, the Company shall send to each Investor written notice of such determination and, if within fifteen (15) days after the effective date of such notice, the Investor shall so request in writing, the Company shall include in such Registration Statement and/or include in such underwritten offering, as applicable, all or any part of such Investor’s Registrable Securities that the Investor requests to be registered and/or included in the underwritten offering, as applicable, except that if, in connection with any underwritten offering for the account of the Company, the managing underwriter(s) thereof shall impose a limitation on the number of Registrable Securities which may be included in such offering because, in such underwriter(s)’ judgment, marketing or other factors dictate such limitation is necessary to facilitate public distribution, then the Company shall be obligated to include in such underwritten offering only such limited portion of the Registrable Securities with respect to which the Investor has requested inclusion hereunder as the underwriter(s) shall permit;

provided, however , that the Company shall not exclude any Registrable Securities unless the Company has first excluded all outstanding securities to be sold for the accounts of any holders of the Company’s equity securities which are not entitled by contract to inclusion of such securities in an underwritten offering or are not entitled to pro rata inclusion with the Registrable Securities; and

provided, further, however , that, after giving effect to the immediately preceding proviso, any exclusion of Registrable Securities shall be made pro rata with holders of other securities having the contractual right to include such securities in such underwritten offering other than holders of securities entitled to inclusion of

 

20


their securities in such underwritten offering by reason of demand registration rights. No right to registration of Registrable Securities under this Section 2(b) shall be construed to limit any registration required under Section 2(a) hereof. If an Investor’s Registrable Securities are included in an underwritten offering pursuant to this Section 2(b), then such Investor shall, unless otherwise agreed by the Company, offer and sell such Registrable Securities in such underwritten offering using the same underwriter or underwriters and, subject to the provisions of this Agreement, on the same terms and conditions as other shares of Common Stock included in such underwritten offering. Notwithstanding anything to the contrary set forth herein, the rights of the Investors pursuant to this Section 2(b) shall only be available in the case of an underwritten offering or in the event the Company fails to timely file, obtain effectiveness or maintain effectiveness of any Registration Statement to be filed pursuant to Section 2(a) or Section 3(b) in accordance with the terms of this Agreement.

3. OBLIGATIONS OF THE COMPANY. In connection with any registration of the Registrable Securities hereunder, the Company shall have the following obligations:

a. The Company shall prepare promptly, and file with the SEC as soon as practicable after such registration obligation arises hereunder (but in no event later than the applicable Filing Deadline), a Registration Statement with respect to the Registrable Securities as provided in Section 2(a), and thereafter use its reasonable best efforts to cause each such Registration Statement relating to Registrable Securities to become effective as soon as possible after such filing, but in any event shall use its reasonable best efforts to cause each such Registration Statement relating to Registrable Securities to become effective no later than the Registration Deadline, and shall use its reasonable best efforts to keep each of such Registration Statement and the Existing Registration Statement current and effective pursuant to Rule 415 at all times after its effective date until such date as is the earlier of (i) the date on which all of the Registrable Securities included in such Registration Statement have been sold and (ii) assuming all of the Warrants will be exercised pursuant to Cash Exercises (as defined in the Warrants), the date on which all of the Registrable Securities included in such Registration Statement (in the opinion of counsel to the Investors) may be immediately sold to the public without registration or restriction (including without limitation as to volume by each holder thereof), and without compliance with any “current public information” requirement, pursuant to Rule 144 under the Securities Act (the “Registration Period”), which Registration Statement (including any amendments or supplements thereto and prospectuses contained therein), except for information provided in writing by an Investor pursuant to Section 4(a), shall not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein, or necessary to make the statements therein not misleading. In the event that Form S-3 is not available for the registration of the resale of any Registrable Securities hereunder (but, for the avoidance of doubt, without in any way affecting the Company’s obligation to register the resale of the Registrable Securities on such other form as is available, as provided in Section 2(a)), (i) the Company shall undertake to file, within twenty (20) days of such time as such form is available for such registration, a post-effective amendment to the Registration Statement then in effect, or otherwise file a Registration Statement on Form S-3, registering such Registrable Securities on Form S-3; provided that the Company shall maintain the effectiveness of the Registration Statement then in effect until such time as a Registration Statement (or post-effective amendment) on Form S-3 covering such Registrable Securities has been declared effective by the SEC, and (ii) the Company shall provide that any Registration Statement on Form S-1 filed hereunder shall incorporate documents by reference (including by way of forward incorporation by reference) to the maximum extent possible.

b. The Company shall prepare and file with the SEC such amendments (including post-effective amendments) and supplements to each Registration Statement and the prospectus used in connection with each Registration Statement as may be necessary to keep each Registration Statement current and effective at all times during the Registration Period, and, during the Registration Period, shall comply with the provisions of the Securities Act with respect to the disposition of all Registrable Securities of the Company

 

21


covered by each Registration Statement until such time as all of such Registrable Securities have been disposed of in accordance with the intended methods of disposition by the seller or sellers thereof as set forth in such Registration Statement. Without limiting the foregoing, no later than August 17, 2018, the Company shall file with the SEC a prospectus supplement that supplements the Initial Prospectus with such information as shall be necessary to reflect the Warrant Transfer (including to provide that Deerfield Partners, L.P. may resell the Registrable Securities underlying the Initial Warrants pursuant to the Existing Registration Statement and the Initial Prospectus) and the transactions contemplated by the Amended Facility Agreement, to include updated information with respect to the Lenders to the extent provided by the Lenders in accordance with this Agreement and to include such other information as may be necessary to enable the Existing Registration Statement to be used for resales of all of the Registrable Securities covered thereby. In the event that on any Trading Day (as defined below) (the “Registration Trigger Date”) the number of shares available under the Registration Statements filed pursuant to this Agreement is insufficient to cover all of the Registrable Securities issued or issuable upon exercise of or otherwise pursuant to the Warrants, including any additional shares of Common Stock issued in connection with any anti-dilution provisions contained in the Warrants, without giving effect to any limitations on the Investors’ ability to exercise the Warrants, the Company shall amend the Registration Statements, or file a new Registration Statement (on the short form available therefor, if applicable), or both, so as to cover the total number of Registrable Securities so issued or issuable (without giving effect to any limitations on exercise contained in the Warrants) as of the Registration Trigger Date as soon as practicable, but in any event within twenty (20) days after the Registration Trigger Date. The Company shall use its best efforts to cause such amendment and/or new Registration Statement to become effective as soon as practicable following the filing thereof, but in any event the Company shall cause such amendment and/or new Registration Statement to become effective within sixty (60) days of the Registration Trigger Date or as promptly as practicable in the event the Company is required to increase its authorized shares. “Trading Day” shall mean any day on which the Common Stock is traded for any period on the NASDAQ Global Select Market (the “NasdaqGS”), or if not the NasdaqGS, the principal securities exchange or other securities market on which the Common Stock is then being traded.

c. The Company shall furnish to each Investor and its legal counsel (i) promptly after the same is prepared and publicly distributed, filed with the SEC or received by the Company, one copy of each Registration Statement and any amendment thereto, each preliminary prospectus and prospectus and each amendment or supplement thereto, and, each letter written by or on behalf of the Company to the SEC or the staff of the SEC, and each item of correspondence from the SEC or the staff of the SEC, in each case relating to such Registration Statement (other than any portion of any thereof which contains information for which the Company has sought or intends to seek confidential treatment, which contains or reflects any material non-public information with respect to the Company or its securities or which relates to Company matters that are in the reasonable judgment of the Company not relevant to the Investor’s interests with respect to the Registrable Securities), and (ii) such number of copies of a prospectus, including a preliminary prospectus, and all amendments and supplements thereto and such other documents as an Investor may reasonably request in order to facilitate the disposition of the Registrable Securities owned by such Investor; provided that the Company may determine in its reasonable judgment to provide any such copies in electronic form only. The Company will promptly notify each of the Investors by electronic mail of the effectiveness of each Registration Statement or any post-effective amendment. The Company will promptly respond to any and all comments received from the SEC, with a view towards causing each Registration Statement or any amendment thereto (including any post-effective amendment to the Existing Registration Statement) to be declared effective by the SEC as soon as practicable and, as soon as practicable, but in no event later than three (3) business days, following the resolution or clearance of all SEC comments or, if applicable, following notification by the SEC that any such Registration Statement or any amendment thereto will not be subject to review, shall file a request for acceleration of effectiveness of such Registration Statement to a time and date not later than two (2) business days after the submission of such request. No later than the first business day after such Registration Statement becomes effective, the

 

22


Company will file with the SEC the final prospectus included therein pursuant to Rule 424 (or successor thereto) under the Securities Act.

d. The Company shall use its reasonable best efforts to (i) register and qualify, in any jurisdiction where registration and/or qualification is required, the Registrable Securities covered by the Registration Statements under such other securities or “blue sky” laws of such jurisdictions in the United States as the Investors shall reasonably request, (ii) prepare and file in those jurisdictions such amendments (including post-effective amendments) and supplements to such registrations and qualifications as may be reasonably necessary to maintain the effectiveness thereof during the Registration Period, (iii) take such other actions as may be reasonably necessary to maintain such registrations and qualifications in effect at all times during the Registration Period, and (iv) take all other actions reasonably necessary or advisable to qualify the Registrable Securities for sale in such jurisdictions; provided, however, that the Company shall not be required in connection therewith or as a condition thereto to (x) qualify to do business in any jurisdiction where it would not otherwise be required to qualify but for this Section 3(d), (y) subject itself to general taxation in any such jurisdiction, or (z) file a general consent to service of process in any such jurisdiction.

e. As promptly as practicable after becoming aware of such event, the Company shall notify each Investor that holds Registrable Securities of the happening of any event, of which the Company has knowledge, as a result of which the prospectus included in any Registration Statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading, and promptly prepare a supplement or amendment to any Registration Statement to correct such untrue statement or omission, and deliver such number of copies of such supplement or amendment to each Investor as such Investor may reasonably request.

f. The Company shall use its reasonable best efforts to prevent the issuance of any stop order or other suspension of effectiveness of any Registration Statement, and, if such an order is issued, to obtain the withdrawal of such order at the earliest possible moment and to notify each Investor that holds Registrable Securities (and, in the event of an underwritten offering, the managing underwriters) of the issuance of such order and the resolution thereof.

g. The Company shall permit a single firm of counsel designated by the Investors (“Legal Counsel”) to review such Registration Statement and all amendments and supplements thereto (as well as all requests for acceleration or effectiveness thereof), a reasonable period of time prior to their filing with the SEC (not less than five (5) business days but not more than eight (8) business days) and not file any documents in a form to which Legal Counsel reasonably objects and will not request acceleration of such Registration Statement without prior notice to Legal Counsel.

h. The Company shall hold in confidence and not make any disclosure of information concerning an Investor provided to the Company unless (i) disclosure of such information is necessary to comply with federal or state securities laws, (ii) the disclosure of such information is necessary to avoid or correct a misstatement or omission in any Registration Statement, (iii) the release of such information is ordered pursuant to a subpoena or other order from a court or governmental body of competent jurisdiction, or (iv) such information has been made generally available to the public other than by disclosure in violation of this or any other agreement. The Company agrees that it shall, upon learning that disclosure of such information concerning any Investor is sought in or by a court or governmental body of competent jurisdiction or through other means, give prompt notice to such Investor prior to making such disclosure, and allow such Investor, at its expense, to undertake appropriate action to prevent disclosure of, or to obtain a protective order for, such information.

i. The Company shall use its reasonable best efforts to cause all the Registrable Securities covered by each Registration Statement to be listed on each securities exchange on which securities of the same class or

 

23


series issued by the Company are then listed, if any, if the listing of such Registrable Securities is then permitted under the rules of such exchange, and, to arrange for at least two market makers to register with the Financial Industry Regulatory Authority, Inc. (“FINRA”) as such with respect to such Registrable Securities.

j. The Company shall provide a transfer agent and registrar, which may be a single entity, for the Registrable Securities not later than the effective date of the initial Registration Statement.

k. The Company shall cooperate with each Investor that holds Registrable Securities being offered and the managing underwriter or underwriters with respect to an applicable Registration Statement, if any, to facilitate the timely (i) preparation and delivery of certificates (not bearing any restrictive legends) representing Registrable Securities to be offered pursuant to such Registration Statement, and enable such certificates to be registered in such names and in such denominations or amounts, as the case may be, or (ii) crediting of the Registrable Securities to be offered pursuant to a Registration Statement to the applicable account (or accounts) with The Depository Trust Company through its Deposit/Withdrawal At Custodian (DWAC) system, in any such case as such Investor or the managing underwriter or underwriters, if any, may reasonably request. Within three (3) business days after a Registration Statement which includes Registrable Securities becomes effective, the Company shall deliver, and shall cause legal counsel selected by the Company to deliver, to the transfer agent for the Registrable Securities (with copies to each Investor) an appropriate instruction and an opinion of such counsel in the form required by the transfer agent in order to issue the Registrable Securities free of restrictive legends.

l. At the reasonable request of an Investor, the Company shall prepare and file with the SEC such amendments (including post-effective amendments) and supplements to a Registration Statement and any prospectus used in connection with the Registration Statement as may be necessary in order to change the plan of distribution set forth in such Registration Statement.

m. The Company shall not, and shall not agree to, allow the holders of any securities of the Company to include any of their securities (other than Registrable Securities) in any Registration Statement filed pursuant to Section 2(a) or Section 3(b) hereof or any amendment or supplement thereto under Section 3(b) hereof without the consent of Investors holding a majority-in-interest of the then outstanding Registrable Securities. In addition, the Company shall not include any securities for its own account or the account of others in any Registration Statement filed pursuant to Section 2(a) or Section 3(b) hereof or any amendment or supplement thereto filed pursuant to Section 3(b) hereof without the consent of Investors holding a majority-in-interest of the then outstanding Registrable Securities.

n. Reserved.

o. The Company shall comply with all applicable laws related to a Registration Statement and offering and sale of securities and all applicable rules and regulations of governmental authorities in connection therewith (including the Securities Act and the Exchange Act and the rules and regulations promulgated by the SEC).

p. If required by the FINRA Corporate Financing Department, the Company shall promptly effect a filing with FINRA pursuant to FINRA Rule 5110 (or successor thereto) with respect to the public offering contemplated by resales of securities under the Registration Statement (an “Issuer Filing”), and pay the filing fee required by such Issuer Filing. The Company shall use its reasonable best efforts to pursue the Issuer Filing until FINRA issues a letter confirming that it does not object to the terms of the offering contemplated by the Registration Statement.

q. If at any time the SEC advises the Company in writing that the offering of some or all of the Registrable

 

24


Securities in a Registration Statement is not eligible to be made on a delayed or continuous basis under the provisions of Rule 415 under the Securities Act, the Company shall use its reasonable best efforts to persuade the SEC that the offering contemplated by a Registration Statement is a bona fide secondary offering and not an offering “by or on behalf of the issuer” as defined in Rule 415 and that none of the Investors is an “underwriter.” The Investors shall have the right to participate or have their respective counsel participate in any meetings or discussions with the SEC regarding the SEC’s position and to comment or have their respective counsel comment on any written submission made to the SEC with respect thereto. No such written submission shall be made to the SEC to which any Investor’s counsel reasonably objects. In the event that, despite the Company’s reasonable best efforts and compliance with the terms of this Section 3(q), the SEC refuses to alter its position, the Company shall remove from the Registration Statement such portion of the Registrable Securities as the SEC requires in writing be removed therefrom. Any such cut-back imposed by the SEC as contemplated by this Section 3(q) shall be imposed on a pro rata basis (based upon the Registrable Securities held by each of the Investors).

r. Notwithstanding anything to the contrary in Section  3(e) , at any time after the effective date of the applicable Registration Statement, the Company may delay the disclosure of material non-public information concerning the Company the disclosure of which at the time is not, in the good faith opinion of the Board of Directors of the Company and its counsel, in the best interest of the Company and not, in the opinion of counsel to the Company, otherwise required (a “ Grace Period ”); provided, that the Company shall (i) promptly notify the Investors in writing of the existence of material non-public information giving rise to a Grace Period (provided that in each notice the Company shall not disclose the content of such material non-public information to any Investor unless otherwise requested in writing by such Investor) and the date on which the Grace Period will begin, and (ii) as soon as such date may be determined, promptly notify the Investors in writing of the date on which the Grace Period ends; and, provided , further , that (A) no Grace Period shall exceed forty-five (45) consecutive days, (B) during any three hundred sixty five (365) day period, such Grace Periods shall not exceed an aggregate of seventy-five (75) days, and (C) the first day of any Grace Period must be at least ten (10) business days after the last day of any prior Grace Period (each Grace Period that satisfies all of the requirements of this Section  3(r) being referred to as an “ Allowable Grace Period ”). For purposes of determining the length of a Grace Period above, the Grace Period shall begin on and include the date the Investors receive the notice referred to in clause (i) and shall end on and include the later of the date the Investors receive the notice referred to in clause (ii) and the date referred to in such notice. The provisions of Section  3(e) hereof shall not be applicable during the period of any Allowable Grace Period, Failure Payments (as defined in the Warrants) shall not accrue on any day during an Allowable Grace Period, and the unavailability of a Registration Statement for resales of the Registrable Securities on any day during an Allowable Grace Period shall not constitute a “Registration Failure” (as defined in the Warrants). Upon expiration of the Grace Period, the Company shall again be bound by the first sentence of Section  3(e) with respect to the information giving rise thereto unless such material non-public information is no longer applicable.

4. OBLIGATIONS OF THE INVESTOR. In connection with the registration of the Registrable Securities, each Investor shall have the following obligations:

a. It shall be a condition precedent to the obligations of the Company to complete the registration pursuant to this Agreement with respect to the Registrable Securities of an Investor that such Investor shall furnish to the Company such information regarding itself, the Registrable Securities held by it and the intended method of disposition of the Registrable Securities held by it as shall be reasonably required to effect the registration of such Registrable Securities and shall execute such documents in connection with such registration as the Company may reasonably request. At least five (5) business days prior to the first anticipated filing date of a Registration Statement, the Company shall notify each Investor of the information the Company requires from such Investor. Any such information shall not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein, or necessary to make

 

25


the statements therein not misleading. An Investor must provide such information to the Company at least two (2) business days prior to the first anticipated filing date of such Registration Statement if such Investor elects to have any Registrable Securities included in the Registration Statement.

b. Each Investor, by such Investor’s acceptance of the Registrable Securities, agrees to cooperate with the Company as reasonably requested by the Company in connection with the preparation and filing of a Registration Statement hereunder, unless such Investor has notified the Company in writing of such Investor’s election to exclude all of the Investor’s Registrable Securities from such Registration Statement.

c. In the event of an underwritten offering pursuant to Section 2(b) in which any Registrable Securities of any Investor are to be included, such Investor agrees to enter into and perform the Investor’s obligations under an underwriting agreement, in usual and customary form, including customary indemnification and contribution obligations (as applicable to selling security holders generally), with the managing underwriter of such offering and take such other actions as are reasonably required in order to expedite or facilitate the disposition of such Investor Registrable Securities.

d. Each Investor agrees that, upon receipt of any notice from the Company of the happening of any event of the kind described in Section 3(e) or 3(f), such Investor will immediately discontinue disposition of Registrable Securities pursuant to the Registration Statement covering such Registrable Securities until such Investor’s receipt of the copies of the supplemented or amended prospectus contemplated by Section 3(e) or 3(f).

e. Each Investor agrees that it will promptly notify the Company of any material changes in the information set forth in a Registration Statement furnished by or regarding such Investor, other than changes in the number of shares beneficially owned.

5. REGISTRATION FAILURE. In the event of a Registration Failure (as defined in the Warrants), the Investors shall be entitled to Failure Payments (as defined in the Warrants) and such other rights as set forth in the Warrants.

6. EXPENSES OF REGISTRATION. All reasonable expenses, other than underwriting discounts and commissions, incurred in connection with registrations, filings or qualifications pursuant to Sections 2 and 3, including, without limitation, all registration, listing and qualification fees, printers and accounting fees, and the fees and disbursements of counsel for the Company shall be borne by the Company.    The Company shall also reimburse the Investors for the reasonable fees and disbursements of Legal Counsel in the aggregate amount up to $25,000 per registration in connection with registrations pursuant to Section 2 or 3 of this Agreement.

7. INDEMNIFICATION. In the event any Registrable Securities are included in a Registration Statement under this Agreement:

a. The Company will indemnify, hold harmless and defend (i) each Investor, (ii) the directors, officers, partners, managers, members, employees and agents of each Investor, and each Person who controls any Investor within the meaning of the Securities Act or the Exchange Act, if any, (iii) any underwriter (as defined in the Securities Act) for each Investor in connection with an underwritten offering pursuant to Section 2(b) hereof, and (iv) the directors, officers, partners and employees of, and each Person who controls, any such underwriter within the meaning of the Securities Act or the Exchange Act, if any (each, an “Indemnified Person”), against any joint or several losses, claims, damages, liabilities or expenses (collectively, together with actions, proceedings or inquiries by any regulatory or self-regulatory organization, whether commenced or threatened, in respect thereof, “Claims”) to which any of them may become subject insofar as such Claims arise out of or are based upon: (i) any untrue statement or alleged

 

26


untrue statement of a material fact in any Registration Statement, or any amendment as supplement thereto, or any filing made under state securities laws as required hereby, or the omission or alleged omission to state therein a material fact required to be stated or necessary to make the statements therein not misleading; (ii) any untrue statement or alleged untrue statement of a material fact contained in any Prospectus, or any amendment or supplement thereto, or the omission or alleged omission to state therein any material fact necessary to make the statements made therein, in the light of the circumstances under which the statements therein were made, not misleading; or (iii) any violation or alleged violation by the Company of the Securities Act, the Exchange Act, any other law, including any state securities law, or any rule or regulation thereunder relating to the offer or sale of the Registrable Securities (the matters in the foregoing clauses (i) through (iii) being, collectively, “Violations”). The Company shall reimburse the Indemnified Person, promptly as such expenses are incurred and are due and payable, for any reasonable legal fees and other reasonable expenses incurred by them in connection with investigating or defending any such Claim. Notwithstanding anything to the contrary contained herein, the indemnification agreement contained in this Section 7(a) shall not apply to a Claim arising out of or based upon a Violation to the extent that such Violation occurs in reliance upon and in conformity with information furnished in writing to the Company by or on behalf of any Indemnified Person expressly for use in connection with the preparation of such Registration Statement or any such amendment thereof or supplement thereto, or (B) to any amounts paid in settlement of any Claim effected without the prior written consent of the Company, which consent shall not be unreasonably withheld or delayed. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of the Indemnified Person and shall survive the transfer of the Registrable Securities by any of the Investors pursuant to Section 10.

b. Promptly after receipt by an Indemnified Person under this Section 7 of notice of the commencement of any action (including any governmental action), such Indemnified Person shall, if a Claim in respect thereof is to be made against the Company under this Section 7, deliver to the Company a written notice of the commencement thereof, and the Company shall have the right to participate in, and, to the extent the Company so desires, to assume control of the defense thereof with counsel mutually satisfactory to the Company and the Indemnified Person, as the case may be;

provided, however , that an Indemnified Person shall have the right to retain its own counsel with the reasonable fees and expenses to be paid by the Company, if, in the reasonable opinion of counsel for such Indemnified Person, the representation by such counsel of the Indemnified Person and the Company would be inappropriate due to actual or potential differing interests between such Indemnified Person and any other party represented by such counsel in such proceeding. The Company shall pay for only one separate legal counsel for the Indemnified Persons, and such legal counsel shall be selected by the Investors. The failure to deliver written notice to the Company within a reasonable time of the commencement of any such action shall not relieve the Company of any liability to the Indemnified Person under this Section 7, except to the extent that the Company is actually prejudiced in its ability to defend such action, and shall not relieve the Company of any liability to the Indemnified Person otherwise than pursuant to this Section 7. The Company shall not, without the prior written consent of the Indemnified Persons, consent to entry of any judgment or enter into any settlement or other compromise with respect to any Claim in respect of which indemnification or contribution may be or has been sought hereunder (whether or not any such Indemnified Party is an actual or potential party to such action or claim) which does not include as an unconditional term thereof the giving by the claimant or plaintiff to the Indemnified Persons of a full release from all liability with respect to such Claim or which includes any admission as to fault or culpability on the part of any Indemnified Person. The indemnification required by this Section 7 shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as any expense, loss, damage or liability is incurred.

c. Each Investor will indemnify, hold harmless and defend (i) the Company, and (ii) the directors, officers, partners, managers, members, employees or agents of the Company, if any (each, a “Company Indemnified

 

27


Person”), against any Claims to which any of them may become subject insofar as such Claims arise out of or are based upon any violation or alleged violation by the Company of the Securities Act, the Exchange Act, any other law, including any state securities law, or any rule or regulation thereunder relating to the offer or sale of the Registrable Securities, which occurs due to the inclusion by the Company in a Registration Statement of false or misleading information about an Investor, where such information was furnished in writing to the Company by or on behalf of such Investor expressly for the purpose of inclusion in such Registration Statement. Notwithstanding anything herein to the contrary, the indemnity agreement contained in this Section 7(c) shall not apply to amounts paid in settlement of any Claim if such settlement is effected without the prior written consent of the Investors, which consent shall not be unreasonably withheld or delayed; and provided, further, however, that an Investor shall be liable under this Section 7(c) for only that amount of a Claim as does not exceed the net amount of proceeds received by such Investor as a result of the sale of Registrable Securities pursuant to such Registration Statement.

d. Promptly after receipt by a Company Indemnified Person under this Section 7 of notice of the commencement of any action (including any governmental action), such Company Indemnified Person shall, if a Claim in respect thereof is to be made against any Investor under this Section 7, deliver to such Investor a written notice of the commencement thereof, and such Investor shall have the right to participate in, and, to the extent such Investor so desires, to assume control of the defense thereof with counsel mutually satisfactory to such Investor and such Company Indemnified Person.

8. CONTRIBUTION. If for any reason the indemnification provided for in Section 7(a) or 7(c) (as applicable) is unavailable to an Indemnified Person or Company Indemnified Person (as applicable) or insufficient to hold it harmless, other than as expressly specified therein, then the indemnifying party shall contribute to the amount paid or payable by the Indemnified Person or Company Indemnified Person (as applicable) as a result of the Claim in such proportion as is appropriate to reflect the relative fault of the Indemnified Person or Company Indemnified Person (as applicable) and the indemnifying party (provided that the relative fault of any Company Indemnified Person shall be deemed to include the fault of all other Company Indemnified Persons), as well as any other relevant equitable considerations. No Person guilty of fraudulent misrepresentation within the meaning of Section 11(f) of the Securities Act shall be entitled to contribution from any Person not guilty of such fraudulent misrepresentation. In no event shall the contribution obligation of an Investor be greater in amount than the net amount of proceeds received by such Investor as a result of the sale of Registrable Securities giving rise to such contribution obligation pursuant to the applicable Registration Statement (net of the aggregate amount of any damages or other amounts such Investor has otherwise been required to pay (pursuant to Section 7(c) or otherwise) by reason of such Investor’s untrue or alleged untrue statement or omission or alleged omission).

9. REPORTS UNDER THE 1934 ACT. With a view to making available to the Investors the benefits of Rule 144 promulgated under the Securities Act or any other similar rule or regulation of the SEC that may at any time permit the Investors to sell securities of the Company to the public without registration, the Company agrees to:

a. make and keep public information available, as those terms are understood and defined in Rule 144;

b. file with the SEC in a timely manner all reports and other documents required of the Company under the Exchange Act so long as the Company remains subject to such requirements and the filing of such reports and other documents is required for the applicable provisions of Rule 144; and

c. so long as any of the Investors owns Registrable Securities, promptly upon request, furnish to such Investor (i) a written statement by the Company that it has complied with the reporting requirements of the Exchange Act as required for applicable provisions of Rule 144, (ii) a copy of the most recent annual or

 

28


quarterly report of the Company and such other reports and documents so filed by the Company and (iii) such other information as may be reasonably requested to permit such Investor to sell such Registrable Securities pursuant to Rule 144 without registration.

10. ASSIGNMENT OF REGISTRATION RIGHTS. The rights under this Agreement shall be automatically assignable by each Investor to any transferee of all or any portion of the Registrable Securities if: (i) such Investor agrees in writing with the transferee or assignee to assign such rights, and a copy of such agreement is furnished to the Company within a reasonable time after such assignment, (ii) the Company is, within a reasonable time after such transfer or assignment, furnished with written notice of (a) the name and address of such transferee or assignee, and (b) the securities with respect to which such registration rights are being transferred or assigned, and (iii) at or before the time the Company receives the written notice contemplated in clause (ii) of this sentence, the transferee or assignee agrees in writing with the Company to be bound by all of the provisions contained herein as applicable to the Investors. In the event that the Company receives written notice from an Investor that it has transferred all or any portion of its Registrable Securities pursuant to this Section, the Company shall have up to ten (10) days to file any amendments or supplements necessary to keep a Registration Statement current and effective pursuant to Rule 415, and the commencement date of any Event of Failure (as defined in the Warrants) or Event of Default (as defined in the Warrants) under the Warrants caused thereby will be extended by ten (10) days. Each Investor shall at all times comply with the restrictions on transfer set forth in Section 8 of the Warrant (to the extent applicable to such Investor), which provisions are hereby incorporated by reference and made a part hereof.

11. AMENDMENT OF REGISTRATION RIGHTS. Provisions of this Agreement may be amended and the observance thereof may be waived (either generally or in a particular instance and either retroactively or prospectively), only with written consent of the Company and the holders of a majority in interest of then-outstanding Registrable Securities. Any amendment or waiver effected in accordance with this Section 11 shall be binding upon each of the Investors and the Company.

12. MISCELLANEOUS.

a. A Person is deemed to hold, and be a holder of, shares of Common Stock or other Registrable Securities whenever such Person owns of record or beneficially through a “street name” holder such shares of Common Stock or other Registrable Securities (or the Warrants or other securities upon exercise, conversion or exchange of which such Registrable Securities are directly or indirectly issuable, without giving effect to any limitations on exercise, conversion or exchange of the Warrants or other securities), and solely for purposes hereof, Registrable Securities shall be deemed outstanding to the extent they are directly or indirectly issuable upon exercise, conversion or exchange of the Warrants or other outstanding securities, Registrable Securities, without giving effect to any limits on exercise, conversion or exchange of the Warrants or other securities. If the Company receives conflicting instructions, notices or elections from two or more Persons with respect to the same Registrable Securities, the Company shall act upon the basis of instructions, notice or election received from the registered owner of such Registrable Securities (or the Warrants or other securities upon exercise, conversion or exchange of which such Registrable Securities are directly or indirectly issuable).

b. Any notices required or permitted to be given under the terms hereof shall be sent by certified or registered mail (return receipt requested) or delivered personally or by courier (including a recognized overnight delivery service) or by electronic mail and shall be effective five days after being placed in the mail, if mailed by regular United States mail, or upon receipt, if delivered personally or by courier (including a recognized overnight delivery service) or by electronic mail, in each case addressed to a party. The addresses for such communications shall be:

 

29


If to the Company:

Endologix, Inc.

2 Musick

Irvine, CA 92618

E-mail: jtejedor@endologix.com

Attn: Vaseem Mahboob, CFO

Attn: James Tejedor, Treasury Manager

With copy to:

DLA Piper LLP (US)

4365 Executive Drive, Suite 1100

San Diego, CA 92101

E-mail: michael.kagnoff@dlapiper.com

Attn: Michael Kagnoff

If to an Investor:

c/o Deerfield Mgmt, L.P.

780 Third Avenue, 37 th Floor

New York, NY 10017

Fax: (212) 599-1248

Email:

Attn: David J. Clark, Esq.

With a copy to:

Katten Muchin Rosenman LLP

575 Madison Avenue

New York, NY 10022

Fax: (212) 940-8776

Email: mark.fisher@kattenlaw.com and mark.wood@kattenlaw.com

Attn: Mark I. Fisher, Esq.

         Mark D. Wood, Esq.

Each party shall provide notice to the other party of any change in address.

c. Failure of any party to exercise any right or remedy under this Agreement or otherwise, or delay by a party in exercising such right or remedy, shall not operate as a waiver thereof.

d. Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York, borough of Manhattan. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or

 

30


proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. The parties hereby waive all rights to a trial by jury. If either party shall commence an action or proceeding to enforce any provision of this Agreement, then the prevailing party in such action or proceeding shall be reimbursed by the other party for its reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.

e. This Agreement and the Warrants constitute the entire agreement among the parties hereto with respect to the subject matter hereof. This Agreement and the Warrants (including all schedules and exhibits thereto) supersede all prior agreements and understandings among the parties hereto with respect to the subject matter hereof.

f. Subject to the requirements of Section 10 hereof, this Agreement shall inure to the benefit of and be binding upon the successors and assigns of each of the parties hereto, and the provisions of Sections 7 and 8 hereof shall inure to the benefit of, and be enforceable by, each Indemnified Person and Company Indemnified Person (as applicable).

g. The headings in this Agreement are for convenience of reference only and shall not limit or otherwise affect the meaning hereof.

h. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original but all of which shall constitute one and the same agreement. This Agreement, once executed by a party, may be delivered to the other party hereto by electronic transmission of a copy of this Agreement bearing the signature of the party so delivering this Agreement.

i. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other parties may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

j. The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Investors by vitiating the intent and purpose of the transactions contemplated hereby. Accordingly, the Company acknowledges that the remedy at law for breach of its obligations hereunder will be inadequate and agrees, in the event of a breach or threatened breach by the Company of any of the provisions hereunder, that the Investors shall be entitled, in addition to all other available remedies in law or in equity, to an injunction or injunctions to prevent or cure breaches of the provisions of this Agreement and to enforce specifically the terms and provisions hereof, without the necessity of showing economic loss and without any bond or other security being required.

k. The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any party.

l. In the event that any provision of this Agreement is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any provision hereof which may

 

31


prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision hereof.

m. In the event an Investor shall sell or otherwise transfer any of such holder’s Registrable Securities, each transferee shall be allocated a pro rata portion of the number of Registrable Securities included in a Registration Statement for such transferor.

n. There shall be no oral modifications or amendments to this Agreement. This Agreement may be modified or amended only in writing.

o. The Company shall not grant any Person any registration rights with respect to shares of Common Stock or any other securities of the Company other than registration rights that will not adversely affect the rights of the Investors hereunder (including by limiting in any way the number of Registrable Securities that could be included in any Registration Statement pursuant to Rule 415) and shall not otherwise enter into any agreement that is inconsistent with the rights granted to the Investors hereunder.

p. The obligations of each Investor hereunder are several and not joint with the obligations of any other Investor, and no provision of this Agreement is intended to confer any obligations on any Investor vis-à-vis any other Investor. Nothing contained herein, and no action taken by any Investor pursuant hereto, shall be deemed to constitute the Investors as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Investors are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated herein.

q. Unless the context otherwise requires, (i) all references to Sections, Schedules or Exhibits are to Sections, Schedules or Exhibits contained in or attached to this Agreement, (ii) words in the singular or plural include the singular and plural, and pronouns stated in either the masculine, the feminine or neuter gender shall include the masculine, feminine and neuter, and (ii) the use of the word “including” in this Agreement shall be by way of example rather than limitation.

[Remainder of page left intentionally blank]

[Signature page follows]

 

 

32


IN WITNESS WHEREOF, the undersigned Investors and the Company have caused this Amended and Restated Registration Rights Agreement to be duly executed as of the date first written above.

 

COMPANY:

 

ENDOLOGIX, INC. , a Delaware corporation

 

By:                                                                                                   
Name:                                                                                             
Title:                                                                                               


IN WITNESS WHEREOF, the undersigned Investors and the Company have caused this Amended and Restated Registration Rights Agreement to be duly executed as of the date first written above.

 

INVESTORS:
DEERFIELD PRIVATE DESIGN FUND IV, L.P.
By: Deerfield Mgmt IV, L.P., General Partner
By: J.E. Flynn Capital IV, LLC, General Partner
By:  

 

Name:   James E. Flynn
Title:   President
DEERFIELD PRIVATE DESIGN FUND III, L.P.
By: Deerfield Mgmt III, L.P., General Partner
By: J.E. Flynn Capital III, LLC, General Partner
By:  

 

Name:   James E. Flynn
Title:   President
DEERFIELD PARTNERS, L.P.
By: Deerfield Mgmt, L.P., General Partner
By: J.E. Flynn Capital, LLC, General Partner
By:  

 

Name:   James E. Flynn
Title:   President


EXHIBIT F

FORM OF COMPLIANCE CERTIFICATE

                     , 20         

Deerfield Private Design Fund IV, L.P.

c/o Deerfield Management Company, L.P.

780 Third Avenue, 37 th Floor

New York, New York 10017

Ladies and Gentlemen:

The undersigned, ENDOLOGIX, INC., a Delaware corporation (“ Borrower ”) pursuant to Section  5.1(h) [and Section  5.1(aa) ] 11 of the Amended and Restated Facility Agreement dated as of [        ], 2018 (as amended, restated, supplemented or otherwise modified from time to time, the “ Facility Agreement ”) between Borrower, the other Loan Parties, Deerfield Private Design Fund IV, L.P. (in its capacity as agent for the Secured Parties, the “ Agent ”) and the “Lenders” from time to time party thereto, hereby delivers this Compliance Certificate (this “ Compliance Certificate ”). Capitalized terms used but not otherwise defined herein are used herein as defined in the Facility Agreement.

[Borrower hereby certifies and warrants to Agent and the Lenders that attached hereto as Annex I is a true, correct and complete copy of its [10-Q][10-K] filing (the “ Report ”) made with the United States Securities and Exchange Commission (the “ SEC ”). The Report complies in all material respects with the applicable requirements of the Exchange Act and does not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The consolidated financial statements included in the Report comply as to form in all material respects with applicable accounting requirements and the published rules and regulations of the SEC with respect thereto, were prepared in accordance with GAAP, consistently applied [(subject, in the case of unaudited quarterly financial statements, to normal year-end adjustments and lack of footnote disclosures)] 12 , and fairly present in all material respects the consolidated financial position of Borrower and its Subsidiaries as of the dates hereof and the consolidated results of their operations, cash flows and changes in stockholders equity for the periods presented [(subject, in the case of unaudited quarterly financial statements, to normal year-end audit adjustments and lack of footnote disclosures)] 13 .] 14 [Borrower hereby certifies and warrants to Agent and the Lenders that attached hereto as Annex I is a true, correct and complete copy of the financial statements and any other materials required under Section 5.1(aa) of the Facility Agreement (the “ Statements ”). The Statements fairly present in all material respects the financial position and condition and results of operations, cash flows and changes in stockholders equity of Borrower and its Subsidiaries as of the dates and for the periods and have been prepared in conformity with GAAP applied on a basis consistent with prior periods.] 15

 

11  

The bracketed portion shall only be included during such periods in which the Borrower is not required to file reports pursuant Section 13 or 15(d) of the Exchange Act.

12  

The bracketed information shall only be included with a 10-Q filing, but not with a 10-K filing.

13  

The bracketed information shall only be included with a 10-Q filing, but not with a 10-K filing.

14  

The bracketed portion shall only be included during such periods in which the Borrower is required to file reports pursuant Section 13 or 15(d) of the Exchange Act.

15  

The bracketed portion shall only be included during such periods in which the Borrower is not required to file reports pursuant Section 13 or 15(d) of the Exchange Act.


Borrower further certifies to Agent and the Lenders that as of the date hereof (a) no Default or Event of Default or (b) event of default under the ABL Debt Documents or the Convertible Note Documents, in each case, has occurred and is continuing or, if such a Default, Event of Default or event of default has occurred and is continuing, set forth below is a description of the nature and period of existence of such Default, Event of Default or event of default and what action Borrower has taken, is undertaking and proposes to take with respect thereto.

As of (a) the last Business Day of each calendar month in the period covered by the [Report][Statements] and (b) each date that a Borrowing Base Certificate (as defined in the ABL Credit Facility) is required to be delivered under the ABL Credit Facility or any other ABL Debt Document, Global Excess Liquidity is [not] less than $22,500,000 in compliance with the provisions and terms of Section  5.2(xxiv) of the Facility Agreement.

The consolidated Net Revenue of the Loan Parties for the Measurement Period covered by the [Report][Statements], tested quarterly, is [not] less than $[155,000,000] 16 [145,000,000] 17 [130,000,000] 18 [140,000,000] 19 in compliance with the provisions and terms of Section  5.2(xxv) of the Facility Agreement.

[The consolidated Net Revenue of the Loan Parties for the last fiscal quarter covered in the [Report][Statements] is not less than 30,000,000.] 20

The aggregate amount of Operating Expenditures made by the Loan Parties and their Subsidiaries for the Measurement Period covered by the [Reports][Statements] is [not] more than $[160,000,000] 21 [140,000,000] 22 .

[The “Fixed Charge Coverage Ratio” (such term, and all components and subcomponents thereof, as defined in the ABL Credit Agreement as of the Agreement Date) for the Measurement Period covered by the [Reports][Statements] is [not] less than 1.00:1.00.] 23

The aggregate amount of consolidated Capital Expenditures made by the Loan Parties and their Subsidiaries does not exceed $[2,500,000] 24 [3,000,000] 25 [5,000,000] 26 [2,000,000] 27 .

 

16  

Include for Measurement Period ending September 30, 2018.

17  

Include for Measurement Period ending December 31, 2018.

18  

Include for Measurement Period ending March 31, 2019 and the last day of each fiscal quarter ending thereafter through (and including) December 31, 2019.

19  

Include for Measurement Periods ending March 31, 2020 and the last day of each fiscal quarter ending thereafter.

20  

Include for Measurement Periods beginning with the fiscal quarter ending March 31, 2019 and on the last day of each fiscal quarter ending thereafter.

21  

Include for Measurement Period ending December 31, 2018.

22  

Include for Measurement Period ending December 31, 2019.

23  

Include following the “Trigger Date” (as defined in the ABL Credit Agreement as of the Agreement Date).

24  

Include for Fiscal Year ending 2018.

25  

Include for Fiscal Year ending 2019.

26  

Include for Fiscal Year ending 2020.

27  

Include for Fiscal Year ending 2021.


As of the most recent testing date of the financial covenants in the ABL Debt Documents (including the financial covenants set forth in Article VII of the ABL Credit Facility), Borrower and its Subsidiaries were [not] in compliance with all such financial covenants.

Detailed calculations of all of the aforementioned financial covenants in the Facility Agreement and the ABL Debt Documents are set forth on Annex II hereto. All such calculations are true, correct and complete.

[If Borrower and its Subsidiaries were not in compliance with any of the aforementioned financial covenants in the Facility Agreement or the ABL Debt Documents, set forth below is a detailed description and calculation of such noncompliance and what action Borrower has taken, is undertaking and proposes to take with respect thereto and whether Borrower reasonably and in good faith believes that Borrower and its Subsidiaries will be in compliance in all future periods and testing dates with such financial covenants (and, if not, a detailed description and calculation of any expected or believed noncompliance in such future periods and for such testing dates): [                    ].]

Notwithstanding anything to the contrary herein or in any other Loan Document, the provisions of (and the information including in) this Compliance Certificate (and any Annex hereto) are subject to Section 5.1(q) of the Facility Agreement.

[Signature follows on next page.]


IN WITNESS WHEREOF, Borrower has caused this Compliance Certificate to be executed and delivered by its Responsible Officer on the date first set forth above.

 

ENDOLOGIX, INC. , a Delaware corporation

 

By:                                                                                                   
Name:                                                                                             
Title:                                                                                               


ANNEX I

TO

COMPLIANCE CERTIFICATE

ANNEX II

TO

COMPLIANCE CERTIFICATE


Schedule P-1

Existing Investments

 

Name of Issuer

  

Description and Value of Security

  

Loan Party/Subsidiary

Cianna Medical, Inc.

   8,677 Shares of Series A Preferred Stock    Endologix, Inc.


Schedule 2.4

List of Agreement Date Lenders and Such Lenders’ Wire Instructions and Information for Notices

 

Name of Lender

  

Wire Instructions/ Address for Payments to
Lender

  

Information for Notices

Deerfield Partners, L.P.   

Citibank, N.A. New York

ABA # 021-000-089

A/C Morgan Stanley & Co. NY

A/C # 38890774

Sub A/C Deerfield Partners, L.P.

Sub A/C # 038-036208

  

Deerfield Partners, L.P.

c/o Deerfield Management Company, L.P.

780 Third Avenue, 37th Floor

New York, NY 10017

Facsimile: 212-599-3075

E-mail: dclark@deerfield.com

Attn: David J. Clark, Esq.

 

With a copy to (which shall not be deemed to constitute notice):

 

Katten Muchin Rosenman LLP

575 Madison Avenue

New York NY 10022-2585

Facsimile: (212) 894-5877

E-mail: mark.fisher@kattenlaw.com and mark.wood@kattenlaw.com

Attn: Mark I. Fisher, Esq.

Attn: Mark D. Wood, Esq.


Name of Lender

  

Wire Instructions/ Address for Payments to
Lender

  

Information for Notices

Deerfield Private Design Fund III, L.P.   

Citibank, N.A. New York

ABA # 021-000-089

A/C Morgan Stanley & Co. NY

A/C # 38890774

Sub A/C Deerfield Private Design Fund III, L.P.

Sub A/C # 038CDKGC9

  

Deerfield Private Design Fund III, L.P.

c/o Deerfield Management Company, L.P.

780 Third Avenue, 37th Floor

New York, NY 10017

Facsimile: 212-599-3075

E-mail: dclark@deerfield.com

Attn: David J. Clark, Esq.

 

With a copy to (which shall not be deemed to constitute notice):

 

Katten Muchin Rosenman LLP

575 Madison Avenue

New York NY 10022-2585

Facsimile: (212) 894-5877

E-mail: mark.fisher@kattenlaw.com and mark.wood@kattenlaw.com

Attn: Mark I. Fisher, Esq.

Attn: Mark D. Wood, Esq.

Deerfield Private Design Fund IV, L.P.   

Citibank, N.A. New York

ABA # 021-000-089

A/C Morgan Stanley & Co. NY

A/C # 38890774

Sub A/C Deerfield Private Design Fund IV, L.P.

Sub A/C # 038CDNH16

  

Deerfield Private Design Fund IV, L.P.

c/o Deerfield Management Company, L.P.

780 Third Avenue, 37th Floor

New York, NY 10017

Facsimile: 212-599-3075

E-mail: dclark@deerfield.com

Attn: David J. Clark, Esq.

 

With a copy to (which shall not be deemed to constitute notice):

 

Katten Muchin Rosenman LLP

575 Madison Avenue

New York NY 10022-2585

Facsimile: (212) 894-5877

E-mail: mark.fisher@kattenlaw.com and mark.wood@kattenlaw.com

Attn: Mark I. Fisher, Esq.

Attn: Mark D. Wood, Esq.


Schedule 3.1(d)

Existing Liens

None.


Schedule 3.1(f)

Existing Indebtedness

None.


Schedule 3.1(h)

Litigation

Vicky Nguyen v. Endologix, Inc., et al.: (Filed January 3, 2017 in the United States District Court, Central District of California; Case No. 2:17-cv-00017). A putative shareholder class action pending in the U.S. District Court for the Central District of California. Lead plaintiff in Nguyen asserts multiple causes of action for securities fraud based on allegations that Borrower and two of its executives misled investors by opining optimistically about Borrower’s prospects for FDA pre-market approval of the Nellix EVAS System. On December 5, 2017, the District Court granted Borrower’s motion to dismiss lead plaintiff’s First Amended Complaint, with leave to amend. On January 9, 2018, lead plaintiff filed a Second Amended Complaint. Borrower intends to move for dismissal of the Second Amended Complaint with prejudice. The hearing on Borrower’s Motion to Dismiss lead plaintiff’s Second Amended Complaint has been set for August 10, 2018.

Derivative Lawsuits: As of June 11, 2017, Four shareholders have filed derivative lawsuits on behalf of Borrower, the nominal plaintiff, based on allegations substantially similar to those alleged by lead plaintiff in Nguyen. Those actions consist of: Sindlinger v. McDermott et al., Case No. BC662280 (Los Angeles Superior Court); Abraham v. McDermott et al., Case No. 30-2018-00968971-CU-BT-CSC (Orange County Superior Court); and Green v. McDermott et al., Case No. 8:17-cv-01155-AB (PLAx), consolidated with Cocco v. McDermott et al., Case No. 8:17-cv-01183-AB (PLAx) (U.S. District Court for the Central District of California). Plaintiffs in the Sindlinger and Green derivative actions have agreed to stay litigation pending resolution of the Nguyen action. Endologix is currently negotiating a similar agreement with the Abraham plaintiff. A related case, Ahmed v. Endologix, Inc., et al. (Filed January 11, 2017 in the United States District Court, Central District of California; Case No. 8:17-cv-00061) was consolidated into Nguyen v. Endologix, Inc.

SEC Investigation: In July 2017, Borrower learned that the United States Securities and Exchange Commission (“SEC”) issued a Formal Order of Investigation to investigate, among other things, events surrounding the Nellix EVAS System and the prospect of its FDA pre-market approval. Borrower is fully cooperating with the investigation. Borrower continues to produce materials responsive to the SEC’s subpoenas.

Certain Notices: The Loan Parties have received three unrelated notices from individuals claiming that certain of our products read on certain issued patents held by such individuals. The Loan Parties, after consultation with independent patent counsel, strongly disagree with these claims; however, it is possible that should these claims proceed to litigation, that Borrower’s aggregate liability arising for monetary judgements or other reliefs arising out of these matters could exceed $2,000,000. Since it is presently not possible to determine the outcome of any future discussions with these individuals in regard to their patents, and whether or not litigation will ensue, or the outcomes associated with potential litigation, no provision has been made in Borrower’s financial statements for the ultimate resolution.


Schedule 3.1(j)

Authorizations

Borrower is required to file a Listing of Additional Shares notification with Nasdaq to cover the shares of Common Stock underlying the Additional Warrants, any shares issuable pursuant to the conversion rights set forth in the First Out Waterfall Notes and any shares issued as Interest Payment Shares.


Schedule 3.1(m)

Real Estate

Owned Real Property :

 

Loan Party or Subsidiary

  

Complete street and mailing address, including zip code

N.A.

  

Leased Real Property :

 

Loan Party or Subsidiary

  

Complete street and mailing

address, including zip code

  

Landlord name and contact information

Endologix, Inc.   

2 Musick, Irvine, County of Orange, California 92618 U.S.A.;

33 and 35 Hammond, Irvine, County of Orange, California 92618 U.S.A.

   The Northwestern Mutual Life Insurance Company
Endologix International Holdings B.V.    Burgemeester Burgerslaan 40, 5245 NH Rosmalen, The Netherlands    N.A.
TriVascular Technologies, Inc.    3910 Brickway Blvd., Santa Rosa, County of Sonoma, CA 95403 U.S.A.    Sonoma Airport Properties LLC
Endologix Singapore Private Limited   

10 Anson Road #21-04 & #21-04A

International Plaza Singapore 079903

   Stamcorp International Pte Ltd.
Endologix International B.V.    Rahmannstraße 11, 65760 Eschborn, Germany    N.A.

Subleased Real Property :

 

Loan Party or Subsidiary

  

Complete street and mailing

address, including zip code

  

Landlord and sublandlord

name and contact information

Other Real Property Operated or Occupied:

 

Loan Party or Subsidiary

  

Complete street and mailing

address, including zip code

  

Nature of use

ELGX South Korea Ltd.    A-311, M-Sate, 114 Beopwon-ro, Songpa-gu, Seoul, South Korea    Office


Schedule 3.1(n)

Intellectual Property

The items disclosed in Schedule 3.1(h) with the lead-in “Certain Notices”.

On May 7, 2018, Borrower received notice from Medtronic, Inc. (“Medtronic”) that Medtronic believes Borrower’s Ovation product appears to use one or more claims of certain Medtronic patents. Borrower is assessing this claim. Medtronic has invited Borrower to engage in discussions to obtain a non-exclusive license to these patents. Borrower has a robust patent portfolio at its disposal, and after conducting analysis believes that one or more of Medtronic’s products appears to use one or more claims of Borrower’s patents. Since it is presently not possible to determine the outcome of any future discussions with Medtronic in regard to the respective parties’ patents, and whether or not litigation will ensue, or the outcomes associated with potential litigation, no provision has been made in Borrower’s financial statements for the ultimate resolution.


Schedule 3.1(x)

Borrower’s Subsidiaries

 

Parent

   Percentage
ownership
  

Name of
Subsidiary

  

Jurisdiction of
Subsidiary

   Date of
formation of
Subsidiary
  

Federal
employer ID no.
of Subsidiary

  

Organizational
identification no. of
Subsidiary

Endologix, Inc.    100%    Nellix, Inc.    Delaware    03/20/2001    94-3398416    3359980
Endologix, Inc.    100%    CVD/RMS Acquisition Corp.    Delaware    12/13/1998    33-0928438    2955166
Endologix, Inc.    100%    RMS/Endologix Sideways Merger Corp.    Delaware    05/30/2002    03-0512974    3530477
Endologix, Inc.    100%    Endologix Singapore Private Limited    Singapore    01/13/2015    N.A.    N.A.
Endologix, Inc.    100%    ELGX International Holdings GP    Cayman Islands    07/05/2011    N.A.    N.A.
Endologix, Inc.    100%    Endologix New Zealand Co.    New Zealand    05/31/2012    N.A.    N.A.
Endologix, Inc.    100%    ELGX South Korea Ltd.    South Korea    12/07/2017    N.A.    N.A.

Endologix, Inc.

ELGX International Holdings GP

   99%

1%

   Endologix Bermuda L.P.    Bermuda    07/24/2012    N.A.    N.A.
Endologix International Holdings B.V.    100%    Endologix Poland spolkda z ograniczona odpowiedzialnoscia    Poland    03/26/2015    N.A.    N.A.
Endologix Bermuda L.P.    100%    Endologix International Holdings B.V.    The Netherlands    08/22/2011    N.A.    N.A.
Endologix International Holdings B.V.    100%    Endologix Italia S.r.l.    Italy    06/04/2012    N.A.    N.A.
Endologix International holdings B.V.    100%    Endologix International B.V.    The Netherlands    08/22/2011    N.A.    N.A.
Endologix, Inc.    100%    TriVascular Technologies, Inc.    Delaware    07/11/2007    87-0807313    4387054
TriVascular Technologies, Inc.    100%    TriVascular, Inc.    California    01/05/1998    68-0402620    C2065374
TriVascular, Inc.    100%    TriVascular Sales, LLC    Texas    08/23/2012    46-0859179    0801644988


Parent

   Percentage
ownership
  

Name of
Subsidiary

  

Jurisdiction of
Subsidiary

   Date of
formation of
Subsidiary
  

Federal
employer ID no.
of Subsidiary

  

Organizational
identification no. of
Subsidiary

TriVascular, Inc.    100%    Endologix Canada, LLC    Delaware    11/25/2014    N.A.    5647226
TriVascular, Inc.    100%    TriVascular Germany GmbH    Germany    05/14/2012    N.A.    N.A.
TriVascular, Inc.    100%    TriVascular Switzerland Sarl    Switzerland    04/30/2010    N.A.    N.A.
TriVascular, Inc.    100%    TriVascular Italia S.R.L.    Italy    04/08/2010    N.A.    N.A.


Schedule 3.1(z)

Borrower’s Outstanding Shares of Stock, Options and Warrants

 

Name of Issuer

  

Authorized

Securities

  

Issued and

Outstanding Securities

  

Certificated
(Yes or No)

  

Loan Party/
Subsidiary
Owner

Endologix, Inc.    170,000,000 Shares of Common Stock, $0.001 par value    84,946,471 Shares of Common Stock Issued and 84,557,225 Outstanding 28    Yes    N.A.
   5,000,000 Shares of Preferred Stock, $0.001 par value, undesignated    Zero Shares of Preferred Stock    Yes, when issued    N.A.
Nellix, Inc.    1,000 Shares of Common Stock, $0.001 par value    100 Shares of Common Stock    Yes    Endologix, Inc.
CVD/RMS Acquisition Corp.    100 Shares of Common Stock, $0.001 par value    100 Shares of Common Stock    Yes    Endologix, Inc.
ELGX South Korea, Ltd.    20,000 Contribution Units, KRW 5,000 par value    20,000 Contribution Units    No    Endologix, Inc.
RMS/Endologix Sideways Merger Corp.    100 Shares of Common Stock, $0.001 par value    100 Shares of Common Stock    Yes    Endologix, Inc.
TriVascular Technologies, Inc.    1,000 Shares of Common Stock, $0.001 par value    100 Shares of Common Stock    Yes    Endologix, Inc.
ELGX International Holdings GP    Unspecified Number of Partnership Interests    Unspecified Number of Partnership Interests    No    Endologix, Inc.
Endologix Bermuda, L.P.    Unspecified Number of Partnership Interests    Unspecified Number of Partnership Interests    No    Endologix, Inc.
Endologix Singapore Private Limited    Unspecified Number of Company Interests    Unspecified Number of Company Interests    No    Endologix, Inc.
Endologix New Zealand Co.    Unspecified Number of Company Interests    Unspecified Number of Company Interests    No    Endologix, Inc.
TriVascular, Inc.    100 Shares of Common stock, $0.01 par value    100 Shares of Common Stock    No    TriVascular Technologies, Inc.

 

28  

As of August 7, 2018. There have been no material changes to such amount as of the Agreement Date.


Name of Issuer

  

Authorized

Securities

  

Issued and

Outstanding Securities

  

Certificated
(Yes or No)

  

Loan
Party/
Subsidiary
Owner

Endologix International Holdings B.V.    Unspecified Number of Company Interests    Unspecified Number of Company Interests    No    Endologix Bermuda, L.P.
Endologix Poland spolkda z ograniczona odpowiedzialnoscia    Unspecified Number of Company Interests    Unspecified Number of Company Interests    No    Endologix International Holdings B.V.
Endologix International B.V.    Unspecified Number of Company Interests    Unspecified Number of Company Interests    No    Endologix International Holdings B.V.
Endologix Italia S.r.l    Unspecified Number of Company Interests    Unspecified Number of Company Interests    No    Endologix International Holdings B.V.
TriVascular Sales LLC    1,000 Units of Membership Interests    1,000 Units of Membership Interests    No    TriVascular, Inc.
Endologix Canada, LLC    1,000 Units of Membership Interests    1,000 Units of Membership Interests    No    TriVascular, Inc.
TriVascular Italia Sarl    Unspecified Number of Company Interests    Unspecified Number of Company Interests    No    TriVascular, Inc.
TriVascular Germany GmbH    Unspecified number of Company Interests    Unspecified number of Company Interests    No    TriVascular, Inc.
TriVascular Switzerland Sárl    Unspecified number of Company Interests    Unspecified number of Company Interests    No    TriVascular, Inc.

Options and Equity Incentive/Compensation Plans:

Equity Awards : Borrower’s 2015 Stock Incentive Plan as amended (the “2015 Plan”) authorizes the grant of equity awards to purchase up to 10.3 million shares of Common Stock. As of July 31, 2018, approximately 9.6 million shares were reserved for issuance under outstanding stock options, including stock options granted under equity compensation plans preceding the 2015 Plan, and 1.6 million shares were subject to unvested restricted stock awards. The outstanding stock options have exercise prices ranging from $1.64 to $17.58 and a weighted average exercise price of $7.28. There have been no material changes to the items discussed in this paragraph as of the Agreement Date.

Amended and Restated 2006 Employee Stock Purchase Plan (the “ESPP”) : As of July 31, 2018, approximately 0.7 million shares of Common Stock were available for issuance under the ESPP. There have been no material changes to such amount as of the Agreement Date.

2017 Inducement Stock Incentive Plan : The Board has reserved 2,000,000 shares of Borrower’s


Common Stock for issuance pursuant to awards granted under the 2017 Inducement Stock Incentive Plan. As of July 31, 2018, approximately 1.5 million shares of Common Stock were available for issuance under this plan. There have been no material changes to such amount as of the Agreement Date.

Non-Plan Inducement Grants : In connection with its merger with TriVascular Technologies, Inc., on February 4, 2016 Borrower issued non-plan inducement stock options to purchase 1.4 million shares of Common Stock at an exercise price of $7.53 per share, and non-plan inducement restricted stock units for 0.3 million shares of Common Stock.

Warrants:

In connection with its merger with TriVascular Technologies, Inc. on February 3, 2016, Borrower assumed unexercised out-of-the-money warrants of TriVascular Technologies, Inc., which converted into warrants to purchase 35,094 shares of Common Stock, 24,272 at an exercise price of $12.58 per share and 10,822 at an exercise price of $28.21 per share.

Pursuant to the terms of the Prior Facility Agreement, Borrower issued warrants to Lenders to purchase an aggregate of 6,470,000 shares of Common Stock of Borrower at an exercise price of $9.23 per share. The number of shares of Common Stock of Borrower into which the warrants are exercisable and the exercise price of the warrants will be adjusted to reflect any stock splits, recapitalizations or similar adjustments in the number of outstanding shares of Common Stock of Borrower.

Pursuant to the Agreement, Borrower is issuing warrants to Lenders to purchase an aggregate of 8,750,000 shares of Common Stock of Borrower at an exercise price equal to the closing bid price on the date of grant. The number of shares of Common Stock of Borrower into which the warrants are exercisable and the exercise price of the warrants will be adjusted to reflect any stock splits, recapitalizations or similar adjustments in the number of outstanding shares of Common Stock of Borrower.

Convertible Notes:

2.25% Convertible Notes : On December 10, 2013, Borrower issued $86.3 million aggregate principal amount of 2.25% Convertible Notes. The initial conversion rate of the 2.25% Convertible Notes is 41.6051 shares of Common Stock per $1,000 principal amount of 2.25% Convertible Notes, which represents an initial conversion price of approximately $24.04 per share. On April 3, 2017, Borrower entered into the Prior Facility Agreement with Deerfield and used proceeds from the Deerfield loan to repurchase $68 million aggregate principal amount of outstanding 2.25% Senior Notes, plus the accrued but unpaid interest thereon, from the holders thereof in privately negotiated transactions. As of the Agreement Date, there is currently $18.278 million aggregate principal amount of 2.25% Convertible Notes outstanding.

3.25% Convertible Notes : On November 2, 2015, Borrower issued $125.0 million aggregate principal amount of 3.25% Convertible Notes. The initial conversion rate of the 3.25% Convertible Notes is 89.4314 shares of Common Stock per $1,000 principal amount of 3.25% Convertible Notes, which represents an initial conversion price of approximately $11.18 per share. Pursuant to the terms of the Facility Agreement with Deerfield, $40.5 million of the aggregate principal amount of the 3.25% Convertible Notes will be cancelled on the Agreement Date, and $84.5 million aggregate principal amount of 3.25% Convertible Notes will remain outstanding thereafter.


Pursuant to this Agreement the Borrower may issue, upon exercise under the Notes by Lenders, Conversion Shares in accordance with the terms of the Notes and Interest Payment Shares in accordance with this Agreement.

Other Rights to Securities of Borrower:

In connection with its merger with Nellix, Inc. (“Nellix”), Borrower agreed to issue shares of Common Stock to the former stockholders of Nellix upon Borrower’s receipt of FDA approval to sell its Nellix EVAS System in the United States (the “PMA Milestone”). The number of shares of Common Stock issuable to the former stockholders of Nellix upon achievement of the PMA Milestone shall equal the quotient obtained by dividing $15.0 million by the average per share closing price of Common Stock on The Nasdaq Global Select Market for each of the 30 consecutive trading days ending with the fifth trading day immediately preceding the date of Borrower’s receipt of FDA approval to sell its Nellix EVAS System in the United States, subject to a stock price floor of $4.50 per share, but not subject to a stock price ceiling.

In June 2018, Borrower received the approval of its stockholders to conduct an exchange program (“Exchange Program”) in which eligible employee stock option holders would have the ability to exchange certain “out-of-the-money” stock options for restricted stock units (“RSUs”) of Borrower pursuant to fixed exchange ratios. Borrower intends to consummate this Exchange Program. The material terms of the Exchange Program are as set forth in proposal 6 of the Company’s definitive proxy statement in respect of its annual meeting of stockholders held on June 14, 2018.

Registration Rights

Registration Rights Agreements dated as of April 3, 2017 and the Agreement Date, respectively, by and among the Borrower the Lenders and Agent. .

Agreement and Plan of Merger and Reorganization, dated October 27, 2010, by and among Borrowerthe, Nepal Acquisition Corporation, Nellix, Inc., certain of Nellix, Inc.’s stockholders listed therein and Essex Woodlands Health Ventures, Inc., as representative of Nellix, Inc.’s stockholders (Section 6.12 contains registration obligation)

At-the-Market Equity Offering Sales Agreement, dated May 31, 2018, by and between Borrower and Stifel, Nicolaus & Company, Incorporated pursuant to which Stifel has agreed to use commercially reasonable efforts to sell on the Company’s behalf up to $50,000,000 in aggregate gross process of the Company’s common stock pursuant to the terms instructed by the Company. The Company is obligated to pay Stifel at a fixed commission rate of up to 3.0% of the gross sales price of its common stock sold pursuant to the agreement.


Schedule 3.1(aa)

Material Contracts

 

 

Cross License Agreement dated as of October 26, 2011, by and between Borrower and Bard Peripheral Vascular, Inc.

 

 

Settlement Agreement, dated October 16, 2012 by and among Borrower, Cook Incorporated, Cook Group and Cook Medical, Inc.

 

 

Standard Industrial/Commercial Multi-Tenant Lease—Net, for 2 Musick, Irvine, California and 33 & 35 Hammond, Irvine, dated June 12, 2013, by and between Borrower and The Northwestern Mutual Life Insurance Company.

 

 

Lease for Santa Rosa facility for the building located at 3910 Brickway Boulevard, Santa Rosa, California as set forth in the Third Amendment to Lease, by and between Trivascular, Inc. and Sonoma Airport Properties LLC and the earlier agreements described herein.


Schedule 3.1(dd)

Environmental

None.


Schedule 3.1(ff)

Labor Relations

None.


Schedule 3.1(gg)

Jurisdiction of Organization, Legal Name, Organizational Identification Number and Chief Executive Office

 

Loan Party

  

Jurisdiction of
organization

   All other
jurisdictions
of
organization
of Loan
Party for 5
years
preceding
the
Agreement
Date
  

Legal name

   All other
legal names
of Loan
Party for 5
years
preceding
the
Agreement
Date
   Organizational
identification
no.
  

Location of chief executive office or sole
place of business: other offices or
facilities

Endologix, Inc.    Delaware    N.A.    Same as loan party name at left    N.A.    2338745    2 Musick, Irvine, County of Orange, California 92618 U.S.A.
Endologix, Inc.    Delaware    N.A.    Same as loan party name at left    N.A.    2338745    33 and 35 Hammond, Irvine, County of Orange, California 92618 U.S.A.
Nellix, Inc.    Delaware    N.A.    Same as loan party name at left    N.A.    3359980    2 Musick, Irvine, County of Orange, California 92618 U.S.A.
CVD/RMS Acquisition Corp.    Delaware    N.A.    Same as loan party name at left    N.A.    2955166    2 Musick, Irvine, County of Orange, California 92618 U.S.A.
TriVascular Technologies, Inc.    Delaware    N.A.    Same as loan party name at left    N.A.    4387054    3910 Brickway Blvd., Santa Rosa, County of Sonoma, CA 95403 U.S.A
TriVascular, Inc.    California    N.A.    Same as loan party name at left    N.A.    C2065374    3910 Brickway Blvd., Santa Rosa, County of Sonoma, CA 95403 U.S.A
Endologix Canada, LLC    Delaware    N.A.    Same as loan party name at left    Trivascular
Canada
LLC
   5647226    3910 Brickway Blvd., Santa Rosa, County of Sonoma, CA 95403 U.S.A


RMS/Endologix Sideways Merger Corp.    Delaware    N.A.    Same as loan party name at left    N.A.    3530477    2 Musick, Irvine, County of Orange, California 92618 U.S.A.
Trivascular Sales LLC    Texas    N.A.    Same as loan party name at left    N.A.    801644988    3910 Brickway Blvd., Santa Rosa, County of Sonoma, CA 95403 U.S.A


Schedule 3.1(hh)

Inventory Location

The following are all of the locations where a Loan Party or any of the Loan Parties’ Subsidiaries, respectively, maintains Inventory:

 

Complete Address

  

Loan Party/Subsidiary

2 Musick, Irvine, County of Orange, CA 92618 U.S.A.    Endologix, Inc.
33 & 35 Hammond, Irvine, County of Orange, CA 92618 U.S.A    Endologix, Inc.
3910 Brickway Blvd., Santa Rosa, County of Sonoma, CA 95403 U.S.A.   

TriVascular Technologies, Inc.

TriVascular, Inc.

10 Anson Road #21-04 & #21-04A

International Plaza Singapore 079903

   Endologix, Inc.
A-311, M-Sate, 114 Beopwon-ro, Songpa-gu, Seoul, South Korea    Endologix, Inc.
Burgemeester Burgerslaan 40, 5245 NH Rosmalen, The Netherlands    Endologix International Holdings B.V.
Rahmannstraße 11, 65760 Eschborn, Germany    Endologix International B.V.

The following are the names and addresses of all warehousemen, bailees, or other third parties who have possession of any of the Loan Parties’ Inventory or the Inventory of any of the Loan Parties’ Subsidiaries:

 

Name

  

Complete Street and Mailing Address, including Zip Code

  

Loan Party/Subsidiary

UPS   

378 Commercial Street, Malden, MA 02148

165 Chubb Avenue, Lyndhurst, NJ 07071

1130 Commerce Blvd, Swedesboro, NJ 08085

2250 Outerloop Drive, Louisville, KY 40219

   Endologix, Inc.
Rhenus    Centaurusweg 123, 5015 TC Tilburg, The Netherlands    Endologix International Holdings B.V.
STOK UK Limited    One Fleet Place, London EC4M 7Ws    Endologix International B.V.


Name

  

Complete Street and Mailing Address, including Zip Code

  

Loan Party/Subsidiary

TNT Express Korea    54 Yangcheon-ro, Gangseo-gu, Seoul 07522    Endologix, Inc.

In addition to the foregoing:

 

   

In the Ordinary Course of Business, the Loan Party or any of the Loan Parties Subsidiaries’ sales representatives hold Trunk Inventory in their possession for sales calls and procedures, which Trunk Inventory is not held at a specific location or locations.

 

   

Certain Inventory of the Loan Party or any of the Loan Parties’ Subsidiaries is held by numerous third parties on a consignment basis at various locations.


Schedule 3.1(uu)

Governmental Notices Regarding Products

Ovation ® System

On August 2018, Borrower intends to issue a global field safety notice related to reinforce information contained within the IFU in order to reduce the occurrence of polymer leaks.


Schedule 3.1 (jjj)

See above Schedule 3.1(z).


Schedule 5.1(q)

Other Loan Documents to Be Form 8-K Exhibits

Each of the following agreements, instruments and documents, including the schedules, exhibits and annexes thereto:

 

   

the Agreement

 

   

the Notes;

 

   

the Security Agreement;

 

   

the Intercompany Subordination Agreement;

 

   

the Intercreditor Agreement;

 

   

the Reaffirmation Agreement;

 

   

the Warrants;

 

   

the Registration Rights Agreement;

 

   

the Patent Security Agreement; and

 

   

the Trademark Security Agreement.


Schedule 5.2(iv)

Contingent Obligations

 

 

Base Capped Call Confirmation, dated December 4, 2013, between the Borrower and Bank of America, N.A.

 

 

Additional Capped Call Confirmation, dated December 5, 2013, between the Borrower and Bank of America, N.A.

The capped call transactions contemplated by the documents listed above relate to the 2.25% Convertible Notes. The capped call transactions are expected to reduce the potential dilution and/or offset the potential cash payments that the Borrower may be required to make in excess of the principal amount upon conversion of the 2.25% Convertible Notes in the event that the market price per share of the Borrower’s common stock, as measured under the terms of the capped call transactions, is greater than the strike price of the capped call transactions, which initially corresponds to the $24.04 conversion price of the 2.25% Convertible Notes. The Borrower will not be required to make any cash payments to Bank of America, N.A. upon the exercise of the options that are a part of the capped call transactions, but rather will be entitled to receive from Bank of America, N.A. a number of shares of the Borrower’s common stock and/or an amount of cash based on the amount by which the market price per share of Common Stock of the Borrower, as measured under the terms of the capped call transactions, is greater than the strike price of the capped call transactions during the relevant valuation period.


Schedule 5.2(vii)

Transactions with Affiliates

Investments of Inventory pursuant to clause (j) of the definition of Permitted Investments

Exhibit 10.3

AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT

AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of August 9, 2018, by and among Endologix, Inc., a Delaware corporation (the “Company”), and Deerfield Private Design Fund IV, L.P., Deerfield Partners, L.P. and Deerfield Private Design Fund III, L.P. (each individually, a “Lender” and together, the “Lenders”).

WHEREAS:

A. In connection with the Facility Agreement, dated as of April 3, 2017, by and among the Company, the Lenders, Deerfield International Master Fund, L.P. (the “Prior Lender”), the other Loan Parties (as defined therein) and Deerfield Private Design Fund IV, L.P., as agent for itself and the other Lenders (as the same has heretofore been amended, modified, restated or otherwise supplemented, the “Existing Facility Agreement”), (i) the Company issued the Initial Warrants (as defined in the Amended Facility Agreement (as defined below)) to the Lenders in the amounts described in the Existing Facility Agreement, each of which Initial Warrants is exercisable into shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”); and

B. In connection with the Facility Agreement, the Company, the Lenders and the Prior Lender executed and delivered that certain Registration Rights Agreement, dated as of April 3, 2017 (the “Existing Registration Rights Agreement”).

C. Pursuant to the Existing Registration Rights Agreement, the Company filed with the United States Securities and Exchange Commission (“SEC”) a Registration Statement (File No. 333-217602) on Form S-3, which registered the resale of an aggregate of 6,470,000 Common Shares issuable upon exercise of the Initial Warrants and was declared effective by the SEC as of May 22, 2017 (the “Existing Registration Statement”). On May 22, 2017, pursuant to Rule 424(b)(3) under the Securities Act (as defined below), the Company filed a final prospectus as part of the Existing Registration Statement (the “Initial Prospectus”). For the avoidance of doubt, the Existing Registration Statements and the Initial Prospectus constitute a Registration Statement and Prospectus (each as defined in this Agreement), respectively, under this Agreement.

D. Effective as of January 1, 2018, the Prior Lender transferred and assigned its Initial Warrants and its rights under the Existing Registration Rights Agreement to Deerfield Partners, L.P. (the “Warrant Transfer”).

F. Contemporaneously with the execution of this Agreement, the Company, the Lenders, the other Loan Parties (as defined therein) and Deerfield Private Design Fund IV, L.P., as agent for itself and the other Lenders, are entering into an Amended and Restated Facility Agreement, dated as of the date hereof (as the same may hereafter be amended, modified, restated or otherwise supplemented from time to time, the “Amended Facility Agreement”), which amends and restates the Existing Facility Agreement in its entirety. All capitalized terms used and not otherwise defined herein shall have the respective meanings set forth in the Amended Facility Agreement.

G. The Amended Facility Agreement, among other things, provides for the issuance of the Additional Warrants (as defined in the Amended Facility Agreement).

H. The parties hereto desire to amend and restate the Existing Registration Rights Agreement to provide for certain changes relating to the issuance of the Additional Warrants.


I. To induce the Lenders to execute and deliver the Amended Facility Agreement, the Company has agreed to provide certain registration rights under the Securities Act of 1933, as amended, and the rules and regulations thereunder, or any similar successor statute (collectively, the “Securities Act”), and applicable state securities laws.

NOW, THEREFORE , in consideration of the premises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and each of the Lenders hereby agree as follows:

1. DEFINITIONS.

a. As used in this Agreement, the following terms shall have the following meanings:

(i) “Additional Filing Deadline” means, with respect to any Registration Statements that may be required pursuant to Section 2(a)(ii), (A) the first date or time that such Registrable Securities may then be included in a Registration Statement if such Registration Statement is required because the SEC shall have notified the Company in writing that certain Registrable Securities were not eligible for inclusion on a previously filed Registration Statement, or (B) if such additional Registration Statement is required for a reason other than as described in (A) above, the twentieth (20 th ) day following the date on which the Company first knows, or reasonably should have known, that such additional Registration Statement is required.

(ii) “Additional Registration Deadline” means, with respect to any additional Registration Statement(s) required pursuant to Section 2(a)(ii), the thirtieth (30 th ) day following (A) the first date or time that such Registrable Securities may then be included in a Registration Statement if such Registration Statement is required because the SEC shall have notified the Company in writing that certain Registrable Securities were not eligible for inclusion on a previously filed Registration Statement, or (B) if such additional Registration Statement is required for a reason other than as described in (A) above, the fortieth (40 th ) day following the date on which the Company first knows, or reasonably should have known, that such additional Registration Statement(s) is required.

(iii) “Investor” means any Lender and any transferee or assignee who agrees to become bound by the provisions of this Agreement in accordance with Section 10 hereof.

(iv) “Exchange Act” means the Securities Exchange Act of 1934, as amended, together with the rules and regulations promulgated thereunder, and any successor statute.

(v) “FINRA” means the Financial Industry Regulatory Authority (or successor thereto).

(vi) “Filing Deadline,” for the Registration Statement required pursuant to Section 2(a)(i), shall mean September 6, 2018, and for each Registration Statement required pursuant to Section 2(a)(ii) shall mean the Additional Filing Deadline.

(vii) “Person” means and includes any natural person, partnership, joint venture, corporation, trust, limited liability company, limited company, joint stock company, unincorporated organization, government entity or any political subdivision or agency thereof, or any other entity.

(viii) “Prospectus” means (i) any prospectus (preliminary or final) included in any Registration Statement (including the Initial Prospectus), as may be amended or supplemented by any prospectus supplement with respect to the terms of the offering of any portion of the Registrable Securities covered by such Registration Statement and by all other amendments and supplements to such prospectus, including post-

 

2


effective amendments, and all material incorporated by reference in such prospectus, and (ii) any “free writing prospectus” as defined in Rule 405 under the Securities Act relating to any offering of Registrable Securities pursuant to a Registration Statement.

(ix) “Register,” “Registered,” and “Registration” refer to a registration effected by preparing and filing a Registration Statement or Statements in compliance with the Securities Act and pursuant to Rule 415, and the declaration or ordering of effectiveness of such Registration Statement by the United States Securities and Exchange Commission (the “SEC”).

(x) “Registrable Securities,” for a given Registration, means (a) any shares of Common Stock (the “Warrant Shares”) issued or issuable upon exercise of, or otherwise pursuant to, the Warrants (without giving effect to any limitations on exercise set forth in the Warrants), (b) any shares of capital stock issued or issuable as a dividend on or in exchange for or otherwise with respect to any of the foregoing, (c) any additional shares of Common Stock issuable in connection with any anti-dilution provisions in the Warrants, (d) any other shares of Common Stock issuable pursuant to the terms of the Warrants or this Agreement, and (e) any securities issued or issuable upon any stock split, dividend or other distribution, recapitalization or similar event with respect to any of the foregoing.

(xi) “Registration Deadline” shall mean, for purposes of the Registration Statement required pursuant to Section 2(a)(i), the earlier of (i) the date that is seventy-five (75) days after the date that the applicable Registration Statement is actually filed or (ii) the date that is seventy-five (75) days after the applicable Filing Deadline and, with respect to any Registration Statement required pursuant to Section 2(a)(ii), the Additional Registration Deadline.

(xii) “Registration Statement(s)” means any registration statement(s) of the Company filed under the Securities Act that covers the resale of any of the Registrable Securities pursuant to the provisions of this Agreement (including the Existing Registration Statement), all amendments and supplements to such Registration Statement, including post-effective amendments, and all exhibits to, and all material incorporated by reference in, such Registration Statement.

(xiii) “Rule 415” means Rule 415 under the Securities Act or any successor rule providing for the offering of securities on a continuous basis

(xiv) “Warrants” means the Warrants (including, for the avoidance of doubt, both the Initial Warrants and the Additional Warrants) issued by the Company pursuant to the Existing Facility Agreement and the Amended Facility Agreement.

2. REGISTRATION.

a. MANDATORY REGISTRATION. (i) Following the Agreement Date, the Company shall prepare, and, on or prior to the applicable Filing Deadline, file with the SEC a Registration Statement (the “Mandatory Registration Statement”) on Form S-3 (or, if Form S-3 is not then available, on such form of Registration Statement as is then available to effect a registration of the Registrable Securities, subject to the consent of the Investors, which consent shall not be unreasonably withheld), covering the resale of all of the Registrable Securities that are not at that time covered by the Existing Registration Statement (as then in effect and available for resale of the Registrable Securities covered thereby), which Registration Statement, to the extent allowable under the Securities Act and the rules and regulations promulgated thereunder (including Rule 416), shall state that such Registration Statement also covers such indeterminate number of additional shares of Common Stock as may become issuable upon exercise of or otherwise pursuant to the Warrants or the Warrant Shares to prevent dilution resulting from stock splits, stock dividends, stock issuances or similar transactions. The number of shares of Common Stock initially

 

3


included in such Registration Statement shall be no less than the aggregate number of Warrant Shares that are then issuable upon exercise of or otherwise pursuant to the Warrants, without regard to any limitations on the Investors’ ability to exercise the Warrants. Each Registration Statement (and each amendment or supplement thereto, and each request for acceleration of effectiveness thereof) shall be provided to (and shall be subject to the approval, which shall not be unreasonably withheld or delayed, of) the Investors and their counsel prior to its filing or other submission.

(ii) If for any reason, despite the Company’s use of its best efforts to include all of the Registrable Securities in the Registration Statement filed pursuant to Section 2 (a)(i) above (and subject to Section 3(q) below), the SEC does not permit all such Registrable Securities to be included in such Registration Statement, or for any other reason any Registrable Securities are not then included in a Registration Statement (including the Existing Registration Statement), then the Company shall prepare, and, as soon as practicable but in no event later than the Additional Filing Deadline, file with the SEC an additional Registration Statement covering the resale of all Registrable Securities not already covered by an existing and effective Registration Statement for an offering to be made on a continuous basis pursuant to Rule 415.

(iii) Unless the SEC does not so permit or otherwise directed by the Buyers, each Registration Statement filed pursuant to this Section 2(a) or Section 3(b) shall include a combined prospectus for the resale of the Registrable Securities registered by such Registration Statement, the Existing Registration Statement and any other Registration Statement previously filed hereunder, and shall be deemed a post-effective amendment to the Existing Registration Statement or, other previously filed Registration Statement in accordance with Rule 429 under the Securities Act.

b. PIGGY-BACK REGISTRATIONS. If at any time prior to the expiration of the Registration Period (as hereinafter defined) the Company shall determine (i) to file with the SEC a registration statement under the Securities Act relating to an offering for its own account or for the account of any other holder of its equity securities (other than securities being registered on Form S-4 or Form S-8 or their then equivalents relating to equity securities to be issued solely in connection with any acquisition of any entity or business or equity securities issuable in connection with stock option or other employee benefit plans), and/or (ii) otherwise to effect an underwritten offering of any securities of the Company of a type included in a then effective Registration Statement, the Company shall send to each Investor written notice of such determination and, if within fifteen (15) days after the effective date of such notice, the Investor shall so request in writing, the Company shall include in such Registration Statement and/or include in such underwritten offering, as applicable, all or any part of such Investor’s Registrable Securities that the Investor requests to be registered and/or included in the underwritten offering, as applicable, except that if, in connection with any underwritten offering for the account of the Company, the managing underwriter(s) thereof shall impose a limitation on the number of Registrable Securities which may be included in such offering because, in such underwriter(s)’ judgment, marketing or other factors dictate such limitation is necessary to facilitate public distribution, then the Company shall be obligated to include in such underwritten offering only such limited portion of the Registrable Securities with respect to which the Investor has requested inclusion hereunder as the underwriter(s) shall permit;

provided, however , that the Company shall not exclude any Registrable Securities unless the Company has first excluded all outstanding securities to be sold for the accounts of any holders of the Company’s equity securities which are not entitled by contract to inclusion of such securities in an underwritten offering or are not entitled to pro rata inclusion with the Registrable Securities; and

provided, further, however , that, after giving effect to the immediately preceding proviso, any exclusion of Registrable Securities shall be made pro rata with holders of other securities having the contractual right to include such securities in such underwritten offering other than holders of securities entitled to

 

4


inclusion of their securities in such underwritten offering by reason of demand registration rights. No right to registration of Registrable Securities under this Section 2(b) shall be construed to limit any registration required under Section 2(a) hereof. If an Investor’s Registrable Securities are included in an underwritten offering pursuant to this Section 2(b), then such Investor shall, unless otherwise agreed by the Company, offer and sell such Registrable Securities in such underwritten offering using the same underwriter or underwriters and, subject to the provisions of this Agreement, on the same terms and conditions as other shares of Common Stock included in such underwritten offering. Notwithstanding anything to the contrary set forth herein, the rights of the Investors pursuant to this Section 2(b) shall only be available in the case of an underwritten offering or in the event the Company fails to timely file, obtain effectiveness or maintain effectiveness of any Registration Statement to be filed pursuant to Section 2(a) or Section 3(b) in accordance with the terms of this Agreement.

3. OBLIGATIONS OF THE COMPANY. In connection with any registration of the Registrable Securities hereunder, the Company shall have the following obligations:

a. The Company shall prepare promptly, and file with the SEC as soon as practicable after such registration obligation arises hereunder (but in no event later than the applicable Filing Deadline), a Registration Statement with respect to the Registrable Securities as provided in Section 2(a), and thereafter use its reasonable best efforts to cause each such Registration Statement relating to Registrable Securities to become effective as soon as possible after such filing, but in any event shall use its reasonable best efforts to cause each such Registration Statement relating to Registrable Securities to become effective no later than the Registration Deadline, and shall use its reasonable best efforts to keep each of such Registration Statement and the Existing Registration Statement current and effective pursuant to Rule 415 at all times after its effective date until such date as is the earlier of (i) the date on which all of the Registrable Securities included in such Registration Statement have been sold and (ii) assuming all of the Warrants will be exercised pursuant to Cash Exercises (as defined in the Warrants), the date on which all of the Registrable Securities included in such Registration Statement (in the opinion of counsel to the Investors) may be immediately sold to the public without registration or restriction (including without limitation as to volume by each holder thereof), and without compliance with any “current public information” requirement, pursuant to Rule 144 under the Securities Act (the “Registration Period”), which Registration Statement (including any amendments or supplements thereto and prospectuses contained therein), except for information provided in writing by an Investor pursuant to Section 4(a), shall not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein, or necessary to make the statements therein not misleading. In the event that Form S-3 is not available for the registration of the resale of any Registrable Securities hereunder (but, for the avoidance of doubt, without in any way affecting the Company’s obligation to register the resale of the Registrable Securities on such other form as is available, as provided in Section 2(a)), (i) the Company shall undertake to file, within twenty (20) days of such time as such form is available for such registration, a post-effective amendment to the Registration Statement then in effect, or otherwise file a Registration Statement on Form S-3, registering such Registrable Securities on Form S-3; provided that the Company shall maintain the effectiveness of the Registration Statement then in effect until such time as a Registration Statement (or post-effective amendment) on Form S-3 covering such Registrable Securities has been declared effective by the SEC, and (ii) the Company shall provide that any Registration Statement on Form S-1 filed hereunder shall incorporate documents by reference (including by way of forward incorporation by reference) to the maximum extent possible.

b. The Company shall prepare and file with the SEC such amendments (including post-effective amendments) and supplements to each Registration Statement and the prospectus used in connection with each Registration Statement as may be necessary to keep each Registration Statement current and effective at all times during the Registration Period, and, during the Registration Period, shall comply with the provisions of the Securities Act with respect to the disposition of all Registrable Securities of the

 

5


Company covered by each Registration Statement until such time as all of such Registrable Securities have been disposed of in accordance with the intended methods of disposition by the seller or sellers thereof as set forth in such Registration Statement. Without limiting the foregoing, no later than August 17, 2018, the Company shall file with the SEC a prospectus supplement that supplements the Initial Prospectus with such information as shall be necessary to reflect the Warrant Transfer (including to provide that Deerfield Partners, L.P. may resell the Registrable Securities underlying the Initial Warrants pursuant to the Existing Registration Statement and the Initial Prospectus) and the transactions contemplated by the Amended Facility Agreement, to include updated information with respect to the Lenders to the extent provided by the Lenders in accordance with this Agreement and to include such other information as may be necessary to enable the Existing Registration Statement to be used for resales of all of the Registrable Securities covered thereby. In the event that on any Trading Day (as defined below) (the “Registration Trigger Date”) the number of shares available under the Registration Statements filed pursuant to this Agreement is insufficient to cover all of the Registrable Securities issued or issuable upon exercise of or otherwise pursuant to the Warrants, including any additional shares of Common Stock issued in connection with any anti-dilution provisions contained in the Warrants, without giving effect to any limitations on the Investors’ ability to exercise the Warrants, the Company shall amend the Registration Statements, or file a new Registration Statement (on the short form available therefor, if applicable), or both, so as to cover the total number of Registrable Securities so issued or issuable (without giving effect to any limitations on exercise contained in the Warrants) as of the Registration Trigger Date as soon as practicable, but in any event within twenty (20) days after the Registration Trigger Date. The Company shall use its best efforts to cause such amendment and/or new Registration Statement to become effective as soon as practicable following the filing thereof, but in any event the Company shall cause such amendment and/or new Registration Statement to become effective within sixty (60) days of the Registration Trigger Date or as promptly as practicable in the event the Company is required to increase its authorized shares. “Trading Day” shall mean any day on which the Common Stock is traded for any period on the NASDAQ Global Select Market (the “NasdaqGS”), or if not the NasdaqGS, the principal securities exchange or other securities market on which the Common Stock is then being traded.

c. The Company shall furnish to each Investor and its legal counsel (i) promptly after the same is prepared and publicly distributed, filed with the SEC or received by the Company, one copy of each Registration Statement and any amendment thereto, each preliminary prospectus and prospectus and each amendment or supplement thereto, and, each letter written by or on behalf of the Company to the SEC or the staff of the SEC, and each item of correspondence from the SEC or the staff of the SEC, in each case relating to such Registration Statement (other than any portion of any thereof which contains information for which the Company has sought or intends to seek confidential treatment, which contains or reflects any material non-public information with respect to the Company or its securities or which relates to Company matters that are in the reasonable judgment of the Company not relevant to the Investor’s interests with respect to the Registrable Securities), and (ii) such number of copies of a prospectus, including a preliminary prospectus, and all amendments and supplements thereto and such other documents as an Investor may reasonably request in order to facilitate the disposition of the Registrable Securities owned by such Investor; provided that the Company may determine in its reasonable judgment to provide any such copies in electronic form only. The Company will promptly notify each of the Investors by electronic mail of the effectiveness of each Registration Statement or any post-effective amendment. The Company will promptly respond to any and all comments received from the SEC, with a view towards causing each Registration Statement or any amendment thereto (including any post-effective amendment to the Existing Registration Statement) to be declared effective by the SEC as soon as practicable and, as soon as practicable, but in no event later than three (3) business days, following the resolution or clearance of all SEC comments or, if applicable, following notification by the SEC that any such Registration Statement or any amendment thereto will not be subject to review, shall file a request for acceleration of effectiveness of such Registration Statement to a time and date not later than two (2) business days after

 

6


the submission of such request. No later than the first business day after such Registration Statement becomes effective, the Company will file with the SEC the final prospectus included therein pursuant to Rule 424 (or successor thereto) under the Securities Act.

d. The Company shall use its reasonable best efforts to (i) register and qualify, in any jurisdiction where registration and/or qualification is required, the Registrable Securities covered by the Registration Statements under such other securities or “blue sky” laws of such jurisdictions in the United States as the Investors shall reasonably request, (ii) prepare and file in those jurisdictions such amendments (including post-effective amendments) and supplements to such registrations and qualifications as may be reasonably necessary to maintain the effectiveness thereof during the Registration Period, (iii) take such other actions as may be reasonably necessary to maintain such registrations and qualifications in effect at all times during the Registration Period, and (iv) take all other actions reasonably necessary or advisable to qualify the Registrable Securities for sale in such jurisdictions; provided, however, that the Company shall not be required in connection therewith or as a condition thereto to (x) qualify to do business in any jurisdiction where it would not otherwise be required to qualify but for this Section 3(d), (y) subject itself to general taxation in any such jurisdiction, or (z) file a general consent to service of process in any such jurisdiction.

e. As promptly as practicable after becoming aware of such event, the Company shall notify each Investor that holds Registrable Securities of the happening of any event, of which the Company has knowledge, as a result of which the prospectus included in any Registration Statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading, and promptly prepare a supplement or amendment to any Registration Statement to correct such untrue statement or omission, and deliver such number of copies of such supplement or amendment to each Investor as such Investor may reasonably request.

f. The Company shall use its reasonable best efforts to prevent the issuance of any stop order or other suspension of effectiveness of any Registration Statement, and, if such an order is issued, to obtain the withdrawal of such order at the earliest possible moment and to notify each Investor that holds Registrable Securities (and, in the event of an underwritten offering, the managing underwriters) of the issuance of such order and the resolution thereof.

g. The Company shall permit a single firm of counsel designated by the Investors (“Legal Counsel”) to review such Registration Statement and all amendments and supplements thereto (as well as all requests for acceleration or effectiveness thereof), a reasonable period of time prior to their filing with the SEC (not less than five (5) business days but not more than eight (8) business days) and not file any documents in a form to which Legal Counsel reasonably objects and will not request acceleration of such Registration Statement without prior notice to Legal Counsel.

h. The Company shall hold in confidence and not make any disclosure of information concerning an Investor provided to the Company unless (i) disclosure of such information is necessary to comply with federal or state securities laws, (ii) the disclosure of such information is necessary to avoid or correct a misstatement or omission in any Registration Statement, (iii) the release of such information is ordered pursuant to a subpoena or other order from a court or governmental body of competent jurisdiction, or (iv) such information has been made generally available to the public other than by disclosure in violation of this or any other agreement. The Company agrees that it shall, upon learning that disclosure of such information concerning any Investor is sought in or by a court or governmental body of competent jurisdiction or through other means, give prompt notice to such Investor prior to making such disclosure, and allow such Investor, at its expense, to undertake appropriate action to prevent disclosure of, or to obtain a protective order for, such information.

 

7


i. The Company shall use its reasonable best efforts to cause all the Registrable Securities covered by each Registration Statement to be listed on each securities exchange on which securities of the same class or series issued by the Company are then listed, if any, if the listing of such Registrable Securities is then permitted under the rules of such exchange, and, to arrange for at least two market makers to register with the Financial Industry Regulatory Authority, Inc. (“FINRA”) as such with respect to such Registrable Securities.

j. The Company shall provide a transfer agent and registrar, which may be a single entity, for the Registrable Securities not later than the effective date of the initial Registration Statement.

k. The Company shall cooperate with each Investor that holds Registrable Securities being offered and the managing underwriter or underwriters with respect to an applicable Registration Statement, if any, to facilitate the timely (i) preparation and delivery of certificates (not bearing any restrictive legends) representing Registrable Securities to be offered pursuant to such Registration Statement, and enable such certificates to be registered in such names and in such denominations or amounts, as the case may be, or (ii) crediting of the Registrable Securities to be offered pursuant to a Registration Statement to the applicable account (or accounts) with The Depository Trust Company through its Deposit/Withdrawal At Custodian (DWAC) system, in any such case as such Investor or the managing underwriter or underwriters, if any, may reasonably request. Within three (3) business days after a Registration Statement which includes Registrable Securities becomes effective, the Company shall deliver, and shall cause legal counsel selected by the Company to deliver, to the transfer agent for the Registrable Securities (with copies to each Investor) an appropriate instruction and an opinion of such counsel in the form required by the transfer agent in order to issue the Registrable Securities free of restrictive legends.

l. At the reasonable request of an Investor, the Company shall prepare and file with the SEC such amendments (including post-effective amendments) and supplements to a Registration Statement and any prospectus used in connection with the Registration Statement as may be necessary in order to change the plan of distribution set forth in such Registration Statement.

m. The Company shall not, and shall not agree to, allow the holders of any securities of the Company to include any of their securities (other than Registrable Securities) in any Registration Statement filed pursuant to Section 2(a) or Section 3(b) hereof or any amendment or supplement thereto under Section 3(b) hereof without the consent of Investors holding a majority-in-interest of the then outstanding Registrable Securities. In addition, the Company shall not include any securities for its own account or the account of others in any Registration Statement filed pursuant to Section 2(a) or Section 3(b) hereof or any amendment or supplement thereto filed pursuant to Section 3(b) hereof without the consent of Investors holding a majority-in-interest of the then outstanding Registrable Securities.

n. Reserved.

o. The Company shall comply with all applicable laws related to a Registration Statement and offering and sale of securities and all applicable rules and regulations of governmental authorities in connection therewith (including the Securities Act and the Exchange Act and the rules and regulations promulgated by the SEC).

p. If required by the FINRA Corporate Financing Department, the Company shall promptly effect a filing with FINRA pursuant to FINRA Rule 5110 (or successor thereto) with respect to the public offering contemplated by resales of securities under the Registration Statement (an “Issuer Filing”), and pay the filing fee required by such Issuer Filing. The Company shall use its reasonable best efforts to pursue the Issuer Filing until FINRA issues a letter confirming that it does not object to the terms of the offering

 

8


contemplated by the Registration Statement.

q. If at any time the SEC advises the Company in writing that the offering of some or all of the Registrable Securities in a Registration Statement is not eligible to be made on a delayed or continuous basis under the provisions of Rule 415 under the Securities Act, the Company shall use its reasonable best efforts to persuade the SEC that the offering contemplated by a Registration Statement is a bona fide secondary offering and not an offering “by or on behalf of the issuer” as defined in Rule 415 and that none of the Investors is an “underwriter.” The Investors shall have the right to participate or have their respective counsel participate in any meetings or discussions with the SEC regarding the SEC’s position and to comment or have their respective counsel comment on any written submission made to the SEC with respect thereto. No such written submission shall be made to the SEC to which any Investor’s counsel reasonably objects. In the event that, despite the Company’s reasonable best efforts and compliance with the terms of this Section 3(q), the SEC refuses to alter its position, the Company shall remove from the Registration Statement such portion of the Registrable Securities as the SEC requires in writing be removed therefrom. Any such cut-back imposed by the SEC as contemplated by this Section 3(q) shall be imposed on a pro rata basis (based upon the Registrable Securities held by each of the Investors).

r. Notwithstanding anything to the contrary in Section  3(e) , at any time after the effective date of the applicable Registration Statement, the Company may delay the disclosure of material non-public information concerning the Company the disclosure of which at the time is not, in the good faith opinion of the Board of Directors of the Company and its counsel, in the best interest of the Company and not, in the opinion of counsel to the Company, otherwise required (a “ Grace Period ”); provided, that the Company shall (i) promptly notify the Investors in writing of the existence of material non-public information giving rise to a Grace Period (provided that in each notice the Company shall not disclose the content of such material non-public information to any Investor unless otherwise requested in writing by such Investor) and the date on which the Grace Period will begin, and (ii) as soon as such date may be determined, promptly notify the Investors in writing of the date on which the Grace Period ends; and, provided , further , that (A) no Grace Period shall exceed forty-five (45) consecutive days, (B) during any three hundred sixty five (365) day period, such Grace Periods shall not exceed an aggregate of seventy-five (75) days, and (C) the first day of any Grace Period must be at least ten (10) business days after the last day of any prior Grace Period (each Grace Period that satisfies all of the requirements of this Section  3(r) being referred to as an “ Allowable Grace Period ”). For purposes of determining the length of a Grace Period above, the Grace Period shall begin on and include the date the Investors receive the notice referred to in clause (i) and shall end on and include the later of the date the Investors receive the notice referred to in clause (ii) and the date referred to in such notice. The provisions of Section  3(e) hereof shall not be applicable during the period of any Allowable Grace Period, Failure Payments (as defined in the Warrants) shall not accrue on any day during an Allowable Grace Period, and the unavailability of a Registration Statement for resales of the Registrable Securities on any day during an Allowable Grace Period shall not constitute a “Registration Failure” (as defined in the Warrants). Upon expiration of the Grace Period, the Company shall again be bound by the first sentence of Section  3(e) with respect to the information giving rise thereto unless such material non-public information is no longer applicable.

4. OBLIGATIONS OF THE INVESTOR. In connection with the registration of the Registrable Securities, each Investor shall have the following obligations:

a. It shall be a condition precedent to the obligations of the Company to complete the registration pursuant to this Agreement with respect to the Registrable Securities of an Investor that such Investor shall furnish to the Company such information regarding itself, the Registrable Securities held by it and the intended method of disposition of the Registrable Securities held by it as shall be reasonably required to effect the registration of such Registrable Securities and shall execute such documents in connection with such

 

9


registration as the Company may reasonably request. At least five (5) business days prior to the first anticipated filing date of a Registration Statement, the Company shall notify each Investor of the information the Company requires from such Investor. Any such information shall not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein, or necessary to make the statements therein not misleading. An Investor must provide such information to the Company at least two (2) business days prior to the first anticipated filing date of such Registration Statement if such Investor elects to have any Registrable Securities included in the Registration Statement.

b. Each Investor, by such Investor’s acceptance of the Registrable Securities, agrees to cooperate with the Company as reasonably requested by the Company in connection with the preparation and filing of a Registration Statement hereunder, unless such Investor has notified the Company in writing of such Investor’s election to exclude all of the Investor’s Registrable Securities from such Registration Statement.

c. In the event of an underwritten offering pursuant to Section 2(b) in which any Registrable Securities of any Investor are to be included, such Investor agrees to enter into and perform the Investor’s obligations under an underwriting agreement, in usual and customary form, including customary indemnification and contribution obligations (as applicable to selling security holders generally), with the managing underwriter of such offering and take such other actions as are reasonably required in order to expedite or facilitate the disposition of such Investor Registrable Securities.

d. Each Investor agrees that, upon receipt of any notice from the Company of the happening of any event of the kind described in Section 3(e) or 3(f), such Investor will immediately discontinue disposition of Registrable Securities pursuant to the Registration Statement covering such Registrable Securities until such Investor’s receipt of the copies of the supplemented or amended prospectus contemplated by Section 3(e) or 3(f).

e. Each Investor agrees that it will promptly notify the Company of any material changes in the information set forth in a Registration Statement furnished by or regarding such Investor, other than changes in the number of shares beneficially owned.

5. REGISTRATION FAILURE. In the event of a Registration Failure (as defined in the Warrants), the Investors shall be entitled to Failure Payments (as defined in the Warrants) and such other rights as set forth in the Warrants.

6. EXPENSES OF REGISTRATION. All reasonable expenses, other than underwriting discounts and commissions, incurred in connection with registrations, filings or qualifications pursuant to Sections 2 and 3, including, without limitation, all registration, listing and qualification fees, printers and accounting fees, and the fees and disbursements of counsel for the Company shall be borne by the Company. The Company shall also reimburse the Investors for the reasonable fees and disbursements of Legal Counsel in the aggregate amount up to $25,000 per registration in connection with registrations pursuant to Section 2 or 3 of this Agreement.

7. INDEMNIFICATION. In the event any Registrable Securities are included in a Registration Statement under this Agreement:

a. The Company will indemnify, hold harmless and defend (i) each Investor, (ii) the directors, officers, partners, managers, members, employees and agents of each Investor, and each Person who controls any Investor within the meaning of the Securities Act or the Exchange Act, if any, (iii) any underwriter (as defined in the Securities Act) for each Investor in connection with an underwritten offering pursuant to Section 2(b) hereof, and (iv) the directors, officers, partners and employees of, and each Person who

 

10


controls, any such underwriter within the meaning of the Securities Act or the Exchange Act, if any (each, an “Indemnified Person”), against any joint or several losses, claims, damages, liabilities or expenses (collectively, together with actions, proceedings or inquiries by any regulatory or self-regulatory organization, whether commenced or threatened, in respect thereof, “Claims”) to which any of them may become subject insofar as such Claims arise out of or are based upon: (i) any untrue statement or alleged untrue statement of a material fact in any Registration Statement, or any amendment as supplement thereto, or any filing made under state securities laws as required hereby, or the omission or alleged omission to state therein a material fact required to be stated or necessary to make the statements therein not misleading; (ii) any untrue statement or alleged untrue statement of a material fact contained in any Prospectus, or any amendment or supplement thereto, or the omission or alleged omission to state therein any material fact necessary to make the statements made therein, in the light of the circumstances under which the statements therein were made, not misleading; or (iii) any violation or alleged violation by the Company of the Securities Act, the Exchange Act, any other law, including any state securities law, or any rule or regulation thereunder relating to the offer or sale of the Registrable Securities (the matters in the foregoing clauses (i) through (iii) being, collectively, “Violations”). The Company shall reimburse the Indemnified Person, promptly as such expenses are incurred and are due and payable, for any reasonable legal fees and other reasonable expenses incurred by them in connection with investigating or defending any such Claim. Notwithstanding anything to the contrary contained herein, the indemnification agreement contained in this Section 7(a) shall not apply to a Claim arising out of or based upon a Violation to the extent that such Violation occurs in reliance upon and in conformity with information furnished in writing to the Company by or on behalf of any Indemnified Person expressly for use in connection with the preparation of such Registration Statement or any such amendment thereof or supplement thereto, or (B) to any amounts paid in settlement of any Claim effected without the prior written consent of the Company, which consent shall not be unreasonably withheld or delayed. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of the Indemnified Person and shall survive the transfer of the Registrable Securities by any of the Investors pursuant to Section 10.

b. Promptly after receipt by an Indemnified Person under this Section 7 of notice of the commencement of any action (including any governmental action), such Indemnified Person shall, if a Claim in respect thereof is to be made against the Company under this Section 7, deliver to the Company a written notice of the commencement thereof, and the Company shall have the right to participate in, and, to the extent the Company so desires, to assume control of the defense thereof with counsel mutually satisfactory to the Company and the Indemnified Person, as the case may be;

provided, however , that an Indemnified Person shall have the right to retain its own counsel with the reasonable fees and expenses to be paid by the Company, if, in the reasonable opinion of counsel for such Indemnified Person, the representation by such counsel of the Indemnified Person and the Company would be inappropriate due to actual or potential differing interests between such Indemnified Person and any other party represented by such counsel in such proceeding. The Company shall pay for only one separate legal counsel for the Indemnified Persons, and such legal counsel shall be selected by the Investors. The failure to deliver written notice to the Company within a reasonable time of the commencement of any such action shall not relieve the Company of any liability to the Indemnified Person under this Section 7, except to the extent that the Company is actually prejudiced in its ability to defend such action, and shall not relieve the Company of any liability to the Indemnified Person otherwise than pursuant to this Section 7. The Company shall not, without the prior written consent of the Indemnified Persons, consent to entry of any judgment or enter into any settlement or other compromise with respect to any Claim in respect of which indemnification or contribution may be or has been sought hereunder (whether or not any such Indemnified Party is an actual or potential party to such action or claim) which does not include as an unconditional term thereof the giving by the claimant or plaintiff to the Indemnified Persons of a full release from all liability with respect to such Claim or which

 

11


includes any admission as to fault or culpability on the part of any Indemnified Person. The indemnification required by this Section 7 shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as any expense, loss, damage or liability is incurred.

c. Each Investor will indemnify, hold harmless and defend (i) the Company, and (ii) the directors, officers, partners, managers, members, employees or agents of the Company, if any (each, a “Company Indemnified Person”), against any Claims to which any of them may become subject insofar as such Claims arise out of or are based upon any violation or alleged violation by the Company of the Securities Act, the Exchange Act, any other law, including any state securities law, or any rule or regulation thereunder relating to the offer or sale of the Registrable Securities, which occurs due to the inclusion by the Company in a Registration Statement of false or misleading information about an Investor, where such information was furnished in writing to the Company by or on behalf of such Investor expressly for the purpose of inclusion in such Registration Statement. Notwithstanding anything herein to the contrary, the indemnity agreement contained in this Section 7(c) shall not apply to amounts paid in settlement of any Claim if such settlement is effected without the prior written consent of the Investors, which consent shall not be unreasonably withheld or delayed; and provided, further, however, that an Investor shall be liable under this Section 7(c) for only that amount of a Claim as does not exceed the net amount of proceeds received by such Investor as a result of the sale of Registrable Securities pursuant to such Registration Statement.

d. Promptly after receipt by a Company Indemnified Person under this Section 7 of notice of the commencement of any action (including any governmental action), such Company Indemnified Person shall, if a Claim in respect thereof is to be made against any Investor under this Section 7, deliver to such Investor a written notice of the commencement thereof, and such Investor shall have the right to participate in, and, to the extent such Investor so desires, to assume control of the defense thereof with counsel mutually satisfactory to such Investor and such Company Indemnified Person.

8. CONTRIBUTION. If for any reason the indemnification provided for in Section 7(a) or 7(c) (as applicable) is unavailable to an Indemnified Person or Company Indemnified Person (as applicable) or insufficient to hold it harmless, other than as expressly specified therein, then the indemnifying party shall contribute to the amount paid or payable by the Indemnified Person or Company Indemnified Person (as applicable) as a result of the Claim in such proportion as is appropriate to reflect the relative fault of the Indemnified Person or Company Indemnified Person (as applicable) and the indemnifying party (provided that the relative fault of any Company Indemnified Person shall be deemed to include the fault of all other Company Indemnified Persons), as well as any other relevant equitable considerations. No Person guilty of fraudulent misrepresentation within the meaning of Section 11(f) of the Securities Act shall be entitled to contribution from any Person not guilty of such fraudulent misrepresentation. In no event shall the contribution obligation of an Investor be greater in amount than the net amount of proceeds received by such Investor as a result of the sale of Registrable Securities giving rise to such contribution obligation pursuant to the applicable Registration Statement (net of the aggregate amount of any damages or other amounts such Investor has otherwise been required to pay (pursuant to Section 7(c) or otherwise) by reason of such Investor’s untrue or alleged untrue statement or omission or alleged omission).

9. REPORTS UNDER THE 1934 ACT. With a view to making available to the Investors the benefits of Rule 144 promulgated under the Securities Act or any other similar rule or regulation of the SEC that may at any time permit the Investors to sell securities of the Company to the public without registration, the Company agrees to:

a. make and keep public information available, as those terms are understood and defined in Rule 144;

 

12


b. file with the SEC in a timely manner all reports and other documents required of the Company under the Exchange Act so long as the Company remains subject to such requirements and the filing of such reports and other documents is required for the applicable provisions of Rule 144; and

c. so long as any of the Investors owns Registrable Securities, promptly upon request, furnish to such Investor (i) a written statement by the Company that it has complied with the reporting requirements of the Exchange Act as required for applicable provisions of Rule 144, (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company and (iii) such other information as may be reasonably requested to permit such Investor to sell such Registrable Securities pursuant to Rule 144 without registration.

10. ASSIGNMENT OF REGISTRATION RIGHTS. The rights under this Agreement shall be automatically assignable by each Investor to any transferee of all or any portion of the Registrable Securities if: (i) such Investor agrees in writing with the transferee or assignee to assign such rights, and a copy of such agreement is furnished to the Company within a reasonable time after such assignment, (ii) the Company is, within a reasonable time after such transfer or assignment, furnished with written notice of (a) the name and address of such transferee or assignee, and (b) the securities with respect to which such registration rights are being transferred or assigned, and (iii) at or before the time the Company receives the written notice contemplated in clause (ii) of this sentence, the transferee or assignee agrees in writing with the Company to be bound by all of the provisions contained herein as applicable to the Investors. In the event that the Company receives written notice from an Investor that it has transferred all or any portion of its Registrable Securities pursuant to this Section, the Company shall have up to ten (10) days to file any amendments or supplements necessary to keep a Registration Statement current and effective pursuant to Rule 415, and the commencement date of any Event of Failure (as defined in the Warrants) or Event of Default (as defined in the Warrants) under the Warrants caused thereby will be extended by ten (10) days. Each Investor shall at all times comply with the restrictions on transfer set forth in Section 8 of the Warrant (to the extent applicable to such Investor), which provisions are hereby incorporated by reference and made a part hereof.

11. AMENDMENT OF REGISTRATION RIGHTS. Provisions of this Agreement may be amended and the observance thereof may be waived (either generally or in a particular instance and either retroactively or prospectively), only with written consent of the Company and the holders of a majority in interest of then-outstanding Registrable Securities. Any amendment or waiver effected in accordance with this Section 11 shall be binding upon each of the Investors and the Company.

12. MISCELLANEOUS.

a. A Person is deemed to hold, and be a holder of, shares of Common Stock or other Registrable Securities whenever such Person owns of record or beneficially through a “street name” holder such shares of Common Stock or other Registrable Securities (or the Warrants or other securities upon exercise, conversion or exchange of which such Registrable Securities are directly or indirectly issuable, without giving effect to any limitations on exercise, conversion or exchange of the Warrants or other securities), and solely for purposes hereof, Registrable Securities shall be deemed outstanding to the extent they are directly or indirectly issuable upon exercise, conversion or exchange of the Warrants or other outstanding securities, Registrable Securities, without giving effect to any limits on exercise, conversion or exchange of the Warrants or other securities. If the Company receives conflicting instructions, notices or elections from two or more Persons with respect to the same Registrable Securities, the Company shall act upon the basis of instructions, notice or election received from the registered owner of such Registrable Securities (or the Warrants or other securities upon exercise, conversion or exchange of which such Registrable Securities are directly or indirectly issuable).

 

13


b. Any notices required or permitted to be given under the terms hereof shall be sent by certified or registered mail (return receipt requested) or delivered personally or by courier (including a recognized overnight delivery service) or by electronic mail and shall be effective five days after being placed in the mail, if mailed by regular United States mail, or upon receipt, if delivered personally or by courier (including a recognized overnight delivery service) or by electronic mail, in each case addressed to a party. The addresses for such communications shall be:

If to the Company:

Endologix, Inc.

2 Musick

Irvine, CA 92618

E-mail: jtejedor@endologix.com

Attn: Vaseem Mahboob, CFO

Attn: James Tejedor, Treasury Manager

With copy to:

DLA Piper LLP (US)

4365 Executive Drive, Suite 1100

San Diego, CA 92101

E-mail: michael.kagnoff@dlapiper.com

Attn: Michael Kagnoff

If to an Investor:

c/o Deerfield Mgmt, L.P.

780 Third Avenue, 37 th Floor

New York, NY 10017

Fax: (212) 599-1248

Email:

Attn: David J. Clark, Esq.

With a copy to:

Katten Muchin Rosenman LLP

575 Madison Avenue

New York, NY 10022

Fax: (212) 940-8776

Email: mark.fisher@kattenlaw.com and mark.wood@kattenlaw.com

Attn: Mark I. Fisher, Esq.

         Mark D. Wood, Esq.

Each party shall provide notice to the other party of any change in address.

c. Failure of any party to exercise any right or remedy under this Agreement or otherwise, or delay by a party in exercising such right or remedy, shall not operate as a waiver thereof.

d. Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that

 

14


all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York, borough of Manhattan. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. The parties hereby waive all rights to a trial by jury. If either party shall commence an action or proceeding to enforce any provision of this Agreement, then the prevailing party in such action or proceeding shall be reimbursed by the other party for its reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.

e. This Agreement and the Warrants constitute the entire agreement among the parties hereto with respect to the subject matter hereof. This Agreement and the Warrants (including all schedules and exhibits thereto) supersede all prior agreements and understandings among the parties hereto with respect to the subject matter hereof.

f. Subject to the requirements of Section 10 hereof, this Agreement shall inure to the benefit of and be binding upon the successors and assigns of each of the parties hereto, and the provisions of Sections 7 and 8 hereof shall inure to the benefit of, and be enforceable by, each Indemnified Person and Company Indemnified Person (as applicable).

g. The headings in this Agreement are for convenience of reference only and shall not limit or otherwise affect the meaning hereof.

h. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original but all of which shall constitute one and the same agreement. This Agreement, once executed by a party, may be delivered to the other party hereto by electronic transmission of a copy of this Agreement bearing the signature of the party so delivering this Agreement.

i. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other parties may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

j. The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Investors by vitiating the intent and purpose of the transactions contemplated hereby. Accordingly, the Company acknowledges that the remedy at law for breach of its obligations hereunder will be inadequate and agrees, in the event of a breach or threatened breach by the Company of any of the provisions hereunder, that the Investors shall be entitled, in addition to all other available remedies in law or in equity, to an injunction or injunctions to prevent or cure breaches of the provisions of this Agreement and to enforce specifically the terms and provisions hereof, without the necessity of showing economic loss and without any bond or other security being required.

 

15


k. The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any party.

l. In the event that any provision of this Agreement is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any provision hereof which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision hereof.

m. In the event an Investor shall sell or otherwise transfer any of such holder’s Registrable Securities, each transferee shall be allocated a pro rata portion of the number of Registrable Securities included in a Registration Statement for such transferor.

n. There shall be no oral modifications or amendments to this Agreement. This Agreement may be modified or amended only in writing.

o. The Company shall not grant any Person any registration rights with respect to shares of Common Stock or any other securities of the Company other than registration rights that will not adversely affect the rights of the Investors hereunder (including by limiting in any way the number of Registrable Securities that could be included in any Registration Statement pursuant to Rule 415) and shall not otherwise enter into any agreement that is inconsistent with the rights granted to the Investors hereunder.

p. The obligations of each Investor hereunder are several and not joint with the obligations of any other Investor, and no provision of this Agreement is intended to confer any obligations on any Investor vis-à-vis any other Investor. Nothing contained herein, and no action taken by any Investor pursuant hereto, shall be deemed to constitute the Investors as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Investors are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated herein.

q. Unless the context otherwise requires, (i) all references to Sections, Schedules or Exhibits are to Sections, Schedules or Exhibits contained in or attached to this Agreement, (ii) words in the singular or plural include the singular and plural, and pronouns stated in either the masculine, the feminine or neuter gender shall include the masculine, feminine and neuter, and (ii) the use of the word “including” in this Agreement shall be by way of example rather than limitation.

[Remainder of page left intentionally blank]

[Signature page follows]

 

16


IN WITNESS WHEREOF, the undersigned Investors and the Company have caused this Amended and Restated Registration Rights Agreement to be duly executed as of the date first written above.

 

COMPANY:
ENDOLOGIX, INC. , a Delaware corporation
By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer

[Signature Page to Registration Rights Agreement]


IN WITNESS WHEREOF, the undersigned Investors and the Company have caused this Amended and Restated Registration Rights Agreement to be duly executed as of the date first written above.

 

INVESTORS:
DEERFIELD PRIVATE DESIGN FUND IV, L.P.
By: Deerfield Mgmt IV, L.P., General Partner
By: J.E. Flynn Capital IV, LLC, General Partner
By:  

/s/ David J. Clark

Name:   David J. Clark
Title:   Authorized Signatory
DEERFIELD PRIVATE DESIGN FUND III, L.P.
By: Deerfield Mgmt III, L.P., General Partner
By: J.E. Flynn Capital III, LLC, General Partner
By:  

/s/ David J. Clark

Name:   David J. Clark
Title:   Authorized Signatory
DEERFIELD PARTNERS, L.P.
By: Deerfield Mgmt, L.P., General Partner
By: J.E. Flynn Capital, LLC, General Partner
By:  

/s/ David J. Clark

Name:   David J. Clark
Title:   Authorized Signatory

 

18

Exhibit 10.4

AMENDED AND RESTATED

GUARANTY AND SECURITY AGREEMENT

dated as of August 9, 2018

by and among

Endologix, Inc.,

as Borrower,

the other Grantors and Guarantors party hereto from time to time

and

Deerfield Private Design Fund IV, L.P.,

as agent for itself and the other Secured Parties


AMENDED AND RESTATED

GUARANTY AND SECURITY AGREEMENT

This AMENDED AND RESTATED GUARANTY AND SECURITY AGREEMENT (this “ Agreement ”), dated as of August 9, 2018, by and among Endologix, Inc., a Delaware corporation (“ Borrower ”), CVD/RMS Acquisition Corp., a Delaware corporation (“ CVD ”), Nellix, Inc., a Delaware corporation (“ Nellix ”), TriVascular Technologies, Inc., a Delaware corporation (“ TriVascular Technologies ”), TriVascular, Inc., a California corporation (“ TriVascular California ”), Endologix Canada, LLC, a Delaware limited liability company (f/k/a TriVascular Canada, LLC) (“ Endologix Canada ”), TriVascular Sales LLC, a Texas limited liability company (“ Sales ”), RMS/Endologix Sideways Merger Corp., a Delaware corporation (“ Sideways ”), each other Person who becomes a party hereto pursuant to Section  8.15 (together with the Borrower, CVD, Nellix, TriVascular Technologies, TriVascular California, Endologix Canada, Sales and Sideways, the “ Grantors ” and each, a “ Grantor ”), each other Person signatory hereto as a “Guarantor” (as defined below) and Deerfield Private Design Fund IV, L.P., as Agent.

RECITALS

A. Borrower, CVD, Nellix, TriVascular Technologies, TriVascular California and Sales previously entered into a certain Guaranty and Security Agreement dated April 3, 2017 (as amended, restated, supplemented and otherwise modified from time to time prior to the effectiveness of the Facility Agreement (defined below) (including by that certain Joinder to Guaranty and Security Agreement, Facility Agreement and Intercreditor Agreement, dated as of May 18, 2017, by and among Sales, Sideways and Agent (the “ Joinder ”)), the “ Existing Guaranty and Security Agreement ”). Pursuant to the Existing Guaranty and Security Agreement and the Joinder, Borrower, the other Grantors and the other Guarantors, among other things, previously (i) agreed to jointly and severally guaranty the Guaranteed Obligations (as defined therein) and (ii) pledged and granted unto Agent, for the benefit of the Secured Parties, security interests and liens in the collateral described therein, in order to secure the Secured Obligations (as defined therein).

B. The Existing Guaranty and Security Agreement and the Joinder were entered into in connection with the Prior Facility Agreement (as defined in the Facility Agreement). The Prior Facility Agreement, among other things and in addition to the other Loan Documents (as defined in the Prior Facility Agreement, such documents are referred to herein as the “ Existing Loan Documents ”), prior to the time of the effectiveness of the Facility Agreement, evidences and governs certain Loans and Obligations (as both such terms are defined in the Prior Facility Agreement).

C. Borrower, the other Loan Parties, the Agent and the Lenders have agreed to certain amendments, restatements, amendments and restatements, supplements and other modifications to the terms of the Existing Loan Documents, and in connection therewith such Persons have amended and restated the Prior Facility Agreement in its entirety pursuant to the terms of the Facility Agreement.

D. Each Grantor will (a) derive substantial direct and indirect benefits from (i) the making of the extensions of credit under the Facility Agreement, (ii) the Agent and the Lenders permitting the Grantors party thereto to enter into the ABL Credit Facility and ABL Debt Documents on the terms and conditions set forth in the Facility Agreement and other Loan Documents and (iii) the amendments, restatements, amendments and restatements, supplements and modifications to the Existing Loan Documents and (b) continue to derive substantial direct and indirect benefits from any prior making of extensions of credit under the Prior Facility Agreement (which continue as Loans and Obligations under the Facility Agreement and the other Loan Documents).


E. As a further condition to the Agent and the Lenders agreeing to the amendments, restatements, amendments and restatements, supplements and modifications to the Existing Loan Documents, and continuing to extend the Loans and other Obligations under the Existing Loan Documents, as amended, restated, amended and restated, supplemented and otherwise modified pursuant to the Loan Documents, the Agent and Lenders are requiring that the parties hereto enter into this Agreement, and thereby amend and restate the Existing Guaranty and Security Agreement in its entirety as set forth herein.

F. In consideration of the premises and to induce the Lenders and Agent to enter into the Facility Agreement and the Loan Documents (including the amendment, restatements, amendments and restatements, supplements and modifications to the Existing Loan Documents) and to permit the Grantors party thereto to enter into the ABL Credit Facility and ABL Debt Documents on the terms and conditions set forth in the Facility Agreement and other Loan Documents and to induce the Lenders to continue to allow their respective extensions of credit and Loans to Borrower under the Facility Agreement to remain outstanding and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto do hereby amend and restate the Existing Guaranty and Security Agreement in its entirety as set forth herein, and hereby covenant and agree, as follows:

SECTION 1 DEFINITIONS.

1.1 Unless otherwise defined herein, terms defined in the Facility Agreement and used herein shall have the meanings given to them in the Facility Agreement, and the following terms are used herein as defined in the UCC (such meanings to be equally applicable to both the singular and plural forms of the terms defined): “accounts”, “certificated security”, “chattel paper”, “commercial tort claims”, “commodity contract”, “deposit accounts”, “documents”, “electronic chattel paper”, “equipment”, “farm products”, “fixture”, “general intangibles”, “goods”, “health care insurance receivables”, “instruments”, “inventory”, “leases”, “letter-of-credit rights”, “money”, “payment intangibles”, “product”, “record”, “securities account”, “security”, “supporting obligations”, and “tangible chattel paper”. It is hereby agreed that the term “instrument” shall not include checks received in the ordinary course of business.

1.2 Whenever used in this Agreement, the Exhibits or the Schedules attached hereto, unless the context otherwise requires, the following terms have the following meanings:

Agreement ” has the meaning set forth in the preamble of this Agreement.

Collateral ” means all of Grantors’ assets, whether now owned or hereafter created, acquired or arising, including without limitation, all of Grantors’ right, title and interest in and to the following:

(a) all goods, accounts (including health care insurance receivables), equipment, inventory, contract rights or rights to payment of money, leases, license agreements and other licenses, franchise agreements, general intangibles, commercial tort claims (including any Identified Claims), documents, instruments (including any promissory notes) (and any distribution of property made on, in respect of or in exchange for such instruments from time to time), chattel paper (whether tangible chattel paper or electronic), cash, Cash Equivalents, deposit accounts, Intellectual Property, Intellectual Property Licenses, securities accounts, fixtures, letter-of-credit rights (whether or not the letter of credit is evidenced by a writing), securities, all other Pledged Collateral and Pledged Investment Property (including any distribution of property made on, in respect of or in exchange for such Pledged Collateral and/or Pledged Investment Property from time to time) and all supporting obligations related to any of the foregoing, and financial assets, wherever located;

 

2


(b) all books and records relating to any of the foregoing;

(c) all property of any Grantor held by any Secured Party, including all property of every description, in the custody of or in transit to such Secured Party for any purpose, including safekeeping, collection or pledge, for the account of such Grantor or as to which such Grantor may have any right or power, including but not limited to cash; and

(d) any and all claims, rights and interests in any of the above and all substitutions for, additions, attachments, accessories, accessions and improvements to and replacements, products, Proceeds and insurance Proceeds of any or all of the foregoing.

Where the context requires, terms relating to the Collateral or any part thereof, when used in relation to a Grantor, shall refer to such Grantor’s Collateral or the relevant part thereof. Notwithstanding the foregoing, “Collateral” shall not include Excluded Property; provided , however , that if and when any assets cease to be Excluded Property, the term “Collateral” shall include such assets and a Lien on and security interest in such assets shall be deemed granted therein pursuant to Section  3.1 hereof.

Copyrights ” means any and all rights in any works of authorship, including (A) copyrights and moral rights, (B) copyright registrations and recordings thereof and all applications in connection therewith including those listed on Schedule 8 , (C) income, license fees, royalties, damages, and payments now and hereafter due or payable under and with respect thereto, including payments under all licenses entered into in connection therewith and damages and payments for past, present, or future infringements thereof, (D) the right to sue for past, present, and future infringements thereof, and (E) all of each Grantor’s rights corresponding thereto throughout the world.

Facility Agreement ” means the Amended and Restated Facility Agreement of even date herewith by and among Borrower, the other Loan Parties party thereto from time to time, Agent and Lenders, as amended, supplemented, restated or otherwise modified from time to time.

Fraudulent Transfer Laws ” has the meaning set forth in Section  2.6 hereof.

Grantor ” has the meaning set forth in the preamble of this Agreement.

Guaranteed Obligations ” means all obligations of each Guarantor under the Loan Documents and all other Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and the Exit Payment).

Guarantors ” means Borrower, CVD, Nellix, TriVascular Technologies, TriVascular, Endologix Canada, Sales, Sideways and any other Person who becomes a party to this Agreement pursuant to Section  8.15 .

Identified Claims ” means the commercial tort claims described on Schedule 5 , as such schedule shall be supplemented from time to time in accordance with the terms and conditions of this Agreement.

Intellectual Property License ” means, with respect to any Grantor (the “ Specified Party ”), (A) any licenses or other similar rights provided to the Specified Party in or with respect to Intellectual Property owned or controlled by any other Person, and (B) any licenses or other similar rights provided to any other Person in or with respect to Intellectual Property owned or controlled by the Specified Party, in each case, including (1) any software license agreements, (2) the license agreements listed on Schedule 9 , and (3) the right to use any of the licenses or other similar rights described in this definition in connection with the enforcement of any Secured Party’s rights under the Loan Documents.

 

3


Issuers ” means the collective reference to each issuer of Pledged Collateral and Pledged Investment Property.

Paid in Full ” and “ Payment in Full ” each means (a) with respect to Guaranteed Obligations, all Guaranteed Obligations have been repaid in full in cash (other than (i) any unasserted contingent indemnification obligations and (ii) any Obligations under any Warrant and the Registration Rights Agreement that are not due or payable at the time when all such other Guaranteed Obligations are repaid in full in cash) and (b) with respect to Secured Obligations, all Secured Obligations have been repaid in full in cash (other than (i) any unasserted contingent indemnification obligations and (ii) any Obligations under any Warrant and the Registration Rights Agreement that are not due or payable at the time when all such other Secured Obligations are repaid in full in cash); provided that the foregoing shall be subject to any reinstatement pursuant to (and the other provisions set forth in) Section  8.18 hereof.

Patents ” means patents and patent applications, including (A) the patents and patent applications listed on Schedule 10 , (B) all continuations, divisionals, continuations-in-part, re-examinations, reissues, and renewals thereof and improvements thereon, (C) all income, royalties, damages and payments now and hereafter due or payable under and with respect thereto, including payments under all licenses entered into in connection therewith and damages and payments for past, present, or future infringements thereof, (D) the right to sue for past, present, and future infringements thereof, and (E) all of each Grantor’s rights corresponding thereto throughout the world.

Pledged Collateral ” means, collectively, the Pledged Equity and the Pledged Debt Instruments.

Pledged Debt Instruments ” means all right, title and interest of any Grantor in instruments evidencing any Indebtedness owed to such Grantor or other obligations owed to such Grantor, including all Indebtedness described on Schedule 1 , issued by the obligors named therein. Pledged Debt Instruments excludes any Excluded Property.

Pledged Equity ” means collectively, all Pledged Interests and Pledged Stock.

Pledged Interests ” shall mean, with respect to each limited liability company, partnership or other organization listed on Schedule 1 , (i) the Stock in such limited liability company, partnership or other organization owned by a Grantor and listed on Schedule 1 , and the certificates, if any, representing such interests and any interest of such Grantor, as applicable, on the books and records of such limited liability company, partnership or other organization or on the books and records of any securities intermediary pertaining to such interests, (ii) the Stock of any other Person whose Stock is at any time hereafter issued or granted to, or held by any Grantor, and (iii) all dividends, distributions, cash, warrants, rights, options, instruments, securities and other property or Proceeds from time to time received, receivable or otherwise distributed in respect of or in exchange for any or all interests set forth in the preceding clauses (i) and (ii). Pledged Interests excludes any Excluded Property.

Pledged Investment Property ” means the collective reference to (i) all “investment property” as such term is defined in Section 9-102(a)(49) of the UCC and (ii) all “financial assets” as such term is defined in Section 8-102(a)(9) of the UCC, other than any Pledged Equity or Pledged Debt Instruments. Pledged Investment Property excludes any Excluded Property.

Pledged Stock ” shall mean, with respect to each corporation listed on Schedule 1 , the Stock of such corporation owned by a Grantor and listed on Schedule 1 , and the certificates, if any, representing such shares and any interest of such Grantor, as applicable, in the entries on the books of the issuer of such shares or on the books of any securities intermediary pertaining to such shares and the Stock of any other Person whose Stock is at any time hereafter issued to or granted to or held by any Grantor, and all dividends,

 

4


distributions, cash, warrants, rights, options, instruments, securities and other property or Proceeds from time to time received, receivable or otherwise distributed in respect of or in exchange for any or all of such shares. Pledged Stock excludes any Excluded Property.

Proceeds ” means all “proceeds” as such term is defined in Section 9-102(a)(64) of the UCC and, in any event, shall include all dividends or other income from the Pledged Investment Property, collections thereon or distributions or payments with respect thereto.

Receivable ” means any right to payment for goods sold or leased or for services rendered, whether or not such right is evidenced by an instrument or chattel paper and whether or not it has been earned by performance (including any accounts).

Secured Obligations ” means the Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and the Exit Payment).

Trademarks ” means any and all trademarks, trade names, registered trademarks, trademark applications, service marks, registered service marks and service mark applications, including (A) the trade names, registered trademarks, trademark applications, registered service marks and service mark applications listed on Schedule 11 , (B) all renewals thereof, (C) all income, royalties, damages and payments now and hereafter due or payable under and with respect thereto, including payments under all licenses entered into in connection therewith and damages and payments for past or future infringements or dilutions thereof, (D) the right to sue for past, present and future infringements and dilutions thereof, (E) the goodwill of each Grantor’s business symbolized by the foregoing or connected therewith, and (F) all of each Grantor’s rights corresponding thereto throughout the world.

Transferred Guarantor ” has the meaning set forth in Section 8.16(c).

SECTION 2 GUARANTY.

2.1 Guaranty .

(a) To induce Lenders to make the Loans and each other Secured Party to make credit available to or for the benefit of one or more Grantors and for the applicable Secured Parties to enter into the Loan Documents, each of the Guarantors hereby, jointly and severally, absolutely, unconditionally and irrevocably, as a primary obligor and not only a surety, guarantees to Agent and the other Secured Parties and their respective successors and permitted assigns, the prompt and complete payment and performance by Borrower and each other Grantor, as applicable, of the Guaranteed Obligations when due (whether at the stated maturity or earlier, by reason of acceleration, any mandatory prepayment required pursuant to the terms of the Financing Agreement or otherwise).

(b) This guaranty includes all present and future Guaranteed Obligations including any under transactions continuing, compromising, extending, increasing, modifying, releasing, or renewing the Guaranteed Obligations, changing the interest rate, payment terms, or other terms and conditions thereof, or creating new or additional Guaranteed Obligations after prior Guaranteed Obligations have been satisfied in whole or in part. To the maximum extent permitted by law, each Guarantor hereby waives any right to revoke this guaranty as to future Guaranteed Obligations. If such a revocation is effective notwithstanding the foregoing waiver, each Guarantor acknowledges and agrees that (i) no such revocation shall be effective until written notice thereof has been received by Agent, (ii) no such revocation shall apply to any Guaranteed Obligations in existence on the date of receipt by Agent of such written notice (including any subsequent continuation, extension, or renewal thereof, or change in the interest rate, payment terms, or other terms and conditions thereof), (iii) no such revocation shall apply to any Guaranteed Obligations

 

5


made or created after such date to the extent made or created pursuant to a legally binding commitment of any Lender in existence on the date of such revocation, (iv) no payment by any Guarantor, Borrower, or from any other source, prior to the date of Agent’s receipt of written notice of such revocation shall reduce the maximum obligation of such Guarantor hereunder, and (v) any payment by Borrower or from any source other than such Guarantor subsequent to the date of such revocation shall first be applied to that portion of the Guaranteed Obligations as to which the revocation is effective and which are not, therefore, Guaranteed hereunder, and to the extent so applied shall not reduce the maximum obligation of such Guarantor hereunder. This guaranty shall be binding upon each Guarantor, its successors and assigns and inure to the benefit of and be enforceable by Agent (for the benefit of the Secured Parties) and its successors, transferees, or assigns.

(c) The guaranty contained in this Section  2 is a guaranty of payment and not of collection and shall remain in full force and effect until all of the Guaranteed Obligations shall have been Paid in Full.

(d) No payment made by Borrower, any of the Guarantors, any other guarantor or any other Person, or received or collected by Agent or the other Secured Parties from Borrower, any of the Guarantors, any other guarantor or any other Person, as applicable, by virtue of any action or proceeding or any set-off or appropriation or application at any time or from time to time in reduction of or in payment of the Guaranteed Obligations shall be deemed to modify, reduce, release or otherwise affect the Liability of any Guarantor hereunder which Guarantor shall, notwithstanding any such payment (other than any payment received or collected from such Guarantor in respect of the Guaranteed Obligations), remain liable for the Guaranteed Obligations until the Guaranteed Obligations are Paid in Full.

2.2 No Subrogation . Notwithstanding any payment made by any Guarantor hereunder or any set-off or application of funds of any Guarantor by Agent or any other Secured Party, no Guarantor shall be entitled to be subrogated to any of the rights of Agent or any other Secured Party against Borrower or any Guarantor or any collateral security or guaranty or right of offset held by Agent or any other Secured Party for the payment of the Guaranteed Obligations, nor shall any Guarantor seek or be entitled to seek any contribution or reimbursement from Borrower or any Guarantor in respect of payments made by such Guarantor hereunder, until all of the Guaranteed Obligations are Paid in Full. If any amount shall be paid to any Guarantor on account of such subrogation rights at any time when all of the Guaranteed Obligations shall not have been Paid in Full, such amount shall be held by such Guarantor in trust for Agent and the other Secured Parties, segregated from other funds of such Guarantor, and shall, forthwith upon receipt by such Guarantor, be turned over to Agent (for the benefit of the Secured Parties) in the exact form received by such Guarantor (duly indorsed by such Guarantor to Agent), to be applied against the Guaranteed Obligations, whether matured or unmatured, as set forth in Section  6.5 hereof.

2.3 Amendments, etc. with respect to the Guaranteed Obligations .

(a) Each Guarantor shall remain obligated hereunder, without any reservation of rights against any Guarantor and without notice to or further assent by any Guarantor, notwithstanding the fact that: (i) any demand for payment of any of the Guaranteed Obligations made by Agent or the other Secured Parties may be rescinded by Agent or the other Secured Parties and any of the Guaranteed Obligations continued, (ii) the Guaranteed Obligations, or the Liability of any other Person upon or for any part thereof, or any collateral security or guaranty therefor or right of offset with respect thereto, may, from time to time, in whole or in part, be renewed, extended, amended, modified, accelerated, compromised, waived, surrendered or released by Agent or any other Secured Party, or (iii) any of the Facility Agreement or the other Loan Documents or any other documents executed and delivered in connection therewith may be amended, modified, supplemented or terminated, in whole or in part, as Agent or any other Secured Party may deem advisable from time to time. Agent and the other Secured Parties shall have no obligation

 

6


to protect, secure, perfect or insure any Lien at any time held by them as security for the Guaranteed Obligations or for the guaranty contained in this Section  2 or any property subject thereto.

(b) Agent or any other Secured Party may, from time to time, in their reasonable discretion and without notice to or demand upon the Guarantors (or any of them), take any or all of the following actions, without discharging or otherwise affecting the Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and the Exit Payment) of any Guarantor hereunder and without incurring any Liability hereunder: (i) receive, take and hold additional Collateral to secure any of the Guaranteed Obligations or any obligation hereunder, (ii) retain or obtain the primary or secondary obligation of any obligor or obligors, in addition to the undersigned, with respect to any of the Guaranteed Obligations, (iii) extend or renew any of the Guaranteed Obligations for one or more periods (whether or not longer than the original period), alter or exchange any of the Guaranteed Obligations or otherwise modify, amend, supplement or otherwise change any Guaranteed Obligation or any Loan Document (including accelerating or otherwise changing the time of payment), or release or compromise any obligation of any of the undersigned hereunder or any obligation of any nature of any other obligor with respect to any of the Guaranteed Obligations or otherwise in connection with the Loan Documents, (iv) release any guaranty or right of offset or their security interest in, or surrender, release or permit any substitution or exchange for, all or any part of any personal property securing any of the Guaranteed Obligations or any obligation hereunder, or extend or renew for one or more periods (whether or not longer than the original period) or release, compromise, alter or exchange any obligations of any nature of any obligor with respect to any such personal property, (v) resort to the undersigned (or any of them) for payment of any of the Guaranteed Obligations when due, whether or not Agent or any other Secured Party shall have resorted to any personal property securing any of the Guaranteed Obligations or any obligation hereunder or shall have proceeded against any other of the undersigned or any other obligor primarily or secondarily obligated with respect to any of the Guaranteed Obligations, (vi) apply to the Guaranteed Obligations any sums by whomever paid or however realized to any Guaranteed Obligation as set forth in Section  6.5 hereof, (vii) refund at any time any payment received by any Secured Party in respect of any Guaranteed Obligation, (viii) sell, exchange, enforce, waive, substitute, liquidate, terminate, release, abandon, fail to perfect, subordinate, accept, substitute, surrender, exchange, affect, impair or otherwise alter or release any Collateral for any Guaranteed Obligation or any other guaranty therefor in any manner, (ix) otherwise deal in any manner with Borrower or any other Guarantor, maker or endorser of any Guaranteed Obligation or any part thereof, and/or (x) settle, release, compromise, collect or otherwise liquidate the Guaranteed Obligations.

2.4 Waivers . To the extent permitted by Applicable Law, each Guarantor hereby unconditionally and irrevocably waives any and all notice of the creation, renewal, extension or accrual of any of the Guaranteed Obligations and notice of or proof of reliance by Agent or any other Secured Party upon the guaranty contained in this Section  2 or acceptance of the guaranty contained in this Section  2 . The Guaranteed Obligations, and any of them, shall conclusively be deemed to have been created, contracted or incurred, or renewed, extended, amended or waived, in reliance upon the guaranty contained in this Section  2 , and all dealings between Borrower and any of the Guarantors, on the one hand, and Agent and the other Secured Parties, on the other hand, likewise shall be conclusively presumed to have been had or consummated in reliance upon the guaranty contained in this Section  2 . To the extent permitted by Applicable Law, each Guarantor hereby unconditionally and irrevocably waives and agrees not to assert any claim, defense, setoff or counterclaim based on (i) diligence, promptness, presentment, protest, requirements for any demand for payment or performance and protest and notice of protest, requirements for any notice of default, dishonor or nonpayment and all other notices whatsoever to or upon Borrower or any of the Guarantors with respect to the Guaranteed Obligations or any part thereof, (ii) notice of the existence or creation or non-payment of all or any of the Guaranteed Obligations, (iii) all diligence in collection or protection of or realization upon any Guaranteed Obligations or any security for or guaranty of any Guaranteed Obligations, (iv) any presentment, demand, protest or further notice or other formality or

 

7


requirements of any kind with respect to any Guaranteed Obligation (including any accrued but unpaid interest thereon) becoming immediately due and payable, and (v) any defense arising by reason of a disability or other defense of Borrower or any Guarantor. No obligation of any Guarantor hereunder shall be discharged other than by Payment in Full in cash of the Guaranteed Obligations. Each Guarantor further waives any right such Guarantor may have under any Applicable Law to require any Secured Party to seek recourse first against Borrower or any other Person, or to realize upon any Collateral for any of the Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and the Exit Payment), as a condition precedent to enforcing such Guarantor’s Liability and obligations under this Guaranty.

2.5 Payments . Each Guarantor hereby guaranties that payments hereunder will be paid to Agent and the other Secured Parties without set-off or counterclaim in Dollars in accordance with Section  2.4 of the Facility Agreement.

2.6 Limitation of Guaranty . Any term or provision of this Agreement or any other Loan Document to the contrary notwithstanding, the maximum aggregate amount for which any Guarantor shall be liable hereunder shall not exceed the maximum amount for which such Guarantor can be liable without rendering this Agreement or any other Loan Document, as it relates to such Guarantor, subject to avoidance under Applicable Laws relating to fraudulent conveyance or fraudulent transfer (including the Uniform Fraudulent Conveyance Act, the Uniform Fraudulent Transfer Act and Section 548 of title 11 of the United States Code or any applicable provisions of comparable Applicable Laws) (collectively, “ Fraudulent Transfer Laws ”). Any analysis of the provisions of this Agreement for purposes of Fraudulent Transfer Laws shall take into account the right of contribution established in Section  2.7 hereof and, for purposes of such analysis, give effect to any discharge of intercompany debt as a result of any payment made under this Agreement.

2.7 Contribution . To the extent that any Guarantor shall be required hereunder to pay any portion of any Guaranteed Obligation exceeding the greater of (i) the amount of the value actually received by such Guarantor and its Subsidiaries from the Loans and other Obligations and (ii) the amount such Guarantor would otherwise have paid if such Guarantor had paid the aggregate amount of the Guaranteed Obligations (excluding the amount thereof repaid by the Borrower and any other Guarantor that is a direct or indirect parent entity of the Borrower) in the same proportion as such Guarantor’s net worth on the date enforcement is sought hereunder bears to the aggregate net worth of all the Guarantors on such date, then such Guarantor shall be reimbursed by such other Guarantors for the amount of such excess, pro rata, based on the respective net worth of such other Guarantors on such date.

2.8 Guaranty Absolute and Unconditional . Each Guarantor hereby waives and agrees not to assert any defense, whether arising in connection with or in respect of any of the following or otherwise, and hereby agrees that its obligations under this Agreement are irrevocable, absolute and unconditional and shall not be discharged as a result of or otherwise affected by any of the following (which may not be pleaded and evidence of which may not be introduced in any proceeding with respect to this Agreement) to the fullest extent not prohibited by Applicable Law:

(a) the invalidity or unenforceability of any obligation of Borrower or any Guarantor under any Loan Document or any other agreement or instrument relating thereto (including any amendment, consent or waiver thereto), or any security for, or other guaranty of, any Guaranteed Obligation or any part thereof, or the lack of perfection or continuing perfection or failure of priority of any security for the Guaranteed Obligations or any part thereof;

(b) the absence of (i) any attempt to collect any Guaranteed Obligation or any part thereof from Borrower or any Guarantor or other action to enforce the same or (ii) any action to enforce any Loan Document or any Lien thereunder;

 

8


(c) the failure by any Person to take any steps to perfect and maintain any Lien on, or to preserve any rights with respect to, any Collateral;

(d) any workout, insolvency, bankruptcy proceeding, reorganization, arrangement, liquidation or dissolution by or against Borrower, any Guarantor or any of Borrower’s Subsidiaries or any procedure, agreement, order, stipulation, election, action or omission thereunder, including any discharge or disallowance of, or bar or stay against collecting, any Guaranteed Obligation (or any interest thereon) in or as a result of any such proceeding;

(e) any foreclosure, whether or not through judicial sale, and any other sale or other disposition of any Collateral or any election following the occurrence of an Event of Default by any Secured Party to proceed separately against any Collateral in accordance with such Secured Party’s rights under any Applicable Law; or

(f) any other defense, setoff, counterclaim or any other circumstance that might otherwise constitute a legal or equitable discharge of Borrower, any Guarantor or any Subsidiary of Borrower, in each case other than the Payment in Full in cash of the Guaranteed Obligations.

2.9 Reliance . Each Guarantor hereby assumes responsibility for keeping itself informed of the financial condition of Borrower, each Guarantor and any other guarantor, maker or endorser of any Guaranteed Obligation or any part thereof, and of all other circumstances bearing upon the risk of nonpayment of any Guaranteed Obligation or any part thereof that diligent inquiry would reveal, and each Guarantor hereby agrees that no Secured Party shall have any duty to advise any Guarantor of information known to it regarding such condition or any such circumstances. In the event any Secured Party, in its sole discretion, undertakes at any time or from time to time to provide any such information to any Guarantor, such Secured Party shall be under no obligation to (i) undertake any investigation not a part of its regular business routine, (ii) disclose any information that such Secured Party, pursuant to accepted or reasonable commercial finance or banking practices, wishes to maintain confidential, or (iii) make any future disclosures of such information or any other information to any Guarantor.

SECTION 3 GRANT OF SECURITY INTEREST .

3.1 Grant . Each Grantor hereby collaterally assigns and grants to Agent, for the benefit of the Secured Parties, a Lien on and security interest in all of its Collateral, as collateral security for the prompt and complete payment and performance when due (whether at the stated maturity, by acceleration or otherwise) of the Secured Obligations. Notwithstanding the foregoing, no Lien or security interest is hereby granted on any Excluded Property. Each Grantor hereby represents and warrants as of (i) the Agreement Date, (ii) the date of each amendment, consent or waiver of this Agreement or the Facility Agreement executed by any Grantor and (iii) solely with respect to any new Grantor that joins this Agreement after the Agreement Date, on the date such new Grantor joins this Agreement, that the Excluded Property, when taken as a whole, is not material to the business operations or financial condition of the Grantors, taken as a whole.

SECTION 4 REPRESENTATIONS AND WARRANTIES.

To induce Agent and Lenders to enter into the Facility Agreement and to induce Lenders to make extensions of credit to Borrower thereunder, each Grantor jointly and severally hereby represents and warrants to Agent and the other Secured Parties that the following are true, correct and complete, in each case to the extent and in the manner set forth herein, on the Agreement Date and as of (i) the Agreement Date, (ii) the date of each amendment, consent or waiver of this Agreement or the Facility Agreement

 

9


executed by any Grantor and (iii) solely with respect to any new Grantor that joins this Agreement after the Agreement Date, on the date such new Grantor joins this Agreement:

4.1 Title; No Other Liens . Except for the Lien granted to Agent pursuant to this Agreement and other Permitted Liens, such Grantor owns, or has rights or the power to transfer rights in, each item of the Collateral free and clear of any and all Liens of others. Such Grantor (i) is the record and beneficial owner of the Collateral pledged by it hereunder constituting instruments or certificates and (ii) has rights in or the power to transfer each other item of Collateral in which a Lien is granted by it hereunder, free and clear of any other Lien (other than Permitted Liens). No effective financing statement or other public notice with respect to all or any part of the Collateral is on file or of record in any public office, except filings evidencing Permitted Liens.

4.2 Perfected Liens . The security interests granted in the Collateral pursuant to this Agreement (i) will constitute valid and continuing perfected security interests in all of the Grantors’ rights in the Collateral in favor of Agent as collateral security for the Secured Obligations, enforceable in accordance with the terms hereof, except as such enforceability may be limited by applicable insolvency, bankruptcy, reorganization, moratorium or other similar laws affecting creditors’ rights generally, upon (A) in the case of all Collateral in which a security interest may be perfected by filing a financing statement under the UCC, completion of the filings and other actions specified on Schedule 2 (which filings and other documents referred to on Schedule 2 have been delivered to Agent in completed form), (B) with respect to any deposit account or securities account, the execution of Control Agreements, (C) in the case of all Copyrights, Trademarks and Patents for which UCC filings are insufficient, all appropriate filings having been made with the applicable Intellectual Property registries, including but not limited to the United States Copyright Office or the United States Patent and Trademark Office, as applicable, (D) in the case of letter-of-credit rights that are not supporting obligations of Collateral, the execution of a contractual obligation granting control to Agent over such letter-of-credit rights and (E) in the case of electronic chattel paper with payment or amounts owing thereon in excess of $250,000 in the aggregate, the completion of all steps necessary to grant control to Agent over such electronic chattel paper; and (ii) shall be prior to all other Liens on the Collateral except for Permitted Priority Liens, upon (A) in the case of all Pledged Collateral and Pledged Investment Property, the delivery thereof to Agent (for the benefit of the Secured Parties) of such Pledged Collateral and Pledged Investment Property consisting of instruments and certificates, in each case properly endorsed for transfer to Agent (for the benefit of the Secured Parties) or in blank, (B) in the case of all Pledged Investment Property not in certificated form and deposit accounts, the execution of Control Agreements with respect to such Pledged Investment Property and deposit accounts and (C) in the case of all other instruments and tangible chattel paper that has aggregate payments or amounts owing thereunder in excess of $250,000 in the aggregate that are not Pledged Collateral or Pledged Investment Property, the delivery thereof to Agent (for the benefit of the Secured Parties) of such instruments and tangible chattel paper. Except as set forth in this Section  4.2 or as otherwise provided in the Facility Agreement, all actions by each Grantor necessary or otherwise requested by Agent to perfect the Liens granted hereunder on the Collateral have been duly taken.

4.3 Grantor Information . On the Agreement Date, Schedule 3 sets forth (i) each Grantor’s and each Guarantor’s jurisdiction of organization, (ii) the location of each Grantor’s and each Guarantor’s chief executive office, (iii) each Grantor’s and each Guarantor’s exact legal name as it appears on its organizational documents and (iv) each Grantor’s organizational identification number (to the extent a Grantor or Guarantor is organized in a jurisdiction which assigns such numbers) and federal employer identification number.

4.4 Collateral Locations . On the Agreement Date, Schedule 4 sets forth (i) each place of business of each Grantor and each Guarantor (including its chief executive office), (ii) all locations where any material portion of inventory and equipment owned by each Grantor is kept (other than

 

10


(A) inventory or equipment that is otherwise in transit or out for repair, refurbishment or processing in the Ordinary Course of Business, (B) de minimis amounts of inventory with sales personnel and at medical facilities or (C) otherwise disposed of in a transaction permitted by the Facility Agreement), (iii) all locations where each Grantor’s books and records concerning the Collateral are kept and (iv) whether each such Collateral location and place of business (including each Grantor’s chief executive office) is owned or leased (and if leased, specifies the complete name and notice address of each lessor) or otherwise occupied (and if otherwise occupied, describes the nature of such occupation). On the Agreement Date, no Collateral (other than (A) inventory or equipment that is otherwise in transit or out for repair, refurbishment or processing in the Ordinary Course of Business, (B) de minimis amounts of inventory with sales personnel and at medical facilities or (C) otherwise disposed of in a transaction permitted by the Facility Agreement) is located outside the United States or in the possession of any lessor, bailee, warehouseman or consignee, except as indicated on Schedule 4 .

4.5 Certain Property . None of the Collateral constitutes, or is the Proceeds of, (i) farm products, (ii) as-extracted collateral, (iii) timber to be cut or (iv) vessels, aircraft or any other personal property subject to any certificate of title or other registration statute of the United States, any State or other jurisdiction, except for motor vehicles owned by the Grantors and used by employees of the Grantors in the Ordinary Course of Business.

4.6 Pledged Collateral and Pledged Investment Property .

(a) The Pledged Collateral pledged by each Grantor hereunder is listed on Schedule  1 and, with respect to the Pledged Equity, constitutes all the issued and outstanding equity interests of each Issuer owned by such Grantor as set forth on Schedule 1 . None of the Pledged Equity is a certificated security or otherwise represented or evidenced by any certificate other than the Pledged Equity in Nellix, Inc., CVD/RMS Acquisition Corp., RMS/Endologix Sideways Merger Corp., TriVascular, Inc. and TriVascular Technologies, Inc, and no foreign Issuer has certificated its Stock nor is any Grantor (or any representative, agent or any other Related Party of any Grantor) holding any certificate of Stock of any foreign Issuer.

(b) All of the Pledged Equity has been duly authorized and validly issued and, in the case of shares of capital stock and membership interests, is fully paid and nonassessable.

(c) Each of the Pledged Equity, Pledged Debt Instruments and Pledged Investment Property constitutes the legal, valid and binding obligation of the obligor with respect thereto, enforceable in accordance with its terms, except as such enforceability may be limited by applicable insolvency, bankruptcy, reorganization, moratorium or other similar laws affecting creditors’ rights generally.

(d) Schedule 1A lists all Pledged Investment Property owned by each Grantor. Each Grantor is the record and beneficial owner of, and has good and valid title to, the Pledged Investment Property pledged by it hereunder, free of any and all Liens or options in favor of, or claims of, any other Person, except Permitted Liens.

(e) All Pledged Collateral (other than uncertificated Pledged Equity) and all Pledged Investment Property consisting of instruments and certificates has been delivered to Agent (for the benefit of the Secured Parties) in accordance with Section  5.1 hereof to the extent required thereby.

(f) Upon the occurrence and during the continuance of an Event of Default, Agent shall be entitled to exercise all of the rights of the Grantor granting the security interest in any Pledged Equity, and a transferee or assignee of such Pledged Equity shall become a holder of such Pledged Equity to the same extent as such Grantor and be entitled to participate in the management of the Issuer of such

 

11


Pledged Equity, and, subject to Agent’s exercise of remedies pursuant to Section  6 hereof, upon the transfer of the entire interest of such Grantor, such Grantor shall, by operation of law, cease to be a holder of such Pledged Equity.

4.7 Receivables .

(a) No amount over $250,000 in the aggregate payable to a Grantor under or in connection with any account is evidenced by any instrument or chattel paper which, to the extent required hereunder, has not been delivered to Agent (for the benefit of the Secured Parties), properly endorsed for transfer.

(b) No obligor on any Receivable in excess of $250,000 in the aggregate is a Governmental Authority, unless any assignment of claims act or law has been complied with for the benefit of Agent.

4.8 Facility Agreement . Each Grantor and each Guarantor makes each of the representations and warranties made by Borrower in Section  3.1 of the Facility Agreement to the extent applicable to it on the date such Grantor or Guarantor becomes a party hereto (which representations and warranties shall be deemed to be re-made (i) as of the date of each amendment, consent or waiver of this Agreement or the Facility Agreement executed by any Grantor and (iii) solely with respect to any new Grantor that joins this Agreement after the Agreement Date, on the date such new Grantor joins this Agreement). Such representations and warranties shall be incorporated herein by this reference as if fully set forth herein.

4.9 Commercial Tort Claims . The only commercial tort claims that any Grantor is asserting or intends to assert in which the potential recovery exceeds $250,000 in the aggregate are those listed on Schedule 5 , as may be supplemented from time to time by delivery thereof to Agent, which sets forth such information separately for each Grantor.

4.10 Enforcement . No material permit, notice to or filing with any Governmental Authority or any other Person or any material consent from any Person is required for the exercise by Agent of its rights (including voting rights) provided for in this Agreement or the enforcement of remedies in respect of the Collateral pursuant to this Agreement, including the transfer of any Collateral, except (i) as may be required in connection with the disposition of any portion of the Pledged Collateral by laws affecting the offering and sale of securities generally, (ii) any approvals that may be required to be obtained from any bailees or landlords to collect the Collateral, (iii) permits or consents which have been obtained and notices or filings which have been made, and (iv) any requirements set forth in any assignment of claims act and laws.

4.11 Accounts . Set forth on Schedule 6 (as such Schedule may be expressly updated from time to time to reflect changes resulting from transactions permitted under the Loan Documents) is a listing of all of Grantors’ and their Subsidiaries’ deposit accounts and securities accounts, including, with respect to each bank or securities intermediary (a) the name and address of such Person, and (b) the account numbers of the deposit accounts or securities accounts maintained with such Person.

4.12 Real Estate . Schedule 7 sets forth all Real Estate owned by any of the Grantors as of the Agreement Date.

4.13 Intellectual Property . As of the Agreement Date: (i)  Schedule 8 provides a complete and correct list of all registered Copyrights owned by any Grantor and all other Copyrights owned by any Grantor and material to the conduct of the business of any Grantor; (ii)  Schedule 9 provides a

 

12


complete and correct list of all Intellectual Property Licenses (other than license agreements for commercially available off-the-shelf software that is generally available to the public which have been licensed to a Grantor pursuant to end-user licenses) entered into by any Grantor that are material to the business of such Grantor, including any Intellectual Property Licenses that relate to Intellectual Property that is incorporated in any Inventory, software, or other product marketed, sold, licensed, or distributed by such Grantor; (iii)  Schedule 10 provides a complete and correct list of all Patents owned by any Grantor; and (iv)  Schedule 11 provides a complete and correct list of all registered Trademarks owned by any Grantor and all other Trademarks owned by any Grantor and material to the conduct of the business of any Grantor.

SECTION 5 COVENANTS .

Each Grantor covenants and agrees with Agent that, from and after the date of this Agreement until the Secured Obligations and the Guaranteed Obligations, as applicable, shall have been Paid in Full:

5.1 Delivery of Instruments, Certificated Securities and Chattel Paper .

(a) Such Grantor shall (i) deliver to Agent (for the benefit of the Secured Parties), in suitable form for transfer and in form and substance reasonably satisfactory to Agent, (A) all certificated Pledged Equity, together with stock powers or other suitable instruments for transfer, executed in blank, (B) all Pledged Debt Instruments and (C) all certificates and instruments evidencing Pledged Investment Property and (ii) to the extent required by Section  5.1(k) of the Facility Agreement, maintain all other Pledged Investment Property in an account that is subject to a Control Agreement. No foreign Issuer shall issue certificates of its Stock unless the foregoing provisions of this paragraph are complied with.

(b) If any amount in excess of $250,000 in the aggregate payable under or in connection with any Collateral owned by such Grantor shall be or become evidenced by an instrument or tangible chattel paper other than such instrument delivered in accordance with this Section  5.1 and in the possession of Agent, such Grantor shall notify Agent, and upon the written request of Agent, mark all such instruments and tangible chattel paper with the following legend: “This writing and the obligations evidenced or secured hereby are subject to the security interest of Deerfield Private Design Fund IV, L.P., as Agent” and, at the written request of Agent, shall promptly deliver such instrument or tangible chattel paper to Agent (for the benefit of the Secured Parties), duly indorsed in a manner reasonably satisfactory to Agent.

(c) Such Grantor shall not grant “control” (within the meaning of such term under Article 9-106 of the UCC) over any Pledged Collateral or Pledged Investment Property to any Person other than Agent (for the benefit of the Secured Parties) or, to the extent permitted under (and subject to the terms of) the Intercreditor Agreement and subject to the terms of Section  8.21 , the ABL Agent.

(d) If such Grantor is or becomes the beneficiary of a letter of credit that is (i) not a supporting obligation of any Collateral and (ii) in excess of $250,000 in the aggregate, such Grantor shall promptly, and in any event within five (5) Business Days after becoming a beneficiary, notify Agent thereof and shall use commercially reasonable efforts to enter into a contractual arrangement reasonably requested by the Agent with respect to the letter-of-credit rights under such letter of credit. Such contractual arrangement shall assign such letter-of-credit rights to Agent and such assignment shall be sufficient to grant control for the purposes of Section 9-107 of the UCC (or any similar section under any equivalent UCC). Such contractual arrangement shall also direct all payments thereunder to an account subject to a Control Agreement. The provisions of the contractual arrangement shall be in form and substance reasonably satisfactory to Agent.

 

13


(e) If any amount in excess of $250,000 in the aggregate payable under or in connection with any Collateral owned by such Grantor shall be or become evidenced by electronic chattel paper, such Grantor shall take all commercially reasonable steps necessary to grant Agent control of all such electronic chattel paper for the purposes of Section 9-105 of the UCC (or any similar section under any equivalent UCC) and all “transferable records” as defined in each of the Uniform Electronic Transactions Act and the Electronic Signatures in Global and National Commerce Act.

(f) In the event that an Event of Default shall have occurred and be continuing, upon the request of Agent, any instrument, certificated security or chattel paper not theretofore delivered to Agent and at such time being held by such Grantor shall be promptly (and, in any event, within five (5) Business Days) delivered to Agent (for the benefit of the Secured Parties), duly indorsed in a manner satisfactory to Agent, to be held as Collateral pursuant to this Agreement and in the case of electronic chattel paper, such Grantor shall cause Agent to have control thereof within the meaning set forth in Section 9-105 of the UCC. In the event that an Event of Default shall have occurred and be continuing, Agent shall have the right, at any time in its discretion and without notice to any Grantor, to (i) transfer to or to register in its name or in the name of its nominees any Pledged Collateral or any Pledged Investment Property and (ii) exchange any certificate or instrument representing or evidencing any Pledged Collateral or any Pledged Investment Property for certificates or instruments of smaller or larger denominations.

5.2 Maintenance of Perfected Security Interest; Further Documentation .

(a) Such Grantor shall maintain the security interests created by this Agreement as perfected security interests (to the extent such security interests can be perfected by the filing of UCC financing statements (and, with respect to commercial tort claims, to the extent any commercial tort claims are sufficiently identified herein)) having at least the priority described in Section  4.2 hereof, and shall defend such security interests against the claims and demands of all Persons whomsoever (other than holders of Permitted Liens).

(b) Subject to Section  5.1(q) of the Facility Agreement, such Grantor will furnish to Agent from time to time statements and schedules further identifying and describing the assets and property of such Grantor and such other reports in connection therewith as Agent may reasonably request, all in reasonable detail in form and substance reasonably satisfactory to Agent.

(c) At any time and from time to time, upon the written request of Agent, and at Grantor’s sole expense, such Grantor will, for the purpose of obtaining or preserving the full benefits of this Agreement and of the rights and powers herein granted, promptly and duly execute and deliver, and have recorded, such further instruments and documents and take such further actions as Agent may reasonably request, including (i) filing or authorizing the filing of any financing or continuation statements under the UCC (or other similar laws) in effect in any jurisdiction with respect to the security interests created hereby; (ii) in the case of Pledged Collateral, Pledged Investment Property and any other relevant Collateral, taking any such reasonably requested actions necessary to enable Agent (on behalf of the Secured Parties) to obtain “control” (within the meaning of the applicable UCC) with respect to such Pledged Collateral, Pledged Investment Property and other Collateral to the extent required to be pledged hereunder; (iii) if requested by Agent, delivering, to the extent permitted by Applicable Law, any original motor vehicle certificates of title for vehicles in the aggregate with a fair market value in excess of $250,000 received by such Grantor from the applicable secretary of state or other Governmental Authority after information reflecting Agent’s security interest has been recorded in such motor vehicles to the extent required to be pledged thereunder; (iv) use of commercially reasonable efforts to secure all approvals necessary or appropriate for the assignment to or the benefit of Agent of any contractual obligation held by such Grantor and to enforce the security interests hereunder; and (v) subject to Section  5.1(k) of the Facility Agreement, executing and delivering any Control Agreements with respect to deposit, securities, commodity and

 

14


similar accounts.

(d) Such Grantor shall not use or permit any Collateral to be used unlawfully or in violation of any provision of any Loan Document or any policy of insurance covering the Collateral.

5.3 Changes in Locations, Name, etc . Such Grantor shall not, except upon 10 Business Days’ prior written notice to Agent (or such lesser notice as Agent may agree to in writing in its sole discretion) and delivery to Agent of (i) all additional financing statements and other documents reasonably requested by Agent as to the validity, perfection and priority of the security interests provided for herein and (ii) if applicable, a written supplement to Schedule 4 showing any additional location at which inventory or equipment shall be kept (other than (A) inventory or equipment that is otherwise in transit or out for repair, refurbishment or processing in the Ordinary Course of Business, (B) de minimis amounts of inventory with sales personnel and at medical facilities or (C) otherwise disposed of in a transaction permitted by the Facility Agreement):

(a) permit any of the inventory or equipment comprising Collateral to be kept at a location subject to the possession or control of any warehouse, consignee, bailee, or any of the Grantors’ agents or processors other than those listed on Schedule 4 , other than (i) the inventory or equipment that is otherwise in transit or out for repair, refurbishment or processing in the Ordinary Course of Business, (ii) de minimis amounts of inventory with sales personnel and at medical facilities or (iii) otherwise disposed of in a transaction permitted by the Facility Agreement;

(b) change its jurisdiction of organization or the location of its chief executive office from that specified on Schedule 3 or in any subsequent notice delivered pursuant to this Section  5.3 ; or

(c) change its name, organizational identification number (if any), identity or corporate structure, except as permitted by Section  5.2(i) of the Facility Agreement upon prior written notice thereof to the Agent.

5.4 Notices . Such Grantor will advise Agent in writing promptly, in reasonable detail, of:

(a) any Lien (other than Permitted Liens) on any of the Collateral; and

(b) the occurrence of any other event which would reasonably be expected to have a Material Adverse Effect on the Collateral or on the Liens created hereby.

5.5 Pledged Investment Property and Pledged Collateral .

(a) If such Grantor shall become entitled to receive or shall receive any certificate, option or rights in respect of the Stock of any Issuer, whether in addition to, in substitution of, as a conversion of, or in exchange for, any of the Pledged Equity, or otherwise in respect thereof, such Stock shall be Pledged Equity (to the extent consistent with the percentage of such Grantor’s Stock in such Issuer pledged hereunder, as set forth on Schedule 1 ) and such Grantor shall accept the same as the agent of Agent, hold the same in trust for Agent (for the benefit of the Secured Parties) and deliver the same forthwith to Agent (for the benefit of the Secured Parties) in the exact form received, duly indorsed by such Grantor to Agent (for the benefit of the Secured Parties), if required by Agent, together with an undated instrument of transfer covering such certificate duly executed in blank by such Grantor and with, if Agent so request, signature guarantied, to be held by Agent (for the benefit of the Secured Parties), subject to the terms hereof, as additional Collateral for the Secured Obligations.

 

15


(b) Upon the occurrence and during the continuance of an Event of Default and the request of Agent, (i) any sums paid upon or in respect of the Pledged Collateral or Pledged Investment Property upon the liquidation or dissolution of any Issuer shall be paid over to Agent (for the benefit of the Secured Parties) to be held by it hereunder as additional Collateral for the Secured Obligations, and (ii) in case any distribution of capital shall be made on or in respect of the Pledged Collateral, or any property shall be distributed upon or with respect to the Pledged Collateral, pursuant to the recapitalization or reclassification of the capital of any Issuer or pursuant to the reorganization thereof, the property so distributed shall, unless otherwise subject to a perfected Lien in favor of Agent, be delivered to Agent (for the benefit of the Secured Parties) to be held by it hereunder as additional Collateral for the Secured Obligations. Upon the occurrence and during the continuance of an Event of Default, if any sums of money or property so paid or distributed in respect of the Pledged Investment Property shall be received by a Grantor, such Grantor shall, at the request of Agent and until such money or property is paid or delivered to the applicable Secured Parties, hold such money or property in trust for Agent (for the benefit of the Secured Parties), segregated from other funds of such Grantor, as additional Collateral for the Secured Obligations.

(c) Without the prior written consent of Agent, no Grantor will (i) vote to enable, or take any other action, to permit any Issuer to issue any Stock of any nature or to issue any other securities or interests convertible into or granting the right to purchase or exchange for any Stock of any nature of any Issuer, except, in each case, as permitted by the Facility Agreement, (ii) sell, assign, transfer, exchange, or otherwise dispose of, or grant any option with respect to, the Pledged Investment Property or Proceeds thereof other than any such action which is permitted by the Facility Agreement, (iii) create, incur or permit to exist any Lien or option in favor of, or any claim of any Person with respect to, any of the Pledged Investment Property or Proceeds thereof, or any interest therein, except for Permitted Liens, or (iv) enter into any agreement or undertaking restricting the right or ability of such Grantor or Agent to sell, assign or transfer any of the Pledged Investment Property or Proceeds thereof, except with respect to Permitted Liens and any such action which is permitted by the Facility Agreement.

(d) In the case of each Grantor which is an Issuer, such Issuer agrees that (i) it will be bound by the terms of this Agreement relating to the Pledged Equity issued by it and will comply with such terms insofar as such terms are applicable to it, (ii) it will notify Agent promptly in writing of the occurrence of any of the events described in Sections 5.5(a) and 5.5(b) hereof with respect to the Pledged Equity issued by it and (iii) the terms of Sections 6.3(c) and 6.7 hereof shall apply to such Grantor with respect to all actions that may be required of it pursuant to Section  6.3(c) or 6.7 hereof regarding the Pledged Equity issued by it.

5.6 Receivables . Other than in the Ordinary Course of Business consistent with its past practice, such Grantor will not (i) grant any extension of the time of payment of any Receivable, (ii) compromise or settle any Receivable for less than the full amount thereof, (iii) release, wholly or partially, any Person liable for the payment of any Receivable, (iv) allow any credit or discount whatsoever on any Receivable or (v) amend, supplement or modify any Receivable in any manner that would reasonably be expected to adversely affect the value thereof, in each case, unless taking the foregoing actions would not reasonably be expected, individually or in the aggregate, to cause a Material Adverse Effect.

5.7 Intellectual Property . Except as permitted by the Facility Agreement, or except, in each case, where the failure to do so could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, provided that no such Material Adverse Effect qualifier should apply to Section  5.7(h) hereof:

(a) Upon the request of Agent, in order to facilitate filings with the United States Patent and Trademark Office and the United States Copyright Office, each Grantor shall execute and

 

16


deliver to Agent one or more Copyright Security Agreements, Trademark Security Agreements, or Patent Security Agreements to further evidence Agent’s Lien on such Grantor’s Patents, Trademarks, or Copyrights, and the General Intangibles of such Grantor relating thereto or represented thereby.

(b) Such Grantor (either itself or through licensees) will (i) continue to use each Trademark (owned by such Grantor), in order to maintain such Trademark in full force and effect free from any claim of abandonment for non-use, (ii) maintain as in the past the quality of products and services offered under such Trademark, (iii) use, and cause its licensees and sublicensees to use, such Trademark with the appropriate notice of registration and all other notices and legends required by Applicable Law, (iv) not adopt or use any mark which is confusingly similar or a colorable imitation of such Trademark unless Agent shall obtain a perfected security interest in such Trademark pursuant to this Agreement and (v) not (and not permit any licensee or sublicensee thereof to) do any act or omit to do any act whereby such Trademark (or any goodwill associated therewith) may become destroyed, harmed, invalidated or impaired in any way.

(c) Each Grantor (either itself or through licensees) will not do any act, or omit to do any act, whereby as a result of such act or omission, any Patent owned by such Grantor may become unenforceable, invalidated, forfeited, abandoned or dedicated to the public, will employ, and cause its licensees and sublicensees to employ, each such Patent with the appropriate notice of registration and all other notices and legends required by Applicable Law, and will take commercially reasonable steps to establish and preserve the Patents in any patentable invention under Applicable Law.

(d) Each Grantor (either itself or through licensees) (i) will employ, and cause its licensees and sublicensees to employ, each Copyright owned by such Grantor with the appropriate notice of registration and all other notices and legends required by Applicable Law, and (ii) will not (and will not permit any licensee or sublicensee thereof to) do any act or omit to do any act whereby such Copyrights may become invalidated or otherwise impaired, and (iii) will not (either itself or through licensees or sublicensees) do any act whereby any such Copyrights may fall into the public domain.

(e) Each Grantor (either itself or through licensees or sublicensees) will not (and will not permit any licensee or sublicensee thereof to) do any act or omit to do any act whereby any trade secret may become unenforceable under any Applicable Law and each Grantor shall take reasonable steps to maintain the confidentiality of, and otherwise protect and enforce its rights in, the Intellectual Property that is necessary in or material to the conduct of such Grantor’s business, including, as applicable (A) protecting the secrecy and confidentiality of its confidential information and trade secrets by having and enforcing a policy requiring all current employees, consultants, licensees, vendors and contractors with access to such information to execute appropriate confidentiality agreements; (B) taking actions reasonably necessary to ensure that no trade secret falls into the public domain due to any action of any Grantor; and (C) protecting the secrecy and confidentiality of the source code of all software programs and applications of which it is the owner or licensee by having and enforcing a policy requiring any licensees (or sublicensees) of such source code to enter into license agreements with commercially reasonable use and non-disclosure restrictions.

(f) Such Grantor (either itself or through licensees or sublicensees) will not do any act that infringes, misappropriates, dilutes, violates or otherwise impairs the Intellectual Property or intellectual property rights of any other Person.

(g) Such Grantor will notify Agent promptly if it knows, or has reason to know, that any application or registration relating to any Intellectual Property owned by such Grantor may become unenforceable, invalidated, forfeited, abandoned or dedicated to the public, or of any determination or development (including the institution of, or any such determination or development in, any proceeding in

 

17


the United States Patent and Trademark Office, the United States Copyright Office or any court or tribunal in any country) regarding such Grantor’s ownership of, or the validity of, any such Intellectual Property or such Grantor’s right to register the same or to own and maintain the same.

(h) At the time of delivery of any Perfection Certificate required by Section  5.1(t) of the Facility Agreement, each Grantor will notify Agent of applications filed for the registration of any Intellectual Property with the United States Patent and Trademark Office, the United States Copyright Office or any similar office or agency in any other country or any political subdivision thereof. Upon the request of Agent, within five (5) Business Days, such Grantor shall execute and deliver, and have recorded, any and all agreements, instruments, documents, and papers as Agent may request to evidence Agent’s security interest in any Intellectual Property owned by such Grantor, including any Copyright, Patent or Trademark and the goodwill and general intangibles of such Grantor relating thereto or represented thereby.

(i) Such Grantor will take all actions that are necessary or reasonably requested by Agent to maintain and pursue each application (and to obtain the relevant registration or recordation) and to maintain each registration and recordation of all Intellectual Property owned by it.

(j) In the event that any Intellectual Property owned by a Grantor is, to its knowledge, infringed upon or misappropriated or diluted by a third party, such Grantor shall, subject to Section 5.1(q) of the Facility Agreement, (i) take such actions as such Grantor shall reasonably deem appropriate under the circumstances to protect such Intellectual Property and (ii) promptly notify Agent after it learns thereof and sue for infringement, misappropriation or dilution, to seek injunctive relief where appropriate and to recover any and all damages for such infringement, misappropriation or dilution.

(k) Each Grantor shall require all employees, consultants, and contractors of such Grantor who are involved in the creation or development of any Intellectual Property for such Grantor to sign agreements that presently assigned all Intellectual Property created or developed for the Grantor to such Grantor, and obligate such employee, consulting or contractor to hold all confidential information of the Grantor (or of any other Person and held by the Grantor) in confidence.

(l) Grantors acknowledge and agree that no Secured Party shall have any duties with respect to any Intellectual Property or Intellectual Property Licenses of any Grantor. Without limiting the generality of this Section  5.7(l) , Grantors acknowledge and agree that no Secured Party shall be under any obligation to take any steps necessary to preserve rights in the Collateral consisting of Intellectual Property or Intellectual Property Licenses against any other Person, but any Secured Party may do so at its option from and after the occurrence and during the continuance of an Event of Default, and all expenses incurred in connection therewith (including reasonable fees and expenses of attorneys and other professionals) shall be for the sole account of Borrower and the other Grantors.

5.8 [ Reserved ].

5.9 Other Matters.

(a) Each Grantor authorizes Agent and its Affiliates directors, partners, officers, employees, agents, counsel and advisors to, at any time and from time to time, file or record financing statements, continuation statements, amendments thereto, and other filing or recording documents or instruments with respect to any Collateral in such forms and in such offices as Agent or such other Person reasonably determines appropriate to perfect, or continue or maintain perfection of, the security interests of Agent under this Agreement, and such statements, amendments, documents, and instruments may describe the Collateral covered thereby as “all assets of the debtor” of each Grantor, or words of similar effect and may contain any other information required pursuant to the UCC for the sufficiency of filing office

 

18


acceptance of any financing statement, continuation statement or amendment, and each Grantor agrees to furnish any such information to Agent promptly upon Agent’s reasonable request. Any such financing statement, continuation statement or amendment may be signed by Agent on behalf of any Grantor and may be filed at any time in any jurisdiction. A copy of this Agreement shall be sufficient as a financing statement or other filing or recording document or instrument for filing or recording in any jurisdiction. Such Grantor also hereby ratifies its authorization for Agent to have filed any initial financing statement or amendment thereto under the UCC (or other similar laws) in effect in any jurisdiction if filed prior to the date hereof. To the extent permitted by law, each Grantor hereby (i) waives any right under the UCC or any other Applicable Law to receive notice and/or copies of any filed or recorded financing statements, amendments thereto, continuations thereof or termination statements and (ii) releases and excuses each Secured Party from any obligation under the UCC or any other Applicable Law to provide notice or a copy of any such filed or recorded documents. As this Agreement constitutes an amendment and restatement of the Existing Guaranty and Security Agreement, the parties to this Agreement do hereby acknowledge and agree that those financing statements currently on record naming the applicable Grantors as “Debtor” and the Agent as “Secured Party”, shall continue in full force and effect (as amended, if applicable) and shall continue to perfect the security interests and Liens granted under the Existing Guaranty and Security Agreement and reaffirmed, ratified and re-granted under this Agreement.

(b) Each Grantor shall, at any time and from time and to time, take such steps as the Agent may reasonably request for Agent to insure the continued perfection and priority of Agent’s security interest in any of the Collateral and of the preservation of its rights therein.

(c) If any Grantor shall at any time, acquire a commercial tort claim as set forth in Section  4.9 hereof, such Grantor shall promptly notify Agent thereof in writing and supplement Schedule 5 , therein providing a reasonable description and summary thereof, and upon delivery thereof to Agent, such Grantor shall be deemed to thereby grant to Agent (and such Grantor hereby grants to Agent) a Lien in and to such commercial tort claim and all Proceeds thereof, all upon the terms of and governed by this Agreement, and such Grantor shall execute and deliver to Agent, in each case in form and substance reasonably satisfactory to Agent, any document, and take all other action, deemed by Agent to be reasonably necessary or appropriate for Agent to obtain, for the benefit of the Secured Parties, a perfected security interest in all such commercial tort claims. Any supplement to Schedule 5 delivered pursuant to this Section  5.9(c) shall, after the receipt thereof by Agent, become part of Schedule 5 for all purposes hereunder other than in respect of representations and warranties made prior to the date of such receipt.

5.10 Facility Agreement . Each of the Grantors covenants that it will, and, if necessary, will cause or enable Borrower to, fully comply with each of the covenants and other agreements set forth in the Facility Agreement.

5.11 Agent May Purchase Insurance . If a Grantor at any time or times hereafter shall fail to obtain, maintain or provide to Agent evidence of any of the policies of insurance or other items required under Section  5.1(e) of the Facility Agreement or to pay any premium relating thereto, then Agent, without waiving or releasing any obligation or default by such Grantor hereunder, may (but shall be under no obligation to) obtain and maintain such policies of insurance and pay such premiums and take such other actions with respect thereto as Agent deems advisable upon notice to such Grantor. Such insurance, if obtained by Agent, may, but need not, protect such Grantor’s interests or pay any claim made by or against such Grantor with respect to the Collateral. Such insurance may be more expensive than the cost of insurance such Grantor may be able to obtain on its own and may be cancelled only upon such Grantor providing evidence that it has obtained the insurance as required above. All sums disbursed by Agent in connection with any such actions shall constitute Secured Obligations and Guaranteed Obligations payable upon demand.

 

19


5.12 Further Assurances .

(a) Each Grantor agrees that from time to time, at its own expense, such Grantor will promptly execute and deliver all further instruments and documents, and take all further action, that Agent may reasonably request, in order to perfect and protect the security interest and Lien granted hereby, to create, perfect or protect the security interest and Lien purported to be granted hereby or to enable Agent to exercise and enforce its rights and remedies hereunder with respect to any of the Collateral.

(b) Grantor acknowledges that it is not authorized to file any financing statement or amendment or termination statement with respect to any financing statement filed in connection with this Agreement, the other Loan Documents or the Existing Loan Documents without the prior written consent of Agent, subject to such Grantor’s rights under Section 9-509(d)(2) of the UCC.

SECTION 6 REMEDIAL PROVISIONS.

6.1 Certain Matters Relating to Receivables . Subject to, in each case, the terms of the Intercreditor Agreement (to the extent applicable):

(a) At any time and from time to time after the occurrence and during the continuance of an Event of Default, Agent shall have the right to make test verifications of the Receivables in any manner and through any medium that it reasonably considers advisable, and each Grantor shall furnish all such assistance and information as Agent may reasonably require in connection with such test verifications. At any time and from time to time after the occurrence and during the continuance of an Event of Default, upon request of the Agent and at the expense of the relevant Grantor, such Grantor shall cause independent public accountants or others satisfactory to Agent to furnish to Agent reports showing reconciliations, agings and test verifications of, and trial balances for, the Receivables.

(b) If requested by Agent at any time after the occurrence and during the continuance of an Event of Default, any payments of Receivables, when collected by any Grantor, (i) shall be forthwith (and, in any event, within two (2) Business Days) deposited by such Grantor in the exact form received, duly indorsed by such Grantor to Agent (for the benefit of the Secured Parties) and upon notice to such Grantor, in a collateral account maintained under the sole dominion and control of Agent, subject to withdrawal by Agent as provided in Section  6.4 hereof, and (ii) until so turned over, shall be held by such Grantor in trust for Agent (for the benefit of the Secured Parties), segregated from other funds of such Grantor. Each such deposit of Proceeds of Receivables shall be accompanied by a report identifying in reasonable detail the nature and source of the payments included in the deposit.

(c) At any time and from time to time after the occurrence and during the continuance of an Event of Default, at the request of Agent, each Grantor shall deliver to Agent all original and other documents evidencing, and relating to, the agreements and transactions which gave rise to the Receivables, including all original orders, invoices and shipping receipts and notify account debtors that the accounts or general intangibles that are Collateral have been collaterally assigned to Agent and that payments in respect thereof shall be made directly to Agent.

(d) Each Grantor hereby irrevocably authorizes and empowers Agent, in Agent’s sole discretion, at any time after the occurrence and during the continuance of an Event of Default, without notice to such Grantor: (i) to limit or terminate the ability of a Grantor to collect its Receivables or any thereof; to assert, either directly or on behalf of such Grantor, any claim such Grantor may from time to time have against account debtors and to otherwise enforce such Grantor’s rights against such account debtors; (ii) to receive and collect any and all damages, awards and other monies resulting therefrom and to apply the same to the Secured Obligations as set forth in Section  6.5 hereof; and (iii) in its own name or in the

 

20


name of others, to communicate with account debtors to verify with them to Agent’s reasonable satisfaction the existence, amount and terms of any account or amounts due under any general intangible that is Collateral.

6.2 Communications with Obligors; Grantors Remain Liable .

(a) Agent in its own name or in the name of others may at any time after the occurrence and during the continuance of an Event of Default communicate with obligors under the Receivables to verify with them to Agent’s satisfaction the existence, amount and terms of any Receivables

(b) Subject to the terms of the Intercreditor Agreement (to the extent applicable), upon the request of Agent at any time after the occurrence and during the continuance of an Event of Default, each Grantor shall notify obligors on the Receivables that the Receivables have been assigned to Agent and that payments in respect thereof shall be made directly to Agent.

(c) Anything herein to the contrary notwithstanding, each Grantor shall remain liable in respect of each of the Receivables to observe and perform all the conditions and obligations to be observed and performed by it thereunder, all in accordance with the terms of any agreement giving rise thereto. No Secured Party shall have any obligation or Liability under any Receivable (or any agreement giving rise thereto) by reason of or arising out of any Loan Document or the receipt by Agent or any other Secured Party of any payment relating thereto, nor shall any Secured Party be obligated in any manner to perform any of the obligations of any Grantor under or pursuant to any Receivable (or any agreement giving rise thereto), to make any payment, to make any inquiry as to the nature or the sufficiency of any payment received by it or as to the sufficiency of any performance by any party thereunder, to present or file any claim, to take any action to enforce any performance or to collect the payment of any amounts which may have been assigned to it or to which it may be entitled at any time or times.

6.3 Pledged Investment Property and Pledged Collateral .

(a) Unless an Event of Default shall have occurred and be continuing and until Agent has notified Borrower otherwise, each Grantor shall be permitted to receive all cash dividends and distributions paid in respect of the Pledged Collateral and all payments made in respect of the Pledged Investment Property, to the extent permitted in the Facility Agreement, and to exercise all voting and other rights with respect to the Pledged Collateral and Pledged Investment Property; provided , that no vote shall be cast or other right exercised or action taken that could be reasonably likely to materially impair the Collateral or which would be inconsistent with or result in any violation of any provision of the Facility Agreement, this Agreement or any other Loan Document.

(b) If an Event of Default shall occur and be continuing: (i) Agent shall have the right to receive any and all cash dividends and distributions, payments or other Proceeds paid in respect of the Pledged Collateral and Pledged Investment Property and make application thereof to the Secured Obligations as set forth in Section  6.5 hereof, (ii) Agent shall have the right to cause any or all of the Pledged Collateral and Pledged Investment Property to be registered in the name of Agent or its nominee and (iii) Agent or its nominee may exercise (x) all voting, consent, corporate and other rights pertaining to such Pledged Collateral and Pledged Investment Property at any meeting of shareholders, partners or members, as the case may be, of the relevant Issuer or Issuers or otherwise (or by written consent) and (y) any and all rights of conversion, exchange and subscription and any other rights, privileges or options pertaining to such Pledged Collateral and Pledged Investment Property as if it were the absolute owner thereof (including the right to exchange at its discretion any and all of the Pledged Collateral and Pledged Investment Property upon the merger, amalgamation, consolidation, reorganization, recapitalization or other fundamental change in the corporate or other structure of any Issuer, or upon the exercise by any

 

21


Grantor or Agent of any right, privilege or option pertaining to such Pledged Collateral and Pledged Investment Property, and in connection therewith, the right to deposit and deliver any and all of the Pledged Collateral and Pledged Investment Property with any committee, depositary, transfer agent, registrar or other designated agency upon such terms and conditions as Agent may determine), all without Liability other than to the extent such Liability is a result of its own willful misconduct or gross negligence as determined by a court of competent jurisdiction in a final non-appealable order or to account for property actually received by it, but Agent shall have no duty to any Grantor to exercise any such right, privilege or option and shall not be responsible for any failure to do so or delay in so doing.

(c) Each Grantor hereby expressly and irrevocably authorizes and instructs, without any further instructions from such Grantor, each Issuer of the Pledged Collateral and Pledged Investment Property pledged by such Grantor hereunder to (i) comply with any instruction received by it from Agent in writing that (x) states that an Event of Default has occurred and is continuing and (y) is otherwise in accordance with the terms of this Agreement, and each Grantor agrees that each Issuer shall be fully protected in so complying and (ii) unless otherwise permitted under the Loan Documents, pay any dividends, distributions or other payments with respect to the Pledged Collateral and Pledged Investment Property directly to Agent.

(d) In order to permit Agent to exercise the voting and other consensual rights that it is entitled to exercise pursuant hereto and to receive all dividends and other distributions that it is entitled to receive hereunder, (i) during the existence of an Event of Default, each Grantor shall promptly execute and deliver (or cause to be executed and delivered) to Agent all such proxies, dividend payment orders and other instruments as Agent may from time to time reasonably request and (ii) without limiting the effect of clause (i) above, such Grantor hereby grants to Agent an irrevocable proxy to vote all or any part of the Pledged Collateral and the Pledged Investment Property and to exercise all other rights, powers, privileges and remedies to which a holder of the Pledged Collateral or the Pledged Investment Property, as applicable, would be entitled (including giving or withholding written consents of shareholders, partners or members, as the case may be, calling special meetings of shareholders, partners or members, as the case may be, and voting at such meetings), which proxy shall be effective, automatically and without the necessity of any action (including any transfer of any Pledged Collateral or Pledged Investment Property on the record books of the Issuer thereof) by any other person (including the Issuer of such Pledged Collateral or Pledged Investment Property, as applicable, or any officer or agent thereof) solely during the continuance of an Event of Default and which proxy shall only terminate upon the Payment in Full in cash of the Secured Obligations or upon an express waiver in writing by Agent and the Required Lenders of the underlying Event of Default in accordance with the terms of the Facility Agreement.

6.4 Proceeds to be Turned Over to Agent . In addition to the rights of Agent specified in Section  6.1 hereof with respect to payments of Receivables, if an Event of Default shall occur and be continuing and Agent has notified Borrower of the Grantors’ obligations under this Section  6.4 , all Proceeds received by any Grantor consisting of cash, checks and other cash equivalent items shall be held by such Grantor in trust for Agent (for the benefit of the Secured Parties), segregated from other funds of such Grantor, and shall, upon written request of Agent, forthwith upon receipt by such Grantor, be turned over to Agent in the exact form received by such Grantor (duly indorsed by such Grantor to Agent, if required). Subject to the terms of the Intercreditor Agreement (if applicable), all Proceeds received by Agent under this Section  6.4 shall be held by Agent in a collateral account maintained under its sole dominion and control. All Proceeds, while held by Agent (for the benefit of the Secured Parties) in any collateral account (or by such Grantor in trust for Agent (for the benefit of the Secured Parties)) established pursuant hereto, shall continue to be held as collateral security for the Secured Obligations and shall not constitute payment thereof until applied as provided in Section  6.5 hereof.

6.5 Application of Proceeds . Agent may apply all or any part of Proceeds from the

 

22


sale of, or other realization upon, all or any part of the Collateral (after deducting all reasonable and documented external attorneys’ and other fees and out-of-pocket costs and expenses of every kind incurred in connection therewith or incidental to the care or safekeeping of any Collateral or in any way relating to the Collateral or the rights of Agent and any other Secured Party hereunder) in payment of the Secured Obligations in such order as the Agent shall determine in its discretion, and may pay any other amount required by any Applicable Law. Any balance of such Proceeds remaining after the Secured Obligations and the Guaranteed Obligations (as applicable) shall have been Paid in Full shall be paid over to the applicable Grantor or to whomsoever may be lawfully entitled to receive the same. The parties hereto understand and agree that the exercise of remedies hereunder with respect to accounts arising under any Third Party Payor program may be subject to Applicable Law.

6.6 UCC and Other Remedies . If an Event of Default shall occur and be continuing, Agent may exercise, in addition to all other rights and remedies granted to them in this Agreement and in any other instrument or agreement securing, evidencing or relating to the Secured Obligations, all rights and remedies of a secured party under the UCC or any other Applicable Law. Without limiting the generality of the foregoing, Agent, without demand of performance or other demand, presentment, protest, advertisement or notice of any kind (except any notice required by law referred to below) to or upon any Grantor or any other Person (all and each of which demands, defenses (other than defense of payment), advertisements and notices are hereby waived), may in such circumstances forthwith collect, receive, appropriate and realize upon the Collateral, or any part thereof, and/or may forthwith sell, lease, assign, give options to purchase, or otherwise dispose of and deliver the Collateral or any part thereof (or contract to do any of the foregoing), in one or more parcels at public or private sale or sales, at any exchange, broker’s board or office of Agent or elsewhere upon such terms and conditions as they may deem advisable and at such prices as it may deem best, for cash or on credit or for future delivery with assumption of any credit risk. Agent shall have the right upon any such public sale or sales, and, to the extent permitted by law, upon any such private sale or sales, to purchase the whole or any part of the Collateral so sold, free of any right or equity of redemption in any Grantor, which right or equity is hereby waived and released. Each Grantor further agrees, at Agent’s request, to assemble the Collateral and make it available to Agent at places which Agent shall reasonably select, whether at such Grantor’s premises or elsewhere in connection with the exercise of Agent’s remedies hereunder. Agent shall apply the net Proceeds of any action taken by it pursuant to this Section  6.6 , after deducting all reasonable documented out-of-pocket costs and expenses of every kind incurred in connection therewith or incidental to the care or safekeeping of any of the Collateral or in any way relating to the Collateral or the rights of Agent hereunder, to the payment in whole or in part of the Secured Obligations, as set forth in Section  6.5 hereof. To the extent permitted by Applicable Law, each Grantor waives all claims, damages and demands it may acquire against Agent arising out of the exercise by them of any rights hereunder. If any notice of a proposed sale or other disposition of Collateral shall be required by law, such notice shall be deemed reasonable and proper if given at least 10 calendar days before such sale or other disposition. Agent shall not be obligated to make any sale of Collateral regardless of notification of sale having been given. Agent may adjourn any public sale from time to time by announcement at the time and place fixed therefor, and such sale may, without further notice, be made at the time and place to which it was so adjourned. Each Grantor agrees that (A) the internet shall constitute a “place” for purposes of Section 9-610(b) of the UCC and (B) to the extent notification of sale shall be required by law, notification by mail of the URL where a sale will occur and the time when a sale will commence at least ten (10) days prior to the sale shall constitute a reasonable notification for purposes of Section 9-611(b) of the UCC. Each Grantor agrees that any sale of Collateral to a licensor pursuant to the terms of a license agreement between such licensor and a Grantor is sufficient to constitute a commercially reasonable sale (including as to method, terms, manner, and time) within the meaning of Section 9-610 of the UCC.

6.7 Private Sale . Each Grantor recognizes that Agent may be unable to effect a public sale of any or all the Pledged Collateral and Pledged Investment Property, by reason of certain prohibitions

 

23


contained in the Securities Act and applicable state or foreign securities laws or otherwise, or may otherwise determine that a public sale is impracticable, not desirable or not commercially reasonable, and, accordingly, and may resort to one or more private sales thereof to a restricted group of purchasers that will be obliged to agree, among other things, to acquire such securities for their own account for investment and not with a view to the distribution or resale thereof. Each Grantor acknowledges and agrees that any such private sale may result in prices and other terms less favorable than if such sale were a public sale and, notwithstanding such circumstances, agrees that any such private sale shall be deemed to have been made in a commercially reasonable manner. Agent shall be under no obligation to delay a sale of any of the Pledged Collateral or Pledged Investment Property for the period of time necessary to permit the Issuer thereof to register such securities or other interests for public sale under the Securities Act, or under applicable state or foreign securities laws, even if such Issuer would agree to do so.

Each Grantor agrees to use its commercially reasonable efforts to do or cause to be done all such other acts as may be necessary to make such sale or sales of all or any portion of the Pledged Collateral and Pledged Investment Property pursuant to this Section  6.7 and Section  6.11 hereof valid and binding and in compliance with Applicable Law. Each Grantor further agrees that a breach of any of the covenants contained herein will cause irreparable injury to Agent and the other Secured Parties, that Agent and the other Secured Parties have no adequate remedy at law in respect of such breach and, as a consequence, that each and every covenant contained herein shall be specifically enforceable against such Grantor (except as such enforceability may be limited by applicable insolvency, bankruptcy, reorganization, moratorium or other similar laws affecting creditors’ rights generally), and such Grantor hereby waives and agrees not to assert any defenses against an action for specific performance of such covenants. Until all of the Secured Obligations and all of the Guaranteed Obligations are Paid in Full, each Grantor postpones until such date any and all rights of contribution or subrogation upon the sale or disposition of all or any portion of the Pledged Collateral and Pledged Investment Property by Agent.

6.8 Deficiency . Each Grantor shall remain liable for any deficiency if the Proceeds of any sale or other disposition of any Collateral are insufficient to Pay in Full the Secured Obligations and the fees and disbursements of any attorneys employed by Agent or any other Secured Party to collect such deficiency.

6.9 Licenses . Solely for the purpose of enabling Agent (for the benefit of the Secured Parties) to exercise rights and remedies following and during the continuation of an Event of Default (including in order to take possession of, collect, receive, assemble, process, appropriate, remove, realize upon, sell, assign, convey, transfer or grant options to purchase any Collateral), each Grantor hereby grants to Agent, for the benefit of the Secured Parties, (i) an irrevocable, nonexclusive license (exercisable without payment of royalty or other compensation to such Grantor) including in such license the right to use, practice, license or sublicense any Intellectual Property now owned or hereafter acquired by such Grantor, and wherever the same may be located, and including in such license access to all media in which any of the licensed items may be recorded or stored and to all computer software and programs used for the compilation or printout thereof, and (ii) an irrevocable license (without payment of rent or other compensation to such Grantor) to use, operate and occupy all Real Estate owned, operated, leased, subleased or otherwise occupied by such Grantor; provided, in each case, that no such licenses shall be granted with respect to any Excluded Property.

6.10 Reserved.

6.11 Disposition of Collateral . Without limiting the generality of the foregoing, to the fullest extent not prohibited by Applicable Law, Agent may, without demand of performance or other demand, presentment, protest, advertisement or notice of any kind (except any notice required by law referred to below) to or upon any Grantor or any other Person (all and each of which demands, defenses,

 

24


advertisements and notices are hereby waived), upon the occurrence and during the continuance of any Event of Default (personally or through its agents or attorneys), (i) enter upon the premises where any Collateral is located, without any obligation to pay rent, through self-help, without judicial process, without first obtaining a final judgment or giving any Grantor or any other Person notice or opportunity for a hearing on Agent’s claim or action, (ii) collect, receive, appropriate and realize upon any Collateral and (iii) sell, assign, convey, transfer, grant option or options to purchase and deliver any Collateral (and enter into contractual obligations to do any of the foregoing), in one or more parcels at public or private sale or sales, at any exchange, broker’s board or office of any Secured Party or elsewhere upon such terms and conditions as it may deem advisable and at such prices as it may deem best, for cash or on credit or for future delivery without assumption of any credit risk. Agent shall have the right, upon any such public sale or sales and, to the extent permitted by the UCC and other Applicable Law, upon any such private sale, to purchase the whole or any part of the Collateral so sold, free of any right or equity of redemption of any Grantor, which right or equity is hereby waived and released.

6.12 Management of the Collateral . Each Grantor further agrees, that, upon the occurrence and during the continuance of any Event of Default and to the fullest extent not prohibited by Applicable Law and, in each case, subject to the terms of the Intercreditor Agreement (if applicable), (i) at Agent’s written request, it shall assemble the Collateral and make it available to Agent at places that Agent shall reasonably select, whether at such Grantor’s premises or elsewhere, (ii) without limiting the foregoing, Agent also has the right to require that each Grantor store and keep any Collateral pending further action by Agent and, while any such Collateral is so stored or kept, provide such guards and maintenance services as shall be necessary to protect the same and to preserve and maintain such Collateral in good condition, (iii) until Agent is able to sell, assign, convey or transfer any Collateral, Agent shall have the right to hold or use such Collateral to the extent that it deems appropriate for the purpose of preserving the Collateral or its value or for any other purpose deemed appropriate by Agent, and (iv) Agent may, if it so elects, seek the appointment of a receiver or keeper to take possession of any Collateral and to enforce any of Agent’s remedies (for the benefit of the Secured Parties), with respect to such appointment without prior notice or hearing as to such appointment. Agent shall not have any obligation to any Grantor to maintain or preserve the rights of any Grantor as against third parties with respect to any Collateral while such Collateral is in the possession of Agent.

6.13 Direct Obligation . Neither Agent nor any other Secured Party shall be required to make any demand upon, or pursue or exhaust any right or remedy against, any Grantor, any other Guarantor, any other Loan Party or any other Person with respect to the payment of the Secured Obligations or the Guaranteed Obligations or to pursue or exhaust any right or remedy with respect to any Collateral therefor or any direct or indirect guaranty thereof. All of the rights and remedies of Agent and any other Secured Party under any Loan Document shall be cumulative, may be exercised individually or concurrently and not exclusive of any other rights or remedies provided by any Applicable Law. To the extent it may lawfully do so, each Grantor absolutely and irrevocably waives and relinquishes the benefit and advantage of, and covenants not to assert against Agent or any other Secured Party, any valuation, stay, appraisement, extension, redemption or similar laws and any and all rights or defenses it may have as a surety, now or hereafter existing, arising out of the exercise by them of any rights hereunder. If any notice of a proposed sale or other disposition of any Collateral shall be required by law, such notice shall be deemed reasonable and proper if given at least ten (10) calendar days before such sale or other disposition.

6.14 Commercially Reasonable . To the extent that any Applicable Law impose duties on Agent to exercise remedies in a commercially reasonable manner, each Grantor acknowledges and agrees that it is not commercially unreasonable for Agent to do any of the following:

(a) fail to incur significant costs, expenses or other Liabilities reasonably deemed as such by Agent to prepare any Collateral for disposition or otherwise to complete raw material or work in

 

25


process into finished goods or other finished products for disposition;

(b) fail to obtain permits, or other consents, for access to any Collateral to sell or for the collection or sale of any Collateral, or, if not required by other Applicable Law, fail to obtain Permits or other consents for the collection or disposition of any Collateral;

(c) fail to exercise remedies against account debtors or other Persons obligated on any Collateral or to remove Liens on any Collateral or to remove any adverse claims against any Collateral;

(d) advertise dispositions of any Collateral through publications or media of general circulation, whether or not such Collateral is of a specialized nature, or to contact other Persons, whether or not in the same business as any Grantor, for expressions of interest in acquiring any such Collateral;

(e) exercise collection remedies against account debtors and other Persons obligated on any Collateral, directly or through the use of collection agencies or other collection specialists, hire one or more professional auctioneers to assist in the disposition of any Collateral, whether or not such Collateral is of a specialized nature, or, to the extent deemed appropriate by Agent, obtain the services of other brokers, investment bankers, consultants and other professionals to assist Agent in the collection or disposition of any Collateral, or utilize Internet sites that provide for the auction of assets of the types included in the Collateral or that have the reasonable capacity of doing so, or that match buyers and sellers of assets to dispose of any Collateral;

(f) dispose of assets in wholesale rather than retail markets;

(g) disclaim disposition warranties, such as title, possession or quiet enjoyment; or

(h) purchase insurance or credit enhancements to insure Agent against risks of loss, collection or disposition of any Collateral or to provide to Agent a guaranteed return from the collection or disposition of any Collateral.

Each Grantor acknowledges that the purpose of this Section  6.14 is to provide a non-exhaustive list of actions or omissions that are commercially reasonable when exercising remedies against any Collateral and that other actions or omissions by any Secured Party shall not be deemed commercially unreasonable solely on account of not being indicated in this Section  6.14 . Without limitation upon the foregoing, nothing contained in this Section  6.14 shall be construed to grant any rights to any Grantor or to impose any duties on Agent or any other Secured Party that would not have been granted or imposed by this Agreement or by Applicable Law in the absence of this Section  6.14 .

SECTION 7 AGENT.

7.1 Agent’s Appointment as Attorney-in-Fact .

(a) Each Grantor hereby irrevocably constitutes and appoints Agent and any Affiliates, directors, partners, officers, employees, agents, counsel and advisors thereof, with full power of substitution, as its true and lawful attorney-in-fact with full power and authority in the place and stead of such Grantor and in the name of such Grantor or in its own name, for the purpose of carrying out the terms of the Loan Documents, to, upon the occurrence and during the continuance of an Event of Default, take any appropriate action and to execute any document or instrument that may be necessary or desirable to accomplish the purposes of the Loan Documents, and, without limiting the generality of the foregoing, each Grantor hereby gives Agent and its Affiliates, directors, partners, officers, employees, agents, counsel and advisors the power and right, on behalf of such Grantor, without notice to or assent by such Grantor, to do

 

26


any of the following when an Event of Default has occurred and is continuing (subject, as applicable, to compliance by Agent with Applicable Law with respect to Accounts arising under any Third Party Payor programs):

(i) in the name of such Grantor, in its own name or otherwise, take possession of and indorse and collect any check, draft, note, acceptance or other instrument for the payment of moneys due under any account or general intangible that is Collateral or with respect to any other Collateral and file any claim or take any other action or proceeding in any court of law or equity or otherwise deemed appropriate by Agent for the purpose of collecting any such moneys due under any account or general intangible that is Collateral or with respect to any other Collateral whenever payable;

(ii) in the case of any Intellectual Property owned by and, in the case of Copyrights, exclusively licensed to such Grantor (to the extent not constituting Excluded Property and to the extent permitted under the applicable Intellectual Property), execute, deliver and have recorded any document that Agent may request in accordance with this Agreement to evidence, effect, publicize or record Agent’s security interest in such Intellectual Property and the goodwill and general intangibles of such Grantor relating thereto or represented thereby;

(iii) pay or discharge taxes and Liens levied or placed on or threatened against any Collateral, effect any repair or pay any insurance called for by the terms of the Facility Agreement (including all or any part of the premiums therefor and the costs thereof);

(iv) execute, in connection with any sale provided for in Section  6.7 or Section  6.11 hereof, any document to effect or otherwise necessary or appropriate in relation to evidence the sale of any Collateral; or

(v) (A) direct any party liable for any payment under any Collateral to make payment of any moneys due or to become due thereunder directly to Agent or as Agent shall direct, (B) ask or demand for, and collect and receive payment of and receipt for, any moneys, claims and other amounts due or to become due at any time in respect of or arising out of any Collateral, (C) sign and indorse any invoice, freight or express bill, bill of lading, storage or warehouse receipt, draft against debtors, assignment, verification, notice and other document in connection with any Collateral, (D) commence and prosecute any suit, action or proceeding at law or in equity in any court of competent jurisdiction to collect any Collateral and to enforce any other right in respect of any Collateral, (E) defend any actions, suits, proceedings, audits, claims, demands, orders or disputes brought against such Grantor with respect to any Collateral, (F) settle, compromise or adjust any such actions, suits, proceedings, audits, claims, demands, orders or disputes that are related to Collateral and, in connection therewith, give such discharges or releases as Agent may deem appropriate, (G) assign any Intellectual Property owned by any Grantor or any Intellectual Property Licenses of any Grantor where such Grantor is the licensor thereunder (to the extent not constituting Excluded Property and to the extent permitted under the applicable Intellectual Property or Intellectual Property License, as applicable) throughout the world on such terms and conditions and in such manner as Agent shall in its sole discretion determine (except, with respect to Trademarks, subject to reasonable quality control in favor of such Grantor), including the execution and filing of any document necessary to effectuate or record such assignment, or (H) generally, sell, assign, convey, transfer or grant a Lien on, make any Contractual Obligation with respect to and otherwise deal with, any Collateral as fully and completely as though Agent were the absolute owner thereof for all purposes and do, at Agent’s option, at any time or from time to time, all acts and things that Agent deems necessary to protect, preserve or realize upon any Collateral

 

27


and the Secured Parties’ security interests therein and to effect the intent of the Loan Documents, all as fully and effectively as such Grantor might do;

(vi) if any Grantor fails to perform or comply with any Contractual Obligation contained herein, then during the existence of an Event of Default, Agent, at its option, but without any obligation so to do, may perform or comply, or otherwise cause performance or compliance, with such Contractual Obligation;

(vii) receive and open all mail addressed to any Grantor and to notify postal authorities to change the address for the delivery of mail to such Grantor to that of Agent; or

(viii) use any Intellectual Property or Intellectual Property Licenses of such Grantor, including but not limited to any labels, Patents, Trademarks, trade names, URLs, domain names, industrial designs, Copyrights, or advertising matter, in preparing for sale, advertising for sale, or selling Inventory or other Collateral and to collect any amounts due under Accounts, contracts or negotiable Collateral of such Grantor.

(b) The expenses of Agent incurred in connection with actions undertaken as provided in this Section  7.1 , together with, during the existence of an Event of Default as set forth in Section  2.7(b) of the Facility Agreement, interest thereon at a rate set forth in Section  2.7(b) of the Facility Agreement, from the date of payment by Agent to the date reimbursed by the relevant Grantor, shall be payable by such Grantor to Agent on written demand by Agent to Borrower.

(c) Each Grantor hereby ratifies all that said attorneys shall lawfully do or cause to be done by virtue of, and in accordance with, this Section  7.1 . All powers, authorizations and agencies contained in this Agreement are coupled with an interest and are irrevocable until this Agreement is terminated and the security interests created hereby are released.

7.2 Authority of Agent. Each Grantor acknowledges that the rights and responsibilities of Agent under this Agreement with respect to any action taken by Agent or the exercise or non-exercise by Agent of any option, voting right, request, judgment or other right or remedy provided for herein or resulting or arising out of this Agreement shall, as between Agent and the other Secured Parties, be governed by the Facility Agreement and by such other agreements with respect thereto as may exist from time to time among them, but, as between Agent and any Grantor, Agent shall be conclusively presumed to be acting as agent for the Secured Parties with full and valid authority so to act or refrain from acting, and no Grantor shall be under any obligation or entitlement to make any inquiry respecting such authority.

7.3 Duty; Obligations and Liabilities .

(a) Agent’s sole duty with respect to the custody, safekeeping and physical preservation of the Collateral in its possession shall be to deal with it in the same manner as Agent deals with similar property for its own account. The powers conferred on Agent hereunder are solely to protect Agent’s interest in the Collateral and shall not impose any duty upon Agent to exercise any such powers. Agent shall be accountable only for amounts that it receives as a result of the exercise of such powers, and neither it nor any of its Affiliates, directors, partners, officers, employees, agents, counsel or advisors shall be responsible to any Grantor for any act or failure to act hereunder, except for their own gross negligence, bad faith or willful misconduct, in each case, as determined by a court of competent jurisdiction in a final non-appealable order. In addition, Agent shall not be liable or responsible for any loss or damage to any Collateral, or for any diminution in the value thereof, by reason of the act or omission of any warehousemen, carrier, forwarding agency, consignee or other bailee if such Person has been selected by Agent in good faith.

 

28


(b) No Secured Party and no Affiliates, directors, partners, officers, employees, agents, counsel or advisors thereof shall be liable for failure to demand, collect or realize upon any Collateral or for any delay in doing so or shall be under any obligation to sell or otherwise dispose of any Collateral upon the request of any Grantor or any other Person or to take any other action whatsoever with regard to any Collateral. The powers conferred on Agent hereunder shall not impose any duty upon any other Secured Party to exercise any such powers. The other Secured Parties shall be accountable only for amounts that they actually receive as a result of the exercise of such powers, and neither they nor any of their respective officers, directors, employees or agents shall be responsible to any Grantor for any act or failure to act hereunder, except for their own gross negligence or willful misconduct as determined by a court of competent jurisdiction in a final non-appealable order.

SECTION 8 MISCELLANEOUS.

8.1 Amendments in Writing . The provisions of this Agreement may be waived, modified, supplemented or amended only by an instrument in writing signed by Borrower and Agent; provided , however , that annexes and schedules, as applicable, to this Agreement may be supplemented or modified (but no existing provisions may be modified and no Collateral may be released, except with respect to the removal of items on the schedules in connection with a sale or other Disposition of Collateral, a merger or Acquisition, in each case, that is permitted under the Facility Agreement) as set forth in Section  5 and Section  8.15 hereof. Notwithstanding anything to the contrary in the first sentence of this Section  8.1 , any time period for performance under this Agreement may be extended, at any time, by Agent in its sole discretion.

8.2 Notices . All notices, requests and demands to or upon Agent or any Guarantor or Grantor hereunder shall be addressed to such party and effected in the manner provided for in Section  6.1 of the Facility Agreement and each Guarantor and Grantor hereby appoints the Borrower as its agent to receive notices hereunder.

8.3 Indemnification by Grantors . Each Grantor and each Guarantor agrees to jointly and severally indemnify, pay, and hold Agent, the other Secured Parties and the Secured Parties’ Affiliates, officers, directors, employees, agents, and attorneys (the “ Indemnitees ”) harmless against losses and Liabilities to the extent set forth in Section  6.11 of the Facility Agreement, the terms of which are incorporated herein by reference as though set forth fully herein. The provisions in this Section  8.3 shall survive Payment in Full of all Secured Obligations and of all Guaranteed Obligations, any foreclosure under, or any modification, release or discharge of, any or all of the Collateral, and termination of this Agreement.

8.4 Enforcement Expenses .

(a) The terms of Section  6.3 of the Facility Agreement with respect to costs and expenses are incorporated herein by reference, mutatis mutandis , and the parties hereto agree to such terms.

(b) The agreements in this Section  8.4 shall survive Payment in Full of all Secured Obligations and the Guaranteed Obligations, any foreclosure under, or any modification, release or discharge of, any or all of the Collateral, and termination of this Agreement.

8.5 Nature of Remedies . All Secured Obligations and Guaranteed Obligations of each Grantor and rights of Agent and the other Secured Parties expressed herein or in any other Loan Document shall be in addition to and not in limitation of those provided by Applicable Law. No failure to exercise and no delay in exercising, on the part of Agent or the other Secured Parties, any right, remedy, power or privilege hereunder, shall operate as a waiver thereof; nor shall any single or partial exercise of any right,

 

29


remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege.

8.6 Counterparts; Effectiveness . This Agreement may be executed in several counterparts, and by each Party on separate counterparts, each of which and any photocopies, facsimile copies and other electronic methods of transmission thereof shall be deemed an original, but all of which together shall constitute one and the same agreement.

8.7 Severability . If any provision of this Agreement or any of the other Loan Documents shall be invalid, illegal or unenforceable in any respect under any law, the validity, legality and enforceability of the remaining provisions hereof or thereof shall not in any way be affected or impaired thereby. The parties hereto shall endeavor in good faith negotiations to replace the invalid, illegal or unenforceable provisions with valid provisions the economic effect of which comes as close as possible to that of the invalid, illegal or unenforceable provision.

8.8 Entire Agreement . This Agreement contains the entire understanding of the parties hereto with respect to the matters covered hereby and supersedes any and all other written and oral communications, negotiations, commitments and writings with respect thereto. All Exhibits, Schedules and Annexes referred to herein are incorporated in this Agreement by reference and constitute a part of this Agreement. If any provision contained in this Agreement conflicts with any provision of the Facility Agreement, then with regard to such conflicting provisions, the Facility Agreement shall govern and control.

8.9 Successors; Assigns . This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns, except, notwithstanding anything to the contrary in this Agreement or any other Loan Document, that Grantors and Guarantors may not assign their rights or obligations hereunder and any such purported, prohibited or attempted assignment shall be void ab initio .

8.10 Applicable Law . ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK APPLICABLE TO CONTRACTS MADE AND TO BE PERFORMED IN SUCH STATE.

8.11 Consent to Jurisdiction . EACH PARTY AGREES THAT ALL LEGAL PROCEEDINGS CONCERNING THE INTERPRETATIONS, ENFORCEMENT AND DEFENSE OF THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT AND, UNLESS OTHERWISE EXPRESSLY STATED THEREIN, THE OTHER LOAN DOCUMENTS (WHETHER BROUGHT AGAINST A PARTY HERETO OR ITS RESPECTIVE AFFILIATES, DIRECTORS, OFFICERS, SHAREHOLDERS, EMPLOYEES OR AGENTS) SHALL BE COMMENCED EXCLUSIVELY IN THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN. EACH PARTY HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR UNDER THE OTHER LOAN DOCUMENTS OR IN CONNECTION HEREWITH OR WITH THE OTHER LOAN DOCUMENTS OR WITH ANY TRANSACTION CONTEMPLATED HEREBY OR DISCUSSED HEREIN, AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT, OR THAT SUCH SUIT, ACTION OR PROCEEDING IS IMPROPER OR IS AN INCONVENIENT VENUE FOR SUCH PROCEEDING.

 

30


EACH PARTY HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE OF DELIVERY) TO SUCH PARTY AT THE ADDRESS IN EFFECT FOR NOTICES TO IT UNDER THIS AGREEMENT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY OTHER MANNER PERMITTED BY LAW.

8.12 Waiver of Jury Trial . THE PARTIES HERETO, TO THE EXTENT PERMITTED BY LAW, WAIVE ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, SUIT, OR PROCEEDING ARISING OUT OF, IN CONNECTION WITH OR RELATING TO, THIS AGREEMENT, THE OTHER LOAN DOCUMENTS AND ANY TRANSACTION CONTEMPLATED HEREBY AND THEREBY. THIS WAIVER APPLIES TO ANY ACTION, SUIT OR PROCEEDING WHETHER SOUNDING IN TORT, CONTRACT OR OTHERWISE. EACH PARTY HERETO (A) CERTIFIES THAT NO OTHER PARTY AND NO AGENT, REPRESENTATIVE OR OTHER PERSON AFFILIATED WITH OR RELATED TO ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THE LOAN DOCUMENTS, AS APPLICABLE, BY THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 8.12 .

8.13 Set-off . Each Grantor agrees that Agent and the other Secured Parties have all rights of set-off and bankers’ lien provided by Applicable Law, and in addition thereto, each Grantor agrees that at any time any Event of Default exists, Agent and the other Secured Parties may apply to the payment of any Secured Obligations and the Guaranteed Obligations as set forth in Section  6.5 hereof, whether or not then due, any and all balances, credits, deposits, accounts or moneys of such Grantor then or thereafter with the Secured Parties.

8.14 Acknowledgements . Each Grantor and each Guarantor hereby acknowledges that:

(a) it has been advised by counsel in the negotiation, execution and delivery of this Agreement and the other Loan Documents to which it is a party;

(b) Neither Agent nor any other Secured Party have any fiduciary relationship with or duty to any Grantor or Guarantor arising out of or in connection with this Agreement or any of the other Loan Documents, and the relationship between the Grantors and Guarantors, on the one hand, and Agent and the other Secured Parties, on the other hand, in connection herewith or therewith is solely that of debtor and creditor; and

(c) no joint venture is created hereby or by the other Loan Documents or otherwise exists by virtue of the transactions contemplated hereby among the Grantors, Guarantors and the Secured Parties.

8.15 Additional Grantors/Guarantors . The Grantors shall cause each Person, upon becoming a Subsidiary of a Grantor (other than any Excluded Subsidiary) or upon becoming a Subsidiary, limited liability company, other entity or other Person for which any Grantor divides or splits itself into (or that receives any assets or property of such Grantor from any such division or split), to guaranty Borrower’s and the other Grantors’ performance of the Secured Obligations and the Guaranteed Obligations and grant to Agent, for the benefit of the Secured Parties, a security interest in the personal property of such Person (to

 

31


the extent such personal property would constitute Collateral) to secure the Secured Obligations, its performance under the Facility Agreement and the other Loan Documents to the extent a party thereto and Borrower’s, each Guarantor’s and the other Grantors’ performance of the Secured Obligations by becoming a party to this Agreement. Upon execution and delivery by such Person of a joinder agreement in the form of Annex I hereto, such Person shall become a Grantor and Guarantor for all purposes of this Agreement.

8.16 Releases .

(a) At such time as the Secured Obligations have been Paid in Full, the Collateral shall be automatically released from the Liens created hereby and this Agreement shall automatically terminate (other than those provisions expressly surviving the Payment in Full of the Secured Obligations or the Guaranteed Obligations), all without delivery of any instrument or performance of any act by any party, and all rights to the Collateral shall automatically revert to the Grantors. At such time as the Guaranteed Obligations have been Paid in Full, subject to Section  8.18 , the guarantees provided in Section  2 and the remainder of this Agreement shall automatically terminate (other than those provisions expressly surviving the Payment in Full of the Secured Obligations or the Guaranteed Obligations, including those specific provisions of Section  8 hereof expressly surviving Payment in Full of the Secured Obligations or the Guaranteed Obligations). At the request and sole expense of any Grantor following any such Payment in Full of the Secured Obligations, Agent shall promptly deliver to the Grantors any Collateral held by Agent hereunder, and execute and deliver to the Grantors such documents as the Grantors shall reasonably request in writing to evidence the termination and release of the Liens in the Collateral. At the request and sole expense of any Grantor following any such Payment in Full of the Guaranteed Obligations, Agent shall execute and deliver to the Grantors such documents as the Grantors shall reasonably request in writing to evidence the termination of the guarantees provided in Section  2 .

(b) If any of the Collateral shall be sold, transferred or otherwise disposed of by any Grantor in a transaction permitted by the Facility Agreement or with the written consent of Agent and the Required Lenders, then Agent, at the reasonable written request and sole expense of such Grantor, shall execute and deliver to such Grantor all releases or other documents reasonably necessary for the release of the Liens created hereby on such Collateral; provided that Borrower shall have delivered to Agent, with reasonable notice prior to the date of the proposed release, a written request for release identifying the relevant Grantor, together with a certification by Borrower stating that such transaction is in compliance with the Facility Agreement and the other Loan Documents (including the relevant provision of the Loan Documents pursuant to which such transfer or other disposition is permitted, together with any additional evidence reasonably requested by Agent).

(c) If, in compliance with the terms and provisions of the Loan Documents, (i) all or substantially all of the Stock of any Guarantor is sold or otherwise transferred to a Person or Persons none of which is a Loan Party in a transaction permitted under the Loan Documents or with the written consent of Agent and the Required Lenders or (ii) any Guarantor becomes an Excluded Subsidiary as a result of a transaction permitted under the Loan Documents (any such Guarantor, and any Guarantor referred to in clause (i), a “ Transferred Guarantor ”), such Transferred Guarantor shall, upon the consummation of such sale or transfer or other transaction, be automatically released from its obligations under this Agreement (including under this Section  8.16 ) and the other Loan Documents, including its obligations to pledge and grant any Collateral owned by it and, in the case of a sale of all or substantially all of the Stock of the Transferred Guarantor, the pledge of such Stock to the Agent hereunder shall be automatically released, and, so long as the Borrower shall have provided the Agent such certifications or documents as the Agent shall reasonably request, the Agent, at the sole expense of the Grantors, shall take such actions as are reasonably necessary and requested by the Grantors in writing to effect each release described in this Section  8.16 .

 

32


8.17 Obligations and Liens Absolute and Unconditional . Each Grantor and each Guarantor understands and agrees that the obligations of each Grantor under this Agreement shall be construed as continuing, absolute and unconditional without regard to (i) the validity or enforceability of any Loan Document, any of the Secured Obligations or any other collateral security therefor or guaranty or right of offset with respect thereto at any time or from time to time held by Agent or any other Secured Party, (ii) any defense, set-off or counterclaim (other than a defense of payment or performance) which may at any time be available to or be asserted by any Grantor, Guarantor or any other Person against Agent or any other Secured Party, or (iii) any other circumstance whatsoever (with or without notice to or knowledge of any Grantor or Guarantor) which constitutes, or might be construed to constitute, an equitable or legal discharge of any Grantor or Guarantor for the Secured Obligations or the Guaranteed Obligations, in bankruptcy or in any other instance. When making any demand hereunder or otherwise pursuing its rights and remedies hereunder against any Grantor or Guarantor, Agent and any other Secured Party may, but shall be under no obligation to, make a similar demand on or otherwise pursue such rights and remedies as they may have against any other Grantor or Guarantor or any other Person or against any collateral security for the Secured Obligations or guaranty for the Guaranteed Obligations or any right of offset with respect thereto, and any failure by Agent or any other Secured Party to make any such demand, to pursue such other rights or remedies or to collect any payments from any other Grantor or Guarantor or any other Person or to realize upon any such collateral security or guaranty or to exercise any such right of offset, or any release of any other Grantor or Guarantor or any other Person or any such collateral security, guaranty or right of offset, shall not relieve any Grantor or Guarantor of any obligation or Liability hereunder, and shall not impair or affect the rights and remedies, whether express, implied or available as a matter of law, of Agent or any other Secured Party against any Grantor or Guarantor. For the purposes hereof “demand” shall include the commencement and continuance of any legal proceedings.

8.18 Reinstatement . Each Grantor and Guarantor agrees that, if any payment made by any Loan Party or other Person and applied to the Secured Obligations or the Guaranteed Obligations is at any time annulled, avoided, set aside, rescinded, invalidated, declared to be fraudulent or preferential or otherwise required to be refunded or repaid, or the Proceeds of any Collateral are required to be returned by any Secured Party to such Loan Party, its estate, trustee, receiver or any other party, including any Grantor or Guarantor, under any applicable bankruptcy law, state or federal law, common law or equitable cause, then, to the extent such payment or repayment is annulled, avoided, set aside, rescinded, invalidated, refunded, repaid or returned, any Lien or other Collateral securing such liability with respect to the Secured Obligations and any guarantee herein securing the Guaranteed Obligations shall be and remain in full force and effect, as fully as if such payment had never been made. If, prior to any of the foregoing, (i) any Lien or other Collateral securing such Grantor’s Secured Obligations or Guarantor’s Guaranteed Obligations shall have been released or terminated by virtue of the foregoing or (ii) any provision of the guaranty hereunder shall have been terminated, cancelled or surrendered in connection with the foregoing payment, such Lien, other Collateral, guaranty or other provision shall be reinstated in full force and effect and such prior release, termination, cancellation or surrender shall not diminish, release, discharge, impair or otherwise affect the obligations of any such Grantor in respect of any Lien or other Collateral securing, or any such Guarantor in respect of any guaranty guaranteeing such obligation or the amount of such payment. This Section  8.18 shall survive the termination of this Agreement pursuant to Section  8.16 or otherwise. The provisions in this Section  8.18 shall survive Payment in Full of all Secured Obligations and of all Guaranteed Obligations, any foreclosure under, or any modification, release or discharge of, any or all of the Collateral, and termination of this Agreement.

8.19 Independent Obligations . The obligations of each Grantor and each Guarantor hereunder are independent of and separate from the Secured Obligations and the Guaranteed Obligations. During the continuance of any Event of Default, Agent may, at its sole election, proceed directly and at once, without notice, against any Grantor, any Guarantor and any Collateral to collect and recover the full amount of any Secured Obligation or Guaranteed Obligation (as applicable) then due, without first

 

33


proceeding against any other Grantor, any Guarantor, any other Loan Party or any other Collateral or any guaranty and without first joining any other Grantor, any other Guarantor or any other Loan Party in any proceeding.

8.20 No Waiver by Course of Conduct . No Secured Party shall by any act (except by a written signed instrument by the required Persons pursuant to Section  8.1 hereof and Section  6.6 of the Facility Agreement), delay, indulgence, omission or otherwise be deemed to have waived any right or remedy hereunder or to have acquiesced in any Default or Event of Default. No failure to exercise, nor any delay in exercising, on the part of any Secured Party, any right, power or privilege hereunder or under any other Loan Document shall operate as a waiver thereof. No single or partial exercise of any right, power or privilege hereunder or under any other Loan Document shall preclude any other or further exercise thereof or the exercise of any other right, power or privilege. A waiver by any Secured Party of any right or remedy hereunder or any other Loan Document on any one occasion shall not be construed as a bar to any right or remedy that such Secured Party would otherwise have on any future occasion.

8.21 Intercreditor Agreement . This Agreement is subject, in the manner and the extent, to the terms set forth in the Intercreditor Agreement. Any Collateral held by (or in the possession or control of) the ABL Agent (or its agents or bailees) shall be held as agent and bailee for security and Lien perfection purposes in favor of Agent (for the benefit of the Secured Parties) in accordance with the terms of the Intercreditor Agreement and the Loan Documents.

8.22 Relation to Other Loan Documents . The provisions of this Agreement shall be read and construed with the other Loan Documents referred to below in the manner so indicated. The provisions of any Copyright Security Agreement(s), Trademark Security Agreement(s), and Patent Security Agreement(s) are supplemental to the provisions of this Agreement, and nothing contained in any Copyright Security Agreement(s), Trademark Security Agreement(s), or Patent Security Agreement(s) shall limit any of the rights or remedies of Agent hereunder. In the event of any conflict between any provision in this Agreement and a provision in a Copyright Security Agreement, Trademark Security Agreement or Patent Security Agreement, such provision of this Agreement shall control.

8.23 Amendment and Restatement; Continuation of Obligations and Liens; No Novation .

(a) This Agreement does not extinguish the outstanding obligations of the Grantors evidenced by the Existing Guaranty and Security Agreement or discharge or release any Lien or security interest or any other security under the Existing Loan Documents or the Loan Documents, all of which obligations, Liens and security interests continue under this Agreement and the other Loan Documents (in each case, as expanded, increased and enlarged hereby, as applicable). Nothing herein contained shall be construed as a substitution or novation of the original obligations or other obligations (including, without limitation, any “Guaranteed Obligations” or “Secured Obligations”) under the Existing Guaranty and Security Agreement, which shall remain in full force and effect, except as amended hereby and by the other Loan Documents, and shall continue at all times under this Agreement, as amended hereby and thereby.

(b) All of the security interests, Liens and collateral granted under the Existing Guaranty and Security Agreement are hereby reaffirmed, ratified and confirmed in all respects and all parties hereto agree that such security interests, Liens and collateral continue under this Agreement.

(c) Each Grantor acknowledges and confirms that, as of the Agreement Date, it has no defense, set off, claim or counterclaim arising on or prior to the Agreement Date against any of the Secured Parties with regard to the indebtedness, liabilities and obligations created under the Existing Guaranty and Security Agreement and the Liens and security interests granted pursuant to the Existing Loan Documents

 

34


to secure the indebtedness, liabilities and obligations (including, without limitation, the “Guaranteed Obligations”, the “Secured Obligations” and the “Obligations,” as applicable) of the Grantors to the Secured Parties under the Existing Guaranty and Security Agreement, as amended and restated hereby, and that the term “Obligations” as used in the Loan Documents (or any other term used therein to describe or refer to the indebtedness, liabilities and obligations of the Grantors to the Secured Parties) includes, without limitation, the indebtedness, liabilities and obligations of the Guarantors under this Agreement, as the same further may be amended, modified, supplemented and/or restated from time to time. The Loan Documents and all agreements, instruments and documents executed or delivered in connection with any of the foregoing shall each be deemed to be amended to the extent necessary to give effect to the provisions of this Section 8.23. From and after the date hereof, all references in the Loan Documents to the “Guaranty and Security Agreement” shall be deemed to refer to this Agreement. From and after the date hereof, all references in the Loan Documents to (i) a “Guarantor” or the “Guarantors” shall be deemed to refer to the defined terms “Guarantor” or the “Guarantors” (as applicable) under this Agreement, (ii) the “Guaranteed Obligations” shall be deemed to refer to the defined term “Guaranteed Obligations” under this Agreement and (iii) the “Secured Obligations” shall be deemed to refer to the defined term “Secured Obligations” under this Agreement. Cross-references in the Loan Documents to particular section numbers in the Existing Guaranty and Security Agreement shall be deemed to be cross-references to the corresponding sections, as applicable, of this Agreement.

(d) The provisions of Sections 6.29, 6.30 and 6.31 of the Facility Agreement are incorporated herein mutatis mutandis .

[SIGNATURE PAGES FOLLOW]

 

35


IN WITNESS WHEREOF, each of the undersigned has caused this Agreement to be duly executed and delivered as of the date first above written.

 

GRANTORS AND GUARANTORS:     ENDOLOGIX, INC.,
      a Delaware corporation,
as Grantor and Guarantor
      By:  

/s/ Vaseem Mahboob

      Name: Vaseem Mahboob
      Title: Chief Financial Officer
      CVD/RMS ACQUISITION CORP.,
      a Delaware corporation,
as Grantor and Guarantor
      By:  

/s/ Vaseem Mahboob

      Name: Vaseem Mahboob
      Title: Chief Financial Officer and Secretary
      NELLIX, INC.,
      a Delaware corporation,
as Grantor and Guarantor
      By:  

/s/ Vaseem, Mahboob

      Name: Vaseem Mahboob
      Title: Chief Financial Officer and Secretary
      TRIVASCULAR TECHNOLOGIES, INC.,
      a Delaware corporation,
as Grantor and Guarantor
      By:  

/s/ Vaseem Mahboob

      Name: Vaseem Mahboob
      Title: Chief Financial Officer and Secretary

 

 

[Signature Page to Amended and Restated Guaranty and Security Agreement]


GRANTORS AND GUARANTORS
CONTINUED:
    TRIVASCULAR, INC.,
      a California corporation,
as Grantor and Guarantor
      By:  

/s/ Vaseem Mahboob

      Name: Vaseem Mahboob
      Title: Chief Financial Officer and Secretary
      ENDOLOGIX CANADA, LLC,
      a Delaware limited liability company,
as Grantor and Guarantor
      By:  

/s/ Vaseem Mahboob

      Name: Vaseem Mahboob
      Title: Chief Financial Officer and Secretary
      TRIVASCULAR SALES LLC,
      a Texas limited liability company,
as Grantor and Guarantor
      By:  

/s/ Vaseem Mahboob

      Name: Vaseem Mahboob
      Title: Chief Financial Officer and Secretary
      RMS/ENDOLOGIX SIDEWAYS MERGER CORP.,
      a Delaware corporation,
as Grantor and Guarantor
      By:  

/s/ Vaseem Mahboob

      Name: Vaseem Mahboob
      Title: Chief Financial Officer and Secretary

 

 

[Signature Page to Amended and Restated Guaranty and Security Agreement]


AGENT:    

DEERFIELD PRIVATE DESIGN FUND IV, L.P.,

as Agent

      By: Deerfield Mgmt IV, L.P., General Partner
      By: J.E. Flynn Capital IV, LLC, General Partner
      By:  

/s/ David J. Clark                                        

      Name:   David J. Clark
      Title:   Authorized Signatory

 

 

[Signature Page to Amended and Restated Guaranty and Security Agreement]


ANNEX I

FORM OF JOINDER TO GUARANTY AND SECURITY AGREEMENT

This JOINDER AGREEMENT (this “ Agreement ”) dated as of [            ], 20[        ] is executed by the undersigned in favor of Deerfield Private Design Fund IV, L.P., as Agent, for the benefit of the Secured Parties in connection with that certain Amended and Restated Guaranty and Security Agreement dated as of August 9, 2018, by and among Agent and the Guarantors and Grantors party thereto (as amended, restated, supplemented or otherwise modified from time to time, the “ Guaranty and Security Agreement ”). Capitalized terms not otherwise defined herein are being used herein as defined in the Guaranty and Security Agreement, or if not defined therein, in the Facility Agreement (as defined therein).

Each Person signatory hereto is required to execute this Agreement pursuant to Section  8.15 of the Guaranty and Security Agreement.

In consideration of the premises and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each such Person hereby agrees as follows:

1. Each such Person assumes all the obligations of a Grantor and a Guarantor under the Guaranty and Security Agreement and agrees that such Person is a Grantor and a Guarantor and bound as a Grantor and a Guarantor under the terms of the Guaranty and Security Agreement, as if it had been an original signatory to such agreement. In furtherance of the foregoing, such Person hereby mortgages, pledges, assigns, hypothecates and transfers to Agent, for the benefit of the Secured Parties, and hereby grants to Agent, for the benefit of the Secured Parties, a Lien on and security interest in all of its Collateral, as collateral security for the prompt and complete payment and performance when due (whether at the stated maturity, by acceleration or otherwise) of the Secured Obligations. For the avoidance of doubt, the Collateral does not include any Excluded Property.

2. Schedules 1, 1A, 2, 3, 4, 5, 6, 7, 8, 9 and 10 of the Guaranty and Security Agreement are hereby amended to add the information relating to each such Person set out on Schedules 1, 1A, 2, 3, 4, 5, 6, 7, 8, 9 and 10, respectively, hereof. Each such Person hereby makes to Agent and the other Secured Parties the representations and warranties set forth in the Guaranty and Security Agreement applicable to such Person and the applicable Collateral and confirms that such representations and warranties are true and correct in all material respects (without duplication of any materiality qualifier) as of the date hereof after giving effect to such amendment to such Schedules (except to the extent stated to relate to a specific earlier date, in which case, as of such earlier date).

3. In furtherance of its obligations under Section  5.2 of the Guaranty and Security Agreement, each such Person agrees to deliver to Agent appropriately complete UCC financing statements naming such Person as debtor and Agent as secured party, and describing its Collateral and such other documentation as Agent (or its successors or assigns) may require to evidence, protect and perfect the Liens created by the Guaranty and Security Agreement, as modified hereby. Each such Person acknowledges the authorizations given to Agent and its Related Parties and their counsel under the Section  5.9 of the Guaranty and Security Agreement and otherwise.

4. Each such Person’s address for notices under the Guaranty and Security Agreement shall be the address of the Borrower set forth in the Facility Agreement and each such Person hereby appoints the Borrower as its agent to receive notices hereunder.


5. Agent acknowledges that upon the effectiveness of this Agreement, the undersigned shall have the rights of a Grantor and Guarantor under the Guaranty and Security Agreement.

6. This Agreement shall be deemed to be part of, and a modification to, the Guaranty and Security Agreement and shall be governed by all the terms and provisions of the Guaranty and Security Agreement, with respect to the modifications intended to be made to such agreement, which terms are incorporated herein by reference, are ratified and confirmed and shall continue in full force and effect as valid and binding agreements of each such person or entity enforceable against such Person, except as such enforceability may be limited by applicable insolvency, bankruptcy, reorganization, moratorium or other similar laws affecting creditors’ rights generally. Each such Person hereby waives notice of Agent’s acceptance of this Agreement. Each such Person will deliver an executed original of this Agreement to Agent. This Agreement may be executed in several counterparts, and by each Party on separate counterparts, each of which and any photocopies, facsimile copies and other electronic methods of transmission thereof shall be deemed an original, but all of which together shall constitute one and the same agreement.

 

 

[remainder of page intentionally left blank]


IN WITNESS WHEREOF, each of the undersigned has caused this Agreement to be duly executed and delivered as of the date first above written.

 

[add signature block for each new Grantor]

[                                           ] ,

a [                          ], as a Grantor and Guarantor

By:  

 

Name:  

 

Acknowledged and agreed to as of the year and date first written above :
AGENT :
DEERFIELD PRIVATE DESIGN FUND IV, L.P. , as Agent
By: Deerfield Mgmt IV, L.P., General Partner
By: J.E. Flynn Capital IV, LLC, General Partner
By:  

                                  

Name:   James E. Flynn
Title:   President


SCHEDULE 1

PLEDGED EQUITY AND PLEDGED DEBT INSTRUMENTS

Pledged Equity :

 

Grantor
(owner of
Record of
such Pledged
Equity)

  

Issuer

  

Par Value

  

No. of
Shares,
Units or
Interests
Owned

  

Total
Shares,
Units or
Interests
Authorized
and
Outstanding

  

Percentage
of Shares, Units or
Interests Owned

  

Certificate
(Indicate
No.)

Endologix, Inc.    Nellix, Inc.    $0.001    100 Shares    1,000 Shares Authorized; 100 Shares Outstanding    100%    65
Endologix, Inc.    CVD/RMS Acquisition Corp.    $0.001    100 Shares    100 Shares Authorized and Outstanding    100%    4
Endologix, Inc.    RMS/Endologix Sideways Merger Corp.    $0.001    100 Shares    100 Shares Authorized and Outstanding    100%    Com-1
Endologix, Inc.    TriVascular Technologies, Inc.    $0.001    100 Shares    1,000 Shares Authorized; 100 Shares Outstanding    100%    60
Endologix, Inc.    ELGX International Holdings GP    N.A.    Unspecified Number of Partnership Interests    Unspecified Number of Partnership Interests    100%    N.A.
Endologix, Inc.    Endologix Bermuda L.P.    N.A.    Unspecified Number of Partnership Interests    Unspecified Number of Partnership Interests    99%    N.A.


Grantor
(owner of
Record of
such Pledged
Equity)

  

Issuer

  

Par Value

  

No. of
Shares,
Units or
Interests
Owned

  

Total
Shares,
Units or
Interests
Authorized
and
Outstanding

  

Percentage
of Shares, Units or
Interests Owned

  

Certificate

(Indicate
No.)

ELGX International Holdings GP    Endologix Bermuda L.P.    N.A.    Unspecified Number of Partnership Interests    Unspecified Number of Partnership Interests    1%    N.A.
Endologix, Inc.    Endologix Singapore Private Limited    N.A.    Unspecified Number of Company Interests    Unspecified Number of Company Interests    100%    N.A.
Endologix, Inc.    Endologix New Zealand Co.    N.A.    Unspecified Number of Company Interests    Unspecified Number of Company Interests    100%    N.A.
Endologix, Inc.    ELGX South Korea Ltd    N.A.    Unspecified Number of Company Interests    Unspecified Number of Company Interests    100%    N.A.
TriVascular Technologies, Inc.    TriVascular,Inc.    $0.01    100 Shares    100 Shares Authorized and Outstanding    100%    CS-4
TriVascular, Inc.    TriVascular Sales LLC    N.A.    1,000 Units of Membership Interests    1,000 Units of Membership Interests    100%    N.A.
TriVascular, Inc.    TriVascular
Germany
GmbH
   N.A.    Unspecified number of Company Interests    Unspecified number of Company Interests    100%    N.A.
TriVascular, Inc.    TriVascular
Switzerland
Sarl
   N.A.    Unspecified number of Company Interests    Unspecified number of Company Interests    100%    N.A.
TriVascular,    Endologix    N.A.    1,000 Units of Membership    1,000 Units of    100%    N.A.


Grantor
(owner of
Record of
such Pledged
Equity)

  

Issuer

  

Par
Value

  

No. of
Shares,
Units or
Interests
Owned

  

Total
Shares,
Units or
Interests
Authorized
and
Outstanding

  

Percentage
of Shares, Units or
Interests Owned

  

Certificate
(Indicate
No.)

Inc.    Canada, LLC       Interests    Membership Interests      
TriVascular, Inc.    TriVascular, Inc.
Italia Sarl
   N.A.    Unspecified Number of Company Interests    Unspecified Number of Company Interests    100%    N.A.
Endologix Bermuda L.P.    Endologix International Holdings B.V.    N.A.    Unspecified Number of Company Interests    Unspecified Number of Company Interests    100%    N.A.
Endologix International Holdings B.V.    Endologix Poland spolkda z ograniczona odpowiedzialnoscia    N.A.    Unspecified Number of Company Interests    Unspecified Number of Company Interests    100%    N.A.
Endologix International Holdings B.V.    Endologix Italia Sarl    N.A.    Unspecified Number of Company Interests    Unspecified Number of Company Interests    100%    N.A.
Endologix International Holdings B.V.    Endologix International B.V.    N.A.    Unspecified Number of Company Interests    Unspecified Number of Company Interests    100%    N.A.

Pledged Debt Instruments :

 

Grantor (owner
of Record of such
Pledged Debt
Instrument)

  

Issuer

  

Description of Debt

  

Final
Maturity

  

Principal
Amount

  

Certificate
(Indicate
No.)

N.A.               


SCHEDULE 1A

PLEDGED INVESTMENT PROPERTY

 

Name of Issuer

  

Description and Value of Security

  

Loan Party/Subsidiary

Cianna Medical, Inc.    8,677 Shares of Series A Preferred Stock    Endologix, Inc.

See Schedule 1.


SCHEDULE 2

FILINGS AND PERFECTION

To be attached.


FIRST SUPPLEMENT TO TRADEMARK SECURITY AGREEMENT

This FIRST SUPPLEMENT TO TRADEMARK SECURITY AGREEMENT (this “ Supplement ”) made as of August 9, 2018, by Endologix, Inc., a Delaware corporation (“ Endologix ” or “ Borrower ”), and TriVascular, Inc., a Delaware corporation (“ TriVascular ”; TriVascular and Endologix are each individually a “ Grantor ” and collectively “ Grantors ”), in favor of Deerfield Private Design Fund IV, L.P., in its capacity as Agent for the Secured Parties (each as defined in the Facility Agreement referenced below) (in such capacity, “ Grantee ”):

W I T N E S S E T H

WHEREAS, Borrower, the other Loan Parties (including TriVascular) from time to time party thereto, the financial institutions from time to time party thereto as Lenders and Grantee have entered into that certain Amended and Restated Facility Agreement dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “ Facility Agreement ”), pursuant to which Grantee and the Lenders have agreed, subject to the terms and conditions thereof, to make certain loans to, and other credit accommodations in favor of, Borrower (collectively, the “ Loans ”).

WHEREAS, pursuant to the terms of that certain Amended and Restated Guaranty and Security Agreement dated as of the date hereof, by and among Grantee, Grantors and the other Loan Parties from time to time party thereto (as the same may be amended, restated, supplemented or otherwise modified from time to time, the “ Guaranty and Security Agreement ”), Grantors have granted to Grantee, for its benefit and the benefit of the other Secured Parties, a security interest and Lien upon substantially all assets (including the Collateral) of Grantors, including all right, title and interest of Grantors in, to and under all now owned and hereafter acquired (a) trademarks, trade names, corporate names, company names, business names, fictitious business names, trade styles, trade dress, service marks, logos and other source or business identifiers of each Grantor, and all goodwill associated therewith, now existing or hereafter adopted or acquired, all registrations and recordings thereof, and all applications in connection therewith, whether in the United States Patent and Trademark Office or in any similar office or agency of the United States, any state thereof or any other country or any political subdivision thereof, or otherwise, and all common-law rights related thereto, and (b) the right to obtain all renewals thereof (all of the foregoing in clauses (a) and (b), collectively, together with “Trademarks” as defined in the Guaranty and Security Agreement, “ Trademarks ”), together with the goodwill of the business symbolized by Grantors’ Trademarks, and all income, royalties, damages and payments with respect to the foregoing, to secure the payment of all Secured Obligations, in each case other than Excluded Property.

WHEREAS, Grantors and Grantee are parties to that certain Trademark Security Agreement, dated April 3, 2017 (as the same heretofore may have been and hereafter may be amended, restated, supplemented or otherwise modified from time to time, the “Trademark Security Agreement”).


NOW, THEREFORE, in consideration of the premises set forth herein and for other good and valuable consideration, receipt and sufficiency of which are hereby acknowledged, Grantors agree to supplement the Trademark Security Agreement as follows:

(e) Incorporation of Facility Agreement, Guaranty and Security Agreement and Trademark Security Agreement . The representations and warranties contained in the Facility Agreement, the Guaranty and Security Agreement and the Trademark Security Agreement to the extent applicable to Grantors are hereby incorporated herein in their entirety by this reference thereto. The provisions of Sections 1.2 and 6.4 of the Facility Agreement are incorporated herein by reference thereto mutatis mutandis . Unless otherwise noted herein, all capitalized terms used herein but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Guaranty and Security Agreement, or if not defined therein, in the Facility Agreement. In the event of a conflict between a provision of the Guaranty and Security Agreement and a provision of this Supplement (or the Trademark Security Agreement as amended and/or supplemented by this Supplement), the provision of the Guaranty and Security Agreement shall control.

(f) Grant and Reaffirmation of Grant of Security Interests . To secure the payment of the Secured Obligations, Grantors hereby grant to Grantee, for its benefit and the benefit of the other Secured Parties, and hereby reaffirm their prior grant pursuant to the Guaranty and Security Agreement and the Trademark Security Agreement of, a continuing Lien on and security interest in Grantors’ entire right, title and interest in and to the following (all of the following items or types of property being herein collectively referred to as the “ Trademark Collateral ”), whether now owned or existing or hereafter created, acquired or arising:

each Trademark listed on Schedule A annexed hereto and all other Trademarks, together with any reissues, continuations or extensions thereof, all of the goodwill of the business connected with the use of, and symbolized by, each such Trademark, and all proceeds and products with respect to the foregoing; and

all income, royalties, damages and payments relating to the foregoing, including without limitation, damages payable with respect to any claim by Grantors against third parties for past, present or future (i) infringement or dilution of each such Trademark, or (ii) injury to the goodwill associated with each such Trademark, and all proceeds and products with respect to the foregoing.

Notwithstanding the foregoing, no Trademark Collateral shall include any Excluded Property.

(g) Incorporation of the Trademark Security Agreement . The terms and provisions of the Trademark Security Agreement are hereby incorporated by reference, and this Supplement shall be considered an amendment and supplement to and part of the Trademark Security Agreement, all of the provisions of which Trademark Security Agreement are and remain in full force and effect. Any reference after the date hereof in any Loan Document to the Trademark Security Agreement shall be a reference to the Trademark Security Agreement as amended and supplemented by this Supplement.

(h) Reaffirmation of Obligations . Each Grantor hereby reaffirms its obligations (including, without limitation, the Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and any Exit Payment)) under the Trademark Security Agreement, the Guaranty and Security Agreement and all other Loan Documents. Each Grantor hereby further ratifies and reaffirms the validity and enforceability of all of the Liens and security interests heretofore granted, pursuant to and in connection with the Trademark Security Agreement, the Security Agreement or any other Loan Document, to Grantee


(for the benefit of the Secured Parties), as collateral security for the obligations (including, without limitation, the Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and any Exit Payment)) under the Loan Documents in accordance with their respective terms, and acknowledges that all of such Liens and security interests, and all Collateral (including, without limitation, the Trademark Collateral (as defined in the Trademark Security Agreement)) heretofore pledged as security for such obligations (including, without limitation, the Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and any Exit Payment)), continue to be and remain collateral for such obligations (including, without limitation, the Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and any Exit Payment)) from and after the date hereof.

(i) Ratification . Each Grantor hereby restates, ratifies and reaffirms each and every term and condition set forth in the Trademark Security Agreement effective as of the date hereof and as amended hereby.

(j) Governing Law . This Supplement is governed by and construed and enforced in accordance with the laws of the State of New York applicable to contracts made and to be performed in such State.

(k) Counterparts . This Supplement may be executed in several counterparts, and by each Party on separate counterparts, each of which and any photocopies, facsimile copies and other electronic methods of transmission thereof shall be deemed an original, but all of which together shall constitute one and the same agreement.

[Signature Page Follows]


IN WITNESS WHEREOF, each Grantor has duly executed this Supplement as of the date first written above.

 

ENDOLOGIX, INC.
By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer

First Supplement to Trademark Security Agreement


IN WITNESS WHEREOF, each Grantor has duly executed this Supplement as of the date first written above.

 

TRIVASCULAR, INC.
By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer and Secretary

First Supplement to Trademark Security Agreement


Agreed and accepted as of

the date first written above:

DEERFIELD PRIVATE DESIGN FUND IV, L.P. , as Agent and Grantee
By: Deerfield Mgmt IV, L.P., General Partner
By: J.E. Flynn Capital IV, LLC, General Partner
By: /s/ David J. Clark                                    
Name: David J. Clark
Title: Authorized Signatory

First Supplement to Trademark Security Agreement


SCHEDULE A

 

Mark

  

Application No.

  

Application Date

  

Registration No.

  

Registration

Date

  

Status of

Mark

  

Owner/

Applicant

DURAPLY    86362822    8/11/14    5433696    3/27/18    Registered    Endologix, Inc.
EVAS FORWARD    86116940    11/12/13    5306786    10/10/17    Registered    Endologix, Inc.
VELA    85857988    2/22/13    5296578    9/26/17    Registered    Endologix, Inc.
ANGIOTIP    85767055    10/30/12    5205176    5/16/17    Registered    Endologix, Inc.
ACTIVESEAL    85518608    1/17/12    5396605    2/6/18    Registered    Endologix, Inc.
OVATION ALTO    86047894    8/26/13    5195890    5/2/17    Registered    TriVascular, Inc.
DESIGN ONLY    86854470    12/18/18    N/A    N/A   

Published (Pending) –

Intent to Use

   Endologix, Inc.
ALLEGRO    86758465    9/16/15    N/A    N/A   

Published (Pending) –

Intent to Use

   TriVascular, Inc.
VERTA    87116482    7/26/16    N/A    N/A   

Pending

(Intent to use)

   Endologix, Inc.

 

 

First Supplement to Trademark Security Agreement


FIRST SUPPLEMENT TO PATENT SECURITY AGREEMENT

This FIRST SUPPLEMENT TO PATENT SECURITY AGREEMENT (this “ Supplement ”) made as of August 9, 2018, by Endologix, Inc., a Delaware corporation (“ Endologix ” or “ Borrower ”), Nellix, Inc., a Delaware corporation (“ Nellix ”), TriVascular, Inc., a Delaware corporation (“ TriVascular ”; TriVascular, Endologix and Nellix are each individually a “ Grantor ” and collectively “ Grantors ”), in favor of Deerfield Private Design Fund IV, L.P., in its capacity as Agent for the Secured Parties (each as defined in the Facility Agreement referenced below) (in such capacity, “ Grantee ”):

W I T N E S S E T H

WHEREAS, Borrower, the other Loan Parties (including Nellix and TriVascular) from time to time party thereto, the financial institutions from time to time party thereto as Lenders and Grantee have entered into that certain Amended and Restated Facility Agreement dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “ Facility Agreement ”), pursuant to which Grantee and the Lenders have agreed, subject to the terms and conditions thereof, to make certain loans to, and other credit accommodations in favor of, Borrower (collectively, the “ Loans ”).

WHEREAS, pursuant to the terms of that certain Amended and Restated Guaranty and Security Agreement dated as of the date hereof, by and among Grantee, Grantors and the other Loan Parties from time to time party thereto (as the same may be amended, restated, supplemented or otherwise modified from time to time, the “ Guaranty and Security Agreement ”), Grantors have granted to Grantee, for its benefit and the benefit of the other Secured Parties, a security interest and Lien upon substantially all assets (including the Collateral) of Grantors, including all right, title and interest of Grantors in, to and under all now owned and hereafter acquired (a) letters patent of the United States or any political subdivision thereof of each Grantor, all reissues and extensions thereof and all goodwill associated therewith, (b) applications for letters patent of the United States and all divisions of each Grantor, continuations and continuations-in-part thereof and (c) rights to, and the rights to obtain any reissues, reexaminations, continuations, continuations-in-part, divisionals, renewals and extensions of all the foregoing (all of the foregoing in clauses (a), (b) and (c), collectively, together with all “Patents” as defined in the Guaranty and Security Agreement, “ Patents ”), together with the goodwill of the business symbolized by Grantors’ Patents, and all income, royalties, damages and payments with respect to the foregoing, to secure the payment of all Secured Obligations, in each case other than Excluded Property.

WHEREAS, Grantors and Grantee are parties to a certain Patent Security Agreement dated April 3, 2017 (as the same heretofore may have been and hereafter may be amended, restated, supplemented or otherwise modified from time to time, the “ Patent Security Agreement ”).

NOW, THEREFORE, in consideration of the premises set forth herein and for other good and valuable consideration, receipt and sufficiency of which are hereby acknowledged, Grantors agree to supplement the Patent Security Agreement as follows:


1. Incorporation of Facility Agreement, Guaranty and Security Agreement and Patent Security Agreement . The representations and warranties contained in the Facility Agreement, the Guaranty and Security Agreement and the Patent Security Agreement to the extent applicable to Grantors are hereby incorporated herein in their entirety by this reference thereto. The provisions of Sections 1.2 and 6.4 of the Facility Agreement are incorporated herein by reference thereto mutatis mutandis . Unless otherwise noted herein, all capitalized terms used herein but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Guaranty and Security Agreement, or if not defined therein, in the Facility Agreement. In the event of a conflict between a provision of the Guaranty and Security Agreement and a provision of this Supplement (or the Patent Security Agreement as amended and/or supplemented by this Supplement), the provision of the Guaranty and Security Agreement shall control.

2. Grant and Reaffirmation of Grant of Security Interests . To secure the payment of the Secured Obligations, Grantors grant to Grantee, for its benefit and the benefit of the other Secured Parties, and hereby reaffirm their prior grant pursuant to the Guaranty and Security Agreement and the Patent Security Agreement of, a continuing Lien on and security interest in Grantors’ entire right, title and interest in and to the following (all of the following items or types of property being herein collectively referred to as the “ Patent Collateral ”), whether now owned or existing or hereafter created, acquired or arising:

(a) each Patent listed on Schedule A annexed hereto and all other Patents, together with any reissues, reexaminations, continuations, continuations-in-part, divisionals, renewals and extensions thereof, all of the goodwill of the business connected with the use of, and symbolized by, each such Patent, and all proceeds and products with respect to the foregoing; and

(b) all income, royalties, damages and payments at any time due or payable or asserted under and with respect to the foregoing, including without limitation, damages payable with respect to any claim by Grantors against third parties for past, present or future (i) infringement or dilution of each such Patent, or (ii) injury to the goodwill associated with each such Patent, and all proceeds and products with respect to the foregoing.

Notwithstanding the foregoing, no Patent Collateral shall include any Excluded Property.

3. Incorporation of the Patent Security Agreement . The terms and provisions of the Patent Security Agreement are hereby incorporated by reference and this Supplement shall be considered an amendment and supplement to and part of the Patent Security Agreement, all of the provisions of which Patent Security Agreement are and remain in full force and effect. Any reference after the date hereof in any Loan Document to the Patent Security Agreement shall be a reference to the Patent Security Agreement as amended and supplemented by this Supplement.

4. Reaffirmation of Obligations . Each Grantor hereby reaffirms its obligations (including, without limitation, the Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and any Exit Payment)) under the Patent Security Agreement, the Guaranty and Security Agreement and all other Loan Documents. Each Grantor hereby further ratifies and reaffirms the validity and enforceability of all of the Liens and security interests


heretofore granted, pursuant to and in connection with the Patent Security Agreement, the Security Agreement or any other Loan Document, to Grantee (for the benefit of the Secured Parties), as collateral security for the obligations (including, without limitation, the Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and any Exit Payment)) under the Loan Documents in accordance with their respective terms, and acknowledges that all of such Liens and security interests, and all Collateral (including, without limitation, the Patent Collateral (as defined in the Patent Security Agreement)) heretofore pledged as security for such obligations (including, without limitation, the Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and any Exit Payment)), continue to be and remain collateral for such obligations (including, without limitation, the Obligations(including any Non-Callable Make Whole Amount, any CoC Fee and any Exit Payment)) from and after the date hereof.

5. Ratification . Each Grantor hereby restates, ratifies and reaffirms each and every term and condition set forth in the Patent Security Agreement effective as of the date hereof and as amended hereby.

6. Governing Law . This Supplement is governed by and construed and enforced in accordance with the laws of the State of New York applicable to contracts made and to be performed in such State.

7. Counterparts . This Supplement may be executed in several counterparts, and by each Party on separate counterparts, each of which and any photocopies, facsimile copies and other electronic methods of transmission thereof shall be deemed an original, but all of which together shall constitute one and the same agreement.

[Signature Page Follows]


IN WITNESS WHEREOF, each Grantor has duly executed this Supplement as of the date first written above.

 

ENDOLOGIX, INC.
By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer

 

First Supplement to Patent Security Agreement


IN WITNESS WHEREOF, each Grantor has duly executed this Supplement as of the date first written above.

 

NELLIX, INC.
By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer and Secretary

 

First Supplement to Patent Security Agreement


IN WITNESS WHEREOF, each Grantor has duly executed this Supplement as of the date first written above.

 

TRIVASCULAR, INC.
By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer and Secretary

 

First Supplement to Patent Security Agreement


Agreed and Accepted
As of the Date First Written Above:
DEERFIELD PRIVATE DESIGN FUND IV, L.P. , as Agent and Grantee as Agent
By: Deerfield Mgmt IV, L.P., General Partner
By: J.E. Flynn Capital IV, LLC, General Partner
By:  

/s/ David J. Clark

Name:   David J. Clark
Title:   Authorized Signatory

 

First Supplement to Patent Security Agreement


SCHEDULE A

 

Description/Title

  

Application
No.

  

Application
Date

  

Patent No.

  

Registration
Date

  

Owner/

Applicant

Bifurcated vascular graft
deployment device
   09505038    2/16/00    6210422    4/3/01    Endologix, Inc.
Method of deploying
bifurcated vascular graft
   09086247    5/28/98    6156063    12/5/00    Endologix, Inc.
Bifurcated vascular graft
deployment device
   08802478    2/20/97    6090128    7/18/00    Endologix, Inc.
Inflatable implant    12628623    12/1/09    N/A    N/A    Trivascular, Inc.
Ptfe layers and methods of
manufacturing
   12250946    10/14/08    N/A    N/A    Trivascular, Inc.
Ptfe layers and methods of
manufacturing
   12250915    10/14/08    N/A    N/A    Trivascular, Inc.
Hybrid modular
endovascular graft
   11097718    4/1/05    N/A    N/A    Trivascular, Inc.
Non-degradable low
swelling, water soluble
radiopaque hydrogel polymer
   11097467    4/1/05    N/A    N/A    Trivascular, Inc.
Delivery system and method
for bifurcated graft
   11205793    8/15/05    N/A    N/A    Trivascular, Inc.
Methods, compositions
and devices for embolizing body
lumens
   11031311    1/7/05    N/A    N/A    Trivascular, Inc.
Endoluminal prosthesis
endoleak management
   10691849    10/22/03    N/A    N/A    Trivascular, Inc.
Layered endovascular graft    10803153    3/17/04    N/A    N/A    Trivascular, Inc.
Delivery system and method
for bifurcated graft
   10686863    10/16/03    N/A    N/A    Trivascular, Inc.
Inflatable intraluminal graft    10289137    11/5/02    N/A    N/A    Trivascular, Inc.
Endovascular graft    10289136    11/5/02    N/A    N/A    Trivascular, Inc.
Advanced endovascular graft    10091641    3/5/02    N/A    N/A    Trivascular, Inc.

 

 

 

First Supplement to Patent Security Agreement


Description/Title

  

Application
No.

  

Application
Date

  

Patent No.

  

Registration
Date

  

Owner/

Applicant

Delivery system and method
for bifurcated graft
   10122474    4/11/02    N/A    N/A    Trivascular, Inc.
Layered endovascular graft    09970576    10/3/01    N/A    N/A    Trivascular, Inc.
Dual inflatable arterial
prosthesis
   15540246    6/27/17    N/A    N/A    Endologix, Inc.
Catheter system and methods
of using same
   15632064    6/23/17    N/A    N/A    Endologix, Inc.
Catheter system and methods
of using same
   15639028    6/30/17    N/A    N/A    Endologix, Inc.
Apparatus and method of
placement of a graft or graft
system
   15610242    5/31/17    N/A    N/A    Endologix, Inc.
Stent graft delivery system    15676869    8/14/17    N/A    N/A    Nellix, Inc.        
Endovascular graft    15686214    8/25/17    N/A    N/A    TriVascular, Inc.
Advanced endovascular graft    15686218    8/25/17    N/A    N/A    TriVascular, Inc.
Endovascular graft for
aneurysms involving major
branch vessels
   15638559    6/30/17    N/A    N/A    TriVascular, Inc.
Systems and methods for
guidewire crossover for
bifurcated
   15491074    4/19/17    N/A    N/A    TriVascular, Inc.
Low profile stent graft and
delivery system
   15263469    9/13/16    N/A    N/A    TriVascular, Inc.
Endoluminal prosthesis
systems and methods
   15737223    12/15/17    N/A    N/A    Endologix, Inc.
Endovascular graft systems
and methods for deployment
in main and branch arteries
   65/529663    7/7/17    N/A    N/A    Endologix, Inc.
Stent grants and methods of
enhancing flexibility of stent
grafts by thermal pleating
   65/532737    7/14/17    N/A    N/A    Endologix, Inc.
Endoluminal device and
polymer
   62/575827    10/23/17    N/A    N/A    Endologix, Inc.

 

 

First Supplement to Patent Security Agreement


Description/Title

  

Application
No.

  

Application
Date

  

Patent
No.

  

Registration
Date

  

Owner/

Applicant

Systems and Methods with
Stents and Filling Structure
   62/382207    8/31/16    N/A    N/A    Endologix, Inc.
STENTS, GRAFTS,
DELIVERY SYSTEMS,
AND METHODS
   62/481560    4/4/17    N/A    N/A    Endologix, Inc.
ENDOVASCULAR
SYSTEMS, DEVICES,
AND METHODS
ALLOWING FOR BRANCH DEVICE
PLACEMENT IN POCKET
OF MAIN GRAFT
   62/489213    4/24/17    N/A    N/A    Endologix, Inc.
ENDOVASCULAR GRAFT
SYSTEMS AND
METHODS FOR
DEPLOYMENT IN MAIN AND
BRANCH ARTERIES
   62/529669    7/7/17    N/A    N/A    Endologix, Inc.

STENT GRAFTS AND
METHODS OF ENHANCING
FLEXIBILITY OF STENT GRAFTS BY THERMAL

PLEATING

   62/532737    7/14/17    N/A    N/A    Endologix, Inc.
STENT GRAFT    15/911629    3/5/18    N/A    N/A    Endologix, Inc.
INTERNAL ILIAC
PRESERVATION
DEVICES AND METHODS
   15/965649    4/__/18    N/A    N/A    Endologix, Inc.
MODULATION OF
INFLAMMATORY
RESPONSE FOLLOWING ENDOVASCULAR
TREATMENT
   62/661569    4/23/18    N/A    N/A    Endologix, Inc.
ADVANCED KINK
RESISTANT STENT
GRAFT
   16/005269    6/11/18    N/A    N/A    Endologix, Inc.
LOW PROFILE STENT
GRAFT AND DELIVERY
SYSTEM
   15/985572    5/21/18    N/A    N/A    Endologix, Inc.

 

 

First Supplement to Patent Security Agreement


Description/Title

  

Application
No.

  

Application
Date

  

Patent No.

  

Registration
Date

  

Owner/

Applicant

SYSTEMS AND
METHODS WITH STENT
AND FILLING
STRUCTURE
   15/774511    8/30/17    N/A    N/A    Endologix, Inc.
LONGITUDINALLY
EXTENDABLE STENT
GRAFT SYSTEMS AND
METHODS
   15/774548    1/23/18    N/A    N/A    Endologix, Inc.
GRAFT SYSTEMS
HAVING FILLING
STRUCTURES
SUPPORTED BY
SCAFFOLDS AND
METHODS FOR THEIR
USE
   16/035497    7/13/18    N/A    N/A    Endologix, Inc.
PRE-FIXATION DEVICE
FOR NELLIX AND OTHER
EVAS DEVICES
   62/678956    5/31/18    N/A    N/A    Endologix, Inc.
SYSTEMS AND
METHODS WITH
FENESTRATED GRAFT
AND FILLING
STRUCTURE
   16/066595       N/A    N/A    Endologix, Inc.
MODULATION OF
INFLAMMATORY
RESPONSE FOLLOWING
ENDOVASCULAR
TREATMENT
   62/661569    4/23/18    N/A    N/A    Endologix, Inc.
ENDOLUMINAL DEVICE
AND POLYMER
   62/575827    10/23/17    N/A    N/A    Endologix, Inc.
Implantable vascular graft    12/860280    8/20/10    20100318174       Endologix, Inc.
Endoluminal vascular
prosthesis
   11/623679    1/16/07    2007012412       Endologix, Inc.
Delivery catheter for
endovascular device
   13/835491    3/15/13    9498363    11/22/16    Trivascular, Inc.
Stent-graft with improved
flexibility
   15568834    10/24/17    N/A    N/A    TriVascular, Inc.

 

 

First Supplement to Patent Security Agreement


Description/Title

  

Application
No.

  

Application
Date

  

Patent No.

  

Registration
Date

  

Owner/

Applicant

System and methods of
Endovasular Aneurysm
Treatment
   14682414    8/21/17    N/A    N/A    Nellix, Inc.
Stent graft systems with
restraints in circumferential
channels and methods thereof
   62/678961    5/31/18    N/A    N/A    Endologix, Inc.
Percutaneous method and
device to treat dissections
   15/429090    2/9/17    N/A    N/A    Endologix, Inc.
Endovascular delivery
system with an improved radiopague
marker scheme
   16/049560    7/30/18    N/A    N/A    Nellix, Inc.

 

 

First Supplement to Patent Security Agreement


SCHEDULE 3

GRANTOR INFORMATION

 

GRANTOR
(exact legal name)

  

STATE/
COUNTRY
OF
ORGANIZATION

  

FEDERAL
EMPLOYER
IDENTIFICATION
NUMBER

  

CHIEF EXECUTIVE
OFFICE

   ORGANIZATIONAL
IDENTIFICATION
NUMBER
Endologix, Inc.    Delaware    68-0328265    2 Musick, Irvine, County
of Orange, CA 92618 U.S.A.
   2338745
CVD/RMS Acquisition Corp.    Delaware    33-0928438    2 Musick, Irvine, County
of Orange, CA 92618 U.S.A.
   2955166
RMS/Endologix Sideways Merger Corp    Delaware    03-0512974    2 Musick, Irvine, County
of Orange, CA 92618 U.S.A.
   3530477
Nellix, Inc.    Delaware    94-3398416    2 Musick, Irvine, County
of Orange, CA 92618 U.S.A.
   3359980
TriVascular Technologies, Inc.    Delaware    87-0807313    3910 Brickway Blvd.,
County of Santa Rosa,
Sonoma, CA 95403 U.S.A.
   4387054
TriVascular, Inc.    California    68-0402620    3910 Brickway Blvd.,
Santa Rosa, County of
Sonoma, CA 95403 U.S.A.
   C2065374
Endologix
Canada, LLC
   Delaware    47-2442872    3910 Brickway Blvd.,
Santa Rosa, County of
Sonoma, CA 95403 U.S.A.
   5647226
TriVascular Sales LLC    Texas    46-0859179    3910 Brickway Blvd.,
Santa Rosa, County of
Sonoma, CA 95403 U.S.A.
   801644988


SCHEDULE 4

PLACES OF BUSINESS / LOCATION OF COLLATERAL

 

Grantor

  

Location

  

Specify
Whether
Location
Has
(i) Inventory
and/or
Equipment,
(ii) Books
and
Records, or
(iii) Both

  

Interest

  

Lessor/Property

Owner/Lessee

Endologix, Inc.    2 Musick, Irvine,
County of Orange,
CA 92618 U.S.A.
   Both    Lease    The Northwestern Mutual Life Insurance Company, att: William A. Budge, 19 Hammond, Suite 501, Irvine, California 92618
Endologix, Inc.    33 & 35 Hammond, Irvine, County of Orange, CA 92618 U.S.A    Inventory and/or Equipment    Lease    The Northwestern Mutual Life Insurance Company, att: William A. Budge, 19 Hammond, Suite 501, Irvine, California 92618
Endologix, Inc.   

378 Commercial Street, Malden, MA 02148

165 Chubb Avenue, Lyndhurst, NJ 07071

1130 Commerce Blvd, Swedesboro, NJ 08085

2250 Outerloop Drive, Louisville, KY 40219

   Inventory
and/or
Equipment
   Third
Party
Warehouse
   UPS
Endologix, Inc.    54 Yangcheon-ro, Gangseo-gu, Seoul 07522    Inventory
and/or
Equipment (no other Collateral is located at this location)
   Third
Party
Warehouse
   TNT Express Korea
Endologix, Inc.   

10 Anson Road #21-04 & #21-04A

International Plaza

   Inventory
and/or
Equipment (no other
   Occupied    Endologix Singapore Private Limited


Grantor

  

Location

  

Specify
Whether
Location
Has
(i) Inventory
and/or
Equipment,
(ii) Books
and
Records, or
(iii) Both

  

Interest

  

Lessor/Property

Owner/Lessee

   Singapore 079903    Collateral is located at this location)      
Endologix, Inc.    A-311, M-Sate, 114 Beopwon-ro, Songpa-gu, Seoul, South Korea    Inventory
and/or
Equipment (no other
Collateral is located at this location)
   Occupied    N.A.
Endologix, Inc.    Grantor and each Guarantor’s sales representatives hold Trunk Inventory in their possession for sales calls and procedures, which Trunk Inventory is not held at a specific location or locations.    Inventory
and/or
Equipment (no other Collateral is located at this location)
   N.A.    N.A.
   Certain Inventory of the Grantor and each Guarantor is held by numerous third parties on a consignment basis at various locations.    Inventory
and/or
Equipment (no other Collateral is located at this location)
   N.A.    N.A.
CVD/RMS
Acquisition
Corp.
   2 Musick, Irvine,
County of Orange,
CA 92618 U.S.A.
   Books and Records    Occupied    The Northwestern Mutual Life Insurance Company, attn: William A. Budge, 19 Hammond, Suite 501, Irvine, California 92618
Nellix, Inc.    2 Musick, Irvine,
County of Orange,
CA 92618 U.S.A.
   Books and Records    Occupied    The Northwestern Mutual Life Insurance Company, attn: William A. Budge, 19 Hammond, Suite 501, Irvine, California 92618


Grantor

  

Location

  

Specify
Whether
Location
Has
(i) Inventory
and/or
Equipment,
(ii) Books
and
Records, or
(iii) Both

  

Interest

  

Lessor/Property

Owner/Lessee

RMS/Endologix Sideways Merger Corp.    2 Musick, Irvine,
County of Orange,
CA 92618 U.S.A.
   Books and Records    Occupied    The Northwestern Mutual Life Insurance Company, attn: William A. Budge, 19 Hammond, Suite 501, Irvine, California 92618
TriVascular
Technologies,
Inc.
   3910 Brickway
Blvd., Santa Rosa,
County of Sonoma,
CA 95403 U.S.A.
   Books and Records    Occupied    Sonoma Airport
Properties LLC
TriVascular, Inc.    3910 Brickway
Blvd., Santa Rosa,
County of Sonoma,
CA 95403 U.S.A.
   Both    Lease    Sonoma Airport
Properties LLC
TriVascular Sales LLC    3910 Brickway
Blvd., Santa Rosa,
County of Sonoma,
CA 95403 U.S.A.
   Books and Records    Occupied    Sonoma Airport
Properties LLC
Endologix
Canada, LLC
   3910 Brickway
Blvd., Santa Rosa,
County of
Sonoma, CA
95403 U.S.A.
   Books and Records    Occupied    Sonoma Airport
Properties LLC


SCHEDULE 5

COMMERCIAL TORT CLAIMS

None.


SCHEDULE 6

ACCOUNTS

 

ENTITY    COUNTRY    ACCT    CURR    BANK    USE
Endologix Inc    US    XXXXX1702    USD    Bank of America    Operating account
Endologix Inc    US    XXXXX1689    USD    Bank of America    Payroll account
Endologix Inc    US    XXXXX5279    USD    Wells Fargo    Old Operating account
Endologix Inc    US    XXXXX5311    USD    Wells Fargo    Old payroll account
Endologix Inc    Us    XXXXX3910    USD    Bank of America    Lockbox account
Endologix Inc    US    XXXXX4066    USD    Bank of America    Credit Card Cash Collateral account
Trivascular Inc    US    XXXXX5539    USD    Silicon Valley Bank    Operating account
Trivascular Inc    The Netherlands    XXXXX8640    EUR    KBC Bank NV Nederland    Currency account
Trivascular Inc    UK London    XXXXX8709    GBP    National Westminster Bank    Currency account
Trivascular Sales LLC    US    XXXXX7400    USD    Silicon Valley Bank    Payroll account
Endologix Canada LLC    Canada    XXXXX7912    CAD    Bank of Montreal    Operating account


SCHEDULE 7

REAL PROPERTY

None.


SCHEDULE 8

COPYRIGHTS

None.


SCHEDULE 9

INTELLECTUAL PROPERTY LICENSES

 

1.

Inbound License Agreement, dated as of February 22, 2006, by and between Incept LLC and Nellix, Inc.

 

2.

Inbound Amendment No. 1. to License Agreement, dated as of April 30, 2012, by and between Incept LLC and Nellix, Inc.

 

3.

Inbound Amendment No. 2 to License Agreement, dated as of December 3, 2014, by and between Incept LLC and Nellix, Inc.

 

4.

Inbound Master License Agreement, dated as of May 5, 2008, by and between SurModics, Inc. and Endologix, Inc.

 

5.

Inbound Development and OEM Device Supply Agreement, dated as of August 5, 2015, by and between Bard Peripheral Vascular, Inc. and Endologix, Inc.

 

6.

Inbound License Agreement, dated as of June 22, 2011, by and between NorMedix, LLC and Endologix, Inc.

 

7.

Inbound Settlement and Patent License Agreement, dated as of March 17, 2016, by and between LifePort Sciences, LLC and Endologix, Inc.

 

8.

Inbound License Agreement, dated as of July 23, 2013, by and between Thomas L. Fogarty and Endologix, Inc.

 

9.

Inbound License Agreement, dated as of March 28, 2008, by and between Trivascular, Inc. (formerly Trivascular 2, Inc.) and Boston Scientific Scimed, Inc. and Endovascular Technologies, Inc.


SCHEDULE 10

PATENTS

See attached.


PATENT SCHEDULE

 

Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC.    US    Stent graft    US9757262B2    US13943246A    2013-07-16
ENDOLOGIX INC.    US    Catheter system and methods of using same    US9700701B2    US13544426A    2012-07-09
ENDOLOGIX INC.    US    Catheter system and methods of using same    US9687374B2    US15379268A    2016-12-14
ENDOLOGIX INC.    US    Percutaneous method and device to treat dissections    US9579103B2    US12771711A    2010-04-30
ENDOLOGIX INC.    US    Catheter system and methods of using same    US9549835B2    US14462485A    2014-08-18


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC.    US    Method and system for treating aneurysms    US9415195B2    US13441762A    2012-04-06
ENDOLOGIX INC.    US    Devices and methods to treat vascular dissections    US9393100B2    US13988175A    2013-05-17
ENDOLOGIX INC.    US    Method for forming materials in situ within a medical device    US9289536B2    US14201332A    2014-03-07
ENDOLOGIX INC.    US    Apparatus and method of placement of a graft or graft system    US9149381B2    US14172126A    2014-02-04
ENDOLOGIX INC.    US    Stent graft    US8821564B2    US13397952A    2012-02-16
ENDOLOGIX INC.    US    Apparatus and methods for repairing aneurysms    US8814928B2    US12616928A    2009-11-12


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC.    US    Catheter system and methods of using same    US8808350B2    US13408952A    2012-02-29
ENDOLOGIX INC.    US    Graft systems having semi-permeable filling structures and methods for their use    US8801768B2    US13355705A    2012-01-23
ENDOLOGIX INC    US    Bifurcated graft deployment systems and methods    US8764812B2    US13745682A    2013-01-18
ENDOLOGIX INC.    US    Apparatus and method of placement of a graft or graft system    US8672989B2    US13546950A    2012-07-11
ENDOLOGIX INC.    US    Graft deployment system    US8568466B2    US13269332A    2011-10-07
ENDOLOGIX INC.    US    Dual concentric guidewire and methods of bifurcated graft deployment    US8523931B2    US11623022A    2007-01-12


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC.    US    Stent graft    US8491646B2    US12837398A    2010-07-15
ENDOLOGIX INC.    US    Endolumenal vascular prosthesis with neointima inhibiting polymeric sleeve    US8377110B2    US10820455A    2004-04-08
ENDOLOGIX INC.    US    Bifurcated graft deployment systems and methods    US8357192B2    US13046541A    2011-03-11
ENDOLOGIX INC.    US    Bifurcated graft deployment systems and methods    US8236040B2    US12101863A    2008-04-11
ENDOLOGIX INC.    US    Catheter system and methods of using same    US8216295B2    US12496446A    2009-07-01
ENDOLOGIX INC.    US    Apparatus and method of placement of a graft or graft system    US8221494B2    US12390346A    2009-02-20


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC.    US    Methods and systems for endovascular aneurysm treatment    US8182525B2    US12421297A    2009-04-09
ENDOLOGIX INC.    US    Single puncture bifurcation graft deployment system    US8167925B2    US12732095A    2010-03-25
ENDOLOGIX INC.    US    Bifurcation graft deployment catheter    US8147535B2    US11189101A    2005-07-25
ENDOLOGIX INC.    US    Material for creating multi-layered films and methods for making the same    US8133559B2    US13100483A    2011-05-04
ENDOLOGIX INC.    US    Stent graft    US8118856B2    US12844266A    2010-07-27
ENDOLOGIX INC.    US    Graft systems having filling structures supported by scaffolds and methods for their use    US8048145B2    US11413460A    2006-04-28


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC.    US    Graft deployment system    US8034100B2    US10722367A    2003-11-25
ENDOLOGIX INC.    US    Material for creating multi-layered films and methods for making the same    US7951448B2    US12858274A    2010-08-17
ENDOLOGIX INC    US    Self expanding bifurcated endovascular prosthesis    US7892277B2    US11417883A    2006-05-03
ENDOLOGIX INC.    US    Material for creating multi-layered films and methods for making the same    US7790273B2    US11752750A    2007-05-23
ENDOLOGIX INC.    US    Devices for repairing aneurysms    US7682383B2    US10481386A    2004-06-14
ENDOLOGIX INC.    US    System and methods for endovascular aneurysm treatment    US7666220B2    US11482503A    2006-07-07


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC.    US    Methods and systems for endovascular aneurysm treatment    US7530988B2    US11187471A    2005-07-22
ENDOLOGIX INC    US    Self expanding bifurcated endovascular prosthesis    US7520895B2    US10119525A    2002-04-08
ENDOLOGIX INC    US    Bifurcation graft deployment catheter    US6953475B2    US10675060A    2003-09-30
ENDOLOGIX INC.    US    Implantable vascular graft    US6733523B2    US09891620A    2001-06-26
ENDOLOGIX INC    US    Single puncture bifurcation graft
deployment system
   US6663665B2    US09795993A    2001-02-28
ENDOLOGIX INC.    US    Bifurcation graft deployment catheter    US6660030B2    US09747094A    2000-12-22


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC    US    Endoluminal vascular prosthesis    US6508835B1    US09723979A    2000-11-28
ENDOLOGIX INC.    US    Bifurcation graft deployment catheter    US6500202B1    US09525778A    2000-03-15
ENDOLOGIX INC.    US    Dual wire placement catheter    US6440161B1    US09348356A    1999-07-07
ENDOLOGIX INC.    US    Single puncture bifurcation graft
deployment system
   US6261316B1    US09266661A    1999-03-11
ENDOLOGIX INC.    US    Articulating bifurcation graft    US6197049B1    US09251363A    1999-02-17
ENDOLOGIX INC.    US    Endoluminal vascular prosthesis    US6187036B1    US09210280A    1998-12-11


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC.    US    Segmented stent for flexible stent delivery system    US6187034B1    US09229856A    1999-01-13
ENDOLOGIX INC.    US    Endoluminal vascular prosthesis    US6077296A    US0934689A    1998-03-04
ENDOLOGIX INC.    US    Stent delivery system featuring a flexible balloon    US6022359A    US09229519A    1999-01-13
ENDOLOGIX INC.    US    Radially expandable stent featuring accordion stops    US5931866A    US09028305A    1998-02-24
ENDOLOGIX INC.    US    DUAL INFLATABLE ARTERIAL PROSTHESIS    US20180021045A1    US15540246A    2017-06-27
ENDOLOGIX INC.    US    CATHETER SYSTEM AND METHODS OF USING SAME    US20170304098A1    US15632064A    2017-06-23


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC.    US    CATHETER SYSTEM AND METHODS OF USING SAME    US20170296791A1    US15639028A    2017-06-30
ENDOLOGIX INC    US    APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM    US20170266025A1    US15610242A    2017-05-31
ENDOLOGIX INC.    US    MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES    US20170239035A1    US15310198A    2016-11-10
ENDOLOGIX INC.    US    METHODS AND SYSTEMS FOR ANEURYSM TREATMENT USING FILLING STRUCTURES    US20170238937A1    US15438682A    2017-02-21
ENDOLOGIX INC    US    APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM    US20170128246A1    US15414499A    2017-01-24
ENDOLOGIX INC    US    METHOD AND SYSTEM FOR TREATING ANEURYSMS    US20170007263A1    US15205365A    2016-07-08


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC.    US    METHOD FOR FORMING HYDROGELS AND MATERIALS THEREFOR    US20160367731A1    US15256462A    2016-09-02
ENDOLOGIX INC.    US    DEVICES AND METHODS TO TREAT VASCULAR DISSECTIONS    US20160302798A1    US15194159A    2016-06-27
ENDOLOGIX INC.    US    SYSTEMS AND METHODS FOR FORMING MATERIALS IN SITU WITHIN A MEDICAL DEVICE    US20160030051A1    US14776385A    2015-09-14
ENDOLOGIX INC    US    APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM    US20150366688A1    US14840428A    2015-08-31
ENDOLOGIX INC.    US    METHOD AND SYSTEM FOR TREATING ANEURYSMS    US20150250989A1    US14717938A    2015-05-20
ENDOLOGIX INC.    US    FENESTRATED PROSTHESIS    US20150173923A1    US14581675A    2014-12-23


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC.    US    Apparatus and Methods for Repairing Aneurysms    US20150012081A1    US14330812A    2014-07-14
ENDOLOGIX INC.    US    STENT GRAFT    US9907642    US14461308A    2014-08-15
ENDOLOGIX INC    US    ENDOLUMENAL VASCULAR PROSTHESIS WITH NEOINTIMA INHIBITING POLYMERIC SLEEVE    US20130253638A1    US13731908A    2012-12-31
ENDOLOGIX INC.    US    Methods and Systems for Treating Aneurysms    US20120184982A1    US13354094A    2012-01-19
ENDOLOGIX INC.    US    APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM    US20120109279A1    US13287907A    2011-11-02
ENDOLOGIX INC.    US    FILLING STRUCTURE FOR A GRAFT SYSTEM AND METHODS OF USE    US20110276078A1    US12966852A    2010-12-13


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC    US    SELF EXPANDING BIFURCATED ENDOVASCULAR PROSTHESIS    US20110224782A1    US13027077A    2011-02-14
ENDOLOGIX INC.    US    ENDOLUMINAL VASCULAR PROSTHESIS    US20110218617A1    US13039157A    2011-03-02
ENDOLOGIX INC    US    APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM    US20110054587A1    US12769546A    2010-04-28
ENDOLOGIX INC    US    IMPLANTABLE VASCULAR GRAFT    US20100318174A1    US12860280A    2010-08-20
ENDOLOGIX INC    US    IMPLANTABLE VASCULAR GRAFT    US20100318181A1    US12860310A    2010-08-20
ENDOLOGIX INC.    US    UTILIZATION OF MURAL THROMBUS FOR LOCAL DRUG DELIVERY INTO VASCULAR TISSUE    US20100261662A1    US12757900A    2010-04-09


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC    US    GRAFT DEPLOYMENT SYSTEM    US20100179636A1    US12726257A    2010-03-17
ENDOLOGIX INC.    US    STENT GRAFT DELIVERY SYSTEM    US20100036360A1    US12429474A    2009-04-24
ENDOLOGIX INC.    US    DOCKING APPARATUS AND METHODS OF USE    US20090319029A1    US12478208A    2009-06-04
ENDOLOGIX INC.    US    GRAFT ENDOFRAME HAVING AXIALLY VARIABLE CHARACTERISTICS    US20100004728A1    US12371087A    2009-02-13
ENDOLOGIX INC.    US    METHOD AND AGENT FOR IN-SITU STABILIZATION OF VASCULAR TISSUE    US20090155337A1    US12269677A    2008-11-12
ENDOLOGIX INC.    US    STENT    US20090105806A1    US12257149A    2008-10-23


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC.    US    Multi-segmented graft deployment system    US20080071343A1    US11522292A    2006-09-15
ENDOLOGIX INC    US    IMPLANTABLE VASCULAR GRAFT    US20070299497A1    US11764715A    2007-06-18
ENDOLOGIX INC.    US    Methods and systems for aneurysm treatment using filling structures    US20070150041A1    US11444603A    2006-05-31
ENDOLOGIX INC    US    ENDOLUMINAL VASCULAR PROSTHESIS    US20070112412A1    US11623679A    2007-01-16
ENDOLOGIX INC.    US    Method and apparatus for decompressing aneurysms    US20070078506A1    US11580201A    2006-10-12
ENDOLOGIX INC.    US    Method and apparatus for decompressing aneurysms    US20050245891A1    US11104303A    2005-04-12


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC.    US    Vascular stent-graft apparatus    US20040167607A1    US10787404A    2004-02-24
ENDOLOGIX INC.    US    Stent-graft with positioning anchor    US20040116997A1    US10668901A    2003-09-22
ENDOLOGIX INC.    US    Flexible vascular graft    US20010025195A1    US09728582A    2000-12-01
ENDOLOGIX INC    US    MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES    US20170239035A1    US15310198A    2016-11-10
ENDOLOGIX INC    US    DUAL INFLATABLE ARTERIAL PROSTHESIS    US20180021045A1    US15540246A    2017-06-27
ENDOLOGIX INC    US    ENDOLUMINAL PROSTHESIS SYSTEMS AND METHODS       US15737223    2017-12-15


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC    US    Systems and Methods with Stents and Filling Structure       62/382207    2016-08-31
ENDOLOGIX INC    US    STENTS, GRAFTS, DELIVERY SYSTEMS, AND METHODS       62/481560    2017-04-04
ENDOLOGIX INC    US    ENDOVASCULAR SYSTEMS, DEVICES, AND METHODS ALLOWING FOR BRANCH DEVICE PLACEMENT IN POCKET OF MAIN GRAFT       62/489213    2017-04-24
ENDOLOGIX INC    US    ENDOVASCULAR GRAFT SYSTEMS AND METHODS FOR DEPLOYMENT IN MAIN AND BRANCH ARTERIES       62/529669    2017-07-07
ENDOLOGIX INC    US    STENT GRAFTS AND METHODS OF ENHANCING FLEXIBILITY OF STENT GRAFTS BY THERMAL PLEATING       62/532737    2017-07-14
ENDOLOGIX INC    US    STENT GRAFT       15/911629    2018-03-05


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC    US    INTERNAL ILIAC PRESERVATION DEVICES AND METHODS       15/965649    2018-04-
ENDOLOGIX INC    US   

MODULATION OF INFLAMMATORY

RESPONSE FOLLOWING
ENDOVASCULAR TREATMENT

      62/661569    2018-4-23
ENDOLOGIX INC    US    ADVANCED KINK RESISTANT STENT GRAFT       16/005269    2018-6-11
ENDOLOGIX INC    US    LOW PROFILE STENT GRAFT AND DELIVERY SYSTEM       15/985572    2018-5-21
ENDOLOGIX INC    US    SYSTEMS AND METHODS WITH STENT AND FILLING STRUCTURE       15/774511    2017-8-30
ENDOLOGIX INC    US   

LONGITUDINALLY EXTENDABLE

STENT GRAFT SYSTEMS AND
METHODS

      15/774548    2018-1-23


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC    US   

GRAFT SYSTEMS HAVING FILLING

STRUCTURES SUPPORTED BY
SCAFFOLDS AND METHODS FOR THEIR USE

      16/035497    2018-7-13
ENDOLOGIX INC    US    PRE-FIXATION DEVICE FOR NELLIX AND OTHER EVAS DEVICES       62/678956    2018-5-31
ENDOLOGIX INC    US    SYSTEMS AND METHODS WITH FENESTRATED GRAFT AND FILLING STRUCTURE       16/066595   
ENDOLOGIX INC    US   

MODULATION OF INFLAMMATORY

RESPONSE FOLLOWING
ENDOVASCULAR TREATMENT

      62/661569    2018-4-23
ENDOLOGIX INC.    US    FENESTRATED PROSTHESIS    US8945202    12/769581    2015-2-3
ENDOLOGIX INC.    US    Fenestrated prosthesis    US8945202    12/769581    4/28/10


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX, INC.    US   

Bifurcated vascular graft deployment

device

   US6210422    09/505038    2/16/00
ENDOLOGIX, INC.    US    Method of deploying bifurcated vascular graft    US6156063    09/086247    5/28/98
ENDOLOGIX, INC.    US   

Bifurcated vascular graft deployment

device

   US6090128    08/802478    2/20/97
ENDOLOGIX, INC.    US   

Endovascular prosthesis with improved

sealing means for aneurysmal arterial
disease and method of use

   US5665117    08/620072    3/21/96
ENDOLOGIX, INC.    US    Locking assembly for coupling guidewire to delivery system       15/317905    12/9/16
Endologix, Inc. and The Cleveland Clinic Foundation    US    Fenestrated prosthesis    US8945202    US12769581    4/28/10


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

Endologix, Inc.    US   

Single puncture bifurcation graft

deployment system

   US7691135    US10690227    10/21/03
Endologix, Inc.    US    Bifurcated vascular graft and method and apparatus for deploying same    US6951572    US10639255    8/12/03
Endologix, Inc.    US    Radiation delivery balloon catheter    US6699170    US09688396    10/16/00
Endologix, Inc.    US    Dual wire placement catheter    US6689157    US10035729    12/21/01
Endologix, Inc.    US    Method for delivering radiation to an intraluminal site in the body    US6685618    US09944649    8/31/01
Endologix, Inc.    US    Radiation delivery catheters and dosimetry methods    US6491619    US09648563    8/25/00


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

Endologix, Inc.    US    Endoluminal vascular prosthesis    US6331190    US09483411    1/14/00
Endologix, Inc.    US   

Bifurcated vascular graft deployment

device

   US6210422    US09505038    2/16/00
Endologix, Inc.    US    Method of deploying bifurcated vascular graft    US6156063    US09086247    5/28/98
Endologix, Inc.    US   

Bifurcated vascular graft deployment

device

   US6090128    US08802478    2/20/97
Endologix, Inc.    US    Axially non-contracting flexible radially expandable stent    US6083259    US09192803    11/16/98
Endologix, Inc.    US   

Endovascular prosthesis with improved

sealing means for aneurysmal arterial
disease and method of use

   US5665117    US08620072    3/21/96


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

Endologix, Inc.    US    Apparatus and method of placement of a graft or graft system       US14172126    2/4/14
Endologix, Inc. and The Cleveland Clinic Foundation    US    Apparatus and method of placement of a graft or graft system       US12769506    4/28/10
Endologix, Inc.    US    Stent graft delivery system       US12429474    4/24/09
ENDOLOGIX INC    WO    ENDOLUMINAL PROSTHESIS SYSTEMS AND METHODS    WO2016210363A1    PCT/US2016/039414    2016-06-24
ENDOLOGIX INC    JP    MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES    JP2017517321A    JP2016569901    2015-05-05
ENDOLOGIX INC    CN    Endoluminal Prosthesis Systems and Methods       201680037099.X    2017-12-22


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC    JP    DUAL INFLATABLE ARTERIAL PROSTHESIS       2017-534803    2017-06-28
ENDOLOGIX INC    US    ENDOLUMINAL DEVICE AND POLYMER       62/575827    2017-10-23
TRIVASCULAR INC    US    Advanced Endovascular Graft    US9788934B2    US14799656A    2015-07-15
ENDOLOGIX INC    WO    DUAL INFLATABLE ARTERIAL PROSTHESIS    WO2016109757A1    PCT/US2015/068204    2015-12-30
ENDOLOGIX INC    WO    SYSTEMS AND METHODS WITH FENESTRATED GRAFT AND FILLING STRUCTURE    WO2017117068A1    PCT/US2016/068575    2016-12-23
ENDOLOGIX INC    WO    SYSTEMS AND METHODS WITH GRAFT BODY, INFLATABLE FILL CHANNEL, AND FILLING STRUCTURE    WO2017197313A1    PCT/US2017/032490    2017-05-12


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC    PCT    SYSTEMS AND METHODS WITH STENT AND FILLING STRUCTURE       PCT/US2017/049482    2017-08-30
ENDOLOGIX INC    PCT    LONGITUDINALLY EXTENDABLE STENT GRAFT SYSTEMS AND METHODS       PCT/US2018/014920    2018-01-23
ENDOLOGIX INC    PCT    STENT GRAFTS AND METHODS OF ENHANCING FLEXIBILITY OF STENT GRAFTS BY THERMAL PLEATING       PCT/US2018/042158    2018-7-13
ENDOLOGIX INC    PCT   

ENDOVASCULAR SYSTEMS,

DEVICES, AND METHODS
ALLOWING FOR BRANCH DEVICE PLACEMENT IN CHANNEL OF MAIN GRAFT

      PCT/US2018/028959    2018-4-23
ENDOLOGIX INC    PCT    ENDOVASCULAR GRAFT SYSTEMS AND METHODS FOR DEPLOYMENT IN MAIN AND BRANCH ARTERIES       PCT/US2018/041152    7/6/2018


ENDOLOGIX INC    EP    DUAL CONCENTRIC GUIDEWIRE AND METHODS OF BIFURCATED GRAFT DEPLOYMENT | DOPPELTER KONZENTRISCHER FÜHRUNGSDRAHT UND VERFAHREN ZUM EINSATZ EINES VERZWEIGTEN IMPLANTATS | FIL DE GUIDAGE CONCENTRIQUE    EP2117631B1    EP2008727613A    2008-01-11


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

     

MIXTE ET PROCÉDÉS DE

DÉPLOIEMENT DE GREFFON À DEUX BRANCHES

        
ENDOLOGIX INC    EP   

DEVICES FOR REPAIRING

ANEURYSMS | VORRICHTUNG ZUM AUSBESSERN EINES ANEURYSMAS | DISPOSITIFS DE REPARATION D’ANEVRISMES

   EP1397089B1    EP2002730505A    2002-06-17
ENDOLOGIX INC    EP    CATHETER SYSTEM | Kathetersystem | Systèmes de cathéter    EP2520320B1    EP2012178965A    2009-06-30
ENDOLOGIX INC    EP   

DEVICES FOR REPAIRING

ANEURYSMS | VORRICHTUNG ZUM AUSBESSERN EINES ANEURYSMAS | PROTHÈSE POUR LE TRAITEMENT DES ANÉVRISMES

   EP2260795B1    EP201011024A    2002-06-17
ENDOLOGIX INC    EP    SYSTEMS FOR ANEURYSM TREATMENT USING FILLING STRUCTURES | SYSTEME ZUR BEHANDLUNG VON ANEURYSMEN UNTER VERWENDUNG VON FÜLLSTRUKTUREN | SYSTEMES POUR LE TRAITEMENT DE L’ANEVRISME UTILISANT DES STRUCTURES DE REMPLISSAGE    EP1962722B1    EP2006850439A    2006-12-18


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC    EP    GRAFT SYSTEMS HAVING FILLING STRUCTURES SUPPORTED BY SCAFFOLDS | TRANSPLANTATIONSSYSTEM MIT DURCH GERÜSTE UNTERSTÜTZTEN FÜLLSTRUKTUREN | SYSTEMES DE GREFFE PRESENTANT DES STRUCTURES DE REMPLISSAGE SOUTENUES PAR DES ECHAFAUDAGES    EP1874231B1    EP2006751879A    2006-04-28
ENDOLOGIX INC    EP    GRAFT DEPLOYMENT SYSTEM | IMPLANTAT-ABLAGESYSTEM | SYSTEME DE DEPLOIEMENT DE TUBE PROTHETIQUE    EP1572034B1    EP2003790040A    2003-11-25
ENDOLOGIX INC    EP    STENT GRAFT | STENT-IMPLANTAT | GREFFON DE STENT    EP2459127B1    EP2010806904A    2010-07-27
ENDOLOGIX INC    EP    STENT-GRAFT WITH POSITIONING ANCHOR | STENT-GRAFT MIT POSITIONIERUNGSVERANKERUNG | ENDOPROTHESE A ANCRAGE DE POSITIONNEMENT    EP1542616B1    EP2003754880A    2003-09-22
ENDOLOGIX INC    EP    Systems for endovascular aneurysm treatment | Systeme zur endovaskulären Aneurysma-Therapie | Systèmes pour le traitement d’anévrismes endovasculaires    EP2422745B1    EP2011180827A    2005-07-22


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC    EP    Catheter system | Kathetersystem | Système de cathéter    EP2293838B1    EP2009774381A    2009-06-30
ENDOLOGIX INC    EP    Systems for endovascular aneurysm treatment | Systeme zur Behandlung von endovaskulären Aneurysmen | Systèmes pour le traitement d’anévrisme endovasculaire    EP1778131B1    EP2005773726A    2005-07-22
ENDOLOGIX INC    EP    IMPLANTABLE VASCULAR GRAFT | IMPLANTIERBARE GEFÄSSPROTHESE | GREFFE VASCULAIRE IMPLANTABLE    EP1333787B1    EP2001990900A    2001-11-08
ENDOLOGIX INC    EP    Bifurcated vascular graft and method and apparatus for deploying same | Abzweigendes Gefässtransplantat sowie Verfahren und Gerät zu dessen Entfaltung | Implant vasculaire à deux branches, procédé et appareil pour sa mise en place    EP1009325B1    EP1998906274A    1998-02-06
ENDOLOGIX INC    EP    SINGLE PUNCTURE BIFURCATION GRAFT DEPLOYMENT SYSTEM | EINE EINZIGE PUNKTION ERFORDENDES ENTFALTUNGSSYSTEM FÜR EIN GEFÄSSIMPLANTAT MIT VERZWEIGUNG | SYSTEME DE DEPLOIEMENT D’UNE GREFFE AU NIVEAU D’UNE BIFURCATION, A L’AIDE D’UN SEUL ORIFICE    EP1159024B1    EP2000916167A    2000-03-07


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC    EP    SELF EXPANDING BIFURCATED ENDOVASCULAR PROSTHESIS | SELBSTEXPANDIERENDE, SICH VERZWEIGENDE, ENDOVASKULARE PROTHESE | PROTHESE ENDOVASCULAIRE BIFURQUEE A DILATATION AUTOMATIQUE    EP1087729B1    EP1999957012A    1999-05-28
ENDOLOGIX INC    EP    ENDOLUMINAL VASCULAR
PROSTHESIS | PROTHESE IM
INNEREN EINES GEFÄSSES |
PROTHESE VASCULAIRE
ENDOLUMINALE
   EP1059893B1    EP1998930137A    1998-06-15
ENDOLOGIX INC    EP    ENDOLUMINAL VASCULAR PROSTHESIS | ENDOLUMINALE VASKULÄRE PROTHESE | PROTHESE VASCULAIRE ENDOLUMINALE    EP1146833B1    EP1999973254A    1999-11-10
ENDOLOGIX INC    EP    DUAL INFLATABLE ARTERIAL PROSTHESIS | DOPPELTE AUFBLASBARE ARTERIENPROTHESE | DOUBLE PROTHÈSE ARTÉRIELLE GONFLABLE    EP3240508A1    EP2015876323A    2015-12-30
ENDOLOGIX INC    EP    FORMING HYDROGELS AND MATERIALS THEREFOR | HERSTELLUNG VON HYDROGELEN UND MATERIALIEN DAFÜR | FORMATION D’HYDROGELS ET MATÉRIAUX POUR CEUX-CI    EP3113722A4    EP2015758921A    2015-03-06


ENDOLOGIX INC    EP    MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES | MODULARE STENTPROTHESENSYSTEME UND VERFAHREN MIT AUFBLASBAREN    EP3148483A4    EP2015800658A    2015-05-05


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

      FÜLLSTRUKTUREN | SYSTÈMES ET PROCÉDÉS DE GREFFE D’ENDOPROTHÈSE MODULAIRE COMPRENANT DES STRUCTURES DE REMPLISSAGE GONFLABLES         
ENDOLOGIX INC    EP    LOCKING ASSEMBLY FOR COUPLING GUIDEWIRE TO DELIVERY SYSTEM | VERRIEGELUNGSANORDNUNG ZUR KOPPLUNG EINES FÜHRUNGSDRAHTS AN EIN AUSGABESYSTEM | ENSEMBLE DE VERROUILLAGE POUR ACCOUPLER UN FIL-GUIDE À UN SYSTÈME DE DISTRIBUTION    EP3139860A1    EP2016790254A    2016-06-29
ENDOLOGIX INC    EP    FILLING STRUCTURE FOR A GRAFT SYSTEM AND METHODS OF USE | FÜLLSTRUKTUR FÜR EIN PROTHESENSYSTEM UND VERWENDUNGSVERFAHREN | STRUCTURE DE REMPLISSAGE POUR UN SYSTÈME DE GREFFE ET PROCÉDÉ D’UTILISATION    EP2519191A4    EP2010841580A    2010-12-21
ENDOLOGIX INC    EP    METHOD FOR FORMING MATERIALS IN SITU WITHIN A MEDICAL DEVICE | VERFAHREN ZUR HERSTELLUNG VON MATERIALIEN IN SITU IN EINER MEDIZINISCHEN VORRICHTUNG | MÉTHODE DE FORMATION DE MATÉRIAUX IN SITU DANS UN DISPOSITIF MÉDICAL    EP2968692A1    EP2014712991A    2014-03-07


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC    EP    DOCKING APPARATUS AND METHODS OF USE | ANDOCKVORRICHTUNG UND VERWENDUNGSVERFAHREN | APPAREIL DE FIXATION ET PROCÉDÉS D’UTILISATION    EP2299933A4    EP2009770704A    2009-06-04
ENDOLOGIX INC    EP    SEALING APPARATUS AND METHODS OF USE | VERSCHLUSSGERÄT UND ANWENDUNGSVERFAHREN | DISPOSITIF DE FERMETURE ET PROCÉDÉS D’UTILISATION ASSOCIÉS    EP2299931A4    EP2009759453A    2009-06-04
ENDOLOGIX INC    EP    BIFURCATED GRAFT DEPLOYMENT SYSTEMS AND METHODS | SYSTEME UND VERFAHREN ZUR FREISETZUNG EINER BIFURKATIONSPROTHESE | SYSTÈMES DE DÉPLOIEMENT DE GREFFON À PLUSIEURS BRANCHES, ET PROCÉDÉS    EP2268227A4    EP2009730087A    2009-04-10
ENDOLOGIX INC    EP    METHOD AND SYSTEM FOR ENDOVASCULAR ANEURYSM TREATMENT | VERFAHREN UND SYSTEM ZUR ENDOVASKULÄREN BEHANDLUNG VON ANEURYSMEN | PROCÉDÉ ET SYSTÈME POUR TRAITEMENT D’ANÉVRISME ENDOVASCULAIRE    EP2693980A1    EP2012716880A    2012-04-06


ENDOLOGIX INC    EP    STENT GRAFT DELIVERY SYSTEM | STENTGRAFT-ABLAGESYSTEM | SYSTÈME DE MISE EN PLACE D ENDOPROTHÈSE VASCULAIRE    EP2278939A4    EP2009733719A    2009-04-24


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC    EP    CATHETER SYSTEM AND METHODS OF USING SAME | KATHETERSYSTEM UND VERFAHREN ZU SEINER VERWENDUNG | SYSTÈME DE CATHÉTER ET SES PROCÉDÉS D’UTILISATION    EP2680915A1    EP2012709432A    2012-02-29
ENDOLOGIX INC    EP    APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM | VORRICHTUNG UND VERFAHREN ZUR POSITIONIERUNG EINER GEFÄSSPROTHESE BZW. EINES GEFÄSSPROTHESENSYSTEMS | APPAREIL ET PROCÉDÉ DE DISPOSITION DE GREFFE OU DE SYSTÈME DE GREFFE    EP2635241A2    EP2011781956A    2011-11-02
ENDOLOGIX INC    EP    APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM | VORRICHTUNG UND VERFAHREN ZUR POSITIONIERUNG EINER GEFÄSSPROTHESE BZW. EINES GEFÄSSPROTHESENSYSTEMS | APPAREIL ET PROCÉDÉ DE PLACEMENT D’UNE GREFFE OU D’UN SYSTÈME DE GREFFE    EP2429452A1    EP2010717383A    2010-04-28
ENDOLOGIX INC    WO    SYSTEMS AND METHODS WITH GRAFT BODY, INFLATABLE FILL CHANNEL, AND FILLING STRUCTURE | SYSTÈMES ET PROCÉDÉS À CORPS DE GREFFE, CANAL DE REMPLISSAGE GONFLABLE ET STRUCTURE DE REMPLISSAGE    WO2017197313A1    PCT/US2017/32490A    2017-05-12


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC    WO    SYSTEMS AND METHODS WITH FENESTRATED GRAFT AND FILLING STRUCTURE | SYSTÈMES ET PROCÉDÉS AVEC GREFFON FENESTRÉ ET STRUCTURE DE REMPLISSAGE    WO2017117068A1    PCT/US2016/68575A    2016-12-23
ENDOLOGIX INC    WO    LOCKING ASSEMBLY FOR COUPLING GUIDEWIRE TO DELIVERY SYSTEM | ENSEMBLE DE VERROUILLAGE POUR ACCOUPLER UN FIL-GUIDE À UN SYSTÈME DE DISTRIBUTION    WO2017004265A1    PCT/US2016/40197A    2016-06-29
ENDOLOGIX INC    WO    ENDOLUMINAL PROSTHESIS SYSTEMS AND METHODS | SYSTÈMES ET PROCÉDÉS DE PROTHÈSE ENDOLUMINALE    WO2016210363A1    PCT/US2016/39414A    2016-06-24
ENDOLOGIX INC    WO    DUAL INFLATABLE ARTERIAL PROSTHESIS | DOUBLE PROTHÈSE ARTÉRIELLE GONFLABLE    WO2016109757A1    PCT/US2015/68204A    2015-12-30
ENDOLOGIX INC    WO    MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES | SYSTÈMES ET PROCÉDÉS DE GREFFE D’ENDOPROTHÈSE MODULAIRE COMPRENANT DES STRUCTURES DE REMPLISSAGE GONFLABLES    WO2015183489A1    PCT/US2015/29292A    2015-05-05


ENDOLOGIX INC    WO    FORMING HYDROGELS AND MATERIALS THEREFOR | FORMATION D’HYDROGELS ET MATÉRIAUX POUR CEUX-CI    WO2015134906A1    PCT/US2015/19251A    2015-03-06


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC    WO    METHOD FOR FORMING MATERIALS IN SITU WITHIN A MEDICAL DEVICE | MÉTHODE DE FORMATION DE MATÉRIAUX IN SITU DANS UN DISPOSITIF MÉDICAL    WO2014159093A1    PCT/US2014/21928A    2014-03-07
ENDOLOGIX INC    WO    METHOD AND SYSTEM FOR ENDOVASCULAR ANEURYSM TREATMENT | PROCÉDÉ ET SYSTÈME POUR TRAITEMENT D’ANÉVRISME ENDOVASCULAIRE    WO2012139054A1    PCT/US2012/32612A    2012-04-06
ENDOLOGIX INC    WO    APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM | APPAREIL ET PROCÉDÉ DE DISPOSITION DE GREFFE OU DE SYSTÈME DE GREFFE    WO2012061526A3    PCT/US2011/59012A    2011-11-02
ENDOLOGIX INC    WO    CATHETER SYSTEM AND METHODS OF USING SAME | SYSTÈME DE CATHÉTER ET SES PROCÉDÉS D’UTILISATION    WO2012118901A1    PCT/US2012/27151A    2012-02-29
ENDOLOGIX INC    WO    METHODS AND SYSTEMS FOR TREATING ANEURYSMS | PROCÉDÉS ET SYSTÈMES DE TRAITEMENT D’ANÉVRISMES    WO2012100059A1    PCT/US2012/21878A    2012-01-19
ENDOLOGIX INC    WO    DEVICES AND METHODS TO TREAT VASCULAR DISSECTIONS | DISPOSITIFS ET PROCÉDÉS DE TRAITEMENT DE DISSECTIONS VASCULAIRES    WO2012068298A1    PCT/US2011/61061A    2011-11-16


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC    WO    STENT GRAFT | ENDOPROTHÈSE COUVERTE    WO2011017123A3    PCT/US2010/43432A    2010-07-27
ENDOLOGIX INC    WO    STENT GRAFT | ENDOPROTHÈSE COUVERTE    WO2011008989A3    PCT/US2010/42181A    2010-07-15
ENDOLOGIX INC    WO    PERCUTANEOUS METHOD AND DEVICE TO TREAT DISSECTIONS | PROCÉDÉ ET DISPOSITIF PERCUTANÉS POUR TRAITER DES DISSECTIONS    WO2010127305A3    PCT/US2010/33274A    2010-04-30
ENDOLOGIX INC    WO    APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM | APPAREIL ET PROCÉDÉ DE PLACEMENT D’UNE GREFFE OU D’UN SYSTÈME DE GREFFE    WO2010127040A1    PCT/US2010/32843A    2010-04-28
ENDOLOGIX INC    WO    BIFURCATED GRAFT DEPLOYMENT SYSTEMS AND METHODS | SYSTÈMES DE DÉPLOIEMENT DE GREFFON À PLUSIEURS BRANCHES, ET PROCÉDÉS    WO2009126906A8    PCT/US2009/40239A    2009-04-10
ENDOLOGIX INC    WO    CATHETER SYSTEM | SYSTÈME DE CATHÉTER    WO2010002931A1    PCT/US2009/49316A    2009-06-30


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC    WO   

DESIGN AND METHOD OF

PLACEMENT OF A GRAFT OR GRAFT SYSTEM | CONCEPTION ET PROCÉDÉ DE MISE EN PLACE D’UN GREFFON OU D’UN SYSTÈME DE GREFFONS | CONCEPTION ET PROCÉDÉ DE MISE EN PLACE D’UN GREFFON OU D’UN SYSTÈME DE GREFFONS

   WO2009105699A1    PCT/US2009/34755A    2009-02-20
ENDOLOGIX INC    WO    METHOD AND AGENT FOR IN-SITU STABILIZATION OF VASCULAR TISSUE | PROCÉDÉ ET AGENT DE STABILISATION <I>IN SITU</I> DU TISSU VASCULAIRE    WO2009064806A1    PCT/US2008/83267A    2008-11-12
ENDOLOGIX INC    WO    STENT | ENDOPROTHÈSE VASCULAIRE    WO2009055615A1    PCT/US2008/81022A    2008-10-23
ENDOLOGIX INC    DE    EINE EINZIGE PUNKTION ERFORDENDES ENTFALTUNGSSYSTEM FÜR EIN GEFÄSSIMPLANTAT MIT VERZWEIGUNG    DE60031381T2    DE60031381A    2000-03-07
ENDOLOGIX INC    DE    SELBSTEXPANDIERENDE, SICH VERZWEIGENDE, ENDOVASKULARE PROTHESE    DE69933560T2    DE69933560A    1999-05-28
ENDOLOGIX INC    DE    ENDOLUMINALE VASKULÄRE PROTHESE    DE69927055T2    DE69927055A    1999-11-10


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC    AU    Bifurcated vascular graft and method and apparatus for deploying same | Bifurcated vascular graft deployment device    AU725117B2    AU199861540A    1998-02-06
ENDOLOGIX INC    AU    Implantable vascular graft    AU200230661A    AU200230661A    2001-11-08
ENDOLOGIX INC    EP    DEVICES FOR REPAIRING ANEURYSMS    EP1397089    EP02730505.1    2017-04-19
ENDOLOGIX INC    EP    DEVICES FOR REPAIRING ANEURYSMS    EP1397089    EP02730505.1    2017-04-19
ENDOLOGIX INC    EP    DEVICES FOR REPAIRING ANEURYSMS    EP1397089    EP02730505.1    2017-04-19
ENDOLOGIX INC    EP    DEVICES FOR REPAIRING ANEURYSMS    EP2260795    EP10011024.6    2016-05-25


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC    EP    DEVICES FOR REPAIRING ANEURYSMS    EP2260795    EP10011024.6    2016-05-25
ENDOLOGIX INC    EP    DEVICES FOR REPAIRING ANEURYSMS    EP2260795    EP10011024.6    2016-05-25
ENDOLOGIX INC    EP    DEVICES FOR REPAIRING ANEURYSMS    EP2260795    EP10011024.6    2016-05-25
ENDOLOGIX INC    EP    DEVICES FOR REPAIRING ANEURYSMS    EP2260795    EP10011024.6    2016-05-25
ENDOLOGIX INC    EP    ADVANCED KINK-RESISTANT STENT GRAFT    EP2833827    13714471.3    2018-01-31
ENDOLOGIX INC    EP    ADVANCED KINK-RESISTANT STENT GRAFT    EP2833827    13714471.3    2018-01-31


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC    EP    LOW PROFILE STENT GRAFT AND DELIVERY SYSTEM       EP13717893.5    2014-11-06
ENDOLOGIX INC    EP    MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES       EP15800658.5    2016-11-21
ENDOLOGIX INC    EP    ANEURYSM SAC ACCESS CONDUIT       15852460.3    2017-04-12
ENDOLOGIX INC    EP    DUAL INFLATABLE ARTERIAL PROSTHESIS       15876323.5    2017-07-13
ENDOLOGIX INC    EP    Endoluminal Prosthesis Systems and Methods       16815450.8    2017-12-19
ENDOLOGIX INC    CN    MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES       2015800393484    2017-01-19


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC    CN    DUAL INFLATABLE ARTERIAL PROSTHESIS       2015800763903    2017-08-17
ENDOLOGIX INC    JP    MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES       2016-569901    2016-11-28
ENDOLOGIX INC    CN    Endoluminal Prosthesis Systems and Methods       201680037099.X    2017-12-22
ENDOLOGIX INC    JP    DUAL INFLATABLE ARTERIAL PROSTHESIS       2017-534803    2017-06-28
ENDOLOGIX INC    JP    Endoluminal Prosthesis Systems and Methods       PCT/US2016/039414    2017-12-22


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

NELLIX INC.    US    Stent-graft with positioning anchor    US9814612B2    US14697433A    2015-10-21
NELLIX INC.    US    System and methods for endovascular aneurysm treatment    US9737425B2    US14537749A    2014-11-10
NELLIX INC.    US    Stent graft delivery system    US9730700B2    US14586110A    2015-04-23
NELLIX INC.    US    Methods for deploying a positioning anchor with a stent-graft    US9113999B2    US11876458A    2007-10-22
NELLIX INC.    US    Sealing apparatus and methods of use    US8945199B2    US12478225A    2009-06-04
NELLIX INC.    US    Stent graft delivery system    US8926682B2    US13243941A    2011-09-23


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

NELLIX INC.    US    System and methods for endovascular aneurysm treatment    US8906084B2    US12684074A    2010-01-07
NELLIX INC.    US    Graft systems having filling structures supported by scaffolds and methods for their use    US8870941B2    US13285897A    2011-10-31
NELLIX INC.    US    STENT GRAFT DELIVERY SYSTEM    US20180028192A1    US15676869A    2017-08-14
NELLIX INC.    US    SEALING APPRATUS AND METHODS OF USE    US20150148892A1    US14612048A    2015-02-02
NELLIX INC.    US    GRAFT SYSTEMS HAVING FILLING STRUCTURES SUPPORTED BY SCAFFOLDS AND METHODS FOR THEIR USE    US10022249    US14525019A    2014-10-27
NELLIX, INC.    US    System and methods of Endovascular Aneurysm Treatment       14/682414    8/21/17


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

Nellix, Inc.    US    Vascular stent-graft apparatus and forming method    US6695833    US09671550    9/27/00
ENDOLOGIX INC    EP    Systems for endovascular aneurysm treatment | Systeme zur Behandlung von endovaskulären Aneurysmen | Systèmes pour le traitement d’anévrisme endovasculaire    EP1778131B1    EP2005773726A    2005-07-22
NELLIX INC.    EP    Method for forming a vascular stent-graft | Verfahren zur Herstellung eines vaskulären Stent-Grafts | Procédé de formation d’un stent-greffe vasculaire.    EP1355587B1    EP2001973590A    2001-09-26
NELLIX INC    EP    METHODS AND SYSTEMS FOR ANEURYSM TREATMENT USING FILLING STRUCTURES | VERFAHREN UND SYSTEME ZUR BEHANDLUNG VON ANEURYSMEN UNTER VERWENDUNG VON FÜLLSTRUKTUREN | PROCEDES ET SYSTEMES POUR LE TRAITEMENT DE L’ANEVRISME UTILISANT DES STRUCTURES DE REMPLISSAGE    EP1962722A4    EP2006850439A    2006-12-18
ENDOLOGIX INC    EP    Systems for endovascular aneurysm treatment | Systeme zur endovaskulären Aneurysma-Therapie | Systèmes pour le traitement d’anévrismes endovasculaires    EP2422745A1    EP2011180827A    2005-07-22


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX INC    EP    DOCKING APPARATUS AND METHODS OF USE | ANDOCKVORRICHTUNG UND VERWENDUNGSVERFAHREN | APPAREIL DE FIXATION ET PROCÉDÉS D’UTILISATION    EP2299933A1    EP2009770704A    2009-06-04
ENDOLOGIX INC    EP    SEALING APPARATUS AND METHODS OF USE | VERSCHLUSSGERÄT UND ANWENDUNGSVERFAHREN | DISPOSITIF DE FERMETURE ET PROCÉDÉS D’UTILISATION ASSOCIÉS    EP2299931A1    EP2009759453A    2009-06-04
ENDOLOGIX INC    EP    STENT GRAFT DELIVERY SYSTEM | STENTGRAFT-ABLAGESYSTEM | SYSTÈME DE MISE EN PLACE D ENDOPROTHÈSE VASCULAIRE    EP2278939A1    EP2009733719A    2009-04-24
ENDOLOGIX INC    EP    GRAFT SYSTEMS HAVING FILLING STRUCTURES SUPPORTED BY SCAFFOLDS | TRANSPLANTATIONSSYSTEM MIT DURCH GERÜSTE UNTERSTÜTZTEN FÜLLSTRUKTUREN | SYSTEMES DE GREFFE PRESENTANT DES STRUCTURES DE REMPLISSAGE SOUTENUES PAR DES ECHAFAUDAGES    EP1874231A2    EP2006751879A    2006-04-28
ENDOLOGIX INC    EP    STENT-GRAFT WITH POSITIONING ANCHOR | STENT-GRAFT MIT POSITIONIERUNGSVERANKERUNG | ENDOPROTHESE A ANCRAGE DE POSITIONNEMENT    EP1542616A2    EP2003754880A    2003-09-22


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

NELLIX INC.    WO    FILLING STRUCTURE FOR A GRAFT SYSTEM AND METHODS OF USE | STRUCTURE DE REMPLISSAGE POUR UN SYSTÈME DE GREFFE ET PROCÉDÉ D’UTILISATION    WO2011082040A1    PCT/US2010/061621    2010-12-21
NELLIX INC.    WO    DOCKING APPARATUS AND METHODS OF USE | APPAREIL DE FIXATION ET PROCÉDÉS D’UTILISATION    WO2009158170A1    PCT/US2009/046308    2009-06-04
NELLIX INC.    WO    SEALING APPARATUS AND METHODS OF USE | DISPOSITIF DE FERMETURE ET PROCÉDÉS D’UTILISATION ASSOCIÉS | DISPOSITIF DE FERMETURE ET PROCÉDÉS D’UTILISATION ASSOCIÉS    WO2009149294A1    PCT/US2009/046310    2009-06-04
NELLIX INC.    WO    STENT GRAFT DELIVERY SYSTEM | SYSTÈME DE MISE EN PLACE D’ENDOPROTHÈSE VASCULAIRE | SYSTÈME DE MISE EN PLACE D’ENDOPROTHÈSE VASCULAIRE    WO2009132309A1    PCT/US2009/041718    2009-04-24
NELLIX INC.    WO    GRAFT ENDOFRAME HAVING AXIALLY VARIABLE CHARACTERISTICS | ENDOCADRE DE GREFFE AYANT DES CARACTÉRISTIQUES VARIABLES AXIALEMENT    WO2009103011A1    PCT/US2009/034136    2009-02-13
TRIVASCULAR INC.    US    Endovascular graft    US9867727B2    US14320773A    2014-07-01


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC.    US    Advanced endovascular graft    US9788934B2    US14799656A    2015-07-15
TRIVASCULAR INC.    US    Endovascular graft for aneurysms involving major branch vessels    US9724186B2    US14050835A    2013-10-10
TRIVASCULAR INC.    US    System and method of pivoted stent deployment    US9713523B2    US14452343A    2014-08-05
TRIVASCULAR INC.    US    Systems and methods for guidewire crossover for bifurcated prostheses    US9655754B2    US14323059A    2014-07-03
TRIVASCULAR INC.    US    Bifurcated endovascular prosthesis having tethered contralateral leg    US9585774B2    US14823076A    2015-08-11
TRIVASCULAR INC.    US    PTFE layers and methods of
manufacturing
   US9549829B2    US14458349A    2014-08-13


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC.    US    Delivery catheter for endovascular device    US9498363B2    US13835491A    2013-03-15
TRIVASCULAR INC    US    Low profile stent and delivery system    US9463101B2    US14923477A    2015-10-27
TRIVASCULAR INC.    US    PTFE layers and methods of
manufacturing
   US9446553B2    US14230318A    2014-03-31
TRIVASCULAR INC.    US    Endovascular graft joint and method for manufacture    US9351858B2    US14704013A    2015-05-05
TRIVASCULAR INC.    US    Non-degradable, low swelling, water soluble radiopaque hydrogel polymer    US9308301B2    US13089960A    2011-04-19
TRIVASCULAR INC.    US    Endovascular delivery system with an improved radiopaque marker scheme    US9233015B2    US13803050A    2013-03-14


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC.    US    Low profile stent graft and delivery system    US9192462B2    US13803037A    2013-03-14
TRIVASCULAR INC.    US    Fenestrated inflatable graft    US9144486B2    US13652471A    2012-10-15
TRIVASCULAR INC.    US    Bifurcated endovascular prosthesis having tethered contralateral leg    US9132025B2    US13803067A    2013-03-14
TRIVASCULAR INC.    US    Endovascular delivery system with flexible and torqueable hypotube    US9066828B2    US13803062A    2013-03-14
TRIVASCULAR INC.    US    Endovascular graft joint and method for manufacture    US9050754B2    US12729182A    2010-03-22
TRIVASCULAR INC.    US    Durable stent graft with tapered struts and stable delivery methods and devices    US8992595B2    US13799207A    2013-03-13


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC.    US    In vitro testing of endovascular device    US8978448B2    US13649066A    2012-10-10
TRIVASCULAR INC.    US    Advanced endovascular graft delivery system and method of treatment    US8900288B2    US12566104A    2009-09-24
TRIVASCULAR INC.    US    Method of delivering advanced endovascular graft and system    US8864814B2    US13246651A    2011-09-27
TRIVASCULAR INC.    US    PTFE layers and methods of
manufacturing
   US8840824B2    US12910281A    2010-10-22
TRIVASCULAR INC.    US    Endovascular graft    US8801769B2    US13737351A    2013-01-09
TRIVASCULAR INC.    US    Apparatus for manufacturing an endovascular graft section    US8783316B2    US12697504A    2010-02-01


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC.    US    PTFE layers and methods of
manufacturing
   US8728372B2    US12915636A    2010-10-29
TRIVASCULAR INC.    US    Advanced endovascular graft    US8709065B2    US12491336A    2009-06-25
TRIVASCULAR INC.    US    Virtual prototyping and testing for medical device development    US8666714B2    US13523765A    2012-06-14
TRIVASCULAR INC.    US    Asymmetric stent apparatus and method    US8663309B2    US11861828A    2007-09-26
TRIVASCULAR INC.    US    Endovascular graft    US8361136B2    US12566793A    2009-09-25
TRIVASCULAR INC.    US    Endovascular graft joint and method for manufacture    US8348989B2    US11429735A    2006-05-08


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC.    US    Delivery system and method for bifurcated graft    US8328861B2    US11941434A    2007-11-16
TRIVASCULAR INC.    US    Endovascular graft and method of delivery    US8241346B2    US13246643A    2011-09-27
TRIVASCULAR INC.    US    Inflatable porous implants and methods for drug delivery    US8267989B2    US12860364A    2010-08-20
TRIVASCULAR INC.    US    Inflatable intraluminal graft    US8226708B1    US10168053A    2002-06-14
TRIVASCULAR INC.    US    Stent and delivery system for deployment thereof    US8226701B2    US11861756A    2007-09-26
TRIVASCULAR INC.    US    Virtual prototyping and testing for medical device development    US8224632B2    US12904994A    2010-10-14


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC.    US    Dual chamber cuff structure    US8216297B2    US11504434A    2006-08-14
TRIVASCULAR INC.    US    Barbed radially expandable stent    US8167927B2    US13245661A    2011-09-26
TRIVASCULAR INC.    US    Securement assembly and method for expandable endovascular device    US8083789B2    US11941450A    2007-11-16
TRIVASCULAR INC.    US    System and method of pivoted stent deployment    US8066755B2    US11861716A    2007-09-26
TRIVASCULAR INC.    US    Constant force material delivery system and method    US7971751B2    US12724068A    2010-03-15
TRIVASCULAR INC.    US    Passive hemostatic sheath valve    US7901379B2    US11298285A    2005-12-09


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC.    US    Virtual prototyping and testing for medical device development    US7840393B1    US09679725A    2000-10-04
TRIVASCULAR INC.    US    Inflatable porous implants and methods for drug delivery    US7803178B2    US10769532A    2004-01-30
TRIVASCULAR INC.    US    Advanced endovascular graft    US7766954B2    US11333595A    2006-01-17
TRIVASCULAR INC.    US    Constant force material delivery system and method    US7708163B2    US11360077A    2006-02-23
TRIVASCULAR INC.    US    Endovascular graft joint and method for manufacture    US7682475B2    US11870748A    2007-10-11
TRIVASCULAR INC.    US    Method for manufacturing an endovascular graft section    US7678217B2    US11522490A    2006-09-15


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC.    US    Inflatable implant    US7632291B2    US10461853A    2003-06-13
TRIVASCULAR INC.    US    Endovascular graft    US7615071B2    US11390732A    2006-03-28
TRIVASCULAR INC.    US    Delivery system and method for
expandable intracorporeal device
   US7338518B2    US11201028A    2005-08-10
TRIVASCULAR INC.    US    Passive hemostatic sheath valve    US7241276B2    US10636871A    2003-08-06
TRIVASCULAR INC.    US    Advanced endovascular graft    US7147660B2    US10327711A    2002-12-20
TRIVASCULAR INC.    US    Kink resistant endovascular graft    US7150758B2    US10384103A    2003-03-06


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC.    US    Radially expandable stent    US7147661B2    US10029559A    2001-12-20
TRIVASCULAR INC.    US    Method and apparatus for shape forming endovascular graft material    US7147455B2    US10868292A    2004-06-14
TRIVASCULAR INC.    US    Method for manufacturing an endovascular graft section    US7125464B2    US10029557A    2001-12-20
TRIVASCULAR INC.    US    Endovascular graft    US7081129B2    US10132754A    2002-04-24
TRIVASCULAR INC.    US    Endovascular graft joint and method for manufacture    US7090693B1    US10029584A    2001-12-20
TRIVASCULAR INC.    US    Delivery system and method for
expandable intracorporeal device
   US7066951B2    US10419312A    2003-04-17


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC.    US    Method and apparatus for shape forming endovascular graft material    US6776604B1    US10029570A    2001-12-20
TRIVASCULAR INC.    US    Delivery system and method for bifurcated endovascular graft    US6761733B2    US09917371A    2001-07-27
TRIVASCULAR INC.    US    Delivery system and method for endovascular graft    US6733521B2    US09834278A    2001-04-11
TRIVASCULAR INC.    US    Delivery system and method for
expandable intracorporeal device
   US6602280B2    US09774733A    2001-01-31
TRIVASCULAR INC.    US    Endovascular graft    US6395019B2    US09133978A    1998-08-14
TRIVASCULAR INC    US    ENDOVASCULAR GRAFT    US20170348125A1    US15686214A    2017-08-25


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC    US    ADVANCED ENDOVASCULAR GRAFT    US20170348087A1    US15686218A    2017-08-25
TRIVASCULAR INC    US    ENDOVASCUALR GRAFT FOR ANEURYSMS INVOLVING MAJOR BRANCH VESSELS    US20170296327A1    US15638559A    2017-06-30
TRIVASCULAR INC    US    SYSTEMS AND METHODS FOR GUIDEWIRE CROSSOVER FOR BIFURCATED PROSTHESES    US20170216064A1    US15491074A    2017-04-19
TRIVASCULAR INC    US    Low Profile Stent Graft and Delivery System    US9987123    US15263469A    2016-09-13
TRIVASCULAR INC    US    BIFURCATED ENDOVASCULAR PROSTHESIS HAVING TETHERED CONTRALATERAL LEG    US20170035549A1    US15299542A    2016-10-21
TRIVASCULAR INC.    US    DELIVERY CATHETER FOR ENDOVASCULAR DEVICE    US20170035590A1    US15298166A    2016-10-19


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC    US    PTFE LAYERS AND METHODS OF MANUFACTURING    US20160367354A1    US15251011A    2016-08-30
TRIVASCULAR INC    US    ENDOVASCULAR DELIVERY SYSTEM WITH AN IMPROVED RADIOPAQUE MARKER SCHEME    US10034787    US14970621A    2015-12-16
TRIVASCULAR INC    US    NON-DEGRADABLE, LOW SWELLING, WATER SOLUBLE RADIOPAQUE HYDROGEL POLYMER    US20160193392A1    US15068415A    2016-03-11
TRIVASCULAR INC.    US    INTERNAL ILIAC PRESERVATION DEVICES AND METHODS    US9956101    US14958085A    2015-12-03
TRIVASCULAR INC.    US    STENT GRAFT DELIVERY SYSTEM WITH ACCESS CONDUIT    US20160113796A1    US14920828A    2015-10-22
TRIVASCULAR INC.    US    ENDOVASCULAR DELIVERY SYSTEM WITH FLEXIBLE AND TORQUEABLE HYPOTUBE    US20150265446A1    US14717080A    2015-05-20


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC.    US    INFLATABLE OCCLUSION WIRE- BALLOON FOR AORTIC APPLICATIONS    US20150250481A1    US14643217A    2015-03-10
TRIVASCULAR INC.    US    ADVANCED ENDOVASCULAR GRAFT AND DELIVERY SYSTEM    US20150164667A1    US14631818A    2015-02-25
TRIVASCULAR INC.    US    DURABLE STENT GRAFT WITH TAPERED STRUTS AND STABLE DELIVERY METHODS AND DEVICES    US20150157479A1    US14615337A    2015-02-05
TRIVASCULAR INC.    US    TANDEM MODULAR ENDOGRAFT    US20150088244A1    US14492674A    2014-09-22
TRIVASCULAR INC.    US    ENDOLEAK ISOLATION SLEEVES AND METHODS OF USE    US20150073523A1    US14481834A    2014-09-09
TRIVASCULAR INC.    US    GATE WIRE FOR CONTRALATERAL LEG ACCESS    US20140194970A1    US14151373A    2014-01-09


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC.    US    SAC LINER FOR ANEURYSM REPAIR    US20140194973A1    US14151195A    2014-01-09
TRIVASCULAR INC.    US    ASYMMETRIC STENT APPARATUS AND METHOD    US20140135899A1    US14157350A    2014-01-16
TRIVASCULAR INC.    US    LOW PROFILE STENT GRAFT AND DELIVERY SYSTEM    US20130268056A1    US13803033A    2013-03-14
TRIVASCULAR INC.    US    ADVANCED KINK RESISTANT STENT GRAFT    US9993328    US13803046A    2013-03-14
TRIVASCULAR INC.    US    VASCULAR GRAFT HAVING
LIMITED END STRUCTURE
   US20130096665A1    US13650705A    2012-10-12
TRIVASCULAR INC.    US    INFLATABLE INTRALUMINAL GRAFT    US20120265290A1    US13532887A    2012-06-26


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC.    US    ADVANCED ENDOVASCULAR GRAFT AND DELIVERY SYSTEM    US20120191174A1    US13297219A    2011-11-15
TRIVASCULAR INC.    US    SYSTEM AND METHOD OF PIVOTED STENT DEPLOYMENT    US20120083870A1    US13277117A    2011-10-19
TRIVASCULAR INC.    US    BARBED RADIALLY EXPANDABLE STENT WITH SLOTTED STRUTS    US20120016457A1    US13245652A    2011-09-26
TRIVASCULAR INC.    US    FILL TUBE MANIFOLD AND DELIVERY METHODS FOR ENDOVASCULAR GRAFT    US20110218609A1    US13024255A    2011-02-09
TRIVASCULAR INC.    US    HINGED ENDOVASCULAR DEVICE    US20100331958A1    US12747499A    2010-09-07
TRIVASCULAR INC.    US    Inflatable Implant    US20100076481A1    US12628623A    2009-12-01


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC.    US    METHOD OF DELIVERING ADVANCED ENDOVASCULAR GRAFT    US20100016943A1    US12566808A    2009-09-25
TRIVASCULAR INC.    US    MODULAR VASCULAR GRAFT FOR LOW PROFILE PERCUTANEOUS DELIVERY    US20090099649A1    US12245620A    2008-10-03
TRIVASCULAR INC.    US    ALIGNMENT STENT APPARATUS AND METHOD    US20090082845A1    US11861746A    2007-09-26
TRIVASCULAR INC.    US    SYSTEM AND METHOD OF
SECURING STENT BARBS
   US20090082847A1    US11861731A    2007-09-26
TRIVASCULAR INC.    US    APPARATUS FOR SECURING STENT BARBS    US20090082841A1    US11861739A    2007-09-26
TRIVASCULAR INC.    US    PTFE LAYERS AND METHODS OF MANUFACTURING    US20090036971A1    US12250915A    2008-10-14


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC.    US    PTFE LAYERS AND METHODS OF MANUFACTURING    US20090036973A1    US12250946A    2008-10-14
TRIVASCULAR INC.    US    Non-degradable, low swelling, water soluble radiopaque hydrogel polymer    US20060222596A1    US11097467A    2005-04-01
TRIVASCULAR INC.    US    Hybrid modular endovascular graft    US20060224232A1    US11097718A    2005-04-01
TRIVASCULAR INC.    US    Delivery system and method for bifurcated graft    US20060009833A1    US11205793A    2005-08-15
TRIVASCULAR INC.    US    Methods, compositions and devices for embolizing body lumens    US20050158272A1    US11031311A    2005-01-07
TRIVASCULAR INC.    US    Endoluminal prosthesis endoleak management    US20050090804A1    US10691849A    2003-10-22


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC.    US    Endovascular graft joint and method for manufacture    US20050027347A1    US10640368A    2003-08-13
TRIVASCULAR INC.    US    Layered endovascular graft    US20040220664A1    US10803153A    2004-03-17
TRIVASCULAR INC.    US    Delivery system and method for bifurcated graft    US20040138734A1    US10686863A    2003-10-16
TRIVASCULAR INC.    US    Endovascular graft    US20030216802A1    US10289136A    2002-11-05
TRIVASCULAR INC.    US    Inflatable intraluminal graft    US20030225453A1    US10289137A    2002-11-05
TRIVASCULAR INC.    US    Advanced endovascular graft    US20030120338A1    US10091641A    2002-03-05


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC.    US    Delivery system and method for bifurcated graft    US20030004560A1    US10122474A    2002-04-11
TRIVASCULAR INC.    US    Layered endovascular graft    US20020010508A1    US09970576A    2001-10-04
TRIVASCULAR, INC.    US    Stent-graft with improved flexibility       15/568834    10/24/17
Trivascular, Inc.    US    Passive hemostatic sheath valve    US7901379    US11298285    12/9/05
Trivascular, Inc.    US    Fluid mixing apparatus and method    US7178978    US10658074    9/8/03
Trivascular, Inc.    US   

Delivery system and method for

expandable intracorporeal device

   US6602280    US09774733    1/31/01


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

Trivascular, Inc.    US    Endovascular graft    US6395019    US09133978    8/14/98
Trivascular, Inc.    US    Layered endovascular graft    US6331191    US09200317    11/25/98
Trivascular, Inc.    US    Endovascular graft having longitudinally displaceable sections    US6132457    US09177295    10/22/98
Trivascular, Inc.    US    Low profile stent graft and delivery system       US15263469    9/13/16
Trivascular, Inc.    US    Delivery catheter for endovascular device       US15298166    10/19/16
Trivascular, Inc.    US    Bifurcated endovascular prosthesis having tethered contralateral leg       US15299542    10/21/16


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

Trivascular, Inc.    US    Ptfe layers and methods of manufacturing       US15251011    8/30/16
Trivascular, Inc.    US    Endovascular delivery system with an improved radiopaque marker scheme       US14970621    12/16/15
Trivascular, Inc.    US   

Non-degradable, low swelling, water

soluble radiopaque hydrogel polymer

      US15068415    3/11/16
Trivascular, Inc.    US   

Internal iliac preservation devices and

methods

      US14958085    12/3/15
Trivascular, Inc.    US    Stent graft delivery system with access conduit       US14920828    10/22/15
Trivascular, Inc.    US    Bifurcated endovascular prosthesis having tethered contralateral leg       US14823076    8/11/15


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

Trivascular, Inc.    US    Low profile stent and delivery system       US14923477    10/27/15
Trivascular, Inc.    US    Endovascular delivery system with flexible and torqueable hypotube       US14717080    5/20/15
Trivascular, Inc.    US    Inflatable occlusion wire-balloon for aortic applications       US14643217    3/10/15
Trivascular, Inc.    US    Advanced endovascular graft and delivery system       US14631818    2/25/15
Trivascular, Inc.    US    Durable stent graft with tapered struts and stable delivery methods and devices       US14615337    2/5/15
Trivascular, Inc.    US    Tandem modular endograft       US14492674    9/22/14


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

Trivascular, Inc.    US    Endoleak isolation sleeves and methods of use       US14481834    9/9/14
Trivascular, Inc.    US    Sac liner for aneurysm repair       US14151195    1/9/14
Trivascular, Inc.    US    Gate wire for contralateral leg access       US14151373    1/9/14
Trivascular, Inc.    US    Asymmetric stent apparatus and method       US14157350    1/16/14
Trivascular, Inc.    US    Low profile stent graft and delivery system       US13803033    3/14/13
Trivascular, Inc.    US    Advanced kink resistant stent graft       US13803046    3/14/13


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

Trivascular, Inc.    US    Vascular graft having limited end structure       US13650705    10/12/12
Trivascular, Inc.    US    Inflatable intraluminal graft       US13532887    6/26/12
Trivascular, Inc.    US    Advanced endovascular graft and delivery system       US13297219    11/15/01
Trivascular, Inc.    US   

System and method of pivoted stent

deployment

      US13277117    10/19/11
Trivascular, Inc.    US   

Barbed radially expandable stent with

slotted struts

      US13245652    9/26/11
Trivascular, Inc.    US    Fill tube manifold and delivery methods for endovascular graft       US13024255    2/9/11


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

Trivascular, Inc.    US    Hinged endovascular device       US12747499    9/7/10
Trivascular, Inc.    US    Inflatable implant       US12628623    12/1/09
Trivascular, Inc.    US   

Method of delivering advanced

endovascular graft

      US12566808    9/25/09
Trivascular, Inc.    US    Modular vascular graft for low profile percutaneous delivery       US12245620    10/3/08
Trivascular, Inc.    US    System and method of securing stent barbs       US11861731    9/26/07
Trivascular, Inc.    US    Alignment stent apparatus and method       US11861746    9/26/07


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

Trivascular, Inc.    US    Apparatus for securing stent barbs       US11861739    9/26/07
Trivascular, Inc.    US    Ptfe layers and methods of manufacturing       US12250946    10/14/08
Trivascular, Inc.    US    Ptfe layers and methods of manufacturing       US12250915    10/14/08
Trivascular, Inc.    US    Ptfe layers and methods of manufacturing       US11106150    4/13/05
Trivascular, Inc.    US    Ptfe layers and methods of manufacturing       US11106131    4/13/05
Trivascular, Inc.    US    Hybrid modular endovascular graft       US11097718    4/1/05


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

Trivascular, Inc.    US   

Non-degradable low swelling, water

soluble radiopaque hydrogel polymer

      US11097467    4/1/05
Trivascular, Inc.    US    Delivery system and method for bifurcated graft       US11205793    8/15/05
Trivascular, Inc.    US    Modular endovascular graft       US11077938    3/11/05
Trivascular, Inc.    US    Methods, compositions and devices for embolizing body lumens       US11031311    1/7/05
Trivascular, Inc.    US   

Endoluminal prosthesis endoleak

management

      US10691849    10/22/03
Trivascular, Inc.    US    Endovascular graft joint and method for manufacture       US10640368    8/13/03


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

Trivascular, Inc.    US    Layered endovascular graft       US10803153    3/17/04
Trivascular, Inc.    US    Delivery system and method for bifurcated graft       US10686863    10/16/03
Trivascular, Inc.    US    Inflatable intraluminal graft       US10289137    11/5/02
Trivascular, Inc.    US    Endovascular graft       US10289136    11/5/02
Trivascular, Inc.    US    Advanced endovascular graft       US10091641    3/5/02
Trivascular, Inc.    US    Delivery system and method for bifurcated graft       US10122474    4/11/02


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

Trivascular, Inc.    US    Layered endovascular graft       US09970576    10/3/01
TRIVASCULAR INC.    EP    ADVANCED KINK-RESISTANT STENT GRAFT | HOCHENTWICKELTES KNICKBESTÄNDIGES STENTTRANSPLANTAT | ENDOPROTHÈSE ÉVOLUÉE RÉSISTANT AU PLIAGE    EP2833827B1    EP2013714471A    2013-03-21
TRIVASCULAR INC.    EP    INFLATABLE IMPLANT | AUFBLASBARES IMPLANTAT | IMPLANT GONFLABLE    EP1635738B1    EP2004776568A    2004-06-14
TRIVASCULAR INC.    EP   

ENDOVASCULAR GRAFT FOR ANEURYSMS INVOLVING MAJOR BRANCH VESSELS | ENDOVASKULÄRES

TRANSPLANTAT FÜR ANEURYSMEN MIT BETEILIGUNG VON GROSSEN VERZWEIGTEN GEFÄSSEN | GREFFON ENDOVASCULAIRE POUR ANÉVRISMES METTANT EN JEU DES VAISSEAUX RAMIFIÉS PRINCIPAUX

   EP2906144B1    EP2013780282A    2013-10-10


TRIVASCULAR INC.    EP    ADVANCED ENDOVASCULAR GRAFT AND DELIVERY SYSTEM | FORTSCHRITTLICHES ENDOVASKULÄRES TRANSPLANTAT UND SYSTEM ZU SEINER VERABREICHUNG | GREFFE ENDOVASCULAIRE AVANCÉE ET    EP2640319B1    EP2011841183A    2011-11-15


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

      SYSTÈME DE POSE ASSOCIÉ         
TRIVASCULAR INC.    EP    DELIVERY CATHETER FOR ENDOVASCULAR DEVICE | EINFÜHRKATHETER FÜR EINE ENDOVASKULÄRE VORRICHTUNG | CATHÉTER DE DÉLIVRANCE POUR DISPOSITIF ENDOVASCULAIRE    EP2833845B1    EP2013771941A    2013-04-01
TRIVASCULAR INC.    EP    Endovascular graft | Endovaskuläres Gewebe | Greffe endovasculaire    EP1464301B1    EP200475832A    1999-02-09
TRIVASCULAR INC.    EP    PTFE LAYERS AND METHODS OF MANUFACTURING | PTFE-LAGEN UND HERSTELLUNGSVERFAHREN | COUCHES DE PTFE ET PROCEDES DE FABRICATION    EP1888318B1    EP2006740124A    2006-03-30
TRIVASCULAR INC.    EP    ADVANCED ENDOVASCULAR GRAFT | FORTSCHRITTLICHES ENDOVASKULÄRES TRANSPLANTAT | GREFFON ENDOVASCULAIRE EVOLUE    EP1467679B1    EP2002796047A    2002-12-20


TRIVASCULAR INC.    EP    Non-degradable low swelling, water soluble radiopaque hydrogels | Nicht abbaubares, schwach anschwellendes, wasserlösliches röntgendichtes Hydrogelpolymer | Polymère absorbant l’eau, radiopaque, soluble dans l’eau, à faible gonflement et non dégradable    EP2332590B1    EP2010194236A    2006-03-28


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC.    EP    Endovascular graft | Endovaskuläres Transplantat | Greffe endovasculaire    EP2147658B1    EP200913660A    1999-02-09
TRIVASCULAR INC.    EP    Kink resistant endovascular graft | Knickbeständiges Stentimplantat | Stent à greffer resistant au pliage    EP2319456B1    EP2010183146A    2004-03-05
TRIVASCULAR INC.    EP    Delivery system for graft | Abgabesystem für Graft | Système de mise en place pour prothèse    EP2145607B1    EP2009175398A    2004-10-15
TRIVASCULAR INC.    EP    DELIVERY SYSTEM FOR BIFURCATED GRAFT | VORRICHTUNG ZUR PLATZIERUNG VON ZWEIGETEILTEN ENDOPROTHESEN | SYSTEME DE MISE EN PLACE D’UN GREFFON A BIFURCATION    EP1377234B1    EP2002725639A    2002-04-11
TRIVASCULAR INC.    EP    Advanced endovascular graft | Erweitertes endovaskuläres Transplantat | Greffe endovasculaire évoluée    EP2135583B1    EP20099090A    2002-12-20
TRIVASCULAR INC.    EP    KINK RESISTANT ENDOVASCULAR GRAFT | KNICKFESTES ENDOVASKULÄRES IMPLANTAT | IMPLANT ENDOVASCULAIRE RÉSISTANT A LA DÉFORMATION    EP1601314B1    EP2004718097A    2004-03-05


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC.    EP    NON-DEGRADABLE LOW SWELLING, WATER SOLUBLE RADIOPAQUE HYDROGELS | NICHT-ABBAUBARE WENIG QUELLENDE WASSERLÖSLICHE RÖNTGENDICHTE HYDROGELS | HYDROGEL RADIOPAQUE, SOLUBLE DANS L’EAU, NON DEGRADABLE ET A FAIBLE GONFLEMENT    EP1874370B1    EP2006739747A    2006-03-28
TRIVASCULAR INC.    EP    INFLATABLE INTRALUMINAL GRAFT | AUFBLASBARER INTRALUMINALER PFROPFEN | GREFFON INTRALUMINAL GONFLABLE    EP1176926B1    EP2000907760A    2000-03-03
TRIVASCULAR INC.    EP    ENDOVASCULAR GRAFT | ENDOVASKULÄRES IMPLANTAT | GREFFON ENDOVASCULAIRE    EP1054648B1    EP1999906812A    1999-02-09
TRIVASCULAR INC.    EP    STENT GRAFT DELIVERY SYSTEM WITH ACCESS CONDUIT | STENTGRAFTEINFÜHRUNGSSYSTEM MIT ZUGANGSKANAL | SYSTEME DE POSE DE GREFFE ET PROTHESE ENDOVASCULAIRE AVEC CONDUIT D’ACCES    EP3209249A1    EP2015852460A    2015-10-22


TRIVASCULAR INC.    EP    INTERNAL ILIAC PRESERVATION DEVICES AND METHODS | VORRICHTUNGEN UND VERFAHREN ZUR INTERNEN BECKENKONSERVIERUNG | DISPOSITIFS ET PROCÉDÉS DE PRÉSERVATION DE L’ILIAQUE INTERNE    EP3226814A1    EP2015816618A    2015-12-03


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC.    EP    INFLATABLE OCCLUSION WIRE- BALLOON FOR AORTIC APPLICATIONS | AUFBLASBARER OKKLUSIONSDRAHTBALLON FÜR ANWENDUNGEN IN DER AORTA | BALLONNET DE FIL D’OCCLUSION GONFLABLE POUR APPLICATIONS AORTIQUES    EP3116439A1    EP2015711020A    2015-03-10
TRIVASCULAR INC.    EP    SYSTEMS FOR GUIDEWIRE CROSSOVER FOR BIFURCATED PROSTHESES | SYSTEME FÜR FÜHRUNGSDRAHTÜBERGANG FÜR VERZWEIGTE PROTHESEN | SYSTÈMES POUR UN CROISEMENT DE FIL-GUIDE POUR DES PROTHÈSES BIFURQUÉES    EP3091944A1    EP2014752969A    2014-07-30
TRIVASCULAR INC.    Germany   

SYSTEMS FOR GUIDEWIRE

CROSSOVER FOR BIFURCATED
PROSTHESES

   3091944    14752969.7    7/18/2018
TRIVASCULAR INC.    UK   

SYSTEMS FOR GUIDEWIRE

CROSSOVER FOR BIFURCATED
PROSTHESES

   3091944    14752969.7    7/18/2018
TRIVASCULAR INC.    IT   

SYSTEMS FOR GUIDEWIRE

CROSSOVER FOR BIFURCATED
PROSTHESES

   3091944    14752969.7    7/18/2018


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC.    EP    TANDEM MODULAR ENDOGRAFT | MODULARES TANDEM-ENDOGRAFT | ENDOGREFFE MODULAIRE EN TANDEM    EP3049021A1    EP2014782021A    2014-09-23
TRIVASCULAR INC.    EP    DURABLE STENT GRAFT WITH TAPERED STRUTS AND STABLE DELIVERY METHODS AND DEVICES | DAUERHAFTES STENTIMPLANTAT MIT KONISCHEN STREBEN UND STABILE FREISETZUNGSVERFAHREN SOWIE VORRICHTUNGEN | ENDOPROTHÈSE VASCULAIRE DURABLE AVEC ENTRETOISES CONIQUES ET PROCÉDÉS ET DISPOSITIFS DE DÉLIVRANCE STABLES    EP2833830A4    EP2013772199A    2013-03-29
TRIVASCULAR INC.    EP    ENDOVASCULAR DELIVERY SYSTEM WITH AN IMPROVED RADIOPAQUE MARKER SCHEME | ENDOVASKULÄRES FREISETZUNGSSYSTEM MIT VERBESSERTEM RÖNTGENMARKERSCHEMA | SYSTÈME DE POSE ENDOVASCULAIRE AYANT UNE TECHNIQUE DE MARQUEUR RADIO-OPAQUE AMÉLIORÉE    EP2861189A1    EP2013733113A    2013-05-31


TRIVASCULAR INC.    EP    BIFURCATED ENDOVASCULAR PROSTHESIS HAVING TETHERED CONTRALATERAL LEG | GEGABELTE ENDOVASKULÄRE PROTHESE MIT ANGEBUNDENEM KONTRALATERALEM BEIN | PROTHÈSE ENDOVASCULAIRE    EP2861183A1    EP2013733115A    2013-05-31


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

      BIFURQUÉE POSSÉDANT UNE JAMBE CONTROLATÉRALE AVEC ATTACHE         
TRIVASCULAR INC.    EP    LOW PROFILE STENT GRAFT AND DELIVERY SYSTEM | FLACHES STENTTRANSPLANTAT UND FREISETZUNGSSYSTEM | ENDOPROTHÈSE VASCULAIRE À PROFIL BAS ET SYSTÈME DE DÉLIVRANCE    EP2833829A1    EP2013717893A    2013-03-21
TRIVASCULAR INC    EP    ALIGNMENT STENT APPARATUS AND METHOD | VORRICHTUNG UND VERFAHREN ZUR STENTAUSRICHTUNG | APPAREIL D’ENDOPROTHÈSE D’ALIGNEMENT ET PROCÉDÉ    EP2194919A4    EP2008834027A    2008-09-25
TRIVASCULAR INC    EP    MODULAR VASCULAR GRAFT FOR LOW PROFILE PERCUTANEOUS DELIVERY | MODULARER GEFÄSSERSATZ FÜR PERKUTANE FREISETZUNG MIT NIEDRIGEM PROFIL | GREFFON VASCULAIRE MODULAIRE POUR ADMINISTRATION PERCUTANÉE À PROFIL RÉDUIT    EP2194921A4    EP2008835032A    2008-10-03


TRIVASCULAR INC    EP    METHOD AND APPARATUS FOR MANUFACTURING AN ENDOVASCULAR GRAFT SECTION | VERFAHREN UND VORRICHTUNG ZUR HERSTELLUNG EINES ENDOVASKULÄREN TRANSPLANTATABSCHNITTS | PROCEDE ET APPAREIL DE    EP1465685A4    EP2002805657A    2002-12-20


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

      FABRICATION D’UNE SECTION DE GREFFON ENDOCORONAIRE         
TRIVASCULAR INC    WO    ENDOLUMINAL PROSTHESIS DEPLOYMENT DEVICES AND METHODS | DISPOSITIFS ET PROCÉDÉS DE DÉPLOIEMENT DE PROTHÈSE ENDOLUMINALE    WO2017019913A1    WO2016US44583A    2016-07-28
TRIVASCULAR INC    WO    STENT-GRAFT WITH IMPROVED FLEXIBILITY | GREFFON DE STENT À FLEXIBILITÉ AMÉLIORÉE    WO2016183128A1    WO2016US31728A    2016-05-11
TRIVASCULAR INC    WO    BALLOON ASSISTED ENDOLUMINAL PROSTHESIS DEPLOYMENT | DÉPLOIEMENT DE PROTHÈSE ENDOLUMINALE ASSISTÉ PAR BALLONNET    WO2016191602A1    WO2016US34427A    2016-05-26
TRIVASCULAR INC    WO    INTERNAL ILIAC PRESERVATION DEVICES AND METHODS | DISPOSITIFS ET PROCÉDÉS DE PRÉSERVATION DE L’ILIAQUE INTERNE    WO2016090112A1    WO2015US63686A    2015-12-03
TRIVASCULAR INC    WO    STENT GRAFT DELIVERY SYSTEM WITH ACCESS CONDUIT | SYSTEME DE POSE DE GREFFE ET PROTHESE ENDOVASCULAIRE AVEC CONDUIT D’ACCES    WO2016065208A1    WO2015US57016A    2015-10-22


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC    WO    INFLATABLE OCCLUSION WIRE- BALLOON FOR AORTIC APPLICATIONS | BALLONNET DE FIL D’OCCLUSION GONFLABLE POUR APPLICATIONS AORTIQUES    WO2015138402A1    WO2015US19626A    2015-03-10
TRIVASCULAR INC    WO    SYSTEMS AND METHODS FOR GUIDEWIRE CROSSOVER FOR BIFURCATED PROSTHESES | SYSTÈMES ET PROCÉDÉS POUR UN CROISEMENT DE FIL-GUIDE POUR DES PROTHÈSES BIFURQUÉES    WO2015105530A1    WO2014US48769A    2014-07-30
TRIVASCULAR INC    WO    TANDEM MODULAR ENDOGRAFT | ENDOGREFFE MODULAIRE EN TANDEM    WO2015048004A1    WO2014US56953A    2014-09-23
TRIVASCULAR INC    WO    ENDOVASCULAR GRAFT FOR ANEURYSMS INVOLVING MAJOR BRANCH VESSELS | GREFFON ENDOVASCULAIRE POUR ANÉVRISMES METTANT EN JEU DES VAISSEAUX RAMIFIÉS PRINCIPAUX    WO2014059114A3    WO2013US64290A    2013-10-10
TRIVASCULAR INC    WO    SAC LINER FOR ANEURYSM REPAIR | REVÊTEMENT SAC POUR RÉPARATION D’ANÉVRISME    WO2014110231A3    WO2014US10828A    2014-01-09
TRIVASCULAR INC    WO    GATE WIRE FOR CONTRALATERAL LEG ACCESS | FIL GUIDE POUR PERMETTRE UN ACCÈS À UN JAMBAGE CONTROLATÉRAL    WO2014110254A1    WO2014US10870A    2014-01-09


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC    WO    BIFURCATED ENDOVASCULAR PROSTHESIS HAVING TETHERED CONTRALATERAL LEG | PROTHÈSE ENDOVASCULAIRE BIFURQUÉE POSSÉDANT UNE JAMBE CONTROLATÉRALE AVEC ATTACHE    WO2013188134A1    WO2013US43630A    2013-05-31
TRIVASCULAR INC    WO    ENDOVASCULAR DELIVERY SYSTEM WITH AN IMPROVED RADIOPAQUE MARKER SCHEME | SYSTÈME DE POSE ENDOVASCULAIRE AYANT UNE TECHNIQUE DE MARQUEUR RADIO-OPAQUE AMÉLIORÉE    WO2013188132A1    WO2013US43615A    2013-05-31
TRIVASCULAR INC    WO    ENDOVASCULAR DELIVERY SYSTEM WITH FLEXIBLE AND TORQUEABLE HYPOTUBE | SYSTÈME DE POSE ENDOVASCULAIRE POURVU D’UN HYPOTUBE FLEXIBLE ET POUVANT ÊTRE SOUMIS À UN COUPLE DE TORSION    WO2013188133A1    WO2013US43623A    2013-05-31
TRIVASCULAR INC    WO    DELIVERY CATHETER FOR ENDOVASCULAR DEVICE | CATHÉTER DE DÉLIVRANCE POUR DISPOSITIF ENDOVASCULAIRE    WO2013151924A1    WO2013US34787A    2013-04-01


TRIVASCULAR INC    WO    DURABLE STENT GRAFT WITH TAPERED STRUTS AND STABLE DELIVERY METHODS AND DEVICES | ENDOPROTHÈSE VASCULAIRE DURABLE AVEC ENTRETOISES CONIQUES ET PROCÉDÉS ET DISPOSITIFS DE DÉLIVRANCE STABLES    WO2013151896A1    WO2013US34654A    2013-03-29


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC    WO    LOW PROFILE STENT GRAFT AND DELIVERY SYSTEM | ENDOPROTHÈSE VASCULAIRE À PROFIL BAS ET SYSTÈME DE DÉLIVRANCE    WO2013151793A1    WO2013US33250A    2013-03-21
TRIVASCULAR INC    WO    ADVANCED KINK-RESISTANT STENT GRAFT | ENDOPROTHÈSE ÉVOLUÉE RÉSISTANT AU PLIAGE    WO2013151794A3    WO2013US33252A    2013-03-21
TRIVASCULAR INC    WO    ADVANCED ENDOVASCULAR GRAFT AND DELIVERY SYSTEM | GREFFE ENDOVASCULAIRE AVANCÉE ET SYSTÈME DE POSE ASSOCIÉ    WO2012068175A3    WO2011US60873A    2011-11-15
TRIVASCULAR INC    WO    FILL TUBE MANIFOLD AND DELIVERY METHODS FOR ENDOVASCULAR GRAFT | COLLECTEUR DE TUBE DE REMPLISSAGE ET PROCÉDÉS DE POSE DE GREFFON ENDOVASCULAIRE    WO2011100367A3    WO2011US24248A    2011-02-09
TRIVASCULAR INC    DE    ENDOVASKULÄRES IMPLANTAT    DE69918272T2    DE69918272A    1999-02-09


TRIVASCULAR INC    CA    VIRTUAL PROTOTYPING AND TESTING FOR MEDICAL DEVICE DEVELOPMENT | ESSAI ET PROTOTYPAGE VIRTUELS DE MISE AU POINT DE DISPOSITIFS MEDICAUX    CA2424252C    CA2424252A    2001-09-28


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC    CA    DELIVERY SYSTEM AND METHOD FOR BIFURCATED GRAFT | METHODE ET SYSTEME DE MISE EN PLACE D’UN GREFFON A BIFURCATION    CA2443104C    CA2443104A    2002-04-11
TRIVASCULAR INC    CA    ENDOVASCULAR GRAFT | GREFFON ENDOVASCULAIRE    CA2501892C    CA2501892A    1999-02-09
TRIVASCULAR INC    CA    INFLATABLE INTRALUMINAL GRAFT | GREFFON INTRALUMINAL GONFLABLE    CA2640263C    CA2640263A    2000-03-03
TRIVASCULAR INC    CA    INFLATABLE INTRALUMINAL GRAFT | GREFFON INTRALUMINAL GONFLABLE    CA2376253C    CA2376253A    2000-03-03
TRIVASCULAR INC    CA    ENDOVASCULAR GRAFT | GREFFON ENDOVASCULAIRE    CA2319052C    CA2319052A    1999-02-09
TRIVASCULAR INC    AU    Modular vascular graft for low profile percutaneous delivery    AU2008308474B2    AU2008308474A    2008-10-03
TRIVASCULAR INC    AU    Advanced endovascular graft    AU2009230748B2    AU2009230748A    2009-10-26
TRIVASCULAR INC    AU    Advanced endovascular graft    AU2009201682B2    AU2009201682A    2009-04-28
TRIVASCULAR INC    AU    Method and apparatus for manufacturing an endovascular graft section    AU2008258148B2    AU2008258148A    2008-12-17
TRIVASCULAR INC    AU    Advanced endovascular graft    AU2002360765C1    AU2002360765A    2002-12-20


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC    AU    Method and apparatus for manufacturing an endovascular graft section    AU2002366805B8    AU2002366805A    2002-12-20
TRIVASCULAR INC    AU    Virtual prototyping and testing for medical device development    AU2001293179A1    AU2001293179A    2001-09-28
TRIVASCULAR INC    AU    Delivery system and method for
expandable intracorporeal device
   AU200133250A    AU200133250A    2001-02-01
TRIVASCULAR INC    JP    ADVANCED KINK-RESISTANT STENT GRAFT    6297023    2015-504610    3/2/2018
TRIVASCULAR INC    UK   

INFLATABLEOCCLUSIONWIRE-

BALLOON FOR AORTIC
APPLICATIONS

   15711020.6    3116439    2/7/2018
TRIVASCULAR INC    UK   

PASSIVE HEMOSTATIC SHEATH

VALVE

   04780128.7    1651135    2/28/2018
TRIVASCULAR INC    CN    MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES       201810370663.0    2015-5-5
ENDOLOGIX, INC.    CN    CATHETER SYSTEM AND METHODS OF USING SAME    ZL201510649289.4    201510649289.4    2018-6-8
ENDOLOGIX, INC.    JP    CATHETER SYSTEM AND METHODS OF USING SAME    6294669    2013-556828    2018-2-23
TRIVASCULAR INC    Germany   

PASSIVE HEMOSTATIC SHEATH

VALVE

   1651135    04780128.7    2018-2-28
ENDOLOGIX, INC.    JP    BALLOON ASSISTED ENDOLUMINAL PROSTHESIS DEPLOYMENT       2017-560952    5/26/2016


ENDOLOGIX, Inc.    EP    SYSTEMS AND METHODS WITH FENESTRATED GRAFT AND FILLING STRUCTURE       16882476.1    12/23/2016


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

ENDOLOGIX, Inc.    JP    SYSTEMS AND METHODS WITH FENESTRATED GRAFT AND FILLING STRUCTURE       2018-534852    12/23/2016
ENDOLOGIX INC.    US   

STENT GRAFT SYSTEMS WITH

RESTRAINTS IN CIRCUMFERENTIAL

CHANNELS AND METHODS
THEREOF

      62/678961    5/31/2018
ENDOLOGIX INC.    US   

PERCUTANEOUS METHOD AND

DEVICE TO TREAT DISSECTIONS

      15/429090    2/9/2017
NELLIX, INC.    US   

SYSTEM AND METHODS FOR

ENDOVASCULAR ANEURYSM
TREATMENT

   2018-0064566    15/682414    8/21/2017
TRIVASCULAR INC.    US   

ENDOVASCULAR DELIVERY

SYSTEM WITH AN IMPROVED
RADIOPAQUE MARKER SCHEME

      16/049560    7/30/2018
ENDOLOGIX INC.    PCT    SINGLE PUNCTURE BIFURCATION GRAFT DEPLOYMENT SYSTEM    WO2000053251    PCT/US2000/006070    3/7/2000
ENDOLOGIX INC.    PCT    GRAFT DEPLOYMENT SYSTEM    WO2004047885    PCT/US2003/37685    11/25/2003
ENDOLOGIX INC.    PCT   

DUAL CONCENTRIC GUIDEWIRE

AND METHODS OF BIFURCATED GRAFT DEPLOYMENT

   WO2008089097    PCT/US2008/050915    1/11/2008
ENDOLOGIX INC.    PCT   

ENDOLUMENAL VASCULAR

PROSTHESIS WITH NEOINTIMA
INHIBITING POLYMERIC SLEEVE

   WO2005096997    PCT/US2005/11522    4/6/2005
ENDOLOGIX INC.    PCT    IMPLANTABLE VASCULAR GRAFT    WO2002039888    PCT/US2001/47028    11/8/2001
ENDOLOGIX INC.    PCT    DUAL WIRE PLACEMENT CATHETER    WO2001003762    PCT/US2000/016352    6/14/2000
ENDOLOGIX INC.    PCT   

MULTI-SEGMENTED GRAFT

DEPLOYMENT SYSTEM

   WO2008034106    PCT/US2007/78565    9/14/2007


ENDOLOGIX INC.    PCT    METHOD AND APPARATUS FOR DECOMPRESSING ANEURYSMS    WO2005099807    PCT/US2005/12306    4/12/2005


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application
Date

TRIVASCULAR INC.    EP   

ENDOLUMINAL PROSTHESIS

DEPLOYMENT DEVICES AND
METHODS

   3328326    16831382.3    7/28/2016
TRIVASCULAR INC.    EP    BALLOON ASSISTED ENDOLUMINAL PROSTHESIS DEPLOYMENT    3302356    16800744.1    5/26/2016
TRIVASCULAR INC.    EP   

STENT-GRAFT WITH IMPROVED

FLEXIBILITY

   3294210    16793394.4    5/11/2016
TRIVASCULAR INC.    EP    PTFE LAYERS AND METHODS OF MANUFACTURING    3095585    16171681.6    3/30/2006


SCHEDULE 11

TRADEMARKS

See attached.


Trademarks

 

Grantor

  

Country

  

Mark

  

Application No.

  

Application Date

  

Registration No.

  

Registration Date

Endologix, Inc.    U.S.    LOGO    86/854470    12/18/15      
Endologix, Inc.    U.S.    ACTIVESEAL    85/518,608    01/17/12    5396605    02/06/18
Endologix, Inc.    U.S.    AFX    85/069,068    06/22/10    4214460    09/25/12
Endologix, Inc.    U.S.    ANGIOTIP    85/767055    10/30/12    5205176    05/16/17
Endologix, Inc.    U.S.    DURAPLY    86/362822    08/11/14    5433696    3/27/18
Endologix, Inc.    U.S.    ENDOLOGIX    75/323,314    07/11/97    2257799    06/29/99
Endologix, Inc.    U.S.    EVAS FORWARD    86/116940    11/12/13    5306786    10/10/17
Endologix, Inc.    U.S.    INNOVATION
TAKING SHAPE
   85/369,728    07/12/11    4220343    10/09/12
Endologix, Inc.    U.S.    INNOVATION
THAT EMPOWERS
   85/514516    01/11/12    4841631    10/27/15
Endologix, Inc.    U.S.    INTELIX    86/316249    06/20/14    5059968    10/11/16
Endologix, Inc.    U.S.    INTUITRAK    77/494,729    06/09/08    3649757    07/07/09
Endologix, Inc.    U.S.    INTUITRAK
DELIVERY
SYSTEM
   77/520,529    07/11/08    3649866   

07/07/09


Endologix, Inc.    U.S.    NELLIX    77/090544    01/24/07    3880178   

11/23/10


Endologix, Inc.    U.S.    POWERLINK    75/658,969    03/12/99    2456038   

05/29/01

Endologix, Inc.    U.S.    POWERLINK XL    78/718,728    09/22/05    3573999   

02/10/09

Endologix, Inc.    U.S.    SUREPASS    78/965,443    08/31/06    3593259   

03/17/09

Endologix, Inc.    U.S.    VELA    85/857988    02/22/13    5296578   

09/26/17

Endologix, Inc.    U.S.    XPAND    85/126,464    09/09/10    4168563   

07/03/12

Endologix, Inc.    Argentina    LOGO    3514846    06/16/16    2888199   

05/19/17

Endologix, Inc.    Argentina    LOGO    3514844    06/16/16    2888198   

05/19/17

Endologix, Inc.    Argentina    LOGO    3514844    06/16/16      
Endologix, Inc.    Argentina    LOGO    3514842    06/16/16    2888196   

05/19/17

Endologix, Inc.    Argentina    AFX    3064304    01/27/11    2496722   

04/04/12

Endologix, Inc.    Argentina    DURAPLY    3386456    02/11/15    2773735   

12/09/15

Endologix, Inc.    Argentina    INTELIX    3375648    12/19/14    2766285   

12/04/15

Endologix, Inc.    Argentina    INTELIX    3375649    12/19/14    2766286   

11/04/15


Endologix, Inc.    Argentina    INTELIX    3375650    12/19/14    2766287    11/04/15
Endologix, Inc.    Argentina    NELLIX    3243024    05/02/13    2658594    06/26/14
Endologix, Inc.    Argentina    VELA    3271551    08/22/13    2808433    06/03/16
Endologix, Inc.    Argentina    XPAND    3072929    03/16/11    2506706    06/01/12
Endologix, Inc.    Australia    LOGO    1326557    06/14/16    1326557    04/24/17
Endologix, Inc.    Australia    DURAPLY    1710503    02/10/15    1710503    11/04/15
Endologix, Inc.    Australia    INTELIX    1247823    12/19/14    1247823    11/25/16
Endologix, Inc.    Brazil    LOGO    911.201.521    06/17/16      
Endologix, Inc.    Brazil    LOGO    911.201.572    06/17/16      
Endologix, Inc.    Brazil    LOGO    911.201.599    06/17/16      
Endologix, Inc.    Brazil    LOGO    911.201.602    06/17/16      


Endologix, Inc.    Brazil    ACTIVESEAL    909861684    08/20/15      


Endologix, Inc.    Brazil    AFX    830891226    12/21/10      
Endologix, Inc.    Brazil    AFX    912186283    01/19/17      
Endologix, Inc.    Brazil    DURAPLY    909861722    08/20/15      
Endologix, Inc.    Brazil    INTELIX    909861749    08/20/15      
Endologix, Inc.    Brazil    INTELIX    909861765    08/20/15      
Endologix, Inc.    Brazil    INTELIX    909861773    08/20/15      
Endologix, Inc.    Brazil    NELLIX    840506538    05/06/13    840506538    02/16/16
Endologix, Inc.    Brazil    VELA    840618530    08/22/13      
Endologix, Inc.    Canada    DURAPLY    1714718    02/10/15      
Endologix, Inc.    Canada    INTELIX    1707569    12/17/14      
Endologix, Inc.    Canada    VELA    1640416    08/21/13      
Endologix, Inc.    Chile    XPAND    1137099    12/30/14    1187135    11/27/15
Endologix, Inc.    China    LOGO    1326551    06/14/16      
Endologix, Inc.    China    DURAPLY    1257411    02/10/15    1257411    02/10/15
Endologix, Inc.    China    INTELIX    1247823    12/19/14    1247823    12/19/14
Endologix, Inc.    Colombia    AFX    16-133051    05/11/26    582446    11/17/17
Endologix, Inc.    Colombia    ENDOLOGIX    16-121402    05/11/16    582446    11/17/17


Endologix, Inc.    Colombia    XPAND    1246435    12/26/14    1246435    12/26/14


Endologix, Inc.    European
Community
   AFX    009609884    12/20/10    009609884    12/01/11
Endologix, Inc.    European
Community
   ANGIOTIP    011780129    04/30/13    011780129    09/24/13
Endologix, Inc.    European
Community
   CLASSICAL
REMODELING
   4598728    08/19/05    4598728    08/02/06
Endologix, Inc.    European
Community
   DURAPLY    1257411    02/10/15    1257411    02/10/15
Endologix, Inc.    European
Community
   ENDOLOGIX, INC.    720649    01/12/98    720649    01/12/98
Endologix, Inc.    European
Community
   INTELIX    13361399    10/15/14      
Endologix, Inc.    European
Community
   INTUITRAK    7453401    11/28/08    7453401    09/21/09
Endologix, Inc.    European
Community
   INTUITRAK
DELIVERY
SYSTEM
   7513302    12/23/08    7513302    07/21/09
Endologix, Inc.    European
Community
   NELLIX    011771011    04/26/13    011771011    09/18/13
Endologix, Inc.    European
Community
   POWERLINK XL    5002977    03/22/06    5002977    04/11/07
Endologix, Inc.    European
Community
   VISIFLEX
DELIVERY
SYSTEM
   5075528    04/24/06    5075528    04/16/07


Endologix, Inc.    European
Community
   VISIFLEX SURE
PASS
   5749338    02/28/07    5749338    01/31/08


Endologix, Inc.    European Union    LOGO    1326551    06/14/16    1326551    06/12/17
Endologix, Inc.    France    POWERLINK    043299490    09/13/99    043299490    12/31/04
Endologix, Inc.    Hong Kong    DURAPLY    303301280    02/15/15    303301280    10/05/15
Endologix, Inc.    Hong Kong    INTELIX    303240954    12/18/14    303240954    09/07/16
Endologix, Inc.    Italy    POWERLINK    001724    09/13/99    0001376420    02/27/08
Endologix, Inc.    Japan    LOGO    1326551    06/14/16    1326551    05/02/17
Endologix, Inc.    Japan    ACTIVESEAL    2015-078597    08/17/15    5857166    06/10/16
Endologix, Inc.    Japan    AFX    2015-078596    08/17/15    5824704    02/05/16
Endologix, Inc.    Japan    DURAPLY    1257411    02/10/15    1257411    01/19/16
Endologix, Inc.    Japan    ENDOLOGIX, INC.    1155/1998    01/12/98    4352035    01/14/00
Endologix, Inc.    Japan    INTELIX    1247823    12/19/14    1247823    10/27/15
Endologix, Inc.    Japan    NELLIX    2013-031634    04/25/13    5613989    09/06/13
Endologix, Inc.    Japan    VELA    2013-6/4901    08/21/13      
Endologix, Inc.    Japan    VISIFLEX
DELIVERY
SYSTEM
   2006-035170    04/17/06    4974084    07/28/06


Endologix, Inc.    Japan    VISIFLEX
SUREPASS
   2007-017236    02/28/07    5066349    07/27/07


Endologix, Inc.    Korea    DURAPLY    1257411    02/10/15    1257411    02/10/15
Endologix, Inc.    Korea    INTELIX    1247823    12/19/14    1247823    06/13/16
Endologix, Inc.    Malaysia    DURAPLY    2015052019    02/11/15    2015052019    12/29/16
Endologix, Inc.    Malaysia    INTELIX    2014069128    12/18/14    2014069128    04/22/16
Endologix, Inc.    Malaysia    INTELIX    2014069135    12/18/14    2014069135    05/10/16
Endologix, Inc.    Mexico    XPAND    1246435    12/26/14    1246435    07/26/16
Endologix, Inc.    New Zealand    DURAPLY    1024501    02/10/15    1024501    12/02/15
Endologix, Inc.    New Zealand    INTELIX    1247823    12/19/14    1019974    09/27/16
Endologix, Inc.    Peru    XPAND    601318    12/29/14    00223114    04/22/15
Endologix, Inc.    Singapore    DURAPLY    40201513229    02/10/15    40201513229    01/06/16
Endologix, Inc.    Singapore    INTELIX    40201508694    12/19/14    40201508694    11/11/15
Endologix, Inc.    Taiwan    DURAPLY    104008448    02/11/15    1764288    04/16/16
Endologix, Inc.    Taiwan    INTELIX    103072703    12/18/14    1740066    11/16/15
Endologix, Inc.    Thailand    DURAPLY    973443    02/11/15    171110590    09/28/17
Endologix, Inc.    Thailand    INTELIX    966979    12/19/14      
Endologix, Inc.    Thailand    INTELIX    966980    12/19/14      
Endologix, Inc.    United Kingdom    POWERLINK    2369587    09/13/99    2369587    12/09/05
Endologix, Inc.    Venezuela    XPAND    20754-14    12/30/14    P352404    06/07/16
Endologix, Inc.    Vietnam    DURAPLY    1257411    02/10/15    1257411    11/03/16


Endologix, Inc.    Vietnam    INTELIX    1247823    12/19/14    1247823    05/21/15
Endologix, Inc.    U.S.    ALTO    87/906,099    5/3/2018      
Endologix, Inc.    U.S.    VERTA    87/116,482    7/26/2016      
TriVascular, Inc.    U.S.    ALLEGRO    86/758,465    9/16/2015      
TriVascular, Inc.    U.S.    CUSTOMSEAL    86/047,875    8/26/2013    4,732,342    5/5/2015
TriVascular, Inc.    U.S.    OVATION    77/941,535    2/22/2010    4,440,468    11/26/2013
TriVascular, Inc.    U.S.    OVATION ALTO    86/047,894    8/26/2013    5,195,890    5/2/2017
TriVascular, Inc.    U.S.    OVATION PRIME    85/900,037    4/10/2013    4,452,625    12/17/2013
TriVascular, Inc.    U.S.    LOGO    85/832,445    1/25/2013    4,449,077    12/10/2013
TriVascular, Inc.    U.S.    TRIVASCULAR    75/879,907    12/21/1999    2,867,015    7/27/2004
TriVascular, Inc.    U.S.    LOGO    85/831,355    1/24/2013    4,395,789    9/3/2013
TriVascular, Inc.    Australia    CUSTOMSEAL    1608471    2/27/2014    1608471    1/21/2015
TriVascular, Inc.    Australia    OVATION    1379343    8/20/2010    1379343    1/10/2011
TriVascular, Inc.    Australia    OVATION ALTO    1608211    2/26/2014    1608211    5/28/2014
TriVascular, Inc.    Australia    OVATION PRIME    1583683    10/2/2013    1583683    1/7/2014
TriVascular, Inc.    Australia    LOGO    1537921    1/29/2013    1537921    7/31/2013
TriVascular, Inc.    Australia    TRIVASCULAR    888603    9/7/2001    888603    9/7/2001


TriVascular, Inc.    Australia    LOGO    983475    12/30/2003    983475    8/16/2004


TriVascular, Inc.    Brazil    CUSTOMSEAL    840.803.346    2/26/2014    840803346    10/18/2016
TriVascular, Inc.    Brazil    OVATION    830727035    8/20/2010    830727035    1/6/2015
TriVascular, Inc.    Brazil    OVATION ALTO    840.803.419    2/26/2014      
TriVascular, Inc.    Brazil    OVATION PRIME    840.666.152    10/4/2013    840666152    8/23/2016
TriVascular, Inc.    Brazil    LOGO    830854487    11/24/2010    830854487    6/3/2014
TriVascular, Inc.    Canada    CUSTOMSEAL    1,665,277    2/25/2014      
TriVascular, Inc.    Canada    OVATION    1493184    8/20/2010    TMA858,759    8/28/2013
TriVascular, Inc.    Canada    OVATION ALTO    1,665,276    2/25/2014      
TriVascular, Inc.    Canada    OVATION PRIME    1,645,991    10/2/2013      
TriVascular, Inc.    Canada    LOGO    1,611,335    1/25/2013    TMA934,553    4/12/2016
TriVascular, Inc.    Canada    TRIVASCULAR    1,612,136    1/31/2013    TMA882,992    7/29/2014
TriVascular, Inc.    Canada    LOGO    1200748    12/30/2003    TMA825955    6/8/2012
TriVascular, Inc.    China    CUSTOMSEAL    14075157    2/26/2014    14075157    4/28/2015
TriVascular, Inc.    China    OVATION    8598413    8/23/2010    8598413    11/7/2011
TriVascular, Inc.    China    OVATION ALTO    14075158    2/26/2014    14075158    4/28/2015
TriVascular, Inc.    China    OVATION PRIME    13321289    10/8/2013    13321289    6/21/2015


TriVascular, Inc.    China    LOGO    8898103    11/30/2010    8898103    12/14/2011


TriVascular, Inc.    EUTM    OVATION    009325234    8/20/2010    009325234    2/3/2011
TriVascular, Inc.    EUTM    OVATION ALTO    012636908    2/25/2014    012636908    7/16/2014
TriVascular, Inc.    EUTM    OVATION PRIME    012189148    10/2/2013    012189148    2/26/2014
TriVascular, Inc.    EUTM    LOGO    011523305    1/28/2013    011523305    6/24/2013
TriVascular, Inc.    EUTM    TRIVASCULAR    002374593    9/13/2001    002374593    3/12/2003
TriVascular, Inc.    EUTM    LOGO    003598836    12/31/2003    003598836    4/29/2005
TriVascular, Inc.    EUTM    TRIVASCULAR2 &
Design
   007457344    11/27/2008    007457344    6/16/2009
TriVascular, Inc.    India    OVATION    2012141    8/20/2010    2012141    8/23/2016
TriVascular, Inc.    India    LOGO    2060383    11/29/2010    2060383    11/29/2010
TriVascular, Inc.    Japan    CUSTOMSEAL    2014-14237    2/26/2014    5672406    5/23/2014
TriVascular, Inc.    Japan    OVATION    2010-065871    8/20/2010    5614976    9/13/2013
TriVascular, Inc.    Japan    OVATION ALTO    2014-14238    2/26/2014    5672407    5/23/2014
TriVascular, Inc.    Japan    OVATION PRIME    2013-024875    4/4/2013    5613251    9/6/2013
TriVascular, Inc.    Japan    LOGO    2013-5504    1/30/2013    5643434    1/17/2014
TriVascular, Inc.    Japan    TRIVASCULAR    2001-115594    12/27/2001    4731627    12/5/2003
TriVascular, Inc.    Japan    LOGO    2004-030615    3/18/2004    4778040    6/11/2004


TriVascular, Inc.    Mexico    OVATION    1113689    8/20/2010    1235645    8/20/2010
TriVascular, Inc.    Mexico    LOGO    1139285    12/2/2010    1213946    4/27/2011

Exhibit 10.5

Execution Version

GUARANTY AND SECURITY AGREEMENT

dated as of August 9, 2018

by and among

Endologix, Inc.,

as Borrower Representative,

the other Grantors, Borrowers and Guarantors party hereto from time to time

and

DEERFIELD ELGX REVOLVER, LLC,

as agent for itself and the other Secured Parties

 


GUARANTY AND SECURITY AGREEMENT

This GUARANTY AND SECURITY AGREEMENT (this “ Agreement ”), dated as of August 9, 2018, by and among Endologix, Inc., a Delaware corporation (“ Borrower Representative ”), CVD/RMS Acquisition Corp., a Delaware corporation (“ CVD ”), Nellix, Inc., a Delaware corporation (“ Nellix ”), TriVascular Technologies, Inc., a Delaware corporation (“ TriVascular Technologies ”), TriVascular, Inc., a California corporation (“ TriVascular California ”), Endologix Canada, LLC, a Delaware limited liability company (“ Endologix Canada ”), TriVascular Sales LLC, a Texas limited liability company (“ Sales ”), RMS/Endologix Sideways Merger Corp., a Delaware corporation (“ Sideways ”), each other Person who becomes a party hereto pursuant to Section  8.15 (together with the Borrower Representative, CVD, Nellix, TriVascular Technologies, TriVascular California, Endologix Canada, Sales and Sideways, the “ Grantors ” or the “ Borrowers ” and each, a “ Grantor ” or a “ Borrower ”), each other Person signatory hereto as a “ Guarantor ” (as defined below) and Deerfield ELGX Revolver, LLC, as Agent.

RECITALS

A. The Lenders have agreed to extend credit to Borrowers pursuant to the Credit Agreement (defined below). Each Borrower is affiliated with each other Grantor and Guarantor.

B. Borrowers, the other Grantors and the other Guarantors are engaged in interrelated businesses, and each Grantor and each Guarantor will derive substantial direct and indirect benefit from extensions of credit under the Credit Agreement.

C. It is a condition precedent to Lenders’ obligation to make their respective extensions of credit and provide the Revolver Commitments to the Borrowers under the Credit Agreement that the Grantors and the Guarantors shall have executed and delivered this Agreement to Agent.

In consideration of the premises and to induce Lenders and Agent to enter into the Credit Agreement and the other Loan Documents to which they are a party and to induce Lenders to make their respective extensions of credit to the Borrower thereunder, each Grantor and each Guarantor hereby agrees with Agent (for the benefit of the Secured Parties) as follows:

SECTION 1. DEFINITIONS .

1.1 Unless otherwise defined herein, terms defined in the Credit Agreement and used herein shall have the meanings given to them in the Credit Agreement, and the following terms are used herein as defined in the UCC (such meanings to be equally applicable to both the singular and plural forms of the terms defined): “accounts”, “certificated security”, “chattel paper”, “commercial tort claims”, “commodity contract”, “deposit accounts”, “documents”, “electronic chattel paper”, “equipment”, “farm products”, “fixture”, “general intangibles”, “goods”, “health care insurance receivables”, “instruments”, “inventory”, “leases”, “letter-of-credit rights”, “money”, “payment intangibles”, “product”, “record”, “securities account”, “security”, “supporting obligations”, and “tangible chattel paper”. It is hereby agreed that the term “instrument” shall not include checks received in the ordinary course of business.

1.2 Whenever used in this Agreement, the Exhibits or the Schedules attached hereto, unless the context otherwise requires, the following terms have the following meanings:

Agreement ” has the meaning set forth in the preamble of this Agreement.


Collateral ” means all of Grantors’ assets, whether now owned or hereafter created, acquired or arising, including without limitation, all of Grantors’ right, title and interest in and to the following:

(a) all goods, accounts (including health care insurance receivables), equipment, inventory, contract rights or rights to payment of money, leases, license agreements and other licenses, franchise agreements, general intangibles, commercial tort claims (including any Identified Claims), documents, instruments (including any promissory notes) (and any distribution of property made on, in respect of or in exchange for such instruments from time to time), chattel paper (whether tangible chattel paper or electronic), cash, Cash Equivalents, deposit accounts, Intellectual Property, Intellectual Property Licenses, securities accounts, fixtures, letter-of-credit rights (whether or not the letter of credit is evidenced by a writing), securities, all other Pledged Collateral and Pledged Investment Property (including any distribution of property made on, in respect of or in exchange for such Pledged Collateral and/or Pledged Investment Property from time to time) and all supporting obligations related to any of the foregoing, and financial assets, wherever located;

(b) all books and records relating to any of the foregoing;

(c) all property of any Grantor held by any Secured Party, including all property of every description, in the custody of or in transit to such Secured Party for any purpose, including safekeeping, collection or pledge, for the account of such Grantor or as to which such Grantor may have any right or power, including but not limited to cash; and

(d) any and all claims, rights and interests in any of the above and all substitutions for, additions, attachments, accessories, accessions and improvements to and replacements, products, Proceeds and insurance Proceeds of any or all of the foregoing.

Where the context requires, terms relating to the Collateral or any part thereof, when used in relation to a Grantor, shall refer to such Grantor’s Collateral or the relevant part thereof. Notwithstanding the foregoing, “Collateral” shall not include Excluded Property; provided , however , that if and when any assets cease to be Excluded Property, the term “Collateral” shall include such assets and a Lien on and security interest in such assets shall be deemed granted therein pursuant to Section  3.1 hereof.

Copyrights ” means any and all rights in any works of authorship, including (A) copyrights and moral rights, (B) copyright registrations and recordings thereof and all applications in connection therewith including those listed on Schedule 8, (C) income, license fees, royalties, damages, and payments now and hereafter due or payable under and with respect thereto, including payments under all licenses entered into in connection therewith and damages and payments for past, present, or future infringements thereof, (D) the right to sue for past, present, and future infringements thereof, and (E) all of each Grantor’s rights corresponding thereto throughout the world.

Credit Agreement ” means the Credit Agreement of even date herewith by and among Borrowers, the other Loan Parties party thereto from time to time, Agent and Lenders, as amended, supplemented, restated or otherwise modified from time to time.

Fraudulent Transfer Laws ” has the meaning set forth in Section  2.6 hereof.

Grantor ” has the meaning set forth in the preamble of this Agreement.

 

3


Guaranteed Obligations ” means all obligations of each Guarantor under the Loan Documents and all other Obligations (including the fees and other amounts set forth in Section 2.09 of the Credit Agreement).

Guarantors ” means each Borrower and any other Person who becomes a party to this Agreement pursuant to Section  8.15 .

Identified Claims ” means the commercial tort claims described on Schedule 5 , as such schedule shall be supplemented from time to time in accordance with the terms and conditions of this Agreement.

Intellectual Property License ” means, with respect to any Grantor (the “ Specified Party ”), (A) any licenses or other similar rights provided to the Specified Party in or with respect to Intellectual Property owned or controlled by any other Person, and (B) any licenses or other similar rights provided to any other Person in or with respect to Intellectual Property owned or controlled by the Specified Party, in each case, including (1) any software license agreements, (2) the license agreements listed on Schedule 9 , and (3) the right to use any of the licenses or other similar rights described in this definition in connection with the enforcement of the Lender Group’s rights under the Loan Documents.

Issuers ” means the collective reference to each issuer of Pledged Collateral and Pledged Investment Property.

Paid in Full ” and “ Payment in Full ” each means (a) with respect to Guaranteed Obligations, all Guaranteed Obligations have been repaid in full in cash (other than any unasserted contingent indemnification obligations) and all Commitments have been terminated and (b) with respect to Secured Obligations, all Secured Obligations have been repaid in full in cash (other than any unasserted contingent indemnification obligations) and all Commitments have been terminated; provided that the foregoing shall be subject to any reinstatement pursuant to (and the other provisions set forth in) Section  8.18 ).

Patents ” means patents and patent applications, including (A) the patents and patent applications listed on Schedule 10, (B) all continuations, divisionals, continuations-in-part, re-examinations, reissues, and renewals thereof and improvements thereon, (C) all income, royalties, damages and payments now and hereafter due or payable under and with respect thereto, including payments under all licenses entered into in connection therewith and damages and payments for past, present, or future infringements thereof, (D) the right to sue for past, present, and future infringements thereof, and (E) all of each Grantor’s rights corresponding thereto throughout the world.

Pledged Collateral ” means, collectively, the Pledged Equity and the Pledged Debt Instruments.

Pledged Debt Instruments ” means all right, title and interest of any Grantor in instruments evidencing any Indebtedness owed to such Grantor or other obligations owed to such Grantor, including all Indebtedness described on Schedule 1 , issued by the obligors named therein. Pledged Debt Instruments excludes any Excluded Property.

Pledged Equity ” means collectively, all Pledged Interests and Pledged Stock.

Pledged Interests ” shall mean, with respect to each limited liability company, partnership or other organization listed on Schedule 1 , (i) the Stock in such limited liability company, partnership or other organization owned by a Grantor and listed on Schedule 1 , and the certificates, if any, representing such interests and any interest of such Grantor, as applicable, on the books and records of such limited liability company, partnership or other organization or on the books and records of any securities

 

4


intermediary pertaining to such interests, (ii) the Stock of any other Person whose Stock is at any time hereafter issued or granted to, or held by any Grantor, and (iii) all dividends, distributions, cash, warrants, rights, options, instruments, securities and other property or Proceeds from time to time received, receivable or otherwise distributed in respect of or in exchange for any or all interests set forth in the preceding clauses (i) and (ii). Pledged Interests excludes any Excluded Property.

Pledged Investment Property ” means the collective reference to (i) all “investment property” as such term is defined in Section 9-102(a)(49) of the UCC and (ii) all “financial assets” as such term is defined in Section 8-102(a)(9) of the UCC, other than any Pledged Equity or Pledged Debt Instruments. Pledged Investment Property excludes any Excluded Property.

Pledged Stock ” shall mean, with respect to each corporation listed on Schedule 1 , the Stock of such corporation owned by a Grantor and listed on Schedule 1 , and the certificates, if any, representing such shares and any interest of such Grantor, as applicable, in the entries on the books of the issuer of such shares or on the books of any securities intermediary pertaining to such shares and the Stock of any other Person whose Stock is at any time hereafter issued to or granted to or held by any Grantor, and all dividends, distributions, cash, warrants, rights, options, instruments, securities and other property or Proceeds from time to time received, receivable or otherwise distributed in respect of or in exchange for any or all of such shares. Pledged Stock excludes any Excluded Property.

Proceeds ” means all “proceeds” as such term is defined in Section 9-102(a)(64) of the UCC and, in any event, shall include all dividends or other income from the Pledged Investment Property, collections thereon or distributions or payments with respect thereto.

Receivable ” means any right to payment for goods sold or leased or for services rendered, whether or not such right is evidenced by an instrument or chattel paper and whether or not it has been earned by performance (including any accounts).

Secured Obligations ” means the Obligations (including the fees and other amounts set forth in Section 2.09 of the Credit Agreement).

Trademarks ” means any and all trademarks, trade names, registered trademarks, trademark applications, service marks, registered service marks and service mark applications, including (A) the trade names, registered trademarks, trademark applications, registered service marks and service mark applications listed on Schedule 11, (B) all renewals thereof, (C) all income, royalties, damages and payments now and hereafter due or payable under and with respect thereto, including payments under all licenses entered into in connection therewith and damages and payments for past or future infringements or dilutions thereof, (D) the right to sue for past, present and future infringements and dilutions thereof, (E) the goodwill of each Grantor’s business symbolized by the foregoing or connected therewith, and (F) all of each Grantor’s rights corresponding thereto throughout the world.

Transferred Guarantor ” has the meaning set forth in Section  8.16(c) .

SECTION 2. GUARANTY .

2.1 Guaranty .

(a) To induce Lenders to make the Loans and each other Secured Party to make credit available to or for the benefit of one or more Grantors and for the applicable Secured Parties to enter into the Loan Documents, each of the Guarantors hereby, jointly and severally, absolutely,

 

5


unconditionally and irrevocably, as a primary obligor and not only a surety, guarantees to Agent and the other Secured Parties and their respective successors and permitted assigns, the prompt and complete payment and performance by Borrowers and each other Grantor, as applicable, of the Guaranteed Obligations when due (whether at the stated maturity or earlier, by reason of acceleration, any mandatory prepayment required pursuant to the terms of the Financing Agreement or otherwise).

(b) This Guaranty includes all present and future Guaranteed Obligations including any under transactions continuing, compromising, extending, increasing, modifying, releasing, or renewing the Guaranteed Obligations, changing the interest rate, payment terms, or other terms and conditions thereof, or creating new or additional Guaranteed Obligations after prior Guaranteed Obligations have been satisfied in whole or in part. To the maximum extent permitted by law, each Guarantor hereby waives any right to revoke this Guaranty as to future Guaranteed Obligations. If such a revocation is effective notwithstanding the foregoing waiver, each Guarantor acknowledges and agrees that (i) no such revocation shall be effective until written notice thereof has been received by Agent, (ii) no such revocation shall apply to any Guaranteed Obligations in existence on the date of receipt by Agent of such written notice (including any subsequent continuation, extension, or renewal thereof, or change in the interest rate, payment terms, or other terms and conditions thereof), (iii) no such revocation shall apply to any Guaranteed Obligations made or created after such date to the extent made or created pursuant to a legally binding commitment of any member of the Lender Group in existence on the date of such revocation, (iv) no payment by any Guarantor, any Borrower, or from any other source, prior to the date of Agent’s receipt of written notice of such revocation shall reduce the maximum obligation of such Guarantor hereunder, and (v) any payment by any Borrower or from any source other than such Guarantor subsequent to the date of such revocation shall first be applied to that portion of the Guaranteed Obligations as to which the revocation is effective and which are not, therefore, Guaranteed hereunder, and to the extent so applied shall not reduce the maximum obligation of such Guarantor hereunder. This Guaranty shall be binding upon each Guarantor, its successors and assigns and inure to the benefit of and be enforceable by Agent (for the benefit of the Lender Group) and its successors, transferees, or assigns.

(c) The guaranty contained in this Section  2 is a guaranty of payment and not of collection and shall remain in full force and effect until all of the Guaranteed Obligations shall have been Paid in Full.

(d) No payment made by any Borrower, any of the Guarantors, any other guarantor or any other Person, or received or collected by Agent or the other Secured Parties from any Borrower, any of the Guarantors, any other guarantor or any other Person, as applicable, by virtue of any action or proceeding or any set-off or appropriation or application at any time or from time to time in reduction of or in payment of the Guaranteed Obligations shall be deemed to modify, reduce, release or otherwise affect the Liability of any Guarantor hereunder which Guarantor shall, notwithstanding any such payment (other than any payment received or collected from such Guarantor in respect of the Guaranteed Obligations), remain liable for the Guaranteed Obligations until the Guaranteed Obligations are Paid in Full.

2.2 No Subrogation . Notwithstanding any payment made by any Guarantor hereunder or any set-off or application of funds of any Guarantor by Agent or any other Secured Party, no Guarantor shall be entitled to be subrogated to any of the rights of Agent or any other Secured Party against any Borrower or any Guarantor or any collateral security or guaranty or right of offset held by Agent or any other Secured Party for the payment of the Guaranteed Obligations, nor shall any Guarantor seek or be entitled to seek any contribution or reimbursement from any Borrower or any Guarantor in respect of payments made by such Guarantor hereunder, until all of the Guaranteed Obligations are Paid in Full. If any amount shall be paid to any Guarantor on account of such subrogation rights at any time

 

6


when all of the Guaranteed Obligations shall not have been Paid in Full, such amount shall be held by such Guarantor in trust for Agent and the other Secured Parties, segregated from other funds of such Guarantor, and shall, forthwith upon receipt by such Guarantor, be turned over to Agent (for the benefit of the Secured Parties) in the exact form received by such Guarantor (duly indorsed by such Guarantor to Agent), to be applied against the Guaranteed Obligations, whether matured or unmatured, as set forth in Section  6.5 hereof.

2.3 Amendments, etc. with respect to the Guaranteed Obligations .

(a) Each Guarantor shall remain obligated hereunder, without any reservation of rights against any Guarantor and without notice to or further assent by any Guarantor, notwithstanding the fact that: (i) any demand for payment of any of the Guaranteed Obligations made by Agent or the other Secured Parties may be rescinded by Agent or the other Secured Parties and any of the Guaranteed Obligations continued, (ii) the Guaranteed Obligations, or the Liability of any other Person upon or for any part thereof, or any collateral security or guaranty therefor or right of offset with respect thereto, may, from time to time, in whole or in part, be renewed, extended, amended, modified, accelerated, compromised, waived, surrendered or released by Agent or any other Secured Party, or (iii) any of the Credit Agreement or the other Loan Documents or any other documents executed and delivered in connection therewith may be amended, modified, supplemented or terminated, in whole or in part, as Agent or any other Secured Party may deem advisable from time to time. Agent and the other Secured Parties shall have no obligation to protect, secure, perfect or insure any Lien at any time held by them as security for the Guaranteed Obligations or for the guaranty contained in this Section  2 or any property subject thereto.

(b) Agent or any other Secured Party may, from time to time, in their reasonable discretion and without notice to or demand upon the Guarantors (or any of them), take any or all of the following actions, without discharging or otherwise affecting the Obligations (including the fees and other amounts set forth in Section 2.09 of the Credit Agreement) of any Guarantor hereunder and without incurring any Liability hereunder: (i) receive, take and hold additional Collateral to secure any of the Guaranteed Obligations or any obligation hereunder, (ii) retain or obtain the primary or secondary obligation of any obligor or obligors, in addition to the undersigned, with respect to any of the Guaranteed Obligations, (iii) extend or renew any of the Guaranteed Obligations for one or more periods (whether or not longer than the original period), alter or exchange any of the Guaranteed Obligations or otherwise modify, amend, supplement or otherwise change any Guaranteed Obligation or any Loan Document (including accelerating or otherwise changing the time of payment), or release or compromise any obligation of any of the undersigned hereunder or any obligation of any nature of any other obligor with respect to any of the Guaranteed Obligations or otherwise in connection with the Loan Documents, (iv) release any guaranty or right of offset or their security interest in, or surrender, release or permit any substitution or exchange for, all or any part of any personal property securing any of the Guaranteed Obligations or any obligation hereunder, or extend or renew for one or more periods (whether or not longer than the original period) or release, compromise, alter or exchange any obligations of any nature of any obligor with respect to any such personal property, (v) resort to the undersigned (or any of them) for payment of any of the Guaranteed Obligations when due, whether or not Agent or any other Secured Party shall have resorted to any personal property securing any of the Guaranteed Obligations or any obligation hereunder or shall have proceeded against any other of the undersigned or any other obligor primarily or secondarily obligated with respect to any of the Guaranteed Obligations, (vi) apply to the Guaranteed Obligations any sums by whomever paid or however realized to any Guaranteed Obligation as set forth in Section  6.5 hereof, (vii) refund at any time any payment received by any Secured Party in respect of any Guaranteed Obligation, (viii) sell, exchange, enforce, waive, substitute, liquidate, terminate, release, abandon, fail to perfect, subordinate, accept, substitute, surrender, exchange, affect,

 

7


impair or otherwise alter or release any Collateral for any Guaranteed Obligation or any other guaranty therefor in any manner, (ix) otherwise deal in any manner with any Borrower or any other Guarantor, maker or endorser of any Guaranteed Obligation or any part thereof, and/or (x) settle, release, compromise, collect or otherwise liquidate the Guaranteed Obligations.

2.4 Waivers . To the extent permitted by Applicable Law, each Guarantor hereby unconditionally and irrevocably waives any and all notice of the creation, renewal, extension or accrual of any of the Guaranteed Obligations and notice of or proof of reliance by Agent or any other Secured Party upon the guaranty contained in this Section  2 or acceptance of the guaranty contained in this Section  2 . The Guaranteed Obligations, and any of them, shall conclusively be deemed to have been created, contracted or incurred, or renewed, extended, amended or waived, in reliance upon the guaranty contained in this Section  2, and all dealings between any Borrower and any of the Guarantors, on the one hand, and Agent and the other Secured Parties, on the other hand, likewise shall be conclusively presumed to have been had or consummated in reliance upon the guaranty contained in this Section  2 . To the extent permitted by Applicable Law, each Guarantor hereby unconditionally and irrevocably waives and agrees not to assert any claim, defense, setoff or counterclaim based on (i) diligence, promptness, presentment, protest, requirements for any demand for payment or performance and protest and notice of protest, requirements for any notice of default, dishonor or nonpayment and all other notices whatsoever to or upon any Borrower or any of the Guarantors with respect to the Guaranteed Obligations or any part thereof, (ii) notice of the existence or creation or non-payment of all or any of the Guaranteed Obligations, (iii) all diligence in collection or protection of or realization upon any Guaranteed Obligations or any security for or guaranty of any Guaranteed Obligations, (iv) any presentment, demand, protest or further notice or other formality or requirements of any kind with respect to any Guaranteed Obligation (including any accrued but unpaid interest thereon) becoming immediately due and payable, and (v) any defense arising by reason of a disability or other defense of Borrower or any Guarantor. No obligation of any Guarantor hereunder shall be discharged other than by Payment in Full in cash of the Guaranteed Obligations. Each Guarantor further waives any right such Guarantor may have under any Applicable Law to require any Secured Party to seek recourse first against any Borrower or any other Person, or to realize upon any Collateral for any of the Obligations (including the fees and other amounts set forth in Section 2.09 of the Credit Agreement), as a condition precedent to enforcing such Guarantor’s Liability and obligations under this Guaranty.

2.5 Payments . Each Guarantor hereby guaranties that payments hereunder will be paid to Agent and the other Secured Parties without set-off or counterclaim in Dollars in accordance with Section  2.4 of the Credit Agreement.

2.6 Limitation of Guaranty . Any term or provision of this Agreement or any other Loan Document to the contrary notwithstanding, the maximum aggregate amount for which any Guarantor shall be liable hereunder shall not exceed the maximum amount for which such Guarantor can be liable without rendering this Agreement or any other Loan Document, as it relates to such Guarantor, subject to avoidance under Applicable Laws relating to fraudulent conveyance or fraudulent transfer (including the Uniform Fraudulent Conveyance Act, the Uniform Fraudulent Transfer Act and Section 548 of title 11 of the United States Code or any applicable provisions of comparable Applicable Laws) (collectively, “ Fraudulent Transfer Laws ”). Any analysis of the provisions of this Agreement for purposes of Fraudulent Transfer Laws shall take into account the right of contribution established in Section  2.7 hereof and, for purposes of such analysis, give effect to any discharge of intercompany debt as a result of any payment made under this Agreement.

2.7 Contribution . To the extent that any Guarantor shall be required hereunder to pay any portion of any Guaranteed Obligation exceeding the greater of (i) the amount of the value

 

8


actually received by such Guarantor and its Subsidiaries from the Loans and other Obligations and (ii) the amount such Guarantor would otherwise have paid if such Guarantor had paid the aggregate amount of the Guaranteed Obligations (excluding the amount thereof repaid by any Borrower and any other Guarantor that is a direct or indirect parent entity of any Borrower) in the same proportion as such Guarantor’s net worth on the date enforcement is sought hereunder bears to the aggregate net worth of all the Guarantors on such date, then such Guarantor shall be reimbursed by such other Guarantors for the amount of such excess, pro rata, based on the respective net worth of such other Guarantors on such date.

2.8 Guaranty Absolute and Unconditional . Each Guarantor hereby waives and agrees not to assert any defense, whether arising in connection with or in respect of any of the following or otherwise, and hereby agrees that its obligations under this Agreement are irrevocable, absolute and unconditional and shall not be discharged as a result of or otherwise affected by any of the following (which may not be pleaded and evidence of which may not be introduced in any proceeding with respect to this Agreement) to the fullest extent not prohibited by Applicable Law:

(a) the invalidity or unenforceability of any obligation of any Borrower or any Guarantor under any Loan Document or any other agreement or instrument relating thereto (including any amendment, consent or waiver thereto), or any security for, or other guaranty of, any Guaranteed Obligation or any part thereof, or the lack of perfection or continuing perfection or failure of priority of any security for the Guaranteed Obligations or any part thereof;

(b) the absence of (i) any attempt to collect any Guaranteed Obligation or any part thereof from any Borrower or any Guarantor or other action to enforce the same or (ii) any action to enforce any Loan Document or any Lien thereunder;

(c) the failure by any Person to take any steps to perfect and maintain any Lien on, or to preserve any rights with respect to, any Collateral;

(d) any workout, insolvency, bankruptcy proceeding, reorganization, arrangement, liquidation or dissolution by or against any Borrower, any Guarantor or any of Borrower’s Subsidiaries or any procedure, agreement, order, stipulation, election, action or omission thereunder, including any discharge or disallowance of, or bar or stay against collecting, any Guaranteed Obligation (or any interest thereon) in or as a result of any such proceeding;

(e) any foreclosure, whether or not through judicial sale, and any other sale or other disposition of any Collateral or any election following the occurrence of an Event of Default by any Secured Party to proceed separately against any Collateral in accordance with such Secured Party’s rights under any Applicable Law; or

(f) any other defense, setoff, counterclaim or any other circumstance that might otherwise constitute a legal or equitable discharge of any Borrower, any Guarantor or any Subsidiary of any Borrower, in each case other than the Payment in Full in cash of the Guaranteed Obligations.

2.9 Reliance . Each Guarantor hereby assumes responsibility for keeping itself informed of the financial condition of Borrowers, each Guarantor and any other guarantor, maker or endorser of any Guaranteed Obligation or any part thereof, and of all other circumstances bearing upon the risk of nonpayment of any Guaranteed Obligation or any part thereof that diligent inquiry would reveal, and each Guarantor hereby agrees that no Secured Party shall have any duty to advise any Guarantor of information known to it regarding such condition or any such circumstances. In the event any Secured Party, in its sole discretion, undertakes at any time or from time to time to provide any such

 

9


information to any Guarantor, such Secured Party shall be under no obligation to (i) undertake any investigation not a part of its regular business routine, (ii) disclose any information that such Secured Party, pursuant to accepted or reasonable commercial finance or banking practices, wishes to maintain confidential, or (iii) make any future disclosures of such information or any other information to any Guarantor.

SECTION 3. GRANT OF SECURITY INTEREST .

3.1 Grant . Each Grantor hereby collaterally assigns and grants to Agent, for the benefit of the Secured Parties, a Lien on and security interest in all of its Collateral, as collateral security for the prompt and complete payment and performance when due (whether at the stated maturity, by acceleration or otherwise) of the Secured Obligations. Notwithstanding the foregoing, no Lien or security interest is hereby granted on any Excluded Property. Each Grantor hereby represents and warrants as of (i) the Closing Date, (ii) the date of the making of each Revolving Loan (or other extension of credit) made thereafter, (iii) the date of each amendment, consent or waiver of this Agreement or the Credit Agreement executed by any Grantor and (iv) solely with respect to any new Grantor that joins this Agreement after the Closing Date, on the date such new Grantor joins this Agreement, that the Excluded Property, when taken as a whole, is not material to the business operations or financial condition of the Grantors, taken as a whole.

SECTION 4. REPRESENTATIONS AND WARRANTIES .

To induce Agent and Lenders to enter into the Credit Agreement and to induce Lenders to make extensions of credit to Borrowers thereunder, each Grantor jointly and severally hereby represents and warrants to Agent and the other Secured Parties that the following are true, correct and complete, in each case to the extent and in the manner set forth herein, on the Closing Date and as of (i) the Closing Date, (ii) the date of the making of each Revolving Loan (or other extension of credit) made thereafter, (iii) the date of each amendment, consent or waiver of this Agreement or the Credit Agreement executed by any Grantor and (iv) solely with respect to any new Grantor that joins this Agreement after the Closing Date, on the date such new Grantor joins this Agreement:

4.1 Title; No Other Liens . Except for the Lien granted to Agent pursuant to this Agreement and other Permitted Liens, such Grantor owns, or has rights or the power to transfer rights in, each item of the Collateral free and clear of any and all Liens of others. Such Grantor (i) is the record and beneficial owner of the Collateral pledged by it hereunder constituting instruments or certificates and (ii) has rights in or the power to transfer each other item of Collateral in which a Lien is granted by it hereunder, free and clear of any other Lien (other than Permitted Liens). No effective financing statement or other public notice with respect to all or any part of the Collateral is on file or of record in any public office, except filings evidencing Permitted Liens.

4.2 Perfected Liens . The security interests granted in the Collateral pursuant to this Agreement (i) will constitute valid and continuing perfected security interests in all of the Grantors’ rights in the Collateral in favor of Agent as collateral security for the Secured Obligations, enforceable in accordance with the terms hereof, except as such enforceability may be limited by applicable insolvency, bankruptcy, reorganization, moratorium or other similar laws affecting creditors’ rights generally, upon (A) in the case of all Collateral in which a security interest may be perfected by filing a financing statement under the UCC, completion of the filings and other actions specified on Schedule 2 (which filings and other documents referred to on Schedule 2 have been delivered to Agent in completed form), (B) with respect to any deposit account or securities account, the execution of Control Agreements, (C) in the case of all Copyrights, Trademarks and Patents for which UCC filings are insufficient, all appropriate

 

10


filings having been made with the applicable Intellectual Property registries, including but not limited to the United States Copyright Office or the United States Patent and Trademark Office, as applicable, (D) in the case of letter-of-credit rights that are not supporting obligations of Collateral, the execution of a contractual obligation granting control to Agent over such letter-of-credit rights and (E) in the case of electronic chattel paper with payment or amounts owing thereon in excess of $250,000 in the aggregate, the completion of all steps necessary to grant control to Agent over such electronic chattel paper; and (ii) shall be prior to all other Liens on the Collateral except for Permitted Priority Liens, upon (A) in the case of all Pledged Collateral and Pledged Investment Property, the delivery thereof to Agent (for the benefit of the Secured Parties) of such Pledged Collateral and Pledged Investment Property consisting of instruments and certificates, in each case properly endorsed for transfer to Agent (for the benefit of the Secured Parties) or in blank, (B) in the case of all Pledged Investment Property not in certificated form and deposit accounts, the execution of Control Agreements with respect to such Pledged Investment Property and deposit accounts and (C) in the case of all other instruments and tangible chattel paper that has aggregate payments or amounts owing thereunder in excess of $250,000 in the aggregate that are not Pledged Collateral or Pledged Investment Property, the delivery thereof to Agent (for the benefit of the Secured Parties) of such instruments and tangible chattel paper. Except as set forth in this Section  4.2 or as otherwise provided in the Credit Agreement, all actions by each Grantor necessary or otherwise requested by Agent to perfect the Liens granted hereunder on the Collateral have been duly taken.

4.3 Grantor Information . On the Closing Date, Schedule 3 sets forth (i) each Grantor’s and each Guarantor’s jurisdiction of organization, (ii) the location of each Grantor’s and each Guarantor’s chief executive office, (iii) each Grantor’s and each Guarantor’s exact legal name as it appears on its organizational documents and (iv) each Grantor’s organizational identification number (to the extent a Grantor or Guarantor is organized in a jurisdiction which assigns such numbers) and federal employer identification number.

4.4 Collateral Locations . On the Closing Date, Schedule 4 sets forth (i) each place of business of each Grantor and each Guarantor (including its chief executive office), (ii) all locations where any material portion of inventory and equipment owned by each Grantor is kept (other than (A) inventory or equipment that is otherwise in transit or out for repair, refurbishment or processing in the Ordinary Course of Business, (B) de minimis amounts of inventory with sales personnel and at medical facilities or (C) otherwise disposed of in a transaction permitted by the Credit Agreement), (iii) all locations where each Grantor’s books and records concerning the Collateral are kept and (iv) whether each such Collateral location and place of business (including each Grantor’s chief executive office) is owned or leased (and if leased, specifies the complete name and notice address of each lessor) or otherwise occupied (and if otherwise occupied, describes the nature of such occupation). On the Closing Date, no Collateral (other than (A) inventory or equipment that is otherwise in transit or out for repair, refurbishment or processing in the Ordinary Course of Business, (B) de minimis amounts of inventory with sales personnel and at medical facilities or (C) otherwise disposed of in a transaction permitted by the Credit Agreement) is located outside the United States or in the possession of any lessor, bailee, warehouseman or consignee, except as indicated on Schedule  4 .

4.5 Certain Property . None of the Collateral constitutes, or is the Proceeds of, (i) farm products, (ii) as-extracted collateral, (iii) timber to be cut or (iv) vessels, aircraft or any other personal property subject to any certificate of title or other registration statute of the United States, any State or other jurisdiction, except for motor vehicles owned by the Grantors and used by employees of the Grantors in the Ordinary Course of Business.

4.6 Pledged Collateral and Pledged Investment Property .

 

11


(a) The Pledged Collateral pledged by each Grantor hereunder is listed on Schedule  1 and, with respect to the Pledged Equity, constitutes all the issued and outstanding equity interests of each Issuer owned by such Grantor as set forth on Schedule 1 . None of the Pledged Equity is a certificated security or otherwise represented or evidenced by any certificate other than the Pledged Equity in Nellix, Inc., CVD/RMS Acquisition Corp., RMS/Endologix Sideways Merger Corp., TriVascular, Inc., and TriVascular Technologies, Inc., and no foreign Issuer has certificated its Stock nor is any Grantor (or any representative, agent or any other Related Party of any Grantor) holding any certificate of Stock of any foreign Issuer.

(b) All of the Pledged Equity has been duly authorized and validly issued and, in the case of shares of capital stock and membership interests, is fully paid and nonassessable.

(c) Each of the Pledged Equity, Pledged Debt Instruments and Pledged Investment Property constitutes the legal, valid and binding obligation of the obligor with respect thereto, enforceable in accordance with its terms, except as such enforceability may be limited by applicable insolvency, bankruptcy, reorganization, moratorium or other similar laws affecting creditors’ rights generally.

(d) Schedule 1A lists all Pledged Investment Property owned by each Grantor. Each Grantor is the record and beneficial owner of, and has good and valid title to, the Pledged Investment Property pledged by it hereunder, free of any and all Liens or options in favor of, or claims of, any other Person, except Permitted Liens.

(e) All Pledged Collateral (other than uncertificated Pledged Equity) and all Pledged Investment Property consisting of instruments and certificates has been delivered to Agent (for the benefit of the Secured Parties) in accordance with Section  5.1 hereof to the extent required thereby.

(f) Upon the occurrence and during the continuance of an Event of Default, Agent shall be entitled to exercise all of the rights of the Grantor granting the security interest in any Pledged Equity, and a transferee or assignee of such Pledged Equity shall become a holder of such Pledged Equity to the same extent as such Grantor and be entitled to participate in the management of the Issuer of such Pledged Equity, and, subject to Agent’s exercise of remedies pursuant to Section  6 hereof, upon the transfer of the entire interest of such Grantor, such Grantor shall, by operation of law, cease to be a holder of such Pledged Equity.

4.7 Receivables .

(a) No amount over $250,000 in the aggregate payable to a Grantor under or in connection with any account is evidenced by any instrument or chattel paper which, to the extent required hereunder, has not been delivered to Agent (for the benefit of the Secured Parties), properly endorsed for transfer.

(b) No obligor on any Receivable in excess of $250,000 in the aggregate is a Governmental Authority, unless any assignment of claims act or law has been complied with for the benefit of Agent.

4.8 Credit Agreement . Each Grantor and each Guarantor makes each of the representations and warranties made by Borrowers in Article IV of the Credit Agreement to the extent applicable to it on the date such Grantor or Guarantor becomes a party hereto (which representations and warranties shall be deemed to be re-made (i) as of the date of each amendment, consent or waiver of this Agreement or the Credit Agreement executed by any Grantor and (iii) solely with respect to any new Grantor that joins this Agreement after the Closing Date, on the date such new

 

12


Grantor joins this Agreement). Such representations and warranties shall be incorporated herein by this reference as if fully set forth herein.

4.9 Commercial Tort Claims . The only commercial tort claims that any Grantor is asserting or intends to assert in which the potential recovery exceeds $250,000 in the aggregate are those listed on Schedule 5 , as may be supplemented from time to time by delivery thereof to Agent, which sets forth such information separately for each Grantor.

4.10 Enforcement . No material permit, notice to or filing with any Governmental Authority or any other Person or any material consent from any Person is required for the exercise by Agent of its rights (including voting rights) provided for in this Agreement or the enforcement of remedies in respect of the Collateral pursuant to this Agreement, including the transfer of any Collateral, except (i) as may be required in connection with the disposition of any portion of the Pledged Collateral by laws affecting the offering and sale of securities generally, (ii) any approvals that may be required to be obtained from any bailees or landlords to collect the Collateral, (iii) permits or consents which have been obtained and notices or filings which have been made, and (iv) any requirements set forth in any assignment of claims act and laws.

4.11 Accounts . Set forth on Schedule 6 , as such Schedule may be updated from time to time to reflect changes resulting from transactions permitted under the Loan Documents) is a listing of all of Grantors’ and their Subsidiaries’ Deposit Accounts and Securities Accounts, including, with respect to each bank or securities intermediary (a) the name and address of such Person, and (b) the account numbers of the Deposit Accounts or Securities Accounts maintained with such Person.

4.12 Real Property . Schedule 7 sets forth all Real Property owned by any of the Grantors as of the Closing Date.

4.13 Intellectual Property . As of the Closing Date: (i)  Schedule 8 provides a complete and correct list of all registered Copyrights owned by any Grantor and all other Copyrights owned by any Grantor and material to the conduct of the business of any Grantor; (ii) Schedule 9 provides a complete and correct list of all Intellectual Property Licenses (other than license agreements for commercially available off-the-shelf software that is generally available to the public which have been licensed to a Grantor pursuant to end-user licenses) entered into by any Grantor that are material to the business of such Grantor, including any Intellectual Property Licenses that relate to Intellectual Property that is incorporated in any Inventory, software, or other product marketed, sold, licensed, or distributed by such Grantor; (iii)  Schedule 10 provides a complete and correct list of all Patents owned by any Grantor; and (iv)  Schedule 11 provides a complete and correct list of all registered Trademarks owned by any Grantor and all other Trademarks owned by any Grantor and material to the conduct of the business of any Grantor.

SECTION 5. COVENANTS .

Each Grantor covenants and agrees with Agent that, from and after the date of this Agreement until the Secured Obligations and the Guaranteed Obligations, as applicable, shall have been Paid in Full:

5.1 Delivery of Instruments, Certificated Securities and Chattel Paper .

 

13


(a) Such Grantor shall (i) deliver to Agent (for the benefit of the Secured Parties), in suitable form for transfer and in form and substance reasonably satisfactory to Agent, (A) all certificated Pledged Equity, together with stock powers or other suitable instruments for transfer, executed in blank, (B) all Pledged Debt Instruments and (C) all certificates and instruments evidencing Pledged Investment Property and (ii) to the extent required by Section  5.08 of the Credit Agreement, maintain all other Pledged Investment Property in an account that is subject to a Control Agreement. No foreign Issuer shall issue certificates of its Stock unless the foregoing provisions of this paragraph are complied with.

(b) If any amount in excess of $250,000 in the aggregate payable under or in connection with any Collateral owned by such Grantor shall be or become evidenced by an instrument or tangible chattel paper other than such instrument delivered in accordance with this Section  5.1 and in the possession of Agent, such Grantor shall notify Agent, and upon the written request of Agent, mark all such instruments and tangible chattel paper with the following legend: “This writing and the obligations evidenced or secured hereby are subject to the security interest of Deerfield ELGX Revolver, LLC, as Agent” and, at the written request of Agent, shall promptly deliver such instrument or tangible chattel paper to Agent (for the benefit of the Secured Parties), duly indorsed in a manner reasonably satisfactory to Agent.

(c) Such Grantor shall not grant “control” (within the meaning of such term under Article 9-106 of the UCC) over any Pledged Collateral or Pledged Investment Property to any Person other than Agent (for the benefit of the Secured Parties) or, to the extent permitted under (and subject to the terms of) the Intercreditor Agreement and subject to the terms of Section  8.21 , the Term Agent.

(d) If such Grantor is or becomes the beneficiary of a letter of credit that is (i) not a supporting obligation of any Collateral and (ii) in excess of $250,000 in the aggregate, such Grantor shall promptly, and in any event within five (5) Business Days after becoming a beneficiary, notify Agent thereof and shall use commercially reasonable efforts to enter into a contractual arrangement reasonably requested by the Agent with respect to the letter-of-credit rights under such letter of credit. Such contractual arrangement shall assign such letter-of-credit rights to Agent and such assignment shall be sufficient to grant control for the purposes of Section 9-107 of the UCC (or any similar section under any equivalent UCC). Such contractual arrangement shall also direct all payments thereunder to an account subject to a Control Agreement. The provisions of the contractual arrangement shall be in form and substance reasonably satisfactory to Agent.

(e) If any amount in excess of $250,000 in the aggregate payable under or in connection with any Collateral owned by such Grantor shall be or become evidenced by electronic chattel paper, such Grantor shall take all commercially reasonable steps necessary to grant Agent control of all such electronic chattel paper for the purposes of Section 9-105 of the UCC (or any similar section under any equivalent UCC) and all “transferable records” as defined in each of the Uniform Electronic Transactions Act and the Electronic Signatures in Global and National Commerce Act.

(f) In the event that an Event of Default shall have occurred and be continuing, upon the request of Agent, any instrument, certificated security or chattel paper not theretofore delivered to Agent and at such time being held by such Grantor shall be promptly (and, in any event, within five (5) Business Days) delivered to Agent (for the benefit of the Secured Parties), duly indorsed in a manner satisfactory to Agent, to be held as Collateral pursuant to this Agreement and in the case of electronic chattel paper, such Grantor shall cause Agent to have control thereof within the meaning set forth in Section 9-105 of the UCC. In the event that an Event of Default shall have occurred and be continuing, Agent shall have the right, at any time in its discretion and without notice to any Grantor, to (i) transfer to or to register in its name or in the name of its nominees any Pledged Collateral or any Pledged Investment

 

14


Property and (ii) exchange any certificate or instrument representing or evidencing any Pledged Collateral or any Pledged Investment Property for certificates or instruments of smaller or larger denominations.

5.2 Maintenance of Perfected Security Interest; Further Documentation .

(a) Such Grantor shall maintain the security interests created by this Agreement as perfected security interests (to the extent such security interests can be perfected by the filing of UCC financing statements (and, with respect to commercial tort claims, to the extent any commercial tort claims are sufficiently identified herein)) having at least the priority described in Section  4.2 hereof, and shall defend such security interests against the claims and demands of all Persons whomsoever (other than holders of Permitted Liens).

(b) Subject to (other than, with respect to the Third Party Agent, during any Third Party Agent Retention Period) Section  5.20 of the Credit Agreement, such Grantor will furnish to Agent from time to time statements and schedules further identifying and describing the assets and property of such Grantor and such other reports in connection therewith as Agent may reasonably request, all in reasonable detail in form and substance reasonably satisfactory to Agent.

(c) At any time and from time to time, upon the written request of Agent, and at Grantor’s sole expense, such Grantor will, for the purpose of obtaining or preserving the full benefits of this Agreement and of the rights and powers herein granted, promptly and duly execute and deliver, and have recorded, such further instruments and documents and take such further actions as Agent may reasonably request, including (i) filing or authorizing the filing of any financing or continuation statements under the UCC (or other similar laws) in effect in any jurisdiction with respect to the security interests created hereby; (ii) in the case of Pledged Collateral, Pledged Investment Property and any other relevant Collateral, taking any such reasonably requested actions necessary to enable Agent (on behalf of the Secured Parties) to obtain “control” (within the meaning of the applicable UCC) with respect to such Pledged Collateral, Pledged Investment Property and other Collateral to the extent required to be pledged hereunder; (iii) if requested by Agent, delivering, to the extent permitted by Applicable Law, any original motor vehicle certificates of title for vehicles in the aggregate with a fair market value in excess of $250,000 received by such Grantor from the applicable secretary of state or other Governmental Authority after information reflecting Agent’s security interest has been recorded in such motor vehicles to the extent required to be pledged thereunder; (iv) use of commercially reasonable efforts to secure all approvals necessary or appropriate for the assignment to or the benefit of Agent of any contractual obligation held by such Grantor and to enforce the security interests hereunder; and (v) subject to Section  5.08) of the Credit Agreement, executing and delivering any Control Agreements with respect to deposit, securities, commodity and similar accounts.

(d) Such Grantor shall not use or permit any Collateral to be used unlawfully or in violation of any provision of any Loan Document or any policy of insurance covering the Collateral.

5.3 Changes in Locations, Name, etc. Such Grantor shall not, except upon 10 Business Days’ prior written notice to Agent (or such lesser notice as Agent may agree to in writing in its sole discretion) and delivery to Agent of (i) all additional financing statements and other documents reasonably requested by Agent as to the validity, perfection and priority of the security interests provided for herein and (ii) if applicable, a written supplement to Schedule  4 showing any additional location at which inventory or equipment shall be kept (other than (A) inventory or equipment that is otherwise in transit or out for repair, refurbishment or processing in the Ordinary Course of Business, (B) de minimis amounts of inventory with sales personnel and at medical facilities or (C) otherwise disposed of in a transaction permitted by the Credit Agreement):

 

15


(a) permit any of the inventory or equipment comprising Collateral to be kept at a location subject to the possession or control of any warehouse, consignee, bailee, or any of the Grantors’ agents or processors other than those listed on Schedule 4 , other than (i) the inventory or equipment that is otherwise in transit or out for repair, refurbishment or processing in the Ordinary Course of Business, (ii) de minimis amounts of inventory with sales personnel and at medical facilities or (iii) otherwise disposed of in a transaction permitted by the Credit Agreement;

(b) change its jurisdiction of organization or the location of its chief executive office from that specified on Schedule 3 or in any subsequent notice delivered pursuant to this Section  5.3 ; or

(c) change its name, organizational identification number (if any), identity or corporate structure, except as permitted by Section  6.01 of the Credit Agreement upon prior written notice thereof to the Agent.

5.4 Notices . Such Grantor will advise Agent in writing promptly, in reasonable detail, of:

(a) any Lien (other than Permitted Liens) on any of the Collateral; and

(b) the occurrence of any other event which would reasonably be expected to have a Material Adverse Effect on the Collateral or on the Liens created hereby.

5.5 Pledged Investment Property and Pledged Collateral .

(a) If such Grantor shall become entitled to receive or shall receive any certificate, option or rights in respect of the Stock of any Issuer, whether in addition to, in substitution of, as a conversion of, or in exchange for, any of the Pledged Equity, or otherwise in respect thereof, such Stock shall be Pledged Equity (to the extent consistent with the percentage of such Grantor’s Stock in such Issuer pledged hereunder, as set forth on Schedule  1 ) and such Grantor shall accept the same as the agent of Agent, hold the same in trust for Agent (for the benefit of the Secured Parties) and deliver the same forthwith to Agent (for the benefit of the Secured Parties) in the exact form received, duly indorsed by such Grantor to Agent (for the benefit of the Secured Parties), if required by Agent, together with an undated instrument of transfer covering such certificate duly executed in blank by such Grantor and with, if Agent so requests, signature Guaranteed, to be held by Agent (for the benefit of the Secured Parties), subject to the terms hereof, as additional Collateral for the Secured Obligations.

(b) Upon the occurrence and during the continuance of an Event of Default and the request of Agent, (i) any sums paid upon or in respect of the Pledged Collateral or Pledged Investment Property upon the liquidation or dissolution of any Issuer shall be paid over to Agent (for the benefit of the Secured Parties) to be held by it hereunder as additional Collateral for the Secured Obligations, and (ii) in case any distribution of capital shall be made on or in respect of the Pledged Collateral, or any property shall be distributed upon or with respect to the Pledged Collateral, pursuant to the recapitalization or reclassification of the capital of any Issuer or pursuant to the reorganization thereof, the property so distributed shall, unless otherwise subject to a perfected Lien in favor of Agent, be delivered to Agent (for the benefit of the Secured Parties) to be held by it hereunder as additional Collateral for the Secured Obligations. Upon the occurrence and during the continuance of an Event of Default, if any sums of money or property so paid or distributed in respect of the Pledged Investment Property shall be received by a Grantor, such Grantor shall, at the request of Agent and until such money or property is paid or delivered to the applicable Secured Parties, hold such money or property in trust for Agent (for the

 

16


benefit of the Secured Parties), segregated from other funds of such Grantor, as additional Collateral for the Secured Obligations.

(c) Without the prior written consent of Agent, no Grantor will (i) vote to enable, or take any other action, to permit any Issuer to issue any Stock of any nature or to issue any other securities or interests convertible into or granting the right to purchase or exchange for any Stock of any nature of any Issuer, except, in each case, as permitted by the Credit Agreement, (ii) sell, assign, transfer, exchange, or otherwise dispose of, or grant any option with respect to, the Pledged Investment Property or Proceeds thereof other than any such action which is permitted by the Credit Agreement, (iii) create, incur or permit to exist any Lien or option in favor of, or any claim of any Person with respect to, any of the Pledged Investment Property or Proceeds thereof, or any interest therein, except for Permitted Liens, or (iv) enter into any agreement or undertaking restricting the right or ability of such Grantor or Agent to sell, assign or transfer any of the Pledged Investment Property or Proceeds thereof, except with respect to Permitted Liens and any such action which is permitted by the Credit Agreement.

(d) In the case of each Grantor which is an Issuer, such Issuer agrees that (i) it will be bound by the terms of this Agreement relating to the Pledged Equity issued by it and will comply with such terms insofar as such terms are applicable to it, (ii) it will notify Agent promptly in writing of the occurrence of any of the events described in Sections 5.5(a) and 5.5(b) hereof with respect to the Pledged Equity issued by it and (iii) the terms of Sections  6.3(c) and 6.7 hereof shall apply to such Grantor with respect to all actions that may be required of it pursuant to Section  6.3(c) hereof regarding the Pledged Equity issued by it.

5.6 Receivables . Other than in the Ordinary Course of Business consistent with its past practice, such Grantor will not (i) grant any extension of the time of payment of any Receivable, (ii) compromise or settle any Receivable for less than the full amount thereof, (iii) release, wholly or partially, any Person liable for the payment of any Receivable, (iv) allow any credit or discount whatsoever on any Receivable or (v) amend, supplement or modify any Receivable in any manner that would reasonably be expected to adversely affect the value thereof, in each case, unless taking the foregoing actions would not reasonably be expected, individually or in the aggregate, to cause a Material Adverse Effect.

5.7 Intellectual Property . Except as permitted by the Credit Agreement, or except, in each case, where the failure to do so could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect ( provided that no such Material Adverse Effect qualifier should apply to Section  5.7(h) ):

(a) Upon the request of Agent, in order to facilitate filings with the United States Patent and Trademark Office and the United States Copyright Office, each Grantor shall execute and deliver to Agent one or more Copyright Security Agreements, Trademark Security Agreements, or Patent Security Agreements to further evidence Agent’s Lien on such Grantor’s Patents, Trademarks, or Copyrights, and the General Intangibles of such Grantor relating thereto or represented thereby.

(b) Such Grantor (either itself or through licensees) will (i) continue to use each Trademark (owned by such Grantor), in order to maintain such Trademark in full force and effect free from any claim of abandonment for non-use, (ii) maintain as in the past the quality of products and services offered under such Trademark, (iii) use, and cause its licensees and sublicensees to use, such Trademark with the appropriate notice of registration and all other notices and legends required by Applicable Law, (iv) not adopt or use any mark which is confusingly similar or a colorable imitation of such Trademark unless Agent shall obtain a perfected security interest in such Trademark pursuant to this

 

17


Agreement and (v) not (and not permit any licensee or sublicensee thereof to) do any act or omit to do any act whereby such Trademark (or any goodwill associated therewith) may become destroyed, harmed, invalidated or impaired in any way.

(c) Each Grantor (either itself or through licensees) will not do any act, or omit to do any act, whereby as a result of such act or omission, any Patent owned by such Grantor may become unenforceable, invalidated, forfeited, abandoned or dedicated to the public, will employ, and cause its licensees and sublicensees to employ, each such Patent with the appropriate notice of registration and all other notices and legends required by Applicable Law, and will take commercially reasonable steps to establish and preserve the Patents in any patentable invention under Applicable Law.

(d) Each Grantor (either itself or through licensees) (i) will employ, and cause its licensees and sublicensees to employ, each Copyright owned by such Grantor with the appropriate notice of registration and all other notices and legends required by Applicable Law, and (ii) will not (and will not permit any licensee or sublicensee thereof to) do any act or omit to do any act whereby such Copyrights may become invalidated or otherwise impaired, and (iii) will not (either itself or through licensees or sublicensees) do any act whereby any such Copyrights may fall into the public domain.

(e) Each Grantor (either itself or through licensees or sublicensees) will not (and will not permit any licensee or sublicensee thereof to) do any act or omit to do any act whereby any trade secret may become unenforceable under any Applicable Law and each Grantor shall take reasonable steps to maintain the confidentiality of, and otherwise protect and enforce its rights in, the Intellectual Property that is necessary in or material to the conduct of such Grantor’s business, including, as applicable (A) protecting the secrecy and confidentiality of its confidential information and trade secrets by having and enforcing a policy requiring all current employees, consultants, licensees, vendors and contractors with access to such information to execute appropriate confidentiality agreements; (B) taking actions reasonably necessary to ensure that no trade secret falls into the public domain due to any action of any Grantor; and (C) protecting the secrecy and confidentiality of the source code of all software programs and applications of which it is the owner or licensee by having and enforcing a policy requiring any licensees (or sublicensees) of such source code to enter into license agreements with commercially reasonable use and non-disclosure restrictions.

(f) Such Grantor (either itself or through licensees or sublicensees) will not do any act that infringes, misappropriates, dilutes, violates or otherwise impairs the Intellectual Property or intellectual property rights of any other Person.

(g) Such Grantor will notify Agent promptly if it knows, or has reason to know, that any application or registration relating to any Intellectual Property owned by such Grantor may become unenforceable, invalidated, forfeited, abandoned or dedicated to the public, or of any determination or development (including the institution of, or any such determination or development in, any proceeding in the United States Patent and Trademark Office, the United States Copyright Office or any court or tribunal in any country) regarding such Grantor’s ownership of, or the validity of, any such Intellectual Property or such Grantor’s right to register the same or to own and maintain the same.

(h) At the time of delivery of (A) if Endologix is required to file reports pursuant to Section 13 or 15(d) of the Exchange Act, the 10-Q and 10K filings (or, if earlier, the time delivery thereof is required by the SEC) as required by Section 5.05(a)(ii) or (B) if Endologix is not required to file reports pursuant to Section 13 of 15(d) of the Exchange Act, the quarterly and annual financial statements as required by Section 5.05(c), each Grantor will notify Agent of applications filed for the registration of any Intellectual Property with the United States Patent and Trademark Office, the United States Copyright

 

18


Office or any similar office or agency in any other country or any political subdivision thereof. Upon the request of Agent, within five (5) Business Days, such Grantor shall execute and deliver, and have recorded, any and all agreements, instruments, documents, and papers as Agent may request to evidence Agent’s security interest in any Intellectual Property owned by such Grantor, including any Copyright, Patent or Trademark and the goodwill and general intangibles of such Grantor relating thereto or represented thereby.

(i) Such Grantor will take all actions that are necessary or reasonably requested by Agent to maintain and pursue each application (and to obtain the relevant registration or recordation) and to maintain each registration and recordation of all Intellectual Property owned by it.

(j) In the event that any Intellectual Property owned by a Grantor is, to its knowledge, infringed upon or misappropriated or diluted by a third party, such Grantor shall, subject to (other than, with respect to the Third Party Agent, during any Third Party Agent Retention Period) Section  5.20 of the Credit Agreement, (i) take such actions as such Grantor shall reasonably deem appropriate under the circumstances to protect such Intellectual Property and (ii) promptly notify Agent after it learns thereof and sue for infringement, misappropriation or dilution, to seek injunctive relief where appropriate and to recover any and all damages for such infringement, misappropriation or dilution.

(k) Each Grantor shall require all employees, consultants, and contractors of such Grantor who are involved in the creation or development of any Intellectual Property for such Grantor to sign agreements that presently assigned all Intellectual Property created or developed for the Grantor to such Grantor, and obligate such employee, consulting or contractor to hold all confidential information of the Grantor (or of any other Person and held by the Grantor) in confidence.

(l) Grantors acknowledge and agree that the Lender Group shall have no duties with respect to any Intellectual Property or Intellectual Property Licenses of any Grantor. Without limiting the generality of this Section  5.7(k) , Grantors acknowledge and agree that no member of the Lender Group shall be under any obligation to take any steps necessary to preserve rights in the Collateral consisting of Intellectual Property or Intellectual Property Licenses against any other Person, but any member of the Lender Group may do so at its option from and after the occurrence and during the continuance of an Event of Default, and all expenses incurred in connection therewith (including reasonable fees and expenses of attorneys and other professionals) shall be for the sole account of Borrowers and the other Grantors and shall be chargeable to the Loan Account.

5.8 Other Matters .

(a) Each Grantor authorizes Agent and its Affiliates directors, partners, officers, employees, agents, counsel and advisors and any Third Party Agent to, at any time and from time to time, file or record financing statements, continuation statements, amendments thereto, and other filing or recording documents or instruments with respect to any Collateral in such forms and in such offices as Agent or such other Person reasonably determines appropriate to perfect, or continue or maintain perfection of, the security interests of Agent under this Agreement, and such statements, amendments, documents, and instruments may describe the Collateral covered thereby as “all assets of the debtor” of each Grantor, or words of similar effect and may contain any other information required pursuant to the UCC for the sufficiency of

 

19


filing office acceptance of any financing statement, continuation statement or amendment, and each Grantor agrees to furnish any such information to Agent promptly upon Agent’s reasonable request. Any such financing statement, continuation statement or amendment may be signed by Agent on behalf of any Grantor and may be filed at any time in any jurisdiction. A copy of this Agreement shall be sufficient as a financing statement or other filing or recording document or instrument for filing or recording in any jurisdiction. Such Grantor also hereby ratifies its authorization for Agent and any Third Party Agent to have filed any initial financing statement or amendment thereto under the UCC (or other similar laws) in effect in any jurisdiction if filed prior to the date hereof To the extent permitted by law, each Grantor hereby (i) waives any right under the UCC or any other Applicable Law to receive notice and/or copies of any filed or recorded financing statements, amendments thereto, continuations thereof or termination statements and (ii) releases and excuses each Secured Party from any obligation under the UCC or any other Applicable Law to provide notice or a copy of any such filed or recorded documents.

(b) Each Grantor shall, at any time and from time and to time, take such steps as the Agent may reasonably request for Agent to insure the continued perfection and priority of Agent’s security interest in any of the Collateral and of the preservation of its rights therein.

(c) If any Grantor shall at any time, acquire a commercial tort claim as set forth in Section  4.9 hereof, such Grantor shall promptly notify Agent thereof in writing and supplement Schedule 5 , therein providing a reasonable description and summary thereof, and upon delivery thereof to Agent, such Grantor shall be deemed to thereby grant to Agent (and such Grantor hereby grants to Agent) a Lien in and to such commercial tort claim and all Proceeds thereof, all upon the terms of and governed by this Agreement, and such Grantor shall execute and deliver to Agent, in each case in form and substance reasonably satisfactory to Agent, any document, and take all other action, deemed by Agent to be reasonably necessary or appropriate for Agent to obtain, for the benefit of the Secured Parties, a perfected security interest in all such commercial tort claims. Any supplement to Schedule 5 delivered pursuant to this Section  5.8(c) shall, after the receipt thereof by Agent, become part of Schedule 5 for all purposes hereunder other than in respect of representations and warranties made prior to the date of such receipt.

5.9 Credit Agreement . Each of the Grantors covenants that it will, and, if necessary, will cause or enable each Borrower to, fully comply with each of the covenants and other agreements set forth in the Credit Agreement.

5.10 Agent May Purchase Insurance . If a Grantor at any time or times hereafter shall fail to obtain, maintain or provide to Agent evidence of any of the policies of insurance or other items required under Section  5.03 of the Credit Agreement or to pay any premium relating thereto, then Agent, without waiving or releasing any obligation or default by such Grantor hereunder, may (but shall be under no obligation to) obtain and maintain such policies of insurance and pay such premiums and take such other actions with respect thereto as Agent deems advisable upon notice to such Grantor. Such insurance, if obtained by Agent, may, but need not, protect such Grantor’s interests or pay any claim made by or against such Grantor with respect to the Collateral. Such insurance may be more expensive than the cost of insurance such Grantor may be able to obtain on its own and may be cancelled only upon such Grantor providing evidence that it has obtained the insurance as required above. All sums disbursed by Agent in connection with any such actions shall constitute Secured Obligations and Guaranteed Obligations payable upon demand.

5.11 Further Assurances .

(a) Each Grantor agrees that from time to time, at its own expense, such Grantor will promptly execute and deliver all further instruments and documents, and take all further action, that Agent may reasonably request, in order to perfect and protect the security interest and Lien granted hereby, to create, perfect or protect the security interest and Lien purported to be granted hereby or to enable Agent to exercise and enforce its rights and remedies hereunder with respect to any of the Collateral.

 

 

20


(b) Grantor acknowledges that it is not authorized to file any financing statement or amendment or termination statement with respect to any financing statement filed in connection with this Agreement or the other Loan Documents without the prior written consent of Agent, subject to such Grantor’s rights under Section 9-509(d)(2) of the Code.

SECTION 6. REMEDIAL PROVISIONS .

6.1 Certain Matters Relating to Receivables . Subject to, in each case, the terms of the Intercreditor Agreement (to the extent applicable):

(a) At any time and from time to time after the occurrence and during the continuance of an Event of Default, Agent shall have the right to make test verifications of the Receivables in any manner and through any medium that it reasonably considers advisable, and each Grantor shall furnish all such assistance and information as Agent may reasonably require in connection with such test verifications. At any time and from time to time after the occurrence and during the continuance of an Event of Default, upon request of the Agent and at the expense of the relevant Grantor, such Grantor shall cause independent public accountants or others satisfactory to Agent to furnish to Agent reports showing reconciliations, agings and test verifications of, and trial balances for, the Receivables.

(b) If requested by Agent at any time after the occurrence and during the continuance of an Event of Default, any payments of Receivables, when collected by any Grantor, (i) shall be forthwith (and, in any event, within two (2) Business Days) deposited by such Grantor in the exact form received, duly indorsed by such Grantor to Agent (for the benefit of the Secured Parties) and upon notice to such Grantor, in a collateral account maintained under the sole dominion and control of Agent, subject to withdrawal by Agent as provided in Section  6.4 hereof, and (ii) until so turned over, shall be held by such Grantor in trust for Agent (for the benefit of the Secured Parties), segregated from other funds of such Grantor. Each such deposit of Proceeds of Receivables shall be accompanied by a report identifying in reasonable detail the nature and source of the payments included in the deposit.

(c) At any time and from time to time after the occurrence and during the continuance of an Event of Default, at the request of Agent, each Grantor shall deliver to Agent all original and other documents evidencing, and relating to, the agreements and transactions which gave rise to the Receivables, including all original orders, invoices and shipping receipts and notify account debtors that the accounts or general intangibles that are Collateral have been collaterally assigned to Agent and that payments in respect thereof shall be made directly to Agent.

(d) Each Grantor hereby irrevocably authorizes and empowers Agent, in Agent’s sole discretion, at any time after the occurrence and during the continuance of an Event of Default, without notice to such Grantor: (i) to limit or terminate the ability of a Grantor to collect its Receivables or any thereof; to assert, either directly or on behalf of such Grantor, any claim such Grantor may from time to time have against account debtors and to otherwise enforce such Grantor’s rights against such account debtors; (ii) to receive and collect any and all damages, awards and other monies resulting therefrom and to apply the same to the Secured Obligations as set forth in Section  6.5 hereof; and (iii) in its own name or in the name of others, to communicate with account debtors to verify with them to Agent’s reasonable satisfaction the existence, amount and terms of any account or amounts due under any general intangible that is Collateral.

6.2 Communications with Obligors; Grantors Remain Liable .

 

 

21


(a) Agent in its own name or in the name of others may at any time after the occurrence and during the continuance of an Event of Default communicate with obligors under the Receivables to verify with them to Agent’s satisfaction the existence, amount and terms of any Receivables

(b) Subject to the terms of the Intercreditor Agreement (to the extent applicable), upon the request of Agent at any time after the occurrence and during the continuance of an Event of Default, each Grantor shall notify obligors on the Receivables that the Receivables have been assigned to Agent and that payments in respect thereof shall be made directly to Agent.

(c) Anything herein to the contrary notwithstanding, each Grantor shall remain liable in respect of each of the Receivables to observe and perform all the conditions and obligations to be observed and performed by it thereunder, all in accordance with the terms of any agreement giving rise thereto. No Secured Party shall have any obligation or Liability under any Receivable (or any agreement giving rise thereto) by reason of or arising out of any Loan Document or the receipt by Agent or any other Secured Party of any payment relating thereto, nor shall any Secured Party be obligated in any manner to perform any of the obligations of any Grantor under or pursuant to any Receivable (or any agreement giving rise thereto), to make any payment, to make any inquiry as to the nature or the sufficiency of any payment received by it or as to the sufficiency of any performance by any party thereunder, to present or file any claim, to take any action to enforce any performance or to collect the payment of any amounts which may have been assigned to it or to which it may be entitled at any time or times.

6.3 Pledged Investment Property and Pledged Collateral .

(a) Unless an Event of Default shall have occurred and be continuing and until Agent has notified Borrower Representative otherwise, each Grantor shall be permitted to receive all cash dividends and distributions paid in respect of the Pledged Collateral and all payments made in respect of the Pledged Investment Property, to the extent permitted in the Credit Agreement, and to exercise all voting and other rights with respect to the Pledged Collateral and Pledged Investment Property; provided , that no vote shall be cast or other right exercised or action taken that could be reasonably likely to materially impair the Collateral or which would be inconsistent with or result in any violation of any provision of the Credit Agreement, this Agreement or any other Loan Document.

(b) If an Event of Default shall occur and be continuing: (i) Agent shall have the right to receive any and all cash dividends and distributions, payments or other Proceeds paid in respect of the Pledged Collateral and Pledged Investment Property and make application thereof to the Secured Obligations as set forth in Section  6.5 hereof, (ii) Agent shall have the right to cause any or all of the Pledged Collateral and Pledged Investment Property to be registered in the name of Agent or its nominee and (iii) Agent or its nominee may exercise (x) all voting, consent, corporate and other rights pertaining to such Pledged Collateral and Pledged Investment Property at any meeting of shareholders, partners or members, as the case may be, of the relevant Issuer or Issuers or otherwise (or by written consent) and (y) any and all rights of conversion, exchange and subscription and any other rights, privileges or options pertaining to such Pledged Collateral and Pledged Investment Property as if it were the absolute owner thereof (including the right to exchange at its discretion any and all of the Pledged Collateral and Pledged Investment Property upon the merger, amalgamation, consolidation, reorganization, recapitalization or other fundamental change in the corporate or other structure of any Issuer, or upon the exercise by any Grantor or Agent of any right, privilege or option pertaining to such Pledged Collateral and Pledged Investment Property, and in connection therewith, the right to deposit and deliver any and all of the Pledged Collateral and Pledged Investment Property with any committee, depositary, transfer agent, registrar or other designated agency upon such terms and conditions as Agent may determine), all without

 

22


Liability other than to the extent such Liability is a result of its own willful misconduct or gross negligence as determined by a court of competent jurisdiction in a final non-appealable order or to account for property actually received by it, but Agent shall have no duty to any Grantor to exercise any such right, privilege or option and shall not be responsible for any failure to do so or delay in so doing.

(c) Each Grantor hereby expressly and irrevocably authorizes and instructs, without any further instructions from such Grantor, each Issuer of the Pledged Collateral and Pledged Investment Property pledged by such Grantor hereunder to (i) comply with any instruction received by it from Agent in writing that (x) states that an Event of Default has occurred and is continuing and (y) is otherwise in accordance with the terms of this Agreement, and each Grantor agrees that each Issuer shall be fully protected in so complying and (ii) unless otherwise permitted under the Loan Documents, pay any dividends, distributions or other payments with respect to the Pledged Collateral and Pledged Investment Property directly to Agent.

(d) In order to permit Agent to exercise the voting and other consensual rights that it is entitled to exercise pursuant hereto and to receive all dividends and other distributions that it is entitled to receive hereunder, (i) during the existence of an Event of Default, each Grantor shall promptly execute and deliver (or cause to be executed and delivered) to Agent all such proxies, dividend payment orders and other instruments as Agent may from time to time reasonably request and (ii) without limiting the effect of clause (i) above, such Grantor hereby grants to Agent an irrevocable proxy to vote all or any part of the Pledged Collateral and the Pledged Investment Property and to exercise all other rights, powers, privileges and remedies to which a holder of the Pledged Collateral or the Pledged Investment Property, as applicable, would be entitled (including giving or withholding written consents of shareholders, partners or members, as the case may be, calling special meetings of shareholders, partners or members, as the case may be, and voting at such meetings), which proxy shall be effective, automatically and without the necessity of any action (including any transfer of any Pledged Collateral or Pledged Investment Property on the record books of the Issuer thereof) by any other person (including the Issuer of such Pledged Collateral or Pledged Investment Property, as applicable, or any officer or agent thereof) solely during the continuance of an Event of Default and which proxy shall only terminate upon the Payment in Full in cash of the Secured Obligations or upon an express waiver in writing by Agent and the Required Lenders of the underlying Event of Default in accordance with the terms of the Credit Agreement.

6.4 Proceeds to be Turned Over to Agent . In addition to the rights of Agent specified in Section  6.1 hereof with respect to payments of Receivables, if an Event of Default shall occur and be continuing and Agent has notified Borrower Representative of the Grantors’ obligations under this Section  6.4 , all Proceeds received by any Grantor consisting of cash, checks and other cash equivalent items shall be held by such Grantor in trust for Agent (for the benefit of the Secured Parties), segregated from other funds of such Grantor, and shall, upon written request of Agent, forthwith upon receipt by such Grantor, be turned over to Agent in the exact form received by such Grantor (duly indorsed by such Grantor to Agent, if required). Subject to the terms of the Intercreditor Agreement (if applicable), all Proceeds received by Agent under this Section  6.4 shall be held by Agent in a collateral account maintained under its sole dominion and control. All Proceeds, while held by Agent (for the benefit of the Secured Parties) in any collateral account (or by such Grantor in trust for Agent (for the benefit of the Secured Parties)) established pursuant hereto, shall continue to be held as collateral security for the Secured Obligations and shall not constitute payment thereof until applied as provided in Section  6.5 hereof.

6.5 Application of Proceeds . Agent may apply all or any part of Proceeds from the sale of, or other realization upon, all or any part of the Collateral (after deducting all reasonable and

 

23


documented external attorneys’ and other fees and out-of-pocket costs and expenses of every kind incurred in connection therewith or incidental to the care or safekeeping of any Collateral or in any way relating to the Collateral or the rights of Agent and any other Secured Party hereunder) in payment of the Secured Obligations in such order as the Agent shall determine in its discretion, and may pay any other amount required by any Applicable Law. Any balance of such Proceeds remaining after the Secured Obligations and the Guaranteed Obligations (as applicable) shall have been Paid in Full shall be paid over to the applicable Grantor or to whomsoever may be lawfully entitled to receive the same. The parties hereto understand and agree that the exercise of remedies hereunder with respect to accounts arising under any Third Party Payor program may be subject to Applicable Law.

6.6 Code and Other Remedies . If an Event of Default shall occur and be continuing, Agent may exercise, in addition to all other rights and remedies granted to them in this Agreement and in any other instrument or agreement securing, evidencing or relating to the Secured Obligations, all rights and remedies of a secured party under the UCC or any other Applicable Law. Without limiting the generality of the foregoing, Agent, without demand of performance or other demand, presentment, protest, advertisement or notice of any kind (except any notice required by law referred to below) to or upon any Grantor or any other Person (all and each of which demands, defenses (other than defense of payment), advertisements and notices are hereby waived), may in such circumstances forthwith collect, receive, appropriate and realize upon the Collateral, or any part thereof, and/or may forthwith sell, lease, assign, give options to purchase, or otherwise dispose of and deliver the Collateral or any part thereof (or contract to do any of the foregoing), in one or more parcels at public or private sale or sales, at any exchange, broker’s board or office of Agent or elsewhere upon such terms and conditions as they may deem advisable and at such prices as it may deem best, for cash or on credit or for future delivery with assumption of any credit risk. Agent shall have the right upon any such public sale or sales, and, to the extent permitted by law, upon any such private sale or sales, to purchase the whole or any part of the Collateral so sold, free of any right or equity of redemption in any Grantor, which right or equity is hereby waived and released. Each Grantor further agrees, at Agent’s request, to assemble the Collateral and make it available to Agent at places which Agent shall reasonably select, whether at such Grantor’s premises or elsewhere in connection with the exercise of Agent’s remedies hereunder. Agent shall apply the net Proceeds of any action taken by it pursuant to this Section  6.6 , after deducting all reasonable documented out-of-pocket costs and expenses of every kind incurred in connection therewith or incidental to the care or safekeeping of any of the Collateral or in any way relating to the Collateral or the rights of Agent hereunder, to the payment in whole or in part of the Secured Obligations, as set forth in Section  6.5 hereof. To the extent permitted by Applicable Law, each Grantor waives all claims, damages and demands it may acquire against Agent arising out of the exercise by them of any rights hereunder. If any notice of a proposed sale or other disposition of Collateral shall be required by law, such notice shall be deemed reasonable and proper if given at least 10 calendar days before such sale or other disposition. Agent shall not be obligated to make any sale of Collateral regardless of notification of sale having been given. Agent may adjourn any public sale from time to time by announcement at the time and place fixed therefor, and such sale may, without further notice, be made at the time and place to which it was so adjourned. Each Grantor agrees that (A) the internet shall constitute a “place” for purposes of Section 9-610(b) of the Code and (B) to the extent notification of sale shall be required by law, notification by mail of the URL where a sale will occur and the time when a sale will commence at least ten (10) days prior to the sale shall constitute a reasonable notification for purposes of Section 9-611(b) of the Code. Each Grantor agrees that any sale of Collateral to a licensor pursuant to the terms of a license agreement between such licensor and a Grantor is sufficient to constitute a commercially reasonable sale (including as to method, terms, manner, and time) within the meaning of Section 9-610 of the Code.

6.7 Private Sale . Each Grantor recognizes that Agent may be unable to effect a public sale of any or all the Pledged Collateral and Pledged Investment Property, by reason of certain

 

24


prohibitions contained in the Securities Act and applicable state or foreign securities laws or otherwise, or may otherwise determine that a public sale is impracticable, not desirable or not commercially reasonable, and, accordingly, and may resort to one or more private sales thereof to a restricted group of purchasers that will be obliged to agree, among other things, to acquire such securities for their own account for investment and not with a view to the distribution or resale thereof. Each Grantor acknowledges and agrees that any such private sale may result in prices and other terms less favorable than if such sale were a public sale and, notwithstanding such circumstances, agrees that any such private sale shall be deemed to have been made in a commercially reasonable manner. Agent shall be under no obligation to delay a sale of any of the Pledged Collateral or Pledged Investment Property for the period of time necessary to permit the Issuer thereof to register such securities or other interests for public sale under the Securities Act, or under applicable state or foreign securities laws, even if such Issuer would agree to do so.

Each Grantor agrees to use its commercially reasonable efforts to do or cause to be done all such other acts as may be necessary to make such sale or sales of all or any portion of the Pledged Collateral and Pledged Investment Property pursuant to this Section  6.7 and Section  6.10 hereof valid and binding and in compliance with Applicable Law. Each Grantor further agrees that a breach of any of the covenants contained herein will cause irreparable injury to Agent and the other Secured Parties, that Agent and the other Secured Parties have no adequate remedy at law in respect of such breach and, as a consequence, that each and every covenant contained herein shall be specifically enforceable against such Grantor (except as such enforceability may be limited by applicable insolvency, bankruptcy, reorganization, moratorium or other similar laws affecting creditors’ rights generally), and such Grantor hereby waives and agrees not to assert any defenses against an action for specific performance of such covenants. Until all of the Secured Obligations and all of the Guaranteed Obligations are Paid in Full, each Grantor postpones until such date any and all rights of contribution or subrogation upon the sale or disposition of all or any portion of the Pledged Collateral and Pledged Investment Property by Agent.

6.8 Deficiency . Each Grantor shall remain liable for any deficiency if the Proceeds of any sale or other disposition of any Collateral are insufficient to Pay in Full the Secured Obligations and the fees and disbursements of any attorneys employed by Agent or any other Secured Party to collect such deficiency.

6.9 Licenses . Solely for the purpose of enabling Agent (for the benefit of the Secured Parties) to exercise rights and remedies following and during the continuation of an Event of Default (including in order to take possession of, collect, receive, assemble, process, appropriate, remove, realize upon, sell, assign, convey, transfer or grant options to purchase any Collateral), each Grantor hereby grants to Agent, for the benefit of the Secured Parties, (i) an irrevocable, nonexclusive license (exercisable without payment of royalty or other compensation to such Grantor) including in such license the right to use, practice, license or sublicense any Intellectual Property now owned or hereafter acquired by such Grantor, and wherever the same may be located, and including in such license access to all media in which any of the licensed items may be recorded or stored and to all computer software and programs used for the compilation or printout thereof, and (ii) an irrevocable license (without payment of rent or other compensation to such Grantor) to use, operate and occupy all Real Estate owned, operated, leased, subleased or otherwise occupied by such Grantor; provided, in each case, that no such licenses shall be granted with respect to any Excluded Property.

6.10 Disposition of Collateral . Without limiting the generality of the foregoing, to the fullest extent not prohibited by Applicable Law, Agent may, without demand of performance or other demand, presentment, protest, advertisement or notice of any kind (except any notice required by law referred to below) to or upon any Grantor or any other Person (all and each of which demands, defenses, advertisements and notices are hereby waived), upon the occurrence and during the continuance of any

 

25


Event of Default (personally or through its agents or attorneys), (i) enter upon the premises where any Collateral is located, without any obligation to pay rent, through self-help, without judicial process, without first obtaining a final judgment or giving any Grantor or any other Person notice or opportunity for a hearing on Agent’s claim or action, (ii) collect, receive, appropriate and realize upon any Collateral and (iii) sell, assign, convey, transfer, grant option or options to purchase and deliver any Collateral (and enter into contractual obligations to do any of the foregoing), in one or more parcels at public or private sale or sales, at any exchange, broker’s board or office of any Secured Party or elsewhere upon such terms and conditions as it may deem advisable and at such prices as it may deem best, for cash or on credit or for future delivery without assumption of any credit risk. Agent shall have the right, upon any such public sale or sales and, to the extent permitted by the UCC and other Applicable Law, upon any such private sale, to purchase the whole or any part of the Collateral so sold, free of any right or equity of redemption of any Grantor, which right or equity is hereby waived and released.

6.11 Management of the Collateral . Each Grantor further agrees, that, upon the occurrence and during the continuance of any Event of Default and to the fullest extent not prohibited by Applicable Law and, in each case, subject to the terms of the Intercreditor Agreement (if applicable), (i) at Agent’s written request, it shall assemble the Collateral and make it available to Agent at places that Agent shall reasonably select, whether at such Grantor’s premises or elsewhere, (ii) without limiting the foregoing, Agent also has the right to require that each Grantor store and keep any Collateral pending further action by Agent and, while any such Collateral is so stored or kept, provide such guards and maintenance services as shall be necessary to protect the same and to preserve and maintain such Collateral in good condition, (iii) until Agent is able to sell, assign, convey or transfer any Collateral, Agent shall have the right to hold or use such Collateral to the extent that it deems appropriate for the purpose of preserving the Collateral or its value or for any other purpose deemed appropriate by Agent, and (iv) Agent may, if it so elects, seek the appointment of a receiver or keeper to take possession of any Collateral and to enforce any of Agent’s remedies (for the benefit of the Secured Parties), with respect to such appointment without prior notice or hearing as to such appointment. Agent shall not have any obligation to any Grantor to maintain or preserve the rights of any Grantor as against third parties with respect to any Collateral while such Collateral is in the possession of Agent.

6.12 Direct Obligation . Neither Agent nor any other Secured Party shall be required to make any demand upon, or pursue or exhaust any right or remedy against, any Grantor, any other Guarantor, any other Loan Party or any other Person with respect to the payment of the Secured Obligations or the Guaranteed Obligations or to pursue or exhaust any right or remedy with respect to any Collateral therefor or any direct or indirect guaranty thereof All of the rights and remedies of Agent and any other Secured Party under any Loan Document shall be cumulative, may be exercised individually or concurrently and not exclusive of any other rights or remedies provided by any Applicable Law. To the extent it may lawfully do so, each Grantor absolutely and irrevocably waives and relinquishes the benefit and advantage of, and covenants not to assert against Agent or any other Secured Party, any valuation, stay, appraisement, extension, redemption or similar laws and any and all rights or defenses it may have as a surety, now or hereafter existing, arising out of the exercise by them of any rights hereunder. If any notice of a proposed sale or other disposition of any Collateral shall be required by law, such notice shall be deemed reasonable and proper if given at least ten (10) calendar days before such sale or other disposition.

6.13 Commercially Reasonable . To the extent that any Applicable Law impose duties on Agent to exercise remedies in a commercially reasonable manner, each Grantor acknowledges and agrees that it is not commercially unreasonable for Agent to do any of the following:

 

26


(a) fail to incur significant costs, expenses or other Liabilities reasonably deemed as such by Agent to prepare any Collateral for disposition or otherwise to complete raw material or work in process into finished goods or other finished products for disposition;

(b) fail to obtain permits, or other consents, for access to any Collateral to sell or for the collection or sale of any Collateral, or, if not required by other Applicable Law, fail to obtain Permits or other consents for the collection or disposition of any Collateral;

(c) fail to exercise remedies against account debtors or other Persons obligated on any Collateral or to remove Liens on any Collateral or to remove any adverse claims against any Collateral;

(d) advertise dispositions of any Collateral through publications or media of general circulation, whether or not such Collateral is of a specialized nature, or to contact other Persons, whether or not in the same business as any Grantor, for expressions of interest in acquiring any such Collateral;

(e) exercise collection remedies against account debtors and other Persons obligated on any Collateral, directly or through the use of collection agencies or other collection specialists, hire one or more professional auctioneers to assist in the disposition of any Collateral, whether or not such Collateral is of a specialized nature, or, to the extent deemed appropriate by Agent, obtain the services of other brokers, investment bankers, consultants and other professionals to assist Agent in the collection or disposition of any Collateral, or utilize Internet sites that provide for the auction of assets of the types included in the Collateral or that have the reasonable capacity of doing so, or that match buyers and sellers of assets to dispose of any Collateral;

(f) dispose of assets in wholesale rather than retail markets;

(g) disclaim disposition warranties, such as title, possession or quiet enjoyment; or

(h) purchase insurance or credit enhancements to insure Agent against risks of loss, collection or disposition of any Collateral or to provide to Agent a guaranteed return from the collection or disposition of any Collateral.

Each Grantor acknowledges that the purpose of this Section  6.13 is to provide a non-exhaustive list of actions or omissions that are commercially reasonable when exercising remedies against any Collateral and that other actions or omissions by any Secured Party shall not be deemed commercially unreasonable solely on account of not being indicated in this Section  6.13. Without limitation upon the foregoing, nothing contained in this Section  6.13 shall be construed to grant any rights to any Grantor or to impose any duties on Agent or any other Secured Party that would not have been granted or imposed by this Agreement or by Applicable Law in the absence of this Section  6.13 .

SECTION 7. AGENT .

7.1 Agent’s Appointment as Attorney-in-Fact .

(a) Each Grantor hereby irrevocably constitutes and appoints Agent and any Affiliates, directors, partners, officers, employees, agents, counsel and advisors thereof, with full power of substitution, as its true and lawful attorney-in-fact with full power and authority in the place and stead of such Grantor and in the name of such Grantor or in its own name, for the purpose of carrying out the terms of the Loan Documents, to, upon the occurrence and during the continuance of an Event of Default,

 

27


take any appropriate action and to execute any document or instrument that may be necessary or desirable to accomplish the purposes of the Loan Documents, and, without limiting the generality of the foregoing, each Grantor hereby gives Agent and its Affiliates, directors, partners, officers, employees, agents, counsel and advisors the power and right, on behalf of such Grantor, without notice to or assent by such Grantor, to do any of the following when an Event of Default has occurred and is continuing (subject, as applicable, to compliance by Agent with Applicable Law with respect to Accounts arising under any Third Party Payor programs):

(i) in the name of such Grantor, in its own name or otherwise, take possession of and indorse and collect any check, draft, note, acceptance or other instrument for the payment of moneys due under any account or general intangible that is Collateral or with respect to any other Collateral and file any claim or take any other action or proceeding in any court of law or equity or otherwise deemed appropriate by Agent for the purpose of collecting any such moneys due under any account or general intangible that is Collateral or with respect to any other Collateral whenever payable;

(ii) in the case of any Intellectual Property owned by and, in the case of Copyrights, exclusively licensed to such Grantor (to the extent not constituting Excluded Property and to the extent permitted under the applicable Intellectual Property), execute, deliver and have recorded any document that Agent may request in accordance with this Agreement to evidence, effect, publicize or record Agent’s security interest in such Intellectual Property and the goodwill and general intangibles of such Grantor relating thereto or represented thereby;

(iii) pay or discharge taxes and Liens levied or placed on or threatened against any Collateral, effect any repair or pay any insurance called for by the terms of the Credit Agreement (including all or any part of the premiums therefor and the costs thereof);

(iv) execute, in connection with any sale provided for in Section  6.7 or Section  6.10 hereof, any document to effect or otherwise necessary or appropriate in relation to evidence the sale of any Collateral; or

(v) (A) direct any party liable for any payment under any Collateral to make payment of any moneys due or to become due thereunder directly to Agent or as Agent shall direct, (B) ask or demand for, and collect and receive payment of and receipt for, any moneys, claims and other amounts due or to become due at any time in respect of or arising out of any Collateral, (C) sign and indorse any invoice, freight or express bill, bill of lading, storage or warehouse receipt, draft against debtors, assignment, verification, notice and other document in connection with any Collateral, (D) commence and prosecute any suit, action or proceeding at law or in equity in any court of competent jurisdiction to collect any Collateral and to enforce any other right in respect of any Collateral, (E) defend any actions, suits, proceedings, audits, claims, demands, orders or disputes brought against such Grantor with respect to any Collateral, (F) settle, compromise or adjust any such actions, suits, proceedings, audits, claims, demands, orders or disputes that are related to Collateral and, in connection therewith, give such discharges or releases as Agent may deem appropriate, (G) assign any Intellectual Property owned by any Grantor or any Intellectual Property Licenses of any Grantor where such Grantor is the licensor thereunder (to the extent not constituting Excluded Property and to the extent permitted under the applicable Intellectual Property or Intellectual Property License, as applicable) throughout the world on such terms and conditions and in such manner as Agent shall in its sole discretion determine (except, with respect to Trademarks, subject to reasonable quality control in favor of

 

28


such Grantor), including the execution and filing of any document necessary to effectuate or record such assignment, or (H) generally, sell, assign, convey, transfer or grant a Lien on, make any Contractual Obligation with respect to and otherwise deal with, any Collateral as fully and completely as though Agent were the absolute owner thereof for all purposes and do, at Agent’s option, at any time or from time to time, all acts and things that Agent deems necessary to protect, preserve or realize upon any Collateral and the Secured Parties’ security interests therein and to effect the intent of the Loan Documents, all as fully and effectively as such Grantor might do;

(vi) if any Grantor fails to perform or comply with any Contractual Obligation contained herein, then during the existence of an Event of Default, Agent, at its option, but without any obligation so to do, may perform or comply, or otherwise cause performance or compliance, with such Contractual Obligation;

(vii) receive and open all mail addressed to any Grantor and to notify postal authorities to change the address for the delivery of mail to such Grantor to that of Agent; or

(viii) use any Intellectual Property or Intellectual Property Licenses of such Grantor, including but not limited to any labels, Patents, Trademarks, trade names, URLs, domain names, industrial designs, Copyrights, or advertising matter, in preparing for sale, advertising for sale, or selling Inventory or other Collateral and to collect any amounts due under Accounts, contracts or negotiable Collateral of such Grantor.

(b) The expenses of Agent incurred in connection with actions undertaken as provided in this Section  7.1 , together with, during the existence of an Event of Default as set forth in Section  2.05(c) of the Credit Agreement, interest thereon at a rate set forth in Section  2.05(c) of the Credit Agreement, from the date of payment by Agent to the date reimbursed by the relevant Grantor, shall be payable by such Grantor to Agent on written demand by Agent to Borrower Representative.

(c) Each Grantor hereby ratifies all that said attorneys shall lawfully do or cause to be done by virtue of, and in accordance with, this Section  7.1 . All powers, authorizations and agencies contained in this Agreement are coupled with an interest and are irrevocable until this Agreement is terminated and the security interests created hereby are released.

7.2 Authority of Agent . Each Grantor acknowledges that the rights and responsibilities of Agent under this Agreement with respect to any action taken by Agent or the exercise or non-exercise by Agent of any option, voting right, request, judgment or other right or remedy provided for herein or resulting or arising out of this Agreement shall, as between Agent and the other Secured Parties, be governed by the Credit Agreement and by such other agreements with respect thereto as may exist from time to time among them, but, as between Agent and any Grantor, Agent shall be conclusively presumed to be acting as agent for the Secured Parties with full and valid authority so to act or refrain from acting, and no Grantor shall be under any obligation or entitlement to make any inquiry respecting such authority.

7.3 Duty; Obligations and Liabilities .

(a) Agent’s sole duty with respect to the custody, safekeeping and physical preservation of the Collateral in its possession shall be to deal with it in the same manner as Agent deals with similar property for its own account. The powers conferred on Agent hereunder are solely to protect Agent’s interest in the Collateral and shall not impose any duty upon Agent to exercise any such powers. Agent shall be accountable only for amounts that it receives as a result of the exercise of such powers, and

 

29


neither it nor any of its Affiliates, directors, partners, officers, employees, agents, counsel or advisors shall be responsible to any Grantor for any act or failure to act hereunder, except for their own gross negligence, bad faith or willful misconduct, in each case, as determined by a court of competent jurisdiction in a final non-appealable order. In addition, Agent shall not be liable or responsible for any loss or damage to any Collateral, or for any diminution in the value thereof, by reason of the act or omission of any warehousemen, carrier, forwarding agency, consignee or other bailee if such Person has been selected by Agent in good faith.

(b) No Secured Party and no Affiliates, directors, partners, officers, employees, agents, counsel or advisors thereof shall be liable for failure to demand, collect or realize upon any Collateral or for any delay in doing so or shall be under any obligation to sell or otherwise dispose of any Collateral upon the request of any Grantor or any other Person or to take any other action whatsoever with regard to any Collateral. The powers conferred on Agent hereunder shall not impose any duty upon any other Secured Party to exercise any such powers. The other Secured Parties shall be accountable only for amounts that they actually receive as a result of the exercise of such powers, and neither they nor any of their respective officers, directors, employees or agents shall be responsible to any Grantor for any act or failure to act hereunder, except for their own gross negligence or willful misconduct as determined by a court of competent jurisdiction in a final non-appealable order.

SECTION 8. MISCELLANEOUS .

8.1 Amendments in Writing . The provisions of this Agreement may be waived, modified, supplemented or amended only by an instrument in writing signed by Borrowers and Agent; provided , however , that annexes and schedules, as applicable, to this Agreement may be supplemented or modified (but no existing provisions may be modified and no Collateral may be released, except with respect to the removal of items on the schedules in connection with a sale or other Disposition of Collateral, a merger or Acquisition, in each case, that is permitted under the Credit Agreement) as set forth in Section  5 and Section  8.15 hereof. Notwithstanding anything to the contrary in the first sentence of this Section  8.1 , any time period for performance under this Agreement may be extended, at any time, by Agent in its sole discretion.

8.2 Notices . All notices, requests and demands to or upon Agent or any Guarantor or Grantor hereunder shall be addressed to such party and effected in the manner provided for in Article XI of the Credit Agreement and each Guarantor and Grantor hereby appoints the Borrower Representative as its agent to receive notices hereunder.

8.3 Indemnification by Grantors . Each Grantor and each Guarantor agrees to jointly and severally indemnify, pay, and hold Agent, the other Secured Parties and the Secured Parties’ Affiliates, officers, directors, employees, agents, and attorneys (the “ Indemnitees ”) harmless against losses and Liabilities to the extent set forth in Section  10.03 of the Credit Agreement, the terms of which are incorporated herein by reference as though set forth fully herein. The provisions in this Section  8.3 shall survive Payment in Full of all Secured Obligations and of all Guaranteed Obligations, any foreclosure under, or any modification, release or discharge of, any or all of the Collateral, and termination of this Agreement.

8.4 Enforcement Expenses .

(a) The terms of Section  15.07 of the Credit Agreement with respect to costs and expenses are incorporated herein by reference, mutatis mutandis, and the parties hereto agree to such terms.

 

30


(b) The agreements in this Section  8.4 shall survive Payment in Full of all Secured Obligations and the Guaranteed Obligations, any foreclosure under, or any modification, release or discharge of, any or all of the Collateral, and termination of this Agreement.

8.5 Nature of Remedies . All Secured Obligations and Guaranteed Obligations of each Grantor and rights of Agent and the other Secured Parties expressed herein or in any other Loan Document shall be in addition to and not in limitation of those provided by Applicable Law. No failure to exercise and no delay in exercising, on the part of Agent or the other Secured Parties, any right, remedy, power or privilege hereunder, shall operate as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege.

8.6 Counterparts; Effectiveness . This Agreement may be executed in several counterparts, and by each Party on separate counterparts, each of which and any photocopies, facsimile copies and other electronic methods of transmission thereof shall be deemed an original, but all of which together shall constitute one and the same agreement.

8.7 Severability . If any provision of this Agreement or any of the other Loan Documents shall be invalid, illegal or unenforceable in any respect under any law, the validity, legality and enforceability of the remaining provisions hereof or thereof shall not in any way be affected or impaired thereby. The parties hereto shall endeavor in good faith negotiations to replace the invalid, illegal or unenforceable provisions with valid provisions the economic effect of which comes as close as possible to that of the invalid, illegal or unenforceable provision.

8.8 Entire Agreement . This Agreement contains the entire understanding of the parties hereto with respect to the matters covered hereby and supersedes any and all other written and oral communications, negotiations, commitments and writings with respect thereto. All Exhibits, Schedules and Annexes referred to herein are incorporated in this Agreement by reference and constitute a part of this Agreement. If any provision contained in this Agreement conflicts with any provision of the Credit Agreement, then with regard to such conflicting provisions, the Credit Agreement shall govern and control.

8.9 Successors; Assigns . This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns, except, notwithstanding anything to the contrary in this Agreement or any other Loan Document, that Grantors and Guarantors may not assign their rights or obligations hereunder and any such purported, prohibited or attempted assignment shall be void ab initio.

8.10 Applicable Law . THE VALIDITY OF THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS (UNLESS EXPRESSLY PROVIDED TO THE CONTRARY IN ANOTHER LOAN DOCUMENT IN RESPECT OF SUCH OTHER LOAN DOCUMENT), THE CONSTRUCTION, INTERPRETATION, AND ENFORCEMENT HEREOF AND THEREOF, THE RIGHTS OF THE PARTIES HERETO AND THERETO WITH RESPECT TO ALL MATTERS ARISING HEREUNDER OR THEREUNDER OR RELATED HERETO OR THERETO, AND ANY CLAIMS, CONTROVERSIES OR DISPUTES ARISING HEREUNDER OR THEREUNDER OR RELATED HERETO OR THERETO SHALL BE DETERMINED UNDER, GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK.

8.11 Consent to Jurisdiction; Venue .

 

31


(a) GRANTORS AND GUARANTORS HEREBY IRREVOCABLY AND UNCONDITIONALLY SUBMIT TO THE EXCLUSIVE JURISDICTION OF THE COMMERCIAL DIVISION NEW YORK STATE SUPREME COURT AND THE FEDERAL COURTS, IN EACH CASE, SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN (AND, IN EACH CASE, THE APPLICABLE STATE AND FEDERAL APPEALS COURTS SITTING IN THE CITY OF NEW YORK OR, IF NOT AVAILABLE OR APPLICABLE, THE STATE OF NEW YORK), IN ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO ANY LOAN DOCUMENTS, OR FOR RECOGNITION OR ENFORCEMENT OF ANY JUDGMENT. EACH OF THE PARTIES HERETO AGREES THAT A FINAL JUDGMENT IN ANY SUCH ACTION OR PROCEEDING SHALL BE CONCLUSIVE AND MAY BE ENFORCED IN OTHER JURISDICTIONS BY SUIT ON THE JUDGMENT OR IN ANY OTHER MANNER PROVIDED BY LAW. NOTHING IN THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT SHALL AFFECT ANY RIGHT THAT AGENT MAY OTHERWISE HAVE TO BRING ANY ACTION OR PROCEEDING RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT AGAINST ANY LOAN PARTY OR ITS PROPERTIES IN THE COURTS OF ANY JURISDICTION.

(b) THE PARTIES AGREE THAT ALL ACTIONS OR PROCEEDINGS ARISING IN CONNECTION WITH THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS SHALL BE TRIED AND LITIGATED ONLY IN THE STATE AND, TO THE EXTENT PERMITTED BY APPLICABLE LAW, FEDERAL COURTS LOCATED IN THE COUNTY OF NEW YORK, STATE OF NEW YORK; PROVIDED , THAT ANY SUIT SEEKING ENFORCEMENT AGAINST ANY COLLATERAL OR OTHER PROPERTY MAY BE BROUGHT, AT AGENT’S OPTION, IN THE COURTS OF ANY JURISDICTION WHERE AGENT ELECTS TO BRING SUCH ACTION OR WHERE SUCH COLLATERAL OR OTHER PROPERTY MAY BE FOUND. GRANTORS, GUARANTORS AND EACH MEMBER OF THE LENDER GROUP WAIVE, TO THE EXTENT PERMITTED UNDER APPLICABLE LAW, ANY RIGHT EACH MAY HAVE TO ASSERT THE DOCTRINE OF FORUM NON CONVENIENS OR TO OBJECT TO VENUE TO THE EXTENT ANY PROCEEDING IS BROUGHT IN ACCORDANCE WITH THIS SECTION 8.11 .

8.12 Waiver of Jury Trial . TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, GRANTORS, GUARANTORS AND EACH MEMBER OF THE LENDER GROUP HEREBY WAIVE THEIR RESPECTIVE RIGHTS, IF ANY, TO A JURY TRIAL OF ANY CLAIM, CONTROVERSY, DISPUTE OR CAUSE OF ACTION DIRECTLY OR INDIRECTLY BASED UPON OR ARISING OUT OF ANY OF THE LOAN DOCUMENTS OR ANY OF THE TRANSACTIONS CONTEMPLATED THEREIN, INCLUDING CONTRACT CLAIMS, TORT CLAIMS, BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW OR STATUTORY CLAIMS (EACH A “ CLAIM ”). GRANTORS, GUARANTORS AND EACH MEMBER OF THE LENDER GROUP REPRESENT THAT EACH HAS REVIEWED THIS WAIVER AND EACH KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. IN THE EVENT OF LITIGATION, A COPY OF THIS AGREEMENT MAY BE FILED AS A WRITTEN CONSENT TO A TRIAL BY THE COURT.

8.13 Set-off . Each Grantor agrees that Agent and the other Secured Parties have all rights of set-off and bankers’ lien provided by Applicable Law, and in addition thereto, each Grantor agrees that at any time any Event of Default exists, Agent and the other Secured Parties may apply to the payment of any Secured Obligations and the Guaranteed Obligations as set forth in Section  6.5 hereof, whether or not then due, any and all balances, credits, deposits, accounts or moneys of such Grantor then or thereafter with the Secured Parties.

 

 

32


8.14 Acknowledgements . Each Grantor and each Guarantor hereby acknowledges that:

(a) it has been advised by counsel in the negotiation, execution and delivery of this Agreement and the other Loan Documents to which it is a party;

(b) Neither Agent nor any other Secured Party have any fiduciary relationship with or duty to any Grantor or Guarantor arising out of or in connection with this Agreement or any of the other Loan Documents, and the relationship between the Grantors and Guarantors, on the one hand, and Agent and the other Secured Parties, on the other hand, in connection herewith or therewith is solely that of debtor and creditor; and

(c) no joint venture is created hereby or by the other Loan Documents or otherwise exists by virtue of the transactions contemplated hereby among the Grantors, Guarantors and the Secured Parties.

8.15 Additional Grantors/Guarantors . The Grantors shall cause each Person, upon becoming a Subsidiary of a Grantor (other than any Excluded Subsidiary) or upon becoming a Subsidiary, limited liability company, other entity or other Person for which any Grantor divides or splits itself into (or that receives any assets or property of such Grantor from any such division or split), to guaranty Borrowers’ and the other Grantors’ performance of the Secured Obligations and the Guaranteed Obligations and grant to Agent, for the benefit of the Secured Parties, a security interest in the personal property of such Person (to the extent such personal property would constitute Collateral) to secure the Secured Obligations, its performance under the Credit Agreement and the other Loan Documents and Borrowers’, each Guarantor’s and the other Grantors’ performance of the Secured Obligations by becoming a party to this Agreement. Upon execution and delivery by such Person of a joinder agreement in the form of Annex I hereto, such Person shall become a Grantor and Guarantor for all purposes of this Agreement.

8.16 Releases .

(a) At such time as the Secured Obligations have been Paid in Full, the Collateral shall be automatically released from the Liens created hereby and this Agreement shall automatically terminate (other than those provisions expressly surviving the Payment in Full of the Secured Obligations or the Guaranteed Obligations), all without delivery of any instrument or performance of any act by any party, and all rights to the Collateral shall automatically revert to the Grantors. At such time as the Guaranteed Obligations have been Paid in Full, subject to Section  8.18 , the guarantees provided in Section  2 and the remainder of this Agreement shall automatically terminate (other than those provisions expressly surviving the Payment in Full of the Secured Obligations or the Guaranteed Obligations, including those specific provisions of Section  8 hereof expressly surviving Payment in Full of the Secured Obligations or the Guaranteed Obligations). At the request and sole expense of any Grantor following any such Payment in Full of the Secured Obligations, Agent shall promptly deliver to the Grantors any Collateral held by Agent hereunder, and execute and deliver to the Grantors such documents as the Grantors shall reasonably request in writing to evidence the termination and release of the Liens in the Collateral. At the request and sole expense of any Grantor following any such Payment in Full of the Guaranteed Obligations, Agent shall execute and deliver to the Grantors such documents as the Grantors shall reasonably request in writing to evidence the termination of the guarantees provided in Section  2 .

(b) If any of the Collateral shall be sold, transferred or otherwise disposed of by any Grantor in a transaction permitted by the Credit Agreement or with the written consent of Agent and the

 

33


Required Lenders, then Agent, at the reasonable written request and sole expense of such Grantor, shall execute and deliver to such Grantor all releases or other documents reasonably necessary for the release of the Liens created hereby on such Collateral; provided that Borrowers shall have delivered to Agent, with reasonable notice prior to the date of the proposed release, a written request for release identifying the relevant Grantor, together with a certification by Borrowers stating that such transaction is in compliance with the Credit Agreement and the other Loan Documents (including the relevant provision of the Loan Documents pursuant to which such transfer or other disposition is permitted, together with any additional evidence reasonably requested by Agent).

(c) If, in compliance with the terms and provisions of the Loan Documents, (i) all or substantially all of the Stock of any Guarantor is sold or otherwise transferred to a Person or Persons none of which is a Loan Party in a transaction permitted under the Loan Documents or with the written consent of Agent and the Required Lenders or (ii) any Guarantor becomes an Excluded Subsidiary as a result of a transaction permitted under the Loan Documents (any such Guarantor, and any Guarantor referred to in clause (i), a “Transferred Guarantor” ), such Transferred Guarantor shall, upon the consummation of such sale or transfer or other transaction, be automatically released from its obligations under this Agreement (including under this Section  8.16 ) and the other Loan Documents, including its obligations to pledge and grant any Collateral owned by it and, in the case of a sale of all or substantially all of the Stock of the Transferred Guarantor, the pledge of such Stock to the Agent hereunder shall be automatically released, and, so long as the Borrowers shall have provided the Agent such certifications or documents as the Agent shall reasonably request, the Agent, at the sole expense of the Grantors, shall take such actions as are reasonably necessary and requested by the Grantors in writing to effect each release described in this Section  8.16 .

8.17 Obligations and Liens Absolute and Unconditional . Each Grantor and each Guarantor understands and agrees that the obligations of each Grantor under this Agreement shall be construed as continuing, absolute and unconditional without regard to (i) the validity or enforceability of any Loan Document, any of the Secured Obligations or any other collateral security therefor or guaranty or right of offset with respect thereto at any time or from time to time held by Agent or any other Secured Party, (ii) any defense, set-off or counterclaim (other than a defense of payment or performance) which may at any time be available to or be asserted by any Grantor, Guarantor or any other Person against Agent or any other Secured Party, or (iii) any other circumstance whatsoever (with or without notice to or knowledge of any Grantor or Guarantor) which constitutes, or might be construed to constitute, an equitable or legal discharge of any Grantor or Guarantor for the Secured Obligations or the Guaranteed Obligations, in bankruptcy or in any other instance. When making any demand hereunder or otherwise pursuing its rights and remedies hereunder against any Grantor or Guarantor, Agent and any other Secured Party may, but shall be under no obligation to, make a similar demand on or otherwise pursue such rights and remedies as they may have against any other Grantor or Guarantor or any other Person or against any collateral security for the Secured Obligations or guaranty for the Guaranteed Obligations or any right of offset with respect thereto, and any failure by Agent or any other Secured Party to make any such demand, to pursue such other rights or remedies or to collect any payments from any other Grantor or Guarantor or any other Person or to realize upon any such collateral security or guaranty or to exercise any such right of offset, or any release of any other Grantor or Guarantor or any other Person or any such collateral security, guaranty or right of offset, shall not relieve any Grantor or Guarantor of any obligation or Liability hereunder, and shall not impair or affect the rights and remedies, whether express, implied or available as a matter of law, of Agent or any other Secured Party against any Grantor or Guarantor. For the purposes hereof “demand” shall include the commencement and continuance of any legal proceedings.

 

 

34


8.18 Reinstatement . Each Grantor and Guarantor agrees that, if any payment made by any Loan Party or other Person and applied to the Secured Obligations or the Guaranteed Obligations is at any time annulled, avoided, set aside, rescinded, invalidated, declared to be fraudulent or preferential or otherwise required to be refunded or repaid, or the Proceeds of any Collateral are required to be returned by any Secured Party to such Loan Party, its estate, trustee, receiver or any other party, including any Grantor or Guarantor, under any applicable bankruptcy law, state or federal law, common law or equitable cause, then, to the extent such payment or repayment is annulled, avoided, set aside, rescinded, invalidated, refunded, repaid or returned, any Lien or other Collateral securing such liability with respect to the Secured Obligations and any guarantee herein securing the Guaranteed Obligations shall be and remain in full force and effect, as fully as if such payment had never been made. If, prior to any of the foregoing, (i) any Lien or other Collateral securing such Grantor’s Secured Obligations or Guarantor’s Guaranteed Obligations shall have been released or terminated by virtue of the foregoing or (ii) any provision of the guaranty hereunder shall have been terminated, cancelled or surrendered in connection with the foregoing payment, such Lien, other Collateral, guaranty or other provision shall be reinstated in full force and effect and such prior release, termination, cancellation or surrender shall not diminish, release, discharge, impair or otherwise affect the obligations of any such Grantor in respect of any Lien or other Collateral securing, or any such Guarantor in respect of any guaranty guaranteeing such obligation or the amount of such payment. This Section  8.18 shall survive the termination of this Agreement pursuant to Section  8.16 or otherwise. The provisions in this Section  8.18 shall survive Payment in Full of all Secured Obligations and of all Guaranteed Obligations, any foreclosure under, or any modification, release or discharge of, any or all of the Collateral, and termination of this Agreement.

8.19 Independent Obligations . The obligations of each Grantor and each Guarantor hereunder are independent of and separate from the Secured Obligations and the Guaranteed Obligations. During the continuance of any Event of Default, Agent may, at its sole election, proceed directly and at once, without notice, against any Grantor, any Guarantor and any Collateral to collect and recover the full amount of any Secured Obligation or Guaranteed Obligation (as applicable) then due, without first proceeding against any other Grantor, any Guarantor, any other Loan Party or any other Collateral or any guaranty and without first joining any other Grantor, any other Guarantor or any other Loan Party in any proceeding.

8.20 No Waiver by Course of Conduct . No Secured Party shall by any act (except by a written signed instrument by the required Persons pursuant to Section  8.1 hereof and Section  6.6 of the Credit Agreement), delay, indulgence, omission or otherwise be deemed to have waived any right or remedy hereunder or to have acquiesced in any Default or Event of Default. No failure to exercise, nor any delay in exercising, on the part of any Secured Party, any right, power or privilege hereunder or under any other Loan Document shall operate as a waiver thereof No single or partial exercise of any right, power or privilege hereunder or under any other Loan Document shall preclude any other or further exercise thereof or the exercise of any other right, power or privilege. A waiver by any Secured Party of any right or remedy hereunder or any other Loan Document on any one occasion shall not be construed as a bar to any right or remedy that such Secured Party would otherwise have on any future occasion.

8.21 Intercreditor Agreement . This Agreement is subject, in the manner and the extent, to the terms set forth in the Intercreditor Agreement. Any Collateral held by (or in the possession or control of) the Term Agent (or its agents or bailees) shall be held as agent and bailee for security and Lien perfection purposes in favor of Agent (for the benefit of the Secured Parties) in accordance with the terms of the Intercreditor Agreement and the Loan Documents.

8.22 Relation to Other Loan Documents . The provisions of this Agreement shall be read and construed with the other Loan Documents referred to below in the manner so indicated.

 

 

35


(a) In the event of any conflict between any provision in this Agreement and a provision in the Credit Agreement, such provision of the Credit Agreement shall control.

(b) The provisions of the Copyright Security Agreements, Trademark Security Agreements, and Patent Security Agreements are supplemental to the provisions of this Agreement, and nothing contained in the Copyright Security Agreements, Trademark Security Agreements, or the Patent Security Agreements shall limit any of the rights or remedies of Agent hereunder. In the event of any conflict between any provision in this Agreement and a provision in a Copyright Security Agreement, Trademark Security Agreement or Patent Security Agreement, such provision of this Agreement shall control.

[SIGNATURE PAGES FOLLOW]

 

36


IN WITNESS WHEREOF, each of the undersigned has caused this Agreement to be duly executed and delivered as of the date first above written.

 

GRANTORS AND GUARANTORS:     ENDOLOGIX, INC.,
    a Delaware corporation,
as Grantor and Guarantor
    By:  

/s/ Vaseem Mahboob

    Name:   Vaseem Mahboob
    Title:   Chief Financial Officer
    CVD/RMS ACQUISITION CORP.,
    a Delaware corporation,
as Grantor and Guarantor
    By:  

/s/ Vaseem Mahboob

    Name:   Vaseem Mahboob
    Title:   Chief Financial Officer and Secretary
    NELLIX, INC.,
    a Delaware corporation,
as Grantor and Guarantor
    By:  

/s/ Vaseem Mahboob

    Name:   Vaseem Mahboob
    Title:   Chief Financial Officer and Secretary
    TRIVASCULAR TECHNOLOGIES, INC.,
    a Delaware corporation,
as Grantor and Guarantor
    By:  

/s/ Vaseem Mahboob

    Name:   Vaseem Mahboob
    Title:   Chief Financial Officer and Secretary

 

[Signature Page to Guaranty and Security Agreement]


GRANTORS AND GUARANTORS CONTINUED:     TRIVASCULAR, INC.,
    a California corporation,
as Grantor and Guarantor
    By:  

/s/ Vaseem Mahboob

    Name:   Vaseem Mahboob
    Title:   Chief Financial Officer and Secretary
    ENDOLOGIX CANADA, LLC,
    a Delaware limited liability company,
as Grantor and Guarantor
    By:  

/s/ Vaseem Mahboob

    Name:   Vaseem Mahboob
    Title:   Chief Financial Officer and Secretary
    TRIVASCULAR SALES, LLC,
    a Texas limited liability company,
as Grantor and Guarantor
    By:  

/s/ Vaseem Mahboob

    Name:   Vaseem Mahboob
    Title:   Chief Financial Officer and Secretary
   

RMS/ENDOLOGIX SIDEWAYS MERGER

CORP.,

    a Delaware corporation,
as Grantor and Guarantor
    By:  

/s/ Vaseem Mahboob

    Name:   Vaseem Mahboob
    Title:   Chief Financial Officer and Secretary

[Signature Page to Guaranty and Security Agreement]


AGENT:     DEERFIELD ELGX REVOLVER, LLC , as Agent
   

By: Deerfield Management Company, L.P. (Series C), Manager

 

By: Flynn Management LLC, General Partner

    By:  

/s/ David J. Clark

    Name:   David J. Clark
    Title:   Authorized Signatory

[Signature Page to Guaranty and Security Agreement]


SCHEDULE 1

PLEDGED EQUITY AND PLEDGED DEBT INSTRUMENTS

Pledged Equity:

 

Grantor
(owner of
Record of
such Pledged
Equity)

  

Issuer

   Par
Value
    

No. of
Shares,
Units or
Interests
Owned

  

Total
Shares,
Units or
Interests
Authorized
and
Outstanding

   Percentage
of Shares,
Units or
Interests
Owned
    

Certificate
(Indicate
No.)

Endologix, Inc.

   Nellix, Inc.    $ 0.001      100 Shares    1,000 Shares Authorized; 100 Shares Outstanding      100    65

Endologix, Inc.

   CVD/RMS
Acquisition
Corp.
   $ 0.001      100 Shares    100 Shares Authorized and Outstanding      100    4

Endologix, Inc.

   RMS/Endologix Sideways Merger Corp.    $ 0.001      100 Shares    100 Shares Authorized and Outstanding      100    Com-1

Endologix, Inc.

   TriVascular Technologies, Inc.    $ 0.001      100 Shares    1,000 Shares Authorized; 100 Shares Outstanding      100    60

Endologix, Inc.

   ELGX International Holdings GP      N.A.      Unspecified Number of Partnership Interests    Unspecified Number of Partnership Interests      100    N.A.

Endologix, Inc.

   Endologix Bermuda L.P.      N.A.      Unspecified Number of Partnership Interests    Unspecified Number of Partnership Interests      99    N.A.


Grantor
(owner of
Record of
such Pledged
Equity)

  

Issuer

   Par
Value
    

No. of
Shares,
Units or
Interests
Owned

  

Total
Shares,
Units or
Interests
Authorized
and
Outstanding

   Percentage
of Shares,
Units or
Interests
Owned
    

Certificate
(Indicate
No.)

ELGX International Holdings GP

   Endologix Bermuda L.P.      N.A.      Unspecified Number of Partnership Interests    Unspecified Number of Partnership Interests      1    N.A.

Endologix, Inc.

   Endologix Singapore Private Limited      N.A.      Unspecified Number of Company Interests    Unspecified Number of Company Interests      100    N.A.

Endologix, Inc.

   Endologix New Zealand Co.      N.A.      Unspecified Number of Company Interests    Unspecified Number of Company Interests      100    N.A.

Endologix, Inc.

   ELGX South Korea Ltd      N.A.      Unspecified Number of Company Interests    Unspecified Number of Company Interests      100    N.A.

TriVascular Technologies, Inc.

   TriVascular,
Inc.
   $ 0.01      100 Shares    100 Shares Authorized and Outstanding      100    CS-4

TriVascular, Inc.

   TriVascular Sales LLC      N.A.      1,000 Units of Membership Interests    1,000 Units of Membership Interests      100    N.A.

TriVascular, Inc.

   TriVascular
Germany
GmbH
     N.A.      Unspecified number of Company Interests    Unspecified number of Company Interests      100    N.A.

TriVascular, Inc.

   TriVascular
Switzerland
Sarl
     N.A.      Unspecified number of Company Interests    Unspecified number of Company Interests      100    N.A.


Grantor
(owner of
Record of
such Pledged
Equity)

  

Issuer

   Par
Value
    

No. of
Shares,
Units or
Interests
Owned

  

Total
Shares,
Units or
Interests
Authorized
and
Outstanding

   Percentage
of Shares,
Units or
Interests
Owned
    

Certificate
(Indicate
No.)

TriVascular, Inc.

   Endologix Canada, LLC      N.A.      1,000 Units of Membership Interests    1,000 Units of Membership Interests      100    N.A.

TriVascular, Inc.

   TriVascular, Inc.
Italia Sarl
     N.A.      Unspecified Number of Company Interests    Unspecified Number of Company Interests      100    N.A.

Endologix Bermuda L.P.

   Endologix International Holdings B.V.      N.A.      Unspecified Number of Company Interests    Unspecified Number of Company Interests      100    N.A.

Endologix International Holdings B.V.

   Endologix Poland spolkda z ograniczona odpowiedzialnoscia      N.A.      Unspecified Number of Company Interests    Unspecified Number of Company Interests      100    N.A.

Endologix International Holdings B.V.

   Endologix
Italia Sarl
     N.A.      Unspecified Number of Company Interests    Unspecified Number of Company Interests      100    N.A.

Endologix International Holdings B.V.

   Endologix International B.V.      N.A.      Unspecified Number of Company Interests    Unspecified Number of Company Interests      100    N.A.

Pledged Debt Instruments :

 

Grantor (owner
of Record of such
Pledged Debt
Instrument)

  

Issuer

  

Description of Debt

  

Final
Maturity

  

Principal
Amount

  

Certificate
(Indicate
No.)

N.A.

              


SCHEDULE 1A

PLEDGED INVESTMENT PROPERTY

 

Name of Issuer

   Description and Value of Security    Loan Party/Subsidiary
Cianna Medical, Inc.    8,677 Shares of Series
A Preferred Stock
   Endologix, Inc.

See Schedule 1.


SCHEDULE 2

FILINGS AND PERFECTION

To be attached.


Execution Version

PATENT SECURITY AGREEMENT

This PATENT SECURITY AGREEMENT (this “ Patent Security Agreement ”) is made this 9 th day of August, 2018, by and among the Grantors listed on the signature pages hereof (collectively, jointly and severally, “ Grantors ” and each individually “ Grantor ”), and DEERFIELD ELGX REVOLVER, LLC , a Delaware limited liability company, in its capacity as agent for each member of the Lender Group (in such capacity, together with its successors and assigns in such capacity, “ Agent ”).

W I T N E S S E T H :

WHEREAS, pursuant to that certain Credit Agreement dated as of August 9, 2018 (as amended, restated, supplemented, or otherwise modified from time to time, the “ Credit Agreement ”) by and among ENDOLOGIX, INC. , a Delaware corporation (“ Endologix ”), each of its direct and indirect Subsidiaries set forth on the signature pages thereto and any additional borrower that may thereafter be added to the Credit Agreement (individually as a “ Borrower ”, and collectively with any entities that become party thereto as Borrower and each of their successors and permitted assigns, the “ Borrowers ”), the lenders party thereto as “Lenders” (such Lenders, together with their respective successors and assigns in such capacity, each, individually, a “ Lender ” and, collectively, the “ Lenders ”), and Agent, the Lender Group has agreed to make certain financial accommodations available to the Borrowers from time to time pursuant to the terms and conditions thereof;

WHEREAS, the members of the Lender Group are willing to make the financial accommodations to the Borrowers as provided for in the Credit Agreement and the other Loan Documents, but only upon the condition, among others, that Grantors shall have executed and delivered to Agent, for the benefit of the Lender Group, that certain Guaranty and Security Agreement, dated as of August 9, 2018 (including all annexes, exhibits or schedules thereto, as from time to time amended, restated, supplemented or otherwise modified, the “ Guaranty and Security Agreement ”); and

WHEREAS, pursuant to the Guaranty and Security Agreement, Grantors are required to execute and deliver to Agent, for the benefit of the Lender Group, this Patent Security Agreement.

NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each Grantor hereby agrees as follows:

1. DEFINED TERMS . All initially capitalized terms used but not otherwise defined herein have the meanings given to them in the Guaranty and Security Agreement or, if not defined therein, in the Credit Agreement, and this Patent Security Agreement shall be subject to the rules of construction set forth in Section 1.04 of the Credit Agreement, which rules of construction are incorporated herein by this reference, mutatis mutandis .

2. GRANT OF SECURITY INTEREST IN PATENT COLLATERAL . Each Grantor hereby unconditionally grants, assigns, and pledges to Agent, for the benefit of each member of the Lender Group, to secure the Secured Obligations, a continuing security interest (referred to in this Patent Security Agreement as the “ Security Interest ”) in all of such Grantor’s right, title and interest in and to the following, whether now owned or hereafter acquired or arising (collectively, the “ Patent Collateral ”):

(a) all of its Patents and Patent Intellectual Property Licenses to which it is a party including those referred to on Schedule I ;

 

1


(b) all divisionals, continuations, continuations-in-part, reissues, reexaminations, or extensions of the foregoing; and

(c) all products and proceeds of the foregoing, including any claim by such Grantor against third parties for past, present or future infringement of any Patent or any Patent exclusively licensed under any Intellectual Property License, including the right to receive damages, or right to receive license fees, royalties, and other compensation under any Patent Intellectual Property License.

3. SECURITY FOR SECURED OBLIGATIONS . This Patent Security Agreement and the Security Interest created hereby secures the payment and performance of the Secured Obligations, whether now existing or arising hereafter. Without limiting the generality of the foregoing, this Patent Security Agreement secures the payment of all amounts which constitute part of the Secured Obligations and would be owed by Grantors, or any of them, to Agent, the other members of the Lender Group or any of them, whether or not they are unenforceable or not allowable due to the existence of an Insolvency Proceeding involving any Grantor.

4. PROTECTION OF PATENT SECURITY INTEREST BY GRANTORS . Each Grantor shall, at its sole cost, expense and risk, in connection with the operation of its business, comply with the requirements set forth in Section  6 of the Guaranty and Security Agreement in respect of the Patent Collateral.

5. REPRESENTATIONS AND WARRANTIES . Each Grantor represents and warrants that:

(a) Schedule I hereto is a true, correct and complete list of all Patents and Patent Intellectual Property Licenses in which each Grantor purports to have an ownership or license interest.

(b) Such Grantor has the legal right and authority to enter into this Patent Security Agreement and perform its terms.

(c) If such Grantor amends its name, such Grantor shall provide copies of such amendment documentation to Agent and shall, if necessary, re-register such Grantor’s Patents and Patent Intellectual Property Licenses with the appropriate Governmental Authority and shall execute and deliver such agreements or documentation as Agent shall reasonably request in writing to maintain a perfected first priority security interest in the Patent Collateral subject to Permitted Liens.

6. SECURITY AGREEMENT . The Security Interest in the Collateral granted pursuant to this Patent Security Agreement is granted in conjunction with the security interests granted to Agent, for the benefit of the Lender Group, pursuant to the Guaranty and Security Agreement. Each Grantor hereby acknowledges and affirms that the rights and remedies of Agent with respect to the Security Interest in the Patent Collateral made and granted hereby are more fully set forth in the Guaranty and Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein. To the extent there is any inconsistency between this Patent Security Agreement and the Guaranty and Security Agreement, the Guaranty and Security Agreement shall control.

7. AUTHORIZATION TO SUPPLEMENT . If any Grantor shall obtain rights to any new patent application or issued patent or become entitled to the benefit of any patent application or patent for any divisional, continuation, continuation-in-part, reissue, or reexamination of any existing patent or patent application, the provisions of this Patent Security Agreement shall automatically apply thereto. Each Grantor shall notify Agent of applications filed for the registration of any Patents with the United

 

2


States Patent Office in accordance with Section 5.7(g) of the Guaranty and Security Agreement. Without limiting Grantors’ obligations under this Section, Grantors hereby authorize Agent unilaterally to modify this Patent Security Agreement by amending Schedule I to include any such new patent rights of each Grantor. Notwithstanding the foregoing, no failure to so modify this Patent Security Agreement or amend Schedule I shall in any way affect, invalidate or detract from Agent’s continuing security interest in all Collateral, whether or not listed on Schedule I.

8. NO VIOLATION OF LOAN DOCUMENTS . The representations, warranties or covenants contained herein are supplemental to those representations, warranties and covenants contained in the other Loan Documents, and shall not be deemed to modify any such representation, warranty or covenant contained in any other Loan Document.

9. GRANTOR’S RIGHTS TO ENFORCE PATENTS . Prior to Agent’s giving of notice to Grantor following the occurrence and during the continuance of an Event of Default, such Grantor shall have the exclusive right to sue for past, present and future infringement of the Patent Collateral, including the right to seek injunctions and/or money damages, in an effort by such Grantor to protect the Patent Collateral against encroachment by third parties, provided, however, that:

(a) Any money damages awarded or received by such Grantor on account of such suit (or the threat of such suit) shall constitute Patent Collateral.

(b) Any damages recovered in any action pursuant to this Section, net of costs and attorneys’ fees reasonably incurred, shall be applied in accordance with the Credit Agreement and the Guaranty and Security Agreement.

(c) Following the occurrence and during the continuance of any Event of Default, Agent, by notice to any Grantor may terminate or limit such Grantor’s rights under this Section 9.

10. RIGHTS UPON DEFAULT . Upon the occurrence and during the continuance of any Event of Default, Agent may exercise all rights and remedies as provided for in the Guaranty and Security Agreement.

11. NO LIMITATION; LOAN DOCUMENTS . This Patent Security Agreement has been executed and delivered by each Grantor for the purpose of recording the security interest granted to Agent with respect to the Patent Collateral with the United States Patent Office. The security interest granted hereby has been granted as a supplement to, and not in limitation of, the security interest granted to Agent, for the benefit of the Lender Group, under the Guaranty and Security Agreement and the other Loan Documents. The other Loan Documents (and all rights and remedies of Grantor, Agent, and Lenders thereunder) shall remain in full force and effect in accordance with their terms.

12. TERMINATION; RELEASE OF PATENT COLLATERAL . This Patent Security Agreement and all obligations of each Grantor and Agent hereunder shall terminate on the date upon which the Obligations have been Paid in Full. Upon termination of this Patent Security Agreement, Agent shall, at the reasonable expense of the Grantor, take such actions required by the Credit Agreement or the Guaranty and Security Agreement or as otherwise reasonably requested by Grantor to release its security interest in the Patent Collateral.

13. BINDING EFFECT; BENEFITS . This Patent Security Agreement shall be binding upon each Grantor and its successors and assigns, and shall inure to the benefit of Agent, Lenders and their respective successors and assigns.

 

3


14. COUNTERPARTS . This Patent Security Agreement is a Loan Document. This Patent Security Agreement may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, shall be deemed to be an original, and all of which, when taken together, shall constitute but one and the same Patent Security Agreement. Delivery of an executed counterpart of this Patent Security Agreement by telefacsimile or other electronic method of transmission shall be equally as effective as delivery of an original executed counterpart of this Patent Security Agreement. Any party delivering an executed counterpart of this Patent Security Agreement by telefacsimile or other electronic method of transmission also shall deliver an original executed counterpart of this Patent Security Agreement but the failure to deliver an original executed counterpart shall not affect the validity, enforceability, and binding effect of this Patent Security Agreement.

15. CHOICE OF LAW AND VENUE, JURY TRIAL WAIVER, AND JUDICIAL REFERENCE PROVISION . THIS PATENT SECURITY AGREEMENT SHALL BE SUBJECT TO THE PROVISIONS REGARDING CHOICE OF LAW AND VENUE, JURY TRIAL WAIVER, AND JUDICIAL REFERENCE SET FORTH IN SECTIONS 8.11 AND 8.12 OF THE GUARANTY AND SECURITY AGREEMENT, AND SUCH PROVISIONS ARE INCORPORATED HEREIN BY THIS REFERENCE, MUTATIS MUTANDIS .

[signature page follows]

 

4


Execution Version

IN WITNESS WHEREOF, the parties hereto have caused this Patent Security Agreement to be executed and delivered as of the day and year first above written.

 

GRANTORS:     ENDOLOGIX, INC.
    By:  

/s/ Vaseem Mahboob

    Name:   Vaseem Mahboob
    Title:   Chief Financial Officer
    NELLIX, INC.
    By:  

/s/ Vaseem Mahboob

    Name:   Vaseem Mahboob
    Title:   Chief Financial Officer and Secretary
    TRIVASCULAR, INC.
    By:  

/s/ Vaseem Mahboob

    Name:   Vaseem Mahboob
    Title:   Chief Financial Officer and Secretary

 

5


IN WITNESS WHEREOF, the parties hereto have caused this Patent Security Agreement to be executed and delivered as of the day and year first above written.

 

    ACCEPTED AND ACKNOWLEDGED BY:
AGENT:     DEERFIELD ELGX REVOLVER, LLC
    by: Deerfield Management Company, L.P. (Series C), Manager
    By: Flynn Management LLC, General Partner
    By:  

/s/ David J. Clark

    Name:   David J. Clark
    Title:   Authorized Signatory

 

6


SCHEDULE I

to

PATENT SECURITY AGREEMENT

Patents

 

Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC.   US   Stent graft   US9757262B2   US13943246A   2013-07-16
ENDOLOGIX INC.   US   Catheter system and methods of using same   US9700701B2   US13544426A   2012-07-09
ENDOLOGIX INC.   US   Catheter system and methods of using same   US9687374B2   US15379268A   2016-12-14
ENDOLOGIX INC.   US   Percutaneous method and device to treat dissections   US9579103B2   US12771711A   2010-04-30

 

7


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC.   US   Catheter system and methods of using same   US9549835B2   US14462485A   2014-08-18
ENDOLOGIX INC.   US   Method and system for treating aneurysms   US9415195B2   US13441762A   2012-04-06
ENDOLOGIX INC.   US   Devices and methods to treat vascular dissections   US9393100B2   US13988175A   2013-05-17
ENDOLOGIX INC.   US   Method for forming materials in situ within a medical device   US9289536B2   US14201332A   2014-03-07
ENDOLOGIX INC.   US   Apparatus and method of placement of a graft or graft system   US9149381B2   US14172126A   2014-02-04

 

8


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC.   US   Stent graft   US8821564B2   US13397952A   2012-02-16
ENDOLOGIX INC.   US   Apparatus and methods for repairing aneurysms   US8814928B2   US12616928A   2009-11-12
ENDOLOGIX INC.   US   Catheter system and methods of using same   US8808350B2   US13408952A   2012-02-29
ENDOLOGIX INC.   US   Graft systems having semi-permeable filling structures and methods for their use   US8801768B2   US13355705A   2012-01-23
ENDOLOGIX INC   US   Bifurcated graft deployment systems and methods   US8764812B2   US13745682A   2013-01-18

 

9


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC.   US   Apparatus and method of placement of a graft or graft system   US8672989B2   US13546950A   2012-07-11
ENDOLOGIX INC.   US   Graft deployment system   US8568466B2   US13269332A   2011-10-07
ENDOLOGIX INC.   US   Dual concentric guidewire and methods of bifurcated graft deployment   US8523931B2   US11623022A   2007-01-12
ENDOLOGIX INC.   US   Stent graft   US8491646B2   US12837398A   2010-07-15
ENDOLOGIX INC.   US   Endolumenal vascular prosthesis with neointima inhibiting polymeric sleeve   US8377110B2   US10820455A   2004-04-08

 

10


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC.   US   Bifurcated graft deployment systems and methods   US8357192B2   US13046541A   2011-03-11
ENDOLOGIX INC.   US   Bifurcated graft deployment systems and methods   US8236040B2   US12101863A   2008-04-11
ENDOLOGIX INC.   US   Catheter system and methods of using same   US8216295B2   US12496446A   2009-07-01
ENDOLOGIX INC.   US   Apparatus and method of placement of a graft or graft system   US8221494B2   US12390346A   2009-02-20
ENDOLOGIX INC.   US   Methods and systems for endovascular aneurysm treatment   US8182525B2   US12421297A   2009-04-09

 

11


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC.   US   Single puncture bifurcation graft deployment system   US8167925B2   US12732095A   2010-03-25
ENDOLOGIX INC.   US   Bifurcation graft deployment catheter   US8147535B2   US11189101A   2005-07-25
ENDOLOGIX INC.   US   Material for creating multi-layered films and methods for making the same   US8133559B2   US13100483A   2011-05-04
ENDOLOGIX INC.   US   Stent graft   US8118856B2   US12844266A   2010-07-27
ENDOLOGIX INC.   US   Graft systems having filling structures supported by scaffolds and methods for their use   US8048145B2   US11413460A   2006-04-28

 

12


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC.   US   Graft deployment system   US8034100B2   US10722367A   2003-11-25
ENDOLOGIX INC.   US   Material for creating multi-layered films and methods for making the same   US7951448B2   US12858274A   2010-08-17
ENDOLOGIX INC   US   Self expanding bifurcated endovascular prosthesis   US7892277B2   US11417883A   2006-05-03
ENDOLOGIX INC.   US   Material for creating multi-layered films and methods for making the same   US7790273B2   US11752750A   2007-05-23
ENDOLOGIX INC.   US   Devices for repairing aneurysms   US7682383B2   US10481386A   2004-06-14

 

13


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC.   US   System and methods for endovascular aneurysm treatment   US7666220B2   US11482503A   2006-07-07
ENDOLOGIX INC.   US   Methods and systems for endovascular aneurysm treatment   US7530988B2   US11187471A   2005-07-22
ENDOLOGIX INC   US   Self expanding bifurcated endovascular prosthesis   US7520895B2   US10119525A   2002-04-08
ENDOLOGIX INC   US   Bifurcation graft deployment catheter   US6953475B2   US10675060A   2003-09-30
ENDOLOGIX INC.   US   Implantable vascular graft   US6733523B2   US09891620A   2001-06-26

 

14


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC   US   Single puncture bifurcation graft deployment system   US6663665B2   US09795993A   2001-02-28
ENDOLOGIX INC.   US   Bifurcation graft deployment catheter   US6660030B2   US09747094A   2000-12-22
ENDOLOGIX INC   US   Endoluminal vascular prosthesis   US6508835B1   US09723979A   2000-11-28
ENDOLOGIX INC.   US   Bifurcation graft deployment catheter   US6500202B1   US09525778A   2000-03-15
ENDOLOGIX INC.   US   Dual wire placement catheter   US6440161B1   US09348356A   1999-07-07

 

15


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC.   US   Single puncture bifurcation graft deployment system   US6261316B1   US09266661A   1999-03-11
ENDOLOGIX INC.   US   Articulating bifurcation graft   US6197049B1   US09251363A   1999-02-17
ENDOLOGIX INC.   US   Endoluminal vascular prosthesis   US6187036B1   US09210280A   1998-12-11
ENDOLOGIX INC.   US   Segmented stent for flexible stent delivery system   US6187034B1   US09229856A   1999-01-13
ENDOLOGIX INC.   US   Endoluminal vascular prosthesis   US6077296A   US0934689A   1998-03-04

 

16


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC.   US   Stent delivery system featuring a flexible balloon   US6022359A   US09229519A   1999-01-13
ENDOLOGIX INC.   US   Radially expandable stent featuring accordion stops   US5931866A   US09028305A   1998-02-24
ENDOLOGIX INC.   US   DUAL INFLATABLE ARTERIAL PROSTHESIS   US20180021045A1   US15540246A   2017-06-27
ENDOLOGIX INC.   US   CATHETER SYSTEM AND METHODS OF USING SAME   US20170304098A1   US15632064A   2017-06-23
ENDOLOGIX INC.   US   CATHETER SYSTEM AND METHODS OF USING SAME   US20170296791A1   US15639028A   2017-06-30

 

17


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC   US   APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM   US20170266025A1   US15610242A   2017-05-31
ENDOLOGIX INC.   US   MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES   US20170239035A1   US15310198A   2016-11-10
ENDOLOGIX INC.   US   METHODS AND SYSTEMS FOR ANEURYSM TREATMENT USING FILLING STRUCTURES   US20170238937A1   US15438682A   2017-02-21
ENDOLOGIX INC   US   APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM   US20170128246A1   US15414499A   2017-01-24
ENDOLOGIX INC   US   METHOD AND SYSTEM FOR TREATING ANEURYSMS   US20170007263A1   US15205365A   2016-07-08

 

18


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC.   US   METHOD FOR FORMING HYDROGELS AND MATERIALS THEREFOR   US20160367731A1   US15256462A   2016-09-02
ENDOLOGIX INC.   US   DEVICES AND METHODS TO TREAT VASCULAR DISSECTIONS   US20160302798A1   US15194159A   2016-06-27
ENDOLOGIX INC.   US   SYSTEMS AND METHODS FOR FORMING MATERIALS IN SITU WITHIN A MEDICAL DEVICE   US20160030051A1   US14776385A   2015-09-14
ENDOLOGIX INC   US   APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM   US20150366688A1   US14840428A   2015-08-31
ENDOLOGIX INC.   US   METHOD AND SYSTEM FOR TREATING ANEURYSMS   US20150250989A1   US14717938A   2015-05-20

 

19


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC.   US   FENESTRATED PROSTHESIS   US20150173923A1   US14581675A   2014-12-23
ENDOLOGIX INC.   US   Apparatus and Methods for Repairing Aneurysms   US20150012081A1   US14330812A   2014-07-14
ENDOLOGIX INC.   US   STENT GRAFT   US9907642   US14461308A   2014-08-15
ENDOLOGIX INC   US   ENDOLUMENAL VASCULAR PROSTHESIS WITH NEOINTIMA INHIBITING POLYMERIC SLEEVE   US20130253638A1   US13731908A   2012-12-31
ENDOLOGIX INC.   US   Methods and Systems for Treating Aneurysms   US20120184982A1   US13354094A   2012-01-19

 

20


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC.   US   APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM   US20120109279A1   US13287907A   2011-11-02
ENDOLOGIX INC.   US   FILLING STRUCTURE FOR A GRAFT SYSTEM AND METHODS OF USE   US20110276078A1   US12966852A   2010-12-13
ENDOLOGIX INC   US   SELF EXPANDING BIFURCATED ENDOVASCULAR PROSTHESIS   US20110224782A1   US13027077A   2011-02-14
ENDOLOGIX INC.   US   ENDOLUMINAL VASCULAR PROSTHESIS   US20110218617A1   US13039157A   2011-03-02
ENDOLOGIX INC   US   APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM   US20110054587A1   US12769546A   2010-04-28

 

21


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC   US   IMPLANTABLE VASCULAR GRAFT   US20100318174A1   US12860280A   2010-08-20
ENDOLOGIX INC   US   IMPLANTABLE VASCULAR GRAFT   US20100318181A1   US12860310A   2010-08-20
ENDOLOGIX INC.   US   UTILIZATION OF MURAL THROMBUS FOR LOCAL DRUG DELIVERY INTO VASCULAR TISSUE   US20100261662A1   US12757900A   2010-04-09
ENDOLOGIX INC   US   GRAFT DEPLOYMENT SYSTEM   US20100179636A1   US12726257A   2010-03-17
ENDOLOGIX INC.   US   STENT GRAFT DELIVERY SYSTEM   US20100036360A1   US12429474A   2009-04-24

 

22


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC.   US   DOCKING APPARATUS AND METHODS OF USE   US20090319029A1   US12478208A   2009-06-04
ENDOLOGIX INC.   US   GRAFT ENDOFRAME HAVING AXIALLY VARIABLE CHARACTERISTICS   US20100004728A1   US12371087A   2009-02-13
ENDOLOGIX INC.   US   METHOD AND AGENT FOR IN-SITU STABILIZATION OF VASCULAR TISSUE   US20090155337A1   US12269677A   2008-11-12
ENDOLOGIX INC.   US   STENT   US20090105806A1   US12257149A   2008-10-23
ENDOLOGIX INC.   US   Multi-segmented graft deployment system   US20080071343A1   US11522292A   2006-09-15

 

23


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC   US   IMPLANTABLE VASCULAR GRAFT   US20070299497A1   US11764715A   2007-06-18
ENDOLOGIX INC.   US   Methods and systems for aneurysm treatment using filling structures   US20070150041A1   US11444603A   2006-05-31
ENDOLOGIX INC   US   ENDOLUMINAL VASCULAR PROSTHESIS   US20070112412A1   US11623679A   2007-01-16
ENDOLOGIX INC.   US   Method and apparatus for decompressing aneurysms   US20070078506A1   US11580201A   2006-10-12
ENDOLOGIX INC.   US   Method and apparatus for decompressing aneurysms   US20050245891A1   US11104303A   2005-04-12

 

24


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC.   US   Vascular stent-graft apparatus   US20040167607A1   US10787404A   2004-02-24
ENDOLOGIX INC.   US   Stent-graft with positioning anchor   US20040116997A1   US10668901A   2003-09-22
ENDOLOGIX INC.   US   Flexible vascular graft   US20010025195A1   US09728582A   2000-12-01
ENDOLOGIX INC   US   MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES   US20170239035A1   US15310198A   2016-11-10
ENDOLOGIX INC   US   DUAL INFLATABLE ARTERIAL PROSTHESIS   US20180021045A1   US15540246A   2017-06-27

 

25


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC   US   ENDOLUMINAL PROSTHESIS SYSTEMS AND METHODS     US15737223   2017-12-15
ENDOLOGIX INC   US   Systems and Methods with Stents and Filling Structure     62/382207   2016-08-31
ENDOLOGIX INC   US   STENTS, GRAFTS, DELIVERY SYSTEMS, AND METHODS     62/481560   2017-04-04
ENDOLOGIX INC   US   ENDOVASCULAR SYSTEMS, DEVICES, AND METHODS ALLOWING FOR BRANCH DEVICE PLACEMENT IN POCKET OF MAIN GRAFT     62/489213   2017-04-24
ENDOLOGIX INC   US   ENDOVASCULAR GRAFT SYSTEMS AND METHODS FOR DEPLOYMENT IN MAIN AND BRANCH ARTERIES     62/529669   2017-07-07

 

26


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC   US   STENT GRAFTS AND METHODS OF ENHANCING FLEXIBILITY OF STENT GRAFTS BY THERMAL PLEATING     62/532737   2017-07-14
ENDOLOGIX INC   US   STENT GRAFT     15/911629   2018-03-05
ENDOLOGIX INC   US   INTERNAL ILIAC PRESERVATION DEVICES AND METHODS     15/965649   2018-04-
ENDOLOGIX INC   US   MODULATION OF INFLAMMATORY RESPONSE FOLLOWING ENDOVASCULAR TREATMENT     62/661569   2018-4-23
ENDOLOGIX INC   US   ADVANCED KINK RESISTANT STENT GRAFT     16/005269   2018-6-11

 

27


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC   US   LOW PROFILE STENT GRAFT AND DELIVERY SYSTEM     15/985572   2018-5-21
ENDOLOGIX INC   US   SYSTEMS AND METHODS WITH STENT AND FILLING STRUCTURE     15/774511   2017-8-30
ENDOLOGIX INC   US   LONGITUDINALLY EXTENDABLE STENT GRAFT SYSTEMS AND METHODS     15/774548   2018-1-23
ENDOLOGIX INC   US   GRAFT SYSTEMS HAVING FILLING STRUCTURES SUPPORTED BY SCAFFOLDS AND METHODS FOR THEIR USE     16/035497   2018-7-13
ENDOLOGIX INC   US   PRE-FIXATION DEVICE FOR NELLIX AND OTHER EVAS DEVICES     62/678956   2018-5-31

 

28


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC   US   SYSTEMS AND METHODS WITH FENESTRATED GRAFT AND FILLING STRUCTURE     16/066595  
ENDOLOGIX INC   US   MODULATION OF INFLAMMATORY RESPONSE FOLLOWING ENDOVASCULAR TREATMENT     62/661569   2018-4-23
ENDOLOGIX INC.   US   FENESTRATED PROSTHESIS   US8945202   12/769581   2015-2-3
ENDOLOGIX INC.   US   Fenestrated prosthesis   US8945202   12/769581   4/28/10
ENDOLOGIX, INC.   US   Bifurcated vascular graft deployment device   US6210422   09/505038   2/16/00

 

29


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX, INC.   US   Method of deploying bifurcated vascular graft   US6156063   09/086247   5/28/98
ENDOLOGIX, INC.   US   Bifurcated vascular graft deployment device   US6090128   08/802478   2/20/97
ENDOLOGIX, INC.   US   Endovascular prosthesis with improved sealing means for aneurysmal arterial disease and method of use   US5665117   08/620072   3/21/96
ENDOLOGIX, INC.   US   Locking assembly for coupling guidewire to delivery system     15/317905   12/9/16
Endologix, Inc. and The Cleveland Clinic Foundation   US   Fenestrated prosthesis   US8945202   US12769581   4/28/10

 

30


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

Endologix, Inc.   US   Single puncture bifurcation graft deployment system   US7691135   US10690227   10/21/03
Endologix, Inc.   US   Bifurcated vascular graft and method and apparatus for deploying same   US6951572   US10639255   8/12/03
Endologix, Inc.   US   Radiation delivery balloon catheter   US6699170   US09688396   10/16/00
Endologix, Inc.   US   Dual wire placement catheter   US6689157   US10035729   12/21/01
Endologix, Inc.   US   Method for delivering radiation to an intraluminal site in the body   US6685618   US09944649   8/31/01

 

31


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

Endologix, Inc.   US   Radiation delivery catheters and dosimetry methods   US6491619   US09648563   8/25/00
Endologix, Inc.   US   Endoluminal vascular prosthesis   US6331190   US09483411   1/14/00
Endologix, Inc.   US   Bifurcated vascular graft deployment device   US6210422   US09505038   2/16/00
Endologix, Inc.   US   Method of deploying bifurcated vascular graft   US6156063   US09086247   5/28/98
Endologix, Inc.   US   Bifurcated vascular graft deployment device   US6090128   US08802478   2/20/97

 

32


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

Endologix, Inc.   US   Axially non-contracting flexible radially expandable stent   US6083259   US09192803   11/16/98
Endologix, Inc.   US   Endovascular prosthesis with improved sealing means for aneurysmal arterial disease and method of use   US5665117   US08620072   3/21/96
Endologix, Inc.   US   Apparatus and method of placement of a graft or graft system     US14172126   2/4/14
Endologix, Inc. and The Cleveland Clinic Foundation   US   Apparatus and method of placement of a graft or graft system     US12769506   4/28/10
Endologix, Inc.   US   Stent graft delivery system     US12429474   4/24/09

 

33


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC   US   ENDOLUMINAL DEVICE AND POLYMER     62/575827   2017-10-23
TRIVASCULAR INC   US   Advanced Endovascular Graft   US9788934B2   US14799656A   2015-07-15
NELLIX INC.   US   Stent-graft with positioning anchor   US9814612B2   US14697433A   2015-10-21
NELLIX INC.   US   System and methods for endovascular aneurysm treatment   US9737425B2   US14537749A   2014-11-10
NELLIX INC.   US   Stent graft delivery system   US9730700B2   US14586110A   2015-04-23

 

34


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

NELLIX INC.   US   Methods for deploying a positioning anchor with a stent-graft   US9113999B2   US11876458A   2007-10-22
NELLIX INC.   US   Sealing apparatus and methods of use   US8945199B2   US12478225A   2009-06-04
NELLIX INC.   US   Stent graft delivery system   US8926682B2   US13243941A   2011-09-23
NELLIX INC.   US   System and methods for endovascular aneurysm treatment   US8906084B2   US12684074A   2010-01-07
NELLIX INC.   US   Graft systems having filling structures supported by scaffolds and methods for their use   US8870941B2   US13285897A   2011-10-31

 

35


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

NELLIX INC.   US   STENT GRAFT DELIVERY SYSTEM   US20180028192A1   US15676869A   2017-08-14
NELLIX INC.   US   SEALING APPRATUS AND METHODS OF USE   US20150148892A1   US14612048A   2015-02-02
NELLIX INC.   US   GRAFT SYSTEMS HAVING FILLING STRUCTURES SUPPORTED BY SCAFFOLDS AND METHODS FOR THEIR USE   US10022249   US14525019A   2014-10-27
NELLIX, INC.   US   System and methods of Endovascular Aneurysm Treatment     14/682414   8/21/17
Nellix, Inc.   US   Vascular stent-graft apparatus and forming method   US6695833   US09671550   9/27/00

 

36


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC.   US   Endovascular graft   US9867727B2   US14320773A   2014-07-01
TRIVASCULAR INC.   US   Advanced endovascular graft   US9788934B2   US14799656A   2015-07-15
TRIVASCULAR INC.   US   Endovascular graft for aneurysms involving major branch vessels   US9724186B2   US14050835A   2013-10-10
TRIVASCULAR INC.   US   System and method of pivoted stent deployment   US9713523B2   US14452343A   2014-08-05
TRIVASCULAR INC.   US   Systems and methods for guidewire crossover for bifurcated prostheses   US9655754B2   US14323059A   2014-07-03

 

37


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC.   US   Bifurcated endovascular prosthesis having tethered contralateral leg   US9585774B2   US14823076A   2015-08-11
TRIVASCULAR INC.   US   PTFE layers and methods of manufacturing   US9549829B2   US14458349A   2014-08-13
TRIVASCULAR INC.   US   Delivery catheter for endovascular device   US9498363B2   US13835491A   2013-03-15
TRIVASCULAR INC   US   Low profile stent and delivery system   US9463101B2   US14923477A   2015-10-27
TRIVASCULAR INC.   US   PTFE layers and methods of manufacturing   US9446553B2   US14230318A   2014-03-31

 

38


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC.   US   Endovascular graft joint and method for manufacture   US9351858B2   US14704013A   2015-05-05
TRIVASCULAR INC.   US   Non-degradable, low swelling, water soluble radiopaque hydrogel polymer   US9308301B2   US13089960A   2011-04-19
TRIVASCULAR INC.   US   Endovascular delivery system with an improved radiopaque marker scheme   US9233015B2   US13803050A   2013-03-14
TRIVASCULAR INC.   US   Low profile stent graft and delivery system   US9192462B2   US13803037A   2013-03-14
TRIVASCULAR INC.   US   Fenestrated inflatable graft   US9144486B2   US13652471A   2012-10-15

 

39


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC.   US   Bifurcated endovascular prosthesis having tethered contralateral leg   US9132025B2   US13803067A   2013-03-14
TRIVASCULAR INC.   US   Endovascular delivery system with flexible and torqueable hypotube   US9066828B2   US13803062A   2013-03-14
TRIVASCULAR INC.   US   Endovascular graft joint and method for manufacture   US9050754B2   US12729182A   2010-03-22
TRIVASCULAR INC.   US   Durable stent graft with tapered struts and stable delivery methods and devices   US8992595B2   US13799207A   2013-03-13
TRIVASCULAR INC.   US   In vitro testing of endovascular device   US8978448B2   US13649066A   2012-10-10

 

40


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC.   US   Advanced endovascular graft delivery system and method of treatment   US8900288B2   US12566104A   2009-09-24
TRIVASCULAR INC.   US   Method of delivering advanced endovascular graft and system   US8864814B2   US13246651A   2011-09-27
TRIVASCULAR INC.   US   PTFE layers and methods of manufacturing   US8840824B2   US12910281A   2010-10-22
TRIVASCULAR INC.   US   Endovascular graft   US8801769B2   US13737351A   2013-01-09
TRIVASCULAR INC.   US   Apparatus for manufacturing an endovascular graft section   US8783316B2   US12697504A   2010-02-01

 

41


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC.   US   PTFE layers and methods of manufacturing   US8728372B2   US12915636A   2010-10-29
TRIVASCULAR INC.   US   Advanced endovascular graft   US8709065B2   US12491336A   2009-06-25
TRIVASCULAR INC.   US   Virtual prototyping and testing for medical device development   US8666714B2   US13523765A   2012-06-14
TRIVASCULAR INC.   US   Asymmetric stent apparatus and method   US8663309B2   US11861828A   2007-09-26
TRIVASCULAR INC.   US   Endovascular graft   US8361136B2   US12566793A   2009-09-25

 

42


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC.   US   Endovascular graft joint and method for manufacture   US8348989B2   US11429735A   2006-05-08
TRIVASCULAR INC.   US   Delivery system and method for bifurcated graft   US8328861B2   US11941434A   2007-11-16
TRIVASCULAR INC.   US   Endovascular graft and method of delivery   US8241346B2   US13246643A   2011-09-27
TRIVASCULAR INC.   US   Inflatable porous implants and methods for drug delivery   US8267989B2   US12860364A   2010-08-20
TRIVASCULAR INC.   US   Inflatable intraluminal graft   US8226708B1   US10168053A   2002-06-14

 

43


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC.   US   Stent and delivery system for deployment thereof   US8226701B2   US11861756A   2007-09-26
TRIVASCULAR INC.   US   Virtual prototyping and testing for medical device development   US8224632B2   US12904994A   2010-10-14
TRIVASCULAR INC.   US   Dual chamber cuff structure   US8216297B2   US11504434A   2006-08-14
TRIVASCULAR INC.   US   Barbed radially expandable stent   US8167927B2   US13245661A   2011-09-26
TRIVASCULAR INC.   US   Securement assembly and method for expandable endovascular device   US8083789B2   US11941450A   2007-11-16

 

44


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC.   US   System and method of pivoted stent deployment   US8066755B2   US11861716A   2007-09-26
TRIVASCULAR INC.   US   Constant force material delivery system and method   US7971751B2   US12724068A   2010-03-15
TRIVASCULAR INC.   US   Passive hemostatic sheath valve   US7901379B2   US11298285A   2005-12-09
TRIVASCULAR INC.   US   Virtual prototyping and testing for medical device development   US7840393B1   US09679725A   2000-10-04
TRIVASCULAR INC.   US   Inflatable porous implants and methods for drug delivery   US7803178B2   US10769532A   2004-01-30

 

45


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC.   US   Advanced endovascular graft   US7766954B2   US11333595A   2006-01-17
TRIVASCULAR INC.   US   Constant force material delivery system and method   US7708163B2   US11360077A   2006-02-23
TRIVASCULAR INC.   US   Endovascular graft joint and method for manufacture   US7682475B2   US11870748A   2007-10-11
TRIVASCULAR INC.   US   Method for manufacturing an endovascular graft section   US7678217B2   US11522490A   2006-09-15
TRIVASCULAR INC.   US   Inflatable implant   US7632291B2   US10461853A   2003-06-13

 

46


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC.   US   Endovascular graft   US7615071B2   US11390732A   2006-03-28
TRIVASCULAR INC.   US   Delivery system and method for expandable intracorporeal device   US7338518B2   US11201028A   2005-08-10
TRIVASCULAR INC.   US   Passive hemostatic sheath valve   US7241276B2   US10636871A   2003-08-06
TRIVASCULAR INC.   US   Advanced endovascular graft   US7147660B2   US10327711A   2002-12-20
TRIVASCULAR INC.   US   Kink resistant endovascular graft   US7150758B2   US10384103A   2003-03-06

 

47


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC.   US   Radially expandable stent   US7147661B2   US10029559A   2001-12-20
TRIVASCULAR INC.   US   Method and apparatus for shape forming endovascular graft material   US7147455B2   US10868292A   2004-06-14
TRIVASCULAR INC.   US   Method for manufacturing an endovascular graft section   US7125464B2   US10029557A   2001-12-20
TRIVASCULAR INC.   US   Endovascular graft   US7081129B2   US10132754A   2002-04-24
TRIVASCULAR INC.   US   Endovascular graft joint and method for manufacture   US7090693B1   US10029584A   2001-12-20

 

48


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC.   US   Delivery system and method for expandable intracorporeal device   US7066951B2   US10419312A   2003-04-17
TRIVASCULAR INC.   US   Method and apparatus for shape forming endovascular graft material   US6776604B1   US10029570A   2001-12-20
TRIVASCULAR INC.   US   Delivery system and method for bifurcated endovascular graft   US6761733B2   US09917371A   2001-07-27
TRIVASCULAR INC.   US   Delivery system and method for endovascular graft   US6733521B2   US09834278A   2001-04-11
TRIVASCULAR INC.   US   Delivery system and method for expandable intracorporeal device   US6602280B2   US09774733A   2001-01-31

 

49


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC.   US   Endovascular graft   US6395019B2   US09133978A   1998-08-14
TRIVASCULAR INC   US   ENDOVASCULAR GRAFT   US20170348125A1   US15686214A   2017-08-25
TRIVASCULAR INC   US   ADVANCED ENDOVASCULAR GRAFT   US20170348087A1   US15686218A   2017-08-25
TRIVASCULAR INC   US   ENDOVASCUALR GRAFT FOR ANEURYSMS INVOLVING MAJOR BRANCH VESSELS   US20170296327A1   US15638559A   2017-06-30
TRIVASCULAR INC   US   SYSTEMS AND METHODS FOR GUIDEWIRE CROSSOVER FOR BIFURCATED PROSTHESES   US20170216064A1   US15491074A   2017-04-19

 

50


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC   US   Low Profile Stent Graft and Delivery System   US9987123   US15263469A   2016-09-13
TRIVASCULAR INC   US   BIFURCATED ENDOVASCULAR PROSTHESIS HAVING TETHERED CONTRALATERAL LEG   US20170035549A1   US15299542A   2016-10-21
TRIVASCULAR INC.   US   DELIVERY CATHETER FOR ENDOVASCULAR DEVICE   US20170035590A1   US15298166A   2016-10-19
TRIVASCULAR INC   US   PTFE LAYERS AND METHODS OF MANUFACTURING   US20160367354A1   US15251011A   2016-08-30
TRIVASCULAR INC   US   ENDOVASCULAR DELIVERY SYSTEM WITH AN IMPROVED RADIOPAQUE MARKER SCHEME   US10034787   US14970621A   2015-12-16

 

51


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC   US   NON-DEGRADABLE, LOW SWELLING, WATER SOLUBLE RADIOPAQUE HYDROGEL POLYMER   US20160193392A1   US15068415A   2016-03-11
TRIVASCULAR INC.   US   INTERNAL ILIAC PRESERVATION DEVICES AND METHODS   US9956101   US14958085A   2015-12-03
TRIVASCULAR INC.   US   STENT GRAFT DELIVERY SYSTEM WITH ACCESS CONDUIT   US20160113796A1   US14920828A   2015-10-22
TRIVASCULAR INC.   US   ENDOVASCULAR DELIVERY SYSTEM WITH FLEXIBLE AND TORQUEABLE HYPOTUBE   US20150265446A1   US14717080A   2015-05-20
TRIVASCULAR INC.   US   INFLATABLE OCCLUSION WIRE-BALLOON FOR AORTIC APPLICATIONS   US20150250481A1   US14643217A   2015-03-10

 

52


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC.   US   ADVANCED ENDOVASCULAR GRAFT AND DELIVERY SYSTEM   US20150164667A1   US14631818A   2015-02-25
TRIVASCULAR INC.   US   DURABLE STENT GRAFT WITH TAPERED STRUTS AND STABLE DELIVERY METHODS AND DEVICES   US20150157479A1   US14615337A   2015-02-05
TRIVASCULAR INC.   US   TANDEM MODULAR ENDOGRAFT   US20150088244A1   US14492674A   2014-09-22
TRIVASCULAR INC.   US   ENDOLEAK ISOLATION SLEEVES AND METHODS OF USE   US20150073523A1   US14481834A   2014-09-09
TRIVASCULAR INC.   US   GATE WIRE FOR CONTRALATERAL LEG ACCESS   US20140194970A1   US14151373A   2014-01-09

 

53


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC.   US   SAC LINER FOR ANEURYSM REPAIR   US20140194973A1   US14151195A   2014-01-09
TRIVASCULAR INC.   US   ASYMMETRIC STENT APPARATUS AND METHOD   US20140135899A1   US14157350A   2014-01-16
TRIVASCULAR INC.   US   LOW PROFILE STENT GRAFT AND DELIVERY SYSTEM   US20130268056A1   US13803033A   2013-03-14
TRIVASCULAR INC.   US   ADVANCED KINK RESISTANT STENT GRAFT   US9993328   US13803046A   2013-03-14
TRIVASCULAR INC.   US   VASCULAR GRAFT HAVING LIMITED END STRUCTURE   US20130096665A1   US13650705A   2012-10-12

 

54


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC.   US   INFLATABLE INTRALUMINAL GRAFT   US20120265290A1   US13532887A   2012-06-26
TRIVASCULAR INC.   US   ADVANCED ENDOVASCULAR GRAFT AND DELIVERY SYSTEM   US20120191174A1   US13297219A   2011-11-15
TRIVASCULAR INC.   US   SYSTEM AND METHOD OF PIVOTED STENT DEPLOYMENT   US20120083870A1   US13277117A   2011-10-19
TRIVASCULAR INC.   US   BARBED RADIALLY EXPANDABLE STENT WITH SLOTTED STRUTS   US20120016457A1   US13245652A   2011-09-26
TRIVASCULAR INC.   US   FILL TUBE MANIFOLD AND DELIVERY METHODS FOR ENDOVASCULAR GRAFT   US20110218609A1   US13024255A   2011-02-09

 

55


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC.   US   HINGED ENDOVASCULAR DEVICE   US20100331958A1   US12747499A   2010-09-07
TRIVASCULAR INC.   US   Inflatable Implant   US20100076481A1   US12628623A   2009-12-01
TRIVASCULAR INC.   US   METHOD OF DELIVERING ADVANCED ENDOVASCULAR GRAFT   US20100016943A1   US12566808A   2009-09-25
TRIVASCULAR INC.   US   MODULAR VASCULAR GRAFT FOR LOW PROFILE PERCUTANEOUS DELIVERY   US20090099649A1   US12245620A   2008-10-03
TRIVASCULAR INC.   US   ALIGNMENT STENT APPARATUS AND METHOD   US20090082845A1   US11861746A   2007-09-26

 

56


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC.   US   SYSTEM AND METHOD OF SECURING STENT BARBS   US20090082847A1   US11861731A   2007-09-26
TRIVASCULAR INC.   US   APPARATUS FOR SECURING STENT BARBS   US20090082841A1   US11861739A   2007-09-26
TRIVASCULAR INC.   US   PTFE LAYERS AND METHODS OF MANUFACTURING   US20090036971A1   US12250915A   2008-10-14
TRIVASCULAR INC.   US   PTFE LAYERS AND METHODS OF MANUFACTURING   US20090036973A1   US12250946A   2008-10-14
TRIVASCULAR INC.   US   Non-degradable, low swelling, water soluble radiopaque hydrogel polymer   US20060222596A1   US11097467A   2005-04-01

 

57


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC.   US   Hybrid modular endovascular graft   US20060224232A1   US11097718A   2005-04-01
TRIVASCULAR INC.   US   Delivery system and method for bifurcated graft   US20060009833A1   US11205793A   2005-08-15
TRIVASCULAR INC.   US   Methods, compositions and devices for embolizing body lumens   US20050158272A1   US11031311A   2005-01-07
TRIVASCULAR INC.   US   Endoluminal prosthesis endoleak management   US20050090804A1   US10691849A   2003-10-22
TRIVASCULAR INC.   US   Endovascular graft joint and method for manufacture   US20050027347A1   US10640368A   2003-08-13

 

58


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC.   US   Layered endovascular graft   US20040220664A1   US10803153A   2004-03-17
TRIVASCULAR INC.   US   Delivery system and method for bifurcated graft   US20040138734A1   US10686863A   2003-10-16
TRIVASCULAR INC.   US   Endovascular graft   US20030216802A1   US10289136A   2002-11-05
TRIVASCULAR INC.   US   Inflatable intraluminal graft   US20030225453A1   US10289137A   2002-11-05
TRIVASCULAR INC.   US   Advanced endovascular graft   US20030120338A1   US10091641A   2002-03-05

 

59


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC.   US   Delivery system and method for bifurcated graft   US20030004560A1   US10122474A   2002-04-11
TRIVASCULAR INC.   US   Layered endovascular graft   US20020010508A1   US09970576A   2001-10-04
TRIVASCULAR, INC.   US   Stent-graft with improved flexibility     15/568834   10/24/17
Trivascular, Inc.   US   Passive hemostatic sheath valve   US7901379   US11298285   12/9/05
Trivascular, Inc.   US   Fluid mixing apparatus and method   US7178978   US10658074   9/8/03

 

60


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

Trivascular, Inc.   US   Delivery system and method for expandable intracorporeal device   US6602280   US09774733   1/31/01
Trivascular, Inc.   US   Endovascular graft   US6395019   US09133978   8/14/98
Trivascular, Inc.   US   Layered endovascular graft   US6331191   US09200317   11/25/98
Trivascular, Inc.   US   Endovascular graft having longitudinally displaceable sections   US6132457   US09177295   10/22/98
Trivascular, Inc.   US   Low profile stent graft and delivery system     US15263469   9/13/16

 

61


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

Trivascular, Inc.   US   Delivery catheter for endovascular device     US15298166   10/19/16
Trivascular, Inc.   US   Bifurcated endovascular prosthesis having tethered contralateral leg     US15299542   10/21/16
Trivascular, Inc.   US   Ptfe layers and methods of manufacturing     US15251011   8/30/16
Trivascular, Inc.   US   Endovascular delivery system with an improved radiopaque marker scheme     US14970621   12/16/15
Trivascular, Inc.   US   Non-degradable, low swelling, water soluble radiopaque hydrogel polymer     US15068415   3/11/16

 

62


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

Trivascular, Inc.   US   Internal iliac preservation devices and methods     US14958085   12/3/15
Trivascular, Inc.   US   Stent graft delivery system with access conduit     US14920828   10/22/15
Trivascular, Inc.   US   Bifurcated endovascular prosthesis having tethered contralateral leg     US14823076   8/11/15
Trivascular, Inc.   US   Low profile stent and delivery system     US14923477   10/27/15
Trivascular, Inc.   US   Endovascular delivery system with flexible and torqueable hypotube     US14717080   5/20/15

 

63


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

Trivascular, Inc.   US   Inflatable occlusion wire-balloon for aortic applications     US14643217   3/10/15
Trivascular, Inc.   US   Advanced endovascular graft and delivery system     US14631818   2/25/15
Trivascular, Inc.   US   Durable stent graft with tapered struts and stable delivery methods and devices     US14615337   2/5/15
Trivascular, Inc.   US   Tandem modular endograft     US14492674   9/22/14
Trivascular, Inc.   US   Endoleak isolation sleeves and methods of use     US14481834   9/9/14

 

64


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

Trivascular, Inc.   US   Sac liner for aneurysm repair     US14151195   1/9/14
Trivascular, Inc.   US   Gate wire for contralateral leg access     US14151373   1/9/14
Trivascular, Inc.   US   Asymmetric stent apparatus and method     US14157350   1/16/14
Trivascular, Inc.   US   Low profile stent graft and delivery system     US13803033   3/14/13
Trivascular, Inc.   US   Advanced kink resistant stent graft     US13803046   3/14/13

 

65


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

Trivascular, Inc.   US   Vascular graft having limited end structure     US13650705   10/12/12
Trivascular, Inc.   US   Inflatable intraluminal graft     US13532887   6/26/12
Trivascular, Inc.   US   Advanced endovascular graft and delivery system     US13297219   11/15/01
Trivascular, Inc.   US   System and method of pivoted stent deployment     US13277117   10/19/11
Trivascular, Inc.   US   Barbed radially expandable stent with slotted struts     US13245652   9/26/11

 

66


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

Trivascular, Inc.   US   Fill tube manifold and delivery methods for endovascular graft     US13024255   2/9/11
Trivascular, Inc.   US   Hinged endovascular device     US12747499   9/7/10
Trivascular, Inc.   US   Inflatable implant     US12628623   12/1/09
Trivascular, Inc.   US   Method of delivering advanced endovascular graft     US12566808   9/25/09
Trivascular, Inc.   US   Modular vascular graft for low profile percutaneous delivery     US12245620   10/3/08

 

67


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

Trivascular, Inc.   US   System and method of securing stent barbs     US11861731   9/26/07
Trivascular, Inc.   US   Alignment stent apparatus and method     US11861746   9/26/07
Trivascular, Inc.   US   Apparatus for securing stent barbs     US11861739   9/26/07
Trivascular, Inc.   US   Ptfe layers and methods of manufacturing     US12250946   10/14/08
Trivascular, Inc.   US   Ptfe layers and methods of manufacturing     US12250915   10/14/08

 

68


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

Trivascular, Inc.   US   Ptfe layers and methods of manufacturing     US11106150   4/13/05
Trivascular, Inc.   US   Ptfe layers and methods of manufacturing     US11106131   4/13/05
Trivascular, Inc.   US   Hybrid modular endovascular graft     US11097718   4/1/05
Trivascular, Inc.   US   Non-degradable low swelling, water soluble radiopaque hydrogel polymer     US11097467   4/1/05
Trivascular, Inc.   US   Delivery system and method for bifurcated graft     US11205793   8/15/05

 

69


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

Trivascular, Inc.   US   Modular endovascular graft     US11077938   3/11/05
Trivascular, Inc.   US   Methods, compositions and devices for embolizing body lumens     US11031311   1/7/05
Trivascular, Inc.   US   Endoluminal prosthesis endoleak management     US10691849   10/22/03
Trivascular, Inc.   US   Endovascular graft joint and method for manufacture     US10640368   8/13/03
Trivascular, Inc.   US   Layered endovascular graft     US10803153   3/17/04

 

70


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

Trivascular, Inc.   US   Delivery system and method for bifurcated graft     US10686863   10/16/03
Trivascular, Inc.   US   Inflatable intraluminal graft     US10289137   11/5/02
Trivascular, Inc.   US   Endovascular graft     US10289136   11/5/02
Trivascular, Inc.   US   Advanced endovascular graft     US10091641   3/5/02
Trivascular, Inc.   US   Delivery system and method for bifurcated graft     US10122474   4/11/02

 

71


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

Trivascular, Inc.   US   Layered endovascular graft     US09970576   10/3/01
ENDOLOGIX INC.   US   STENT GRAFT SYSTEMS WITH RESTRAINTS IN CIRCUMFERENTIAL CHANNELS AND METHODS THEREOF     62/678961   5/31/2018
ENDOLOGIX INC.   US   PERCUTANEOUS METHOD AND DEVICE TO TREAT DISSECTIONS     15/429090   2/9/2017
NELLIX, INC.   US   SYSTEM AND METHODS FOR ENDOVASCULAR ANEURYSM TREATMENT   2018-0064566   15/682414   8/21/2017
TRIVASCULAR INC.   US   ENDOVASCULAR DELIVERY SYSTEM WITH AN IMPROVED RADIOPAQUE MARKER SCHEME     16/049560   7/30/2018

 

72


Execution Version

TRADEMARK SECURITY AGREEMENT

This TRADEMARK SECURITY AGREEMENT (this “ Trademark Security Agreement ”) is made this 9 th day of August, 2018, by and among the Grantors listed on the signature pages hereof (collectively, jointly and severally, “ Grantors ” and each individually “ Grantor ”), and DEERFIELD ELGX REVOLVER, LLC , a Delaware limited liability company, in its capacity as agent for each member of the Lender Group (in such capacity, together with its successors and assigns in such capacity, “ Agent ”).

W I T N E S S E T H :

WHEREAS, pursuant to that certain Credit Agreement dated as of August 9, 2018 (as amended, restated, supplemented, or otherwise modified from time to time, the “ Credit Agreement ”) by and among ENDOLOGIX, INC. , a Delaware corporation (“ Endologix ”), each of its direct and indirect Subsidiaries set forth on the signature pages thereto and any additional borrower that may thereafter be added to the Credit Agreement (individually as a “ Borrower ”, and collectively with any entities that become party thereto as Borrower and each of their successors and permitted assigns, the “ Borrowers ”), the lenders party thereto as “Lenders” (such Lenders, together with their respective successors and assigns in such capacity, each, individually, a “ Lender ” and, collectively, the “ Lenders ”), and Agent, the Lender Group has agreed to make certain financial accommodations available to the Borrowers from time to time pursuant to the terms and conditions thereof;

WHEREAS, the members of the Lender Group are willing to make the financial accommodations to the Borrowers as provided for in the Credit Agreement and the other Loan Documents, but only upon the condition, among others, that Grantors shall have executed and delivered to Agent, for the benefit of the Lender Group, that certain Guaranty and Security Agreement, dated as of August 9, 2018 (including all annexes, exhibits or schedules thereto, as from time to time amended, restated, supplemented or otherwise modified, the “ Guaranty and Security Agreement ”); and

WHEREAS, pursuant to the Guaranty and Security Agreement, Grantors are required to execute and deliver to Agent, for the benefit of the Lender Group, this Trademark Security Agreement.

NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each Grantor hereby agrees as follows:

1. DEFINED TERMS . All initially capitalized terms used but not otherwise defined herein have the meanings given to them in the Guaranty and Security Agreement or, if not defined therein, in the Credit Agreement, and this Trademark Security Agreement shall be subject to the rules of construction set forth in Section 1.04 of the Credit Agreement, which rules of construction are incorporated herein by this reference, mutatis mutandis .

2. GRANT OF SECURITY INTEREST IN TRADEMARK COLLATERAL . Each Grantor hereby unconditionally grants, assigns, and pledges to Agent, for the benefit of each member of the Lender Group, to secure the Secured Obligations, a continuing security interest (referred to in this Trademark Security Agreement as the “ Security Interest ”) in all of such Grantor’s right, title and interest in and to the following, whether now owned or hereafter acquired or arising (collectively, the “ Trademark Collateral ”):

(a) all of its Trademarks and Trademark Intellectual Property Licenses to which it is a party including those referred to on Schedule I ;

 

1


(b) all goodwill of the business connected with the use of, and symbolized by, each Trademark and each Trademark Intellectual Property License; and

(c) all products and proceeds (as that term is defined in the Code) of the foregoing, including any claim by such Grantor against third parties for past, present or future (i) infringement or dilution of any Trademark or any Trademarks exclusively licensed under any Intellectual Property License, including right to receive any damages, (ii) injury to the goodwill associated with any Trademark, or (iii) right to receive license fees, royalties, and other compensation under any Trademark Intellectual Property License.

3. SECURITY FOR SECURED OBLIGATIONS . This Trademark Security Agreement and the Security Interest created hereby secures the payment and performance of the Secured Obligations, whether now existing or arising hereafter. Without limiting the generality of the foregoing, this Trademark Security Agreement secures the payment of all amounts which constitute part of the Secured Obligations and would be owed by Grantors, or any of them, to Agent, the other members of the Lender Group or any of them, whether or not they are unenforceable or not allowable due to the existence of an Insolvency Proceeding involving any Grantor.

4. PROTECTION OF TRADEMARK SECURITY INTEREST BY GRANTORS . Each Grantor shall, at its sole cost, reasonable expense and risk, in connection with the operation of its business, comply with the requirements set forth in Section  6 of the Guaranty and Security Agreement in respect of the Trademark Collateral.

5. REPRESENTATIONS AND WARRANTIES . Each Grantor represents and warrants that:

(a) Schedule I hereto is a true, correct and complete list of all Trademarks and Trademark Intellectual Property Licenses in which each Grantor purports to have an ownership or license interest.

(b) Such Grantor has the legal right and authority to enter into this Trademark Security Agreement and perform its terms.

(c) If such Grantor amends its name, such Grantor shall provide copies of such amendment documentation to Agent and shall, if necessary, re-register such Grantor’s Trademarks and Trademark Intellectual Property Licenses with the appropriate Governmental Authority and shall execute and deliver such agreements or documentation as Agent shall reasonably request in writing to maintain a perfected first priority security interest in the Trademark Collateral subject to Permitted Liens.

6. SECURITY AGREEMENT . The Security Interest in the Collateral granted pursuant to this Trademark Security Agreement is granted in conjunction with the security interests granted to Agent, for the benefit of the Lender Group, pursuant to the Guaranty and Security Agreement. Each Grantor hereby acknowledges and affirms that the rights and remedies of Agent with respect to the Security Interest in the Trademark Collateral made and granted hereby are more fully set forth in the Guaranty and Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein. To the extent there is any inconsistency between this Trademark Security Agreement and the Guaranty and Security Agreement, the Guaranty and Security Agreement shall control.

7. AUTHORIZATION TO SUPPLEMENT . If any Grantor shall obtain rights to any new trademarks, the provisions of this Trademark Security Agreement shall automatically apply thereto. Each

 

2


Grantor shall notify Agent of applications filed for the registration of any Trademarks with the United States Trademark Office in accordance with Section 5.7(g) of the Guaranty and Security Agreement. Without limiting Grantors’ obligations under this Section, Grantors hereby authorize Agent unilaterally to modify this Trademark Security Agreement by amending Schedule I to include any such new trademark rights of each Grantor. Notwithstanding the foregoing, no failure to so modify this Trademark Security Agreement or amend Schedule I shall in any way affect, invalidate or detract from Agent’s continuing security interest in all Collateral, whether or not listed on Schedule I.

8. NO VIOLATION OF LOAN DOCUMENTS . The representations, warranties or covenants contained herein are supplemental to those representations, warranties and covenants contained in the other Loan Documents, and shall not be deemed to modify any such representation, warranty or covenant contained in any other Loan Document.

9. GRANTOR’S RIGHTS TO ENFORCE TRADEMARKS . Prior to Agent’s giving of notice to Grantor following the occurrence and during the continuance of an Event of Default, such Grantor shall have the exclusive right to sue for past, present and future infringement of the Trademark Collateral, including the right to seek injunctions and/or money damages, in an effort by such Grantor to protect the Trademark Collateral against encroachment by third parties, provided, however, that:

(a) Any money damages awarded or received by such Grantor on account of such suit (or the threat of such suit) shall constitute Trademark Collateral.

(b) Any damages recovered in any action pursuant to this Section, net of costs and attorneys’ fees reasonably incurred, shall be applied in accordance with the Credit Agreement and the Guaranty and Security Agreement.

(c) Following the occurrence and during the continuance of any Event of Default, Agent, by notice to any Grantor may terminate or limit such Grantor’s rights under this Section 9.

10. RIGHTS UPON DEFAULT . Upon the occurrence and during the continuance of any Event of Default, Agent may exercise all rights and remedies as provided for in the Guaranty and Security Agreement.

11. NO LIMITATION; LOAN DOCUMENTS . This Trademark Security Agreement has been executed and delivered by each Grantor for the purpose of recording the security interest granted to Agent with respect to the Trademark Collateral with the United States Trademark Office. The security interest granted hereby has been granted as a supplement to, and not in limitation of, the security interest granted to Agent, for the benefit of the Lender Group, under the Guaranty and Security Agreement and the other Loan Documents. The other Loan Documents (and all rights and remedies of Grantor, Agent, and Lenders thereunder) shall remain in full force and effect in accordance with their terms.

12. TERMINATION; RELEASE OF TRADEMARK COLLATERAL . This Trademark Security Agreement and all obligations of each Grantor and Agent hereunder shall terminate on the date upon which the Obligations have been Paid in Full. Upon termination of this Trademark Security Agreement, Agent shall, at the reasonable expense of the Grantor, take such actions required by the Credit Agreement or the Guaranty and Security Agreement or as otherwise reasonably requested by Grantor to release its security interest in the Trademark Collateral.

 

 

3


13. BINDING EFFECT; BENEFITS . This Trademark Security Agreement shall be binding upon each Grantor and its successors and assigns, and shall inure to the benefit of Agent, Lenders and their respective successors and assigns.

14. COUNTERPARTS . This Trademark Security Agreement is a Loan Document. This Trademark Security Agreement may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, shall be deemed to be an original, and all of which, when taken together, shall constitute but one and the same Trademark Security Agreement. Delivery of an executed counterpart of this Trademark Security Agreement by telefacsimile or other electronic method of transmission shall be equally as effective as delivery of an original executed counterpart of this Trademark Security Agreement. Any party delivering an executed counterpart of this Trademark Security Agreement by telefacsimile or other electronic method of transmission also shall deliver an original executed counterpart of this Trademark Security Agreement but the failure to deliver an original executed counterpart shall not affect the validity, enforceability, and binding effect of this Trademark Security Agreement.

15. CHOICE OF LAW AND VENUE, JURY TRIAL WAIVER, AND JUDICIAL REFERENCE PROVISION . THIS TRADEMARK SECURITY AGREEMENT SHALL BE SUBJECT TO THE PROVISIONS REGARDING CHOICE OF LAW AND VENUE, JURY TRIAL WAIVER, AND JUDICIAL REFERENCE SET FORTH IN SECTIONS 8.11 AND 8.12 OF THE GUARANTY AND SECURITY AGREEMENT, AND SUCH PROVISIONS ARE INCORPORATED HEREIN BY THIS REFERENCE, MUTATIS MUTANDIS .

[signature page follows]

 

4


IN WITNESS WHEREOF, the parties hereto have caused this Trademark Security Agreement to be executed and delivered as of the day and year first above written.

 

GRANTORS:     ENDOLOGIX, INC.
    By:  

/s/ Vaseem Mahboob

    Name:   Vaseem Mahboob
    Title:   Chief Financial Officer
    TRIVASCULAR, INC.
    By:  

/s/ Vaseem Mahboob

    Name:   Vaseem Mahboob
    Title:   Chief Financial Officer and Secretary

 

[SIGNATURE PAGE TO TRADEMARK SECURITY AGREEMENT]


IN WITNESS WHEREOF, the parties hereto have caused this Trademark Security Agreement to be executed and delivered as of the day and year first above written.

 

   

ACCEPTED AND ACKNOWLEDGED BY:

 

AGENT:    

DEERFIELD ELGX REVOLVER, LLC

by: Deerfield Management Company, L.P. (Series C), Manager

By: Flynn Management LLC, General Partner

    By:  

/s/ David J. Clark

   

Name:

Title:

 

David J. Clark

Authorized Signatory

 

6


SCHEDULE I

to

TRADEMARK SECURITY AGREEMENT

Trademark Registrations/Applications

 

Grantor

  

Country

  

Mark

   Registration No.    Registration Date
Endologix, Inc.    USA    DURAPLY    5433696    3/27/18
Endologix, Inc.    USA    INTELIX    5059968    10/11/16
Endologix, Inc.    USA    EVAS FORWARD    5306786    10/10/17
Endologix, Inc.    USA    VELA    5296578    9/26/17
Endologix, Inc.    USA    ANGIOTIP    5205176    5/16/17
Endologix, Inc.    USA    ACTIVESEAL    5396605    2/6/18
Endologix, Inc.    USA    INNOVATION THAT EMPOWERS    4841631    10/27/15
Endologix, Inc.    USA    INNOVATION TAKING SHAPE    4220343    10/9/12
Endologix, Inc.    USA    XPAND    4168563    7/3/12
Endologix, Inc.    USA    AFX    4214460    9/25/12
Endologix, Inc.    USA    INTUITRAK DELIVERY SYSTEM    3649866    7/7/09
Endologix, Inc.    USA    INTUITRAK    3649757    7/7/09
Endologix, Inc.    USA    NELLIX    3880178    11/23/10
Endologix, Inc.    USA    SUREPASS    3593259    3/17/09
Endologix, Inc.    USA    POWERLINK XL    3573999    2/10/09
Endologix, Inc.    USA    POWERLINK    2456038    5/29/01
Endologix, Inc.    USA    ENDOLOGIX    2257799    6/29/99
TriVascular, Inc.    USA    OVATION ALTO    5195890    5/2/17
TriVascular, Inc.    USA    CUSTOMSEAL    4732342    5/5/15
TriVascular, Inc.    USA    OVATION PRIME    4452625    12/17/13
TriVascular, Inc.    USA    OVATION PRIME ABDOMINAL STENT GRAFT SYSTEM    4449077    12/10/13
TriVascular, Inc.    USA    TRIVASCULAR    4395789    9/3/13
TriVascular, Inc.    USA    OVATION    4440468    11/26/13
TriVascular, Inc.    USA    TRIVASCULAR    2867015    7/27/04


SCHEDULE 3

GRANTOR INFORMATION

 

GRANTOR
(exact legal name)

  

STATE/COUNTRY
OF
ORGANIZATION

  

FEDERAL
EMPLOYER
IDENTIFICATION
NUMBER

  

CHIEF EXECUTIVE
OFFICE

  

ORGANIZATIONAL
IDENTIFICATION
NUMBER

Endologix, Inc.    Delaware    68-0328265    2 Musick, Irvine, County
of Orange, CA 92618 U.S.A.
   2338745
CVD/RMS Acquisition Corp.    Delaware    33-0928438    2 Musick, Irvine, County
of Orange, CA 92618 U.S.A.
   2955166
RMS/Endologix Sideways Merger Corp    Delaware    03-0512974    2 Musick, Irvine, County
of Orange, CA 92618 U.S.A.
   3530477
Nellix, Inc.    Delaware    94-3398416    2 Musick, Irvine, County
of Orange, CA 92618 U.S.A.
   3359980
TriVascular Technologies, Inc.    Delaware    87-0807313    3910 Brickway Blvd.,
County of Santa Rosa,
Sonoma, CA 95403 U.S.A.
   4387054
TriVascular, Inc.    California    68-0402620    3910 Brickway Blvd.,
Santa Rosa, County of
Sonoma, CA 95403 U.S.A.
   C2065374
Endologix
Canada, LLC
   Delaware    47-2442872    3910 Brickway Blvd.,
Santa Rosa, County of
Sonoma, CA 95403 U.S.A.
   5647226
TriVascular Sales LLC    Texas    46-0859179    3910 Brickway Blvd.,
Santa Rosa, County of
Sonoma, CA 95403 U.S.A.
   801644988


SCHEDULE 4

PLACES OF BUSINESS / LOCATION OF COLLATERAL

 

Grantor

  

Location

  

Specify Whether
Location Has
(i) Inventory
and/or Equipment,
(ii) Books and
Records, or (iii) Both

  

Interest

  

Lessor/Property

Owner/Lessee

Endologix, Inc.    2 Musick, Irvine, County of Orange, CA 92618 U.S.A.    Both    Lease    The Northwestern Mutual Life Insurance Company, att: William A. Budge, 19 Hammond, Suite 501, Irvine, California 92618
Endologix, Inc.    33 & 35 Hammond, Irvine, County of Orange, CA 92618 U.S.A    Inventory and/or Equipment    Lease    The Northwestern Mutual Life Insurance Company, att: William A. Budge, 19 Hammond, Suite 501, Irvine, California 92618
Endologix, Inc.   

378 Commercial Street, Malden, MA 02148

 

165 Chubb Avenue, Lyndhurst, NJ 07071

 

1130 Commerce Blvd, Swedesboro, NJ 08085

 

2250 Outerloop Drive, Louisville, KY 40219

   Inventory and/or Equipment    Third Party Warehouse    UPS
Endologix, Inc.    54 Yangcheon-ro, Gangseo-gu, Seoul 07522    Inventory and/or Equipment (no other Collateral is located at this location)    Third Party Warehouse    TNT Express Korea


Grantor

  

Location

  

Specify Whether
Location Has
(i) Inventory
and/or Equipment,
(ii) Books and
Records, or (iii) Both

  

Interest

  

Lessor/Property

Owner/Lessee

Endologix, Inc.    10 Anson Road #21-04 & #21-04A International Plaza Singapore 079903    Inventory and/or
Equipment (no other Collateral is located at this location)
   Occupied    Endologix Singapore Private Limited
Endologix, Inc.    A-311, M-Sate, 114 Beopwon-ro, Songpa-gu, Seoul, South Korea    Inventory and/or
Equipment (no other Collateral is located at this location)
   Occupied    N.A.
Endologix, Inc.    Grantor and each Guarantor’s sales representatives hold Trunk Inventory in their possession for sales calls and procedures, which Trunk Inventory is not held at a specific location or locations.   

Inventory and/or
Equipment (no other Collateral is located at this location)

 

  

N.A.

 

  

N.A.

 

  

Certain Inventory of the Grantor and each Guarantor is held by numerous third parties on a consignment basis at various locations.

  

Inventory and/or
Equipment (no other Collateral is located at this location)

  

N.A.

  

N.A.


Grantor

  

Location

  

Specify Whether
Location Has
(i) Inventory
and/or Equipment,
(ii) Books and
Records, or (iii) Both

  

Interest

  

Lessor/Property

Owner/Lessee

CVD/RMS Acquisition Corp.    2 Musick, Irvine, County of Orange, CA 92618 U.S.A.    Books and Records    Occupied    The Northwestern Mutual Life Insurance Company, attn: William A. Budge, 19 Hammond, Suite 501, Irvine, California 92618
Nellix, Inc.    2 Musick, Irvine, County of Orange, CA 92618 U.S.A.    Books and Records    Occupied    The Northwestern Mutual Life Insurance Company, attn: William A. Budge, 19 Hammond, Suite 501, Irvine, California 92618
RMS/Endologix Sideways Merger Corp.    2 Musick, Irvine, County of Orange, CA 92618 U.S.A.    Books and Records    Occupied    The Northwestern Mutual Life Insurance Company, attn: William A. Budge, 19 Hammond, Suite 501, Irvine, California 92618
TriVascular Technologies,
Inc.
   3910 Brickway Blvd., Santa Rosa, County of Sonoma, CA 95403 U.S.A.    Books and Records    Occupied    Sonoma Airport Properties LLC
TriVascular, Inc.    3910 Brickway Blvd., Santa Rosa, County of Sonoma, CA 95403 U.S.A.    Both    Lease    Sonoma Airport Properties LLC
TriVascular Sales LLC    3910 Brickway Blvd., Santa Rosa, County of Sonoma, CA 95403 U.S.A.    Books and Records    Occupied    Sonoma Airport Properties LLC
Endologix Canada, LLC    3910 Brickway Blvd., Santa Rosa, County of Sonoma, CA 95403 U.S.A.    Books and Records    Occupied    Sonoma Airport Properties LLC


SCHEDULE 5

COMMERCIAL TORT CLAIMS

None.


SCHEDULE 6

ACCOUNTS

 

ENTITY    COUNTRY    ACCT         CURR    BANK    USE
Endologix Inc    US    XXXXX1702    USD       Bank of America    Operating account
Endologix Inc    US    XXXXX1689    USD       Bank of America    Payroll account
Endologix Inc    US    XXXXX5279    USD       Wells Fargo    Old Operating account
Endologix Inc    US    XXXXX5311    USD       Wells Fargo    Old payroll account
Endologix Inc    US    XXXXX3910    USD       Bank of America    Lockbox account
Endologix Inc    US    XXXXX4066    USD       Bank of America    Credit Card Cash Collateral account
Trivascular Inc    US    XXXXX5539    USD       Silicon Valley Bank    Operating account
Trivascular Inc    The Netherlands    XXXXX8640    EUR       KBC Bank NV Nederland    Currency account
Trivascular Inc    UK London    XXXXX8709    GBP       National Westminster Bank    Currency account
Trivascular Sales LLC    US    XXXXX7400    USD       Silicon Valley Bank    Payroll account
Endologix Canada LLC    Canada    XXXXX7912    CAD       Bank of Montreal    Operating account


SCHEDULE 7

REAL PROPERTY

None.


SCHEDULE 8

COPYRIGHTS

None.


SCHEDULE 9

INTELLECTUAL PROPERTY LICENSES

 

  1.

Inbound License Agreement, dated as of February 22, 2006, by and between Incept LLC and Nellix, Inc.

 

  2.

Inbound Amendment No. 1. to License Agreement, dated as of April 30, 2012, by and between Incept LLC and Nellix, Inc.

 

  3.

Inbound Amendment No. 2 to License Agreement, dated as of December 3, 2014, by and between Incept LLC and Nellix, Inc.

 

  4.

Inbound Master License Agreement, dated as of May 5, 2008, by and between SurModics, Inc. and Endologix, Inc.

 

  5.

Inbound Development and OEM Device Supply Agreement, dated as of August 5, 2015, by and between Bard Peripheral Vascular, Inc. and Endologix, Inc.

 

  6.

Inbound License Agreement, dated as of June 22, 2011, by and between NorMedix, LLC and Endologix, Inc.

 

  7.

Inbound Settlement and Patent License Agreement, dated as of March 17, 2016, by and between LifePort Sciences, LLC and Endologix, Inc.

 

  8.

Inbound License Agreement, dated as of July 23, 2013, by and between Thomas L. Fogarty and Endologix, Inc.

 

  9.

Inbound License Agreement, dated as of March 28, 2008, by and between Trivascular, Inc. (formerly Trivascular 2, Inc.) and Boston Scientific Scimed, Inc. and Endovascular Technologies, Inc.


SCHEDULE 10

PATENTS

See attached.


PATENT SCHEDULE

 

Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC.   US   Stent graft   US9757262B2   US13943246A   2013-07-16
ENDOLOGIX INC.   US   Catheter system and methods of using same   US9700701B2   US13544426A   2012-07-09
ENDOLOGIX INC.   US   Catheter system and methods of using same   US9687374B2   US15379268A   2016-12-14
ENDOLOGIX INC.   US   Percutaneous method and device to treat dissections   US9579103B2   US12771711A   2010-04-30
ENDOLOGIX INC.   US   Catheter system and methods of using same   US9549835B2   US14462485A   2014-08-18


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC.   US   Method and system for treating aneurysms   US9415195B2   US13441762A   2012-04-06
ENDOLOGIX INC.   US   Devices and methods to treat vascular dissections   US9393100B2   US13988175A   2013-05-17
ENDOLOGIX INC.   US   Method for forming materials in situ within a medical device   US9289536B2   US14201332A   2014-03-07
ENDOLOGIX INC.   US   Apparatus and method of placement of a graft or graft system   US9149381B2   US14172126A   2014-02-04
ENDOLOGIX INC.   US   Stent graft   US8821564B2   US13397952A   2012-02-16
ENDOLOGIX INC.   US   Apparatus and methods for repairing aneurysms   US8814928B2   US12616928A   2009-11-12


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC.   US   Catheter system and methods of using same   US8808350B2   US13408952A   2012-02-29
ENDOLOGIX INC.   US   Graft systems having semi-permeable filling structures and methods for their use   US8801768B2   US13355705A   2012-01-23
ENDOLOGIX INC   US   Bifurcated graft deployment systems and methods   US8764812B2   US13745682A   2013-01-18
ENDOLOGIX INC.   US   Apparatus and method of placement of a graft or graft system   US8672989B2   US13546950A   2012-07-11
ENDOLOGIX INC.   US   Graft deployment system   US8568466B2   US13269332A   2011-10-07
ENDOLOGIX INC.   US   Dual concentric guidewire and methods of bifurcated graft deployment   US8523931B2   US11623022A   2007-01-12


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC.   US   Stent graft   US8491646B2   US12837398A   2010-07-15
ENDOLOGIX INC.   US   Endolumenal vascular prosthesis with neointima inhibiting polymeric sleeve   US8377110B2   US10820455A   2004-04-08
ENDOLOGIX INC.   US   Bifurcated graft deployment systems and methods   US8357192B2   US13046541A   2011-03-11
ENDOLOGIX INC.   US   Bifurcated graft deployment systems and methods   US8236040B2   US12101863A   2008-04-11
ENDOLOGIX INC.   US   Catheter system and methods of using same   US8216295B2   US12496446A   2009-07-01
ENDOLOGIX INC.   US   Apparatus and method of placement of a graft or graft system   US8221494B2   US12390346A   2009-02-20


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC.   US   Methods and systems for endovascular aneurysm treatment   US8182525B2   US12421297A   2009-04-09
ENDOLOGIX INC.   US  

Single puncture bifurcation graft

deployment system

  US8167925B2   US12732095A   2010-03-25
ENDOLOGIX INC.   US   Bifurcation graft deployment catheter   US8147535B2   US11189101A   2005-07-25
ENDOLOGIX INC.   US   Material for creating multi-layered films and methods for making the same   US8133559B2   US13100483A   2011-05-04
ENDOLOGIX INC.   US   Stent graft   US8118856B2   US12844266A   2010-07-27
ENDOLOGIX INC.   US   Graft systems having filling structures supported by scaffolds and methods for their use   US8048145B2   US11413460A   2006-04-28


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC.   US   Graft deployment system   US8034100B2   US10722367A   2003-11-25
ENDOLOGIX INC.   US   Material for creating multi-layered films and methods for making the same   US7951448B2   US12858274A   2010-08-17
ENDOLOGIX INC   US   Self expanding bifurcated endovascular prosthesis   US7892277B2   US11417883A   2006-05-03
ENDOLOGIX INC.   US   Material for creating multi-layered films and methods for making the same   US7790273B2   US11752750A   2007-05-23
ENDOLOGIX INC.   US   Devices for repairing aneurysms   US7682383B2   US10481386A   2004-06-14
ENDOLOGIX INC.   US   System and methods for endovascular aneurysm treatment   US7666220B2   US11482503A   2006-07-07


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC.   US   Methods and systems for endovascular aneurysm treatment   US7530988B2   US11187471A   2005-07-22
ENDOLOGIX INC   US   Self expanding bifurcated endovascular prosthesis   US7520895B2   US10119525A   2002-04-08
ENDOLOGIX INC   US   Bifurcation graft deployment catheter   US6953475B2   US10675060A   2003-09-30
ENDOLOGIX INC.   US   Implantable vascular graft   US6733523B2   US09891620A   2001-06-26
ENDOLOGIX INC   US  

Single puncture bifurcation graft

deployment system

  US6663665B2   US09795993A   2001-02-28
ENDOLOGIX INC.   US   Bifurcation graft deployment catheter   US6660030B2   US09747094A   2000-12-22


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC   US   Endoluminal vascular prosthesis   US6508835B1   US09723979A   2000-11-28
ENDOLOGIX INC.   US   Bifurcation graft deployment catheter   US6500202B1   US09525778A   2000-03-15
ENDOLOGIX INC.   US   Dual wire placement catheter   US6440161B1   US09348356A   1999-07-07
ENDOLOGIX INC.   US  

Single puncture bifurcation graft

deployment system

  US6261316B1   US09266661A   1999-03-11
ENDOLOGIX INC.   US   Articulating bifurcation graft   US6197049B1   US09251363A   1999-02-17
ENDOLOGIX INC.   US   Endoluminal vascular prosthesis   US6187036B1   US09210280A   1998-12-11


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC.   US   Segmented stent for flexible stent delivery system   US6187034B1   US09229856A   1999-01-13
ENDOLOGIX INC.   US   Endoluminal vascular prosthesis   US6077296A   US0934689A   1998-03-04
ENDOLOGIX INC.   US   Stent delivery system featuring a flexible balloon   US6022359A   US09229519A   1999-01-13
ENDOLOGIX INC.   US   Radially expandable stent featuring accordion stops   US5931866A   US09028305A   1998-02-24
ENDOLOGIX INC.   US   DUAL INFLATABLE ARTERIAL PROSTHESIS   US20180021045A1   US15540246A   2017-06-27
ENDOLOGIX INC.   US   CATHETER SYSTEM AND METHODS OF USING SAME   US20170304098A1   US15632064A   2017-06-23


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC.   US   CATHETER SYSTEM AND METHODS OF USING SAME   US20170296791A1   US15639028A   2017-06-30
ENDOLOGIX INC   US   APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM   US20170266025A1   US15610242A   2017-05-31
ENDOLOGIX INC.   US   MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES   US20170239035A1   US15310198A   2016-11-10
ENDOLOGIX INC.   US   METHODS AND SYSTEMS FOR ANEURYSM TREATMENT USING FILLING STRUCTURES   US20170238937A1   US15438682A   2017-02-21
ENDOLOGIX INC   US   APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM   US20170128246A1   US15414499A   2017-01-24
ENDOLOGIX INC   US   METHOD AND SYSTEM FOR TREATING ANEURYSMS   US20170007263A1   US15205365A   2016-07-08


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC.   US   METHOD FOR FORMING HYDROGELS AND MATERIALS THEREFOR   US20160367731A1   US15256462A   2016-09-02
ENDOLOGIX INC.   US   DEVICES AND METHODS TO TREAT VASCULAR DISSECTIONS   US20160302798A1   US15194159A   2016-06-27
ENDOLOGIX INC.   US   SYSTEMS AND METHODS FOR FORMING MATERIALS IN SITU WITHIN A MEDICAL DEVICE   US20160030051A1   US14776385A   2015-09-14
ENDOLOGIX INC   US   APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM   US20150366688A1   US14840428A   2015-08-31
ENDOLOGIX INC.   US   METHOD AND SYSTEM FOR TREATING ANEURYSMS   US20150250989A1   US14717938A   2015-05-20
ENDOLOGIX INC.   US   FENESTRATED PROSTHESIS   US20150173923A1   US14581675A   2014-12-23


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC.   US   Apparatus and Methods for Repairing Aneurysms   US20150012081A1   US14330812A   2014-07-14
ENDOLOGIX INC.   US   STENT GRAFT   US9907642   US14461308A   2014-08-15
ENDOLOGIX INC   US   ENDOLUMENAL VASCULAR PROSTHESIS WITH NEOINTIMA INHIBITING POLYMERIC SLEEVE   US20130253638A1   US13731908A   2012-12-31
ENDOLOGIX INC.   US   Methods and Systems for Treating Aneurysms   US20120184982A1   US13354094A   2012-01-19
ENDOLOGIX INC.   US   APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM   US20120109279A1   US13287907A   2011-11-02
ENDOLOGIX INC.   US   FILLING STRUCTURE FOR A GRAFT SYSTEM AND METHODS OF USE   US20110276078A1   US12966852A   2010-12-13


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC   US   SELF EXPANDING BIFURCATED ENDOVASCULAR PROSTHESIS   US20110224782A1   US13027077A   2011-02-14
ENDOLOGIX INC.   US   ENDOLUMINAL VASCULAR PROSTHESIS   US20110218617A1   US13039157A   2011-03-02
ENDOLOGIX INC   US   APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM   US20110054587A1   US12769546A   2010-04-28
ENDOLOGIX INC   US   IMPLANTABLE VASCULAR GRAFT   US20100318174A1   US12860280A   2010-08-20
ENDOLOGIX INC   US   IMPLANTABLE VASCULAR GRAFT   US20100318181A1   US12860310A   2010-08-20
ENDOLOGIX INC.   US   UTILIZATION OF MURAL THROMBUS FOR LOCAL DRUG DELIVERY INTO VASCULAR TISSUE   US20100261662A1   US12757900A   2010-04-09


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC   US   GRAFT DEPLOYMENT SYSTEM   US20100179636A1   US12726257A   2010-03-17
ENDOLOGIX INC.   US   STENT GRAFT DELIVERY SYSTEM   US20100036360A1   US12429474A   2009-04-24
ENDOLOGIX INC.   US   DOCKING APPARATUS AND METHODS OF USE   US20090319029A1   US12478208A   2009-06-04
ENDOLOGIX INC.   US   GRAFT ENDOFRAME HAVING AXIALLY VARIABLE CHARACTERISTICS   US20100004728A1   US12371087A   2009-02-13
ENDOLOGIX INC.   US   METHOD AND AGENT FOR IN-SITU STABILIZATION OF VASCULAR TISSUE   US20090155337A1   US12269677A   2008-11-12
ENDOLOGIX INC.   US   STENT   US20090105806A1   US12257149A   2008-10-23


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC.   US   Multi-segmented graft deployment system   US20080071343A1   US11522292A   2006-09-15
ENDOLOGIX INC   US   IMPLANTABLE VASCULAR GRAFT   US20070299497A1   US11764715A   2007-06-18
ENDOLOGIX INC.   US   Methods and systems for aneurysm treatment using filling structures   US20070150041A1   US11444603A   2006-05-31
ENDOLOGIX INC   US   ENDOLUMINAL VASCULAR PROSTHESIS   US20070112412A1   US11623679A   2007-01-16
ENDOLOGIX INC.   US   Method and apparatus for decompressing aneurysms   US20070078506A1   US11580201A   2006-10-12
ENDOLOGIX INC.   US   Method and apparatus for decompressing aneurysms   US20050245891A1   US11104303A   2005-04-12


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC.   US   Vascular stent-graft apparatus   US20040167607A1   US10787404A   2004-02-24
ENDOLOGIX INC.   US   Stent-graft with positioning anchor   US20040116997A1   US10668901A   2003-09-22
ENDOLOGIX INC.   US   Flexible vascular graft   US20010025195A1   US09728582A   2000-12-01
ENDOLOGIX INC   US   MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES   US20170239035A1   US15310198A   2016-11-10
ENDOLOGIX INC   US   DUAL INFLATABLE ARTERIAL PROSTHESIS   US20180021045A1   US15540246A   2017-06-27
ENDOLOGIX INC   US   ENDOLUMINAL PROSTHESIS SYSTEMS AND METHODS     US15737223   2017-12-15


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC   US   Systems and Methods with Stents and Filling Structure     62/382207   2016-08-31
ENDOLOGIX INC   US   STENTS, GRAFTS, DELIVERY SYSTEMS, AND METHODS     62/481560   2017-04-04
ENDOLOGIX INC   US   ENDOVASCULAR SYSTEMS, DEVICES, AND METHODS ALLOWING FOR BRANCH DEVICE PLACEMENT IN POCKET OF MAIN GRAFT     62/489213   2017-04-24
ENDOLOGIX INC   US   ENDOVASCULAR GRAFT SYSTEMS AND METHODS FOR DEPLOYMENT IN MAIN AND BRANCH ARTERIES     62/529669   2017-07-07
ENDOLOGIX INC   US   STENT GRAFTS AND METHODS OF ENHANCING FLEXIBILITY OF STENT GRAFTS BY THERMAL PLEATING     62/532737   2017-07-14
ENDOLOGIX INC   US   STENT GRAFT     15/911629   2018-03-05


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC   US   INTERNAL ILIAC PRESERVATION DEVICES AND METHODS     15/965649   2018-04-
ENDOLOGIX INC   US  

MODULATION OF INFLAMMATORY

RESPONSE FOLLOWING

ENDOVASCULAR TREATMENT

    62/661569   2018-4-23
ENDOLOGIX INC   US   ADVANCED KINK RESISTANT STENT GRAFT     16/005269   2018-6-11
ENDOLOGIX INC   US   LOW PROFILE STENT GRAFT AND DELIVERY SYSTEM     15/985572   2018-5-21
ENDOLOGIX INC   US   SYSTEMS AND METHODS WITH STENT AND FILLING STRUCTURE     15/774511   2017-8-30
ENDOLOGIX INC   US  

LONGITUDINALLY EXTENDABLE

STENT GRAFT SYSTEMS AND

METHODS

    15/774548   2018-1-23


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC   US  

GRAFT SYSTEMS HAVING FILLING

STRUCTURES SUPPORTED BY

SCAFFOLDS AND METHODS FOR THEIR USE

    16/035497   2018-7-13
ENDOLOGIX INC   US   PRE-FIXATION DEVICE FOR NELLIX AND OTHER EVAS DEVICES     62/678956   2018-5-31
ENDOLOGIX INC   US   SYSTEMS AND METHODS WITH FENESTRATED GRAFT AND FILLING STRUCTURE     16/066595  
ENDOLOGIX INC   US  

MODULATION OF INFLAMMATORY

RESPONSE FOLLOWING

ENDOVASCULAR TREATMENT

    62/661569   2018-4-23
ENDOLOGIX INC.   US   FENESTRATED PROSTHESIS   US8945202   12/769581   2015-2-3
ENDOLOGIX INC.   US   Fenestrated prosthesis   US8945202   12/769581   4/28/10


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX, INC.   US  

Bifurcated vascular graft deployment

device

  US6210422   09/505038   2/16/00
ENDOLOGIX, INC.   US   Method of deploying bifurcated vascular graft   US6156063   09/086247   5/28/98
ENDOLOGIX, INC.   US  

Bifurcated vascular graft deployment

device

  US6090128   08/802478   2/20/97
ENDOLOGIX, INC.   US  

Endovascular prosthesis with improved

sealing means for aneurysmal arterial

disease and method of use

  US5665117   08/620072   3/21/96
ENDOLOGIX, INC.   US   Locking assembly for coupling guidewire to delivery system     15/317905   12/9/16
Endologix, Inc. and The Cleveland Clinic Foundation   US   Fenestrated prosthesis   US8945202   US12769581   4/28/10


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

Endologix, Inc.   US  

Single puncture bifurcation graft

deployment system

  US7691135   US10690227   10/21/03
Endologix, Inc.   US   Bifurcated vascular graft and method and apparatus for deploying same   US6951572   US10639255   8/12/03
Endologix, Inc.   US   Radiation delivery balloon catheter   US6699170   US09688396   10/16/00
Endologix, Inc.   US   Dual wire placement catheter   US6689157   US10035729   12/21/01
Endologix, Inc.   US   Method for delivering radiation to an intraluminal site in the body   US6685618   US09944649   8/31/01
Endologix, Inc.   US   Radiation delivery catheters and dosimetry methods   US6491619   US09648563   8/25/00


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

Endologix, Inc.   US   Endoluminal vascular prosthesis   US6331190   US09483411   1/14/00
Endologix, Inc.   US  

Bifurcated vascular graft deployment

device

  US6210422   US09505038   2/16/00
Endologix, Inc.   US   Method of deploying bifurcated vascular graft   US6156063   US09086247   5/28/98
Endologix, Inc.   US  

Bifurcated vascular graft deployment

device

  US6090128   US08802478   2/20/97
Endologix, Inc.   US   Axially non-contracting flexible radially expandable stent   US6083259   US09192803   11/16/98
Endologix, Inc.   US  

Endovascular prosthesis with improved

sealing means for aneurysmal arterial

disease and method of use

  US5665117   US08620072   3/21/96


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

Endologix, Inc.   US   Apparatus and method of placement of a graft or graft system     US14172126   2/4/14
Endologix, Inc. and The Cleveland Clinic Foundation   US   Apparatus and method of placement of a graft or graft system     US12769506   4/28/10
Endologix, Inc.   US   Stent graft delivery system     US12429474   4/24/09
ENDOLOGIX INC   WO   ENDOLUMINAL PROSTHESIS SYSTEMS AND METHODS   WO2016210363A1   PCT/US2016/039414   2016-06-24
ENDOLOGIX INC   JP   MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES   JP2017517321A   JP2016569901   2015-05-05
ENDOLOGIX INC   CN   Endoluminal Prosthesis Systems and Methods     201680037099.X   2017-12-22


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC   JP   DUAL INFLATABLE ARTERIAL PROSTHESIS     2017-534803   2017-06-28
ENDOLOGIX INC   US   ENDOLUMINAL DEVICE AND POLYMER     62/575827   2017-10-23
TRIVASCULAR INC   US   Advanced Endovascular Graft   US9788934B2   US14799656A   2015-07-15
ENDOLOGIX INC   WO   DUAL INFLATABLE ARTERIAL PROSTHESIS   WO2016109757A1   PCT/US2015/068204   2015-12-30
ENDOLOGIX INC   WO   SYSTEMS AND METHODS WITH FENESTRATED GRAFT AND FILLING STRUCTURE   WO2017117068A1   PCT/US2016/068575   2016-12-23
ENDOLOGIX INC   WO   SYSTEMS AND METHODS WITH GRAFT BODY, INFLATABLE FILL CHANNEL, AND FILLING STRUCTURE   WO2017197313A1   PCT/US2017/032490   2017-05-12


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC   PCT   SYSTEMS AND METHODS WITH STENT AND FILLING STRUCTURE     PCT/US2017/049482   2017-08-30
ENDOLOGIX INC   PCT   LONGITUDINALLY EXTENDABLE STENT GRAFT SYSTEMS AND METHODS     PCT/US2018/014920   2018-01-23
ENDOLOGIX INC   PCT   STENT GRAFTS AND METHODS OF ENHANCING FLEXIBILITY OF STENT GRAFTS BY THERMAL PLEATING     PCT/US2018/042158   2018-7-13
ENDOLOGIX INC   PCT  

ENDOVASCULAR SYSTEMS,

DEVICES, AND METHODS

ALLOWING FOR BRANCH DEVICE PLACEMENT IN CHANNEL OF MAIN GRAFT

    PCT/US2018/028959   2018-4-23
ENDOLOGIX INC   PCT   ENDOVASCULAR GRAFT SYSTEMS AND METHODS FOR DEPLOYMENT IN MAIN AND BRANCH ARTERIES     PCT/US2018/041152   7/6/2018
ENDOLOGIX INC   EP   DUAL CONCENTRIC GUIDEWIRE AND METHODS OF BIFURCATED GRAFT DEPLOYMENT | DOPPELTER KONZENTRISCHER FÜHRUNGSDRAHT UND VERFAHREN ZUM EINSATZ EINES VERZWEIGTEN IMPLANTATS | FIL DE GUIDAGE CONCENTRIQUE   EP2117631B1   EP2008727613A   2008-01-11


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

   

MIXTE ET PROCÉDÉS DE

DÉPLOIEMENT DE GREFFON À DEUX BRANCHES

     
ENDOLOGIX INC   EP  

DEVICES FOR REPAIRING

ANEURYSMS | VORRICHTUNG ZUM AUSBESSERN EINES ANEURYSMAS | DISPOSITIFS DE REPARATION D’ANEVRISMES

  EP1397089B1   EP2002730505A   2002-06-17
ENDOLOGIX INC   EP   CATHETER SYSTEM | Kathetersystem | Systèmes de cathéter   EP2520320B1   EP2012178965A   2009-06-30
ENDOLOGIX INC   EP  

DEVICES FOR REPAIRING

ANEURYSMS | VORRICHTUNG ZUM AUSBESSERN EINES ANEURYSMAS | PROTHÈSE POUR LE TRAITEMENT DES ANÉVRISMES

  EP2260795B1   EP201011024A   2002-06-17
ENDOLOGIX INC   EP   SYSTEMS FOR ANEURYSM TREATMENT USING FILLING STRUCTURES | SYSTEME ZUR BEHANDLUNG VON ANEURYSMEN UNTER VERWENDUNG VON FÜLLSTRUKTUREN | SYSTEMES POUR LE TRAITEMENT DE L’ANEVRISME UTILISANT DES STRUCTURES DE REMPLISSAGE   EP1962722B1   EP2006850439A   2006-12-18


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC   EP   GRAFT SYSTEMS HAVING FILLING STRUCTURES SUPPORTED BY SCAFFOLDS | TRANSPLANTATIONSSYSTEM MIT DURCH GERÜSTE UNTERSTÜTZTEN FÜLLSTRUKTUREN | SYSTEMES DE GREFFE PRESENTANT DES STRUCTURES DE REMPLISSAGE SOUTENUES PAR DES ECHAFAUDAGES   EP1874231B1   EP2006751879A   2006-04-28
ENDOLOGIX INC   EP   GRAFT DEPLOYMENT SYSTEM | IMPLANTAT-ABLAGESYSTEM | SYSTEME DE DEPLOIEMENT DE TUBE PROTHETIQUE   EP1572034B1   EP2003790040A   2003-11-25
ENDOLOGIX INC   EP   STENT GRAFT | STENT-IMPLANTAT | GREFFON DE STENT   EP2459127B1   EP2010806904A   2010-07-27
ENDOLOGIX INC   EP   STENT-GRAFT WITH POSITIONING ANCHOR | STENT-GRAFT MIT POSITIONIERUNGSVERANKERUNG | ENDOPROTHESE A ANCRAGE DE POSITIONNEMENT   EP1542616B1   EP2003754880A   2003-09-22
ENDOLOGIX INC   EP   Systems for endovascular aneurysm treatment | Systeme zur endovaskulären Aneurysma-Therapie | Systèmes pour le traitement d’anévrismes endovasculaires   EP2422745B1   EP2011180827A   2005-07-22


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC   EP   Catheter system | Kathetersystem | Système de cathéter   EP2293838B1   EP2009774381A   2009-06-30
ENDOLOGIX INC   EP   Systems for endovascular aneurysm treatment | Systeme zur Behandlung von endovaskulären Aneurysmen | Systèmes pour le traitement d’anévrisme endovasculaire   EP1778131B1   EP2005773726A   2005-07-22
ENDOLOGIX INC   EP   IMPLANTABLE VASCULAR GRAFT | IMPLANTIERBARE GEFÄSSPROTHESE | GREFFE VASCULAIRE IMPLANTABLE   EP1333787B1   EP2001990900A   2001-11-08
ENDOLOGIX INC   EP   Bifurcated vascular graft and method and apparatus for deploying same | Abzweigendes Gefässtransplantat sowie Verfahren und Gerät zu dessen Entfaltung | Implant vasculaire à deux branches, procédé et appareil pour sa mise en place   EP1009325B1   EP1998906274A   1998-02-06
ENDOLOGIX INC   EP   SINGLE PUNCTURE BIFURCATION GRAFT DEPLOYMENT SYSTEM | EINE EINZIGE PUNKTION ERFORDENDES ENTFALTUNGSSYSTEM FÜR EIN GEFÄSSIMPLANTAT MIT VERZWEIGUNG | SYSTEME DE DEPLOIEMENT D’UNE GREFFE AU NIVEAU D’UNE BIFURCATION, A L’AIDE D’UN SEUL ORIFICE   EP1159024B1   EP2000916167A   2000-03-07


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC   EP   SELF EXPANDING BIFURCATED ENDOVASCULAR PROSTHESIS | SELBSTEXPANDIERENDE, SICH VERZWEIGENDE, ENDOVASKULARE PROTHESE | PROTHESE ENDOVASCULAIRE BIFURQUEE A DILATATION AUTOMATIQUE   EP1087729B1   EP1999957012A   1999-05-28
ENDOLOGIX INC   EP  

ENDOLUMINAL VASCULAR

PROSTHESIS | PROTHESE IM

INNEREN EINES GEFÄSSES |

PROTHESE VASCULAIRE

ENDOLUMINALE

  EP1059893B1   EP1998930137A   1998-06-15
ENDOLOGIX INC   EP   ENDOLUMINAL VASCULAR PROSTHESIS | ENDOLUMINALE VASKULÄRE PROTHESE | PROTHESE VASCULAIRE ENDOLUMINALE   EP1146833B1   EP1999973254A   1999-11-10
ENDOLOGIX INC   EP   DUAL INFLATABLE ARTERIAL PROSTHESIS | DOPPELTE AUFBLASBARE ARTERIENPROTHESE | DOUBLE PROTHÈSE ARTÉRIELLE GONFLABLE   EP3240508A1   EP2015876323A   2015-12-30
ENDOLOGIX INC   EP   FORMING HYDROGELS AND MATERIALS THEREFOR | HERSTELLUNG VON HYDROGELEN UND MATERIALIEN DAFÜR | FORMATION D’HYDROGELS ET MATÉRIAUX POUR CEUX-CI   EP3113722A4   EP2015758921A   2015-03-06
ENDOLOGIX INC   EP   MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES | MODULARE STENTPROTHESENSYSTEME UND VERFAHREN MIT AUFBLASBAREN   EP3148483A4   EP2015800658A   2015-05-05


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

    FÜLLSTRUKTUREN | SYSTÈMES ET PROCÉDÉS DE GREFFE D’ENDOPROTHÈSE MODULAIRE COMPRENANT DES STRUCTURES DE REMPLISSAGE GONFLABLES      
ENDOLOGIX INC   EP   LOCKING ASSEMBLY FOR COUPLING GUIDEWIRE TO DELIVERY SYSTEM | VERRIEGELUNGSANORDNUNG ZUR KOPPLUNG EINES FÜHRUNGSDRAHTS AN EIN AUSGABESYSTEM | ENSEMBLE DE VERROUILLAGE POUR ACCOUPLER UN FIL-GUIDE À UN SYSTÈME DE DISTRIBUTION   EP3139860A1   EP2016790254A   2016-06-29
ENDOLOGIX INC   EP   FILLING STRUCTURE FOR A GRAFT SYSTEM AND METHODS OF USE | FÜLLSTRUKTUR FÜR EIN PROTHESENSYSTEM UND VERWENDUNGSVERFAHREN | STRUCTURE DE REMPLISSAGE POUR UN SYSTÈME DE GREFFE ET PROCÉDÉ D’UTILISATION   EP2519191A4   EP2010841580A   2010-12-21
ENDOLOGIX INC   EP   METHOD FOR FORMING MATERIALS IN SITU WITHIN A MEDICAL DEVICE | VERFAHREN ZUR HERSTELLUNG VON MATERIALIEN IN SITU IN EINER MEDIZINISCHEN VORRICHTUNG | MÉTHODE DE FORMATION DE MATÉRIAUX IN SITU DANS UN DISPOSITIF MÉDICAL   EP2968692A1   EP2014712991A   2014-03-07


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC   EP   DOCKING APPARATUS AND METHODS OF USE | ANDOCKVORRICHTUNG UND VERWENDUNGSVERFAHREN | APPAREIL DE FIXATION ET PROCÉDÉS D’UTILISATION   EP2299933A4   EP2009770704A   2009-06-04
ENDOLOGIX INC   EP   SEALING APPARATUS AND METHODS OF USE | VERSCHLUSSGERÄT UND ANWENDUNGSVERFAHREN | DISPOSITIF DE FERMETURE ET PROCÉDÉS D’UTILISATION ASSOCIÉS   EP2299931A4   EP2009759453A   2009-06-04
ENDOLOGIX INC   EP   BIFURCATED GRAFT DEPLOYMENT SYSTEMS AND METHODS | SYSTEME UND VERFAHREN ZUR FREISETZUNG EINER BIFURKATIONSPROTHESE | SYSTÈMES DE DÉPLOIEMENT DE GREFFON À PLUSIEURS BRANCHES, ET PROCÉDÉS   EP2268227A4   EP2009730087A   2009-04-10
ENDOLOGIX INC   EP   METHOD AND SYSTEM FOR ENDOVASCULAR ANEURYSM TREATMENT | VERFAHREN UND SYSTEM ZUR ENDOVASKULÄREN BEHANDLUNG VON ANEURYSMEN | PROCÉDÉ ET SYSTÈME POUR TRAITEMENT D’ANÉVRISME ENDOVASCULAIRE   EP2693980A1   EP2012716880A   2012-04-06
ENDOLOGIX INC   EP   STENT GRAFT DELIVERY SYSTEM | STENTGRAFT-ABLAGESYSTEM | SYSTÈME DE MISE EN PLACE D ENDOPROTHÈSE VASCULAIRE   EP2278939A4   EP2009733719A   2009-04-24


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC   EP   CATHETER SYSTEM AND METHODS OF USING SAME | KATHETERSYSTEM UND VERFAHREN ZU SEINER VERWENDUNG | SYSTÈME DE CATHÉTER ET SES PROCÉDÉS D’UTILISATION   EP2680915A1   EP2012709432A   2012-02-29
ENDOLOGIX INC   EP   APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM | VORRICHTUNG UND VERFAHREN ZUR POSITIONIERUNG EINER GEFÄSSPROTHESE BZW. EINES GEFÄSSPROTHESENSYSTEMS | APPAREIL ET PROCÉDÉ DE DISPOSITION DE GREFFE OU DE SYSTÈME DE GREFFE   EP2635241A2   EP2011781956A   2011-11-02
ENDOLOGIX INC   EP   APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM | VORRICHTUNG UND VERFAHREN ZUR POSITIONIERUNG EINER GEFÄSSPROTHESE BZW. EINES GEFÄSSPROTHESENSYSTEMS | APPAREIL ET PROCÉDÉ DE PLACEMENT D’UNE GREFFE OU D’UN SYSTÈME DE GREFFE   EP2429452A1   EP2010717383A   2010-04-28
ENDOLOGIX INC   WO   SYSTEMS AND METHODS WITH GRAFT BODY, INFLATABLE FILL CHANNEL, AND FILLING STRUCTURE | SYSTÈMES ET PROCÉDÉS À CORPS DE GREFFE, CANAL DE REMPLISSAGE GONFLABLE ET STRUCTURE DE REMPLISSAGE   WO2017197313A1   PCT/US2017/32490A   2017-05-12


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC   WO   SYSTEMS AND METHODS WITH FENESTRATED GRAFT AND FILLING STRUCTURE | SYSTÈMES ET PROCÉDÉS AVEC GREFFON FENESTRÉ ET STRUCTURE DE REMPLISSAGE   WO2017117068A1   PCT/US2016/68575A   2016-12-23
ENDOLOGIX INC   WO   LOCKING ASSEMBLY FOR COUPLING GUIDEWIRE TO DELIVERY SYSTEM | ENSEMBLE DE VERROUILLAGE POUR ACCOUPLER UN FIL-GUIDE À UN SYSTÈME DE DISTRIBUTION   WO2017004265A1   PCT/US2016/40197A   2016-06-29
ENDOLOGIX INC   WO   ENDOLUMINAL PROSTHESIS SYSTEMS AND METHODS | SYSTÈMES ET PROCÉDÉS DE PROTHÈSE ENDOLUMINALE   WO2016210363A1   PCT/US2016/39414A   2016-06-24
ENDOLOGIX INC   WO   DUAL INFLATABLE ARTERIAL PROSTHESIS | DOUBLE PROTHÈSE ARTÉRIELLE GONFLABLE   WO2016109757A1   PCT/US2015/68204A   2015-12-30
ENDOLOGIX INC   WO   MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES | SYSTÈMES ET PROCÉDÉS DE GREFFE D’ENDOPROTHÈSE MODULAIRE COMPRENANT DES STRUCTURES DE REMPLISSAGE GONFLABLES   WO2015183489A1   PCT/US2015/29292A   2015-05-05
ENDOLOGIX INC   WO   FORMING HYDROGELS AND MATERIALS THEREFOR | FORMATION D’HYDROGELS ET MATÉRIAUX POUR CEUX-CI   WO2015134906A1   PCT/US2015/19251A   2015-03-06


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC   WO   METHOD FOR FORMING MATERIALS IN SITU WITHIN A MEDICAL DEVICE | MÉTHODE DE FORMATION DE MATÉRIAUX IN SITU DANS UN DISPOSITIF MÉDICAL   WO2014159093A1   PCT/US2014/21928A   2014-03-07
ENDOLOGIX INC   WO   METHOD AND SYSTEM FOR ENDOVASCULAR ANEURYSM TREATMENT | PROCÉDÉ ET SYSTÈME POUR TRAITEMENT D’ANÉVRISME ENDOVASCULAIRE   WO2012139054A1   PCT/US2012/32612A   2012-04-06
ENDOLOGIX INC   WO   APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM | APPAREIL ET PROCÉDÉ DE DISPOSITION DE GREFFE OU DE SYSTÈME DE GREFFE   WO2012061526A3   PCT/US2011/59012A   2011-11-02
ENDOLOGIX INC   WO   CATHETER SYSTEM AND METHODS OF USING SAME | SYSTÈME DE CATHÉTER ET SES PROCÉDÉS D’UTILISATION   WO2012118901A1   PCT/US2012/27151A   2012-02-29
ENDOLOGIX INC   WO   METHODS AND SYSTEMS FOR TREATING ANEURYSMS | PROCÉDÉS ET SYSTÈMES DE TRAITEMENT D’ANÉVRISMES   WO2012100059A1   PCT/US2012/21878A   2012-01-19
ENDOLOGIX INC   WO   DEVICES AND METHODS TO TREAT VASCULAR DISSECTIONS | DISPOSITIFS ET PROCÉDÉS DE TRAITEMENT DE DISSECTIONS VASCULAIRES   WO2012068298A1   PCT/US2011/61061A   2011-11-16


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC   WO   STENT GRAFT | ENDOPROTHÈSE COUVERTE   WO2011017123A3   PCT/US2010/43432A   2010-07-27
ENDOLOGIX INC   WO   STENT GRAFT | ENDOPROTHÈSE COUVERTE   WO2011008989A3   PCT/US2010/42181A   2010-07-15
ENDOLOGIX INC   WO   PERCUTANEOUS METHOD AND DEVICE TO TREAT DISSECTIONS | PROCÉDÉ ET DISPOSITIF PERCUTANÉS POUR TRAITER DES DISSECTIONS   WO2010127305A3   PCT/US2010/33274A   2010-04-30
ENDOLOGIX INC   WO   APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM | APPAREIL ET PROCÉDÉ DE PLACEMENT D’UNE GREFFE OU D’UN SYSTÈME DE GREFFE   WO2010127040A1   PCT/US2010/32843A   2010-04-28
ENDOLOGIX INC   WO   BIFURCATED GRAFT DEPLOYMENT SYSTEMS AND METHODS | SYSTÈMES DE DÉPLOIEMENT DE GREFFON À PLUSIEURS BRANCHES, ET PROCÉDÉS   WO2009126906A8   PCT/US2009/40239A   2009-04-10
ENDOLOGIX INC   WO   CATHETER SYSTEM | SYSTÈME DE CATHÉTER   WO2010002931A1   PCT/US2009/49316A   2009-06-30


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC   WO  

DESIGN AND METHOD OF

PLACEMENT OF A GRAFT OR GRAFT SYSTEM | CONCEPTION ET PROCÉDÉ DE MISE EN PLACE D’UN GREFFON OU D’UN SYSTÈME DE GREFFONS | CONCEPTION ET PROCÉDÉ DE MISE EN PLACE D’UN GREFFON OU D’UN SYSTÈME DE GREFFONS

  WO2009105699A1   PCT/US2009/34755A   2009-02-20
ENDOLOGIX INC   WO   METHOD AND AGENT FOR IN-SITU STABILIZATION OF VASCULAR TISSUE | PROCÉDÉ ET AGENT DE STABILISATION <I>IN SITU</I> DU TISSU VASCULAIRE   WO2009064806A1   PCT/US2008/83267A   2008-11-12
ENDOLOGIX INC   WO   STENT | ENDOPROTHÈSE VASCULAIRE   WO2009055615A1   PCT/US2008/81022A   2008-10-23
ENDOLOGIX INC   DE   EINE EINZIGE PUNKTION ERFORDENDES ENTFALTUNGSSYSTEM FÜR EIN GEFÄSSIMPLANTAT MIT VERZWEIGUNG   DE60031381T2   DE60031381A   2000-03-07
ENDOLOGIX INC   DE   SELBSTEXPANDIERENDE, SICH VERZWEIGENDE, ENDOVASKULARE PROTHESE   DE69933560T2   DE69933560A   1999-05-28
ENDOLOGIX INC   DE   ENDOLUMINALE VASKULÄRE PROTHESE   DE69927055T2   DE69927055A   1999-11-10


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC   AU   Bifurcated vascular graft and method and apparatus for deploying same | Bifurcated vascular graft deployment device   AU725117B2   AU199861540A   1998-02-06
ENDOLOGIX INC   AU   Implantable vascular graft   AU200230661A   AU200230661A   2001-11-08
ENDOLOGIX INC   EP   DEVICES FOR REPAIRING ANEURYSMS   EP1397089   EP02730505.1   2017-04-19
ENDOLOGIX INC   EP   DEVICES FOR REPAIRING ANEURYSMS   EP1397089   EP02730505.1   2017-04-19
ENDOLOGIX INC   EP   DEVICES FOR REPAIRING ANEURYSMS   EP1397089   EP02730505.1   2017-04-19
ENDOLOGIX INC   EP   DEVICES FOR REPAIRING ANEURYSMS   EP2260795   EP10011024.6   2016-05-25


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC   EP   DEVICES FOR REPAIRING ANEURYSMS   EP2260795   EP10011024.6   2016-05-25
ENDOLOGIX INC   EP   DEVICES FOR REPAIRING ANEURYSMS   EP2260795   EP10011024.6   2016-05-25
ENDOLOGIX INC   EP   DEVICES FOR REPAIRING ANEURYSMS   EP2260795   EP10011024.6   2016-05-25
ENDOLOGIX INC   EP   DEVICES FOR REPAIRING ANEURYSMS   EP2260795   EP10011024.6   2016-05-25
ENDOLOGIX INC   EP   ADVANCED KINK-RESISTANT STENT GRAFT   EP2833827   13714471.3   2018-01-31
ENDOLOGIX INC   EP   ADVANCED KINK-RESISTANT STENT GRAFT   EP2833827   13714471.3   2018-01-31


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC   EP   LOW PROFILE STENT GRAFT AND DELIVERY SYSTEM     EP13717893.5   2014-11-06
ENDOLOGIX INC   EP   MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES     EP15800658.5   2016-11-21
ENDOLOGIX INC   EP   ANEURYSM SAC ACCESS CONDUIT     15852460.3   2017-04-12
ENDOLOGIX INC   EP   DUAL INFLATABLE ARTERIAL PROSTHESIS     15876323.5   2017-07-13
ENDOLOGIX INC   EP   Endoluminal Prosthesis Systems and Methods     16815450.8   2017-12-19
ENDOLOGIX INC   CN   MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES     2015800393484   2017-01-19


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC   CN   DUAL INFLATABLE ARTERIAL PROSTHESIS     2015800763903   2017-08-17
ENDOLOGIX INC   JP   MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES     2016-569901   2016-11-28
ENDOLOGIX INC   CN   Endoluminal Prosthesis Systems and Methods     201680037099.X   2017-12-22
ENDOLOGIX INC   JP   DUAL INFLATABLE ARTERIAL PROSTHESIS     2017-534803   2017-06-28
ENDOLOGIX INC   JP   Endoluminal Prosthesis Systems and Methods     PCT/US2016/039414   2017-12-22


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

NELLIX INC.   US   Stent-graft with positioning anchor   US9814612B2   US14697433A   2015-10-21
NELLIX INC.   US   System and methods for endovascular aneurysm treatment   US9737425B2   US14537749A   2014-11-10
NELLIX INC.   US   Stent graft delivery system   US9730700B2   US14586110A   2015-04-23
NELLIX INC.   US   Methods for deploying a positioning anchor with a stent-graft   US9113999B2   US11876458A   2007-10-22
NELLIX INC.   US   Sealing apparatus and methods of use   US8945199B2   US12478225A   2009-06-04
NELLIX INC.   US   Stent graft delivery system   US8926682B2   US13243941A   2011-09-23


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

NELLIX INC.   US   System and methods for endovascular aneurysm treatment   US8906084B2   US12684074A   2010-01-07
NELLIX INC.   US   Graft systems having filling structures supported by scaffolds and methods for their use   US8870941B2   US13285897A   2011-10-31
NELLIX INC.   US   STENT GRAFT DELIVERY SYSTEM   US20180028192A1   US15676869A   2017-08-14
NELLIX INC.   US   SEALING APPRATUS AND METHODS OF USE   US20150148892A1   US14612048A   2015-02-02
NELLIX INC.   US   GRAFT SYSTEMS HAVING FILLING STRUCTURES SUPPORTED BY SCAFFOLDS AND METHODS FOR THEIR USE   US10022249   US14525019A   2014-10-27
NELLIX, INC.   US   System and methods of Endovascular Aneurysm Treatment     14/682414   8/21/17


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

Nellix, Inc.   US   Vascular stent-graft apparatus and forming method   US6695833   US09671550   9/27/00
ENDOLOGIX INC   EP   Systems for endovascular aneurysm treatment | Systeme zur Behandlung von endovaskulären Aneurysmen | Systèmes pour le traitement d’anévrisme endovasculaire   EP1778131B1   EP2005773726A   2005-07-22
NELLIX INC.   EP   Method for forming a vascular stent-graft | Verfahren zur Herstellung eines vaskulären Stent-Grafts | Procédé de formation d’un stent-greffe vasculaire.   EP1355587B1   EP2001973590A   2001-09-26
NELLIX INC   EP   METHODS AND SYSTEMS FOR ANEURYSM TREATMENT USING FILLING STRUCTURES | VERFAHREN UND SYSTEME ZUR BEHANDLUNG VON ANEURYSMEN UNTER VERWENDUNG VON FÜLLSTRUKTUREN | PROCEDES ET SYSTEMES POUR LE TRAITEMENT DE L’ANEVRISME UTILISANT DES STRUCTURES DE REMPLISSAGE   EP1962722A4   EP2006850439A   2006-12-18
ENDOLOGIX INC   EP   Systems for endovascular aneurysm treatment | Systeme zur endovaskulären Aneurysma-Therapie | Systèmes pour le traitement d’anévrismes endovasculaires   EP2422745A1   EP2011180827A   2005-07-22


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX INC   EP   DOCKING APPARATUS AND METHODS OF USE | ANDOCKVORRICHTUNG UND VERWENDUNGSVERFAHREN | APPAREIL DE FIXATION ET PROCÉDÉS D’UTILISATION   EP2299933A1   EP2009770704A   2009-06-04
ENDOLOGIX INC   EP   SEALING APPARATUS AND METHODS OF USE | VERSCHLUSSGERÄT UND ANWENDUNGSVERFAHREN | DISPOSITIF DE FERMETURE ET PROCÉDÉS D’UTILISATION ASSOCIÉS   EP2299931A1   EP2009759453A   2009-06-04
ENDOLOGIX INC   EP   STENT GRAFT DELIVERY SYSTEM | STENTGRAFT-ABLAGESYSTEM | SYSTÈME DE MISE EN PLACE D ENDOPROTHÈSE VASCULAIRE   EP2278939A1   EP2009733719A   2009-04-24
ENDOLOGIX INC   EP   GRAFT SYSTEMS HAVING FILLING STRUCTURES SUPPORTED BY SCAFFOLDS | TRANSPLANTATIONSSYSTEM MIT DURCH GERÜSTE UNTERSTÜTZTEN FÜLLSTRUKTUREN | SYSTEMES DE GREFFE PRESENTANT DES STRUCTURES DE REMPLISSAGE SOUTENUES PAR DES ECHAFAUDAGES   EP1874231A2   EP2006751879A   2006-04-28
ENDOLOGIX INC   EP   STENT-GRAFT WITH POSITIONING ANCHOR | STENT-GRAFT MIT POSITIONIERUNGSVERANKERUNG | ENDOPROTHESE A ANCRAGE DE POSITIONNEMENT   EP1542616A2   EP2003754880A   2003-09-22


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

NELLIX INC.   WO   FILLING STRUCTURE FOR A GRAFT SYSTEM AND METHODS OF USE | STRUCTURE DE REMPLISSAGE POUR UN SYSTÈME DE GREFFE ET PROCÉDÉ D’UTILISATION   WO2011082040A1   PCT/US2010/061621   2010-12-21
NELLIX INC.   WO   DOCKING APPARATUS AND METHODS OF USE | APPAREIL DE FIXATION ET PROCÉDÉS D’UTILISATION   WO2009158170A1   PCT/US2009/046308   2009-06-04
NELLIX INC.   WO   SEALING APPARATUS AND METHODS OF USE | DISPOSITIF DE FERMETURE ET PROCÉDÉS D’UTILISATION ASSOCIÉS | DISPOSITIF DE FERMETURE ET PROCÉDÉS D’UTILISATION ASSOCIÉS   WO2009149294A1   PCT/US2009/046310   2009-06-04
NELLIX INC.   WO   STENT GRAFT DELIVERY SYSTEM | SYSTÈME DE MISE EN PLACE D’ENDOPROTHÈSE VASCULAIRE | SYSTÈME DE MISE EN PLACE D’ENDOPROTHÈSE VASCULAIRE   WO2009132309A1   PCT/US2009/041718   2009-04-24
NELLIX INC.   WO   GRAFT ENDOFRAME HAVING AXIALLY VARIABLE CHARACTERISTICS | ENDOCADRE DE GREFFE AYANT DES CARACTÉRISTIQUES VARIABLES AXIALEMENT   WO2009103011A1   PCT/US2009/034136   2009-02-13
TRIVASCULAR INC.   US   Endovascular graft   US9867727B2   US14320773A   2014-07-01


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC.   US   Advanced endovascular graft   US9788934B2   US14799656A   2015-07-15
TRIVASCULAR INC.   US   Endovascular graft for aneurysms involving major branch vessels   US9724186B2   US14050835A   2013-10-10
TRIVASCULAR INC.   US   System and method of pivoted stent deployment   US9713523B2   US14452343A   2014-08-05
TRIVASCULAR INC.   US   Systems and methods for guidewire crossover for bifurcated prostheses   US9655754B2   US14323059A   2014-07-03
TRIVASCULAR INC.   US   Bifurcated endovascular prosthesis having tethered contralateral leg   US9585774B2   US14823076A   2015-08-11
TRIVASCULAR INC.   US  

PTFE layers and methods of

manufacturing

  US9549829B2   US14458349A   2014-08-13


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC.   US   Delivery catheter for endovascular device   US9498363B2   US13835491A   2013-03-15
TRIVASCULAR INC   US   Low profile stent and delivery system   US9463101B2   US14923477A   2015-10-27
TRIVASCULAR INC.   US  

PTFE layers and methods of

manufacturing

  US9446553B2   US14230318A   2014-03-31
TRIVASCULAR INC.   US   Endovascular graft joint and method for manufacture   US9351858B2   US14704013A   2015-05-05
TRIVASCULAR INC.   US   Non-degradable, low swelling, water soluble radiopaque hydrogel polymer   US9308301B2   US13089960A   2011-04-19
TRIVASCULAR INC.   US   Endovascular delivery system with an improved radiopaque marker scheme   US9233015B2   US13803050A   2013-03-14


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC.   US   Low profile stent graft and delivery system   US9192462B2   US13803037A   2013-03-14
TRIVASCULAR INC.   US   Fenestrated inflatable graft   US9144486B2   US13652471A   2012-10-15
TRIVASCULAR INC.   US   Bifurcated endovascular prosthesis having tethered contralateral leg   US9132025B2   US13803067A   2013-03-14
TRIVASCULAR INC.   US   Endovascular delivery system with flexible and torqueable hypotube   US9066828B2   US13803062A   2013-03-14
TRIVASCULAR INC.   US   Endovascular graft joint and method for manufacture   US9050754B2   US12729182A   2010-03-22
TRIVASCULAR INC.   US   Durable stent graft with tapered struts and stable delivery methods and devices   US8992595B2   US13799207A   2013-03-13


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC.   US   In vitro testing of endovascular device   US8978448B2   US13649066A   2012-10-10
TRIVASCULAR INC.   US   Advanced endovascular graft delivery system and method of treatment   US8900288B2   US12566104A   2009-09-24
TRIVASCULAR INC.   US   Method of delivering advanced endovascular graft and system   US8864814B2   US13246651A   2011-09-27
TRIVASCULAR INC.   US  

PTFE layers and methods of

manufacturing

  US8840824B2   US12910281A   2010-10-22
TRIVASCULAR INC.   US   Endovascular graft   US8801769B2   US13737351A   2013-01-09
TRIVASCULAR INC.   US   Apparatus for manufacturing an endovascular graft section   US8783316B2   US12697504A   2010-02-01


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC.   US  

PTFE layers and methods of

manufacturing

  US8728372B2   US12915636A   2010-10-29
TRIVASCULAR INC.   US   Advanced endovascular graft   US8709065B2   US12491336A   2009-06-25
TRIVASCULAR INC.   US   Virtual prototyping and testing for medical device development   US8666714B2   US13523765A   2012-06-14
TRIVASCULAR INC.   US   Asymmetric stent apparatus and method   US8663309B2   US11861828A   2007-09-26
TRIVASCULAR INC.   US   Endovascular graft   US8361136B2   US12566793A   2009-09-25
TRIVASCULAR INC.   US   Endovascular graft joint and method for manufacture   US8348989B2   US11429735A   2006-05-08


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC.   US   Delivery system and method for bifurcated graft   US8328861B2   US11941434A   2007-11-16
TRIVASCULAR INC.   US   Endovascular graft and method of delivery   US8241346B2   US13246643A   2011-09-27
TRIVASCULAR INC.   US   Inflatable porous implants and methods for drug delivery   US8267989B2   US12860364A   2010-08-20
TRIVASCULAR INC.   US   Inflatable intraluminal graft   US8226708B1   US10168053A   2002-06-14
TRIVASCULAR INC.   US   Stent and delivery system for deployment thereof   US8226701B2   US11861756A   2007-09-26
TRIVASCULAR INC.   US   Virtual prototyping and testing for medical device development   US8224632B2   US12904994A   2010-10-14


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC.   US   Dual chamber cuff structure   US8216297B2   US11504434A   2006-08-14
TRIVASCULAR INC.   US   Barbed radially expandable stent   US8167927B2   US13245661A   2011-09-26
TRIVASCULAR INC.   US   Securement assembly and method for expandable endovascular device   US8083789B2   US11941450A   2007-11-16
TRIVASCULAR INC.   US   System and method of pivoted stent deployment   US8066755B2   US11861716A   2007-09-26
TRIVASCULAR INC.   US   Constant force material delivery system and method   US7971751B2   US12724068A   2010-03-15
TRIVASCULAR INC.   US   Passive hemostatic sheath valve   US7901379B2   US11298285A   2005-12-09


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC.   US   Virtual prototyping and testing for medical device development   US7840393B1   US09679725A   2000-10-04
TRIVASCULAR INC.   US   Inflatable porous implants and methods for drug delivery   US7803178B2   US10769532A   2004-01-30
TRIVASCULAR INC.   US   Advanced endovascular graft   US7766954B2   US11333595A   2006-01-17
TRIVASCULAR INC.   US   Constant force material delivery system and method   US7708163B2   US11360077A   2006-02-23
TRIVASCULAR INC.   US   Endovascular graft joint and method for manufacture   US7682475B2   US11870748A   2007-10-11
TRIVASCULAR INC.   US   Method for manufacturing an endovascular graft section   US7678217B2   US11522490A   2006-09-15


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC.   US   Inflatable implant   US7632291B2   US10461853A   2003-06-13
TRIVASCULAR INC.   US   Endovascular graft   US7615071B2   US11390732A   2006-03-28
TRIVASCULAR INC.   US  

Delivery system and method for

expandable intracorporeal device

  US7338518B2   US11201028A   2005-08-10
TRIVASCULAR INC.   US   Passive hemostatic sheath valve   US7241276B2   US10636871A   2003-08-06
TRIVASCULAR INC.   US   Advanced endovascular graft   US7147660B2   US10327711A   2002-12-20
TRIVASCULAR INC.   US   Kink resistant endovascular graft   US7150758B2   US10384103A   2003-03-06


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC.   US   Radially expandable stent   US7147661B2   US10029559A   2001-12-20
TRIVASCULAR INC.   US   Method and apparatus for shape forming endovascular graft material   US7147455B2   US10868292A   2004-06-14
TRIVASCULAR INC.   US   Method for manufacturing an endovascular graft section   US7125464B2   US10029557A   2001-12-20
TRIVASCULAR INC.   US   Endovascular graft   US7081129B2   US10132754A   2002-04-24
TRIVASCULAR INC.   US   Endovascular graft joint and method for manufacture   US7090693B1   US10029584A   2001-12-20
TRIVASCULAR INC.   US  

Delivery system and method for

expandable intracorporeal device

  US7066951B2   US10419312A   2003-04-17


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC.   US   Method and apparatus for shape forming endovascular graft material   US6776604B1   US10029570A   2001-12-20
TRIVASCULAR INC.   US   Delivery system and method for bifurcated endovascular graft   US6761733B2   US09917371A   2001-07-27
TRIVASCULAR INC.   US   Delivery system and method for endovascular graft   US6733521B2   US09834278A   2001-04-11
TRIVASCULAR INC.   US  

Delivery system and method for

expandable intracorporeal device

  US6602280B2   US09774733A   2001-01-31
TRIVASCULAR INC.   US   Endovascular graft   US6395019B2   US09133978A   1998-08-14
TRIVASCULAR INC   US   ENDOVASCULAR GRAFT   US20170348125A1   US15686214A   2017-08-25


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC   US   ADVANCED ENDOVASCULAR GRAFT   US20170348087A1   US15686218A   2017-08-25
TRIVASCULAR INC   US   ENDOVASCUALR GRAFT FOR ANEURYSMS INVOLVING MAJOR BRANCH VESSELS   US20170296327A1   US15638559A   2017-06-30
TRIVASCULAR INC   US   SYSTEMS AND METHODS FOR GUIDEWIRE CROSSOVER FOR BIFURCATED PROSTHESES   US20170216064A1   US15491074A   2017-04-19
TRIVASCULAR INC   US   Low Profile Stent Graft and Delivery System   US9987123   US15263469A   2016-09-13
TRIVASCULAR INC   US   BIFURCATED ENDOVASCULAR PROSTHESIS HAVING TETHERED CONTRALATERAL LEG   US20170035549A1   US15299542A   2016-10-21
TRIVASCULAR INC.   US   DELIVERY CATHETER FOR ENDOVASCULAR DEVICE   US20170035590A1   US15298166A   2016-10-19


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC   US   PTFE LAYERS AND METHODS OF MANUFACTURING   US20160367354A1   US15251011A   2016-08-30
TRIVASCULAR INC   US   ENDOVASCULAR DELIVERY SYSTEM WITH AN IMPROVED RADIOPAQUE MARKER SCHEME   US10034787   US14970621A   2015-12-16
TRIVASCULAR INC   US   NON-DEGRADABLE, LOW SWELLING, WATER SOLUBLE RADIOPAQUE HYDROGEL POLYMER   US20160193392A1   US15068415A   2016-03-11
TRIVASCULAR INC.   US   INTERNAL ILIAC PRESERVATION DEVICES AND METHODS   US9956101   US14958085A   2015-12-03
TRIVASCULAR INC.   US   STENT GRAFT DELIVERY SYSTEM WITH ACCESS CONDUIT   US20160113796A1   US14920828A   2015-10-22
TRIVASCULAR INC.   US   ENDOVASCULAR DELIVERY SYSTEM WITH FLEXIBLE AND TORQUEABLE HYPOTUBE   US20150265446A1   US14717080A   2015-05-20


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC.   US   INFLATABLE OCCLUSION WIRE- BALLOON FOR AORTIC APPLICATIONS   US20150250481A1   US14643217A   2015-03-10
TRIVASCULAR INC.   US   ADVANCED ENDOVASCULAR GRAFT AND DELIVERY SYSTEM   US20150164667A1   US14631818A   2015-02-25
TRIVASCULAR INC.   US   DURABLE STENT GRAFT WITH TAPERED STRUTS AND STABLE DELIVERY METHODS AND DEVICES   US20150157479A1   US14615337A   2015-02-05
TRIVASCULAR INC.   US   TANDEM MODULAR ENDOGRAFT   US20150088244A1   US14492674A   2014-09-22
TRIVASCULAR INC.   US   ENDOLEAK ISOLATION SLEEVES AND METHODS OF USE   US20150073523A1   US14481834A   2014-09-09
TRIVASCULAR INC.   US   GATE WIRE FOR CONTRALATERAL LEG ACCESS   US20140194970A1   US14151373A   2014-01-09


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC.   US   SAC LINER FOR ANEURYSM REPAIR   US20140194973A1   US14151195A   2014-01-09
TRIVASCULAR INC.   US   ASYMMETRIC STENT APPARATUS AND METHOD   US20140135899A1   US14157350A   2014-01-16
TRIVASCULAR INC.   US   LOW PROFILE STENT GRAFT AND DELIVERY SYSTEM   US20130268056A1   US13803033A   2013-03-14
TRIVASCULAR INC.   US   ADVANCED KINK RESISTANT STENT GRAFT   US9993328   US13803046A   2013-03-14
TRIVASCULAR INC.   US  

VASCULAR GRAFT HAVING

LIMITED END STRUCTURE

  US20130096665A1   US13650705A   2012-10-12
TRIVASCULAR INC.   US   INFLATABLE INTRALUMINAL GRAFT   US20120265290A1   US13532887A   2012-06-26


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC.   US   ADVANCED ENDOVASCULAR GRAFT AND DELIVERY SYSTEM   US20120191174A1   US13297219A   2011-11-15
TRIVASCULAR INC.   US   SYSTEM AND METHOD OF PIVOTED STENT DEPLOYMENT   US20120083870A1   US13277117A   2011-10-19
TRIVASCULAR INC.   US   BARBED RADIALLY EXPANDABLE STENT WITH SLOTTED STRUTS   US20120016457A1   US13245652A   2011-09-26
TRIVASCULAR INC.   US   FILL TUBE MANIFOLD AND DELIVERY METHODS FOR ENDOVASCULAR GRAFT   US20110218609A1   US13024255A   2011-02-09
TRIVASCULAR INC.   US   HINGED ENDOVASCULAR DEVICE   US20100331958A1   US12747499A   2010-09-07
TRIVASCULAR INC.   US   Inflatable Implant   US20100076481A1   US12628623A   2009-12-01


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC.   US   METHOD OF DELIVERING ADVANCED ENDOVASCULAR GRAFT   US20100016943A1   US12566808A   2009-09-25
TRIVASCULAR INC.   US   MODULAR VASCULAR GRAFT FOR LOW PROFILE PERCUTANEOUS DELIVERY   US20090099649A1   US12245620A   2008-10-03
TRIVASCULAR INC.   US   ALIGNMENT STENT APPARATUS AND METHOD   US20090082845A1   US11861746A   2007-09-26
TRIVASCULAR INC.   US  

SYSTEM AND METHOD OF

SECURING STENT BARBS

  US20090082847A1   US11861731A   2007-09-26
TRIVASCULAR INC.   US   APPARATUS FOR SECURING STENT BARBS   US20090082841A1   US11861739A   2007-09-26
TRIVASCULAR INC.   US   PTFE LAYERS AND METHODS OF MANUFACTURING   US20090036971A1   US12250915A   2008-10-14


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC.   US   PTFE LAYERS AND METHODS OF MANUFACTURING   US20090036973A1   US12250946A   2008-10-14
TRIVASCULAR INC.   US   Non-degradable, low swelling, water soluble radiopaque hydrogel polymer   US20060222596A1   US11097467A   2005-04-01
TRIVASCULAR INC.   US   Hybrid modular endovascular graft   US20060224232A1   US11097718A   2005-04-01
TRIVASCULAR INC.   US   Delivery system and method for bifurcated graft   US20060009833A1   US11205793A   2005-08-15
TRIVASCULAR INC.   US   Methods, compositions and devices for embolizing body lumens   US20050158272A1   US11031311A   2005-01-07
TRIVASCULAR INC.   US   Endoluminal prosthesis endoleak management   US20050090804A1   US10691849A   2003-10-22


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC.   US   Endovascular graft joint and method for manufacture   US20050027347A1   US10640368A   2003-08-13
TRIVASCULAR INC.   US   Layered endovascular graft   US20040220664A1   US10803153A   2004-03-17
TRIVASCULAR INC.   US   Delivery system and method for bifurcated graft   US20040138734A1   US10686863A   2003-10-16
TRIVASCULAR INC.   US   Endovascular graft   US20030216802A1   US10289136A   2002-11-05
TRIVASCULAR INC.   US   Inflatable intraluminal graft   US20030225453A1   US10289137A   2002-11-05
TRIVASCULAR INC.   US   Advanced endovascular graft   US20030120338A1   US10091641A   2002-03-05


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC.   US   Delivery system and method for bifurcated graft   US20030004560A1   US10122474A   2002-04-11
TRIVASCULAR INC.   US   Layered endovascular graft   US20020010508A1   US09970576A   2001-10-04
TRIVASCULAR, INC.   US   Stent-graft with improved flexibility     15/568834   10/24/17
Trivascular, Inc.   US   Passive hemostatic sheath valve   US7901379   US11298285   12/9/05
Trivascular, Inc.   US   Fluid mixing apparatus and method   US7178978   US10658074   9/8/03
Trivascular, Inc.   US  

Delivery system and method for

expandable intracorporeal device

  US6602280   US09774733   1/31/01


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

Trivascular, Inc.   US   Endovascular graft   US6395019   US09133978   8/14/98
Trivascular, Inc.   US   Layered endovascular graft   US6331191   US09200317   11/25/98
Trivascular, Inc.   US   Endovascular graft having longitudinally displaceable sections   US6132457   US09177295   10/22/98
Trivascular, Inc.   US   Low profile stent graft and delivery system     US15263469   9/13/16
Trivascular, Inc.   US   Delivery catheter for endovascular device     US15298166   10/19/16
Trivascular, Inc.   US   Bifurcated endovascular prosthesis having tethered contralateral leg     US15299542   10/21/16


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

Trivascular, Inc.   US   Ptfe layers and methods of manufacturing     US15251011   8/30/16
Trivascular, Inc.   US   Endovascular delivery system with an improved radiopaque marker scheme     US14970621   12/16/15
Trivascular, Inc.   US  

Non-degradable, low swelling, water

soluble radiopaque hydrogel polymer

    US15068415   3/11/16
Trivascular, Inc.   US  

Internal iliac preservation devices and

methods

    US14958085   12/3/15
Trivascular, Inc.   US   Stent graft delivery system with access conduit     US14920828   10/22/15
Trivascular, Inc.   US   Bifurcated endovascular prosthesis having tethered contralateral leg     US14823076   8/11/15


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

Trivascular, Inc.   US   Low profile stent and delivery system     US14923477   10/27/15
Trivascular, Inc.   US   Endovascular delivery system with flexible and torqueable hypotube     US14717080   5/20/15
Trivascular, Inc.   US   Inflatable occlusion wire-balloon for aortic applications     US14643217   3/10/15
Trivascular, Inc.   US   Advanced endovascular graft and delivery system     US14631818   2/25/15
Trivascular, Inc.   US   Durable stent graft with tapered struts and stable delivery methods and devices     US14615337   2/5/15
Trivascular, Inc.   US   Tandem modular endograft     US14492674   9/22/14


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

Trivascular, Inc.   US   Endoleak isolation sleeves and methods of use     US14481834   9/9/14
Trivascular, Inc.   US   Sac liner for aneurysm repair     US14151195   1/9/14
Trivascular, Inc.   US   Gate wire for contralateral leg access     US14151373   1/9/14
Trivascular, Inc.   US   Asymmetric stent apparatus and method     US14157350   1/16/14
Trivascular, Inc.   US   Low profile stent graft and delivery system     US13803033   3/14/13
Trivascular, Inc.   US   Advanced kink resistant stent graft     US13803046   3/14/13


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

Trivascular, Inc.   US   Vascular graft having limited end structure     US13650705   10/12/12
Trivascular, Inc.   US   Inflatable intraluminal graft     US13532887   6/26/12
Trivascular, Inc.   US   Advanced endovascular graft and delivery system     US13297219   11/15/01
Trivascular, Inc.   US  

System and method of pivoted stent

deployment

    US13277117   10/19/11
Trivascular, Inc.   US  

Barbed radially expandable stent with

slotted struts

    US13245652   9/26/11
Trivascular, Inc.   US   Fill tube manifold and delivery methods for endovascular graft     US13024255   2/9/11


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

Trivascular, Inc.   US   Hinged endovascular device     US12747499   9/7/10
Trivascular, Inc.   US   Inflatable implant     US12628623   12/1/09
Trivascular, Inc.   US  

Method of delivering advanced

endovascular graft

    US12566808   9/25/09
Trivascular, Inc.   US   Modular vascular graft for low profile percutaneous delivery     US12245620   10/3/08
Trivascular, Inc.   US   System and method of securing stent barbs     US11861731   9/26/07
Trivascular, Inc.   US   Alignment stent apparatus and method     US11861746   9/26/07


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

Trivascular, Inc.   US   Apparatus for securing stent barbs     US11861739   9/26/07
Trivascular, Inc.   US   Ptfe layers and methods of manufacturing     US12250946   10/14/08
Trivascular, Inc.   US   Ptfe layers and methods of manufacturing     US12250915   10/14/08
Trivascular, Inc.   US   Ptfe layers and methods of manufacturing     US11106150   4/13/05
Trivascular, Inc.   US   Ptfe layers and methods of manufacturing     US11106131   4/13/05
Trivascular, Inc.   US   Hybrid modular endovascular graft     US11097718   4/1/05


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

Trivascular, Inc.   US  

Non-degradable low swelling, water

soluble radiopaque hydrogel polymer

    US11097467   4/1/05
Trivascular, Inc.   US   Delivery system and method for bifurcated graft     US11205793   8/15/05
Trivascular, Inc.   US   Modular endovascular graft     US11077938   3/11/05
Trivascular, Inc.   US   Methods, compositions and devices for embolizing body lumens     US11031311   1/7/05
Trivascular, Inc.   US  

Endoluminal prosthesis endoleak

management

    US10691849   10/22/03
Trivascular, Inc.   US   Endovascular graft joint and method for manufacture     US10640368   8/13/03


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

Trivascular, Inc.   US   Layered endovascular graft     US10803153   3/17/04
Trivascular, Inc.   US   Delivery system and method for bifurcated graft     US10686863   10/16/03
Trivascular, Inc.   US   Inflatable intraluminal graft     US10289137   11/5/02
Trivascular, Inc.   US   Endovascular graft     US10289136   11/5/02
Trivascular, Inc.   US   Advanced endovascular graft     US10091641   3/5/02
Trivascular, Inc.   US   Delivery system and method for bifurcated graft     US10122474   4/11/02


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

Trivascular, Inc.   US   Layered endovascular graft     US09970576   10/3/01
TRIVASCULAR INC.   EP   ADVANCED KINK-RESISTANT STENT GRAFT | HOCHENTWICKELTES KNICKBESTÄNDIGES STENTTRANSPLANTAT | ENDOPROTHÈSE ÉVOLUÉE RÉSISTANT AU PLIAGE   EP2833827B1   EP2013714471A   2013-03-21
TRIVASCULAR INC.   EP   INFLATABLE IMPLANT | AUFBLASBARES IMPLANTAT | IMPLANT GONFLABLE   EP1635738B1   EP2004776568A   2004-06-14
TRIVASCULAR INC.   EP  

ENDOVASCULAR GRAFT FOR ANEURYSMS INVOLVING MAJOR BRANCH VESSELS | ENDOVASKULÄRES

TRANSPLANTAT FÜR ANEURYSMEN MIT BETEILIGUNG VON GROSSEN VERZWEIGTEN GEFÄSSEN | GREFFON ENDOVASCULAIRE POUR ANÉVRISMES METTANT EN JEU DES VAISSEAUX RAMIFIÉS PRINCIPAUX

  EP2906144B1   EP2013780282A   2013-10-10
TRIVASCULAR INC.   EP   ADVANCED ENDOVASCULAR GRAFT AND DELIVERY SYSTEM | FORTSCHRITTLICHES ENDOVASKULÄRES TRANSPLANTAT UND SYSTEM ZU SEINER VERABREICHUNG | GREFFE ENDOVASCULAIRE AVANCÉE ET SYSTÈME DE POSE ASSOCIÉ   EP2640319B1   EP2011841183A   2011-11-15


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC.   EP   DELIVERY CATHETER FOR ENDOVASCULAR DEVICE | EINFÜHRKATHETER FÜR EINE ENDOVASKULÄRE VORRICHTUNG | CATHÉTER DE DÉLIVRANCE POUR DISPOSITIF ENDOVASCULAIRE   EP2833845B1   EP2013771941A   2013-04-01
TRIVASCULAR INC.   EP   Endovascular graft | Endovaskuläres Gewebe | Greffe endovasculaire   EP1464301B1   EP200475832A   1999-02-09
TRIVASCULAR INC.   EP   PTFE LAYERS AND METHODS OF MANUFACTURING | PTFE-LAGEN UND HERSTELLUNGSVERFAHREN | COUCHES DE PTFE ET PROCEDES DE FABRICATION   EP1888318B1   EP2006740124A   2006-03-30
TRIVASCULAR INC.   EP   ADVANCED ENDOVASCULAR GRAFT | FORTSCHRITTLICHES ENDOVASKULÄRES TRANSPLANTAT | GREFFON ENDOVASCULAIRE EVOLUE   EP1467679B1   EP2002796047A   2002-12-20
TRIVASCULAR INC.   EP   Non-degradable low swelling, water soluble radiopaque hydrogels | Nicht abbaubares, schwach anschwellendes, wasserlösliches röntgendichtes Hydrogelpolymer | Polymère absorbant l’eau, radiopaque, soluble dans l’eau, à faible gonflement et non dégradable   EP2332590B1   EP2010194236A   2006-03-28


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC.   EP   Endovascular graft | Endovaskuläres Transplantat | Greffe endovasculaire   EP2147658B1   EP200913660A   1999-02-09
TRIVASCULAR INC.   EP   Kink resistant endovascular graft | Knickbeständiges Stentimplantat | Stent à greffer resistant au pliage   EP2319456B1   EP2010183146A   2004-03-05
TRIVASCULAR INC.   EP   Delivery system for graft | Abgabesystem für Graft | Système de mise en place pour prothèse   EP2145607B1   EP2009175398A   2004-10-15
TRIVASCULAR INC.   EP   DELIVERY SYSTEM FOR BIFURCATED GRAFT | VORRICHTUNG ZUR PLATZIERUNG VON ZWEIGETEILTEN ENDOPROTHESEN | SYSTEME DE MISE EN PLACE D’UN GREFFON A BIFURCATION   EP1377234B1   EP2002725639A   2002-04-11
TRIVASCULAR INC.   EP   Advanced endovascular graft | Erweitertes endovaskuläres Transplantat | Greffe endovasculaire évoluée   EP2135583B1   EP20099090A   2002-12-20
TRIVASCULAR INC.   EP   KINK RESISTANT ENDOVASCULAR GRAFT | KNICKFESTES ENDOVASKULÄRES IMPLANTAT | IMPLANT ENDOVASCULAIRE RÉSISTANT A LA DÉFORMATION   EP1601314B1   EP2004718097A   2004-03-05


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC.   EP   NON-DEGRADABLE LOW SWELLING, WATER SOLUBLE RADIOPAQUE HYDROGELS | NICHT-ABBAUBARE WENIG QUELLENDE WASSERLÖSLICHE RÖNTGENDICHTE HYDROGELS | HYDROGEL RADIOPAQUE, SOLUBLE DANS L’EAU, NON DEGRADABLE ET A FAIBLE GONFLEMENT   EP1874370B1   EP2006739747A   2006-03-28
TRIVASCULAR INC.   EP   INFLATABLE INTRALUMINAL GRAFT | AUFBLASBARER INTRALUMINALER PFROPFEN | GREFFON INTRALUMINAL GONFLABLE   EP1176926B1   EP2000907760A   2000-03-03
TRIVASCULAR INC.   EP   ENDOVASCULAR GRAFT | ENDOVASKULÄRES IMPLANTAT | GREFFON ENDOVASCULAIRE   EP1054648B1   EP1999906812A   1999-02-09
TRIVASCULAR INC.   EP   STENT GRAFT DELIVERY SYSTEM WITH ACCESS CONDUIT | STENTGRAFTEINFÜHRUNGSSYSTEM MIT ZUGANGSKANAL | SYSTEME DE POSE DE GREFFE ET PROTHESE ENDOVASCULAIRE AVEC CONDUIT D’ACCES   EP3209249A1   EP2015852460A   2015-10-22
TRIVASCULAR INC.   EP   INTERNAL ILIAC PRESERVATION DEVICES AND METHODS | VORRICHTUNGEN UND VERFAHREN ZUR INTERNEN BECKENKONSERVIERUNG | DISPOSITIFS ET PROCÉDÉS DE PRÉSERVATION DE L’ILIAQUE INTERNE   EP3226814A1   EP2015816618A   2015-12-03


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC.   EP   INFLATABLE OCCLUSION WIRE- BALLOON FOR AORTIC APPLICATIONS | AUFBLASBARER OKKLUSIONSDRAHTBALLON FÜR ANWENDUNGEN IN DER AORTA | BALLONNET DE FIL D’OCCLUSION GONFLABLE POUR APPLICATIONS AORTIQUES   EP3116439A1   EP2015711020A   2015-03-10
TRIVASCULAR INC.   EP   SYSTEMS FOR GUIDEWIRE CROSSOVER FOR BIFURCATED PROSTHESES | SYSTEME FÜR FÜHRUNGSDRAHTÜBERGANG FÜR VERZWEIGTE PROTHESEN | SYSTÈMES POUR UN CROISEMENT DE FIL-GUIDE POUR DES PROTHÈSES BIFURQUÉES   EP3091944A1   EP2014752969A   2014-07-30
TRIVASCULAR INC.   Germany  

SYSTEMS FOR GUIDEWIRE

CROSSOVER FOR BIFURCATED

PROSTHESES

  3091944   14752969.7   7/18/2018
TRIVASCULAR INC.   UK  

SYSTEMS FOR GUIDEWIRE

CROSSOVER FOR BIFURCATED

PROSTHESES

  3091944   14752969.7   7/18/2018
TRIVASCULAR INC.   IT  

SYSTEMS FOR GUIDEWIRE

CROSSOVER FOR BIFURCATED

PROSTHESES

  3091944   14752969.7   7/18/2018


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC.   EP   TANDEM MODULAR ENDOGRAFT | MODULARES TANDEM-ENDOGRAFT | ENDOGREFFE MODULAIRE EN TANDEM   EP3049021A1   EP2014782021A   2014-09-23
TRIVASCULAR INC.   EP   DURABLE STENT GRAFT WITH TAPERED STRUTS AND STABLE DELIVERY METHODS AND DEVICES | DAUERHAFTES STENTIMPLANTAT MIT KONISCHEN STREBEN UND STABILE FREISETZUNGSVERFAHREN SOWIE VORRICHTUNGEN | ENDOPROTHÈSE VASCULAIRE DURABLE AVEC ENTRETOISES CONIQUES ET PROCÉDÉS ET DISPOSITIFS DE DÉLIVRANCE STABLES   EP2833830A4   EP2013772199A   2013-03-29
TRIVASCULAR INC.   EP   ENDOVASCULAR DELIVERY SYSTEM WITH AN IMPROVED RADIOPAQUE MARKER SCHEME | ENDOVASKULÄRES FREISETZUNGSSYSTEM MIT VERBESSERTEM RÖNTGENMARKERSCHEMA | SYSTÈME DE POSE ENDOVASCULAIRE AYANT UNE TECHNIQUE DE MARQUEUR RADIO-OPAQUE AMÉLIORÉE   EP2861189A1   EP2013733113A   2013-05-31
TRIVASCULAR INC.   EP   BIFURCATED ENDOVASCULAR PROSTHESIS HAVING TETHERED CONTRALATERAL LEG | GEGABELTE ENDOVASKULÄRE PROTHESE MIT ANGEBUNDENEM KONTRALATERALEM BEIN | PROTHÈSE ENDOVASCULAIRE   EP2861183A1   EP2013733115A   2013-05-31


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

    BIFURQUÉE POSSÉDANT UNE JAMBE CONTROLATÉRALE AVEC ATTACHE      
TRIVASCULAR INC.   EP   LOW PROFILE STENT GRAFT AND DELIVERY SYSTEM | FLACHES STENTTRANSPLANTAT UND FREISETZUNGSSYSTEM | ENDOPROTHÈSE VASCULAIRE À PROFIL BAS ET SYSTÈME DE DÉLIVRANCE   EP2833829A1   EP2013717893A   2013-03-21
TRIVASCULAR INC   EP   ALIGNMENT STENT APPARATUS AND METHOD | VORRICHTUNG UND VERFAHREN ZUR STENTAUSRICHTUNG | APPAREIL D’ENDOPROTHÈSE D’ALIGNEMENT ET PROCÉDÉ   EP2194919A4   EP2008834027A   2008-09-25
TRIVASCULAR INC   EP   MODULAR VASCULAR GRAFT FOR LOW PROFILE PERCUTANEOUS DELIVERY | MODULARER GEFÄSSERSATZ FÜR PERKUTANE FREISETZUNG MIT NIEDRIGEM PROFIL | GREFFON VASCULAIRE MODULAIRE POUR ADMINISTRATION PERCUTANÉE À PROFIL RÉDUIT   EP2194921A4   EP2008835032A   2008-10-03
TRIVASCULAR INC   EP   METHOD AND APPARATUS FOR MANUFACTURING AN ENDOVASCULAR GRAFT SECTION | VERFAHREN UND VORRICHTUNG ZUR HERSTELLUNG EINES ENDOVASKULÄREN TRANSPLANTATABSCHNITTS | PROCEDE ET APPAREIL DE   EP1465685A4   EP2002805657A   2002-12-20


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

    FABRICATION D’UNE SECTION DE GREFFON ENDOCORONAIRE      
TRIVASCULAR INC   WO   ENDOLUMINAL PROSTHESIS DEPLOYMENT DEVICES AND METHODS | DISPOSITIFS ET PROCÉDÉS DE DÉPLOIEMENT DE PROTHÈSE ENDOLUMINALE   WO2017019913A1   WO2016US44583A   2016-07-28
TRIVASCULAR INC   WO   STENT-GRAFT WITH IMPROVED FLEXIBILITY | GREFFON DE STENT À FLEXIBILITÉ AMÉLIORÉE   WO2016183128A1   WO2016US31728A   2016-05-11
TRIVASCULAR INC   WO   BALLOON ASSISTED ENDOLUMINAL PROSTHESIS DEPLOYMENT | DÉPLOIEMENT DE PROTHÈSE ENDOLUMINALE ASSISTÉ PAR BALLONNET   WO2016191602A1   WO2016US34427A   2016-05-26
TRIVASCULAR INC   WO   INTERNAL ILIAC PRESERVATION DEVICES AND METHODS | DISPOSITIFS ET PROCÉDÉS DE PRÉSERVATION DE L’ILIAQUE INTERNE   WO2016090112A1   WO2015US63686A   2015-12-03
TRIVASCULAR INC   WO   STENT GRAFT DELIVERY SYSTEM WITH ACCESS CONDUIT | SYSTEME DE POSE DE GREFFE ET PROTHESE ENDOVASCULAIRE AVEC CONDUIT D’ACCES   WO2016065208A1   WO2015US57016A   2015-10-22


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC   WO   INFLATABLE OCCLUSION WIRE- BALLOON FOR AORTIC APPLICATIONS | BALLONNET DE FIL D’OCCLUSION GONFLABLE POUR APPLICATIONS AORTIQUES   WO2015138402A1   WO2015US19626A   2015-03-10
TRIVASCULAR INC   WO   SYSTEMS AND METHODS FOR GUIDEWIRE CROSSOVER FOR BIFURCATED PROSTHESES | SYSTÈMES ET PROCÉDÉS POUR UN CROISEMENT DE FIL-GUIDE POUR DES PROTHÈSES BIFURQUÉES   WO2015105530A1   WO2014US48769A   2014-07-30
TRIVASCULAR INC   WO   TANDEM MODULAR ENDOGRAFT | ENDOGREFFE MODULAIRE EN TANDEM   WO2015048004A1   WO2014US56953A   2014-09-23
TRIVASCULAR INC   WO   ENDOVASCULAR GRAFT FOR ANEURYSMS INVOLVING MAJOR BRANCH VESSELS | GREFFON ENDOVASCULAIRE POUR ANÉVRISMES METTANT EN JEU DES VAISSEAUX RAMIFIÉS PRINCIPAUX   WO2014059114A3   WO2013US64290A   2013-10-10
TRIVASCULAR INC   WO   SAC LINER FOR ANEURYSM REPAIR | REVÊTEMENT SAC POUR RÉPARATION D’ANÉVRISME   WO2014110231A3   WO2014US10828A   2014-01-09
TRIVASCULAR INC   WO   GATE WIRE FOR CONTRALATERAL LEG ACCESS | FIL GUIDE POUR PERMETTRE UN ACCÈS À UN JAMBAGE CONTROLATÉRAL   WO2014110254A1   WO2014US10870A   2014-01-09


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC   WO   BIFURCATED ENDOVASCULAR PROSTHESIS HAVING TETHERED CONTRALATERAL LEG | PROTHÈSE ENDOVASCULAIRE BIFURQUÉE POSSÉDANT UNE JAMBE CONTROLATÉRALE AVEC ATTACHE   WO2013188134A1   WO2013US43630A   2013-05-31
TRIVASCULAR INC   WO   ENDOVASCULAR DELIVERY SYSTEM WITH AN IMPROVED RADIOPAQUE MARKER SCHEME | SYSTÈME DE POSE ENDOVASCULAIRE AYANT UNE TECHNIQUE DE MARQUEUR RADIO-OPAQUE AMÉLIORÉE   WO2013188132A1   WO2013US43615A   2013-05-31
TRIVASCULAR INC   WO   ENDOVASCULAR DELIVERY SYSTEM WITH FLEXIBLE AND TORQUEABLE HYPOTUBE | SYSTÈME DE POSE ENDOVASCULAIRE POURVU D’UN HYPOTUBE FLEXIBLE ET POUVANT ÊTRE SOUMIS À UN COUPLE DE TORSION   WO2013188133A1   WO2013US43623A   2013-05-31
TRIVASCULAR INC   WO   DELIVERY CATHETER FOR ENDOVASCULAR DEVICE | CATHÉTER DE DÉLIVRANCE POUR DISPOSITIF ENDOVASCULAIRE   WO2013151924A1   WO2013US34787A   2013-04-01
TRIVASCULAR INC   WO   DURABLE STENT GRAFT WITH TAPERED STRUTS AND STABLE DELIVERY METHODS AND DEVICES | ENDOPROTHÈSE VASCULAIRE DURABLE AVEC ENTRETOISES CONIQUES ET PROCÉDÉS ET DISPOSITIFS DE DÉLIVRANCE STABLES   WO2013151896A1   WO2013US34654A   2013-03-29


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC   WO   LOW PROFILE STENT GRAFT AND DELIVERY SYSTEM | ENDOPROTHÈSE VASCULAIRE À PROFIL BAS ET SYSTÈME DE DÉLIVRANCE   WO2013151793A1   WO2013US33250A   2013-03-21
TRIVASCULAR INC   WO   ADVANCED KINK-RESISTANT STENT GRAFT | ENDOPROTHÈSE ÉVOLUÉE RÉSISTANT AU PLIAGE   WO2013151794A3   WO2013US33252A   2013-03-21
TRIVASCULAR INC   WO   ADVANCED ENDOVASCULAR GRAFT AND DELIVERY SYSTEM | GREFFE ENDOVASCULAIRE AVANCÉE ET SYSTÈME DE POSE ASSOCIÉ   WO2012068175A3   WO2011US60873A   2011-11-15
TRIVASCULAR INC   WO   FILL TUBE MANIFOLD AND DELIVERY METHODS FOR ENDOVASCULAR GRAFT | COLLECTEUR DE TUBE DE REMPLISSAGE ET PROCÉDÉS DE POSE DE GREFFON ENDOVASCULAIRE   WO2011100367A3   WO2011US24248A   2011-02-09
TRIVASCULAR INC   DE   ENDOVASKULÄRES IMPLANTAT   DE69918272T2   DE69918272A   1999-02-09
TRIVASCULAR INC   CA   VIRTUAL PROTOTYPING AND TESTING FOR MEDICAL DEVICE DEVELOPMENT | ESSAI ET PROTOTYPAGE VIRTUELS DE MISE AU POINT DE DISPOSITIFS MEDICAUX   CA2424252C   CA2424252A   2001-09-28


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC   CA   DELIVERY SYSTEM AND METHOD FOR BIFURCATED GRAFT | METHODE ET SYSTEME DE MISE EN PLACE D’UN GREFFON A BIFURCATION   CA2443104C   CA2443104A   2002-04-11
TRIVASCULAR INC   CA   ENDOVASCULAR GRAFT | GREFFON ENDOVASCULAIRE   CA2501892C   CA2501892A   1999-02-09
TRIVASCULAR INC   CA   INFLATABLE INTRALUMINAL GRAFT | GREFFON INTRALUMINAL GONFLABLE   CA2640263C   CA2640263A   2000-03-03
TRIVASCULAR INC   CA   INFLATABLE INTRALUMINAL GRAFT | GREFFON INTRALUMINAL GONFLABLE   CA2376253C   CA2376253A   2000-03-03
TRIVASCULAR INC   CA   ENDOVASCULAR GRAFT | GREFFON ENDOVASCULAIRE   CA2319052C   CA2319052A   1999-02-09
TRIVASCULAR INC   AU   Modular vascular graft for low profile percutaneous delivery   AU2008308474B2   AU2008308474A   2008-10-03
TRIVASCULAR INC   AU   Advanced endovascular graft   AU2009230748B2   AU2009230748A   2009-10-26
TRIVASCULAR INC   AU   Advanced endovascular graft   AU2009201682B2   AU2009201682A   2009-04-28
TRIVASCULAR INC   AU   Method and apparatus for manufacturing an endovascular graft section   AU2008258148B2   AU2008258148A   2008-12-17
TRIVASCULAR INC   AU   Advanced endovascular graft   AU2002360765C1   AU2002360765A   2002-12-20


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC   AU   Method and apparatus for manufacturing an endovascular graft section   AU2002366805B8   AU2002366805A   2002-12-20
TRIVASCULAR INC   AU   Virtual prototyping and testing for medical device development   AU2001293179A1   AU2001293179A   2001-09-28
TRIVASCULAR INC   AU  

Delivery system and method for

expandable intracorporeal device

  AU200133250A   AU200133250A   2001-02-01
TRIVASCULAR INC   JP   ADVANCED KINK-RESISTANT STENT GRAFT   6297023   2015-504610   3/2/2018
TRIVASCULAR INC   UK  

INFLATABLE OCCLUSION WIRE-

BALLOON FOR AORTIC

APPLICATIONS

  15711020.6   3116439   2/7/2018
TRIVASCULAR INC   UK  

PASSIVE HEMOSTATIC SHEATH

VALVE

  04780128.7   1651135   2/28/2018
TRIVASCULAR INC   CN   MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES     201810370663.0   2015-5-5
ENDOLOGIX, INC.   CN   CATHETER SYSTEM AND METHODS OF USING SAME   ZL201510649289.4   201510649289.4   2018-6-8
ENDOLOGIX, INC.   JP   CATHETER SYSTEM AND METHODS OF USING SAME   6294669   2013-556828   2018-2-23
TRIVASCULAR INC   Germany  

PASSIVE HEMOSTATIC SHEATH

VALVE

  1651135   04780128.7   2018-2-28
ENDOLOGIX, INC.   JP   BALLOON ASSISTED ENDOLUMINAL PROSTHESIS DEPLOYMENT     2017-560952   5/26/2016
ENDOLOGIX, Inc.   EP   SYSTEMS AND METHODS WITH FENESTRATED GRAFT AND FILLING STRUCTURE     16882476.1   12/23/2016


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

ENDOLOGIX, Inc.   JP   SYSTEMS AND METHODS WITH FENESTRATED GRAFT AND FILLING STRUCTURE     2018-534852   12/23/2016
ENDOLOGIX INC.   US  

STENT GRAFT SYSTEMS WITH

RESTRAINTS IN CIRCUMFERENTIAL

CHANNELS AND METHODS

THEREOF

    62/678961   5/31/2018
ENDOLOGIX INC.   US  

PERCUTANEOUS METHOD AND

DEVICE TO TREAT DISSECTIONS

    15/429090   2/9/2017
NELLIX, INC.   US  

SYSTEM AND METHODS FOR

ENDOVASCULAR ANEURYSM

TREATMENT

  2018-0064566   15/682414   8/21/2017
TRIVASCULAR INC.   US  

ENDOVASCULAR DELIVERY

SYSTEM WITH AN IMPROVED

RADIOPAQUE MARKER SCHEME

    16/049560   7/30/2018
ENDOLOGIX INC.   PCT   SINGLE PUNCTURE BIFURCATION GRAFT DEPLOYMENT SYSTEM   WO2000053251   PCT/US2000/006070   3/7/2000
ENDOLOGIX INC.   PCT   GRAFT DEPLOYMENT SYSTEM   WO2004047885   PCT/US2003/37685   11/25/2003
ENDOLOGIX INC.   PCT  

DUAL CONCENTRIC GUIDEWIRE

AND METHODS OF BIFURCATED GRAFT DEPLOYMENT

  WO2008089097   PCT/US2008/050915   1/11/2008
ENDOLOGIX INC.   PCT  

ENDOLUMENAL VASCULAR

PROSTHESIS WITH NEOINTIMA

INHIBITING POLYMERIC SLEEVE

  WO2005096997   PCT/US2005/11522   4/6/2005
ENDOLOGIX INC.   PCT   IMPLANTABLE VASCULAR GRAFT   WO2002039888   PCT/US2001/47028   11/8/2001
ENDOLOGIX INC.   PCT   DUAL WIRE PLACEMENT CATHETER   WO2001003762   PCT/US2000/016352   6/14/2000
ENDOLOGIX INC.   PCT  

MULTI-SEGMENTED GRAFT

DEPLOYMENT SYSTEM

  WO2008034106   PCT/US2007/78565   9/14/2007
ENDOLOGIX INC.   PCT   METHOD AND APPARATUS FOR DECOMPRESSING ANEURYSMS   WO2005099807   PCT/US2005/12306   4/12/2005


Grantor

 

Country

 

Patent

 

Publication/

Patent No.

 

Application

Number

 

Application

Date

TRIVASCULAR INC.   EP  

ENDOLUMINAL PROSTHESIS

DEPLOYMENT DEVICES AND

METHODS

  3328326   16831382.3   7/28/2016
TRIVASCULAR INC.   EP   BALLOON ASSISTED ENDOLUMINAL PROSTHESIS DEPLOYMENT   3302356   16800744.1   5/26/2016
TRIVASCULAR INC.   EP  

STENT-GRAFT WITH IMPROVED

FLEXIBILITY

  3294210   16793394.4   5/11/2016
TRIVASCULAR INC.   EP   PTFE LAYERS AND METHODS OF MANUFACTURING   3095585   16171681.6   3/30/2006


SCHEDULE 11

TRADEMARKS

See attached.


Trademarks

 

Grantor

  

Country

  

Mark

  

Application No.

  

Application Date

  

Registration No.

  

Registration Date

Endologix, Inc.    U.S.    LOGO    86/854470    12/18/15      
Endologix, Inc.    U.S.    ACTIVESEAL    85/518,608    01/17/12    5396605    02/06/18
Endologix, Inc.    U.S.    AFX    85/069,068    06/22/10    4214460    09/25/12
Endologix, Inc.    U.S.    ANGIOTIP    85/767055    10/30/12    5205176    05/16/17
Endologix, Inc.    U.S.    DURAPLY    86/362822    08/11/14    5433696    3/27/18
Endologix, Inc.    U.S.    ENDOLOGIX    75/323,314    07/11/97    2257799    06/29/99
Endologix, Inc.    U.S.    EVAS FORWARD    86/116940    11/12/13    5306786    10/10/17
Endologix, Inc.    U.S.   

INNOVATION

TAKING SHAPE

   85/369,728    07/12/11    4220343    10/09/12
Endologix, Inc.    U.S.   

INNOVATION

THAT EMPOWERS

   85/514516    01/11/12    4841631    10/27/15
Endologix, Inc.    U.S.    INTELIX    86/316249    06/20/14    5059968    10/11/16
Endologix, Inc.    U.S.    INTUITRAK    77/494,729    06/09/08    3649757    07/07/09
Endologix, Inc.    U.S.   

INTUITRAK

DELIVERY

SYSTEM

   77/520,529    07/11/08    3649866    07/07/09
Endologix, Inc.    U.S.    NELLIX    77/090544    01/24/07    3880178    11/23/10


Endologix, Inc.    U.S.    POWERLINK    75/658,969    03/12/99    2456038    05/29/01
Endologix, Inc.    U.S.    POWERLINK XL    78/718,728    09/22/05    3573999    02/10/09
Endologix, Inc.    U.S.    SUREPASS    78/965,443    08/31/06    3593259    03/17/09
Endologix, Inc.    U.S.    VELA    85/857988    02/22/13    5296578    09/26/17
Endologix, Inc.    U.S.    XPAND    85/126,464    09/09/10    4168563    07/03/12
Endologix, Inc.    Argentina    LOGO    3514846    06/16/16    2888199    05/19/17
Endologix, Inc.    Argentina    LOGO    3514844    06/16/16    2888198    05/19/17
Endologix, Inc.    Argentina    LOGO    3514844    06/16/16      
Endologix, Inc.    Argentina    LOGO    3514842    06/16/16    2888196    05/19/17
Endologix, Inc.    Argentina    AFX    3064304    01/27/11    2496722    04/04/12
Endologix, Inc.    Argentina    DURAPLY    3386456    02/11/15    2773735    12/09/15
Endologix, Inc.    Argentina    INTELIX    3375648    12/19/14    2766285    12/04/15
Endologix, Inc.    Argentina    INTELIX    3375649    12/19/14    2766286    11/04/15


Endologix, Inc.    Argentina    INTELIX    3375650    12/19/14    2766287    11/04/15
Endologix, Inc.    Argentina    NELLIX    3243024    05/02/13    2658594    06/26/14
Endologix, Inc.    Argentina    VELA    3271551    08/22/13    2808433    06/03/16
Endologix, Inc.    Argentina    XPAND    3072929    03/16/11    2506706    06/01/12
Endologix, Inc.    Australia    LOGO    1326557    06/14/16    1326557    04/24/17
Endologix, Inc.    Australia    DURAPLY    1710503    02/10/15    1710503    11/04/15
Endologix, Inc.    Australia    INTELIX    1247823    12/19/14    1247823    11/25/16
Endologix, Inc.    Brazil    LOGO    911.201.521    06/17/16      
Endologix, Inc.    Brazil    LOGO    911.201.572    06/17/16      
Endologix, Inc.    Brazil    LOGO    911.201.599    06/17/16      
Endologix, Inc.    Brazil    LOGO    911.201.602    06/17/16      
Endologix, Inc.    Brazil    ACTIVESEAL    909861684    08/20/15      


Endologix, Inc.    Brazil    AFX    830891226    12/21/10      
Endologix, Inc.    Brazil    AFX    912186283    01/19/17      
Endologix, Inc.    Brazil    DURAPLY    909861722    08/20/15      
Endologix, Inc.    Brazil    INTELIX    909861749    08/20/15      
Endologix, Inc.    Brazil    INTELIX    909861765    08/20/15      
Endologix, Inc.    Brazil    INTELIX    909861773    08/20/15      
Endologix, Inc.    Brazil    NELLIX    840506538    05/06/13    840506538    02/16/16
Endologix, Inc.    Brazil    VELA    840618530    08/22/13      
Endologix, Inc.    Canada    DURAPLY    1714718    02/10/15      
Endologix, Inc.    Canada    INTELIX    1707569    12/17/14      
Endologix, Inc.    Canada    VELA    1640416    08/21/13      
Endologix, Inc.    Chile    XPAND    1137099    12/30/14    1187135    11/27/15
Endologix, Inc.    China    LOGO    1326551    06/14/16      
Endologix, Inc.    China    DURAPLY    1257411    02/10/15    1257411    02/10/15
Endologix, Inc.    China    INTELIX    1247823    12/19/14    1247823    12/19/14
Endologix, Inc.    Colombia    AFX    16-133051    05/11/26    582446    11/17/17
Endologix, Inc.    Colombia    ENDOLOGIX    16-121402    05/11/16    582446    11/17/17
Endologix, Inc.    Colombia    XPAND    1246435    12/26/14    1246435    12/26/14


Endologix, Inc.   

European

Community

   AFX    009609884    12/20/10    009609884    12/01/11
Endologix, Inc.   

European

Community

   ANGIOTIP    011780129    04/30/13    011780129    09/24/13
Endologix, Inc.   

European

Community

  

CLASSICAL

REMODELING

   4598728    08/19/05    4598728    08/02/06
Endologix, Inc.   

European

Community

   DURAPLY    1257411    02/10/15    1257411    02/10/15
Endologix, Inc.   

European

Community

   ENDOLOGIX, INC.    720649    01/12/98    720649    01/12/98
Endologix, Inc.   

European

Community

   INTELIX    13361399    10/15/14      
Endologix, Inc.   

European

Community

   INTUITRAK    7453401    11/28/08    7453401    09/21/09
Endologix, Inc.   

European

Community

  

INTUITRAK

DELIVERY

SYSTEM

   7513302    12/23/08    7513302    07/21/09
Endologix, Inc.   

European

Community

   NELLIX    011771011    04/26/13    011771011    09/18/13
Endologix, Inc.   

European

Community

   POWERLINK XL    5002977    03/22/06    5002977    04/11/07
Endologix, Inc.   

European

Community

  

VISIFLEX

DELIVERY

SYSTEM

   5075528    04/24/06    5075528    04/16/07
Endologix, Inc.   

European

Community

  

VISIFLEX SURE

PASS

   5749338    02/28/07    5749338    01/31/08


Endologix, Inc.    European Union    LOGO    1326551    06/14/16    1326551    06/12/17
Endologix, Inc.    France    POWERLINK    043299490    09/13/99    043299490    12/31/04
Endologix, Inc.    Hong Kong    DURAPLY    303301280    02/15/15    303301280    10/05/15
Endologix, Inc.    Hong Kong    INTELIX    303240954    12/18/14    303240954    09/07/16
Endologix, Inc.    Italy    POWERLINK    001724    09/13/99    0001376420    02/27/08
Endologix, Inc.    Japan    LOGO    1326551    06/14/16    1326551    05/02/17
Endologix, Inc.    Japan    ACTIVESEAL    2015-078597    08/17/15    5857166    06/10/16
Endologix, Inc.    Japan    AFX    2015-078596    08/17/15    5824704    02/05/16
Endologix, Inc.    Japan    DURAPLY    1257411    02/10/15    1257411    01/19/16
Endologix, Inc.    Japan    ENDOLOGIX, INC.    1155/1998    01/12/98    4352035    01/14/00
Endologix, Inc.    Japan    INTELIX    1247823    12/19/14    1247823    10/27/15
Endologix, Inc.    Japan    NELLIX    2013-031634    04/25/13    5613989    09/06/13
Endologix, Inc.    Japan    VELA    2013-6/4901    08/21/13      
Endologix, Inc.    Japan   

VISIFLEX

DELIVERY

SYSTEM

   2006-035170    04/17/06    4974084    07/28/06
Endologix, Inc.    Japan   

VISIFLEX

SUREPASS

   2007-017236    02/28/07    5066349    07/27/07


Endologix, Inc.    Korea    DURAPLY    1257411    02/10/15    1257411    02/10/15
Endologix, Inc.    Korea    INTELIX    1247823    12/19/14    1247823    06/13/16
Endologix, Inc.    Malaysia    DURAPLY    2015052019    02/11/15    2015052019    12/29/16
Endologix, Inc.    Malaysia    INTELIX    2014069128    12/18/14    2014069128    04/22/16
Endologix, Inc.    Malaysia    INTELIX    2014069135    12/18/14    2014069135    05/10/16
Endologix, Inc.    Mexico    XPAND    1246435    12/26/14    1246435    07/26/16
Endologix, Inc.    New Zealand    DURAPLY    1024501    02/10/15    1024501    12/02/15
Endologix, Inc.    New Zealand    INTELIX    1247823    12/19/14    1019974    09/27/16
Endologix, Inc.    Peru    XPAND    601318    12/29/14    00223114    04/22/15
Endologix, Inc.    Singapore    DURAPLY    40201513229    02/10/15    40201513229    01/06/16
Endologix, Inc.    Singapore    INTELIX    40201508694    12/19/14    40201508694    11/11/15
Endologix, Inc.    Taiwan    DURAPLY    104008448    02/11/15    1764288    04/16/16
Endologix, Inc.    Taiwan    INTELIX    103072703    12/18/14    1740066    11/16/15
Endologix, Inc.    Thailand    DURAPLY    973443    02/11/15    171110590    09/28/17
Endologix, Inc.    Thailand    INTELIX    966979    12/19/14      
Endologix, Inc.    Thailand    INTELIX    966980    12/19/14      
Endologix, Inc.    United Kingdom    POWERLINK    2369587    09/13/99    2369587    12/09/05
Endologix, Inc.    Venezuela    XPAND    20754-14    12/30/14    P352404    06/07/16
Endologix, Inc.    Vietnam    DURAPLY    1257411    02/10/15    1257411    11/03/16


Endologix, Inc.    Vietnam    INTELIX    1247823    12/19/14    1247823    05/21/15
Endologix, Inc.    U.S.    ALTO    87/906,099    5/3/2018      
Endologix, Inc.    U.S.    VERTA    87/116,482    7/26/2016      
TriVascular, Inc.    U.S.    ALLEGRO    86/758,465    9/16/2015      
TriVascular, Inc.    U.S.    CUSTOMSEAL    86/047,875    8/26/2013    4,732,342    5/5/2015
TriVascular, Inc.    U.S.    OVATION    77/941,535    2/22/2010    4,440,468    11/26/2013
TriVascular, Inc.    U.S.    OVATION ALTO    86/047,894    8/26/2013    5,195,890    5/2/2017
TriVascular, Inc.    U.S.    OVATION PRIME    85/900,037    4/10/2013    4,452,625    12/17/2013
TriVascular, Inc.    U.S.    LOGO    85/832,445    1/25/2013    4,449,077    12/10/2013
TriVascular, Inc.    U.S.    TRIVASCULAR    75/879,907    12/21/1999    2,867,015    7/27/2004
TriVascular, Inc.    U.S.    LOGO    85/831,355    1/24/2013    4,395,789    9/3/2013
TriVascular, Inc.    Australia    CUSTOMSEAL    1608471    2/27/2014    1608471    1/21/2015
TriVascular, Inc.    Australia    OVATION    1379343    8/20/2010    1379343    1/10/2011
TriVascular, Inc.    Australia    OVATION ALTO    1608211    2/26/2014    1608211    5/28/2014
TriVascular, Inc.    Australia    OVATION PRIME    1583683    10/2/2013    1583683    1/7/2014
TriVascular, Inc.    Australia    LOGO    1537921    1/29/2013    1537921    7/31/2013
TriVascular, Inc.    Australia    TRIVASCULAR    888603    9/7/2001    888603    9/7/2001
TriVascular, Inc.    Australia    LOGO    983475    12/30/2003    983475    8/16/2004


TriVascular, Inc.    Brazil    CUSTOMSEAL    840.803.346    2/26/2014    840803346    10/18/2016
TriVascular, Inc.    Brazil    OVATION    830727035    8/20/2010    830727035    1/6/2015
TriVascular, Inc.    Brazil    OVATION ALTO    840.803.419    2/26/2014      
TriVascular, Inc.    Brazil    OVATION PRIME    840.666.152    10/4/2013    840666152    8/23/2016
TriVascular, Inc.    Brazil    LOGO    830854487    11/24/2010    830854487    6/3/2014
TriVascular, Inc.    Canada    CUSTOMSEAL    1,665,277    2/25/2014      
TriVascular, Inc.    Canada    OVATION    1493184    8/20/2010    TMA858,759    8/28/2013
TriVascular, Inc.    Canada    OVATION ALTO    1,665,276    2/25/2014      
TriVascular, Inc.    Canada    OVATION PRIME    1,645,991    10/2/2013      
TriVascular, Inc.    Canada    LOGO    1,611,335    1/25/2013    TMA934,553    4/12/2016
TriVascular, Inc.    Canada    TRIVASCULAR    1,612,136    1/31/2013    TMA882,992    7/29/2014
TriVascular, Inc.    Canada    LOGO    1200748    12/30/2003    TMA825955    6/8/2012
TriVascular, Inc.    China    CUSTOMSEAL    14075157    2/26/2014    14075157    4/28/2015
TriVascular, Inc.    China    OVATION    8598413    8/23/2010    8598413    11/7/2011
TriVascular, Inc.    China    OVATION ALTO    14075158    2/26/2014    14075158    4/28/2015
TriVascular, Inc.    China    OVATION PRIME    13321289    10/8/2013    13321289    6/21/2015

TriVascular, Inc.

   China    LOGO    8898103    11/30/2010    8898103    12/14/2011


TriVascular, Inc.    EUTM    OVATION    009325234    8/20/2010    009325234    2/3/2011
TriVascular, Inc.    EUTM    OVATION ALTO    012636908    2/25/2014    012636908    7/16/2014
TriVascular, Inc.    EUTM    OVATION PRIME    012189148    10/2/2013    012189148    2/26/2014
TriVascular, Inc.    EUTM    LOGO    011523305    1/28/2013    011523305    6/24/2013
TriVascular, Inc.    EUTM    TRIVASCULAR    002374593    9/13/2001    002374593    3/12/2003
TriVascular, Inc.    EUTM    LOGO    003598836    12/31/2003    003598836    4/29/2005
TriVascular, Inc.    EUTM   

TRIVASCULAR2 &

Design

   007457344    11/27/2008    007457344    6/16/2009
TriVascular, Inc.    India    OVATION    2012141    8/20/2010    2012141    8/23/2016
TriVascular, Inc.    India    LOGO    2060383    11/29/2010    2060383    11/29/2010
TriVascular, Inc.    Japan    CUSTOMSEAL    2014-14237    2/26/2014    5672406    5/23/2014
TriVascular, Inc.    Japan    OVATION    2010-065871    8/20/2010    5614976    9/13/2013
TriVascular, Inc.    Japan    OVATION ALTO    2014-14238    2/26/2014    5672407    5/23/2014
TriVascular, Inc.    Japan    OVATION PRIME    2013-024875    4/4/2013    5613251    9/6/2013
TriVascular, Inc.    Japan    LOGO    2013-5504    1/30/2013    5643434    1/17/2014
TriVascular, Inc.    Japan    TRIVASCULAR    2001-115594    12/27/2001    4731627    12/5/2003
TriVascular, Inc.    Japan    LOGO    2004-030615    3/18/2004    4778040    6/11/2004
TriVascular, Inc.    Mexico    OVATION    1113689    8/20/2010    1235645    8/20/2010
TriVascular, Inc.    Mexico    LOGO    1139285    12/2/2010    1213946    4/27/2011

Exhibit 10.6

INTERCOMPANY SUBORDINATION AGREEMENT

THIS INTERCOMPANY SUBORDINATION AGREEMENT (this “ Subordination Agreement ”), dated as of August 9, 2018 is made among the companies from time to time party hereto (the “ Companies ”), and Deerfield Private Design Fund IV, L.P. , a Delaware limited partnership (“ Deerfield PDF ”), as agent (in such capacity, together with its successors and assigns in such capacity, the “ Agent ”) for the Secured Parties (as defined in the below-defined Facility Agreement).

WHEREAS, Endologix, Inc., a Delaware corporation (the “ Borrower ”), the other Companies from time to time party thereto, the lenders from time to time party thereto (the “ Lenders ”) and Agent are parties to that certain Amended and Restated Facility Agreement, dated as of even date herewith (as amended, restated, supplemented or otherwise modified from time to time, the “ Facility Agreement ”), pursuant to which the Lenders have made loans and other financial accommodations to the Borrower and the other Companies and have agreed to make certain amendments and restatements to the Prior Facility Agreement (as defined in the Facility Agreement);

WHEREAS, the Companies have entered into that certain Amended and Restated Guaranty and Security Agreement, dated as of even date herewith (as amended, restated, supplemented or otherwise modified from time to time, the “ Amended and Restated Guaranty and Security Agreement ”), in favor of Agent, pursuant to which such Companies (together with any other Person (as defined in the below-defined Facility Agreement) who is a “Guarantor,” as defined in the Facility Agreement, the “ Guarantors ;” and together with the Borrower, the “ Obligors ”) have guaranteed the obligations (including any Non-Callable Make Whole Amount, any CoC Fee, the Exit Payment and all other Obligations) of the Borrower and the other Companies under the Facility Agreement and the other Loan Documents;

WHEREAS, each Company has made or may make certain loans or advances from time to time to one or more Obligors; and

WHEREAS, in order to induce the Agent and the Lenders to (a) continue to allow the Loans and other financial accommodations under the Loan Documents to remain outstanding, (b) provide for the amendment and restatement of the Prior Facility Agreement and (c) permit the ABL Credit Facility pursuant to the terms of the Facility Agreement and the other Loan Documents, each Company has agreed to the subordination of such indebtedness of each Obligor to such Company, upon the terms and subject to the conditions set forth in this Subordination Agreement.

NOW, THEREFORE, in consideration of the mutual promises, covenants, conditions, representations, and warranties set forth herein and for other good and valuable consideration, the parties hereto agree as follows:


SECTION 1. Definitions; Interpretation .

(a) Terms Defined in Facility Agreement . All capitalized terms used in this Subordination Agreement and not otherwise defined herein shall have the meanings assigned to them in the Facility Agreement.

(b) Certain Defined Terms . As used in this Subordination Agreement, the following terms shall have the following meanings:

Discharge of Senior Indebtedness ” means the Final Payment.

Insolvency Events ” has the meaning set forth in Section  3 .

Intercompany Subordinated Debt ” means, with respect to each Company, all indebtedness, liabilities, and other obligations of each Obligor owing to such Company, whether now existing or hereafter arising, and whether due or to become due, absolute or contingent, liquidated or unliquidated, determined or undetermined, including all fees and all other amounts payable by any Obligor to such Company under or in connection with any documents or instruments related thereto.

Intercompany Subordinated Debt Payment ” means any payment or distribution by or on behalf of the Obligors, directly or indirectly, of assets of the Obligors of any kind or character, whether in cash, property, or securities for or on account of the Intercompany Subordinated Debt, including on account of the purchase, redemption, or other acquisition of Intercompany Subordinated Debt, as a result of a collection, sale, or other disposition of collateral, or by setoff, exchange, or in any other manner.

Senior Indebtedness ” means the Obligations (as defined in the Facility Agreement) and other indebtedness and liabilities of the Obligors to the Secured Parties under or in connection with the Facility Agreement, the Amended and Restated Guaranty and Security Agreement and/or the other Loan Documents, including any Non-Callable Make Whole Amount, any CoC Fee, the Exit Payment, all unpaid principal of the outstanding Loans, all interest accrued thereon (including all interest that, but for the provisions of the Bankruptcy Code, would have accrued), all fees due under the Facility Agreement and the other Loan Documents (including all fees that, but for the provisions of the Bankruptcy Code, would have accrued), and all other amounts payable by the Obligors to the Agent and the other Secured Parties thereunder or in connection therewith, whether now existing or hereafter arising, and whether due or to become due, absolute or contingent, liquidated or unliquidated, determined or undetermined.

(c) Interpretation . Unless the context of this Subordination Agreement clearly requires otherwise, references to the plural include the singular, references to the singular include the plural, the term “including” is not limiting, and the term “or” has, except where otherwise indicated, the inclusive meaning represented by the phrase “and/or.” The words “hereof,” “herein,” “hereby,” “hereunder,” and similar terms in this Subordination Agreement refer to this Subordination Agreement as a whole and not to any particular provision of this Subordination Agreement. Section, subsection, clause, schedule, and exhibit references are to this Subordination Agreement unless otherwise specified. References to agreements and other

 

-2-


contractual instruments shall be deemed to include all subsequent amendments and other modifications thereto. References to statutes or regulations are to be construed as including all statutory and regulatory provisions consolidating, amending, or replacing the statute or regulation referred to. The captions and headings are for convenience of reference only and shall not affect the construction of this Subordination Agreement.

SECTION 2. Subordination to Payment of Senior Indebtedness . As to each Company, all payments on account of the Intercompany Subordinated Debt shall be subject, subordinate, and junior, in right of payment and exercise of remedies, to the extent and in the manner set forth herein, to the prior Discharge of Senior Indebtedness.

SECTION 3. Subordination Upon Any Distribution of Assets of the Obligor s . As to each Company, in the event of any payment or distribution of assets of any Obligor (the “ Affected Obligor ”) of any kind or character, whether in cash, property, or securities, upon the dissolution, winding up, or total or partial liquidation or reorganization, readjustment, arrangement, or similar proceeding relating to such Obligor or its property, whether voluntary or involuntary, or in bankruptcy, insolvency, receivership, arrangement, or similar proceedings or upon an assignment for the benefit of creditors, or upon any other marshaling or composition of the assets and liabilities of such Obligor, or otherwise (such events, other than any such events permitted by the Loan Documents, collectively, the “ Insolvency Events ”): (i) the Discharge of Senior Indebtedness must have occurred before any Intercompany Subordinated Debt Payment is made by or on behalf of the Affected Obligor; and (ii) to the extent permitted by Applicable Law, any Intercompany Subordinated Debt Payment to which such Company would be entitled except for the provisions hereof, shall be paid or delivered by the trustee in bankruptcy, receiver, assignee for the benefit of creditors, or other liquidating agent making such payment or distribution directly to Agent, for the benefit of itself and the other Secured Parties, for application to the payment of the Senior Indebtedness in accordance with clause (i) and Section 2.3(d) of the Facility Agreement, after giving effect to any concurrent payment or distribution or provision therefor to Agent or any other Secured Party in respect of such Senior Indebtedness.

SECTION 4. Payments on Intercompany Subordinated Debt .

(a) Permitted Payments . So long as no Event of Default would result therefrom or has occurred and is continuing, each Obligor may make, and each Company shall be entitled to accept and receive, payments on account of the Intercompany Subordinated Debt in the ordinary course of business and any other payment permitted by the Loan Documents, in each case, in accordance with the terms of the Loan Documents.

(b) No Payment Upon Senior Indebtedness Defaults . Upon the occurrence of any Event of Default, and until such Event of Default is cured or waived in accordance with the terms of the Facility Agreement, each Obligor shall not make, and each Company shall not accept or receive, any Intercompany Subordinated Debt Payment; provided , however , notwithstanding the foregoing, (i) any Obligor may pay to the Borrower, and the Borrower may accept and receive payments on account of any Intercompany Subordinated Debt owed to the Borrower so long as such payments are immediately remitted to a deposit account or securities account that is subject to a Control Agreement and (ii) any Obligor that is not the Borrower may

 

-3-


pay to a Guarantor, and a Guarantor may accept and receive payments on account of any Intercompany Subordinated Debt owed to such Guarantor so long as such payments are immediately remitted to a deposit account or securities account that is subject to a Control Agreement; provided , further , that each Obligor shall be permitted to make any such payments missed due to the application of this sentence upon the written waiver of any such Event of Default in accordance with the terms of the Facility Agreement.

SECTION 5. Subordination of Remedies . Until the Discharge of Senior Indebtedness, following the occurrence of any Event of Default and until such Event of Default is cured or waived in accordance with the terms of the Facility Agreement, each Company shall not, without the prior written consent of Agent:

(a) accelerate, make demand, or otherwise make due and payable prior to the original due date thereof any Intercompany Subordinated Debt or bring suit or institute any other actions or proceedings to enforce its rights or interests in respect of the obligations of any Obligor owing to such Company;

(b) exercise any rights under or with respect to guaranties of the Intercompany Subordinated Debt, if any;

(c) exercise any rights to set-offs and counterclaims in respect of any indebtedness, liabilities, or obligations of such Company to any Obligor against any of the Intercompany Subordinated Debt; or

(d) commence, or cause to be commenced, or join with any creditor other than Agent and the other Secured Parties in commencing, any bankruptcy, insolvency, or receivership proceeding against any Obligor.

SECTION 6. Payment Over to Agent . In the event that, notwithstanding the provisions of Section  3 , Section  4 , and Section  5 , any Intercompany Subordinated Debt Payments shall be received in contravention of Section  3 , Section  4 , or Section  5 by any Company before the Discharge of Senior Indebtedness has occurred, such Intercompany Subordinated Debt Payments shall be held in trust for the benefit of Agent, for the benefit of itself and the other Secured Parties, and shall be paid over or delivered to Agent, for the benefit of the itself and the other Secured Parties, for application to the payment, in full, in cash or Cash Equivalents of all Senior Indebtedness remaining unpaid to the extent necessary to give effect to Section  3 , Section  4 , and Section  5 and to the extent necessary to cause a Discharge of Senior Indebtedness to occur, after giving effect to any concurrent payments or distributions to Agent or any other Secured Party in respect of the Senior Indebtedness.

SECTION 7. Insolvency .

(a) Authorization to Agent . If, while any Intercompany Subordinated Debt is outstanding, any Insolvency Event shall occur and be continuing with respect to any Obligor or its property: (i) Agent hereby is irrevocably authorized and empowered (in the name of each Company or otherwise), but shall have no obligation, to demand, sue for, collect, and receive every payment or distribution in respect of the Intercompany Subordinated Debt owing by the

 

-4-


Affected Obligor and give acquittance therefor and to file claims and proofs of claim (as set forth below in Section 7(b)) and take such other action (including voting such Intercompany Subordinated Debt) as it may deem necessary or advisable for the exercise or enforcement of any of the rights or interests of Agent or any other Secured Party; and (ii) each Company shall promptly take such action as Agent reasonably may request (A) to collect the Intercompany Subordinated Debt owing by the Affected Obligor for the account of Agent and the other Secured Parties and to file appropriate claims or proofs of claim in respect of the Intercompany Subordinated Debt, (B) to execute and deliver to Agent such powers of attorney, assignments, and other instruments as it may request to enable it to enforce any and all claims with respect to such Intercompany Subordinated Debt, and (C) to collect and receive any and all Intercompany Subordinated Debt Payments owing by the Affected Obligor.

(b) Rights in Insolvency Events .

(i) Each of the Companies hereby authorizes and empowers the Agent, for the benefit of itself and the other Secured Parties, in any Insolvency Event to file a proof of claim on behalf of such Company with respect to the Intercompany Subordinated Debt owing by the Affected Obligor (A) if such Company fails to file such proof of claim prior to thirty (30) days before the expiration of the time period during which such claims must be submitted, or (B) if the Agent, exercising reasonable discretion, believes that any statements or assertions in a proof of claim filed by such Company are not consistent with the terms and conditions hereof; provided , however , that any failure of the Agent to file such proof of claim shall not be deemed to be a waiver by the Agent of any of the rights and benefits granted herein by such Company. Each Company shall provide the Agent with a copy of any proof of claim filed by such Company in any Insolvency Event.

(ii) Each Company hereby irrevocably grants the Agent the sole and exclusive authority and power in any Insolvency Event, unless and until this Subordination Agreement is terminated in accordance with its terms: (A) to accept and receive any payment or distribution which may be payable or deliverable at any time upon or in respect of the Intercompany Subordinated Debt owing by the Affected Obligor; and (B) to take such other action as may be necessary or advisable to effectuate the foregoing. Each Company shall provide to the Agent all information and documents necessary to present claims or seek enforcement as described in the immediately preceding sentence.

(iii) Each of the Companies hereby agrees that, while it shall retain the right to vote its claims and, except as otherwise provided in this Subordination Agreement, otherwise act in any Insolvency Event relative to any Obligor (including, without limitation, the right to vote to accept or reject any plan of partial or complete liquidation, reorganization, arrangement, composition, or extension), such Company shall not: (A) take any action or vote in any way so as to directly or indirectly challenge or contest (1) the validity or the enforceability of the Facility Agreement, the Amended and Restated Guaranty and Security Agreement, the other Loan Documents, or the Liens and security interests granted to Agent with respect to the Senior Indebtedness, (2) the rights and duties of Agent or the other Secured Parties established in the Facility Agreement, the Amended and Restated Guaranty and Security Agreement or any other Loan Document, or (3) the validity or enforceability of this Subordination Agreement; (B) seek,

 

-5-


or acquiesce in any request, to dismiss any Insolvency Event or to convert an Insolvency Event under chapter 11 of the Bankruptcy Code to a case under chapter 7 of the Bankruptcy Code; (C) seek, or acquiesce in any request for, the appointment of a trustee or examiner with expanded powers for any Obligor; (D) propose, vote in favor of or otherwise approve a plan of reorganization, arrangement or liquidation, or file any motion or pleading in support of any plan of reorganization, arrangement or liquidation, unless it provides for the Discharge of Senior Indebtedness or unless Agent has approved of the treatment of its claims with respect to the Senior Indebtedness under such plan; (E) object to the treatment under a plan of reorganization or arrangement of Agent’s claims with respect to the Senior Indebtedness; (F) seek relief from the automatic stay of Section 362 of the Bankruptcy Code or any other stay in any Insolvency Event in respect of any portion of the Collateral; or (G) directly or indirectly oppose any relief requested or supported by Agent, on behalf of the itself and the other Secured Parties, including any sale or other disposition of property free and clear of the Liens and security interests of any Company under Section 363(f) of Title 11 of the United States Code or any other similar provision of Applicable Law.

SECTION 8. Certain Agreements of Each Company .

(a) No Benefits . Each Company understands that there may be various agreements between Agent, the other Secured Parties and the Obligors evidencing and governing the Senior Indebtedness, and each Company acknowledges and agrees that (except to the extent provided in any such agreement) such agreements are not intended to confer any benefits on such Company and that neither Agent nor any other Secured Party shall have any obligation to such Company (except to the extent expressly provided in any such agreement) or any other Person to exercise any rights, enforce any remedies, or take any actions which may be available to them under such agreements.

(b) No Interference . Each Company acknowledges that each Obligor has granted to Agent, for the benefit of the Secured Parties, security interests in all of such Obligor’s assets, and agrees not to interfere with or in any manner oppose a disposition of any Collateral by Agent in accordance with Applicable Law.

(c) Reliance by Agent and the Other Secured Parties . Each Company acknowledges and agrees that Agent and the other Secured Parties will have relied upon and will continue to rely upon the subordination provisions provided for herein and the other provisions hereof in entering into the Loan Documents (including in amending and restating certain of the Prior Loan Documents) and making or issuing the Loan.

(d) Waivers . Each Company hereby waives any and all notice of the incurrence of the Senior Indebtedness or any part thereof and any right to require marshaling of assets.

(e) Rights of Agent and the Other Secured Parties Not Affected . Each Company hereby agrees that at any time and from time to time, without notice to or the consent of such Company, without incurring responsibility to such Company, and without impairing or releasing the subordination provided for herein or otherwise impairing the rights of Agent or any

 

-6-


other Secured Party hereunder, (i) the time for any Obligor’s performance of or compliance with any of its agreements contained in the Loan Documents may be extended or such performance or compliance may be waived by Agent and/or the Lenders (in accordance with the Loan Documents); (ii) the agreements of any Obligor with respect to the Loan Documents may from time to time be modified by such Obligor, Agent and the Lenders (in accordance with the Loan Documents) for the purpose of adding any requirements thereto or changing in any manner the rights and obligations of such Obligor, Agent or the Lenders thereunder; (iii) the manner, place, or terms for payment of Senior Indebtedness or any portion thereof may be altered or the terms for payment extended, or the Senior Indebtedness may be renewed in whole or in part; (iv) the maturity of the Senior Indebtedness may be accelerated in accordance with the terms of any present or future agreement by any Obligor, Agent and the Lenders (in accordance with the Loan Documents); (v) any Collateral may be sold, exchanged, released, or substituted in accordance with the Loan Documents and any Lien in favor of Agent or any other Secured Party may be terminated, subordinated, or fail to be perfected or become unperfected; (vi) any Person liable in any manner for Senior Indebtedness may be discharged, released, or substituted; and (vii) all other rights against the Obligors, any other Person, or with respect to any Collateral may be exercised (or Agent or any other Secured Party may waive or refrain from exercising such rights in accordance with the Loan Documents).

(f) Rights of Agent and the Other Secured Parties Not to Be Impaired . No right of Agent or any other Secured Party to enforce the subordination provided for herein or to exercise its other rights hereunder shall at any time in any way be prejudiced or impaired by any act or failure to act by any Company, Agent or any other Secured Party hereunder or under or in connection with the other Loan Documents or by any noncompliance by any Company with the term and provisions and covenants herein or in any other Loan Document, regardless of any knowledge thereof Agent or any other Secured Party may have or otherwise be charged with.

(g) Financial Condition of the Obligors . Except as provided under the Facility Agreement, no Company shall have any right to require Agent or any other Secured Party to obtain or disclose any information with respect to: (i) the financial condition or character of any Obligor or the ability of the Obligors to pay and perform Senior Indebtedness; (ii) the Senior Indebtedness; (iii) the Collateral or other security for any or all of the Senior Indebtedness; (iv) the existence or nonexistence of any guarantees of, or any other subordination agreements with respect to, all or any part of the Senior Indebtedness; (v) any action or inaction on the part of Agent, any other Secured Party or any other Person; or (vi) any other matter, fact, or occurrence whatsoever.

(h) Acquisition of Liens or Guaranties . No Company shall, without the prior written consent of Agent, acquire any right or interest in or to any Collateral not owned by such Company or accept any guaranties for the Intercompany Subordinated Debt, except as expressly permitted by the Loan Documents.

(i) Release of Liens . In the event of any private or public sale or other disposition of all or any portion of the Collateral by or with the consent of the Agent in accordance with the Loan Documents, or as otherwise permitted by the Facility Agreement, at any time prior to the date upon which the Discharge of Senior Indebtedness shall have occurred,

 

-7-


each Company agrees that such sale or disposition will be free and clear of the Liens and security interests securing the Intercompany Subordinated Debt (if any) of such Company and, if the sale or other disposition includes Stock in any Obligor, such Company agrees to release the Persons whose Stock is sold or disposed of from all Intercompany Subordinated Debt so long as the Agent also releases the Persons whose Stock is sold or disposed of from all Senior Indebtedness. In furtherance thereof, each Company agrees that (i) the Agent is authorized to file any and all UCC Lien releases and/or terminations of the Liens and security interests held by such Company in connection with such a sale or other disposition, and (ii) it will execute any and all Lien and security interest releases or other documents reasonably requested by the Agent in connection therewith.

SECTION 9. Subrogation, etc .

(a) Subrogation . Until Discharge of the Senior Indebtedness and the full payment and satisfaction of all Obligations under the Warrant, any Stock and the Registration Rights Agreement, subject to Section  10(b) , each Company hereby waives any and all rights that it may acquire by way of subrogation under this Subordination Agreement, by reason of any payment or distribution to Agent or any other Secured Party hereunder or otherwise.

(b) Payments Over to the Companies . If any payment or distribution to which any Company would otherwise have been entitled but for the provisions of Section  3 , Section  4 , or Section  5 shall have been applied pursuant to the provisions of Section  3 , Section  4 , or Section  5 to the payment of all amounts payable under the Senior Indebtedness, subject to Section  10(b) , such Company shall be entitled to receive from Agent or any other Secured Party, as the case may be, any payments or distributions received by such Person in excess of the amount sufficient to cause the Discharge of Senior Indebtedness and the full payment and satisfaction of all Obligations under the Warrant, any Stock and the Registration Rights Agreement. If any such excess payment is made to Agent or any Lender, such Person shall promptly remit such excess to such Company and until so remitted shall hold such excess payment for the benefit of such Company.

SECTION 10. Continuing Agreement; Reinstatement .

(a) Continuing Agreement . This Subordination Agreement is a continuing agreement of subordination and shall continue in effect and be binding upon each Company until the Discharge of Senior Indebtedness has occurred. The subordinations, agreements, and priorities set forth herein shall remain in full force and effect regardless of whether any party hereto in the future seeks to rescind, amend, terminate, or reform, by litigation or otherwise, its respective agreements with any other Company.

(b) Reinstatement . If any Secured Party receives payment or property on account of the Senior Indebtedness, and the payment is subsequently invalidated, avoided, declared to be fraudulent or preferential, set aside, or otherwise required to be transferred to a trustee, receiver, an Obligor, an estate of an Obligor or any other Person (a “Recovery” ), then, to the extent of the Recovery, the Senior Indebtedness intended to have been satisfied by such payment or property will be reinstated as Senior Indebtedness on the date of the Recovery, and

 

-8-


no Discharge of Senior Indebtedness will be deemed to have occurred for all purposes hereunder. If this Subordination Agreement is terminated prior to a Recovery, this Subordination Agreement will be automatically reinstated in full force and effect, and such prior termination will not diminish, release, discharge, impair, or otherwise affect the obligations of the parties hereto from (or prior to) the date of reinstatement. Upon any such reinstatement of Senior Indebtedness, the Companies will deliver to Agent any payments, other amounts or property (or proceeds thereof) received between the date of Discharge of Senior Indebtedness and the Recovery. The Companies may not benefit from a Recovery, and any distribution, payment or transfer made to any Company as a result of a Recovery will be paid or transferred over to Agent immediately upon the occurrence of such Recovery for application to (and/or the benefit of) Senior Indebtedness.

SECTION 11. Transfer of Intercompany Subordinated Debt . No Company may assign or transfer its rights and obligations in respect of the Intercompany Subordinated Debt, except as expressly permitted by the Loan Documents, without the prior written consent of Agent, and any such transferee or assignee, as a condition to acquiring an interest in the Intercompany Subordinated Debt shall agree to be bound hereby, in form satisfactory to Agent. Any prohibited assignment or transfer by any Company shall be void ab initio .

SECTION 12. Obligations of the Obligors Not Affected . The provisions of this Subordination Agreement are intended solely for the purpose of defining the relative rights of each Company against the Obligors, on the one hand, and of Agent and the other Secured Parties against the Obligors, on the other hand. Nothing contained in this Subordination Agreement shall (i) impair, as between each Company and each Obligor, the obligation of such Obligor to pay its respective obligations with respect to the Intercompany Subordinated Debt as and when the same shall become due and payable, or (ii) otherwise affect the relative rights of each Company against each Obligor, on the one hand, and of the creditors (other than Agent and the other Secured Parties) of the Obligors against the Companies, on the other hand.

SECTION 13. Endorsement of Documents; Further Assurances and Additional Acts .

(a) Endorsement of Documents . At the request of Agent, all documents, agreements and instruments evidencing any of the Intercompany Subordinated Debt, if any, shall be endorsed with a legend noting that such documents and instruments are subject to this Subordination Agreement, and each Company shall promptly deliver to Agent evidence of the same.

(b) Further Assurances and Additional Acts . Each Company shall execute, acknowledge, deliver, file, notarize, and register at its own expense all such further agreements, instruments, certificates, financing statements, documents, and assurances, and perform such acts as Agent reasonably shall deem necessary or appropriate to effectuate the purposes of this Subordination Agreement, and promptly provide Agent with evidence of the foregoing reasonably satisfactory in form and substance to Agent.

 

-9-


SECTION 14. Notices . All notices and other communications provided for hereunder shall, unless otherwise stated herein, be in writing (including by facsimile or other electronic method of transmission) and shall be mailed, sent, or delivered in accordance with the notice provisions contained in the Facility Agreement.

SECTION 15. No Waiver; Cumulative Remedies . No failure on the part of Agent or any other Secured Party to exercise, and no delay in exercising, any right, remedy, power, or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such right, remedy, power, or privilege preclude any other or further exercise thereof or the exercise of any other right, remedy, power, or privilege. The rights and remedies under this Subordination Agreement are cumulative and not exclusive of any rights, remedies, powers, and privileges that may otherwise be available to Agent or any other Secured Party.

SECTION 16. Survival . All covenants, agreements, representations and warranties made in this Subordination Agreement shall, except to the extent otherwise provided herein, survive the execution and delivery of this Subordination Agreement, and shall continue in full force and effect until the Discharge of Senior Indebtedness has occurred.

SECTION 17. Benefits of Agreement . This Subordination Agreement is entered into for the sole protection and benefit of the parties hereto (and the benefit of the Secured Parties that are not party hereto) and their permitted successors and assigns, and no other Person shall be a direct or indirect beneficiary of, or shall have any direct or indirect cause of action or claim in connection with, this Subordination Agreement.

SECTION 18. Binding Effect . This Subordination Agreement shall be binding upon, inure to the benefit of and be enforceable by each Company, Agent, each other Secured Party and their respective permitted successors and permitted assigns.

SECTION 19. GOVERNING LAW . ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS SUBORDINATION AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK APPLICABLE TO CONTRACTS MADE AND TO BE PERFORMED IN SUCH STATE. .

SECTION 20. SUBMISSION TO JURISDICTION . Each party hereto agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Subordination Agreement (whether brought against a party hereto or its respective Affiliates, directors, officers, shareholders, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York, Borough of Manhattan. Each party hereto hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, or that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereto hereby irrevocably waives personal service of process and

 

-10-


consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Subordination Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. THE PARTIES HERETO, TO THE EXTENT PERMITTED BY APPLICABLE LAW, WAIVE ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, SUIT, OR PROCEEDING ARISING OUT OF, IN CONNECTION WITH OR RELATING TO, THIS SUBORDINATION AGREEMENT AND ANY TRANSACTION CONTEMPLATED HEREBY. THIS WAIVER APPLIES TO ANY ACTION, SUIT OR PROCEEDING WHETHER SOUNDING IN TORT, CONTRACT OR OTHERWISE. EACH PARTY HERETO (A) CERTIFIES THAT NO OTHER PARTY AND NO AGENT, REPRESENTATIVE OR OTHER PERSON AFFILIATED WITH OR RELATED TO ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS SUBORDINATION AGREEMENT BY THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 20.

SECTION 21. Entire Agreement; Amendments and Waivers .

(a) Entire Agreement . This Subordination Agreement constitutes the entire agreement of each of the Companies, Agent and each of the other Secured Parties with respect to the matters set forth herein and supersedes any prior agreements, commitments, draft, communications, discussions and understandings, oral or written, with respect thereto.

(b) Amendments and Waivers . No amendment, restatement or other modification to any provision of this Subordination Agreement shall in any event be effective unless the same shall be in writing and signed by each of the Companies and Agent; and no waiver of any provision of this Subordination Agreement, or consent to any departure by any Company therefrom, shall in any event be effective unless the same shall be in writing and signed by Agent. Any such amendment, restatement, other modification waiver, or consent shall be effective only in the specific instance and for the specific purpose for which given.

SECTION 22. Conflicts . In case of any conflict or inconsistency between any terms of this Subordination Agreement, on the one hand, and any documents, agreement or instruments in respect of the Intercompany Subordinated Debt, on the other hand, then the terms of this Subordination Agreement shall control.

SECTION 23. Severability . Whenever possible, each provision of this Subordination Agreement shall be interpreted in such manner as to be effective and valid under all Applicable Laws and regulations. If, however, any provision of this Subordination Agreement shall be prohibited by or invalid under any such Applicable Law or regulation in any jurisdiction, it shall, as to such jurisdiction, be deemed modified to conform to the minimum requirements of such Applicable Law or regulation, or, if for any reason it is not deemed so

 

-11-


modified, it shall be ineffective and invalid only to the extent of such prohibition or invalidity without affecting the remaining provisions of this Subordination Agreement or the validity or effectiveness of such provision in any other jurisdiction.

SECTION 24. Interpretation . This Subordination Agreement is the result of negotiations between, and has been reviewed by the respective counsel to, the Companies, Agent and each other Secured Party and is the product of all parties hereto. Accordingly, this Subordination Agreement shall not be construed against Agent or any other Secured Party merely because of their involvement in the preparation hereof.

SECTION 25. Counterparts . This Subordination Agreement may be executed in several counterparts, and by each party hereto on separate counterparts, each of which and any photocopies, facsimile copies and other electronic methods of transmission thereof shall be deemed an original, but all of which together shall constitute one and the same agreement..

SECTION 26. Termination of Agreement . Subject to Section  10(b) , upon the Discharge of Senior Indebtedness, this Subordination Agreement shall terminate and Agent shall promptly, upon the request of the Borrower and at the sole expense of the Borrower, execute and deliver to the Borrower such documents and instruments as shall be reasonably necessary to evidence such termination.

[Signature page follows.]

 

-12-


IN WITNESS WHEREOF, the undersigned have executed and delivered this Subordination Agreement as of the date first written above.

 

ENDOLOGIX, INC. , a Delaware corporation, as a Company and an Obligor
By:  

/s/ Vaseem Mahboob

  Name: Vaseem Mahboob
  Title: Chief Financial Officer
CVD/RMS ACQUISITION CORP. , a Delaware corporation, as a Company and an Obligor
By:  

/s/ Vaseem Mahboob

  Name: Vaseem Mahboob
  Title: Chief Financial Officer and Secretary
NELLIX, INC. , a Delaware corporation, as a Company and an Obligor
By:  

/s/ Vaseem Mahboob

  Name: Vaseem Mahboob
  Title: Chief Financial Officer and Secretary
TRIVASCULAR TECHNOLOGIES, INC. , a Delaware corporation, as a Company and an Obligor
By:  

/s/ Vaseem Mahboob

 

Name: Vaseem Mahboob

 

Title: Chief Financial Officer and Secretary

[Signature Page to Intercompany Subordination Agreement]


TRIVASCULAR, INC. , a California corporation, as a Company and an Obligor
By:  

/s/ Vaseem Mahboob

  Name: Vaseem Mahboob
  Title: Chief Financial Officer and Secretary
ENDOLOGIX CANADA, LLC , a Delaware limited liability company, as a Company and an Obligor
By:  

/s/ Vaseem Mahboob

  Name: Vaseem Mahboob
  Title: Chief Financial Officer and Secretary

 

TRIVASCULAR SALES LLC ,

a Texas limited liability company, as a Company and an Obligor

By:  

/s/ Vaseem Mahboob

Name: Vaseem Mahboob
Title: Chief Financial Officer and Secretary
RMS/ENDOLOGIX SIDEWAYS MERGER CORP. , a Delaware corporation, as a Company and an Obligor
By:  

/s/ Vaseem Mahboob

Name: Vaseem Mahboob
Title: Chief Financial Officer and Secretary

[Signature Page to Intercompany Subordination Agreement]


DEERFIELD PRIVATE DESIGN FUND IV, L.P.,
as Agent
By: Deerfield Mgmt IV, L.P., General Partner
By: J.E. Flynn Capital IV, LLC, General Partner
By:  

/s/ David J. Clark

Name:   David J. Clark
Title:   Authorized Signatory

[Signature Page to Intercompany Subordination Agreement]

Exhibit 10.7

Execution Version

INTERCOMPANY SUBORDINATION AGREEMENT

THIS INTERCOMPANY SUBORDINATION AGREEMENT (this “ Subordination Agreement ”), dated as of August 9, 2018 is made among the companies from time to time party hereto (the “ Companies ”), and Deerfield ELGX Revolver, LLC , a Delaware limited liability company, as agent (in such capacity, together with its successors and assigns in such capacity, the “ Agent ”) for the Lender Group (as defined in the below-defined Credit Agreement).

WHEREAS, Endologix, Inc., a Delaware corporation (“ Endologix ”), each of its direct and indirect Subsidiaries set forth on the signature pages thereto and any additional borrower that may be thereafter be added thereto (together with Endologix, the “ Borrowers ” and each individually, a “ Borrower ”), the lenders from time to time party thereto (the “ Lenders ”) and Agent are parties to that certain Credit Agreement, dated as of even date herewith (as amended, restated, supplemented or otherwise modified from time to time, the “ Credit Agreement ”), pursuant to which the Lenders have provided Revolver Commitments and have made Loans and/or other financial accommodations to the Borrowers;

WHEREAS, the Companies have entered into that certain Guaranty and Security Agreement, dated as of even date herewith (as amended, restated, supplemented or otherwise modified from time to time, the “ Guaranty and Security Agreement ”), in favor of Agent, pursuant to which such Companies (together with any other Person (as defined in the below-defined Credit Agreement) who is a “Guarantor,” as defined in the Credit Agreement, the “ Guarantors ;” the “ Obligors ”) have guaranteed the obligations (including any Liquidated Damages, any Applicable Revolver Reduction Premium, the remaining Commitment Fee and the other Obligations) of the Borrowers and the other Companies under the Credit Agreement and the other Loan Documents;

WHEREAS, each Company has made or may make certain loans or advances from time to time to one or more Obligors; and

WHEREAS, in order to induce the Agent and the Lenders to make the Loans and other financial accommodations and provide for Revolver Commitments under the Loan Documents, each Company has agreed to the subordination of such indebtedness of each Obligor to such Company, upon the terms and subject to the conditions set forth in this Subordination Agreement.

NOW, THEREFORE, in consideration of the mutual promises, covenants, conditions, representations, and warranties set forth herein and for other good and valuable consideration, the parties hereto agree as follows:

SECTION 1. Definitions; Interpretation .

(a) Terms Defined in Credit Agreement . All capitalized terms used in this Subordination Agreement and not otherwise defined herein shall have the meanings assigned to them in the Credit Agreement.


(b) Certain Defined Terms . As used in this Subordination Agreement, the following terms shall have the following meanings:

Discharge of Senior Indebtedness ” means the payment in cash of all amounts owing on account of the outstanding principal amount of the Loans and any other Obligations (including any Liquidated Damages, any Applicable Revolver Reduction Premium and the remaining Commitment Fee) owing by the Borrowers and the other Loan Parties to the Lender Group pursuant to the Loan Documents and the termination of all of the Commitments; provided that the foregoing shall be subject to the second sentence of Section 17.07 of the Credit Agreement and Section  10(b) .

Insolvency Events ” has the meaning set forth in Section  3 .

Intercompany Subordinated Debt ” means, with respect to each Company, all indebtedness, liabilities, and other obligations of each Obligor owing to such Company, whether now existing or hereafter arising, and whether due or to become due, absolute or contingent, liquidated or unliquidated, determined or undetermined, including all fees and all other amounts payable by any Obligor to such Company under or in connection with any documents or instruments related thereto.

Intercompany Subordinated Debt Payment ” means any payment or distribution by or on behalf of the Obligors, directly or indirectly, of assets of the Obligors of any kind or character, whether in cash, property, or securities for or on account of the Intercompany Subordinated Debt, including on account of the purchase, redemption, or other acquisition of Intercompany Subordinated Debt, as a result of a collection, sale, or other disposition of collateral, or by setoff, exchange, or in any other manner.

Senior Indebtedness ” means the Obligations (as defined in the Credit Agreement) and other indebtedness and liabilities of the Obligors to the Lender Group under or in connection with the Credit Agreement, the Guaranty and Security Agreement and/or the other Loan Documents, including any Liquidated Damages, any Applicable Revolver Reduction Premium, the remaining Commitment Fee, all unpaid principal of the outstanding Loans, all interest accrued thereon (including all interest that, but for the provisions of the Bankruptcy Code, would have accrued), all fees due under the Credit Agreement and the other Loan Documents (including all fees that, but for the provisions of the Bankruptcy Code, would have accrued), and all other amounts payable by the Obligors to the Agent and the other members of the Lender Group thereunder or in connection therewith, whether now existing or hereafter arising, and whether due or to become due, absolute or contingent, liquidated or unliquidated, determined or undetermined.

(c) Interpretation . Unless the context of this Subordination Agreement clearly requires otherwise, references to the plural include the singular, references to the singular include the plural, the term “including” is not limiting, and the term “or” has, except where otherwise indicated, the inclusive meaning represented by the phrase “and/or.” The words “hereof,” “herein,” “hereby,” “hereunder,” and similar terms in this Subordination Agreement refer to this Subordination Agreement as a whole and not to any particular provision of this Subordination

 

-2-


Agreement. Section, subsection, clause, schedule, and exhibit references are to this Subordination Agreement unless otherwise specified. References to agreements and other contractual instruments shall be deemed to include all subsequent amendments and other modifications thereto. References to statutes or regulations are to be construed as including all statutory and regulatory provisions consolidating, amending, or replacing the statute or regulation referred to. The captions and headings are for convenience of reference only and shall not affect the construction of this Subordination Agreement.

SECTION 2. Subordination to Payment of Senior Indebtedness . As to each Company, all payments on account of the Intercompany Subordinated Debt shall be subject, subordinate, and junior, in right of payment and exercise of remedies, to the extent and in the manner set forth herein, to the prior Discharge of Senior Indebtedness.

SECTION 3. Subordination Upon Any Distribution of Assets of the Obligor s . As to each Company, in the event of any payment or distribution of assets of any Obligor (the “ Affected Obligor ”) of any kind or character, whether in cash, property, or securities, upon the dissolution, winding up, or total or partial liquidation or reorganization, readjustment, arrangement, or similar proceeding relating to such Obligor or its property, whether voluntary or involuntary, or in bankruptcy, insolvency, receivership, arrangement, or similar proceedings or upon an assignment for the benefit of creditors, or upon any other marshaling or composition of the assets and liabilities of such Obligor, or otherwise (such events, other than any such events permitted by the Loan Documents, collectively, the “ Insolvency Events ”): (i) the Discharge of Senior Indebtedness must have occurred before any Intercompany Subordinated Debt Payment is made by or on behalf of the Affected Obligor; and (ii) to the extent permitted by Applicable Law, any Intercompany Subordinated Debt Payment to which such Company would be entitled except for the provisions hereof, shall be paid or delivered by the trustee in bankruptcy, receiver, assignee for the benefit of creditors, or other liquidating agent making such payment or distribution directly to Agent, for the benefit of itself and the other members of the Lender Group, for application to the payment of the Senior Indebtedness in accordance with clause (i) and Section 2.03(f) of the Credit Agreement, after giving effect to any concurrent payment or distribution or provision therefor to Agent or any other member of the Lender Group in respect of such Senior Indebtedness.

SECTION 4. Payments on Intercompany Subordinated Debt .

(a) Permitted Payments . So long as no Event of Default would result therefrom or has occurred and is continuing, each Obligor may make, and each Company shall be entitled to accept and receive, payments on account of the Intercompany Subordinated Debt in the ordinary course of business and any other payment permitted by the Loan Documents, in each case, in accordance with the terms of the Loan Documents.

(b) No Payment Upon Senior Indebtedness Defaults . Upon the occurrence of any Event of Default, and until such Event of Default is cured or waived in accordance with the terms of the Credit Agreement, each Obligor shall not make, and each Company shall not accept or receive, any Intercompany Subordinated Debt Payment; provided , however , notwithstanding the foregoing, (i) any Obligor may pay to the Borrowers, and the Borrowers may accept and

 

-3-


receive payments on account of any Intercompany Subordinated Debt owed to the Borrowers so long as such payments are immediately remitted to a deposit account or securities account that is subject to a Control Agreement and (ii) any Obligor that is not a Borrower may pay to a Guarantor, and a Guarantor may accept and receive payments on account of any Intercompany Subordinated Debt owed to such Guarantor so long as such payments are immediately remitted to a deposit account or securities account that is subject to a Control Agreement; provided , further , that each Obligor shall be permitted to make any such payments missed due to the application of this sentence upon the written waiver of any such Event of Default in accordance with the terms of the Credit Agreement.

SECTION 5. Subordination of Remedies . Until the Discharge of Senior Indebtedness, following the occurrence of any Event of Default and until such Event of Default is cured or waived in accordance with the terms of the Credit Agreement, each Company shall not, without the prior written consent of Agent:

(a) accelerate, make demand, or otherwise make due and payable prior to the original due date thereof any Intercompany Subordinated Debt or bring suit or institute any other actions or proceedings to enforce its rights or interests in respect of the obligations of any Obligor owing to such Company;

(b) exercise any rights under or with respect to guaranties of the Intercompany Subordinated Debt, if any;

(c) exercise any rights to set-offs and counterclaims in respect of any indebtedness, liabilities, or obligations of such Company to any Obligor against any of the Intercompany Subordinated Debt; or

(d) commence, or cause to be commenced, or join with any creditor other than Agent and the other members of the Lender Group in commencing, any bankruptcy, insolvency, or receivership proceeding against any Obligor.

SECTION 6. Payment Over to Agent . In the event that, notwithstanding the provisions of Section  3 , Section  4 , and Section  5 , any Intercompany Subordinated Debt Payments shall be received in contravention of Section  3 , Section  4 , or Section  5 by any Company before the Discharge of Senior Indebtedness has occurred, such Intercompany Subordinated Debt Payments shall be held in trust for the benefit of Agent, for the benefit of itself and the other members of the Lender Group, and shall be paid over or delivered to Agent, for the benefit of the itself and the other members of the Lender Group, for application to the payment, in full, in cash or Cash Equivalents of all Senior Indebtedness remaining unpaid to the extent necessary to give effect to Section  3 , Section  4 , and Section  5 and to the extent necessary to cause a Discharge of Senior Indebtedness to occur, after giving effect to any concurrent payments or distributions to Agent or any other members of the Lender Group in respect of the Senior Indebtedness.

SECTION 7. Insolvency .

 

-4-


(a) Authorization to Agent . If, while any Intercompany Subordinated Debt is outstanding, any Insolvency Event shall occur and be continuing with respect to any Obligor or its property: (i) Agent hereby is irrevocably authorized and empowered (in the name of each Company or otherwise), but shall have no obligation, to demand, sue for, collect, and receive every payment or distribution in respect of the Intercompany Subordinated Debt owing by the Affected Obligor and give acquittance therefor and to file claims and proofs of claim (as set forth below in Section 7(b)) and take such other action (including voting such Intercompany Subordinated Debt) as it may deem necessary or advisable for the exercise or enforcement of any of the rights or interests of Agent or any other member of the Lender Group; and (ii) each Company shall promptly take such action as Agent reasonably may request (A) to collect the Intercompany Subordinated Debt owing by the Affected Obligor for the account of Agent and the other members of the Lender Group and to file appropriate claims or proofs of claim in respect of the Intercompany Subordinated Debt, (B) to execute and deliver to Agent such powers of attorney, assignments, and other instruments as it may request to enable it to enforce any and all claims with respect to such Intercompany Subordinated Debt, and (C) to collect and receive any and all Intercompany Subordinated Debt Payments owing by the Affected Obligor.

(b) Rights in Insolvency Events .

(i) Each of the Companies hereby authorizes and empowers the Agent, for the benefit of itself and the other members of the Lender Group, in any Insolvency Event to file a proof of claim on behalf of such Company with respect to the Intercompany Subordinated Debt owing by the Affected Obligor (A) if such Company fails to file such proof of claim prior to thirty (30) days before the expiration of the time period during which such claims must be submitted, or (B) if the Agent, exercising reasonable discretion, believes that any statements or assertions in a proof of claim filed by such Company are not consistent with the terms and conditions hereof; provided , however , that any failure of the Agent to file such proof of claim shall not be deemed to be a waiver by the Agent of any of the rights and benefits granted herein by such Company. Each Company shall provide the Agent with a copy of any proof of claim filed by such Company in any Insolvency Event.

(ii) Each Company hereby irrevocably grants the Agent the sole and exclusive authority and power in any Insolvency Event, unless and until this Subordination Agreement is terminated in accordance with its terms: (A) to accept and receive any payment or distribution which may be payable or deliverable at any time upon or in respect of the Intercompany Subordinated Debt owing by the Affected Obligor; and (B) to take such other action as may be necessary or advisable to effectuate the foregoing. Each Company shall provide to the Agent all information and documents necessary to present claims or seek enforcement as described in the immediately preceding sentence.

(iii) Each of the Companies hereby agrees that, while it shall retain the right to vote its claims and, except as otherwise provided in this Subordination Agreement, otherwise act in any Insolvency Event relative to any Obligor (including, without limitation, the right to vote to accept or reject any plan of partial or complete liquidation, reorganization, arrangement, composition, or extension), such Company shall not: (A) take any action or vote in any way so as to directly or indirectly challenge or contest (1) the validity or the enforceability of

 

-5-


the Credit Agreement, the Guaranty and Security Agreement, the other Loan Documents, or the Liens and security interests granted to Agent with respect to the Senior Indebtedness, (2) the rights and duties of Agent or the other members of the Lender Group established in the Credit Agreement, the Guaranty and Security Agreement or any other Loan Document, or (3) the validity or enforceability of this Subordination Agreement; (B) seek, or acquiesce in any request, to dismiss any Insolvency Event or to convert an Insolvency Event under chapter 11 of the Bankruptcy Code to a case under chapter 7 of the Bankruptcy Code; (C) seek, or acquiesce in any request for, the appointment of a trustee or examiner with expanded powers for any Obligor; (D) propose, vote in favor of or otherwise approve a plan of reorganization, arrangement or liquidation, or file any motion or pleading in support of any plan of reorganization, arrangement or liquidation, unless it provides for the Discharge of Senior Indebtedness or unless Agent has approved of the treatment of its claims with respect to the Senior Indebtedness under such plan; (E) object to the treatment under a plan of reorganization or arrangement of Agent’s claims with respect to the Senior Indebtedness; (F) seek relief from the automatic stay of Section 362 of the Bankruptcy Code or any other stay in any Insolvency Event in respect of any portion of the Collateral; or (G) directly or indirectly oppose any relief requested or supported by Agent, on behalf of the itself and the other members of the Lender Group, including any sale or other disposition of property free and clear of the Liens and security interests of any Company under Section 363(f) of Title 11 of the United States Code or any other similar provision of Applicable Law.

SECTION 8. Certain Agreements of Each Company .

(a) No Benefits . Each Company understands that there may be various agreements between Agent, the other members of the Lender Group and the Obligors evidencing and governing the Senior Indebtedness, and each Company acknowledges and agrees that (except to the extent provided in any such agreement) such agreements are not intended to confer any benefits on such Company and that neither Agent nor any other member of the Lender Group shall have any obligation to such Company (except to the extent expressly provided in any such agreement) or any other Person to exercise any rights, enforce any remedies, or take any actions which may be available to them under such agreements.

(b) No Interference . Each Company acknowledges that each Obligor has granted to Agent, for the benefit of the members of the Lender Group, security interests in all of such Obligor’s assets, and agrees not to interfere with or in any manner oppose a disposition of any Collateral by Agent in accordance with Applicable Law.

(c) Reliance by Agent and the Other Members of the Lender Group . Each Company acknowledges and agrees that Agent and the other members of the Lender Group will have relied upon and will continue to rely upon the subordination provisions provided for herein and the other provisions hereof in entering into the Loan Documents (including in amending and restating certain of the Prior Loan Documents) and making or issuing the Loan.

(d) Waivers . Each Company hereby waives any and all notice of the incurrence of the Senior Indebtedness or any part thereof and any right to require marshaling of assets.

 

-6-


(e) Rights of Agent and the Other Members of the Lender Group Not Affected . Each Company hereby agrees that at any time and from time to time, without notice to or the consent of such Company, without incurring responsibility to such Company, and without impairing or releasing the subordination provided for herein or otherwise impairing the rights of Agent or any other members of the Lender Group hereunder, (i) the time for any Obligor’s performance of or compliance with any of its agreements contained in the Loan Documents may be extended or such performance or compliance may be waived by Agent and/or the Lenders (in accordance with the Loan Documents); (ii) the agreements of any Obligor with respect to the Loan Documents may from time to time be modified by such Obligor, Agent and the Lenders (in accordance with the Loan Documents) for the purpose of adding any requirements thereto or changing in any manner the rights and obligations of such Obligor, Agent or the Lenders thereunder; (iii) the manner, place, or terms for payment of Senior Indebtedness or any portion thereof may be altered or the terms for payment extended, or the Senior Indebtedness may be renewed in whole or in part; (iv) the maturity of the Senior Indebtedness may be accelerated in accordance with the terms of any present or future agreement by any Obligor, Agent and the Lenders (in accordance with the Loan Documents); (v) any Collateral may be sold, exchanged, released, or substituted in accordance with the Loan Documents and any Lien in favor of Agent or any other members of the Lender Group may be terminated, subordinated, or fail to be perfected or become unperfected; (vi) any Person liable in any manner for Senior Indebtedness may be discharged, released, or substituted; and (vii) all other rights against the Obligors, any other Person, or with respect to any Collateral may be exercised (or Agent or any other members of the Lender Group may waive or refrain from exercising such rights in accordance with the Loan Documents).

(f) Rights of Agent and the Other Members of the Lender Group Not to Be Impaired . No right of Agent or any other members of the Lender Group to enforce the subordination provided for herein or to exercise its other rights hereunder shall at any time in any way be prejudiced or impaired by any act or failure to act by any Company, Agent or any other members of the Lender Group hereunder or under or in connection with the other Loan Documents or by any noncompliance by any Company with the term and provisions and covenants herein or in any other Loan Document, regardless of any knowledge thereof Agent or any other member of the Lender Group may have or otherwise be charged with.

(g) Financial Condition of the Obligors . Except as provided under the Credit Agreement, no Company shall have any right to require Agent or any other member of the Lender Group to obtain or disclose any information with respect to: (i) the financial condition or character of any Obligor or the ability of the Obligors to pay and perform Senior Indebtedness; (ii) the Senior Indebtedness; (iii) the Collateral or other security for any or all of the Senior Indebtedness; (iv) the existence or nonexistence of any guarantees of, or any other subordination agreements with respect to, all or any part of the Senior Indebtedness; (v) any action or inaction on the part of Agent, any other member of the Lender Group or any other Person; or (vi) any other matter, fact, or occurrence whatsoever.

(h) Acquisition of Liens or Guaranties . No Company shall, without the prior written consent of Agent, acquire any right or interest in or to any Collateral not owned by such

 

-7-


Company or accept any guaranties for the Intercompany Subordinated Debt, except as expressly permitted by the Loan Documents.

(i) Release of Liens . In the event of any private or public sale or other disposition of all or any portion of the Collateral by or with the consent of the Agent in accordance with the Loan Documents, or as otherwise permitted by the Credit Agreement, at any time prior to the date upon which the Discharge of Senior Indebtedness shall have occurred, each Company agrees that such sale or disposition will be free and clear of the Liens and security interests securing the Intercompany Subordinated Debt (if any) of such Company and, if the sale or other disposition includes Stock in any Obligor, such Company agrees to release the Persons whose Stock is sold or disposed of from all Intercompany Subordinated Debt so long as the Agent also releases the Persons whose Stock is sold or disposed of from all Senior Indebtedness. In furtherance thereof, each Company agrees that (i) the Agent is authorized to file any and all UCC Lien releases and/or terminations of the Liens and security interests held by such Company in connection with such a sale or other disposition, and (ii) it will execute any and all Lien and security interest releases or other documents reasonably requested by the Agent in connection therewith.

SECTION 9. Subrogation, etc .

(a) Subrogation . Until Discharge of the Senior Indebtedness and the full payment and satisfaction of all Obligations, subject to Section  10(b) , each Company hereby waives any and all rights that it may acquire by way of subrogation under this Subordination Agreement, by reason of any payment or distribution to Agent or any other member of the Lender Group hereunder or otherwise.

(b) Payments Over to the Companies . If any payment or distribution to which any Company would otherwise have been entitled but for the provisions of Section  3 , Section  4 , or Section  5 shall have been applied pursuant to the provisions of Section  3 , Section  4 , or Section  5 to the payment of all amounts payable under the Senior Indebtedness, subject to Section  10(b) , such Company shall be entitled to receive from Agent or any other member of the Lender Group, as the case may be, any payments or distributions received by such Person in excess of the amount sufficient to cause the Discharge of Senior Indebtedness. If any such excess payment is made to Agent or any Lender, such Person shall promptly remit such excess to such Company and until so remitted shall hold such excess payment for the benefit of such Company.

SECTION 10. Continuing Agreement; Reinstatement .

(a) Continuing Agreement . This Subordination Agreement is a continuing agreement of subordination and shall continue in effect and be binding upon each Company until the Discharge of Senior Indebtedness has occurred. The subordinations, agreements, and priorities set forth herein shall remain in full force and effect regardless of whether any party hereto in the future seeks to rescind, amend, terminate, or reform, by litigation or otherwise, its respective agreements with any other Company.

 

-8-


(b) Reinstatement . If any member of the Lender Group receives payment or property on account of the Senior Indebtedness, and the payment is subsequently invalidated, avoided, declared to be fraudulent or preferential, set aside, or otherwise required to be transferred to a trustee, receiver, an Obligor, an estate of an Obligor or any other Person (a “Recovery” ), then, to the extent of the Recovery, the Senior Indebtedness intended to have been satisfied by such payment or property will be reinstated as Senior Indebtedness on the date of the Recovery, and no Discharge of Senior Indebtedness will be deemed to have occurred for all purposes hereunder. If this Subordination Agreement is terminated prior to a Recovery, this Subordination Agreement will be automatically reinstated in full force and effect, and such prior termination will not diminish, release, discharge, impair, or otherwise affect the obligations of the parties hereto from (or prior to) the date of reinstatement. Upon any such reinstatement of Senior Indebtedness, the Companies will deliver to Agent any payments, other amounts or property (or proceeds thereof) received between the date of Discharge of Senior Indebtedness and the Recovery. The Companies may not benefit from a Recovery, and any distribution, payment or transfer made to any Company as a result of a Recovery will be paid or transferred over to Agent immediately upon the occurrence of such Recovery for application to (and/or the benefit of) Senior Indebtedness.

SECTION 11. Transfer of Intercompany Subordinated Debt . No Company may assign or transfer its rights and obligations in respect of the Intercompany Subordinated Debt, except as expressly permitted by the Loan Documents, without the prior written consent of Agent, and any such transferee or assignee, as a condition to acquiring an interest in the Intercompany Subordinated Debt shall agree to be bound hereby, in form satisfactory to Agent. Any prohibited assignment or transfer by any Company shall be void ab initio .

SECTION 12. Obligations of the Obligors Not Affected . The provisions of this Subordination Agreement are intended solely for the purpose of defining the relative rights of each Company against the Obligors, on the one hand, and of Agent and the other members of the Lender Group against the Obligors, on the other hand. Nothing contained in this Subordination Agreement shall (i) impair, as between each Company and each Obligor, the obligation of such Obligor to pay its respective obligations with respect to the Intercompany Subordinated Debt as and when the same shall become due and payable, or (ii) otherwise affect the relative rights of each Company against each Obligor, on the one hand, and of the creditors (other than Agent and the other members of the Lender Group) of the Obligors against the Companies, on the other hand.

SECTION 13. Endorsement of Documents; Further Assurances and Additional Acts .

(a) Endorsement of Documents . At the request of Agent, all documents, agreements and instruments evidencing any of the Intercompany Subordinated Debt, if any, shall be endorsed with a legend noting that such documents and instruments are subject to this Subordination Agreement, and each Company shall promptly deliver to Agent evidence of the same.

 

-9-


(b) Further Assurances and Additional Acts . Each Company shall execute, acknowledge, deliver, file, notarize, and register at its own expense all such further agreements, instruments, certificates, financing statements, documents, and assurances, and perform such acts as Agent reasonably shall deem necessary or appropriate to effectuate the purposes of this Subordination Agreement, and promptly provide Agent with evidence of the foregoing reasonably satisfactory in form and substance to Agent.

SECTION 14. Notices . All notices and other communications provided for hereunder shall, unless otherwise stated herein, be in writing (including by facsimile or other electronic method of transmission) and shall be mailed, sent, or delivered in accordance with the notice provisions contained in the Credit Agreement.

SECTION 15. No Waiver; Cumulative Remedies . No failure on the part of Agent or any other member of the Lender Group to exercise, and no delay in exercising, any right, remedy, power, or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such right, remedy, power, or privilege preclude any other or further exercise thereof or the exercise of any other right, remedy, power, or privilege. The rights and remedies under this Subordination Agreement are cumulative and not exclusive of any rights, remedies, powers, and privileges that may otherwise be available to Agent or any other member of the Lender Group.

SECTION 16. Survival . All covenants, agreements, representations and warranties made in this Subordination Agreement shall, except to the extent otherwise provided herein, survive the execution and delivery of this Subordination Agreement, and shall continue in full force and effect until the Discharge of Senior Indebtedness has occurred.

SECTION 17. Benefits of Agreement . This Subordination Agreement is entered into for the sole protection and benefit of the parties hereto (and the benefit of the members of the Lender Group that are not party hereto) and their permitted successors and assigns, and no other Person shall be a direct or indirect beneficiary of, or shall have any direct or indirect cause of action or claim in connection with, this Subordination Agreement.

SECTION 18. Binding Effect . This Subordination Agreement shall be binding upon, inure to the benefit of and be enforceable by each Company, Agent, each other member of the Lender Group and their respective permitted successors and permitted assigns.

SECTION 19. GOVERNING LAW . ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS SUBORDINATION AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK APPLICABLE TO CONTRACTS MADE AND TO BE PERFORMED IN SUCH STATE.

SECTION 20. SUBMISSION TO JURISDICTION . Each party hereto agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Subordination Agreement (whether brought against a party hereto or its respective Affiliates, directors, officers, shareholders, employees or agents) shall be

 

-10-


commenced exclusively in the state and federal courts sitting in the City of New York, Borough of Manhattan. Each party hereto hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, or that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereto hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Subordination Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. THE PARTIES HERETO, TO THE EXTENT PERMITTED BY APPLICABLE LAW, WAIVE ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, SUIT, OR PROCEEDING ARISING OUT OF, IN CONNECTION WITH OR RELATING TO, THIS SUBORDINATION AGREEMENT AND ANY TRANSACTION CONTEMPLATED HEREBY. THIS WAIVER APPLIES TO ANY ACTION, SUIT OR PROCEEDING WHETHER SOUNDING IN TORT, CONTRACT OR OTHERWISE. EACH PARTY HERETO (A) CERTIFIES THAT NO OTHER PARTY AND NO AGENT, REPRESENTATIVE OR OTHER PERSON AFFILIATED WITH OR RELATED TO ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS SUBORDINATION AGREEMENT BY THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 20.

SECTION 21. Entire Agreement; Amendments and Waivers .

(a) Entire Agreement . This Subordination Agreement constitutes the entire agreement of each of the Companies, Agent and each of the other member of the Lender Group with respect to the matters set forth herein and supersedes any prior agreements, commitments, draft, communications, discussions and understandings, oral or written, with respect thereto.

(b) Amendments and Waivers . No amendment, restatement or other modification to any provision of this Subordination Agreement shall in any event be effective unless the same shall be in writing and signed by each of the Companies and Agent; and no waiver of any provision of this Subordination Agreement, or consent to any departure by any Company therefrom, shall in any event be effective unless the same shall be in writing and signed by Agent. Any such amendment, restatement, other modification waiver, or consent shall be effective only in the specific instance and for the specific purpose for which given.

SECTION 22. Conflicts . In case of any conflict or inconsistency between any terms of this Subordination Agreement, on the one hand, and any documents, agreement or

 

-11-


instruments in respect of the Intercompany Subordinated Debt, on the other hand, then the terms of this Subordination Agreement shall control.

SECTION 23. Severability . Whenever possible, each provision of this Subordination Agreement shall be interpreted in such manner as to be effective and valid under all Applicable Laws and regulations. If, however, any provision of this Subordination Agreement shall be prohibited by or invalid under any such Applicable Law or regulation in any jurisdiction, it shall, as to such jurisdiction, be deemed modified to conform to the minimum requirements of such Applicable Law or regulation, or, if for any reason it is not deemed so modified, it shall be ineffective and invalid only to the extent of such prohibition or invalidity without affecting the remaining provisions of this Subordination Agreement or the validity or effectiveness of such provision in any other jurisdiction.

SECTION 24. Interpretation . This Subordination Agreement is the result of negotiations between, and has been reviewed by the respective counsel to, the Companies, Agent and each other member of the Lender Group and is the product of all parties hereto. Accordingly, this Subordination Agreement shall not be construed against Agent or any other member of the Lender Group merely because of their involvement in the preparation hereof.

SECTION 25. Counterparts . This Subordination Agreement may be executed in several counterparts, and by each party hereto on separate counterparts, each of which and any photocopies, facsimile copies and other electronic methods of transmission thereof shall be deemed an original, but all of which together shall constitute one and the same agreement..

SECTION 26. Termination of Agreement . Subject to Section  10(b) , upon the Discharge of Senior Indebtedness, this Subordination Agreement shall terminate and Agent shall promptly, upon the request of the Borrowers and at the sole expense of the Borrowers, execute and deliver to the Borrower Representative such documents and instruments as shall be reasonably necessary to evidence such termination.

[Signature page follows.]

 

 

-12-


IN WITNESS WHEREOF, the undersigned have executed and delivered this Subordination Agreement as of the date first written above.

 

ENDOLOGIX, INC. , a Delaware corporation, as a Company and an Obligor
By:   /s/ Vaseem Mahboob
 

Name: Vaseem Mahboob

 

Title:   Chief Financial Officer

CVD/RMS ACQUISITION CORP. , a Delaware corporation, as a Company and an Obligor
By:   /s/ Vaseem Mahboob
 

Name: Vaseem Mahboob

 

Title:   Chief Financial Officer and Secretary

NELLIX, INC. , a Delaware corporation, as a Company and an Obligor
By:   /s/ Vaseem Mahboob
 

Name: Vaseem Mahboob

 

Title:   Chief Financial Officer and Secretary

TRIVASCULAR TECHNOLOGIES, INC. , a Delaware corporation, as a Company and an Obligor
By:   /s/ Vaseem Mahboob
 

Name: Vaseem Mahboob

 

Title:   Chief Financial Officer and Secretary

[Signature Page to Intercompany Subordination Agreement]


TRIVASCULAR, INC. , a California corporation, as a Company and an Obligor
By:   /s/ Vaseem Mahboob
 

Name: Vaseem Mahboob

 

Title:   Chief Financial Officer and Secretary

ENDOLOGIX CANADA, LLC , a Delaware limited liability company, as a Company and an Obligor
By:   /s/ Vaseem Mahboob
 

Name: Vaseem Mahboob

 

Title:   Chief Financial Officer and Secretary

TRIVASCULAR SALES LLC ,

a Texas limited liability company, as a Company and an Obligor

By:   /s/ Vaseem Mahboob
 

Name: Vaseem Mahboob

 

Title:   Chief Financial Officer and Secretary

RMS/ENDOLOGIX SIDEWAYS MERGER CORP. , a Delaware corporation, as a Company and an Obligor
By:   /s/ Vaseem Mahboob
 

Name: Vaseem Mahboob

 

Title:   Chief Financial Officer and Secretary

[Signature Page to Intercompany Subordination Agreement]


DEERFIELD ELGX REVOLVER, LLC,

as Agent

By: Deerfield Management Company, L.P.

(Series C), Manager

By: Flynn Management LLC, General Partner
By:   /s/ David J. Clark
Name:   David J. Clark
Title:   Authorized Signatory

[Signature Page to Intercompany Subordination Agreement]

Exhibit 10.8

INTERCREDITOR AGREEMENT

This INTERCREDITOR AGREEMENT , is dated as of August 9, 2018 (as amended, restated, supplemented or otherwise modified from time to time, this “ Agreement ”), and entered into by and between (i) Deerfield Private Design Fund IV, L.P., in its capacity as agent for the Facility Secured Parties (as defined below), including its successors and assigns in such capacity from time to time (“ Facility Agent ”), and (ii) Deerfield ELGX Revolver, LLC, in its capacity as administrative agent for the ABL Secured Parties (as defined below), including its successors and assigns in such capacity from time to time and any “Third Party Agent” (as defined in the below-defined Facility Agreement) during any “Third Party Agent Retention Period” (as defined in the below-defined Facility Agreement) (“ ABL Agent ”). Capitalized terms used in this Agreement have the meanings assigned to them in Section 1 below or elsewhere in this Agreement.

RECITALS

WHEREAS , Endologix, Inc., a Delaware corporation (“ Endologix ”), certain of the Subsidiaries of Endologix party thereto from time to time as “Loan Parties” (such Subsidiaries, together with Endologix, the “ Facility Loan Parties ”), the lenders party thereto from time to time (such lenders, together with their successors and assigns, the “ Facility Lenders ”) and Facility Agent, have entered into that certain Amended and Restated Facility Agreement, dated as of the date hereof (as amended, restated, supplemented, modified, replaced or refinanced from time to time, the “ Facility Agreement ”), providing for, among other things, amendments and restatements to the terms of the prior facility agreement and permitting the term loans previously made to Endologix to remain outstanding;

WHEREAS , Endologix, certain of the Subsidiaries of Endologix party thereto from time to time as “Borrowers” (such Subsidiaries, together with Endologix, the “ ABL Borrowers ”), the lenders party thereto from time to time (such lenders, together with their successors and assigns, the “ ABL Lenders ”) and ABL Agent, have entered into that certain Credit and Security Agreement, dated as of the date hereof (as amended, restated, supplemented, modified, replaced or refinanced from time to time, the “ ABL Agreement ”), providing for, among other things, a revolving credit facility to be available to the ABL Borrowers;

WHEREAS , the obligations of Endologix and its applicable Subsidiaries under the Facility Agreement and the other Facility Documents (as defined below) and the ABL Agreement and the other ABL Documents (as defined below) are secured by Liens (as defined below) on substantially all of the assets of Endologix and such Subsidiaries, including the Collateral (as defined below);

WHEREAS , the Facility Documents and the ABL Documents provide, among other things, that the parties thereto shall set forth in this Agreement their respective rights and remedies with respect to certain repayment provisions and the Collateral;

WHEREAS , in order to induce Facility Agent and the Facility Secured Parties to consent to the Grantors (as defined below) incurring the ABL Obligations (as defined below) and to induce the Facility Lenders to extend credit and other financial accommodations and lend monies to or for the benefit of Endologix, ABL Agent (on behalf of the ABL Secured Parties) has agreed to the intercreditor arrangements and other terms and provisions set forth in this Agreement; and

WHEREAS , in order to induce ABL Agent and the other ABL Secured Parties to consent to the Grantors incurring the Facility Obligations and to induce the ABL Lenders to extend credit and other financial accommodations and lend monies to or for the benefit of the ABL Borrowers, Facility Agent (on


behalf of the Facility Secured Parties) has agreed to the intercreditor arrangements and other terms and provisions set forth in this Agreement.

AGREEMENT

NOW, THEREFORE , in consideration of the foregoing, the mutual covenants and obligations herein set forth and for other good and valuable consideration, the sufficiency and receipt of which are hereby acknowledged, the parties hereto, intending to be legally bound, hereby agree as follows:

SECTION 1. DEFINITIONS .

1.1. Defined Terms. As used in this Agreement (including the Preamble and the Recitals), the following terms shall have the following meanings:

ABL Agent ” has the meaning assigned to such term in the Preamble to this Agreement.

ABL Agreement ” has the meaning assigned to such term in the Recitals to this Agreement.

ABL Borrowers ” has the meaning assigned to such term in the Recitals to this Agreement.

ABL Collateral ” means the “Collateral” (as defined in the ABL Agreement) and all other assets and property pledged (or purported to be pledged) or granted a Lien on (or purported to be granted a Lien on) by the ABL Loan Parties to (and on behalf of) the ABL Secured Parties under the ABL Documents.

ABL Documents ” means the ABL Agreement, the other “Loan Documents” (as defined in the ABL Agreement) and all other agreements, instruments and documents related to the ABL Agreement, as amended, restated, supplemented or otherwise modified from time to time.

ABL Event of Default ” means any “Event of Default” (as defined in ABL Agreement).

ABL/First Out Waterfall Loans ” means the ABL Loans and the First Out Waterfall Loans, as the context may so require

ABL/First Out Waterfall Secured Party ” means any ABL Secured Party and any First Out Waterfall Secured Party, as the context may so require

“ABL/ First Out Waterfall Secured Parties Pro Rata Share ” means, as of any date of determination, (a) with respect to any ABL/First Out Waterfall Secured Party receiving any payments, repayments, redemptions, prepayments or distributions under this Agreement, the percentage obtained by dividing (i) the outstanding principal amount of the ABL/First Out Waterfall Loans of such ABL/First Out Waterfall Secured Party by (ii) the sum of the aggregate outstanding principal amount of all ABL/First Out Waterfall Loans of all ABL/First Out Waterfall Secured Parties; and (b) with respect to any other purpose with respect to any ABL/First Out Waterfall Secured Party, the percentage obtained by dividing (i) the outstanding principal amount of the ABL/First Out Waterfall Loans and, to the extent applicable, the remaining available ABL Revolving Loan Commitments at such time of any such ABL/First Out Secured Party that is also an ABL Secured Party by (ii) the sum of the aggregate outstanding principal amount of all ABL/First Out Waterfall Loans and all remaining available ABL Revolving Loan Commitments of all ABL/First Out Waterfall Secured Parties that are also ABL Secured Parties.

 

2


ABL Lenders ” has the meaning assigned to such term in the Recitals to this Agreement.

ABL Liens ” means all Liens pledged (or purported to be pledged) or granted (or purported to be granted) to the ABL Secured Parties under the ABL Documents on the Collateral securing the ABL Obligations.

ABL Loan Parties ” means the ABL Borrowers and the other “Loan Parties” (as defined in the ABL Agreement).

ABL Loans ” means the “Loans” (as defined in the ABL Agreement).

ABL Obligations ” means all “Obligations” (as defined in the ABL Agreement) and all other indebtedness, liabilities and other obligations owed or incurred by the ABL Loan Parties under the ABL Documents, including all interest accrued or accruing (or which would, absent commencement of an Insolvency or Liquidation Proceeding, accrue) after commencement of an Insolvency or Liquidation Proceeding in accordance with the rate specified in the relevant ABL Document whether or not the claim for such interest is allowed as a claim in such Insolvency or Liquidation Proceeding.

ABL Required Lenders ” means the “Required Lenders” (as defined in the ABL Agreement).

ABL Revolving Loan Commitments ” means the “Revolver Commitments” (as defined in the ABL Agreement).

ABL Secured Parties ” means ABL Agent, the ABL Lenders, the “Indemnified Persons” (as defined in the ABL Agreement), the other members of the “Lender Group” (as defined in the ABL Agreement) and any other holders of the ABL Obligations.

Affiliate ” means, with respect to any Person, (a) any Person that directly or indirectly controls such Person, (b) any Person which is controlled by or is under common control with such controlling Person, and (c) each of such Person’s (other than, with respect to any Lender, any Lender’s) officers or directors (or Persons functioning in substantially similar roles) and the spouses, parents, descendants and siblings of such officers, directors or other Persons. As used in this definition, the term “control” of a Person means the possession, directly or indirectly, of the power to vote five percent (5%) or more of any class of voting securities of such Person or to direct or cause the direction of the management or policies of a Person, whether through the ownership of voting securities, by contract or otherwise. Notwithstanding the foregoing, no Secured Party shall be deemed to be an Affiliate of any Grantor.

Agent ” means ABL Agent and Facility Agent, as the context may so require.

Agreement ” has the meaning assigned to such term in the Preamble to this Agreement.

Application Event ” means the occurrence of (a) a failure by the Grantors to repay all of the Obligations (other than (y) unasserted contingent indemnification obligations and (z) those Obligations under any Warrant or the Registration Rights Agreement that are not (or do not become) due or payable on the maturity date of such Obligations) in full in cash on the maturity date of such Obligations, (b) any Insolvency or Liquidation Proceeding, (c) any acceleration of the Obligations, (d) a foreclosure or an exercise of rights or remedies on any of the Collateral at the time of, or after, an ABL Event of Default or a

 

3


Facility Event of Default has occurred and is continuing, (e) any exercise of remedies by any of the Secured Parties at the time of, or after, an Event of Default has occurred and is continuing or (f) any “Application Event” (as defined in the Facility Agreement).

Bankruptcy Code ” means Title 11 of the United States Code entitled “Bankruptcy,” as now and hereafter in effect, or any successor statute.

Collateral ” means all of the assets and property of any Grantor, whether real, personal or mixed, constituting both ABL Collateral and Facility Collateral.

Commodity Account ” means “commodity account” (as defined in Section 9-102(14) of the UCC).

Deposit Accounts means “deposit account” (as defined in Section 9-102(29) of the UCC).

Discharge of ABL Obligations ” means:

(a) payment in full in cash of the principal of and interest (including interest accruing on or after the commencement of any Insolvency or Liquidation Proceeding, whether or not such interest would be allowed in such Insolvency or Liquidation Proceeding) and any fees on all ABL Obligations;

(b) payment in full in cash of all other outstanding ABL Obligations (other than unasserted contingent indemnification obligations), including any that are due and payable or otherwise accrued and owing at or prior to the time such principal, interest and fees are paid; and

(c) permanent termination or permanent expiration of all commitments, if any, to extend credit (including the ABL Revolving Loan Commitments) by any ABL Secured Party under the ABL Documents.

Discharge of Facility Obligations ” means:

(a) payment in full in cash of the principal of and interest (including interest accruing on or after the commencement of any Insolvency or Liquidation Proceeding, whether or not such interest would be allowed in such Insolvency or Liquidation Proceeding), any fees and any Facility Non-Callable Make Whole Amount on all Facility Obligations (other than (i) any unasserted contingent indemnification obligations and (ii) any amounts owed under any Warrant or the Registration Rights Agreement that are not due or payable at the time when all other Facility Obligations are paid in full in cash);

(b) payment in full in cash of all other outstanding Facility Obligations (other than (i) any unasserted contingent indemnification obligations and (ii) any amounts owed under any Warrant or the Registration Rights Agreement that are not due or payable at the time when all other Facility Obligations are paid in full in cash), including any that are due and payable or otherwise accrued and owing at or prior to the time such principal, interest and fees and any applicable Facility Non-Callable Make Whole Amount and Facility CoC Fee, and the Exit Payment, are paid; and

(c) permanent termination or permanent expiration of all commitments, if any, to extend credit by any Facility Secured Party under the Facility Documents.

 

4


Endologix ” has the meaning assigned to such term in the Recitals to this Agreement.

Facility Agent ” has the meaning assigned to such term in the Preamble to this Agreement.

Facility Agreement ” has the meaning assigned to such term in the Recitals to this Agreement.

Facility CoC Fee ” means any “CoC Fee” (as defined in the Facility Agreement).

Facility Collateral ” means the “Collateral” (as defined in the Facility Agreement) and all other assets and property pledged (or purported to be pledged) or granted a Lien on (or purported to be granted a Lien on) by the Facility Loan Parties to (or on behalf of) the Facility Secured Parties under the Facility Documents.

Facility Documents ” means the Facility Agreement, the other “Loan Documents” (as defined in the Facility Agreement) and all other agreements, instruments and documents related to the Facility Agreement, as amended, restated, supplemented or otherwise modified from time to time.

Facility Event of Default ” means “Event of Default” (as defined in the Facility Agreement).

Facility Exit Payment ” means the “Exit Payment” (as defined in the Facility Agreement).

Facility Lenders ” has the meaning assigned to such term in the Recitals to this Agreement.

Facility Liens ” means all Liens pledged (or purported to be pledged) or granted (or purported to be granted) to the Facility Secured Parties under the Facility Documents on the Collateral securing the Facility Obligations.

Facility Loan Parties ” has the meaning assigned to such term in the Recitals to this Agreement.

Facility Loans ” means “Loans” (as defined in the Facility Agreement).

Facility Non-Callable Make Whole Amount ” means any “Non-Callable Make Whole Amount” (as defined in the Facility Agreement).

Facility Obligations ” means all “Obligations” (as defined in the Facility Agreement) and all other indebtedness, liabilities and other obligations owed or incurred by the Facility Loan Parties under the Facility Documents (including any Facility Non-Callable Make Whole Amount, any Facility CoC Fee and the Facility Exit Payment), including all interest accrued or accruing (or which would, absent commencement of an Insolvency or Liquidation Proceeding, accrue) after commencement of an Insolvency or Liquidation Proceeding in accordance with the rate specified in the relevant ABL Document whether or not the claim for such interest is allowed as a claim in such Insolvency or Liquidation Proceeding.

Facility Required Lenders ” means the “Required Lenders” (as defined in the Facility Agreement).

 

5


Facility Secured Parties ” means Facility Agent, the Facility Lenders, the other “Secured Parties” (as defined in the Facility Agreement) and any other holders of Facility Obligations.

First Out Waterfall Loans ” means the Facility Loans (other than the Last Out Waterfall Loans).

First Out Waterfall Obligations ” means the Facility Obligations (other than the Last Out Obligations).

First Out Waterfall Secured Parties ” means the Facility Secured Parties (other than the Last Out Waterfall Lenders).

Grantors ” means the ABL Loan Parties and the Facility Loan Parties.

Insolvency or Liquidation Proceeding ” means:

(a) any voluntary or involuntary case or proceeding under the Bankruptcy Code with respect to any Grantor;

(b) any other voluntary or involuntary insolvency, reorganization or bankruptcy case or proceeding, or any receivership, liquidation, reorganization or other similar case or proceeding with respect to any Grantor or with respect to its assets or property;

(c) any liquidation, dissolution, reorganization or winding up of any Grantor whether voluntary or involuntary and whether or not involving insolvency or bankruptcy; or

(d) any assignment for the benefit of creditors or any other marshalling of assets and liabilities of any Grantor.

Last Out Waterfall Loans ” means the “Last Out Waterfall Loans” (as defined in the Facility Agreement).

Last Out Waterfall Obligations ” means the “Last Out Waterfall Obligations” (as defined in the Facility Agreement).

Last Out Waterfall Secured Parties ” means the “Last Out Waterfall Secured Parties” (as defined in the Facility Agreement.

Last Out Waterfall Secured Parties Pro Rata Share ” means, as of any date of determination, the percentage obtained by dividing (a) the outstanding principal amount of the Last Out Waterfall Loans of such Last Out Waterfall Secured Party by (b) the sum of the aggregate outstanding principal amount of all Last Out Waterfall Loans of all Last Out Waterfall Secured Parties.

Lien ” means any lien, pledge, preferential arrangement, mortgage, security interest, deed of trust, charge, assignment, hypothecation, title retention or other encumbrance on or with respect to assets, property or interest in assets or property having the practical effect of constituting a security interest, in each case with respect to the payment of any obligation with, or from the proceeds of, any asset or revenue of any kind. For purposes of this Agreement, any Grantor or any Subsidiary shall be deemed to own subject to a Lien any asset which it has acquired or holds subject

 

6


to the interest of a vendor or lessor under any conditional sale agreement, capital lease or other title retention agreement relating to such asset.

Loan Documents ” means the ABL Documents and the Facility Documents, as the context may so require

Loans ” means the ABL Loans and the Facility Loans, as the context may so require.

Obligations ” means the ABL Obligations and the Facility Obligations, as the context may so require.

Person ” means and includes any natural person, individual, partnership, joint venture, corporation, trust, limited liability company, limited liability partnership, joint stock company, unincorporated organization, government entity or any political subdivision or agency thereof, or any other entity.

Possessory/Control Collateral ” means any Collateral that is in the possession or control of any Agent (or in the possession or control of its agents or bailees), to the extent that possession or control thereof perfects a Lien thereon under the UCC or other applicable law.

Post-Application Event Payment Amounts ” has the meaning assigned to such term in Section 5.

Registration Rights Agreement ” means the “Registration Rights Agreement” (as defined in the Facility Agreement).

Secured Party ” means any ABL Secured Party and any Facility Secured Party, as the context may so require.

Securities Account ” means “securities account” (as defined in Section 8-501(a) of the UCC).

Subsidiary ” or “ Subsidiaries ” means, with respect to any Person, (a) any corporation of which an aggregate of more than fifty percent (50%) of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, capital stock of any other class or classes of such corporation shall have or might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, owned legally or beneficially by such Person or one or more Subsidiaries of such Person, or with respect to which any such Person has the right to vote or designate the vote of more than fifty percent (50%) of such capital stock whether by proxy, agreement, operation of law or otherwise, and (b) any partnership or limited liability company in which such Person and/or one or more Subsidiaries of such Person shall have an interest (whether in the form of voting or participation in profits or capital contribution) of more than fifty percent (50%) or of which any such Person is a general partner or may exercise the powers of a general partner. Unless the context otherwise requires, each reference to a Subsidiary shall be a reference to a Subsidiary of a Grantor.

UCC ” means the Uniform Commercial Code (or any similar or equivalent legislation) as in effect from time to time in any applicable jurisdiction, and, if the applicable jurisdiction shall not have any Uniform Commercial Code, the Uniform Commercial Code as in effect from time to time in the State of New York.

 

7


Warrants ” means the “Warrants” (as defined in the Facility Agreement).

1.2. Terms Generally. The definitions of terms in this Agreement shall apply equally to the singular and plural forms of the terms defined. Whenever the context may require, any pronoun shall include the corresponding masculine, feminine and neuter forms. The words “include,” “includes” and “including” shall be deemed to be followed by the phrase “without limitation.” The word “will” shall be construed to have the same meaning and effect as the word “shall.” Unless the context requires otherwise:

(a) any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, restated, supplemented, modified, renewed or extended;

(b) any reference herein to any Person shall be construed to include such Person’s permitted successors and assigns;

(c) the words “herein,” “hereof” and “hereunder,” and words of similar import, shall be construed to refer to this Agreement in its entirety and not to any particular provision hereof;

(d) all references herein to Sections shall be construed to refer to Sections of this Agreement; and

(e) the words “asset” and “property” shall be construed to have the same meaning and effect and to refer to any and all tangible and intangible assets and properties, including cash, securities, accounts and contract rights.

SECTION 2. LIEN PRIORITIES.

2.1. Pari Passu Liens. Notwithstanding the date, time, method, manner or order of grant, attachment, validity or perfection of any ABL Liens or any Facility Liens and notwithstanding any provision of the UCC, or any other applicable law or the ABL Documents or the Facility Documents, ABL Agent, on behalf of the ABL Secured Parties, and ABL Agent, on behalf of the ABL Secured Parties, hereby agree that:

(a) any ABL Lien, regardless of how acquired, whether by grant, possession, statute, operation of law, subrogation or otherwise, shall be pari passu in all respects with any Facility Lien; and

(b) any Facility Lien, regardless of how acquired, whether by grant, possession, statute, operation of law, subrogation or otherwise, shall be pari passu in all respects with any ABL Lien.

2.2. Prohibition on Contesting Liens. Each of ABL Agent, on behalf of the ABL Secured Parties, and Facility Agent, on behalf of the Facility Secured Parties, agrees that it will not (and hereby waives any right to) contest or support any other Person in contesting, in any proceeding (including any Insolvency or Liquidation Proceeding), the creation, perfection, priority, validity or enforceability of any Facility Lien or any ABL Lien, as the case may be, or the terms or provisions of this Agreement.

SECTION 3. GRATUITOUS BAILEE/AGENT FOR PERFECTION AND CONTROL.

3.1. Each Agent agrees to hold any Possessory/Control Collateral from time to time in its possession or control (or in the possession or control of its agents or bailees) as gratuitous bailee for the benefit of each other Secured Party (such bailment being intended, among other things, to satisfy the

 

8


requirements of Sections 8-106(d)(3), 8-301(a)(2) and 9-313(c) of the UCC) and any successor or assignee, solely for the purpose of perfecting the Lien granted in such Possessory/Control Collateral, in each case, subject to the terms and conditions of this Section 3.1. Solely with respect to (i) any Deposit Accounts constituting Collateral under the control (within the meaning of Section 9-104 of the UCC) of any Agent, (ii) any Securities Accounts constituting Collateral under the control (within the meaning of Section 8-106 of the UCC) of any Agent and (iii) any Commodity Accounts constituting Collateral under the control (within the meaning of Section 9-106 of the UCC) of any Agent, in each case, each such Agent agrees to also hold control over such Deposit Accounts, Securities Accounts and Commodity Accounts, as applicable, as gratuitous agent for each other Secured Party and any successor or assignee solely for the purpose of perfecting the Lien in such Deposit Accounts, Securities Accounts and Commodity Accounts, as applicable, subject to the terms and conditions of this Section 3.1.

3.2. No Agent shall have any obligation whatsoever to the other Agent (including any other Secured Parties such other Agent is acting on behalf of) to ensure that the Possessory/Control Collateral is genuine or owned by any of the Grantors or to preserve rights or benefits of any Person except as expressly set forth in this Section 3.1. The duties or responsibilities of each Agent under this Section 3.1 shall be limited solely to holding any Possessory/Control Collateral in its possession or control as gratuitous bailee or as gratuitous agent, as applicable, in accordance with this Section 3.1 and delivering the Possessory/Control Collateral as provided in Section 3.4 below.

3.3. None of the Agents or any of the other Secured Parties shall have by reason of this Agreement or any other document, instrument or agreement a fiduciary relationship in respect of the other Agent or any other Secured Party, and each Agent (on behalf of itself and each other Secured Party for which it is acting as “Agent” for) hereby waives and releases the other Agent and the other Secured Parties from all claims and liabilities arising pursuant to any Agent’s role under this Section 3.1 as gratuitous bailee or gratuitous agent, as applicable, with respect to the Possessory/Control Collateral.

3.4. At any time there is a Discharge of ABL Obligations or a Discharge of Facility Obligations (but not both), the applicable Agent involved in such discharge shall deliver the remaining Possessory/Control Collateral in its possession (if any) together with any necessary endorsements (which endorsement shall be without recourse and without any representation or warranty) to the other Agent (so as to allow such Person to obtain possession or control of such Possessory/Control Collateral). The Agent transferring such Possessory/Control Collateral in connection with such discharge further agrees to take all other action reasonably requested by the other Agent at the sole expense of the Grantors in connection with such other Agent obtaining a first-priority Lien in the remaining Possessory/Control Collateral.

SECTION 4. ENFORCEMENT.

4.1. Exercise of Remedies.

(a) Whether or not any Insolvency or Liquidation Proceeding has been commenced by or against any Grantor,

(1) neither ABL Agent nor any other ABL Secured Party will exercise or seek to exercise any rights or remedies with respect to any Collateral or institute any action or proceeding with respect to such rights or remedies without obtaining the prior written consent of Facility Agent (which consent shall be given upon request of the Facility Required Lenders to Facility Agent under the Facility Agreement); and

(2) neither Facility Agent nor any other Facility Secured Party will exercise or seek to exercise any rights or remedies with respect to any Collateral or institute any action or proceeding

 

9


with respect to such rights or remedies without obtaining the prior written consent of ABL Agent (which consent shall be given upon request of the ABL Required Lenders to ABL Agent under the ABL Agreement).

(b) Notwithstanding the foregoing,

(1) ABL Agent and any other ABL Secured Party may:

(A) file a claim or statement of interest with respect to the ABL Obligations; provided that an Insolvency or Liquidation Proceeding has been commenced by or against any Grantor;

(B) take any action in order to create, perfect, preserve or protect its Lien on the Collateral;

(C) file any necessary responsive or defensive pleadings in opposition to any motion, claim, adversary proceeding or other pleading made by any Person objecting to or otherwise seeking the avoidance or disallowance of the claims of the ABL Secured Parties, including, without limitation, any claims secured by the Collateral, if any, in each case in accordance with the terms of this Agreement;

(D) exercise any rights or remedies, file any pleadings, objections, motions or agreements which assert rights or interests available to unsecured creditors of the Grantors arising under any Insolvency or Liquidation Proceeding, the bankruptcy laws or applicable non-bankruptcy law, so long as such actions would not conflict with an express agreement of ABL Agent or the other ABL Secured Parties contained in this Agreement; provided that in the event that any ABL Secured Party becomes a judgment lien creditor in respect of the Collateral as a result of its enforcement of its rights as an unsecured creditor with respect to the ABL Obligations, such judgment lien shall be subject to the terms of this Agreement for all purposes as the other Liens securing the ABL Obligations are subject to this Agreement; and

(E) vote on any plan of reorganization, file any proof of claim, make other filings and make any arguments and motions that are, in each case, in accordance with the terms of this Agreement, with respect to the ABL Obligations and the Collateral.

(2) Facility Agent and any other Facility Secured Party may:

(A) file a claim or statement of interest with respect to the Facility Obligations; provided that an Insolvency or Liquidation Proceeding has been commenced by or against any Grantor;

(B) take any action in order to create, perfect, preserve or protect its Lien on the Collateral;

(C) file any necessary responsive or defensive pleadings in opposition to any motion, claim, adversary proceeding or other pleading made by any person objecting to or otherwise seeking the avoidance or disallowance of the claims of the Facility Secured Parties, including, without limitation, any claims secured by the Collateral, if any, in each case in accordance with the terms of this Agreement;

 

10


(D) exercise any rights or remedies, file any pleadings, objections, motions or agreements which assert rights or interests available to unsecured creditors of the Grantors arising under any Insolvency or Liquidation Proceeding, the bankruptcy laws or applicable non-bankruptcy law, so long as such actions would not conflict with an express agreement of Facility Agent or the other Facility Secured Parties contained in this Agreement; provided that in the event that any Facility Secured Party becomes a judgment lien creditor in respect of Collateral as a result of its enforcement of its rights as an unsecured creditor with respect to the Facility Obligations, such judgment lien shall be subject to the terms of this Agreement for all purposes as the other Liens securing the Facility Obligations are subject to this Agreement; and

(E) vote on any plan of reorganization, file any proof of claim, make other filings and make any arguments and motions that are, in each case, in accordance with the terms of this Agreement, with respect to the Facility Obligations and the Collateral.

(c) Except as specifically set forth in Section 4, nothing in this Agreement shall prohibit the receipt by:

(1) ABL Agent or any other ABL Secured Party of the required payments of interest, principal and other amounts owed in respect of the ABL Obligations so long as such receipt is not the direct or indirect result of the exercise by ABL Agent or any other ABL Secured Party of rights or remedies as a secured creditor (including set off) or enforcement in contravention of this Agreement of any Lien held by any of them; and

(2) Facility Agent or any other Facility Secured Party of the required payments of interest, principal and other amounts owed in respect of the Facility Obligations so long as such receipt is not the direct or indirect result of the exercise by Facility Agent or any other Facility Secured Party of rights or remedies as a secured creditor (including set off) or enforcement in contravention of this Agreement of any Lien held by any of them.

(d) Nothing in this Agreement impairs or otherwise adversely affects any rights or remedies:

(1) ABL Agent or the other ABL Secured Parties may have with respect to the ABL Collateral; or

(2) Facility Agent or the other Facility Secured Parties may have with respect to the Facility Collateral.

SECTION 5. APPLICATION OF POST-APPLICATION EVENT PAYMENT AMOUNTS

Notwithstanding any provision to the contrary in the ABL Documents or the Facility Documents, but subject to Section 6.16 hereof, ABL Agent, on behalf of the ABL Secured Parties, Facility Agent, on behalf of the Facility Secured Parties, and the Grantors hereby agree that if any Secured Party receives any prepayment, repayment, redemption, payment or other distribution after the occurrence and continuance of an Application Event (all such amounts and proceeds therefrom collectively referred to as “ Post-Application Payment Amounts ”), such Post-Application Payment Amounts shall be applied to the Obligations in the following order (but otherwise in accordance with the terms and conditions of the ABL Agreement and the Facility Agreement): (1) first, ratably to all fees, costs and expenses (including any attorneys’ fees) owed to ABL/First Out Waterfall Secured Parties under the Loan Documents, (ii) second, ratably to accrued and unpaid interest owed to the ABL/First Out Waterfall Secured Parties under the Loan

 

11


Documents, (iii) third, ratably to the principal amount of the ABL/First Out Waterfall Loans (including any Non-Callable Make Whole Amount, any CoC Fee and the First Out Waterfall Loan Exit Payment (each as defined in the Facility Agreement) and any amounts owed under Section 2.09 of the ABL Agreement, in each case, if applicable) owed to the ABL/First Out Waterfall Secured Parties, (iv) fourth, ratably to all other ABL/First Out Waterfall Obligations (other than any First Out Waterfall Obligations in respect of any Warrant or the Registration Rights Agreement that are not at such time owing, due or unpaid) owing to the ABL/First Out Waterfall Secured Parties, and with respect to any such ABL/First Out Waterfall Obligations owed to the ABL/First Out Waterfall Secured Parties, shall be allocated ratably among the ABL/First Out Waterfall Secured Parties based on their pro rata share of such other ABL/First Out Waterfall Secured Parties, (v) fifth, ratably to all fees, costs and expenses (including any attorneys’ fees) owed to any Last Out Waterfall Secured Party under the Facility Documents, (vi) sixth, ratably to accrued and unpaid interest owed to the Last Out Waterfall Secured Parties under the Facility Documents, (vii) seventh, ratably to the principal amount of the Last Out Waterfall Loans (including any Non-Callable Make Whole Amount, any CoC Fee and the Last Out Waterfall Loan Exit Payment, if applicable) owed to the Last Out Waterfall Secured Parties, and (viii) eighth, ratably to all other Last Out Waterfall Obligations owing to any Last Out Waterfall Secured Party, and, with respect to any such Last Out Waterfall Obligations owed to the Last Out Waterfall Secured Parties, shall be allocated ratably among the Last Out Waterfall Secured Parties based on their pro rata share of such other Last Out Waterfall Obligations.

SECTION 6. MISCELLANEOUS.

6.1. Termination. This Agreement shall terminate and be of no further force and effect upon the earlier to occur of (a) the date of Discharge of ABL Obligations and (b) the date of Discharge of Facility Obligations.

6.2. Obligations Unconditional. All rights, interests, agreements and obligations of ABL Agent and the other ABL Secured Parties and the Facility Agent and the other Facility Secured Parties, respectively, hereunder shall remain in full force and effect irrespective of:

(a) any lack of validity or enforceability of any ABL Documents or any Facility Documents;

(b) except as otherwise expressly set forth in this Agreement, any change in the time, manner or place of payment of, or in any other terms of, all or any of the ABL Obligations or the Facility Obligations, or any amendment or waiver or other modification, including any increase in the amount thereof, whether by course of conduct or otherwise, of the terms of any ABL Document or any Facility Document;

(c) except as otherwise expressly set forth in this Agreement, any exchange of any Lien in any Collateral or any other collateral, or any amendment, waiver or other modification, whether in writing or by course of conduct or otherwise, of all or any of the ABL Obligations or the Facility Obligations or any guaranty thereof; or

(d) the commencement of any Insolvency or Liquidation Proceeding in respect of the any Grantor.

6.3. Conflicts. In the event of any conflict between the provisions of this Agreement and the provisions of the ABL Documents or the Facility Documents, the provisions of this Agreement shall govern and control.

6.4. Effectiveness; Severability. This Agreement shall become effective when executed and delivered by the parties hereto. Each of ABL Agent, on behalf of the ABL Secured Parties, and Facility

 

12


Agent, on behalf of the Facility Secured Parties, hereby waives any right it may have under applicable law to revoke this Agreement or any of the provisions of this Agreement. The terms of this Agreement shall survive, and shall continue in full force and effect, in any Insolvency or Liquidation Proceeding. The relative rights of the Secured Parties in or to any distributions from or in respect of any Collateral or proceeds of Collateral, shall continue after the commencement of any Insolvency or Liquidation Proceeding. Accordingly, the provisions of this Agreement are intended to be and shall be enforceable as a subordination agreement within the meaning of Section 510 of the Bankruptcy Code (or similar bankruptcy law). Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction shall not invalidate the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. All references to any Grantor shall include such Grantor as debtor and debtor in possession and any receiver or trustee for such Grantor (as the case may be) in any Insolvency or Liquidation Proceeding.

6.5. Amendments; Waivers. No amendment, restatement, supplement, modification or waiver of any of the provisions of this Agreement by ABL Agent or Facility Agent shall be deemed to be made unless the same shall be in writing signed by each of ABL Agent and Facility Agent; provided that any such amendment, restatement, supplement, modification or waiver that directly adversely affects any Last Out Waterfall Security Party shall require the written consent of such Last Out Waterfall Secured Party. Each waiver, if any, shall be a waiver only with respect to the specific instance involved and shall in no way impair the rights of the parties making such waiver or the obligations of the other parties to such party in any other respect or at any other time. Notwithstanding the foregoing, the Grantors shall not have any right to consent to or approve any amendment, restatement, supplement, modification or waiver of any provision of this Agreement.

6.6. SUBMISSION TO JURISDICTION; WAIVERS.

(a) ALL JUDICIAL PROCEEDINGS BROUGHT AGAINST ANY PARTY OR GRANTOR ARISING OUT OF OR RELATING HERETO MAY BE BROUGHT IN ANY STATE OR FEDERAL COURT OF COMPETENT JURISDICTION IN THE STATE, COUNTY AND CITY OF NEW YORK (INCLUDING, WITHOUT LIMITATION, THE COMMERCIAL DIVISION, NEW YORK STATE SUPREME COURT). BY EXECUTING AND DELIVERING THIS AGREEMENT, EACH PARTY (AND EACH GRANTOR BY ACKOWLEDGING AND AGREEING TO THIS AGREEMENT), FOR ITSELF AND IN CONNECTION WITH ITS PROPERTIES, IRREVOCABLY:

(1) ACCEPTS GENERALLY AND UNCONDITIONALLY THE NONEXCLUSIVE JURISDICTION AND VENUE OF SUCH COURTS;

(2) WAIVES ANY DEFENSE OF FORUM NON CONVENIENS;

(3) AGREES THAT SERVICE OF ALL PROCESS IN ANY SUCH PROCEEDING IN ANY SUCH COURT MAY BE MADE BY REGISTERED OR CERTIFIED MAIL, RETURN RECEIPT REQUESTED, TO THE APPLICABLE PARTY AT ITS ADDRESS PROVIDED IN ACCORDANCE WITH SECTION 6.8; AND

(4) AGREES THAT SERVICE AS PROVIDED IN CLAUSE (3) ABOVE IS SUFFICIENT TO CONFER PERSONAL JURISDICTION OVER THE APPLICABLE PARTY IN ANY SUCH PROCEEDING IN ANY SUCH COURT, AND OTHERWISE CONSTITUTES EFFECTIVE AND BINDING SERVICE IN EVERY RESPECT.

(b) EACH OF THE PARTIES HERETO (AND EACH GRANTOR) HEREBY AGREES TO WAIVE ITS RESPECTIVE RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION

 

13


BASED UPON OR ARISING HEREUNDER. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER HEREOF, INCLUDING CONTRACT CLAIMS, TORT CLAIMS, BREACH OF DUTY CLAIMS AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. EACH PARTY HERETO (AND EACH GRANTOR) ACKNOWLEDGES THAT THIS WAIVER IS A MATERIAL INDUCEMENT TO ENTER INTO A BUSINESS RELATIONSHIP THAT EACH HAS ALREADY RELIED ON THIS WAIVER IN ENTERING INTO THIS AGREEMENT (OR WITH RESPECT TO EACH GRANTOR, IN ACKNOWLEDGING AND AGREEING TO THIS AGREEMENT), AND THAT EACH WILL CONTINUE TO RELY ON THIS WAIVER IN ITS RELATED FUTURE DEALINGS. EACH PARTY HERETO (AND EACH GRANTOR) FURTHER REPRESENTS AND WARRANTS THAT IT HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL AND THAT IT KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. THIS WAIVER IS IRREVOCABLE; MEANING THAT IT MAY NOT BE MODIFIED EITHER ORALLY OR IN WRITING (OTHER THAN BY A MUTUAL WRITTEN WAIVER SPECIFICALLY REFERRING TO THIS SECTION 6.7(b) AND EXECUTED BY EACH OF THE PARTIES HERETO), AND THIS WAIVER SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS OR MODIFICATIONS HERETO. IN THE EVENT OF LITIGATION, THIS AGREEMENT MAY BE FILED AS A WRITTEN CONSENT TO A TRIAL BY THE COURT.

(c) EACH OF THE PARTIES HERETO (AND EACH GRANTOR) WAIVES ANY RIGHT IT MAY HAVE TO TRIAL BY JURY IN RESPECT OF ANY LITIGATION BASED ON, OR ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT, ANY ABL DOCUMENT OR ANY FACILITY DOCUMENT, OR ANY COURSE OF CONDUCT, COURSE OF DEALING, VERBAL OR WRITTEN STATEMENT OR ACTION OF ANY PARTY HERETO.

6.7. Notices. All notices to the ABL Secured Parties and the Facility Secured Parties permitted or required under this Agreement shall be sent to ABL Agent (on behalf of the ABL Secured Parties) and Facility Agent (on behalf of the Facility Secured Parties), respectively. Unless otherwise specifically provided herein, any notice hereunder shall be in writing and may be personally served, telexed or sent by telefacsimile, electronic mail or United States mail or courier service and shall be deemed to have been given when delivered in person or by courier service and signed for against receipt thereof, upon receipt of electronic mail, telefacsimile or telex, or three business days after depositing it in the United States mail with postage prepaid and properly addressed (or one business day after depositing with an overnight mail service). For the purposes hereof, the addresses of the parties hereto shall be as set forth below (and the addresses of the Grantors shall be as set forth in the ABL Agreement and the Facility Agreement, as applicable), or at such other address as may be designated by such party in a written notice to all of the other parties.

If to Facility Agent:

c/o Deerfield Management Company, L.P.

780 Third Avenue, 37th Floor

New York, NY 10017

Facsimile: 212-599-3075

E-mail: dclark@deerfield.com

Attn: David J. Clark, Esq.

With a copy to (which shall not be deemed to constitute notice):

Katten Muchin Rosenman LLP

 

14


2029 Century Park East, Suite 2600

Los Angeles, CA 90067-3012

Facsimile: (310) 788-4471

E-mail: kristopher.ring@kattenlaw.com and mark.wood@kattenlaw.com

Attn: Kristopher J. Ring, Esq.

Attn: Mark D. Wood, Esq.

If to ABL Agent:

c/o Deerfield Management Company, L.P.

780 Third Avenue, 37th Floor

New York, NY 10017

Facsimile: 212-599-3075

E-mail: dclark@deerfield.com

Attn: David J. Clark, Esq.

With a copy to (which shall not be deemed to constitute notice):

Katten Muchin Rosenman LLP

2029 Century Park East, Suite 2600

Los Angeles, CA 90067-3012

Facsimile: (310) 788-4471

E-mail: kristopher.ring@kattenlaw.com and mark.wood@kattenlaw.com

Attn: Kristopher J. Ring, Esq.

Attn: Mark D. Wood, Esq.

6.8. Further Assurances. ABL Agent, on behalf of the ABL Secured Parties, and Facility Agent, on behalf of the Facility Secured Parties, and the Grantors (by acknowledging and agreeing to this Agreement), agree that each of them shall take such further action and shall execute and deliver such additional documents, instruments and agreements as any Agent may reasonably request to effectuate the terms and provisions set forth in, or contemplated by, this Agreement.

6.9. APPLICABLE LAW. THIS AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO CONFLICT OF LAWS PRINCIPLES (OTHER THAN SECTIONS 5-1401 AND 5-1402 OF THE NEW YORK GENERAL OBLIGATIONS LAW) THEREOF.

6.10. Binding on Successors and Assigns. This Agreement shall be binding upon the Agents and the other Secured Parties, and the Grantors (from acknowledging and agreeing to this Agreement), and their respective successors and assigns; provided that no Grantor shall assign any of its rights (if any) or obligations under this Agreement and any such attempted or prohibited assignment shall be absolutely void ab initio . Any successor or assign of any Agent shall assume all of such prior Agent’s obligations hereunder and shall execute and deliver a joinder to this Agreement to the extent requested in writing by the other Agent and in form mutually reasonably acceptable to both Agents.

6.11. Specific Performance. Each of the Agents may demand specific performance of this Agreement. ABL Agent, on behalf of the ABL Secured Parties, and Facility Agent, on behalf of the Facility Secured Parties, hereby irrevocably waive any defense based on the adequacy of a remedy at law and any other defense which might be asserted to bar the remedy of specific performance in any action which may

 

15


be brought by ABL Agent or the other ABL Secured Parties or Facility Agent or the other Facility Secured Parties, as the case may be.

6.12. Counterparts. This Agreement may be executed in counterparts (and by different parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. Delivery of an executed counterpart of a signature page of this Agreement or any document or instrument delivered in connection herewith by facsimile or other electronic methods of transmission shall be effective as delivery of a manually executed counterpart of this Agreement or such other document or instrument, as applicable.

6.13. No Third Party Beneficiaries. This Agreement and the rights and benefits hereof shall inure to the benefit of each of the parties hereto and its respective successors and assigns and shall inure to the benefit of each of the Secured Parties. Nothing in this Agreement shall impair, as between the Grantors, on the one hand, and the ABL Secured Parties, on the other hand, or as between the Grantors, on the one hand, and the Facility Secured Parties, on the other hand, the Obligations of the Grantors (including any obligations to pay principal, interest, fees, make whole amounts (including the Facility Non-Callable Make Whole Amount) and other amounts and payments as provided in the ABL Documents and the Facility Documents, respectively). Subject to the provisions of the last sentence of Section 6.5 hereof and to Section 6.16 hereof, none of the Grantors or any other creditor thereof shall have any rights hereunder and no Grantor may rely on the terms hereof.

6.14. Provisions Solely to Define Relative Rights. The provisions of this Agreement are and are intended solely for the purpose of defining the relative rights of ABL Agent and the other ABL Secured Parties, on the one hand, and Facility Agent and the other Facility Secured Parties, on the other hand. Nothing in this Agreement is intended to or shall impair the obligations (including the Obligations) of any Grantor, which obligations are absolute and unconditional, to pay or perform the ABL Obligations and the Facility Obligations as and when the same shall become due and payable in accordance with their terms.

6.15. Additional Grantors . The Grantors shall cause each of their Subsidiaries that becomes a Grantor to acknowledge and consent to the terms of this Agreement by causing such Subsidiary to execute and deliver to the parties hereto a Grantor Joinder, substantially in the form of Annex A hereto, pursuant to which such Subsidiary shall agree to be bound by the terms of the attached Acknowledgment and Agreement to the same extent as if it had executed and delivered same as of the date hereof.

[signature page follows]

 

16


IN WITNESS WHEREOF, the parties hereto have executed this Intercreditor Agreement as of the date first written above.

 

DEERFIELD PRIVATE DESIGN FUND IV, L.P.,
as Facility Agent
By: Deerfield Mgmt IV, L.P., General Partner
By: J.E. Flynn Capital IV, LLC, General Partner
By:  

/s/ David J. Clark

  Name:   David J. Clark
  Title:   Authorized Signatory
DEERFIELD ELGX REVOLVER, LLC,
as ABL Agent
By: Deerfield Management Company, L.P. (Series C), Manager
By: Flynn Management LLC, General Partner
By:  

/s/ David J. Clark

  Name:   David J. Clark
  Title:   Authorized Signatory

[Signature Page to Intercreditor Agreement]


ACKNOWLEDGMENT AND AGREEMENT

Each of the undersigned hereby acknowledges and agrees as of August 9, 2018 to the representations, terms and provisions of the Intercreditor Agreement, dated as of the date hereof (the “ Intercreditor Agreement ”; capitalized terms used herein without definition shall have the meaning assigned thereto in the Intercreditor Agreement), by and between Deerfield Private Design Fund IV, L.P., as Facility Agent, and Deerfield ELGX Revolver, LLC, as ABL Agent, of which this Acknowledgment and Agreement is a part. By its signature below, the undersigned agrees that it shall, together with its successors and assigns, be bound by the provisions hereof that are applicable to it, that it shall not do any act or perform any obligation which is in contravention with the agreements set forth herein or in the Intercreditor Agreement and that it shall recognize all rights granted hereby to the Secured Parties.

Each of the undersigned agrees that (a) if either ABL Agent or Facility Agent holds Collateral it does so as bailee (under the UCC or other applicable law) for the other and is hereby authorized to and may turn over to any other Secured Party upon request therefor any such Collateral, after all obligations and indebtedness of the undersigned to the bailee Secured Party have been fully paid and performed, or as otherwise provided in the Intercreditor Agreement, and (b) it will execute and deliver such additional documents, instruments and agreements and take such additional action as may be reasonably requested by any Secured Party to effectuate the provisions and purposes of the foregoing Intercreditor Agreement and to continue without interruption the first priority Lien of the Agents granted on such Collateral being turned over. Each of the undersigned agrees to provide to each Agent a copy of each Grantor Joinder hereto executed and delivered pursuant to Section 6.15 of the Intercreditor Agreement.

Each of the undersigned acknowledges and agrees that, (i) although it may sign this Acknowledgement and Agreement, it is not a party to the Intercreditor Agreement and does not and will not receive any right, benefit, priority or interest under or because of the existence of the Intercreditor Agreement, (ii) any breach by the undersigned of any of its obligations under the Intercreditor Agreement or this Acknowledgment and Agreement will constitute an Event of Default under the terms of each of the ABL Agreement and Facility Agreement and (iii) the terms of the Intercreditor Agreement shall not give any Grantor, nor modify any, substantive rights vis-à-vis any Secured Party, nor modify any obligations or liabilities owing to such Secured Party by such Grantor, under any instrument, document, agreement or arrangement and (x) as between the ABL Secured Parties and the Grantor, the ABL Documents remain in full force and effect as written and are in no way modified hereby, and (y) as between the Facility Secured Parties and the Grantors, the Facility Documents remain in full force and effect as written and are in no way modified hereby.

[signature page follows]


Acknowledged and agreed:     ENDOLOGIX, INC., a Delaware corporation
    By:  

/s/ Vaseem Mahboob

    Name:   Vaseem Mahboob
    Title:   Chief Financial Officer
    CVD/RMS ACQUISITION CORP., a Delaware corporation
    By:  

/s/ Vaseem Mahboob

    Name:   Vaseem Mahboob
    Title:   Chief Financial Officer and Secretary
    NELLIX, INC., a Delaware corporation
    By:  

/s/ Vaseem Mahboob

    Name:   Vaseem Mahboob
    Title:   Chief Financial Officer and Secretary
    TRIVASCULAR TECHNOLOGIES, INC., a Delaware corporation
    By:  

/s/ Vaseem Mahboob

    Name:   Vaseem Mahboob
    Title:   Chief Financial Officer and Secretary
   

TRIVASCULAR, INC., a California

corporation

    By:  

/s/ Vaseem Mahboob

    Name:   Vaseem Mahboob
    Title:   Chief Financial Officer and Secretary
    ENDOLOGIX CANADA, LLC, a Delaware limited liability company
    By:  

/s/ Vaseem Mahboob

    Name:   Vaseem Mahboob
    Title:   Chief Financial Officer and Secretary
    TRIVASCULAR SALES LLC, a Texas limited liability company
    By:  

/s/ Vaseem Mahboob

    Name:   Vaseem Mahboob
    Title:   Chief Financial Officer and Secretary

[Signature Page to Intercreditor Agreement]


RMS/ENDOLOGIX SIDEWAYS MERGER CORP.,

a Delaware corporation

By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer and Secretary

[Signature Page to Intercreditor Agreement]


Annex A

to

Intercreditor Agreement

Form of Grantor Joinder

Reference is made to that certain Intercreditor Agreement, dated as of August 9, 2018 (as amended, restated, supplemented or otherwise modified from time to time in accordance with the terms thereof, the “ Intercreditor Agreement ”), by and between Deerfield Private Design Fund IV, L.P., as Facility Agent, and Deerfield ELGX Revolver, LLC, as ABL Agent, and which was acknowledged and agreed to by the existing Grantors pursuant to the Acknowledgment and Agreement dated as of August 9, 2018 (the “ Intercreditor Acknowledgement and Agreement ”). Capitalized terms used herein without definition shall have the meaning assigned thereto in the Intercreditor Agreement.

This Grantor Joinder, dated as of                     , 20     (this “ Grantor Joinder ”), is being delivered pursuant to Section 6.15 of the Intercreditor Agreement.

The undersigned,                                 , a                                      (the “ Additional Grantor ”), hereby agrees to become a party to the Intercreditor Acknowledgement and Agreement as a Grantor thereunder, for all purposes thereof on the terms set forth therein, and to be bound by the terms of the Intercreditor Acknowledgment and Agreement as fully as if the Additional Grantor had executed and delivered the Intercreditor Acknowledgement and Agreement as of the date thereof.

This Grantor Joinder may be executed in counterparts (and by different parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. Delivery of an executed counterpart of a signature page of this Grantor Joinder by facsimile or other electronic methods of transmission shall be effective as delivery of a manually executed counterpart of this Grantor Joinder.

[signature page follow]

 

Annex A - 1


IN WITNESS WHEREOF, the Additional Grantor has caused this Grantor Joinder to be duly executed by its authorized representative as of the day and year first above written.

 

[ADDITIONAL GRANTOR]
[______________________________]
By:  

                                                      

Name:  

                 

Title:  

                 

Exhibit 10.9

REAFFIRMATION AGREEMENT

This REAFFIRMATION AGREEMENT (this “ Reaffirmation ”) is made and entered into as of August 9, 2018, by ENDOLOGIX, INC. , a Delaware corporation (“ Borrower ”), CVD/RMS ACQUISITION CORP. , a Delaware corporation (“ CVD/RMS ”), NELLIX, INC. , a Delaware corporation (“ Nellix ”), TRIVASCULAR, INC. , a California corporation (“ TriVascular ”), TRIVASCULAR TECHNOLOGIES, INC. , a Delaware corporation (“ Technologies ”), ENDOLOGIX CANADA, LLC , a Delaware limited liability company (f/k/a TriVascular Canada, LLC) (“ Canada ”), TRIVASCULAR SALES LLC , a Texas limited liability company (“ Sales ”) and RMS/ENDOLOGIX SIDEWAYS MERGER CORP. , a Delaware corporation (“ Sideways ”; together with Borrower, CVD/RMS, Nellix, TriVascular, Technologies, Canada and Sales, individually and collectively, the “ Obligors ”) in favor of DEERFIELD PRIVATE DESIGN FUND IV, L.P. , as Agent for the Secured Parties. All initially capitalized terms used herein (including in the preamble and recitals hereof) without definition shall have the meanings ascribed thereto in the below-defined Amended and Restated Facility Agreement.

W I T N E S S E T H :

WHEREAS , certain Obligors, Agent and the lenders party thereto are parties to that certain Facility Agreement, dated as of April 3, 2017 (as amended, restated, supplemented, or otherwise modified from time to time prior to the date hereof, the “ Existing Facility Agreement ”);

WHEREAS , in connection with the Existing Facility Agreement, each Obligor has executed certain Loan Documents (as such term is defined in the Existing Facility Agreement) (to the extent that such Loan Documents are not being amended and restated in connection with the Amended and Restated Facility Agreement, each an “ Obligor Agreement ” and collectively, the “ Obligor Agreements ”);

WHEREAS , each Obligor, the lenders party thereto as “Lenders” (each of such Lenders, together with their respective successors and permitted assigns, are referred to hereinafter as a “ Lender ”), and Agent are concurrently herewith entering into that certain Amended and Restated Facility Agreement (as amended, restated, supplemented, or otherwise modified from time to time, the “ Amended and Restated Facility Agreement ”), whereby the Lenders have agreed to make certain financial accommodations available to the Obligors from time to time pursuant to the terms and conditions thereof and the Agent and the Lenders have agreed to make certain amendments to the Existing Facility Agreement and permit the ABL Credit Facility and the ABL Debt Documents on the terms set forth in the Amended and Restated Facility Agreement and other Loan Documents; and

WHEREAS , in connection with the execution and delivery of the Amended and Restated Facility Agreement and any other Loan Documents in connection therewith, each Obligor desires to expressly ratify, reaffirm and confirm each Obligor Agreement executed by such Obligor and the rights granted thereby in favor of Agent (for its benefit and the benefit of the other Secured Parties) and to agree and acknowledge the joint and several liability between all Obligors of the Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and the Exit Payment).

NOW, THEREFORE , in consideration of the foregoing premises and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

1. Each Obligor hereby ratifies, reaffirms and confirms each Obligor Agreement to which it is a party, and its payment and performance obligations, contingent or otherwise, thereunder and does hereby acknowledge that any rights granted thereby in favor of Agent (for its benefit and the benefit of


the other Secured Parties) are and shall remain in full force and effect subsequent to the Agreement Date, as though each such Obligor Agreement was executed in full by such Obligor as of the date hereof, subject to any amendments made to the Loan Documents on the Agreement Date. Each Obligor also hereby ratifies, reaffirms and confirms all prior and/or concurrent grants of security interests and Liens or “control” (within the meaning of Articles 8 and 9 under the applicable UCC, “ Control ”) in favor of Agent or any other Secured Party in all of such Obligor’s right, title, and interest in, to, and under the Collateral under each Loan Document (including each Obligor Agreement), subject to any amendments made to the Loan Documents on the Agreement Date.

2. Each Obligor confirms and agrees that to the extent that any such Obligor Agreement purports to assign or pledge to Agent or any Secured Party or to grant to Agent or any other Secured Party a security interest in or Lien on, any collateral (including, without limitation, the Collateral) or to provide Control to Agent or any other Secured Party as security for the obligations (including, without limitation, the Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and the Exit Payment) as defined in any Loan Document including any Obligor Agreement) of any Obligor or any other Loan Party, as the case may be, from time to time existing in respect of the Amended and Restated Facility Agreement, or any Loan Document, such pledge or assignment or grant of the security interest or Lien or Control is hereby ratified, reaffirmed and confirmed in all respects, and shall constitute and be deemed a pledge or assignment or grant of the security interest or Lien or Control under the Amended and Restated Facility Agreement and the Loan Documents subject to any amendments made to the Loan Documents on the Agreement Date. Without limiting the generality of the foregoing, each Obligor hereby confirms and agrees that any security interest or Lien granted (or Control provided) in any Obligor Agreement shall secure the obligations (including, without limitation, the Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and the Exit Payment) as defined in any Loan Document including any Obligor Agreement) under the Amended and Restated Facility Agreement and the other Loan Documents, as applicable. Each Obligor hereby further ratifies, reaffirms and confirms the validity and enforceability of all of the Liens and security interests heretofore granted and Control provided, pursuant to and in connection with any Obligor Agreement or any other Loan Document, to Agent or any other Secured Party, as collateral security for the obligations (including, without limitation, the Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and the Exit Payment)) under the Loan Documents in accordance with their respective terms, and acknowledges that all of such Liens and security interests and Control, and all Collateral heretofore pledged as security for such obligations (including, without limitation, the Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and the Exit Payment)), continue to be and remain collateral for such obligations (including, without limitation, Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and the Exit Payment)) from and after the date hereof subject to any amendments made to the Loan Documents on the Agreement Date.

3. Upon and after the effectiveness of this Reaffirmation, each Obligor confirms and agrees that each reference in any Obligor Agreement to (i) “the Facility Agreement” or words of like import referring to the Amended and Restated Facility Agreement shall mean and be a reference to the Amended and Restated Facility Agreement and (ii) each reference to any other agreement, instrument or document that is an Existing Loan Document that is being amended or amended and restated in connection with the amendment and restatement of the Existing Facility Agreement shall mean and be a reference to such agreement, instrument or document as amended or amended and restated.

4. Each Obligor hereby further acknowledges that Agent’s solicitation of ratification, reaffirmation and confirmation of each such Obligor Agreement pursuant to this Reaffirmation is not a condition to the continued effectiveness of each such Obligor Agreement.

 

2


5. With respect to all Obligations (including, without limitation, all obligations under each Obligor Agreement and each Loan Document, including any Non-Callable Make Whole Amount, any CoC Fee and the Exit Payment), each Obligor accepts, reaffirms, confirms and ratifies and agrees to joint and several liability hereunder, thereunder and under the other Loan Documents and the Obligor Agreements, pursuant to the terms hereof and thereof, in consideration of the financial accommodations to be provided by the Secured Parties under the Amended and Restated Facility Agreement and the other Loan Documents, for the mutual benefit, directly and indirectly, of each Obligor and in consideration of the undertakings of the other Obligors to accept joint and several liability for the Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and the Exit Payment). Notwithstanding anything to the contrary in any Existing Loan Document, Obligor Agreement or any Loan Document, all Obligors hereby reaffirm, confirm and agree that all of the Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and the Exit Payment) are joint and several among the Obligors, pursuant to the terms of the Loan Documents. If and to the extent that any Obligor shall fail to make any payment with respect to any of the Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and the Exit Payment) as and when due or to perform any of the Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and the Exit Payment) in accordance with the terms of the applicable Loan Documents and Obligor Agreements, then in each such event the other Obligors will make such payment with respect to, or perform, such Obligations until such time as all of the Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and the Exit Payment) are paid in full (subject to the second sentence of Section 6.22 to the Amended and Restated Facility Agreement), pursuant to the terms of the Loan Documents. The Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and the Exit Payment) of each Obligor under the provisions of this Section 5 constitute the absolute and unconditional, full recourse Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and the Exit Payment) of each Obligor enforceable against each Obligor to the full extent of its properties and assets, irrespective of the validity, regularity or enforceability of the provisions of this Reaffirmation (other than this sentence of this Section 5) or any other circumstances whatsoever but subject to the terms of the Loan Documents.

6. This Reaffirmation is a Loan Document. This Reaffirmation may be executed in several counterparts, and by each party on separate counterparts, each of which and any photocopies, facsimile copies and other electronic methods of transmission thereof shall be deemed an original, but all of which together shall constitute one and the same agreement.

7. THIS REAFFIRMATION SHALL BE SUBJECT TO THE PROVISIONS REGARDING GOVERNING LAW, CONSENT TO JURISDICITION AND WAIVER OF JURY TRIAL SET FORTH IN SECTION 6.4 OF THE AMENDED AND RESTATED FACILITY AGREEMENT, AND SUCH PROVISIONS ARE INCORPORATED HEREIN BY THIS REFERENCE, MUTATIS MUTANDIS .

8. As of the date hereof, each Obligor, for itself and on behalf of its successors, assigns, and officers, directors, employees, agents and attorneys, and any Person acting for or on behalf of, or claiming through it, hereby waives, releases, remises and forever discharges each Secured Party, each of their respective Affiliates and successors in title, and past, present and future officers, directors, employees, limited partners, general partners, investors, attorneys, assigns, subsidiaries, shareholders, trustees, agents and other professionals of the foregoing entities and all other Persons and entities to whom any Secured Party would be liable if such Persons were found to be liable to such Obligor (each a “ Releasee ” and collectively, the “ Releasees ”), from any and all past, present and future claims, suits, liens, lawsuits, amounts paid in settlement, debts, deficiencies, disbursements, demands, obligations, liabilities, causes of action, damages, losses, costs and expenses of any kind or character, whether based in equity, law, contract, tort, implied or express warranty, strict liability, criminal or civil statute or common law (each a “ Claim ” and collectively, the “ Claims ”), whether known or unknown, fixed or contingent, direct,

 

3


indirect, or derivative, asserted or unasserted, matured or unmatured, foreseen or unforeseen, past or present, liquidated or unliquidated, suspected or unsuspected, which such Obligor ever had from the beginning of the world until the date hereof against any such Releasee which relates, directly or indirectly to the Amended and Restated Facility Agreement, any other Loan Document (as defined therein and including any Obligor Agreement), the Stock owned by any Releasee or to any acts or omissions of any such Releasee with respect to the Amended and Restated Facility Agreement or any other Loan Document (as defined therein and including, without limitation, any Obligor Agreement) or any Stock owned by any Releasee, or to the lender-borrower relationship evidenced by the Loan Documents (as defined in the Amended and Restated Facility Agreement and including any Obligor Agreement) or the Warrant/Stock holder or owner-issuer of Warrant/Stock holder issuer, expressly excluding the duties and obligations of Agent and the Lenders set forth in the Amended and Restated Facility Agreement and the other Loan Documents to occur solely after the Agreement Date. As to each and every Claim released hereunder, each Obligor hereby agrees, represents and warrants that it has received the advice of legal counsel with regard to the releases contained herein, and having been so advised, specifically waives the benefit of the provisions of Section 1542 of the Civil Code of California which provides as follows:

“A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.”

As to each and every Claim released hereunder, each Obligor also waives the benefit of each other similar provision of applicable federal or state law (including without limitation the laws of the State of New York), if any, pertaining to general releases after having been advised by legal counsel to such Obligor with respect thereto.

Each Obligor acknowledges that it may hereafter discover facts different from or in addition to those now known or believed to be true with respect to such Claims and agrees that this Reaffirmation shall be and remain effective in all respects notwithstanding any such differences or additional facts. Each Obligor understands, acknowledges and agrees that the release set forth above may be pleaded as a full and complete defense and may be used as a basis for an injunction against any action, suit or other proceeding which may be instituted, prosecuted or attempted in breach of the provisions of such release.

Each Obligor hereby agrees, represents, and warrants that (a) such party has not voluntarily, by operation of law or otherwise, assigned, conveyed, transferred or encumbered, either directly or indirectly, in whole or in part, any right to or interest in any of the Claims released pursuant to this Section 8; (b) this Reaffirmation has been entered into without force or duress, of the free will of each Obligor, and the decision of such undersigned to enter into this Reaffirmation is a fully informed decision and such undersigned is aware of all legal and other ramifications of each such decision; and (c) such Obligor has read and understands this Reaffirmation (including, without limitation, the release granted in this Section 8), has consulted with and been represented by independent legal counsel of its own choosing in negotiations for and the preparation of this Reaffirmation, has read this Reaffirmation in full and final form, and has been advised by its counsel of its rights and obligations hereunder

Each Obligor, for itself and on behalf of its successors, assigns, and Affiliates and their respective officers, directors, employees, agents and attorneys, and any Person acting for or on behalf of, or claiming through it, hereby absolutely, unconditionally and irrevocably, covenants and agrees with and in favor of each Releasee above that it will not sue (at law, in equity, in any regulatory proceeding or otherwise) any Releasee on the basis of any Claim released, remised and discharged by such Person pursuant to the above release in this Section 8. Each Obligor further agrees that it shall not dispute the

 

4


validity or enforceability of the Amended and Restated Facility Agreement, any of the other Loan Documents (including, without limitation, each Obligor Agreement), or any of its obligations thereunder, or the creation, validity, perfection, priority, enforceability or the extent of Agent’s security interest or Lien on any item of Collateral under the Amended and Restated Facility Agreement and the other Loan Documents (including each Obligor Agreement) or the providing of any Control under any Control Agreement or any other Loan Document. If any Obligor violates the foregoing covenant, such Obligor, for itself and its successors, assigns and legal representatives, agrees to pay, in addition to such other damages as any Releasee may sustain as a result of such violation, all attorneys’ fees, expenses and costs and any other fees, expenses and costs incurred by such Releasee as a result of such violation.

[remainder of page intentionally left blank]

 

5


IN WITNESS WHEREOF , Obligor has caused this Reaffirmation to be duly executed as of the date first above written.

 

OBLIGORS:   ENDOLOGIX, INC. ,
  a Delaware corporation
  By:   

/s/ Vaseem Mahboob

  Name: Vaseem Mahboob
  Title: Chief Financial Officer
 

CVD/RMS ACQUISITION CORP. ,

a Delaware corporation

  By:   

/s/ Vaseem Mahboob

  Name: Vaseem Mahboob
  Title: Chief Financial Officer and Secretary
 

NELLIX, INC. ,

a Delaware corporation

  By:   

/s/ Vaseem Mahboob

  Name: Vaseem Mahboob
  Title: Chief Financial Officer and Secretary
 

TRIVASCULAR, INC. ,

a California corporation

  By:   

/s/ Vaseem Mahboob

  Name: Vaseem Mahboob
  Title: Chief Financial Officer and Secretary
 

TRIVASCULAR TECHNOLOGIES, INC. ,

a Delaware corporation

  By:   

/s/ Vaseem Mahboob

  Name: Vaseem Mahboob
  Title: Chief Financial Officer and Secretary

[SIGNATURE PAGE TO REAFFIRMATION AGREEMENT

(AMENDED AND RESTATED FACILITY AGREEMENT)]


ENDOLOGIX CANADA, LLC ,

a Delaware limited liability company

By:  

/s/ Vaseem Mahboob

Name: Vaseem Mahboob
Title: Chief Financial Officer and Secretary

TRIVASCULAR SALES LLC ,

a Texas limited liability company

By:  

/s/ Vaseem Mahboob

Name: Vaseem Mahboob
Title: Chief Financial Officer and Secretary

RMS/ENDOLOGIX SIDEWAYS MERGER CORP. ,

a Delaware corporation

By:  

/s/ Vaseem Mahboob

Name: Vaseem Mahboob
Title: Chief Financial Officer and Secretary

[SIGNATURE PAGE TO REAFFIRMATION AGREEMENT

(AMENDED AND RESTATED FACILITY AGREEMENT)]


AGENT :

 

DEERFIELD PRIVATE DESIGN FUND IV, L.P.

 

By: Deerfield Mgmt IV, L.P., General Partner

 

By: J.E. Flynn Capital IV, LLC, General Partner

By:  

/s/ David J. Clark

Name:

Title:

 

David J. Clark

Authorized Signatory

[SIGNATURE PAGE TO REAFFIRMATION AGREEMENT

(AMENDED AND RESTATED FACILITY AGREEMENT)]

Exhibit 10.10

Execution Version

PATENT SECURITY AGREEMENT

This PATENT SECURITY AGREEMENT (this “ Patent Security Agreement ”) is made this 9 th day of August, 2018, by and among the Grantors listed on the signature pages hereof (collectively, jointly and severally, “ Grantors ” and each individually “ Grantor ”), and DEERFIELD ELGX REVOLVER, LLC , a Delaware limited liability company, in its capacity as agent for each member of the Lender Group (in such capacity, together with its successors and assigns in such capacity, “ Agent ”).

W I T N E S S E T H :

WHEREAS, pursuant to that certain Credit Agreement dated as of August 9, 2018 (as amended, restated, supplemented, or otherwise modified from time to time, the “ Credit Agreement ”) by and among ENDOLOGIX, INC. , a Delaware corporation (“ Endologix ”), each of its direct and indirect Subsidiaries set forth on the signature pages thereto and any additional borrower that may thereafter be added to the Credit Agreement (individually as a “ Borrower ”, and collectively with any entities that become party thereto as Borrower and each of their successors and permitted assigns, the “ Borrowers ”), the lenders party thereto as “Lenders” (such Lenders, together with their respective successors and assigns in such capacity, each, individually, a “ Lender ” and, collectively, the “ Lenders ”), and Agent, the Lender Group has agreed to make certain financial accommodations available to the Borrowers from time to time pursuant to the terms and conditions thereof;

WHEREAS, the members of the Lender Group are willing to make the financial accommodations to the Borrowers as provided for in the Credit Agreement and the other Loan Documents, but only upon the condition, among others, that Grantors shall have executed and delivered to Agent, for the benefit of the Lender Group, that certain Guaranty and Security Agreement, dated as of August 9, 2018 (including all annexes, exhibits or schedules thereto, as from time to time amended, restated, supplemented or otherwise modified, the “ Guaranty and Security Agreement ”); and

WHEREAS, pursuant to the Guaranty and Security Agreement, Grantors are required to execute and deliver to Agent, for the benefit of the Lender Group, this Patent Security Agreement.

NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each Grantor hereby agrees as follows:

1. DEFINED TERMS . All initially capitalized terms used but not otherwise defined herein have the meanings given to them in the Guaranty and Security Agreement or, if not defined therein, in the Credit Agreement, and this Patent Security Agreement shall be subject to the rules of construction set forth in Section 1.04 of the Credit Agreement, which rules of construction are incorporated herein by this reference, mutatis mutandis .

2. GRANT OF SECURITY INTEREST IN PATENT COLLATERAL . Each Grantor hereby unconditionally grants, assigns, and pledges to Agent, for the benefit of each member of the Lender Group, to secure the Secured Obligations, a continuing security interest

 

1


(referred to in this Patent Security Agreement as the “ Security Interest ”) in all of such Grantor’s right, title and interest in and to the following, whether now owned or hereafter acquired or arising (collectively, the “ Patent Collateral ”):

(a) all of its Patents and Patent Intellectual Property Licenses to which it is a party including those referred to on Schedule I ;

(b) all divisionals, continuations, continuations-in-part, reissues, reexaminations, or extensions of the foregoing; and

(c) all products and proceeds of the foregoing, including any claim by such Grantor against third parties for past, present or future infringement of any Patent or any Patent exclusively licensed under any Intellectual Property License, including the right to receive damages, or right to receive license fees, royalties, and other compensation under any Patent Intellectual Property License.

3. SECURITY FOR SECURED OBLIGATIONS . This Patent Security Agreement and the Security Interest created hereby secures the payment and performance of the Secured Obligations, whether now existing or arising hereafter. Without limiting the generality of the foregoing, this Patent Security Agreement secures the payment of all amounts which constitute part of the Secured Obligations and would be owed by Grantors, or any of them, to Agent, the other members of the Lender Group or any of them, whether or not they are unenforceable or not allowable due to the existence of an Insolvency Proceeding involving any Grantor.

4. PROTECTION OF PATENT SECURITY INTEREST BY GRANTORS . Each Grantor shall, at its sole cost, expense and risk, in connection with the operation of its business, comply with the requirements set forth in Section  6 of the Guaranty and Security Agreement in respect of the Patent Collateral.

5. REPRESENTATIONS AND WARRANTIES . Each Grantor represents and warrants that:

(a) Schedule I hereto is a true, correct and complete list of all Patents and Patent Intellectual Property Licenses in which each Grantor purports to have an ownership or license interest.

(b) Such Grantor has the legal right and authority to enter into this Patent Security Agreement and perform its terms.

(c) If such Grantor amends its name, such Grantor shall provide copies of such amendment documentation to Agent and shall, if necessary, re-register such Grantor’s Patents and Patent Intellectual Property Licenses with the appropriate Governmental Authority and shall execute and deliver such agreements or documentation as Agent shall reasonably request in writing to maintain a perfected first priority security interest in the Patent Collateral subject to Permitted Liens.

6. SECURITY AGREEMENT . The Security Interest in the Collateral granted pursuant to this Patent Security Agreement is granted in conjunction with the security interests

 

2


granted to Agent, for the benefit of the Lender Group, pursuant to the Guaranty and Security Agreement. Each Grantor hereby acknowledges and affirms that the rights and remedies of Agent with respect to the Security Interest in the Patent Collateral made and granted hereby are more fully set forth in the Guaranty and Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein. To the extent there is any inconsistency between this Patent Security Agreement and the Guaranty and Security Agreement, the Guaranty and Security Agreement shall control.

7. AUTHORIZATION TO SUPPLEMENT . If any Grantor shall obtain rights to any new patent application or issued patent or become entitled to the benefit of any patent application or patent for any divisional, continuation, continuation-in-part, reissue, or reexamination of any existing patent or patent application, the provisions of this Patent Security Agreement shall automatically apply thereto. Each Grantor shall notify Agent of applications filed for the registration of any Patents with the United States Patent Office in accordance with Section 5.7(g) of the Guaranty and Security Agreement. Without limiting Grantors’ obligations under this Section, Grantors hereby authorize Agent unilaterally to modify this Patent Security Agreement by amending Schedule I to include any such new patent rights of each Grantor. Notwithstanding the foregoing, no failure to so modify this Patent Security Agreement or amend Schedule I shall in any way affect, invalidate or detract from Agent’s continuing security interest in all Collateral, whether or not listed on Schedule I.

8. NO VIOLATION OF LOAN DOCUMENTS . The representations, warranties or covenants contained herein are supplemental to those representations, warranties and covenants contained in the other Loan Documents, and shall not be deemed to modify any such representation, warranty or covenant contained in any other Loan Document.

9. GRANTOR’S RIGHTS TO ENFORCE PATENTS . Prior to Agent’s giving of notice to Grantor following the occurrence and during the continuance of an Event of Default, such Grantor shall have the exclusive right to sue for past, present and future infringement of the Patent Collateral, including the right to seek injunctions and/or money damages, in an effort by such Grantor to protect the Patent Collateral against encroachment by third parties, provided, however, that:

(a) Any money damages awarded or received by such Grantor on account of such suit (or the threat of such suit) shall constitute Patent Collateral.

(b) Any damages recovered in any action pursuant to this Section, net of costs and attorneys’ fees reasonably incurred, shall be applied in accordance with the Credit Agreement and the Guaranty and Security Agreement.

(c) Following the occurrence and during the continuance of any Event of Default, Agent, by notice to any Grantor may terminate or limit such Grantor’s rights under this Section 9.

10. RIGHTS UPON DEFAULT . Upon the occurrence and during the continuance of any Event of Default, Agent may exercise all rights and remedies as provided for in the Guaranty and Security Agreement.

 

3


11. NO LIMITATION; LOAN DOCUMENTS . This Patent Security Agreement has been executed and delivered by each Grantor for the purpose of recording the security interest granted to Agent with respect to the Patent Collateral with the United States Patent Office. The security interest granted hereby has been granted as a supplement to, and not in limitation of, the security interest granted to Agent, for the benefit of the Lender Group, under the Guaranty and Security Agreement and the other Loan Documents. The other Loan Documents (and all rights and remedies of Grantor, Agent, and Lenders thereunder) shall remain in full force and effect in accordance with their terms.

12. TERMINATION; RELEASE OF PATENT COLLATERAL . This Patent Security Agreement and all obligations of each Grantor and Agent hereunder shall terminate on the date upon which the Obligations have been Paid in Full. Upon termination of this Patent Security Agreement, Agent shall, at the reasonable expense of the Grantor, take such actions required by the Credit Agreement or the Guaranty and Security Agreement or as otherwise reasonably requested by Grantor to release its security interest in the Patent Collateral.

13. BINDING EFFECT; BENEFITS . This Patent Security Agreement shall be binding upon each Grantor and its successors and assigns, and shall inure to the benefit of Agent, Lenders and their respective successors and assigns.

14. COUNTERPARTS . This Patent Security Agreement is a Loan Document. This Patent Security Agreement may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, shall be deemed to be an original, and all of which, when taken together, shall constitute but one and the same Patent Security Agreement. Delivery of an executed counterpart of this Patent Security Agreement by telefacsimile or other electronic method of transmission shall be equally as effective as delivery of an original executed counterpart of this Patent Security Agreement. Any party delivering an executed counterpart of this Patent Security Agreement by telefacsimile or other electronic method of transmission also shall deliver an original executed counterpart of this Patent Security Agreement but the failure to deliver an original executed counterpart shall not affect the validity, enforceability, and binding effect of this Patent Security Agreement.

15. CHOICE OF LAW AND VENUE, JURY TRIAL WAIVER, AND JUDICIAL REFERENCE PROVISION . THIS PATENT SECURITY AGREEMENT SHALL BE SUBJECT TO THE PROVISIONS REGARDING CHOICE OF LAW AND VENUE, JURY TRIAL WAIVER, AND JUDICIAL REFERENCE SET FORTH IN SECTIONS 8.11 AND 8.12 OF THE GUARANTY AND SECURITY AGREEMENT, AND SUCH PROVISIONS ARE INCORPORATED HEREIN BY THIS REFERENCE, MUTATIS MUTANDIS .

[signature page follows]

 

4


IN WITNESS WHEREOF, the parties hereto have caused this Patent Security Agreement to be executed and delivered as of the day and year first above written.

 

GRANTORS:     ENDOLOGIX, INC.
    By:  

/s/ Vaseem Mahboob

    Name: Vaseem Mahboob
    Title: Chief Financial Officer
    NELLIX, INC.
    By:  

/s/ Vaseem Mahboob

    Name: Vaseem Mahboob
    Title: Chief Financial Officer and Secretary
    TRIVASCULAR, INC.
    By:  

/s/ Vaseem Mahboob

    Name: Vaseem Mahboob
    Title: Chief Financial Officer and Secretary

[SIGNATURE PAGE TO PATENT SECURITY AGREEMENT]


IN WITNESS WHEREOF, the parties hereto have caused this Patent Security Agreement to be executed and delivered as of the day and year first above written.

 

    ACCEPTED AND ACKNOWLEDGED BY:
AGENT:     DEERFIELD ELGX REVOLVER, LLC
    by: Deerfield Management Company, L.P. (Series C), Manager
    By: Flynn Management LLC, General Partner
    By:  

/s/ David J. Clark

    Name: David J. Clark
    Title: Authorized Signatory

 

6


SCHEDULE I

to

PATENT SECURITY AGREEMENT

Patents

 

Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

ENDOLOGIX INC.    US    Stent graft    US9757262B2    US13943246A    2013-07-16
ENDOLOGIX INC.    US    Catheter system and methods of using same    US9700701B2    US13544426A    2012-07-09
ENDOLOGIX INC.    US    Catheter system and methods of using same    US9687374B2    US15379268A    2016-12-14
ENDOLOGIX INC.    US    Percutaneous method and device to treat dissections    US9579103B2    US12771711A    2010-04-30


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

ENDOLOGIX INC.    US    Catheter system and methods of using same    US9549835B2    US14462485A    2014-08-18
ENDOLOGIX INC.    US    Method and system for treating aneurysms    US9415195B2    US13441762A    2012-04-06
ENDOLOGIX INC.    US    Devices and methods to treat vascular dissections    US9393100B2    US13988175A    2013-05-17
ENDOLOGIX INC.    US    Method for forming materials in situ within a medical device    US9289536B2    US14201332A    2014-03-07
ENDOLOGIX INC.    US    Apparatus and method of placement of a graft or graft system    US9149381B2    US14172126A    2014-02-04

 

2


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

ENDOLOGIX INC.    US    Stent graft    US8821564B2    US13397952A    2012-02-16
ENDOLOGIX INC.    US    Apparatus and methods for repairing aneurysms    US8814928B2    US12616928A    2009-11-12
ENDOLOGIX INC.    US    Catheter system and methods of using same    US8808350B2    US13408952A    2012-02-29
ENDOLOGIX INC.    US    Graft systems having semi-permeable filling structures and methods for their use    US8801768B2    US13355705A    2012-01-23
ENDOLOGIX INC    US    Bifurcated graft deployment systems and methods    US8764812B2    US13745682A    2013-01-18

 

3


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

ENDOLOGIX INC.    US    Apparatus and method of placement of a graft or graft system    US8672989B2    US13546950A    2012-07-11
ENDOLOGIX INC.    US    Graft deployment system    US8568466B2    US13269332A    2011-10-07
ENDOLOGIX INC.    US    Dual concentric guidewire and methods of bifurcated graft deployment    US8523931B2    US11623022A    2007-01-12
ENDOLOGIX INC.    US    Stent graft    US8491646B2    US12837398A    2010-07-15
ENDOLOGIX INC.    US    Endolumenal vascular prosthesis with neointima inhibiting polymeric sleeve    US8377110B2    US10820455A    2004-04-08

 

4


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

ENDOLOGIX INC.    US    Bifurcated graft deployment systems and methods    US8357192B2    US13046541A    2011-03-11
ENDOLOGIX INC.    US    Bifurcated graft deployment systems and methods    US8236040B2    US12101863A    2008-04-11
ENDOLOGIX INC.    US    Catheter system and methods of using same    US8216295B2    US12496446A    2009-07-01
ENDOLOGIX INC.    US    Apparatus and method of placement of a graft or graft system    US8221494B2    US12390346A    2009-02-20
ENDOLOGIX INC.    US    Methods and systems for endovascular aneurysm treatment    US8182525B2    US12421297A    2009-04-09

 

5


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

ENDOLOGIX INC.    US    Single puncture bifurcation graft deployment system    US8167925B2    US12732095A    2010-03-25
ENDOLOGIX INC.    US    Bifurcation graft deployment catheter    US8147535B2    US11189101A    2005-07-25
ENDOLOGIX INC.    US    Material for creating multi-layered films and methods for making the same    US8133559B2    US13100483A    2011-05-04
ENDOLOGIX INC.    US    Stent graft    US8118856B2    US12844266A    2010-07-27
ENDOLOGIX INC.    US    Graft systems having filling structures supported by scaffolds and methods for their use    US8048145B2    US11413460A    2006-04-28

 

6


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

ENDOLOGIX INC.    US    Graft deployment system    US8034100B2    US10722367A    2003-11-25
ENDOLOGIX INC.    US    Material for creating multi-layered films and methods for making the same    US7951448B2    US12858274A    2010-08-17
ENDOLOGIX INC    US    Self expanding bifurcated endovascular prosthesis    US7892277B2    US11417883A    2006-05-03
ENDOLOGIX INC.    US    Material for creating multi-layered films and methods for making the same    US7790273B2    US11752750A    2007-05-23
ENDOLOGIX INC.    US    Devices for repairing aneurysms    US7682383B2    US10481386A    2004-06-14

 

7


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

ENDOLOGIX INC.    US    System and methods for endovascular aneurysm treatment    US7666220B2    US11482503A    2006-07-07
ENDOLOGIX INC.    US    Methods and systems for endovascular aneurysm treatment    US7530988B2    US11187471A    2005-07-22
ENDOLOGIX INC    US    Self expanding bifurcated endovascular prosthesis    US7520895B2    US10119525A    2002-04-08
ENDOLOGIX INC    US    Bifurcation graft deployment catheter    US6953475B2    US10675060A    2003-09-30
ENDOLOGIX INC.    US    Implantable vascular graft    US6733523B2    US09891620A    2001-06-26

 

8


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

ENDOLOGIX INC    US    Single puncture bifurcation graft deployment system    US6663665B2    US09795993A    2001-02-28
ENDOLOGIX INC.    US    Bifurcation graft deployment catheter    US6660030B2    US09747094A    2000-12-22
ENDOLOGIX INC    US    Endoluminal vascular prosthesis    US6508835B1    US09723979A    2000-11-28
ENDOLOGIX INC.    US    Bifurcation graft deployment catheter    US6500202B1    US09525778A    2000-03-15
ENDOLOGIX INC.    US    Dual wire placement catheter    US6440161B1    US09348356A    1999-07-07

 

9


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

ENDOLOGIX INC.    US    Single puncture bifurcation graft deployment system    US6261316B1    US09266661A    1999-03-11
ENDOLOGIX INC.    US    Articulating bifurcation graft    US6197049B1    US09251363A    1999-02-17
ENDOLOGIX INC.    US    Endoluminal vascular prosthesis    US6187036B1    US09210280A    1998-12-11
ENDOLOGIX INC.    US    Segmented stent for flexible stent delivery system    US6187034B1    US09229856A    1999-01-13
ENDOLOGIX INC.    US    Endoluminal vascular prosthesis    US6077296A    US0934689A    1998-03-04

 

10


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

ENDOLOGIX INC.    US    Stent delivery system featuring a flexible balloon    US6022359A    US09229519A    1999-01-13
ENDOLOGIX INC.    US    Radially expandable stent featuring accordion stops    US5931866A    US09028305A    1998-02-24
ENDOLOGIX INC.    US    DUAL INFLATABLE ARTERIAL PROSTHESIS    US20180021045A1    US15540246A    2017-06-27
ENDOLOGIX INC.    US    CATHETER SYSTEM AND METHODS OF USING SAME    US20170304098A1    US15632064A    2017-06-23
ENDOLOGIX INC.    US    CATHETER SYSTEM AND METHODS OF USING SAME    US20170296791A1    US15639028A    2017-06-30

 

11


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

ENDOLOGIX INC    US    APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM    US20170266025A1    US15610242A    2017-05-31
ENDOLOGIX INC.    US    MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES    US20170239035A1    US15310198A    2016-11-10
ENDOLOGIX INC.    US    METHODS AND SYSTEMS FOR ANEURYSM TREATMENT USING FILLING STRUCTURES    US20170238937A1    US15438682A    2017-02-21
ENDOLOGIX INC    US    APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM    US20170128246A1    US15414499A    2017-01-24
ENDOLOGIX INC    US    METHOD AND SYSTEM FOR TREATING ANEURYSMS    US20170007263A1    US15205365A    2016-07-08

 

12


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

ENDOLOGIX INC.    US    METHOD FOR FORMING HYDROGELS AND MATERIALS THEREFOR    US20160367731A1    US15256462A    2016-09-02
ENDOLOGIX INC.    US    DEVICES AND METHODS TO TREAT VASCULAR DISSECTIONS    US20160302798A1    US15194159A    2016-06-27
ENDOLOGIX INC.    US    SYSTEMS AND METHODS FOR FORMING MATERIALS IN SITU WITHIN A MEDICAL DEVICE    US20160030051A1    US14776385A    2015-09-14
ENDOLOGIX INC    US    APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM    US20150366688A1    US14840428A    2015-08-31
ENDOLOGIX INC.    US    METHOD AND SYSTEM FOR TREATING ANEURYSMS    US20150250989A1    US14717938A    2015-05-20

 

13


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

ENDOLOGIX INC.    US    FENESTRATED PROSTHESIS    US20150173923A1    US14581675A    2014-12-23
ENDOLOGIX INC.    US    Apparatus and Methods for Repairing Aneurysms    US20150012081A1    US14330812A    2014-07-14
ENDOLOGIX INC.    US    STENT GRAFT    US9907642    US14461308A    2014-08-15
ENDOLOGIX INC    US    ENDOLUMENAL VASCULAR PROSTHESIS WITH NEOINTIMA INHIBITING POLYMERIC SLEEVE    US20130253638A1    US13731908A    2012-12-31
ENDOLOGIX INC.    US    Methods and Systems for Treating Aneurysms    US20120184982A1    US13354094A    2012-01-19

 

14


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

ENDOLOGIX INC.    US    APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM    US20120109279A1    US13287907A    2011-11-02
ENDOLOGIX INC.    US    FILLING STRUCTURE FOR A GRAFT SYSTEM AND METHODS OF USE    US20110276078A1    US12966852A    2010-12-13
ENDOLOGIX INC    US    SELF EXPANDING BIFURCATED ENDOVASCULAR PROSTHESIS    US20110224782A1    US13027077A    2011-02-14
ENDOLOGIX INC.    US    ENDOLUMINAL VASCULAR PROSTHESIS    US20110218617A1    US13039157A    2011-03-02
ENDOLOGIX INC    US    APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM    US20110054587A1    US12769546A    2010-04-28

 

15


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

ENDOLOGIX INC    US    IMPLANTABLE VASCULAR GRAFT    US20100318174A1    US12860280A    2010-08-20
ENDOLOGIX INC    US    IMPLANTABLE VASCULAR GRAFT    US20100318181A1    US12860310A    2010-08-20
ENDOLOGIX INC.    US    UTILIZATION OF MURAL THROMBUS FOR LOCAL DRUG DELIVERY INTO VASCULAR TISSUE    US20100261662A1    US12757900A    2010-04-09
ENDOLOGIX INC    US    GRAFT DEPLOYMENT SYSTEM    US20100179636A1    US12726257A    2010-03-17
ENDOLOGIX INC.    US    STENT GRAFT DELIVERY SYSTEM    US20100036360A1    US12429474A    2009-04-24

 

16


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

ENDOLOGIX INC.    US    DOCKING APPARATUS AND METHODS OF USE    US20090319029A1    US12478208A    2009-06-04
ENDOLOGIX INC.    US    GRAFT ENDOFRAME HAVING AXIALLY VARIABLE CHARACTERISTICS    US20100004728A1    US12371087A    2009-02-13
ENDOLOGIX INC.    US    METHOD AND AGENT FOR IN-SITU STABILIZATION OF VASCULAR TISSUE    US20090155337A1    US12269677A    2008-11-12
ENDOLOGIX INC.    US    STENT    US20090105806A1    US12257149A    2008-10-23
ENDOLOGIX INC.    US    Multi-segmented graft deployment system    US20080071343A1    US11522292A    2006-09-15

 

17


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

ENDOLOGIX INC    US    IMPLANTABLE VASCULAR GRAFT    US20070299497A1    US11764715A    2007-06-18
ENDOLOGIX INC.    US    Methods and systems for aneurysm treatment using filling structures    US20070150041A1    US11444603A    2006-05-31
ENDOLOGIX INC    US    ENDOLUMINAL VASCULAR PROSTHESIS    US20070112412A1    US11623679A    2007-01-16
ENDOLOGIX INC.    US    Method and apparatus for decompressing aneurysms    US20070078506A1    US11580201A    2006-10-12
ENDOLOGIX INC.    US    Method and apparatus for decompressing aneurysms    US20050245891A1    US11104303A    2005-04-12

 

18


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

ENDOLOGIX INC.    US    Vascular stent-graft apparatus    US20040167607A1    US10787404A    2004-02-24
ENDOLOGIX INC.    US    Stent-graft with positioning anchor    US20040116997A1    US10668901A    2003-09-22
ENDOLOGIX INC.    US    Flexible vascular graft    US20010025195A1    US09728582A    2000-12-01
ENDOLOGIX INC    US    MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES    US20170239035A1    US15310198A    2016-11-10
ENDOLOGIX INC    US    DUAL INFLATABLE ARTERIAL PROSTHESIS    US20180021045A1    US15540246A    2017-06-27

 

19


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

ENDOLOGIX INC    US    ENDOLUMINAL PROSTHESIS SYSTEMS AND METHODS       US15737223    2017-12-15
ENDOLOGIX INC    US    Systems and Methods with Stents and Filling Structure       62/382207    2016-08-31
ENDOLOGIX INC    US    STENTS, GRAFTS, DELIVERY SYSTEMS, AND METHODS       62/481560    2017-04-04
ENDOLOGIX INC    US    ENDOVASCULAR SYSTEMS, DEVICES, AND METHODS ALLOWING FOR BRANCH DEVICE PLACEMENT IN POCKET OF MAIN GRAFT       62/489213    2017-04-24
ENDOLOGIX INC    US    ENDOVASCULAR GRAFT SYSTEMS AND METHODS FOR DEPLOYMENT IN MAIN AND BRANCH ARTERIES       62/529669    2017-07-07

 

20


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

ENDOLOGIX INC    US    STENT GRAFTS AND METHODS OF ENHANCING FLEXIBILITY OF STENT GRAFTS BY THERMAL PLEATING       62/532737    2017-07-14
ENDOLOGIX INC    US    STENT GRAFT       15/911629    2018-03-05
ENDOLOGIX INC    US    INTERNAL ILIAC PRESERVATION DEVICES AND METHODS       15/965649    2018-04-
ENDOLOGIX INC    US    MODULATION OF INFLAMMATORY RESPONSE FOLLOWING ENDOVASCULAR TREATMENT       62/661569    2018-4-23
ENDOLOGIX INC    US    ADVANCED KINK RESISTANT STENT GRAFT       16/005269    2018-6-11

 

21


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

ENDOLOGIX INC    US    LOW PROFILE STENT GRAFT AND DELIVERY SYSTEM       15/985572    2018-5-21
ENDOLOGIX INC    US    SYSTEMS AND METHODS WITH STENT AND FILLING STRUCTURE       15/774511    2017-8-30
ENDOLOGIX INC    US    LONGITUDINALLY EXTENDABLE STENT GRAFT SYSTEMS AND METHODS       15/774548    2018-1-23
ENDOLOGIX INC    US    GRAFT SYSTEMS HAVING FILLING STRUCTURES SUPPORTED BY SCAFFOLDS AND METHODS FOR THEIR USE       16/035497    2018-7-13
ENDOLOGIX INC    US    PRE-FIXATION DEVICE FOR NELLIX AND OTHER EVAS DEVICES       62/678956    2018-5-31

 

22


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

ENDOLOGIX INC    US    SYSTEMS AND METHODS WITH FENESTRATED GRAFT AND FILLING STRUCTURE       16/066595   
ENDOLOGIX INC    US    MODULATION OF INFLAMMATORY RESPONSE FOLLOWING ENDOVASCULAR TREATMENT       62/661569    2018-4-23
ENDOLOGIX INC.    US    FENESTRATED PROSTHESIS    US8945202    12/769581    2015-2-3
ENDOLOGIX INC.    US    Fenestrated prosthesis    US8945202    12/769581    4/28/10
ENDOLOGIX, INC.    US    Bifurcated vascular graft deployment device    US6210422    09/505038    2/16/00

 

23


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

ENDOLOGIX, INC.    US    Method of deploying bifurcated vascular graft    US6156063    09/086247    5/28/98
ENDOLOGIX, INC.    US    Bifurcated vascular graft deployment device    US6090128    08/802478    2/20/97
ENDOLOGIX, INC.    US    Endovascular prosthesis with improved sealing means for aneurysmal arterial disease and method of use    US5665117    08/620072    3/21/96
ENDOLOGIX, INC.    US    Locking assembly for coupling guidewire to delivery system       15/317905    12/9/16
Endologix, Inc. and The Cleveland Clinic Foundation    US    Fenestrated prosthesis    US8945202    US12769581    4/28/10

 

24


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

Endologix, Inc.    US    Single puncture bifurcation graft deployment system    US7691135    US10690227    10/21/03
Endologix, Inc.    US    Bifurcated vascular graft and method and apparatus for deploying same    US6951572    US10639255    8/12/03
Endologix, Inc.    US    Radiation delivery balloon catheter    US6699170    US09688396    10/16/00
Endologix, Inc.    US    Dual wire placement catheter    US6689157    US10035729    12/21/01
Endologix, Inc.    US    Method for delivering radiation to an intraluminal site in the body    US6685618    US09944649    8/31/01

 

25


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

Endologix, Inc.    US    Radiation delivery catheters and dosimetry methods    US6491619    US09648563    8/25/00
Endologix, Inc.    US    Endoluminal vascular prosthesis    US6331190    US09483411    1/14/00
Endologix, Inc.    US    Bifurcated vascular graft deployment device    US6210422    US09505038    2/16/00
Endologix, Inc.    US    Method of deploying bifurcated vascular graft    US6156063    US09086247    5/28/98
Endologix, Inc.    US    Bifurcated vascular graft deployment device    US6090128    US08802478    2/20/97

 

26


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

Endologix, Inc.    US    Axially non-contracting flexible radially expandable stent    US6083259    US09192803    11/16/98
Endologix, Inc.    US    Endovascular prosthesis with improved sealing means for aneurysmal arterial disease and method of use    US5665117    US08620072    3/21/96
Endologix, Inc.    US    Apparatus and method of placement of a graft or graft system       US14172126    2/4/14
Endologix, Inc. and The Cleveland Clinic Foundation    US    Apparatus and method of placement of a graft or graft system       US12769506    4/28/10
Endologix, Inc.    US    Stent graft delivery system       US12429474    4/24/09

 

27


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

ENDOLOGIX INC    US    ENDOLUMINAL DEVICE AND POLYMER       62/575827    2017-10-23
TRIVASCULAR INC    US    Advanced Endovascular Graft    US9788934B2    US14799656A    2015-07-15
NELLIX INC.    US    Stent-graft with positioning anchor    US9814612B2    US14697433A    2015-10-21
NELLIX INC.    US    System and methods for endovascular aneurysm treatment    US9737425B2    US14537749A    2014-11-10
NELLIX INC.    US    Stent graft delivery system    US9730700B2    US14586110A    2015-04-23

 

28


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

NELLIX INC.    US    Methods for deploying a positioning anchor with a stent-graft    US9113999B2    US11876458A    2007-10-22
NELLIX INC.    US    Sealing apparatus and methods of use    US8945199B2    US12478225A    2009-06-04
NELLIX INC.    US    Stent graft delivery system    US8926682B2    US13243941A    2011-09-23
NELLIX INC.    US    System and methods for endovascular aneurysm treatment    US8906084B2    US12684074A    2010-01-07
NELLIX INC.    US    Graft systems having filling structures supported by scaffolds and methods for their use    US8870941B2    US13285897A    2011-10-31

 

29


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

NELLIX INC.    US    STENT GRAFT DELIVERY SYSTEM    US20180028192A1    US15676869A    2017-08-14
NELLIX INC.    US    SEALING APPRATUS AND METHODS OF USE    US20150148892A1    US14612048A    2015-02-02
NELLIX INC.    US    GRAFT SYSTEMS HAVING FILLING STRUCTURES SUPPORTED BY SCAFFOLDS AND METHODS FOR THEIR USE    US10022249    US14525019A    2014-10-27
NELLIX, INC.    US    System and methods of Endovascular Aneurysm Treatment       14/682414    8/21/17
Nellix, Inc.    US    Vascular stent-graft apparatus and forming method    US6695833    US09671550    9/27/00

 

30


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

TRIVASCULAR INC.    US    Endovascular graft    US9867727B2    US14320773A    2014-07-01
TRIVASCULAR INC.    US    Advanced endovascular graft    US9788934B2    US14799656A    2015-07-15
TRIVASCULAR INC.    US    Endovascular graft for aneurysms involving major branch vessels    US9724186B2    US14050835A    2013-10-10
TRIVASCULAR INC.    US    System and method of pivoted stent deployment    US9713523B2    US14452343A    2014-08-05
TRIVASCULAR INC.    US    Systems and methods for guidewire crossover for bifurcated prostheses    US9655754B2    US14323059A    2014-07-03

 

31


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

TRIVASCULAR INC.    US    Bifurcated endovascular prosthesis having tethered contralateral leg    US9585774B2    US14823076A    2015-08-11
TRIVASCULAR INC.    US    PTFE layers and methods of manufacturing    US9549829B2    US14458349A    2014-08-13
TRIVASCULAR INC.    US    Delivery catheter for endovascular device    US9498363B2    US13835491A    2013-03-15
TRIVASCULAR INC    US    Low profile stent and delivery system    US9463101B2    US14923477A    2015-10-27
TRIVASCULAR INC.    US    PTFE layers and methods of manufacturing    US9446553B2    US14230318A    2014-03-31

 

32


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

TRIVASCULAR INC.    US    Endovascular graft joint and method for manufacture    US9351858B2    US14704013A    2015-05-05
TRIVASCULAR INC.    US    Non-degradable, low swelling, water soluble radiopaque hydrogel polymer    US9308301B2    US13089960A    2011-04-19
TRIVASCULAR INC.    US    Endovascular delivery system with an improved radiopaque marker scheme    US9233015B2    US13803050A    2013-03-14
TRIVASCULAR INC.    US    Low profile stent graft and delivery system    US9192462B2    US13803037A    2013-03-14
TRIVASCULAR INC.    US    Fenestrated inflatable graft    US9144486B2    US13652471A    2012-10-15

 

33


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

TRIVASCULAR INC.    US    Bifurcated endovascular prosthesis having tethered contralateral leg    US9132025B2    US13803067A    2013-03-14
TRIVASCULAR INC.    US    Endovascular delivery system with flexible and torqueable hypotube    US9066828B2    US13803062A    2013-03-14
TRIVASCULAR INC.    US    Endovascular graft joint and method for manufacture    US9050754B2    US12729182A    2010-03-22
TRIVASCULAR INC.    US    Durable stent graft with tapered struts and stable delivery methods and devices    US8992595B2    US13799207A    2013-03-13
TRIVASCULAR INC.    US    In vitro testing of endovascular device    US8978448B2    US13649066A    2012-10-10

 

34


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

TRIVASCULAR INC.    US    Advanced endovascular graft delivery system and method of treatment    US8900288B2    US12566104A    2009-09-24
TRIVASCULAR INC.    US    Method of delivering advanced endovascular graft and system    US8864814B2    US13246651A    2011-09-27
TRIVASCULAR INC.    US    PTFE layers and methods of manufacturing    US8840824B2    US12910281A    2010-10-22
TRIVASCULAR INC.    US    Endovascular graft    US8801769B2    US13737351A    2013-01-09
TRIVASCULAR INC.    US    Apparatus for manufacturing an endovascular graft section    US8783316B2    US12697504A    2010-02-01

 

35


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

TRIVASCULAR INC.    US    PTFE layers and methods of manufacturing    US8728372B2    US12915636A    2010-10-29
TRIVASCULAR INC.    US    Advanced endovascular graft    US8709065B2    US12491336A    2009-06-25
TRIVASCULAR INC.    US    Virtual prototyping and testing for medical device development    US8666714B2    US13523765A    2012-06-14
TRIVASCULAR INC.    US    Asymmetric stent apparatus and method    US8663309B2    US11861828A    2007-09-26
TRIVASCULAR INC.    US    Endovascular graft    US8361136B2    US12566793A    2009-09-25

 

36


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

TRIVASCULAR INC.    US    Endovascular graft joint and method for manufacture    US8348989B2    US11429735A    2006-05-08
TRIVASCULAR INC.    US    Delivery system and method for bifurcated graft    US8328861B2    US11941434A    2007-11-16
TRIVASCULAR INC.    US    Endovascular graft and method of delivery    US8241346B2    US13246643A    2011-09-27
TRIVASCULAR INC.    US    Inflatable porous implants and methods for drug delivery    US8267989B2    US12860364A    2010-08-20
TRIVASCULAR INC.    US    Inflatable intraluminal graft    US8226708B1    US10168053A    2002-06-14

 

37


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

TRIVASCULAR INC.    US    Stent and delivery system for deployment thereof    US8226701B2    US11861756A    2007-09-26
TRIVASCULAR INC.    US    Virtual prototyping and testing for medical device development    US8224632B2    US12904994A    2010-10-14
TRIVASCULAR INC.    US    Dual chamber cuff structure    US8216297B2    US11504434A    2006-08-14
TRIVASCULAR INC.    US    Barbed radially expandable stent    US8167927B2    US13245661A    2011-09-26
TRIVASCULAR INC.    US    Securement assembly and method for expandable endovascular device    US8083789B2    US11941450A    2007-11-16

 

38


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

TRIVASCULAR INC.    US    System and method of pivoted stent deployment    US8066755B2    US11861716A    2007-09-26
TRIVASCULAR INC.    US    Constant force material delivery system and method    US7971751B2    US12724068A    2010-03-15
TRIVASCULAR INC.    US    Passive hemostatic sheath valve    US7901379B2    US11298285A    2005-12-09
TRIVASCULAR INC.    US    Virtual prototyping and testing for medical device development    US7840393B1    US09679725A    2000-10-04
TRIVASCULAR INC.    US    Inflatable porous implants and methods for drug delivery    US7803178B2    US10769532A    2004-01-30

 

39


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

TRIVASCULAR INC.    US    Advanced endovascular graft    US7766954B2    US11333595A    2006-01-17
TRIVASCULAR INC.    US    Constant force material delivery system and method    US7708163B2    US11360077A    2006-02-23
TRIVASCULAR INC.    US    Endovascular graft joint and method for manufacture    US7682475B2    US11870748A    2007-10-11
TRIVASCULAR INC.    US    Method for manufacturing an endovascular graft section    US7678217B2    US11522490A    2006-09-15
TRIVASCULAR INC.    US    Inflatable implant    US7632291B2    US10461853A    2003-06-13

 

40


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

TRIVASCULAR INC.    US    Endovascular graft    US7615071B2    US11390732A    2006-03-28
TRIVASCULAR INC.    US    Delivery system and method for expandable intracorporeal device    US7338518B2    US11201028A    2005-08-10
TRIVASCULAR INC.    US    Passive hemostatic sheath valve    US7241276B2    US10636871A    2003-08-06
TRIVASCULAR INC.    US    Advanced endovascular graft    US7147660B2    US10327711A    2002-12-20
TRIVASCULAR INC.    US    Kink resistant endovascular graft    US7150758B2    US10384103A    2003-03-06

 

41


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

TRIVASCULAR INC.    US    Radially expandable stent    US7147661B2    US10029559A    2001-12-20
TRIVASCULAR INC.    US    Method and apparatus for shape forming endovascular graft material    US7147455B2    US10868292A    2004-06-14
TRIVASCULAR INC.    US    Method for manufacturing an endovascular graft section    US7125464B2    US10029557A    2001-12-20
TRIVASCULAR INC.    US    Endovascular graft    US7081129B2    US10132754A    2002-04-24
TRIVASCULAR INC.    US    Endovascular graft joint and method for manufacture    US7090693B1    US10029584A    2001-12-20

 

42


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

TRIVASCULAR INC.    US    Delivery system and method for expandable intracorporeal device    US7066951B2    US10419312A    2003-04-17
TRIVASCULAR INC.    US    Method and apparatus for shape forming endovascular graft material    US6776604B1    US10029570A    2001-12-20
TRIVASCULAR INC.    US    Delivery system and method for bifurcated endovascular graft    US6761733B2    US09917371A    2001-07-27
TRIVASCULAR INC.    US    Delivery system and method for endovascular graft    US6733521B2    US09834278A    2001-04-11
TRIVASCULAR INC.    US    Delivery system and method for expandable intracorporeal device    US6602280B2    US09774733A    2001-01-31

 

43


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

TRIVASCULAR INC.    US    Endovascular graft    US6395019B2    US09133978A    1998-08-14
TRIVASCULAR INC    US    ENDOVASCULAR GRAFT    US20170348125A1    US15686214A    2017-08-25
TRIVASCULAR INC    US    ADVANCED ENDOVASCULAR GRAFT    US20170348087A1    US15686218A    2017-08-25
TRIVASCULAR INC    US    ENDOVASCUALR GRAFT FOR ANEURYSMS INVOLVING MAJOR BRANCH VESSELS    US20170296327A1    US15638559A    2017-06-30
TRIVASCULAR INC    US    SYSTEMS AND METHODS FOR GUIDEWIRE CROSSOVER FOR BIFURCATED PROSTHESES    US20170216064A1    US15491074A    2017-04-19

 

44


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

TRIVASCULAR INC    US    Low Profile Stent Graft and Delivery System    US9987123    US15263469A    2016-09-13
TRIVASCULAR INC    US    BIFURCATED ENDOVASCULAR PROSTHESIS HAVING TETHERED CONTRALATERAL LEG    US20170035549A1    US15299542A    2016-10-21
TRIVASCULAR INC.    US    DELIVERY CATHETER FOR ENDOVASCULAR DEVICE    US20170035590A1    US15298166A    2016-10-19
TRIVASCULAR INC    US    PTFE LAYERS AND METHODS OF MANUFACTURING    US20160367354A1    US15251011A    2016-08-30
TRIVASCULAR INC    US    ENDOVASCULAR DELIVERY SYSTEM WITH AN IMPROVED RADIOPAQUE MARKER SCHEME    US10034787    US14970621A    2015-12-16

 

45


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

TRIVASCULAR INC    US    NON-DEGRADABLE, LOW SWELLING, WATER SOLUBLE RADIOPAQUE HYDROGEL POLYMER    US20160193392A1    US15068415A    2016-03-11
TRIVASCULAR INC.    US    INTERNAL ILIAC PRESERVATION DEVICES AND METHODS    US9956101    US14958085A    2015-12-03
TRIVASCULAR INC.    US    STENT GRAFT DELIVERY SYSTEM WITH ACCESS CONDUIT    US20160113796A1    US14920828A    2015-10-22
TRIVASCULAR INC.    US    ENDOVASCULAR DELIVERY SYSTEM WITH FLEXIBLE AND TORQUEABLE HYPOTUBE    US20150265446A1    US14717080A    2015-05-20
TRIVASCULAR INC.    US    INFLATABLE OCCLUSION WIRE-BALLOON FOR AORTIC APPLICATIONS    US20150250481A1    US14643217A    2015-03-10

 

46


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

TRIVASCULAR INC.    US    ADVANCED ENDOVASCULAR GRAFT AND DELIVERY SYSTEM    US20150164667A1    US14631818A    2015-02-25
TRIVASCULAR INC.    US    DURABLE STENT GRAFT WITH TAPERED STRUTS AND STABLE DELIVERY METHODS AND DEVICES    US20150157479A1    US14615337A    2015-02-05
TRIVASCULAR INC.    US    TANDEM MODULAR ENDOGRAFT    US20150088244A1    US14492674A    2014-09-22
TRIVASCULAR INC.    US    ENDOLEAK ISOLATION SLEEVES AND METHODS OF USE    US20150073523A1    US14481834A    2014-09-09
TRIVASCULAR INC.    US    GATE WIRE FOR CONTRALATERAL LEG ACCESS    US20140194970A1    US14151373A    2014-01-09

 

47


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

TRIVASCULAR INC.    US    SAC LINER FOR ANEURYSM REPAIR    US20140194973A1    US14151195A    2014-01-09
TRIVASCULAR INC.    US    ASYMMETRIC STENT APPARATUS AND METHOD    US20140135899A1    US14157350A    2014-01-16
TRIVASCULAR INC.    US    LOW PROFILE STENT GRAFT AND DELIVERY SYSTEM    US20130268056A1    US13803033A    2013-03-14
TRIVASCULAR INC.    US    ADVANCED KINK RESISTANT STENT GRAFT    US9993328    US13803046A    2013-03-14
TRIVASCULAR INC.    US    VASCULAR GRAFT HAVING LIMITED END STRUCTURE    US20130096665A1    US13650705A    2012-10-12

 

48


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

TRIVASCULAR INC.    US    INFLATABLE INTRALUMINAL GRAFT    US20120265290A1    US13532887A    2012-06-26
TRIVASCULAR INC.    US    ADVANCED ENDOVASCULAR GRAFT AND DELIVERY SYSTEM    US20120191174A1    US13297219A    2011-11-15
TRIVASCULAR INC.    US    SYSTEM AND METHOD OF PIVOTED STENT DEPLOYMENT    US20120083870A1    US13277117A    2011-10-19
TRIVASCULAR INC.    US    BARBED RADIALLY EXPANDABLE STENT WITH SLOTTED STRUTS    US20120016457A1    US13245652A    2011-09-26
TRIVASCULAR INC.    US    FILL TUBE MANIFOLD AND DELIVERY METHODS FOR ENDOVASCULAR GRAFT    US20110218609A1    US13024255A    2011-02-09

 

49


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

TRIVASCULAR INC.    US    HINGED ENDOVASCULAR DEVICE    US20100331958A1    US12747499A    2010-09-07
TRIVASCULAR INC.    US    Inflatable Implant    US20100076481A1    US12628623A    2009-12-01
TRIVASCULAR INC.    US    METHOD OF DELIVERING ADVANCED ENDOVASCULAR GRAFT    US20100016943A1    US12566808A    2009-09-25
TRIVASCULAR INC.    US    MODULAR VASCULAR GRAFT FOR LOW PROFILE PERCUTANEOUS DELIVERY    US20090099649A1    US12245620A    2008-10-03
TRIVASCULAR INC.    US    ALIGNMENT STENT APPARATUS AND METHOD    US20090082845A1    US11861746A    2007-09-26

 

50


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

TRIVASCULAR INC.    US    SYSTEM AND METHOD OF SECURING STENT BARBS    US20090082847A1    US11861731A    2007-09-26
TRIVASCULAR INC.    US    APPARATUS FOR SECURING STENT BARBS    US20090082841A1    US11861739A    2007-09-26
TRIVASCULAR INC.    US    PTFE LAYERS AND METHODS OF MANUFACTURING    US20090036971A1    US12250915A    2008-10-14
TRIVASCULAR INC.    US    PTFE LAYERS AND METHODS OF MANUFACTURING    US20090036973A1    US12250946A    2008-10-14
TRIVASCULAR INC.    US    Non-degradable, low swelling, water soluble radiopaque hydrogel polymer    US20060222596A1    US11097467A    2005-04-01

 

51


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

TRIVASCULAR INC.    US    Hybrid modular endovascular graft    US20060224232A1    US11097718A    2005-04-01
TRIVASCULAR INC.    US    Delivery system and method for bifurcated graft    US20060009833A1    US11205793A    2005-08-15
TRIVASCULAR INC.    US    Methods, compositions and devices for embolizing body lumens    US20050158272A1    US11031311A    2005-01-07
TRIVASCULAR INC.    US    Endoluminal prosthesis endoleak management    US20050090804A1    US10691849A    2003-10-22
TRIVASCULAR INC.    US    Endovascular graft joint and method for manufacture    US20050027347A1    US10640368A    2003-08-13

 

52


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

TRIVASCULAR INC.    US    Layered endovascular graft    US20040220664A1    US10803153A    2004-03-17
TRIVASCULAR INC.    US    Delivery system and method for bifurcated graft    US20040138734A1    US10686863A    2003-10-16
TRIVASCULAR INC.    US    Endovascular graft    US20030216802A1    US10289136A    2002-11-05
TRIVASCULAR INC.    US    Inflatable intraluminal graft    US20030225453A1    US10289137A    2002-11-05
TRIVASCULAR INC.    US    Advanced endovascular graft    US20030120338A1    US10091641A    2002-03-05

 

53


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

TRIVASCULAR INC.    US    Delivery system and method for bifurcated graft    US20030004560A1    US10122474A    2002-04-11
TRIVASCULAR INC.    US    Layered endovascular graft    US20020010508A1    US09970576A    2001-10-04
TRIVASCULAR, INC.    US    Stent-graft with improved flexibility       15/568834    10/24/17
Trivascular, Inc.    US    Passive hemostatic sheath valve    US7901379    US11298285    12/9/05
Trivascular, Inc.    US    Fluid mixing apparatus and method    US7178978    US10658074    9/8/03

 

54


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

Trivascular, Inc.    US    Delivery system and method for expandable intracorporeal device    US6602280    US09774733    1/31/01
Trivascular, Inc.    US    Endovascular graft    US6395019    US09133978    8/14/98
Trivascular, Inc.    US    Layered endovascular graft    US6331191    US09200317    11/25/98
Trivascular, Inc.    US    Endovascular graft having longitudinally displaceable sections    US6132457    US09177295    10/22/98
Trivascular, Inc.    US    Low profile stent graft and delivery system       US15263469    9/13/16

 

55


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

Trivascular, Inc.    US    Delivery catheter for endovascular device       US15298166    10/19/16
Trivascular, Inc.    US    Bifurcated endovascular prosthesis having tethered contralateral leg       US15299542    10/21/16
Trivascular, Inc.    US    Ptfe layers and methods of manufacturing       US15251011    8/30/16
Trivascular, Inc.    US    Endovascular delivery system with an improved radiopaque marker scheme       US14970621    12/16/15
Trivascular, Inc.    US    Non-degradable, low swelling, water soluble radiopaque hydrogel polymer       US15068415    3/11/16

 

56


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

Trivascular, Inc.    US    Internal iliac preservation devices and methods       US14958085    12/3/15
Trivascular, Inc.    US    Stent graft delivery system with access conduit       US14920828    10/22/15
Trivascular, Inc.    US    Bifurcated endovascular prosthesis having tethered contralateral leg       US14823076    8/11/15
Trivascular, Inc.    US    Low profile stent and delivery system       US14923477    10/27/15
Trivascular, Inc.    US    Endovascular delivery system with flexible and torqueable hypotube       US14717080    5/20/15

 

57


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

Trivascular, Inc.    US    Inflatable occlusion wire-balloon for aortic applications       US14643217    3/10/15
Trivascular, Inc.    US    Advanced endovascular graft and delivery system       US14631818    2/25/15
Trivascular, Inc.    US    Durable stent graft with tapered struts and stable delivery methods and devices       US14615337    2/5/15
Trivascular, Inc.    US    Tandem modular endograft       US14492674    9/22/14
Trivascular, Inc.    US    Endoleak isolation sleeves and methods of use       US14481834    9/9/14

 

58


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

Trivascular, Inc.    US    Sac liner for aneurysm repair       US14151195    1/9/14
Trivascular, Inc.    US    Gate wire for contralateral leg access       US14151373    1/9/14
Trivascular, Inc.    US    Asymmetric stent apparatus and method       US14157350    1/16/14
Trivascular, Inc.    US    Low profile stent graft and delivery system       US13803033    3/14/13
Trivascular, Inc.    US    Advanced kink resistant stent graft       US13803046    3/14/13

 

59


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

Trivascular, Inc.    US    Vascular graft having limited end structure       US13650705    10/12/12
Trivascular, Inc.    US    Inflatable intraluminal graft       US13532887    6/26/12
Trivascular, Inc.    US    Advanced endovascular graft and delivery system       US13297219    11/15/01
Trivascular, Inc.    US    System and method of pivoted stent deployment       US13277117    10/19/11
Trivascular, Inc.    US    Barbed radially expandable stent with slotted struts       US13245652    9/26/11

 

60


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

Trivascular, Inc.    US    Fill tube manifold and delivery methods for endovascular graft       US13024255    2/9/11
Trivascular, Inc.    US    Hinged endovascular device       US12747499    9/7/10
Trivascular, Inc.    US    Inflatable implant       US12628623    12/1/09
Trivascular, Inc.    US    Method of delivering advanced endovascular graft       US12566808    9/25/09
Trivascular, Inc.    US    Modular vascular graft for low profile percutaneous delivery       US12245620    10/3/08

 

61


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

Trivascular, Inc.    US    System and method of securing stent barbs       US11861731    9/26/07
Trivascular, Inc.    US    Alignment stent apparatus and method       US11861746    9/26/07
Trivascular, Inc.    US    Apparatus for securing stent barbs       US11861739    9/26/07
Trivascular, Inc.    US    Ptfe layers and methods of manufacturing       US12250946    10/14/08
Trivascular, Inc.    US    Ptfe layers and methods of manufacturing       US12250915    10/14/08

 

62


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

Trivascular, Inc.    US    Ptfe layers and methods of manufacturing       US11106150    4/13/05
Trivascular, Inc.    US    Ptfe layers and methods of manufacturing       US11106131    4/13/05
Trivascular, Inc.    US    Hybrid modular endovascular graft       US11097718    4/1/05
Trivascular, Inc.    US    Non-degradable low swelling, water soluble radiopaque hydrogel polymer       US11097467    4/1/05
Trivascular, Inc.    US    Delivery system and method for bifurcated graft       US11205793    8/15/05

 

63


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

Trivascular, Inc.    US    Modular endovascular graft       US11077938    3/11/05
Trivascular, Inc.    US    Methods, compositions and devices for embolizing body lumens       US11031311    1/7/05
Trivascular, Inc.    US    Endoluminal prosthesis endoleak management       US10691849    10/22/03
Trivascular, Inc.    US    Endovascular graft joint and method for manufacture       US10640368    8/13/03
Trivascular, Inc.    US    Layered endovascular graft       US10803153    3/17/04

 

64


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

Trivascular, Inc.    US    Delivery system and method for bifurcated graft       US10686863    10/16/03
Trivascular, Inc.    US    Inflatable intraluminal graft       US10289137    11/5/02
Trivascular, Inc.    US    Endovascular graft       US10289136    11/5/02
Trivascular, Inc.    US    Advanced endovascular graft       US10091641    3/5/02
Trivascular, Inc.    US    Delivery system and method for bifurcated graft       US10122474    4/11/02

 

65


Grantor

  

Country

  

Patent

  

Publication/Patent No.

  

Application Number

  

Application Date

Trivascular, Inc.    US    Layered endovascular graft       US09970576    10/3/01
ENDOLOGIX INC.    US    STENT GRAFT SYSTEMS WITH RESTRAINTS IN CIRCUMFERENTIAL CHANNELS AND METHODS THEREOF       62/678961    5/31/2018
ENDOLOGIX INC.    US    PERCUTANEOUS METHOD AND DEVICE TO TREAT DISSECTIONS       15/429090    2/9/2017
NELLIX, INC.    US    SYSTEM AND METHODS FOR ENDOVASCULAR ANEURYSM TREATMENT    2018-0064566    15/682414    8/21/2017
TRIVASCULAR INC.    US    ENDOVASCULAR DELIVERY SYSTEM WITH AN IMPROVED RADIOPAQUE MARKER SCHEME       16/049560    7/30/2018

 

 

66

Exhibit 10.11

Execution Version

TRADEMARK SECURITY AGREEMENT

This TRADEMARK SECURITY AGREEMENT (this “ Trademark Security Agreement ”) is made this 9 th day of August, 2018, by and among the Grantors listed on the signature pages hereof (collectively, jointly and severally, “ Grantors ” and each individually “ Grantor ”), and DEERFIELD ELGX REVOLVER, LLC , a Delaware limited liability company, in its capacity as agent for each member of the Lender Group (in such capacity, together with its successors and assigns in such capacity, “ Agent ”).

W I T N E S S E T H :

WHEREAS, pursuant to that certain Credit Agreement dated as of August 9, 2018 (as amended, restated, supplemented, or otherwise modified from time to time, the “ Credit Agreement ”) by and among ENDOLOGIX, INC. , a Delaware corporation (“ Endologix ”), each of its direct and indirect Subsidiaries set forth on the signature pages thereto and any additional borrower that may thereafter be added to the Credit Agreement (individually as a “ Borrower ”, and collectively with any entities that become party thereto as Borrower and each of their successors and permitted assigns, the “ Borrowers ”), the lenders party thereto as “Lenders” (such Lenders, together with their respective successors and assigns in such capacity, each, individually, a “ Lender ” and, collectively, the “ Lenders ”), and Agent, the Lender Group has agreed to make certain financial accommodations available to the Borrowers from time to time pursuant to the terms and conditions thereof;

WHEREAS, the members of the Lender Group are willing to make the financial accommodations to the Borrowers as provided for in the Credit Agreement and the other Loan Documents, but only upon the condition, among others, that Grantors shall have executed and delivered to Agent, for the benefit of the Lender Group, that certain Guaranty and Security Agreement, dated as of August 9, 2018 (including all annexes, exhibits or schedules thereto, as from time to time amended, restated, supplemented or otherwise modified, the “ Guaranty and Security Agreement ”); and

WHEREAS, pursuant to the Guaranty and Security Agreement, Grantors are required to execute and deliver to Agent, for the benefit of the Lender Group, this Trademark Security Agreement.

NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each Grantor hereby agrees as follows:

1. DEFINED TERMS . All initially capitalized terms used but not otherwise defined herein have the meanings given to them in the Guaranty and Security Agreement or, if not defined therein, in the Credit Agreement, and this Trademark Security Agreement shall be subject to the rules of construction set forth in Section 1.04 of the Credit Agreement, which rules of construction are incorporated herein by this reference, mutatis mutandis .

2. GRANT OF SECURITY INTEREST IN TRADEMARK COLLATERAL . Each Grantor hereby unconditionally grants, assigns, and pledges to Agent, for the benefit of each member of the Lender Group, to secure the Secured Obligations, a continuing security interest


(referred to in this Trademark Security Agreement as the “ Security Interest ”) in all of such Grantor’s right, title and interest in and to the following, whether now owned or hereafter acquired or arising (collectively, the “ Trademark Collateral ”):

(a) all of its Trademarks and Trademark Intellectual Property Licenses to which it is a party including those referred to on Schedule I ;

(b) all goodwill of the business connected with the use of, and symbolized by, each Trademark and each Trademark Intellectual Property License; and

(c) all products and proceeds (as that term is defined in the Code) of the foregoing, including any claim by such Grantor against third parties for past, present or future (i) infringement or dilution of any Trademark or any Trademarks exclusively licensed under any Intellectual Property License, including right to receive any damages, (ii) injury to the goodwill associated with any Trademark, or (iii) right to receive license fees, royalties, and other compensation under any Trademark Intellectual Property License.

3. SECURITY FOR SECURED OBLIGATIONS . This Trademark Security Agreement and the Security Interest created hereby secures the payment and performance of the Secured Obligations, whether now existing or arising hereafter. Without limiting the generality of the foregoing, this Trademark Security Agreement secures the payment of all amounts which constitute part of the Secured Obligations and would be owed by Grantors, or any of them, to Agent, the other members of the Lender Group or any of them, whether or not they are unenforceable or not allowable due to the existence of an Insolvency Proceeding involving any Grantor.

4. PROTECTION OF TRADEMARK SECURITY INTEREST BY GRANTORS . Each Grantor shall, at its sole cost, reasonable expense and risk, in connection with the operation of its business, comply with the requirements set forth in Section  6 of the Guaranty and Security Agreement in respect of the Trademark Collateral.

5. REPRESENTATIONS AND WARRANTIES . Each Grantor represents and warrants that:

(a) Schedule I hereto is a true, correct and complete list of all Trademarks and Trademark Intellectual Property Licenses in which each Grantor purports to have an ownership or license interest.

(b) Such Grantor has the legal right and authority to enter into this Trademark Security Agreement and perform its terms.

(c) If such Grantor amends its name, such Grantor shall provide copies of such amendment documentation to Agent and shall, if necessary, re-register such Grantor’s Trademarks and Trademark Intellectual Property Licenses with the appropriate Governmental Authority and shall execute and deliver such agreements or documentation as Agent shall reasonably request in writing to maintain a perfected first priority security interest in the Trademark Collateral subject to Permitted Liens.

 

2


6. SECURITY AGREEMENT . The Security Interest in the Collateral granted pursuant to this Trademark Security Agreement is granted in conjunction with the security interests granted to Agent, for the benefit of the Lender Group, pursuant to the Guaranty and Security Agreement. Each Grantor hereby acknowledges and affirms that the rights and remedies of Agent with respect to the Security Interest in the Trademark Collateral made and granted hereby are more fully set forth in the Guaranty and Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein. To the extent there is any inconsistency between this Trademark Security Agreement and the Guaranty and Security Agreement, the Guaranty and Security Agreement shall control.

7. AUTHORIZATION TO SUPPLEMENT . If any Grantor shall obtain rights to any new trademarks, the provisions of this Trademark Security Agreement shall automatically apply thereto. Each Grantor shall notify Agent of applications filed for the registration of any Trademarks with the United States Trademark Office in accordance with Section 5.7(g) of the Guaranty and Security Agreement. Without limiting Grantors’ obligations under this Section, Grantors hereby authorize Agent unilaterally to modify this Trademark Security Agreement by amending Schedule I to include any such new trademark rights of each Grantor. Notwithstanding the foregoing, no failure to so modify this Trademark Security Agreement or amend Schedule I shall in any way affect, invalidate or detract from Agent’s continuing security interest in all Collateral, whether or not listed on Schedule I.

8. NO VIOLATION OF LOAN DOCUMENTS . The representations, warranties or covenants contained herein are supplemental to those representations, warranties and covenants contained in the other Loan Documents, and shall not be deemed to modify any such representation, warranty or covenant contained in any other Loan Document.

9. GRANTOR’S RIGHTS TO ENFORCE TRADEMARKS . Prior to Agent’s giving of notice to Grantor following the occurrence and during the continuance of an Event of Default, such Grantor shall have the exclusive right to sue for past, present and future infringement of the Trademark Collateral, including the right to seek injunctions and/or money damages, in an effort by such Grantor to protect the Trademark Collateral against encroachment by third parties, provided, however, that:

(a) Any money damages awarded or received by such Grantor on account of such suit (or the threat of such suit) shall constitute Trademark Collateral.

(b) Any damages recovered in any action pursuant to this Section, net of costs and attorneys’ fees reasonably incurred, shall be applied in accordance with the Credit Agreement and the Guaranty and Security Agreement.

(c) Following the occurrence and during the continuance of any Event of Default, Agent, by notice to any Grantor may terminate or limit such Grantor’s rights under this Section 9.

10. RIGHTS UPON DEFAULT . Upon the occurrence and during the continuance of any Event of Default, Agent may exercise all rights and remedies as provided for in the Guaranty and Security Agreement.

 

3


11. NO LIMITATION; LOAN DOCUMENTS . This Trademark Security Agreement has been executed and delivered by each Grantor for the purpose of recording the security interest granted to Agent with respect to the Trademark Collateral with the United States Trademark Office. The security interest granted hereby has been granted as a supplement to, and not in limitation of, the security interest granted to Agent, for the benefit of the Lender Group, under the Guaranty and Security Agreement and the other Loan Documents. The other Loan Documents (and all rights and remedies of Grantor, Agent, and Lenders thereunder) shall remain in full force and effect in accordance with their terms.

12. TERMINATION; RELEASE OF TRADEMARK COLLATERAL . This Trademark Security Agreement and all obligations of each Grantor and Agent hereunder shall terminate on the date upon which the Obligations have been Paid in Full. Upon termination of this Trademark Security Agreement, Agent shall, at the reasonable expense of the Grantor, take such actions required by the Credit Agreement or the Guaranty and Security Agreement or as otherwise reasonably requested by Grantor to release its security interest in the Trademark Collateral.

13. BINDING EFFECT; BENEFITS . This Trademark Security Agreement shall be binding upon each Grantor and its successors and assigns, and shall inure to the benefit of Agent, Lenders and their respective successors and assigns.

14. COUNTERPARTS . This Trademark Security Agreement is a Loan Document. This Trademark Security Agreement may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, shall be deemed to be an original, and all of which, when taken together, shall constitute but one and the same Trademark Security Agreement. Delivery of an executed counterpart of this Trademark Security Agreement by telefacsimile or other electronic method of transmission shall be equally as effective as delivery of an original executed counterpart of this Trademark Security Agreement. Any party delivering an executed counterpart of this Trademark Security Agreement by telefacsimile or other electronic method of transmission also shall deliver an original executed counterpart of this Trademark Security Agreement but the failure to deliver an original executed counterpart shall not affect the validity, enforceability, and binding effect of this Trademark Security Agreement.

15. CHOICE OF LAW AND VENUE, JURY TRIAL WAIVER, AND JUDICIAL REFERENCE PROVISION . THIS TRADEMARK SECURITY AGREEMENT SHALL BE SUBJECT TO THE PROVISIONS REGARDING CHOICE OF LAW AND VENUE, JURY TRIAL WAIVER, AND JUDICIAL REFERENCE SET FORTH IN SECTIONS 8.11 AND 8.12 OF THE GUARANTY AND SECURITY AGREEMENT, AND SUCH PROVISIONS ARE INCORPORATED HEREIN BY THIS REFERENCE, MUTATIS MUTANDIS .

[signature page follows]

 

4


IN WITNESS WHEREOF, the parties hereto have caused this Trademark Security Agreement to be executed and delivered as of the day and year first above written.

 

GRANTORS:     ENDOLOGIX, INC.
    By:  

/s/ Vaseem Mahboob

    Name: Vaseem Mahboob
    Title: Chief Financial Officer
    TRIVASCULAR, INC.
    By:  

/s/ Vaseem Mahboob

    Name: Vaseem Mahboob
    Title: Chief Financial Officer and Secretary

[SIGNATURE PAGE TO TRADEMARK SECURITY AGREEMENT]


IN WITNESS WHEREOF, the parties hereto have caused this Trademark Security Agreement to be executed and delivered as of the day and year first above written.

   ACCEPTED AND ACKNOWLEDGED BY:
AGENT:    DEERFIELD ELGX REVOLVER, LLC
   by: Deerfield Management Company, L.P. (Series C), Manager
   By: Flynn Management LLC, General Partner
   By: /s/ David J. Clark                                
   Name: David J. Clark
   Title: Authorized Signatory

 

6


SCHEDULE I

to

TRADEMARK SECURITY AGREEMENT

Trademark Registrations/Applications

 

Grantor

  

Country

  

Mark

  

Registration No.

  

Registration Date

Endologix, Inc.    USA    DURAPLY    5433696    3/27/18
Endologix, Inc.    USA    INTELIX    5059968    10/11/16
Endologix, Inc.    USA    EVAS FORWARD    5306786    10/10/17
Endologix, Inc.    USA    VELA    5296578    9/26/17
Endologix, Inc.    USA    ANGIOTIP    5205176    5/16/17
Endologix, Inc.    USA    ACTIVESEAL    5396605    2/6/18
Endologix, Inc.    USA    INNOVATION THAT EMPOWERS    4841631    10/27/15
Endologix, Inc.    USA    INNOVATION TAKING SHAPE    4220343    10/9/12
Endologix, Inc.    USA    XPAND    4168563    7/3/12
Endologix, Inc.    USA    AFX    4214460    9/25/12
Endologix, Inc.    USA    INTUITRAK DELIVERY SYSTEM    3649866    7/7/09
Endologix, Inc.    USA    INTUITRAK    3649757    7/7/09
Endologix, Inc.    USA    NELLIX    3880178    11/23/10
Endologix, Inc.    USA    SUREPASS    3593259    3/17/09
Endologix, Inc.    USA    POWERLINK XL    3573999    2/10/09
Endologix, Inc.    USA    POWERLINK    2456038    5/29/01
Endologix, Inc.    USA    ENDOLOGIX    2257799    6/29/99
TriVascular, Inc.    USA    OVATION ALTO    5195890    5/2/17
TriVascular, Inc.    USA    CUSTOMSEAL    4732342    5/5/15
TriVascular, Inc.    USA    OVATION PRIME    4452625    12/17/13
TriVascular, Inc.    USA    OVATION PRIME ABDOMINAL STENT GRAFT SYSTEM    4449077    12/10/13
TriVascular, Inc.    USA    TRIVASCULAR    4395789    9/3/13
TriVascular, Inc.    USA    OVATION    4440468    11/26/13
TriVascular, Inc.    USA    TRIVASCULAR    2867015    7/27/04

Exhibit 10.12

FIRST SUPPLEMENT TO PATENT SECURITY AGREEMENT

This FIRST SUPPLEMENT TO PATENT SECURITY AGREEMENT (this “ Supplement ”) made as of August 9, 2018, by Endologix, Inc., a Delaware corporation (“ Endologix ” or “ Borrower ”), Nellix, Inc., a Delaware corporation (“ Nellix ”), TriVascular, Inc., a Delaware corporation (“ TriVascular ”; TriVascular, Endologix and Nellix are each individually a “ Grantor ” and collectively “ Grantors ”), in favor of Deerfield Private Design Fund IV, L.P., in its capacity as Agent for the Secured Parties (each as defined in the Facility Agreement referenced below) (in such capacity, “ Grantee ”):

W I T N E S S E T H

WHEREAS, Borrower, the other Loan Parties (including Nellix and TriVascular) from time to time party thereto, the financial institutions from time to time party thereto as Lenders and Grantee have entered into that certain Amended and Restated Facility Agreement dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “ Facility Agreement ”), pursuant to which Grantee and the Lenders have agreed, subject to the terms and conditions thereof, to make certain loans to, and other credit accommodations in favor of, Borrower (collectively, the “ Loans ”).

WHEREAS, pursuant to the terms of that certain Amended and Restated Guaranty and Security Agreement dated as of the date hereof, by and among Grantee, Grantors and the other Loan Parties from time to time party thereto (as the same may be amended, restated, supplemented or otherwise modified from time to time, the “ Guaranty and Security Agreement ”), Grantors have granted to Grantee, for its benefit and the benefit of the other Secured Parties, a security interest and Lien upon substantially all assets (including the Collateral) of Grantors, including all right, title and interest of Grantors in, to and under all now owned and hereafter acquired (a) letters patent of the United States or any political subdivision thereof of each Grantor, all reissues and extensions thereof and all goodwill associated therewith, (b) applications for letters patent of the United States and all divisions of each Grantor, continuations and continuations-in-part thereof and (c) rights to, and the rights to obtain any reissues, reexaminations, continuations, continuations-in-part, divisionals, renewals and extensions of all the foregoing (all of the foregoing in clauses (a), (b) and (c), collectively, together with all “Patents” as defined in the Guaranty and Security Agreement, “ Patents ”), together with the goodwill of the business symbolized by Grantors’ Patents, and all income, royalties, damages and payments with respect to the foregoing, to secure the payment of all Secured Obligations, in each case other than Excluded Property.

WHEREAS, Grantors and Grantee are parties to a certain Patent Security Agreement dated April 3, 2017 (as the same heretofore may have been and hereafter may be amended, restated, supplemented or otherwise modified from time to time, the “ Patent Security Agreement ”).

NOW, THEREFORE, in consideration of the premises set forth herein and for other good and valuable consideration, receipt and sufficiency of which are hereby acknowledged, Grantors agree to supplement the Patent Security Agreement as follows:

1. Incorporation of Facility Agreement, Guaranty and Security Agreement and Patent Security Agreement . The representations and warranties contained in the Facility


Agreement, the Guaranty and Security Agreement and the Patent Security Agreement to the extent applicable to Grantors are hereby incorporated herein in their entirety by this reference thereto. The provisions of Sections 1.2 and 6.4 of the Facility Agreement are incorporated herein by reference thereto mutatis mutandis . Unless otherwise noted herein, all capitalized terms used herein but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Guaranty and Security Agreement, or if not defined therein, in the Facility Agreement. In the event of a conflict between a provision of the Guaranty and Security Agreement and a provision of this Supplement (or the Patent Security Agreement as amended and/or supplemented by this Supplement), the provision of the Guaranty and Security Agreement shall control.

2. Grant and Reaffirmation of Grant of Security Interests . To secure the payment of the Secured Obligations, Grantors grant to Grantee, for its benefit and the benefit of the other Secured Parties, and hereby reaffirm their prior grant pursuant to the Guaranty and Security Agreement and the Patent Security Agreement of, a continuing Lien on and security interest in Grantors’ entire right, title and interest in and to the following (all of the following items or types of property being herein collectively referred to as the “ Patent Collateral ”), whether now owned or existing or hereafter created, acquired or arising:

(a) each Patent listed on Schedule A annexed hereto and all other Patents, together with any reissues, reexaminations, continuations, continuations-in-part, divisionals, renewals and extensions thereof, all of the goodwill of the business connected with the use of, and symbolized by, each such Patent, and all proceeds and products with respect to the foregoing; and

(b) all income, royalties, damages and payments at any time due or payable or asserted under and with respect to the foregoing, including without limitation, damages payable with respect to any claim by Grantors against third parties for past, present or future (i) infringement or dilution of each such Patent, or (ii) injury to the goodwill associated with each such Patent, and all proceeds and products with respect to the foregoing.

Notwithstanding the foregoing, no Patent Collateral shall include any Excluded Property.

3. Incorporation of the Patent Security Agreement . The terms and provisions of the Patent Security Agreement are hereby incorporated by reference and this Supplement shall be considered an amendment and supplement to and part of the Patent Security Agreement, all of the provisions of which Patent Security Agreement are and remain in full force and effect. Any reference after the date hereof in any Loan Document to the Patent Security Agreement shall be a reference to the Patent Security Agreement as amended and supplemented by this Supplement.

4. Reaffirmation of Obligations . Each Grantor hereby reaffirms its obligations (including, without limitation, the Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and any Exit Payment)) under the Patent Security Agreement, the Guaranty and Security Agreement and all other Loan Documents. Each Grantor hereby further ratifies and reaffirms the validity and enforceability of all of the Liens and security interests heretofore granted, pursuant to and in connection with the Patent Security Agreement, the Security Agreement or any other Loan Document, to Grantee (for the benefit of the Secured Parties), as collateral security for the obligations (including, without limitation, the Obligations


(including any Non-Callable Make Whole Amount, any CoC Fee and any Exit Payment)) under the Loan Documents in accordance with their respective terms, and acknowledges that all of such Liens and security interests, and all Collateral (including, without limitation, the Patent Collateral (as defined in the Patent Security Agreement)) heretofore pledged as security for such obligations (including, without limitation, the Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and any Exit Payment)), continue to be and remain collateral for such obligations (including, without limitation, the Obligations(including any Non-Callable Make Whole Amount, any CoC Fee and any Exit Payment)) from and after the date hereof.

5. Ratification . Each Grantor hereby restates, ratifies and reaffirms each and every term and condition set forth in the Patent Security Agreement effective as of the date hereof and as amended hereby.

6. Governing Law . This Supplement is governed by and construed and enforced in accordance with the laws of the State of New York applicable to contracts made and to be performed in such State.

7. Counterparts . This Supplement may be executed in several counterparts, and by each Party on separate counterparts, each of which and any photocopies, facsimile copies and other electronic methods of transmission thereof shall be deemed an original, but all of which together shall constitute one and the same agreement.

[Signature Page Follows]


IN WITNESS WHEREOF, each Grantor has duly executed this Supplement as of the date first written above.

 

ENDOLOGIX, INC.
By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer

First Supplement to Patent Security Agreement


IN WITNESS WHEREOF, each Grantor has duly executed this Supplement as of the date first written above.

 

NELLIX, INC.
By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer and Secretary

First Supplement to Patent Security Agreement


IN WITNESS WHEREOF, each Grantor has duly executed this Supplement as of the date first written above.

 

TRIVASCULAR, INC.
By:  

/s/ Vaseem Mahboob

Name:   Vaseem Mahboob
Title:   Chief Financial Officer and Secretary

First Supplement to Patent Security Agreement


Agreed and Accepted

As of the Date First Written Above:

DEERFIELD PRIVATE DESIGN FUND IV, L.P. , as Agent and Grantee

as Agent

 

By: Deerfield Mgmt IV, L.P., General Partner

 

By: J.E. Flynn Capital IV, LLC, General Partner

By:  

/s/ David J. Clark

Name:   David J. Clark
Title:   Authorized Signatory

First Supplement to Patent Security Agreement


SCHEDULE A

 

Description/Title

   Application
No.
   Application
Date
   Patent No.    Registration
Date
  

Owner/

Applicant

Bifurcated vascular graft deployment device    09505038    2/16/00    6210422    4/3/01    Endologix, Inc.
Method of deploying bifurcated vascular graft    09086247    5/28/98    6156063    12/5/00    Endologix, Inc.
Bifurcated vascular graft deployment device    08802478    2/20/97    6090128    7/18/00    Endologix, Inc.
Inflatable implant    12628623    12/1/09    N/A    N/A    Trivascular, Inc.
Ptfe layers and methods of manufacturing    12250946    10/14/08    N/A    N/A    Trivascular, Inc.
Ptfe layers and methods of manufacturing    12250915    10/14/08    N/A    N/A    Trivascular, Inc.
Hybrid modular endovascular graft    11097718    4/1/05    N/A    N/A    Trivascular, Inc.
Non-degradable low swelling, water soluble radiopaque hydrogel polymer    11097467    4/1/05    N/A    N/A    Trivascular, Inc.
Delivery system and method for bifurcated graft    11205793    8/15/05    N/A    N/A    Trivascular, Inc.
Methods, compositions and devices for embolizing body lumens    11031311    1/7/05    N/A    N/A    Trivascular, Inc.
Endoluminal prosthesis endoleak management    10691849    10/22/03    N/A    N/A    Trivascular, Inc.
Layered endovascular graft    10803153    3/17/04    N/A    N/A    Trivascular, Inc.


Description/Title

   Application
No.
   Application
Date
  

Patent No.

  

Registration
Date

  

Owner/

Applicant

Delivery system and method for bifurcated graft    10686863    10/16/03    N/A    N/A    Trivascular, Inc.
Inflatable intraluminal graft    10289137    11/5/02    N/A    N/A    Trivascular, Inc.
Endovascular graft    10289136    11/5/02    N/A    N/A    Trivascular, Inc.
Advanced endovascular graft    10091641    3/5/02    N/A    N/A    Trivascular, Inc.
Delivery system and method for bifurcated graft    10122474    4/11/02    N/A    N/A    Trivascular, Inc.
Layered endovascular graft    09970576    10/3/01    N/A    N/A    Trivascular, Inc.
Dual inflatable arterial prosthesis    15540246    6/27/17    N/A    N/A    Endologix, Inc.
Catheter system and methods of using same    15632064    6/23/17    N/A    N/A    Endologix, Inc.
Catheter system and methods of using same    15639028    6/30/17    N/A    N/A    Endologix, Inc.
Apparatus and method of placement of a graft or graft system    15610242    5/31/17    N/A    N/A    Endologix, Inc.
Stent graft delivery system    15676869    8/14/17    N/A    N/A    Nellix, Inc.
Endovascular graft    15686214    8/25/17    N/A    N/A    TriVascular, Inc.
Advanced endovascular graft    15686218    8/25/17    N/A    N/A    TriVascular, Inc.
Endovascular graft for aneurysms involving major branch vessels    15638559    6/30/17    N/A    N/A    TriVascular, Inc.
Systems and methods for guidewire crossover for bifurcated    15491074    4/19/17    N/A    N/A    TriVascular, Inc.


Description/Title

   Application
No.
   Application
Date
  

Patent
No.

  

Registration
Date

  

Owner/

Applicant

Low profile stent graft and delivery system    15263469    9/13/16    N/A    N/A    TriVascular, Inc.
Endoluminal prosthesis systems and methods    15737223    12/15/17    N/A    N/A    Endologix, Inc.
Endovascular graft systems and methods for deployment in main and branch arteries    65/529663    7/7/17    N/A    N/A    Endologix, Inc.
Stent grants and methods of enhancing flexibility of stent grafts by thermal pleating    65/532737    7/14/17    N/A    N/A    Endologix, Inc.
Endoluminal device and polymer    62/575827    10/23/17    N/A    N/A    Endologix, Inc.
Systems and Methods with Stents and Filling Structure    62/382207    8/31/16    N/A    N/A    Endologix, Inc.
STENTS, GRAFTS, DELIVERY SYSTEMS, AND METHODS    62/481560    4/4/17    N/A    N/A    Endologix, Inc.
ENDOVASCULAR SYSTEMS, DEVICES, AND METHODS ALLOWING FOR BRANCH DEVICE PLACEMENT IN POCKET OF MAIN GRAFT    62/489213    4/24/17    N/A    N/A    Endologix, Inc.
ENDOVASCULAR GRAFT SYSTEMS AND METHODS FOR DEPLOYMENT IN MAIN AND BRANCH ARTERIES    62/529669    7/7/17    N/A    N/A    Endologix, Inc.


Description/Title

   Application
No.
   Application
Date
  

Patent
No.

  

Registration
Date

  

Owner/

Applicant

STENT GRAFTS AND METHODS OF ENHANCING FLEXIBILITY OF STENT GRAFTS BY THERMAL PLEATING    62/532737    7/14/17    N/A    N/A    Endologix, Inc.
STENT GRAFT    15/911629    3/5/18    N/A    N/A    Endologix, Inc.
INTERNAL ILIAC PRESERVATION DEVICES AND METHODS    15/965649    4/__/18    N/A    N/A    Endologix, Inc.
MODULATION OF INFLAMMATORY RESPONSE FOLLOWING ENDOVASCULAR TREATMENT    62/661569    4/23/18    N/A    N/A    Endologix, Inc.
ADVANCED KINK RESISTANT STENT GRAFT    16/005269    6/11/18    N/A    N/A    Endologix, Inc.
LOW PROFILE STENT GRAFT AND DELIVERY SYSTEM    15/985572    5/21/18    N/A    N/A    Endologix, Inc.
SYSTEMS AND METHODS WITH STENT AND FILLING STRUCTURE    15/774511    8/30/17    N/A    N/A    Endologix, Inc.
LONGITUDINALLY EXTENDABLE STENT GRAFT SYSTEMS AND METHODS    15/774548    1/23/18    N/A    N/A    Endologix, Inc.


Description/Title

   Application
No.
   Application
Date
  

Patent No.

  

Registration
Date

  

Owner/

Applicant

GRAFT SYSTEMS HAVING FILLING STRUCTURES SUPPORTED BY SCAFFOLDS AND METHODS FOR THEIR USE    16/035497    7/13/18    N/A    N/A    Endologix, Inc.
PRE-FIXATION DEVICE FOR NELLIX AND OTHER EVAS DEVICES    62/678956    5/31/18    N/A    N/A    Endologix, Inc.
SYSTEMS AND METHODS WITH FENESTRATED GRAFT AND FILLING STRUCTURE    16/066595       N/A    N/A    Endologix, Inc.
MODULATION OF INFLAMMATORY RESPONSE FOLLOWING ENDOVASCULAR TREATMENT    62/661569    4/23/18    N/A    N/A    Endologix, Inc.
ENDOLUMINAL DEVICE AND POLYMER    62/575827    10/23/17    N/A    N/A    Endologix, Inc.
Implantable vascular graft    12/860280    8/20/10    20100318174       Endologix, Inc.
Endoluminal vascular prosthesis    11/623679    1/16/07    2007012412       Endologix, Inc.
Delivery catheter for endovascular device    13/835491    3/15/13    9498363    11/22/16    Trivascular, Inc.
Stent-graft with improved flexibility    15568834    10/24/17    N/A    N/A    TriVascular, Inc.
System and methods of Endovasular Aneurysm Treatment    14682414    8/21/17    N/A    N/A    Nellix, Inc.


Description/Title

   Application
No.
   Application
Date
  

Patent No.

  

Registration
Date

  

Owner/

Applicant

Stent graft systems with restraints in circumferential channels and methods thereof    62/678961    5/31/18    N/A    N/A    Endologix, Inc.
Percutaneous method and device to treat dissections    15/429090    2/9/17    N/A    N/A    Endologix, Inc.
Endovascular delivery system with an improved radiopague marker scheme    16/049560    7/30/18    N/A    N/A    Nellix, Inc.

Exhibit 10.13

FIRST SUPPLEMENT TO TRADEMARK SECURITY AGREEMENT

This FIRST SUPPLEMENT TO TRADEMARK SECURITY AGREEMENT (this “ Supplement ”) made as of August 9, 2018, by Endologix, Inc., a Delaware corporation (“ Endologix ” or “ Borrower ”), and TriVascular, Inc., a Delaware corporation (“ TriVascular ”; TriVascular and Endologix are each individually a “ Grantor ” and collectively “ Grantors ”), in favor of Deerfield Private Design Fund IV, L.P., in its capacity as Agent for the Secured Parties (each as defined in the Facility Agreement referenced below) (in such capacity, “ Grantee ”):

W I T N E S S E T H

WHEREAS, Borrower, the other Loan Parties (including TriVascular) from time to time party thereto, the financial institutions from time to time party thereto as Lenders and Grantee have entered into that certain Amended and Restated Facility Agreement dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “ Facility Agreement ”), pursuant to which Grantee and the Lenders have agreed, subject to the terms and conditions thereof, to make certain loans to, and other credit accommodations in favor of, Borrower (collectively, the “ Loans ”).

WHEREAS, pursuant to the terms of that certain Amended and Restated Guaranty and Security Agreement dated as of the date hereof, by and among Grantee, Grantors and the other Loan Parties from time to time party thereto (as the same may be amended, restated, supplemented or otherwise modified from time to time, the “ Guaranty and Security Agreement ”), Grantors have granted to Grantee, for its benefit and the benefit of the other Secured Parties, a security interest and Lien upon substantially all assets (including the Collateral) of Grantors, including all right, title and interest of Grantors in, to and under all now owned and hereafter acquired (a) trademarks, trade names, corporate names, company names, business names, fictitious business names, trade styles, trade dress, service marks, logos and other source or business identifiers of each Grantor, and all goodwill associated therewith, now existing or hereafter adopted or acquired, all registrations and recordings thereof, and all applications in connection therewith, whether in the United States Patent and Trademark Office or in any similar office or agency of the United States, any state thereof or any other country or any political subdivision thereof, or otherwise, and all common-law rights related thereto, and (b) the right to obtain all renewals thereof (all of the foregoing in clauses (a) and (b), collectively, together with “Trademarks” as defined in the Guaranty and Security Agreement, “ Trademarks ”), together with the goodwill of the business symbolized by Grantors’ Trademarks, and all income, royalties, damages and payments with respect to the foregoing, to secure the payment of all Secured Obligations, in each case other than Excluded Property.

WHEREAS, Grantors and Grantee are parties to that certain Trademark Security Agreement, dated April 3, 2017 (as the same heretofore may have been and hereafter may be amended, restated, supplemented or otherwise modified from time to time, the “Trademark Security Agreement”).


NOW, THEREFORE, in consideration of the premises set forth herein and for other good and valuable consideration, receipt and sufficiency of which are hereby acknowledged, Grantors agree to supplement the Trademark Security Agreement as follows:

1. Incorporation of Facility Agreement, Guaranty and Security Agreement and Trademark Security Agreement . The representations and warranties contained in the Facility Agreement, the Guaranty and Security Agreement and the Trademark Security Agreement to the extent applicable to Grantors are hereby incorporated herein in their entirety by this reference thereto. The provisions of Sections 1.2 and 6.4 of the Facility Agreement are incorporated herein by reference thereto mutatis mutandis . Unless otherwise noted herein, all capitalized terms used herein but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Guaranty and Security Agreement, or if not defined therein, in the Facility Agreement. In the event of a conflict between a provision of the Guaranty and Security Agreement and a provision of this Supplement (or the Trademark Security Agreement as amended and/or supplemented by this Supplement), the provision of the Guaranty and Security Agreement shall control.

2. Grant and Reaffirmation of Grant of Security Interests . To secure the payment of the Secured Obligations, Grantors hereby grant to Grantee, for its benefit and the benefit of the other Secured Parties, and hereby reaffirm their prior grant pursuant to the Guaranty and Security Agreement and the Trademark Security Agreement of, a continuing Lien on and security interest in Grantors’ entire right, title and interest in and to the following (all of the following items or types of property being herein collectively referred to as the “ Trademark Collateral ”), whether now owned or existing or hereafter created, acquired or arising:

(a) each Trademark listed on Schedule A annexed hereto and all other Trademarks, together with any reissues, continuations or extensions thereof, all of the goodwill of the business connected with the use of, and symbolized by, each such Trademark, and all proceeds and products with respect to the foregoing; and

(b) all income, royalties, damages and payments relating to the foregoing, including without limitation, damages payable with respect to any claim by Grantors against third parties for past, present or future (i) infringement or dilution of each such Trademark, or (ii) injury to the goodwill associated with each such Trademark, and all proceeds and products with respect to the foregoing.

Notwithstanding the foregoing, no Trademark Collateral shall include any Excluded Property.

3. Incorporation of the Trademark Security Agreement . The terms and provisions of the Trademark Security Agreement are hereby incorporated by reference, and this Supplement shall be considered an amendment and supplement to and part of the Trademark Security Agreement, all of the provisions of which Trademark Security Agreement are and remain in full force and effect. Any reference after the date hereof in any Loan Document to the Trademark Security Agreement shall be a reference to the Trademark Security Agreement as amended and supplemented by this Supplement.


4. Reaffirmation of Obligations. Each Grantor hereby reaffirms its obligations (including, without limitation, the Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and any Exit Payment)) under the Trademark Security Agreement, the Guaranty and Security Agreement and all other Loan Documents. Each Grantor hereby further ratifies and reaffirms the validity and enforceability of all of the Liens and security interests heretofore granted, pursuant to and in connection with the Trademark Security Agreement, the Security Agreement or any other Loan Document, to Grantee (for the benefit of the Secured Parties), as collateral security for the obligations (including, without limitation, the Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and any Exit Payment)) under the Loan Documents in accordance with their respective terms, and acknowledges that all of such Liens and security interests, and all Collateral (including, without limitation, the Trademark Collateral (as defined in the Trademark Security Agreement)) heretofore pledged as security for such obligations (including, without limitation, the Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and any Exit Payment)), continue to be and remain collateral for such obligations (including, without limitation, the Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and any Exit Payment)) from and after the date hereof.

5. Ratification . Each Grantor hereby restates, ratifies and reaffirms each and every term and condition set forth in the Trademark Security Agreement effective as of the date hereof and as amended hereby.

6. Governing Law . This Supplement is governed by and construed and enforced in accordance with the laws of the State of New York applicable to contracts made and to be performed in such State.

7. Counterparts . This Supplement may be executed in several counterparts, and by each Party on separate counterparts, each of which and any photocopies, facsimile copies and other electronic methods of transmission thereof shall be deemed an original, but all of which together shall constitute one and the same agreement.

[Signature Page Follows]


IN WITNESS WHEREOF, each Grantor has duly executed this Supplement as of the date first written above.

 

ENDOLOGIX, INC.

By:   /s/ Vaseem Mahboob
Name:   Vaseem Mahboob
Title:   Chief Financial Officer

First Supplement to Trademark Security Agreement


IN WITNESS WHEREOF, each Grantor has duly executed this Supplement as of the date first written above.

 

TRIVASCULAR, INC.

By:   /s/ Vaseem Mahboob
Name:   Vaseem Mahboob
Title:   Chief Financial Officer and Secretary

First Supplement to Trademark Security Agreement


Agreed and accepted as of

the date first written above:

 

DEERFIELD PRIVATE DESIGN FUND IV, L.P. , as Agent and Grantee
By: Deerfield Mgmt IV, L.P., General Partner
By: J.E. Flynn Capital IV, LLC, General Partner
By:   /s/ David J. Clark
Name:   David J. Clark
Title:   Authorized Signatory

First Supplement to Trademark Security Agreement


SCHEDULE A

 

Mark

  

Application No.

  

Application Date

  

Registration No.

  

Registration Date

  

Status of Mark

  

Owner/

Applicant

DURAPLY    86362822    8/11/14    5433696    3/27/18    Registered    Endologix, Inc.
EVAS FORWARD    86116940    11/12/13    5306786    10/10/17    Registered    Endologix, Inc.
VELA    85857988    2/22/13    5296578    9/26/17    Registered    Endologix, Inc.
ANGIOTIP    85767055    10/30/12    5205176    5/16/17    Registered    Endologix, Inc.
ACTIVESEAL    85518608    1/17/12    5396605    2/6/18    Registered    Endologix, Inc.
OVATION ALTO    86047894    8/26/13    5195890    5/2/17    Registered    TriVascular, Inc.
DESIGN ONLY    86854470    12/18/18    N/A    N/A    Published (Pending) – Intent to Use    Endologix, Inc.
ALLEGRO    86758465    9/16/15    N/A    N/A    Published (Pending) – Intent to Use    TriVascular, Inc.
VERTA    87116482    7/26/16    N/A    N/A    Pending (Intent to use)    Endologix, Inc.